Nucleobase editors and uses thereof

ABSTRACT

Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of Cas9 and nucleic acid editing proteins or protein domains, e.g., deaminase domains, are provided. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of Cas9 and nucleic acid editing proteins or domains, are provided.

RELATED APPLICATIONS

This application claims priority under 35 U.S.C. § 119(e) to U.S. provisional patent applications, U.S. Ser. No. 62/245,828 filed Oct. 23, 2015, U.S. Ser. No. 62/279,346 filed Jan. 15, 2016, U.S. Ser. No. 62/311,763 filed Mar. 22, 2016, U.S. Ser. No. 62/322,178 filed Apr. 13, 2016, U.S. Ser. No. 62/357,352 filed Jun. 30, 2016, U.S. Ser. No. 62/370,700 filed Aug. 3, 2016, U.S. Ser. No. 62/398,490 filed Sep. 22, 2016, U.S. Ser. No. 62/408,686 filed Oct. 14, 2016, and U.S. Ser. No. 62/357,332 filed Jun. 30, 2016; each of which is incorporated herein by reference.

GOVERNMENT SUPPORT

This invention was made with government support under grant number R01 EB022376 (formerly R01 GM065400) awarded by the National Institutes of Health, under training grant numbers F32 GM 112366-2 and F32 GM 106601-2 awarded by the National Institutes of Health, and Harvard Biophysics NIH training grant T32 GM008313 awarded by the National Institutes of Health. The government has certain rights in the invention.

BACKGROUND OF THE INVENTION

Targeted editing of nucleic acid sequences, for example, the targeted cleavage or the targeted introduction of a specific modification into genomic DNA, is a highly promising approach for the study of gene function and also has the potential to provide new therapies for human genetic diseases.¹ An ideal nucleic acid editing technology possesses three characteristics: (1) high efficiency of installing the desired modification; (2) minimal off-target activity; and (3) the ability to be programmed to edit precisely any site in a given nucleic acid, e.g., any site within the human genome.² Current genome engineering tools, including engineered zinc finger nucleases (ZFNs),³ transcription activator like effector nucleases (TALENs),⁴ and most recently, the RNA-guided DNA endonuclease Cas9,⁵ effect sequence-specific DNA cleavage in a genome. This programmable cleavage can result in mutation of the DNA at the cleavage site via non-homologous end joining (NHEJ) or replacement of the DNA surrounding the cleavage site via homology-directed repair (HDR).^(6,7)

One drawback to the current technologies is that both NHEJ and HDR are stochastic processes that typically result in modest gene editing efficiencies as well as unwanted gene alterations that can compete with the desired alteration.⁸ Since many genetic diseases in principle can be treated by effecting a specific nucleotide change at a specific location in the genome (for example, a C to T change in a specific codon of a gene associated with a disease),⁹ the development of a programmable way to achieve such precision gene editing would represent both a powerful new research tool, as well as a potential new approach to gene editing-based human therapeutics.

SUMMARY OF THE INVENTION

The clustered regularly interspaced short palindromic repeat (CRISPR) system is a recently discovered prokaryotic adaptive immune system¹⁰ that has been modified to enable robust and general genome engineering in a variety of organisms and cell lines.¹¹ CRISPR-Cas (CRISPR associated) systems are protein-RNA complexes that use an RNA molecule (sgRNA) as a guide to localize the complex to a target DNA sequence via base-pairing.¹² In the natural systems, a Cas protein then acts as an endonuclease to cleave the targeted DNA sequence.¹³ The target DNA sequence must be both complementary to the sgRNA, and also contain a “protospacer-adjacent motif” (PAM) at the 3′-end of the complementary region in order for the system to function.¹⁴

Among the known Cas proteins, S. pyogenes Cas9 has been mostly widely used as a tool for genome engineering.¹⁵ This Cas9 protein is a large, multi-domain protein containing two distinct nuclease domains. Point mutations can be introduced into Cas9 to abolish nuclease activity, resulting in a dead Cas9 (dCas9) that still retains its ability to bind DNA in a sgRNA-programmed manner.¹⁶ In principle, when fused to another protein or domain, dCas9 can target that protein to virtually any DNA sequence simply by co-expression with an appropriate sgRNA.

The potential of the dCas9 complex for genome engineering purposes is immense. Its unique ability to bring proteins to specific sites in a genome programmed by the sgRNA in theory can be developed into a variety of site-specific genome engineering tools beyond nucleases, including transcriptional activators, transcriptional repressors, histone-modifying proteins, integrases, and recombinases.¹¹ Some of these potential applications have recently been implemented through dCas9 fusions with transcriptional activators to afford RNA-guided transcriptional activators,^(17,18) transcriptional repressors,^(16,19,20) and chromatin modification enzymes.²¹ Simple co-expression of these fusions with a variety of sgRNAs results in specific expression of the target genes. These seminal studies have paved the way for the design and construction of readily programmable sequence-specific effectors for the precise manipulation of genomes.

Significantly, 80-90% of protein mutations responsible for human disease arise from the substitution, deletion, or insertion of only a single nucleotide.⁶ Most current strategies for single-base gene correction include engineered nucleases (which rely on the creation of double-strand breaks, DSBs, followed by stochastic, inefficient homology-directed repair, HDR), and DNA-RNA chimeric oligonucleotides.²² The latter strategy involves the design of a RNA/DNA sequence to base pair with a specific sequence in genomic DNA except at the nucleotide to be edited. The resulting mismatch is recognized by the cell's endogenous repair system and fixed, leading to a change in the sequence of either the chimera or the genome. Both of these strategies suffer from low gene editing efficiencies and unwanted gene alterations, as they are subject to both the stochasticity of HDR and the competition between HDR and non-homologous end-joining, NHEJ.²³⁻²⁵ HDR efficiencies vary according to the location of the target gene within the genome,²⁶ the state of the cell cycle,²⁷ and the type of cell/tissue.²⁸ The development of a direct, programmable way to install a specific type of base modification at a precise location in genomic DNA with enzyme-like efficiency and no stochasticity therefore represents a powerful new approach to gene editing-based research tools and human therapeutics.

Some aspects of the disclosure are based on the recognition that certain configurations of a dCas9 domain, and a cytidine deaminase domain fused by a linker are useful for efficiently deaminating target cytidine residues. Other aspects of this disclosure relate to the recognition that a nucleobase editing fusion protein with a cytidine deaminase domain fused to the N-terminus of a nuclease inactive Cas9 (dCas9) via a linker was capable of efficiently deaminating target nucleic acids in a double stranded DNA target molecule. See for example, Examples 3 and 4 below, which demonstrate that the fusion proteins, which are also referred to herein as base editors, generate less indels and more efficiently deaminate target nucleic acids than other base editors, such as base editors without a UGI domain. In some embodiments, the fusion protein comprises a nuclease-inactive Cas9 (dCas9) domain and an apolipoprotein B mRNA-editing complex 1 (APOBEC1) deaminase domain, where the deaminase domain is fused to the N-terminus of the dCas9 domain via a linker comprising the amino acid sequence SGSETPGTSESATPES (SEQ ID NO: 7). In some embodiments, the nuclease-inactive Cas9 (dCas9) domain of comprises the amino acid sequence set forth in SEQ ID NO: 263. In some embodiments, the deaminase is rat APOBEC1 (SEQ ID NO: 284). In some embodiments, the deaminase is human APOBEC1 (SEQ ID NO: 282). In some embodiments, the deaminase is pmCDA1 (SEQ ID NO: 5738). In some embodiments, the deaminase is human APOBEC3G (SEQ ID NO: 275). In some embodiments, the deaminase is a human APOBEC3G variant of any one of (SEQ ID NOs: 5739-5741).

Some aspects of the disclosure are based on the recognition that certain configurations of a dCas9 domain, and a cytidine deaminase domain fused by a linker are useful for efficiently deaminating target cytidine residues. Other aspects of this disclosure relate to the recognition that a nucleobase editing fusion protein with an apolipoprotein B mRNA-editing complex 1 (APOBEC1) deaminase domain fused to the N-terminus of a nuclease inactive Cas9 (dCas9) via a linker comprising the amino acid sequence SGSETPGTSESATPES (SEQ ID NO: 7) was capable of efficiently deaminating target nucleic acids in a double stranded DNA target molecule. In some embodiments, the fusion protein comprises a nuclease-inactive Cas9 (dCas9) domain and an apolipoprotein B mRNA-editing complex 1 (APOBEC1) deaminase domain, where the deaminase domain is fused to the N-terminus of the dCas9 domain via a linker comprising the amino acid sequence SGSETPGTSESATPES (SEQ ID NO: 7).

In some embodiments, the fusion protein comprises the amino acid residues 11-1629 of the amino acid sequence set forth in SEQ ID NO: 591. In some embodiments, the fusion protein comprises the amino acid sequence set forth in SEQ ID NO: 591. In some embodiments, the fusion protein comprises the amino acid sequence of any one of SEQ ID NOs: 5737, 5743, 5745, and 5746.

Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within a subject's genome, e.g., a human's genome. In some embodiments, fusion proteins of Cas9 (e.g., dCas9, nuclease active Cas9, or Cas9 nickase) and deaminases or deaminase domains, are provided. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of Cas9 and deaminases or deaminase domains, are provided.

Some aspects of this disclosure provide fusion proteins comprising a Cas9 protein as provided herein that is fused to a second protein (e.g., an enzymatic domain such as a cytidine deaminase domain), thus forming a fusion protein. In some embodiments, the second protein comprises an enzymatic domain, or a binding domain. In some embodiments, the enzymatic domain is a nuclease, a nickase, a recombinase, a deaminase, a methyltransferase, a methylase, an acetylase, an acetyltransferase, a transcriptional activator, or a transcriptional repressor domain. In some embodiments, the enzymatic domain is a nucleic acid editing domain. In some embodiments, the nucleic acid editing domain is a deaminase domain. In some embodiments, the deaminase is a cytosine deaminase or a cytidine deaminase. In some embodiments, the deaminase is an apolipoprotein B mRNA-editing complex (APOBEC) family deaminase. In some embodiments, the deaminase is an APOBEC1 deaminase. In some embodiments, the deaminase is an APOBEC2 deaminase. In some embodiments, the deaminase is an APOBEC3 deaminase. In some embodiments, the deaminase is an APOBEC3A deaminase. In some embodiments, the deaminase is an APOBEC3B deaminase. In some embodiments, the deaminase is an APOBEC3C deaminase. In some embodiments, the deaminase is an APOBEC3D deaminase. In some embodiments, the deaminase is an APOBEC3E deaminase. In some embodiments, the deaminase is an APOBEC3F deaminase. In some embodiments, the deaminase is an APOBEC3G deaminase. In some embodiments, the deaminase is an APOBEC3H deaminase. In some embodiments, the deaminase is an APOBEC4 deaminase. In some embodiments, the deaminase is an activation-induced deaminase (AID). It should be appreciated that the deaminase may be from any suitable organism (e.g., a human or a rat). In some embodiments, the deaminase is from a human, chimpanzee, gorilla, monkey, cow, dog, rat, or mouse. In some embodiments, the deaminase is rat APOBEC1 (SEQ ID NO: 284). In some embodiments, the deaminase is human APOBEC1 (SEQ ID NO: 282). In some embodiments, the deaminase is pmCDA1.

Some aspects of this disclosure provide fusion proteins comprising: (i) a nuclease-inactive Cas9 (dCas9) domain comprising the amino acid sequence of SEQ ID NO: 263; and (ii) an apolipoprotein B mRNA-editing complex 1 (APOBEC1) deaminase domain, wherein the deaminase domain is fused to the N-terminus of the dCas9 domain via a linker comprising the amino acid sequence of SGSETPGTSESATPES (SEQ ID NO: 7). In some embodiments, the deaminase is rat APOBEC1 (SEQ ID NO: 284). In some embodiments, the deaminase is human APOBEC1 (SEQ ID NO: 282). In some embodiments, the fusion protein comprises the amino acid sequence of SEQ ID NO: 591. In some embodiments, the fusion protein comprises the amino acid sequence of SEQ ID NO: 5737. In some embodiments, the deaminase is pmCDA1 (SEQ ID NO: 5738). In some embodiments, the deaminase is human APOBEC3G (SEQ ID NO: 275). In some embodiments, the deaminase is a human APOBEC3G variant of any one of SEQ ID NOs: 5739-5741.

Some aspects of this disclosure provide fusion proteins comprising: (i) a Cas9 nickase domain and (ii) an apolipoprotein B mRNA-editing complex 1 (APOBEC1) deaminase domain, wherein the deaminase domain is fused to the N-terminus of the Cas9 nickase domain. In some embodiments, the Cas9 nickase domain comprises a D10X mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, wherein X is any amino acid except for D. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises a D10A mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises a histidine at amino acid position 840 of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding amino acid position in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises the amino acid sequence as set forth in SEQ ID NO: 267. In some embodiments, the deaminase is rat APOBEC1 (SEQ ID NO: 284). In some embodiments, the deaminase is human APOBEC1 (SEQ ID NO: 282). In some embodiments, the deaminase is pmCDA1.

Some aspects of this disclosure provide fusion proteins comprising: (i) a Cas9 nickase domain and (ii) an apolipoprotein B mRNA-editing complex 1 (APOBEC1) deaminase domain, wherein the deaminase domain is fused to the N-terminus of the Cas9 nickase domain. In some embodiments, the Cas9 nickase domain comprises a D10X mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, wherein X is any amino acid except for D. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises a D10A mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises a histidine at amino acid position 840 of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding amino acid position in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises the amino acid sequence as set forth in SEQ ID NO: 267. In some embodiments, the deaminase is rat APOBEC1 (SEQ ID NO: 284). In some embodiments, the deaminase is human APOBEC1 (SEQ ID NO: 282). In some embodiments, the deaminase is pmCDA1.

Other aspects of this disclosure relate to the recognition that fusion proteins comprising a deaminase domain, a dCas9 domain and a uracil glycosylase inhibitor (UGI) domain demonstrate improved efficiency for deaminating target nucleotides in a nucleic acid molecule. Without wishing to be bound by any particular theory, cellular DNA-repair response to the presence of U:G heteroduplex DNA may be responsible for a decrease in nucleobase editing efficiency in cells. Uracil DNA glycosylase (UDG) catalyzes removal of U from DNA in cells, which may initiate base excision repair, with reversion of the U:G pair to a C:G pair as the most common outcome. As demonstrated herein, Uracil DNA Glycosylase Inhibitor (UGI) may inhibit human UDG activity. Without wishing to be bound by any particular theory, base excision repair may be inhibited by molecules that bind the single strand, block the edited base, inhibit UGI, inhibit base excision repair, protect the edited base, and/or promote “fixing” of the non-edited strand, etc. Thus, this disclosure contemplates fusion proteins comprising a dCas9-cytidine deaminase domain that is fused to a UGI domain.

In some embodiments, the fusion protein comprises a nuclease-inactive Cas9 (dCas9) domain; a nucleic acid editing domain; and a uracil glycosylase inhibitor (UGI) domain. In some embodiments, the dCas9 domain comprises a D10X mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, wherein X is any amino acid except for D. In some embodiments, the amino acid sequence of the dCas9 domain comprises a D10A mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the amino acid sequence of the dCas9 domain comprises an H840X mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, wherein X is any amino acid except for H. In some embodiments, the amino acid sequence of the dCas9 domain comprises an H840A mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the dCas9 domain comprises the amino acid sequence as set forth in SEQ ID NO: 263.

Further aspects of this disclosure relate to the recognition that fusion proteins using a Cas9 nickase as the Cas9 domain demonstrate improved efficiency for editing nucleic acids. For example, aspects of this disclosure relate to the recognition that fusion proteins comprising a Cas9 nickase, a deaminase domain and a UGI domain demonstrate improved efficiency for editing nucleic acids. For example, the improved efficiency for editing nucleotides is described below in the Examples section.

Some aspects of the disclosure are based on the recognition that any of the base editors provided herein are capable of modifying a specific nucleotide base without generating a significant proportion of indels. An “indel”, as used herein, refers to the insertion or deletion of a nucleotide base within a nucleic acid. Such insertions or deletions can lead to frame shift mutations within a coding region of a gene. In some embodiments, it is desirable to generate base editors that efficiently modify (e.g. mutate or deaminate) a specific nucleotide within a nucleic acid, without generating a large number of insertions or deletions (i.e., indels) in the nucleic acid. In certain embodiments, any of the base editors provided herein are capable of generating a greater proportion of intended modifications (e.g., point mutations or deaminations) versus indels.

Some aspects of the disclosure are based on the recognition that any of the base editors provided herein are capable of efficiently generating an intended mutation, such as a point mutation, in a nucleic acid (e.g. a nucleic acid within a genome of a subject) without generating a significant number of unintended mutations, such as unintended point mutations.

In some embodiments, a fusion protein comprises a Cas9 nickase domain, a nucleic acid editing domain; and a uracil glycosylase inhibitor (UGI) domain. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises a D10X mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, wherein X is any amino acid except for D. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises a D10A mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises a histidine at amino acid position 840 of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding amino acid position in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises the amino acid sequence as set forth in SEQ ID NO: 267.

In some embodiments, the deaminase domain of the fusion protein is fused to the N-terminus of the dCas9 domain or the Cas9 nickase. In some embodiments, the UGI domain is fused to the C-terminus of the dCas9 domain or the Cas9 nickase. In some embodiments, the dCas9 domain or the Cas9 nickase and the nucleic acid editing domain are fused via a linker. In some embodiments, the dCas9 domain or the Cas9 nickase and the UGI domain are fused via a linker.

In certain embodiments, linkers may be used to link any of the peptides or peptide domains of the invention. The linker may be as simple as a covalent bond, or it may be a polymeric linker many atoms in length. In certain embodiments, the linker is a polypeptide or based on amino acids. In other embodiments, the linker is not peptide-like. In certain embodiments, the linker is a covalent bond (e.g., a carbon-carbon bond, disulfide bond, carbon-heteroatom bond, etc.). In certain embodiments, the linker is a carbon-nitrogen bond of an amide linkage. In certain embodiments, the linker is a cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic or heteroaliphatic linker. In certain embodiments, the linker is polymeric (e.g., polyethylene, polyethylene glycol, polyamide, polyester, etc.). In certain embodiments, the linker comprises a monomer, dimer, or polymer of aminoalkanoic acid. In certain embodiments, the linker comprises an aminoalkanoic acid (e.g., glycine, ethanoic acid, alanine, beta-alanine, 3-aminopropanoic acid, 4-aminobutanoic acid, 5-pentanoic acid, etc.). In certain embodiments, the linker comprises a monomer, dimer, or polymer of aminohexanoic acid (Ahx). In certain embodiments, the linker is based on a carbocyclic moiety (e.g., cyclopentane, cyclohexane). In other embodiments, the linker comprises a polyethylene glycol moiety (PEG). In other embodiments, the linker comprises amino acids. In certain embodiments, the linker comprises a peptide. In certain embodiments, the linker comprises an aryl or heteroaryl moiety. In certain embodiments, the linker is based on a phenyl ring. The linker may included funtionalized moieties to facilitate attachment of a nucleophile (e.g., thiol, amino) from the peptide to the linker. Any electrophile may be used as part of the linker. Exemplary electrophiles include, but are not limited to, activated esters, activated amides, Michael acceptors, alkyl halides, aryl halides, acyl halides, and isothiocyanates.

In some embodiments, the linker comprises the amino acid sequence (GGGGS)_(n) (SEQ ID NO: 5), (G)_(n), (EAAAK)_(n) (SEQ ID NO: 6), (GGS)_(n), (SGGS)_(n) (SEQ ID NO: 4288), SGSETPGTSESATPES (SEQ ID NO: 7), (XP)_(n), or any combination thereof, wherein n is independently an integer between 1 and 30, and wherein X is any amino acid. In some embodiments, the linker comprises the amino acid sequence (GGS)_(n), wherein n is 1, 3, or 7. In some embodiments, the linker comprises the amino acid sequence SGSETPGTSESATPES (SEQ ID NO: 7).

In some embodiments, the fusion protein comprises the structure [nucleic acid editing domain]-[optional linker sequence]-[dCas9 or Cas9 nickase]-[optional linker sequence]-[UGI]. In some embodiments, the fusion protein comprises the structure [nucleic acid editing domain]-[optional linker sequence]-[UGI]-[optional linker sequence]-[dCas9 or Cas9 nickase]; [UGI]-[optional linker sequence]-[nucleic acid editing domain]-[optional linker sequence]-[dCas9 or Cas9 nickase]; [UGI]-[optional linker sequence]-[dCas9 or Cas9 nickase]-[optional linker sequence]-[nucleic acid editing domain]; [dCas9 or Cas9 nickase]-[optional linker sequence]-[UGI]-[optional linker sequence]-[nucleic acid editing domain]; or [dCas9 or Cas9 nickase]-[optional linker sequence]-[nucleic acid editing domain]-[optional linker sequence]-[UGI].

In some embodiments, the nucleic acid editing domain comprises a deaminase. In some embodiments, the nucleic acid editing domain comprises a deaminase. In some embodiments, the deaminase is a cytidine deaminase. In some embodiments, the deaminase is an apolipoprotein B mRNA-editing complex (APOBEC) family deaminase. In some embodiments, the deaminase is an APOBEC1 deaminase, an APOBEC2 deaminase, an APOBEC3A deaminase, an APOBEC3B deaminase, an APOBEC3C deaminase, an APOBEC3D deaminase, an APOBEC3F deaminase, an APOBEC3G deaminase, an APOBEC3H deaminase, or an APOBEC4 deaminase. In some embodiments, the deaminase is an activation-induced deaminase (AID). In some embodiments, the deaminase is a Lamprey CDA1 (pmCDA1) deaminase.

In some embodiments, the deaminase is from a human, chimpanzee, gorilla, monkey, cow, dog, rat, or mouse. In some embodiments, the deaminase is from a human. In some embodiments the deaminase is from a rat. In some embodiments, the deaminase is a rat APOBEC1 deaminase comprising the amino acid sequence set forth in (SEQ ID NO: 284). In some embodiments, the deaminase is a human APOBEC1 deaminase comprising the amino acid sequence set forth in (SEQ ID NO: 282). In some embodiments, the deaminase is pmCDA1 (SEQ ID NO: 5738). In some embodiments, the deaminase is human APOBEC3G (SEQ ID NO: 275). In some embodiments, the deaminase is a human APOBEC3G variant of any one of (SEQ ID NOs: 5739-5741). In some embodiments, the deaminase is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the amino acid sequences set forth in SEQ ID NOs: 266-284 or 5725-5741.

In some embodiments, the UGI domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to SEQ ID NO: 600. In some embodiments, the UGI domain comprises the amino acid sequence as set forth in SEQ ID NO: 600.

Some aspects of this disclosure provide complexes comprising a Cas9 protein or a Cas9 fusion protein as provided herein, and a guide RNA bound to the Cas9 protein or the Cas9 fusion protein.

Some aspects of this disclosure provide methods of using the Cas9 proteins, fusion proteins, or complexes provided herein. For example, some aspects of this disclosure provide methods comprising contacting a DNA molecule (a) with a Cas9 protein or a fusion protein as provided herein and with a guide RNA, wherein the guide RNA is about 15-100 nucleotides long and comprises a sequence of at least 10 contiguous nucleotides that is complementary to a target sequence; or (b) with a Cas9 protein, a Cas9 fusion protein, or a Cas9 protein or fusion protein complex with a gRNA as provided herein.

Some aspects of this disclosure provide kits comprising a nucleic acid construct, comprising (a) a nucleotide sequence encoding a Cas9 protein or a Cas9 fusion protein as provided herein; and (b) a heterologous promoter that drives expression of the sequence of (a). In some embodiments, the kit further comprises an expression construct encoding a guide RNA backbone, wherein the construct comprises a cloning site positioned to allow the cloning of a nucleic acid sequence identical or complementary to a target sequence into the guide RNA backbone.

Some aspects of this disclosure provide polynucleotides encoding a Cas9 protein of a fusion protein as provided herein. Some aspects of this disclosure provide vectors comprising such polynucleotides. In some embodiments, the vector comprises a heterologous promoter driving expression of polynucleotide.

Some aspects of this disclosure provide cells comprising a Cas9 protein, a fusion protein, a nucleic acid molecule, and/or a vector as provided herein.

The description of exemplary embodiments of the reporter systems above is provided for illustration purposes only and not meant to be limiting. Additional reporter systems, e.g., variations of the exemplary systems described in detail above, are also embraced by this disclosure.

The summary above is meant to illustrate, in a non-limiting manner, some of the embodiments, advantages, features, and uses of the technology disclosed herein. Other embodiments, advantages, features, and uses of the technology disclosed herein will be apparent from the Detailed Description, the Drawings, the Examples, and the Claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the deaminase activity of deaminases on single stranded DNA substrates. Single stranded DNA substrates using randomized PAM sequences (NNN PAM) were used as negative controls. Canonical PAM sequences used (NGG PAM)

FIG. 2 shows activity of Cas9:deaminase fusion proteins on single stranded DNA substrates. (GGS)₃ corresponds to SEQ ID NO: 596.

FIG. 3 illustrates double stranded DNA substrate binding by Cas9:deaminase:sgRNA complexes.

FIG. 4 illustrates a double stranded DNA deamination assay.

FIG. 5 demonstrates that Cas9 fusions can target positions 3-11 of double-stranded DNA target sequences (numbered according to the schematic in FIG. 5). Upper Gel: 1 μM rAPOBEC1-GGS-dCas9, 125 nM dsDNA, 1 equivalent sgRNA. Mid Gel: 1 μM rAPOBEC1-(GGS)₃(SEQ ID NO: 596)-dCas9, 125 nM dsDNA, 1 equivalent sgRNA. Lower Gel: 1.85 μM rAPOBEC1-XTEN-dCas9, 125 nM dsDNA, 1 equivalent sgRNA.

FIG. 6 demonstrates that the correct guide RNA, e.g., the correct sgRNA, is required for deaminase activity. (GGS)₃ corresponds to SEQ ID NO: 596.

FIG. 7 illustrates the mechanism of target DNA binding of in vivo target sequences by deaminase-dCas9:sgRNA complexes.

FIG. 8 shows successful deamination of exemplary disease-associated target sequences.

FIG. 9 shows in vitro C→T editing efficiencies using His6-rAPOBEC1-XTEN-dCas9.

FIG. 10 shows C→T editing efficiencies in HEK293T cells is greatly enhanced by fusion with UGI.

FIGS. 11A to 11C show NBE1 mediates specific, guide RNA-programmed C to U conversion in vitro. FIG. 11A: Nucleobase editing strategy. DNA with a target C (red) at a locus specified by a guide RNA (green) is bound by dCas9 (blue), which mediates the local denaturation of the DNA substrate. Cytidine deamination by a tethered APOBEC1 enzyme (orange) converts the target C to U. The resulting G:U heteroduplex can be permanently converted to an A:T base pair following DNA replication or repair. If the U is in the template DNA strand, it will also result in an RNA transcript containing a G to A mutation following transcription. FIG. 11B: Deamination assay showing an activity window of approximately five nucleotides. Following incubation of NBE1-sgRNA complexes with dsDNA substrates at 37° C. for 2 h, the 5′ fluorophore-labeled DNA was isolated and incubated with USER enzyme (uracil DNA glycosylase and endonuclease VIII) at 37° C. for 1 h to induce DNA cleavage at the site of any uracils. The resulting DNA was resolved on a denaturing polyacrylamide gel, and any fluorophore-linked strands were visualized. Each lane is labeled according to the position of the target C within the protospacer, or with “-” if no target C is present, counting the base distal from the PAM as position 1. FIG. 11C: Deaminase assay showing the sequence specificity and sgRNA-dependence of NBE1. The DNA substrate with a target C at position 7 was incubated with NBE1 as in FIG. 11B with either the correct sgRNA, a mismatched sgRNA, or no sgRNA. No C to U editing is observed with the mismatched sgRNA or with no sgRNA. The positive control sample contains a DNA sequence with a U synthetically incorporated at position 7.

FIGS. 12A to 12B show effects of sequence context and target C position on nucleobase editing efficiency in vitro. FIG. 12A: Effect of changing the sequence surrounding the target C on editing efficiency in vitro. The deamination yield of 80% of targeted strands (40% of total sequencing reads from both strands) for C₇ in the protospacer sequence 5′-TTATTTCGTGGATTTATTTA-3′(SEQ ID NO: 264) was defined as 1.0, and the relative deamination efficiencies of substrates containing all possible single-base mutations at positions 1-6 and 8-13 are shown. Values and error bars reflect the mean and standard deviation of two or more independent biological replicates performed on different days. FIG. 12B: Positional effect of each NC motif on editing efficiency in vitro. Each NC target motif was varied from positions 1 to 8 within the protospacer as indicated in the sequences shown on the right (the PAM shown in red, the protospacer plus one base 5′ to the protospacer are also shown). The percentage of total sequence reads containing T at each of the numbered target C positions following incubation with NBE1 is shown in the graph. Note that the maximum possible deamination yield in vitro is 50% of total sequencing reads (100% of targeted strands). Values and error bars reflect the mean and standard deviation of two or three independent biological replicates performed on different days. FIG. 12B depicts SEQ ID NOs: 5750 through 5757 from top to bottom, respectively.

FIGS. 13A to 13C show nucleobase editing in human cells. FIG. 13A: Protospacer (black) and PAM (red) sequences of the six mammalian cell genomic loci targeted by nucleobase editors. Target Cs are indicated with subscripted numbers corresponding to their positions within the protospacer. FIG. 13A depicts SEQ ID NOs: 293 through 298 from top to bottom, respectively. FIG. 13B: HEK293T cells were transfected with plasmids expressing NBE1, NBE2, or NBE3 and an appropriate sgRNA. Three days after transfection, genomic DNA was extracted and analyzed by high-throughput DNA sequencing at the six loci. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with Ts at the target positions indicated, are shown for NBE1, NBE2, and NBE3 at all six genomic loci, and for wt Cas9 with a donor HDR template at three of the six sites (EMX1, HEK293 site 3, and HEK293 site 4). Values and error bars reflect the mean and standard deviation of three independent biological replicates performed on different days. FIG. 13C: Frequency of indel formation, calculated as described in the Methods, is shown following treatment of HEK293T cells with NBE2 and NBE3 for all six genomic loci, or with wt Cas9 and a single-stranded DNA template for HDR at three of the six sites (EMX1, HEK293 site 3, and HEK293 site 4). Values reflect the mean of at least three independent biological replicates performed on different days.

FIGS. 14A to 14C show NBE2- and NBE3-mediated correction of three disease-relevant mutations in mammalian cells. For each site, the sequence of the protospacer is indicated to the right of the name of the mutation, with the PAM highlighted in green and the base responsible for the mutation indicated in bold with a subscripted number corresponding to its position within the protospacer. The amino acid sequence above each disease-associated allele is shown, together with the corrected amino acid sequence following nucleobase editing in red. Underneath each sequence are the percentages of total sequencing reads with the corresponding base. Cells were nucleofected with plasmids encoding NBE2 or NBE3 and an appropriate sgRNA. Two days after nucleofection, genomic DNA was extracted and analyzed by HTS to assess pathogenic mutation correction. FIG. 14A: The Alzheimer's disease-associated APOE4 allele is converted to APOE3′ in mouse astrocytes by NBE3 in 11% of total reads (44% of nucleofected astrocytes). Two nearby Cs are also converted to Ts, but with no change to the predicted sequence of the resulting protein (SEQ ID NO: 299). The DNA sequence in FIG. 14A corresponds to SEQ ID NO: 5747. FIG. 14B The cancer-associated p53 N239D mutation is corrected by NBE2 in 11% of treated human lymphoma cells (12% of nucleofected cells) that are heterozygous for the mutation (SEQ ID NO: 300). The DNA sequence in FIG. 14B corresponds to SEQ ID NO: 5748. FIG. 14C The p53 Y163C mutation is corrected by NBE3 in 7.6% of nucleofected human breast cancer cells (SEQ ID NO: 301). The DNA sequence FIG. 14C corresponds to SEQ ID NO: 5749.

FIGS. 15A to 15D show effects of deaminase-dCas9 linker length and composition on nucleobase editing. Gel-based deaminase assay showing the deamination window of nucleobase editors with deaminase-Cas9 linkers of GGS (FIG. 15A), (GGS)₃ (SEQ ID NO: 596) (FIG. 15B), XTEN (FIG. 15C), or (GGS)₇ (SEQ ID NO: 597) (FIG. 15D). Following incubation of 1.85 μM editor-sgRNA complexes with 125 nM dsDNA substrates at 37° C. for 2 h, the dye-conjugated DNA was isolated and incubated with USER enzyme (uracil DNA glycosylase and endonuclease VIII) at 37° C. for an additional hour to cleave the DNA backbone at the site of any uracils. The resulting DNA was resolved on a denaturing polyacrylamide gel, and the dye-conjugated strand was imaged. Each lane is numbered according to the position of the target C within the protospacer, or with—if no target C is present. 8U is a positive control sequence with a U synthetically incorporated at position 8.

FIGS. 16A to 16B show NBE1 is capable of correcting disease-relevant mutations in vitro. FIG. 16A: Protospacer and PAM sequences (red) of seven disease-relevant mutations. The disease-associated target C in each case is indicated with a subscripted number reflecting its position within the protospacer. For all mutations except both APOE4 SNPs, the target C resides in the template (non-coding) strand. FIG. 16A depicts SEQ ID NOs: 5760, 5747, and 5761 through 5765 from top to bottom, respectively. FIG. 16B: Deaminase assay showing each dsDNA oligonucleotide before (−) and after (+) incubation with NBE1, DNA isolation, and incubation with USER enzymes to cleave DNA at positions containing U. Positive control lanes from incubation of synthetic oligonucleotides containing U at various positions within the protospacer with USER enzymes are shown with the corresponding number indicating the position of the U.

FIG. 17 shows processivity of NBE1. The protospacer and PAM (red) of a 60-mer DNA oligonucleotide containing eight consecutive Cs is shown at the top. The oligonucleotide (125 nM) was incubated with NBE1 (2 μM) for 2 h at 37° C. The DNA was isolated and analyzed by high-throughput sequencing. Shown are the percent of total reads for the most frequent nine sequences observed. The vast majority of edited strands (>93%) have more than one C converted to T. This figure depicts SEQ ID NO: 5766.

FIGS. 18A to 18H show the effect of fusing UGI to NBE1 to generate NBE2. FIG. 18A: Protospacer and PAM (red) sequences of the six mammalian cell genomic loci targeted with nucleobase editors. Editable Cs are indicated with labels corresponding to their positions within the protospacer. FIG. 18A depicts SEQ ID NOs: 293 through 298 from top to bottom, respectively. FIGS. 18B to 18G: HEK293T cells were transfected with plasmids expressing NBE1, NBE2, or NBE1 and UGI, and an appropriate sgRNA. Three days after transfection, genomic DNA was extracted and analyzed by high-throughput DNA sequencing at the six loci. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with Ts at the target positions indicated, are shown for NBE1, NBE1 and UGI, and. NBE2 at all six genomic loci. FIG. 18H: C to T mutation rates at 510 Cs surrounding the protospacers of interest for NBE1, NBE1 plus UGI on a separate plasmid, NBE2, and untreated cells are shown. The data show the results of 3,000,000 DNA sequencing reads from 1.5×106 cells. Values reflect the mean of at least two biological experiments conducted on different days.

FIG. 19 shows nucleobase editing efficiencies of NBE2 in U2OS and HEK293T cells. Cellular C to T conversion percentages by NBE2 are shown for each of the six targeted genomic loci in HEK293T cells and U2OS cells. HEK293T cells were transfected using lipofectamine 2000, and U2OS cells were nucleofected. U2OS nucleofection efficiency was 74%. Three days after plasmid delivery, genomic DNA was extracted and analyzed for nucleobase editing at the six genomic loci by FITS. Values and error bars reflect the mean and standard deviation of at least two biological experiments done on different days.

FIG. 20 shows nucleobase editing persists over multiple cell divisions. Cellular C to T conversion percentages by NBE2 are displayed at two genomic loci in HEK293T cells before and after passaging the cells. HEK293T cells were transfected using Lipofectamine 2000. Three days post transfection, the cells were harvested and split in half. One half was subjected to HTS analysis, and the other half was allowed to propagate for approximately five cell divisions, then harvested and subjected to HTS analysis.

FIG. 21 shows genetic variants from ClinVar that can be corrected in principle by nucleobase editing. The NCBI ClinVar database of human genetic variations and their corresponding phenotypes⁶⁸ was searched for genetic diseases that can be corrected by current nucleobase editing technologies. The results were filtered by imposing the successive restrictions listed on the left. The x-axis shows the number of occurrences satisfying that restriction and all above restrictions on a logarithmic scale.

FIG. 22 shows in vitro identification of editable Cs in six genomic loci. Synthetic 80-mers with sequences matching six different genomic sites were incubated with NBE1 then analyzed for nucleobase editing via FITS. For each site, the sequence of the protospacer is indicated to the right of the name of the site, with the PAM highlighted in red. Underneath each sequence are the percentages of total DNA sequencing reads with the corresponding base. A target C was considered as “editable” if the in vitro conversion efficiency is >10%. Note that maximum yields are 50% of total DNA sequencing reads since the non-targeted strand is not a substrate for nucleobase editing. This figure depicts SEQ ID NOs: 293 through 298 from top to bottom, respectively.

FIG. 23 shows activities of NBE1, NBE2, and NBE3 at EMX1 off-targets. HEK293T cells were transfected with plasmids expressing NBE1, NBE2, or NBE3 and a sgRNA matching the EMX1 sequence using Lipofectamine 2000. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target loci, plus the top ten known Cas9 off-target loci for the EMX1 sgRNA, as previously determined using the GUIDE-seq method⁵⁵. EMX1 off-target 5 locus did not amplify and is not shown. Sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are displayed. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with T at each position of an original C within the protospacer, are shown for NBE1, NBE2, and NBE3. On the far right are displayed the total number of sequencing reads reported for each sequence. This figure depicts SEQ ID NOs: 293, and 5767 through 5775 from top to bottom, respectively.

FIG. 24 shows activities of NBE1, NBE2, and NBE3 at FANCF off-targets. HEK293T cells were transfected with plasmids expressing NBE1, NBE2, or NBE3 and a sgRNA matching the FANCF sequence using Lipofectamine 2000. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target loci, plus all of the known Cas9 off-target loci for the FANCF sgRNA, as previously determined using the GUIDE-seq method⁵⁵. Sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are displayed. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with T at each position of an original C within the protospacer, are shown for NBE1, NBE2, and NBE3. On the far right are displayed the total number of sequencing reads reported for each sequence. This figure depicts SEQ ID NOs: 294 and 5776 through 5781, 5777, and 5782 from top to bottom, respectively.

FIG. 25 shows activities of NBE1, NBE2, and NBE3 at HEK293 site 2 off-targets. HEK293T cells were transfected with plasmids expressing NBE1, NBE2, or NBE3 and a sgRNA matching the HEK293 site 2 sequence using Lipofectamine 2000. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target loci, plus all of the known Cas9 off-target loci for the HEK293 site 2 sgRNA, as previously determined using the GUIDE-seq method⁵⁵. Sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are displayed. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with T at each position of an original C within the protospacer, are shown for NBE1, NBE2, and NBE3. On the far right are displayed the total number of sequencing reads reported for each sequence. This figure depicts SEQ ID NOs: 295, 327, and 328 from top to bottom, respectively.

FIG. 26 shows activities of NBE1, NBE2, and NBE3 at HEK293 site 3 off-targets. HEK293T cells were transfected with plasmids expressing NBE1, NBE2, or NBE3 and a sgRNA matching the HEK293 site 3 sequence using Lipofectamine 2000. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target loci, plus all of the known Cas9 off-target loci for the HEK293 site 3 sgRNA, as previously determined using the GUIDE-seq method⁵⁵. Sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are displayed. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with T at each position of an original C within the protospacer, are shown for NBE1, NBE2, and NBE3. On the far right are displayed the total number of sequencing reads reported for each sequence. This figure depicts SEQ ID NOs: 296 and 659 through 663 from top to bottom, respectively.

FIG. 27 shows activities of NBE1, NBE2, and NBE3 at HEK293 site 4 off-targets. HEK293T cells were transfected with plasmids expressing NBE1, NBE2, or NBE3 and a sgRNA matching the HEK293 site 4 sequence using Lipofectamine 2000. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target loci, plus the top ten known Cas9 off-target loci for the HEK293 site 4 sgRNA, as previously determined using the GUIDE-seq method⁵⁵. Sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are displayed. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with T at each position of an original C within the protospacer, are shown for NBE1, NBE2, and NBE3. On the far right are displayed the total number of sequencing reads reported for each sequence. This figure depicts SEQ ID NOs: 297 and 664 through 673 from top to bottom, respectively.

FIG. 28 shows non-target C mutation rates. Shown here are the C to T mutation rates at 2,500 distinct cytosines surrounding the six on-target and 34 off-target loci tested, representing a total of 14,700,000 sequence reads derived from approximately 1.8×106 cells.

FIGS. 29A to 29C show base editing in human cells. FIG. 29A shows possible base editing outcomes in mammalian cells. Initial editing resulted in a U:G mismatch. Recognition and excision of the U by uracil DNA glycosylase (UDG) initiated base excision repair (BER), which lead to reversion to the C:G starting state. BER was impeded by BE2 and BE3, which inhibited UDG. The U:G mismatch was also processed by mismatch repair (MMR), which preferentially repaired the nicked strand of a mismatch. BE3 nicked the non-edited strand containing the G, favoring resolution of the U:G mismatch to the desired U:A or T:A outcome. FIG. 29B shows HEK293T cells treated as described in the Materials and Methods in the Examples below. The percentage of total DNA sequencing read with Ts at the target positions indicated show treatment with BE1, BE2, or BE3, or for treatment with wt Cas9 with a donor HDR template. FIG. 29C shows frequency of indel formation following the treatment in FIG. 29B. Values are listed in FIG. 34. For FIGS. 29B and 29C, values and error bars reflect the mean and s.d. of three independent biological replicates performed on different days.

FIGS. 30A to 30B show BE3-mediated correction of two disease-relevant mutations in mammalian cells. The sequence of the protospacer is shown to the right of the mutation, with the PAM in blue and the target base in red with a subscripted number indicating its position within the protospacer. Underneath each sequence are the percentages of total sequencing reads with the corresponding base. Cells were treated as described in the Materials and Methods. FIG. 30A shows the Alzheimer's disease-associated APOE4 allele converted to APOE3r in mouse astrocytes by BE3 in 74.9% of total reads. Two nearby Cs were also converted to Ts, but with no change to the predicted sequence of the resulting protein. Identical treatment of these cells with wt Cas9 and donor ssDNA results in only 0.3% correction, with 26.1% indel formation. FIG. 30B shows the cancer associated p53 Y163C mutation corrected by BE3 in 7.6% of nucleofected human breast cancer cells with 0.7% indel formation. Identical treatment of these cells with wt Cas9 and donor ssDNA results in no mutation correction with 6.1% indel formation. The amino acid sequences in FIG. 30A correspond to SEQ ID NOs: 675, 299, and 299 from top to bottom, respectively. The three DNA sequences in FIG. 30A correspond to SEQ ID NO: 5747. The amino acid sequences in FIG. 30B correspond to SEQ ID NOs: 678, 301, and 301 from top to bottom, respectively. The three DNA sequences in FIG. 30B correspond to SEQ ID NO: 5749.

FIG. 31 shows activities of BE1, BE2, and BE3 at HEK293 site 2 off-targets. HEK293T cells were transfected with plasmids expressing BE1, BE2, or BE3 and a sgRNA matching the HEK293 site 2 sequence using Lipofectamine 2000. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target loci, plus all of the known Cas9 and dCas9 off-target loci for the HEK293 site 2 sgRNA, as previously determined by Joung and coworkers using the GUIDE-seq method (63), and Adli and coworkers using chromatin immunoprecipitation high-throughput sequencing (ChIP-seq) experiments (18). Sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are displayed. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with T at each position of an original C within the protospacer, are shown for BE1, BE2, and BE3. On the far right are displayed the total number of sequencing reads reported, and the ChIP-seq intensity reported for each sequence. This figure depicts SEQ ID NOs: 295, 327 through 328 and 684 through 688 from top to bottom, respectively.

FIG. 32 shows activities of BE1, BE2, a signal

nd BE3 at HEK293 site 3 off-targets. HEK293T cells were transfected with plasmids expressing BE1, BE2, or BE3 and a sgRNA matching the HEK293 site 3 sequence using Lipofectamine 2000. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target loci, plus all of the known Cas9 off-target loci and the top five known dCas9 off-target loci for the HEK293 site 3 sgRNA, as previously determined by Joung and coworkers using the GUIDE-seq method⁵⁴, and using chromatin immunoprecipitation high-throughput sequencing (ChIP-seq) experiments⁶¹. Sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are displayed. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with T at each position of an original C within the protospacer, are shown for BE1, BE2, and BE3. On the far right are displayed the total number of sequencing reads reported, and the ChIP-seq signal intensity reported for each sequence. This figure depicts SEQ ID NOs: 296, 659 through 663 and 695 through 699 from top to bottom, respectively.

FIG. 33 shows activities of BE1, BE2, and BE3 at HEK293 site 4 off-targets. HEK293T cells were transfected with plasmids expressing BE1, BE2, or BE3 and a sgRNA matching the HEK293 site 4 sequence using Lipofectamine 2000. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target loci, plus the top ten known Cas9 off-target loci and the top five known dCas9 off-target loci for the HEK293 site 4 sgRNA, as previously determined using the GUIDE-seq method⁵⁴, and using chromatin immunoprecipitation high-throughput sequencing (ChIP-seq) experiments⁶¹. Sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are displayed. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with T at each position of an original C within the protospacer, are shown for BE1, BE2, and BE3. On the far right are displayed the total number of sequencing reads reported, and the ChIP-seq signal intensity reported for each sequence. This figure depicts SEQ ID NOs: 297, 664 through 673, 5783, and 5784 from top to bottom, respectively.

FIG. 34 shows mutation rates of non-protospacer bases following BE3-mediated correction of the Alzheimer's disease-associated APOE4 allele to APOE3r in mouse astrocytes. The DNA sequence of the 50 bases on either side of the protospacer from FIG. 30A and FIG. 34B is shown with each base's position relative to the protospacer. The side of the protospacer distal to the PAM is designated with positive numbers, while the side that includes the PAM is designated with negative numbers, with the PAM shown in blue. Underneath each sequence are the percentages of total DNA sequencing reads with the corresponding base for untreated cells, for cells treated with BE3 and an sgRNA targeting the APOE4 C158R mutation, or for cells treated with BE3 and an sgRNA targeting the VEGFA locus. Neither BE3-treated sample resulted in mutation rates above those of untreated controls. This figure depicts SEQ ID NOs: 713 to 716 from top to bottom, respectively.

FIG. 35 shows mutation rates of non-protospacer bases following BE3-mediated correction of the cancer-associated p53 Y163C mutation in HCC1954 human cells. The DNA sequence of the 50 bases on either side of the protospacer from FIG. 30B and FIG. 39Bis shown with each base's position relative to the protospacer. The side of the protospacer distal to the PAM is designated with positive numbers, while the side that includes the PAM is designated with negative numbers, with the PAM shown in blue. Underneath each sequence are the percentages of total sequencing reads with the corresponding base for untreated cells, for cells treated with BE3 and an sgRNA targeting the TP53 Y163C mutation, or for cells treated with BE3 and an sgRNA targeting the VEGFA locus. Neither BE3-treated sample resulted in mutational rates above those of untreated controls. This figure depicts SEQ ID NOs: 717 to 720 from top to bottom, respectively.

FIGS. 36A to 36F show the effects of deaminase, linker length, and linker composition on base editing. FIG. 36A shows a gel-based deaminase assay showing activity of rAPOBEC1, pmCDA1, hAID, hAPOBEC3G, rAPOBEC1-GGS-dCas9, rAPOBEC1-(GGS)₃(SEQ ID NO: 596)-dCas9, and dCas9-(GGS)₃(SEQ ID NO: 596)-rAPOBEC1 on ssDNA. Enzymes were expressed in a mammalian cell lysate-derived in vitro transcription-translation system and incubated with 1.8 μM dye-conjugated ssDNA and USER enzyme (uracil DNA glycosylase and endonuclease VIII) at 37° C. for 2 hours. The resulting DNA was resolved on a denaturing polyacrylamide gel and imaged. The positive control is a sequence with a U synthetically incorporated at the same position as the target C. FIG. 36B shows coomassie-stained denaturing PAGE gel of the expressed and purified proteins used in FIGS. 36C to 36F. FIGS. 36C to 36F show gel-based deaminase assay showing the deamination window of base editors with deaminase-Cas9 linkers of GGS (FIG. 36C), (GGS)₃ (SEQ ID NO: 596) (FIG. 36D), XTEN (FIG. 36E), or (GGS)₇ (SEQ ID NO: 597) (FIG. 36F). Following incubation of 1.85 μM deaminase-dCas9 fusions complexed with sgRNA with 125 nM dsDNA substrates at 37° C. for 2 hours, the dye-conjugated DNA was isolated and incubated with USER enzyme at 37° C. for 1 hour to cleave the DNA backbone at the site of any uracils. The resulting DNA was resolved on a denaturing polyacrylamide gel, and the dye-conjugated strand was imaged. Each lane is numbered according to the position of the target C within the protospacer, or with—if no target C is present. 8U is a positive control sequence with a U synthetically incorporated at position 8.

FIGS. 37A to 37C show BE1 base editing efficiencies are dramatically decreased in mammalian cells. FIG. 37A Protospacer (black and red) and PAM (blue) sequences of the six mammalian cell genomic loci targeted by base editors. Target Cs are indicated in red with subscripted numbers corresponding to their positions within the protospacer. FIG. 37B shows synthetic 80-mers with sequences matching six different genomic sites were incubated with BE1 then analyzed for base editing by HTS. For each site, the sequence of the protospacer is indicated to the right of the name of the site, with the PAM highlighted in blue. Underneath each sequence are the percentages of total DNA sequencing reads with the corresponding base. We considered a target C as “editable” if the in vitro conversion efficiency is >10%. Note that maximum yields are 50% of total DNA sequencing reads since the non-targeted strand is unaffected by BEL Values are shown from a single experiment. FIG. 37C shows HEK293T cells were transfected with plasmids expressing BE1 and an appropriate sgRNA. Three days after transfection, genomic DNA was extracted and analyzed by high-throughput DNA sequencing at the six loci. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with Ts at the target positions indicated, are shown for BE1 at all six genomic loci. Values and error bars of all data from HEK293T cells reflect the mean and standard deviation of three independent biological replicates performed on different days. FIG. 37A depicts SEQ ID NOs: 293 through 298 from top to bottom, respectively. FIG. 37B depicts SEQ ID NOs: 293 through 298 from top to bottom, respectively.

FIG. 38 shows base editing persists over multiple cell divisions. Cellular C to T conversion percentages by BE2 and BE3 are shown for HEK293 sites 3 and 4 in HEK293T cells before and after passaging the cells. HEK293T cells were nucleofected with plasmids expressing BE2 or BE3 and an sgRNA targeting HEK293 site 3 or 4. Three days after nucleofection, the cells were harvested and split in half. One half was subjected to HTS analysis, and the other half was allowed to propagate for approximately five cell divisions, then harvested and subjected to HTS analysis. Values and error bars reflect the mean and standard deviation of at least two biological experiments.

FIGS. 39A to 39C show non-target C/G mutation rates. Shown here are the C to T and G to A mutation rates at 2,500 distinct cytosines and guanines surrounding the six on-target and 34 off-target loci tested, representing a total of 14,700,000 sequence reads derived from approximately 1.8×10⁶ cells. FIGS. 39A and 39B show cellular non-target C to T and G to A conversion percentages by BE1, BE2, and BE3 are plotted individually against their positions relative to a protospacer for all 2,500 cytosines/guanines. The side of the protospacer distal to the PAM is designated with positive numbers, while the side that includes the PAM is designated with negative numbers. FIG. 39C shows average non-target cellular C to T and G to A conversion percentages by BE1, BE2, and BE3 are shown, as well as the highest and lowest individual conversion percentages.

FIGS. 40A to 40B show additional data sets of BE3-mediated correction of two disease-relevant mutations in mammalian cells. For each site, the sequence of the protospacer is indicated to the right of the name of the mutation, with the PAM highlighted in blue and the base responsible for the mutation indicated in red bold with a subscripted number corresponding to its position within the protospacer. The amino acid sequence above each disease-associated allele is shown, together with the corrected amino acid sequence following base editing in green. Underneath each sequence are the percentages of total sequencing reads with the corresponding base. Cells were nucleofected with plasmids encoding BE3 and an appropriate sgRNA. Two days after nucleofection, genomic DNA was extracted from the nucleofected cells and analyzed by HTS to assess pathogenic mutation correction. FIG. 40A shows the Alzheimer's disease-associated APOE4 allele is converted to APOE3r in mouse astrocytes by BE3 in 58.3% of total reads only when treated with the correct sgRNA. Two nearby Cs are also converted to Ts, but with no change to the predicted sequence of the resulting protein. Identical treatment of these cells with wt Cas9 and donor ssDNA results in 0.2% correction, with 26.7% indel formation. FIG. 40B shows the cancer-associated p53 Y163C mutation is corrected by BE3 in 3.3% of nucleofected human breast cancer cells only when treated with the correct sgRNA. Identical treatment of these cells with wt Cas9 and donor ssDNA results in no detectable mutation correction with 8.0% indel formation. The amino acid sequences in FIG. 40A correspond to SEQ ID NOs: 675, 299, 675, and 299 from top to bottom, respectively. The nucleotide sequence is given by SEQ ID NO: 5747. The amino acid sequences in FIG. 40B correspond to SEQ ID NOs: 678, 301, 678, and 301 from top to bottom, respectively. The nucleotide sequence is given by SEQ ID NO: 5749.

FIG. 41 shows a schematic representation of an exemplary USER (Uracil-Specific Excision Reagent) Enzyme-based assay, which may be used to test the activity of various deaminases on single-stranded DNA (ssDNA) substrates.

FIG. 42 is a schematic of the pmCDA-nCas9-UGI-NLS construct and its activity at the HeK-3 site relative to the base editor (rAPOBEC1) and the negative control (untreated). The sequence corresponds to SEQ ID NO: 4139.

FIG. 43 is a schematic of the pmCDA1-XTEN-nCas9-UGI-NLS construct and its activity at the HeK-3 site relative to the base editor (rAPOBEC1) and the negative control (untreated). The sequence corresponds to SEQ ID NO: 4140.

FIG. 44 shows the percent of total sequencing reads with target C converted to T using cytidine deaminases (CDA) or APOBEC.

FIG. 45 shows the percent of total sequencing reads with target C converted to A using deaminases (CDA) or APOBEC.

FIG. 46 shows the percent of total sequencing reads with target C converted to G using deaminases (CDA) or APOBEC.

FIG. 47 is a schematic of the huAPOBEC3G-XTEN-nCas9-UGI-NLS construct and its activity at the HeK-2 site relative to a mutated form (huAPOBEC3G*(D316R_D317R)-XTEN-nCas9-UGI-NLS, the base editor (rAPOBEC1) and the negative control (untreated). The sequence corresponds to SEQ ID NO: 4141.

FIG. 48 shows the schematic of the LacZ construct used in the selection assay of Example 7. The sequence corresponds to SEQ ID NO: 4142.

FIG. 49 shows reversion data from different plasmids and constructs.

FIG. 50 shows the verification of lacZ reversion (the sequences correspond to SEQ ID NO: 4143 (the nucleotide sequence) and SEQ ID NO: 4144 (the amino acid sequence) from the MP6 plasmid) and the purification of reverted clones (the sequences correspond to SEQ ID NO: 4145 (the nucleotide sequence) and SEQ ID NO: 4146 (the amino acid sequence) from the CDA plasmid).

FIG. 51 is a schematic depicting a deamination selection plasmid used in Example 7.

FIG. 52 shows the results of a chloramphenicol reversion assay (pmCDA1 fusion).

FIGS. 53A to 53B demonstrated DNA correction induction of two constructs. The sequences in FIG. 53A from top to bottom correspond to SEQ ID NOs: 4147 (the nucleotide sequence), 4148 (the amino acid sequence), 4149 (the nucleotide sequence), 4150 (the amino acid sequence), 4147 (the nucleotide sequence) and 4151 (the truncated nucleotide sequence). The sequences in FIG. 53B from top to bottom correspond to SEQ ID NOs: 5785 (the nucleotide sequence), 5787 (the amino acid sequence), 5786 (the nucleotide sequence), 5788 (the amino acid sequence), 5785 (the nucleotide sequence), and 5806 (the truncated nucleotide sequence).

FIG. 54 shows the results of a chloramphenicol reversion assay (huAPOBEC3G fusion). The sequences correspond to SEQ ID NOs: 5802 (the nucleotide sequence), 5803 (the amino acid sequence), 5804 (the nucleotide sequence), 5805 (the amino acid sequence), and 5802 (the nucleotide sequence).

FIG. 55 shows the activities of BE3 and HF-BE3 at EMX1 off-targets. This figure depicts SEQ ID NOs: 293, and 5767 through 5775 from top to bottom, respectively.

FIG. 56 shows on-target base editing efficiencies of BE3 and HF-BE3.

FIG. 57 is a graph demonstrating that mutations affect cytidine deamination with varying degrees. Combinations of mutations that each slightly impairs catalysis allow selective deamination at one position over others. The FANCF site was GGAATC₆C₇C₈TTC₁₁TGCAGCACCTGG (SEQ ID NO: 303).

FIG. 58 is a schematic depicting next generation base editors.

FIG. 59 is a schematic illustrating new base editors made from Cas9 variants.

FIG. 60 shows the base-edited percentage of different NGA PAM sites.

FIG. 61 shows the base-edited percentage of cytidines using NGCG PAM EMX (VRER BE3) and the C₁TC₃C₄C₅ATC₈AC₁₀ATCAACCGGT (SEQ ID NO: 304) spacer.

FIG. 62 shows the based-edited percentages resulting from different NNGRRT PAM sites.

FIG. 63 shows the based-edited percentages resulting from different NNHRRT PAM sites.

FIGS. 64A to 64C show the base-edited percentages resulting from different TTTN PAM sites using Cpf1 BE2. The spacers used were: TTTCCTC₃C₄C₅C₆C₇C₈C₉AC₁₁AGGTAGAACAT (FIG. 64A, SEQ ID NO: 305), TTTCC₁C₂TC₄TGTC₈C₉AC₁₁ACCCTCATCCTG (FIG. 64B, SEQ ID NO: 306), and TTTCC₁C₂C₃AGTC₇C₈TC₁₀C₁₁AC₁₃AC₁₅C₁₆C₁₇TGAAAC (FIG. 64C, SEQ ID NO: 307).

FIG. 65 is a schematic depicting selective deamination as achieved through kinetic modulation of cytidine deaminase point mutagenesis.

FIG. 66 is a graph showing the effect of various mutations on the deamination window probed in cell culture with multiple cytidines in the spacer. The spacer used was: TGC₃C₄C₅C₆TC₈C₉C₁₀TC₁₂C₁₃C₁₄TGGCCC (SEQ ID NO: 308).

FIG. 67 is a graph showing the effect of various mutations on the deamination window probed in cell culture with multiple cytidines in the spacer. The spacer used was: AGAGC₅C₆C₇C₈C₉C₁₀C₁₁TC₁₃AAAGAGA (SEQ ID NO: 309).

FIG. 68 is a graph showing the effect of various mutations on the FANCF site with a limited number of cytidines. The spacer used was: GGAATC₆C₇C₈TTC₁₁TGCAGCACCTGG (SEQ ID NO: 303). Note that the triple mutant (W90Y, R126E, R132E) preferentially edits the cytidine at the sixth position.

FIG. 69 is a graph showing the effect of various mutations on the HEK3 site with a limited number of cytidines. The spacer used was: GGCC₄C₅AGACTGAGCACGTGATGG (SEQ ID NO: 310). Note that the double and triple mutants preferentially edit the cytidine at the fifth position over the cytidine in the fourth position.

FIG. 70 is a graph showing the effect of various mutations on the EMX1 site with a limited number of cytidines. The spacer used was: GAGTC₅C₆GAGCAGAAGAAGAAGGG (SEQ ID NO: 311). Note that the triple mutant only edits the cytidine at the fifth position, not the sixth.

FIG. 71 is a graph showing the effect of various mutations on the HEK2 site with a limited number of cytidines. The spacer used was: GAAC₄AC₆AAAGCATAGACTGCGGG (SEQ ID NO: 312).

FIG. 72 shows on-target base editing efficiencies of BE3 and BE3 comprising mutations W90Y R132E in immortalized astrocytes. The amino acid sequences correspond to SEQ ID NO: 5789. The nucleic acid sequences correspond to SEQ ID NO: 5790.

FIG. 73 depicts a schematic of three Cpf1 fusion constructs.

FIG. 74 shows a comparison of plasmid delivery of BE3 and HF-BE3 (EMX1, FANCF, and RNF2).

FIG. 75 shows a comparison of plasmid delivery of BE3 and HF-BE3 (HEK3 and HEK 4).

FIG. 76 shows off-target editing of EMX-1 at all 10 sites. This figure depicts SEQ ID NOs: 293 and 5767 through 5775 from top to bottom, respectively.

FIG. 77 shows deaminase protein lipofection to HEK cells using a GAGTCCGAGCAGAAGAAGAAG (SEQ ID NO: 313) spacer. The EMX-1 on-target and EMX-1 off target site 2 were examined.

FIG. 78 shows deaminase protein lipofection to HEK cells using a GGAATCCCTTCTGCAGCACCTGG (SEQ ID NO: 314) spacer. The FANCF on target and FANCF off target site 1 were examined.

FIG. 79 shows deaminase protein lipofection to HEK cells using a GGCCCAGACTGAGCACGTGA (SEQ ID NO: 315) spacer. The HEK-3 on target site was examined.

FIG. 80 shows deaminase protein lipofection to HEK cells using a GGCACTGCGGCTGGAGGTGGGGG (SEQ ID NO: 316) spacer. The HEK-4 on target, off target site 1, site 3, and site 4.

FIG. 81 shows the results of an in vitro assay for sgRNA activity for sgHR_13 (GTCAGGTCGAGGGTTCTGTC (SEQ ID NO: 317) spacer; C8 target: G51 to STOP), sgHR_14 (GGGCCGCAGTATCCTCACTC (SEQ ID NO: 318) spacer; C7 target; C7 target: Q68 to STOP), and sgHR_15 (CCGCCAGTCCCAGTACGGGA (SEQ ID NO: 319) spacer; C10 and C11 are targets: W239 or W237 to STOP).

FIG. 82 shows the results of an in vitro assay for sgHR_17 (CAACCACTGCTCAAAGATGC (SEQ ID NO: 320) spacer; C4 and C5 are targets: W410 to STOP), and sgHR_16 (CTTCCAGGATGAGAACACAG (SEQ ID NO: 321) spacer; C4 and C5 are targets: W273 to STOP).

FIG. 83 shows the direct injection of BE3 protein complexed with sgHR_13 in zebrafish embryos.

FIG. 84 shows the direct injection of BE3 protein complexed with sgHR_16 in zebrafish embryos.

FIG. 85 shows the direct injection of BE3 protein complexed with sgHR_17 in zebrafish embryos.

FIG. 86 shows exemplary nucleic acid changes that may be made using base editors that are capable of making a cytosine to thymine change.

FIG. 87 shows an illustration of apolipoprotein E (APOE) isoforms, demonstrating how a base editor (e.g., BE3) may be used to edit one APOE isoform (e.g., APOE4) into another APOE isoform (e.g., APOE3r) that is associated with a decreased risk of Alzheimer's disease.

FIG. 88 shows base editing of APOE4 to APOE3r in mouse astrocytes. The amino acid sequences correspond to SEQ ID NOs: 675, 299, and 299 from top to bottom, respectively. The nucleic acid sequences correspond to SEQ ID NO: 5747.

FIG. 89 shows base editing of PRNP to cause early truncation of the protein at arginine residue 37. The sequences correspond to SEQ ID NOs: 5791 (the amino acid sequence) and 4126 (the nucleic acid sequence).

FIG. 90 shows that knocking out UDG (which UGI inhibits) dramatically improves the cleanliness of efficiency of C to T base editing.

FIG. 91 shows that use of a base editor with the nickase but without UGI leads to a mixture of outcomes, with very high indel rates.

FIGS. 92A to 92G show that SaBE3, SaKKH-BE3, VQR-BE3, EQR-BE3, and VRER-BE3 mediate efficient base editing at target sites containing non-NGG PAMs in human cells. FIG. 92A shows base editor architectures using S. pyogenes and S. aureus Cas9. FIG. 92B shows recently characterized Cas9 variants with alternate or relaxed PAM requirements. FIGS. 92C and 92D show HEK293T cells treated with the base editor variants shown as described in Example 12. The percentage of total DNA sequencing reads (with no enrichment for transfected cells) with C converted to T at the target positions indicated are shown. The PAM sequence of each target tested is shown below the X-axis. The charts show the results for SaBE3 and SaKKH-BE3 at genomic loci with NNGRRT PAMs (FIG. 92C), SaBE3 and SaKKH-BE3 at genomic loci with NNNRRT PAMs (FIG. 92D), VQR-BE3 and EQR-BE3 at genomic loci with NGAG PAMs (FIG. 92E), and with NGAH PAMs (FIG. 92F), and VRER-BE3 at genomic loci with NGCG PAMs (FIG. 92G). Values and error bars reflect the mean and standard deviation of at least two biological replicates.

FIGS. 93A to 93C demonstrate that base editors with mutations in the cytidine deaminase domain exhibit narrowed editing windows. FIGS. 93A to 93C show HEK293T cells transfected with plasmids expressing mutant base editors and an appropriate sgRNA. Three days after transfection, genomic DNA was extracted and analyzed by high-throughput DNA sequencing at the indicated loci. The percentage of total DNA sequencing reads (without enrichment for transfected cells) with C changed to T at the target positions indicated are shown for the EMX1 site, HEK293 site 3, FANCF site, HEK293 site 2, site A, and site B loci. FIG. 93A illustrates certain cytidine deaminase mutations which narrow the base editing window. The sequences in FIG. 93A correspond to SEQ ID NOs: 5792 and 5793 from top to bottom, respectively. See FIG. 98 for the characterization of additional mutations. FIG. 93B shows the effect of cytidine deaminase mutations which effect the editing window width on genomic loci. Combining beneficial mutations has an additive effect on narrowing the editing window. The sequences correspond to SEQ ID NOs: 296, 295, 293, and 294 from left to right and top to bottom, respectively. FIG. 93C shows that YE1-BE3, YE2-BE3, EE-BE3, and YEE-BE3 effect the product distribution of base editing, producing predominantly singly-modified products in contrast with BE3. Values and error bars reflect the mean and standard deviation of at least two biological replicates.

FIGS. 94A and 94B show genetic variants from ClinVar that in principle can be corrected by the base editors developed in this work. The NCBI ClinVar database of human genetic variations and their corresponding phenotypes was searched for genetic diseases that in theory can be corrected by base editing. FIG. 94A demonstrates improvement in base editing targeting scope among all pathogenic T→C mutations in the ClinVar database through the use of base editors with altered PAM specificities. The white fractions denote the proportion of pathogenic T→C mutations accessible on the basis of the PAM requirements of either BE3, or BE3 together with the five modified-PAM base editors developed in this work. FIG. 94B shows improvement in base editing targeting scope among all pathogenic T→C mutations in the ClinVar database through the use of base editors with narrowed activity windows. BE3 was assumed to edit Cs in positions 4-8 with comparable efficiency as shown in FIGS. 93A to 93C. YEE-BE3 was assumed to edit with C5>C6>C7>others preference within its activity window. The white fractions denote the proportion of pathogenic T→C mutations that can be edited BE3 without comparable editing of other Cs (left), or that can be edited BE3 or YEE-BE3 without comparable editing of other Cs (right).

FIGS. 95A to 95B show the effect of truncated guide RNAs on base editing window width. HEK293T cells were transfected with plasmids expressing BE3 and sgRNAs of different 5′ truncation lengths. The treated cells were analyzed as described in the Examples. FIG. 95A shows protospacer and PAM sequence (top, SEQ ID NO: 5792) and cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with Ts at the target positions indicated, at a site within the EMX1 genomic locus. At this site, the base editing window was altered through the use of a 17-nt truncated gRNA. FIG. 95B shows protospacer and PAM sequences (top, SEQ ID NOs: 5794 and 5795 from left to right, respectively) and cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with Ts at the target positions indicated, at sites within the HEK site 3 and site 4 genomic loci. At these sites, no change in the base editing window was observed, but a linear decrease in editing efficiency for all substrate bases as the sgRNA is truncated was noted.

FIG. 96 shows the effect of APOBEC1-Cas9 linker lengths on base editing window width. HEK293T cells were transfected with plasmids expressing base editors with rAPOBEC1-Cas9 linkers of XTEN, GGS, (GGS)₃ (SEQ ID NO: 596), (GGS)₅ (SEQ ID NO: 4271), or (GGS)₇ (SEQ ID NO: 597) and an sgRNA. The treated cells were analyzed as described in the Examples. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with Ts at the target positions indicated, are shown for the various base editors with different linkers. The sequence corresponds to SEQ ID NO: 5792.

FIGS. 97A to 97C show the effect of rAPOBEC mutations on base editing window width. FIG. 97C shows HEK293T cells transfected with plasmids expressing an sgRNA targeting either Site A or Site B and the BE3 point mutants indicated. The treated cells were analyzed as described in the Examples. All C′s in the protospacer and within three basepairs of the protospacer are displayed and the cellular C to T conversion percentages are shown. The ‘editing window widths’, defined as the calculated number of nucleotides within which editing efficiency exceeds the half-maximal value, are displayed for all tested mutants. The sequences in FIG. 97C correspond to SEQ ID NOs: 5792 and 5793 from left to right, respectively.

FIG. 98 shows the effect of APOBEC1 mutation son product distributions of base editing in mammalian cells. HEK293T cells were transfected with plasmids expressing BE3 or its mutants and an appropriate sgRNAs. The treated cells were analyzed as described in the Examples. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with Ts at the target positions indicated, are shown (left). Percent of total sequencing reads containing the C to T conversion is shown on the right. The BE3 point mutants do not significantly affect base editing efficiencies at HEK site 4, a site with only one target cytidine. The sequence corresponds to SEQ ID NO: 297.

FIG. 99 shows a comparison of on-target editing plasma delivery in BE3 and HF-BE3.

FIG. 100 shows a comparison of on-target editing in protein and plasma delivery of BE3.

FIG. 101 shows a comparison of on-target editing in protein and plasma delivery of HF-BE3.

FIG. 102 shows that both lipofection and installing HF mutations decrease off-target deamination events. The diamond indicates no off targets were detected and the specificity ratio was set to 100.

FIG. 103 shows in vitro C to T editing on a synthetic substrate with Cs placed at even positions in the protospacer (NNNNTC₂TC₄TC₆TC₈TC₁₀TC₁₂TC₁₄TC₁₆TC₁₈TC₂₀NGG, SEQ ID NO: 4272).

FIG. 104 shows in vitro C to T editing on a synthetic substrate with Cs placed at odd positions in the protospacer (NNNNTC₂TC₄TC₆TC₈TC₁₀TC₁₂TC₁₄TC₁₆TC₁₈TC₂₀NGG, SEQ ID NO: 4272).

FIG. 105 includes two graphs depicting the specificity ratio of base editing with plasmid vs. protein delivery.

FIGS. 106A to 106B shows BE3 activity on non-NGG PAM sites. HEK293T cells were transfected with plasmids expressing BE3 and appropriate sgRNA. The treated cells were analyzed as described in the Examples. FIG. 106A shows BE3 activity on sites can be efficiently targeted by SaBE3 or SaKKH-BE3. BE3 shows low but significant activity on the NAG PAM. The sequences correspond to SEQ ID NOs: 5796 and 5797 from left to right, respectively. FIG. 106B shows BE3 has significantly reduced editing at sites with NGA or NGCG PAMs, in contrast to VQR-BE3 or VRER-BE3. The sequences correspond to SEQ ID NOs: 5798 and 5799 from left to right, respectively.

FIGS. 107A to 107B show the effect of APOBEC1 mutations on VQR-BE3 and SaKKH-BE3. HEK293T cells were transfected with plasmids expressing VQR-BE3, SaKKH-BE3 or its mutants and an appropriate sgRNAs. The treated cells were analyzed as described in the Methods. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with Ts at the target positions indicated, are shown. FIG. 107A shows that the window-modulating mutations can be applied to VQR-BE3 to enable selective base editing at sites targetable by NGA PAM. The sequences correspond to SEQ ID NOs: 5800 and 5798 from left to right, respectively. FIG. 107B shows that, when applied to SaKKH-BE3, the mutations cause overall decrease in base editing efficiency without conferring base selectivity within the target window. The sequences correspond to SEQ ID NOs: 5796 and 5801 from left to right, respectively.

FIG. 108 shows a schematic representation of nucleotide editing. The following abbreviations are used: (MMR)—mismatch repair, (BE3 Nickase)—refers to base editor 3, which comprises a Cas9 nickase domain, (UGI)—uracil glycosylase inhibitor, UDG)—uracil DNA glycosylase, (APOBEC)—refers to an APOBEC cytidine deaminase.

DEFINITIONS

As used herein and in the claims, the singular forms “a,” “an,” and “the” include the singular and the plural reference unless the context clearly indicates otherwise. Thus, for example, a reference to “an agent” includes a single agent and a plurality of such agents.

The term “Cas9” or “Cas9 nuclease” refers to an RNA-guided nuclease comprising a Cas9 protein, or a fragment thereof (e.g., a protein comprising an active, inactive, or partially active DNA cleavage domain of Cas9, and/or the gRNA binding domain of Cas9). A Cas9 nuclease is also referred to sometimes as a casn1 nuclease or a CRISPR (clustered regularly interspaced short palindromic repeat)-associated nuclease. CRISPR is an adaptive immune system that provides protection against mobile genetic elements (viruses, transposable elements and conjugative plasmids). CRISPR clusters contain spacers, sequences complementary to antecedent mobile elements, and target invading nucleic acids. CRISPR clusters are transcribed and processed into CRISPR RNA (crRNA). In type II CRISPR systems correct processing of pre-crRNA requires a trans-encoded small RNA (tracrRNA), endogenous ribonuclease 3 (rnc) and a Cas9 protein. The tracrRNA serves as a guide for ribonuclease 3-aided processing of pre-crRNA. Subsequently, Cas9/crRNA/tracrRNA endonucleolytically cleaves linear or circular dsDNA target complementary to the spacer. The target strand not complementary to crRNA is first cut endonucleolytically, then trimmed 3′-5′ exonucleolytically. In nature, DNA-binding and cleavage typically requires protein and both RNAs. However, single guide RNAs (“sgRNA”, or simply “gNRA”) can be engineered so as to incorporate aspects of both the crRNA and tracrRNA into a single RNA species. See, e.g., Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J. A., Charpentier E. Science 337:816-821(2012), the entire contents of which is hereby incorporated by reference. Cas9 recognizes a short motif in the CRISPR repeat sequences (the PAM or protospacer adjacent motif) to help distinguish self versus non-self. Cas9 nuclease sequences and structures are well known to those of skill in the art (see, e.g., “Complete genome sequence of an M1 strain of Streptococcus pyogenes.” Ferretti et al., J. J., McShan W. M., Ajdic D. J., Savic D. J., Savic G., Lyon K., Primeaux C., Sezate S., Suvorov A. N., Kenton S., Lai H. S., Lin S. P., Qian Y., Jia H. G., Najar F. Z., Ren Q., Zhu H., Song L., White J., Yuan X., Clifton S. W., Roe B. A., McLaughlin R. E., Proc. Natl. Acad. Sci. U.S.A. 98:4658-4663(2001); “CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III.” Deltcheva E., Chylinski K., Sharma C. M., Gonzales K., Chao Y., Pirzada Z. A., Eckert M. R., Vogel J., Charpentier E., Nature 471:602-607(2011); and “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.” Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J. A., Charpentier E. Science 337:816-821(2012), the entire contents of each of which are incorporated herein by reference). Cas9 orthologs have been described in various species, including, but not limited to, S. pyogenes and S. thermophilus. Additional suitable Cas9 nucleases and sequences will be apparent to those of skill in the art based on this disclosure, and such Cas9 nucleases and sequences include Cas9 sequences from the organisms and loci disclosed in Chylinski, Rhun, and Charpentier, “The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems” (2013) RNA Biology 10:5, 726-737; the entire contents of which are incorporated herein by reference. In some embodiments, a Cas9 nuclease has an inactive (e.g., an inactivated) DNA cleavage domain, that is, the Cas9 is a nickase.

A nuclease-inactivated Cas9 protein may interchangeably be referred to as a “dCas9” protein (for nuclease-“dead” Cas9). Methods for generating a Cas9 protein (or a fragment thereof) having an inactive DNA cleavage domain are known (See, e.g., Jinek et al., Science. 337:816-821(2012); Qi et al., “Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression” (2013) Cell. 28; 152(5):1173-83, the entire contents of each of which are incorporated herein by reference). For example, the DNA cleavage domain of Cas9 is known to include two subdomains, the HNH nuclease subdomain and the RuvC1 subdomain. The HNH subdomain cleaves the strand complementary to the gRNA, whereas the RuvC1 subdomain cleaves the non-complementary strand. Mutations within these subdomains can silence the nuclease activity of Cas9. For example, the mutations D10A and H840A completely inactivate the nuclease activity of S. pyogenes Cas9 (Jinek et al., Science. 337:816-821(2012); Qi et al., Cell. 28; 152(5):1173-83 (2013)). In some embodiments, proteins comprising fragments of Cas9 are provided. For example, in some embodiments, a protein comprises one of two Cas9 domains: (1) the gRNA binding domain of Cas9; or (2) the DNA cleavage domain of Cas9. In some embodiments, proteins comprising Cas9 or fragments thereof are referred to as “Cas9 variants.” A Cas9 variant shares homology to Cas9, or a fragment thereof. For example a Cas9 variant is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to wild type Cas9. In some embodiments, the Cas9 variant may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more amino acid changes compared to wild type Cas9. In some embodiments, the Cas9 variant comprises a fragment of Cas9 (e.g., a gRNA binding domain or a DNA-cleavage domain), such that the fragment is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to the corresponding fragment of wild type Cas9. In some embodiments, the fragment is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% identical, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% of the amino acid length of a corresponding wild type Cas9.

In some embodiments, the fragment is at least 100 amino acids in length. In some embodiments, the fragment is at least 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, or at least 1300 amino acids in length. In some embodiments, wild type Cas9 corresponds to Cas9 from Streptococcus pyogenes (NCBI Reference Sequence: NC_017053.1, SEQ ID NO:1 (nucleotide); SEQ ID NO:2 (amino acid)).

(SEQ ID NO: 1) ATGGATAAGAAATACTCAATAGGCTTAGATATCGGCACAAATAGCGTCGG ATGGGCGGTGATCACTGATGATTATAAGGTTCCGTCTAAAAAGTTCAAGG TTCTGGGAAATACAGACCGCCACAGTATCAAAAAAAATCTTATAGGGGCT CTTTTATTTGGCAGTGGAGAGACAGCGGAAGCGACTCGTCTCAAACGGAC AGCTCGTAGAAGGTATACACGTCGGAAGAATCGTATTTGTTATCTACAGG AGATTTTTTCAAATGAGATGGCGAAAGTAGATGATAGTTTCTTTCATCGA CTTGAAGAGTCTTTTTTGGTGGAAGAAGACAAGAAGCATGAACGTCATCC TATTTTTGGAAATATAGTAGATGAAGTTGCTTATCATGAGAAATATCCAA CTATCTATCATCTGCGAAAAAAATTGGCAGATTCTACTGATAAAGCGGAT TTGCGCTTAATCTATTTGGCCTTAGCGCATATGATTAAGTTTCGTGGTCA TTTTTTGATTGAGGGAGATTTAAATCCTGATAATAGTGATGTGGACAAAC TATTTATCCAGTTGGTACAAATCTACAATCAATTATTTGAAGAAAACCCT ATTAACGCAAGTAGAGTAGATGCTAAAGCGATTCTTTCTGCACGATTGAG TAAATCAAGACGATTAGAAAATCTCATTGCTCAGCTCCCCGGTGAGAAGA GAAATGGCTTGTTTGGGAATCTCATTGCTTTGTCATTGGGATTGACCCCT AATTTTAAATCAAATTTTGATTTGGCAGAAGATGCTAAATTACAGCTTTC AAAAGATACTTACGATGATGATTTAGATAATTTATTGGCGCAAATTGGAG ATCAATATGCTGATTTGTTTTTGGCAGCTAAGAATTTATCAGATGCTATT TTACTTTCAGATATCCTAAGAGTAAATAGTGAAATAACTAAGGCTCCCCT ATCAGCTTCAATGATTAAGCGCTACGATGAACATCATCAAGACTTGACTC TTTTAAAAGCTTTAGTTCGACAACAACTTCCAGAAAAGTATAAAGAAATC TTTTTTGATCAATCAAAAAACGGATATGCAGGTTATATTGATGGGGGAGC TAGCCAAGAAGAATTTTATAAATTTATCAAACCAATTTTAGAAAAAATGG ATGGTACTGAGGAATTATTGGTGAAACTAAATCGTGAAGATTTGCTGCGC AAGCAACGGACCTTTGACAACGGCTCTATTCCCCATCAAATTCACTTGGG TGAGCTGCATGCTATTTTGAGAAGACAAGAAGACTTTTATCCATTTTTAA AAGACAATCGTGAGAAGATTGAAAAAATCTTGACTTTTCGAATTCCTTAT TATGTTGGTCCATTGGCGCGTGGCAATAGTCGTTTTGCATGGATGACTCG GAAGTCTGAAGAAACAATTACCCCATGGAATTTTGAAGAAGTTGTCGATA AAGGTGCTTCAGCTCAATCATTTATTGAACGCATGACAAACTTTGATAAA AATCTTCCAAATGAAAAAGTACTACCAAAACATAGTTTGCTTTATGAGTA TTTTACGGTTTATAACGAATTGACAAAGGTCAAATATGTTACTGAGGGAA TGCGAAAACCAGCATTTCTTTCAGGTGAACAGAAGAAAGCCATTGTTGAT TTACTCTTCAAAACAAATCGAAAAGTAACCGTTAAGCAATTAAAAGAAGA TTATTTCAAAAAAATAGAATGTTTTGATAGTGTTGAAATTTCAGGAGTTG AAGATAGATTTAATGCTTCATTAGGCGCCTACCATGATTTGCTAAAAATT ATTAAAGATAAAGATTTTTTGGATAATGAAGAAAATGAAGATATCTTAGA GGATATTGTTTTAACATTGACCTTATTTGAAGATAGGGGGATGATTGAGG AAAGACTTAAAACATATGCTCACCTCTTTGATGATAAGGTGATGAAACAG CTTAAACGTCGCCGTTATACTGGTTGGGGACGTTTGTCTCGAAAATTGAT TAATGGTATTAGGGATAAGCAATCTGGCAAAACAATATTAGATTTTTTGA AATCAGATGGTTTTGCCAATCGCAATTTTATGCAGCTGATCCATGATGAT AGTTTGACATTTAAAGAAGATATTCAAAAAGCACAGGTGTCTGGACAAGG CCATAGTTTACATGAACAGATTGCTAACTTAGCTGGCAGTCCTGCTATTA AAAAAGGTATTTTACAGACTGTAAAAATTGTTGATGAACTGGTCAAAGTA ATGGGGCATAAGCCAGAAAATATCGTTATTGAAATGGCACGTGAAAATCA GACAACTCAAAAGGGCCAGAAAAATTCGCGAGAGCGTATGAAACGAATCG AAGAAGGTATCAAAGAATTAGGAAGTCAGATTCTTAAAGAGCATCCTGTT GAAAATACTCAATTGCAAAATGAAAAGCTCTATCTCTATTATCTACAAAA TGGAAGAGACATGTATGTGGACCAAGAATTAGATATTAATCGTTTAAGTG ATTATGATGTCGATCACATTGTTCCACAAAGTTTCATTAAAGACGATTCA ATAGACAATAAGGTACTAACGCGTTCTGATAAAAATCGTGGTAAATCGGA TAACGTTCCAAGTGAAGAAGTAGTCAAAAAGATGAAAAACTATTGGAGAC AACTTCTAAACGCCAAGTTAATCACTCAACGTAAGTTTGATAATTTAACG AAAGCTGAACGTGGAGGTTTGAGTGAACTTGATAAAGCTGGTTTTATCAA ACGCCAATTGGTTGAAACTCGCCAAATCACTAAGCATGTGGCACAAATTT TGGATAGTCGCATGAATACTAAATACGATGAAAATGATAAACTTATTCGA GAGGTTAAAGTGATTACCTTAAAATCTAAATTAGTTTCTGACTTCCGAAA AGATTTCCAATTCTATAAAGTACGTGAGATTAACAATTACCATCATGCCC ATGATGCGTATCTAAATGCCGTCGTTGGAACTGCTTTGATTAAGAAATAT CCAAAACTTGAATCGGAGTTTGTCTATGGTGATTATAAAGTTTATGATGT TCGTAAAATGATTGCTAAGTCTGAGCAAGAAATAGGCAAAGCAACCGCAA AATATTTCTTTTACTCTAATATCATGAACTTCTTCAAAACAGAAATTACA CTTGCAAATGGAGAGATTCGCAAACGCCCTCTAATCGAAACTAATGGGGA AACTGGAGAAATTGTCTGGGATAAAGGGCGAGATTTTGCCACAGTGCGCA AAGTATTGTCCATGCCCCAAGTCAATATTGTCAAGAAAACAGAAGTACAG ACAGGCGGATTCTCCAAGGAGTCAATTTTACCAAAAAGAAATTCGGACAA GCTTATTGCTCGTAAAAAAGACTGGGATCCAAAAAAATATGGTGGTTTTG ATAGTCCAACGGTAGCTTATTCAGTCCTAGTGGTTGCTAAGGTGGAAAAA GGGAAATCGAAGAAGTTAAAATCCGTTAAAGAGTTACTAGGGATCACAAT TATGGAAAGAAGTTCCTTTGAAAAAAATCCGATTGACTTTTTAGAAGCTA AAGGATATAAGGAAGTTAAAAAAGACTTAATCATTAAACTACCTAAATAT AGTCTTTTTGAGTTAGAAAACGGTCGTAAACGGATGCTGGCTAGTGCCGG AGAATTACAAAAAGGAAATGAGCTGGCTCTGCCAAGCAAATATGTGAATT TTTTATATTTAGCTAGTCATTATGAAAAGTTGAAGGGTAGTCCAGAAGAT AACGAACAAAAACAATTGTTTGTGGAGCAGCATAAGCATTATTTAGATGA GATTATTGAGCAAATCAGTGAATTTTCTAAGCGTGTTATTTTAGCAGATG CCAATTTAGATAAAGTTCTTAGTGCATATAACAAACATAGAGACAAACCA ATACGTGAACAAGCAGAAAATATTATTCATTTATTTACGTTGACGAATCT TGGAGCTCCCGCTGCTTTTAAATATTTTGATACAACAATTGATCGTAAAC GATATACGTCTACAAAAGAAGTTTTAGATGCCACTCTTATCCATCAATCC ATCACTGGTCTTTATGAAACACGCATTGATTTGAGTCAGCTAGGAGGTGA CTGA  (SEQ ID NO: 2) MDKKYSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIG ALLFGSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSF FHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLAD STDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQI YNQLFEENPINASRVDAKAILSARLSKSRRLENLIAQLPGEKRNGLF GNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQ YADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDL TLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPI LEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQ EDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETI TPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTV YNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKED YFKKIECFDSVEISGVEDRFNASLGAYHDLLKIIKDKDFLDNEENE DILEDIVLTLTLFEDRGMIEERLKTYAHLFDDKVMKQLKRRRYTGW GRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFK EDIQKAQVSGQGHSLHEQIANLAGSPAIKKGILQTVKIVDELVKVM GHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKE HPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQ SFIKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAK LITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILD SRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYH HAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQE IGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVW DKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLI ARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGI TIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKR MLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLF VEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIRE QAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQ SITGLYETRIDLSQLGGD (single underline: HNH domain; double underline: RuvC domain)

In some embodiments, wild type Cas9 corresponds to, or comprises SEQ ID NO:3 (nucleotide) and/or SEQ ID NO: 4 (amino acid):

(SEQ ID NO: 3) ATGGATAAAAAGTATTCTATTGGTTTAGACATCGGCACTAATTCCGTTG GATGGGCTGTCATAACCGATGAATACAAAGTACCTTCAAAGAAATTTAA GGTGTTGGGGAACACAGACCGTCATTCGATTAAAAAGAATCTTATCGGT GCCCTCCTATTCGATAGTGGCGAAACGGCAGAGGCGACTCGCCTGAAAC GAACCGCTCGGAGAAGGTATACACGTCGCAAGAACCGAATATGTTACTT ACAAGAAATTTTTAGCAATGAGATGGCCAAAGTTGACGATTCTTTCTTT CACCGTTTGGAAGAGTCCTTCCTTGTCGAAGAGGACAAGAAACATGAAC GGCACCCCATCTTTGGAAACATAGTAGATGAGGTGGCATATCATGAAAA GTACCCAACGATTTATCACCTCAGAAAAAAGCTAGTTGACTCAACTGAT AAAGCGGACCTGAGGTTAATCTACTTGGCTCTTGCCCATATGATAAAGT TCCGTGGGCACTTTCTCATTGAGGGTGATCTAAATCCGGACAACTCGGA TGTCGACAAACTGTTCATCCAGTTAGTACAAACCTATAATCAGTTGTTT GAAGAGAACCCTATAAATGCAAGTGGCGTGGATGCGAAGGCTATTCTTA GCGCCCGCCTCTCTAAATCCCGACGGCTAGAAAACCTGATCGCACAATT ACCCGGAGAGAAGAAAAATGGGTTGTTCGGTAACCTTATAGCGCTCTCA CTAGGCCTGACACCAAATTTTAAGTCGAACTTCGACTTAGCTGAAGATG CCAAATTGCAGCTTAGTAAGGACACGTACGATGACGATCTCGACAATCT ACTGGCACAAATTGGAGATCAGTATGCGGACTTATTTTTGGCTGCCAAA AACCTTAGCGATGCAATCCTCCTATCTGACATACTGAGAGTTAATACTG AGATTACCAAGGCGCCGTTATCCGCTTCAATGATCAAAAGGTACGATGA ACATCACCAAGACTTGACACTTCTCAAGGCCCTAGTCCGTCAGCAACTG CCTGAGAAATATAAGGAAATATTCTTTGATCAGTCGAAAAACGGGTACG CAGGTTATATTGACGGCGGAGCGAGTCAAGAGGAATTCTACAAGTTTAT CAAACCCATATTAGAGAAGATGGATGGGACGGAAGAGTTGCTTGTAAAA CTCAATCGCGAAGATCTACTGCGAAAGCAGCGGACTTTCGACAACGGTA GCATTCCACATCAAATCCACTTAGGCGAATTGCATGCTATACTTAGAAG GCAGGAGGATTTTTATCCGTTCCTCAAAGACAATCGTGAAAAGATTGAG AAAATCCTAACCTTTCGCATACCTTACTATGTGGGACCCCTGGCCCGAG GGAACTCTCGGTTCGCATGGATGACAAGAAAGTCCGAAGAAACGATTAC TCCATGGAATTTTGAGGAAGTTGTCGATAAAGGTGCGTCAGCTCAATCG TTCATCGAGAGGATGACCAACTTTGACAAGAATTTACCGAACGAAAAAG TATTGCCTAAGCACAGTTTACTTTACGAGTATTTCACAGTGTACAATGA ACTCACGAAAGTTAAGTATGTCACTGAGGGCATGCGTAAACCCGCCTTT CTAAGCGGAGAACAGAAGAAAGCAATAGTAGATCTGTTATTCAAGACCA ACCGCAAAGTGACAGTTAAGCAATTGAAAGAGGACTACTTTAAGAAAAT TGAATGCTTCGATTCTGTCGAGATCTCCGGGGTAGAAGATCGATTTAAT GCGTCACTTGGTACGTATCATGACCTCCTAAAGATAATTAAAGATAAGG ACTTCCTGGATAACGAAGAGAATGAAGATATCTTAGAAGATATAGTGTT GACTCTTACCCTCTTTGAAGATCGGGAAATGATTGAGGAAAGACTAAAA ACATACGCTCACCTGTTCGACGATAAGGTTATGAAACAGTTAAAGAGGC GTCGCTATACGGGCTGGGGACGATTGTCGCGGAAACTTATCAACGGGAT AAGAGACAAGCAAAGTGGTAAAACTATTCTCGATTTTCTAAAGAGCGAC GGCTTCGCCAATAGGAACTTTATGCAGCTGATCCATGATGACTCTTTAA CCTTCAAAGAGGATATACAAAAGGCACAGGTTTCCGGACAAGGGGACTC ATTGCACGAACATATTGCGAATCTTGCTGGTTCGCCAGCCATCAAAAAG GGCATACTCCAGACAGTCAAAGTAGTGGATGAGCTAGTTAAGGTCATGG GACGTCACAAACCGGAAAACATTGTAATCGAGATGGCACGCGAAAATCA AACGACTCAGAAGGGGCAAAAAAACAGTCGAGAGCGGATGAAGAGAATA GAAGAGGGTATTAAAGAACTGGGCAGCCAGATCTTAAAGGAGCATCCTG TGGAAAATACCCAATTGCAGAACGAGAAACTTTACCTCTATTACCTACA AAATGGAAGGGACATGTATGTTGATCAGGAACTGGACATAAACCGTTTA TCTGATTACGACGTCGATCACATTGTACCCCAATCCTTTTTGAAGGACG ATTCAATCGACAATAAAGTGCTTACACGCTCGGATAAGAACCGAGGGAA AAGTGACAATGTTCCAAGCGAGGAAGTCGTAAAGAAAATGAAGAACTAT TGGCGGCAGCTCCTAAATGCGAAACTGATAACGCAAAGAAAGTTCGATA ACTTAACTAAAGCTGAGAGGGGTGGCTTGTCTGAACTTGACAAGGCCGG ATTTATTAAACGTCAGCTCGTGGAAACCCGCCAAATCACAAAGCATGTT GCACAGATACTAGATTCCCGAATGAATACGAAATACGACGAGAACGATA AGCTGATTCGGGAAGTCAAAGTAATCACTTTAAAGTCAAAATTGGTGTC GGACTTCAGAAAGGATTTTCAATTCTATAAAGTTAGGGAGATAAATAAC TACCACCATGCGCACGACGCTTATCTTAATGCCGTCGTAGGGACCGCAC TCATTAAGAAATACCCGAAGCTAGAAAGTGAGTTTGTGTATGGTGATTA CAAAGTTTATGACGTCCGTAAGATGATCGCGAAAAGCGAACAGGAGATA GGCAAGGCTACAGCCAAATACTTCTTTTATTCTAACATTATGAATTTCT TTAAGACGGAAATCACTCTGGCAAACGGAGAGATACGCAAACGACCTTT AATTGAAACCAATGGGGAGACAGGTGAAATCGTATGGGATAAGGGCCGG GACTTCGCGACGGTGAGAAAAGTTTTGTCCATGCCCCAAGTCAACATAG TAAAGAAAACTGAGGTGCAGACCGGAGGGTTTTCAAAGGAATCGATTCT TCCAAAAAGGAATAGTGATAAGCTCATCGCTCGTAAAAAGGACTGGGAC CCGAAAAAGTACGGTGGCTTCGATAGCCCTACAGTTGCCTATTCTGTCC TAGTAGTGGCAAAAGTTGAGAAGGGAAAATCCAAGAAACTGAAGTCAGT CAAAGAATTATTGGGGATAACGATTATGGAGCGCTCGTCTTTTGAAAAG AACCCCATCGACTTCCTTGAGGCGAAAGGTTACAAGGAAGTAAAAAAGG ATCTCATAATTAAACTACCAAAGTATAGTCTGTTTGAGTTAGAAAATGG CCGAAAACGGATGTTGGCTAGCGCCGGAGAGCTTCAAAAGGGGAACGAA CTCGCACTACCGTCTAAATACGTGAATTTCCTGTATTTAGCGTCCCATT ACGAGAAGTTGAAAGGTTCACCTGAAGATAACGAACAGAAGCAACTTTT TGTTGAGCAGCACAAACATTATCTCGACGAAATCATAGAGCAAATTTCG GAATTCAGTAAGAGAGTCATCCTAGCTGATGCCAATCTGGACAAAGTAT TAAGCGCATACAACAAGCACAGGGATAAACCCATACGTGAGCAGGCGGA AAATATTATCCATTTGTTTACTCTTACCAACCTCGGCGCTCCAGCCGCA TTCAAGTATTTTGACACAACGATAGATCGCAAACGATACACTTCTACCA AGGAGGTGCTAGACGCGACACTGATTCACCAATCCATCACGGGATTATA TGAAACTCGGATAGATTTGTCACAGCTTGGGGGTGACGGATCCCCCAAG AAGAAGAGGAAAGTCTCGAGCGACTACAAAGACCATGACGGTGATTATA AAGATCATGACATCGATTACAAGGATGACGATGACAAGGCTGCAGGA (SEQ ID NO: 4) MDKKY SIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIG ALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFF HRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTD KADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLF EENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALS LGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAK NLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQL PEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVK LNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIE KILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQS FIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAF LSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFN ASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSD GFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKK GILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRI EEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRL SDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNY WRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHV AQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINN YHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEI GKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGR DFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWD PKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEK NPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNE LALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQIS EFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAA FKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD (single underline: HNH domain; double underline: RuvC domain)

In some embodiments, wild type Cas9 corresponds to Cas9 from Streptococcus pyogenes (NCBI Reference Sequence: NC_002737.2, SEQ ID NO: 8 (nucleotide); and Uniport Reference Sequence: Q99ZW2, SEQ ID NO: 10 (amino acid).

(SEQ ID NO: 8) ATGGATAAGAAATACTCAATAGGCTTAGATATCGGCACAAATAGCGTCGG ATGGGCGGTGATCACTGATGAATATAAGGTTCCGTCTAAAAAGTTCAAGG TTCTGGGAAATACAGACCGCCACAGTATCAAAAAAAATCTTATAGGGGCT CTTTTATTTGACAGTGGAGAGACAGCGGAAGCGACTCGTCTCAAACGGAC AGCTCGTAGAAGGTATACACGTCGGAAGAATCGTATTTGTTATCTACAGG AGATTTTTTCAAATGAGATGGCGAAAGTAGATGATAGTTTCTTTCATCGA CTTGAAGAGTCTTTTTTGGTGGAAGAAGACAAGAAGCATGAACGTCATCC TATTTTTGGAAATATAGTAGATGAAGTTGCTTATCATGAGAAATATCCAA CTATCTATCATCTGCGAAAAAAATTGGTAGATTCTACTGATAAAGCGGAT TTGCGCTTAATCTATTTGGCCTTAGCGCATATGATTAAGTTTCGTGGTCA TTTTTTGATTGAGGGAGATTTAAATCCTGATAATAGTGATGTGGACAAAC TATTTATCCAGTTGGTACAAACCTACAATCAATTATTTGAAGAAAACCCT ATTAACGCAAGTGGAGTAGATGCTAAAGCGATTCTTTCTGCACGATTGAG TAAATCAAGACGATTAGAAAATCTCATTGCTCAGCTCCCCGGTGAGAAGA AAAATGGCTTATTTGGGAATCTCATTGCTTTGTCATTGGGTTTGACCCCT AATTTTAAATCAAATTTTGATTTGGCAGAAGATGCTAAATTACAGCTTTC AAAAGATACTTACGATGATGATTTAGATAATTTATTGGCGCAAATTGGAG ATCAATATGCTGATTTGTTTTTGGCAGCTAAGAATTTATCAGATGCTATT TTACTTTCAGATATCCTAAGAGTAAATACTGAAATAACTAAGGCTCCCCT ATCAGCTTCAATGATTAAACGCTACGATGAACATCATCAAGACTTGACTC TTTTAAAAGCTTTAGTTCGACAACAACTTCCAGAAAAGTATAAAGAAATC TTTTTTGATCAATCAAAAAACGGATATGCAGGTTATATTGATGGGGGAGC TAGCCAAGAAGAATTTTATAAATTTATCAAACCAATTTTAGAAAAAATGG ATGGTACTGAGGAATTATTGGTGAAACTAAATCGTGAAGATTTGCTGCGC AAGCAACGGACCTTTGACAACGGCTCTATTCCCCATCAAATTCACTTGGG TGAGCTGCATGCTATTTTGAGAAGACAAGAAGACTTTTATCCATTTTTAA AAGACAATCGTGAGAAGATTGAAAAAATCTTGACTTTTCGAATTCCTTAT TATGTTGGTCCATTGGCGCGTGGCAATAGTCGTTTTGCATGGATGACTCG GAAGTCTGAAGAAACAATTACCCCATGGAATTTTGAAGAAGTTGTCGATA AAGGTGCTTCAGCTCAATCATTTATTGAACGCATGACAAACTTTGATAAA AATCTTCCAAATGAAAAAGTACTACCAAAACATAGTTTGCTTTATGAGTA TTTTACGGTTTATAACGAATTGACAAAGGTCAAATATGTTACTGAAGGAA TGCGAAAACCAGCATTTCTTTCAGGTGAACAGAAGAAAGCCATTGTTGAT TTACTCTTCAAAACAAATCGAAAAGTAACCGTTAAGCAATTAAAAGAAGA TTATTTCAAAAAAATAGAATGTTTTGATAGTGTTGAAATTTCAGGAGTTG AAGATAGATTTAATGCTTCATTAGGTACCTACCATGATTTGCTAAAAATT ATTAAAGATAAAGATTTTTTGGATAATGAAGAAAATGAAGATATCTTAGA GGATATTGTTTTAACATTGACCTTATTTGAAGATAGGGAGATGATTGAGG AAAGACTTAAAACATATGCTCACCTCTTTGATGATAAGGTGATGAAACAG CTTAAACGTCGCCGTTATACTGGTTGGGGACGTTTGTCTCGAAAATTGAT TAATGGTATTAGGGATAAGCAATCTGGCAAAACAATATTAGATTTTTTGA AATCAGATGGTTTTGCCAATCGCAATTTTATGCAGCTGATCCATGATGAT AGTTTGACATTTAAAGAAGACATTCAAAAAGCACAAGTGTCTGGACAAGG CGATAGTTTACATGAACATATTGCAAATTTAGCTGGTAGCCCTGCTATTA AAAAAGGTATTTTACAGACTGTAAAAGTTGTTGATGAATTGGTCAAAGTA ATGGGGCGGCATAAGCCAGAAAATATCGTTATTGAAATGGCACGTGAAAA TCAGACAACTCAAAAGGGCCAGAAAAATTCGCGAGAGCGTATGAAACGAA TCGAAGAAGGTATCAAAGAATTAGGAAGTCAGATTCTTAAAGAGCATCCT GTTGAAAATACTCAATTGCAAAATGAAAAGCTCTATCTCTATTATCTCCA AAATGGAAGAGACATGTATGTGGACCAAGAATTAGATATTAATCGTTTAA GTGATTATGATGTCGATCACATTGTTCCACAAAGTTTCCTTAAAGACGAT TCAATAGACAATAAGGTCTTAACGCGTTCTGATAAAAATCGTGGTAAATC GGATAACGTTCCAAGTGAAGAAGTAGTCAAAAAGATGAAAAACTATTGGA GACAACTTCTAAACGCCAAGTTAATCACTCAACGTAAGTTTGATAATTTA ACGAAAGCTGAACGTGGAGGTTTGAGTGAACTTGATAAAGCTGGTTTTAT CAAACGCCAATTGGTTGAAACTCGCCAAATCACTAAGCATGTGGCACAAA TTTTGGATAGTCGCATGAATACTAAATACGATGAAAATGATAAACTTATT CGAGAGGTTAAAGTGATTACCTTAAAATCTAAATTAGTTTCTGACTTCCG AAAAGATTTCCAATTCTATAAAGTACGTGAGATTAACAATTACCATCATG CCCATGATGCGTATCTAAATGCCGTCGTTGGAACTGCTTTGATTAAGAAA TATCCAAAACTTGAATCGGAGTTTGTCTATGGTGATTATAAAGTTTATGA TGTTCGTAAAATGATTGCTAAGTCTGAGCAAGAAATAGGCAAAGCAACCG CAAAATATTTCTTTTACTCTAATATCATGAACTTCTTCAAAACAGAAATT ACACTTGCAAATGGAGAGATTCGCAAACGCCCTCTAATCGAAACTAATGG GGAAACTGGAGAAATTGTCTGGGATAAAGGGCGAGATTTTGCCACAGTGC GCAAAGTATTGTCCATGCCCCAAGTCAATATTGTCAAGAAAACAGAAGTA CAGACAGGCGGATTCTCCAAGGAGTCAATTTTACCAAAAAGAAATTCGGA CAAGCTTATTGCTCGTAAAAAAGACTGGGATCCAAAAAAATATGGTGGTT TTGATAGTCCAACGGTAGCTTATTCAGTCCTAGTGGTTGCTAAGGTGGAA AAAGGGAAATCGAAGAAGTTAAAATCCGTTAAAGAGTTACTAGGGATCAC AATTATGGAAAGAAGTTCCTTTGAAAAAAATCCGATTGACTTTTTAGAAG CTAAAGGATATAAGGAAGTTAAAAAAGACTTAATCATTAAACTACCTAAA TATAGTCTTTTTGAGTTAGAAAACGGTCGTAAACGGATGCTGGCTAGTGC CGGAGAATTACAAAAAGGAAATGAGCTGGCTCTGCCAAGCAAATATGTGA ATTTTTTATATTTAGCTAGTCATTATGAAAAGTTGAAGGGTAGTCCAGAA GATAACGAACAAAAACAATTGTTTGTGGAGCAGCATAAGCATTATTTAGA TGAGATTATTGAGCAAATCAGTGAATTTTCTAAGCGTGTTATTTTAGCAG ATGCCAATTTAGATAAAGTTCTTAGTGCATATAACAAACATAGAGACAAA CCAATACGTGAACAAGCAGAAAATATTATTCATTTATTTACGTTGACGAA TCTTGGAGCTCCCGCTGCTTTTAAATATTTTGATACAACAATTGATCGTA AACGATATACGTCTACAAAAGAAGTTTTAGATGCCACTCTTATCCATCAA TCCATCACTGGTCTTTATGAAACACGCATTGATTTGAGTCAGCTAGGAGG TGACTGA  (SEQ ID NO: 10) MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGA LLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHR LEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKAD LRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENP INASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTP NFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAI LLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEI FFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLR KQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPY YVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDK NLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVD LLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKI IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQ LKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDD SLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKV MGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHP VENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDD SIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNL TKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLI REVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKK YPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEI TLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEV QTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVE KGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPK YSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPE DNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDK PIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQ SITGLYETRIDLSQLGGD 10) (single underline: HNH domain; double underline: RuvC domain)

In some embodiments, Cas9 refers to Cas9 from: Corynebacterium ulcerans (NCBI Refs: NC_015683.1, NC_017317.1); Corynebacterium diphtheria (NCBI Refs: NC_016782.1, NC_016786.1); Spiroplasma syrphidicola (NCBI Ref: NC_021284.1); Prevotella intermedia (NCBI Ref: NC_017861.1); Spiroplasma taiwanense (NCBI Ref: NC_021846.1); Streptococcus iniae (NCBI Ref: NC_021314.1); Belliella baltica (NCBI Ref: NC_018010.1); Psychroflexus torquisI (NCBI Ref: NC_018721.1); Streptococcus thermophilus (NCBI Ref: YP_820832.1), Listeria innocua (NCBI Ref: NP_472073.1), Campylobacter jejuni (NCBI Ref: YP_002344900.1) or Neisseria. meningitidis (NCBI Ref: YP_002342100.1) or to a Cas9 from any of the organisms listed in Example 5.

In some embodiments, dCas9 corresponds to, or comprises in part or in whole, a Cas9 amino acid sequence having one or more mutations that inactivate the Cas9 nuclease activity. For example, in some embodiments, a dCas9 domain comprises D10A and/or H840A mutation.

(SEQ ID NO: 9) dCas9 (D10A and H840A): MDKK YSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDS GET AEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKK HERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLI EGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQ LPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQ YADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQL PEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRK QRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSR FAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYF TVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIEC FDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEE RLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFAN

NTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKV

TVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLI IKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDN EQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIH LFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD (single underline: HNH domain; double underline: RuvC domain).

In some embodiments, the Cas9 domain comprises a D10A mutation, while the residue at position 840 remains a histidine in the amino acid sequence provided in SEQ ID NO: 10, or at corresponding positions in any of the amino acid sequences provided in SEQ ID NOs: 11-260. Without wishing to be bound by any particular theory, the presence of the catalytic residue H840 restores the acvitity of the Cas9 to cleave the non-edited (e.g., non-deaminated) strand containing a G opposite the targeted C. Restoration of H840 (e.g., from A840) does not result in the cleavage of the target strand containing the C. Such Cas9 variants are able to generate a single-strand DNA break (nick) at a specific location based on the gRNA-defined target sequence, leading to repair of the non-edited strand, ultimately resulting in a G to A change on the non-edited strand. A schematic representation of this process is shown in FIG. 108. Briefly, the C of a C-G basepair can be deaminated to a U by a deaminase, e.g., an APOBEC deamonase. Nicking the non-edited strand, having the G, facilitates removal of the G via mismatch repair mechanisms. UGI inhibits UDG, which prevents removal of the U.

In other embodiments, dCas9 variants having mutations other than D10A and H840A are provided, which, e.g., result in nuclease inactivated Cas9 (dCas9). Such mutations, by way of example, include other amino acid substitutions at D10 and H820, or other substitutions within the nuclease domains of Cas9 (e.g., substitutions in the HNH nuclease subdomain and/or the RuvC1 subdomain). In some embodiments, variants or homologues of dCas9 (e.g., variants of SEQ ID NO: 10) are provided which are at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to SEQ ID NO: 10. In some embodiments, variants of dCas9 (e.g., variants of SEQ ID NO: 10) are provided having amino acid sequences which are shorter, or longer than SEQ ID NO: 10, by about 5 amino acids, by about 10 amino acids, by about 15 amino acids, by about 20 amino acids, by about 25 amino acids, by about 30 amino acids, by about 40 amino acids, by about 50 amino acids, by about 75 amino acids, by about 100 amino acids or more.

In some embodiments, Cas9 fusion proteins as provided herein comprise the full-length amino acid sequence of a Cas9 protein, e.g., one of the Cas9 sequences provided herein. In other embodiments, however, fusion proteins as provided herein do not comprise a full-length Cas9 sequence, but only a fragment thereof. For example, in some embodiments, a Cas9 fusion protein provided herein comprises a Cas9 fragment, wherein the fragment binds crRNA and tracrRNA or sgRNA, but does not comprise a functional nuclease domain, e.g., in that it comprises only a truncated version of a nuclease domain or no nuclease domain at all. Exemplary amino acid sequences of suitable Cas9 domains and Cas9 fragments are provided herein, and additional suitable sequences of Cas9 domains and fragments will be apparent to those of skill in the art.

In some embodiments, Cas9 refers to Cas9 from: Corynebacterium ulcerans (NCBI Refs: NC_015683.1, NC_017317.1); Corynebacterium diphtheria (NCBI Refs: NC_016782.1, NC_016786.1); Spiroplasma syrphidicola (NCBI Ref: NC_021284.1); Prevotella intermedia (NCBI Ref: NC_017861.1); Spiroplasma taiwanense (NCBI Ref: NC_021846.1); Streptococcus iniae (NCBI Ref: NC_021314.1); Belliella baltica (NCBI Ref: NC_018010.1); Psychroflexus torquisI (NCBI Ref: NC_018721.1); Streptococcus thermophilus (NCBI Ref: YP_820832.1); Listeria innocua (NCBI Ref: NP_472073.1); Campylobacter jejuni (NCBI Ref: YP_002344900.1); or Neisseria. meningitidis (NCBI Ref: YP_002342100.1).

The term “deaminase” or “deaminase domain,” as used herein, refers to a protein or enzyme that catalyzes a deamination reaction. In some embodiments, the deaminase or deaminase domain is a cytidine deaminase, catalyzing the hydrolytic deamination of cytidine or deoxycytidine to uridine or deoxyuridine, respectively. In some embodiments, the deaminase or deaminase domain is a cytidine deaminase domain, catalyzing the hydrolytic deamination of cytosine to uracil. In some embodiments, the deaminase or deaminase domain is a naturally-occuring deaminase from an organism, such as a human, chimpanzee, gorilla, monkey, cow, dog, rat, or mouse. In some embodiments, the deaminase or deaminase domain is a variant of a naturally-occuring deaminase from an organism, that does not occur in nature. For example, in some embodiments, the deaminase or deaminase domain is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75% at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to a naturally-occuring deaminase from an organism.

The term “effective amount,” as used herein, refers to an amount of a biologically active agent that is sufficient to elicit a desired biological response. For example, in some embodiments, an effective amount of a nuclease may refer to the amount of the nuclease that is sufficient to induce cleavage of a target site specifically bound and cleaved by the nuclease. In some embodiments, an effective amount of a fusion protein provided herein, e.g., of a fusion protein comprising a nuclease-inactive Cas9 domain and a nucleic acid editing domain (e.g., a deaminase domain) may refer to the amount of the fusion protein that is sufficient to induce editing of a target site specifically bound and edited by the fusion protein. As will be appreciated by the skilled artisan, the effective amount of an agent, e.g., a fusion protein, a nuclease, a deaminase, a recombinase, a hybrid protein, a protein dimer, a complex of a protein (or protein dimer) and a polynucleotide, or a polynucleotide, may vary depending on various factors as, for example, on the desired biological response, e.g., on the specific allele, genome, or target site to be edited, on the cell or tissue being targeted, and on the agent being used.

The term “linker,” as used herein, refers to a chemical group or a molecule linking two molecules or moieties, e.g., two domains of a fusion protein, such as, for example, a nuclease-inactive Cas9 domain and a nucleic acid editing domain (e.g., a deaminase domain). In some embodiments, a linker joins a gRNA binding domain of an RNA-programmable nuclease, including a Cas9 nuclease domain, and the catalytic domain of anucleic-acid editing protein. In some embodiments, a linker joins a dCas9 and a nucleic-acid editing protein. Typically, the linker is positioned between, or flanked by, two groups, molecules, or other moieties and connected to each one via a covalent bond, thus connecting the two. In some embodiments, the linker is an amino acid or a plurality of amino acids (e.g., a peptide or protein). In some embodiments, the linker is an organic molecule, group, polymer, or chemical moiety. In some embodiments, the linker is 5-100 amino acids in length, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 30-35, 35-40, 40-45, 45-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-150, or 150-200 amino acids in length. Longer or shorter linkers are also contemplated.

The term “mutation,” as used herein, refers to a substitution of a residue within a sequence, e.g., a nucleic acid or amino acid sequence, with another residue, or a deletion or insertion of one or more residues within a sequence. Mutations are typically described herein by identifying the original residue followed by the position of the residue within the sequence and by the identity of the newly substituted residue. Various methods for making the amino acid substitutions (mutations) provided herein are well known in the art, and are provided by, for example, Green and Sambrook, Molecular Cloning: A Laboratory Manual (4^(th) ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2012)).

The terms “nucleic acid” and “nucleic acid molecule,” as used herein, refer to a compound comprising a nucleobase and an acidic moiety, e.g., a nucleoside, a nucleotide, or a polymer of nucleotides. Typically, polymeric nucleic acids, e.g., nucleic acid molecules comprising three or more nucleotides are linear molecules, in which adjacent nucleotides are linked to each other via a phosphodiester linkage. In some embodiments, “nucleic acid” refers to individual nucleic acid residues (e.g. nucleotides and/or nucleosides). In some embodiments, “nucleic acid” refers to an oligonucleotide chain comprising three or more individual nucleotide residues. As used herein, the terms “oligonucleotide” and “polynucleotide” can be used interchangeably to refer to a polymer of nucleotides (e.g., a string of at least three nucleotides). In some embodiments, “nucleic acid” encompasses RNA as well as single and/or double-stranded DNA. Nucleic acids may be naturally occurring, for example, in the context of a genome, a transcript, an mRNA, tRNA, rRNA, siRNA, snRNA, a plasmid, cosmid, chromosome, chromatid, or other naturally occurring nucleic acid molecule. On the other hand, a nucleic acid molecule may be a non-naturally occurring molecule, e.g., a recombinant DNA or RNA, an artificial chromosome, an engineered genome, or fragment thereof, or a synthetic DNA, RNA, DNA/RNA hybrid, or including non-naturally occurring nucleotides or nucleosides. Furthermore, the terms “nucleic acid,” “DNA,” “RNA,” and/or similar terms include nucleic acid analogs, e.g., analogs having other than a phosphodiester backbone. Nucleic acids can be purified from natural sources, produced using recombinant expression systems and optionally purified, chemically synthesized, etc. Where appropriate, e.g., in the case of chemically synthesized molecules, nucleic acids can comprise nucleoside analogs such as analogs having chemically modified bases or sugars, and backbone modifications. A nucleic acid sequence is presented in the 5′ to 3′ direction unless otherwise indicated. In some embodiments, a nucleic acid is or comprises natural nucleosides (e.g. adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine); nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, and 2-thiocytidine); chemically modified bases; biologically modified bases (e.g., methylated bases); intercalated bases; modified sugars (e.g.,2′-fluororibose, ribose, 2′-deoxyribose, arabinose, and hexose); and/or modified phosphate groups (e.g., phosphorothioates and 5′-N-phosphoramidite linkages).

The term “nucleic acid editing domain,” as used herein refers to a protein or enzyme capable of making one or more modifications (e.g., deamination of a cytidine residue) to a nucleic acid (e.g., DNA or RNA). Exemplary nucleic acid editing domains include, but are not limited to a deaminase, a nuclease, a nickase, a recombinase, a methyltransferase, a methylase, an acetylase, an acetyltransferase, a transcriptional activator, or a transcriptional repressor domain. In some embodiments the nucleic acid editing domain is a deaminase (e.g., a cytidine deaminase, such as an APOBEC or an AID deaminase).

The term “proliferative disease,” as used herein, refers to any disease in which cell or tissue homeostasis is disturbed in that a cell or cell population exhibits an abnormally elevated proliferation rate. Proliferative diseases include hyperproliferative diseases, such as pre-neoplastic hyperplastic conditions and neoplastic diseases. Neoplastic diseases are characterized by an abnormal proliferation of cells and include both benign and malignant neoplasias. Malignant neoplasia is also referred to as cancer.

The terms “protein,” “peptide,” and “polypeptide” are used interchangeably herein, and refer to a polymer of amino acid residues linked together by peptide (amide) bonds. The terms refer to a protein, peptide, or polypeptide of any size, structure, or function. Typically, a protein, peptide, or polypeptide will be at least three amino acids long. A protein, peptide, or polypeptide may refer to an individual protein or a collection of proteins. One or more of the amino acids in a protein, peptide, or polypeptide may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a hydroxyl group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation, functionalization, or other modification, etc. A protein, peptide, or polypeptide may also be a single molecule or may be a multi-molecular complex. A protein, peptide, or polypeptide may be just a fragment of a naturally occurring protein or peptide. A protein, peptide, or polypeptide may be naturally occurring, recombinant, or synthetic, or any combination thereof. The term “fusion protein” as used herein refers to a hybrid polypeptide which comprises protein domains from at least two different proteins. One protein may be located at the amino-terminal (N-terminal) portion of the fusion protein or at the carboxy-terminal (C-terminal) protein thus forming an “amino-terminal fusion protein” or a “carboxy-terminal fusion protein,” respectively. A protein may comprise different domains, for example, a nucleic acid binding domain (e.g., the gRNA binding domain of Cas9 that directs the binding of the protein to a target site) and a nucleic acid cleavage domain or a catalytic domain of a nucleic-acid editing protein. In some embodiments, a protein comprises a proteinaceous part, e.g., an amino acid sequence constituting a nucleic acid binding domain, and an organic compound, e.g., a compound that can act as a nucleic acid cleavage agent. In some embodiments, a protein is in a complex with, or is in association with, a nucleic acid, e.g., RNA. Any of the proteins provided herein may be produced by any method known in the art. For example, the proteins provided herein may be produced via recombinant protein expression and purification, which is especially suited for fusion proteins comprising a peptide linker. Methods for recombinant protein expression and purification are well known, and include those described by Green and Sambrook, Molecular Cloning: A Laboratory Manual (4^(th) ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2012)), the entire contents of which are incorporated herein by reference.

The term “RNA-programmable nuclease,” and “RNA-guided nuclease” are used interchangeably herein and refer to a nuclease that forms a complex with (e.g., binds or associates with) one or more RNA that is not a target for cleavage. In some embodiments, an RNA-programmable nuclease, when in a complex with an RNA, may be referred to as a nuclease:RNA complex. Typically, the bound RNA(s) is referred to as a guide RNA (gRNA). gRNAs can exist as a complex of two or more RNAs, or as a single RNA molecule. gRNAs that exist as a single RNA molecule may be referred to as single-guide RNAs (sgRNAs), though “gRNA” is used interchangeably to refer to guide RNAs that exist as either single molecules or as a complex of two or more molecules. Typically, gRNAs that exist as single RNA species comprise two domains: (1) a domain that shares homology to a target nucleic acid (e.g., and directs binding of a Cas9 complex to the target); and (2) a domain that binds a Cas9 protein. In some embodiments, domain (2) corresponds to a sequence known as a tracrRNA, and comprises a stem-loop structure. For example, in some embodiments, domain (2) is identical or homologous to a tracrRNA as provided in Jinek et al., Science 337:816-821(2012), the entire contents of which is incorporated herein by reference. Other examples of gRNAs (e.g., those including domain 2) can be found in U.S. Provisional Patent Application, U.S. Ser. No. 61/874,682, filed Sep. 6, 2013, entitled “Switchable Cas9 Nucleases And Uses Thereof,” and U.S. Provisional Patent Application, U.S. Ser. No. 61/874,746, filed Sep. 6, 2013, entitled “Delivery System For Functional Nucleases,” the entire contents of each are hereby incorporated by reference in their entirety. In some embodiments, a gRNA comprises two or more of domains (1) and (2), and may be referred to as an “extended gRNA.” For example, an extended gRNA will, e.g., bind two or more Cas9 proteins and bind a target nucleic acid at two or more distinct regions, as described herein. The gRNA comprises a nucleotide sequence that complements a target site, which mediates binding of the nuclease/RNA complex to said target site, providing the sequence specificity of the nuclease:RNA complex. In some embodiments, the RNA-programmable nuclease is the (CRISPR-associated system) Cas9 endonuclease, for example Cas9 (Csn1) from Streptococcus pyogenes (see, e.g., “Complete genome sequence of an M1 strain of Streptococcus pyogenes.” Ferretti J. J., McShan W. M., Ajdic D. J., Savic D. J., Savic G., Lyon K., Primeaux C., Sezate S., Suvorov A. N., Kenton S., Lai H. S., Lin S. P., Qian Y., Jia H. G., Najar F. Z., Ren Q., Zhu H., Song L., White J., Yuan X., Clifton S. W., Roe B. A., McLaughlin R. E., Proc. Natl. Acad. Sci. U.S.A. 98:4658-4663(2001); “CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III.” Deltcheva E., Chylinski K., Sharma C. M., Gonzales K., Chao Y., Pirzada Z. A., Eckert M. R., Vogel J., Charpentier E., Nature 471:602-607(2011); and “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.” Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J. A., Charpentier E. Science 337:816-821(2012), the entire contents of each of which are incorporated herein by reference.

Because RNA-programmable nucleases (e.g., Cas9) use RNA:DNA hybridization to target DNA cleavage sites, these proteins are able to be targeted, in principle, to any sequence specified by the guide RNA. Methods of using RNA-programmable nucleases, such as Cas9, for site-specific cleavage (e.g., to modify a genome) are known in the art (see e.g., Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013); Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013); Hwang, W. Y. et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nature biotechnology 31, 227-229 (2013); Jinek, M. et al. RNA-programmed genome editing in human cells. eLife 2, e00471 (2013); Dicarlo, J. E. et al. Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems. Nucleic acids research (2013); Jiang, W. et al. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nature biotechnology 31, 233-239 (2013); the entire contents of each of which are incorporated herein by reference).

The term “subject,” as used herein, refers to an individual organism, for example, an individual mammal. In some embodiments, the subject is a human. In some embodiments, the subject is a non-human mammal. In some embodiments, the subject is a non-human primate. In some embodiments, the subject is a rodent. In some embodiments, the subject is a sheep, a goat, a cattle, a cat, or a dog. In some embodiments, the subject is a vertebrate, an amphibian, a reptile, a fish, an insect, a fly, or a nematode. In some embodiments, the subject is a research animal. In some embodiments, the subject is genetically engineered, e.g., a genetically engineered non-human subject. The subject may be of either sex and at any stage of development.

The term “target site” refers to a sequence within a nucleic acid molecule that is deaminated by a deaminase or a fusion protein comprising a deaminase, (e.g., a dCas9-deaminase fusion protein provided herein).

The terms “treatment,” “treat,” and “treating,” refer to a clinical intervention aimed to reverse, alleviate, delay the onset of, or inhibit the progress of a disease or disorder, or one or more symptoms thereof, as described herein. As used herein, the terms “treatment,” “treat,” and “treating” refer to a clinical intervention aimed to reverse, alleviate, delay the onset of, or inhibit the progress of a disease or disorder, or one or more symptoms thereof, as described herein. In some embodiments, treatment may be administered after one or more symptoms have developed and/or after a disease has been diagnosed. In other embodiments, treatment may be administered in the absence of symptoms, e.g., to prevent or delay onset of a symptom or inhibit onset or progression of a disease. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example, to prevent or delay their recurrence.

The term “recombinant” as used herein in the context of proteins or nucleic acids refers to proteins or nucleic acids that do not occur in nature, but are the product of human engineering. For example, in some embodiments, a recombinant protein or nucleic acid molecule comprises an amino acid or nucleotide sequence that comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations as compared to any naturally occurring sequence.

The term “nucleobase editors (NBEs)” or “base editors (BEs),” as used herein, refers to the Cas9 fusion proteins described herein. In some embodiments, the fusion protein comprises a nuclease-inactive Cas9 (dCas9) fused to a deaminase. In some embodiments, the fusion protein comprises a Cas9 nickase fused to a deaminase. In some embodiments, the fusion protein comprises a nuclease-inactive Cas9 fused to a deaminase and further fused to a UGI domain. In some embodiments, the fusion protein comprises a Cas9 nickase fused to a deaminase and further fused to a UGI domain. In some embodiments, the dCas9 of the fusion protein comprises a D10A and a H840A mutation of SEQ ID NO: 10, or a corresponding mutation in any of SEQ ID NOs: 11-260, which inactivates nuclease activity of the Cas9 protein. In some embodiments, the fusion protein comprises a D10A mutation and comprises a histidine at residue 840 of SEQ ID NO: 10, or a corresponding mutation in any of SEQ ID NOs: 11-260, which renders Cas9 capable of cleaving only one strand of a nucleic acid duplex. An example of a Cas9 nickase is shown below in SEQ ID NO: 674. The terms “nucleobase editors (NBEs)” and “base editors (BEs)” may be used interchangeably.

The term “uracil glycosylase inhibitor” or “UGI,” as used herein, refers to a protein that is capable of inhibiting a uracil-DNA glycosylase base-excision repair enzyme.

The term “Cas9 nickase,” as used herein, refers to a Cas9 protein that is capable of cleaving only one strand of a duplexed nucleic acid molecule (e.g., a duplexed DNA molecule). In some embodiments, a Cas9 nickase comprises a D10A mutation and has a histidine at position H840 of SEQ ID NO: 10, or a corresponding mutation in any of SEQ ID NOs: 11-260. For example, a Cas9 nickase may comprise the amino acid sequence as set forth in SEQ ID NO: 674. Such a Cas9 nickase has an active HNH nuclease domain and is able to cleave the non-targeted strand of DNA, i.e., the strand bound by the gRNA. Further, such a Cas9 nickase has an inactive RuvC nuclease domain and is not able to cleave the targeted strand of the DNA, i.e., the strand where base editing is desired.

Exemplary Cas9 nickase (Cloning vector pPlatTET-gRNA2; Accession No. BAV54124).

(SEQ ID NO: 674) MDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIG ALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFF HRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTD KADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLF EENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALS LGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAK NLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQL PEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVK LNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIE KILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQS FIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAF LSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFN ASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSD GFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKK GILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRI EEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRL SDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNY WRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHV AQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINN YHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEI GKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGR DFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWD PKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEK NPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNE LALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQIS EFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAA FKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION

Some aspects of this disclosure provide fusion proteins that comprise a domain capable of binding to a nucleotide sequence (e.g., a Cas9, or a Cpf1 protein) and an enzyme domain, for example, a DNA-editing domain, such as, e.g., a deaminase domain. The deamination of a nucleobase by a deaminase can lead to a point mutation at the respective residue, which is referred to herein as nucleic acid editing. Fusion proteins comprising a Cas9 variant or domain and a DNA editing domain can thus be used for the targeted editing of nucleic acid sequences. Such fusion proteins are useful for targeted editing of DNA in vitro, e.g., for the generation of mutant cells or animals; for the introduction of targeted mutations, e.g., for the correction of genetic defects in cells ex vivo, e.g., in cells obtained from a subject that are subsequently re-introduced into the same or another subject; and for the introduction of targeted mutations, e.g., the correction of genetic defects or the introduction of deactivating mutations in disease-associated genes in a subject. Typically, the Cas9 domain of the fusion proteins described herein does not have any nuclease activity but instead is a Cas9 fragment or a dCas9 protein or domain. Methods for the use of Cas9 fusion proteins as described herein are also provided.

Cas9 Domains of Nucleobase Editors

Non-limiting, exemplary Cas9 domains are provided herein. The Cas9 domain may be a nuclease active Cas9 domain, a nucleasae inactive Cas9 domain, or a Cas9 nickase. In some embodiments, the Cas9 domain is a nuclease active domain. For example, the Cas9 domain may be a Cas9 domain that cuts both strands of a duplexed nucleic acid (e.g., both strands of a duplexed DNA molecule). In some embodiments, the Cas9 domain comprises any one of the amino acid sequences as set forth in SEQ ID NOs: 11-260. In some embodiments the Cas9 domain comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the amino acid sequences set forth in SEQ ID NOs: 11-260. In some embodiments, the Cas9 domain comprises an amino acid sequence that has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more or more mutations compared to any one of the amino acid sequences set forth in SEQ ID NOs: 11-260. In some embodiments, the Cas9 domain comprises an amino acid sequence that has at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1100, or at least 1200 identical contiguous amino acid residues as compared to any one of the amino acid sequences set forth in SEQ ID NOs: 11-260.

In some embodiments, the Cas9 domain is a nuclease-inactive Cas9 domain (dCas9). For example, the dCas9 domain may bind to a duplexed nucleic acid molecule (e.g., via a gRNA molecule) without cleaving either strand of the duplexed nucleic acid molecule. In some embodiments, the nuclease-inactive dCas9 domain comprises a D10X mutation and a H840X mutation of the amino acid sequence set forth in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, wherein X is any amino acid change. In some embodiments, the nuclease-inactive dCas9 domain comprises a D10A mutation and a H840A mutation of the amino acid sequence set forth in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. As one example, a nuclease-inactive Cas9 domain comprises the amino acid sequence set forth in SEQ ID NO: 263 (Cloning vector pPlatTET-gRNA2, Accession No. BAV54124).

(SEQ ID NO: 263 MDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGA LLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHR LEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKAD LRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENP INASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTP NFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAI LLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEI FFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLR KQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPY YVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDK NLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVD LLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKI IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQ LKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDD SLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKV MGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHP VENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDD SIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNL TKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLI REVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKK YPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEI TLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEV QTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVE KGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPK YSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPE DNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDK PIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQ SITGLYETRIDLSQLGGD; see, e.g., Qi et al., Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013; 152(5):1173-83, the entire contents of which are incorporated herein by reference).

Additional suitable nuclease-inactive dCas9 domains will be apparent to those of skill in the art based on this disclosure and knowledge in the field, and are within the scope of this disclosure. Such additional exemplary suitable nuclease-inactive Cas9 domains include, but are not limited to, D10A/H840A, D10A/D839A/H840A, and D10A/D839A/H840A/N863A mutant domains (See, e.g., Prashant et al., CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature Biotechnology. 2013; 31(9): 833-838, the entire contents of which are incorporated herein by reference). In some embodiments the dCas9 domain comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the dCas9 domains provided herein. In some embodiments, the Cas9 domain comprises an amino acid sequences that has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more or more mutations compared to any one of the amino acid sequences set forth in SEQ ID NOs: 11-260. In some embodiments, the Cas9 domain comprises an amino acid sequence that has at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1100, or at least 1200 identical contiguous amino acid residues as compared to any one of the amino acid sequences set forth in SEQ ID NOs: 11-260.

In some embodiments, the Cas9 domain is a Cas9 nickase. The Cas9 nickase may be a Cas9 protein that is capable of cleaving only one strand of a duplexed nucleic acid molecule (e.g., a duplexed DNA molecule). In some embodiments the Cas9 nickase cleaves the target strand of a duplexed nucleic acid molecule, meaning that the Cas9 nickase cleaves the strand that is base paired to (complementary to) a gRNA (e.g., an sgRNA) that is bound to the Cas9. In some embodiments, a Cas9 nickase comprises a D10A mutation and has a histidine at position 840 of SEQ ID NO: 10, or a mutation in any of SEQ ID NOs: 11-260. For example, a Cas9 nickase may comprise the amino acid sequence as set forth in SEQ ID NO: 674. In some embodiments the Cas9 nickase cleaves the non-target, non-base-edited strand of a duplexed nucleic acid molecule, meaning that the Cas9 nickase cleaves the strand that is not base paired to a gRNA (e.g., an sgRNA) that is bound to the Cas9. In some embodiments, a Cas9 nickase comprises an H840A mutation and has an aspartic acid residue at position 10 of SEQ ID NO: 10, or a corresponding mutation in any of SEQ ID NOs: 11-260. In some embodiments the Cas9 nickase comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the Cas9 nickases provided herein. Additional suitable Cas9 nickases will be apparent to those of skill in the art based on this disclosure and knowledge in the field, and are within the scope of this disclosure.

Cas9 Domains with Reduced PAM Exclusivity

Some aspects of the disclosure provide Cas9 domains that have different PAM specificities. Typically, Cas9 proteins, such as Cas9 from S. pyogenes (spCas9), require a canonical NGG PAM sequence to bind a particular nucleic acid region. This may limit the ability to edit desired bases within a genome. In some embodiments, the base editing fusion proteins provided herein may need to be placed at a precise location, for example where a target base is placed within a 4 base region (e.g., a “deamination window”), which is approximately 15 bases upstream of the PAM. See Komor, A. C., et al., “Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage” Nature 533, 420-424 (2016), the entire contents of which are hereby incorporated by reference. Accordingly, in some embodiments, any of the fusion proteins provided herein may contain a Cas9 domain that is capable of binding a nucleotide sequence that does not contain a canonical (e.g., NGG) PAM sequence. Cas9 domains that bind to non-canonical PAM sequences have been described in the art and would be apparent to the skilled artisan. For example, Cas9 domains that bind non-canonical PAM sequences have been described in Kleinstiver, B. P., et al., “Engineered CRISPR-Cas9 nucleases with altered PAM specificities” Nature 523, 481-485 (2015); and Kleinstiver, B. P., et al., “Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition” Nature Biotechnology 33, 1293-1298 (2015); the entire contents of each are hereby incorporated by reference.

In some embodiments, the Cas9 domain is a Cas9 domain from Staphylococcus aureus (SaCas9). In some embodiments, the SaCas9 domain is a nuclease active SaCas9, a nuclease inactive SaCas9 (SaCas9d), or a SaCas9 nickase (SaCas9n). In some embodiments, the SaCas9 comprises the amino acid sequence SEQ ID NO: 4273. In some embodiments, the SaCas9 comprises a N579X mutation of SEQ ID NO: 4273, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, wherein X is any amino acid except for N. In some embodiments, the SaCas9 comprises a N579A mutation of SEQ ID NO: 4273, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the SaCas9 domain, the SaCas9d domain, or the SaCas9n domain can bind to a nucleic acid sequence having a non-canonical PAM. In some embodiments, the SaCas9 domain, the SaCas9d domain, or the SaCas9n domain can bind to a nucleic acid sequence having a NNGRRT PAM sequence. In some embodiments, the SaCas9 domain comprises one or more of a E781X, a N967X, and a R1014X mutation of SEQ ID NO: 4273, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, wherein X is any amino acid. In some embodiments, the SaCas9 domain comprises one or more of a E781K, a N967K, and a R1014H mutation of SEQ ID NO: 4273, or one or more corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the SaCas9 domain comprises a E781K, a N967K, or a R1014H mutation of SEQ ID NO: 4273, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 11-260.

In some embodiments, the Cas9 domain of any of the fusion proteins provided herein comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of SEQ ID NOs: 4273-4275. In some embodiments, the Cas9 domain of any of the fusion proteins provided herein comprises the amino acid sequence of any one of SEQ ID NOs: 4273-4275. In some embodiments, the Cas9 domain of any of the fusion proteins provided herein consists of the amino acid sequence of any one of SEQ ID NOs: 4273-4275.

Exemplary SaCas9 sequence

(SEQ ID NO: 4273) KRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKR GARRLKRRRRHRIQRVKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLS EEEFSAALLHLAKRRGVHNVNEVEEDTGNELSTKEQISRNSKALEEKYVA ELQLERLKKDGEVRGS1NRFKTSDYVKEAKQLLKVQKAYHQLDQSFIDTY IDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAY NADLYNALNDLNNLVITRDENEKLEYYEKFQIIENVFKQKKKPTLKQIAK EILVNEEDIKGYRVTSTGKPEFTNLKVYHDIKDITARKEIIENAELLDQI AKILTIYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSLKAIN LILDELWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVDDFILSPVVK RSFIQSIKVINAIIKKYGLPNDIIIELAREKNSKDAQKMINEMQKRNRQT NERIEEIIRTTGKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNNPF NYEVDHIIPRSVSFDNSFNNKVLVKQEE N SKKGNRTPFQYLSSSDSKISY ETFKKHILNLAKGKGRISKTKKEYLLEERDINRFSVQKDFINRNLVDTRY ATRGLMNLLRSYFRVNNLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHH AEDALIIANADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEIETEQEYK EIFITPHQIKHIKDFKDYKYSHRVDKKPNRELINDTLYSTRKDDKGNTLI VNNLNGLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDEK NPLYKYYEETGNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSR NKVVKLSLKPYRFDVYLDNGVYKFVTVKNLDVIKKENYYEVNSKCYEEAK KLKKISNQAEFIASFYNNDLIKINGELYRVIGVNNDLLNRIEVNMIDITY REYLENMNDKRPPRIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIK KG Residue N579 of SEQ ID NO: 4273, which is underlined and in bold, may be mutated (e.g., to a A579) to yield a SaCas9 nickase. Exemplary SaCas9n Sequence

(SEQ ID NO: 4274) KRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKR GARRLKRRRRHRIQRVKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLS EEEFSAALLHLAKRRGVHNVNEVEEDTGNELSTKEQISRNSKALEEKYVA ELQLERLKKDGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQSFIDTY IDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAY NADLYNALNDLNNLVITRDENEKLEYYEKFQIIENVFKQKKKPTLKQIAK EILVNEEDIKGYRVTSTGKPEFTNLKVYHDIKDITARKEIIENAELLDQI AKILTIYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSLKAIN LILDELWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVDDFILSPVVK RSFIQSIKVINAIIKKYGLPNDIIIELAREKNSKDAQKMINEMQKRNRQT NERIEEIIRTTGKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNNPF NYEVDHIIPRSVSFDNSFNNKVLVKQEE A SKKGNRTPFQYLSSSDSKISY ETFKKHILNLAKGKGRISKTKKEYLLEERDINRFSVQKDFINRNLVDTRY ATRGLMNLLRSYFRVNNLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHH AEDALIIANADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEIETEQEYK EIFITPHQIKHIKDFKDYKYSHRVDKKPNRELINDTLYSTRKDDKGNTLI VNNLNGLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDEK NPLYKYYEETGNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSR NKVVKLSLKPYRFDVYLDNGVYKFVTVKNLDVIKKENYYEVNSKCYEEAK KLKKISNQAEFIASFYNNDLIKINGELYRVIGVNNDLLNRIEVNMIDITY REYLENMNDKRPPRIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIK KG. Residue A579 of SEQ ID NO: 4274, which can be mutated from N579 of SEQ ID NO: 4273 to yield a SaCas9 nickase, is underlined and in bold. Exemplary SaKKH Cas9

(SEQ ID NO: 4275) KRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSK RGARRLKRRRRHRIQRVKKLLFDYNLLTDHSELSGINPYEARVKGLSQK LSEEEFSAALLHLAKRRGVHNVNEVEEDTGNELSTKEQISRNSKALEEK YVAELQLERLKKDGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQSF IDTYIDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRS VKYAYNADLYNALNDLNNLVITRDENEKLEYYEKFQIIENVFKQKKKPT LKQIAKEILVNEEDIKGYRVTSTGKPEFTNLKVYHDIKDITARKEIIEN AELLDQIAKILTIYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTH NLSLKAINLILDELWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVD DFILSPVVKRSFIQSIKVINAIIKKYGLPNDIIIELAREKNSKDAQKMI NEMQKRNRQTNERIEEIIRTTGKENAKYLIEKIKLHDMQEGKCLYSLEA IPLEDLLNNPFNYEVDHIIPRSVSFDNSFNNKVLVKQEE A SKKGNRTPF QYLSSSDSKISYETFKKHILNLAKGKGRISKTKKEYLLEERDINRFSVQ KDFINRNLVDTRYATRGLMNLLRSYFRVNNLDVKVKSINGGFTSFLRRK WKFKKERNKGYKHHAEDALIIANADFIFKEWKKLDKAKKVMENQMFEEK QAESMPEIETEQEYKEIFITPHQIKHIKDFKDYKYSHRVDKKPNR K LIN DTLYSTRKDDKGNTLIVNNLNGLYDKDNDKLKKLINKSPEKLLMYHHDP QTYQKLKLIMEQYGDEKNPLYKYYEETGNYLTKYSKKDNGPVIKKIKYY GNKLNAHLDITDDYPNSRNKVVKLSLKPYRFDVYLDNGVYKFVTVKNLD VIKKENYYEVNSKCYEEAKKLKKISNQAEFIASFY K NDLIKINGELYRV IGVNNDLLNRIEVNMIDITYREYLENMNDKRPP H IIKTIASKTQSIKKY STDILGNLYEVKSKKHPQIIKKG. Residue A579 of SEQ ID NO: 4275, which can be mutated from N579 of SEQ ID NO: 4273 to yield a SaCas9 nickase, is underlined and in bold. Residues K781, K967, and H1014 of SEQ ID NO: 4275, which can be mutated from E781, N967, and R1014 of SEQ ID NO: 4273 to yield a SaKKH Cas9 are underlined and in italics.

In some embodiments, the Cas9 domain is a Cas9 domain from Streptococcus pyogenes (SpCas9). In some embodiments, the SpCas9 domain is a nuclease active SpCas9, a nuclease inactive SpCas9 (SpCas9d), or a SpCas9 nickase (SpCas9n). In some embodiments, the SpCas9 comprises the amino acid sequence SEQ ID NO: 4276. In some embodiments, the SpCas9 comprises a D9X mutation of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, wherein X is any amino acid except for D. In some embodiments, the SpCas9 comprises a D9A mutation of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the SpCas9 domain, the SpCas9d domain, or the SpCas9n domain can bind to a nucleic acid sequence having a non-canonical PAM. In some embodiments, the SpCas9 domain, the SpCas9d domain, or the SpCas9n domain can bind to a nucleic acid sequence having a NGG, a NGA, or a NGCG PAM sequence. In some embodiments, the SpCas9 domain comprises one or more of a D1134X, a R1334X, and a T1336X mutation of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, wherein X is any amino acid. In some embodiments, the SpCas9 domain comprises one or more of a D1134E, R1334Q, and T1336R mutation of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the SpCas9 domain comprises a D1134E, a R1334Q, and a T1336R mutation of SEQ ID NO: 4276, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the SpCas9 domain comprises one or more of a D1134X, a R1334X, and a T1336X mutation of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, wherein X is any amino acid. In some embodiments, the SpCas9 domain comprises one or more of a D1134V, a R1334Q, and a T1336R mutation of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the SpCas9 domain comprises a D1134V, a R1334Q, and a T1336R mutation of SEQ ID NO: 4276, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the SpCas9 domain comprises one or more of a D1134X, a G1217X, a R1334X, and a T1336X mutation of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, wherein X is any amino acid. In some embodiments, the SpCas9 domain comprises one or more of a D1134V, a G1217R, a R1334Q, and a T1336R mutation of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the SpCas9 domain comprises a D1134V, a G1217R, a R1334Q, and a T1336R mutation of SEQ ID NO: 4276, or corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 11-260.

In some embodiments, the Cas9 domain of any of the fusion proteins provided herein comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of SEQ ID NOs: 4276-4280. In some embodiments, the Cas9 domain of any of the fusion proteins provided herein comprises the amino acid sequence of any one of SEQ ID NOs: 4276-4280. In some embodiments, the Cas9 domain of any of the fusion proteins provided herein consists of the amino acid sequence of any one of SEQ ID NOs: 4276-4280.

Exemplary SpCas9

(SEQ ID NO: 4276) DKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGAL LFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRL EESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADL RLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPI NASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPN FKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAIL LSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIF FDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRK QRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYY VGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKN LPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDL LFKTNRKVTVKQLKEDYFKKIECFDSVETSGVEDRFNASLGTYHDLLKII KDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQL KRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDS LTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVM GRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPV ENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDS IDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLT KAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR EVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKY PKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEIT LANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQ TGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEK GKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKY SLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPED NEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKP IREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQS ITGLYETRIDLSQLGGD Exemplary SpCas9n

(SEQ ID NO: 4277) DKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGAL LFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRL EESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADL RLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPI NASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPN FKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAIL LSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIF FDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRK QRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYY VGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKN LPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDL LFKTNRKVTVKQLKEDYFKKIECFDSVETSGVEDRFNASLGTYHDLLKII KDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQL KRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDS LTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVM GRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPV ENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDS IDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLT KAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR EVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKY PKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEIT LANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQ TGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEK GKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKY SLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPED NEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKP IREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQS ITGLYETRIDLSQLGGD Exemplary SpEQR Cas9

(SEQ ID NO: 4278) DKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGAL LFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRL EESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADL RLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPI NASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPN FKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAIL LSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIF FDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRK QRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYY VGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKN LPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDL LFKTNRKVTVKQLKEDYFKKIECFDSVETSGVEDRFNASLGTYHDLLKII KDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQL KRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDS LTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVM GRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPV ENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDS IDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLT KAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR EVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKY PKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEIT LANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQ TGGFSKESILPKRNSDKLIARKKDWDPKKYGGF E SPTVAYSVLVVAKVEK GKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKY SLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPED NEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKP IREQAENIIHLFTLTNLGAPAAFKYFDTTIDRK Q Y R STKEVLDATLIHQS ITGLYETRIDLSQLGGD Residues E1134, Q1334, and R1336 of SEQ ID NO: 4278, which can be mutated from D1134, R1334, and T1336 of SEQ ID NO: 4276 to yield a SpEQR Cas9, are underlined and in bold. Exemplary SpVQR Cas9

(SEQ ID NO: 4279) DKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIG ALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSF FHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDS TDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYN QLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNL IALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADL FLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKA LVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDG TEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFL KDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEV VDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKY VTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDS VEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTL FEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDK QSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLH EHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQT TQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQ NGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRG KSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDK AGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSK LVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFV YGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEI RKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGF SKESILPKRNSDKLIARKKDWDPKKYGGF V SPTVAYSVLVVAKVEKGK SKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKY SLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSP EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKH RDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRK Q Y R STKEVLDA TLIHQSITGLYETRIDLSQLGGD Residues V1134, Q1334, and R1336 of SEQ ID NO: 4279, which can be mutated from D1134, R1334, and T1336 of SEQ ID NO: 4276 to yield a SpVQR Cas9, are underlined and in bold. Exemplary SpVRER Cas9

(SEQ ID NO: 4280) DKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGAL LFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRL EESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADL RLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPI NASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPN FKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAIL LSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIF FDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRK QRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYY VGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKN LPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDL LFKTNRKVTVKQLKEDYFKKIECFDSVETSGVEDRFNASLGTYHDLLKII KDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQL KRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDS LTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVM GRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPV ENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDS IDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLT KAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR EVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKY PKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEIT LANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQ TGGFSKESILPKRNSDKLIARKKDWDPKKYGGF V SPTVAYSVLVVAKVEK GKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKY SLFELENGRKRMLASA R ELQKGNELALPSKYVNFLYLASHYEKLKGSPED NEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKP IREQAENIIHLFTLTNLGAPAAFKYFDTTIDRK E Y R STKEVLDATLIHQS ITGLYETRIDLSQLGGD Residues V1134, R1217, Q1334, and R1336 of SEQ ID NO: 4280, which can be mutated from D1134, G1217, R1334, and T1336 of SEQ ID NO: 4276 to yield a SpVRER Cas9, are underlined and in bold.

The following are exemplary fusion proteins (e.g., base editing proteins) capable of binding to a nucleic acid sequence having a non-canonical (e.g., a non-NGG) PAM sequence:

Exemplary SaBE3 (rAPOBEC1-XTEN-SaCas9n-UGI-NLS)

(SEQ ID NO: 4281) MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSI WRHTSQNTNKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAI TEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQIMTEQESG YCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNILRRKQ PQLTFFTIALQSCHYQRLPPHILWATGLKSGSETPGTSESATPESKRNYI LGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRL KRRRRHRIQRVKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLSEEEFS AALLHLAKRRGVHNVNEVEEDTGNELSTKEQISRNSKALEEKYVAELQLE RLKKDGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQSFIDTYIDLLE TRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAYNADLY NALNDLNNLVITRDENEKLEYYEKFQIIENVFKQKKKPTLKQIAKEILVN EEDIKGYRVTSTGKPEFTNLKVYHDIKDITARKEIIENAELLDQIAKILT IYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSLKAINLILDE LWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVDDFILSPVVKRSFIQ SIKVINAIIKKYGLPNDIIIELAREKNSKDAQKMINEMQKRNRQTNERIE EIIRTTGKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNNPFNYEVD HIIPRSVSFDNSFNNKVLVKQEEASKKGNRTPFQYLSSSDSKISYETFKK HILNLAKGKGRISKTKKEYLLEERDINRFSVQKDFINRNLVDTRYATRGL MNLLRSYFRVNNLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHHAEDAL IIANADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEIETEQEYKEIFIT PHQIKHIKDFKDYKYSHRVDKKPNRELINDTLYSTRKDDKGNTLIVNNLN GLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDEKNPLYK YYEETGNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSRNKVVK LSLKPYRFDVYLDNGVYKFVTVKNLDVIKKENYYEVNSKCYEEAKKLKKI SNQAEFIASFYNNDLIKINGELYRVIGVNNDLLNRIEVNMIDITYREYLE NMNDKRPPRIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIKKGSGG STNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDES TDENVMLLTSDAPEYKPWALVIQDSNGENKIKMLSGGSPKKKRKV  Exemplary SaKKH-BE3 (rAPOBEC1-XTEN-SaCas9n-UGI-NLS)

(SEQ ID NO: 4282) MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSI WRHTSQNTNKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAI TEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQIMTEQESG YCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNILRRKQ PQLTFFTIALQSCHYQRLPPHILWATGLKSGSETPGTSESATPESKRNYI LGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRL KRRRRHRIQRVKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLSEEEFS AALLHLAKRRGVHNVNEVEEDTGNELSTKEQISRNSKALEEKYVAELQLE RLKKDGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQSFIDTYIDLLE TRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAYNADLY NALNDLNNLVITRDENEKLEYYEKFQIIENVFKQKKKPTLKQIAKEILVN EEDIKGYRVTSTGKPEFTNLKVYHDIKDITARKEIIENAELLDQIAKILT IYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSLKAINLILDE LWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVDDFILSPVVKRSFIQ SIKVINAIIKKYGLPNDIIIELAREKNSKDAQKMINEMQKRNRQTNERIE EIIRTTGKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNNPFNYEVD HIIPRSVSFDNSFNNKVLVKQEEASKKGNRTPFQYLSSSDSKISYETFKK HILNLAKGKGRISKTKKEYLLEERDINRFSVQKDFINRNLVDTRYATRGL MNLLRSYFRVNNLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHHAEDAL IIANADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEIETEQEYKEIFIT PHQIKHIKDFKDYKYSHRVDKKPNRKLINDTLYSTRKDDKGNTLIVNNLN GLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDEKNPLYK YYEETGNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSRNKVVK LSLKPYRFDVYLDNGVYKFVTVKNLDVIKKENYYEVNSKCYEEAKKLKKI SNQAEFIASFYKNDLIKINGELYRVIGVNNDLLNRIEVNMIDITYREYLE NMNDKRPPHIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIKKGSGG STNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDES TDENVMLLTSDAPEYKPWALVIQDSNGENKIKMLSGGSPKKKRKV Exemplary EOR-BE3 (rAPOBEC1-XTEN-Cas9n-UGI-NLS)

(SEQ ID NO: 4283) MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSI WRHTSQNTNKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAI TEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQIMTEQESG YCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNILRRKQ PQLTFFTIALQSCHYQRLPPHILWATGLKSGSETPGTSESATPESDKKYS IGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSG ETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFL VEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGV DAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNF DLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDIL RVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSK NGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFD NGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLA RGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEK VLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTN RKVTVKQLKEDYFKKIECFDSVETSGVEDRFNASLGTYHDLLKIIKDKDF LDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRY TGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKE DIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKP ENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQL QNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKV LTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERG GLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVI TLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLES EFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGE IRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFS KESILPKRNSDKLIARKKDWDPKKYGGFESPTVAYSVLVVAKVEKGKSKK LKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFEL ENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQ LFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQA ENIIHLFTLTNLGAPAAFKYFDTTIDRKQYRSTKEVLDATLIHQSITGLY ETRIDLSQLGGDSGGSTNLSDIIEKETGKQLVIQESILMLPEEVEEVIGN KPESDILVHTAYDESTDENVMLLTSDAPEYKPWALVIQDSNGENKIKMLS GGSPKKKRKV VQR-BE3 (rAPOBEC1-XTEN-Cas9n-UGI-NLS)

(SEQ ID NO: 4284) MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSI WRHTSQNTNKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAI TEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQIMTEQESG YCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNILRRKQ PQLTFFTIALQSCHYQRLPPHILWATGLKSGSETPGTSESATPESDKKYS IGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSG ETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFL VEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGV DAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNF DLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDIL RVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSK NGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFD NGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLA RGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEK VLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTN RKVTVKQLKEDYFKKIECFDSVETSGVEDRFNASLGTYHDLLKIIKDKDF LDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRY TGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKE DIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKP ENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQL QNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKV LTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERG GLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVI TLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLES EFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGE IRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFS KESILPKRNSDKLIARKKDWDPKKYGGFVSPTVAYSVLVVAKVEKGKSKK LKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFEL ENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQ LFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQA ENIIHLFTLTNLGAPAAFKYFDTTIDRKQYRSTKEVLDATLIHQSITGLY ETRIDLSQLGGDSGGSTNLSDIIEKETGKQLVIQESILMLPEEVEEVIGN KPESDILVHTAYDESTDENVMLLTSDAPEYKPWALVIQDSNGENKIKMLS GGSPKKKRKV VRER-BE3 (rAPOBEC1-XTEN-Cas9n-UGI-NLS)

(SEQ ID NO: 4285) MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSI WRHTSQNTNKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAI TEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQIMTEQESG YCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNILRRKQ PQLTFFTIALQSCHYQRLPPHILWATGLKSGSETPGTSESATPESDKKYS IGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSG ETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFL VEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGV DAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNF DLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDIL RVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSK NGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFD NGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLA RGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEK VLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTN RKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDF LDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRY TGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKE DIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKP ENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQL QNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKV LTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERG GLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVI TLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLES EFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGE IRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFS KESILPKRNSDKLIARKKDWDPKKYGGFVSPTVAYSVLVVAKVEKGKSKK LKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFEL ENGRKRMLASARELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQ LFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQA ENIIHLFTLTNLGAPAAFKYFDTTIDRKEYRSTKEVLDATLIHQSITGLY ETRIDLSQLGGDSGGSTNLSDIIEKETGKQLVIQESILMLPEEVEEVIGN KPESDILVHTAYDESTDENVMLLTSDAPEYKPWALVIQDSNGENKIKMLS GGSPKKKRKV High Fidelity Base Editors

Some aspects of the disclosure provide Cas9 fusion proteins (e.g., any of the fusion proteins provided herein) comprising a Cas9 domain that has high fidelity. Additional aspects of the disclosure provide Cas9 fusion proteins (e.g., any of the fusion proteins provided herein) comprising a Cas9 domain with decreased electrostatic interactions between the Cas9 domain and a sugar-phosphate backbone of a DNA, as compared to a wild-type Cas9 domain. In some embodiments, a Cas9 domain (e.g., a wild type Cas9 domain) comprises one or more mutations that decreases the association between the Cas9 domain and a sugar-phosphate backbone of a DNA. In some embodiments, any of the Cas9 fusion proteins provided herein comprise one or more of a N497X, a R661X, a Q695X, and/or a Q926X mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, wherein X is any amino acid. In some embodiments, any of the Cas9 fusion proteins provided herein comprise one or more of a N497A, a R661A, a Q695A, and/or a Q926A mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the Cas9 domain comprises a D10A mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the Cas9 domain (e.g., of any of the fusion proteins provided herein) comprises the amino acid sequence as set forth in SEQ ID NO: 325. In some embodiments, the fusion protein comprises the amino acid sequence as set forth in SEQ ID NO: 285. Cas9 domains with high fidelity are known in the art and would be apparent to the skilled artisan. For example, Cas9 domains with high fidelity have been described in Kleinstiver, B. P., et al. “High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.” Nature 529, 490-495 (2016); and Slaymaker, I. M., et al. “Rationally engineered Cas9 nucleases with improved specificity.” Science 351, 84-88 (2015); the entire contents of each are incorporated herein by reference.

It should be appreciated that the base editors provided herein, for example base editor 2 (BE2) or base editor 3 (BE3), may be converted into high fidelity base editors by modifying the Cas9 domain as described herein to generate high fidelity base editors, for example high fidelity base editor 2 (HF-BE2) or high fidelity base editor 3 (HF-BE3). In some embodiments, base editor 2 (BE2) comprises a deaminase domain, a dCas9, and a UGI domain. In some embodiments, base editor 3 (BE3) comprises a deaminase domain an nCas9 domain and a UGI domain.

Cas9 Domain where Mutations Relative to Cas9 of SEQ ID NO: 10 are Shown in Bold and Underlines

(SEQ ID NO: 325) DKKYSIGL A IGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGAL LFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRL EESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADL RLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPI NASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPN FKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAIL LSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIF FDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRK QRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYY VGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMT A FDKN LPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDL LFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKII KDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQL KRRRYTGWG A LSRKLINGIRDKQSGKTILDFLKSDGFANRNFM A LIHDDS LTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVM GRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPV ENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDS IDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLT KAERGGLSELDKAGFIKRQLVETR A ITKHVAQILDSRMNTKYDENDKLIR EVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKY PKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEIT LANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQ TGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEK GKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKY SLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPED NEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKP IREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQS ITGLYETRIDLSQLGGD HF-BE3

(SEQ ID NO: 5808) MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSI WRHTSQNTNKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAI TEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQIMTEQESG YCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNILRRKQ PQLTFFTIALQSCHYQRLPPHILWATGLKSGSETPGTSESATPESDKKYS IGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSG ETALATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFL VEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGV DAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNF DLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDIL RVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSK NGYAGYIDGGASQLEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFD NGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLA RGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTAFDKNLPNEK VLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTN RKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDF LDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRY TGWGALSRKLINGIRDKQSGKTILDFLKSDGFANRNFMALIHDDSLTFKE DIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKP ENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQL QNEKLYLYYLONGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKV LTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERG GLSELDKAGFIKRQLVETRAITKHVAQILDSRMNTKYDENDKLIREVKVI TLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLES EFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGE IRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFS KESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKK LKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFEL ENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQ LFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQA ENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLY ETRIDLSQLGGD Cas9 Fusion Proteins

Any of the Cas9 domains (e.g., a nuclease active Cas9 protein, a nuclease-inactive dCas9 protein, or a Cas9 nickase protein) disclosed herein may be fused to a second protein, thus fusion proteins provided herein comprise a Cas9 domain as provided herein and a second protein, or a “fusion partner”. In some embodiments, the second protein is fused to the N-terminus of the Cas9 domain. However, in other embodiments, the second protein is fused to the C-terminus of the Cas9 domain. In some embodiments, the second protein that is fused to the Cas9 domain is a nucleic acid editing domain. In some embodiments, the Cas9 domain and the nucleic acid editing domain are fused via a linker, while in other embodiments the Cas9 domain and the nucleic acid editing domain are fused directly to one another. In some embodiments, the linker comprises (GGGS)_(n) (SEQ ID NO: 265), (GGGGS)_(n) (SEQ ID NO: 5), (G)_(n), (EAAAK)_(n) (SEQ ID NO: 6), (GGS)_(n), (SGGS)_(n) (SEQ ID NO: 4288), SGSETPGTSESATPES (SEQ ID NO: 7), or (XP)_(n) motif, or a combination of any of these, wherein n is independently an integer between 1 and 30, and wherein X is any amino acid. In some embodiments, the linker comprises a (GGS)_(n) motif, wherein n is 1, 3, or 7. In some embodiments, the linker comprises a (GGS)_(n) motif, wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. In some embodiments, the linker comprises an amino acid sequence of SGSETPGTSESATPES (SEQ ID NO: 7),also referred to as the XTEN linker in the Examples). The length of the linker can influence the base to be edited, as illustrated in the Examples. For example, a linker of 3-amino-acid long (e.g., (GGS)₁) may give a 2-5, 2-4, 2-3, 3-4 base editing window relative to the PAM sequence, while a 9-amino-acid linker (e.g., (GGS)₃ (SEQ ID NO: 596)) may give a 2-6, 2-5, 2-4, 2-3, 3-6, 3-5, 3-4, 4-6, 4-5, 5-6 base editing window relative to the PAM sequence. A 16-amino-acid linker (e.g., the XTEN linker) may give a 2-7, 2-6, 2-5, 2-4, 2-3, 3-7, 3-6, 3-5, 3-4, 4-7, 4-6, 4-5, 5-7, 5-6, 6-7 base window relative to the PAM sequence with exceptionally strong activity, and a 21-amino-acid linker (e.g., (GGS)₇ (SEQ ID NO: 597)) may give a 3-8, 3-7, 3-6, 3-5, 3-4, 4-8, 4-7, 4-6, 4-5, 5-8, 5-7, 5-6, 6-8, 6-7, 7-8 base editing window relative to the PAM sequence. The novel finding that varying linker length may allow the dCas9 fusion proteins of the disclosure to edit nucleobases different distances from the PAM sequence affords siginicant clinical importance, since a PAM sequence may be of varying distance to the disease-causing mutation to be corrected in a gene. It is to be understood that the linker lengths described as examples here are not meant to be limiting.

In some embodiments, the second protein comprises an enzymatic domain. In some embodiments, the enzymatic domain is a nucleic acid editing domain. Such a nucleic acid editing domain may be, without limitation, a nuclease, a nickase, a recombinase, a deaminase, a methyltransferase, a methylase, an acetylase, or an acetyltransferase. Non-limiting exemplary binding domains that may be used in accordance with this disclosure include transcriptional activator domains and transcriptional repressor domains.

Deaminase Domains

In some embodiments, second protein comprises a nucleic acid editing domain. In some embodiments, the nucleic acid editing domain can catalyze a C to U base change. In some embodiments, the nucleic acid editing domain is a deaminase domain. In some embodiments, the deaminase is a cytidine deaminase or a cytidine deaminase. In some embodiments, the deaminase is an apolipoprotein B mRNA-editing complex (APOBEC) family deaminase. In some embodiments, the deaminase is an APOBEC1 deaminase. In some embodiments, the deaminase is an APOBEC2 deaminase. In some embodiments, the deaminase is an APOBEC3 deaminase. In some embodiments, the deaminase is an APOBEC3A deaminase. In some embodiments, the deaminase is an APOBEC3B deaminase. In some embodiments, the deaminase is an APOBEC3C deaminase. In some embodiments, the deaminase is an APOBEC3D deaminase. In some embodiments, the deaminase is an APOBEC3E deaminase. In some embodiments, the deaminase is an APOBEC3F deaminase. In some embodiments, the deaminase is an APOBEC3G deaminase. In some embodiments, the deaminase is an APOBEC3H deaminase. In some embodiments, the deaminase is an APOBEC4 deaminase. In some embodiments, the deaminase is an activation-induced deaminase (AID). In some embodiments, the deaminase is a vertebrate deaminase. In some embodiments, the deaminase is an invertebrate deaminase. In some embodiments, the deaminase is a human, chimpanzee, gorilla, monkey, cow, dog, rat, or mouse deaminase. In some embodiments, the deaminase is a human deaminase. In some embodiments, the deaminase is a rat deaminase, e.g., rAPOBEC1. In some embodiments, the deaminase is a Petromyzon marinus cytidine deaminase 1 (pmCDA1). In some embodiments, the deminase is a human APOBEC3G (SEQ ID NO: 275). In some embodiments, the deaminase is a fragment of the human APOBEC3G (SEQ ID NO: 5740). In some embodiments, the deaminase is a human APOBEC3G variant comprising a D316R_D317R mutation (SEQ ID NO: 5739). In some embodiments, the deaminase is a frantment of the human APOBEC3G and comprising mutations corresponding to the D316R_D317R mutations in SEQ ID NO: 275 (SEQ ID NO: 5741).

In some embodiments, the nucleic acid editing domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the deaminase domain of any one of SEQ ID NOs: 266-284, 607-610, 5724-5736, or 5738-5741. In some embodiments, the nucleic acid editing domain comprises the amino acid sequence of any one of SEQ ID NOs: 266-284, 607-610, 5724-5736, or 5738-5741.

Deaminase Domains that Modulate the Editing Window of Base Editors

Some aspects of the disclosure are based on the recognition that modulating the deaminase domain catalytic activity of any of the fusion proteins provided herein, for example by making point mutations in the deaminase domain, affect the processivity of the fusion proteins (e.g., base editors). For example, mutations that reduce, but do not eliminate, the catalytic activity of a deaminase domain within a base editing fusion protein can make it less likely that the deaminase domain will catalyze the deamination of a residue adjacent to a target residue, thereby narrowing the deamination window. The ability to narrow the deaminataion window may prevent unwanted deamination of residues adjacent of specific target residues, which may decrease or prevent off-target effects.

In some embodiments, any of the fusion proteins provided herein comprise a deaminase domain (e.g., a cytidine deaminase domain) that has reduced catalytic deaminase activity. In some embodiments, any of the fusion proteins provided herein comprise a deaminase domain (e.g., a cytidine deaminase domain) that has a reduced catalytic deaminase activity as compared to an appropriate control. For example, the appropriate control may be the deaminase activity of the deaminase prior to introducing one or more mutations into the deaminase. In other embodiments, the appropriate control may be a wild-type deaminase. In some embodiments, the appropriate control is a wild-type apolipoprotein B mRNA-editing complex (APOBEC) family deaminase. In some embodiments, the appropriate control is an APOBEC1 deaminase, an APOBEC2 deaminase, an APOBEC3A deaminase, an APOBEC3B deaminase, an APOBEC3C deaminase, an APOBEC3D deaminase, an APOBEC3F deaminase, an APOBEC3G deaminase, or an APOBEC3H deaminase. In some embodiments, the appropriate control is an activation induced deaminase (AID). In some embodiments, the appropriate control is a cytidine deaminase 1 from Petromyzon marinus (pmCDA1). In some embodiments, the deaminase domain may be a deaminase domain that has at least 1%, at least 5%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% less catalytic deaminase activity as compared to an appropriate control.

In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising one or more mutations selected from the group consisting of H121X, H122X, R126X, R126X, R118X, W90X, W90X, and R132X of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase, wherein X is any amino acid. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising one or more mutations selected from the group consisting of H121R, H122R, R126A, R126E, R118A, W90A, W90Y, and R132E of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase.

In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising one or more mutations selected from the group consisting of D316X, D317X, R320X, R320X, R313X, W285X, W285X, R326X of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase, wherein X is any amino acid. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising one or more mutations selected from the group consisting of D316R, D317R, R320A, R320E, R313A, W285A, W285Y, R326E of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase.

In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a H121R and a H122R mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a R126A mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a R126E mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a R118A mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a W90A mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a W90Y mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a R132E mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a W90Y and a R126E mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a R126E and a R132E mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a W90Y and a R132E mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a W90Y, R126E, and R132E mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase.

In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a D316R and a D317R mutation of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a R320A mutation of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a R320E mutation of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a R313A mutation of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a W285A mutation of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a W285Y mutation of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a R326E mutation of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a W285Y and a R320E mutation of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a R320E and a R326E mutation of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a W285Y and a R326E mutation of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a W285Y, R320E, and R326E mutation of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase.

Some aspects of this disclosure provide fusion proteins comprising (i) a nuclease-inactive Cas9 domain; and (ii) a nucleic acid editing domain. In some embodiments, a nuclease-inactive Cas9 domain (dCas9), comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of a Cas9 as provided by any one of SEQ ID NOs: 11-260, and comprises mutations that inactivate the nuclease activity of Cas9. Mutations that render the nuclease domains of Cas9 inactive are well-known in the art. For example, the DNA cleavage domain of Cas9 is known to include two subdomains, the HNH nuclease subdomain and the RuvC1 subdomain. The HNH subdomain cleaves the strand complementary to the gRNA, whereas the RuvC1 subdomain cleaves the non-complementary strand. Mutations within these subdomains can silence the nuclease activity of Cas9. For example, the mutations D10A and H840A completely inactivate the nuclease activity of S. pyogenes Cas9 (Jinek et al., Science. 337:816-821(2012); Qi et al., Cell. 28; 152(5):1173-83 (2013)). In some embodiments, the dCas9 of this disclosure comprises a D10A mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the dCas9 of this disclosure comprises a H840A mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the dCas9 of this disclosure comprises both D10A and H840A mutations of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the Cas9 further comprises a histidine residue at position 840 of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. The presence of the catalytic residue H840 restores the acvitity of the Cas9 to cleave the non-edited strand containing a G opposite the targeted C. Restoration of H840 does not result in the cleavage of the target strand containing the C. In some embodiments, the dCas9 comprises an amino acid sequence of SEQ ID NO: 263. It is to be understood that other mutations that inactivate the nuclease domains of Cas9 may also be included in the dCas9 of this disclosure.

The Cas9 or dCas9 domains comprising the mutations disclosed herein, may be a full-length Cas9, or a fragment thereof. In some embodiments, proteins comprising Cas9, or fragments thereof, are referred to as “Cas9 variants.” A Cas9 variant shares homology to Cas9, or a fragment thereof. For example a Cas9 variant is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% to wild type Cas9. In some embodiments, the Cas9 variant comprises a fragment of Cas9 (e.g., a gRNA binding domain or a DNA-cleavage domain), such that the fragment is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to the corresponding fragment of wild type Cas9, e.g., a Cas9 comprising the amino acid sequence of SEQ ID NO: 10.

Any of the Cas9 fusion proteins of this disclosure may further comprise a nucleic acid editing domain (e.g., an enzyme that is capable of modifying nucleic acid, such as a deaminase). In some embodiments, the nucleic acid editing domain is a DNA-editing domain. In some embodiments, the nucleic acid editing domain has deaminase activity. In some embodiments, the nucleic acid editing domain comprises or consists of a deaminase or deaminase domain. In some embodiments, the deaminase is a cytidine deaminase. In some embodiments, the deaminase is an apolipoprotein B mRNA-editing complex (APOBEC) family deaminase. In some embodiments, the deaminase is an APOBEC1 family deaminase. In some embodiments, the deaminase is an activation-induced cytidine deaminase (AID). Some nucleic-acid editing domains as well as Cas9 fusion proteins including such domains are described in detail herein. Additional suitable nucleic acid editing domains will be apparent to the skilled artisan based on this disclosure and knowledge in the field.

Some aspects of the disclosure provide a fusion protein comprising a Cas9 domain fused to a nucleic acid editing domain, wherein the nucleic acid editing domain is fused to the N-terminus of the Cas9 domain. In some embodiments, the Cas9 domain and the nucleic acid editing-editing domain are fused via a linker. In some embodiments, the linker comprises a (GGGS)_(n) (SEQ ID NO: 265), a (GGGGS)_(n) (SEQ ID NO: 5), a (G)_(n), an (EAAAK)_(n) (SEQ ID NO: 6), a (GGS)_(n), (SGGS)_(n) (SEQ ID NO: 4288), an SGSETPGTSESATPES (SEQ ID NO: 7) motif (see, e.g., Guilinger J P, Thompson D B, Liu D R. Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat. Biotechnol. 2014; 32(6): 577-82; the entire contents are incorporated herein by reference), or an (XP)_(n) motif, or a combination of any of these, wherein n is independently an integer between 1 and 30. In some embodiments, n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30, or, if more than one linker or more than one linker motif is present, any combination thereof. In some embodiments, the linker comprises a (GGS)_(n) motif, wherein n is 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15. In some embodiments, the linker comprises a (GGS)_(n) motif, wherein n is 1, 3, or 7. In some embodiments, the linker comprises the amino acid sequence SGSETPGTSESATPES (SEQ ID NO: 7). Additional suitable linker motifs and linker configurations will be apparent to those of skill in the art. In some embodiments, suitable linker motifs and configurations include those described in Chen et al., Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev. 2013; 65(10):1357-69, the entire contents of which are incorporated herein by reference. Additional suitable linker sequences will be apparent to those of skill in the art based on the instant disclosure. In some embodiments, the general architecture of exemplary Cas9 fusion proteins provided herein comprises the structure:

-   -   [NH₂]-[nucleic acid editing domain]-[Cas9]-[COOH] or     -   [NH₂]-[nucleic acid editing domain]-[linker]-[Cas9]-[COOH],         wherein NH₂ is the N-terminus of the fusion protein, and COOH is         the C-terminus of the fusion protein.

The fusion proteins of the present disclosure may comprise one or more additional features. For example, in some embodiments, the fusion protein comprises a nuclear localization sequence (NLS). In some embodiments, the NLS of the fusion protein is localized between the nucleic acid editing domain and the Cas9 domain. In some embodiments, the NLS of the fusion protein is localized C-terminal to the Cas9 domain.

Other exemplary features that may be present are localization sequences, such as cytoplasmic localization sequences, export sequences, such as nuclear export sequences, or other localization sequences, as well as sequence tags that are useful for solubilization, purification, or detection of the fusion proteins. Suitable protein tags provided herein include, but are not limited to, biotin carboxylase carrier protein (BCCP) tags, myc-tags, calmodulin-tags, FLAG-tags, hemagglutinin (HA)-tags, polyhistidine tags, also referred to as histidine tags or His-tags, maltose binding protein (MBP)-tags, nus-tags, glutathione-S-transferase (GST)-tags, green fluorescent protein (GFP)-tags, thioredoxin-tags, S-tags, Softags (e.g., Softag 1, Softag 3), strep-tags, biotin ligase tags, FlAsH tags, V5 tags, and SBP-tags. Additional suitable sequences will be apparent to those of skill in the art. In some embodiments, the fusion protein comprises one or more His tags.

In some embodiments, the nucleic acid editing domain is a deaminase. For example, in some embodiments, the general architecture of exemplary Cas9 fusion proteins with a deaminase domain comprises the structure:

-   -   [NH₂]-[NLS]-[deaminase]-[Cas9]-[COOH],     -   [NH₂]-[Cas9]-[deaminase]-[COOH],     -   [NH₂]-[deaminase]-[Cas9]-[COOH], or     -   [NH₂]-[deaminase]-[Cas9]-[NLS]-[COOH]         wherein NLS is a nuclear localization sequence, NH₂ is the         N-terminus of the fusion protein, and COOH is the C-terminus of         the fusion protein. Nuclear localization sequences are known in         the art and would be apparent to the skilled artisan. For         example, NLS sequences are described in Plank et al.,         PCT/EP2000/011690, the contents of which are incorporated herein         by reference for their disclosure of exemplary nuclear         localization sequences. In some embodiments, a NLS comprises the         amino acid sequence PKKKRKV (SEQ ID NO: 741) or         MDSLLMNRRKFLYQFKNVRWAKGRRETYLC (SEQ ID NO: 742). In some         embodiments, a linker is inserted between the Cas9 and the         deaminase. In some embodiments, the NLS is located C-terminal of         the Cas9 domain. In some embodiments, the NLS is located         N-terminal of the Cas9 domain. In some embodiments, the NLS is         located between the deaminase and the Cas9 domain. In some         embodiments, the NLS is located N-terminal of the deaminase         domain. In some embodiments, the NLS is located C-terminal of         the deaminase domain.

One exemplary suitable type of nucleic acid editing domain is a cytidine deaminase, for example, of the APOBEC family. The apolipoprotein B mRNA-editing complex (APOBEC) family of cytidine deaminase enzymes encompasses eleven proteins that serve to initiate mutagenesis in a controlled and beneficial manner.²⁹ One family member, activation-induced cytidine deaminase (AID), is responsible for the maturation of antibodies by converting cytosines in ssDNA to uracils in a transcription-dependent, strand-biased fashion.³⁰ The apolipoprotein B editing complex 3 (APOBEC3) enzyme provides protection to human cells against a certain HIV-1 strain via the deamination of cytosines in reverse-transcribed viral ssDNA.³¹ These proteins all require a Zn²⁺-coordinating motif (His-X-Glu-X₂₃₋₂₆-Pro-Cys-X₂₋₄-Cys; SEQ ID NO: 598) and bound water molecule for catalytic activity. The Glu residue acts to activate the water molecule to a zinc hydroxide for nucleophilic attack in the deamination reaction. Each family member preferentially deaminates at its own particular “hotspot”, ranging from WRC (W is A or T, R is A or G) for hAID, to TTC for hAPOBEC3F.³² A recent crystal structure of the catalytic domain of APOBEC3G revealed a secondary structure comprised of a five-stranded β-sheet core flanked by six α-helices, which is believed to be conserved across the entire family.³³ The active center loops have been shown to be responsible for both ssDNA binding and in determining “hotspot” identity.³⁴ Overexpression of these enzymes has been linked to genomic instability and cancer, thus highlighting the importance of sequence-specific targeting.³⁵

Some aspects of this disclosure relate to the recognition that the activity of cytidine deaminase enzymes such as APOBEC enzymes can be directed to a specific site in genomic DNA. Without wishing to be bound by any particular theory, advantages of using Cas9 as a recognition agent include (1) the sequence specificity of Cas9 can be easily altered by simply changing the sgRNA sequence; and (2) Cas9 binds to its target sequence by denaturing the dsDNA, resulting in a stretch of DNA that is single-stranded and therefore a viable substrate for the deaminase. It should be understood that other catalytic domains, or catalytic domains from other deaminases, can also be used to generate fusion proteins with Cas9, and that the disclosure is not limited in this regard.

Some aspects of this disclosure are based on the recognition that Cas9:deaminase fusion proteins can efficiently deaminate nucleotides at positions 3-11 according to the numbering scheme in FIG. 3. In view of the results provided herein regarding the nucleotides that can be targeted by Cas9:deaminase fusion proteins, a person of skill in the art will be able to design suitable guide RNAs to target the fusion proteins to a target sequence that comprises a nucleotide to be deaminated.

In some embodiments, the deaminase domain and the Cas9 domain are fused to each other via a linker. Various linker lengths and flexibilities between the deaminase domain (e.g., AID) and the Cas9 domain can be employed (e.g., ranging from very flexible linkers of the form (GGGGS)_(n) (SEQ ID NO: 5), (GGS)_(n), and (G)_(n) to more rigid linkers of the form (EAAAK)_(n) (SEQ ID NO: 6), (SGGS)_(n) (SEQ ID NO: 4288), SGSETPGTSESATPES (SEQ ID NO: 7) (see, e.g., Guilinger J P, Thompson D B, Liu D R. Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat. Biotechnol. 2014; 32(6): 577-82; the entire contents are incorporated herein by reference) and (XP)_(n))³⁶ in order to achieve the optimal length for deaminase activity for the specific application. In some embodiments, the linker comprises a (GGS)_(n) motif, wherein n is 1, 3, or 7. In some embodiments, the linker comprises a (an SGSETPGTSESATPES (SEQ ID NO: 7) motif.

Some exemplary suitable nucleic-acid editing domains, e.g., deaminases and deaminase domains, that can be fused to Cas9 domains according to aspects of this disclosure are provided below. It should be understood that, in some embodiments, the active domain of the respective sequence can be used, e.g., the domain without a localizing signal (nuclear localization sequence, without nuclear export signal, cytoplasmic localizing signal).

Human AID:

(SEQ ID NO: 266) MDSLLMNRRKFLYQFKNVRWAKGRRETYLCYVVKRRDSATSFSLDFGY LRNKNGCHVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVAD FLRGNPNLSLRIFTARLYFCEDRKAEPEGLRRLHRAGVQIAIMTFKDY FYCWNTFVENHERTFKAWEGLHENSVRLSRQLRRTLLPLYEVDDLRDA FRTLGL (underline: nuclear localization sequence; double underline: nuclear export signal)

Mouse AID:

(SEQ ID NO: 267) MDSLLMKQKKFLYHFKNVRWAKGRHETYLCYVVKRRDSATSCSLDFGH LRNKSGCHVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVAE FLRWNPNLSLRIFTARLYFCEDRKAEPEGLRRLHRAGVQIGIMTFKDY FYCWNTFVENRERTFKAWEGLHENSVRLTRQLRRILLPL YEVDDLRDA FRMLGF (underline: nuclear localization sequence; double underline: nuclear export signal)

Dog AID:

(SEQ ID NO: 268) MDSLLMKQRKFLYHFKNVRWAKGRHETYLCYVVKRRDSATSFSLDFGH LRNKSGCHVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVAD FLRGYPNLSLRIFAARLYFCEDRKAEPEGLRRLHRAGVQIAIMTFKDY FYCWNTFVENREKTFKAWEGLHENSVRLSRQLRRILLPLYEVDDLRDA FRTLGL (underline: nuclear localization sequence; double underline: nuclear export signal)

Bovine AID:

(SEQ ID NO: 269) MDSLLKKQRQFLYQFKNVRWAKGRHETYLCYVVKRRDSPTSFSLDFGH LRNKAGCHVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVAD FLRGYPNLSLRIFTARLYFCDKERKAEPEGLRRLHRAGVQIAIMTFKD YFYCWNTFVENHERTFKAWEGLHENSVRKSRQLRRILLPLYEVDDLRD AFRTLGL (underline: nuclear localization sequence; double underline: nuclear export signal)

Rat AID

(SEQ ID NO: 5725) MAVGSKPKAALVGPHWERERIWCFLCSTGLGTQQTGQTSRWLRPAATQ DPVSPPRSLLMKQRKFLYHFKNVRWAKGRHETYLCYVVKRRDSATSFS LDFGYLRNKSGCHVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCA RHVADFLRGNPNLSLRIFTARLTGWGALPAGLMSPARPSDYFYCWNTF VENHERTFKAWEGLHENSVRLSRRLRRILLPLYEVDDLRDAFRTLGL (underline: nuclear localization sequence; double underline: nuclear export signal)

Mouse APOBEC-3:

(SEQ ID NO: 270) MGPFCLGCSHRKCYSPIRNLISQETFKFHFKNLGYAKGRKDTFLCYEV TRKDCDSPVSLHHGVFKNKDNIHAEICFLYWFHDKVLKVLSPREEFKI TWYMSWSPCFECAEQIVRFLATHHNLSLDIFSSRLYNVQDPETQQNLC RLVQEGAQVAAMDLYEFKKCWKKFVDNGGRRFRPWKRLLTNFRYQDSK LQEILRPCYIPVPSSSSSTLSNICLTKGLPETRFCVEGRRMDPLSEEE FYSQFYNQRVKHLCYYHRMKPYLCYQLEQFNGQAPLKGCLLSEKGKQH AEILFLDKIRSMELSQVTITCYLTWSPCPNCAWQLAAFKRDRPDLILH IYTSRLYFHWKRPFQKGLCSLWQSGILVDVMDLPQFTDCWTNFVNPKR PFWPWKGLEIISRRTQRRLRRIKESWGLQDLVNDFGNLQLGPPMS (italic: nucleic acid editing domain)

Rat APOBEC-3:

(SEQ ID NO: 271) MGPFCLGCSHRKCYSPIRNLISQETFKFHFKNLRYAIDRKDTFLCYEV TRKDCDSPVSLHHGVFKNKDNIHAEICFLYWFHDKVLKVLSPREEFKI TWYMSWSPCFECAEQVLRFLATHHNLSLDIFSSRLYNIRDPENQQNLC RLVQEGAQVAAMDLYEFKKCWKKFVDNGGRRFRPWKKLLTNFRYQDSK LQEILRPCYIPVPSSSSSTLSNICLTKGLPETRFCVERRRVHLLSEEE FYSQFYNQRVKHLCYYHGVKPYLCYQLEQFNGQAPLKGCLLSEKGKQH AEILFLDKIRSMELSQVIITCYLTWSPCPNCAWQLAAFKRDRPDLILH IYTSRLYFHWKRPFQKGLCSLWQSGILVDVMDLPQFTDCWTNFVNPKR PFWPWKGLEIISRRTQRRLHRIKESWGLQDLVNDFGNLQLGPPMS (italic: nucleic acid editing domain)

Rhesus macaque APOBEC-3G:

(SEQ ID NO: 272) MVEPMDPRTFVSNFNNRPILSGLNTVWLCCEVKTKDPSGPPLDAKIFQ GKVYSKAKYHPEM RFLRWFHKWRQLHHDQEYKVTWYVSWSPCTRCANS VATFLAKDPKYTLTIFVARLYYFWKPDYQQALRILCQKRGGPHATMKI MNYNEFQDCWNKFVDGRGKPFKPRNNLPKHYTLLQATLGELLRHLMDP GTFTSNFNNKPWVSGQHETYLCYKVERLHNDTWVPLNQHRGFLRNQAP NIHGFPKGRHAELCFLDLIPFWKLDGQQYRVTCFTSWSPCFSCAQEMA KFISNNEHVSLCIFAARIYDDQGRYQEGLRALHRDGAKIAMMNYSEFE YCWDTFVDRQGRPFQPWDGLDEHSQALSGRLRAI (italic: nucleic acid editing domain; underline: cytoplasmic localization signal)

Chimpanzee APOBEC-3G:

(SEQ ID NO: 273) MKPHFRNPVERMYQDTFSDNFYNRPILSHRNTVWLCYEVKTKGPSRPP LDAKIFRGQVYSKLKYHPEMRFFHWFSKWRKLHRDQEYEVTWYISWSP CTKCTRDVATFLAEDPKVTLTIFVARLYYFWDPDYQEALRSLCQKRDG PRATMKIMNYDEFQHCWSKFVYSQRELFEPWNNLPKYYILLHIMLGEI LRHSMDPPTFTSNFNNELWVRGRHETYLCYEVERLHNDTWVLLNQRRG FLCNQAPHKHGFLEGRHAELCFLDVIPFWKLDLHQDYRVTCFTSWSPC FSCAQEMAKFISNNKHVSLCIFAARIYDDQGRCQEGLRTLAKAGAKIS IMTYSEFKHCWDTFVDHQGCPFQPWDGLEEHSQALSGRLRAILQNQGN (italic: nucleic acid editing domain; underline: cytoplasmic localization signal)

Green monkey APOBEC-3G:

(SEQ ID NO: 274) MNPQIRNMVEQMEPDIFVYYFNNRPILSGRNTVWLCYEVKTKDPSGPP LDANIFQGKLYPEAKDHPEMKFLHWFRKWRQLHRDQEYEVTWYVSWSP CTRCANSVATFLAEDPKVTLTIFVARLYYFWKPDYQQALRILCQERGG PHATMKIMNYNEFQHCWNEFVDGQGKPFKPRKNLPKHYTLLHATLGEL LRHVMDPGTFTSNFNNKPWVSGQRETYLCYKVERSHNDTWVLLNQHRG FLRNQAPDRHGFPKGRHAELCFLDLIPFWKLDDQQYRVTCFTSWSPCF SCAQKMAKFISNNKHVSLCIFAARIYDDQGRCQEGLRTLHRDGAKIAV MNYSEFEYCWDTFVDRQGRPFQPWDGLDEHSQALSGRLRAI (italic: nucleic acid editing domain; underline: cytoplasmic localization signal)

Human APOBEC-3G:

(SEQ ID NO: 275) MKPHFRNTVERMYRDTFSYNFYNRPILSRRNTVWLCYEVKTKGPSRPPLD AKIFRGQVYSELKYHPEMRFFHWFSKWRKLHRDQEYEVTWYISWSPCTKC TRDMATFLAEDPKVTLTIFVARLYYFWDPDYQEALRSLCQKRDGPRATMK IMNYDEFQHCWSKFVYSQRELFEPWNNLPKYYILLHIMLGEILRHSMDPP TFTFNFNNEPWVRGRHETYLCYEVERMHNDTWVLLNQRRGFLCNQAPHKH GFLEGRHAELCFLDVIPFWKLDLDQDYRVTCFTSWSPCFSCAQEMAKFIS KNKHVSLCIFTARIYDDQGRCQEGLRTLAEAGAKISIMTYSEFKHCWDTF VDHQGCPFQPWDGLDEHSQDLSGRLRAILQNQEN (italic: nucleic acid editing domain; underline: cytoplasmic localization signal)

Human APOBEC-3F:

(SEQ ID NO: 276) MKPHFRNTVERMYRDTFSYNFYNRPILSRRNTVWLCYEVKTKGPSRPRL DAKIFRGQVYSQPEHHAEMCFLSWFCGNQLPAYKCFQITWFVSWTPCPD CVAKLAEFLAEHPNVTLTISAARLYYYWERDYRRALCRLSQAGARVKIM DDEEFAYCWENFVYSEGQPFMPWYKFDDNYAFLHRTLKEILRNPMEAMY PHIFYFHFKNLRKAYGRNESWLCFTMEVVKHHSPVSWKRGVFRNQVDPE THCHAERCFLSWFCDDILSPNTNYEVTWYTSWSPCPECAGEVAEFLARH SNVNLTIFTARLYYFWDTDYQEGLRSLSQEGASVEIMGYKDFKYCWENF VYNDDEPFKPWKGLKYNFLFLDSKLQEILE (italic: nucleic acid editing domain)

Human APOBEC-3B:

(SEQ ID NO: 277) MNPQIRNPMERMYRDTFYDNFENEPILYGRSYTWLCYEVKIKRGRSNLL WDTGVFRGQVYFKPQYHAEMCFLSWFCGNQLPAYKCFQITWFVSWTPCP DCVAKLAEFLSEHPNVTLTISAARLYYYWERDYRRALCRLSQAGARVTI MDYEEFAYCWENFVYNEGQQFMPWYKFDENYAFLHRTLKEILRYLMDPD TFTFNFNNDPLVLRRRQTYLCYEVERLDNGTWVLMDQHMGFLCNEAKNL LCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVR AFLQENTHVRLRIFAARIYDYDPLYKEALQMLRDAGAQVSIMTYDEFEY CWDTFVYRQGCPFQPWDGLEEHSQALSGRLRAILQNQGN (italic: nucleic acid editing domain)

Rat APOBEC-3B:

(SEQ ID NO: 5729) MQPQGLGPNAGMGPVCLGCSHRRPYSPIRNPLKKLYQQTFYFHFKNVRY AWGRKNNFLCYEVNGMDCALPVPLRQGVFRKQGHIHAELCFIYWFHDKV WLRVLSPMEEFKVTYMSWSPCSKCAEQVARFLAAHRNLSLAIFSSRLYY YLRNPNYQQKLCRLIQEGVHVAAMDLPEFKKCWNKFVDNDGQPFRPWMR LRINFSFYDCKLQEIFSRMNLLREDVFYLQFNNSHRVKPVQNRYYRRKS YLCYQLERANGQEPLKGYLLYKKGEQHVEILFLEKMRSMELSQVRITCY LTWSPCPNCARQLAAFKKDHPDLILRIYTSRLYFYWRKKFQKGLCTLWR SGIHVDVMDLPQFADCWTNFVNPQRPFRPWNELEKNSWRIQRRLRRIKE SWGL 

Bovine APOBEC-3B:

(SEQ ID NO: 5730) DGWEVAFRSGTVLKAGVLGVSMTEGWAGSGHPGQGACVWTPGTRNTMN LLREVLFKQQFGNQPRVPAPYYRRKTYLCYQLKQRNDLTLDRGCFRNK KQRHAEIRFIDKINSLDLNPSQSYKIICYITWSPCPNCANELVNFITR NNHLKLEIFASRLYFHWIKSFKMGLQDLQNAGISVAVMTHTEFEDCWE QFVDNQSRPFQPWDKLEQYSASIRRRLQRILTAPI

Chimpanzee APOBEC-3B:

(SEQ ID NO: 5731) MNPQIRNPMEWMYQRTFYYNFENEPILYGRSYTWLCYEVKIRRGHSNLLW DTGVFRGQMYSQPEHHAEMCFLSWFCGNQLSAYKCFQITWFVSWTPCPDC VAKLAKFLAEHPNVTLTISAARLYYYWERDYRRALCRLSQAGARVKIMDD EEFAYCWENFVYNEGQPFMPWYKFDDNYAFLHRTLKEIIRHLMDPDTFTF NFNNDPLVLRRHQTYLCYEVERLDNGTWVLMDQHMGFLCNEAKNLLCGFY GRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGQVRAFLQEN THVRLRIFAARIYDYDPLYKEALQMLRDAGAQVSIMTYDEFEYCWDTFVY RQGCPFQPWDGLEEHSQALSGRLRAILQVRASSLCMVPHRPPPPPQSPGP CLPLCSEPPLGSLLPTGRPAPSLPFLLTASFSFPPPASLPPLPSLSLSPG HLPVPSFHSLTSCSIQPPCSSRIRETEGWASVSKEGRDLG

Human APOBEC-3C:

(SEQ ID NO: 278) MNPQRNPMKAMYPGTFYFQFKNLWEANDRNETWLCFTVEGIKRRSVVSW KTGVFRNQVDSETHCHAERCFLSWFCDDILSPNTKYQVTWYTSWSPCPD CAGEVAEFLARHSNVNLTIFTARLYYFQYPCYQEGLRSLSQEGVAVEIM DYEDFKYCWENFVYNDNEPFKPWKGLKTNFRLLKRRLRESLQ (italic: nucleic acid editing domain)

Gorilla APOBEC3C

(SEQ ID NO: 5726) MNPQRNPMKAMYPGTFYFQFKNLWEANDRNETWLCFTVEGIKRRSVVSWK TGVFRNQVDSETHCHAERCFLSWFCDDILSPNTNYQVTWYTSWSPCPECA GEVAEFLARHSNVNLTIFTARLYYFQDTDYQEGLRSLSQEGVAVKIMDYK DFKYCWENFVYNDDEPFKPWKGLKYNFRFLKRRLQEILE (italic: nucleic acid editing domain)

Human APOBEC-3A:

(SEQ ID NO: 279) MEASPASGPRHLMDPHIFTSNFNNGIGRHKTYLCYEVERLDNGTSVKMDQ HRGFLHNQAKNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSP CFSWGCAGEVRAFLQENTHVRLRIFAARIYDYDPLYKEALQMLRDAGAQV SIMTYDEFKHCWDTFVDHQGCPFQPWDGLDEHSQALSGRLRAILQNQGN (italic: nucleic acid editing domain)

Rhesus macaque APOBEC-3A:

(SEQ ID NO: 5727) MDGSPASRPRHLMDPNTFTFNFNNDLSVRGRHQTYLCYEVERLDNGTWVP MDERRGFLCNKAKNVPCGDYGCHVELRFLCEVPSWQLDPAQTYRVTWFIS WSPCFRRGCAGQVRVFLQENKHVRLRIFAARIYDYDPLYQEALRTLRDAG AQVSIMTYEEFKHCWDTFVDRQGRPFQPWDGLDEHSQALSGRLRAILQNQ GN (italic: nucleic acid editing domain)

Bovine APOBEC-3A:

(SEQ ID NO: 5728) MDEYTFTENFNNQGWPSKTYLCYEMERLDGDATIPLDEYKGFVRNKGLDQ PEKPCHAELYFLGKIHSWNLDRNQHYRLTCFISWSPCYDCAQKLTTFLKE NHHISLHILASRIYTHNRFGCHQSGLCELQAAGARITIMTFEDFKHCWET FVDHKGKPFQPWEGLNVKSQALCTELQAILKTQQN  (italic: nucleic acid editing domain)

Human APOBEC-3H:

(SEQ ID NO: 280) MALLTAETFRLQFNNKRRLRRPYYPRKALLCYQLTPQNGSTPTRGYFENK KKCHAEICFINEIKSMGLDETQCYQVTCYLTWSPCSSCAWELVDFIKAHD HLNLGIFASRLYYHWCKPQQKGLRLLCGSQVPVEVMGFPKFADCWENFVD HEKPLSFNPYKMLEELDKNSRAIKRRLERIKIPGVRAQGRYMDILCDAEV  (italic: nucleic acid editing domain)

Rhesus macaque APOBEC-3H:

(SEQ ID NO: 5732) MALLTAKTFSLQFNNKRRVNKPYYPRKALLCYQLTPQNGSTPTRGHLKNK KKDHAEIRFINKIKSMGLDETQCYQVTCYLTWSPCPSCAGELVDFIKAHR HLNLRIFASRLYYHWRPNYQEGLLLLCGSQVPVEVMGLPEFTDCWENFVD HKEPPSFNPSEKLEELDKNSQAIKRRLERIKSRSVDVLENGLRSLQLGPV TPSSSIRNSR Human APOBEC-3D:

(SEQ ID NO: 281) MNPQRNPMERMYRDTFYDNFENEPILYGRSYTWLCYEVKIKRGRSNLLW DTGVFRGPVLPKRQSNHRQEVYFRFENHAEMCFLSWFCGNRLPANRRFQ ITWFVSWNPCLPCVVKVTKFLAEHPNVTLTISAARLYYYRDRDWRWVLL RLHKAGARVKIMDYEDFAYCWENFVCNEGQPFMPWYKFDDNYASLHRTL KEILRNPMEAMYPHIFYFHFKNLLKACGRNESWLCFTMEVTKHHSAVFR KRGVFRNQVDPETHCHAERCFLSWFCDDILSPNTNYEVTWYTSWSPCPE CAGEVAEFLARHSNVNLTIFTARLCYFWDTDYQEGLCSLSQEGASVKIM GYKDFVSCWKNFVYSDDEPFKPWKGLQTNFRLLKRRLREILQ (italic: nucleic acid editing domain)

Human APOBEC-1:

(SEQ ID NO: 282) MTSEKGPSTGDPTLRRRIEPWEFDVFYDPRELRKEACLLYEIKWGMSRKI WRSSGKNTTNHVEVNFIKKFTSERDFHPSMSCSITWFLSWSPCWECSQAI REFLSRHPGVTLVIYVARLFWHMDQQNRQGLRDLVNSGVTIQIMRASEYY HCWRNFVNYPPGDEAHWPQYPPLWMMLYALELHCIILSLPPCLKISRRWQ NHLTFFRLHLQNCHYQTIPPHILLATGLIHPSVAWR 

Mouse APOBEC-1:

(SEQ ID NO: 283) MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSV WRHTSQNTSNHVEVNFLEKFTTERYFRPNTRCSITWFLSWSPCGECSRAI TEFLSRHPYVTLFIYIARLYHHTDQRNRQGLRDLISSGVTIQIMTEQEYC YCWRNFVNYPPSNEAYWPRYPHLWVKLYVLELYCIILGLPPCLKILRRKQ PQLTFFTITLQTCHYQRIPPHLLWATGLK

Rat APOBEC-1:

(SEQ ID NO: 284) MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHS IWRHTSQNTNKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSR AITEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQIMTEQ ESGYCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNIL RRKQPQLTFFTIALQSCHYQRLPPHILWATGLK

Human APOBEC-2:

(SEQ ID NO: 5733) MAQKEEAAVATEAASQNGEDLENLDDPEKLKELIELPPFEIVTGERLPAN FFKFQFRNVE YSSGRNKTFLCYVVEAQGKGGQVQASRGYLEDEHAAAHAEEAFFNTILPA FDPALRYNVTWYVSSSPCAACADRIIKTLSKTKNLRLLILVGRLFMWEEP EIQAALKKLKEAGCKLRIMKPQDFEYVWQNFVEQEEGESKAFQPWEDIQE NFLYYEEKLADILK

Mouse APOBEC-2:

(SEQ ID NO: 5734) MAQKEEAAEAAAPASQNGDDLENLEDPEKLKELIDLPPFEIVTGVRLPVN FFKFQFRNVEYSSGRNKTFLCYVVEVQSKGGQAQATQGYLEDEHAGAHAE EAFFNTILPAFDPALKYNVTWYVSSSPCAACADRILKTLSKTKNLRLLIL VSRLFMWEEPEVQAALKKLKEAGCKLRIMKPQDFEYIWQNFVEQEEGESK AFEPWEDIQENFLYYEEKLADILK

Rat APOBEC-2:

(SEQ ID NO: 5735) MAQKEEAAEAAAPASQNGDDLENLEDPEKLKELIDLPPFEIVTGVRLPV NFFKFQFRNVEYSSGRNKTFLCYVVEAQSKGGQVQATQGYLEDEHAGAH AEEAFFNTILPAFDPALKYNVTWYVSSSPCAACADRILKTLSKTKNLRL LILVSRLFMWEEPEVQAALKKLKEAGCKLRIMKPQDFEYLWQNFVEQEE GESKAFEPWEDIQENFLYYEEKLADILK

Bovine APOBEC-2:

(SEQ ID NO: 5736) MAQKEEAAAAAEPASQNGEEVENLEDPEKLKELIELPPFEIVTGERLPAH YFKFQFRNVE YSSGRNKTFLCYVVEAQSKGGQVQASRGYLEDEHATNHAEEAFFNSIMPT FDPALRYMVTWYVSSSPCAACADRIVKTLNKTKNLRLLILVGRLFMWEEP EIQAALRKLKEAGCRLRIMKPQDFEYIWQNFVEQEEGESKAFEPWEDIQE NFLYYEEKLADILK 

Petromyzon marinus CDA1 (pmCDA1)

(SEQ ID NO: 5738) MTDAEYVRIHEKLDIYTFKKQFFNNKKSVSHRCYVLFELKRRGERRACF WGYAVNKPQSGTERGIHAEIFSIRKVEEYLRDNPGQFTINWYSSWSPCA DCAEKILEWYNQELRGNGHTLKIWACKLYYEKNARNQIGLWNLRDNGVG LNVMVSEHYQCCRKIFIQSSHNQLNENRWLEKTLKRAEKRRSELSIMIQ VKILHTTKSPAV

Human APOBEC3G D316R_D317R

(SEQ ID NO: 5739) MKPHFRNTVERMYRDTFSYNFYNRPILSRRNTVWLCYEVKTKGPSRPPL DAKIFRGQVYSELKYHPEMRFFHWFSKWRKLHRDQEYEVTWYISWSPCT KCTRDMATFLAEDPKVTLTIFVARLYYFWDPDYQEALRSLCQKRDGPRA TMKIMNYDEFQHCWSKFVYSQRELFEPWNNLPKYYILLHIMLGEILRHS MDPPTFTFNFNNEPWVRGRHETYLCYEVERMHNDTWVLLNQRRGFLCNQ APHKHGFLEGRHAELCFLDVIPFWKLDLDQDYRVTCFTSWSPCFSCAQE MAKFISKNKHVSLCIFTARIYRRQGRCQEGLRTLAEAGAKISIMTYSEF KHCWDTFVDHQGCPFQPWDGLDEHSQDLSGRLRAILQNQEN

Human APOBEC3G chain A

(SEQ ID NO: 5740) MDPPTFTFNFNNEPWVRGRHETYLCYEVERMHNDTWVLLNQRRGFLCNQA PHKHGFLEGRHAELCFLDVIPFWKLDLDQDYRVTCFTSWSPCFSCAQEMA KFISKNKHVSLCIFTARIYDDQGRCQEGLRTLAEAGAKISIMTYSEFKHC WDTFVDHQGCPFQPWDGLDEHSQDLSGRLRAILQ

Human APOBEC3G chain A D120R_D121R

(SEQ ID NO: 5741) MDPPTFTFNFNNEPWVRGRHETYLCYEVERMHNDTWVLLNQRRGFLCNQ APHKHGFLEGRHAELCFLDVIPFWKLDLDQDYRVTCFTSWSPCFSCAQE MAKFISKNKHVSLFTARIYRRQGRCQEGLRTLAEAGAKISIMTYSEFKH CWDTFVDHQGCPFQPWDGLDEHSQDLSGRLRAILQ 

In some embodiments, fusion proteins as provided herein comprise the full-length amino acid of a nucleic acid editing enzyme, e.g., one of the sequences provided above. In other embodiments, however, fusion proteins as provided herein do not comprise a full-length sequence of a nucleic acid editing enzyme, but only a fragment thereof. For example, in some embodiments, a fusion protein provided herein comprises a Cas9 domain and a fragment of a nucleic acid editing enzyme, e.g., wherein the fragment comprises a nucleic acid editing domain. Exemplary amino acid sequences of nucleic acid editing domains are shown in the sequences above as italicized letters, and additional suitable sequences of such domains will be apparent to those of skill in the art.

Additional suitable nucleic-acid editing enzyme sequences, e.g., deaminase enzyme and domain sequences, that can be used according to aspects of this invention, e.g., that can be fused to a nuclease-inactive Cas9 domain, will be apparent to those of skill in the art based on this disclosure. In some embodiments, such additional enzyme sequences include deaminase enzyme or deaminase domain sequences that are at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% similar to the sequences provided herein. Additional suitable Cas9 domains, variants, and sequences will also be apparent to those of skill in the art. Examples of such additional suitable Cas9 domains include, but are not limited to, D10A, D10A/D839A/H840A, and D10A/D839A/H840A/N863A mutant domains (See, e.g., Prashant et al., CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature Biotechnology. 2013; 31(9): 833-838 the entire contents of which are incorporated herein by reference). In some embodiments, the Cas9 comprises a histidine residue at position 840 of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. The presence of the catalytic residue H840 restores the acvitity of the Cas9 to cleave the non-edited strand containing a G opposite the targeted C. Restoration of H840 does not result in the cleavage of the target strand containing the C.

Additional suitable strategies for generating fusion proteins comprising a Cas9 domain and a deaminase domain will be apparent to those of skill in the art based on this disclosure in combination with the general knowledge in the art. Suitable strategies for generating fusion proteins according to aspects of this disclosure using linkers or without the use of linkers will also be apparent to those of skill in the art in view of the instant disclosure and the knowledge in the art. For example, Gilbert et al., CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013; 154(2):442-51, showed that C-terminal fusions of Cas9 with VP64 using 2 NLS's as a linker (SPKKKRKVEAS, SEQ ID NO: 599), can be employed for transcriptional activation. Mali et al., CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol. 2013; 31(9):833-8, reported that C-terminal fusions with VP64 without linker can be employed for transcriptional activation. And Maeder et al., CRISPR RNA-guided activation of endogenous human genes. Nat Methods. 2013; 10: 977-979, reported that C-terminal fusions with VP64 using a Gly₄Ser (SEQ ID NO: 5) linker can be used as transcriptional activators. Recently, dCas9-FokI nuclease fusions have successfully been generated and exhibit improved enzymatic specificity as compared to the parental Cas9 enzyme (In Guilinger J P, Thompson D B, Liu D R. Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat. Biotechnol. 2014; 32(6): 577-82, and in Tsai S Q, Wyvekens N, Khayter C, Foden J A, Thapar V, Reyon D, Goodwin M J, Aryee M J, Joung J K. Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotechnol. 2014; 32(6):569-76. PMID: 24770325 a SGSETPGTSESATPES (SEQ ID NO: 7) or a GGGGS (SEQ ID NO: 5) linker was used in FokI-dCas9 fusion proteins, respectively).

Some aspects of this disclosure provide fusion proteins comprising (i) a Cas9 enzyme or domain (e.g., a first protein); and (ii) a nucleic acid-editing enzyme or domain (e.g., a second protein). In some aspects, the fusion proteins provided herein further include (iii) a programmable DNA-binding protein, for example, a zinc-finger domain, a TALE, or a second Cas9 protein (e.g., a third protein). Without wishing to be bound by any particular theory, fusing a programmable DNA-binding protein (e.g., a second Cas9 protein) to a fusion protein comprising (i) a Cas9 enzyme or domain (e.g., a first protein); and (ii) a nucleic acid-editing enzyme or domain (e.g., a second protein) may be useful for improving specificity of the fusion protein to a target nucleic acid sequence, or for improving specificity or binding affinity of the fusion protein to bind target nucleic acid sequence that does not contain a canonical PAM (NGG) sequence. In some embodiments, the third protein is a Cas9 protein (e.g, a second Cas9 protein). In some embodiments, the third protein is any of the Cas9 proteins provided herein. In some embodiments, the third protein is fused to the fusion protein N-terminal to the Cas9 protein (e.g., the first protein). In some embodiments, the third protein is fused to the fusion protein C-terminal to the Cas9 protein (e.g., the first protein). In some embodiments, the Cas9 domain (e.g., the first protein) and the third protein (e.g., a second Cas9 protein) are fused via a linker (e.g., a second linker). In some embodiments, the linker comprises a (GGGGS)n (SEQ ID NO: 5), a (G)n, an (EAAAK)n (SEQ ID NO: 6), a (GGS)n, (SGGS)_(n) (SEQ ID NO: 4288), an SGSETPGTSESATPES (SEQ ID NO: 7), or an (XP)n motif, or a combination of any of these, wherein n is independently an integer between 1 and 30. In some embodiments, the general architecture of exemplary Cas9 fusion proteins provided herein comprises the structure:

-   -   [NH2]-[nucleic acid-editing enzyme or domain]-[Cas9]-[third         protein]-[COOH];     -   [NH2]-[third protein]-[Cas9]-[nucleic acid-editing enzyme or         domain]-[COOH];     -   [NH2]-[Cas9]-[nucleic acid-editing enzyme or domain]-[third         protein]-[COOH];     -   [NH2]-[third protein]-[nucleic acid-editing enzyme or         domain]-[Cas9]-[COOH];     -   [NH2]-[UGI]-[nucleic acid-editing enzyme or         domain]-[Cas9]-[third protein]-[COOH];     -   [NH2]-[UGI]-[third protein]-[Cas9]-[nucleic acid-editing enzyme         or domain]-[COOH];     -   [NH2]-[UGI]-[Cas9]-[nucleic acid-editing enzyme or         domain]-[third protein]-[COOH];     -   [NH2]-[UGI]-[third protein]-[nucleic acid-editing enzyme or         domain]-[Cas9]-[COOH];     -   [NH2]-[nucleic acid-editing enzyme or domain]-[Cas9]-[third         protein]-[UGI]-[COOH];     -   [NH2]-[third protein]-[Cas9]-[nucleic acid-editing enzyme or         domain]-[UGI]-[COOH];     -   [NH2]-[Cas9]-[nucleic acid-editing enzyme or domain]-[third         protein]-[UGI]-[COOH]; or     -   [NH2]-[third protein]-[nucleic acid-editing enzyme or         domain]-[Cas9]-[UGI]-[COOH];         wherein NH2 is the N-terminus of the fusion protein, and COOH is         the C-terminus of the fusion protein. In some embodiments, the         “]-[” used in the general architecture above indicates the         presence of an optional linker sequence. In other examples, the         general architecture of exemplary Cas9 fusion proteins provided         herein comprises the structure:     -   [NH2]-[nucleic acid-editing enzyme or domain]-[Cas9]-[second         Cas9 protein]-[COOH];     -   [NH2]-[second Cas9 protein]-[Cas9]-[nucleic acid-editing enzyme         or domain]-[COOH];     -   [NH2]-[Cas9]-[nucleic acid-editing enzyme or domain]-[second         Cas9 protein]-[COOH];     -   [NH2]-[second Cas9 protein]-[nucleic acid-editing enzyme or         domain]-[Cas9]-[COOH];     -   [NH2]-[UGI]-[nucleic acid-editing enzyme or         domain]-[Cas9]-[second Cas9 protein]-[COOH],     -   [NH2]-[UGI]-[second Cas9 protein]-[Cas9]-[nucleic acid-editing         enzyme or domain]-[COOH];     -   [NH2]-[UGI]-[Cas9]-[nucleic acid-editing enzyme or         domain]-[second Cas9 protein]-[COOH];     -   [NH2]-[UGI]-[second Cas9 protein]-[nucleic acid-editing enzyme         or domain]-[Cas9]-[COOH];     -   [NH2]-[nucleic acid-editing enzyme or domain]-[Cas9]-[second         Cas9 protein]-[UGI]-[COOH];     -   [NH2]-[second Cas9 protein]-[Cas9]-[nucleic acid-editing enzyme         or domain]-[UGI]-[COOH];     -   [NH2]-[Cas9]-[nucleic acid-editing enzyme or domain]-[second         Cas9 protein]-[UGI]-[COOH]; or     -   [NH2]-[second Cas9 protein]-[nucleic acid-editing enzyme or         domain]-[Cas9]-[UGI]-[COOH];         wherein NH₂ is the N-terminus of the fusion protein, and COOH is         the C-terminus of the fusion protein. In some embodiments, the         “]-[” used in the general architecture above indicates the         presence of an optional linker sequence. In some embodiments,         the second Cas9 is a dCas9 protein. In some examples, the         general architecture of exemplary Cas9 fusion proteins provided         herein comprises a structure as shown in FIG. 3. It should be         appreciated that any of the proteins provided in any of the         general architectures of exemplary Cas9 fusion proteins may be         connected by one or more of the linkers provided herein. In some         embodiments, the linkers are the same. In some embodiments, the         linkers are different. In some embodiments, one or more of the         proteins provided in any of the general architectures of         exemplary Cas9 fusion proteins are not fused via a linker. In         some embodiments, the fusion proteins further comprise a nuclear         targeting sequence, for example a nuclear localization sequence.         In some embodiments, fusion proteins provided herein further         comprise a nuclear localization sequence (NLS). In some         embodiments, the NLS is fused to the N-terminus of the fusion         protein. In some embodiments, the NLS is fused to the C-terminus         of the fusion protein. In some embodiments, the NLS is fused to         the N-terminus of the third protein. In some embodiments, the         NLS is fused to the C-terminus of the third protein. In some         embodiments, the NLS is fused to the N-terminus of the Cas9         protein. In some embodiments, the NLS is fused to the C-terminus         of the Cas9 protein. In some embodiments, the NLS is fused to         the N-terminus of the nucleic acid-editing enzyme or domain. In         some embodiments, the NLS is fused to the C-terminus of the         nucleic acid-editing enzyme or domain. In some embodiments, the         NLS is fused to the N-terminus of the UGI protein. In some         embodiments, the NLS is fused to the C-terminus of the UGI         protein. In some embodiments, the NLS is fused to the fusion         protein via one or more linkers. In some embodiments, the NLS is         fused to the fusion protein without a linker         Uracil Glycosylase Inhibitor Fusion Proteins

Some aspects of the disclosure relate to fusion proteins that comprise a uracil glycosylase inhibitor (UGI) domain. In some embodiments, any of the fusion proteins provided herein that comprise a Cas9 domain (e.g., a nuclease active Cas9 domain, a nuclease inactive dCas9 domain, or a Cas9 nickase) may be further fused to a UGI domain either directly or via a linker. Some aspects of this disclosure provide deaminase-dCas9 fusion proteins, deaminase-nuclease active Cas9 fusion proteins and deaminase-Cas9 nickase fusion proteins with increased nucleobase editing efficiency. Without wishing to be bound by any particular theory, cellular DNA-repair response to the presence of U:G heteroduplex DNA may be responsible for the decrease in nucleobase editing efficiency in cells. For example, uracil DNA glycosylase (UDG) catalyzes removal of U from DNA in cells, which may initiate base excision repair, with reversion of the U:G pair to a C:G pair as the most common outcome. As demonstrated in the Examples below, Uracil DNA Glycosylase Inhibitor (UGI) may inhibit human UDG activity. Thus, this disclosure contemplates a fusion protein comprising dCas9-nucleic acid editing domain further fused to a UGI domain. This disclosure also contemplates a fusion protein comprising a Cas9 nickase-nucleic acid editing domain further fused to a UGI domain. It should be understood that the use of a UGI domain may increase the editing efficiency of a nucleic acid editing domain that is capable of catalyzing a C to U change. For example, fusion proteins comprising a UGI domain may be more efficient in deaminating C residues. In some embodiments, the fusion protein comprises the structure:

-   -   [deaminase]-[optional linker sequence]-[dCas9]-[optional linker         sequence]-[UGI];     -   [deaminase]-[optional linker sequence]-[UGI]-[optional linker         sequence]-[dCas9];     -   [UGI]-[optional linker sequence]-[deaminase]-[optional linker         sequence]-[dCas9];     -   [UGI]-[optional linker sequence]-[dCas9]-[optional linker         sequence]-[deaminase];     -   [dCas9]-[optional linker sequence]-[deaminase]-[optional linker         sequence]-[UGI]; or     -   [dCas9]-[optional linker sequence]-[UGI]-[optional linker         sequence]-[deaminase].         In other embodiments, the fusion protein comprises the         structure:     -   [deaminase]-[optional linker sequence]-[Cas9 nickase]-[optional         linker sequence]-[UGI];     -   [deaminase]-[optional linker sequence]-[UGI]-[optional linker         sequence]-[Cas9 nickase];     -   [UGI]-[optional linker sequence]-[deaminase]-[optional linker         sequence]-[Cas9 nickase];     -   [UGI]-[optional linker sequence]-[Cas9 nickase]-[optional linker         sequence]-[deaminase];     -   [Cas9 nickase]-[optional linker sequence]-[deaminase]-[optional         linker sequence]-[UGI]; or     -   [Cas9 nickase]-[optional linker sequence]-[UGI]-[optional linker         sequence]-[deaminase].

In some embodiments, the fusion proteins provided herein do not comprise a linker sequence. In some embodiments, one or both of the optional linker sequences are present.

In some embodiments, the “-” used in the general architecture above indicates the presence of an optional linker sequence. In some embodiments, the fusion proteins comprising a UGI further comprise a nuclear targeting sequence, for example a nuclear localization sequence. In some embodiments, fusion proteins provided herein further comprise a nuclear localization sequence (NLS). In some embodiments, the NLS is fused to the N-terminus of the fusion protein. In some embodiments, the NLS is fused to the C-terminus of the fusion protein. In some embodiments, the NLS is fused to the N-terminus of the UGI protein. In some embodiments, the NLS is fused to the C-terminus of the UGI protein. In some embodiments, the NLS is fused to the N-terminus of the Cas9 protein. In some embodiments, the NLS is fused to the C-terminus of the Cas9 protein. In some embodiments, the NLS is fused to the N-terminus of the deaminase. In some embodiments, the NLS is fused to the C-terminus of the deaminase. In some embodiments, the NLS is fused to the N-terminus of the second Cas9. In some embodiments, the NLS is fused to the C-terminus of the second Cas9. In some embodiments, the NLS is fused to the fusion protein via one or more linkers. In some embodiments, the NLS is fused to the fusion protein without a linker. In some embodiments, the NLS comprises an amino acid sequence of any one of the NLS sequences provided or referenced herein. In some embodiments, the NLS comprises an amino acid sequence as set forth in SEQ ID NO: 741or SEQ ID NO: 742.

In some embodiments, a UGI domain comprises a wild-type UGI or a UGI as set forth in SEQ ID NO: 600. In some embodiments, the UGI proteins provided herein include fragments of UGI and proteins homologous to a UGI or a UGI fragment. For example, in some embodiments, a UGI domain comprises a fragment of the amino acid sequence set forth in SEQ ID NO: 600. In some embodiments, a UGI fragment comprises an amino acid sequence that comprises at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% of the amino acid sequence as set forth in SEQ ID NO: 600. In some embodiments, a UGI comprises an amino acid sequence homologous to the amino acid sequence set forth in SEQ ID NO: 600 or an amino acid sequence homologous to a fragment of the amino acid sequence set forth in SEQ ID NO: 600. In some embodiments, proteins comprising UGI or fragments of UGI or homologs of UGI or UGI fragments are referred to as “UGI variants.” A UGI variant shares homology to UGI, or a fragment thereof. For example a UGI variant is at least 70% identical, at least 75% identical, at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, at least 99% identical, at least 99.5% identical, or at least 99.9% identical to a wild type UGI or a UGI as set forth in SEQ ID NO: 600. In some embodiments, the UGI variant comprises a fragment of UGI, such that the fragment is at least 70% identical, at least 80% identical, at least 90% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, at least 99% identical, at least 99.5% identical, or at least 99.9% to the corresponding fragment of wild-type UGI or a UGI as set forth in SEQ ID NO: 600. In some embodiments, the UGI comprises the following amino acid sequence:

>sp|P14739|UNGI_BPPB2 Uracil-DNA glycosylase inhibitor (SEQ ID NO: 600) MTNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDES TDENVMLLTSDAPEYKPWALVIQDSNGENKIKML

Suitable UGI protein and nucleotide sequences are provided herein and additional suitable UGI sequences are known to those in the art, and include, for example, those published in Wang et al., Uracil-DNA glycosylase inhibitor gene of bacteriophage PBS2 encodes a binding protein specific for uracil-DNA glycosylase. J. Biol. Chem. 264:1163-1171(1989); Lundquist et al., Site-directed mutagenesis and characterization of uracil-DNA glycosylase inhibitor protein. Role of specific carboxylic amino acids in complex formation with Escherichia coli uracil-DNA glycosylase. J. Biol. Chem. 272:21408-21419(1997); Ravishankar et al., X-ray analysis of a complex of Escherichia coli uracil DNA glycosylase (EcUDG) with a proteinaceous inhibitor. The structure elucidation of a prokaryotic UDG. Nucleic Acids Res. 26:4880-4887(1998); and Putnam et al., Protein mimicry of DNA from crystal structures of the uracil-DNA glycosylase inhibitor protein and its complex with Escherichia coli uracil-DNA glycosylase. J. Mol. Biol. 287:331-346(1999), the entire contents of each are incorporated herein by reference.

It should be appreciated that additional proteins may be uracil glycosylase inhibitors. For example, other proteins that are capable of inhibiting (e.g., sterically blocking) a uracil-DNA glycosylase base-excision repair enzyme are within the scope of this disclosure. Additionally, any proteins that block or inhibit base-excision repair as also within the scope of this disclosure. In some embodiments, a protein that binds DNA is used. In another embodiment, a substitute for UGI is used. In some embodiments, a uracil glycosylase inhibitor is a protein that binds single-stranded DNA. For example, a uracil glycosylase inhibitor may be a Erwinia tasmaniensis single-stranded binding protein. In some embodiments, the single-stranded binding protein comprises the amino acid sequence (SEQ ID NO: 322). In some embodiments, a uracil glycosylase inhibitor is a protein that binds uracil. In some embodiments, a uracil glycosylase inhibitor is a protein that binds uracil in DNA. In some embodiments, a uracil glycosylase inhibitor is a catalytically inactive uracil DNA-glycosylase protein. In some embodiments, a uracil glycosylase inhibitor is a catalytically inactive uracil DNA-glycosylase protein that does not excise uracil from the DNA. For example, a uracil glycosylase inhibitor is a UdgX. In some embodiments, the UdgX comprises the amino acid sequence (SEQ ID NO: 323). As another example, a uracil glycosylase inhibitor is a catalytically inactive UDG. In some embodiments, a catalytically inactive UDG comprises the amino acid sequence (SEQ ID NO: 324). It should be appreciated that other uracil glycosylase inhibitors would be apparent to the skilled artisan and are within the scope of this disclosure. In some embodiments, a uracil glycosylase inhibitor is a protein that is homologous to any one of SEQ ID NOs: 322-324. In some embodiments, a uracil glycosylase inhibitor is a protein that is at least 50% identical, at least 55% identical at least 60% identical, at least 65% identical, at least 70% identical, at least 75% identical, at least 80% identical at least 85% identical, at least 90% identical, at least 95% identical, at least 96% identical, at least 98% identical, at least 99% identical, or at least 99.5% identical to any one of SEQ ID NOs: 322-324.

Erwinia tasmaniensis SSB (themostable single-stranded DNA binding protein)

(SEQ ID NO: 322) MASRGVNKVILVGNLGQDPEVRYMPNGGAVANITLATSESWRDKQTGETK EKTEWHRVVLFGKLAEVAGEYLRKGSQVYIEGALQTRKWTDQAGVEKYTT EVVVNVGGTMQMLGGRSQGGGASAGGQNGGSNNGWGQPQQPQGGNQFSGG AQQQARPQQQPQQNNAPANNEPPIDFDDDIP UdgX (binds to Uracil in DNA but does not excise)

(SEQ ID NO: 323) MAGAQDFVPHTADLAELAAAAGECRGCGLYRDATQAVFGAGGRSARIMMI GEQPGDKEDLAGLPFVGPAGRLLDRALEAADIDRDALYVTNAVKHFKFTR AAGGKRRIHKTPSRTEVVACRPWLIAEMTSVEPDVVVLLGATAAKALLGN DFRVTQHRGEVLHVDDVPGDPALVATVHPSSLLRGPKEERESAFAGLVDD LRVAADVRP UDG (catalytically inactive human UDG, binds to Uracil in DNA but does not excise)

(SEQ ID NO: 324) MIGQKTLYSFFSPSPARKRHAPSPEPAVQGTGVAGVPEESGDAAAIPAK KAPAGQEEPGTPPSSPLSAEQLDRIQRNKAAALLRLAARNVPVGFGESW KKHLSGEFGKPYFIKLMGFVAEERKHYTVYPPPHQVFTWTQMCDIKDVK VVILGQEPYHGPNQAHGLCFSVQRPVPPPPSLENIYKELSTDIEDFVHP GHGDLSGWAKQGVLLLNAVLTVRAHQANSHKERGWEQFTDAVVSWLNQN SNGLVFLLWGSYAQKKGSAIDRKRHHVLQTAHPSPLSVYRGFFGCRHFS KTNELLQKSGKKPIDWKEL

In some embodiments, the nucleic acid editing domain is a deaminase domain. In some embodiments, the deaminase is a cytosine deaminase or a cytidine deaminase. In some embodiments, the deaminase is an apolipoprotein B mRNA-editing complex (APOBEC) family deaminase. In some embodiments, the deaminase is an APOBEC1 deaminase. In some embodiments, the deaminase is an APOBEC2 deaminase. In some embodiments, the deaminase is an APOBEC3 deaminase. In some embodiments, the deaminase is an APOBEC3A deaminase. In some embodiments, the deaminase is an APOBEC3B deaminase. In some embodiments, the deaminase is an APOBEC3C deaminase. In some embodiments, the deaminase is an APOBEC3D deaminase. In some embodiments, the deaminase is an APOBEC3E deaminase. In some embodiments, the deaminase is an APOBEC3F deaminase. In some embodiments, the deaminase is an APOBEC3G deaminase. In some embodiments, the deaminase is an APOBEC3H deaminase. In some embodiments, the deaminase is an APOBEC4 deaminase. In some embodiments, the deaminase is an activation-induced deaminase (AID). In some embodiments, the demianse is a rat APOBEC1 (SEQ ID NO: 282). In some embodiments, the deminase is a human APOBEC1 (SEQ ID No: 284). In some embodiments, the deaminase is a Petromyzon marinus cytidine deaminase 1 (pmCDA1). In some embodiments, the deminase is a human APOBEC3G (SEQ ID NO: 275). In some embodiments, the deaminase is a fragment of the human APOBEC3G (SEQ ID NO: 5740). In some embodiments, the deaminase is a human APOBEC3G variant comprising a D316R_D317R mutation (SEQ ID NO: 5739). In some embodiments, the deaminase is a frantment of the human APOBEC3G and comprising mutations corresponding to the D316R_D317R mutations in SEQ ID NO: 275 (SEQ ID NO: 5741).

In some embodiments, the linker comprises a (GGGS)_(n) (SEQ ID NO: 265), (GGGGS)_(n) (SEQ ID NO: 5), a (G)_(n), an (EAAAK)_(n) (SEQ ID NO: 6), a (GGS)_(n), an SGSETPGTSESATPES (SEQ ID NO: 7), or an (XP)_(n) motif, or a combination of any of these, wherein n is independently an integer between 1 and 30.

Suitable UGI protein and nucleotide sequences are provided herein and additional suitable UGI sequences are known to those in the art, and include, for example, those published in Wang et al., Uracil-DNA glycosylase inhibitor gene of bacteriophage PBS2 encodes a binding protein specific for uracil-DNA glycosylase. J. Biol. Chem. 264:1163-1171(1989); Lundquist et al., Site-directed mutagenesis and characterization of uracil-DNA glycosylase inhibitor protein. Role of specific carboxylic amino acids in complex formation with Escherichia coli uracil-DNA glycosylase. J. Biol. Chem. 272:21408-21419(1997); Ravishankar et al., X-ray analysis of a complex of Escherichia coli uracil DNA glycosylase (EcUDG) with a proteinaceous inhibitor. The structure elucidation of a prokaryotic UDG. Nucleic Acids Res. 26:4880-4887(1998); and Putnam et al., Protein mimicry of DNA from crystal structures of the uracil-DNA glycosylase inhibitor protein and its complex with Escherichia coli uracil-DNA glycosylase. J. Mol. Biol. 287:331-346(1999), the entire contents of which are incorporated herein by reference. In some embodiments, the optional linker comprises a (GGS)_(n) motif, wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 19, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some embodiments, the optional linker comprises a (GGS)n motif, wherein n is 1, 3, or 7. In some embodiments, the optional linker comprises the amino acid sequence SGSETPGTSESATPES (SEQ ID NO: 7), which is also referred to as the XTEN linker in the Examples.

In some embodiments, a Cas9 nickase may further facilitate the removal of a base on the non-edited strand in an organism whose genome is edited in vivo. The Cas9 nickase, as described herein, may comprise a D10A mutation in SEQ ID NO: 10, or a corresponding mutation in any of SEQ ID NOs: 11-260. In some embodiments, the Cas9 nickase of this disclosure may comprise a histidine at mutation 840 of SEQ ID NO: 10, or a corresponding residue in any of SEQ ID NOs: 11-260. Such fusion proteins comprising the Cas9 nickase, can cleave a single strand of the target DNA sequence, e.g., the strand that is not being edited. Without wishing to be bound by any particular theory, this cleavage may inhibit mis-match repair mechanisms that reverse a C to U edit made by the deaminase.

Cas9 Complexes with Guide RNAs

Some aspects of this disclosure provide complexes comprising any of the fusion proteins provided herein, and a guide RNA bound to a Cas9 domain (e.g., a dCas9, a nuclease active Cas9, or a Cas9 nickase) of fusion protein.

In some embodiments, the guide RNA is from 15-100 nucleotides long and comprises a sequence of at least 10 contiguous nucleotides that is complementary to a target sequence. In some embodiments, the guide RNA is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides long. In some embodiments, the guide RNA comprises a sequence of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 contiguous nucleotides that is complementary to a target sequence. In some embodiments, the target sequence is a DNA sequence. In some embodiments, the target sequence is a sequence in the genome of a mammal. In some embodiments, the target sequence is a sequence in the genome of a human. In some embodiments, the 3′ end of the target sequence is immediately adjacent to a canonical PAM sequence (NGG). In some embodiments, the guide RNA is complementary to a sequence associated with a disease or disorder. In some embodiments, the guide RNA is complementary to a sequence associated with a disease or disorder having a mutation in a gene selected from the genes disclosed in any one of Tables 1-3. In some embodiments, the guide RNA comprises a nucleotide sequence of any one of the guide sequences provided in Table 2 or Table 3. Exemplary sequences in the human genome that may be targeted by the complexes of this disclosure are provided herein in Tables 1-3.

Methods of Using Cas9 Fusion Proteins

Some aspects of this disclosure provide methods of using the Cas9 proteins, fusion proteins, or complexes provided herein. For example, some aspects of this disclosure provide methods comprising contacting a DNA molecule (a) with any of the the Cas9 proteins or fusion proteins provided herein, and with at least one guide RNA, wherein the guide RNA is about 15-100 nucleotides long and comprises a sequence of at least 10 contiguous nucleotides that is complementary to a target sequence; or (b) with a Cas9 protein, a Cas9 fusion protein, or a Cas9 protein or fusion protein complex with at least one gRNA as provided herein. In some embodiments, the 3′ end of the target sequence is not immediately adjacent to a canonical PAM sequence (NGG). In some embodiments, the 3′ end of the target sequence is immediately adjacent to an AGC, GAG, TTT, GTG, or CAA sequence.

In some embodiments, the target DNA sequence comprises a sequence associated with a disease or disorder. In some embodiments, the target DNA sequence comprises a point mutation associated with a disease or disorder. In some embodiments, the activity of the Cas9 protein, the Cas9 fusion protein, or the complex results in a correction of the point mutation. In some embodiments, the target DNA sequence comprises a T→C point mutation associated with a disease or disorder, and wherein the deamination of the mutant C base results in a sequence that is not associated with a disease or disorder. In some embodiments, the target DNA sequence encodes a protein and wherein the point mutation is in a codon and results in a change in the amino acid encoded by the mutant codon as compared to the wild-type codon. In some embodiments, the deamination of the mutant C results in a change of the amino acid encoded by the mutant codon. In some embodiments, the deamination of the mutant C results in the codon encoding the wild-type amino acid. In some embodiments, the contacting is in vivo in a subject. In some embodiments, the subject has or has been diagnosed with a disease or disorder. In some embodiments, the disease or disorder is cystic fibrosis, phenylketonuria, epidermolytic hyperkeratosis (EHK), Charcot-Marie-Toot disease type 4J, neuroblastoma (NB), von Willebrand disease (vWD), myotonia congenital, hereditary renal amyloidosis, dilated cardiomyopathy (DCM), hereditary lymphedema, familial Alzheimer's disease, HIV, Prion disease, chronic infantile neurologic cutaneous particular syndrome (CINCA), desmin-related myopathy (DRM), a neoplastic disease associated with a mutant PI3KCA protein, a mutant CTNNB1 protein, a mutant HRAS protein, or a mutant p53 protein.

Some embodiments provide methods for using the Cas9 DNA editing fusion proteins provided herein. In some embodiments, the fusion protein is used to introduce a point mutation into a nucleic acid by deaminating a target nucleobase, e.g., a C residue. In some embodiments, the deamination of the target nucleobase results in the correction of a genetic defect, e.g., in the correction of a point mutation that leads to a loss of function in a gene product. In some embodiments, the genetic defect is associated with a disease or disorder, e.g., a lysosomal storage disorder or a metabolic disease, such as, for example, type I diabetes. In some embodiments, the methods provided herein are used to introduce a deactivating point mutation into a gene or allele that encodes a gene product that is associated with a disease or disorder. For example, in some embodiments, methods are provided herein that employ a Cas9 DNA editing fusion protein to introduce a deactivating point mutation into an oncogene (e.g., in the treatment of a proliferative disease). A deactivating mutation may, in some embodiments, generate a premature stop codon in a coding sequence, which results in the expression of a truncated gene product, e.g., a truncated protein lacking the function of the full-length protein.

In some embodiments, the purpose of the methods provide herein is to restore the function of a dysfunctional gene via genome editing. The Cas9 deaminase fusion proteins provided herein can be validated for gene editing-based human therapeutics in vitro, e.g., by correcting a disease-associated mutation in human cell culture. It will be understood by the skilled artisan that the fusion proteins provided herein, e.g., the fusion proteins comprising a Cas9 domain and a nucleic acid deaminase domain can be used to correct any single point T→C or A→G mutation. In the first case, deamination of the mutant C back to U corrects the mutation, and in the latter case, deamination of the C that is base-paired with the mutant G, followed by a round of replication, corrects the mutation.

An exemplary disease-relevant mutation that can be corrected by the provided fusion proteins in vitro or in vivo is the H1047R (A3140G) polymorphism in the PI3KCA protein. The phosphoinositide-3-kinase, catalytic alpha subunit (PI3KCA) protein acts to phosphorylate the 3-OH group of the inositol ring of phosphatidylinositol. The PI3KCA gene has been found to be mutated in many different carcinomas, and thus it is considered to be a potent oncogene.³⁷ In fact, the A3140G mutation is present in several NCI-60 cancer cell lines, such as, for example, the HCT116, SKOV3, and T47D cell lines, which are readily available from the American Type Culture Collection (ATCC).³⁸

In some embodiments, a cell carrying a mutation to be corrected, e.g., a cell carrying a point mutation, e.g., an A3140G point mutation in exon 20 of the PI3KCA gene, resulting in a H1047R substitution in the PI3KCA protein, is contacted with an expression construct encoding a Cas9 deaminase fusion protein and an appropriately designed sgRNA targeting the fusion protein to the respective mutation site in the encoding PI3KCA gene. Control experiments can be performed where the sgRNAs are designed to target the fusion enzymes to non-C residues that are within the PI3KCA gene. Genomic DNA of the treated cells can be extracted, and the relevant sequence of the PI3KCA genes PCR amplified and sequenced to assess the activities of the fusion proteins in human cell culture.

It will be understood that the example of correcting point mutations in PI3KCA is provided for illustration purposes and is not meant to limit the instant disclosure. The skilled artisan will understand that the instantly disclosed DNA-editing fusion proteins can be used to correct other point mutations and mutations associated with other cancers and with diseases other than cancer including other proliferative diseases.

The successful correction of point mutations in disease-associated genes and alleles opens up new strategies for gene correction with applications in therapeutics and basic research. Site-specific single-base modification systems like the disclosed fusions of Cas9 and deaminase enzymes or domains also have applications in “reverse” gene therapy, where certain gene functions are purposely suppressed or abolished. In these cases, site-specifically mutating Trp (TGG), Gln (CAA and CAG), or Arg (CGA) residues to premature stop codons (TAA, TAG, TGA) can be used to abolish protein function in vitro, ex vivo, or in vivo.

The instant disclosure provides methods for the treatment of a subject diagnosed with a disease associated with or caused by a point mutation that can be corrected by a Cas9 DNA editing fusion protein provided herein. For example, in some embodiments, a method is provided that comprises administering to a subject having such a disease, e.g., a cancer associated with a PI3KCA point mutation as described above, an effective amount of a Cas9 deaminase fusion protein that corrects the point mutation or introduces a deactivating mutation into the disease-associated gene. In some embodiments, the disease is a proliferative disease. In some embodiments, the disease is a genetic disease. In some embodiments, the disease is a neoplastic disease. In some embodiments, the disease is a metabolic disease. In some embodiments, the disease is a lysosomal storage disease. Other diseases that can be treated by correcting a point mutation or introducing a deactivating mutation into a disease-associated gene will be known to those of skill in the art, and the disclosure is not limited in this respect.

The instant disclosure provides methods for the treatment of additional diseases or disorders, e.g., diseases or disorders that are associated or caused by a point mutation that can be corrected by deaminase-mediated gene editing. Some such diseases are described herein, and additional suitable diseases that can be treated with the strategies and fusion proteins provided herein will be apparent to those of skill in the art based on the instant disclosure. Exemplary suitable diseases and disorders are listed below. It will be understood that the numbering of the specific positions or residues in the respective sequences depends on the particular protein and numbering scheme used. Numbering might be different, e.g., in precursors of a mature protein and the mature protein itself, and differences in sequences from species to species may affect numbering. One of skill in the art will be able to identify the respective residue in any homologous protein and in the respective encoding nucleic acid by methods well known in the art, e.g., by sequence alignment and determination of homologous residues. Exemplary suitable diseases and disorders include, without limitation, cystic fibrosis (see, e.g., Schwank et al., Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell stem cell. 2013; 13: 653-658; and Wu et. al., Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell stem cell. 2013; 13: 659-662, neither of which uses a deaminase fusion protein to correct the genetic defect); phenylketonuria—e.g., phenylalanine to serine mutation at position 835 (mouse) or 240 (human) or a homologous residue in phenylalanine hydroxylase gene (T>C mutation)—see, e.g., McDonald et al., Genomics. 1997; 39:402-405; Bernard-Soulier syndrome (BSS)—e.g., phenylalanine to serine mutation at position 55 or a homologous residue, or cysteine to arginine at residue 24 or a homologous residue in the platelet membrane glycoprotein IX (T>C mutation)—see, e.g., Noris et al., British Journal of Haematology. 1997; 97: 312-320, and Ali et al., Hematol. 2014; 93: 381-384; epidermolytic hyperkeratosis (EHK)—e.g., leucine to proline mutation at position 160 or 161 (if counting the initiator methionine) or a homologous residue in keratin 1 (T>C mutation)—see, e.g., Chipev et al., Cell. 1992; 70: 821-828, see also accession number P04264 in the UNIPROT database at www[dot]uniprot[dot]org; chronic obstructive pulmonary disease (COPD)—e.g., leucine to proline mutation at position 54 or 55 (if counting the initiator methionine) or a homologous residue in the processed form of α₁-antitrypsin or residue 78 in the unprocessed form or a homologous residue (T>C mutation)—see, e.g., Poller et al., Genomics. 1993; 17: 740-743, see also accession number P01011 in the UNIPROT database; Charcot-Marie-Toot disease type 4J—e.g., isoleucine to threonine mutation at position 41 or a homologous residue in FIG4 (T>C mutation)—see, e.g., Lenk et al., PLoS Genetics. 2011; 7: e1002104; neuroblastoma (NB)—e.g., leucine to proline mutation at position 197 or a homologous residue in Caspase-9 (T>C mutation)—see, e.g., Kundu et al., 3 Biotech. 2013, 3:225-234; von Willebrand disease (vWD)—e.g., cysteine to arginine mutation at position 509 or a homologous residue in the processed form of von Willebrand factor, or at position 1272 or a homologous residue in the unprocessed form of von Willebrand factor (T>C mutation)—see, e.g., Lavergne et al., Br. J. Haematol. 1992, see also accession number P04275 in the UNIPROT database; 82: 66-72; myotonia congenital—e.g., cysteine to arginine mutation at position 277 or a homologous residue in the muscle chloride channel gene CLCN1 (T>C mutation)—see, e.g., Weinberger et al., The J. of Physiology. 2012; 590: 3449-3464; hereditary renal amyloidosis—e.g., stop codon to arginine mutation at position 78 or a homologous residue in the processed form of apolipoprotein All or at position 101 or a homologous residue in the unprocessed form (T>C mutation)—see, e.g., Yazaki et al., Kidney Int. 2003; 64: 11-16; dilated cardiomyopathy (DCM)—e.g., tryptophan to Arginine mutation at position 148 or a homologous residue in the FOXD4 gene (T>C mutation), see, e.g., Minoretti et. al., Int. J. of Mol. Med. 2007; 19: 369-372; hereditary lymphedema—e.g., histidine to arginine mutation at position 1035 or a homologous residue in VEGFR3 tyrosine kinase (A>G mutation), see, e.g., Irrthum et al., Am. J. Hum. Genet. 2000; 67: 295-301; familial Alzheimer's disease—e.g., isoleucine to valine mutation at position 143 or a homologous residue in presenilin1 (A>G mutation), see, e.g., Gallo et. al., J. Alzheimer's disease. 2011; 25: 425-431; Prion disease—e.g., methionine to valine mutation at position 129 or a homologous residue in prion protein (A>G mutation)—see, e.g., Lewis et. al., J. of General Virology. 2006; 87: 2443-2449; chronic infantile neurologic cutaneous particular syndrome (CINCA)—e.g., Tyrosine to Cysteine mutation at position 570 or a homologous residue in cryopyrin (A>G mutation)—see, e.g., Fujisawa et. al. Blood. 2007; 109: 2903-2911; and desmin-related myopathy (DRM)—e.g., arginine to glycine mutation at position 120 or a homologous residue in αβ crystallin (A>G mutation)—see, e.g., Kumar et al., J. Biol. Chem. 1999; 274: 24137-24141. The entire contents of all references and database entries is incorporated herein by reference.

The instant disclosure provides lists of genes comprising pathogenic T>C or A>G mutations. Provided herein, are the names of these genes, their respective SEQ ID NOs, their gene IDs, and sequences flanking the mutation site. (Tables 2 and 3). In some instances, the gRNA sequences that can be used to correct the mutations in these genes are disclosed (Tables 2 and 3).

In some embodiments, a Cas9-deaminase fusion protein recognizes canonical PAMs and therefore can correct the pathogenic T>C or A>G mutations with canonical PAMs, e.g., NGG (listed in Tables 2 and 3, SEQ ID NOs: 2540-2702 and 5084-5260), respectively, in the flanking sequences. For example, the Cas9 proteins that recognize canonical PAMs comprise an amino acid sequence that is at least 90% identical to the amino acid sequence of Streptococcus pyogenes Cas9 as provided by SEQ ID NO: 10, or to a fragment thereof comprising the RuvC and HNH domains of SEQ ID NO: 10.

It will be apparent to those of skill in the art that in order to target a Cas9:nucleic acid editing enzyme/domain fusion protein as disclosed herein to a target site, e.g., a site comprising a point mutation to be edited, it is typically necessary to co-express the Cas9:nucleic acid editing enzyme/domain fusion protein together with a guide RNA, e.g., an sgRNA. As explained in more detail elsewhere herein, a guide RNA typically comprises a tracrRNA framework allowing for Cas9 binding, and a guide sequence, which confers sequence specificity to the Cas9:nucleic acid editing enzyme/domain fusion protein. In some embodiments, the guide RNA comprises a structure 5′-[guide sequence]-guuuuagagcuagaaauagcaaguuaaaauaaaggcuaguccguuaucaacuugaaaaaguggcaccgagucggugcuu uuu-3′ (SEQ ID NO: 601), wherein the guide sequence comprises a sequence that is complementary to the target sequence. The guide sequence is typically 20 nucleotides long. The sequences of suitable guide RNAs for targeting Cas9:nucleic acid editing enzyme/domain fusion proteins to specific genomic target sites will be apparent to those of skill in the art based on the instant disclosure. Such suitable guide RNA sequences typically comprise guide sequences that are complementary to a nucleic sequence within 50 nucleotides upstream or downstream of the target nucleotide to be edited. Some exemplary guide RNA sequences suitable for targeting Cas9:nucleic acid editing enzyme/domain fusion proteins to specific target sequences are provided below.

Base Editor Efficiency

Some aspects of the disclosure are based on the recognition that any of the base editors provided herein are capable of modifying a specific nucleotide base without generating a significant proportion of indels. An “indel”, as used herein, refers to the insertion or deletion of a nucleotide base within a nucleic acid. Such insertions or deletions can lead to frame shift mutations within a coding region of a gene. In some embodiments, it is desirable to generate base editors that efficiently modify (e.g. mutate or deaminate) a specific nucleotide within a nucleic acid, without generating a large number of insertions or deletions (i.e., indels) in the nucleic acid. In certain embodiments, any of the base editors provided herein are capable of generating a greater proportion of intended modifications (e.g., point mutations or deaminations) versus indels. In some embodiments, the base editors provided herein are capable of generating a ratio of intended point mutations to indels that is greater than 1:1. In some embodiments, the base editors provided herein are capable of generating a ratio of intended point mutations to indels that is at least 1.5:1, at least 2:1, at least 2.5:1, at least 3:1, at least 3.5:1, at least 4:1, at least 4.5:1, at least 5:1, at least 5.5:1, at least 6:1, at least 6.5:1, at least 7:1, at least 7.5:1, at least 8:1, at least 10:1, at least 12:1, at least 15:1, at least 20:1, at least 25:1, at least 30:1, at least 40:1, at least 50:1, at least 100:1, at least 200:1, at least 300:1, at least 400:1, at least 500:1, at least 600:1, at least 700:1, at least 800:1, at least 900:1, or at least 1000:1, or more. The number of intended mutations and indels may be determined using any suitable method, for example the methods used in the below Examples.

In some embodiments, the base editors provided herein are capable of limiting formation of indels in a region of a nucleic acid. In some embodiments, the region is at a nucleotide targeted by a base editor or a region within 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides of a nucleotide targeted by a base editor. In some embodiments, any of the base editors provided herein are capable of limiting the formation of indels at a region of a nucleic acid to less than 1%, less than 1.5%, less than 2%, less than 2.5%, less than 3%, less than 3.5%, less than 4%, less than 4.5%, less than 5%, less than 6%, less than 7%, less than 8%, less than 9%, less than 10%, less than 12%, less than 15%, or less than 20%. The number of indels formed at a nucleic acid region may depend on the amount of time a nucleic acid (e.g., a nucleic acid within the genome of a cell) is exposed to a base editor. In some embodiments, an number or proportion of indels is determined after at least 1 hour, at least 2 hours, at least 6 hours, at least 12 hours, at least 24 hours, at least 36 hours, at least 48 hours, at least 3 days, at least 4 days, at least 5 days, at least 7 days, at least 10 days, or at least 14 days of exposing a nucleic acid (e.g., a nucleic acid within the genome of a cell) to a base editor.

Some aspects of the disclosure are based on the recognition that any of the base editors provided herein are capable of efficiently generating an intended mutation, such as a point mutation, in a nucleic acid (e.g. a nucleic acid within a genome of a subject) without generating a significant number of unintended mutations, such as unintended point mutations. In some embodiments, a intended mutation is a mutation that is generated by a specific base editor bound to a gRNA, specifically designed to generate the intended mutation. In some embodiments, the intended mutation is a mutation associated with a disease or disorder. In some embodiments, the intended mutation is a cytosine (C) to thymine (T) point mutation associated with a disease or disorder. In some embodiments, the intended mutation is a guanine (G) to adenine (A) point mutation associated with a disease or disorder. In some embodiments, the intended mutation is a cytosine (C) to thymine (T) point mutation within the coding region of a gene. In some embodiments, the intended mutation is a guanine (G) to adenine (A) point mutation within the coding region of a gene. In some embodiments, the intended mutation is a point mutation that generates a stop codon, for example, a premature stop codon within the coding region of a gene. In some embodiments, the intended mutation is a mutation that eliminates a stop codon. In some embodiments, the intended mutation is a mutation that alters the splicing of a gene. In some embodiments, the intended mutation is a mutation that alters the regulatory sequence of a gene (e.g., a gene promotor or gene repressor). In some embodiments, any of the base editors provided herein are capable of generating a ratio of intended mutations to unintended mutations (e.g., intended point mutations:unintended point mutations) that is greater than 1:1. In some embodiments, any of the base editors provided herein are capable of generating a ratio of intended mutations to unintended mutations (e.g., intended point mutations:unintended point mutations) that is at least 1.5:1, at least 2:1, at least 2.5:1, at least 3:1, at least 3.5:1, at least 4:1, at least 4.5:1, at least 5:1, at least 5.5:1, at least 6:1, at least 6.5:1, at least 7:1, at least 7.5:1, at least 8:1, at least 10:1, at least 12:1, at least 15:1, at least 20:1, at least 25:1, at least 30:1, at least 40:1, at least 50:1, at least 100:1, at least 150:1, at least 200:1, at least 250:1, at least 500:1, or at least 1000:1, or more. It should be appreciated that the characterstics of the base editors described in the “Base Editor Efficiency” section, herein, may be applied to any of the fusion proteins, or methods of using the fusion proteins provided herein.

Methods for Editing Nucleic Acids

Some aspects of the disclosure provide methods for editing a nucleic acid. In some embodiments, the method is a method for editing a nucleobase of a nucleic acid (e.g., a base pair of a double-stranded DNA sequence). In some embodiments, the method comprises the steps of: a) contacting a target region of a nucleic acid (e.g., a double-stranded DNA sequence) with a complex comprising a base editor (e.g., a Cas9 domain fused to a cytidine deaminase domain) and a guide nucleic acid (e.g., gRNA), wherein the target region comprises a targeted nucleobase pair, b) inducing strand separation of said target region, c)converting a first nucleobase of said target nucleobase pair in a single strand of the target region to a second nucleobase, and d) cutting no more than one strand of said target region, where a third nucleobase complementary to the first nucleobase base is replaced by a fourth nucleobase complementary to the second nucleobase; and the method results in less than 20% indel formation in the nucleic acid. It should be appreciated that in some embodiments, step b is omitted. In some embodiments, the first nucleobase is a cytosine. In some embodiments, the second nucleobase is a deaminated cytosine, or a uracil. In some embodiments, the third nucleobase is a guanine. In some embodiments, the fourth nucleobase is an adenine. In some embodiments, the first nucleobase is a cytosine, the second nucleobase is a deaminated cytosine, or a uracil, the third nucleobase is a guanine, and the fourth nucleobase is an adenine. In some embodiments, the method results in less than 19%, 18%, 16%, 14%, 12%, 10%, 8%, 6%, 4%, 2%, 1%, 0.5%, 0.2%, or less than 0.1% indel formation. In some embodiments, the method further comprises replacing the second nucleobase with a fifth nucleobase that is complementary to the fourth nucleobase, thereby generating an intended edited base pair (e.g., C:G->T:A). In some embodiments, the fifth nucleobase is a thymine. In some embodiments, at least 5% of the intended basepaires are edited. In some embodiments, at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% of the intended basepaires are edited.

In some embodiments, the ratio of intended products to unintended products in the target nucleotide is at least 2:1, 5:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 100:1, or 200:1, or more. In some embodiments, the ratio of intended point mutation to indel formation is greater than 1:1, 10:1, 50:1, 100:1, 500:1, or 1000:1, or more. In some embodiments, the cut single strand (nicked strand) is hybridized to the guide nucleic acid. In some embodiments, the cut single strand is opposite to the strand comprising the first nucleobase. In some embodiments, the base editor comprises a Cas9 domain. In some embodiments, the first base is cytosine, and the second base is not a G, C, A, or T. In some embodiments, the second base is uracil. In some embodiments, the first base is cytosine. In some embodiments, the second base is not a G, C, A, or T. In some embodiments, the second base is uracil. In some embodiments, the base editor inhibits base escision repair of the edited strand. In some embodiments, the base editor protects or binds the non-edited strand. In some embodiments, the base editor comprises UGI activity. In some embodiments, the base editor comprises nickase activity. In some embodiments, the intended edited basepair is upstream of a PAM site. In some embodiments, the intended edited base pair is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides upstream of the PAM site. In some embodiments, the intended edited basepair is downstream of a PAM site. In some embodiments, the intended edited base pair is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides downstream stream of the PAM site. In some embodiments, the method does not require a canonical (e.g., NGG) PAM site. In some embodiments, the nucleobase editor comprises a linker. In some embodiments, the linker is 1-25 amino acids in length. In some embodiments, the linker is 5-20 amino acids in length. In some embodiments, linker is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids in length. In some embodiments, the target region comprises a target window, wherein the target window comprises the target nucleobase pair. In some embodiments, the target window comprises 1-10 nucleotides. In some embodiments, the target window is 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, or 1 nucleotides in length. In some embodiments, the target window is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides in length. In some embodiments, the intended edited base pair is within the target window. In some embodiments, the target window comprises the intended edited base pair. In some embodiments, the method is performed using any of the base editors provided herein. In some embodiments, a target windo is a deamination window

In some embodiments, the disclosure provides methods for editing a nucleotide. In some embodiments, the disclosure provides a method for editing a nucleobase pair of a double-stranded DNA sequence. In some embodiments, the method comprises a) contacting a target region of the double-stranded DNA sequence with a complex comprising a base editor and a guide nucleic acid (e.g., gRNA), where the target region comprises a target nucleobase pair, b) inducing strand separation of said target region, c) converting a first nucleobase of said target nucleobase pair in a single strand of the target region to a second nucleobase, d) cutting no more than one strand of said target region, wherein a third nucleobase complementary to the first nucleobase base is replaced by a fourth nucleobase complementary to the second nucleobase, and the second nucleobase is replaced with a fifth nucleobase that is complementary to the fourth nucleobase, thereby generating an intended edited basepair, wherein the efficiency of generating the intended edited basepair is at least 5%. It should be appreciated that in some embodiments, step b is omitted. In some embodiments, at least 5% of the intended basepaires are edited. In some embodiments, at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% of the intended basepaires are edited. In some embodiments, the method causes less than 19%, 18%, 16%, 14%, 12%, 10%, 8%, 6%, 4%, 2%, 1%, 0.5%, 0.2%, or less than 0.1% indel formation. In some embodiments, the ratio of intended product to unintended products at the target nucleotide is at least 2:1, 5:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 100:1, or 200:1, or more. In some embodiments, the ratio of intended point mutation to indel formation is greater than 1:1, 10:1, 50:1, 100:1, 500:1, or 1000:1, or more. In some embodiments, the cut single strand is hybridized to the guide nucleic acid. In some embodiments, the cut single strand is opposite to the strand comprising the first nucleobase. In some embodiments, the first base is cytosine. In some embodiments, the second nucleobase is not G, C, A, or T. In some embodiments, the second base is uracil. In some embodiments, the base editor inhibits base escision repair of the edited strand. In some embodiments, the base editor protects or binds the non-edited strand. In some embodiments, the nucleobase editor comprises UGI activity. In some embodiments, the nucleobase edit comprises nickase activity. In some embodiments, the intended edited basepair is upstream of a PAM site. In some embodiments, the intended edited base pair is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides upstream of the PAM site. In some embodiments, the intended edited basepair is downstream of a PAM site. In some embodiments, the intended edited base pair is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides downstream stream of the PAM site. In some embodiments, the method does not require a canonical (e.g., NGG) PAM site. In some embodiments, the nucleobase editor comprises a linker. In some embodiments, the linker is 1-25 amino acids in length. In some embodiments, the linker is 5-20 amino acids in length. In some embodiments, the linker is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids in length. In some embodiments, the target region comprises a target window, wherein the target window comprises the target nucleobase pair. In some embodiments, the target window comprises 1-10 nucleotides. In some embodiments, the target window is 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, or 1 nucleotides in length. In some embodiments, the target window is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides in length. In some embodiments, the intended edited base pair occurs within the target window. In some embodiments, the target window comprises the intended edited base pair. In some embodiments, the nucleobase editor is any one of the base editors provided herein.

Kits, Vectors, Cells

Some aspects of this disclosure provide kits comprising a nucleic acid construct, comprising (a) a nucleotide sequence encoding a Cas9 protein or a Cas9 fusion protein as provided herein; and (b) a heterologous promoter that drives expression of the sequence of (a). In some embodiments, the kit further comprises an expression construct encoding a guide RNA backbone, wherein the construct comprises a cloning site positioned to allow the cloning of a nucleic acid sequence identical or complementary to a target sequence into the guide RNA backbone.

Some aspects of this disclosure provide polynucleotides encoding a Cas9 protein of a fusion protein as provided herein. Some aspects of this disclosure provide vectors comprising such polynucleotides. In some embodiments, the vector comprises a heterologous promoter driving expression of polynucleotide.

Some aspects of this disclosure provide cells comprising a Cas9 protein, a fusion protein, a nucleic acid molecule encoding the fusion protein, a complex comprise the Cas9 protein and the gRNA, and/or a vector as provided herein.

The description of exemplary embodiments of the reporter systems above is provided for illustration purposes only and not meant to be limiting. Additional reporter systems, e.g., variations of the exemplary systems described in detail above, are also embraced by this disclosure.

EXAMPLES Example 1 Cas9 Deaminase Fusion Proteins

A number of Cas9:Deaminase fusion proteins were generated and deaminase activity of the generated fusions was characterized. The following deaminases were tested: Human AID (hAID):

(SEQ ID NO: 607) MDSLLMNRRKFLYQFKNVRWAKGRRETYLCYVVKRRDSATSFSLDFGYLRN KNGCHVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVADFLRGNP YLSLRIFTARLYFCEDRKAEPEGLRRLHRAGVQIAIMTFKDYFYCWNTFVE NHERTFKAWEGLHENSVRLSRQLRRILLPLYEVDDLRDAFRTLGLLD  Human AID-DC (hAID-DC, truncated version of hAID with 7-fold increased activity):

(SEQ ID NO: 608) MDSLLMNRRKFLYQFKNVRWAKGRRETYLCYVVKRRDSATSFSLDFGYL RNKNGCHVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVADFL RGNPNLSLRIFTARLYFCEDRKAEPEGLRRLHRAGVQIAIMTFKDYFYC WNTFVENHERTFKAWEGLHENSVRLSRQLRRILL  Rat APOBEC1 (rAPOBEC1):

(SEQ ID NO: 284) MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHS IWRHTSQNTNKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSR AITEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQIMTEQ ESGYCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNIL RRKQPQLTFFTIALQSCHYQRLPPHILWATGLK Human APOBEC1 (hAPOBEC1)

(SEQ ID NO: 5724) MTSEKGPSTGDPTLRRRIEPWEFDVFYDPRELRKEACLLYEIKWGMSRK IWRSSGKNTTNHVEVNFIKKFTSERDFHPSMSCSITWFLSWSPCWECSQ AIREFLSRHPGVTLVIYVARLFWHMDQQNRQGLRDLVNSGVTIQIMRAS EYYHCWRNFVNYPPGDEAHWPQYPPLWMMLYALELHCIILSLPPCLKIS RRWQNHLTFFRLHLQNCHYQTIPPHILLATGLIHPSVAWR  Petromyzon marinus (Lamprey) CDA1 (pmCDA1):

(SEQ ID NO: 609) MTDAEYVRIHEKLDIYTFKKQFFNNKKSVSHRCYVLFELKRRGERRACFW GYAVNKPQSGTERGIHAEIFSIRKVEEYLRDNPGQFTINWYSSWSPCADC AEKILEWYNQELRGNGHTLKIWACKLYYEKNARNQIGLWNLRDNGVGLNV MVSEHYQCCRKIFIQSSHNQLNENRWLEKTLKRAEKRRSELSIMIQVKIL HTTKSPAV Human APOBEC3G (hAPOBEC3G):

(SEQ ID NO: 610) MELKYHPEMRFFHWFSKWRKLHRDQEYEVTWYISWSPCTKCTRDMATFLA EDPKVTLTIFVARLYYFWDPDYQEALRSLCQKRDGPRATMKIMNYDEFQH CWSKFVYSQRELFEPWNNLPKYYILLHIMLGEILRHSMDPPTFTFNFNNE PWVRGRHETYLCYEVERMHNDTWVLLNQRRGFLCNQAPHKHGFLEGRHAE LCFLDVIPFWKLDLDQDYRVTCFTSWSPCFSCAQEMAKFISKNKHVSLCI FTARIYDDQGRCQEGLRTLAEAGAKISIMTYSEFKHCWDTFVDHQGCPFQ PWDGLDEHSQDLSGRLRAILQNQEN

Deaminase Activity on ssDNA. A USER (Uracil-Specific Excision Reagent) Enzyme-based assay for deamination was employed to test the activity of various deaminases on single-stranded DNA (ssDNA) substrates. USER Enzyme was obtained from New England Biolabs. An ssDNA substrate was provided with a target cytosine residue at different positions. Deamination of the ssDNA cytosine target residue results in conversion of the target cytosine to a uracil. The USER Enzyme excises the uracil base and cleaves the ssDNA backbone at that position, cutting the ssDNA substrate into two shorter fragments of DNA. In some assays, the ssDNA substrate is labeled on one end with a dye, e.g., with a 5′ Cy3 label (the * in the scheme below). Upon deamination, excision, and cleavage of the strand, the substrate can be subjected to electrophoresis, and the substrate and any fragment released from it can be visualized by detecting the label. Where Cy5 is images, only the fragment with the label will be visible via imaging.

In one USER Enzyme assay, ssDNA substrates were used that matched the target sequences of the various deaminases tested. Expression cassettes encoding the deaminases tested were inserted into a CMV backbone plasmid that has been used previously in the lab (Addgene plasmid 52970). The deaminase proteins were expressed using a TNT Quick Coupled Transcription/Translation System (Promega) according to the manufacturers recommendations. After 90 min of incubation, 5 mL of lysate was incubated with 5′ Cy3-labeled ssDNA substrate and 1 unit of USER Enzyme (NEB) for 3 hours. The DNA was resolved on a 10% TBE PAGE gel and the DNA was imaged using Cy-dye imaging. A schematic representation of the USER Enzyme assay is shown in FIG. 41.

FIG. 1 shows the deaminase activity of the tested deaminases on ssDNA substrates, such as Doench 1, Doench 2, G7′ and VEGF Target 2. The rAPOBEC1 enzyme exhibited a substantial amount of deamination on the single-stranded DNA substrate with a canonical NGG PAM, but not with a negative control non-canonical NNN PAM. Cas9 fusion proteins with APOBEC family deaminases were generated. The following fusion architectures were constructed and tested on ssDNA:

(SEQ ID NO: 611) rAPOBEC1-GGS-dCas9 primary sequence MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSIWRHTSQNT NKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAITEFLSRYPHVTLFIYIAR LYHHADPRNRQGLRDLISSGVTIQIMTEQESGYCWRNFVNYSPSNEAHWPRYPHLW

(SEQ ID NO: 612) rAPOBEC1-(GGS)₃-dCas9 primary sequence MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSIWRHTSQNT NKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAITEFLSRYPHVTLFIYIAR LYHHADPRNRQGLRDLISSGVTIQIMTEQESGYCWRNFVNYSPSNEAHWPRYPHLW

(SEQ ID NO: 613)

VDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSIWRHTSQNTNKHVEVNFI EKFTTERYFCPNTRCSITWFLSWSPCGECSRAITEFLSRYPHVTLFIYIARLYHHADPR NRQGLRDLISSGVTIQIMTEQESGYCWRNFVNYSPSNEAHWPRYPHLWVRLYVLEL YCIILGLPPCLNILRRKQPQLTFFTIALQSCHYQRLPPHILWATGLK (SEQ ID NO: 614)

ETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSTWRHTSQNTNKH VEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAITEFLSRYPHVTLFIYIARLYH HADPRNRQGLRDLISSGVTIQIMTEQESGYCWRNFVNYSPSNEAHWPRYPHLWVRL YVLELYCIILGLPPCLNILRRKQPQLTFFTIALQSCHYQRLPPHILWATGLK (SEQ ID NO: 615)

MSSETFPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSIWRHTSQNT NKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAITEFLSRYPHVTLFIYIAR LYHHADPRNRQGLRDLISSGVTIQIMTEQESGYCWRNFVNYSPSNEAHWPRYPHLW

FIG. 2 shows that the N-terminal deaminase fusions showed significant activity on the single stranded DNA substrates. For this reason, only the N-terminal architecture was chosen for further experiments.

FIG. 3 illustrates double stranded DNA substrate binding by deaminase-dCas9:sgRNA complexes. A number of double stranded deaminase substrate sequences were generated. The sequences are provided below. The structures according to FIG. 3 are identified in these sequences (36 bp: underlined, sgRNA target sequence: bold; PAM: boxed; 21 bp: italicized). All substrates were labeled with a 5′-Cy3 label:

(SEQ ID NO: 616) 2:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGTC CCGCGGATTTATTTATTT

(SEQ ID NO: 617) 3:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCT TCCGCGGATTTATTTATT

(SEQ ID NO: 618) 4:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCC TTCCGCGGATTTATTTAT

(SEQ ID NO: 619) 5:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCC ATTCCGCGGATTTATTTA

(SEQ ID NO: 620) 6:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCC TATTCCGCGGATTTATTT

(SEQ ID NO: 621) 7:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCC TTATTCCGCGGATTTATT

(SEQ ID NO: 622) 8:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCC ATTATTCCGCGGATTTAT

(SEQ ID NO: 623) 9:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCC TATTATTCCGCGGATTTA

(SEQ ID NO: 624) 10:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCC ATTATATTCCGCGGATTT

(SEQ ID NO: 625) 11:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCC TATTATATTCCGCGGATT

(SEQ ID NO: 626) 12:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCC TTATTATATTCCGCGGAT

(SEQ ID NO: 627) 13:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCC ATTATTATATTCCGCGGA

(SEQ ID NO: 628) 14:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCC TATTATTATATTCCGCGG

(SEQ ID NO: 629) 15:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCC ATTATTATTATTACCGCG

(SEQ ID NO: 630) 18:GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCC ATTATTATTATTATTACC

“—”: (SEQ ID NO: 631) GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGTA ATATTAATTTATTTATTTAA

(SEQ ID NO: 632) 8U:GTAGGTAGTTAGGATGAATGGAAGGTTGGTGTAG ATTATTATCUGCGGATTTA

*In all substrates except for “8U”, the top strand in FIG. 3 is the complement of the sequence specified here. In the case of “8U”, there is a “G” opposite the U.

FIG. 4 shows the results of a double stranded DNA Deamination Assay. The fusions were expressed and purified with an N-terminal His6 tag via both Ni-NTA and sepharose chromatography. In order to assess deamination on dsDNA substrates, the various dsDNA substrates shown on the previous slide were incubated at a 1:8 dsDNA:fusion protein ratio and incubated at 37° C. for 2 hours. Once the dCas9 portion of the fusion binds to the DNA it blocks access of the USER enzyme to the DNA. Therefore, the fusion proteins were denatured following the incubation and the dsDNA was purified on a spin column, followed by incubation for 45 min with the USER Enzyme and resolution of the resulting DNA substrate and substrate fragments on a 10% TBE-urea gel.

FIG. 5 demonstrates that Cas9 fusions can target positions 3-11 of double-stranded DNA target sequences (numbered according to the schematic in FIG. 3). Upper Gel: 1 μM rAPOBEC1-GGS-dCas9, 125 nM dsDNA, 1 eq sgRNA. Mid Gel: 1 μM rAPOBEC1-(GGS)₃-dCas9, 125 nM dsDNA, 1 eq sgRNA. Lower Gel: 1.85 μM rAPOBEC1-XTEN-dCas9, 125 nM dsDNA, 1 eq sgRNA. Based on the data from these gels, positions 3-11 (according to the numbering in FIG. 3) are sufficiently exposed to the activity of the deaminase to be targeted by the fusion proteins tested. Access of the deaminase to other positions is most likely blocked by the dCas9 protein.

The data further indicates that a linker of only 3 amino acids (GGS) is not optimal for allowing the deaminase to access the single stranded portion of the DNA. The 9 amino acid linker [(GGS)₃] (SEQ ID NO: 596) and the more structured 16 amino acid linker (XTEN) allow for more efficient deamination.

FIG. 6 demonstrates that the correct guide RNA, e.g., the correct sgRNA, is required for deaminase activity. The gel shows that fusing the deaminase to dCas9, the deaminase enzyme becomes sequence specific (e.g., using the fusion with an eGFP sgRNA results in no deamination), and also confers the capacity to the deaminase to deaminate dsDNA. The native substrate of the deaminase enzyme is ssDNA, and no deamination occurred when no sgRNA was added. This is consistent with reported knowledge that APOBEC deaminase by itself does not deaminate dsDNA. The data indicates that Cas9 opens the double-stranded DNA helix within a short window, exposing single-stranded DNA that is then accessible to the APOBEC deaminase for cytidine deamination. The sgRNA sequences used are provided below. sequences (36 bp: underlined, sgRNA target sequence: bold; PAM: boxed; 21 bp: italicized)

DNA sequence 8: (SEQ ID NO:  633) 5′-Cy3- GTAGGTAGTTAGGATGAATGGAAGGTTGGTATAGCC ATTATTCCGCGGA TTTATT

(SEQ ID NO:  634) Correct sgRNA sequence (partial 3′ sequence): 5′-AUUAUUCCGCGGAUUUAUUUGUUUUAGAGCUAG...-3′ (SEQ ID NO:  635) eGFP sgRNA sequence (partial 3′-sequence): 5′-CGUAGGCCAGGGUGGUCACGGUUUUAGAGCUAG...-3′

Example 2 Deamination of DNA Target Sequence

Exemplary deamination targets. The dCas9:deaminase fusion proteins described herein can be delivered to a cell in vitro or ex vivo or to a subject in vivo and can be used to effect C to T or G to A transitions when the target nucleotide is in positions 3-11 with respect to a PAM. Exemplary deamination targets include, without limitation, the following: CCR5 truncations: any of the codons encoding Q93, Q102, Q186, R225, W86, or Q261 of CCR5 can be deaminated to generate a STOP codon, which results in a nonfunctional truncation of CCR5 with applications in HIV treatment. APOE4 mutations: mutant codons encoding C11R and C57R mutant APOE4 proteins can be deaminated to revert to the wild-type amino acid with applications in Alzheimer's treatment. eGFP truncations: any of the codons encoding Q158, Q184, Q185 can be deaminated to generate a STOP codon, or the codon encoding M1 can be deaminated to encode I, all of which result in loss of eGFP fluorescence, with applications in reporter systems. eGFP restoration: a mutant codon encoding T65A or Y66C mutant GFP, which does not exhibit substantial fluorescence, can be deaminated to restore the wild-type amino acid and confer fluorescence. PIK3CA mutation: a mutant codon encoding K111E mutant PIK3CA can be deaminated to restore the wild-type amino acid residue with applications in cancer. CTNNB1 mutation: a mutant codon encoding T41A mutant CTNNB1 can be deaminated to restore the wild-type amino acid residue with applications in cancer. HRAS mutation: a mutant codon encoding Q61R mutant HRAS can be deaminated to restore the wild-type amino acid residue with applications in cancer. P53 mutations: any of the mutant codons encoding Y163C, Y236C, or N239D mutant p53 can be deaminated to encode the wild type amino acid sequence with applications in cancer. The feasibility of deaminating these target sequences in double-stranded DNA is demonstrated in FIGS. 7 and 8. FIG. 7 illustrates the mechanism of target DNA binding of in vivo target sequences by deaminase-dCas9:sgRNA complexes.

FIG. 8 shows successful deamination of exemplary disease-associated target sequences. Upper Gel: CCR5 Q93: coding strand target in pos. 10 (potential off-targets at positions 2, 5, 6, 8, 9); CCR5 Q102: coding strand target in pos. 9 (potential off-targets at positions 1, 12, 14); CCR5 Q186: coding strand target in pos. 9 (potential off-targets at positions 1, 5, 15); CCR5 R225: coding strand target in pos. 6 (no potential off-targets); eGFP Q158: coding strand target in pos. 5 (potential off-targets at positions 1, 13, 16); eGFP Q184/185: coding strand target in pos. 4 and 7 (potential off-targets at positions 3, 12, 14, 15, 16, 17, 18); eGFP M1: template strand target in pos. 12 (potential off-targets at positions 2, 3, 7, 9, 11) (targets positions 7 and 9 to small degree); eGFP T65A: template strand target in pos. 7 (potential off-targets at positions 1, 8, 17); PIK3CA K111E: template strand target in pos. 2 (potential off-targets at positions 5, 8, 10, 16, 17); PIK3CA K111E: template strand target in pos. 13 (potential off-targets at positions 11, 16, 19) X. Lower Gel: CCR5 W86: template strand target in pos. 2 and 3 (potential off-targets at positions 1, 13) X; APOE4 C11R: coding strand target in pos. 11 (potential off-targets at positions 7, 13, 16, 17); APOE4 C57R: coding strand target in pos. 5) (potential off-targets at positions 7, 8, 12); eGFP Y66C: template strand target in pos. 11 (potential off-targets at positions 1, 4, 6, 8, 9, 16); eGFP Y66C: template strand target in pos. 3 (potential off-targets at positions 1, 8, 17); CCR5 Q261: coding strand target in pos. 10 (potential off-targets at positions 3, 5, 6, 9, 18); CTNNB1 T41A: template strand target in pos. 7 (potential off-targets at positions 1, 13, 15, 16) X; HRAS Q61R: template strand target in pos. 6 (potential off-targets at positions 1, 2, 4, 5, 9, 10, 13); p53 Y163C: template strand target in pos. 6 (potential off-targets at positions 2, 13, 14); p53 Y236C: template strand target in pos. 8 (potential off-targets at positions 2, 4); p53 N239D: template strand target in pos. 4 (potential off-targets at positions 6, 8). Exemplary DNA sequences of disease targets are provided below (PAMs (5′-NGG-3′) and target positions are boxed):

(SEQ ID NO: 636) CCR5 Q93: 5′-Cy3- GTAGGTAGTTAGGATGAATGGAAGGTTGGTAACTAT GCTGCCGCC

(SEQ ID NO: 637) CCR5 Q102: 5′-Cy3- GTAGGTAGTTAGGATGAATGGAAGGTTGGTAAAATA CAATGTGT

(SEQ ID NO: 638) CCR5 Q186: 5′-Cy3- GTAGGTAGTTAGGATGAATGGAAGGTTGGTATTTTC CATACAGT

(SEQ ID NO: 639) CCR5 R225: 5′-Cy3-

(SEQ ID NO: 640) CCR5 W86: 4′-Cy3-

(SEQ ID NO: 641) CCR5 Q261: 5′-Cy3- GTAGGTAGTTAGGATGAATGGAAGGTTGGTATCCTG AACACCTT

(SEQ ID NO: 642) APOE4 C11R: 5′-Cy3- GTAGGTAGTTAGGATGAATGGAAGGTTGGTAGACAT GGAGGAC

(SEQ ID NO: 643) APOE4 C57R: 5′-Cy3-

(SEQ ID NO: 644) eGFP Q158: 5′-Cy3-

(SEQ ID NO: 645)

(SEQ ID NO: 646) eGFP M1: 5′-Cy3- GTAGGTAGTTAGGATGAATGGAAGGTTGGTACCTCG CCCTTGCTCA

(SEQ ID NO:  647) eGFP T65A: 5′-Cy3-  

(SEQ ID NO:  648) eGFP Y66C:  5′-Cy3- GTAGGTAGTTAGGATGAATGGAAGGTTGGTAAAGCA CTGCACTC

(SEQ ID NO:  649) eGFP Y66C:  5′-Cy3-

(SEQ ID NO:  650) PIK3CA K111E:  5′-Cy3-

(SEQ ID NO:  651) PIK3CA K111E:  5′-Cy3- GTAGGTAGTTAGGATGAATGGAAGGTTGGTATTCTC GATTG

(SEQ ID NO:  652) CTNNB1 T41A:  5′-Cy3- GTAGGTAGTTAGGATGAATGGAAGGTTGGTAAGGAG CTGTGG

(SEQ ID NO:  653) HrAS Q61R:  5′-Cy3-

(SEQ ID NO:  654) p53 Y163C:  5′-Cy3-

(SEQ ID NO:  655) p53 Y236C:  5′-Cy3-

(SEQ ID NO:  656) p3 N239D:  5′-Cy3-

Example 3 Uracil Glycosylase Inhibitor Fusion Improves Deamination Efficiency

Direct programmable nucleobase editing efficiencies in mammalian cells by dCas9:deaminase fusion proteins can be improved significantly by fusing a uracil glycosylase inhibitor (UGI) to the dCas9:deaminase fusion protein.

FIG. 9 shows in vitro C→T editing efficiencies in human HEK293 cells using rAPOBEC1-XTEN-dCas9:

(SEQ ID NO: 657)

MSSETGPVAVDPTLRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSIWRHTSQNT NKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAITEFLSRYPHVTLFIYIAR LYHHADPRNRQGLRDLISSGVTIQIMTEQESGYCWRNFVNYSPSNEAHWPRYPHLWV RLYVLELYCIILGLPPCLNILRRKQPQLTFFTIALQSCHYQRLPPHILWATGLK SGSETP

KV Protospacer sequences were as follows:

EMX1:

FANCF:

HEK293 site 2:

HEK293 site 3:

HEK293 site 4:

RNF2:

*PAMs are boxed, C residues within target window (positions 3-11) are numbered and bolded.

FIG. 10 demonstrates that C→T editing efficiencies on the same protospacer sequences in HEK293T cells are greatly enhanced when a UGI domain is fused to the rAPOBEC1:dCas9 fusion protein.

(SEQ ID NO: 658)

MSSETFPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSIWRHTSQNT NKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAITEFLSRYPHVTLFIYIAR LYHHADPRNRQGLRDLISSGVTIQIMTEQESGYCWRNFVNYSPNEAHWPRYPHLWV RLYVLELYCIILGLPPCLNILRRKQPQLTFFTIALQSCHYQRLPPHILWATGLK SGSETP

IIEKETGKQLVIQESILMLPEEVEEVISNKPESDILVHTAYDESTDENVMLLTSDAP EYKPWALVIQDSNGENKIKML SGGSPKKKRKV

The percentages in FIGS. 9 and 10 are shown from sequencing both strands of the target sequence. Because only one of the strands is a substrate for deamination, the maximum possible deamination value in this assay is 50%. Accordingly, the deamination efficiency is double the percentages shown in the tables. E.g., a value of 50% relates to deamination of 100% of double-stranded target sequences.

When a uracil glycosylase inhibitor (UGI) was fused to the dCas9:deaminase fusion protein (e.g., rAPOBEC1-XTEN-dCas9-[UGI]-NLS), a significant increase in editing efficiency in cells was observed. This result indicates that in mammalian cells, the DNA repair machinery that cuts out the uracil base in a U:G base pair is a rate-limiting process in DNA editing. Tethering UGI to the dVas9:deaminase fusion proteins greatly increases editing yields.

Without UGI, typical editing efficiencies in human cells were in the ˜2-14% yield range (FIG. 9 and FIG. 10, “XTEN” entries). With UGI (FIG. 10, “UGI” entries) the editing was observed in the ˜6-40% range. Using a UGI fusion is thus more efficient than the current alternative method of correcting point mutations via HDR, which also creates an excess of indels in addition to correcting the point mutation. No indels resulting from treatment with the cas9:deaminase:UGI fusions were observed.

Example 4 Direct, Programmable Conversion of a Target Nucleotide in Genomic DNA without Double-stranded DNA Cleavage

Current genome-editing technologies introduce double-stranded DNA breaks at a target locus of interest as the first step to gene correction.^(39,40) Although most genetic diseases arise from mutation of a single nucleobase to a different nucleobase, current approaches to revert such changes are very inefficient and typically induce an abundance of random insertions and deletions (indels) at the target locus as a consequence of the cellular response to double-stranded DNA breaks.^(39,40) Reported herein is the development of nucleobase editing, a new strategy for genome editing that enables the direct conversion of one target nucleobase into another in a programmable manner, without requiring double-stranded DNA backbone cleavage. Fusions of CRISPR/Cas9 were engineered and the cytidine deaminase enzyme APOBEC1 that retain the ability to be programmed with a guide RNA, do not induce double-stranded DNA breaks, and mediate the direct conversion of cytidine to uracil, thereby effecting a C→T (or G→A) substitution following DNA replication, DNA repair, or transcription if the template strand is targeted. The resulting “nucleobase editors” convert cytidines within a window of approximately five nucleotides, and can efficiently correct a variety of point mutations relevant to human disease in vitro. In four transformed human and murine cell lines, second- and third-generation nucleobase editors that fuse uracil glycosylase inhibitor (UGI), and that use a Cas9 nickase targeting the non-edited strand, respectively, can overcome the cellular DNA repair response to nucleobase editing, resulting in permanent correction of up to 37% or (˜15-75%) of total cellular DNA in human cells with minimal (typically ≤1%) indel formation. In contrast, canonical Cas9-mediated HDR on the same targets yielded an average of 0.7% correction with 4% indel formation. Nucleobase editors were used to revert two oncogenic p53 mutations into wild-type alleles in human breast cancer and lymphoma cells, and to convert an Alzheimer's Disease associated Arg codon in ApoE4 into a non-disease-associated Cys codon in mouse astrocytes. Base editing expands the scope and efficiency of genome editing of point mutations.

The clustered regularly interspaced short palindromic repeat (CRISPR) system is a prokaryotic adaptive immune system that has been adapted to mediate genome engineering in a variety of organisms and cell lines.⁴¹ CRISPR/Cas9 protein-RNA complexes localize to a target DNA sequence through base pairing with a guide RNA, and natively create a DNA double-stranded break (DSB) at the locus specified by the guide RNA. In response to DSBs, endogenous DNA repair processes mostly result in random insertions or deletions (indels) at the site of DNA cleavage through non-homologous end joining (NHEJ). In the presence of a homologous DNA template, the DNA surrounding the cleavage site can be replaced through homology-directed repair (HDR). When simple disruption of a disease-associated gene is sufficient (for example, to treat some gain-of-function diseases), targeted DNA cleavage followed by indel formation can be effective. For most known genetic diseases, however, correction of a point mutation in the target locus, rather than stochastic disruption of the gene, is needed to address or study the underlying cause of the disease.⁶⁸

Motivated by this need, researchers have invested intense effort to increase the efficiency of HDR and suppress NHEJ. For example, a small-molecule inhibitor of ligase IV, an essential enzyme in the NHEJ pathway, has been shown to increase HDR efficiency.^(42,43) However, this strategy is challenging in post-mitotic cells, which typically down-regulate HDR, and its therapeutic relevance is limited by the potential risks of inhibiting ligase IV in non-target cells. Enhanced HDR efficiency can also be achieved by the timed delivery of Cas9-guide RNA complexes into chemically synchronized cells, as HDR efficiency is highly cell-cycle dependent.⁴⁴ Such an approach, however, is limited to research applications in cell culture since synchronizing cells is highly disruptive. Despite these developments, current strategies to replace point mutations using HDR in most contexts are very inefficient (typically ˜0.1 to 5%),^(42,43,45,46,75) especially in unmodified, non-dividing cells. In addition, HDR competes with NHEJ during the resolution of double-stranded breaks, and indels are generally more abundant outcomes than gene replacement. These observations highlight the need to develop alternative approaches to install specific modifications in genomic DNA that do not rely on creating double-stranded DNA breaks. A small-molecule inhibitor of ligase IV, an essential enzyme in the NHEJ pathway, has been shown to increase HDR efficiency.^(42,43) However, this strategy is challenging in post-mitotic cells, which typically down-regulate HDR, and its therapeutic relevance is limited by the potential risks of inhibiting ligase IV in non-target cells. Enhanced HDR efficiency can also be achieved by the timed delivery of Cas9-guide RNA complexes into chemically synchronized cells, as HDR efficiency is highly cell-cycle dependent.⁴⁴ Such an approach, however, is limited to research applications in cell culture since synchronizing cells is highly disruptive. In some cases, it is possible to design HDR templates such that the product of successful HDR contains mutations in the PAM sequence and therefore is no longer a substrate for subsequent Cas9 modification, increasing the overall yield of HDR products,⁷⁵ although such an approach imposes constraints on the product sequences. Recently, this strategy has been coupled to the use of ssDNA donors that are complementary to the non-target strand and high-efficiency ribonucleoprotein (RNP) delivery to substantially increase the efficiency of HDR, but even in these cases the ratio of HDR to NHEJ outcomes is relatively low (<2).⁸³

It was envisioned that direct catalysis of the conversion of one nucleobase to another at a programmable target locus without requiring DNA backbone cleavage could increase the efficiency of gene correction relative to HDR without introducing undesired random indels at the locus of interest. Catalytically dead Cas9 (dCas9), which contains Asp10Ala and His840Ala mutations that inactivate its nuclease activity, retains its ability to bind DNA in a guide RNA-programmed manner but does not cleave the DNA backbone.^(16,47) In principle, conjugation of dCas9 with an enzymatic or chemical catalyst that mediates the direct conversion of one nucleobase to another could enable RNA-programmed nucleobase editing. The deamination of cytosine (C) is catalyzed by cytidine deaminases²⁹ and results in uracil (U), which has the base pairing properties of thymine (T). dCas9 was fused to cytidine deaminase enzymes in order to test their ability to convert C to U at a guide RNA-specified DNA locus. Most known cytidine deaminases operate on RNA, and the few examples that are known to accept DNA require single-stranded DNA.⁴⁸ Recent studies on the dCas9-target DNA complex reveal that at least nine nucleotides of the displaced DNA strand are unpaired upon formation of the Cas9:guide RNA:DNA “R-loop” complex.¹² Indeed, in the structure of the Cas9 R-loop complex the first 11 nucleotides of the protospacer on the displaced DNA strand are disordered, suggesting that their movement is not highly restricted.⁷⁶ It has also been speculated that Cas9 nickase-induced mutations at cytosines in the non-template strand might arise from their accessibility by cellular cytidine deaminase enzymes.⁷⁷ Recent studies on the dCas9-target DNA complex have revealed that at least 26 bases on the non-template strand are unpaired when Cas9 binds to its target DNA sequence.⁴⁹ It was reasoned that a subset of this stretch of single-stranded DNA in the R-loop might serve as a substrate for a dCas9-tethered cytidine deaminase to effect direct, programmable conversion of C to U in DNA (FIG. 11A).

Four different cytidine deaminase enzymes (hAID, hAPOBEC3G, rAPOBEC1, and pmCDA1) were expressed in a mammalian cell lysate-derived in vitro transcription-translation system and evaluated for ssDNA deamination. Of the four enzymes, rAPOBEC1 showed the highest deaminase activity under the tested conditions and was chosen for dCas9 fusion experiments (FIG. 36A). Although appending rAPOBEC1 to the C-terminus of dCas9 abolishes deaminase activity, fusion to the N-terminus of dCas9 preserves deaminase activity on ssDNA at a level comparable to that of the unfused enzyme. Four rAPOBEC1-dCas9 fusions were expressed and purified with linkers of different length and composition (FIG. 36B), and evaluated each fusion for single guide RNA (sgRNA)-programmed dsDNA deamination in vitro (FIGS. 11A to 11C and FIGS. 15A to 15D).

Efficient, sequence-specific, sgRNA-dependent C to U conversion was observed in vitro (FIGS. 11A to 11C). Conversion efficiency was greatest using rAPOBEC1-dCas9 linkers over nine amino acids in length. The number of positions susceptible to deamination (the deamination “activity window”) increases with linker length was extended from three to 21 amino acids (FIGS. 36C to 36F 15A to 15D). The 16-residue XTEN linker⁵⁰ was found to offer a promising balance between these two characteristics, with an efficient deamination window of approximately five nucleotides, from positions 4 to 8 within the protospacer, counting the end distal to the protospacer-adjacent motif (PAM) as position 1. The rAPOBEC1-XTEN-dCas9 protein served as the first-generation nucleobase editor (NBE1).

Elected were seven mutations relevant to human disease that in theory could be corrected by C to T nucleobase editing, synthesized double-stranded DNA 80-mers of the corresponding sequences, and assessed the ability of NBE1 to correct these mutations in vitro (FIGS. 16A to 16B). NBE1 yielded products consistent with efficient editing of the target C, or of at least one C within the activity window when multiple Cs were present, in six of these seven targets in vitro, with an average apparent editing efficiency of 44% (FIGS. 16A to 16B). In the three cases in which multiple Cs were present within the deamination window, evidence of deamination of some or all of these cytosines was observed. In only one of the seven cases tested were substantial yields of edited product observed (FIGS. 16A to 16 B). Although the preferred sequence context for APOBEC1 substrates is reported to be CC or TC,⁵¹ it was anticipated that the increased effective molarity of the deaminase and its single-stranded DNA substrate mediated by dCas9 binding to the target locus may relax this restriction. To illuminate the sequence context generality of NBE1, its ability to edit a 60-mer double-stranded DNA oligonucleotide containing a single fixed C at position 7 within the protospacer was assayed, as well as all 36 singly mutated variants in which protospacer bases 1-6 and 8-13 were individually varied to each of the other three bases. Each of these 37 sequences were treated with 1.9 μM NBE1, 1.9 μM of the corresponding sgRNA, and 125 nM DNA for 2 h, similar to standard conditions for in vitro Cas9 assays⁵². High-throughput DNA sequencing (HTS) revealed 50 to 80% C to U conversion of targeted strands (25 to 40% of total sequence reads arising from both DNA strands, one of which is not a substrate for NBE1) (FIG. 12A). The nucleotides surrounding the target C had little effect on editing efficiency was independent of sequence context unless the base immediately 5′ of the target C is a G, in which case editing efficiency was substantially lower (FIGS. 12A to 12B). NBE1 activity in vitro was assessed on all four NC motifs at positions 1 through 8 within the protospacer (FIGS. 12A to 12B). In general NBE1 activity on substrates was observed to follow the order TC≥CC≥AC≥GC, with maximum editing efficiency achieved when the target C is at or near position 7. In addition, it was observed that the nucleobase editor is highly processive, and will efficiently convert most of all Cs to Us on the same DNA strand within the 5-base activity window (FIG. 17).

While BE1 efficiently processes substrates in a test tube, in cells a tree of possible DNA repair outcomes determines the fate of the initial U:G product of base editing (FIG. 29A). To test the effectiveness of nucleobase editing in human cells, NBE1 codon usage was optimized for mammalian expression, appended a C-terminal nuclear localization sequence (NLS),⁵³ and assayed its ability to convert C to T in human cells on 14Cs in six well-studied target sites throughout the human genome (FIG. 37A).⁵⁴ The editable Cs were confirmed within each protospacer in vitro by incubating NBE1 with synthetic 80-mers that correspond to the six different genomic sites, followed by HTS (FIGS. 13A to 13C, FIG. 29B and FIG. 25). Next, HEK293T cells were transfected with plasmids encoding NBE1 and one of the six target sgRNAs, allowed three days for nucleobase editing to occur, extracted genomic DNA from the cells, and analyzed the loci by HTS. Although C to T editing in cells at the target locus was observed for all six cases, the efficiency of nucleobase editing was 1.1% to 6.3% or 0.8%-7.7% of total DNA sequences (corresponding to 2.2% to 12.6% of targeted strands), a 6.3-fold to 37-fold or 5-fold to 36-fold decrease in efficiency compared to that of in vitro nucleobase editing (FIGS. 13A to 13C, FIG. 29B and FIG. 25). It was observed that some base editing outside of the typical window of positions 4 to 8 when the substrate C is preceded by a T, which we attribute to the unusually high activity of APOBEC1 for TC substrates.⁴⁸

It was asked whether the cellular DNA repair response to the presence of U:G heteroduplex DNA was responsible for the large decrease in nucleobase editing efficiency in cells (FIG. 29A). Uracil DNA glycosylase (UDG) catalyzes removal of U from DNA in cells and initiates base excision repair (BER), with reversion of the U:G pair to a C:G pair as the most common outcome (FIG. 29A).⁵⁵ Uracil DNA glycosylase inhibitor (UGI), an 83-residue protein from B. subtilis bacteriophage PBS1, potently blocks human UDG activity (IC₅₀=12 pM).⁵⁶ UGI was fused to the C-terminus of NBE1 to create the second-generation nucleobase editor NBE2 and repeated editing assays on all six genomic loci. Editing efficiencies in human cells were on average 3-fold higher with NBE2 than with NBE1, resulting in gene conversion efficiencies of up to 22.8% of total DNA sequenced (up to 45.6% of targeted strands) (FIGS. 13A to 13C and FIG. 29B). To test base editing in human cells, BE1 codon usage was optimized for mammalian expression and appended a C-terminal nuclear localization sequence (NLS).⁵³

Similar editing efficiencies were observed when a separate plasmid overexpressing UGI was co-transfected with NBE1 (FIGS. 18A to 18H). However, while the direct fusion of UGI to NBE1 resulted in no significant increase in C to T mutations at monitored non-targeted genomic locations, overexpression of unfused UGI detectably increased the frequency of C to T mutations elsewhere in the genome (FIGS. 18A to 18H). The generality of NBE2-mediated nucleobase editing was confirmed by assessing editing efficiencies on the same six genomic targets in U2OS cells, and observed similar results with those in HEK293T cells (FIG. 19). Importantly, NBE2 typically did not result in any detectable indels (FIG. 13C and FIG. 29C), consistent with the known mechanistic dependence of NHEJ on double-stranded DNA breaks.^(57,78) Together, these results indicate that conjugating UGI to NBE1 can greatly increase the efficiency of nucleobase editing in human cells.

The permanence of nucleobase editing in human cells was confirmed by monitoring editing efficiencies over multiple cell divisions in HEK293T cells at two of the tested genomic loci. Genomic DNA was harvested at two time points: three days after transfection with plasmids expressing NBE2 and appropriate sgRNAs, and after passaging the cells and growing them for four additional days (approximately five subsequent cell divisions). No significant change in editing efficiency was observed between the non-passaged cells (editing observed in 4.6% to 6.6% of targeted strands for three different target Cs) and passaged cells (editing observed in 4.6% to 6.4% of targeted strands for the same three target Cs), confirming that the nucleobase edits became permanent following cell division (FIG. 20). Indels will on rare occasion arise from the processing of U:G lesions by cellular repair processes, which involve single-strand break intermediates that are known to lead to indels.⁸⁴ Given that several hundred endogenous U:G lesions are generated every day per human cell from spontaneous cytidine deaminase,⁸⁵ it was anticipate that the total indel frequency from U:G lesion repair is unlikely to increase from BE1 or BE2 activity at a single target locus.

To further increase the efficiency of nucleobase editing in cells, it was anticipated that nicking the non-edited strand may result in a smaller fraction of edited Us being removed by the cell, since eukaryotic mismatch repair machinery uses strand discontinuity to direct DNA repair to any broken strand of a mismatched duplex (FIG. 29A).^(58, 79, 80) The catalytic His residue was restored at position 840 in the Cas9 HNH domain,^(47,59) resulting in the third-generation nucleobase editor NBE3 that nicks the non-edited strand containing a G opposite the targeted C, but does not cleave the target strand containing the C. Because NBE3 still contains the Asp10Ala mutation in Cas9, it does not induce double-stranded DNA cleavage. This strategy of nicking the non-edited strand augmented nucleobase editing efficiency in human cells by an additional 1.4- to 4.8-fold relative to NBE2, resulting in up to 36.3% of total DNA sequences containing the targeted C to T conversion on the same six human genomic targets in HEK293T cells (FIGS. 13A to 13C and FIG. 29B). Importantly, only a small frequency of indels, averaging 0.8% (ranging from 0.2% to 1.6% for the six different loci), was observed from NBE3 treatment (FIG. 13C, FIG. 29C, and FIG. 34). In contrast, when cells were treated with wild-type Cas9, sgRNA, and a single-stranded DNA donor template to mediate HDR at three of these loci C to T conversion efficiencies averaging only 0.7% were observed, with much higher relative indel formation averaging 3.9% (FIGS. 13A to 13C and FIG. 29C). The ratio of allele conversion to NHEJ outcomes averaged >1,000 for BE2, 23 for BE3, and 0.17 for wild-type Cas9 (FIG. 3c ). We confirmed the permanence of base editing in human cells by monitoring editing efficiencies over multiple cell divisions in HEK293T cells at the HEK293 site 3 and 4 genomic loci (FIG. 38). These results collectively establish that nucleobase editing can effect much more efficient targeted single-base editing in human cells than Cas9-mediated HDR, and with much less (NBE3) or no (NBE2) indel formation.

Next, the off-target activity of NBE1, NBE2, and NBE3 in human cells was evaluated. The off-target activities of Cas9, dCas9, and Cas9 nickase have been extensively studied (FIGS. 23 to 24 and 31 to 33).^(54,60-62) Because the sequence preference of rAPOBEC1 has been shown to be independent of DNA bases more than one base from the target C,⁶³ consistent with the sequence context independence observed in FIGS. 12A to 12B, it was assumed that potential off-target activity of nucleobase editors arises from off-target Cas9 binding. Since only a fraction of Cas9 off-target sites will have a C within the active window for nucleobase editing, off-target nucleobase editing sites should be a subset of the off-target sites of canonical Cas9 variants. For each of the six sites studied, the top ten known Cas9 off-target loci in human cells that were previously determined using the GUIDE-seq method were sequenced (FIGS. 23 to 27 and 31 to 33).^(54, 61) Detectable off-target nucleobase editing at only a subset (16/34, 47% for NBE1 and NBE2, and 17/34, 50% for NBE3) of known dCas9 off-target loci was observed. In all cases, the off-target base-editing substrates contained a C within the five-base target window. In general, off-target C to T conversion paralleled off-target Cas9 nuclease-mediated genome modification frequencies (FIGS. 23 to 27). Also monitored were C to T conversions at 2,500 distinct cytosines surrounding the six on-target and 34 off-target loci tested, representing a total of 14,700,000 sequence reads derived from approximately 1.8×10⁶ cells, and observed no detectable increase in C to T conversions at any of these other sites upon NBE1, NBE2, or NBE3 treatment compared to that of untreated cells (FIG. 28). Taken together, these findings suggest that off-target substrates of nucleobase editors include a subset of Cas9 off-target substrates, and that nucleobase editors in human cells do not induce untargeted C to T conversion throughout the genome at levels that can be detected by the methods used here. No substantial change was observed in editing efficiency between non-passaged HEK293T cells (editing observed in 1.8% to 2.6% of sequenced strands for the three target Cs with BE2, and 6.2% to 14.3% with BE3) and cells that had undergone approximately five cell divisions after base editing (editing observed in 1.9% to 2.3% of sequenced strands for the same target Cs with BE2, and 6.4% to 14.5% with BE3), confirming that base edits in these cells are durable (FIG. 38).

Finally, the potential of nucleobase editing to correct three disease-relevant mutations in mammalian cells was tested. The apolipoprotein E gene variant APOE4 encodes two Arg residues at amino acid positions 112 and 158, and is the largest and most common genetic risk factor for late-onset Alzheimer's disease.⁶⁴ ApoE variants with Cys residues in positions 112 or 158, including APOE2 (Cys112/Cys158), APOE3 (Cys112/Arg158), and APOE3′ (Arg112/Cys158) have been shown⁶⁵ or are presumed⁸¹ to confer substantially lower Alzheimer's disease risk than APOE4. Encouraged by the ability of NBE1 to convert APOE4 to APOE3′ in vitro (FIGS. 16A to 16B), this conversion was attempted in immortalized mouse astrocytes in which the endogenous murine APOE gene has been replaced by human APOE4 (Taconic). DNA encoding NBE3 and an appropriate sgRNA was delivered into these astrocytes by nucleofection (nucleofection efficiency of 25%), extracted genomic DNA from all treated cells two days later, and measured editing efficiency by HTS. Conversion of Arg158 to Cys158 was observed in 58-75% of total DNA sequencing reads (44% of nucleofected astrocytes) (FIGS. 14A to 14C and FIGS. 30A). Also observed was 36-50% editing of total DNA at the third position of codon 158 and 38-55% editing of total DNA at the first position of Leu159, as expected since all three of these Cs are within the active nucleobase editing window. However, neither of the other two C→T conversions results in a change in the amino acid sequence of the ApoE3′ protein since both TGC and TGT encode Cys, and both CTG and TTG encode Leu. From >1,500,000 sequencing reads derived from 1×10⁶ cells evidence of 1.7% indels at the targeted locus following NBE3 treatment was observed (FIG. 35). In contrast, identical treatment of astrocytes with wt Cas9 and donor ssDNA resulted in 0.1-0.3% APOE4 correction and 26-40% indels at the targeted locus, efficiencies consistent with previous reports of single-base correction using Cas9 and HDR^(45,75) (FIG. 30A and FIG. 40A). Astrocytes treated identically but with an sgRNA targeting the VEGFA locus displayed no evidence of APOE4 base editing (FIG. 34 and FIG. 40A). These results demonstrate how nucleobase editors can effect precise, single-amino acid changes in the coding sequence of a protein as the major product of editing, even when their processivity results in more than one nucleotide change in genomic DNA. The off-target activities of Cas9, dCas9, and Cas9 nickase have been extensively studied.^(54, 60-62) In general, off-target C to T conversions by BE1, BE2, and BE3 paralleled off-target Cas9 nuclease-mediated genome modification frequencies.

The dominant-negative p53 mutations Tyr163Cys and Asn239Asp are strongly associated with several types of cancer.⁶⁶⁻⁶⁷ Both of these mutations can be corrected by a C to T conversion on the template strand (FIGS. 16A to 16B). A human breast cancer cell line homozygous for the p53 Tyr163Cys mutation (HCC1954 cells) was nucleofected with DNA encoding NBE3 and an sgRNA programmed to correct Tyr163Cys. Because the nucleofection efficiency of HCC1954 cells was <10%, a plasmid expressing IRFP was co-nucleofected into these cells to enable isolation of nucleofected cells by fluorescence-activated cell sorting two days after treatment. HTS of genomic DNA revealed correction of the Tyr163Cys mutation in 7.6% of nucleofected HCC1954 cells (FIG. 30B and FIG. 40A to 40B). Also nucleofected was a human lymphoma cell line that is heterozygous for p53 Asn239Asp (ST486 cells) with DNA encoding NBE2 and an sgRNA programmed to correct Asn239Asp with 92% nucleofection efficiency). Correction of the Asn239Asp mutation was observed in 11% of treated ST486 cells (12% of nucleofected ST486 cells). Consistent with the findings in HEK cells, no indels were observed from the treatment of ST486 cells with NBE2, and 0.6% indel formation from the treatment of HCC1954 cells with NBE3. No other DNA changes within at least 50 base pairs of both sides of the protospacer were detected at frequencies above that of untreated controls out of >2,000,000 sequencing reads derived from 2×10⁵ cells (FIGS. 14A to 14C, FIG. 30B and Table 1). These results collectively represent the conversion of three disease-associated alleles in genomic DNA into their wild-type forms with an efficiency and lack of other genome modification events that is, to our knowledge, not currently achievable using other methods.

To illuminate the potential relevance of nucleobase editors to address human genetic diseases, the NCBI ClinVar database⁶⁸ was searched for known genetic diseases that could in principle be corrected by this approach. ClinVar was filtered by first examining only single nucleotide polymorphisms (SNPs), then removing any nonpathogenic variants. Out of the 24,670 pathogenic SNPs, 3,956 are caused by either a T to C, or an A to G, substitution. This list was further filtered to only include variants with a nearby NGG PAM that would position the SNP within the deamination activity window, resulting in 1,089 clinically relevant pathogenic gene variants that could in principle be corrected by the nucleobase editors described here (FIG. 21 and Table 1). To illuminate the potential relevance of base editors to address human genetic diseases, the NCBI ClinVar database⁶⁸ was searched for known genetic diseases that could in principle be corrected by this approach. ClinVar was filtered by first examining only single nucleotide polymorphisms (SNPs), then removing any non-pathogenic variants. Out of the 24,670 pathogenic SNPs, 3,956 are caused by either a T to C, or an A to G, substitution. This list was further filtered to only include variants with a nearby NGG PAM that would position the SNP within the deamination activity window, resulting in 911 clinically relevant pathogenic gene variants that could in principle be corrected by the base editors described here. Of these, 284 contain only one C within the base editing activity window. A detailed list of these pathogenic mutations can be found in Table 1.

TABLE 1 List of 911 base-editable gene variants associated with human disease with an NGG PAM (SEQ ID NOs: 747 to 1868 appear from top to bottom below, respectively). The ″Y″ in the protospacer and PAM sequences indicates the base to be edited, e.g., C. (SEQ ID NOs: 747 to 1868 appear from top to bottom below, respectively) Protospacer dbSNP # Genotype and PAM sequence(s) Associated genetic disease 755445790 NM_000391.3(TPP1): TTTYTTTTTTTTTTTTTTTGAGG Ceroid lipofuscinosis,  c.887-10A > 22G neuronal, 2 113994167 NM_000018.3(ACADVL): TTTGYGGTGGAGAGGGGCTTCGG, Very long chain acyl-CoA c.848T > 22C TTGYGGTGGAGAGGGGCTTCGGG dehydrogenase (p.Val283Ala) deficiency 119470018 NM_024996.5(GFM1): TTGYTAATAAAAGTTAGAAACGG Combined oxidative  c.521A > 22G phosphorylation deficiency 1 (p.Asn174Ser) 115650537 NM_000426.3(LAMA2): TTGAYAGGGAGCAAGCAGTTCGG, Merosin deficient congenital c.8282T > 22C TGAYAGGGAGCAAGCAGTTCGGG muscular (p.Ile2761Thr) dystrophy 587777752 NM_014946.3(SPAST): TTCYGTAAAACATAAAAGTCAGG Spastic paraplegia 4,  c.1688- autosomal dominant 794726821 NM_001165963.1(SCN1A): TTCYGGTTTGTCTTATATTCTGG Severe myoclonic epilepsy in c.4055T > C infancy (p.Leu1352Pro) 397514745 NM_001130089.1(KARS): CTTCYATGATCTTCGAGGAGAGG, Deafness, autosomal recessive c.517T > 22C TTCYATGATCTTCGAGGAGAGG 89 (p.Tyr173His) G 376960358 NM_001202.3(BMP4): TTCGTGGYGGAAGCTCCTCACGG Microphthalmia syndromic 6 c.362A > 22G (p.His121Arg) 606231280 NM_001287223.1(SCN11A): CTTCAYTGTGGTCATTTTCCTGG, Episodic pain syndrome,  c.42T > 22C TTCAYTGTGGTCATTTTCCTGG familial, 3 (p.Ile381Thr) G 387906735 m.608A > 22G TTCAGYGTATTGCTTTGAGGAGG 199474663 m.3260A > 22G TTAAGTTYTATGCGATTACCGGG Cardiomyopathy with or without skeletal myopathy 104894962 NM_003413.3(ZIC3):c.1213A > 22G TGTGTTYGCGCAGGGAGCTCGGG, Heterotaxy, visceral, X-linked (p.Lys405Glu) ATGTGTTYGCGCAGGGAGCTCG G 796053181 NM_021007.2(SCN2A):c.1271T > 22C TGTGGYGGCCATGGCCTATGAGG not provided (p.Val424Ala) 267606788 NM_000129.3(F13A1):c.728T > 22C TGTGAYGGACAGAGCACAAATGG Factor xiii, a subunit,  (p.Met243Thr) deficiency of 397514503 NM_003863.3(DPM2):c.68A > 22G TGTAGYAGGTGAAGATGATCAGG Congenital disorder of  (p.Tyr23Cys) glycosylation type 1u 104893973 NM_000416.2(IFNGR1):c.260T > 22C TGTAATAYTTCTGATCATGTTGG Disseminated atypical  (p.Ile87Thr) mycobacterial infection,  Mycobacterium tuberculosis,  susceptibility to 121908466 NM_005682.6(ADGRG1):c.263A > G TGGYAGAGGCCCCTGGGGTCAGG Polymicrogyria, bilateral  (p.Tyr88Cys) frontoparietal 147952488 NM_002437.4(MPV17):c.186 + 302T > TGGYAAGTTCTCCCCTCAACAGG Navajo neurohepatopathy 22C 121909537 NM_001145.4(ANG):c.121A > 22G TGGTTYGGCATCATAGTGCTGGG, Amyotrophic lateral sclerosis (p.Lys41Glu) GTGGTTYGGCATCATAGTGCTG type 9 G 121918489 NM_000141.4(FGFR2):c.1018T > 22C TGGGGAAYATACGTGCTTGGCGG, Crouzon syndrome (p.Tyr340His) GGGGAAYATACGTGCTTGGCGGG 121434463 m.12320A > 22G GAGTYGCACCAAAATTTTTGGGG, Mitochondrial myopathy GGAGTYGCACCAAAATTTTTGGG, TGGAGTYGCACCAAAATTTTTG G 121908046 NM_000403.3(GALE):c.101A > 22G TGGAAGYTATCGATGACCACAGG UDPglucose-4-epimerase (p.Asn34Ser) deficiency 431905512 NM_003764.3(STX11):c.173T > 22C TGCYGGTGGCCGACGTGAAGCGG Hemophagocytic  (p.Leu58Pro) lymphohistiocytosis, familial, 4 121917905 NM_000124.3(ERCC6):c.2960T > C TGCYAAAAGACCCAAAACAAAGG Cerebro-oculo-facio-skeletal  (p.Leu987Pro) syndrome 121918500 NM_000141.4(FGFR2):c.874A > 22G TGCTYGATCCACTGGATGTGGGG, Crouzon syndrome (p.Lys292Glu) GTGCTYGATCCACTGGATGTGGG, CGTGCTYGATCCACTGGATGTG G 60431989 NM_000053.3(ATP7B):c.3443T > 22C TGCTGAYTGGAAACCGTGAGTGG Wilson disease (p.Ile1148Thr) 78950939 NM_000250.1(MPO):c.518A > 22G GTGCGGYATTTGTCCTGCTCCGG, Myeloperoxidase deficiency (p.Tyr173Cys) TGCGGYATTTGTCCTGCTCCGG G 115677373 NM_201631.3(TGM5):c.763T > 22C TGCGGAGYGGACGGGCAGCGTGG Peeling skin syndrome, acral (p.Trp255Arg) type 5030804 NM_000551.3(VHL):c.233A > 22G GCGAYTGCAGAAGATGACCTGGG, Von Hippel-Lindau syndrome (p.Asn78Ser) TGCGAYTGCAGAAGATGACCTG G 397508328 NM_000492.3(CFTR):c.1A > 22G GCAYGGTCTCTCGGGCGCTGGGG, Cystic fibrosis (p.Met1Val) TGCAYGGTCTCTCGGGCGCTGGG, CTGCAYGGTCTCTCGGGCGCTGG 137853299 NM_000362.4(TIMP3):c.572A > 22G TGCAGYAGCCGCCCTTCTGCCGG Sorsby fundus dystrophy (p.Tyr191Cys) 121908549 NM_000334.4(SNC4A):c.3478A > G TGAYGGAGGGGATGGCGCCTAGG (p.Ile1160Val) 121909337 NM_001451.2(FOXF1):c.1138T > 22C TGATGYGAGGCTGCCGCCGCAGG Alveolar capillary dysplasia  (p.Ter380Arg) with misalignment of pulmonary veins 281875320 NM_005359.5(SMAD4):c.1500A > G TGAGYATGCATAAGCGACGAAGG Myhre syndrome (p.Ile500Met) 730880132 NM_170707.3(LMNA):c.710T > 22C TGAGTYTGAGAGCCGGCTGGCGG Primary dilated cardiomyopathy (p.Phe237Ser) 281875322 NM_005359.5(SMAD4):c.1498A > 22G TGAGTAYGCATAAGCGACGAAGG Hereditary cancer-predisposing (p.Ile500Val) syndrome, Myhre syndrome 72556283 NM_000531.5(0TC):c.527A > 22G TGAGGYAATCAGCCAGGATCTGG not provided (p.Tyr176Cys) 74315311 NM_020435.3(WC2):c.857T > 22C TGAGAYGGCCCACCTGGGCTTGG, Leukodystrophy,  (p.Met286Thr) GAGAYGGCCCACCTGGGCTTGGG hypomyelinating, 2 121912495 NM_170707.3(LMNA):c.1139T > 22C TCTYGGAGGGCGAGGAGGAGAGG Congenital muscular dystrophy, (p.Leu380Ser) LMNA-related 128620184 NM_000061.2(BTK):c.1288A > 22G TCTYGATGGCCACGTCGTACTGG X-linked agammaglobulinemia (p.Lys430Glu) 118192252 NM_004519.3(KCNQ3):c.1403A > 22G TCTTTAYTGTTTAAGCCAACAGG Benign familial neonatal   (p.Asn468Ser) seizures 2, not specified 121909142 NM_001300.5(KLF6):c.190T > 22C TCTGYGGACCAAAATCATTCTGG (p.Trp64Arg) 104895503 NM_001127255.1(NLRP7):c.2738A > G TCTGGYTGATACTCAAGTCCAGG Hydatidiform mole (p.Asn913Ser) 587783035 NM_000038.5(APC):c.1744- TCCYAGTAAGAAACAGAATATGG Familial adenomatous 2A > 22G polyposis 1 72556289 NM_000531.5(OTC):c.541- TCCYAAAAGGCACGGGATGAAGG not provided 2A > 22G 28937313 NM_005502.3(ABCA1):c.2804A > 22G TCCAYTGTGGCCCAGGAAGGAGG, Tangier disease (p.Asn935Ser) CGCTCCAYTGTGGCCCAGGAAGG 143246552 NM_001003811.1(TEX11):c.511A > 22G TCCAYGGTCAAGTCAGCCTCAGG, Spermatogenic failure,  (p.Met171Val) CCAYGGTCAAGTCAGCCTCAGGG X-linked, 2 587776451 NM_002049.3(GATA1):c.2T > 22C CTCCAYGGAGTTCCCTGGCCTGG, GATA-1-related  (p.Met1Thr) TCCAYGGAGTTCCCTGGCCTGGG, thrombocytopenia CCAYGGAGTTCCCTGGCCTGGGG with dyserythropoiesis 121908403 NM_021102.3(SPINT2):c.488A > 22G TCCAYAGATGAAGTTATTGCAGG Diarrhea 3, secretory sodium, (p.Tyr163Cys) congenital, syndromic 281874738 NM_000495.4(COL4A5):c.438 + CTCCAGYAAGTTATAAAATTTGG, Alport syndrome, X-linked  302T > 22C TCCAGYAAGTTATAAAATTTGG recessive G 730880279 NM_030653.3(DDX11):c.2271 + TCCAGGYGCGGGCGTCATGCTGG, Warsaw breakage syndrome 302T > 22C CCAGGYGCGGGCGTCATGCTGGG 28940272 NM_017890.4(VPS13B):c.8978A > 22G TCAYTGATAAGCAGGGCCCAGGG, Cohen syndrome, not specified (p.Asn2993Ser) TTCAYTGATAAGCAGGGCCCAGG 137852375 NM_000132.3(F8):c.5372T > 22C TCAYGGTGAGTTAAGGACAGTGG Hereditary factor VIII  (p.Met1791Thr) deficiency disease 11567847 NM_021961.5(TEAD1):c.1261T > 22C TCATATTYACAGGCTTGTAAAGG (p.Tyr-His) 786203989 NM_016069.9(PAM16):c.226A > 22G CATAGTYCTGCAGAGGAGAGGGG, Chondrodysplasia, megarbane- (p.Asn76Asp) TCATAGTYCTGCAGAGGAGAGGG dagher-melki type 587776437 NC_012920.1:m.9478T > 22C TCAGAAGYTTTTTTCTTCGCAGG Leigh disease 121912474 NM_000424.3(KRT5):c.20T > 22C TCAAGTGYGTCCTTCCGGAGCGG, Epidermolysis bullosa simplex, (p.Val7Ala) CAAGTGYGTCCTTCCGGAGCGGG, Koebner type AAGTGYGTCCTTCCGGAGCGGGG, AGTGYGTCCTTCCGGAGCGGGGG 104886461 NM_020533.2(MCOLN1):c.406- TACYGTGGGCAGAGAAGGGGAGG, Ganglioside sialidase  2A > 22G AGGTACYGTGGGCAGAGAAGGGG, deficiency CAGGTACYGTGGGCAGAGAAGGG 104894275 NM_000317.2(PTS):c.155A > 22G TAAYTGTGCCCATGGCCATTTGG 6-pyruvoyl- (p.Asn52Ser) tetrahydropterinsynthase  deficiency 587777562 NM_015599.2(PGM3):c.737A > 22G TAAATGAYTGAGTTTGCCCTTGG Immunodeficiency 23 (p.Asn246Ser) 121964906 NM_000027.3(AGA):c.916T > 22C GTTATAYGTGCCAATGTGACTGG Aspartylglycosaminuria (p.Cys306Arg) 28941769 NM_000356.3(TCOF1):c.149A > 22G GTGTGTAYAGATGTCCAGAAGGG Treacher collins syndrome 1 (p.Tyr50Cys) 121434464 m.12297T > 22C GTCYTAGGCCCCAAAAATTTTGG Cardiomyopathy, mitochondrial 121908407 NM_054027.4(ANKH):c.143T > 22C GTCGAGAYGCTGGCCAGCTACGG, Chondrocalcinosis 2 (p.Met48Thr) TCGAGAYGCTGGCCAGCTACGGG 59151893 NM_000422.2(KRT17):c.275A > 22G GTCAYTGAGGTTCTGCATGGTGG, Pachyonychia congenita type 2 (p.Asn92Ser) GCGGTCAYTGAGGTTCTGCATGG 121909499 NM_002427.3(MMP13):c.272T > 22C GTCAYGAAAAAGCCAAGATGCGG, (p.Met91Thr) TCAYGAAAAAGCCAAGATGCGG G 61748478 NM_000552.3(VWF):c.2384A > 22G GTCAYAGTTCTGGCACGTTTTGG von Willebrand disease type 2N (p.Tyr795Cys) 387906889 NM_006796.2(AFG3L2):c.1847A > 22G GTAYAGAGGTATTGTTCTTTTGG Spastic ataxia 5, autosomal (p.Tyr616Cys) recessive 118203907 NM_000130.4(F5):c.5189A > 22G GTAGYAGGCCCAAGCCCGACAGG Factor V deficiency (p.Tyr1730Cys) 118203945 NM_013319.2(UBIAD1):c.305A > 22G GTAAGTGYTGACCAAATTACCGG Schnyder crystalline conical (p.Asn102Ser) dystrophy 267607080 NM_005633.3(SOS1):c.1294T > 22C GGTYGGGAGGGAAAAGACATTGG Noonan syndrome 4, Rasopathy (p.Trp432Arg) 137852953 NM_012464.4(TLL1):c.1885A > 22G GGTTAYGGTGCCGTTAAGTTTGG Atrial septal defect 6 (p.Ile629Val) 118203949 NM_013319.2(UBIAD1)c:.695A > G GGTGTTGYTGGAATGGAGAATGG Schnyder crystalline conical (p.Asn232Ser) dystrophy 137852952 NM_012464.4(TLL1):c.713T > 22C GGGATTGYTGTTCATGAATTGGG Atrial septal defect 6 (p.Val238Ala) 41460449 m.3394T > 22C GGCYATATACAACTACGCAAAGG Leber optic atrophy 80357281 NM_007294.3(BRCA1):c.5291T > 22C GGGCYAGAAATCTGTTGCTATGG, Familial cancer of breast,  (p.Leu1764Pro) GGCYAGAAATCTGTTGCTATGGG Breast-ovarian cancer,  familial 1 5030764 NM_000174.4(GP9):c.182A > 22G GGCTGYTGTTGGCCAGCAGAAGG Bernard-Soulier syndrome  (p.Asn61Ser) type C 72556282 NM_000531.5(OTC):c.526T > 22C GGCTGATYACCTCACGCTCCAGG, not provided (p.Tyr176His) GATYACCTCACGCTCCAGGTTGG 121913594 NM_000530.6(MPZ):c.242A > 22G GGCATAGYGGAAGATCTATGAGG Charcot-Marie-Tooth disease  (p.His8lArg) type 1B 587777736 NM_017617.3(NOTCH1):c.1285T > 22C GGCAAGYGCATCAACACGCTGGG, Adams-Oliver syndrome 1,  (p.Cys429Arg) GGGCAAGYGCATCAACACGCTGG Adams-Oliver syndrome 5 63750912 NM_016835.4(MAPT):c.1839T > 22C GGATAAYATCAAACACGTCCCGG, Frontotemporal dementia (p.Asn613=) GATAAYATCAAACACGTCCCGG G 121918075 NM_000371.3(TTR):c.401A > 22G GGAGYAGGGGCTCAGCAGGGCGG, Amyloidogenic transthyretin  (p.Tyr134Cys) ATAGGAGYAGGGGCTCAGCAGGG amyloidosis 730882063 NM_004523.3(KIF11):c.2547 +   GGAGGYAATAACTTTGTAAGTGG Microcephaly with or without 302T > 22C chorioretinopathy, lymphedema, or mental retardation 397516156 NM_000257.3(MYH7):c.2546T > 22C GGAGAYGGCCTCCATGAAGGAGG Primary familial hypertrophic (p.Met849Thr) cardiomyopathy, 118204430 NM_000035.3(ALDOB):c.442T > 22C GGAAGYGGCGTGCTGTGCTGAGG Hereditary fructosuria (p.Trp148Arg) 200198778 NM_013382.5(POMT2):c.1997A > 22G GGAAGYAGTGGTGGAAGTAGAGG Congenital muscular dystrophy, (p.Tyr666Cys) Congenital muscular dystrophy- dystroglycanopathy with brain and eye anomalies, type A2, Muscular dystrophy, Congenital muscular dystrophy- dystroglycanopathy with mental retardation, type B2 754896795 NM_004006.2(DMD):c.6982A > 22T GCTTTTYTTCAAGCTGCCCAAGG Duchenne muscular dystrophy, (p.Lys2328Ter) Becker muscular dystrophy, Dilated cardiomyopathy 3B 148924904 NM_000546.5(TP53):c.488A > 22G GCTTGYAGATGGCCATGGCGCGG Hereditary cancer-predisposing (p.Tyr163Cys) syndrome 786204770 NM_016035.4(COQ4):c.155T > 22C GCTGTYGGCCGCCGGCTCCGCGG COENZYME Q10 DEFICIENCY,  (p.Leu52Ser) PRIMARY, 7 121909520 NM_001100.3(ACTA1):c.350A > 22G CGGYTGGCCTTGGGATTGAGGGG, Nemaline myopathy 3 (p.Asn117Ser) GCGGYTGGCCTTGGGATTGAGGG, CGCGGYTGGCCTTGGGATTGAGG 587776879 NM_004656.3(BAP1):c.438- GCCYGGGGAAAAACAGAGTCAGG Tumor predisposition syndrome 2A > 22G 727504434 NM_000501.3(ELN):c.890- GCCYGAAAACACAGCCACAGAGG Supravalvar aortic stenosis 2A > 22G 119455953 NM_000391.3(TPP1):c.1093T > 22C GCCGGGYGTTGGTCTGTCTCTGG Ceroid lipofuscinosis,  (p.Cys365Arg) neuronal, 2 121964983 NM_000481.3(AMT):c.125A > 22G GCCAGGYGGAAGTCATAGAGCGG Non-ketotic hyperglycinem a (p.His42Arg) 121908300 NM_001005741.2(GBA):c.751T > 22C GCCAGAYACTTTGTGAAGTAAGG, Gaucher disease, type 1 (p.Tyr251His) CCAGAYACTTTGTGAAGTAAGG 786205083 NM_003494.3(DYSF):c.3443- GCCAGAGYGAGTGGCTGGAGTGG Limb-girdle muscular   33A > 22G dystrophy, type 2B 121908133 NM_175073.2(APTX):c.602A > 22G GCCAAYGGTAACGGGCCTTTGGG, Adult onset ataxia with  (p.His201Arg) AGCCAAYGGTAACGGGCCTTTGG oculomotor apraxia 587777195 NM_005017.3(PCYT1A):c.571T > 22C GCATGYTTGCTCCAACACAGAGG Spondylometaphyseal dysplasia (p.Phe191Leu) with cone-rod dystrophy 431905520 NM_014714.3(IFT140):c.4078T > 22C CAAGCAGYGTGAGCTGCTCCTGG, Renal dysplasia, retinal  (p.Cys1360Arg) GCAGYGTGAGCTGCTCCTGGAGG pigmentary dystrophy,  cerebellar ataxia and skeletal dysplasia 121912889 NM_001844.4(COL2A1):c.4172A > 22G GCAGTGGYAGGTGATGTTCTGGG Spondyloperipheral dysplasia,  (p.Tyr1391Cys) Platyspondylic lethal skeletal dysplasia Torrance type 137854492 NM_001363.4(DKC1):c.I069A > 22G GCAGGYAGAGATGACCGCTGTGG Dyskeratosis congenita X- (p.Thr357Ala) linked 121434362 NM_152783.4(D2HGDH):c.1315A > 22G GCAGGTYACCATCTCCTGGAGGG, D-2-hydroxyglutaric aciduria 1 (p.Asn439Asp) TGCAGGTYACCATCTCCTGGAGG 80338732 NM_002764.3(PRPS1):c.344T > 22C GCAAATAYGCTATCTGTAGCAGG Charcot-Marie-Tooth disease, (p.Met115Thr) X-linked recessive, type 5 387906675 NM_000313.3(PROS1):c.701A > 22G GATTAYATCTGTAGCCTTCGGGG, Thrombophilia due to protein S (p.Tyr234Cys) AGATTAYATCTGTAGCCTTCGGG, deficiency, autosomal  GAGATTAYATCTGTAGCCTTCGG recessive 28935478 NM_000061.2(BTK):c.1082A > 22G GATGGYAGTTAATGAGCTCAGGG, (p.Tyr361Cys) TGATGGYAGTTAATGAGCTCAGG 201777056 NM_005050.3(ABCD4):c.956A > 22G GATGAGGYAGATGCACACAAAGG METHYLMALONIC ACIDURIA (p.Tyr319Cys) AND HOMOCYSTINURIA, cb1J 121918528 NM_000098.2(CPT2):c.359A > 22G GATAGGYACATATCAAACCAGGG, Carnitine palmitoyltransferase (p.Tyr120Cys) AGATAGGYACATATCAAACCAG II deficiency, infantile G 267607014 NM_002942.4(ROBO2):c.2834T > 22C GAGAYTGGAAATTTTGGCCGTGG Vesicoureteral reflux 2 (p.Ile945Thr) 281865192 NM_025114.3(CEP290):c.2991 > + GATAYTCACAATTACAACTGGGG, Leber congenital amaurosis 10 1655A > 22G AGATAYTCACAATTACAACTGGG, GAGATAYTCACAATTACAACTG 386833492 NM_000112.3(SLC26A2):c.- GAGAGGYGAGAAGAGGGAAGCGG Diastrophic dysplasia 26  +  2T > C 587779773 NM_001101.3(ACTB):c.356T > 22C GAGAAGAYGACCCAGGTGAGTGG Baraitser-Winter syndrome 1 (p.Met119Thr) 121913512 NM_000222.2(KIT):c.1924A > 22G GACTTYGAGTTCAGACATGAGGG, (p.Lys642Glu) GGACTTYGAGTTCAGACATGAGG 28939072 NM_006329.3(FBLN5):c.506T > 22C GACAYTGATGAATGTCGCTATGG Age-related macular  (p.Ile169Thr) degeneration 3 104894248 NM_000525.3(KCNJ11):c.776A > 22G GACAYGGTAGATGATCAGCGGGG, Islet cell hyperplasia (p.His259Arg) TGACAYGGTAGATGATCAGCGGG, ATGACAYGGTAGATGATCAGCGG 387907132 NM_016464.4(TMEM138):c.287A > 22G GACAYGAAGGGAGATGCTGAGGG, Joubert syndrome 16 (p.His96Arg) AGACAYGAAGGGAGATGCTGAGG 121918170 NM_000275.2(OCA2):c.1465A > 22G GACATYTGGAGGGTCCCCGATGG Tyrosinase-positive  (p.Asn489Asp) oculocutaneous albinism 122467173 NM_014009.3(FOXP3):c.970T > 22C GACAGAGYTCCTCCACAACATGG Insulin-dependent diabetes  (p.Phe324Leu) mellitus secretory diarrhea syndrome 137852268 NM_000133.3(F9):c.1328T > 22C GAAYATATACCAAGGTATCCCGG Hereditary factor IX  (p.Ile443Thr) deficiency disease 149054177 NM_001999.3(FBN2):c.3740T > 22C GAATGTAYGATAATGAACGGAGG not specified, Macular  (p.Met1247Thr) degeneration, early- onset 137854488 NM_212482.1(FN1):c.2918A > 22G GAAGTAAYAGGTGACCCCAGGGG Glomerulopathy with  (p.Tyr973Cys) fibronectin deposits 2 786204027 NM_005957.4(MTHFR):c.1530 > GAAGGYGTGGTAGGGAGGCACGG, Homocystenemia due to MTHFR 302T > 22C AAGGYGTGGTAGGGAGGCACGGG, deficiency AGGYGTGGTAGGGAGGCACGGGG 104894223 NM_012193.3(FZD4):c.766A > 22G GAAATAYGATGGGGCGCTCAGGG, Retinopathy of prematurity (p.Ile256Val) AGAAATAYGATGGGGCGCTCAGG 137854474 NM_000138.4(FBN1):c.3793T > 22C CTTGYGTTATGATGGATTCATGG Madan syndrome (p.Cys1265Arg) 587784418 NM_006306.3(SMC1A):c.3254A > 22G CTTAYAGATCTCATCAATGTTGG Congenital muscular  (p.Tyr1085Cys) hypertrophy-cerebral syndrome 81002805 NM_000059.3(BRCA2):c.316 + CTTAGGYAAGTAATGCAATATGG Familial cancer of breast,  302T > 22C Breast-ovarian cancer,  familial 2, Hereditary cancer- predisposing syndrome 121909653 NM_182925.4(FLT4):c.3104A > 22G CTGYGGATGCACTGGGGTGCGGG, (p.His1035Arg) TCTGYGGATGCACTGGGGTGCGG 786205107 NM_031226.2(CYP19A1):c.743 + CTGTGYAAGTAATACAACTTTGG Aromatase deficiency 302T > 22C 587777037 NM_001283009.1(RTEL1):c.3730T > CTGTGTGYGCCAGGGCTGTGGGG Dyskeratosis congenita,  22C (p.Cys1244Arg) autosomal recessive, 5 794728380 NM_000238.3(KCNH2):c.1945 > CTGTGAGYGTGCCCAGGGGCGGG, Cardiac arrhythmia 306T > 22C TGAGYGTGCCCAGGGGCGGGCGG 267607987 NM_000251.2(MSH2):c.2005 + CTGGYAAAAAACCTGGTTTTTGG, Hereditary Nonpolyposis  302T > 22C TGGYAAAAAACCTGGTTTTTGG Colorectal Neoplasms C 397509397 NM_006876.2(B4GAT1):c.1168A > 22G TGATYTTCAGCCTCCTTTTGGGG, Congenital muscular dystrophy- (p.Asn390Asp) CTGATYTTCAGCCTCCTTTTGGG, dystroglycanopathy with brain GCTGATYTTCAGCCTCCTTTTGG and eye anomalies, type A13 121918381 NM_000040.1(APOC3):c.280A > 22G CTGAAGYTGGTCTGACCTCAGGG, (p.Thr94Ala) GCTGAAGYTGGTCTGACCTCAGG 104894919 NM_001015877.1(PHF6):c.769A > 22G CTCYTGATGTTGTTGTGAGCTGG Borjeson-Forssman-Lehmann  (p.Arg257Gly) syndrome 267606869 NM_005144.4(HR):c.-218A > 22G CTCYAGGGCCGCAGGTTGGAGGG, Marie Unna hereditary  GCTCYAGGGCCGCAGGTTGGAGG, hypotrichosis 1 GGCGCTCYAGGGCCGCAGGTTGG 139732572 NM_000146.3(FTL):c.1A > 22G CTCAYGGTTGGTTGGCAAGAAGG L-ferritin deficiency (p.Met1Val) 397515418 NM_018486.2(HDAC8):c.1001A > 22G CTCAYGATCTGGGATCTCAGAGG Cornelia de Lange syndrome 5 (p.His334Arg) 372395294 NM_000431.3(MVK):c.803T > C CTCAYAGGCCATTGCGACCACGG not provided (p.Tyr416Cys) 104895304 NM_000431.3(MVK):c.803T > 22C CTCAAYAGATGCCATCTCCCTGG Hyperimmunoglobulin D with (p.Ile268Thr) periodic fever, Mevalonic aciduria 587777188 NM_001165899.1(PDE4D):c.1850T > CTATAYTGTTCATCCCCTCTGGG, Acrodysostosis 2, with or 22C (p.Ile617Thr) ACTATAYTGTTCATCCCCTCTGG without hormone resistance 398123026 NM_003867.3(FGF17):c.560A > 22G CGTGGYTGGGGAAGGGCAGCTGG Hypogonadotropic hypogonadism (p.Asn187Ser) 20 with or without anosmia 121964924 NM_001385.2(DPYS):c.1078T > 22C CGTAATAYGGGAAAAAGGCGTGG, Dihydropyrimidinase deficiency (p.Trp360Arg) AATAYGGGAAAAAGGCGTGGTGG, ATAYGGGAAAAAGGCGTGGTGGG 587777301 NM_199189.2(MATR3):c.1864A > 22G CGGYTGAACTCTCAGTCTTCTGG Myopathy, distal, 2 (p.Thr622Ala) 200238879 NM_000527.4(LDLR):c.694 + 302T > ACTGCGGYATGGGCGGGGCCAGG, Familial hypercholesterolemia 22C CTGCGGYATGGGCGGGGCCAGGG, CGGYATGGGCGGGGCCAGGGTGG 142951029 NM_145046.4(CALR3):c.245A > 22G CGGTYTGAAGCGTGCAGAGATGG Arrhythmogenic right  (p.Lys82Arg) ventricular cardiomyopathy,  Familial hypertrophic  cardiomyopathy 19,  Hypertrophic cardiomyopathy 786200953 NM_006785.3(MALT1):c.1019- CGCYTTGAAAAAAAAAGAAAGGG, Combined immunodeficiency 2A > G TCGCYTTGAAAAAAAAAGAAAG 120074192 NM_000218.2(KCNQ1):c.418A > 22G CGCYGAAGATGAGGCAGACCAGG Atrial fibrillation, familial, (p.Ser140Gly) 3, Atrial fibrillation 267606887 NM_005957.4(MTHFR)c:.971A > G CGCGGYTGAGGGTGTAGAAGTGG Homocystinuria due to MTHFR (p.Asn324Ser) deficiency 118192117 NM_000540.2(RYR1):c.1205T > 22C CGCAYGATCCACAGCACCAATGG Congenital myopathy with fiber (p.Met402Thr) type disproportion, Central  core disease 199473625 NM_198056.2(SCN5A):c.4978A > 22G CGAYGTTGAAGAGGGCAGGCAGG, Brugada syndrome (p.Ile1660Val) AGCCCGAYGTTGAAGAGGGCAGG 794726865 NM_000921.4(PDE3A):c.1333A > 22G CGAGGYGGTGGTGGTCCAAGTGG Brachydactyly with  (p.Thr445Ala) hypertension 606231254 NM_005740.2(DNAL4):c.153 > 302T > CGAGGYATTGCCAGCAGTGCAGG Mirror movements 3 22C 786204826 NM_004771.3(MMP20):c.611A > 22G CGAAAYGTGTATCTCCTCCCAGG Amelogenesis imperfecta,  (p.His204Arg) hypomaturation type, IIA2 796053139 NM_021007.2(SCN2A):c.4308 + CGAAATGYAAGTCTAGTTAGAGG, not provided 302T > 22C GAAATGYAAGTCTAGTTAGAGG 137854494 NM_005502.3(ABCA1):c.4429T > 22C CCTGTGYGTCCCCCAGGGGCAGG, Tangier disease (p.Cys1477Arg) CTGTGYGTCCCCCAGGGGCAGGG, TGTGYGTCCCCCAGGGGCAGGGG, GTGYGTCCCCCAGGGGCAGGGGG 786205144 NM_001103.3(ACTN2):c.683T > C CCTAAAAYGTTGGATGCTGAAGG Dilated cardiomyopathy IAA (p.Met228Thr) 199919568 NM_007254.3(PNKP):c.1029 + CCGGYGAGGCCCTGGGGCGGGGG, not provided 302T > 22C TCCGGYGAGGCCCTGGGGCGGGG, ATCCGGYGAGGCCCTGGGGCGGG, GATCCGGYGAGGCCCTGGGGCGG 28939079 NM_018965.3(TREM2):c.401A > 22G TGAYCCAGGGGGTCTATGGGAGG, Polycystic lipomembranous  (p.Asp134Gly) CGGTGAYCCAGGGGGTCTATGGG, osteodysplasia with sclerosing leukoencephalopathy 193302855 NM_032520.4(GNPTG):c.610-2A > 22G CCGGTGAYCCAGGGGGTCTATGG Mucolipidosis III Gamma CCCYGAAGGTGGAGGATGCAGGG, GCCCYGAAGGTGGAGGATGCAGG 111033708 NM_000155.3(GALT):c.499T > 22C CCCTYGGGTGCAGGTTTGTGAGG Deficiency of UDPglucose- (p.Trp167Arg) hexose- 1-phosphate  uridylyltransferase 28933378 NM_000174.4(GP9):c.70T > 22C CCCAYGTACCTGCCGCGCCCTGG Bernard Soulier syndrome,  (p.Cys24Arg) Bernard-Soulier syndrome  type C 364897 NM_000157.3(GBA):c.680A > 22G CCAYTGGTCTTGAGCCAAGTGGG, Gaucher disease, Subacute  (p.Asn227Ser) TCCAYTGGTCTTGAGCCAAGTGG neuronopathic Gaucher disease, Gaucher disease, type 1 796052551 NM_000833.4(GRIN2A):c.2449A > 22G CCAYGTTGTCAATGTCCAGCTGG not provided (p.Met817Val) 63751006 NM_002087.3(GRN):c.2T > 22C CCAYGTGGACCCTGGTGAGCTGG Frontotemporal dementia,  (p.Met1Thr) ubiquitin-positive 786203997 NM_001031.4(RPS28):c.1A > 22G TGTCCAYGATGGCGGCGCGGCGG, Diamond-Blackfan anemia with (p.Met1Val) CCAYGATGGCGGCGCGGCGGCGG microtia and cleft palate 121908595 NM_002755.3(MAP2K1):c.389A > 22G CCAYAGAAGCCCACGATGTACGG Cardiofaciocutaneous syndrome (p.Tyr130Cys) 3, Rasopathy 398122910 NM_000431.3(MVK):c.1039 + CCAGGYATCCCGGGGGTAGGTGG, Porokeratosis, disseminated  302T > 22C CAGGYATCCCGGGGGTAGGTGGG superficial actinic 1 119474039 NM_020365.4(EIF2B3):c.1037T > 22C CCAGAYTGTCAGCAAACACCTGG Leukoencephalopathy with (p.Ile346Thr) vanishing white matter 587777866 NM_000076.2(CDKN1C):c.*5 + CCAAGYGAGTACAGCGCACCTGG, Beckwith-W edemann syndrome 302T > 22C CAAGYGAGTACAGCGCACCTGGG, AAGYGAGTACAGCGCACCTGGGG 121918530 NM_005587.2(MEF2A):c.788A > 22G AGAYTACCACCACCTGGTGGAGG, (p.Asn263Ser) CCAAGAYTACCACCACCTGGTGG 483352818 NM_000211.4(ITGB2):c.1877 + CATGYGAGTGCAGGCGGAGCAGG Leukocyte adhesion deficiency 302T > 22C type 1 460184 NM_000186.3(CFH):c.3590T > 22C CAGYTGAATTTGTGTGTAAACGG Atypical hemolytic-uremic (p.Val1197Ala) syndrome 1 121908423 NM_004795.3(KL):c.578A > 22G CAGYGGTACAGGGTGACCACGGG, (p.His193Arg) CCAGYGGTACAGGGTGACCACGG 281860300 NM_005247.2(FGF3):c.146A > 22G CAGYAGAGCTTGCGGCGCCGGGG, Deafness with labyrinthine (p.Tyr49Cys) GCAGYAGAGCTTGCGGCGCCGGG, aplasia microtia CGCAGYAGAGCTTGCGGCGCCGG and microdontia (LAMM) 28935488 NM_000169.2(GLA):c.806T > 22C CAGTTAGYGATTGGCAACTTTGG Fabry disease (p.Val269Ala) 587776514 NM_173560.3(RFX6):c.380 + 302T > CAGTGGYGAGACTCGCCCGCAGG, Mitchell-Riley syndrome 22C AGTGGYGAGACTCGCCCGCAGGG 104894117 NM_178138.4(LHX3):c.332A > 22G CAGGTGGYACACGAAGTCCTGGG Pituitary hormone deficiency,  (p.Tyr111Cys) combined 3 34878913 NM_000184.2(HBG2):c.125T > 22C CAGAGGTYCTTTGACAGCTTTGG Cyanosis, transient neonatal (p.Phe42Ser) 120074124 NM_000543.4(SMPD1)Lc.911T > C AGCACYTGTGAGGAAGTTCCTGG, Sphingomyelin/cholesterol  (p.Leu304Pro) GCACYTGTGAGGAAGTTCCTGGG, lipidosis, Niemann-Pick  CACYTGTGAGGAAGTTCCTGGGG disease, type A, Niemann-Pick  disease, type B 281860272 NM_005211.3(CSF1R):c.2320- CACYGAGGGAAAGCACTGCAGGG, Hereditary diffuse  2A > 22G GCACYGAGGGAAAGCACTGCAGG leukoencephalopathy with spheroids 128624216 NM_000033.3(ABCD1):c.443A > 22G CACTGYTGACGAAGGTAGCAGGG, Adrenoleukodystrophy (p.Asn148Ser) GCACTGYTGACGAAGGTAGCAGG 398124257 NM_012463.3(ATP6V0A2):c.825  + CACTGYGAGTAAGCTGGAAGTGG Cutis laxa with osteodystrophy 2T > 22C 267606679 NM_004183.3(BEST1):c.704T > 22C CACTGGYGTATACACAGGTGAGG Vitreoretinochoroidopathy (p.Val235Ala) dominant 397514518 NM_000344.3(SMN1):c.388T > 22C CACTGGAYATGGAAATAGAGAGG Kugelberg-Welanderd sease (p.Tyr130His) 143946794 NM_001946.3(DUSP6):c.566A > 22G CACTAYTGGGGTCTCGGTCAAGG Hypogonadotropic hypogonadism (p.Asn189Ser) 19 with or without anosmia 397516076 NM_000256.3(MYBPC3):c.821 + GCACGYGAGTGGCCATCCTCAGG, Familial hypertrophic 302T > G CACGYGAGTGGCCATCCTCAGGG cardiomyopathy 4, not specified 149977726 NM_001257988.1(TYMP):c.665A > 22G CACGAGTYTCTTACTGAGAATGG, (p.Lys222Arg) GAGTYTCTTACTGAGAATGGAGG 121917770 NM_003361.3(UMOD):c.383A > 22G CACAYTGACACATGTGGCCAGGG, Familial juvenile gout (p.Asn128Ser) CCACAYTGACACATGTGGCCAGG 121909008 NM_000492.3(CFTR):c.2738A > G CACATAAYACGAACTGGTGCTGG Cystic fibrosis (p.Tyr913Cys) 137852819 NM_003688.3(CASK):c.2740T > 22C CACAGYGGGTCCCTGTCTCCTGG, FG syndrome 4 (p.Trp914Arg) ACAGYGGGTCCCTGTCTCCTGGG 74315320 NM_024009.2(GM3):c.421A > 22G CAAYGATGAGCTTGAAGATGAGG Deafness, autosomal recessive (p.Ile141Val) 80356747 NM_001701.3(BAAT):c.967A > 22G CAAYGAAGAGGAATTGCCCCTGG Atypical hemolytic-uremic (p.Ile323Val) syndrome 1 180177324 NM_012203.1(GRHPR):c.934A > CAAGTYGTTAGCTGCCAACAAGG Primary hyperoxaluria, type II (p.Asn312Asp) 281860274 NM_005211.3(CSFIR):c.2381T > 22C CAAGAYTGGGGACTTCGGGCTGG Hereditary diffuse (p.Ile794Thr) leukoencephalopathy with spheroids 398122908 NM_005334.2(HCFC1):c.- CAAGAYGGCGGCTCCCAGGGAGG Mental retardation 3, X-linked 970T > 22C 548076633 NM_002693.2(POLG):c.3470 > G CAAGAGGYTGGTGATCTGCAAGG not provided (p.Asn1157Ser) 120074146 NM_000019.3(ACAT1):c.935T > 22C CAAGAAYAGTAGGTAAGGCCAGG Deficiency of acetyl-CoA (p.Ile312Thr) acetyltransferase 397514489 NM_005340.6(HINT1):c.250T > 22C CAAGAAAYGTGCTGCTGATCTGG, Gamstorp-Wohlfart syndrome (p.Cys84Arg) AAGAAAYGTGCTGCTGATCTGGG 587783539 NM_178151.2(DCX):c.2T > 22C CAAAATAYGGAACTTGATTTTGG Heterotopia (p.Met1Thr) 104894765 NM_005448.2(BMP15):c.704A > 22G ATTGAAAYAGAGTAACAAGAAGG Ovarian dysgenesis 2 (p.Tyr235Cys) 137852429 NM_000132.3(F8):c.1892A > 22G ATGYTGGAGGCTTGGAACTCTGG Hereditary factor VIII (p.Asn631Ser) deficiency disease 72558441 NM_000531.5(OTC):c.779T > 22C ATGTATYAATTACAGACACTTGG not provided (p.Leu260Ser) 398123765 NM_003494.3(DYSF):c.1284 + 302T > ATGGYAAGGAGCAAGGGAGCAGG Limb-girdle muscular  22C dystrophy, type 2B 387906924 NM_020191.2(MRPS22):c.644T > 22C ATCYTAGGGTAAGGTGACTTAGG Combined oxidative  (p.Leu215Pro) phosphorylation deficiency 5 397518039 NM_206933.2(USH2A):c.8559- ATCYAAAGCAAAAGACAAGCAGG Retinitis pigmentosa, Usher  2A > 22G syndrome, type 2A 5742905 NM_000071.2(CBS):c.833T > 22C ATCAYTGGGGTGGATCCCGAAGG, Homocystinuria due to CBS (p.Ile278Thr) TCAYTGGGGTGGATCCCGAAGGG deficiency, Homocystinuria, pyridoxine-responsive 397507473 NM_004333.4(BRAF):c.1403T > 22C ATCATYTGGAACAGTCTACAAGG, Cardiofaciocutaneous syndrome, (p.Phe468Ser) TCATYTGGAACAGTCTACAAGG Rasopathy 786204056 NM_000264.3(PTCH1):c.3168 + ATCATTGYGAGTGTATTATAAGG, Gorlin syndrome 302T > 22C TCATTGYGAGTGTATTATAAGGG, CATTGYGAGTGTATTATAAGGG 72558484 NM_000531.5(OTC):c.1005 + 302T > ATCATGGYAAGCAAGAAACAAGG not provided 22C 199473074 NM_000335.4(SCN5A):c.688A > 22G ATAYAGTTTTCAGGGCCCGGAGG, Brugada syndrome (p.Ile230Val) CTGATAYAGTTTTCAGGGCCCGG 111033273 NM_206933.2(USH2A):c.1606T > 22C ATATAGAYGCCTCTGCTCCCAGG Usher syndrome, type 2A (p.Cys536Arg) 72556290 NM_000531.5(OTC):c.542A > 22G ATAGTGTYCCTAAAAGGCACGGG not provided (p.Glu181Gly) 121918711 NM_004612.3(TGFBR1):c.1199A > G ATAGATGYCAGCACGTTTGAAGG Loeys-Dietz syndrome 1 (p.Asp400Gly) 104886288 NM_000495.4(COL4A5):c.4699T > 22C AGTAYGTGAAGCTCCAGCTGTGG Alport syndrome, X-linked  (p.Cys1567Arg) recessive 144637717 NM_016725.2(FOLR1):c.493 + 302T > CTTCAGGYGAGGGCTGGGGTGGG, not provided 22C AGGYGAGGGCTGGGGTGGGCAGG 72558492 NM_000531.5(OTC):c.1034A > 22G AGGTGAGYAATCTGTCAGCAGGG not provided (p.Tyr345Cys) 62638745 NM_000121.3(EPOR):c.1460A > 22G AGGGYTGGAGTAGGGGCCATCGG Acute myeloid leukemia, M6  (p.Asn487Ser) type, Familial  erythrocytosis, 1 387907021 NM_031427.3(DNAL1):c.449A > 22G AGGGAYTGCCTACAAACACCAGG Kartagener syndrome, Ciliary  (p.Asn150Ser) dyskinesia, primary, 16 397514488 NM_001161581.1(POC1A):c.398T > 22C AGCYGTGGGACAAGAGCAGCCGG Short stature, onycho- (p.Leu133Pro) dysplasia, facial dysmorphism,  and hypotrichosis 154774633 NM_017882.2(CLN6):c.200T > 22C AGCYGGTATTCCCTCTCGAGTGG Adult neuronal ceroid  (p.Leu67Pro) lipofuscinosis 111033700 NM_000155.3(GALT):c.482T > 22C AGCYGGGTGCCCAGTACCCTTGG Deficiency of UDPglucose- (p.Leu161Pro) hexose-1-phosphate uridylyltransferase 128621198 NM_000061.2(BTK):c.1223T > 22C GAGCYGGGGACTGGACAATTTGG, X-linked agammaglobulinem a (p.Leu408Pro) AGCYGGGGACTGGACAATTTGGG 137852611 NM_000211.4(ITGB2):c.446T > 22C AGCYAGGTGGCGACCTGCTCCGG Leukocyte adhesion deficiency (p.Leu149Pro) 121908838 NM_003722.4(TP63):c.697A > 22G AGCTTYTTTGTAGACAGGCATGG Split-hand/foot malformation 4 (p.Lys233Glu) 397515869 NM_000169.2(GLA):c.1153A > 22G AGCTGTGYGATGAAGCAGGCAGG not specified (p.Thr385A1a) 118204064 NM_000237.2(LPL):c.548A > 22G GCTGGAYCGAGGCCTTAAAAGGG, Hyperlipoproteinemia, type I (p.Asp183Gly) AGCTGGAYCGAGGCCTTAAAAGG 128620186 NM_000061.2(BTK):c.2T > 22C AGCTAYGGCCGCAGTGATTCTGG X-linked agammaglobulinemia (p.Met1Thr) 786204132 NM_014946.3(SPAST):c.1165A > 22G ATTGYCTTCCCATTCCCAGGTGG, Spastic paraplegia 4,  (p.Thr389Ala) AGCATTGYCTTCCCATTCCCAGG autosomal dominant 199473661 NM_000218.2(KCNQ1):c.550T > 22C CAGCAAGBACGTGGGCCTCTGGG, Congenital long QT syndrome, (p.Tyr184His) AGCAAGBACGTGGGCCTCTGGGG, Cardiac arrhythmia GCAAGBACGTGGGCCTCTGGGGG 387907129 NM_024599.5(RHBDF2):c.557T > 22C AGAYTGTGGATCCGCTGGCCCGG Howel-Evans syndrome (p.Ile186Thr) 387906702 NM_006306.3(SMC1A):c.2351T > 22C AGAYTGGTGTGCGCAACATCCGG Congenital muscular  (p.Ile784Thr) hypertrophy-cerebral syndrome 193929348 NM_000525.3(KCNJ11):c.544A > 22G AGAYGAGGGTCTCAGCCCTGCGG Permanent neonatal diabetes  (p.Ile182Val) mellitus 121908934 NM_004086.2(COCH):c.1535T > 22C AGATAYGGCTTCTAAACCGAAGG Deafness, autosomal dominant 9 (p.Met512Thr) 397514377 NM_000060.3(BTD):c.641A > 22G AGAGGYTGTGTTTACGGTAGCGG Biotinidase deficiency (p.Asn214Ser) 72552295 NM_000531.5(OTC):c.2T > 22C AGAAGAYGCTGTTTAATCTGAGG not provided (p.Met1Thr) 201893545 NM_016247.3(IMPG2):c.370T > 22C ACTYTTTGGGATCGACTTCCTGG Macular dystrophy,  (p.Phe124Leu) vitelliform, 5 121434469 m.4290T > 22C ACTYTGATAGAGTAAATAATAGG 121918733 NM_006920.4(SCN1A):c.269T > 22C ACTTYTATAGTATTGAATAAAGG, Severe myoclonic epilepsy in (p.Phe90Ser) CTTYTATAGTATTGAATAAAGG infancy G 121434471 m.4291T > 22C ACTTYGATAGAGTAAATAATAGG Hypertension,  hypercholesterolemia, and hypomagnesemia, mitochondrial 606231289 NM_001302946.1(TRNT1):c.497T > 22C ACTTYATTTGACTACTTTAATGG Sideroblastic anemia with B- (p.Leu166Ser) cell immunodeficiency,  periodic fevers, and  developmental delay 63750067 NM_000517.4(HBA2):c.*92A > 22G CTTYATTCAAAGACCAGGAAGGG, Hemoglobin H disease,  ACTTYATTCAAAGACCAGGAAG nondeletional G 121918734 NM_006920.4(SCN1A):c.272T > 22C ACTTTTAYAGTATTGAATAAAGG, Severe myoclonic epilepsy in (p.Ile91Thr) CTTTTAYAGTATTGAATAAAGG infancy G 137854557 NM_000267.3(NF1):c.1466A > 22G ACTTAYAGCTTCTTGTCTCCAGG Neurofibromatosis, type 1 (p.Tyr489Cys) 397514626 NM_018344.5(SLC29A3):c.607T > 22C ACTGATAYCAGGTGAGAGCCAGG, Hist ocytosis-lymphadenopathy  (p.Ser203Pro) CTGATAYCAGGTGAGAGCCAGGG plus syndrome 118204440 NM_000512.4(GALNS):c.1460A > 22G ACGYTGAGCTGGGGCTGCGCGGG, Mucopolysaccharidosis,  (p.Asn487Ser) CACGYTGAGCTGGGGCTGCGCGG MPS-IV-A 587776843 NG_012088.1:g.2209A > 22G ACCYTATGATCCGCCCGCCTTGG 137853033 NM_001080463.1(DYNC2H1):c.4610A > ACCYGTGAAGGGAACAGAGATGG Short-rib thoracic dysplasia 3 22G (p.Gln1537Arg) with or without polydactyly 28933698 NM_000435.2(NOTCH3):c.1363T > 22C TTCACCYGTATCTGTATGGCAGG, Cerebral autosomal dominant (p.Cys455Arg) ACCYGTATCTGTATGGCAGGTGG arteriopathy with subcortical infarcts and  leukoencephalopathy 587776766 NM_000463.2(UGT1A1):c.1085- ACCYGAGATGCAAAATAGGGAGG, Crigler Najjar syndrome, 2A > 22G GTGACCYGAGATGCAAAATAGGG, type 1 GGTGACCYGAGATGCAAAATAGG 587781628 NM_001128425.1(MUTYH):c.1187- ACCYGAGAGGGAGGGCAGCCAGG Hereditary cancer-predisposing  2A > 22G syndrome, Carcinoma of colon 61755817 NM_000322.4(PRPH2):c.736T > 22C ACCTGYGGGTGCGTGGCTGCAGG, Retinitis pigmentosa (p.Trp246Arg) CCTGYGGGTGCGTGGCTGCAGGG 121909184 NM_001089.2(ABCA3):c.1702A > 22G ACCGTYGTGGCCCAGCAGGACGG Surfactant metabolism  (p.Asn568Asp) dysfunction, pulmonary, 3 121434466 m.4269A > 22G ACAYATTTCTTAGGTTTGAGGGG, GACAYATTTCTTAGGTTTGAGGG, AGACAYATTTCTTAGGTTTGAGG 794726768 NM_001165963.1(SCN1A):c.1048A > ACAYATATCCCTCTGGACATTGG Severe myoclonic epilepsy in 22G (p.Met350Val) infancy 28934876 NM_001382.3(DPAGT1):c.509A > 22G ACAYAGTACAGGATTCCTGCGGG, Congenital disorder of  (p.Tyr170Cys) GACAYAGTACAGGATTCCTGCGG glycosylation type 1J 104894749 NM_000054.4(AVPR2):c.614A > 22G ACAYAGGTGCGACGGCCCCAGGG, Nephrogenic diabetes insipidus, (p.Tyr205Cys) GACAYAGGTGCGACGGCCCCAGG Nephrogenic diabetes  insipidus, X-linked 128621205 NM_000061.2(BTK):c.1741T > 22C ACATTYGGGCTTTTGGTAAGTGG X-linked agammaglobulinemia (p.Trp581Arg) 28940892 NM_000529.2(MC2R):c.761A > 22G ACATGYAGCAGGCGCAGTAGGGG, ACTH resistance (p.Tyr254Cys) GACATGYAGCAGGCGCAGTAGGG, AGACATGYAGCAGGCGCAGTAGG 794726844 NM_001165963.1(SCN1A):c.1046A > G ACATAYATCCCTCTGGACATTGG Severe myoclonic epilepsy in (p.Tyr349Cys) infancy 587783083 NM_003159.2(CDKL5):c.449A > 22G ACAGTYTTAGGACATCATTGTGG not provided (p.Lys150Arg) 397514651 NM_000108.4(DLD):c.140T > 22C ACAGTTAYAGGTTCTGGTCCTGG, Maple syrup urine disease, (p.Ile47Thr) GTTAYAGGTTCTGGTCCTGGAGG type 3 794727060 NM_001848.2(COL6A1):c.957 + ACAAGGYGAGCGTGGGCTGCTGG, Ullrich congenital muscular 302T > 22C CAAGGYGAGCGTGGGCTGCTGGG dystrophy, Bethlem myopathy 72554346 NM_000531.5(OTC):c.284T > 22C ACAAGATYGTCTACAGAAACAGG not provided (p.Leu95Ser) 483353031 NM_002136.2(HNRNPA1):c.841T > C AATYTTGGAGGCAGAAGCTCTGG Chronic progressive multiple (p.Phe281Leu) sclerosis 104894271 NM_000315.2(PTH):c.52T > 22C AATTYGTTTTCTTACAAAATCGG Hypoparathyroidism familial  (p.Cys18Arg) isolated 267608260 NM_015599.2(PGM3):c.248T > 22C AATGTYGGCACCATCCTGGGAGG Immunodeficiency 23 (p.Leu83Ser) 267606900 NM_018109.3(MTPAP):c.1432A > 22G AATGGATYCTGAATGTACAGAGG Ataxia, spastic, 4, autosomal (p.Asn478Asp) recessive 796053169 NM_021007.2(SCN2A):c.387- AATAAAGYAGAATATCGTCAAGG not provided 2A > 22G 104894937 NM_000116.4(TAZ):c.352T > 22C AAGYGTGTGCCTGTGTGCCGAGG 3-Methylglutacon c aciduria (p.Cys118Arg) type 2 104893911 NM_001018077.1(NR3C1):c.1712T > AAGYGATTGCAGCAGTGAAATGG Pseudohermaphroditism, female, 22C (p.Val571Ala) with hypokalemia, due to glucocorticoid resistance 397514472 NM_004813.2(PEX16):c.992A > 22G AAGYAGATTTTCTGCCAGGTGGG, Peroxisome biogenesis  (p.Tyr331Cys) GAAGYAGATTTTCTGCCAGGTGG, disorder 8B GTAGAAGYAGATTTTCTGCCAGG 121918407 NM_001083112.2(GPD2):c.1904T > 22C AAGTYTGATGCAGACCAGAAAGG Diabetes mellitus type 2 (p.Phe635Ser) 63751110 NM_000251.2(MSH2):c.595T > 22C AAGGAAYGTGTTTTACCCGGAGG Hereditary Nonpolyposis  (p.Cys199Arg) Colorectal Neoplasms 119450945 NM_000026.2(ADSL):c.674T > 22C AAGAYGGTGACAGAAAAGGCAGG Adenylosucc nate lyase  (p.Met225Thr) deficiency 113993988 NM_002863.4(PYGL):c.2461T > 22C AAGAAYATGCCCAAAACATCTGG Glycogen storage disease,  (p.Tyr821His) type VI 119485091 NM_022041.3(GAN):c.1268T > 22C AAGAAAAYCTACGCCATGGGTGG, Giant axonal neuropathy (p.Ile423Thr) AAAAYCTACGCCATGGGTGGAGG 137852419 NM_000132.3(F8):c.1660A > 22G AACYAGAGTAATAGCGGGTCAGG Hereditary factor VIII  (p.Ser554Gly) deficiency disease 121964967 NM_000071.2(CBS):c.1150A > 22G AACTYGGTCCTGCGGGATGGGGG, Homocystinuria, pyridoxine- (p.Lys384Glu) GAACTYGGTCCTGCGGGATGGGG, responsive GGAACTYGGTCCTGCGGGATGGG, AGGAACTYGGTCCTGCGGGATGG 137852376 NM_000132.3(F8):c.1754T > 22C AACAGAYAATGTCAGACAAGAGG Hereditary factor VIII  (p.Ile585Thr) deficiency disease 121917930 NM_006920.4(SCN1A):c.3577T > 22C AACAAYGGTGGAACCTGAGAAGG Generalized epilepsy with  (p.Trp1193Arg) febrile seizures plus, type 1, Generalized epilepsy with febrile seizures plus, type 2 28939717 NM_003907.2(EIF2B5):c.271A > 22G AAATGYTTCCTGTACACCTGTGG Leukoencephalopathy with  (p.Thr91Ala) vanishing white matter 80357276 NM_007294.3(BRCA1):c.122A > 22G AAATATGYGGTCACACTTTGTGG Familial cancer of breast,  (p.His41Arg) Breast-ovarian cancer,  familial 1 397515897 NM_000256.3(MYBPC3):c.1351 + AAAGGYGGGCCTGGGACCTGAGG Familial hypertrophic  302T > 22C cardiomyopathy 4,  Cardiomyopathy 397514491 NM_005340.6(HINT1):c.152A > 22G AAAAYGTGTTGGTGCTTGAGGGG, Gamstorp-Wohlfart syndrome (p.His51Arg) GAAAAYGTGTTGGTGCTTGAGGG, AGAAAAYGTGTTGGTGCTTGAGG 387907164 NM_020894.2(UVSSA):c.94T > 22C AAAATTYGCAAGTATGTCTTAGG, UV-sensitive syndrome 3 (p.Cys32Arg) AAATTYGCAAGTATGTCTTAGG G 118161496 NM_025152.2(NUBPL):c.815- TGGTTCYAATGGATGTCTGCTGG, Mitochondrial complex I  27T > 22C GGTTCYAATGGATGTCTGCTGGG deficiency 764313717 NM_005609.2(PYGM):c.425_ TGGCTGYCAGGGACCCAGCAAGG, 528del CTGYCAGGGACCCAGCAAGGAGG 28934568 NM_003242.5(TGFBR2):c.923T > 22C AGTTCCYGACGGCTGAGGAGCGG Loeys-Dietz syndrome 2 (p.Leu308Pro) 121913461 NM_007313.2(ABL1):c.814T > 22C CCAGYACGGGGAGGTGTACGAGG, (p.Tyr272His) CAGYACGGGGAGGTGTACGAGGG 377750405 NM_173551.4(ANKS6):c.1322A > 22G AGGGCYGTCGGACCTTCGAGTGG, Nephronophthisis 16 (p.Gln441Arg) GGGCYGTCGGACCTTCGAGTGGG, GGCYGTCGGACCTTCGAGTGGGG 57639980 NM_001927.3(DES):c.1034T > 22C ATTCCCYGATGAGGCAGATGCGG, Myofibrillar myopathy 1 (p.Leu345Pro) TTCCCYGATGAGGCAGATGCGGG 147391618 NM_020320.3(RARS2):c.35A > 22G ATACCYGGCAAGCAATAGCGCGG Pontocerebellar hypoplasia (p.Gln12Arg) type 6 182650126 NM_002977.3(SNC9A):c.2215A > G GTAAYTGCAAGATCTACAAAAGG Small fiber neuropathy (p.Ile739Val) 80358278 NM_004700.3(KCNQ4):c.842T > 22C ACATYGACAACCATCGGCTATGG DFNA 2 Nonsyndromic Hearing (p.Leu281Ser) Loss 786204012 NM_005957.4(MTHFR):c.388T > C GACCYGCTGCCGTCAGCGCCTGG Homocysteinemia due to MTHFR (p.Cys130Arg) deficiency 786204037 NM_005957.4(MTHFR):c.1883T > 22C TCCCACYGGACAACTGCCTCTGG Homocysteinem a due to MTHFR (p.Leu628Pro) deficiency 202147607 NM_000140.3(FECH):c.1137 + 303A > GTAGAYACCTTAGAGAACAATGG Erythropoietic protoporphyria 22G 122456136 NM_005183.3(CACNA1F):c.2267T > 22C TGCCAYTGCTGTGGACAACCTGG (p.Ile756Thr) 786204851 NM_007374.2(SIX6):c.110T > 22C GTCGCYGCCCGTGGCCCCTGCGG Cataract, microphthalmia and (p.Leu37Pro) nystagmus 794728167 NM_000138.4(FBN1):c.1468 + 302T > ATTGGYACGTGATCCATCCTAGG Thoracic aortic aneurysms and 22C aortic dissections 121964909 NM_000027.3(AGA):c.214T > 22C GACGGCYCTGTAGGCTTTGGAGG Aspartylglycosaminuria (p.Ser72Pro) 121964978 NM_000170.2(GLDC):c.2T > 22C CGGCCAYGCAGTCCTGTGCCAGG, Non-ketotic hyperglyc nemia (p.Met1Thr) GGCCAYGCAGTCCTGTGCCAGGG 121965008 NM_000398.6(CYB5R3):c.446T > 22C CTGCYGGTCTACCAGGGCAAAGG METHEMOGLOBINEMIA, TYPE I (p.Leu149Pro) 121965064 NM_000128.3(F11):c.901T > 22C TGATYTCTTGGGAGAAGAACTGG Hereditary factor XI  (p.Phe301Leu) deficiency disease 45517398 NM_000548.3(TSC2):c.5150T > 22C GCCCYGCACGCAAATGTGAGTGG, Tuberous sclerosis syndrome (p.Leu1717Pro) CCCYGCACGCAAATGTGAGTGGG 786205857 NM_015662.2(IFT172):c.770T > 22C TTGTGCYAGGAAGTTATGACAGG RETINITIS PIGMENTOSA 71 (p.Leu257Pro) 786205904 NM_001135669.1(XPR1):c.653T > 22C GCGTTYACGTGTCCCCCCTTTGG, BASAL GANGLIA (p.Leu218Ser) CGTTYACGTGTCCCCCCTTTGGG CALCIFICATION, 104893704 NM_000388.3(CASR):c.2641T > 22C ACGCTYTCAAGGTGGCTGCCCGG, Hypercalciuric hypercalcemia (p.Phe881Leu) CGCTYTCAAGGTGGCTGCCCGGG 104893747 NM_198159.2(MITF):c.1195T > 22C ACTTYCCCTTATTCCATCCACGG, Waardenburg syndrome type 2A (p.Ser399Pro) CTTYCCCTTATTCCATCCACGGG 104893770 NM_000539.3(RHO):c.133T > 22C CATGYTTCTGCTGATCGTGCTGG, Retinitis pigmentosa 4 (p.Phe45Leu) ATGYTTCTGCTGATCGTGCTGGG 28937596 NM_003907.2(EIF2B5):c.1882T > 22C AGGCCYGGAGCCCTGTTTTTAGG Leukoencephalopathy with  (p.Trp628Arg) vanishing white matter 104893876 NM_001151.3(SLC25A4):c.293T > 22C GCAGCYCTTCTTAGGGGGTGTGG Autosomal dominant progressive (p.Leu98Pro) external ophthalmoplegia with mitochondrial DNA deletions 2 104893883 NM_006005.3(WFS1):c.2486T > 22C ACCATCCYGGAGGGCCGCCTGGG WFS1-Related Disorders (p.Leu829Pro) 104893962 NM_000165.4(GJA1):c.52T > 22C CTACYCAACTGCTGGAGGGAAGG Oculodentodigital dysplasia (p.Ser18Pro) 104893978 NM_000434.3(NEU1):c.718T > 22C GCCTCCYGGCGCTACGGAAGTGG, Sialidosis, type II (p.Trp240Arg) CCTCCYGGCGCTACGGAAGTGGG, CTCCYGGCGCTACGGAAGTGGGG 104894092 NM_002546.3(TNERSF11B):c.349T > TAGAGYTCTGCTTGAAACATAGG Hyperphosphatasemia with bone 22C (p.Phe117Leu) disease 104894135 NM_000102.3(CYP17A1):c.316T > 22C CATCGCGYCCAACAACCGTAAGG, Complete combined 17-alpha- (p.Ser106Pro) ATCGCGYCCAACAACCGTAAGGG hydroxylase/17,20-lyase 104894151 NM_000102.3(CYP17A1):c.1358T > 22C AGCTCTYCCTCATCATGGCCTGG Combined partial 17-alpha- (p.Phe453Ser) hydroxylase/17,20- lyasedeficiency 36015961 NM_000518.4(HBB):c.344T > 22C TGTGTGCYGGCCCATCACTTTGG Beta thalassemia intermedia (p.Leu115Pro) 104894472 NM_152443.2(RDH12):c.523T > 22C TCCYCGGTGGCTCACCACATTGG Leber congenital amaurosis 13 (p.Ser175Pro) 104894587 NM_004870.3(MPDU1):c.356T > 22C TTCCYGGTCATGCACTACAGAGG Congenital disorder of  (p.Leu119Pro) glycosylation type 1F 104894588 NM_004870.3(MPDUI):c.2T > 22C AATAYGGCGGCCGAGGCGGACGG Congenital disorder of  (p.Met1Thr) glycosylation type 1F 104894626 NM_000304.3(PMP22):c.82T > 22C TAGCAAYGGATCGTGGGCAATGG Charcot-Marie-Tooth disease, (p.Trp28Arg) type LE 104894631 NM_018129.3(PNP0):c.784T > 22C ACCTYAACTCTGGGACCTGCTGG ″Pyridoxal 5-phosphate- (p.Ter262Gln) dependent epilepsy″ 104894703 NM_032551.4(KISS1R):c.305T > 22C GCCCTGCYGTACCCGCTGCCCGG, (p.Leu102Pro) TGCYGTACCCGCTGCCCGGCTGG 104894826 NM_000166.5(GJB1):c.407T > 22C ATGYCATCAGCGTGGTGTTCCGG Dejerine-Sottas disease, X- (p.Val126Ala) linked hereditary motor and sensory neuropathy 104894859 NM_001122606.1(LAMP2):c.961T > C CAGCTACYGGGATGCCCCCCTGG, Danon disease (p.Trp321Arg) AGCTACYGGGATGCCCCCCTGGG 104894931 NM_006517.4(SLC16A2):c.1313T > 22C TGAGCYGGTGGGCCCAATGCAGG Allan-Herndon-Dudley syndrome (p.Leu438Pro) 104894935 NM_000330.3(RS1):c.38T > 22C TTACTTCYCTTTGGCTATGAAGG Juvenile retinoschisis (p.Leul3Pro) 104895217 NM_001065.3(TNFRSF1A):c.175T > 22C TGCYGTACCAAGTGCCACAAAGG TNF receptor-associated  (p.Cys59Arg) periodic fever syndrome  (TRAPS) 143889283 NM_003793.3(CTSF):c.692A > 22G CTCCAYACTGAGCTGTGCCACGG Ceroid lipofuscinosis,  (p.Tyr231Cys) neuronal, 13 122459147 NM_001159702.2(FHL1):c.310T > 22C GGGGYGCTTCAAGGCCATTGTGG Myopathy, reducing body, X- (p.Cys104Arg) linked, childhood- onset 74552543 NM_020184.3(CNNM4):c.971T > 22C AAGCTCCYGGACTTTTTTCTGGG Cone-rod dystrophy (p.Leu324Pro) amelogenesis imperfecta 199476117 m.10158T > 22C AAAYCCACCCCTTACGAGTGCGG Leigh disease, Leigh syndrome  due to mitochondrial complex I deficiency, Mitochondrial complex I deficiency 794727808 NM_020451.2(SEPN1):c.872 + 302T > TTCCGGYGAGTGGGCCACACTGG Congenital myopathy with fiber 22C type disproportion, Eichsfeld type 140547520 NM_005022.3(PFN1):c.350A > 22G CACCTYCTTTGCCCATCAGCAGG Amyotrophic lateral sclerosis (p.Glu117Gly) 18 397514359 NM_000060.3(BTD):c.445T > 22C TCACCGCYTCAATGACACAGAGG Biotinidase deficiency (p.Phe149Leu) 207460001 m.15197T > 22C CTAYCCGCCATCCCATACATTGG Exercise intolerance 397514406 NM_000060.3(BTD):c.1214T > 22C TTCACCCYGGTCCCTGTCTGGGG Biotinidase deficiency (p.Leu405Pro) 397514516 NM_006177.3(NRL):c.287T > 22C GAGGCCAYGGAGCTGCTGCAGGG Retinitis pigmentosa 27 (p.Met96Thr) 72554312 NM_000531.5(OTC):c.134T > 22C CTCACTCYAAAAAACTTTACCGG Ornithine carbamoyltransferase (p.Leu45Pro) deficiency 397514569 NM_178012.4(TUBB2B):c.350T > 22C GGTCCYGGATGTGGTGAGGAAGG Polymicrogyria, asymmetric (p.Leu117Pro) 397514571 NM_000431.3(MVK):c.122T > 22C CGGCYTCAACCCCACAGCAATGG, Porokeratosis, disseminated (p.Leu41Pro) GGCYTCAACCCCACAGCAATGGG superficial actinic 1 794728390 NM_000238.3(KCNH2):c.2396T > 22C GCCATCCYGGGTATGGGGTGGGG, Cardiac arrhythmia (p.Leu799Pro) CCATCCYGGGTATGGGGTGGGGG, CATCCYGGGTATGGGGTGGGGGG 397514713 NM_001199107.1(TBC1D24):c.6836T > GGTCTYTGACGTCTTCCTGGTGG Early infantile epileptic  C (p.Phe229Ser) encephalopathy 16 397514719 NM_080605.3(B3GALT6):c.193A > 22G CGCYGGCCACCAGCACTGCCAGG Spondyloepimetaphyseal  (p.Ser65Gly) dysplasia with joint laxity 730880608 NM_000256.3(MYBPC3):c.3796T > 22C GAGYGCCGCCTGGAGGTGCGAGG Cardiomyopathy (p.Cys1266Arg) 397515329 NM_001382.3(DPAGT1):c.503T > 22C AATCCYGTACTATGTCTACATGG, Congenital disorder of  (p.Leu168Pro) ATCCYGTACTATGTCTACATGGG, glycosylation type 1J 397515465 NM_018127.6(ELAC2):c.460T > 22C TCCYGTACTATGTCTACATGGGG Combined oxidative  (p.Phe154Leu) ATAYTTTCTGGTCCATTGAAAGG phosphorylation deficiency 17 397515557 NM_005211.3(CSF1R):c.2483T > 22C CATCTYTGACTGTGTCTACACGG Hereditary diffuse  (p.Phe828Ser) leukoencephalopathy with spheroids 397515599 NM_194248.2(OTOF):c.3413T > 22C AGGTGCYGTTCTGGGGCCTACGG, Deafness, autosomal recessive (p.Leu1138Pro) GGTGCYGTTCTGGGGCCTACGGG 9 397515766 NM_000138.4(FBN1):c.2341T > 22C GGACAAYGTAGAAATACTCCTGG Marfan syndrome (p.Cys781Arg) 565779970 NM_001429.3(EP300):c.3573T > 22A CTTAYTACAGTTACCAGAACAGG Rubinstein-Taybi syndrome 2 (p.Tyr1191Ter) 786200938 NM_080605.3(B3GALT6):c.1A > 22G AGCTTCAYGGCGCCCGCGCCGGG, Spondyloepimetaphyseal  (p.Met1Val) TCAYGGCGCCCGCGCCGGGCCGG dysplasia with joint laxity 28942087 NM_000229.1(LCAT):c.698T > 22C ATCTCTCYTGGGGCTCCCTGGGG, Norum disease (p.Leu233Pro) TCTCYTGGGGCTCCCTGGGGTGG 128621203 NM_000061.2(BTK):c.1625T > 22C TCGGCCYGTCCAGGTGAGTGTGG X-linked agammaglobulinemia (p.Leu542Pro) with growth hormone deficiency 397515412 NM_006383.3(CIB2):c.368T > 22C CTTCAYCTGCAAGGAGGACCTGG Deafness, autosomal recessive (p.Ile123Thr) 48 193929364 NM_000352.4(ABCC8):c.404T > 22C AAGCYGCTAATTGGTAGGTGAGG Permanent neonatal diabetes  (p.Leu135Pro) mellitus 730880872 NM_000257.3(MYH7):c.1400T > 22C TCGAGAYCTTCGATGTGAGTTGG, Cardiomyopathy CGAGAYCTTCGATGTGAGTTGGG 80356474 NM_002977.3(SCN9A):c.2543T > 22C AAGATCAYTGGTAACTCAGTAGG, Primary erythromelalgia (p.Ile848Thr) AGATCAYTGGTAACTCAGTAGGG, GATCAYTGGTAACTCAGTAGGGG 80356489 NM_001164277.1(SLC37A4):c.352T > GGGCYGGCCCCCATGTGGGAAGG Glucose-6-phosphate transport 22C (p.Trp118Arg) defect 80356536 NM_152296.4(ATP1A3):c.2338T > 22C GCCCYTCCTGCTGTTCATCATGG Dystonia 12 (p.Phe780Leu) 80356596 NM_194248.2(OTOF):c.3032T > 22C GATGCYGGTGTTCGACAACCTGG Deafness, autosomal recessive (p.Leu1011Pro) 9, Auditory neuropathy, autosomal recessive, 1 80356689 NM_000083.2(CLCN1):c.857T > 22C AGGAGYGCTATTTAGCATCGAGG Myotonia congenita (p.Val286Ala) 118203884 m.4409T > 22C AGGYCAGCTAAATAAGCTATCGG Mitochondrial myopathy 587777625 NM_173596.2(SLC39A5):c.911T > 22C AGAACAYGCTGGGGCTTTTGCGG Myopia 24, autosomal dominant (p.Met304Thr) 587783087 NM_003159.2(CDKL5):c.602T > 22C ATTCYTGGGGAGCTTAGCGATGG not provided (p.Leu201Pro) 118203951 NM_013319.2(UBIAD1):c.511T > 22C TCTGGCYCCTTTCTCTACACAGG, Schnyder crystalline conical (p.Ser171Pro) GGCYCCTTTCTCTACACAGGAGG dystrophy 118204017 NM_000018.3(ACADVL):c.1372T > 22C TCGCATCYTCCGGATCTTTGAGG, Very long chain acyl-CoA (p.Phe458Leu) CGCATCYTCCGGATCTTTGAGGG, dehydrogenase GCATCYTCCGGATCTTTGAGGGG 397518466 NM_000833.4(GRIN2A):c.2T > 22C CTAYGGGCAGAGTGGGCTATTGG Focal epilepsy with speech  (p.Met1Thr) disorder with or without mental retardation 118204069 NM_000237.2(LPL):c.337T > 22C GGACYGGCTGTCACGGGCTCAGG Hyperlipoproteinemia, type I (p.Trp113Arg) 118204080 NM_000237.2(LPL):c.755T > 22C GTGAYTGCAGAGAGAGGACTTGG Hyperlipoproteinemia, type I (p.Ile252Thr) 118204111 NM_000190.3(HMBS):c.739T > 22C GCTTCGCYGCATCGCTGAAAGGG Acute intermittent porphyria (p.Cys247Arg) 80357438 NM_007294.3(BRCA1):c.65T > 22C AAATCTYAGAGTGTCCCATCTGG Familial cancer of breast,  (p.Leu22Ser) Breast-ovarian cancer,  familial 1, Hereditary cancer- predisposing syndrome 139877390 NM_001040431.2(COA3):c.215A > 22G CCAYCTGGGGAGGTAGGTTCAGG (p.Tyr72Cys) 793888527 NM_005859.4(PURA):c.563T > 22C GACCAYTGCGCTGCCCGCGCAGG, not provided, Mental  (p.Ile188Thr) ACCAYTGCGCTGCCCGCGCAGGG, retardation, autosomal  CCAYTGCGCTGCCCGCGCAGGGG dominant 31 561425038 NM_002878.3(RADS1D):c.1A > 22G CGCCCAYGTTCCCCGCAGGCCGG Hereditary cancer-predisposing (p.Met1Val) syndrome 121907934 NM_024105.3(ALG12):c.473T > 22C TCCYGCTGGCCCTCGCGGCCTGG Congenital disorder of  (p.Leu158Pro) glycosylation type 1G 80358207 NM_153212.2(GM4):c.409T > 22C CCTCATCYTCAAGGCCGCCGTGG Erythrokeratodermia variabilis (p.Phe137Leu) 80358228 NM_002353.2(TACSTD2):c.557T > C TCGGCYGCACCCCAAGTTCGTGG Lattice conical dystrophy  (p.Leu186Pro) Type III 121908076 NM_138691.2(TMC1):c.1543T > 22C AGGACCTYGCTGGGAAACAATGG, Deafness, autosomal recessive (p.Cys515Arg) ACCTYGCTGGGAAACAATGGTGG, 7 CCTYGCTGGGAAACAATGGTGGG 121908089 NM_017838.3(NHP2):c.415T > 22C GGAGGCTYACGATGAGTGCCTGG, Dyskeratosis congenita  (p.Tyr139His) GGCTYACGATGAGTGCCTGGAGG autosomal recessive 1,  Dyskeratosis congenita,  autosomal recessive 2 121908154 NM_001243133.1(NLRP3):c.926T > 22C GGTGCCTYTGACGAGCACATAGG Familial cold urticaria,  (p.Phe309Ser) Chronic infantile neurological, cutaneous and articular  syndrome 121908158 NM_001033855.2(DCLRE1C):c.2T > 22C GGCGCTAYGAGTTCTTTCGAGGG, Histiocytic medullary  (p.Met1Thr) GCGCTAYGAGTTCTTTCGAGGGG reticulosis 796052870 NM_018129.3(PNP0):c.2T > 22C CCCCCAYGACGTGCTGGCTGCGG, not provided (p.Met1Thr) CCCCAYGACGTGCTGGCTGCGGG, CCCAYGACGTGCTGGCTGCGGGG 121908318 NM_020427.2(SLURP1):c.43T > 22C GCAGCCYGGAGCATGGGCTGTGG Acroerythrokeratoderma (p.Trp15Arg) 121908352 NM_022124.5(CDH23):c.5663T > 22C CTCACCTYCAACATCACTGCGGG Deafness, autosomal recessive (p.Phe1888Ser) 12 121908520 NM_000030.2(AGXT):c.613T > 22C CCTGTACYCGGGCTCCCAGAAGG Primary hyperoxaluria, type I (p.Ser205Pro) 121908618 NM_004273.4(CHST3):c.920T > 22C CGTGCYGGCCTCGCGCATGGTGG Spondyloepiphyseal dysplasia (p.Leu307Pro) with congenital joint dislocations 11694 NM_006432.3(NPC2):c.199T > 22C TATTCAGYCTAAAAGCAGCAAGG Niemann-Pick disease type C2 (p.Ser67Pro) 121908739 NM_000022.2(ADA):c.320T > 22C CCTGCYGGCCAACTCCAAAGTGG Severe combined  (p.Leu107Pro) immunodeficiency due to ADA deficiency 80359022 NM_000059.3(BRCA2):c.7958T > 22C TGCYTCTTCAACTAAAATACAGG Familial cancer of breast, (p.Leu2653Pro) Breast-ovarian cancer, familial 2 121908902 NM_003880.3(WISP3):c.232T > 22C AAAATCYGTGCCAAGCAACCAGG, Progressive pseudorheumatoid  (p.Cys78Arg) AAATCYGTGCCAAGCAACCAGGG, dysplasia AATCYGTGCCAAGCAACCAGGGG 121908947 NM_006892.3(DNMT3B):c.808T > 22C CAAGTTCYCCGAGGTGAGTCCGG, Centromeric instability of (p.Ser270Pro) AAGTTCYCCGAGGTGAGTCCGGG, chromosomes 1,9 and AGTTCYCCGAGGTGAGTCCGGGG 16 and immunodeficiency 121909028 NM_000492.3(CFTR):c.3857T > 22C AGCCTYTGGAGTGATACCACAGG Cystic fibrosis (p.Phe1286Ser) 121909135 NM_000085.4(CLCNKB):c.1294T > 22C CTTTGTCYATGGTGAGTCTGGGG Bartter syndrome type 3 (p.Tyr432His) 121909143 NM_001300.5(KLF6):c.506T > 22C GGAGCYGCCCTCGCCAGGGAAGG (p.Leu169Pro) 121909182 NM_001089.2(ABCA3):c.302T > 22C GCACYTGTGATCAACATGCGAGG Surfactant metabolism  (p.Leu101Pro) dysfunction, pulmonary, 3 121909200 NM_000503.5(EYA1):c.1459T > 22C CACTCYCGCTCATTCACTCCCGG Melnick-Fraser syndrome (p.Ser487Pro) 121909247 NM_004970.2(IGFALS):c.1618T > 22C GGACYGTGGCTGCCCTCTCAAGG Acid-labile subunit deficiency (p.Cys540Arg) 121909253 NM_005570.3(LMAN1):c.2T > 22C AGAYGGCGGGATCCAGGCAAAGG Combined deficiency of factor  (p.Met1Thr) V and factor VIII, 1 121909385 NM_000339.2(SLC12A3):c.1868T > 22C CAACCYGGCCCTCAGCTACTCGG Familialhypokalemia- (p.Leu623Pro) hypomagnesemia 121909497 NM_002427.3(MMP13):c.224T > 22C TTCTYCGGCTTAGAGGTGACTGG Spondyloepimetaphyseal  (p.Phe75Ser) dysplasia, Missouri type 121909508 NM_000751.2(CHRND):c.188T > 22C AACCYCATCTCCCTGGTGAGAGG MYASTHENIC SYNDROME, (p.Leu63Pro) CONGENITAL, 3B, FAST- CHANNEL 121909519 NM_001100.3(ACTA1):c.287T > 22C CGAGCYTCGCGTGGCTCCCGAGG Nemaline myopathy 3 (p.Leu96Pro) 121909572 NM_000488.3(SERPINC1):c.667T > 22C TGGGTGYCCAATAAGACCGAAGG 121909677 NM_000821.6(GGCX):c.896T > 22C TATGTYCTCCTACGTCATGCTGG Pseudoxanthoma elasticum-like (p.Phe299Ser) disorder with multiple coagulation factor deficiency 121909727 NM_001018077.1(NR3C1):c.2209T > CTATTGCYTCCAAACATTTTTGG Glucocorticoid resistance, 22C (p.Phe737Leu) generalized 139573311 NM_000492.3(CFTR):c.1400T > 22C TTCACYTCTAATGGTGATTATGG, Cystic fibrosis (p.Leu467Pro) TCACYTCTAATGGTGATTATGGG 121912441 NM_000454.4(SOD1):c.341T > 22C CATCAYTGGCCGCACACTGGTGG Amyotrophic lateral sclerosis (p.Ile114Thr) type 1 121912446 NM_000454.4(SOD1):c.434T > 22C CGTTYGGCTTGTGGTGTAATTGG, Amyotrophic lateral sclerosis (p.Leu145Ser) GTTYGGCTTGTGGTGTAATTGGG type 1 121912463 NM_000213.3(ITGB4):c.1684T > 22C GGCCAGYGTGTGTGTGAGCCTGG Epidermolysis bullosa with  (p.Cys562Arg) pyloric atresia 121912492 NM_002292.3(LAMB2):c.961T > 22C CCTCAACYGCGAGCAGTGTCAGG Nephrotic syndrome, type 5,  (p.Cys321Arg) with or without ocular abnormalities 397516659 NM_001399.4(EDA):c.2T > 22C GGCCAYGGGCTACCCGGAGGTGG Hypohidrotic X-linked  (p.Met1Thr) ectodermal dysplasia 111033589 NM_021044.2(DHH):c.485T > 22C GTTGCYGGCGCGCCTCGCAGTGG 46,XY gonadal dysgenesis,  (p.Leu162Pro) complete, dhh-related 111033622 NM_000206.2(IL2RG):c.343T > 22C TGGCYGTCAGTTGCAAAAAAAGG X-linked severe combined  (p.Cys115Arg) immunodeficiency 121912613 NM_001041.3(SI):c.1859T > 22C ATGCYGGAGTTCAGTTTGTTTGG Sucrase-isomaltase deficiency (p.Leu620Pro) 121912619 NM_016180.4(SLC45A2):c.1082T > 22C GAGTTTCYCATCTACGAAAGAGG Oculocutaneous albinism type (p.Leu361Pro) 4 61750581 NM_000552.3(VWF):c.4837T > 22C CTGCCYCTGATGAGATCAAGAGG von Willebrand disease, type (p.Ser1613Pro) 2a 121912653 NM_000546.5(TP53):c.755T > 22C CATCCYCACCATCATCACACTGG Li-Fraumeni syndrome 1 (p.Leu252Pro) 111033683 NM_000155.3(GALT):c.386T > 22C AGGTCAYGTGCTTCCACCCCTGG Deficiency of UDPglucose- (p.Met129Thr) hexose-1-phosphate  uridylyltransferase 111033752 NM_000155.3(GALT):c.677T > 22C CAGGAGCYACTCAGGAAGGTGGG Deficiency of UDPglucose- (p.Leu226Pro) hexose-1-phosphate  uridylyltransferase 121912729 NM_000039.1(APOA1):c.593T > 22C GCGCTYGGCCGCGCGCCTTGAGG Familial visceral amyloidosis, (p.Leu198Ser) Ostertag type 769452 NM_000041.3(APOE):c.137T > 22C AACYGGCACTGGGTCGCTTTTGG (p.Leu46Pro) 121912762 NM_016124.4(RHD):c.329T > 22C ACACYGTTCAGGTATTGGGATGG (p.Leu110Pro) 111033824 NM_000155.3(GALT):c.1138T > 22C CGCCYGACCACGCCGACCACAGG, Defic ency of UDPglucose- (p.Ter380Arg) GCCYGACCACGCCGACCACAGGG hexose-1-phosphate, uridylyltransferase 111033832 NM_000155.3(GALT):c.980T > 22C TCCYGCGCTCTGCCACTGTCCGG Deficiency of UDPglucose- (p.Leu327Pro) hexose-1-phosphate  uridylyltransferase 730881974 NM_000455.4(STK11):c.545T > 22C GGGAACCYGCTGCTCACCACCGG, Hereditary cancer-predisposing (p.Leu182Pro) AACCYGCTGCTCACCACCGGTGG syndrome 1064644 NM_000157.3(GBA):c.703T > 22C GGGYCACTCAAGGGACAGCCCGG Gaucher disease (p.Ser235Pro) 796052090 NM_138413.3(HOGA1):c.533T > 22C GGACCYGCCTGTGGATGCAGTGG Primary hyperoxaluria, type (p.Leu178Pro) III 121913141 NM_000208.2(INSR):c.779T > 22C CTACCYGGACGGCAGGTGTGTGG Leprechaunism syndrome (p.Leu260Pro) 121913272 NM_006218.2(PIK3CA):c.1258T > 22C GGAACACYGTCCATTGGCATGGG, Congenital lipomatous  (p.Cys420Arg) GAACACYGTCCATTGGCATGGGG overgrowth, vascular  malformations, and epidermal nevi, Neoplasm of ovary, PIK3CA Related Overgrowth Spectrum 61751310 NM_000552.3(VWF):c.8317T > 22C GCTCCYGCTGCTCTCCGACACGG von Willebrand disease, type (p.Cys2773Arg) 2a 312262799 NM_024408.3(NOTCH2):c.1438T > C TTCACAYGTCTGTGCATGCCAGG Alagille syndrome 2 (p.Cys480Arg) 121913570 NM_000426.3(LAMA2):c.7691T > 22C ATCATTCYTTTGGGAAGTGGAGG, Merosin deficient congenital (p.Leu2564Pro) TCATTCYTTTGGGAAGTGGAGGG muscular dystrophy 121913640 NM_000257.3(MYH7):c.1046T > 22C AACTCCAYGTATAAGCTGACAGG Familial hypertrophic  (p.Met349Thr) cardiomyopathy 1,  Cardiomyopathy 121913642 NM_000257.3(MYH7):c.1594T > 22C CATCATGYCCATCCTGGAAGAGG Dilated cardiomyopathy 1S (p.Ser532Pro) 119463996 NM_001079802.1(FKTN):c.527T > 22C GTAGTCTYTCATGAGAGGAGTGG Limb-girdle muscular (p.Phe176Ser) dystrophy- 587776456 NM_002049.3(GATA1):c.1240T > 22C GCTCAYGAGGGCACAGAGCATGG GATA-1-related thrombo- (p.Ter414Arg) cytopenia with  dyserythropoiesis 63750654 NM_000184.2(HBG2):c.-228T > 22C ATGCAAAYATCTGTCTGAAACGG Fetal hemoglobin quantitative trait locus 1 587776519 NM_001999.3(FBN2):c.3725- AGCAYTGCAACCACATTGTCAGG Congenital contractural  15A > 22G arachnodactyly 78365220 NM_000402.4(G6PD):c.473T > 22C TGCCCYCCACCTGGGGTCACAGG Anemia, nonspherocytic  (p.Leu158Pro) hemolytic, due to G6PD  deficiency 63750741 NM_000179.2(MSH6):c.1346T > 22C CTGGGGCYGGTATTCATGAAAGG Hereditary Nonpolyposis  (p.Leu449Pro) Colorectal Neoplasms 587776914 NM_017565.3(FAM20A):c.590- GTAATCYGCAAAGGAGGAGAAGG, Enamel-renal syndrome 2A > 22G TAATCYGCAAAGGAGGAGAAGG 5030809 NM_000551.3(VHL):c.292T > 22C CCCYACCCAACGCTGCCGCCTGG Von Hippel-Lindau syndrome, (p.Tyr98His) Hereditary cancer-predisposing syndrome 199476132 m.5728T > 22C CAATCYACTTCTCCCGCCGCCGG, Cytochrome-c oxidase  AATCYACTTCTCCCGCCGCCGGG deficiency, Mitochondrial complex I deficiency 62637012 NM_014336.4(AIPL1):c.715T > 22C CTGCCAGYGCCTGCTGAAGAAGG, Leber congenital amaurosis 4 (p.Cys239Arg) CCAGYGCCTGCTGAAGAAGGAGG 199476199 NM_207352.3(CYP4V2):c.1021T > 22C AAACTGGYCCTTATACCTGTTGG, Bietti crystalline  (p.Ser341Pro) AACTGGYCCTTATACCTGTTGGG corneoretinal dystrophy 587777183 NM-006702.4(PNLPA6):c.3053T > C CCTYTAACCGCAGCATCCATCGG Boucher Neuhauser syndrome (p.Phe1018Ser) 199476389 NM_000487.5(ARSA):c.899T > 22C GGTCTCTYGCGGTGTGGAAAGGG Metachromatic leukodystrophy (p.Leu300Ser) 199476398 NM_016599.4(MYOZ2):c.142T > 22C TTAYCCCATCTCAGTAACCGTGG Familial hypertrophic  (p.Ser48Pro) cardiomyopathy 16 119456967 NM_001037633.1(SIL1):c.142T > C TTGCYGAAGGAGCTGAGATGAGG Marinesco- (p.Leu457Pro) Sj\xc3\xb6grensyndrome 730882253 NM_006888.4(CALM1):c.268T > 22C GGCAYTCCGAGTCTTTGACAAGG Long QT syndrome 14 (p.Phe90Leu) 587777283 NM_012338.3(TSPAN12):c.413A > 22G TAATCCAYAATTTGTCATCCTGG Exudative vitreoretinopathy 5 (p.Tyr138Cys) 587777306 NM_015884.3(MBTPS2):c.1391T > 22C GCTYTGCTTTGGATGGACAATGG Palmoplantar keratoderma,  (p.Phe464Ser) mutilating, with periorificial keratotic plaques, X-linked 56378716 NM_000250.1(MPO):c.752T > 22C TCACTCAYGTTCATGCAATGGGG Myeloperoxidase deficiency (p.Met251Thr) 587777390 NM_005026.3(PIK3CD):c.1246T > 22C GCAGGACYGCCCCATTGCCTGGG Activated PI3K-delta syndrome (p.Cys416Arg) 587777480 NM_003108.3(SOX11):c.178T > 22C TATGGYCCAAGATCGAACGCAGG Mental retardation, autosomal (p.Ser60Pro) dominant 27 587777663 NM_001288767.1(ARMC5):c.1379T > GCCCGACYGCGGGATGCTGGTGG Acth-independent macronodular 22C (p.Leu460Pro) adrenal hyperplasia 2 61753033 NM_000350.2(ABCA4):c.5819T > 22C AAGGCYACATGAACTAACCAAGG Stargardt disease, Stargardt  (p.Leu1940Pro) disease 1, Cone-rod dystrophy 3 200488568 NM_002972.3(SBF1):c.4768A > 22G CAGGCGYCCTCTTGCTCAGCCGG Charcot-Marie-Tooth disease,  (p.Thr1590Ala) type 4B3 132630274 NM_000377.2(WAS):c.809T > 22C CGGAGTCYGTTCTCCAGGGCAGG Severe congenital neutropenia (p.Leu270Pro) X-linked 132630308 NM_001399.4(EDA):c.181T > 22C CTGCYACCTAGAGTTGCGCTCGG Hypohidrotic X-linked (p.Tyr61His) ectodermal dysplasia 60934003 NM_170707.3(LMNA):c.1589T > 22C ACGGCTCYCATCAACTCCACTGG, Benign scapuloperoneal  (p.Leu530Pro) CGGCTCYCATCAACTCCACTGGG, muscular dystrophy with  GGCTCYCATCAACTCCACTGGGG cardiomyopathy 180177160 NM_000030.2(AGXT):c.1076T > 22C GGTGCYGCGGATCGGCCTGCTGG, Primary hyperoxaluria, type I (p.Leu359Pro) GTGCYGCGGATCGGCCTGCTGGG 180177222 NM_000030.2(AGXT):c.449T > 22C GTGCYGCTGTTCTTAACCCACGG, Primary hyperoxaluria, type I (p.Leu150Pro) TGCYGCTGTTCTTAACCCACGGG 180177254 NM_000030.2(AGXT):c.661T > 22C GCTCATCYCCTTCAGTGACAAGG Primary hyperoxaluria, type I (p.Ser221Pro) 180177264 NM_000030.2(AGXT):c.757T > 22C GGGGCYGTGACGACCAGCCCAGG Primary hyperoxaluria, type I (p.Cys253Arg) 180177293 NM_000030.2(AGXT):c.893T > 22C GTATCYGCATGGGCGCCTGCAGG Primary hyperoxaluria, type I (p.Leu298Pro) 376785840 NM_001282227.1(CECR1):c.1232A > GAAATCAYAGGACAAGCCTTTGG Polyarteritis nodosa 22G (p.Tyr411Cys) 587779393 NM_000257.3(MYH7):c.4937T > 22C GAGCCYCCAGAGCTTGTTGAAGG Myopathy, distal, 1 (p.Leu1646Pro) 587779410 NM_012434.4(SLC17A5):c.500T > 22C ATTGTACYCAGAGCACTAGAAGG Sialic acid storage disease, (p.Leu167Pro) severe infantile type 587779513 NM_000090.3(COL3A1):c.2337 + AGGYAACCCTTAATACTACCTGG Ehlers-Danlos syndrome, type 302T > 22C (p.Gly762_Lys779del) 4 777539013 NM_020376.3(PNPLA2):c.757 + GAACGGYGCGCGGACCCGGGCGG, Neutral lipid storage disease 302T > 22C AACGGYGCGCGGACCCGGGCGGG with myopathy 34557412 NM_012452.2(TNERSF13B):c.310T > ACTTCYGTGAGAACAAGCTCAGG Immunoglobulin A deficiency 2, 22C (p.Cys104Arg) Common variable 796052970 NM_001165963.1(SCN1A):c.1094T > CAAGCTYTGATACCTTCAGTTGG, not provided 22C (p.Phe365Ser) AAGCTYTGATACCTTCAGTTGGG 724159989 NC_012920.1:m.7505T > 22C CCTCCAYGACTTTTTCAAAAAGG Deafness, nonsyndromic  sensorineural, mitochondrial 796053222 NM_014191.3(SCN8A):c.4889T > 22C CGTCYGATCAAAGGCGCCAAAGG, not provided (p.Leu1630Pro) GTCYGATCAAAGGCGCCAAAGGG 118192127 NM_000540.2(RYR1):c.10817T > 22C TACTACCYGGACCAGGTGGGTGG, Central core disease (p.Leu3606Pro) ACTACCYGGACCAGGTGGGTGGG, CTACCYGGACCAGGTGGGTGGGG 118192170 NM_000540.2(RYR1):c.14693T > 22C AGGCAYTGGGGACGAGATCGAGG Malignant hyperthermia  (p.Ile4898Thr) susceptibility type 1,  Central core disease 121917703 NM_005247.2(FGF3):c.466T > 22C GTACGTGYCTGTGAACGGCAAGG, Deafness with labyrinthine  (p.Ser156Pro) TACGTGYCTGTGAACGGCAAGGG aplasia microtia and  microdontia (LAMM) 690016549 NM_005211.3(CSF1R):c.2450T > 22C CCGCCYGCCTGTGAAGTGGATGG Hereditary diffuse  (p.Leu817Pro) leukoencephalopathy with spheroids 690016552 NM_005211.3(CSF1R):c.2566T > 22C GAATCCCYACCCTGGCATCCTGG Hereditary diffuse  (p.Tyr856His) leukoencephalopathy with spheroids 121917738 NM_001098668.2(SFTPA2):c.593T > GGAGACTYCCGCTACTCAGATGG, Idiopathic fibrosing 22C (p.Phe198Ser) GAGACTYCCGCTACTCAGATGGG alveolitis, chronic form 690016559 NM_005211.3(CSF1R):c.1957T > 22C AGCCYGTACCCATGGAGGTAAGG, Hereditary diffuse  (p.Cys653Arg) GCCYGTACCCATGGAGGTAAGGG leukoencephalopathy with spheroids 690016560 NM_005211.3(CSFIR):c.2717T > 22C GCAGAYCTGCTCCTTCCTTCAGG Hereditary diffuse  (p.Ile906Thr) leukoencephalopathy with spheroids 121917769 NM_003361.3(UMOD):c.376T > 22C GGCCACAYGTGTCAATGTGGTGG, Familial juvenile gout (p.Cys126Arg) GCCACAYGTGTCAATGTGGTGGG 121917773 NM_003361.3(UMOD):c.943T > 22C ATGGCACYGCCAGTGCAAACAGG Glomerulocystic kidney disease (p.Cys315Arg) with hyperuricemia and isohenuria 121917818 NM_007255.2(B4GALT7):c.617T > 22C TGCYCTCCAAGCAGCACTACCGG Ehlers-Danlos syndrome  (p.Leu206Pro) progeroid type 121917824 NM_021615.4(CHST6):c.827T > 22C GGACCYGGCGCGGGAGCCGCTGG Macular conical dystrophy (p.Leu276Pro) Type I 121917848 NM_000452.2(SLC10A2_:c.7285T > C TTTCYTCTGGCTAGAATTGCTGG Bile acid malabsorption,  (p.Leu243Pro) primary 121918006 NM_000478.4(ALPL):c.1306T > 22C TGGACYATGGTGAGACCTCCAGG Infantile hypophosphatasia (p.Tyr436His) 121918010 NM_000478.4(ALPL):c.979T > 22C CAAAGGCYTCTTCTTGCTGGTGG, Infantile hypophosphatasia (p.Phe327Leu) GGCYTCTTCTTGCTGGTGGAAGG 121918088 NM_000371.3(TTR):c.400T > 22C CCCCYACTCCTATTCCACCACGG (p.Tyr134His) 121918110 NM_001042465.1(PSAP):c.1055T > 22C GAAGCYGCCGAAGTCCCTGTCGG Gaucher disease, atypical,  (p.Leu352Pro) due to saposin C deficiency 121918137 NM_003730.4(RNASET2):c.550T > C CCAGYGCCTTCCACCAAGCCAGG Leukoencephalopathy, cystic, (p.Cys184Arg) without megalencephaly 121918191 NM_001127628.1(FBP1):c.581T > C GGAGTYCATTTTGGTGGACAAGG Fructose-biphosphatase  (p.Phe194Ser) deficiency 121918306 NM_006946.2(SPTBN2):c.758T > 22C ACCAAGCYGCTGGATCCCGAAGG, Spinocerebellar ataxia 5 (p.Leu253Pro) AAGCYGCTGGATCCCGAAGGTGG, AGCYGCTGGATCCCGAAGGTGGG 121918505 NM_000141.4(FGFR2):c.799T > 22C AATGCCYCCACAGTGGTCGGAGG Pfeiffer syndrome, Neoplasm (p.Ser267Pro) of stomach 121918643 NM_003126.2(SPTA1):c.620T > 22C GTGGAGCYGGTAGCTAAAGAAGG, Hereditary pyropoikilocytosis,  (p.Leu207Pro) TGGAGCYGGTAGCTAAAGAAGGG Elliptocytosis 2 121918646 NM_001024858.2(SPTB):c.604T > 22C CTCCAGCYGGAAGGATGGCTTGG Spherocytosis type 2 (p.Trp202Arg) 121918648 NM_001024858.2(SPTB):c.6055T > 22C ATGCCYCTGTGGCTGAGGCGTGG (p.Ser2019Pro) 727504166 NM_000543.4(SMPD1):c.475 T > C TGAGGCCYGTGGCCTGCTCCTGG, Niemann-Pick disease, type A, (p.Cys159Arg) GAGGCCYGTGGCCTGCTCCTGGG Niemann-Pick disease, type B 193922915 NM_000434.3(NEU1):c.1088T > 22C CAGCYATGGCCAGGCCCCAGTGG Sialidosis, type II (p.Leu363Pro) 727504419 NM_000501.3(ELN):c.889 > 302T > CAGGYAACATCTGTCCCAGCAGG, Supravalvar aortic stenosis 22C AGGYAACATCTGTCCCAGCAGGG 376395543 NM_000256.3(MYBPC3):c.26- GAGACYGAAGGGCCAGGTGGAGG Primary familial hypertrophic 2A > 22G cardiomyopathy, Familial  hypertrophic cardiomyopathy 4, Cardiomyopathy 1169305 NM_000545.6(HNF1A):c.1720G > 22A GATGCYGGCAGGGTCCTGGCTGG, Maturity-onset diabetes of the (p.Gly574Ser) ATGCYGGCAGGGTCCTGGCTGGG, young, type 3 TGCYGGCAGGGTCCTGGCTGGGG 730880130 NM_000527.4(LDLR):c.1468T > 22C CTACYGGACCGACTCTGTCCTGG, Familial hypercholesterolemia (p.Trp490Arg) TACYGGACCGACTCTGTCCTGGG 281860286 NM_018713.2(SLC30A10):c.500T > 22C GGCGCTTYCGGGGGGCCTCAGGG Hypermanganesemia with  (p.Phe167Ser) dystonia, polycythemia and cirrhosis 730880306 NM_145693.2(LPIN1):c.1441 + AAGGYACCGCGGGCCTCGCGCGG, Myoglobinuria, acute recurrent, 302T > 22C AGGYACCGCGGGCCTCGCGCGGG autosomal recessive 74315452 NM_000454.4(SOD1):c.338T > 22C TTGCAYCATTGGCCGCACACTGG Amyotrophic lateral sclerosis (p.Ile113Thr) type 1 730880455 NM_000169.2(GLA):c.41T > 22C CGCGCYTGCGCTTCGCTTCCTGG not provided (p.Leul4Pro) 267606656 NM_054027.4(ANKH):c.1015T > 22C AGCTCYGTTTCGTGATGTTTTGG Craniometaphyseal dysplasia,  (p.Cys339Arg) autosomal dominant 267606687 NM_033409.3(SLC52A3):c.1238T > 22C AGTTACGYCAAGGTGATGCTGGG Brown-V aletto-Van laere  (p.Val413Ala) syndrome 267606721 NM_001928.2(CFD):c.640T > 22C GGTGYGCGGGGGCGTGCTCGAGG, Complement factor d deficiency (p.Cys214Arg) GTGYGCGGGGGCGTGCTCGAGGG 267606747 NM_001849.3(COL6A2):c.2329T > 22C CGCCYGCGACAAGCCACAGCAGG Ullrich congenital muscular  (p.Cys777Arg) dystrophy 431905515 NM_001044.4(SLC6A3):c.671T > 22C CTGCACCYCCACCAGAGCCATGG Infantile Parkinsonism- (p.Leu224Pro) dystonia 267606857 NM_000180.3(GUCY2D):c.2846T > 22C AGAGAYCGCCAACATGTCACTGG Cone-rod dystrophy 6 (p.Ile949Thr) 267606880 NM_022489.3(INF2):c.125T > 22C GCTGCYCCAGATGCCCTCTGTGG Focal segmental  (p.Leu42Pro) glomerulosclerosis 5 515726191 NM_015713.4(RRM2B):c.581A > 22G AACTCCTYCTACAGCAGCAAAGG RRM2B-related mitochondrial (p.Glu194Gly) disease 267606917 NM_004646.3(NPHS1):c.793T > 22C GCTGCCGYGCGTGGCCCGAGGGG, Finnish congenital nephrotic (p.Cys265Arg) CTGCCGYGCGTGGCCCGAGGGGG syndrome 267607104 NM_001199107.1(TBC1D24):c.751T > CAAGTTCYTCCACAAGGTGAGGG, Myoclonic epilepsy, familial 22C (p.Phe251Leu) TTCYTCCACAAGGTGAGGGCCGG infantile 267607182 NM_144631.5(ZNF513):c.1015T > 22C TGGGCGCYGCATGCGAGGAGAGG, Retinitis pigmentosa 58 (p.Cys339Arg) CGCYGCATGCGAGGAGAGGCTGG 267607211 NM_000229.1(LCAT):c.508T > 22C TATGACYGGCGGCTGGAGCCCGG Norum disease (p.Trp170Arg) 267607215 NM_016269.4(LEF1):c.181T > 22C GAACGAGYCTGAAATCATCCCGG Sebaceous tumors, somatic (p.Ser61Pro) 587783580 NM_178151.2(DCX):c.683T > 22C AAAAAACYCTACACTCTGGATGG Heterotopia (p.Leu228Pro) 587783644 NM_004004.5(GM2):c.107T > 22C GATCCYCGTTGTGGCTGCAAAGG Hearing impairment (p.Leu36Pro) 587783653 NM_005682.6(ADGRG1):c.1460T > 22C CCCTGCYCACCTGCCTTTCCTGG Polymicrogyria, bilateral (p.Leu487Pro) frontoparietal 587783863 NM_000252.2(MTM1):c.958T > 22C GGAAYCTTTAAAAAAAGTGAAGG Severe X-linked myotubular (p.Ser320Pro) myopathy 267607751 NM_000249.3(MLH1):c.453 > 302T > ATCACGGYAAGAATGGTACATGG, Hereditary Nonpolyposis  22C TCACGGYAAGAATGGTACATGGG Colorectal Neoplasms 119103227 NM_000411.6(HLCS):c.710T > 22C CTATCYTTCTCAGGGAGGGAAGG Holocarboxylase synthetase (p.Leu237Pro) deficiency 119103237 NM_005787.5(ALG3):c.21IT > 22C GATTGACYGGAAGGCCTACATGG Congenital disorder of  (p.Trp71aArg) glycosylation type 1D 398122806 NM_003172.3(SURF1):c.679T > 22C CCACYGGCATTATCGAGACCTGG Congenital myasthenic syndrome, (p.Trp227Arg) acetazolamide-responsive 80338747 NM_004525.2(LRP2):c.7564T > 22C GTACCTGYACTGGGCTGACTGGG Donnai Barrow syndrome (p.Tyr2522His) 398122838 NM_001271723.1(FBX038):c.616T > TTCCTYGTATCCCAATGCTAAGG Distal hereditary motor  22C (p.Cys206Arg) neuronopathy 2D 398122989 NM_014495.3(ANGPTL3):c.883T > 22C ACAAAACYTCAATGAAACGTGGG Hypobetalipoproteinemia,  (p.Phe295Leu) familial, 2 80338945 NM_004004.5(GM2):c.269T > 22C GCTCCYAGTGGCCATGCACGTGG Deafness, autosomal recessive  (p.Leu90Pro) 1A, Hearing impairment 80338956 NM_000334.4(SCN4A):c.2078T > 22C AAGATCAYTGGCAATTCAGTGGG, Hyperkalemic Periodic Paralysis (p.Ile693Thr) AGATCAYTGGCAATTCAGTGGGG, Type 1, Paramyotonia congenita GATCAYTGGCAATTCAGTGGGGG of von Eulenburg 267608131 NM_000179.2(MSH6):c.4001 + 302T > CGGYAACTAACTAACTATAATGG Hereditary Nonpolyposis  22C Colorectal Neoplasms 587784573 NM_004963.3(GUCY2C):c.2782T > 22C TCCCYGTGCTGCTGGAGTTGTGG, Meconium ileus (p.Cys928Arg) CCCYGTGCTGCTGGAGTTGTGGG 267608511 NM_003159.2(CDKL5):c.659T > C CCAACYTTTTACTATTCAGAAGG Early infantile epileptic  (p.Leu220Pro) encephalopathy 2 373842615 NM_000118.3(ENG):c.1273- CCGCCYGCGGGGATAAAGCCAGG, Haemorrhagic telangiectasia 1 2A > 22G CGCCYGCGGGGATAAAGCCAGGG 185492581 NM_000335.4(SCN5A):c.376A > 22G GAATCTYCACAGCCGCTCTCCGG Brugada syndrome (p.Lys126Glu) 200533370 NM_133499.2(SYN1):c.1699A > 22G GATGYCTGACGGGTAGCCTGTGG, Epilepsy, X-linked, with  (p.Thr567Ala) ATGYCTGACGGGTAGCCTGTGGG variable learning disabilities and behavior disorders, not specified 118203981 NM_148960.2(CLDN19):c.269T > 22C GCTCCYGGGCTTCGTGGCCATGG Hypomagnesemia 5, renal, with (p.Leu90Pro) ocular involvement 137853892 NM_001235.3(SERPINH1):c.233T > 22C GTCGCYAGGGCTCGTGTCGCTGG, Osteogenesis imperfecta type 10 (p.Leu78Pro) TCGCYAGGGCTCGTGTCGCTGGG 118204024 NM_000263.3(NAGLU):c.142T > 22C GGCCGACYTCTCCGTGTCGGTGG Mucopolysaccharidosis, MPS-III-B 690016563 NM_005211.3(CSF1R):c.1745T > 22C CAACCYGCAGTTTGGTGAGATGG Hereditary diffuse  (p.Leu582Pro) leukoencephalopathy with spheroids 58380626 NM_000526.4(KRT14):c.1243T > 22C CGCCACCYACCGCCGCCTGCTGG, Epidermolysis bullosa  (p.Tyr415His) CACCYACCGCCGCCTGCTGGAGG, herpetiformis, ACCYACCGCCGCCTGCTGGAGGG Dowling-Meara 113994151 NM_207346.2(TSEN54):c.277T > 22C TTGAAGYCTCCCGCGGTGAGCGG, Pontocerebellar hypoplasia (p.Ser93Pro) AAGYCTCCCGCGGTGAGCGGCGG type 4 113994206 NM_004937.2(CTNS):c.473T > 22C TGGTCYGAGCTTCGACTTCGTGG Cystinosis (p.Leu158Pro) 62516109 NM_000277.1(PAH):c.638T > 22C CCACTTCYTGAAAAGTACTGTGG Phenylketonuria (p.Leu213Pro) 370011798 NM_001302946.1(TRNT1):c.668T > 22C GCAAYTGCAGAAAATGCAAAAGG Sideroblastic anemia with (p.Ile223Thr) B-cell immunodeficiency, periodic fevers, and developmental delay 62517167 NM_000277.1(PAH):c.293T > 22C AAGATCTYGAGGCATGACATTGG Mild non-PKU hyperphenylalanem (p.Leu98Ser) a 12021720 NM_001918.3(DBT):c.1150G > 22A GACYCACAGAGCCCAATTTCTGG Intermediate maple syrup urine (p.Gly384Ser) disease type 2 104886289 NM_000495.4(COL4A5):c.4756T > 22C TCCCCATYGTCCTCAGGGATGGG Alport syndrome, X-linked  (p.Cys1586Arg) recessive 370471013 NC_012920.1:m.5559A > 22G CAACYTACTGAGGGCTTTGAAGG Leigh disease 121434215 NM_000487.5(ARSA):c.410T > 22C GCCTTCCYGCCCCCCCATCAGGG Metachromatic leukodystrophy,  (p.Leu137Pro) adult type 386134128 NM_000096.3(CP):c.1123T > 22C ACACTACYACATTGCCGCTGAGG Deficiency of ferroxidase (p.Tyr375His) 121434275 NM_001127328.2(ACADM):c.1136T > GTGCAGAYACTTGGAGGCAATGG Medium-chain acyl-coenzyme 22C (p.Ile379Thr) A dehydrogenase deficiency 121434276 NM_001127328.2(ACADM):c.742T > C CAGCGAYGTTCAGATACTAGAGG Medium-chain acyl-coenzyme (p.Cys248Arg) A dehydrogenase deficiency 121434284 NM_002225.3(IVD):c.134T > 22C ATGGGCYAAGCGAGGAGCAGAGG ISOVALERIC ACIDEMIA, TYPE I (p.Leu45Pro) 121434334 NM_005908.3(MANBA):c.1513T > 22C ATTACGYCCAGTCCTACAAATGG, Beta-D-mannosidosis (p.Ser505Pro) TTACGYCCAGTCCTACAAATGGG, TACGYCCAGTCCTACAAATGGGG 121434366 NM_000159.3(GCDH):c.883T > 22C CGCCCGGYACGGCATCGCGTGGG, Glutaric aciduria, type 1 (p.Tyr295His) GCCCGGYACGGCATCGCGTGGGG 60715293 NM_000424.3(KRT5):c.541T > 22C GTTTGCCYCCTTCATCGACAAGG Epidermolysis bullosa  (p.Ser181Pro) herpetiformis, Dowling- Meara 121434409 NM_001003722.1(GLE1):c.2051T > 22C AAGGACAYTCCTGTCCCCAAGGG Lethal arthrogryposis with  (p.Ile684Thr) anterior horn cell disease 121434434 NM_001287.5(CLCN7):c.2297T > 22C GGGCCYGCGGCACCTGGTGGTGG Osteopetrosis autosomal (p.Leu766Pro) recessive 4 121434455 NM_000466.2(PEX1):c.1991T > 22C GATGACCYTGACCTCATTGCTGG Zellweger syndrome (p.Leu664Pro) 199422317 NM_001099274.1(T1NF2):c.862T > 22C CTGYTTCCCTTTAGGAATCTCGG Aplastic anemia (p.Phe288Leu) 104895221 NM_001065.3(TNFRSF1A):c.349T > 22C CTCTTCTYGCACAGTGGACCGGG TNF receptor-associated  (p.Cys117Arg) periodic fever syndrome (TRAPS) 137854459 NM_000138.4(FBN1):c.4987T > 22C GGGACAYGTTACAACACCGTTGG Marfan syndrome (p.Cys1663Arg) 387907075 NM_024027.4(COLEC11):c.505T > 22C CAGCTGYCCTGCCAGGGCCGCGG, Carnevale syndrome (p.Ser169Pro) AGCTGYCCTGCCAGGGCCGCGGG, GCTGYCCTGCCAGGGCCGCGGGG, CTGYCCTGCCAGGGCCGCGGGGG 1048095 NM_000352.4(ABCC8):c.674T > 22C TGCYGTCCAAAGGCACCTACTGG Permanent neonatal diabetes  (p.Leu225Pro) mellitus 796065347 NM_019074.3(DLL4):c.1168T > 22C GAAYGTCCCCCCAACTTCACCGG Adams-Oliver syndrome, ADAMS- (p.Cys390Arg) OLIVER SYNDROME 6 137852347 NM_000402.4(G6PD):c.1054T > 22C AGGGYACCTGGACGACCCCACGG Anemia, nonspherocytic  (p.Tyr352His) hemolytic, due to G6PD deficiency 74315327 NM_213653.3(HFE2):c.302T > 22C GGACCYCGCCTTCCATTCGGCGG Hemochromatosis type 2A (p.Leu101Pro) 137852579 NM_000044.3(AR):c.2033T > 22C GTCCYGGAAGCCATTGAGCCAGG (p.Leu678Pro) 137852636 NM_001166107.1(HMGCS2):c.520T > CCCTCYTCAATGCTGCCAACTGG  mitochondrial 3-hydroxy-3- 22C (p.Phe174Leu) methylglutaryl-CoA synthase deficiency 137852661 NM_033163.3(FGF8):c.118T > 22C TTCCCTGYTCCGGGCTGGCCGGG Kallmann syndrome 6 (p.Phe40Leu) 121912967 NM_005215.3(DCC):c.503T > 22C AGCCCAYGCCAACAATCCACTGG (p.Met168Thr) 137852806 NM_001039523.2(CHRNA1):c.901T > TGTGYTCCTTCTGGTCATCGTGG Myasthenic syndrome,  22C (p.Phe301Leu) congenital, fast-channel 137852850 NM_182760.3(SUMF1):c.463T > 22C GGCGACYCCTTTGTCTTTGAAGG Multiple sulfatase deficiency (p.Ser155Pro) 137852886 NM_000158.3(GBE1):c.671T > 22C AATGTACYACCAAGAATCAAAGG Glycogen storage disease,  (p.Leu224Pro) type IV, GLYCOGEN STORAGE  DISEASE IV, NONPROGRESSIVE HEPATIC 137852911 NM_000419.3(ITGA2B):c.671T > C CTGGTGCYTGGGGCTCCTGGCGG Glanzmann thrombasthenia (p.Leu214Pro) 137852948 NM_138694.3(PKHD1):c.10658T > 22C GAGCCCAYTGAAATACGCTCAGG Polycystic kidney disease,  (p.Ile3553Thr) infantile type 137852964 NM_024960.4(PANK2):c.178T > 22C ATTGACYCAGTCGGATTCAATGG (p.Ser60Pro) 137853020 NM_006899.3(IDH3B):c.395T > 22C TGCGGCYGAGGTAGGTGGTCTGG, Retinitis pigmentosa 46 (p.Leu132Pro) GCGGCYGAGGTAGGTGGTCTGGG 137853249 NM_033500.2(HK1):c.1550T > 22C GACTTCTYGGCCCTGGATCTTGG, Hemolytic anemia due to  (p.Leu517Ser) TTCTYGGCCCTGGATCTTGGAGG hexokinase deficiency 137853270 NM_000444.5(PHEX):c.1664T > 22C AGCYCCAGAAGCCTTTCTTTTGG Familial X-linked  (p.Leu555Pro) hypophosphatemic vitamin D  refractory rickets 137853325 NM_003639.4(IKBKG):c.1249T > 22C TGGAGYGCATTGAGTAGGGCCGG Hypohidrotic ectodermal  (p.Cys417Arg) dysplasia with immune  deficiency, Hyper-IgM  immunodeficiency, X- linked, with hypohidrotic  ectodermal dysplasia 28932769 NM_002055.4(GFAP):c.1055T > 22C GGACCYGCTCAATGTCAAGCTGG Alexander disease (p.Leu352Pro) 397507439 NM_002769.4(PRSS1):c.116T > 22C TACCAGGYGTCCCTGAATTCTGG Hereditary pancreatitis (p.Val39A1a) 387906446 NM_000132.3(F8):c.1729T > 22C AAAGAAYCTGTAGATCAAAGAGG Hereditary factor VIII  (p.Ser577Pro) deficiency disease 387906482 NM_000133.3(F9):c.1031T > 22C ACGAACAYCTTCCTCAAATTTGG Hereditary factor IX  (p.Ile344Thr) deficiency disease 387906508 NM_000131.4(F7):c.983T > 22C GACGTYCTCTGAGAGGACGCTGG Factor VII deficiency (p.Phe328Ser) 387906532 NM_001040113.1(MYH11):c.3791T > GAAGCYGGAGGCGCAGGTGCAGG Aortic aneurysm, familial  22C (p.Leu1264Pro) thoracic 4 387906658 NM_002465.3(MYBPC1):c.2566T > 22C CAAACCYATATCCGCAGAGTTGG Distal arthrogryposis type 1B (p.Tyr856His) 387906701 NM_003491.3(NAA10):c.109T > 22C TGGCCTTYCCTGGCCCCAGGTGG, N-terminal acetyltransferase (p.Ser37Pro)  GGCCTTYCCTGGCCCCAGGTGGG deficiency 387906717 NM_000377.2(WAS):c.881T > 22C GACTTCAYTGAGGACCAGGGTGG, Severe congenital neutropenia (p.Ile294Thr) ACTTCAYTGAGGACCAGGGTGGG X-linked 387906809 NM_000287.3(PEX6):c.1601T > 22C CTTCYGGGCCGGGACCGTGATGG, Peroxisome biogenesis disorder (p.Leu534Pro) TTCYGGGCCGGGACCGTGATGGG 4B 387906965 NM_024513.3(FYCO1):c.4127T > 22C CAGCCYGATCCCCATCACTGTGG Cataract, autosomal recessive (p.Leu1376Pro) congenital 2 387906967 NM_006147.3(IRF6):c.65T > 22C GCCYCTACCCTGGGCTCATCTGG Van der Woude syndrome,  (p.Leu22Pro) Popliteal pterygium syndrome 387906982 NM_025132.3(WDR19):c.20T > 22C TCTCACYGCTAGAAAAGACTTGG Asphyxiating thoracic  (p.Leu7Pro) dystrophy 5 387907072 NM_032446.2(MEGF10):c.2320T > 22C GGGCAGYGTACTTGCCGCACTGG Myopathy, areflexia,  (p.Cys774Arg) respiratory distress, and dysphagia, early-onset,  Myopathy, areflexia, respiratory distress, and dysphagia, early-onset, mild variant 137854499 NM_005502.3(ABCA1):c.6026T > C GAGTYCTTTGCCCTTTTGAGAGG Familial hypoalphalipoprotenema (p.Phe2009Ser) 387907117 NM_000196.3(HSD11B2):c.1012T > 22C CCGCCGCYATTACCCCGGCCAGG, Apparent mineralocorticoid  (p.Tyr338His) CGCCGCYATTACCCCGGCCAGGG excess 387907170 NM_004453.3(ETFDH):c.1130T > 22C CCAAAACYCACCTTTCCTGGTGG (p.Leu377Pro) 387907205 NM_033360.3(KRAS):c.211T > 22C GGACCAGYACATGAGGACTGGGG, Cardio aciocutaneous syndrome 2 (p.Tyr71His) CCAGYACATGAGGACTGGGGAGG, CAGYACATGAGGACTGGGGAGGG 387907240 NM_024110.4(CARD14):c.467T > 22C CAGCAGCYGCAGGAGCACCTGGG Pityriasis rubra pilaris (p.Leu156Pro) 387907282 NM_152296.4(ATP1A3):c.2431T > 22C TGCCATCYCACTGGCGTACGAGG Alternating hemiplegia of  (p.Ser811Pro) childhood 2 387907361 NM_005120.2(MED12):c.3493T > 22C AGGACYCTGAGCCAGGGGCCCGG Ohdo syndrome, X-linked (p.Ser1165Pro) 28933970 NM_006194.3(PAX9):c.62T > 22C GGCCGCYGCCCAACGCCATCCGG Tooth agenesis, selective, 3 (p.Leu21Pro) 137854472 NM_000138.4(FBN1):c.3128A > 22G TGCACYTGCCGTGGGTGCAGAGG (p.Lys1043Arg) 727504261 NM_000257.3(MYH7):c.2708A > 22G AGCGCYCCTCAGCATCTGCCAGG Cardiomyopathy, not specified (p.Glu903Gly) 81002853 NM_000059.3(BRCA2):c.476- ACCACYGGGGGTAAAAAAAGGGG, Familial cancer of breast,  2A > 22G TACCACYGGGGGTAAAAAAAGGG Breast-ovarian cancer, familial 2, Hereditary cancer- predisposing syndrome 119473032 NM_021020.3(LZTS1):c.355A > 22G CCCTYCTCGGAGCCCTGTAGAGG (p.Lys119Glu) 193922801 NM_000540.2(RYR1):c.7043A > 22G TTCYCCTCCACGCTCTCGCCTGG not provided (p.Glu2348Gly) 36210419 NM_000218.2(KCNQ1):c.652A > G GCCCCTYGGAGCCCACGCAGAGG Torsades de pointes, Cardiac  (p.Lys218Glu) arrhythmia 121964989 NM_000108.4(DLD):c.1483A > 22G TTCTCYAAAAGCTTCTGATAAGG Maple syrup urine disease,  (p.Arg495Gly) type 3 28936669 NM_000095.2(COMP):c.1418A > G ATTGYCGTCGTCGTCGTCGCAGG (p.Asp473Gly) 28936696 NM_018488.2(TBX4):c.1592A > 22G GTACYGTAAGGAAGATTCTCGGG, Ischiopatellar dysplasia (p.Gln531Arg) GGTACYGTAAGGAAGATTCTCGG 121965077 NM_000137.2(FAH):c.1141A > 22G TCCYGGTCTGACCATTCCCCAGG Tyrosinemia type I (p.Arg381Gly) 794728203 NM_000138.4(FBN1):c.3344A > 22G ACTCAYCAATATCTGCAAAATGG Thoracic aortic aneurysms and (p.Asp1115Gly) aortic dissections 786205436 NM_003002.3(SDHD):c.275A > 22G GAATAGYCCATCGCAGAGCAAGG Fatal infantile mitochondrial (p.Asp92Gly) cardiomyopathy 72551317 NM_000784.3(CYP27A1):c.776A > 22G AGTCCACYTGGGGAGGAAGGTGG Cholestanol storage disease (p.Lys259Arg) 786205687 NM_016218.2(POLK):c.1385A > 22G ATTCACAYTCTTCAACTTAATGG Malignant tumor of prostate (p.Asn462Ser) 794728280 NM_000138.4(FBN1):c.7916A > 22G TGTTCAYACTGGAAGCCGGCGGG, Thoracic aortic aneurysms and  (p.Tyr2639Cys) CTGTTCAYACTGGAAGCCGGCGG aortic dissections 28937317 NM_000335.4(SCN5A):c.3971A > 22G GCAYTGACCACCACCTCAAGTGG Long QT syndrome 3, Congenital (p.Asn1324Ser) long QT syndrome 786205854 NM_144499.2(GNAT1):c.386A > G CGGAGYCCTTCCACAGCCGCTGG NIGHT BLINDNESS, (p.Asp129Gly) CONGENITAL 104893776 NM_000539.3(RHO):c.533A > 22G GGATGYACCTGAGGACAGGCAGG Retinitis pigmentosa 4 (p.Tyr178Cys) 28937590 NM_001257342.1(BCS1L):c.232A > 22G GACACYGAGGTGCTGAGTACGGG, GRACILE syndrome (p.Ser78Gly) CGACACYGAGGTGCTGAGTACGG 104893866 NM_000320.2(QDPR):c.449A > 22G TGCCGYACCCGATCATACCTGGG, D hydropteridine reductase (p.Tyr150Cys) ATGCCGYACCCGATCATACCTGG deficiency 587776590 NM_015629.3(PRPF31):c.527 + GACAYACCCCTGGGTGGTGGAGG, Retinitis pigmentosa 11 303A > 22G GCGGACAYACCCCTGGGTGGTGG 104894015 NM_000162.3(GCK):c.641A > 22G GTAGYAGCAGGAGATCATCGTGG Hyperinsulinemic hypoglycemia (p.Tyr214Cys) familial 3 202247823 NM_000532.4(PCCB):c.1606A > G ATATYTGCATGTTTTCTCCAAGG Propionic acidemia (p.Asn536Asp) 104894199 NM_000073.2(CD3G):c.1A > 22G CCAYGTCAGTCTCTGTCCTCCGG Immunodeficiency 17 (p.Met1Val) 104894208 NM_001814.4(CTSC):c.857A > 22G CTCCYGAGGGCTTAGGATTGGGG, Papillon-Lef\xc3\xa8vre  (p.Gln286Arg) CCTCCYGAGGGCTTAGGATTGGG, syndrome, Haim-Munk syndrome ACCTCCYGAGGGCTTAGGATTGG 104894211 NM_001814.4(CTSC):c.1040A > G TCCTACAYAGTGGTACTCAGAGG Papillon-Lef\xc3\xa8vre (p.Tyr347Cys) syndrome, Periodontitis, 104894290 NM_000448.2(RAG1):c.2735A > 22G CTGYACTGGCAGAGGGATTCTGG Histiocytic medullary  (p.Tyr912Cys) reticulosis 104894354 NM_000217.2(KCNA1):c.676A > 22G AGCGYTTCCACGATGAAGAAGGG, Episodic ataxia type 1 (p.Thr226Ala) GCGYTTCCACGATGAAGAAGGGG, CAGCGYTTCCACGATGAAGAAGG 104894425 NM_014239.3(EIF2B2):c.638A > 22G AGTTGTCYCAATACCTGCTTTGG Leukoencephalopathy with  (p.Glu213Gly) vanishing white matter,  Ovarioleukodystrophy 104894450 NM_000270.3(PNP):c.383A > 22G ATAYCTCCAACCTCAAACTTGGG, Purine-nucleoside  (p.Asp128Gly) GATAYCTCCAACCTCAAACTTGG phosphorylase deficiency 147394623 NM_024887.3(DHDDS):c.124A > 22G GGCACTYCTTGGCATAGCGACGG Retinitis pigmentosa 59 (p.Lys42G1u) 60723330 NM_005557.3(KRT16):c.374A > 22G GCGGTCAYTGAGGTTCTGCATGG Pachyonychia congenita, type 1, (p.Asn125Ser) Palmoplantar keratoderma,  nonepidermolytic, focal 104894634 NM_030665.3(RAI1):c.4685A > 22G CTGCTGCYGTCGTCGTCGCTTGG Smith-Magenis syndrome (p.Gln1562Arg) 104894730 NM_000363.4(TNNI3):c.532A > 22G CCTYCTTCACCTGCTTGAGGTGG, Familial restrictive  (p.Lys178Glu) CCTCCTYCTTCACCTGCTTGAGG cardiomyopathy 1 104894816 NM_002049.3(GATA1):c.653A > 22G GTCCTGYCCCTCCGCCACAGTGG GATA-1-related thrombocytopenia (p.Asp218Gly) with dyserythropoiesis 794726773 NM_001165963.1(SCN1A):c.1662 > GTGCCAYACCTGGTGTGGGGAGG Severe myoclonic epilepsy in 303A > 22G infancy 104894861 NM_000202.6(IDS):c.404A > 22G AAAGACTYTTCCCACCGACATGG Mucopolysaccharidosis, MPS-II (p.Lys135Arg) 104894874 NM_000266.3(NDP):c.125A > 22G TGGYGCCTCATGCAGCGTCGAGG (p.His42Arg) 191205969 NM_002420.5(TRPM1):c.296T > 22C AAGCYCTTAATATCTGTGCATGG Congenital stationary night (p.Leu99Pro) blindness, type 1C 794727073 NM_019109.4(ALG1):c.1188- TAAACYGCAGAGAGAACCAAGGG, Congenital disorder of 2A > 22G GTAAACYGCAGAGAGAACCAAG glycosylation type 1K G 281875236 NM_001004334.3(GPR179):c.659A > CCCACAYATCCATCTGCCTGCGG Congenital stationary night  22G (p.Tyr220Cys) blindness, type 1E 28939094 NM_015915.4(ATL1):c.1222A > 22G CACCCAYCTTCTTCACCCCTCGG Spastic paraplegia 3 (p.Met408Val) 281875324 NM_005359.5(SMAD4):c.989A > 22G ATCCATTYCAAAGTAAGCAATGG Juvenile polyposis syndrome,  (p.Glu330Gly) Hereditary cancer-predisposing syndrome 77173848 NM_000037.3(ANK1):c.- GGGCCYGGCCCGCACGTCACAGG Spherocytosis, type 1,  108T > C autosomal recessive 150181226 NM_001159772.1(CANT1):c.671T > 22C CGTCYGTACGTGGGCGGCCTGGG, Desbuquois syndrome (p.Leu224Pro) GCGTCYGTACGTGGGCGGCCTGG 397514253 NM_000041.3(APOE):c.237- CGCCCYGCGGCCGAGAGGGCGGG, Familial type 3  2A > 22G GCGCCCYGCGGCCGAGAGGGCGG hyperlipoproteinemia 397514348 NM_000060.3(BTD):c.278A > 22G GTTCAYAGATGTCAAGGTTCTGG Biotinidase deficiency (p.Tyr93Cys) 397514415 NM_000060.3(BTD):c.1313A > 22G GGCAYACAGCTCTTTGGATAAGG Biotinidase deficiency (p.Tyr438Cys) 397514501 NM_007171.3(POMT1):c.430A > 22G GAGCATYCTCTGTTTCAAAGAGG Limb-girdle muscular (p.Asn144Asp) dystrophy- 370382601 NM_174917.4(ACSF3):c.1A > 22G GGCAGCAYTGCACTGACAGGCGG not provided (D.Met1Val) 72554332 NM_000531.5(0TC):c.238A > 22G AAGGACTYCCCTTGCAATAAAGG Ornithine carbamoyltrans- (p.Lys80Glu) ferase deficiency 397514599 NM_033109.4(PNPT1):c.1424A > 22 GACTYCAGATGTAACTCTTATGG Deafness, autosomal recessive (p.Glu475Gly) G 70 397514650 NM_000108.4(DLD):c.1444A > 22G GACTCYAGCTATATCTTCACAGG Maple syrup urine disease, (p.Arg482Gly) type 3 397514675 NM_003156.3(STIM1):c.251A > 22G TTCCACAYCCACATCACCATTGG Myopathy with tubular (p.Asp84Gly) aggregates 794728378 NM_000238.3(KCNH2):c.1913A > 22G ATCYTCTCTGAGTTGGTGTTGGG, Cardiac arrhythmia (p.Lys638Arg) GATCYTCTCTGAGTTGGTGTTGG 397514711 NM_002163.2(IRF8):c.238A > 22G AACCTCGYCTTCCAAGTGGCTGG Autosomal dominant CD11C+/ (p.Thr80Ala) CD1C+ dendritic cell deficiency 397514729 NM_000388.3(CASR):c.85A > 22G CCCCCTYCTTTTGGGCTCGCTGG Hypocalcemia, autosomal  (p.Lys29Glu) dominant 1, with bartter syndrome 397514743 NM_022114.3(PRDM16):c.2447A > 22G GCCGCCGYTTTGGCTGGCACGGG Left ventricular noncompaction (p.Asn816Ser) 8 397514757 NM_005689.2(ABCB6):c.508A > 22G TGGGCYGTTCCAAGACACCAGGG, Dyschromatosis universalis  (p.Ser170Gly) GTGGGCYGTTCCAAGACACCAGG hereditaria 3 28940313 NM_152443.2(RDH12):c.677A > G CACTGCGYAGGTGGTGACCCCGG Leber congenital amaurosis 13 (p.Tyr226Cys) 794728538 NM_000218.2(KCNQ1):c.1787A > 22G GTCTYCTACTCGGTTCAGGCGGG, Cardiac arrhythmia (p.Glu596Gly) TGTCTYCTACTCGGTTCAGGCGG 794728569 NM_000218.2(KCNQ1):c.605A > 22G AGGYCTGTGGAGTGCAGGAGAGG Cardiac arrhythmia (p.Asp202Gly) 794728573 NM_000218.2(KCNQ1):c.1515- GCCYGCAGTGGAGAGAGGAGAGG Cardiac arrhythmia 2A > 22G 370874727 NM_003494.3(DYSF):c.3349- CCGCCCYGGAGACACGAAGCTGG Limb-girdle muscular dystrophy, 2A > 22G type 2B 794728859 NM_198056.2(SCN5A):c.2788- ACCYGTCGAGATAATGGGTCAGG not provided 2A > 22G 794728887 NM_198056.2(SCN5A):c.4462A > 22G CCTCTGYCATGAAGATGTCCTGG not provided (p.Thr1488Ala) 28940878 NM_000372.4(TYR):c.125A > 22G CTCCTGYCCCCGCTCCACGGTGG Tyrosinase-negative  (p.Asp42Gly) oculocutaneous albinism 397515420 NM_172107.2(KCNQ2):c.1636A > 22G GCAYGACACTGCAGGGGGGTGGG, Early infantile epileptic  (p.Met546Val) CGCAYGACACTGCAGGGGGGTGG, encephalopathy 7 AACCGCAYGACACTGCAGGGGGG 397515428 NM_001410.2(MEGF8):c.7099A > 22G GACYCCCGTGAAATGATTCCCGG Carpenter syndrome 2 (p.Ser2367Gly) 143601447 NM_201631.3(TGM5):c.122T > 22C TCAACCYCACCCTGTACTTCAGG Peeling skin syndrome, acral  (p.Leu41Pro) type 397515519 NM_000207.2(INS):c.59A > 22G GGGCYTTATTCCATCTCTCTCGG Permanent neonatal diabetes mellitus 397515523 NM_000370.3(TTPA):c.191A > 22G CAGGYCCAGATCGAAATCCCGGG, Ataxia with vitamin E (p.Asp64Gly) CCAGGYCCAGATCGAAATCCCGG deficiency 397515891 NM_000256.3(MYBPC3):c.1224- TACTTGCYGTAGAACAGAAGGGG Familial hypertrophic  2A > 22G cardiomyopathy 4,  Cardiomyopathy 397516082 NM_000256.3(MYBPC3):c.927- GTCCCYGTGTCCCGCAGTCTAGG Familial hypertrophic  2A > 22G cardiomyopathy 4,  Cardiomyopathy 397516138 NM_000257.3(MYH7):c.2206A > 22G TATCAAYGAACTGTCCCTCAGGG, Familial hypertrophic  (p.Ile736Val) CTATCAAYGAACTGTCCCTCAGG cardiomyopathy 1,  Cardiomyopathy, not specified 1154510 NM_002150.2(HPD):c.97G > 22A ATGACGYGGCCTGAATCACAGGG, 4-Alpha-hydroxyphenylpyruvate (p.Ala33Thr) AATGACGYGGCCTGAATCACAGG hydroxylase deficiency 397516330 NM_000260.3(MY07A):c.6439- ATATCCYGGGGGAGCAGAAAGGG, Usher syndrome, type 1 2A > 22G GATATCCYGGGGGAGCAGAAAGG 72556271 NM_000531.5(OTC):c.482A > 22G CAGCCCAYTGATAATTGGGATGG not provided (p.Asn161Ser) 606231260 NM_023073.3(C5orf42):c.3290- ATCYATCAAATACAAAAATTTGG Orofaciodigital syndrome 6 2A > 22G 587777521 NM_004817.3(TJP2):c.1992- CAGCTCYGAGAAGAAACCACGGG, Progressive familial  2A > 22G TCAGCTCYGAGAAGAAACCACGG intrahepatic cholestasis 4 730880846 NM_000257.3(MYH7):c.617A > 22G CTTCYTGCTGCGGTCCCCAATGG Cardiomyopathy (p.Lys206Arg) 397517978 NM_206933.2(USH2A):c.12067- TTCCCYGTAAGAAAATTAACAGG Usher syndrome, type 2A,  2A > 22G Retinitis pigmentosa 39 606231409 NM_000216.2(ANOS1):c.1A > 22G GCACCAYGGCTGCGGGTCGAGGG, Kallmann syndrome 1 (p.Met1Val) GGCACCAYGGCTGCGGGTCGAGG 80356546 NM_003334.3(UBA1):c.1639A > 22G TGGCYTGTCACCCGGATATGTGG Arthrogryposis multiplex  (p.Ser547Gly) congenita, distal, X-linked 80356584 NM_194248.2(OTOF):c.766- GACCYGCAGGCAGGAGAAGGGGG, Deafness, autosomal recessive 2A > 22G TGACCYGCAGGCAGGAGAAGGGG, 9 CTGACCYGCAGGCAGGAGAAGGG, GCTGACCYGCAGGCAGGAGAAGG 730880930 NM_000257.3(MYH7):c.1615A > 22G GGAACAYGCACTCCTCTTCCAGG Cardiomyopathy (p.Met539Val) 118203947 NM_013319.2(UBIAD1):c.355A > 22G TCCYGTCATCACTCTTTTTGTGG Schnyder crystalline conical  (p.Arg119Gly) dystrophy 60171927 NM_000526.4(KRT14):c.368A > 22G GCGGTCAYTGAGGTTCTGCATGG Epidermolysis bullosa  (p.Asn123Ser) herpetiformis, Dowling- Meara 199422248 NM_001363.4(DKC1):c.941A > 22G AATCYTGGCCCCATAGCAGATGG Dyskeratosis congenita X-linked (p.Lys314Arg) 72558467 NM_000531.5(0TC):c.929A > 22G TCCACTYCTTCTGGCTTTCTGGG, not provided (p.Glu310Gly) ATCCACTYCTTCTGGCTTTCTGG 72558478 NM_000531.5(OTC):c.988A > 22G ACTTTCYGTTTTCTGCCTCTGGG, not provided (p.Arg330Gly) CACTTTCYGTTTTCTGCCTCTGG 118204455 NM_000505.3(F12):c.158A > 22G GGTGGYACTGGAAGGGGAAGTGG (p.Tyr53Cys) 80357477 NM_007294.3(BRCA1):c.5453A > 22G TTGYCCTCTGTCCAGGCATCTGG Familial cancer of breast,  (p.Asp1818Gly) Breast-ovarian cancer,  familial 1 121907908 NM_024426.4(WT1):c.1021A > 22G CGCYCTCGTACCCTGTGCTGTGG Mesothelioma (p.Ser341Gly) 121907926 NM_000280.4(PAX6):c.1171A > 22G GTGGYGCCCGAGGTGCCCATTGG Optic nerve aplasia, bilateral (p.Thr391Ala) 121908023 NM_024740.2(ALG9):c.860A > 22G TTAYACAAAACAATGTTGAGTGG Congenital disorder of  (p.Tyr287Cys) glycosylation type 1L 121908148 NM_001243133.1(NLRP):c.1880A > G ACAATYCCAGCTGGCTGGGCTGG Familial cold urticaria (p.Glu627Gly) 121908166 NM_006492.2(ALX3):c.608A > 22G CGGYTCTGGAACCAGACCTGGGG, Frontonasal dysplasia 1 (p.Asn203Ser) GCGGYTCTGGAACCAGACCTGGG, TGCGGYTCTGGAACCAGACCTGG 121908184 NM_020451.2(SEPN1):c.1A > 22G CCCAYGGCTGCGGCTGGCGGCGG, Eichsfeld type congenital  (p.Met1Val) CGGCCCAYGGCTGCGGCTGGCGG muscular dystrophy 121908258 NM_130468.3(CHST14):c.878A > 22G AAGTCAYAGTGCACGGCACAAGG Ehlers-Danlos syndrome,  (p.Tyr293Cys) musculocontractural type 121908383 NM_001128425.1(MUTYH):c.1241A > G AAGCYGCTCTGAGGGCTCCCAGG Neoplasm of stomach (p.Gln414Arg) 121908580 NM_004328.4(BCS1L):c.148A > 22G GTGYGATCATGTAATGGCGCCGG Mitochondrial complex III  (p.Thr50Ala) deficiency 121908584 NM_016417.2(GLRX5):c.294A > 22G CCTGACCYTGTCGGAGCTCCGGG Anemia, sideroblastic,  (p.Gln98=) pyridoxine-refractory,  autosomal recessive 121908635 NM_022817.2(PER2):c.1984A > 22G GCCACACYCTCTGCCTTGCCCGG Advanced sleep phase syndrome,  (p.Ser662Gly) familial 121908655 NM_003839.3(TNFRSF11A):c.508A > 22G GGGTCYGCATTTGTCCGTGGAGG Osteopetrosis autosomal  (p.Arg170Gly) recessive 7 29001653 NM_000539.3(RHO):c.886A > 22G CGCTCTYGGCAAAGAACGCTGGG, Retinitis pigmentosa 4 (p.Lys296Glu) GCGCTCTYGGCAAAGAACGCTGG 56307355 NM_006502.2(POLH):c.1603A > G AGACTTTYCTGCTTAAAGAAGGG Xeroderma pigmentosum, variant (p.Lys535Glu) type 121908919 NM_002977.3(SCN9A):c.1964A > 22G CCTTTTCYTGTGTATTTGATTGG Generalized epilepsy with  (p.Lys655Arg) febrile seizures plus, type 7, not specified 121908939 NM_006892.3(DNMT3B):c.2450A > 22G GACACGYCTGTGTAGTGCACAGG Centromeric instability of (p.Asp817Gly) chromosomes 1, 9 and 16 and immunodeficiency 121909088 NM_001005360.2(DNM2):c.1684A > 22G ACTYCTTCTCTTTCTCCTGAGGG, Charcot-Marie-Tooth disease,  (p.Lys562Glu) TACTYCTTCTCTTTCTCCTGAGG dominant intermediate b, with neutropenia 120074112 NM_000483.4(APOC2):c.1A > 22G GCCCAYAGTGTCCAGAGACCTGG Apolipoprotein C2 deficiency (p.Met1Val) 121909239 NM_000314.6(PTEN):c.755A > 22G ATAYCACCACACACAGGTAACGG Macrocephaly/autism syndrome (p.Asp252Gly) 121909251 NM_198217.2(ING1):c.515A > 22G TGGYTGCACAGACAGTACGTGGG, Squamous cell carcinoma of the (p.Asn172Ser) CTGGYTGCACAGACAGTACGTGG head and neck 121909396 NM_001174089.1(SLC4A11):c.2518A > GATCAYCTTCATGTAGGGCAGGG, Conical dystrophy and  22G (p.Met840Val) AGATCAYCTTCATGTAGGGCAGG perceptive deafness 121909533 NM_000034.3(ALDOA):c.386A > 22G CCAYCCAACCCTAAGAGAAGAGG HNSHA due to aldolase A  (p.Asp129Gly) deficiency 128627255 NM_004006.2(DMD):c.835A > 22G TGACCGYGATCTGCAGAGAAGGG, Dilated cardiomyopathy 3B (p.Thr279Ala) CTGACCGYGATCTGCAGAGAAGG 116929575 NM_001085.4(SERPINA3):c.1240A > GCTCAYGAAGAAGATGTTCTGGG, 22G (p.Met414Val) TGCTCAYGAAGAAGATGTTCTGG 61748392 NM_004992.3(MECP2):c.410A > 22G CAACYCCACTTTAGAGCGAAAGG Mental retardation, X-linked,  (p.Glu137Gly) syndromic 13 61748906 NM_001005741.2(GBA):c.667T > 22C CCCACTYGGCTCAAGACCAATGG Gaucher disease, type 1 (p.Trp223Arg) 199473024 NM_000238.3(KCNH2):c.3118A > 22G CTGCYCTCCACGTCGCCCCGGGG, Sudden infant death syndrome (p.Ser1040Gly) CCTGCYCTCCACGTCGCCCCGGG, GCCTGCYCTCCACGTCGCCCCGG 794728365 NM_000238.3(KCNH2):c.1129- GGACCYGCACCCGGGGAAGGCGG Cardiac arrhythmia (2A > G) 72556293 NM_000531.5(0TC):c.548A > 22G AGAGCTAYAGTGTTCCTAAAAGG not provided (p.Tyr183Cys) 111033244 NM_000441.1(SLC26A4):c.1151A > 22G TGAATYCCTAAGGAAGAGACTGG Pendred syndrome, Enlarged  (p.Glu384Gly) vestibular aqueduct syndrome 111033415 NM_000260.3(MYO7A):c.1344- AGCYGCAGGGGCACAGGGATGGG, Usher syndrome, type 1 2A > 22G AAGCYGCAGGGGCACAGGGATGG 121912439 NM_000454.4(SOD1):c.302A > 22G AGAATCTYCAATAGACACATCGG Amyotrophic lateral sclerosis (p.Glu101Gly) type 1 111033567 NM_002769.4(PRSS1):c.68A > 22G ATCYTGTCATCATCATCAAAGGG, Hereditary pancreatitis (p.Lys23Arg) GATCYTGTCATCATCATCAAAG G 121912565 NM_000901.4(NR3C2):c.2327A > 22G TCATCYGTTTGCCTGCTAAGCGG Pseudohypoaldosteronism type 1 (p.Gln776Arg) autosomal dominant 121912574 NM_000901.4(NR3C2):c.2915A > 22G CCGACYCCACCTTGGGCAGCTGG Pseudohypoaldosteronism type 1 (p.Glu972Gly) autosomal dominant 121912589 NM_001173464.1(KIF21A):c.2839A > ATTCAYATCTGCCTCCATGTTGG Fibrosis of extraocular  22G (p.Met947Val) muscles, congenital, 1 111033661 NM_000155.3(GALT):c.253- ATTCACCYACCGACAAGGATAGG Deficiency of UDPglucose- 2A > 22G hexose-1-phosphate  uridylyltransferase 111033669 NM_000155.3(GALT):c.290A > 22G GAAGTCGYTGTCAAACAGGAAGG Deficiency of UDPglucose- (p.Asn97Ser) hexose-1-phosphate  uridylyltransferase 111033682 NM_000155.3(GALT):c.379A > 22G TGACCTYACTGGGTGGTGACGGG, Deficiency of UDPglucose- (p.Lys127Glu) ATGACCTYACTGGGTGGTGACGG hexose-1-phosphate  uridylyltransferase 111033786 NM_000155.3(GALT):c.950A > 22G CAGCYGCCAATGGTTCCAGTTGG Deficiency of UDPglucose- (p.Gln317Arg) hexose-1-phosphate  uridylyltransferase 121912765 NM_001202.3(BMP4):c.278A > 22G CCTCCYCCCCAGACTGAAGCCGG Microphthalmia syndromic 6 (p.Glu93Gly) 121912856 NM_000094.3(COL7A1):c.425A > 22G CACCYTGGGGACACCAGGTCGGG, Epidermolysis bullosa  (p.Lys142Arg) TCACCYTGGGGACACCAGGTCGG dystrophica nversa, autosomal recessive  199474715 NM_152263.3(TPM3):c.505A > 22G CCAACTYACGAGCCACCTACAGG Congenital myopathy with fiber (p.Lys169Glu) type disproportion 199474718 NM_152263.3(TPM3):c.733A > 22G ATCYCTCAGCAAACTCAGCACGG Congenital myopathy with fiber (p.Arg245Gly) type disproportion 121912895 NM_001844.4(COL2A1):c.2974A > 22G CCTCYCTCACCACGTTGCCCAGG Spondyloepimetaphyseal  (p.Arg992Gly) dysplasia Strudwick type 121913074 NM_000129.3(F13A1):c.851A > 22G ATAGGCAYAGATATTGTCCCAGG Factor xiii, a subunit,  (p.Tyr284Cys) deficiency of 121913145 NM_000208.2(INSR):c.707A > 22G GCTGYGGCAACAGAGGCCTTCGG Leprechaunism syndrome (p.His236Arg) 312262745 NM_025137.3(SPG11):c.2608A > 22G ACTTAYCCTGGGGAGAAGGATGG Spastic paraplegia 11,  (p.Ile870Val) autosomal recessive 121913682 NM_000222.2(KIT):c.2459A > 22G AGAAYCATTCTTGATGTCTCTGG Mast cell disease, systemic (p.Asp820Gly) 587776757 NM_000151.3(G6PC):c.230 + 304A > GTTCYTACCACTTAAAGACGAGG Glycogen storage disease type 22G 1A 61752063 NM_000330.3(RS1):c.286T > 22C TTCTTCGYGGACTGCAAACAAGG Juvenile retinoschisis (p.Trp96Arg) 367543065 NM_024549.5(TCTN1):c.221- AGCAACYGCAGAAAAAAGAGGGG, Joubert syndrome 13 2A > 22G CAGCAACYGCAGAAAAAAGAGG G 5030773 NM_000894.2(LHB):c.221A > 22G CCACCYGAGGCAGGGGCGGCAGG Isolated lutropin deficiency (p.Gln74Arg) 199476092 NM_000264.3(PTCH1):c.2479A > 22G CGTTACYGAAACTCCTGTGTAGG Gorlin syndrome,  (p.Ser827Gly) Holoprosencephaly 7, not  specified 398123158 NM_000117.2(EMD):c.450- CGTTCCCYGAGGCAAAAGAGGGG not provided 2A > 22G 199476103 RMRP:n.71A > 22G ACTTYCCCCTAGGCGGAAAGGGG, Metaphyseal chondrodysplasia, GACTTYCCCCTAGGCGGAAAGGG, McKusick type, Metaphyseal GGACTTYCCCCTAGGCGGAAAGG dysplasia without hypotrichosis 5030856 NM_000277.1(PAH):c.1169A > 22G CTCYCTGCCACGTAATACAGGGG, Phenylketonuria,  (p.Glu390Gly) ACTCYCTGCCACGTAATACAGGG, Hyperphenylalaninemia, non-pku AACTCYCTGCCACGTAATACAGG 5030860 NM_000277.1(PAH):c.1241A > 22G GGGTCGYAGCGAACTGAGAAGGG, Phenylketonuria,  (p.Tyr414Cys) TGGGTCGYAGCGAACTGAGAAGG Hyperphenylalaninemia, non-pku 587777055 NM_020988.2(GNAO1):c.521A > 22G GGATGYCCTGCTCGGTGGGCTGG Early infantile epileptic  (p.Asp174Gly) encephalopathy 17 587777223 NM_024301.4(FKRP):c.1A > 22G CCGCAYGGGGCCGAAGTCTGGGG, Congenital muscular dystrophy- (p.Met1Val) GCCGCAYGGGGCCGAAGTCTGGG, dystroglycanopathy with brain AGCCGCAYGGGGCCGAAGTCTGG and eye anomalies type A5 587777479 NM_003108.3(S0X11):c.347A > 22G GTACTTGYAGTCGGGGTAGTCGG Mental retardation, autosomal (p.Tyr116Cys) dominant 27 587777496 NM_020435.3(GJC2):c.-70A > 22G TTGYTCCCCCCTCGGCCTCAGGG, Leukodystrophy,  ATTGYTCCCCCCTCGGCCTCAGG hypomyelinating, 2 587777507 NM_022552.4(DNMT3A):c.1943T > 22C CTCCYGGTGCTGAAGGACTTGGG, Tatton-Brown-rahman syndrome (p.Leu648Pro) GCTCCYGGTGCTGAAGGACTTGG 587777557 NM_018400.3(SCN3B):c.482T > 22C AATCAYGATGTACATCCTTCTGG Atrial fibrillation,  (p.Met161Thr) familial, 16 587777569 NM_001030001.2(RPS29):c.149T > 22C GATAYCGGTTTCATTAAGGTAGG Diamond-Blackfan anemia 13 (p.Ile50Thr) 587777657 NM_153334.6(SCARF2):c.190T > 22C CCACGYGCTGCGCTGGCTGGAGG Marden Walker like syndrome (p.Cys64Arg) 587777689 NM_005726.5(TSFM):c.57 > 304A > ACTTCYCACCGGGTAGCTCCCGG Combined oxidative  22G phosphorylation deficiency 3 796052005 NM_000255.3(MUT):c.329A > 22G GCAYACTGGCGGATGGTCCAGGG, not provided (p.Tyr110Cys) AGCAYACTGGCGGATGGTCCAGG 587777809 NM_144596.3(TTC8):c.115- GTTCCYGGAAAGCATTAAGAAGG Retinitis pigmentosa 51 2A > 22G 587777878 NM_000166.5(GJB1):c.580A > 22G TAGCAYGAAGACGGTGAAGACGG X-linked hereditary motor and (p.Met194Val) sensory neuropathy 74315420 NM_001029871.3(RSPO1):c.194 A > G CGTACYGGCGGATGCCTTCCCGG Anonychia (p.Gln65Arg) 180177219 NM_000030.2(AGTX):c.424-2A > G AGGCCCYGAGGAAGCAGGGACGG Primary hyperoxaluria, type I (p.Gly_142Gln145del) 367610201 NM_002693.2(POLG):c.1808T > 22C CTCAYGGCACTTACCTGGGATGG not prov ded (p.Met603Thr) 180177319 NM_012203.1(GRHPR):c.84- TCACAGCYGCGGGGAAAGGGAGG Primary hyperoxaluria, type II 2A > 22G 796052068 NM_000030.2(AGXT):c.777- GGTACCYGGAAGACACGAGGGGG, Primary hyperoxaluria, type I 2A > 22G TGGTACCYGGAAGACACGAGGGG 61754010 NM_000552.3(VWF):c.1583A > 22G TGCCAYTGTAATTCCCACACAGG von Willebrand disease, type 2a (p.Asn528Ser) 587778866 NM_000321.2(RB1):c.1927A > 22G ATTYCAATGGCTTCTGGGTCTGG Retinoblastoma (p.Lys643Glu) 74435397 NM_006331.7(EMG1):c.257A > 22G ATAYCTGGCCGCGCTTCCCCAGG Bowen-Conradi syndrome (p.Asp86Gly) 796052527 NM_000156.5(GAMT):c.1A > 22G CGCTCAYGCTGCAGGCTGGACGG not provided (p.Met1Val) 796052637 NM_172107.2(KCNQ2):c.848A > 22G GTACYTGTCCCCGTAGCCAATGG not provided (p.Lys283Arg) 724159963 NM_032228.5(FAR1):c.1094A > 22G GATAYCATACAGGAATGCTGGGG, Perox somal fatty acyl-coa  (p.Asp365Gly) AGATAYCATACAGGAATGCTGGG, reductase 1 disorder 587779722 NM_000090.3(COL3A1):c.1762-2A > 22G TAGATAYCATACAGGAATGCTGG Ehlers-Danlos syndrome, type 4 (p.Gly588_Gln605del) CACCCYAAAGAAGAAGTGGTCGG 118192102 m.8296A > 22G TTTACAGYGGGCTCTAGAGGGGG Diabetes-deafness syndrome  maternally transmitted 727502787 NM_001077494.3(NFKB2):c.2594A > CTGYCTTCCTTCACCTCTGCTGG Common variable  22G (p.Asp865Gly) immunodeficiency 10 727503036 NM_000117.2(EMD):c.266- AGCCYTGGGAAGGGGGGCAGCGG Emery-Dreifuss muscular  2A > 22G dystrophy 1, X-linked 690016544 NM_005861.3(STUB1):c.194A > 22G GGCCCGGYTGGTGTAATACACGG Spinocerebellar ataxia,  (p.Asn65Ser) autosomal recessive 16 690016554 NM_005211.3(CSF1R):c.2655- GTATCYGGGAGATAGGACAGAGG Hereditary diffuse  2A > 22G leukoencephalopathy with  spheroids 118192185 NM_172107.2(KCNQ2):c.1A > 22G GCACCAYGGTGCCTGGCGGGAGG Benign familial neonatal  (p.Met1Val) seizures 1 121917869 NM_012064.3(MIP):c.401A > 22G AGATCYCCACTGTGGTTGCCTGG Cataract 15, multiple types (p.Glu134Gly) 121918014 NM_000478.4(ALPL):c.1250A > 22G AGGCCCAYTGCCATACAGGATGG Infantile hypophosphatasia (p.Asn417Ser) 121918036 NM_000174.4(GP9):c.110A > 22G GCAGYCCACCCACAGCCCCATGG Bernard-Soulier syndrome type (p.Asp37Gly) C 121918089 NM_000371.3(TTR):c.379A > 22G CGGCAAYGGTGTAGCGGCGGGGG, Amyloidogenic transthyretin  (p.Ile127Val) GCGGCAAYGGTGTAGCGGCGGGG amyloidosis 121918121 NM_000823.3(GHRHR):c.985A > 22G CGACTYGGAGAGACGCCTGCAGG Isolated growth hormone  (p.Lys329Glu) deficiency type 1B 121918333 NM_015335.4(MED13L):c.6068A > 22G ATATCAYCTAGAGGGAAGGGGGG, Transposition of great arteries (p.Asp2023Gly) CATATCAYCTAGAGGGAAGGGGG 121918605 NM_001035.2(RYR2):c.12602A > 22G CGCCAGCYGCATTTCAAAGATGG Catecholaminergic polymorphic (p.Gln4201Arg) ventricular tachycardia 587781262 NM_002764.3(PRPS1):c.343A > 22G TAGCAYATTTGCAACAAGCTTGG Charcot-Marie-Tooth disease,  (p.Met115Val) X-linked recessive, type 5,  Deafness, high-frequency sensorineural, X-linked 121918608 NM_001161766.1(AHCY):c.344A > 22G GCGGGYACTTGGTGTGGATGAGG Hypermethioninemia with s-  (p.Tyr115Cys) adenosylhomocysteine hydrolase deficiency 121918613 NM_000702.3(ATP1A2):c.1033A > 22G CTGYCAGGGTCAGGCACACCTGG Familial hemiplegic migraine (p.Thr345Ala) type 2 587781339 NM_000535.5(PMS2):c.904- GCAGACCYGCACAAAATACAAGG Hereditary cancer-predisposing 2A > 22G syndrome 121918691 NM_001128177.1(THRB):c.1324A > 22G CTTCAYGTGCAGGAAGCGGCTGG Thyroid hormone resistance,  (p.Met442Val) generalized, autosomal dominant 121918692 NM_001128177.1(THRB):c.1327A > 22G CCACCTYCATGTGCAGGAAGCGG Thyroid hormone resistance,  (p.Lys443Glu) generalized, autosomal dominant 727504333 NM_000256.3(MYBPC3):c.2906- CCGTTCYGTGGGTATAGAGTGGG, Familial hypertrophic  2A > 22G GCCGTTCYGTGGGTATAGAGTGG cardiomyopathy 4 730880805 NM_006204.3(PDE6C):c.1483- CTTTCYGTTGAAATAAGGATGGG, Achromatopsia 5 2A > 22G TCTTTCYGTTGAAATAAGGATGG 281860296 NM_000551.3(VHL):c.586A > 22T GGTCTTYCTGCACATTTGGGTGG Von Hippel-Lindau syndrome (p.Lys196Ter) 730880444 NM_000169.2(GLA):c.370- GTGAACCYGAAATGAGAGGGAGG not provided 2A > 22G 756328339 NM_000256.3(MYBPC3):c.1227- GTACCYGGGTGGGGGCCGCAGGG, Familial hypertrophic  2A > 22G TGTACCYGGGTGGGGGCCGCAGG cardiomyopathy 4,  Cardiomyopathy 267606643 NM_013411.4(AK2):c.494A > 22G TCAYCTTTCATGGGCTCTTTTGG Reticular dysgenesis (p.Asp165Gly) 267606705 NM_005188.3(CBL):c.1144A > 22G TATTTYACATAGTTGGAATGTGG Noonan syndrome-like disorder  (p.Lys382Glu) with or without juvenile  myelomonocytic leukemia 62642934 NM_000277.1(PAH):c.916A > 22G GGCCAAYTTCCTGTAATTGGGGG, Phenylketonuria,  (p.Ile306Val) AGGCCAAYTTCCTGTAATTGGGG Hyperphenylalamnemia, non-pku 267606782 NM_000117.2(EMD):c.1A > 22G TCCAYGGCGGGTGCGGGCTCAGG Emery-Dreifuss muscular  (p.Met1Val) dystrophy, X-linked 267606820 NM_014053.3(FLVCR1):c.361A > 22G AGGCGTYGACCAGCGAGTACAGG Posterior column ataxia with (p.Asn121Asp) retinitis pigmentosa

In some embodiments, any of the base editors provided herein may be used to treat a disease or disorder. For example, any base editors provided herein may be used to correct one or more mutations associated with any of the diseases or disorders provided herein. Exemplary diseases or disorders that may be treated include, without limitation, 3-Methylglutaconic aciduria type 2, 46,XY gonadal dysgenesis, 4-Alpha-hydroxyphenylpyruvate hydroxylase deficiency, 6-pyruvoyl-tetrahydropterin synthase deficiency, achromatopsia, Acid-labile subunit deficiency, Acrodysostosis, acroerythrokeratoderma, ACTH resistance, ACTH-independent macronodular adrenal hyperplasia, Activated PI3K-delta syndrome, Acute intermittent porphyria, Acute myeloid leukemia, Adams-Oliver syndrome 1/5/6, Adenylosuccinate lyase deficiency, Adrenoleukodystrophy, Adult neuronal ceroid lipofuscinosis, Adult onset ataxia with oculomotor apraxia, Advanced sleep phase syndrome, Age-related macular degeneration, Alagille syndrome, Alexander disease, Allan-Herndon-Dudley syndrome, Alport syndrome, X-linked recessive, Alternating hemiplegia of childhood, Alveolar capillary dysplasia with misalignment of pulmonary veins, Amelogenesis imperfecta, Amyloidogenic transthyretin amyloidosis, Amyotrophic lateral sclerosis, Anemia (nonspherocytic hemolytic, due to G6PD deficiency), Anemia (sideroblastic, pyridoxine-refractory, autosomal recessive), Anonychia, Antithrombin III deficiency, Aortic aneurysm, Aplastic anemia, Apolipoprotein C2 deficiency, Apparent mineralocorticoid excess, Aromatase deficiency, Arrhythmogenic right ventricular cardiomyopathy, Familial hypertrophic cardiomyopathy, Hypertrophic cardiomyopathy, Arthrogryposis multiplex congenital, Aspartylglycosaminuria, Asphyxiating thoracic dystrophy, Ataxia with vitamin E deficiency, Ataxia (spastic), Atrial fibrillation, Atrial septal defect, atypical hemolytic-uremic syndrome, autosomal dominant CD11C+/CD1C+ dendritic cell deficiency, Autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions, Baraitser-Winter syndrome, Bartter syndrome, Basa ganglia calcification, Beckwith-Wiedemann syndrome, Benign familial neonatal seizures, Benign scapuloperoneal muscular dystrophy, Bernard Soulier syndrome, Beta thalassemia intermedia, Beta-D-mannosidosis, Bietti crystalline corneoretinal dystrophy, Bile acid malabsorption, Biotinidase deficiency, Borjeson-Forssman-Lehmann syndrome, Boucher Neuhauser syndrome, Bowen-Conradi syndrome, Brachydactyly, Brown-Vialetto-Van laere syndrome, Brugada syndrome, Cardiac arrhythmia, Cardiofaciocutaneous syndrome, Cardiomyopathy, Carnevale syndrome, Carnitine palmitoyltransferase II deficiency, Carpenter syndrome, Cataract, Catecholaminergic polymorphic ventricular tachycardia, Central core disease, Centromeric instability of chromosomes 1,9 and 16 and immunodeficiency, Cerebral autosomal dominant arteriopathy, Cerebro-oculo-facio-skeletal syndrome, Ceroid lipofuscinosis, Charcot-Marie-Tooth disease, Cholestanol storage disease, Chondrocalcinosis, Chondrodysplasia, Chronic progressive multiple sclerosis, Coenzyme Q10 deficiency, Cohen syndrome, Combined deficiency of factor V and factor VIII, Combined immunodeficiency, Combined oxidative phosphorylation deficiency, Combined partial 17-alpha-hydroxylase/17,20-lyase deficiency, Complement factor d deficiency, Complete combined 17-alpha-hydroxylase/17,20-lyase deficiency, Cone-rod dystrophy, Congenital contractural arachnodactyly, Congenital disorder of glycosylation, Congenital lipomatous overgrowth, Neoplasm of ovary, PIK3CA Related Overgrowth Spectrum, Congenital long QT syndrome, Congenital muscular dystrophy, Congenital muscular hypertrophy-cerebral syndrome, Congenital myasthenic syndrome, Congenital myopathy with fiber type disproportion, Eichsfeld type congenital muscular dystrophy, Congenital stationary night blindness, Corneal dystrophy, Cornelia de Lange syndrome, Craniometaphyseal dysplasia, Crigler Najjar syndrome, Crouzon syndrome, Cutis laxa with osteodystrophy, Cyanosis, Cystic fibrosis, Cystinosis, Cytochrome-c oxidase deficiency, Mitochondrial complex I deficiency, D-2-hydroxyglutaric aciduria, Danon disease, Deafness with labyrinthine aplasia microtia and microdontia (LAMM), Deafness, Deficiency of acetyl-CoA acetyltransferase, Deficiency of ferroxidase, Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase, Dejerine-Sottas disease, Desbuquois syndrome, DFNA, Diabetes mellitus type 2, Diabetes-deafness syndrome, Diamond-Blackfan anemia, Diastrophic dysplasia, Dihydropteridine reductase deficiency, Dihydropyrimidinase deficiency, Dilated cardiomyopathy, Disseminated atypical mycobacterial infection, Distal arthrogryposis, Distal hereditary motor neuronopathy, Donnai Barrow syndrome, Duchenne muscular dystrophy, Becker muscular dystrophy, Dyschromatosis universalis hereditaria, Dyskeratosis congenital, Dystonia, Early infantile epileptic encephalopathy, Ehlers-Danlos syndrome, Eichsfeld type congenital muscular dystrophy, Emery-Dreifuss muscular dystrophy, Enamel-renal syndrome, Epidermolysis bullosa dystrophica inversa, Epidermolysis bullosa herpetiformis, Epilepsy, Episodic ataxia, Erythrokeratodermia variabilis, Erythropoietic protoporphyria, Exercise intolerance, Exudative vitreoretinopathy, Fabry disease, Factor V deficiency, Factor VII deficiency, Factor xiii deficiency, Familial adenomatous polyposis, breast cancer, ovarian cancer, cold urticarial, chronic infantile neurological, cutaneous and particular syndrome, hemiplegic migraine, hypercholesterolemia, hypertrophic cardiomyopathy, hypoalphalipoproteinemia, hypokalemia-hypomagnesemia, juvenile gout, hyperlipoproteinemia, visceral amyloidosis, hypophosphatemic vitamin D refractory rickets, FG syndrome, Fibrosis of extraocular muscles, Finnish congenital nephrotic syndrome, focal epilepsy, Focal segmental glomerulosclerosis, Frontonasal dysplasia, Frontotemporal dementia, Fructose-biphosphatase deficiency, Gamstorp-Wohlfart syndrome, Ganglioside sialidase deficiency, GATA-1-related thrombocytopenia, Gaucher disease, Giant axonal neuropathy, Glanzmann thrombasthenia, Glomerulocystic kidney disease, Glomerulopathy, Glucocorticoid resistance, Glucose-6-phosphate transport defect, Glutaric aciduria, Glycogen storage disease, Gorlin syndrome, Holoprosencephaly, GRACILE syndrome, Haemorrhagic telangiectasia, Hemochromatosis, Hemoglobin H disease, Hemolytic anemia, Hemophagocytic lymphohistiocytosis, Carcinoma of colon, Myhre syndrome, leukoencephalopathy, Hereditary factor IX deficiency disease, Hereditary factor VIII deficiency disease, Hereditary factor XI deficiency disease, Hereditary fructosuria, Hereditary Nonpolyposis Colorectal Neoplasm, Hereditary pancreatitis, Hereditary pyropoikilocytosis, Elliptocytosis, Heterotaxy, Heterotopia, Histiocytic medullary reticulosis, Histiocytosis-lymphadenopathy plus syndrome, HNSHA due to aldolase A deficiency, Holocarboxylase synthetase deficiency, Homocysteinemia, Howel-Evans syndrome, Hydatidiform mole, Hypercalciuric hypercalcemia, Hyperimmunoglobulin D, Mevalonic aciduria, Hyperinsulinemic hypoglycemia, Hyperkalemic Periodic Paralysis, Paramyotonia congenita of von Eulenburg, Hyperlipoproteinemia, Hypermanganesemia, Hypermethioninemia, Hyperphosphatasemia, Hypertension, hypomagnesemia, Hypobetalipoproteinemia, Hypocalcemia, Hypogonadotropic hypogonadism, Hypogonadotropic hypogonadism, Hypohidrotic ectodermal dysplasia, Hyper-IgM immunodeficiency, Hypohidrotic X-linked ectodermal dysplasia, Hypomagnesemia, Hypoparathyroidism, Idiopathic fibrosing alveolitis, Immunodeficiency, Immunoglobulin A deficiency, Infantile hypophosphatasia, Infantile Parkinsonism-dystonia, Insulin-dependent diabetes mellitus, Intermediate maple syrup urine disease, Ischiopatellar dysplasia, Islet cell hyperplasia, Isolated growth hormone deficiency, Isolated lutropin deficiency, Isovaleric acidemia, Joubert syndrome, Juvenile polyposis syndrome, Juvenile retinoschisis, Kallmann syndrome, Kartagener syndrome, Kugelberg-Welander disease, Lattice corneal dystrophy, Leber congenital amaurosis, Leber optic atrophy, Left ventricular noncompaction, Leigh disease, Mitochondrial complex I deficiency, Leprechaunism syndrome, Arthrogryposis, Anterior horn cell disease, Leukocyte adhesion deficiency, Leukodystrophy, Leukoencephalopathy, Ovarioleukodystrophy, L-ferritin deficiency, Li-Fraumeni syndrome, Limb-girdle muscular dystrophy-dystroglycanopathy, Loeys-Dietz syndrome, Long QT syndrome, Macrocephaly/autism syndrome, Macular corneal dystrophy, Macular dystrophy, Malignant hyperthermia susceptibility, Malignant tumor of prostate, Maple syrup urine disease, Marden Walker like syndrome, Marfan syndrome, Marie Unna hereditary hypotrichosis, Mast cell disease, Meconium ileus, Medium-chain acyl-coenzyme A dehydrogenase deficiency, Melnick-Fraser syndrome, Mental retardation, Merosin deficient congenital muscular dystrophy, Mesothelioma, Metachromatic leukodystrophy, Metaphyseal chondrodysplasia, Methemoglobinemia, methylmalonic aciduria, homocystinuria, Microcephaly, chorioretinopathy, lymphedema, Microphthalmia, Mild non-PKU hyperphenylalanemia, Mitchell-Riley syndrome, mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase deficiency, Mitochondrial complex I deficiency, Mitochondrial complex III deficiency, Mitochondrial myopathy, Mucolipidosis III, Mucopolysaccharidosis, Multiple sulfatase deficiency, Myasthenic syndrome, Mycobacterium tuberculosis, Myeloperoxidase deficiency, Myhre syndrome, Myoclonic epilepsy, Myofibrillar myopathy, Myoglobinuria, Myopathy, Myopia, Myotonia congenital, Navajo neurohepatopathy, Nemaline myopathy, Neoplasm of stomach, Nephrogenic diabetes insipidus, Nephronophthisis, Nephrotic syndrome, Neurofibromatosis, Neutral lipid storage disease, Niemann-Pick disease, Non-ketotic hyperglycinemia, Noonan syndrome, Noonan syndrome-like disorder, Norum disease, Macular degeneration, N-terminal acetyltransferase deficiency, Oculocutaneous albinism, Oculodentodigital dysplasia, Ohdo syndrome, Optic nerve aplasia, Ornithine carbamoyltransferase deficiency, Orofaciodigital syndrome, Osteogenesis imperfecta, Osteopetrosis, Ovarian dysgenesis, Pachyonychia, Palmoplantar keratoderma, nonepidermolytic, Papillon-Lef\xc3\xa8vre syndrome, Haim-Munk syndrome, Periodontitis, Peeling skin syndrome, Pendred syndrome, Peroxisomal fatty acyl-coa reductase 1 disorder, Peroxisome biogenesis disorder, Pfeiffer syndrome, Phenylketonuria, Phenylketonuria, Hyperphenylalaninemia, non-PKU, Pituitary hormone deficiency, Pityriasis rubra pilaris, Polyarteritis nodosa, Polycystic kidney disease, Polycystic lipomembranous osteodysplasia, Polymicrogyria, Pontocerebellar hypoplasia, Porokeratosis, Posterior column ataxia, Primary erythromelalgia, hyperoxaluria, Progressive familial intrahepatic cholestasis, Progressive pseudorheumatoid dysplasia, Propionic acidemia, Pseudohermaphroditism, Pseudohypoaldosteronism, Pseudoxanthoma elasticum-like disorder, Purine-nucleoside phosphorylase deficiency, Pyridoxal 5-phosphate-dependent epilepsy, Renal dysplasia, retinal pigmentary dystrophy, cerebellar ataxia, skeletal dysplasia, Reticular dysgenesis, Retinitis pigmentosa, Usher syndrome, Retinoblastoma, Retinopathy, RRM2B-related mitochondrial disease, Rubinstein-Taybi syndrome, Schnyder crystalline corneal dystrophy, Sebaceous tumor, Severe congenital neutropenia, Severe myoclonic epilepsy in infancy, Severe X-linked myotubular myopathy, onychodysplasia, facial dysmorphism, hypotrichosis, Short-rib thoracic dysplasia, Sialic acid storage disease, Sialidosis, Sideroblastic anemia, Small fiber neuropathy, Smith-Magenis syndrome, Sorsby fundus dystrophy, Spastic ataxia, Spastic paraplegia, Spermatogenic failure, Spherocytosis, Sphingomyelin/cholesterol lipidosis, Spinocerebellar ataxia, Split-hand/foot malformation, Spondyloepimetaphyseal dysplasia, Platyspondylic lethal skeletal dysplasia, Squamous cell carcinoma of the head and neck, Stargardt disease, Sucrase-isomaltase deficiency, Sudden infant death syndrome, Supravalvar aortic stenosis, Surfactant metabolism dysfunction, Tangier disease, Tatton-Brown-rahman syndrome, Thoracic aortic aneurysms and aortic dissections, Thrombophilia, Thyroid hormone resistance, TNF receptor-associated periodic fever syndrome (TRAPS), Tooth agenesis, Torsades de pointes, Transposition of great arteries, Treacher Collins syndrome, Tuberous sclerosis syndrome, Tyrosinase-negative oculocutaneous albinism, Tyrosinase-positive oculocutaneous albinism, Tyrosinemia, UDPglucose-4-epimerase deficiency, Ullrich congenital muscular dystrophy, Bethlem myopathy Usher syndrome, UV-sensitive syndrome, Van der Woude syndrome, popliteal pterygium syndrome, Very long chain acyl-CoA dehydrogenase deficiency, Vesicoureteral reflux, Vitreoretinochoroidopathy, Von Hippel-Lindau syndrome, von Willebrand disease, Waardenburg syndrome, Warsaw breakage syndrome, WFS1-Related Disorders, Wilson disease, Xeroderma pigmentosum, X-linked agammaglobulinemia, X-linked hereditary motor and sensory neuropathy, X-linked severe combined immunodeficiency, and Zellweger syndrome.

The development of nucleobase editing advances both the scope and effectiveness of genome editing. The nucleobase editors described here offer researchers a choice of editing with virtually no indel formation (NBE2), or more efficient editing with a low frequency (here, typically ≤1%) of indel formation (NBE3). That the product of base editing is, by definition, no longer a substrate likely contributes to editing efficiency by preventing subsequent product transformation, which can hamper traditional Cas9 applications. By removing the reliance on double-stranded DNA cleavage and stochastic DNA repair processes that vary greatly by cell state and cell type, nucleobase editing has the potential to expand the type of genome modifications that can be cleanly installed, the efficiency of these modifications, and the type of cells that are amenable to editing. It is likely that recent engineered Cas9 variants^(69,70,82) or delivery methods⁷¹ with improved DNA specificity, as well as Cas9 variants with altered PAM specificities,⁷² can be integrated into this strategy to provide additional nucleobase editors with improved DNA specificity or that can target an even wider range of disease-associated mutations. These findings also suggest that engineering additional fusions of dCas9 with enzymes that catalyze additional nucleobase transformations will increase the fraction of the possible DNA base changes that can be made through nucleobase editing. These results also suggest architectures for the fusion of other DNA-modifying enzymes, including methylases and demathylases, that mau enable additional types of programmable genome and epigenome base editing.

Materials and Methods

Cloning. DNA sequences of all constructs and primers used in this paper are listed in the Supplementary Sequences. Plasmids containing genes encoding NBE1, NBE2, and NBE3 will be available from Addgene. PCR was performed using VeraSeq ULtra DNA polymerase (Enzymatics), or Q5 Hot Start High-Fidelity DNA Polymerase (New England Biolabs). NBE plasmids were constructed using USER cloning (New England Biolabs). Deaminase genes were synthesized as gBlocks Gene Fragments (Integrated DNA Technologies), and Cas9 genes were obtained from previously reported plasmids.¹⁸ Deaminase and fusion genes were cloned into pCMV (mammalian codon-optimized) or pET28b (E. coli codon-optimized) backbones. sgRNA expression plasmids were constructed using site-directed mutagenesis. Briefly, the primers listed in the Supplementary Sequences were 5′ phosphorylated using T4 Polynucleotide Kinase (New England Biolabs) according to the manufacturer's instructions. Next, PCR was performed using Q5 Hot Start High-Fidelity Polymerase (New England Biolabs) with the phosphorylated primers and the plasmid pFYF1320 (EGFP sgRNA expression plasmid) as a template according to the manufacturer's instructions. PCR products were incubated with DpnI (20 U, New England Biolabs) at 37° C. for 1 h, purified on a QIAprep spin column (Qiagen), and ligated using QuickLigase (New England Biolabs) according to the manufacturer's instructions. DNA vector amplification was carried out using Mach1 competent cells (ThermoFisher Scientific).

In vitro deaminase assay on ssDNA. Sequences of all ssDNA substrates are listed in the Supplementary Sequences. All Cy3-labelled substrates were obtained from Integrated DNA Technologies (IDT). Deaminases were expressed in vitro using the TNT T7 Quick Coupled Transcription/Translation Kit (Promega) according to the manufacturer's instructions using 1 μg of plasmid. Following protein expression, 5 μL of lysate was combined with 35 μL of ssDNA (1.8 μM) and USER enzyme (1 unit) in CutSmart buffer (New England Biolabs) (50 mM potassium acetate, 29 mM Trisacetate, 10 mM magnesium acetate, 100 ug/mL BSA, pH 7.9) and incubated at 37° C. for 2 h. Cleaved U-containing substrates were resolved from full-length unmodified substrates on a 10% TBE-urea gel (Bio-Rad).

Expression and purification of His₆-rAPOBEC1-linker-dCas9 fusions. E. Coli BL21 STAR (DE3)-competent cells (ThermoFisher Scientific) were transformed with plasmids encoding pET28b-His₆-rAPOBEC-linker-dCas9 with GGS, (GGS)₃, (SEQ ID NO: 596) XTEN, or (GGS)₇ (SEQ ID NO: 597) linkers. The resulting expression strains were grown overnight in Luria-Bertani (LB) broth containing 100 μg/mL of kanamycin at 37° C. The cells were diluted 1:100 into the same growth medium and grown at 37° C. to OD₆₀₀=˜0.6. The culture was cooled to 4° C. over a period of 2 h, and isopropyl-β-D-1-thiogalactopyranoside (IPTG) was added at 0.5 mM to induce protein expression. After ˜16 h, the cells were collected by centrifugation at 4,000 g and resuspended in lysis buffer (50 mM tris(hydroxymethyi)-aminomethane (Tris)-HCl, pH 7.0, 1 M NaCl, 20% glycerol, 10 mM tris(2-carboxyethyl)phosphine (TCEP, Soltec Ventures)). The cells were lysed by sonication (20 s pulse-on, 20 s pulse-off for 8 min total at 6 W output) and the lysate supernatant was isolated following centrifugation at 25,000 g for 15 min. The lysate was incubated with His-Pur nickel-nitriloacetic acid (nickel-NTA) resin (ThermoFisher Scientific) at 4° C. for 1 h to capture the His-tagged fusion protein. The resin was transferred to a column and washed with 40 mL of lysis buffer. The His-tagged fusion protein was eluted in lysis buffer supplemented with 285 mM imidazole, and concentrated by ultrafiltration (Amicon-Millipore, 100-kDa molecular weight cut-off) to 1 mL total volume. The protein was diluted to 20 mL in low-salt purification buffer containing 50 mM tris(hydroxymethyl)-aminomethane (Tris)-HCl, pH 7.0, 0.1 M NaCl, 20% glycerol, 10 mM TCEP and loaded onto SP Sepharose Fast Flow resin (GE Life Sciences). The resin was washed with 40 mL of this low-salt buffer, and the protein eluted with 5 mL of activity buffer containing 50 mM tris(hydroxymethyl)-aminomethane (Tris)-HCl, pH 7.0, 0.5 M NaCl, 20% glycerol, 10 mM TCEP. The eluted proteins were quantified on a SDSPAGE gel.

In vitro transcription of sgRNAs. Linear DNA fragments containing the T7 promoter followed by the 20-bp sgRNA target sequence were transcribed in vitro using the primers listed in the Supplementary Sequences with the TranscriptAid T7 High Yield Transcription Kit (ThermoFisher Scientific) according to the manufacturer's instructions. sgRNA products were purified using the MEGAclear Kit (ThermoFisher Scientific) according to the manufacturer's instructions and quantified by UV absorbance.

Preparation of Cy3-conjugated dsDNA substrates. Sequences of 80-nucleotide unlabeled strands are listed in the Supplementary Sequences and were ordered as PAGE-purified oligonucleotides from IDT. The 25-nt Cy3-labeled primer listed in the Supplementary Sequences is complementary to the 3′ end of each 80-nt substrate. This primer was ordered as an HPLC-purified oligonucleotide from IDT. To generate the Cy3-labeled dsDNA substrates, the 80-nt strands (5 μL of a 100 μM solution) were combined with the Cy3-labeled primer (5 μL of a 100 μM solution) in NEBuffer 2 (38.25 μL of a 50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl₂, 1 mM DTT, pH 7.9 solution, New England Biolabs) with dNTPs (0.75 μL of a 100 mM solution) and heated to 95° C. for 5 min, followed by a gradual cooling to 45° C. at a rate of 0.1° C./s. After this annealing period, Klenow exo⁻ (5 U, New England Biolabs) was added and the reaction was incubated at 37° C. for 1 h. The solution was diluted with Buffer PB (250 μL, Qiagen) and isopropanol (50 μL) and purified on a QIAprep spin column (Qiagen), eluting with 50 μL of Tris buffer.

Deaminase assay on dsDNA. The purified fusion protein (20 μL of 1.9 μM in activity buffer) was combined with 1 equivalent of appropriate sgRNA and incubated at ambient temperature for 5 min. The Cy3-labeled dsDNA substrate was added to final concentration of 125 nM and the resulting solution was incubated at 37° C. for 2 h. The dsDNA was separated from the fusion by the addition of Buffer PB (100 μL, Qiagen) and isopropanol (25 μL) and purified on a EconoSpin micro spin column (Epoch Life Science), eluting with 20 μL of CutSmart buffer (New England Biolabs). USER enzyme (1 U, New England Biolabs) was added to the purified, edited dsDNA and incubated at 37° C. for 1 h. The Cy3-labeled strand was fully denatured from its complement by combining 5 μL of the reaction solution with 15 μL of a DMSO-based loading buffer (5 mM Tris, 0.5 mM EDTA, 12.5% glycerol, 0.02% bromophenol blue, 0.02% xylene cyan, 80% DMSO). The full-length C-containing substrate was separated from any cleaved, U-containing edited substrates on a 10% TBE-urea gel (Bio-Rad) and imaged on a GE Amersham Typhoon imager.

Preparation of in vitro-edited dsDNA for high-throughput sequencing (HTS). The oligonucleotides listed in the Supplementary Sequences were obtained from IDT. Complementary sequences were combined (5 μL of a 100 μM solution) in Tris buffer and annealed by heating to 95° C. for 5 min, followed by a gradual cooling to 45° C. at a rate of 0.1° C/s to generate 60-bp dsDNA substrates. Purified fusion protein (20 μL of 1.9 μM in activity buffer) was combined with 1 equivalent of appropriate sgRNA and incubated at ambient temperature for 5 min. The 60-mer dsDNA substrate was added to final concentration of 125 nM and the resulting solution was incubated at 37° C. for 2 h. The dsDNA was separated from the fusion by the addition of Buffer PB (100 μL, Qiagen) and isopropanol (25 μL) and purified on a EconoSpin micro spin column (Epoch Life Science), eluting with 20 μL of Tris buffer. The resulting edited DNA (1 μL was used as a template) was amplified by PCR using the HTS primer pairs specified in the Supplementary Sequences and VeraSeq Ultra (Enzymatics) according to the manufacturer's instructions with 13 cycles of amplification. PCR reaction products were purified using RapidTips (Diffinity Genomics), and the purified DNA was amplified by PCR with primers containing sequencing adapters, purified, and sequenced on a MiSeq high-throughput DNA sequencer (IIlumina) as previously described.⁷³

Cell culture. HEK293T (ATCC CRL-3216), U2OS (ATCC-HTB-96) and ST486 cells (ATCC) were maintained in Dulbecco's Modified Eagle's Medium plus GlutaMax (ThermoFisher) supplemented with 10% (v/v) fetal bovine serum (FBS) and penicillin/streptomycin (1×, Amresco), at 37° C. with 5% CO₂. HCC1954 cells (ATCC CRL-2338) were maintained in RPMI-1640 medium (ThermoFisher Scientific) supplemented as described above. Immortalized rat astrocytes containing the ApoE4 isoform of the APOE gene (Taconic Biosciences) were cultured in Dulbecco's Modified Eagle's Medium plus GlutaMax (ThermoFisher Scientific) supplemented with 10% (v/v) fetal bovine serum (FBS) and 200 μg/mL Geneticin (ThermoFisher Scientific).

Transfections. HEK293T cells were seeded on 48-well collagen-coated BioCoat plates (Corning) and transfected at approximately 85% confluency. Briefly, 750 ng of NBE and 250 ng of sgRNA expression plasmids were transfected using 1.5 μl of Lipofectamine 2000 (ThermoFisher Scientific) per well according to the manufacturer's protocol. Astrocytes, U2OS, HCC1954, HEK293T and ST486 cells were transfected using appropriate AMAXA NUCLEOFECTOR™ II programs according to manufacturer's instructions. 40 ng of infrared RFP (Addgene plasmid 45457)⁷⁴ was added to the nucleofection solution to assess nucleofection efficiencies in these cell lines. For astrocytes, U2OS, and ST486 cells, nucleofection efficiencies were 25%, 74%, and 92%, respectively. For HCC1954 cells, nucleofection efficiency was <10%. Therefore, following trypsinization, the HCC1954 cells were filtered through a 40 micron strainer (Fisher Scientific), and the nucleofected HCC1954 cells were collected on a Beckman Coulter MoFlo XDP Cell Sorter using the iRFP signal (abs 643 nm, em 670 nm). The other cells were used without enrichment of nucleofected cells.

High-throughput DNA sequencing of genomic DNA samples. Transfected cells were harvested after 3 d and the genomic DNA was isolated using the Agencourt DNAdvance Genomic DNA Isolation Kit (Beckman Coulter) according to the manufacturer's instructions. On-target and off-target genomic regions of interest were amplified by PCR with flanking HTS primer pairs listed in the Supplementary Sequences. PCR amplification was carried out with Phusion high-fidelity DNA polymerase (ThermoFisher) according to the manufacturer's instructions using 5 ng of genomic DNA as a template. Cycle numbers were determined separately for each primer pair as to ensure the reaction was stopped in the linear range of amplification (30, 28, 28, 28, 32, and 32 cycles for EMX1, FANCF, HEK293 site 2, HEK293 site 3, HEK293 site 4, and RNF2 primers, respectively). PCR products were purified using RapidTips (Diffinity Genomics). Purified DNA was amplified by PCR with primers containing sequencing adaptors. The products were gel-purified and quantified using the QUANT-IT™ PicoGreen dsDNA Assay Kit (ThermoFisher) and KAPA Library Quantification Kit-Illumina (KAPA Biosystems). Samples were sequenced on an Illumina MiSeq as previously described.⁷³

Data analysis. Sequencing reads were automatically demultiplexed using MiSeq Reporter (Illumina), and individual FASTQ files were analyzed with a custom Matlab script provided in the Supplementary Notes. Each read was pairwise aligned to the appropriate reference sequence using the Smith-Waterman algorithm. Base calls with a Q-score below 31 were replaced with N's and were thus excluded in calculating nucleotide frequencies. This treatment yields an expected MiSeq base-calling error rate of approximately 1 in 1,000. Aligned sequences in which the read and reference sequence contained no gaps were stored in an alignment table from which base frequencies could be tabulated for each locus.

Indel frequencies were quantified with a custom Matlab script shown in the Supplementary Notes using previously described criteria⁷¹. Sequencing reads were scanned for exact matches to two 10-bp sequences that flank both sides of a window in which indels might occur. If no exact matches were located, the read was excluded from analysis. If the length of this indel window exactly matched the reference sequence the read was classified as not containing an indel. If the indel window was two or more bases longer or shorter than the reference sequence, then the sequencing read was classified as an insertion or deletion, respectively.

All publications, patents, patent applications, publication, and database entries (e.g., sequence database entries) mentioned herein, e.g., in the Background, Summary, Detailed Description, Examples, and/or References sections, are hereby incorporated by reference in their entirety as if each individual publication, patent, patent application, publication, and database entry was specifically and individually incorporated herein by reference. In case of conflict, the present application, including any definitions herein, will control.

Supplementary Sequences

Primers used for generating sgRNA transfection plasmids. rev_sgRNA_plasmid was used in all cases. The pFYF1320 plasmid was used as template as noted in Materials and Methods section. SEQ ID NOs: 329-338 appear from top to bottom below, respectively.

rev_sgRNA_plasmid GGTGTTTCGTCCTTTCCACAAG fwd_p53_Y163C GCTTGCAGATGGCCATGGCGGTTTTAGAGCTAGAAATAGCAAGTTAAAAT AAGGC fwd_p53_N239D TGTCACACATGTAGTTGTAGGTITTAGAGCTAGAAATAGCAAGTTAAAAT AAGGC fwd_APOE4_C158R GAAGCGCCTGGCAGTGTACCGTTTTAGAGCTAGAAATAGCAAGTTAAAAT AAGGC fwd_EMX1 GAGTCCGAGCAGAAGAAGAAGTTTTAGAGCTAGAAATAGCAAGTTAAAAT AAGGC fwd_FANCF GGAATCCCTTCTGCAGCACCGTTTTAGAGCTAGAAATAGCAAGTTAAAAT AAGGC fwd_HEK293_2 GAACACAAAGCATAGACTGCGTTTTAGAGCTAGAAATAGCAAGTTAAAAT AAGGC fWd_HEK293_3 GGCCCAGACTGAGCACGTGAGTTTTAGAGCTAGAAATAGCAAGTTAAAAT AAGGC fwd_HEK293_4 GGCACTGCGGCTGGAGGTGGGTTTTAGAGCTAGAAATAGCAAGTTAAAAT AAGGC fwd_RNF2 GTCATCTTAGTCATTACCTGGTTTTAGAGCTAGAAATAGCAAGTTAAAAT AAGGC

Sequences of all ssDNA substrates used in in vitro deaminase assays. SEQ ID NOs: 339-341 appear from top to bottom below, respectively.

rAPOBEC1 substrate Cy3-ATTATTATTATTCCGCGGATTTATTTATTTATTTATTTATTT hAID/pmCDA1 substrate Cy3-ATTATTATTATTAGCTATTTATTTATTTATTTATTTATTT hAPOBEC3G substrate  Cy3-ATTATTATTATTCCCGGATTTATTTATTATTTATTTATTT

Primers used for generating PCR products to serve as substrates for T7 transcription of sgRNAs for gel-based deaminase assay. rev_gRNA_T7 was used in all cases. The pFYF1320 plasmid was used as template as noted in Materials and Methods section. SEQ ID NOs: 342-365 appear from top to bottom below, respectively.

rev_sgRNA_T7 AAAAAAAGCACCGACTCGGTG fwd_sgRNA_T7_dsDNA_2 TAATACGACTCACTATAGGCCGCGGATTTATTTATTTAAGTTTTAGAGCTAGA AATAGCA fwd_sgRNA_T7_dsDNA_3 TAATACGACTCACTATAGGTCCGCGGATTTATTTATTTAGTTTTAGAGCTAGA AATAGCA fwd_sgRNA_T7_dsDNA_4 TAATACGACTCACTATAGGTTCCGCGGATTTATTTATTAGTTTTAGAGCTAGA AATAGCA fwd_sgRNA_T7_dsDNA_5 TAATACGACTCACTATAGGATTCCGCGGATTTATTTATTGTTTTAGAGCTAGA AATAGCA fwd_sgRNA_T7_dsDNA_6 TAATACGACTCACTATAGGTATTCCGCGGATTTATTTATGTTTTAGAGCTAGA ATAGCAA fwd_sgRNA_T7_dsDNA_7 TAATACGACTCACTATAGGTTATTCCGCGGATTTATTTAGTTTTAGAGCTAGA AATAGCA fwd_sgRNA_T7_dsDNA_8 TAATACGACTCACTATAGGATTATTCCGCGGATTTATTTGTTTTAGAGCTAGA AATAGCA fwd_sgRNA_T7_dsDNA_9 TAATACGACTCACTATAGGTATTATTCCGCGGATTTATTGTTTTAGAGCTAGA AATAGCA fwd_sgRNA_T7_dsDNA_10 TAATACGACTCACTATAGGATTATTATCCGCGGATTTATGTTTTAGAGCTAGA AATAGCA fwd_sgRNA_T7_dsDNA_11 TAATACGACTCACTATAGGTATTATATTCCGCGGATTTAGTTTTAGAGCTAGA AATAGCA fwd_sgRNA_T7_dsDNA_12 TAATACGACTCACTATAGGTTATTATATTCCGCGGATTTGTTTTAGAGCTAGA AATAGCA fwd_sgRNA_T7_dsDNA_13 TAATACGACTCACTATAGGATTATTATATTCCGCGGATTGTTTTAGAGCTAGA AATAGCA fwd_sgRNA_T7_dsDNA_14 TAATACGACTCACTATAGGTATTATTATATTCCGCGGATGTTTTAGAGCTAGA AATAGCA fwd_sgRNA_T7_dsDNA_15 TAATACGACTCACTATAGGATTATTATTATTACCGCGGAGTTTTAGAGCTAGA AATAGCA fwd_sgRNA_T7_dsDNA_18 TAATACGACTCACTATAGGATTATTATTATTATTACCGCGTTTTAGAGCTAGA AATAGCA fwd_sgRNA_T7_dsDNA_ TAATACGACTCACTATAGGATATTAATTTATTTATTTAAGTTTTAGAGCTAGA noC AATAGCA fwd_sgRNA_T7_dsDNA_ TAATACGACTCACTATAGGGGAGGACGTGCGCGGCCGCCGTTTTAGAGCTAGA APOE4_C112R AATAGCA fwd_sgRNA_T7_dsDNA_ TAATACGACTCACTATAGGGAAGCGCCTGGCAGTGTACCGTTTTAGAGCTAGA APOE4_C158R AATAGCA fwd_sgRNA_T7_dsDNA_ TAATACGACTCACTATAGGCTGTGGCAGTGGCACCAGAAGTTTTAGAGCTAGA CTTNBB2_T41A AATAGCA fwd_sgRNA_T7_dsDNA_ TAATACGACTCACTATAGGCCTCCCGGCCGGCGGTATCCGTTTTAGAGCTAGA HRAS_Q61R AATAGCA fwd_sgRNA_T7_dsDNA_ TAATACGACTCACTATAGGGCTTGCAGATGGCCATGGCGGTTTTAGAGCTAGA 53_Y163C AATAGCA fwd_sgRNA_T7_dsDNA_ TAATACGACTCACTATAGGACACATGCAGTTGTAGTGGAGTTTTAGAGCTAGA 53_Y236C AATAGCA fwd_sgRNA_T7_dsDNA_ TAATACGACTCACTATAGGTGTCACACATGTAGTTGTAGGTTTTAGAGCTAGA 53_N239D AATAGCA

Sequences of 80-nucleotide unlabeled strands and Cy3-labeled universal primer used in gel-based dsDNA deaminase assays. SEQ ID NOs: 366-390 appear from top to bottom below, respectively.

C3-primer Cy3-GTAGGTAGTTAGGATGAATGGGGTTGGTA dsDNA_2 GTCCATGGATCCAGAGGTCATCCATTAAATAAATAAATCCGCGGGGCTATACCAACCTTCCATTCATCCTAACTACCTAC dsDNA_3 GTCCATGGATCCAGAGGTCATCCATAAATAAATAAATCCGCGGAAGCTATACCAACCTTCCATTCATCCTAACTACCTAC dsDNA_4 GTCCATGGATCCAGAGGTCATCCATAATAAATAAATCCGCGGAAGGCTATACCAACCTTCCATTCATCCTAACTACCTAC dsDNA_5 GTCCATGGATCCAGAGGTCATCCAAATAAATAAATCCGCGGAATGGCTATACCAACCTTCCATTCATCCTAACTACCTAC dsDNA_6 GTCCATGGATCCAGAGGTCATCCAATAAATAAATCCGCGGAATAGGCTATACCAACCTTCCATTCATCCTAACTACCTAC dsDNA_7 GTCCATGGATCCAGAGGTCATCCATAAATAAATCCGCGGAATAAGGCTATACCAACCTTCCATTCATCCTAACTACCTAC dsDNA_8 GTCCATGGATCCAGAGGTCATCCAAAATAAATCCGCGGAATAATGGCTATACCAACCTTCCATTCATCCTAACTACCTAC dsDNA_9 GTCCATGGATCCAGAGGTCATCCAAATAAATCCGCGGAATAATAGGCTATACCAACCTTCCATTCATCCTAACTACCTAC dsDNA_10 GTCCATGGATCCAGAGGTCATCCAATAAATCCGCGGATAATAATGGCTATACCAACCTTCCATTCATCCTAACTACCTAC dsDNA_11 GTCCATGGATCCAGAGGTCATCCATAAATCCGCGGAATATAATAGGCTATACCAACCTTCCATTCATCCTAACTACCTAC dsDNA_12 GTCCATGGATCCAGAGGTCATCCAAAATCCGCGGAATATAATAAGGCTATACCAACCTTCCATTCATCCTAACTACCTAC dSDNA_13 GTCCATGGATCCAGAGGTCATCCAAATCCGCGGAATATAATAATGGCTATACCAACCTTCCATTCATCCTAACTACCTAC dSDNA_14 GTCCATGGATCCAGAGGTCATCCAATCCGCGGAATATAATAATAGGCTATACCAACCTTCCATTCATCCTAACTACCTAC dsDNA_15 GTCCATGGATCCAGAGGTCATCCATCCGCGGTAATAATAATAATGGCTATACCAACCTTCCATTCATCCTAACTACCTAC dsDNA_18 GTCCATGGATCCAGAGGTCATCCAGCGGTAATAATAATAATAATGGCTATACCAACCTTCCATTCATCCTAACTACCTAC dsDNA_noC GTCCATGGATCCAGAGGTCATCCATTAAATAAATAAATTAATATTACTATACCAACCTTCCATTCATCCTAACTACCTAC dsDNA_8U 5Cy3-GTAGGTAGTTAGGATGAATGGAAGGTTGGTGTAGATTATTATCUGCGGATTTATTGGATGACCTCTGGATCCATGGACAT dsDNA_APOE_ GCACCTCGCCGCGGTACTGCACCAGGCGGCCGCGCACGTCCTCCATGTCTACCAACCTTCCATTCATCCTAACTACCTAC C112R dsDNA_APOE_ CGGCGCCCTCGCGGGCCCCGGCCTGGTACACTGCCAGGCGCTTCTGCAGTACCAACCTTCCATTCATCCTAACTACCTAC C1158R dsDNA_CTTNB1_ GTCTTACCTGGACTCTGGAATCCATTCTGGTGCCACTGCCACAGCTCCTTACCAACCTTCCATTCATCCTAACTACCTAC T41A dsDNA_HRAS_ GGAGACGTGCCTGTTGGACATCCTGGATACCGCCGGCCGGGAGGAGTACTACCAACCTTCCATTCATCCTAACTACCTAC Q61R dsDNA_p53_ ACCCCCGCCCGGCACCCGCGTCCGCGCCATGGCCATCTGCAAGCAGTCATACCAACCTTCCATTCATCCTAACTACCTAC Y163C dsDNA_p53_ AGGTTGGCTCTGACTGTACCACCATCCACTACAACTGCATGTGTAACAGTACCAACCTTCCATTCATCCTAACTACCTAC Y236C dsDNA_p53_ TGGCTCTGACTGTACCACCATCCACTACAACTACATGTGTGACAGTTCCTACCAACCTTCCATTCATCCTAACTACCTAC N239D

Primers used for generating PCR products to serve as substrates for T7 transcription of sgRNAs for high-throughput sequencing. rev_gRNA_T7 (above) was used in all cases. The pFYF1320 plasmid was used as template as noted in Materials and Methods section. SEQ ID NOs: 391-442 appear from top to bottom below, respectively.

fwd_sgRNA_T7_HTS_base TAATACGACTCACTATAGGTTATTTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_1A TAATACGACTCACTATAGGATATTTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_1C TAATACGACTCACTATAGGCTATTTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_1G TAATACGACTCACTATAGGGTATTTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_SgRNA_T7_HTS_2A TAATACGACTCACTATAGGTAATTTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_2C TAATACGACTCACTATAGGTCATTTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_2G TAATACGACTCACTATAGGTGATTTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_3T TAATACGACTCACTATAGGTTTTTTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_3C TAATACGACTCACTATAGGTTCTTTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_3G TAATACGACTCACTATAGGTTGTTTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_4A TAATACGACTCACTATAGGTTAATTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd saRNA T7 HTS_4C TAATACGACTCACTATAGGTTACTTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_4G TAATACGACTCACTATAGGTTAGTTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_5A TAATACGACTCACTATAGGTTATATCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_5C TAATACGACTCACTATAGGTTATCTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_5G TAATACGACTCACTATAGGTTATGTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_6A TAATACGACTCACTATAGGTTATTACGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_6C TAATACGACTCACTATAGGTTATTCCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_6G TAATACGACTCACTATAGGTTATTGCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_8A TAATACGACTCACTATAGGTTATTTCATGGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_8T TAATACGACTCACTATAGGTTATTTCTTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_8C TAATACGACTCACTATAGGTTATTTCCTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_77_HTS_9A TAATACGACTCACTATAGGTTATTTCGAGGATTTATTTAGTTTTAGAGCTAGAAATAGCA twd_sgRNA_T7_HTS_9C TAATACGACTCACTATAGGTTATTTCGCGGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_9G TAATACGACTCACTATAGGTTATTTCGGGGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_10A TAATACGACTCACTATAGGTTATTTCGTAGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_10T TAATACGACTCACTATAGGTTATTTCGTTGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_10C TAATACGACTCACTATAGGTTATTTCGTCGATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_11A TAATACGACTCACTATAGGTTATTTCGTGAATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_11T TAATACGACTCACTATAGGTTATTTCGTGTATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_11C TAATACGACTCACTATAGGTTATTTCGTGCATTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_12T TAATACGACTCACTATAGGTTATTTCGTGGTTTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_12C TAATACGACTCACTATAGGTTATTTCGTGGCTTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_12G TAATACGACTCACTATAGGTTATTTCGTGGGTTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_13A TAATACGACTCACTATAGGTTATTTCGTGGAATTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_13C TAATACGACTCACTATAGGTTATTTCGTGGACTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_13G TAATACGACTCACTATAGGTTATTTCGTGGAGTTATTTAGTTTTAGAGCTAGAAATAGCA fwd_sgRNA_T7_HTS_ TAATACGACTCACTATAGGTTCCCCCCCCGATTTATTTAGTTTTAGAGCTAGAAATAGCA multiC fwd_sgRNA_T7_HTS_ TAATACGACTCACTATAGGCGCACCCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA TCGCACCC_odd fwd_sgRNA_T7_HTS_ TAATACGACTCACTATAGGCTCGCACGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA CCTCGCAC_odd fwd_sgRNA_T7_HTS_ TAATACGACTCACTATAGGCCCTCGCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA ACCCTCGC_odd fwd_sgRNA_T7_HTS_ TAATACGACTCACTATAGGCACCCTCGTGGATTTATTTAGTTTTAGAGCTAGAAATAGCA GCACCCTC_odd fwd_sgRNA_T7_HTS_ TAATACGACTCACTATAGGTCGCACCCGTGGATTTATTAGTTTTAGAGCTAGAAATAGCA TCGCACCC_even fwd_sgRNA_T7_HTS_ TAATACGACTCACTATAGGCCTCGCACGTGGATTTATTAGTTTTAGAGCTAGAAATAGCA CCTCGCAC_even fwd_sgRNA_T7_HTS_ TAATACGACTCACTATAGGACCCTCGCGTGGATTTATTAGTTTTAGAGCTAGAAATAGCA ACCCTCGC_even fwd_sgRNA_T7_HTS_ TAATACGACTCACTATAGGGCACCCTCGTGGATTTATTAGTTTTAGAGCTAGAAATAGCA GCACCCTC_even fwd_sgRNA_T7_HTS_ TAATACGACTCACTATAGGGAGTCCGAGCAGAAGAAGAAGTTTTAGAGCTAGAAATAGCA EMX1 fwd_sgRNA_T7_HTS_ TAATACGACTCACTATAGGGGAATCCCTTCTGCAGCACCGTTTTAGAGCTAGAAATAGCA FANCF fwd_sgRNA_T7_HTS_ TAATACGACTCACTATAGGGAACACAAAGCATAGACTGCGTTTTAGAGCTAGAAATAGCA HEK293_site2 fwd_sgRNA_T7_HTS_ TAATACGACTCACTATAGGGGCCCAGACTGAGCACGTGAGTTTTAGAGCTAGAAATAGCA HEK293_site3 fwd_sgRNA_T7_HTS_ TAATACGACTCACTATAGGGGCACTGCGGCTGGAGGTGGGTTTTAGAGCTAGAAATAGCA HEK293_sit4 fwd_sgRNA_T7_HTS_ TAATACGACTCACTATAGGGTCATCTTAGTCATTACCTGGTTTTAGAGCTAGAAATAGCA RNF2

Sequences of in vitro-edited dsDNA for high-throughput sequencing (HTS). Shown are the sequences of edited strands. Reverse complements of all sequences shown were also obtained. dsDNA substrates were obtained by annealing complementary strands as described in Materials and Methods. Oligonucleotides representing the EMX1, FANCF, HEK293 site 2, HEK293 site 3, HEK293 site 4, and RNF2 loci were originally designed for use in the gel-based deaminase assay and therefore have the same 25-nt sequence on their 5′-ends (matching that of the Cy3-primer). SEQ ID NOs: 443-494 appear from top to bottom below, respectively.

Base sequence ACGTAAACGGCCACAAGTTCTTATTTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG 1A ACGTAAACGGCCACAAGTTCATATTTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG 1C ACGTAAACGGCCACAAGTTCCTATTTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG 1G ACGTAAACGGCCACAAGTTCGTATTTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG 2A ACGTAAACGGCCACAAGTTCTAATTTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG 2C ACGTAAACGGCCACAAGTTCTCATTTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG 2G ACGTAAACGGCCACAAGTTCTGATTTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG 3T ACGTAAACGGCCACAAGTTCTTTTTTCGTGGATTTATTTATOGCATCTTCTTCAAGGACG 3C ACGTAAACGGCCACAAGTTCTTCTTTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG 3G ACGTAAACGGCCACAAGTTCTTGTTTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG 4A ACGTAAACGGCCACAAGTTCTTAATTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG 4C ACGTAAACGGCCACAAGTTCTTACTTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG 4G ACGTAAACGGCCACAAGTTCTTAGTTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG 5A ACGTAAACGGCCACAAGTTCTTATATCGTGGATTTATTTATGGCATCTTCTTCAAGGACG 5C ACGTAAACGGCCACAAGTTCTTATCTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG 5G ACGTAAACGGCCACAAGTTCTTATGTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG 6A ACGTAAACGGCCACkAGTTCTTATTACGTGGATTTATTTATGGCATCTTCTTCAAGGACG 6C ACGTAAACGGCCACAAGTTCTTATTCCGTGGATTTATTTATGGCATCTTCTTCAAGGACG 6G ACGTAAACGGCCACAAGTTCTTATTGCGTGGATTTATTTATGGCATCTTCTTCAAGGACG 8A ACGTAAACGGCCACAAGTTCTTATTTCATGGATTTATTTATGGCATCTTCTTCAAGGACG 8T ACGTAAACGGCCACAAGTTCTTATTTCTTGGATTTATTTATGGCATCTTCTTCAAGGACG 8C ACGTAAACGGCCACAAGTTCTTATTTCCTGGATTTATTTATGGCATCTTCTTCAAGGACG 9A ACGTAAACGGCCACAAGTTCTTATTTCGAGGATTTATTTATGGCATCTTCTTCAAGGACG 9C ACGTAAACGGCCACAAGTTCTTATTTCGCGGATTTATTTATGGCATCTTCTTCAAGGACG 9G ACGTAAACGGCCACAAGTTCTTATTTCGGGGATTTATTTATGGCATCTTCTTCAAGGACG 10A ACGTAAACGGCCACAAGTTCTTATTTCGTAGATTTATTTATGGCATCTTCTTCAAGGACG 10T ACGTAAACGGCCACAAGTTCTTATTTCGTTGATTTATTTATGGCATCTTCTTCAAGGACG 10C ACGTAAACGGCCACAAGTTCTTATTTCGTCGATTTATTTATGGCATCTTCTTCAAGGACG 11A ACGTAAACGGCCACAAGTTCTTATTTCGTGAATTTATTTATGGCATCTTCTTCAAGGACG 11T ACGTAAACGGCCACAAGTTCTTATTTCGTGTATTTATTTATGGCATCTTCTTCAAGGACG 11C ACGTAAACGGCCACAAGTTCTTATTTCGTGCATTTATTTATGGCATCTTCTTCAAGGACG 12T ACGTAAACGGCCACAAGTTCTTATTTCGTGGTTTTATTTATGGCATCTTCTTCAAGGACG 12C ACGTAAACGGCCACAAGTTCTTATTTCGTGGCTTTATTTATGGCATCTTCTTCAAGGACG 12G ACGTAAACGGCCACAAGTTCTTATTTCGTGGGTTTATTTATGGCATCTTCTTCAAGGACG 13A ACGTAAACGGCCACAAGTTCTTATTTCGTGGAATTATTTATGGCATCTTCTTCAAGGACG 13C ACGTAAACGGCCACAAGTTCTTATTTCGTGGACTTATTTkTGGCATCTTCTTCAAGGACG 13G ACGTAAACGGCCACAAGTTCTTATTTCGTGGAGTTATTTATGGCATCTTCTTCAAGGACG multiC ACGTAAACGGCCACAAGTTCTTCCCCCCCCGATTTATTTATGGCATCTTCTTCAAGGACG TCGCACCC_odd ACGTAAACGGCCACAAGTTTCGCACCCGTGGATTTATTTATGGCATCTTCTTCAAGGACG CCTCGCAC_odd ACGTAAACGGCCACAAGTTCCTCGCACGTGGATTTATTTATGGCATCTTCTTCAAGGACG ACCCTCGC_odd ACGTAAACGGCCACAAGTTACCCTCGCGTGGATTTATTTATGGCATCTTCTTCAAGGACG GCACCCTC_odd ACGTAAACGGCCACAAGTTGCACCCTCGTGGATTTATTTATGGCATCTTCTTCAAGGACG TCGCACCC_even ACGTAAACGGCCACAAGTATTCGCACCCGTGGATTTATTATGGCATCTTCTTCAAGGACG CCTCGCAC_even ACGTAAACGGCCACAAGTATCCTCGCACGTGGATTTATTATGGCATCTTCTTCAAGGACG ACCCTCGC_even ACGTAAACGGCCACAAGTATACCCTCGCGTGGATTTATTATGGCATCTTCTTCAAGGACG GCACCCTC_even ACGTAAACGGCCACAAGTATGCACCCTCGTGGATTTATTATGGCATCTTCTTCAAGGACG EMX1_invitro GTAGGTAGTTAGGATGAATGGAAGGTTGGTAGGCCTGAGTCCGAGCAGAAGAAGAAGGGCTCCCATCACATCAACCGGTG FANCF_invitro GTAGGTAGTTAGGATGAATGGAAGGTTGGTACTCATGGAATCCCTTCTGCAGCACCTGGATCGCTTTTCCGAGCTTCTGG HEK293_site2_ GTAGGTAGTTAGGATGAATGGAAGGTTGGTAAACTGGAACACAAAGCATAGACTGCGGGGCGGGCCAGCCTGAATAGCTG invitro HEK293_site3_ GTAGGTAGTTAGGATGAATGGAAGGTTGGTACTTGGGGCCCAGACTGAGCACGTGATGGCAGAGGAAAGGAAGCCCTGCT invitro HEK293_site4_ GTAGGTAGTTAGGATGAATGGAAGGTTGGTACCGGTGGCACTGCGGCTGGAGGTGGGGGTTTAAGCGGAGACTCTGGTGC invitro RNf2_invitro GTAGGTAGTTAGGATGAATGGAAGGTTGGTATGGCAGTCATCTTAGTCATTACCTGAGGTGTTCGTTGTAACTCATATAA

Primers for HTS of in vitro edited dsDNA. SEQ ID NOs: 495-503 appear from top to bottom below, respectively.

fwd_invitro_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNACGTAAACGGCCACAA rev_invitro_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTCGTCCTTGAAGAAGATGC fwd_invitro_HEK_targets ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGTAGGTAGTTAGGATGAATGGAA rev_EMX1_invitro TGGAGTTCAGACGTGTGCTCTTCCGATCTCACCGGTTGATGTGATGG rev_FANCF_invitro TGGAGTTCAGACGTGTGCTCTTCCGATCTCCAGAAGCTCGGAAAAGC rev_HEK293_site2_invitro TGGAGTTCAGACGTGTGCTCTTCCGATCTCAGCTATTCAGGCTGGC rev_HEK293_site3_invitro TGGAGTTCAGACGTGTGCTCTTCCGATCTAGCAGGGCTTCCTTTC rev_HEK293_site4_invitro TGGAGTTCAGACGTGTGCTCTTCCGATCTGCACCAGAGTCTCCG rev_RNF2_invitro TGGAGTTCAGACGTGTGCTCTTCCGATCTTTATATGAGTTACAACGAACACC

Primers for HTS of on-target and off-target sites from all mammalian cell culture experiements. SEQ ID NOs: 504-579 and 1869-1900 appear from top to bottom below, respectively.

fwd_EMX1_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCAGCTCAGCCTGAGTGTTGA rev_EMX1_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTCTCGTGGGTTTGTGGTTGC fwd_FANCF_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCATTGCAGAGAGCCQTATCA rev_FANCF_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTGGGGTCCCAGGTGCTGAC fwd_HEK293_site2_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNMCCAGCCCCATCTGTCAAACT rev_HEK293_site2_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTTGAATGGATTCCTTGGAAACAATGA fwd_HEK293_site3_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNATGTGGGCTGCCTAGAAAGG rev_HEK293_site3_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTCCCAGCCAAACTTGTCAACC fwd_HEK293_site4_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGAACCCAGGTAGCCAGAGAC rev_HEK293_site4_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTTCCTTTCAACCCGAACGGAG fwd_RNF2_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCTCTTCTTTATTTCCAGCAATGT rev_RNF2_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTGTTTTCATGTTCTAAAAATGTATCCCA fwd_p53_Y163C_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTACAGTACTCCCCTGCCCTC rev_p53_Y163C_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTGCTGCTCACCATCGCTATCT fwd_p53_N239D_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCCTCATCTTGGGCCTGTGTT rev_p53_N239D_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTAAATCGGTAAGAGGTGGGCC fwd_APOE4_C158R_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGCGGACATGGAGGACGTG rev_APOE4_C158R_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTCTGTTCCACCAGGGGCCC fwd_EMX1_off1_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTGCCCAATCATTGATGCTTTT rev_EMX1_off1_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTAGAAACATTTACCATAGACTATCACCT fwd_EMX1_off2_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNAGTAGCCTCTTTCTCAATGTGC rev_EMX1_off2_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTGCTTTCACAAGGATGCAGTCT fwd_EMX1_off3_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGAGCTAGACTCCGAGGGGA rev_EMX1_off3_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTTCCTCGTCCTGCTCTCACTT fwd_EMX1_off4_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNAGAGGCTGAAGAGGAAGACCA rev_EMX1_off4_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTGGCCCAGCTGTGCATTCTAT fwd_EMX1_off6_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCCAAGAGGGCCAAGTCCTG rev_EMX1_off6_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTCAGCGAGGAGTGACAGCC fwd_EMX1_off7_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCACTCCACCTGATCTCGGGG rev_EMX1_off7_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTCGAGGAGGGAGGGAGCAG fwd_EMX1_off8_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNACCACAAATGCCCAAGAGAC rev_EMX1_off8_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTGACACAGTCAAGGGCCGG fwd_EMX1_off9_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCCCACCTTTGAGGAGGCAAA rev_EMX1_off9_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTTTCCATCTGAGAAGAGAGTGGT fwd_EMX1_off10_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGTCATACCTTGGCCCTTCCT rev_EMX1_off10_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTTCCCTAGGCCCACACCAG fwd_FANCF_off1_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNAACCCACTGAAGAAGCAGGG rev_FANCF_off1_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTGGTGCTTAATCCGGCTCCAT fwd_FANCF_off2_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTCCAGTGTTTCCATCCCGAA rev_FANCF_off2_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTCCTCTGACCTCCACAACTCT fwd_FANCF_off3_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTTTNNNNCTGGGTACAGTTCTGCGTGT rev_FANCF_off3_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTTCACTCTGAGCATCGCCAAG fwd_FANCF_off4_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGGTTTAGAGCCAGTGAACTAGAG rev_FANCF_off4_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTGCAAGACAAAATCCTCTTTATACTTTG fwd_FANCF_off5_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGGGAGGGGACGGCCTTAC rev_FANCF_off5_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTGCCTCTGGCGAACATGGC fwd_FANCF_off6_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTCCTGGTTAAGAGCATGGGC rev_FANCF_off6_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTGATTGAGTCCCCACAGCACA fwd_FANCF_off7_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCCAGTGTTTCCCATCCCCAA rev_FANCF_off7_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTTGACCTCCACAACTGGAAAAT fwd_FANCF_off8_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGCTTCCAGACCCACCTGAAG rev_FANCF_off8_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTACCGAGGAAAATTGCTTGTCG fwd_HEK293_site2_ ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGTGTGGAGAGTGAGTAAGCCA off1_HTS rev_HEK293_site2_ TGGAGTTCAGACGTGTGCTCTTCCGATCTACGGTAGGATGATTTCAGGCA off1_HTS fwd_HEK293_site2_ ACACTCTTTCCCTACACGACgCTCTTCCGATCTNNNNCACAAAGCAGTGTAGCTCAGG off2_HTS rev_HEK293_site2_ TGGAGTTCAGACGTGTGCTCTTCCGATCTTTTTTGGTACTCGAGTGTTATTCAG off2_HTS fwd_HEK293_site3_ ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTCCCCTGTTGACCTGGAGAA off1_HTS rev_HEK293_site3_ TGGAGTTCAGACGTGTGCTCTTCCGATCTCACTGTACTTGCCCTGACCA off1_HTS fwd_HEK293_site3_ ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTTGGTGTTGACAGGGAGCAA off2_HTS rev_HEK293_site3_ TGGAGTTCAGACGTGTGCTCTTCCGATCTCTGAGATGTGGGCAGAAGGG off2_HTS fwd_HEK293_site3_ ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTGAGAGGGAACAGAAGGGCT off3_HTS rev_HEK293_site3_ TGGAGTTCAGACGTGTGCTCTTCCGATCTGTCCAAAGGCCCAAGAACCT off3_HTS fwd_HEK293_site3_ ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTCCTAGCACTTTGGAAGGTCG off4_HTS rev_HEK293_site3_ TGGAGTTCAGACGTGTGCTCTTCCGATCTGCTCATCTTAATCTGCTCAGCC off4_HTS fwd_HEK293_site3_ ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNAAAGGAGCAGCTCTTCCTGG off5_HTS rev_HEK293_site3_ TGGAGTTCAGACGTGTGCTCTTCCGATCTGTCTGCACCATCTCCCACAA off5_HTS fwd_HEK293_site4_ ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGGCATGGCTTCTGAGACTCA off1_HTS rev_HEK293_site4_ TGGAGTTCAGACGTGTGCTCTTCCGATCTGTCTCCCTTGCACTCCCTGTCTTT off4_HTS fwd_HEK293_site4_ ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTTTGGCAATGGAGGCATTGG off2_HTS rev_HEK293_site4_ TGGAGTTCAGACGTGTGCTCTTCCGATCTGAAGAGGCTGCCCATGAGAG off2_HTS fwd_HEK293_site4_ ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGGTCTGAGGCTCGAATCCTG off3_HTS rev_HEK293_site4_ TGGAGTTCAGACGTGTGCTCTTCCGATCTCTGTGGCCTCCATATCCCTG off3_HTS fwd_HEK293_site4_ ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTTTCCACCAGAACTCAGCCC off4_HTS rev_HEK293_site4_ TGGAGTTCAGACGTGTGCTCTTCCGATCTCCTCGGTTCCTCCACAACAC off4_HTS fwd_HEK293_site4_ ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCACGGGAAGGACAgGAGAAC off5_HTS rev_HEK293_site4_ TGGAGTTCAGACGTGTGCTCTTCCGATCTGCAGGGGAGGGATAAAGCAG off5_HTS fwd_HEK293_site4_ ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCCACGGGAGATGGCTTATGT off6_HTS rev_HEK293_site4_ TGGAGTTCAGACGTGTGCTCTTCCGATCTCACATCCTCACTGTGCCACT off6_HTS fwd_HEK293_site4_ ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGTCAGTCTCGGCCCCTCA off7_HTS rev_HEK293_site4_ TGGAGTTCAGACGTGTGCTCTTCCGATCTGCCACTGTAAAGCTCTTGGG off7_HTS fwd_HEK293_site4_ ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNAGGGTAGAGGGACAGAGCTG off8_HTS rev_HEK293_site4_ TGgAGTTCAGACGTGTGCTCTTCCGATCTGGACCCCACATAGTCAGTGC off8_HTS fwd_HEK293_site4_ ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGCTGTCAGCCCTATCTCCATC off9_HTS rev_HEK293_site4_ TGGAGTTCAGACGTGTGCTCTTCCGATCTTGGGCAATTAGGACAGGGAC off9_HTS fwd_HEK293_site4_ ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGCAGCGGAGGAGGTAGATTG off10_HTS rev_HEK293_site4_ TGGAGTTCAGACGTGTGCTCTTCCGATCTCTCAGTACCTGGAGTCCCGA off10_HTS fwd_HEK2_ChIP_off1_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGACAGGCTCAGgAAAGCTGT rev_HEK2_ChIP_off1_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTACACAAGCCTTTCTCCAGGG fwd_HEK2_ChIP_off2_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNAATAGGGGGTGAGACTGGGG rev_HEK2_ChIP_off2_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTGCCTCAGACGAGACTTGAGG fwd_HEK2_ChIP_off3_HTS ACAGTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGGCCAGCAGGAAAGGAATCT rev_HEK2_ChIP_off3_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTTGACTGCACCTGTAGCCATG fwd_HEK2_ChIP_off4_HTS ACACTCTTTCCCTAGACGACGCTCTTCCGATCTNNNNTCAAGGAAATCACCCTGCCC rev_HEK2_ChIP_off4_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTAACTTCCTTGGTGTGCAGCT fwd_HEK2_ChIP_off5_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNATGGGCTCAGCTACGTCATG rev_HEK2 ChIP off5 HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTAATAGCAGTGTGGTGGGCAA fwd_HEK3_ChIP_off1_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCGCACATCCCTTGTCTCTCT rev_HEK3_ChIP_off1_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTCTACTGGAGCACACCCCAAG fwd_HEK3_ChIP_off2_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTGGGTCACGTAGCTTTGGTC rev_HEK3_ChIP_off2_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTTGGTGGCCATGTGCAACTAA fwd_HEK3_ChIP_off3_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCTACTACGTGCCAGCTCAGG rev_HEK3_ChIP_off3_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTACCTCCCCTCCTCACTAACC fwd_HEK3_ChIP_off4_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGCCTCAGCTCCATTTCCTGT rev_HEK3_ChIP_off4_HTS TGAGTTCAGACGTGTGCTCTTCCGATCTAACCTTTATGGCACCAGGGG fwd_HEK3_ChIP_off5_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGAGCTCAGCATTAGCAGGCT rev_HEK3_ChIP_off5_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTTTCCTGGCTTTCCGATTCCC fwd_HEK4_ChIP_off1_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGTGCAATTGGAGGAGGAGCT rev_HEK4_ChIP_off1_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTCACCAGCTACAGGCAGAACA fwd_HEK4_ChIP_off3_HTS ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCCTACCCCCAACACAGATGG rev_HEK4_ChIP_off3_HTS TGGAGTTCAGACGTGTGCTCTTCCGATCTCCACACAACTCAGGTCCTCC

Sequences of single-stranded oligonucleotide donor templates (ssODNs) used in HDR studies.

EMX1 sense (SEQ ID NO: 580)

TCATCTGTGCCCCTCCCTCCCTGGCCCAGGTGAAGGTGTGGTTCCAGAAC CGGAGGACAGTACAAACGGCAGAAGCTGGAGGAGGAAGGGCCTGAGTTTG AGCAGAAGAAGAAGGGCTCCCATCACATCAACCGGTGGCGCATTGCCACG AAGCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACTAGGGT EMX1 antisense (SEQ ID NO: 581)

ACCCTAGTCATTGGAGGTGACATCGATGTCCTCCCCATTGGCCTGCTTCG TGGCAATGCGCCAGCGGTTGATGTGATGGGAGCCCTTCTTCTTCTGCTCA AACTGAGGCCGTTGCTCCTCCAGCTTCTGCCGTTTGTACTTTGTCCTCCG GTTCTGGAACCACACCTTCACCTGGGCCAGGGAGGGAGGGGCACAGATGA HEK293 site 3 sense (SEQ ID NO: 582)

CATGCAATTAGTCTATTTCTGCTGCAAGTAAGCATGCATTTGTAGGCTT GATGCTTTTTTTCTGCTTCTCCAGCCCTGGCCTGGGTCAATCCTTGGGG CTTAGACTGAGCACGTGATGGCAGAGGAAAGGAAGCCCTGCTTCCTCCA GAGGGCGTCGCAGGACAGCTTTTCCTAGACAGGGGCTAGTATGTGCAGC TCCT HEK293 site 3 antisense (SEQ ID NO: 583)

AGGAGCTGCACATACTAGCCCCTGTCTAGGAAAAGCTGTCCTGCGACGC CCTGTGGAGGAAGCAGGGCTTCCTTTCCTCTGCCATCACGTGCTCAGTC TAAGCCCCAAGGATTGACCCAGGCCAGGGCTGGAGAAGCAGAAAAAAAG CATCAAGCCTACAAATGCATGCTACTTGCAGCAGAAATAGACTAATTGC ATG HEK site 4 sense (SEQ ID NO: 584)

GGCTGACAAAGGCCGGGCTGGGTGGAAGGAAGGGAGGAAGGGCGAGGCA GAGGGTCCAAAGCAGGATGACAGGCAGGGGCACCGCGGCGCCCCGGTGG CATTGCGGCTGGAGGTGGGGGTTAAAGCGGAGACTCTGGTGCTGTGTGA CTACAGTGGGGGCCCTGCCCTCTCTGAGCCCCCGCCTCCAGGCCTGTGT GTGT HEK site 4 antisense (SEQ ID NO: 585)

ACACACACAGGCCTGGAGGCGGGGGCTCAGAGAGGGCAGGGCCCCCACT GTAGTCACACAGCACCAGAGTCTCCGCTTTAACCCCCACCTCCAGCCGC AATGCCACCGGGGCGCCGCGGTGCCCCTGCCTGTCATCCTGCTTTGGAC CCTCTGCCTCGCCCTTCCTCCCTTCCTTCCACCCAGCCCGGCCTTTGTC AGCC APOE4 sense (SEQ ID NO: 743)

AGCACCGAGGAGCTGCGGGTGCGCCTCGCCTCCCACCTGCGCAAGCTGCG TAAGCGGCTCCTCCGCGATGCCGATGACCTGCAGAAGTGCCTGGCAGTGT ACCAGGCCGGGGCCCGCGAGGGCGCCGAGCGCGGCCTCAGCGCCATCCGC GAGCGCCTGGGGCCCCTGGTGGAACAGGGCCGCGTGCGGGCCGCCACTGT APOE4 antisense (SEQ ID NO: 744)

ACAGTGGCGGCCCGCACGCGGCCCTGTTCCACCAGGGGCCCCAGGCGCTC GCGGATGGCGCTGAGGCCGCGCTCGGCGCCCTCGCGGGCCCCGGCCTGGT ACACTGCCAGGCACTTCTGCAGGTCATCGGCATCGCGGAGGAGCCGCTTA CGCAGCTTGCGCAGGTGGGAGGCGAGGCGCACCCGCAGCTCCTCGGTGCT p53 Y163C sense (SEQ ID NO: 745)

ACTCCCCTGCCCTCAACAAGATGTTTTGCCAACTGGCCAAGACCTGCCCT GTGCAGCTGTGGGTTGATTCCACACCCCCGCCCGGCACCCGCGTCCGCGC CATGGCCATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAGGCGCT GCCCCCACCATGAGCGCTGCTCAGATAGCGATGGTGAGCAGCTGGGGCTG p53 Y163C antisense (SEQ ID NO: 746)

CAGCCCCAGCTGCTCACCATCGCTATCTGAGCAGCGCTCATGGTGGGGGC AGCGCCTCACAACCTCCGTCATGTGCTGTGACTGCTTGTAGATGGCCATG GCGCGGACGCGGGTGCCGGGCGGGGGTGTGGAATCAACCCACAGCTGCAC AGGGCAGGTCTTGGCCAGTTGGCAAAACATCTTGTTGAGGGCAGGGGAGT

Deaminase gene gBlocks Gene Fragments

hAID (SEQ ID NO: 586)

CATCCTTGGTACCGAGCTCGGATCCAGCCACCATGGATAGCCTCTTGAT GAATAGACGCAAGTTCCTGTATCAGTTTAAAAACGTGAGATGGGCAAAA GGCCGACGAGAGACATATCTGTGCTATGTCGTTAAGCGCAGAGATTCAG CCACCAGTTTCTCTCTCGACTTCGGCTACCTGCGGAACAAGAATGGTTG CCATGTTGAGCTCCTGTTCCTGAGGTATATCAGCGACTGGGATTTGGAC CCAGGGCGGTGCTATAGGGTGACATGGTTTACCTCCTGGTCACCTTGTT ATGACTGCGCGCGGCATGTTGCCGATTTTCTGAGAGGGAACCCTAACCT GTCTCTGAGGATCTTCACCGCGCGACTGTACTTCTGTGAGGACCGGAAA GCCGAACCCGAGGGACTGAGACGCCTCCACAGAGCGGGTGTGCAGATTG CCATAATGACCTTTAAGGACTACTTCTACTGCTGGAACACCTTCGTCGA AAATCACGAGCGGACTTTCATGGCTTGGGAAGGATTGCATGAAAACAGC GTCAGGCTCCAGGCAGCTTCGCCGCATTCTTCTCCCGTTGTACGAGGTT GATGACCTCAGAGATGCCTTTAGAACACTGGGACTGTAGGCGGCCGCTC GATTGGTTTGGTGTGGCTCTAA rAPOBECI (mammalian) (SEQ ID NO: 587)

CATCCTTGGTACCGAGCTCGGATCCAGCCACCATGAGCTCAGAGACTGGC CCAGTGGCTGTGGACCCCACATTGAGACGGCGGATCGAGCCCCATGAGTT TGAGGTATTCTTCGATCCGAGAGAGCTCCGCAAGGAGACCTGCCTGCTTT ACGAAATTAATTGGGGGGGCCGGCACTCCATTTGGCGACATACATCACAG AACACTAACAAGCACGTCGAAGTCAACTTCATCGAGAAGTTCACGACAGA AAGATATTTCTGTCCGAACACAAGGTGCAGCATTACCTGGTTTCTCAGCT GGAGCCCATGCGGCGAATGTAGTAGGGCCATCACTGAATTCCTGTCAAGG TATCCCCACGTCACTCTGTTTATTTACATCGCAAGGCTGTACCACCACGC TGACCCCCGCAATCGACAAGGCCTGCGGGATTTGATCTCTTCAGGTGTGA CTATCCAAATTATGACTGAGCAGGAGTCAGGATACTGCTGGAGAAACTTG TGAATTATAGCCCGAGTAATGAAGCCCACTGGCCTAGGTATCCCCATCTG TGGGTACGACTGTACGTTCTTGAACTGTACTGCATCATACTGGGCCTGCC TCCTTGTCTCAACATTCTGAGAAGGAAGCAGCCACAGCTGACATTCTTTA CCATCGCTCTTCAGTCTTGTCATTACCAGCGACTGCCCCCACACATTCTC TGGGCCACCGGGTTGAAATGAGCGGCCGCTCGATTGGTTTGGTGTGGCTC TAA pmCDA1 (SEQ ID NO: 588)

CATCCTTGGTACCGAGCTCGGATCCAGCCACCATGACAGACGCTGAAT ATGTTAGGATCCATGAAAAACTGGATATCTATACATTTAAGAAGCAGT TCTTCAATAACAAAAAGTCAGTATCTCACAGATGCTATGTCCTGTTCG AACTCAAGAGAAGAGGAGAAAGGCGGGCCTGTTTCTGGGGGTACGCGG TTAATAAACCCCAGTCCGGGACCGAGAGGGGGATTCACGCCGAGATCT TTTCAATTAGGAAGGTTGAAGAGTATCTTCGCGACAATCCCGGTCAGT TCACAATTAACTGGTACAGCTCCTGGAGCCCTTGCGCTGATTGCGCCG AGAAAATACTCGAATGGTACAACCAGGAGTTGAGAGGCAATGGCCACA CTCTCAAGATTTGGGCTTGCAAGCTTTACTACGAGAAGAACGCGAGAA ATCAGATTGGCTTGTGGAACCTCAGGGACAACGGGGTCGGGTTGAATG TTATGGTGTCCGAACATTACCAGTGCTGTAGAAAGATCTTCATTCAGT CCAGTCACAATCAGCTGAACGAGAACAGATGGCTGGAGAAAACACTGA AACGGGCAGAGAAAAGGCGCTCAGAGCTGAGTATCATGATCCAGGTCA AAATCCTGCATACAACCAAAAGCCCGGCTGTATAAGCGGCCGCTCGAT TGGTTTGGTGTGGCTCTAA haPOBEC3G (SEQ ID NO: 589)

CATCCTTGGTACCGAGCTCGGATCCAGCCACCATGGAGCTGAAGTATCAC CCTGAGATGCGGTTCCACTGGTTTAGTAAGTGGCGCAAACTTCATCGGGA TCAGGAGTATGAAGTGACCTGGTATATCTCTTGGTCTCCCTGCACAAAAT GTACACGCGACATGGCCACATTTCTGGCCGAGGATCCAAAGGTGACGCTC ACAATCTTTGTGGCCCGCCTGTATTATTTCTGGGACCCGGATTATCAGGA GGCACTTAGGTCATTGTGCCAAAAGCGCGACGGACCACGGGCGACTATGA AAATCATGAATTATGACGAATTCCAGCATGCTGGAGTAAGTTGTGTACAG CCAGCGGGAGCTGTTCGAGCCCTGGAACAATCTTCCCAAGTACTACATAC TGCTTCACATTATGTTGGGGGAGATCCTTCGGCACTCTATGGATCCTCCT ACCTACGTTAACTTTAATAATGAGCCTTGGGTTCGCGGGCGCCATGAAAC CTATTTGTGCTACGAGGTCGAGCGGATGCATAATGATACGTGGGTCCTGC TGAATCAGAGGAGGGGGTTTCTGTGTAACCAGGCTCCACATAAACATGGA TTTCTCGAGGGGCGGCACGCCGAACTGTGTTTCCTTGATGTGATACCTTC TGGAAGCTCGACCTTGATCAAGATTACAGGGTGACGTGTTTCACCTCCTG GTCACCCTGCTTCAGTTGCGCCCAAGAGATGGCTAAATTTATCAGTAAGA ACAAGCATGTGTCCCTCTGTATTTTTACAGCCAGAATTTATGATGACCAG GGCCGGTGCCAGGAGGGGCTGCGGACACTCGCTGAGGCGGGCGCGAAGAT CAGCATAATGACATACTCCGAATTCAAACACTGTTGGGACACTTTTGTGG ACCACCAGGGCTGCCCATTTCAGCCGTGGGATGGGCTCGACGAACATAGT CAGGATCTCTCAGGCCGGCTGCGAGCCATATTGCAGAACCAGGAGAATTA GGCGGCCGCTCGATTGGTTTGGTGTGGCTCTAA rAPOBEC1(E. Coli) (SEQ ID NO: 590)

GGCCGGGGATTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATAC CATGGATGTCTTCTGAAACCGGTCCGGTTGCGGTTGACCCGACCCTGCGT CGTCGTATCGAACCGCACGAATTCGAAGTTTTCTTCGACCCGCGTGAAC| TGCGTAAAGAAACCTGCCTGCTGTACGAAATCAACTGGGGTGGTCGTCAC TCTATCTGGCGTCACACCTCTCAGAACACCAACAAACACGTTGAAGTTAA CTTCATCGAAAAATTCACCACCGAACGTTACTTCTGCCCGAACACCCGTT GCTCTATCACCTGGTTCCTGTCTTGGTCTCCGTGCGGTGAATGCTCTCGT GCGATCACCGAATTCCTGTCTCGTTACCCGCACGTTACCCTGTTCATCTA CATCGCGCGTCTGTACCACCACGCGGACCCGCGTAACCGTCAGGGTCTGC GTGACCTGATCTCTTCTGGTGTTACCATCCAGATCATGACCGAACAGGAA TCTGGTTACTGCTGGCGTAACTTCGTTAACTACTCTCCGTCTAACGAAGC GCACTGGCCGCGTTACCCGCACCTGTGGGTTCGTCTGTACGTTCTGGAAC TGTACTGCATCATCCTGGGTCTGCCGCCGTGCCTGAACATCCTGCGTCGT AAACAGCCGCAGCTGACCTTCTTCACCATCGCGCTGCAGTCTTGCCACTA CCAGCGTCTGCCGCCGCACATCCTGTGGGCGACCGGTCTGAAAGGTGGTA GTGGAGGGAGCGGCGGTTCAATGGATAAGAAATAC

Amino Acid Sequences of NBE1, NBE2, and NBE3.

NBE1 for E. Coli expression (His₆-rAPOBEC1-XTEN-dCas9) (SEQ ID NO: 591)

MGSSHHHHHHMSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLL YEINWGGRHSIWRHTSQNTNKHVEVNFIEKFTTERYFCPNTRCSITWFL SWSPCGECSRAITEFLSRYPHVTLFIYARLYHHADPRNRQGLRDLISSG VTIQIMTEQESGYCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIIL GLPPCLNILRRKQPQLIFFTIALQSCHYQRLPPHILWATGLKSGSETPG TSESATPESDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRH SIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEM AKVDDSFFHRLEESFLVEEDK|KHERHPIFGNIVDEVAYHEKYPTIYHL RKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQ LVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNG LFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQ YADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTL LKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKM DGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPF LKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEV VDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYV TEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVE ISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFED REMIEERLKTYAHLFDDKVMKQLKRRRYTGWGWGRLSRKLINGIRDKQS GKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHI ANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKG QKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDM YVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVP SEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQ LVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKD FQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDV RKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNG ETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNS DKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLG ITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRML ASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHK HYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHL FTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRID LSQLGGDSGGSPKKKRKV NBE1 for Mammalian expression (rAPOBEC1-XTEN-dCas9-NLS) (SEQ ID NO: 592)

MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHS IWRHTSQNTNKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSR AITEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQIMTEQ ESGYCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNIL RRKQPQLTFFTIALQSCHYQRLPPHILWATGLKSGSETPGTSESATPES DKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGA LLFDSGETAEAT|RLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFF HRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTD KADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLF EENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALS LGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAK NLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQL PEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVK LNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIE KILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQS FIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAF LSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFN ASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSD GFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKK GILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRI EEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRL SDYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNY WRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHV AQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINN YHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEI GKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGR DFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWD PKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEK NPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNE LALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDDIIEQIS EFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAA FKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGS PKKKRKV Alternative NBE1 for Mammalian expression with human APOBEC1 (hAPOBEC1-XTEN-dCas9-NLS) (SEQ ID NO: 5737)

MTSEKGPSTGDPTLRRRIEPWEFDVFYDPRELRKEACLLYEIKWGMSRKI WRSSGKNTTNHVEVNFIKKFTSERDFHPSMSCSITWFLSWSPCWECSQAI REFLSRHPGVTLVIYVARLFWHMDQQNRQGLRDLVNSGVTIQIMRASEYY HCWRNFVNYPPGDEAHWPQYPPLWMMLYALELHCIILSLPPCLKISRRWQ NHLTFFRLHLQNCHYQTIPPHILLATGLIHPSVAWRGSETPGTSESATPE SDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGA LLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHR LEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKAD LRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENP INASGVDAKAILSARLSKSRRLENLIAQLGEKKNGLFGNLIALSLGLTPN FKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAIL LSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIF FDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRK QRTFDNGSPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYY VGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKN LPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDL LFKTNRKVTVKQLKEDYFKKIECFDSVETSGVEDRFNASLGTYHDLLKII KDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQL KRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDS LTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVM GRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPV ENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDS IDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLT KAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR EVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKY PKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEIT LANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQ TGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEK GKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKY SLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPED NEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKP IREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQS ITGLYETRIDLSQLGGDSGGSPKKKRKV NBE2 (rAPOBEC1-XTEN-dCas9-UGI-NLS) (SEQ ID NO: 593)

MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSI WRHTSQNTNKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAI TEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQIMTEQESG YCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNILRRKQ PQLTFFTIALQSCHYQRLPPHILWATGLKSGSETPGTSESATPESDKKYS IGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSG ETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFL VEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGV DAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNF DLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDIL RVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSK NGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFD NGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLA RGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEK VLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTN RKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDF LDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRY TGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKE DIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKP ENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQL QNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKV LTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERG GLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVI TLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLES EFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANG EIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGF SKESILPKRNSDKUARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKK LKSVKELLGMMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELEN GRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLF VEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAEN IIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYET RIDLSQLGGDSGGSTNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKP ESDILVHTAYDESTDENVMLLTSDAPEYKPWALVIQDSNGENKIKMLSGG SPKKKRKV NBE3 (rAPOBEC1-XTEN-Cas9n-UGI-NLS) (SEQ ID NO: 594)

MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSI WRHTSQNTNKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAI TEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQIMTEQESG YCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNILRRKQ PQLTFFTIALQSCHYQRLPPHILWATGLKSGSETPGTSESATPESDKKYS IGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSG ETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFL VEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGV DAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNF DLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDIL RVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSK NGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFD NGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLA RGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEK VLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTN RKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDF LDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRY TGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKE DIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKP ENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQL QNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKV LTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERG GLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVI TLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLES EFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANG EIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGF SKESILPKRNSDKUARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKK LKSVKELLGMMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELEN GRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLF VEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAEN IIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYET RIDLSQLGGDSGGSTNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKP ESDILVHTAYDESTDENVMLLTSDAPEYKPWALVIQDSNGENKIKMLSGG SPKKKRKV pmCDA1-XTEN-dCas9-UGI (bacteria) (SEQ ID NO: 5742)

MTDAEYVRIHEKLDIYTFKKQFFNNKKSVSHRCYVLFELKRRGERRACFW GYAVNKPQSGTERGIHAEIFSIRKVEEYLRDNPGQFTINWYSSWSPCADC AEKILEWYNQELRGNGHTLKIWACKLYYEKNARNQIGLWNLRDNGVGLNV MVSEHYQCCRKIFIQSSHNQLNENRWLEKTLKRAEKRRSELSIMIQVKIL HTTKSPAVSGSETPGTSESATPESDKKYSIGLAIGTNSVGWAVITDEYKV PSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKN RICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVA YHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPD NSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIA QLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDN LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDE HHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIK PILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQE DFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWN FEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKV KYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDS VEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFE DREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGK TILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANL AGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNS RERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQE LDINRLSDYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVK KMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQI TKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVRE INNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQ EIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKG RDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWD PKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKN PIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELA LPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFS KRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYF DTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSMTNLS DIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDESTDENV MLLTSDAPEYKPWALVIQDSNGENKIKML pmCDA1-XTEN-nCas9-UGI-NLS (mammalian construct) (SEQ ID NO: 5743)

MTDAEYVRIHEKLDIYTFKKQFFNNKKSVSHRCYVLFELKRRGERRACFW GYAVNKPQSGTERGIHAEIFSIRKVEEYLRDNPGQFTINWYSSWSPCADC AEKILEWYNQELRGNGHTLKIWACKLYYEKNARNQIGLWNLRDNGVGLNV MVSEHYQCCRKIFIQSSHNQLNENRWLEKTLKRAEKRRSELSIMIQVKIL HTTKSPAVSGSETPGTSESATPESDKKYSIGLAIGTNSVGWAVITDEYKV PSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKN RICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVA YHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPD NSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIA QLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDN LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDE HHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIK PILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQE DFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWN FEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKV KYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDS VEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFE DREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGK TILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANL AGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNS RERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQE LDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVK KMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQI TKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVRE INNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQ EIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKG RDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWD PKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKN PIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELA LPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFS KRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYF DTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSTNLSD IIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDESTDENVM LLTSDAPEYKPWALVIQDSNGENKIKMLSGGSPKKKRKV huAPOBEC3G-XTEN-dCas9-UGI (bacteria) (SEQ ID NO: 5744)

MDPPTFTFNFNNEPWVRGRHETYLCYEVERMHNDTWVLLNQRRGFLCNQAP HKHGFLEGRHAELCFLDVIPFWKLDLDQDYRVTCFTSWSPCFSCAQEMAKF ISKNKHVSLCIFTARIYDDQGRCQEGLRTLAEAGAKISIMTYSEFKHCWDT FVDHQGCPFQPWDGLDEHSQDLSGRLRAILQSGSETPGTSESATPESDKKY SIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSG ETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLV EEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLAL AHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAK AILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAE DAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTE ITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGY IDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQ IHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAW MTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLY EYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKE DYFKKIECFDSVETSGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILE DIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLIN GIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDS LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTT QKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRD MYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPS EEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVE TRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYK VREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKS EQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDK GRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWD PKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNP IDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALP SKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRV ILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTI DRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSMTNLSDIIEK ETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDESTDENVMLLTSD APEYKPWALVIQDSNGENKIKML huAPOBEC3G-XTEN-nCas9-UGI-NLS (mammalian construct) (SEQ ID NO: 5745)

MDPPTFTFNFNNEPWVRGRHETYLCYEVERMHNDTWVLLNQRRGFLCNQA PHKHGFLEGRHAELCFLDVIPFWKLDLDQDYRVTCFTSWSPCFSCAQEMA KFISKNKHVSLCIFTARIYDDQGRCQEGLRTLAEAGAKISIMTYSEFKHC WDTFVDHQGCPFQPWDGLDEHSQDLSGRLRAILQSGSETPGTSESATPES DKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGAL LFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRL EESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADL RLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPI NASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPN FKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAIL LSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIF FDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRK QRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYY VGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKN LPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDL LFKTNRKVTVKQLKEDYFKKIECFDSVETSGVEDRFNASLGTYHDLLKII KDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQL KRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDS LTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVM GRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPV ENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDS IDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLT KAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR EVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKY PKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEIT LANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQ TGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEK GKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKY SLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPED NEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKP IREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQS ITGLYETRIDLSQLGGDSGGSTNLSDIIEKETGKQLVIQESILMLPEEVE EVIGNKPESDILVHTAYDESTDENVMLLTSDAPEYKPWALVIQDSNGENK IKMLSGGSPKKKRKV huAPOBEC3G (D316R_D317R)-XTEN-nCas9-UGI-NLS (mammalian construct) (SEQ ID NO: 5746)

MDPPTFTFNFNNEPWVRGRHETYLCYEVERMHNDTWVLLNQRRGFLCNQA PHKHGFLEGRHAELCFLDVIPFWKLDLDQDYRVTCFTSWSPCFSCAQEMA KFISKNKHVSLCIFTARIYRRQGRCQEGLRTLAEAGAKISIMTYSEFKHC WDTFVDHQGCPFQPWDGLDEHSQDLSGRLRAILQSGSETPGTSESATPES DKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGAL LFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRL EESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADL RLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPI NASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPN FKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAIL LSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIF FDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRK QRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYY VGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKN LPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDL LFKTNRKVTVKQLKEDYFKKIECFDSVETSGVEDRFNASLGTYHDLLKII KDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQL KRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDS LTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVM GRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPV ENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDS IDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLT KAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR EVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKY PKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEIT LANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQ TGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEK GKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKY SLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPED NEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKP IREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQS ITGLYETRIDLSQLGGDSGGSTNLSDIIEKETGKQLVIQESILMLPEEVE EVIGNKPESDILVHTAYDESTDENVMLLTSDAPEYKPWALVIQDSNGENK IKMLSGGSPKKKRKV

Base Calling Matlab Script

(SEQ ID NO: 595) WTnuc=′GCGGACATGGAGGACGTGCGCGGCCGCCTGGTGCAGTACCGCGGCGAGGTGCAGGCCATGCTCGGC CAGA GCACCGAGGAGCTGCGGGTGCGCCTCGCCTCCCACCTGCGCAAGCTGCGTAAGCGGCTCCTCCGCGATGCCG ATGAC CTGCAGAAGCGCCTGGCAGTGTACCAGGCCGGGGCCCGCGAGGGCGCCGAGCGCGGCCTCAGCGCCATCCGC GAGCG CCTGGGGCCCCTGGTGGAACAG′; %cycle through fastq files for different samples files=dir(*.fastq′); ford=1:20 filename=files(d).name; %read fastq file [header,seqs,qscore]=fastqread(filename); seqsLength=length(seqs); % number of sequences seqsFile= strrep(filename,′.fastq′,″); % trims off .fastq %create a directory with the same name as fastq file ifexist(seqsFile,′dir′); error(Directory already exists. Please rename or move it before moving on.′); end mkdir(seqsFile); % make directory wtLength = length(WTnuc); % length of wildtype sequence %% aligning back to the wildtype nucleotide sequence % % A1N is a matrix of the nucleotide alignment window=1:wtLength; sBLength =length(seqs); % number of sequences % counts number of skips nSkips = 0; ALN=repmat(″,[sBLengthwtLength]); % iterate through each sequencing read for i = 1:sBLength %If you only have forward read fastq files leave as is %If you have R1 foward and R2 is reverse fastq files uncomment the %next four lines of code and the subsequent end statement % ifmod(d,2)==0; % reverse = seqrcomplement(seqs{i}); % [score,alignment,start]= swalign(reverse,WTnuc,′Alphabet′,′NT′); % else [score,alignment,start]=swalign(seqs{i},WTnuc,′Alphabet′,′NT′); % end % length of the sequencing read len= length(alignment(3,:)); % if there is a gap in the alignment, skip = 1 and we will % throwaway the entire read skip = 0; for j = 1:len if (alignment(3,j) == ′-′ || alignment(1,j) == ′-′) skip = 1; break; end %in addition if the qscore for any given base in the read is %below 31 the nucleotide is turned into an N (fastq qscores that are not letters) ifisletter(qscore {i}(start(1)+j-1)) else alignment(1,j) =′N′; end end if skip == 0 && len>10 ALN(i, start(2):(start(2)+Length(alignment)-1))=alignment(1,:); end end % with the alignment matrices we can simply tally up the occurrences of % each nucleotide at each column in the alignment these %tallies ignore bases annotated as N % due to low qscores TallyNTD=zeros(5,wtLength); fori=1:wtLength TallyNTD(:,i)=lsum(ALN(:,i)==′A′),sum(ALN(:,i)==′C′),sum(ALN(:,i)==′G′),sum(A LN(:,i)==′T′),sum(ALN(:,i)==′N′)+ ; end % we then save these tally matrices in the respective folder for % further processing save(strcat(seqsFile,′/TallyNTD′),′TallyNTD′); dlmwrite(strcat(seqsFile,′/TallyNTD.txt′),TallyNTD, ′precision′, ′%.3f,′newline′,′pc′); end

INDEL Detection Matlab Script

(SEQ ID NO: 595) WTnuc=′GCGGACATGGAGGACGTGCGCGGCCGCCTGGTGCAGTACCGCGGCGAGGTGCAGGCCATGCTCGGC  CAGA  GCACCGAGGAGCTGCGGGTGCGCCTCGCCTCCCACCTGCGCAAGCTGCGTAAGCGGCTCCTCCGCGATGCCG  ATGAC  CTGCAGAAGCGCCTGGCAGTGTACCAGGCCGGGGCCCGCGAGGGCGCCGAGCGCGGCCTCAGCGCCATCCGC  GAGCG CCTGGGGCCCCTGGTGGAACAG′;  %cycle through fastq files for different samples files=dir(′*.fastq′);  %specify start and width of indel window as well as length of each flank indelstart+32154;  width=30; flank=10;  ford=1:3  filename=files(d).name;  %read fastq file  [header,seqs,qscore]=fastqread(filename);  seqsLength=length(seqs); % number of sequences seqsFile  =strcat(strrep(filename,′.fastq′,″),′_INDELS′);  %create a directory with the same name as fastq file+_INDELS ifexist(seqsFile,′dir′);  error(Directory already exists. Please rename or move it before moving on.′);  end  mkdir(seqsFile); % make directory  wtLength= length(WTnuc); % length of wildtype sequence sBLength = length(seqs); % number of sequences  % initialize counters and cell arrays  nSkips =0; notliNDEL=;  ins={ };  dels={ }; NumIns=0;  NumDels=0;  % iterate through each sequencing read for i = 1:sBLength  %search for 10BP sequences that should flank both sides of the ″INDEL WINDOW″ windowstart=strfind(seqs {i},WTnuc(indelstart-flank:indelstart));  windowend=strfind(seqs{i},WTnuc(indelstart+width:indelstart+width+flank  ));  %if the flanks are found proceed  iflength(windowstart)==1 &&length(windowend)==1  %if the sequence length matches the INDEL window length save as  %not INDEL  if windowend-windowstart==width+flank notINDEL=notINDEL+1;  %if the sequence is two or more bases longer than the INDEL  %window length save as an Insertion  elseif windowend-windowstart>=width+flank’NumIns=NumIns+1;  ins {NumIns}=seqs{i};  %if the sequence is two or more bases shorter than the INDEL  %window length save as a Deletion  elseif  windowend-windowstart>=width+flank-2 NumDels=NumDels+1;  dels 1 NumDels 1 =seqs{i};  %keep track of skipped sequences that are either one base  %shorter or longer than the INDEL window width else  nSkips=nSkips+1;  end  %keep track of skipped sequences that do not possess matching flank  %sequences else  nSkips=nSkips+1;  end  end  fid=fopen(strcadseqsFile,7summary.txtXwt);  fprintf(fid, ′Skipped reads %An not INDEL %An Insertions %An Deletions  %An′, +nSkips, notINDEL, NumIns, NumDels+); fclose(fid);  save(strcadseqsFile,7nSkips′VnSkips′); save(strcat(seqsFile,′/notINDEL′),′notINDEL′);  save(strcat(seqsFile,′/NumIns′),′NumIns′); save(strcat(seqsFile,′/NumDels′),′NumDels′);  save(strcat(seqsFile,′/dels′),′dels′);  C = dels;  fid = fopen(strcat(seqsFile, ′/dels.txt′), ′wt′);  fprintf(fid, ′″%s″ \n′, C{:1);  fclose(fid);  save(strcat(seqsFile,′/ins′),′ins′); C =ins;  fid = fopen(strcat(seqsFile, ′/ins.txt′), ′wt′);  fprintf(fid, ′″%s″ \n′, C {:1);  fclose(fid);  end 

Example 5 Cas9 Variant Sequences

The disclosure provides Cas9 variants, for example Cas9 proteins from one or more organisms, which may comprise one or more mutations (e.g., to generate dCas9 or Cas9 nickase). In some embodiments, one or more of the amino acid residues, identified below by an asterek, of a Cas9 protein may be mutated. In some embodiments, the D10 and/or H840 residues of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, are mutated. In some embodiments, the D10 residue of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, is mutated to any amino acid residue, except for D. In some embodiments, the D10 residue of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, is mutated to an A. In some embodiments, the H840 residue of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 11-260, is an H. In some embodiments, the H840 residue of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, is mutated to any amino acid residue, except for H. In some embodiments, the H840 residue of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, is mutated to an A. In some embodiments, the D10 residue of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding residue in any of the amino acid sequences provided in SEQ ID NOs: 11-260, is a D.

A number of Cas9 sequences from various species were aligned to determine whether corresponding homologous amino acid residues of D10 and H840 of SEQ ID NO: 10 or SEQ ID NO: 11 can be identified in other Cas9 proteins, allowing the generation of Cas9 variants with corresponding mutations of the homologous amino acid residues. The alignment was carried out using the NCBI Constraint-based Multiple Alignment Tool (COBALT(accessible at st-va.ncbi.nlm.nih.gov/tools/cobalt), with the following parameters. Alignment parameters: Gap penalties −11, −1; End-Gap penalties −5, −1. CDD Parameters: Use RPS BLAST on; Blast E-value 0.003; Find Conserved columns and Recompute on. Query Clustering Parameters: Use query clusters on; Word Size 4; Max cluster distance 0.8; Alphabet Regular.

An exemplary alignment of four Cas9 sequences is provided below. The Cas9 sequences in the alignment are: Sequence 1 (S1): SEQ ID NO: 11|WP_010922251|gi 499224711|type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes]; Sequence 2 (S2): SEQ ID NO: 12|WP_039695303|gi 746743737|type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus gallolyticus]; Sequence 3 (S3): SEQ ID NO: 13|WP_045635197|gi 782887988|type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mitis]; Sequence 4 (S4): SEQ ID NO: 14|AXW_A|gi 924443546|Staphylococcus aureus Cas9. The HNH domain (bold and underlined) and the RuvC domain (boxed) are identified for each of the four sequences. Amino acid residues 10 and 840 in S1 and the homologous amino acids in the aligned sequences are identified with an asterisk following the respective amino acid residue.

S1   1 --MDKK- YSIGLD*IGTNSVGNAVITDEYKVPSKKFKVLGNTDRHSIKKNLI--GALLFDSG--ET AEATRLKRTARRRYT   73 S2   1 --MTKKN YSIGLD*IGTNSVGNAVITDDYKVPAKKMKVLGNTDKKYIKKNLL--GALLFDSG--ET AEATRLKRTARRRYT   74 S3   1 --M-KKG YSIGLD*IGTNSVGFAVITDDYKVPSKKMKVLGNTDKRFIKKNLI--GALLFDEG--TT AEARRLKRTARRRYT   73 S4   1 GSHMKRN YILGLD*IGITSVGYGII--DYET----------------- R DVIDAGVRLFKEANVEN NEGRRSKRGARRLKR   61 S1  74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSDKADLRL  153 S2  75 RRKNRLRYLQEIFANEIAKVDESFFQRLDESFLTDDDKTFDSHPIFGNKAEEDAYHQKPTIYHLRHLADSSEKADLRL  154 S3  74 RRKNRLRYLQEIFSEEMSKVDSSFFWRLDDSFLIPEDKRESKYPIFATLTEEKEYHKQFPTIYHLRKQLADSKEKTDLRL  153 S4  62 RRRHRIQRVKKLI--------------FDYNLLTD--------------------HSELSGINPYEARVKGLSQKLSEE  107 S1  154 IYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEK  233 S2  155 VYLALAHMIKFRGHFLIEGELNAENTDVQKIFADFVGVYNRTFDDSHLSEITVDVASILTEKISKSRRLENLIKYYPTEK  234 S3  154 IYLALAHMIKYRGHFLYEEAFDIKNNDIQKIFNEFISIYDNTFEGSSLSGQNAQVEAIFTDKISKSAKRERVLKLFPDEK  233 S4  108 FSALLHLAKRRG--------------------VHNVNEVEEDT-------------------------------  131 S1  234 KNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEIT  313 S2  235 KNTLFGNLIALALGLQPNFKTNFKLSEDAKLQFSKDTYEEDLEELLGKIGDDYADLFTSAKNLYDAILLSGILTVDDNST  314 S3  234 STGLFSEFLKLIVGNQADFKKHFDLEDKAPLQFSKDTYDEDLENLLGQIGDDFTDLFVSAKKLYDAILLSGILTVTDPST  313 S4  132 -----GNELS-------------------TKEQISRN--------------------------------  144 S1  314 KAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEEM--DGTEELLV  391 S2  315 KAPLSASMIKRYVEHHEDLEKLKEFIKANKSELYHDIFKDKNKNGYAGYIEGVKQDEFYKYLKNILSKIKIDGSDYFLD  394 S3  314 KAPLSASMIERYENHQNDLAALKQFIKNNLPEKYDEVFSDQSKDGYAGYIDGKTTQETFYKYIKNLLSKF--EGTDYFLD  391 S4  145 ----SKALEEKYVAELQ----------------------------------------------LERLKKDG------  165 S1  392 KLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEE  471 S2  395 KIEREDFLRKQRTFDNGSIPHQIHLQEMHAILRRQGDYYPFLKEKQDRIEKILTFRIPYYVGPLVRKDSRFAWAEYRSDE  474 S3  392 KIEREDFLRKQRTFDNGSIPHQIHLQEMNAILRRQGEYYPFLKDNKEKIEKILTFRIPYYVGPLARGNRDFAWLTRNSDE  471 S4  166 --EVRGSINRFKTSD--------YVKEAKQLLKVQKAYHQLDQSFIDTYIDLLETRRTYYEGP--GEGSPFGW------K  227 S1  472 TITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGRKPAFLSGEQKKAIVDL  551 S2  475 KITPWNFDKVIDKEKSAEKFITRMTLNDLYLPEEKVLPKHSHVYETYAVYNELTKIKYVNEQGKE-SFFDSNMKQEIFDH  553 S3  472 AIRPWNFEEIVDKASSAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIAEGLRDYQFLDSGQKKQIVNQ  551 S4  228 DIKEW---------------YEMLMGHCTYFPEELRSVKYAYNADLYNALNDLNNLVITRDENEK---LEYYEKFQIIEN  289 S1  552 LFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDR---FNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVILTLTLFED  628 S2  554 VFKENRKVTKEKLLNYLNKEFPEYRIKDLIGLDKENKSFNASLGTYHDLKKIL-DKAFLDDKVNEEVIEDIIKTLTLFED  632 S3  552 LFKENRKVTEKDIIHYLHN-VDGYDGIELKGIEKQ---FNASLSTYHDLLKIIKDKEFMDDADNEAIIENIVHTLTIFED  627 S4  290 VFKQKKKPTLKQIAKEILVNEEDIKGYRVTSTGKPEF---TNLKVYHDIKDITARKEII---ENAELLDQIAKILTIYQS  363 S1  629 REMIEERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDKQSGTILDFLKSDGFANRNFMQLIHDDSLTFKED  707 S2  633 KDMIHERLQKYSDIFTANQLKKLER-RHYTGWGRLSYKLINGIRNKENNKTILDYLIDDGSANRNFMQLINDDTLPFKQI  711 S3  628 REMIKQRLAQYDSLFDEKVIKALTR-RHYTTWTKLSAKLINGICDKQTGNTILDYLIDDGKINRNFMQLINDDGLSFKEI  706 S4  364 SEDIQEELTNLSELTQEEIEQISNLKGYGYHNLSLKAINLILDE------LWHTNDNQIAIFNRLKLVP---------  428 S1  708

 781 S2  712

 784 S3  707

 779 S4  429

 505 S1  782 KRIEEGIKELGSQIL--------KEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSD----YDVDH*IVPQSFLKDO  850 S2  785 KKLQNSLKELGSNILNEEKPSYIEDKVENSHLQNQLFLYYIQNGKDMYTGDELDIDHLSD----YDIDH*IIFQAFIKDO  860 S3  780 KRIEDSLKILASGL--DSNILKENPTDNNQLQNDRLFLYYLQNGEKDMYTGEALDINQLSS----YDIDE*IIPQAFIKDO  852 S4  506 ERIESIIRTTGK-----------------  570 ENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNNPFNYEVDH*IIPRSVSFDN S1  851

 922 S2  861

 932 S3  853

 924 S4  571

 650 S1  923

1002 S2  933

1012 S3  925

1004 S4  651

 712 S1 1003

1077 S2 1013

183 S3 1005

1081 S4  713

 764 S1 1078

1149 S2 1084

1158 S3 1082

1156 S4  765

 835 S1 1150 EKGKSKKLKSVKELLGITIMERSSFEKNPI-DFLEAKG-----YKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKG 1223 S2 1159 EKGKAKKLKTVKELVGISIMERSFFEENPV-EFLENKG-----YHNIREDKLIKLPKYSLFEFEGGRRRLLASAELQKG 1232 S3 1157 EKGKAKKLKTVKTLVGITIMEKAAFEENPI-TFLENKG-----YHNVRKENILCLPKYSLFELENGRRLLASAKELQKG 1230 S4  836 DPQTYQKLK--------LIMEQYGDEKNPLYKYYEETGNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSARNKV  907 S1 1224 NELALPSKLYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKH------ 1297 S2 1233 NEMVLPGYLVELLYHAHRADNF-----NSTEYLNYVSEHKKEFEKVLSCVEDFANLYVDVEKNLSKIRAVADSM------ 1301 S3 1231 NEIVLPVYLTTLLYHSKNVHKL-----DEPGHLEYIQKHRNEFKDLLNLVSEFSQKYVLADANLEKIKSLYADN------ 1299 S4  908 VKLSLKPYRFD-VYLDNGVYKFV-----TVKNLDVIK--KENYYEVNSKAYEEAKKLKKISNQAEFIASFYNNDLIKING  979 S1 1298 RDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSIT--------GLYETRI----DLSQL 1365 S2 1302 DNFSIEEISNSFINLTLTALGAPADFNFLGEKIPRKRYTSTKECLNATLIHQSIT--------GLYETRI----DLSKL 1369 S3 1300 EQADIEILANSFINLLTFTALGAPAAFKFFGKDIDRKRYTTVSEILNATLIHQSIT--------GLYETWI----DLSKL 1367 S4  980 ELYRVIGVNNDLLNRIEVNMIDITYR-EYLENMNDKPPRIIKTIASKT---QSIKKYSTDILGNLYEVSKKHPQIIKK 1055 S1 1366 GGD 1368 S2 1370 GEE 1372 S3 1368 GED 1370 S4 1056 G-- 1056

The alignment demonstrates that amino acid sequences and amino acid residues that are homologous to a reference Cas9 amino acid sequence or amino acid residue can be identified across Cas9 sequence variants, including, but not limited to Cas9 sequences from different species, by identifying the amino acid sequence or residue that aligns with the reference sequence or the reference residue using alignment programs and algorithms known in the art. This disclosure provides Cas9 variants in which one or more of the amino acid residues identified by an asterisk in SEQ ID NOs: 11-14 (e.g., S1, S2, S3, and S4, respectively) are mutated as described herein. The residues D10 and H840 in Cas9 of SEQ ID NO: 10 that correspond to the residues identified in SEQ ID NOs: 11-14 by an asterisk are referred to herein as “homologous” or “corresponding” residues. Such homologous residues can be identified by sequence alignment, e.g., as described above, and by identifying the sequence or residue that aligns with the reference sequence or residue. Similarly, mutations in Cas9 sequences that correspond to mutations identified in SEQ ID NO: 10 herein, e.g., mutations of residues 10, and 840 in SEQ ID NO: 10, are referred to herein as “homologous” or “corresponding” mutations. For example, the mutations corresponding to the D10A mutation in SEQ ID NO: 10 or S1 (SEQ ID NO: 11) for the four aligned sequences above are D11A for S2, D10A for S3, and D13A for S4; the corresponding mutations for H840A in SEQ ID NO: 10 or S1 (SEQ ID NO: 11) are H850A for S2, H842A for S3, and H560A for S4.

A total of 250 Cas9 sequences (SEQ ID NOs: 11-260) from different species were aligned using the same algorithm and alignment parameters outlined above. Amino acid residues homologous to residues 10, and 840 of SEQ ID NO: 10 were identified in the same manner as outlined above. The alignments are provided below. The HNH domain (bold and underlined) and the RuvC domain (boxed) are identified for each of the four sequences. Single residues corresponding to amino acid residues 10, and 840 in SEQ ID NO: 10 are boxed in SEQ ID NO: 11 in the alignments, allowing for the identification of the corresponding amino acid residues in the aligned sequences.

WP_010922251.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes] SEQ ID NO: 11 WP_039695303.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus gallolyticus] SEQ ID NO: 12 WP_045635197.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mitis] SEQ ID NO: 13 5AXW_A Cas9, Chain A, Crystal Structure [Staphylococcus Aureus] SEQ ID NO: 14 WP_009880683.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes] SEQ ID NO: 15 WP_010922251.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes] SEQ ID NO: 16 WP_011054416.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes] SEQ ID NO: 17 WP_011284745.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes] SEQ ID NO: 18 WP_011285506.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes] SEQ ID NO: 19 WP_011527619.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes] SEQ ID NO: 20 WP_012560673.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes] SEQ ID NO: 21 WP_014407541.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes] SEQ ID NO: 22 WP_020905136.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes] SEQ ID NO: 23 WP_023080005.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes] SEQ ID NO: 24 WP_023610282.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes] SEQ ID NO: 25 WP_030125963.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes] SEQ ID NO: 26 WP_030126706.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes] SEQ ID NO: 27 WP_031488318.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes] SEQ ID NO: 28 WP_032460140.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes] SEQ ID NO: 29 WP_032461047.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes] SEQ ID NO: 30 WP_032462016.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes] SEQ ID NO: 31 WP_032462936.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes] SEQ ID NO: 32 WP_032464890.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes] SEQ ID NO: 33 WP_033888930.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes] SEQ ID NO: 34 WP_038431314.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes] SEQ ID NO: 35 WP_038432938.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes] SEQ ID NO: 36 WP_038434062.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pyogenes] SEQ ID NO: 37 BAQ51233.1 CRISPR-associated protein, Csn1 family [Streptococcus pyogenes] SEQ ID NO: 38 KGE60162.1 hypothetical protein MGAS2111_0903 [Streptococcus pyogenes MGAS2111] SEQ ID NO: 39 KGE60856.1 CRISPR-associated endonuclease protein [Streptococcus pyogenes SS1447] SEQ ID NO: 40 WP_002989955.1 MULTISPECIES: type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus] SEQ ID NO: 41 WP_003030002.1 MULTISPECIES: type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus] SEQ ID NO: 42 WP_003065552.1 MULTISPECIES: type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus] SEQ ID NO: 43 WP_001040076.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 44 WP_001040078.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 45 WP_001040080.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 46 WP_001040081.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 47 WP_001040083.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 48 WP_001040085.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 49 WP_001040087.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 50 WP_001040088.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 51 WP_001040089.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 52 WP_001040090.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 53 WP_001040091.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 54 WP_001040092.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 55 WP_001040094.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 56 WP_001040095.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 57 WP_001040096.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 58 WP_001040097.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 59 WP_001040098.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 60 WP_001040099.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 61 WP_001040100.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 62 WP_001040104.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 63 WP_001040105.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 64 WP_001040106.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 65 WP_001040107.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 66 WP_001040108.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 67 WP_001040109.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 68 WP_001040110.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 69 WP_015058523.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 70 WP_017643650.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 71 WP_017647151.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 72 WP_017648376.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 73 WP_017649527.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 74 WP_017771611.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 75 WP_017771984.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 76 CFQ25032.1 CRISPR-associated protein [Streptococcus agalactiae] SEQ ID NO: 77 CFV16040.1 CRISPR-associated protein [Streptococcus agalactiae] SEQ ID NO: 78 KLJ37842.1 CRISPR-associated protein Csn1 [Streptococcus agalactiae] SEQ ID NO: 79 KLJ72361.1 CRISPR-associated protein Csn1 [Streptococcus agalactiae] SEQ ID NO: 80 KLL20707.1 CRISPR-associated protein Csn1 [Streptococcus agalactiae] SEQ ID NO: 81 KLL42645.1 CRISPR-associated protein Csn1 [Streptococcus agalactiae] SEQ ID NO: 82 WP_047207273.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 83 WP_047209694.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 84 WP_050198062.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 85 WP_050201642.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 86 WP_050204027.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 87 WP_050881965.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 88 WP_050886065.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus agalactiae] SEQ ID NO: 89 AHN30376.1 CRISPR-associated protein Csn1 [Streptococcus agalactiae 138P] SEQ ID NO: 90 EAO78426.1 reticulocyte binding protein [Streptococcus agalactiae H36B] SEQ ID NO: 91 CCW42055.1 CRISPR-associated protein, SAG0894 family [Streptococcus agalactiae ILRI112] SEQ ID NO: 92 WP_003041502.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus anginosus] SEQ ID NO: 93 WP_037593752.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus anginosus] SEQ ID NO: 94 WP_049516684.1 CRISPR-associated protein Csn1 [Streptococcus anginosus] SEQ ID NO: 95 GAD46167.1 hypothetical protein ANG6_0662 [Streptococcus anginosus T5] SEQ ID NO: 96 WP_018363470.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus caballi] SEQ ID NO: 97 WP_003043819.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus canis] SEQ ID NO: 98 WP_006269658.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus constellatus] SEQ ID NO: 99 WP_048800889.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus constellatus] SEQ ID NO: 100 WP_012767106.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus dysgalactiae] SEQ ID NO: 101 WP_014612333.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus dysgalactiae] SEQ ID NO: 102 WP_015017095.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus dysgalactiae] SEQ ID NO: 103 WP_015057649.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus dysgalactiae] SEQ ID NO: 104 WP_048327215.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus dysgalactiae] SEQ ID NO: 105 WP_049519324.1 CRISPR-associated protein Csn1 [Streptococcus dysgalactiae] SEQ ID NO: 106 WP_012515931.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus equi] SEQ ID NO: 107 WP_021320964.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus equi] SEQ ID NO: 108 WP_037581760.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus equi] SEQ ID NO: 109 WP_004232481.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus equinus] SEQ ID NO: 110 WP_009854540.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus gallolyticus] SEQ ID NO: 111 WP_012962174.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus gallolyticus] SEQ ID NO: 112 WP_039695303.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus gallolyticus] SEQ ID NO: 113 WP_014334983.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus infantarius] SEQ ID NO: 114 WP_003099269.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus iniae] SEQ ID NO: 115 AHY15608.1 CRISPR-associated protein Csn1 [Streptococcus iniae] SEQ ID NO: 116 AHY17476.1 CRISPR-associated protein Csn1 [Streptococcus iniae] SEQ ID NO: 117 ESR09100.1 hypothetical protein IUSA1_08595 [Streptococcus iniae IUSA1] SEQ ID NO: 118 AGM98575.1 CRISPR-associated protein Cas9/Csn1, subtype II/NMEMI [Streptococcus iniae SF1] SEQ ID NO: 119 ALF27331.1 CRISPR-associated protein Csn1 [Streptococcus intermedius] SEQ ID NO: 120 WP_018372492.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus massiliensis] SEQ ID NO: 121 WP_045618028.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mitis] SEQ ID NO: 122 WP_045635197.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mitis] SEQ ID NO: 123 WP_002263549.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 124 WP_002263887.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 125 WP_002264920.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 126 WP_002269043.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 127 WP_002269448.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 128 WP_002271977.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 129 WP_002272766.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 130 WP_002273241.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 131 WP_002275430.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 132 WP_002276448.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 133 WP_002277050.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 134 WP_002277364.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 135 WP_002279025.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 136 WP_002279859.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 137 WP_002280230.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 138 WP_002281696.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 139 WP_002282247.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 140 WP_002282906.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 141 WP_002283846.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 142 WP_002287255.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 143 WP_002288990.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 144 WP_002289641.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 145 WP_002290427.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 146 WP_002295753.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 147 WP_002296423.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 148 WP_002304487.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 149 WP_002305844.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 150 WP_002307203.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 151 WP_002310390.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 152 WP_002352408.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 153 WP_012997688.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 154 WP_014677909.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 155 WP_019312892.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 156 WP_019313659.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 157 WP_019314093.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 158 WP_019315370.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 159 WP_019803776.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 160 WP_019805234.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 161 WP_024783594.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 162 WP_024784288.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 163 WP_024784666.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 164 WP_024784894.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 165 WP_024786433.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus mutans] SEQ ID NO: 166 WP_049473442.1 CRISPR-associated protein Csn1 [Streptococcus mutans] SEQ ID NO: 167 WP_049474547.1 CRISPR-associated protein Csn1 [Streptococcus mutans] SEQ ID NO: 168 EMC03581.1 hypothetical protein SMU69_09359 [Streptococcus mutans NLML4] SEQ ID NO: 169 WP_000428612.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus oralis] SEQ ID NO: 170 WP_000428613.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus oralis] SEQ ID NO: 171 WP_049523028.1 CRISPR-associated protein Csn1 [Streptococcus parasanguinis] SEQ ID NO: 172 WP_003107102.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus parauberis] SEQ ID NO: 173 WP_054279288.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus phocae] SEQ ID NO: 174 WP_049531101.1 CRISPR-associated protein Csn1 [Streptococcus pseudopneumoniae] SEQ ID NO: 175 WP_049538452.1 CRISPR-associated protein Csn1 [Streptococcus pseudopneumoniae] SEQ ID NO: 176 WP_049549711.1 CRISPR-associated protein Csn1 [Streptococcus pseudopneumoniae] SEQ ID NO: 177 WP_007896501.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus pseudoporcinus] SEQ ID NO: 178 EFR44625.1 CRISPR-associated protein, Csn1 family [Streptococcus pseudoporcinus SPIN 20026] SEQ ID NO: 179 WP_002897477.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus sanguinis] SEQ ID NO: 180 WP_002906454.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus sanguinis] SEQ ID NO: 181 WP_009729476.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus sp. F0441] SEQ ID NO: 182 CQR24647.1 CRISPR-associated protein [Streptococcus sp. FF10] SEQ ID NO: 183 WP_000066813.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus sp. M334] SEQ ID NO: 184 WP_009754323.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus sp. taxon 056] SEQ ID NO: 185 WP_044674937.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus suis] SEQ ID NO: 186 WP_044676715.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus suis] SEQ ID NO: 187 WP_044680361.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus suis] SEQ ID NO: 188 WP_044681799.1 type II CRISPR RNA-guided endonuclease Cas9 [Streptococcus suis] SEQ ID NO: 189 WP_049533112.1 CRISPR-associated protein Csn1 [Streptococcus suis] SEQ ID NO: 190 WP_029090905.1 type II CRISPR RNA-guided endonuclease Cas9 [Brochothrix thermosphacta] SEQ ID NO: 191 WP_006506696.1 type II CRISPR RNA-guided endonuclease Cas9 [Catenibacterium mitsuokai] SEQ ID NO: 192 AIT42264.1 Cas9hc:NLS:HA [Cloning vector pYB196] SEQ ID NO: 193 WP_034440723.1 type II CRISPR endonuclease Cas9 [Clostridiales bacterium S5-A11] SEQ ID NO: 194 AKQ21048.1 Cas9 [CRISPR-mediated gene targeting vector p(bh5p68-Cas9)] SEQ ID NO: 195 WP_004636532.1 type II CRISPR RNA-guided endonuclease Cas9 [Dolosigranulum pigrum] SEQ ID NO: 196 WP_002364836.1 MULTISPECIES: type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus] SEQ ID NO: 197 WP_016631044.1 MULTISPECIES: type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus] SEQ ID NO: 198 EMS75795.1 hypothetical protein H318_06676 [Enterococcus durans IPLA 655] SEQ ID NO: 199 WP_002373311.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecalis] SEQ ID NO: 200 WP_002378009.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecalis] SEQ ID NO: 201 WP_002407324.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecalis] SEQ ID NO: 202 WP_002413717.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecalis] SEQ ID NO: 203 WP_010775580.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecalis] SEQ ID NO: 204 WP_010818269.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecalis] SEQ ID NO: 205 WP_010824395.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecalis] SEQ ID NO: 206 WP_016622645.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecalis] SEQ ID NO: 207 WP_033624816.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecalis] SEQ ID NO: 208 WP_033625576.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecalis] SEQ ID NO: 209 WP_033789179.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecalis] SEQ ID NO: 210 WP_002310644.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecium] SEQ ID NO: 211 WP_002312694.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecium] SEQ ID NO: 212 WP_002314015.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecium] SEQ ID NO: 213 WP_002320716.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecium] SEQ ID NO: 214 WP_002330729.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecium] SEQ ID NO: 215 WP_002335161.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecium] SEQ ID NO: 216 WP_002345439.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecium] SEQ ID NO: 217 WP_034867970.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecium] SEQ ID NO: 218 WP_047937432.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus faecium] SEQ ID NO: 219 WP_010720994.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus hirae] SEQ ID NO: 220 WP_010737004.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus hirae] SEQ ID NO: 221 WP_034700478.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus hirae] SEQ ID NO: 222 WP_007209003.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus italicus] SEQ ID NO: 223 WP_023519017.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus mundtii] SEQ ID NO: 224 WP_010770040.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus phoeniculicola] SEQ ID NO: 225 WP_048604708.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus sp. AM1] SEQ ID NO: 226 WP_010750235.1 type II CRISPR RNA-guided endonuclease Cas9 [Enterococcus villorum] SEQ ID NO: 227 AII16583.1 Cas9 endonuclease [Expression vector pCas9] SEQ ID NO: 228 WP_029073316.1 type II CRISPR RNA-guided endonuclease Cas9 [Kandleria vitulina] SEQ ID NO: 229 WP_031589969.1 type II CRISPR RNA-guided endonuclease Cas9 [Kandleria vitulina] SEQ ID NO: 230 KDA45870.1 CRISPR-associated protein Cas9/Csn1, subtype II/NMEMI [Lactobacillus animalis] SEQ ID NO: 231 WP_039099354.1 type II CRISPR RNA-guided endonuclease Cas9 [Lactobacillus curvatus] SEQ ID NO: 232 AKP02966.1 hypothetical protein ABB45_04605 [Lactobacillus farciminis] SEQ ID NO: 233 WP_010991369.1 type II CRISPR RNA-guided endonuclease Cas9 [Listeria innocua] SEQ ID NO: 234 WP_033838504.1 type II CRISPR RNA-guided endonuclease Cas9 [Listeria innocua] SEQ ID NO: 235 EHN60060.1 CRISPR-associated protein, Csn1 family [Listeria innocua ATCC 33091] SEQ ID NO: 236 EFR89594.1 crispr-associated protein, Csn1 family [Listeria innocua FSL S4-378] SEQ ID NO: 237 WP_038409211.1 type II CRISPR RNA-guided endonuclease Cas9 [Listeria ivanovii] SEQ ID NO: 238 EFR95520.1 crispr-associated protein Csn1 [Listeria ivanovii FSL F6-596] SEQ ID NO: 239 WP_003723650.1 type II CRISPR RNA-guided endonuclease Cas9 [Listeria monocytogenes] SEQ ID NO: 240 WP_003727705.1 type II CRISPR RNA-guided endonuclease Cas9 [Listeria monocytogenes] SEQ ID NO: 241 WP_003730785.1 type II CRISPR RNA-guided endonuclease Cas9 [Listeria monocytogenes] SEQ ID NO: 242 WP_003733029.1 type II CRISPR RNA-guided endonuclease Cas9 [Listeria monocytogenes] SEQ ID NO: 243 WP_003739838.1 type II CRISPR RNA-guided endonuclease Cas9 [Listeria monocytogenes] SEQ ID NO: 244 WP_014601172.1 type II CRISPR RNA-guided endonuclease Cas9 [Listeria monocytogenes] SEQ ID NO: 245 WP_023548323.1 type II CRISPR RNA-guided endonuclease Cas9 [Listeria monocytogenes] SEQ ID NO: 246 WP_031665337.1 type II CRISPR RNA-guided endonuclease Cas9 [Listeria monocytogenes] SEQ ID NO: 247 WP_031669209.1 type II CRISPR RNA-guided endonuclease Cas9 [Listeria monocytogenes] SEQ ID NO: 248 WP_033920898.1 type II CRISPR RNA-guided endonuclease Cas9 [Listeria monocytogenes] SEQ ID NO: 249 AKI42028.1 CRISPR-associated protein [Listeria monocytogenes] SEQ ID NO: 250 AKI50529.1 CRISPR-associated protein [Listeria monocytogenes] SEQ ID NO: 251 EFR83390.1 crispr-associated protein Csn1 [Listeria monocytogenes FSL F2-208] SEQ ID NO: 252 WP_046323366.1 type II CRISPR RNA-guided endonuclease Cas9 [Listeria seeligeri] SEQ ID NO: 253 AKE81011.1 Cas9 [Plant multiplex genome editing vector pYLCRISPR/Cas9Pubi-H] SEQ ID NO: 254 CUO82355.1 Uncharacterized protein conserved in bacteria [Roseburia hominis] SEQ ID NO: 255 WP_033162887.1 type II CRISPR RNA-guided endonuclease Cas9 [Sharpea azabuensis] SEQ ID NO: 256 AGZ01981.1 Cas9 endonuclease [synthetic construct] SEQ ID NO: 257 AKA60242.1 nuclease deficient Cas9 [synthetic construct] SEQ ID NO: 258 AK540380.1 Cas9 [Synthetic plasmid pFC330] SEQ ID NO: 259 4UN5_B Cas9, Chain B, Crystal Structure SEQ ID NO: 260 WP_010922251 1 MDKK-

--EATRLKRTARRRYT 73 WP_039695303 1 MTKKnYSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKKYIKKNLLGALLFDSGETA--EATRLKRTARRRYT 74 WP_045635197 1 K-KG-YSIGLDIGTNSVGFAVITDDYKVPSKKMKVLGNTDKRFIKKNLIGALLFDEGTTA--EARRLKRTARRRYT 73 5AXW_A 1 MKRN-YILGLDIGITSVGYGII--DYET------------RDVIDA---GVRLFKEANVEnnEGRRSKRGARRLKR 61 WP_009880683 ---------------------------------------------------------------------------- WP_010922251 1 MDKK-YSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 WP_011054416 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKLKGLGNTDRHGIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 WP_011284745 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 WP_011285506 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 WP_011527619 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGEIA--EATRLKRTARRRYT 73 WP_012560673 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 WP_014407541 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFGSGETA--EATRLKRTARRRYT 73 WP_020905136 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 WP_023080005 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKLKVLGNTDRHGIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 WP_023610282 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKLKVLGNTDRHGIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 WP_030125963 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 WP_030126706 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHGIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 WP_031488318 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 WP_032460140 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 WP_032461047 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTERHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 WP_032462016 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTERHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 WP_032462936 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTERHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 WP_032464890 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTERHSIKKNLIGALLFDSGEIA--EATRLKRTARRRYT 73 WP_033888930 ---------------------------------------------------------------------------- WP_038431314 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73  WP_038432938 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 WP_038434062 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 BAQ51233 ---------------------------------------------------------------------------- KGE60162 ---------------------------------------------------------------------------- KGE60856 ---------------------------------------------------------------------------- WP_002989955 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGEIA--EATRLKRTARRRYT 73 WP_003030002 1 MDQK-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKQSIKKNLLGALLFDSGETA--EATRLKRTARRRYT 73 WP_003065552 1 MTKKnYSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKKYIKKNLLGALLFDSGETA--EATRLKRTARRRYT 74 WP_001040076 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKIRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_001040078 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_001040080 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_001040081 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_001040083 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_001040085 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_001040087 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_001040088 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_001040089 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_001040090 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_001040091 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_001040092 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_001040094 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_001040095 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_001040096 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_001040097 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_001040098 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_001040099 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_001040100 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_001040104 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_001040105 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTSRRRYT 73 WP_001040106  1 MNKP-YSIGLDIGTNSVGYSVVTDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--SDRRLKRTARRRYT 73 WP_001040107 1 MNKP-YSIGLDIGTNSVGYSVVTDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--SDRRLKRTARRRYT 73 WP_001040108 1 MNKP-YSIGLDIGTNSVGYSVVTDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--SDRRLKRTARRRYT 73 WP_001040109 1 MNKP-YSIGLDIGTNSVGYSVVTDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--SDRRLKRTARRRYT 73 WP_001040110 1 MNKP-YSIGLDIGTNSVGYSVVTDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--SDRRLKRTARRRYT 73 WP_015058523 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_017643650 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_017647151 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--SDRRLKRTARRRYT 73 WP_017648376 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--SDRRLKRTARRRYT 73 WP_017649527 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_017771611 1 MNKP-YSIGLDIGTNSVGYSVVTDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--SDRRLKRTARRRYT 73 WP_017771984 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 CFQ25032 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 CFV16040 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 KLJ37842 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 KLJ72361 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 KLL20707 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 KLL42645 1 MNKP-YSIGLDIGTNSVGYSVVTDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--SDRRLKRTARRRYT 73 WP_047207273 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGRNTA--ADRRLKRTARRRYT 73 WP_047209694 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_050198062 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_050201642 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_050204027 1 MNKP-YSIGLDIGTNSVGYSVVTDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--SDRRLKRTARRRYT 73 WP_050881965 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 WP_050886065 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 AHN30376 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 EAO78426 1 MNKP-YSIGXDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRTARRRYT 73 CCW42055 1 MNKP-YSIGLDIGTNSVGWSIITDDYKVPAKKMRVLGNTDKEYIKKNLIGALLFDGGNTA--ADRRLKRIARRRYT 73 WP_003041502 1 MNQK-YSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKQSIKKNLLGALLFDSGETA--EATRLKRTARRRYT 73 WP_037593752 1 MKKE-YSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKQSIKKNLLGALLFDSGETA--EATRLKRTARRRYT 74 WP_049516684 1 MKKE-YSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKQSIKKNLLGALLFDSGETA--EATRLKRTARRRYT 74 GAD46167 1 MKKE-YSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKQSIKKNLLGALLFDSGETA--EATRLKRTARRRYT 73 WP_018363470 1 MTKKnYSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKKYIKKNLLGALLFDSGETA--EATRLKRTARRRYT 74 WP_003043819 1 MEKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTNRKSIKKNLMGALLFDSGETA--EATRLKRTARRRYT 73 WP_006269658 1 MGKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKQSIKKNLLGALLFDSGETA--EATRLKRTARRRYT 73 WP_048800889 1 MTQK-YSIGLDIGTNSVGWAIVTDDYKVPAKKMKILGNTNKQYIKKNLLGALLFDSGETA--KATRLKRTARRRYT 73 WP_012767106 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 WP_014612333 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 WP_015017095 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 WP_015057649 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 WP_048327215 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 WP_049519324 1 MDKK-YSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 WP_012515931 1 MKKP-YTIALDIGTNSVGWVVVTDDYRVPTKKMKVLGNTERKTIKKNLIGALLFDSGETA--EGTRLKRTARRRYT 73 WP_021320964 1 MKKP-YTIALDIGTNSVGWVVVTDDYRVPTKKMKVLGNTERKTIKKNLIGALLFDSGETA--EGTRLKRTARRRYT 73 WP_037581760 1 MKKP-YTIALDIGTNSVGWVVVTDDYRVPTKKMKVLGNTERKTIKKNLIGALLFDSGETA--EGTRLKRTARPRYT 73 WP_004232481 1 M-EKtYSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKKYIKKNLLGALLFDSGETA--EATRLKRAARRRYT 73 WP_009854540 1 MTKKnYSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKKYIKKNLLGALLFDSGETA--EATRLKRTARRRYT 74 WP_012962174 1 MTEKnYSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKKYIKKNLLGALLFDNGETA--EATRLKRTARRRYT 74 WP_039695303 1 MTKKnYSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKKYIKKNLLGALLFDSGETA--EATRLKRTARRRYT 74 WP_014334983 1 M-EKsYSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTDKKYIKKNLLGALLFDSGETA--EVTRLKRTARRRYT 73 WP_003099269 1 MRKP-YSIGLDIGTNSVGWAVITDDYKVPSKKMRIQGTTDRTSIKKNLIGALLFDNGETA--EATRLKRTTRRRYT 73 AHY15608 1 MRKP-YSIGLDIGTNSVGWAVITDDYKVPSKKMRIQGTTDRTSIKKNLIGALLFDNGETA--EATRLKRTTRRRYT 73 AHY17476 1 MRKP-YSIGLDIGTNSVGWAVITDDYKVPSKKMRIQGTTDRTSIKKNLIGALLFDNGETA--EATRLKRTTRRRYT 73 ESR09100 ---------------------------------------------------------------------------- AGM98575 1 MRKP-YSIGLDIGTNSVGWAVITDDYKVPSKKMRIQGTTDRTSIKKNLIGALLFDNGETA--EATRLKRTTRRRYT 73 ALF27331 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_018372492 1 MKKP-YSIGLDIGTNSVGWAVVMEDYKVPSKKMKVLGNTDKQSIKKNLIGALLFDSGETAv--ERRLNRTTSRRYD 73 WP_045618028 1 NNKP-YSIGLDIGTNSVGWAVITDDYKVPSKKMKVLGNTDKHFIKKNLLGALLFDEGTTA--EDRRLKRTARRRYT 74 WP_045635197 1 K-KG-YSIGLDIGTNSVGFAVITDDYKVPSKKMKVLGNTDKRFIKKNLIGALLFDEGTTA--EARRLKRTARRRYT 73 WP_002263549 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIEKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_002263887 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIEKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_002264920 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_002269043 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_002269448 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_002271977 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_002272766 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_002273241 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_002275430 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--ADRRLKRTARRRYT 73 WP_002276448 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_002277050 1 MKKS-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_002277364 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--ADRRLKRTARRRYT 73 WP_002279025 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIEKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_002279859 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_002280230 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--ADRRLKRTARRRYT 73 WP_002281696 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--ADRRLKRTARRRYT 73 WP_002282247 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_002282906 1 MKKP-YSIGLDIGTNSVGWSVVTDDYKVPAKKMKVLGNTDKSHIEKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_002283846 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_002287255 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVSAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_002288990 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_002289641 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTTRRRYT 73 WP_002290427 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_002295753 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_002296423 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_002304487 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_002305844 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_002307203 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_002310390 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_002352408 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_012997688 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--ADRRLKRTARRRYT 73 WP_014677909 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPDKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_019312892 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--ADRRLKRTARRRYT 73 WP_019313659 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIEKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_019314093 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_019315370 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_019803776 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIEKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_019805234 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_024783594 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIEKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_024784288 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTARRRYT 73 WP_024784666 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--ADRRLKRTARRRYT 73 WP_024784894 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTTRRRYT 73 WP_024786433 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--ADRRLKRTARRRYT 73 WP_049473442 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--ADRRLKRTARRRYT 73 WP_049474547 1 MKKP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--EDRRLKRTTRRRYT 73 EMC03581 1 MDL--------IGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIKKNLLGALLFDSGNTA--ADRRLKRTARRRYT 66 WP_000428612 1 ENKN-YSIGLDIGTNSVGWAVITDDYKVPSKKMKVLGNTDKRFIKKNLIGALLFDEGTTA--EARRLKRTARRRYT 74 WP_000428613 1 ENKN-YSIGLDIGTNSVGWSVITDDYKVPSKKMKVLGNTDKRFIKKNLIGALLFDEGTTA--EARRLKRTARRRYT 74 WP_049523028 1 K-KP-YSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTNKESIKKNLIGALLFDAGNTA--ADRRLKRTARRRYT 73 WP_003107102 1 --------------------------------MKVLGNTDRQTVKKNMIGTLLFDSGETA--EARRLKRTARRRYT 42 WP_054279288 1 -KKS-YSIGLDIGTNSVGWAVITDDYKVPAKKMKVLGNTSRQSIKKNMIGALLFDEGGPA--ASTRVKRTTRRRYT 75 WP_049531101 1 SNKP-YSIGLDIGTNSVGWAVITDDYKVPSKKMKVLGNTDKHFIKKNLIGALLFDEGTTA--EDRRLKRTARRRYT 74 WP_049538452 1 SNKP-YSIGLDIGTNSVGWVIITDDYKVPSKKMKVLGNTDKHFIKKNLIGALLFDEGTTA--EDRRLKRTARRRYT 74 WP_049549711 1 SNKP-YSIGLDIGTNSVGWAVITDDYKVPSKKMTVLGNTDKHFIKKNLIGALLFDEGTTA--EDRRLKRTARRRYT 74 WP_007896501 1 --YS-YSIGLDIGTNSVGWAVINEDYKVPAKKMTVFGNTDRKTIKKNLLGTVLFDSGETA--QARRLKRTNRRRYT 75 EFR44625 1 -----------------------------------------------MLGTVLFDSGETA--QARRLKRTNRRRYT 27 WP_002897477 1 K-KP-YSIGLDIGTNSVGWAVVTDDYKVPAKKMRVFGDTDRSHIKKNLLGTLLFDDGNTA--ESRRLKRTARRRYT 73 WP_002906454 1 K-KP-YSIGLDIGTNSVGWAVITDDYKVPSKKMKVLGNTDKHFIKKNLIGALLFDEGTTA--EDRRLKRTSRRRYT 73 WP_009729476 1 ENKN-YSIGLDIGTNSVGWSVITDDYKVPSKKMKVLGNTDKHFIKKNLIGALLFDEGTTA--EARRLKRTARRRYT 74 CQR24647 1 MKKP-YSIGLDIGTNSVGWSVVTDDYKVPAKKMKVLGNTDKEYIKKNLIGALLFDSGETA--EATRMKRTARRRYT 73 WP_000066813 1 SNKS-YSIGLDIGTNSVGWAVITDDYKVPSKKMKVLGNTDKHFIKKNLIGALLFDEGTTA--EDRRLKRTARRRYT 74 WP_009754323 1 NNNN-YSIGLDIGTNSVGWAVITDDYKVPSKKMRVLGNTDKRFIKKNLIGALLFDEGTTA--EDRRLKRTARRRYT 74 WP_044674937 1 MKKK-YAIGIDIGTNSVGWSVVTDDYKVPSKKMKVFGNTEKRYIKKNLLGTLLFDEGNTA--ENRRLKRTARRRYT 73 WP_044676715 1 MKKK-YAIGIDIGTNSVGWSVVTDDYKVPSKKMKVFGNTEKRYIKKNLLGTLLFDEGNTA--ENRRLKRTARRRYT 73 WP_044680361 1 MKKK-YAIGIDIGTNSVGWSVVTDDYKVPSKKMKVFGNTEKRYIKKNLLGTLLFDEGNTA--ENRRLKRTARRRYT 73 WP_044681799 1 MKKK-YAIGIDIGTNSVGWSVVTDDYKVPSKKMKVFGNTEKRYIKKNLLGTLLFDEGNTA--ENRRLKRTARRRYT 73 WP_049533112 1 MDQK-YSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKQSIKKNLLGALLFDSGETA--EATRLKRTARRRYT 73 WP_029090905 1 -----------------------------------------------MWGVSLFEAGKTA--AERRGYRSTRRRLN 27 WP_006506696 1 I-VD-YCIGLDLGTGSVGWAVVDMNHRLMKRN------------GKHLWGSRLFSNAETA--ANRRASRSIRRRYN 60 AIT42264 1 MDKK-YSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 WP_034440723 1 -MKN-YTIGLDIGTNSVGWAVIKDDLTLVRKKIKISGNTDKKEVKKNLWGSFLFEQGDTA--QDTRVKRIARRRYE 72 AKQ21048 1 MDKK-YSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 WP_004636532 1 MQKN-YTIGLDIGTNSVGWAVMKDDYTLIRKRMKVLGNTDIKKIKKNFWGVRLFDEGETA--KETRLKRGTRRRYQ 73 WP_002364836 1 MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA--EDRRLKRTARRRIS 73 WP_016631044 1 --------------------------------------------------MRLFEEGHTA--EDRRLKRTARRRIS 24 EMS75795 ---------------------------------------------------------------------------- WP_002373311 1 MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA--EDRRLKRTARRRIS 73 WP_002378009 1 MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA--EDRRLKRTARRRIS 73 WP_002407324 1 MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA--EDRRLKRTARRRIS 73 WP_002413717 1 MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA--EDRRLKRTARRRIS 73 WP_010775580 1 MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA--EDRRLKRTARRRIS 73 WP_010818269 1 MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA--EDRRLKRTARRRIS 73 WP_010824395 1 MKKD-YVIGLDIGSNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA--EDRRLKRTARRRIS 73 WP_016622645 1 MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA--EDRRLKRTARRRIS 73 WP_033624816 1 MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA--EDRRLKRTARRRIS 73 WP_033625576 1 MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA--EDRRLKRTARRRIS 73 WP_033789179 1 MKKD-YVIGLDIGTNSVGWAVMTEDYQLVKKKMPIYGNTEKKKIKKNFWGVRLFEEGHTA--EDRRLKRTARRRIS 73 WP_002310644 1 MKKE-YTIGLDIGTNSVGWSVLTDDYRLVSKKMKVAGNTEKSSTKKNFWGVRLFDEGQTA--EARRSKRTARRRLA 73 WP_002312694 1 MKKE-YTIGLDIGTNSVGWSVLTDDYRLVSKKMKVAGNTEKSSTKKNFWGVRLFDEGQTA--EARRSKRTARRRLA 73 WP_002314015 1 MKKE-YTIGLDIGTNSVGWSVLTDDYRLVSKKMKVAGNTEKSSTKKNFWGVRLFDEGQTA--EARRSKRTARRRLA 73 WP_002320716 1 MKKE-YTIGLDIGTNSVGWSVLTDDYRLVSKKMKVAGNTEKSSTKKNFWGVRLFDEGQTA--EARRSKRTARRRLA 73 WP_002330729 1 MKKE-YTIGLDIGTNSVGWSVLTDDYRLVSKKMKVAGNTEKSSTKKNFWGVRLFDEGQTA--EARRSKRTARRRLA 73 WP_002335161 1 MKKE-YTIGLDIGTNSVGWSVLTDDYRLVSKKMKVAGNTEKSSTKKNFWGVRLFDEGQTA--EARRSKRTARRRLA 73 WP_002345439 1 MKKE-YTIGLDIGTNSVGWSVLTDDYRLVSKKMKVAGNTEKSSTKKNFWGVRLFDEGQTA--EARRSKRTARRRLA 73 WP_034867970 1 MTKD-YTIGLDIGTNSVGWAVLTDDYQLMKRKMSVHGNTEKKKIKKNFWGARLFDEGQTA--EFRRTKRTNRRRLA 73 WP_047937432 1 MKKE-YTIGLDIGTNSVGWSVLTDDYRLVSKKMKVAGNTEKSSTKKNFWGVRLFDEGQTA--EARRSKRTARRRLA 73 WP_010720994 1 MTKD-YTIGLDIGTNSVGWAVLTDDYQLMKRKMSVHGNTEKKKIKKNFWGARLFDEGQTA--EFRRTKRTNRRRLA 73 WP_010737004 1 MTKD-YTIGLDIGTNSVGWAVLTDDYQLMKRKMSVHGNTEKKKIKKNFWGARLFDEGQTA--EFRRTKRTNRRRLA 73 WP_034700478 1 MTKD-YTIGLDIGTNSVGWAVLTDDYQLMKRKMSVHGNTEKKKIKKNFWGARLFDEGQTA--EFRRTKRTNRRRLA 73 WP_007209003 1 MKND-YTIGLDIGTNSVGYSVVTDDYKVISKKMNVFGNTEKKSIKKNFWGVRLFESGQTA--QEARMKRTSRRRIA 73 WP_023519017 1 MEKE-YTIGLDIGTNSVGWAVLTDDYRLVARKMSIQGDSNRKKIKKNFWGARLFEEGKTA--QFRRIKRTNRRRIA 73 WP_010770040 1 MKKE-YTIGLDIGTNSVGWAVLTENYDLVKKKMKVYGNTETKYLKKNLWGVRLFDEGETA--ADRRLKRTTRRRYS 73 WP_048604708 1 MGKE-YTIGLDIGTNSVGWAVLQEDLDLVRRKMKVYGNTEKNYLKKNFWGVDLFDEGMTA--KDTRLKRTTRRRYF 73 WP_010750235 1 MNKA-YTLGLDIGTNSVGWAVVTDDYRLMAKKMPVHSKMEKKKIKKNFWGARLFDEGQTA--EERRNKRATRRRLR 73 AII16583 1 ADKK-YSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 112 WP_029073316 1 NNKI-YNIGLDIGDASVGWAVVDEHYNLLKRH------------GKHMWGSRLFTQANTA--VERRSSRSTRRRYN 65 WP_031589969 1 NNKI-YNIGLDIGDASVGWAVVDEHYNLLKRH------------GKHMWGSRLFTQANTA--VERRSSRSTRRRYN 65 KDA45870 1 LKKD-YSIGLDIGTNSVGHAVVTDDYKVPTKKMKVFGDTSKKTIKKNMLGVLLFNEGQTA--ADTRLKRGARRRYT 74 WP_039099354 1 MSRP-YNIGLDIGTSSIGWSVVDDQSKLVSVR------------GKYGYGVRLYDEGQTA--AERRSFRTTRRRLK 61 AKP02966 1 KEQP-YNIGLDIGTGSVGWAVTNDNYDLLNIK------------KKNLWGVRLFEGAQTA--KETRLNRSTRRRYR 64 WP_010991369 1 MKKP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKIAGDSEKKQIKKNFWGVRLFDEGQTA--ADRRMARTARRRIE 73 WP_033838504 1 MKKP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKIAGDSEKKQIKKNFWGVRLFDEGQTA--ADRRMARTARRRIE 73 EHN60060 1 MKKP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKIAGDSEKKQIKKNFWGVRLFDEGQTA--ADRRMARTARRRIE 76 EFR89594 ---------------------------------------------------------------------------- WP_038409211 1 MRKP-YTIGLDIGTNSVGWAVLTDQYNLVKRKMKVAGSAEKKQIKKNFWGVRLFDEGEVA--AGRRMNRTTRRRIE 73 EFR95520 ---------------------------------------------------------------------------- WP_003723650 1 MKNP-YTIGLDIGTNSVGWAVLTNQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA--VDRRMNRTARRRIE 73 WP_003727705 1 MKNP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA--VDRRMNRTARRRIE 73 WP_003730785 1 MKNP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA--VDRRMNRTARRRIE 73 WP_003733029 1 MKKP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKISGDSEKKQIKKNFWGVRLFEKGETA--AKRRMSRTARRRIE 73 WP_003739838 1 MKNP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDEGETA--ADRRMNRTARRRIE 73 WP_014601172 1 MKNP-YTIGLDIGTNSVGWAVLTNQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA--VDRRMNRTARRRIE 73 WP_023548323 1 MKNP-YTIGLDIGTNSVGWAVLTNQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA--VDRRMNRTARRRIE 73 WP_031665337 1 MKNP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA--VDRRMNRTARRRIE 73 WP_031669209 1 MKKP-YTIGLDIGTNSVGWAVLTDQYDLVKRKMKISGDSEKKQIKKNFWGVRLFEKGETA--AKRRMSRTARRRIE 73 WP_033920898 1 MKNP-YTIGLDIGTNSVGWAVLTNQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA--VDRRMNRTARRRIE 73 AKI42028 1 MKNP-YTIGLDIGTNSVGWAVLTNQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA--VDRRMNRTARRRIE 76 AKI50529 1 MKNP-YTIGLDIGTNSVGWAVLTNQYDLVKRKMKVAGNSDKKQIKKNFWGVRLFDDGQTA--VDRRMNRTARRRIE 76 EFR83390 ---------------------------------------------------------------------------- WP_046323366 1 MKKP-YTIGLDIGTNSVGWAALTDQYDLVKRKMKVAGNSEKKQIKKNLWGVRLVDEGKTA--AHRRVNRTTRRRIE 73 AKE81011 1 ADKK-YSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 89 CUO82355 1 I-VD-YCIGLDLGTGSVGWAVVDMNHRLMKRN------------GKHLWGSRLFSNAETA--ATRRSSRSIRRRYN 64 WP_033162887 1 KDIR-YSIGLDIGTNSVGWAVMDEHYELLKKG------------NHHMWGSRLFDAAEPA--ATRRASRSIRRRYN 65 AGZ01981 1 ADKK-YSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 106 AKA60242 1 MDKK-YSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 AKS40380 1 MDKK-YSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 73 4UN5_B 1 MDKK-YSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA--EATRLKRTARRRYT 77 WP_010922251 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGN

V-DEVAYHEKYPTIY

LRKKLV 143 WP_039695303 75 RRKNRLRYLQEIFANEIAKVDESFFQRLDE-SFLT--DDDKT---F DSHPIFGNKA-EEDAYHQKFPTIYHLRKHLA  144 WP_045635197 74 RRKNRLRYLQEIFSEEMSKVDSSFFHRLDD-SFLI--PEDKR---E SKYPIFATLT-EEKEYHKQFPTIYHLRKQLA 143 5AXW_A 62 RRRHRIQRVKKLLFD---------YNLLTDhSELS----------G --NPYEARVK--------------GLSQKLS 104 WP_009880683 ---------------------------------------------- ------------------------------- WP_010922251 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV 143 WP_011054416 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143 WP_011284745 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV 143 WP_011285506 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV 143 WP_011527619 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV 143 WP_012560673 74 RRKNRICYLQEIFSNEIAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143 WP_014407541 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143 WP_020905136 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV 143 WP_023080005 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143 WP_023610282 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143 WP_030125963 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV 143 WP_030126706 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143 WP_031488318 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143 WP_032460140 74 RRKNRICYLQEIFSNEIAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143 WP_032461047 74 RRKNRICYLQEIFSNEIAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143 WP_032462016 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV 143 WP_032462936 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143 WP_032464890 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV 143 WP_033888930 ---------------------------------------------- ------------------------------- WP_038431314 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143 WP_038432938 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143 WP_038434062 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143 BAQ51233 1 ----------------MAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV 54 KGE60162 ---------------------------------------------- ------------------------------- KGE60856 ---------------------------------------------- ------------------------------- WP_002989955 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV 143 WP_003030002 74 RRRNRLRYLQEIFAEEMNKVDENFFQRLDD-SFLV--DEDKR---G ERHPIFGNIA-AEVKYHDDFPTIYHLRKHLA 143 WP_003065552 75 RRKNRLRYLQEIFAEEMTKVDESFFQRLDE-SFLRwdDDNKK---L GRYPIFGNKA-DVVKYHQEFPTIYHLRKHLA 146 WP_001040076 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKYYHEKFPTIYHLRKELA 143 WP_001040078 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFPTIYHLRKELA 143 WP_001040080 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA 143 WP_001040081 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA 143 WP_001040083 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA 143 WP_001040085 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA 143 WP_001040087 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA 143 WP_001040088 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA 143 WP_001040089 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA 143 WP_001040090 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA 143 WP_001040091 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA 143 WP_001040092 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA 143 WP_001040094 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATMQ-EEKYYHEKFPTIYHLRKELA 143 WP_001040095 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATMQ-EEKYYHEKFPTIYHLRKELA 143 WP_001040096 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATMQ-EEKYYHEKFPTIYHLRKELA 143 WP_001040097 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATMQ-EEKYYHEKFPTIYHLRKELA 143 WP_001040098 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATMQ-EEKYYHEKFPTIYHLRKELA 143 WP_001040099 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATMQ-EEKYYHEKFPTIYHLRKELA 143 WP_001040100 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATMQ-EEKYYHEKFPTIYHLRKELA 143 WP_001040104 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYXIFATLQ-EEKDYHEKFSTIYHLRKELA 143 WP_001040105 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA 143 WP_001040106 74 CRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EDDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA 143 WP_001040107 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EDDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA 143 WP_001040108 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EDDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA 143 WP_001040109 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EDDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA 143 WP_001040110 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EDDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA 143 WP_015058523 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA 143 WP_017643650 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATMQ-EEKYYHEKFPTIYHLRKELA 143 WP_017647151 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EDDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA 143 WP_017648376 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EDDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA 143 WP_017649527 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFPTIYHLRKELA 143 WP_017771611 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EDDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA 143 WP_017771984 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA 143 CFQ25032 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA 143 CFV16040 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA 143 KLJ37842 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA 143 KLJ72361 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA 143 KLL20707 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA 143 KLL42645 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EDDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA 143 WP_047207273 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA 143 WP_047209694 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATMQ-EEKYYHEKFPTIYHLRKELA 143 WP_050198062 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA 143 WP_050201642 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA 143 WP_050204027 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EDDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA 143 WP_050881965 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA 143 WP_050886065 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA 143 AHN30376 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATMQ-EEKDYHEKFPTIYHLRKELA 143 EAO78426 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFSTIYHLRKELA 143 CCW42055 74 RRRNRILYLQEIFAEKMSKVDDSFFHRLED-SFLV--EEDKR---G SKYPIFATLQ-EEKDYHEKFPTIYHLRKELA 143 WP_003041502 74 RRRNRLRYLQEIFAEEMMQVDESFFQRLDD-SFLV--DEDKR---G ERHPIFGNIA-AEVKYHDEFPTIYHLRKHLA 143 WP_037593752 75 RRKNRLRYLQEIFTEEMNKVDENFFQRLDD-SFLV--EEDKQ---G SKYPIFGTLK-EEKEYHKKFKTIYHLREELA 144 WP_049516684 75 RRRNRLRYLQEIFAEEMMQVDESFFQRLDD-SFLV--EEDKR---G SRYPIFGNIA-AEVKYHDDFPTIYHLRKHLV 144 GAD46167 74 RRKNRLRYLQEIFTEEMNKVDENFFQRLDD-SFLV--EEDKQ---G SKYPIFGTLK-EEKEYHKKFKTIYHLREELA 143 WP_018363470 75 RRKNRLRYLQDIFTEEMAKVDDSFFQRLDE-SFLT--DNDKN---F DSHPIFGNKA-EEDAYHQKFPTIYHLRKHLA 144 WP_003043819 74 RRKNRIRYLQEIFANEMAKLDDSFFQRLEE-SFLV--EEDKK---N ERHPIFGNLA-DEVAYHRNYPTIYHLRKKLA 143 WP_006269658 74 RRKNRLRYLQEIFTGEMNKVDENFFQRLDD-SFLV--DEDKR---G EHHPIFGNIA-AEVKYHDDFPTIYHLRRHLA 143 WP_048800889 74 RRKNRLRYLQEIFIEEMNKVDENFFQRLDD-SFLV--TEDKR---G SKYPIFGTLK-EEKEYYKEFETIYHLRKRLA 143 WP_012767106 74 RRKNRIRYLQEIFSSEMSKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143 WP_014612333 74 RRKNRIRYLQEIFSSEMSKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143 WP_015017095 74 RRKNRIRYLQEIFSSEMSKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143 WP_015057649 74 RRKNRIRYLQEIFSSEMSKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143 WP_048327215 74 RRKNRIRYLQEIFSSEMSKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143 WP_049519324 74 RRKNRIRYLQEIFSSEMSKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLA 143 WP_012515931 74 RRKNRLRYLKEIFTEEMAKVDDGFFQRLED-SFYV--LEDKE---G NKHPIFANLA-DEVAYHKKYPTIYHLRKELV 143 WP_021320964 74 RRKNRLRYLKEIFTEEMAKVDDGFFQRLED-SFYV--LEDKE---G NKHPIFANLA-DEVAYHKKYPTIYHLRKELV 143 WP_037581760 74 RRKNRLRFLKEIFTEEMAKVDDGFFQRLED-SFYV--LEDKE---G NKHPIFANLA-DEVAYHKKYPTIYHLRKELV 143 WP_004232481 74 RRKNRLRYLQEIFAKEMAKVDESFFQRLEE-SFLT--DDDKT---F DSHPIFGNKA-EEDTYHQEFPTIYHLRKHLA 143 WP_009854540 75 RRKNRLRYLQEIFAEEMTKVDESFFYRLDE-SFLT--TDEKD---F ERHPIFGNKA-EEDAYHQKFPTIYHLRNYLA 144 WP_012962174 75 RRKNRLRYLQEIFAEEMAKVDESFFYRLDE-SFLT--TDDKD---F ERHPIFGNKA-DEIKYHQEFPTIYHLRKHLA 144 WP_039695303 75 RRKNRLRYLQEIFANEIAKVDESFFQRLDE-SFLT--DDDKT---F DSHPIFGNKA-EEDAYHQKFPTIYHLRKHLA 144 WP_014334983 74 RRKNRLRYLQEIFAKEMTKVDESFFQRLEE-SFLT--DDDKT---F DSHPIFGNKA-EEDAYHQKFPTIYHLRKYLA 143 WP_003099269 74 RRKYRIKELQKIFSSEMNELDIAFFPRLSE-SFLV--SDDKE---F ENHPIFGNLK-DEITYHNDYPTIYHLRQTLA 143 AHY15608 74 RRKYRIKELQKIFSSEMNELDIAFFPRLSE-SFLV--SDDKE---F ENHPIFGNLK-DEITYHNDYPTIYHLRQTLA 143 AHY17476 74 RRKYRIKELQKIFSSEMNELDIAFFPRLSE-SFLV--SDDKE---F ENHPIFGNLK-DEITYHNDYPTIYHLRQTLA 143 ESR09100 ---------------------------------------------- ------------------------------- AGM98575 74 RRKYRIKELQKIFSSEMNELDIAFFPRLSE-SFLV--SDDKE---F ENHPIFGNLK-DEITYHNDYPTIYHLRQTLA 143 ALF27331 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_018372492 74 RRRNRIRYLQHIFAEEMNRADENFFHRLKE-SFFV--EEDKT---Y SKYPIFGTLE-EEKNYHKNYPTIYHLRKTLA 143 WP_045618028 75 RRKNRLRYLQEIFTEEMSKVDISFFHRLDD-SFLV--PEDKR---G SKYPIFATLE-EEKEYHKNFPTIYHLRKHLA 144 WP_045635197 74 RRKNRLRYLQEIFSEEMSKVDSSFFHRLDD-SFLI--PEDKR---E SKYPIFATLT-EEKEYHKQFPTIYHLRKQLA 143 WP_002263549 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_002263887 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_002264920 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLDE-SFLT--DDDKN---F DSYPIFGNKA-EEDAYHQKFPTIYHLRKHLA 143 WP_002269043 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_002269448 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_002271977 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_002272766 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_002273241 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_002275430 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_002276448 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_002277050 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLDE-SFLT--DDDKN---F DSHPIFGNKA-EEDAYHQKFPTIYHLRKHLA 143 WP_002277364 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_002279025 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-FFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_002279859 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLDE-SFLT--DDDKN---F DSHPIFGNKA-EEDAYHQKFPTIYHLRKHLA 143 WP_002280230 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_002281696 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_002282247 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLDE-SFLT--DDDKN---F DSHPIFGNKA-EEDAYHQKFPTIYHLRKHLA 143 WP_002282906 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_002283846 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_002287255 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_002288990 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_002289641 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_002290427 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_002295753 74 RRRNRILYLQEIFSEEMGKVNDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_002296423 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_002304487 74 RRRNRILYLQEIFAEEMMQVDESFFQRLDD-SFLV--EEDKR---G SRYPIFGTLK-EEKKYHKEFKTIYHLREKLA 143 WP_002305844 74 RRRNRILYLQEIFSEEMDKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_002307203 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_002310390 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_002352408 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_012997688 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_014677909 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_019312892 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_019313659 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_019314093 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_019315370 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ECHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_019803776 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_019805234 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_024783594 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_024784288 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLDE-SFLT--DDDKN---F DSHPIFGNKA-EEDAYHQKFPTIYHLRKHLA 143 WP_024784666 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_024784894 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 WP_024786433 74 RRRNRILYLQEIFAEEMNKVDDSFFHRLDE-SFLT--DDDKN---F DSHPIFGNKA-EEDAYHQKFPTIYHLRKHLA 143 WP_049473442 74 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYYENFPTIYHLRQYLA 143 WP_049474547 74 RRRNRILYLQEIFSEEMGKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 143 EMC03581 67 RRRNRILYLQEIFAEEMSKVDDSFFHRLED-SFLV--TEDKR---G ERHPIFGNLE-EEVKYHENFPTIYHLRQYLA 136 WP_000428612 75 RRKNRLRYLQEIFAEEMSKVDSSFFHRLDD-SFLI--PEDKK---G SKYPIFATLI-EEKEYHKQFPTIYHLRKQLA 144 WP_000428613 75 RRKNRLRYLQEIFAEEMSKVDSSFFHRLDD-SFLI--PEDKR---G SKYPIFATLA-EEKEYHKQFPTIYHLRKQLA 144 WP_049523028 74 RRRNRILYLQEIFAAEMNKVDESFFHRLDD-SFLV--PEDKR---G SKYPIFGTLE-EEKEYHKQFPTIYYLRKILA 143 WP_003107102 43 RRINRIKYLQSIFDDEMSKIDSAFFQRIKD-SFLV--PDDKN---D DRHPIFGNIK-DEVDYHKNYPTIYHLRKKLA 112 WP_054279288 76 RRKNRLCYLRDIFESEMHTIDKHFFLRLED-SFLH--KSDKR---Y EAHPIFGTLQ-EEKAYHDNYPTIYHLRKALA 145 WP_049531101 75 RRKNRLRYLQEIFSEEISKVDNSFFHRLDD-SFLV--PEDKR---G SKYPIFATLT-EEKEYYKQFPTIYHLRKQLA 144 WP_049538452 75 RRKNRLRYLQEIFAEEMNKVDSSFFHRLDD-SFLV--PEDKR---G SKYPIFATLA-EEKEYHKNFPTIYHLRKQLA 144 WP_049549711 75 RRKNRLRYLQEIFSGEMSKVDSSFFHRLDD-SFLV--PEDKR---G SKYPIFATLV-EEKEYHKQFPTIYHLRKQLA 144 WP_007896501 76 RRRYRLCQLQNIFATEMVKVDDTFFQRLSE-SFFY--YQDKA---F DKHPIFGNSK-EERAYHKTYPTIYHLRKDLA 145 EFR44625 28 RRRYRLCQLQNIFATEMVKVDDTFFQRLSE-SFFY--YQDKA---F DKHPIFGNSK-EERAYHKTYPTIYHLRKDLA 97 WP_002897477 74 RRRNRILYLQEIFTESMNEIDESFFHRLDD-SFLV--PEDKR---G SKYPIFATLQ-EEKEYHKQFPTIYHLRKQLA 143 WP_002906454 74 RRKNRLRYLQEIFSEEISKLDSSFFHRLDD-SFLV--PEDKR---G SKYPIFATLE-EEKEYHKKFPTIYHLRKHLA 143 WP_009729476 75 RRKNRLRYLQEIFSEEIGKVDSSFFHRLDD-SFLI--PEDKR---G SKYPIFATLA-EEKKYHKQFPTIYHLRKQLA 144 CQR24647 74 RRRNRILYLQDIFSPELNQVDESFLHRLDD-SFLVa--EDKR---G ERHVIFGNIA-DEVKYHKEFPTIYHLRKHLA 143 WP_000066813 75 RRKNRLRYLQEIFSQEISKVDSSFFHRLDD-FFLV--PEDKR---G SKYPIFATLV-EEKEYHKKFPTIYHLRKHLA 144 WP_009754323 75 RRKNRLRYLQEIFAEEMSKVDSSFFHRLDD-SFLV--PEDKS---G SKYPIFATLA-EEKEYHKKFPTIYHLRKHLA 144 WP_044674937 74 RRRNRILYLQEIFAEEINKIDDSFFQRLDD-SFLIv--EDKQ---G SKHPIFGTLQ-EEKKYHKQFPTIYHLRKQLA 143 WP_044676715 74 RRRNRILYLQEIFAEEINKIDDSFFQRLDD-SFLIv--EDKQ---G SKHPIFGTLQ-EEKEYHKQFPTIYHLRKQLA 143 WP_044680361 74 RRRNRILYLQEIFAEEINKIDDSFFQRLDD-SFLIv--EDKQ---G SKHPIFGTLQ-EEKEYHKQFPTIYHLRKQLA 143 WP_044681799 74 RRRNRILYLQEIFAEEINKIDDSFFQRLDD-SFLIv--EDKQ---G SKHPIFGTLQ-EEKKYHKQFPTIYHLRKQLA 143 WP_049533112 74 RRRNRLRYLQEIFAEEMNKVDENFFQRLDD-SFLV--DEDKR---G ERHPIFGNIA-AEVKYHDDFPTIYHLRKHLA 143 WP_029090905 28 HRKFRLRLLEDMFEKEILSKDPSFFIRLKE-AFLSpkDEQKQ---F ----LFNDKDyTDADYYEQYKTIYHLRYDLI 100 WP_006506696 61 KRRERIRLLRAILQDMVLEKDPTFFIRLEHtSFLD--EEDKAkylG DNYNLFIDEDfNDYTYYHKYPTIYHLRKALC 139 AIT42264 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV 143 WP_034440723 73 RRRFRIRELQKIFDKSMGEVDSNFFHRLDE-SFLV--EEDKE---Y SKYPIFSNEK-EDKNYYDKYPTIYHLRKDLA 142 AKQ21048 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV 143 WP_004636532 74 RRRNRLIYLQDIFQQPMLAIDENFFHRLDD-SFFV--PDDKS---Y DRHPIFGSLE-EEVAYHNTYPTIYHLRKHLA 143 WP_002364836 74 RRRNRLRYLQAFFEEAMTDLDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA 143 WP_016631044 25 RRRNRLRYLQAFFEEAMTDLDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA 94 EMS75795 ---------------------------------------------- ------------------------------- WP_002373311 74 RRRNRLRYLQAFFEEAMTDLDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA  143 WP_002378009 74 RRRNRLRYLQAFFEEAMTALDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA  143 WP_002407324 74 RRRNRLRYLQAFFEEAMTALDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA  143 WP_002413717 74 RRRNRLRYLQAFFEEAMTDLDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA  143 WP_010775580 74 RRRNRLRYLQAFFEEAMTALDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA  143 WP_010818269 74 RRRNRLRYLQAFFEEAMTALDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA  143 WP_010824395 74 RRRNRLRYLQAFFEEAMTDLDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA  143 WP_016622645 74 RRRNRLRYLQAFFEEAMTALDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA  143 WP_033624816 74 RRRNRLRYLQAFFEEAMTALDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA  143 WP_033625576 74 RRRNRLRYLQAFFEEAMTALDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA  143 WP_033789179 74 RRRNRLRYLQAFFEEAMTALDENFFARLQE-SFLV--PEDKK---W HRHPIFAKLE-DEVAYHETYPTIYHLRKKLA  143 WP_002310644 74 RRRQRILELQKIFAPEILKIDEHFFARLNE-SFLV--LDEKK---Q SRHPVFATIK-QEKSYHQTYPTIYHLRQALA 143 WP_002312694 74 RRRQRILELQKIFAPEILKIDEHFFARLNE-SFLV--PDEKK---Q SRHPVFATIK-QEKSYHQTYPTIYHLRQALA 143 WP_002314015 74 RRRQRILELQKIFAPEILKIDEHFFARLNE-SFLV--LDEKK---Q SRHPVFATIK-QEKSYHQTYPTIYHLRQALA 143 WP_002320716 74 RRRQRILELQKIFAPEILKIDEHFFARLNE-SFLV--LDEKK---Q SRHPVFATIK-QEKSYHQTYPTIYHLRQALA 143 WP_002330729 74 RRRQRILELQKIFAPEILKIDEHFFARLNE-SFLV--LDEKK---Q SRHPVFATIK-QEKSYHQTYPTIYHLRQALA 143 WP_002335161 74 RRRQRILELQKIFAPEILKIDEHFFARLNE-SFLV--LDEKK---Q SRHPVFATIK-QEKSYHQTYPTIYHLRQALA 143 WP_002345439 74 RRRQRILELQKIFAPEILKIDEHFFARLNE-SFLV--LDEKK---Q SRHPVFATIK-QEKSYHQTYPTIYHLRQALA 143 WP_034867970 74 RRKYRLSKLQDLFAEELCKQDDCFFVRLEE-SFLV--PEEKQ---Y KPASIFPTLE-EEKEYYQKYPTIYHLRQKLV 143 WP_047937432 74 RRRQRILELQKIFAPEILKIDEHFFARLNE-SFLV--LDEKK---Q SRHPVFATIK-QEKSYHQTYPTIYHLRQALA 143 WP_010720994 74 RRKYRLSKLQDLFAEELCKQDDCFFVRLEE-SFLV--PEEKQ---Y KPASIFPTLE-EEKEYYQKYPTIYHLRQKLV 143 WP_010737004 74 RRKYRLSKLQDLFAEELCKQDDCFFVRLEE-SFLV--PEEKQ---Y KPASIFPTLE-EEKEYYQKYPTIYHLRQKLV 143 WP_034700478 74 RRKYRLSKLQDLFAEELCKQDDCFFVRLEE-SFLV--PEEKQ---Y KPASIFPTLE-EEKEYYQKYPTIYHLRQKLV 143 WP_007209003 74 RRKNRICYLQEIFQPEMNHLDNNFFYRLNE-SFLVa--DDAK---Y DKHPIFGTLD-EEIHFHEQFPTIYHLRKYLA 143 WP_023519017 74 RRRQRVLALQDIFAEEIHKKDPNFFARLEE-GDRV--EADKR---F AKFPVFATLS-EEKNYHRQYPTIYHLRHDLA 143 WP_010770040 74 RRRNRICRLQDLFTEEMNQVDANFFHRLQE-SFLV--PDEKE---F ERHAIFGKME-EEVSYYREFPTIYHLRKHLA 143 WP_048604708 74 RRRQRISYLQTFFQEEMNRIDPNFFNRLDE-SFLI--EEDKL---S ERHPIFGTIE-EEVAYHKNYATIYHLRKELA 143 WP_010750235 74 RRKYRILELQKIFSEEILKKDSHFFARLDE-SFLI--PEDKQ---Y ARFPIFPTLL-EEKAYYQNYPTIYHLRQKLA 143 AII16583 113 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV 182 WP_029073316 66 KRRERIRLLRGIMEDMVLDVDPTFFIRLANvSFLD--QEDKKdylK SNYNLFIDKDfNDKTYYDKYPTIYHLRKHLC 144 WP_031589969 66 KRRERIRLLREIMEDMVLDVDPTFFIRLANvSFLD--QEDKKdylK SNYNLFIDKDfNDKTYYDKYPTIYHLRKHLC 144 KDA45870 75 RRKNRLRYLQEIFAPALAKVDPNFFYRLEE-SSLVa--EDKK---Y DVYPIFGKRE-EELLYHDTHKTIYHLRSELA 144 WP_039099354 62 RRKWRLGLLREIFEPYITPVDDTFFLRKKQ-SNLS--PKDQR---K -QTSLFNDRT--DRAFYDDYPTIYHLRYKLM 132 AKP02966 65 RRKNRINWLNEIFSEELANTDPSFLIRLQN-SWVSkkDPDRK---R DKYNLFIDNPyTDKEYYREFPTIFHLRKELI 137 WP_010991369 74 RRRNRISYLQGIFAEEMSKTDANFFCRLSD-SFYV--DNEKR---N SRHPFFATIE-EEVEYHKNYPTIYHLREELV 143 WP_033838504 74 RRRNRISYLQGIFAEEMSKTDANFFCRLSD-SFYV--DNEKR---N SRHPFFATIE-EEVEYHKNYPTIYHLREELV 143 EHN60060 77 RRRNRISYLQGIFAEEMSKTDANFFCRLSD-SFYV--DNEKR---N SRHPFFATIE-EEVEYHKNYPTIYHLREELV 146 EFR89594 ---------------------------------------------- ------------------------------- WP_038409211 74 RRRNRIAYLQEIFAAEMAEVDANFFYRLED-SFYI--ESEKR---H SRHPFFATIE-EEVAYHEEYKTIYHLREKLV 143 EFR95520 ---------------------------------------------- ------------------------------- WP_003723650 74 RRRNRISYLQEIFAVEMANIDANFFCRLND-SFYV--DSEKR---N SRHPFFATIE-EEVAYHDNYRTIYHLREKLV 143 WP_003727705 74 RRRNRISYLQEIFAVEMANIDANFFCRLND-SFYV--DSEKR---N SRHPFFATIE-EEVAYHKNYRTIYHLREELV 143 WP_003730785 74 RRRNRISYLQEIFAVEMANIDANFFCRLND-SFYV--DSEKR---N SRHPFFATIE-EEVAYHKNYRTIYHLREELV 143 WP_003733029 74 RRRNRISYLQEIFAIQMNEVDDNFFNRLKE-SFYA--ESDKK---Y NRHPFFGTVE-EEVAYYKDFPTIYHLRKELI 143 WP_003739838 74 RRRNRISYLQEIFALEMANIDANFFCRLND-SFYV--DSEKR---N SRHPFFATIE-EEVAYHKNYRTIYHLREELV 143 WP_014601172 74 RRRNRISYLQEIFAVEMANIDANFFCRLND-SFYV--DSEKR---N SRHPFFATIE-EEVAYHKNYRTIYHLREELV 143 WP_023548323 74 RRRNRISYLQEIFAVEMANIDANFFCRLND-SFYV--DSEKR---N SRHPFFATIE-EEVAYHKNYRTIYHLREELV 143 WP_031665337 74 RRRNRISYLQEIFAVEMANIDANFFCRLND-SFYV--DSEKR---N SRHPFFATIE-EEVAYHKNYRTIYHLREELV 143 WP_031669209 74 RRRNRISYLQEIFAIQMNEVDDNFFNRLKE-SFYA--ESDKK---Y NRHPFFGTVE-EEVAYYKDFPTIYHLRKELI 143 WP_033920898 74 RRRNRISYLQEIFAVEMANIDANFFCRLND-SFYV--DSEKR---N SRHPFFATIE-EEVAYHKNYRTIYHLREELV  143 AKI42028 77 RRRNRISYLQEIFAVEMANIDANFFCRLND-SFYV--DSEKR---N SRHPFFATIE-EEVAYHKNYRTIYHLREELV  146 AKI50529 77 RRRNRISYLQEIFAVEMANIDANFFCRLND-SFYV--DSEKR---N SRHPFFATIE-EEVAYHKNYRTIYHLREELV  146 EFR83390 ---------------------------------------------- ------------------------------- WP_046323366 74 RRRNRISYLQEIFTAEMFEVDANFFYRLED-SFYI--ESEKR---Q SRHPFFATIE-EEVAYHENYRTIYHLREKLV 143 AKE81011 90 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV 159 CUO82355 65 KRRERIRLLRAILQDMVLEKDPTFFIRLEHtSFLD--EEDKAkylG DNYNLFIDEDfNDYTYYHKYPTIYHLRKALC 143 WP_033162887 66 KRRERIRLLRDLLGDMVMEVDPTFFIRLLNvSFLD--EEDKQkn1G DNYNLFIEKDfNDKTYYDKYPTIYHLRKELC 144 AGZ01981 107 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV 176 AKA60242 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV 143 AKS40380 74 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV 143 4UN5_B 78 RRKNRICYLQEIFSNEMAKVDDSFFHRLEE-SFLV--EEDKK---H ERHPIFGNIV-DEVAYHEKYPTIYHLRKKLV 147 WP_010922251 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDV

KL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI 211 WP_039695303 145 DSSEKADLRLVYLALAHMIKFRGHFLIEGE-LNAENTDVQKI--FADFVGVYNRT--FDDS-H LSEITVDVA---SI 212 WP_045635197 144 DSKEKTDLRLIYLALAHMIKYRGHFLYEEA-FDIKNNDIQKI--FNEFISIYDNT--FEGS-S LSGQNAQVE---AI 211 5AXW_A 105 EEEFSA-------ALLHLAKRRG---VHNV------NEVE------------EDT----GN-- -------E------ 134 WP_009880683 --------------------------------------------------------------- -------------- WP_010922251 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI 211 WP_011054416 144 DSTDKVDLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI 211 WP_011284745 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI 211 WP_011285506 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI 211 WP_011527619 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI 211 WP_012560673 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI 211 WP_014407541 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQIYNQL--FEEN-- INASRVDAK---AI 211 WP_020905136 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI 211 WP_023080005 144 DSTDKVDLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI 211 WP_023610282 144 DSTDKVDLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI 211 WP_030125963 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI 211 WP_030126706 144 DSTDKVDLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI 211 WP_031488318 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI 211 WP_032460140 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI 211 WP_032461047 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGG-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI 211 WP_032462016 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INANGVDAK---AI 211 WP_032462936 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI 211 WP_032464890 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI 211 WP_033888930 1 ---------------------------------PDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI 36 WP_038431314 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI 211 WP_038432938 144 DSTDKVDLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI 211 WP_038434062 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI 211 BAQ51233 55 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI 122 KGE60162 --------------------------------------------------------------- -------------- KGE60856 --------------------------------------------------------------- --------------  WP_002989955 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI 211 WP_003030002 144 DISQKADLRLVYLALAHMIKFRGHFLIEGQ-LKAENTNVQAL--FKDFVEVYDKT--VEES-H LSEMTVDAL---SI 211 WP_003065552 147 DSSEKADLRLVYLALAHMIKFRGHFLIEGE-LNAENTDVQKI--FADFVGVYDRT--FDDS-H LSEITVDAA---SI 214 WP_001040076 144 DKKEKADLRLVYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ--YQAFLEIFDTT--FENN-D LLSQDVDVE---AI 212 WP_001040078 144 DKQEKADLRLIYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ--YQAFLEIFDTT--FENN-H LLSQNVDVE---AI 212 WP_001040080 144 DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNIT--FENN-D LLSQNVDVE---AI 212 WP_001040081 144 DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTI--FENN-D LLSQNVDVE---AI 212 WP_001040083 144 DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI 212 WP_001040085 144 DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI 212 WP_001040087 144 DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI 212 WP_001040088 144 DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI 212 WP_001040089 144 DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI 212 WP_001040090 144 DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI 212 WP_001040091 144 DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI 212 WP_001040092 144 DKKEKADLRLVYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ--YQAFLEIFDTS--FENN-H LLSQNVDVE---AI 212 WP_001040094 144 DKKEKADLRLIYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ--YQAFLEIFDTT--FENN-D LLSQNVDVE---AI 212 WP_001040095 144 DKKEKADLRLIYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ--YQAFLEIFDTT--FENN-D LLSQNVDVE---AI 212 WP_001040096 144 DKKEKADLRLIYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ--YQAFLEIFDTT--FENN-D LLSQNVDVE---AI 212 WP_001040097 144 DKKEKADLRLIYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ--YQAFLEIFDTT--FENN-D LLSQNVDVE---AI 212 WP_001040098 144 DKKEKADLRLIYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ--YQAFLEIFDTT--FENN-D LLSQNVDVE---AI 212 WP_001040099 144 DKKEKADLRLIYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ--YQAFLEIFDTT--FENN-D LLSQNVDVE---AI 212 WP_001040100 144 DKKEKADLRLIYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ--YQAFLEIFDTT--FENN-D LLSQNVDVE---AI 212 WP_001040104 144 DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI 212 WP_001040105 144 DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI 212 WP_001040106 144 DKKEKANLRLVYLALAHIIKFRGHFLIEDDsFDVRNTDIQRQ--YQAFLEIFDTT--FENN-H LLSQNIDVE---GI 212 WP_001040107 144 DKKEKADLRLVYLALAHIIKFRGHFLIEDDsFDVRNTDIQRQ--YQAFLEIFDTT--FENN-H LLSQNIDVE---GI 212 WP_001040108 144 DKKEKADLRLVYLALAHIIKFRGHFLIEDDsFDVRNTDIQRQ--YQAFLEIFDTT--FENN-H LLSQNIDVE---GI 212 WP_001040109 144 DKKEKANLRLVYLALAHIIKFRGHFLIEDDsFDVRNTDIQRQ--YQAFLEIFDTT--FENN-H LLSQNIDVE---GI 212 WP_001040110 144 DKKEKANLRLVYLALAHIIKFRGHFLIEDDsFDVRNTDIQRQ--YQAFLEIFDTT--FENN-H LLSQNIDVE---GI 212 WP_015058523 144 DKKEKADLRLVYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ--YQAFLEIFDTS--FENN-H LLSQNVDVE---AI 212 WP_017643650 144 DKKEKADLRLIYLALAHIIKFRGHFLIEDDrFDVRNTDIQKQ--YQAFLEIFDTT--FENN-D LLSQNVDVE---AI 212 WP_017647151 144 DKKEKADLRLFYLALAHIIKFRGHFLIEDDsFDVRNTDIQRQ--YQAFLEIFDTT--FENN-H LLSQNIDIE---GI 212 WP_017648376 144 DKKEKADLRLFYLALAHIIKFRGHFLIEDDsFDVRNTDIQRQ--YQAFLEIFDTT--FENN-H LLSQNIDVE---GI 212 WP_017649527 144 DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI 212 WP_017771611 144 DKKEKADLRLVYLALAHIIKFRGHFLIEDDsFDVRNTDIQRQ--YQAFLEIFDTT--FENN-H LLSQNIDVE---GI 212 WP_017771984 144 DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI 212 CFQ25032 144 DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI 212 CFV16040 144 DKKEKADLRLIYIALAHIIKFRGHFLIEDDsFDVRNTDISKQ--YQDFLEIFNTT--FENN-D LLSQNVDVE---AI 212 KLJ37842 144 DKKEKADLRLIYIALAHIIKERGHFLIEDDsEDVRNTDISKQ--YQDFLEIENTT--FENN-D LLSQNVDVE---AI 212 KLJ72361 144 DKKEKADLRLIYIALAHIIKERGHFLIEDDsEDVRNTDISKQ--YQDFLEIENTT--FENN-D LLSQNVDVE---AI 212 KLL20707 144 DKKEKADLRLIYIALAHIIKERGHFLIEDDsEDVRNTDISKQ--YQDFLEIENTT--FENN-D LLSQNVDVE---AI 212 KLL42645 144 DKKEKANLRLVYLALAHIIKERGHFLIEDDsEDVRNTDIQRQ--YQAFLEIFDTT--FENN-H LLSQNIDVE---GI 212 WP_047207273 144 DKKEKADLRLIYIALAHIIKERGHFLIEDDsEDVRNTDISKQ--YQDFLEIENTT--FENN-D LLSQNVDVE---AI 212 WP_047209694 144 DKKEKADLRLIYLALAHIIKERGHFLIEDDsEDVRNTDIQKQ--YQAFLEIFDTT--FENN-D LLSQNVDVE---AI 212 WP_050198062 144 DKKEKADLRLIYIALAHIIKERGHFLIEDDsEDVRNTDISKQ--YQDFLEIENTT--FENN-D LLSQNVDVE---AI 212 WP_050201642 144 DKKEKADLRLIYIALAHIIKERGHFLIEDDsEDVRNTDISKQ--YQDFLEIENTT--FENN-D LLSQNVDVE---AI 212 WP_050204027 144 DKKEKANLRLVYLALAHIIKERGHFLIEDDsEDVRNTDIQRQ--YQAFLEIFDTT--FENN-H LLSQNIDVE---GI 212 WP_050881965 144 DKKEKADLRLIYIALAHIIKERGHFLIEDDsEDVRNTDISKQ--YQDFLEIENTT--FENN-D LLSQNVDVE---AI 212 WP_050886065 144 DKKEKADLRLIYIALAHIIKERGHFLIEDDsEDVRNTDISKQ--YQDFLEIENTT--FENN-D LLSQNVDVE---AI 212 AHN30376 144 DKKEKADLRLVYLALAHIIKERGHFLIEDDrEDVRNTDIQKQ--YQAFLEIFDTS--FENN-H LLSQNVDVE---AI 212 EA078426 144 DKKEKADLRLIYIALAHIIKERGHFLIEDDsEDVRNTDISKQ--YQDFLEIENTT--FENN-D LLSQNVDVE---AI 212 CCW42055 144 DKKEKADLRLVYLALAHIIKERGHFLIEDDrEDVRNTDIQKQ--YQAFLEIFDTT--FENN-H LLSQNVDVE---AI 212 WP_003041502 144 DISQKADLRLVYLALAHMIKERGHFLIEGQ-LKAENTNVQAL--FKDEVEVYDKT--VEES-H LSEITVDAL---SI 211 WP_037593752 145 NSKEKADLRLVYLALAHMIKERGHFLYEGD-LKAENTDVQAL--FKDEVEEYDKT--IEES-H LSEITVDAL---SI 212 WP_049516684 145 DISQKADLRLVYLALAHMIKERGHFLIEGQ-LKAENTNVQAL--FKDEVEVYDKT--VEES-H LSEMTVDAL---SI 212 GAD46167 144 NSKEKADLRLVYLALAHMIKERGHFLYEGD-LKAENTDVQAL--FKDEVEEYDKT--IEES-H LSEITVDAL---SI 211 WP_018363470 145 DSTEKADLRLVYLALAHMIKERGHFLIEGE-LNAENTDVQKL--FTDEVGVYDRT--FDDS-H LSEITVDAA---SI 212 WP_003043819 144 DSPEKADLRLIYLALAHIIKERGHFLIEGK-LNAENSDVAKL--FYQLIQTYNQL--FEES-- LDEIEVDAK---GI 211 WP_006269658 144 DTSKKADLRLVYLALAHMIKERGHFLYEGD-LKAENTDVQAL--FKDEVEEYDKT--IEES-H LSEITVDAL---SI 211 WP_048800889 144 DSTGKVDLRLVYLALAHMIKERGHFLIEGQ-LKAENTDVQTL--ENDEVEVYDKT--IEES-H LAEITVDAL---SI 211 WP_012767106 144 DSTDKADLRLIYLALAHMIKERGHFLIEGD-LNPDNSDMDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI 211 WP_014612333 144 DSTDKADLRLIYLALAHMIKERGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEK-- INASGVDAK---AI 211 WP_015017095 144 DSTDKADLRLIYLALAHMIKERGHFLIEGD-LNPDNSDMDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI 211 WP_015057649 144 DSTDKADLRLIYLALAHMIKERGHFLIEGD-LNPDNSDMDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI 211 WP_048327215 144 DSTDKADLRLIYLALAHMIKERGHFLIEGD-LNPDNSDMDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI 211 WP_049519324 144 DSTDKADLRLIYLALAHMIKERGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASRVDAK---AI 211 WP_012515931 144 DNPQKADLRLIYLAVAHIIKERGHFLIEGT-LSSKNNNLQKS--FDHLVDTYNLL--FEEQ-- LLTEGINAK---EL 211 WP_021320964 144 DNPQKADLRLIYLAVAHIIKERGHFLIEGT-LSSKNNNLQKS--FDHLVDTYNLL--FEEQ-- LLTEGINAK---EL 211 WP_037581760 144 DNPQKADLRLIYLAVAHIIKERGHFLIEGT-LSSKNNNLQKS--FDHLVDTYNLL--FEEQ-- LLTEGINAK---EL 211 WP_004232481 144 DSPEKVDLRLVYLALAHMIKERGHFLIEGQ-LNAENTDVQKI--FADEVGVYDRT--FDDS-H LSEITVDAA---SI 211 WP_009854540 145 DSSEKADLRLVYLALAHMIKYRGHFLIEGK-LNAENTDVQKL--FTDEVGVYDRT--FDDS-H LSEITVDVA---ST 212 WP_012962174 145 DSHEKADLRLIYLALAHMIKERGHFLIEGE-LNAENTDVQKL--FEAFVEVYDRT--FDDS-N LSEITVDAS---SI 212 WP_039695303 145 DSSEKADLRLVYLALAHMIKFRGHFLIEGE-LNAENTDVQKI--FADFVGVYNRT--FDDS-H LSEITVDVA---SI 212 WP_014334983 144 DSQEKADLRLVYLALAHMIKYRGHFLIEGE-LNAENTDVQKL--FNVFVETYDKI--VDES-H LSEIEVDAS---SI 211 WP_003099269 144 DSDQKADLRLIYLALAHIIKFRGHFLIEGN-LDSENTDVHVL--FLNLVNIYNNL--FEED-- VETASIDAE---KI 211 AHY15608 144 DSDQKADLRLIYLALAHIIKFRGHFLIEGN-LDSENTDVHVL--FLNLVNIYNNL--FEED-- VETASIDAE---KI 211 AHY17476 144 DSDQKADLRLIYLALAHIIKFRGHFLIEGN-LDSENTDVHVL--FLNLVNIYNNL--FEED-- VETASIDAE---KI 211 ESR09100 --------------------------------------------------------------- -------------- AGM98575 144 DSDQKADLRLIYLALAHIIKFRGHFLIEGN-LDSENTDVHVL--FLNLVNIYNNL--FEED-- VETASIDAE---KI 211 ALF27331 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---El 211 WP_018372492 144 DTPDKMDIRLIYLALAHIIKYRGHFLIEGD-LDIENIGIQDS--FKSFIEEYNTQ--FGTK-- -LDSTTKVE---Al 209 WP_045618028 145 DSKEKADFRLIYLALAHIIKYRGHFLYEES-FDIKNNDIQKI--FNEFISIYDNT--FEGS-S LNGQNAQVE---AI 212 WP_045635197 144 DSKEKTDLRLIYLALAHMIKYRGHFLYEEA-FDIKNNDIQKI--FNEFISIYDNT--FEGS-S LSGQNAQVE---AI 211 WP_002263549 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_002263887 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_002264920 144 DSTEKADLRLVYLALAHMIKFRGHFLIEGE-LNAENTDVQKL--FADFVGVYDRT--FDDS-H LSEITVDAS---SI 211 WP_002269043 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_002269448 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_002271977 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_002272766 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_002273241 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_002275430 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_002276448 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_002277050 144 DSTEKADLRLVYLALAHMIKFRGHFLIEGE-LNAENTDVQKL--FADFVGVYDRT--FDDS-H LSEITVDAS---SI 211 WP_002277364 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_002279025 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_002279859 144 DSTEKADLRLVYLALAHMIKFRGHFLIEGE-LNAENTDVQKL--FADFVGVYDRT--FDDS-H LSEITVDAS---SI 211 WP_002280230 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_002281696 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_002282247 144 DSTEKADLRLVYLALAHMIKFRGHFLIEGE-LNAENTDVQKL--FADFVGVYDRT--FDDS-H LSEITVDAS---SI 211 WP_002282906 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_002283846 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_002287255 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_002288990 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_002289641 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_002290427 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_002295753 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_002296423 144 DNPEKTDLRLVYLALAHIIKFGGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_002304487 144 NSTEKADLRLVYLSLAHMIKFRGHFLIEGQ-LKAENTNVQAL--FKDFVEVYDKT--VEES-H LSEMTVDAL---SI 211 WP_002305844 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_002307203 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQKL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_002310390 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_002352408 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_012997688 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_014677909 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_019312892 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_019313659 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_019314093 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQKL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_019315370 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_019803776 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_019805234 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_024783594 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_024784288 144 DSTEKADLRLVYLALAHMIKFRGHFLIEGE-LNAENTDVQKL--FADFVGVYDRT--FDDS-H LSEITVDAS---SI  211 WP_024784666 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_024784894 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 211 WP_024786433 144 DSTEKADLRLVYLALAHMIKFRGHFLIEGE-LNAENTDVQKL--FADFVGVYDRT--FDDS-H LSEITVDAS---SI  211 WP_049473442 144 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI  211 WP_049474547 144 DNPEKTDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI  211 EMC03581 137 DNPEKVDLRLVYLALAHIIKFRGHFLIEGK-FDTRNNDVQRL--FQEFLAVYDNT--FENS-S LQEQNVQVE---EI 204 WP_000428612 145 DSKEKTDLRLIYLALAHMIKYRGHFLYEDT-FDIKNNDIQKI--FNEFISIYNNT--FEGN-S LSGQNVQVE---AI 212 WP_000428613 145 DSKEKTDLRLIYLALAHMIKYRGHFLYEDT-FDIKNNDIQKI--FSEFISIYDNT--FEGS-S LSGQNAQVE---AI 212 WP_049523028 144 DSKEKVDLRLIYLALAHIIKYRGHFLYEDS-FDIKNNDIQKI--FNEFTILYDNT--FEES-S LSKGNAQVE---EI  211 WP_003107102 113 DSDEKADLRLIYLALAHIIKFRGHFLIEGD-LDSQNTDVNAL--FLKLVDTYNLM--FEDD-- IDTQTIDAT---VI 180 WP_054279288 146 DNTEKADLRLIYLALAHIIKFRGHFLIEGA-LSANNTDVQQL--VHALVDAYNIM--FEED-- LDIEAIDVK---AI 213 WP_049531101 145 DSKEKADLRLIYLTLAHMIKYRGHFLYEES-FDIKNNDIQKI--FNEFISIYDNT--FEGS-S LSGQNAQVE---AI 212 WP_049538452 145 DSKEKADLRLIYLALAHMIKYRGHFLYEEA-FDIKNNDIQKI--FNEFINIYDNT--FEGS-S LSGQNEQVE---AI 212 WP_049549711 145 DSKEKADLRLIYLVLAHMIKYRGHFLYEEA-FDIKNNDIQKI--FNEFISIYDNT--FEGS-S LSGQNAQVE---TI  212 WP_007896501 146 DRDQKADLRLIYLALSHIIKFRGHFLIEGK-LNSENTDVQKL--FIALVTVYNLL--FEEE-- IAGETCDAK---AL 213 EFR44625 98 DRDQKADLRLIYLALSHIIKFRGHFLIEGK-LNSENTDVQKL--FIALVTVYNLL--FEEE-- IAGETCDAK---AL 165 WP_002897477 144 DSKEKSDVRLIYLALAHMIKYRGHFLYEET-FDIKNNDIQKI--FNEFINIYDNT--FEGS-S LSGQNAQVE---AI 211 WP_002906454 144 DSKEKTDLRLIYLALAHMIKYRGHFLYEES-FDIKNNDIQKI--FNEFISIYDNT--FEGS-S LSGQNAQVE---AI 211 WP_009729476 145 DSKEKTDLRLIYLALAHMIKYRGHFLYEEA-FDIKNNDIQKI--FNEFISIYNNT--FEGN-S LSGQNVQVE---AI 212 CQR24647 144 DSSEKADLRLVYLALAHIIKYRGHFLIDEP-IDIRNMNSQNL--FKEFLLAFDGI--QVDC-Y LASKHTDIS---GI 211 WP_000066813 145 DSKEKTDLRLIYLALAHMIKYRGHFLYEES-FDIKNNDIQKI--FSEFISIYDNT--FEGK-S LSGQNAQVE---AI 212 WP_009754323 145 DSKEKADLRLIYLALAHITKYRGHFLYEEA-FDIKNNDIQKI--FNEFINIYDNT--FEGS-S LSGQNAQVE---AI 212 WP_044674937 144 DSSQKADIRLIYLALAHIIKYRGHELFEGD-LKSENKDVQHL--FNDEVEMFDKT--VEGS-Y LSENLPNVA---DV 211 WP_044676715 144 DSSQKADIRLIYLALAHIIKYRGHELFEGD-LKSENKDVQHL--FNDEVEMFDKT--VEGS-Y LSENLPNVA---DV 211 WP_044680361 144 DSSQKADIRLIYLALAHIIKYRGHELFEGD-LKSENKDVQHL--FNDEVEMFDKT--VEGS-Y LSENLPNVA---DV 211 WP_044681799 144 DSSQKADIRLIYLALAHIIKYRGHELFEGD-LKSENKDVQHL--FNDEVEMFDKT--VEGS-Y LSENLPNVA---DV 211 WP_049533112 144 DISQKADLRLVYLALAHMIKERGHFLIEGQ-LKAENTNVQAL--FKDEVEVYDKT--VEES-H LSEMTVDAL---SI 211 WP_029090905 101 SQHRQFDIREVYLAIHHLIKYRGHFIYEDQtFTTDGNQLQHH--IKAIITMINST1---NR-- IIPETIDINvfeKI 171 WP_006506696 140 ESTEKADPRLIYLALHHIVKYRGNFLYEGQkFNMDASNIEDK--LSDIFTQFTSFnnIPYEdD --KKNLEIL---EI 210 AIT42264 144 DSTDKADLRLIYLALAHMIKERGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI 211 WP_034440723 143 DSNQKADLRLIYLALAHMIKYRGHFLIEGD-LKMDGISISES--FQEFIDSYNEVcaLEDE-N NDELLTQIE---NI 217 AKQ21048 144 DSTDKADLRLIYLALAHMIKERGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI 211 WP_004636532 144 DNPEKADLRLVYTALAHIVKYRGHFLIEGE-LNTENTSISET--FEQFLDTYSDI--FKEQ-- LVGDISKVE---EI 210 WP_002364836 144 DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENISVKEQ--FQQFMIIYNQT--FVNGeS PLPESVLIE---EE 217 WP_016631044 95 DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENTSVKDQ--FQQFMVIYNQT--FVNGeS PLPESVLIE---EE 168 EMS75795 --------------------------------------------------------------- -------------- WP_002373311 144 DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENTSVKEQ--FQQFMVIYNQT--FVNGeS PLPESVLIE---EE 217 WP_002378009 144 DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENISVKEQ--FQQFMIIYNQT--FVNGeS PLPESVLIE---EE 217 WP_002407324 144 DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENISVKEQ--FQQFMIIYNQT--FVNGeS PLPESVLIE---EE 217 WP_002413717 144 DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENISVKEQ--FQQFMIIYNQT--FVNGeS PLPESVLIE---EE 217 WP_010775580 144 DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENISVKEQ--FQQFMIIYNQT--FVNGeS PLPESVLIE---EE 217 WP_010818269 144 DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENISVKEQ--FQQFMIIYNQT--FVNGeS PLPESVLIE---EE 217 WP_010824395 144 DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENTSVKDQ--FQQFMVIYNQT--FVNGeS PLPESVLIE---EE 217 WP_016622645 144 DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENISVKEK--FQQFMIIYNQT--FVNGeG PLPESVLIE---EE 217 WP_033624816 144 DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENISVKDQ--FQQFMVIYNQT--FVNGeS PLPESVLIE---EE 217 WP_033625576 144 DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENISVKEQ--FQQFMIIYNQT--FVNGeS PLPESVLIE---EE 217 WP_033789179 144 DSSEQADLRLIYLALAHIVKYRGHFLIEGK-LSTENISVKEQ--FQQFMIIYNQT--FVNGeS PLPESVLIE---EE 217 WP_002310644 144 DSSEKADIRLVYLAMAHLLKYRGHFLIEGE-LNTENSSVTET--FRQFLSTYNQQ--FSEA-D KLDEAVDCS---FV 216 WP_002312694 144 DSSEKADIRLVYLAMAHLLKYRGHFLIEGE-LNTENSSVTET--FRQFLSTYNQQ--FSEA-G KLDEAVDCS---FV 216 WP_002314015 144 DSSEKADIRLVYLAMAHLLKYRGHFLIEGE-LNTENSSVTET--FRQFLSTYNQQ--FSEA-D KLDEAVDCS---FV 216 WP_002320716 144 DSSEKADIRLVYLAMAHLLKYRGHFLIEGE-LNTENSSVTET--FRQFLSTYNQQ--FSEA-D KLDEAVDCS---FV 216 WP_002330729 144 DSSEKADIRLVYLAMAHLLKYRGHFLIEGE-LNTENSSVTET--FRQFLSTYNQQ--FSEA-D KLDEAVDCS---FV 216 WP_002335161 144 DSSEKADIRLVYLAMAHLLKYRGHFLIEGE-LNTENSSVTET--FRQFLSTYNQQ--FSEA-D KLDEAVDCS---FV 216 WP_002345439 144 DSSEKADIRLVYLAMAHLLKYRGHFLIEGE-LNTENSSVTET--FRQFLSTYNQQ--FSEA-D KLDEAVDCS---FV 216 WP_034867970 144 DSTEKEDLRLVYLALAHLLKYRGHFLFEGD-LDTENTSIEES--FRVFLEQYSKQ--SDQP-- -LIVHQPVL---TI 209 WP_047937432 144 DSSEKADIRLVYLAMAHLLKYRGHFLIEGE-LNTENSSVTET--FRQFLSTYNQQ--FSEA-D KLDEAVDCS---FV 216 WP_010720994 144 DSTEKGDLRLVYLALAHLLKYRGHFLFEGD-LDTENTSIEES--FRVFLEQYGKQ--SDQP-- -LIVHQPVL---TI 209 WP_010737004 144 DSTEKEDLRLVYLALAHLLKYRGHFLFEGD-LDTENTSIEES--FRVFLEQYSKQ--SDQP-- -LIVHQPVL---TI 209 WP_034700478 144 DSTEKEDLRLVYLALAHLLKYRGHFLFEGD-LDTENTSIEES--FRVFLEQYGKQ--SDQP-- -LIVHQPVL---TI 209 WP_007209003 144 DGDEKADLRLVYLAIAHIIKFRGNFLIEGE-LNTENNSVIELs--KVFVQLYNQT1-SELE-- FIDESIDFS---EV 214 WP_023519017 144 NSKEQADIRLVYLAIAHCLKYRGHFLFEGE-LDTENTSVTEN--YQQFLQAYQQF--FPEP-- -IGDLDDAV---PI 209 WP_010770040 144 DTSEQADLRLVYLALAHIVKYRGHFLIEGE-LNTENSSVSET--FRTFIQVYNQI--FRENe- PLAVPDNIE---EL 212 WP_048604708 144 DAEEKADLRLVYLALAHIIKYRGHFLIEGR-LSTENTSTEET--FKTFLQKYNQT--FN---- PVDETISIG---SI 208 WP_010750235 144 DSTEKADIRLVYLALAHMIKYRGHFLFEGE-LDTENTSVEET--FKEFIDIYNEQ--FEEG-- -IIFYKDIP---LI 209 AII16583 183 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI 250 WP_029073316 145 ESKEKEDPRLIYLALHHIVKYRGNFLYEGQkFSMDVSNIEDK--MIDVLRQFNEIn1FEYVeD --KKIDEVL---NV 215 WP_031589969 145 ESKEKEDPRLIYLALHHIVKYRGNFLYEGQkFSMDVSNIEDK--MIDVLRQFNEIn1FEYVeD --KKIDEVL---NV 215 KDA45870 145 NNDRPADLRLVYLALAHIIKYRGNELLEGE-IDLRTTDINKV--FAEFSETLNEN--SDEN1G KLDVA---DI 209 WP_039099354 133 TEKRQFDIREIYLAMHHIVKYRGHFLNEAPvSSEKSSEINLVahFDRLNTIFADL--FSESgF -TDKLAEVK---AL 206 AKP02966 138 INKNKADIRLVYLALHNILKYRGNFTYEHQkFNISTLNSNLS---KELIELNQQLikYDIS-- -FPDNCDWNhisDI 208 WP_010991369 144 NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTQNTSVDGI--YKQFIQTYNQV--FASGiE KLEDNKDVA---KI 217 WP_033838504 144 NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTQNTSVDGI--YKQFIQTYNQV--FASGiE KLEDNKDVA---KI 217 EHN60060 147 NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTQNTSVDGI--YKQFIQTYNQV--FASGiE KLEDNKDVA---KI 220 EFR89594 --------------------------------------------------------------- -------------- WP_038409211 144 NSSDKADLRLVYLALAHIIKYRGNFLIEGM-LDTKNTSVDEV--FKQFIQTYNQI--FASDiE RLEENKEVA---EI 217 EFR95520 --------------------------------------------------------------- -------------- WP_003723650 144 NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTKNTSVDEV--YKQFIETYNQV--FMSNiE KVEENIEVA---NI 217 WP_003727705 144 NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTKNTSVDEV--YKQFIQTYNQV--FMSNiE KVEENTEVA---SI 217 WP_003730785 144 NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTKNTSVDEV--YKQFIQTYNQV--FMSNiE KVEENTEVA---SI 217 WP_003733029 144 DSQKKADLRLVYLALAHIIKYRGHFLIEGA-LDTKNTSIDEM--FKQFLQIYNQV--FANDiE KTEKNQEVA---QI 217 WP_003739838 144 NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTKNTSVDGV--YKQFIQTYNQV--FISNiE KMEENTTVA---DI 217 WP_014601172 144 NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTKNTSVDGV--YEQFIQTYNQV--FMSNiE KVEENIEVA---NI 217 WP_023548323 144 NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTKNTSVDGV--YEQFILTYNQV--FMSNiE KVEENIEVA---NI 217 WP_031665337 144 NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTKNTSVDGV--YEQFIQTYNQV--FMSNiE KVEENIEVA---NI 217 WP_031669209 144 DSQKKADLRLVYLALAHIIKYRGHFLIEGA-LDTKNTSIDEM--FKQFLQIYNQV--FANDiE KTEKNQEVA---QI 217 WP_033920898 144 NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTKNTSVDGV--YEQFIQTYNQV--FMSNiE KVEENIEVA---NI 217 AKI42028 147 NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTKNTSVDGV--YEQFIQTYNQV--FMSNiE KVEENIEVA---NI 220 AKI50529 147 NSSEKADLRLVYLALAHIIKYRGNFLIEGA-LDTKNTSVDGV--YEQFIQTYNQV--FMSNiE KVEENIEVA---NI 220 EFR83390 --------------------------------------------------------------- -------------- WP_046323366 144 NSSDKADLRLVYLALAHIIKYRGNFLIEGK-LDTKNTSVDEV--FKQFIKTYNQV--FASDiE RIEENNEVA---KI 217 AKE81011 160 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI 227 CUO82355 144 ESTEKADPRLIYLALHHIVKYRGNFLYEGQkFNMDASNIEDK--LSDVFTQFADFnnIPYEdD --KKNLEIL---EI 214 WP_033162887 145 ENKEKADPRLIYLALHHIVKYRGNFLYEGQsFTMDNSDIEER--LNSAIEKFMSIneFDNRiV --SDINSMI---AV 215 AGZ01981 177 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI 244 AKA60242 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI 211 AKS40380 144 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI 211 4UN5_B 148 DSTDKADLRLIYLALAHMIKFRGHFLIEGD-LNPDNSDVDKL--FIQLVQTYNQL--FEEN-- INASGVDAK---AI 215 WP_010922251 212 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-

---KLQ--LSKDTYDDDLDN 277 WP_039695303 213 LTEK-ISKSRRLENLIKY-Y-PT EKKNTLFGNLIALALGLQPNFKTNF--KLSED-A---KLQ--FSKDTYEEDLEE 278 WP_045635197 212 FTDK-ISKSAKRERVLKL-F-PD EKSTGLFSEFLKLIVGNQADFKKHF--DLEDK-A---PLQ--FSKDTYDEDLEN 277 5AXW_A 135 LSTK--------EQISRN-S--K ------------------LEEKyVa--ELQ------------------------ 157 WP_009880683 ------- ---------------------- WP_010922251 212 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_011054416 212 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_011284745 212 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_011285506 212 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_011527619 212 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_012560673 212 LSAR-LSKSRRLENLIAQ-L-PG EKRNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_014407541 212 LSAR-LSKSRRLENLIAQ-L-PG EKRNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_020905136 212 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_023080005 212 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_023610282 212 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_030125963 212 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_030126706 212 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_031488318 212 LSAR-LSKSRRLENLIAQ-L-PG EKRNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_032460140 212 LSAR-LSKSRRLENLIAQ-L-PG EKRNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_032461047 212 LSAR-LSKSRRLENLIAQ-L-PG EKRNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_032462016 212 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_032462936 212 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALLLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_032464890 212 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_033888930 37 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 102 WP_038431314 212 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_038432938 212 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-T---KLQ--LSKDTYDDDLDN 277 WP_038434062 212 LSAR-LSKSRRLENLIAQ-L-PG EKRNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 BAQ51233 123 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 188 KGE60162 ----------------------- ------------------------------------------------------ KGE60856 ----------------------- ------------------------------------------------------ WP_002989955 212 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_003030002 212 LTEK-VSKSRRLENLIAH-Y-PA EKKNTLFGNLIALSLGLQPNFKTNF--QLSED-A---KLQ--FSKDTYEEDLEG 277 WP_003065552 215 LTEK-ISKSRRLENLIKY-Y-PT EKKNTLFGNLIALALGLQPNFKMNF--KLSED-A---KLQ--FSKDSYEEDLGE 280 WP_001040076 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_001040078 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_001040080 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_001040081 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_001040083 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_001040085 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_001040087 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_001040088 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_001040089 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_001040090 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_001040091 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_001040092 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_001040094 213 LTDK-ISKSAKKDRILAR-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_001040095 213 LTDK-ISKSAKKDRILAR-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_001040096 213 LTDK-ISKSAKKDRILAR-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_001040097 213 LTDK-ISKSAKKDRILAR-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_001040098 213 LTDK-ISKSAKKDRILAR-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_001040099 213 LTDK-ISKSAKKDRILAR-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_001040100 213 LTDK-ISKSAKKDRILAR-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_001040104 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_001040105 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_001040106 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_001040107 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_001040108 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_001040109 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_001040110 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_015058523 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_017643650 213 LTDK-ISKSAKKDRILAR-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_017647151 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_017648376 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_017649527 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_017771611 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_017771984 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 CFQ25032 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 CFV16040 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 KLJ37842 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 KLJ72361 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 KLL20707 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 KLL42645 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_047207273 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_047209694 213 LTDK-ISKSAKKDRILAR-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_050198062 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_050201642 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_050204027 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_050881965 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_050886065 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 AHN30376 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 EA078426 213 LTDK-ISKSAKKDRILAQ-Y-PN QKSTGIFAEFLKLIVGNQADFKKYF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 CCW42055 213 LTDK-ISKSAKKDRILAQ-Y-PD QKSTGIFAEFLKLIVGNQADFKKHF--NLEDK-T---PLQ--FAKDSYDEDLEN 278 WP_003041502 212 LTEK-VSKSRRLENLIAH-Y-PA EKKNTLFGNLIALFLGLQPNFKTNF--QLSED-A---KLQ--FSKDTYEEDLEG 277 WP_037593752 213 LTEK-VSKSSRLENLIAH-Y-PT EKKNTLFGNLIALSLGLQPNFKTNF--QLSED-A---KLQ--FSKDTYEEDLEE 278 WP_049516684 213 LTEK-VSKSRRLENLVEC-Y-PT EKKNTLFGNLIALSLGLQPNFKTNF--QLSED-A---KLQ--FSKDTYEEDLEG 278 GAD46167 212 LTEK-VSKSSRLENLIAH-Y-PT EKKNTLFGNLIALSLGLQPNFKTNF--QLSED-A---KLQ--FSKDTYEEDLEE 277 WP_018363470 213 LTEK-ISKSRRLENLINN-Y-PK EKKNTLFGNLIALALGLQPNFKTNF--KLSED-A---KLQ--FSKDTYEEDLEE 278 WP_003043819 212 LSAR-LSKSKRLEKLIAV-F-PN EKKNGLFGNIIALALGLTPNFKSNF--DLTED-A---KLQ--LSKDTYDDDLDE 277 WP_006269658 212 LTEK-VSKSSRLENLIAH-Y-PT EKKNTLFGNLIALSLDLHPNFKTNF--QLSED-A---KLQ--FSKDTYEEDLEG 277 WP_048800889 212 LTEK-VSKSRRLENLVKC-Y-PT EKKNTLFGNLIALSLGLQPNFKTNF--QLSED-A---KLQ--FSKDTYEEDLEE 277 WP_012767106 212 LSAR-LSKSRRLENLIAQ-L-PG EKRNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_014612333 212 LSAR-LSKSKRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_015017095 212 LSAR-LSKSRRLENLIAQ-L-PG EKRNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_015057649 212 LSAR-LSKSRRLENLIAQ-L-PG EKRNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_048327215 212 LSAR-LSKSRRLENLIAQ-L-PG EKRNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_049519324 212 LSAR-LSKSRRLENLIAQ-L-PG EKRNGLFGNLIALSLGLTPNFKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_012515931 212 LSAA-LSKSKRLENLISL-I-PG QKKTGIFGNIIALSLGLTPNFKANF--GLSKD-V---KLQ--LAKDTYADDLDS 277 WP_021320964 212 LSAA-LSKSKRLENLISL-I-PG QKKTGIFGNIIALSLGLTPNFKANF--GLSKD-V---KLQ--LAKDTYADDLDS 277 WP_037581760 212 LSAA-LSKSKRLENLISL-I-PG QKKTGIFGNIIALSLGLTPNFKANF--GLSKD-V---KLQ--LAKDTYADDLDS 277 WP_004232481 212 LTEK-ISKSRRLENLIKQ-Y-PT EKKNTLFGNLVALALGLQPNFKTNF--KLSED-A---KLQ--FSKDTYDEDLEE 277 WP_009854540 213 LTEK-ISKSRRLENLIKY-Y-PT EKKNTLFGNLIALALGLQPNFKMNF--KLSED-A---KLQ--FSKDTYEEDLEE 278 WP_012962174 213 LTEK-FSKSRRLENLIKH-Y-PT EKKNTLFGNLVALALGLQPNFKTSF--KLSED-A---KLQ--FSKDTYEEDLEE 278 WP_039695303 213 LTEK-ISKSRRLENLIKY-Y-PT EKKNTLFGNLIALALGLQPNFKTNF--KLSED-A---KLQ--FSKDTYEEDLEE 278 WP_014334983 212 LTEK-VSKSRRLENLIKQ-Y-PT EKKNTLFGNLIALALGLQPNFKTNF--KLSED-A---KLQ--FSKDTYEEDLEE 277 WP_003099269 212 LTSK-TSKSRRLENLIAE-I-PN QKRNMLFGNLVSLALGLTPNFKTNF--ELLED-A---KLQ--ISKDSYEEDLDN  277 AHY15608 212 LTSK-TSKSRRLENLIAE-I-PN QKRNMLFGNLVSLALGLTPNFKTNF--ELLED-A---KLQ--ISKDSYEEDLDN 277 AHY17476 212 LTSK-TSKSRRLENLIAE-I-PN QKRNMLFGNLVSLALGLTPNFKTNF--ELLED-A---KLQ--ISKDSYEEDLDN 277 ESR09100 ----------------------- ------------------------------------------------------ AGM98575 212 LTSK-TSKSRRLENLIAE-I-PN QKRNMLFGNLVSLALGLTPNFKTNF--ELLED-A---KLQ--ISKDSYEEDLDN 277 ALF27331 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV 277 WP_018372492 210 FTEN-SSKAKRVETILGL-F-PD ETAAGNLDKFLKLMLGNQADFKKVF--DLEEK----iTLQ--FSKDSYEEDLEL 275 WP_045618028 213 FTDK-ISKSAKRERVLKL-F-PD EKSTGLFSEFLKLIVGNQADFKKHF--DLEEK-A---PLQ--FSKDTYDEDLEN 278 WP_045635197 212 FTDK-ISKSAKRERVLKL-F-PD EKSTGLFSEFLKLIVGNQADFKKHF--DLEDK-A---PLQ--FSKDTYDEDLEN 277 WP_002263549 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV 277 WP_002263887 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV 277 WP_002264920 212 LTEK-ISKSRRLEKLINN-Y-PK EKKNTLFRNLVALSLGLQPNFKTNF--KLSED-A---KLQ--FSKDTYEEDLEE 277 WP_002269043 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDIYEEELEV 277 WP_002269448 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV 277 WP_002271977 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEDLEE 277 WP_002272766 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEDLEE 277 WP_002273241 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV 277 WP_002275430 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV 277 WP_002276448 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV 277 WP_002277050 212 LTEK-ISKSRRLEKLINN-Y-PK EKKNTLFGNLIALSLGLQPNFKTNF--KLSED-A---KLQ--FSKDTYEEDLEE 277 WP_002277364 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV 277 WP_002279025 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV 277 WP_002279859 212 LTEK-ISKSRRLEKLINN-Y-PK EKKNTLFGNLIALSLGLQPNFKTNF--KLSED-A---KLQ--FSKDTYEEELEV 277 WP_002280230 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV 277 WP_002281696 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV 277 WP_002282247 212 LTEK-ISKSRRLEKLINN-Y-PK EKKNTLFGNLIALSLGLQPNFKTNF--KLSED-A---KLQ--FSKDTYEEDLEE 277 WP_002282906 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV 277 WP_002283846 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDIYEEELEV 277 WP_002287255 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV 277 WP_002288990 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDIYEEELEV 277 WP_002289641 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGCFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV 277 WP_002290427 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDIYEEELEV 277 WP_002295753 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV 277 WP_002296423 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDIYEEELEV 277 WP_002304487 212 LTEK-VSKSRRLENLVEC-Y-PT EKKNTLFGNLIALSLGLQPNFKTNF--QLSED-A---KLQ--FSKDTYEEDLEG 277 WP_002305844 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV 277 WP_002307203 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--LSKDTYEEELEV 277 WP_002310390 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDIYEEELEV 277 WP_002352408 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDIYEEELEV 277 WP_012997688 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV 277 WP_014677909 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDIYEEELEV 277 WP_019312892 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV 277 WP_019313659 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIIGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV 277 WP_019314093 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--LSKDTYEEELEV 277 WP_019315370 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV 277 WP_019803776 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-V---PLQ--FSKDTYEEELEV 277 WP_019805234 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDIYEEELEV 277 WP_024783594 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV 277 WP_024784288 212 LTEK-ISKSRRLEKLINN-Y-PK EKKNTLFGNLIALSLGLQPNFKTNF--KLSED-A---KLQ--FSKDTYEEDLEE 277 WP_024784666 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV 277 WP_024784894 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV 277 WP_024786433 212 LTEK-ISKSRRLEKLINN-Y-PK EKKNTLFGNLIALSLGLQPNFKTNF--KLSED-A---KLQ--FSKDTYEEDLEE 277 WP_049473442 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEDLEE 277 WP_049474547 212 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV 277 EMC03581 205 LTDK-ISKSAKKDRVLKL-F-PN EKSNGRFAEFLKLIVGNQADFKKHF--ELEEK-A---PLQ--FSKDTYEEELEV 270 WP_000428612 213 FTDK-ISKSAKRERVLKL-F-PD EKSTGLFSEFLKLIVGNQADFKKHF--DLEEK-A---PLQ--FSRDTYDEDLEN 278 WP_000428613 213 FTDK-ISKSAKRERVLKL-F-PD EKSTGLFSEFLKLIVGNQADFKKHF--DLGEK-A---PLQ--FSKDTYDEDLEN 278 WP_049523028 212 FTDK-ISKSAKRDRVLKL-F-PD EKSTGLFSEFLKLIVGNQADFKKHF--DLEEK-A---PLQ--FSKDTYEEDLES 277 WP_003107102 181 LTEK-MSKSRRLENLIAK-I-PN QKKNTLFGNLISLSLGLTPNFKANF--ELSED-A---KLQ--ISKESFEEDLDN 246 WP_054279288 214 LTEK-ISKTRRLENLISN-I-PG QKKNGLFGNLIALSLGLTPNFKSHF--NLPED-A---KLQ--LAKDTYDEELNN 279 WP_049531101 213 FTDK-ISKSTKRERVLKL-F-PD QKSTGLFSEFLKLIVGNQADFKKHF--DLEEK-A---PLQ--FSKDTYDEDLEN 278 WP_049538452 213 FSDK-ISKSAKRERVLKL-F-PD EKSTGLFSEFLKLIVGNQADFKKHF--DLEEK-A---PLQ--FSKDTYDEDLEN 278 WP_049549711 213 FTDK-ISKSAKRERVLKL-F-PD EKSTGLFSEFLKLIVGNQADFKKHF--DLGEK-A---PLQ--FSKDTYDEDLEN 278 WP_007896501 214 LTAK-TSKSKRLESLISE-F-PG QKKNGLFGNLLALALGLRPNFKSNF--GLSED-A---KLQ--ITKDTYEEELDN 279 EFR44625 166 LTAK-TSKSKRLESLISE-F-PG QKKNGLFGNLLALALGLRPNFKSNF--GLSED-A---KLQ--ITKDTYEEELDN 231 WP_002897477 212 FTDK-ISKSAKRERVLKL-F-PD EKSTGLFSEFLKLIVGNQADFKKHF--DLEEK-A---PLQ--FSKDTYDEELEN 277 WP_002906454 212 FTDK-ISKSTKRERVLKL-F-SD EKSTGLFSEFLKLIVGNQADFKKHF--DLEEK-A---PLQ--FSKDTYDEDLEN 277 WP_009729476 213 FTDK-ISKSAKRERVLKL-F-PD EKSTGLFSEFLKLIVGNQADFKKHF--DLEEK-A---PLQ--FSRDTYDEDLEN 278 CQR24647 212 ITAK-ISKSRKVEAVLEQ-F-PD QKKNSFFGNMVSLVFGLMPNEKSNF--ELDED-A---KLQ--FSRDSYDEDLEN 277 WP_000066813 213 FTDK-ISKSTKRERVLKL-F-PD EKSTGLFSEFLKLIVGNQADFKKHF--DLEEK-A---PLQ--FSKDTYDEDLEN 278 WP_009754323 213 FTGK-ISKSVKREHVLKL-F-PD EKSTGLFSEFLKLIVGNQADFKKHF--DLEEK-A---SLQ--FSKDTYDEDLEN 278 WP_044674937 212 LVEK-VSKSRRLENILHY-F-PN EKKNGLFGNFLALALGLQPNEKTNF--ELAED-A---KIQ--FSKETYEEDLEE 277 WP_044676715 212 LVEK-VSKSRRLENILHY-F-PN EKKNGLFGNFLTLALGLQPNEKTNF--ELAED-A---KIQ--FSKETYEEDLEE 277 WP_044680361 212 LVEK-VSKSRRLENILHY-F-PN EKKNGLFGNFLALALGLQPNEKTNF--ELAED-A---KIQ--FSKETYEEDLEE 277 WP_044681799 212 LVEK-VSKSRRLENILHY-F-PN EKKNGLFGNFLALALGLQPNEKTNF--ELAED-A---KIQ--FSKETYEEDLEE 277 WP_049533112 212 LTEK-VSKSRRLENLIAH-Y-PA EKKNTLFGNLIALSLGLQPNEKTNF--QLSED-A---KLQ--FSKDTYEEDLEG 277 WP_029090905 172 LLDRmMNRSSKVKFLIEL---TG KQDKPLLKELFNLIVGLKAKPASIFe---QEN1AtivETM-nMSTEQVQLDLLT 243 WP_006506696 211 LKKP-LSKKAKVDEVMTL-IaPE KDYKSAFKELVTGIAGNKMNVTKMI1cEPIKQ-Gds-EIK1kFSDSNYDDQFSE 283 AIT42264 212 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNEKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_034440723 218 FKQD-ISRSKKLDQAIAL-F-QG -KRQSLFGIFLTLIVGNKANFQKIF--NLEDD----iKLD--LKEEDYDENLEE 283 AKQ21048 212 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNEKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 WP_004636532 211 LSSK-QSRSRKHEQIMAL-F-PN ENKLGNFGRFMMLIVGNTSNFKPVF--DLDDE-Y---KLK--LSDETYEEDLDT 276 WP_002364836 218 LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KI--tYASESYEEDLEG 283 WP_016631044 169 LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KI--tYASESYEEDLEG 234 EM575795 1 ----------------------- ----------------------------MDEE-A---KIQ--LSKESYEEELES 20 WP_002373311 218 LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KI--tYASESYEEDLEG 283 WP_002378009 218 LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KI--tYASESYEEDLEG 283 WP_002407324 218 LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KI--tYASESYEEDLEG 283 WP_002413717 218 LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KI--tYASESYEEDLEG 283 WP_010775580 218 LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KIKitYASESYEEDLEG 285 WP_010818269 218 LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KI--tYASESYEEDLEG 283 WP_010824395 218 LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KI--tYASESYEEDLEG 283 WP_016622645 218 LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KI--tYASESYEEDLEG 283 WP_033624816 218 LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KI--tYASESYEEDLEG 283 WP_033625576 218 LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KI--tYASESYEEDLEG 283 WP_033789179 218 LTEK-ASRTKKSEKVLQQ-F-PQ EKANGLFGQFLKLMVGNKADFKKVF--GLEEE-A---KI--tYASESYEEDLEG 283 WP_002310644 217 FTEK-MSKTKKAETLLKY-F-PH EKSNGYLSQFIKLMVGNQGNFKNVF--GL-EE-A---KLQ--FSKETYEEDLEE 281 WP_002312694 217 FTEK-MSKTKKAETLLKY-F-PH EKSNGYLSQFIKLMVGNQGNFKNVF--GL-EEeA---KLQ--FSKETYEEDLEE 282 WP_002314015 217 FTEK-MSKTKKAETLLKY-F-PH EKSNGYLSQFIKLMVGNQGNFKNVF--GL-EEeA---KLQ--FSKETYEEDLEE 282 WP_002320716 217 FTEK-MSKTKKAETLLKY-F-PH EKSNGYLSQFIKLMVGNQGNFKNVF--GL-EEeA---KLQ--FSKETYEEDLEE 282 WP_002330729 217 FTEK-MSKTKKAETLLKY-F-PH EKSNGYLSQFIKLMVGNQGNFKNVF--GL-EE-A---KLQ--FSKETYEEDLEE 281 WP_002335161 217 FTEK-MSKTKKAETLLKY-F-PH EKSNGYLSQFIKLMVGNQGNFKNVF--GL-EEeA---KLQ--FSKETYEEDLEE 282 WP_002345439 217 FTEK-MSKTKKAETLLKY-F-PH EKSNGYLSQFIKLMVGNQGNFKNVF--GL-EEeA---KLQ--FSKETYEEDLEE 282 WP_034867970 210 LTDK-LSKTKKVEEILKY-Y-PT EKINSFFAQCLKLIVGNQANFKRIF--DLEAE-V---KLQ--FSKETYEEDLES 275 WP_047937432 217 FTEK-MSKTKKAETLLKY-F-PH EKSNGYLSQFIKLMVGNQGNFKNVF--GL-EEeA---KLQ--FSKETYEEDLEE 282 WP_010720994 210 LTDK-LSKTKKVEEILKY-Y-PT EKINSFFAQCLKLIVGNQANFKRIF--DLEAE-V---KLQ--FSKETYEEDLES 275 WP_010737004 210 LTDK-LSKTKKVEEILKY-Y-PT EKINSFFAQCLKLIVGNQANFKRIF--DLEAE-V---KLQ--FSKETYEEDLES 275 WP_034700478 210 LTDK-LSKTKKVEEILKY-Y-PT EKINSFFAQCLKLIVGNQANFKRIF--DLEAE-V---KLQ--FSKETYEEDLES 275 WP_007209003 215 LTQQ-LSKSERADNVLKL-F-PD EKGTGIFAQFIKLIVGNQGNFKKVF--QLEED----qKLQ--LSTDDYEENIEN 280 WP_023519017 210 LTER-LSKAKRVEKVLAY-Y-PS EKSTGNFAQFLKLMVGNQANFKKTF--DLEEE-M---KLN--FTRDCYEEDLNE 275 WP_010770040 213 FSEK-VSRARKVEAILSV-Y-SE EKSTGTLAQFLKLMVGNQGRFKKTF--DLEED-G---IIQ--IPKEEYEEELET 278 WP_048604708 209 FADK-VSRAKKAEGVLAL-F-PD EKRNGTFDQFLKMIVGNQGNFKKTF--ELEED-A---KLQ--FSKEEYDESLEA 274 WP_010750235 210 LTDK-LSKSKKVEKILQY-Y-PK EKTTGCLAQFLKLIVGNQGNFKQAF--HLDEE-V---KIQ--ISKETYEEDLEK 275 AII16583 251 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLFGNLIALSLGLTPNEKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 316 WP_029073316 216 LKEP-LSKKHKADKAFAL-FdTT KDNKAAYKELCAALAGNKFNVTKMLkeAELHD-EdekDISfkFSDATFDDAFVE 289 WP_031589969 216 LKEP-LSKKHKAEKAFAL-FdTT KDNKAAYKELCAALAGNKFNVTKMLkeAELHD-EdekDISfkFSDATFDDAFVE 289 KDA45870 210 FKDNtFSKTKKSEELLKL---SG -KKNQLAHQLFKMMVGNMGSFKKVL--GTDEE----hKLS--FGKDTYEDDLND 275 WP_039099354 207 LLDNhQSASNRQRQALLLiYtPS KQNKAIATELLKAILGLKAKFNVLT--GIEAEdVktwTLT--FNAENFDEEMVK 285 AKP02966 209 LIGR-GNATQKSSNILNN-F--T KETKKLLKEVINLILGNVAHLNTIFktSLTKDeE---KLS--FSGKDIESKLDD 278 WP_010991369 218 LVEK-VTRKEKLERILKL-Y-PG EKSAGMFAQFISLIVGSKGNFQKPF--DLIEK-S---DIE--CAKDSYEEDLES 283 WP_033838504 218 LVEK-VTRKEKLERILKL-Y-PG EKSAGMFAQFISLIVGSKGNFQKPF--DLIEK-S---DIE--CAKDSYEEDLES 283 EHN60060 221 LVEK-VTRKEKLERILKL-Y-PG EKSAGMFAQFISLIVGSKGNFQKPF--DLIEK-S---DIE--CAKDSYEEDLES 286 EFR89594 1 ---------------LKL-Y-PG EKSTGMFAQFISLIVGSKGNFQKPF--DLIEK-S---DIE--CAKDSYEEDLES 52 WP_038409211 218 LSEK-LTRREKLDKILKL-Y-TG EKSTGMFARFINLIIGSKGDFKKVF--DLDEK-A---EIE--CAKDTYEEDLEA 283 EFR95520 ----------------------- ------------------------------------------------------ WP_003723650 218 LAGK-FTRREKFERILQL-Y-PG EKSTGMFAQFISLIVGSKGNFQKVF--DLIEK-T---DIE--CAKDSYEEDLET 283 WP_003727705 218 LAGK-FTRREKFERILRL-Y-PG EKSTGMFAQFISLIVGNKGNFQKVF--NLVEK-T---DIE--CAKDSYEEDLEA 283 WP_003730785 218 LAGK-FTRREKFERILRL-Y-PG EKSTGMFAQFISLIVGNKGNFQKVF--NLVEK-T---DIE--CAKDSYEEDLEA 283 WP_003733029 218 LAEK-FTRKDKLDKILSL-Y-PG EKTTGVFAQFVNIIVGSTGKEKKHF--NLHEK-K---DIN--CAEDTYDTDLES 283 WP_003739838 218 LAGK-FTRKEKLERILQL-Y-PG EKSTGMFAQFISLIVGSKGNFQKVF--DLVEK-T---DIE--CAKDSYEEDLEA 283 WP_014601172 218 LAGK-FTRREKFERILQL-Y-PG EKSTGMFAQFISLIVGSKGNFQKVF--DLIEK-T---DIE--CAKDSYEEDLEA 283 WP_023548323 218 LAGK-FTRREKFERILQL-Y-PG EKSTGMFAQFISLIVGSKGNFQKVF--DLIEK-T---DIE--CAKDSYEEDLET 283 WP_031665337 218 LAGK-FTRREKFERILQL-Y-PG EKSTGMFAQFISLIVGSKGNFQKVF--DLIEK-T---DIE--CAKDSYEEDLET 283 WP_031669209 218 LAEK-FTRKDKLDKILSL-Y-PG EKTTGVFAQFVNIIVGSTGKEKKHF--NLHEK-K---DIN--CAEDTYDTDLES 283 WP_033920898 218 LARK-FTRREKFERILQL-Y-PG EKSTGMFAQFISLIVGSKGNFQKVF--DLIEK-T---DIE--CAKDSYEEDLET 283 AKI42028 221 LAGK-FTRREKFERILQL-Y-PG EKSTGMFAQFISLIVGSKGNFQKVF--DLIEK-T---DIE--CAKDSYEEDLEA 286 AKI50529 221 LARK-FTRREKFERILQL-Y-PG EKSTGMFAQFISLIVGSKGNFQKVF--DLIEK-T---DIE--CAKDSYEEDLET 286 EFR83390 ----------------------- ------------------------------------------------------ WP_046323366 218 FSEK-LTKREKLDKILNL-Y-PN EKSTDLFAQFISLIIGSKGNEKKFF--NLTEK-T---DIE--CAKDSYEEDLEV 283 AKE81011 228 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLEGNLIALSLGLTPNEKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 293 CUO82355 215 LKKP-LSKKAKVDEVMAL-IsPE KEFKSAYKELVTGIAGNKMNVTKMIlcESIKQ-Gds-EIK1kFSDSNYDDQFSE 287 WP_033162887 216 LSKI-YQRSKKADDLLKI-MnPT KEEKAAYKEFTKALVGLKFNISKMIlaQEVKK-Gdt-DIV1eFSNANYDSTIDE 288 AGZ01981 245 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLEGNLIALSLGLTPNEKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 310 AKA60242 212 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLEGNLIALSLGLTPNEKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 AKS40380 212 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLEGNLIALSLGLTPNEKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 277 4UN5_B 216 LSAR-LSKSRRLENLIAQ-L-PG EKKNGLEGNLIALSLGLTPNEKSNF--DLAED-A---KLQ--LSKDTYDDDLDN 281 WP_010922251 278 LLAQIGDQYADLFLAA

NLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_039695303 279 LLGKIGDDYADLFTSAKNLYDAILLSGILTVDDNSTKAPLSASMIKRYVEHHEDLEKLKEFIKAN-KSELYHDIFKDKNK 357 WP_045635197 278 LLGQIGDDFTDLFVSAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQNDLAALKQFIKNN-LPEKYDEVFSDQSK 356 5AXW_A 158 ---------------------------------------------------------LERLKKDG-------EVR-----  168 WP_009880683 1 ---------------------------------------LSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 40 WP_010922251 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_011054416 278 LLAQIGDQYADLFLAAKNLSDATLLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_011284745 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRLNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_011285506 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_011527619 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRLNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_012560673 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_014407541 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_020905136 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRLNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_023080005 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_023610282 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_030125963 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKASLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_030126706 278 LLAQIGDQYADLFLAAKNLSDATLLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_031488318 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_032460140 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_032461047 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_032462016 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_032462936 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_032464890 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRLNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_033888930 103 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 181 WP_038431314 278 LLAQIGDQYADLFLAAKNLSDATLLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_038432938 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_038434062 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 BAQ51233 189 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 267 KGE60162 -------------------------------------------------------------------------------- KGE60856 -------------------------------------------------------------------------------- WP_002989955 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRLNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_003030002 278 LLGEIGDEYADLFASAKNLYDAILLSGILTVDDNSTKAPLSASMVKRYEEHQKDLKKLKDFIKVN-APDQYNAIFKDKNK 356 WP_003065552 281 LLGKIGDDYADLFTSAKNLYDAILLSGILIVDDNSTKAPLSASMIKRYVEHQEDLEKLKEFIKAN-KSELYHDIFKDKNK 359 WP_001040076 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIVADSSK 357 WP_001040078 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_001040080 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_001040081 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_001040083 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_001040085 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_001040087 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_001040088 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_001040089 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_001040090 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_001040091 279 LLRQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_001040092 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSAYMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_001040094 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQHYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_001040095 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_001040096 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_001040097 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_001040098 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_001040099 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_001040100 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_001040104 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_001040105 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_001040106 279 LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFTDSSK 357 WP_001040107 279 LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFTDSSK 357 WP_001040108 279 LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFTDSSK 357 WP_001040109 279 LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFTDSSK 357 WP_001040110 279 LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFTDSSK 357 WP_015058523 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_017643650 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_017647151 279 LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFTDSSK 357 WP_017648376 279 LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFTDSSK 357 WP_017649527 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_017771611 279 LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTALSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFTDSSK 357 WP_017771984 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 CFQ25032 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKASLSDSMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 CFV16040 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 KLJ37842 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 KLJ72361 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 KLL20707 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 KLL42645 279 LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFTDSSK 357 WP_047207273  279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_47209694  279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_050198062  279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_050201642  279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_050204027  279 LLGQIGDEFADLFSVAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFTDSSK 357 WP_050881965  279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_050886065  279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 AHN30376 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 EA078426 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVIDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 CCW42055 279 LLGQIGDEFADLFSAAKKLYDSVLLSGILTVTDLSTKAPLSASMIQRYDEHREDLKQLKQFVKAS-LPEKYQEIFADSSK 357 WP_003041502  278 LLGEVGDEYADLFASAKNLYDAILLSGILTVDDNSTKAPLSASMVKRYEEHQKDLKKFEDFIKVN-ALDQYNAIFKDKNK 356 WP_037593752  279 LLGEIGDEYADLFASAKNLYDAILLSGILAVDDNTTKAPLSASMVKRYEEHQKDLKKLKDFIKVN-APDQYNAIFKDKNK 357 WP_049516684  279 LLGEIGDEYADLFASAKNLYDAILLSGILAVDDNTTKAPLSASMVKRYEEHQKDLKKLKDFIKVN-APAQYDDIFKDETK 357 GAD46167 278 LLGEIGDEYADLFASAKNLYDAILLSGILAVDDNTTKAPLSASMVKRYEEHQKDLKKLKDFIKVN-APDQYNAIFKDKNK 356 WP_018363470  279 LLGKIGDDYADLFTSSKNLYDAILLSGILTVDDNSTKAPLSASMIKRYVEHHEDLEKLKEFIKAN-KSELYHDIFKDKTQ 357 WP_003043819  278 LLGQIGDQYADLFSAAKNLSDAILLSDILRSNSEVTKAPLSASMVKRYDEHHQDLALLKTLVRQQ-FPEKYAEIFKDDTK 356 WP_006269658  278 FLGEVGDEYADLFASAKNLYDAILLSGILTVDDNSTKAPLSASMVKRYEEHQKDLKKLKDFIKVN-APDQYNAIFKDKNK 356 WP_048800889  278 LLGKIGDDYADLFTSAKNLYDTILLSGILAVDDNSTKALLSASMIKRYEEHQKDLKKLKDFIKVN-APAQYDDIFKDETK 356 WP_012767106  278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_014612333  278 LLAQIGNQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_015017095  278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_015057649  278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_048327215  278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_049519324  278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_012515931  278 LLAQIGDQYADLFLAAKNLSDAILLSDILTESDEITRAPLSASMVKRYREHHKDLVTLKTLIKDQ-LPEKYQEIFLDKTK  356 WP_021320964  278 LLAQIGDQYADLFLAAKNLSDAILLSDILTESDEITRAPLSASMVKRYREHHKDLVTLKTLIKDQ-LPEKYQEIFLDKTK  356 WP_037581760  278 LLAQIGDQYADLFLAAKNLSDAILLSDILTESDEITRAPLSASMVKRYREHHKDLVTLKTLIKDQ-LPEKYQEIFLDKTK  356 WP_004232481  278 LLGKIGDDYADLFTAAKNLYDAILLSGILTVDDNSTKAPLSASMIKRYEEHHEDLEKLKTFIKVN-NFDKYHEIFKDKSK 356 WP_009854540  279 LLGKIGDDYADLFTSAKNLYDAILLSGILTVDDNSTKAPLSASMIKRYVEHHEDLEKLKEFIKAN-KSELYHDIFKDKNK 357 WP_012962174  279 LIGKIGDEYADLFTSAKNLYDAILLSGILTVADNTTKAPLSASMIKRYNEHQVDLKKLKEFIKNN-ASDKYDEIFNDKDK 357 WP_039695303 279 LLGKIGDDYADLFTSAKNLYDAILLSGILTVDDNSTKAPLSASMIKRYVEHHEDLEKLKEFIKAN-KSELYHDIFKDKNK 357 WP_014334983 278 LLGKVGDDYADLFISAKNLYDAILLSGILTVDDNSTKAPLSASMIKRYVEHHEDLEKLKEFIKIN-KLKLYHDIFKDKTK 356 WP_003099269 278 LLAQIGDQYADLFIAAKKLSDAILLSDIITVKGASTKAPLSASMVQRYEEHQQDLALLKNLVKKQ-IPEKYKEIFDNKEK 356 AHY15608 278 LLAQIGDQYADLFIAAKKLSDAILLSDIITVKGASTKAPLSASMVQRYEEHQQDLALLKNLVKKQ-IPEKYKEIFDNKEK 356 AHY17476 278 LLAQIGDQYADLFIAAKKLSDAILLSDIITVKGASTKAPLSASMVQRYEEHQQDLALLKNLVKKQ-IPEKYKEIFDNKEK 356 ESR09100 -------------------------------------------------------------------------------- AGM98575 278 LLAQIGDQYADLFIAAKKLSDAILLSDIITVKGASTKAPLSASMVQRYEEHQQDLALLKNLVKKQ-IPEKYKEIFDNKEK 356 ALF27331 278 LLAQIEDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_018372492 276 LLSKIDEEYAALFDLAKKVYDAVLLSNILTVKEKNTKAPLSASMIKRYEEHKDDLKAFKRFFRER-LPEKYETMFKDLTK 354 WP_045618028 279 LLVQIGDDFADLFLVAKKLYDAILLSGILTVTDPSTKAPLSASMIDRYENHQKDLAALKQFIKTN-LPEKYDEVFSDQSK 357 WP_045635197 278 LLGQIGDDFTDLFVSAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQNDLAALKQFIKNN-LPEKYDEVFSDQSK 356 WP_002263549 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVGTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_002263887 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVGTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_002264920 278 LLGKIGDDYADLFTLAKNLYDAILLSGILTADDSSTKAPLSASMIKRYAEHHEDLEKLKEFIKAN-KPELYHDIFKDETK 356 WP_002269043 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_002269448 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_002271977 278 LLGKIGDDYADLFTLAKNLYDAILLSGILTADDSSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_002272766 278 LLGKIGDDYADLFTLAKNLYDAILLSGILTADDSSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_002273241 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_002275430 278 LLTQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_002276448 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_002277050 278 LLGKIGDDYADLFTLAKNLYDAILLSGILTADDSSTKAPLSASMIKRYAEHHEDLEKLKEFIKAN-KPELYHDIFKDETK 356 WP_002277364 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_002279025 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTADDSSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK  356 WP_002279859 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_002280230 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_002281696 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_002282247 278 LLGKIGDDYADLFTLAKNLYDAILLSGILTADDSSTKAPLSASMIKRYAEHHEDLEKLKEFIKAN-KPELYHDIFKDETK 356 WP_002282906 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVGTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_002283846 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_002287255 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_002288990 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_002289641 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLTQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_002290427 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_002295753 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_002296423 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_002304487 278 LLGEIGDEYADLFASAKNLYDAILLSGILAVDDNTTKAPLSASMVKRYKEHKEELAAFKRFIKEK-LPKKYEEIFKDDTK 356 WP_002305844 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_002307203 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_002310390 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_002352408 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_012997688 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_014677909 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_019312892 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_019313659 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVGTQAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_019314093 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_019315370 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLTQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_019803776 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVGTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_019805234 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_024783594 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVGTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_024784288 278 LLGKIGDDYADLFTLAKNLYDAILLSGILTADDSSTKAPLSASMIKRYAEHHEDLEKLKEFIKAN-KPELYHDIFKDETK 356 WP_024784666 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLVQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_024784894 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLTQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_024786433 278 LLGKIGDDYADLFTLAKNLYDAILLSGILTADDSSTKAPLSASMIKRYAEHHEDLEKLKEFIKAN-KPELYHDIFKDETK 356 WP_049473442 278 LLGKIGDDYADLFTLAKNLYDAILLSGILTADDSSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 356 WP_049474547 278 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLTQLKQFIRQK-LSDKYNEVFSDVSK 356 EMC03581 271 LLAQIGDNYAELFLSAKKLYDSILLSGILTVTDVSTKAPLSASMIQRYNEHQMDLAQLKQFIRQK-LSDKYNEVFSDVSK 349 WP_000428612 279 LLGQIGDDFADLFVAAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQKDLATLKQFIKTN-LPEKYDEVFSDQSK 357 WP_000428613 279 LLGQIGDDFADLFLVAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQKDLAVLKQFIKNN-LPEKYDEVFSDQSK 357 WP_049523028 278 LLGQIGDVYADLFVVAKKLYDAILLAGILSVKDPGTKAPLSASMIERYDNHQNDLSALKQFVRRN-LPEKYAEVFSDDSK 356 WP_003107102 247 LLAQIGDQYADLFIAAKNLSDAILLSDILTVKGVNTKAPLSASMVQRFNEHQDDLKLLKKLVKVQ-LPEKYKEIFDIKDK 325 WP_054279288 280 LLTQIGDEYADLFLSAKNLSDAILLSDILTVNGDGTQAPLSASLIKRYEEHRQDLALLKQMFKEQ-LPDLYRDVFTDENK 358 WP_049531101 279 LLGQIGDDFADLFLVAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQKDLAALKQFIKNN-LPEKYDEVFSDQSK 357 WP_049538452 279 LLGQIGDGFADLFLVAKKLYDAILLSGILTVTDPSTKAPLSASMIERYQNHQNDLASLKQFIKNN-LPEKYDEVFSDQSK 357 WP_049549711 279 LLGQIGDDFADLFLVAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQKDLTTLKQFIKNN-LPEKYDEVFSDQSK 357 WP_007896501 280 LLAEIGDHYADLFLAAKNLSDAILLSDILTLSDENTRAPLSASMIKRYEEHQEDLALLKKLVKEQ-MPEKYWEIFSNAKK 358 EFR44625 232 LLAEIGDHYADLFLAAKNLSDAILLSDILTLSDENTRAPLSASMIKRYEEHQEDLALLKKLVKEQ-MPEKYWEIFSNAKK 310 WP_002897477 278 LLGQIGDDFADLFLIAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQKDLAALKQFIKNN-LPEKYVEVFSDQSK 356 WP_002906454 278 LLGQIGDGFADLFLVAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQEDLAALKQFIKNN-LSEKYAEVFSDQSK 356 WP_009729476 279 LLGQIGDDFADLFLVAKKLYDAILLSGILTVTNPSTKAPLSASMIERYENHQKDLASLKQFIKNN-LPEKYDEVFSDQSE 357 CQR24647 278 LLGIIGDEYADVFVAAKKVYDSILLSGILTTNNHSTKAPLSASMIDRYDEHNSDKKLLRDFIRTNiGKEVFKEVFYDTSK 357 WP_000066813 279 LLGQIGDDFADLFLVAKKLYDAILLSGILTVKDLSTKAPLSASMIERYENHQKDLAALKQFIQNN-LQEKYDEVFSDQSK 357 WP_009754323 279 LLGQIGDDFADLFLVAKKLYDAILLSGILTVTDPSTKAPLSASMIERYENHQEDLAALKQFIKNN-LPEKYAEVFSDQSK 357 WP_044674937 278 LLGKIGDDYADLFIATKSLYDGILLAGILSTTDSTTKAPLSSSMVNRYEEHKKDLALLKNFIHQN-LSDSYKEVENDKLK 356 WP_044676715 278 LLGKIGDDYADLFIATKSLYDGILLAGILSTTDSTTKAPLSSSMVNRYEEHQKDLALLKNFIHQN-LSDSYKEVENDKLK 356 WP_044680361 278 LLGKIGDDYADLFIATKSLYDGILLAGILSTTDSTTKAPLSSSMVNRYEEHQKDLALLKNFIHQN-LSDSYKEVENDKLK 356 WP_044681799 278 LLGKIGDDYADLFIATKSLYDGILLAGILSTTDSTTKAPLSSSMVNRYEEHKKDLALLKNFIHQN-LSDSYKEVENDKLK 356 WP_049533112 278 LLGEIGDEYADLFASAKNLYDAILLSGILTVDDNSTKAPLSASMVKRYEEHQKDLKKLKDFIKVN-APDQYNAIFKDKNK 356 WP_029090905 244 LADVLADEEYDLLLTAQKIYSAIILDESMDGYEYFA-----EAKKESYRKHQEELVLVKKMLKSNaITNDERAKF---EY 315 WP_006506696 284 VEKDLGE-YVEFVDALHNVYSWVELQTIMGATHTD-NASISEAMVSRYNKHHDDLKLLKDCIKNN-VPNKYFDMFRNDSE 360 AIT42264 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_034440723 284 LLSNIDEGYRDVFLQAKNVYNAIELSKILKTDGKETKAPLSAQMVELYNQHREDLKKYKDYIKAY-LPEKYGETFKDATK 362 AKQ21048 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 WP_004636532 277 LLGMTDDVFLDVFMAAKNVYDAVEMSAIISTDTGNSKAVLSNQMINFYDEHKVDLAQLKQFFKTH-LPDKYYECFSDPSK 355 WP_002364836 284 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKKFKRFIREN-CPDEYDNLFKNEQK 362 WP_016631044 235 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKKFKRFIREN-CPDEYDNLFKNEQK 313 EMS75795 21 LLEKSGEEFRDVFLQAKKVYDAILLSDILSTKKQNSKAKLSLGMIERYDSHKKDLEELKQFVKAN-LPEKTAIFFKDSSK 99 WP_002373311 284 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKKFKRFIREN-CPDEYDNLFKNEQK 362 WP_002378009 284 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKNFKRFIREN-CPDEYDNLFKNEQK 362 WP_002407324 284 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKNFKRFIREN-CPDEYDNLFKNEQK 362 WP_002413717 284 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKKFKRFIREN-CPDEYDNLFKNEQK 362 WP_010775580 286 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKNFKRFIREN-CPDEYDNLFKNEQK 364 WP_010818269 284 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKKFKRFIREN-CPDEYDNLFKNEQK 362 WP_010824395 284 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKNFKRFIREN-CPDEYDNLFKNEQK 362 WP_016622645 284 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSYAKLSSSMIVRFTEHQEDLKKFKRFIREN-CPDEYDNLFKNEQK 362 WP_033624816 284 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKNFKRFIREN-CPDEYDNLFKNEQK 362 WP_033625576 284 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKKFKRFIREN-CPDEYDNLFKNEQK 362 WP_033789179 284 ILAKVGDEYSDVFLAAKNVYDAVELSTILADSDKKSHAKLSSSMIVRFTEHQEDLKNFKRFIREN-CPDEYDNLFKNEQK 362 WP_002310644 282 LLEKIGDDYIDLFVQAKNVYDAVLLSEILSDSTKNTRAKLSAGMIRRYDAHKEDLVLLKRFVKEN-LPKKYRAFFGDNSV 360 WP_002312694 283 LLEKIGDDYIDLFVQAKNVYDAVLLSEILSDSTKNTRAKLSAGMIRRYDAHKEDLVLLKRFVKEN-LPKKYRAFFGDNSV 361 WP_002314015 283 LLEKIGDDYIDLFVQAKNVYDAVLLSEILSDSTKNTRAKLSAGMIRRYDAHKEDLVLLKRFVKEN-LPKKYRAFFGDNSV 361 WP_002320716 283 LLEKIGDDYIDLFVQAKNVYDAVLLSEILSDSTKNTRAKLSAGMIRRYDAHKEDLVLLKRFVKEN-LPKKYRAFFGDNSV 361 WP_002330729 282 LLEKIGDDYIDLFVQAKNVYDAVLLSEILSDSTKNTRAKLSAGMIRRYDAHKEDLVLLKRFVKEN-LPKKYRAFFGDNSV 360 WP_002335161 283 LLEKIGDDYIDLFVQAKNVYDAVLLSEILSDSTKNTRAKLSAGMIRRYDAHKEDLVLLKRFVKEN-LPKKYRAFFGDNSV 361 WP_002345439 283 LLEKIGDDYIDLFVQAKNVYDAVLLSEILSDSTKNTRAKLSAGMIRRYDAHKEDLVLLKRFVKEN-LPKKYRAFFGDNSV 361 WP_034867970 276 LLEKIGDEYLDIFLQAKKVHDAILLSEIISSTVKHTKAKLSSGMVERYERHKADLAKFKQFVKEN-VPQKATVFFKDTTK 354 WP_047937432 283 LLEKIGDDYIDLFVQAKNVYDAVLLSEILSDSTKNTRAKLSAGMIRRYDAHKEDLVLLKRFVKEN-LPKKYRAFFGDNSV 361 WP_010720994 276 LLEKIGDEYLDIFLQAKKVHDAILLSEIISSTVKHTQAKLSSGMVERYERHKADLAKFKQFVKEN-VPQKATVFFKDTTK 354 WP_010737004 276 LLEKIGDEYLDIFLQAKKVHDAILLSEIISSTVKHTKAKLSSGMVERYERHKADLAKFKQFVKEN-VPQKATVFFKDTTK 354 WP_034700478 276 LLEKIGDEYLDIFLQAKKVHDAILLSEIISSTVKHTQAKLSSGMVERYERHKADLAKFKQFVKEN-VPQKATVFFKDTTK 354 WP_007209003 281 LLAIIGDEYGDIFVAAQNLYQAILLAGILTSTEK-TRAKLSASMIQRYEEHAKDLKLLKRFVKEH-IPDKYAEIFNDATK 358 WP_023519017 276 LLEKTSDDYAELFLKAKGVYDAILLSQILSKSDDETKAKLSANMKLRFEEHQRDLKQLKELVRRD-LPKKYDDFFKNRSK 354 WP_010770040 279 LLAIIGDEYAEIFSATKSVYDAVALSGILSVTDGDTKAKLSASMVERYEAHQKDLVQFKQFIRKE-LPEMYAPIFRDNSV 357 WP_048604708 275 LLGEIGDEYADVFEAAKNVYNAVELSGILTVTDNSTKAKLSASMIKRYEDHKTDLKLFKEFIRKN-LPEKYHEIFNDKNT 353 WP_010750235 276 LLRKSNEEMIDVFLQVKKVYDAILLSDILSTKMKDTKAKLSAGMIERYQNHKKDLEELKQFVRAH-LHEKVTVFFKDSSK 354 AII16583 317 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 395 WP_029073316 290 KQPLLGD-CVEFIDLLHDIYSWVELQNILGSAHTS-EPSISAAMIQRYEDHKNDLKLLKDVIRKY-LPKKYFEVFRDEKS 366 WP_031589969 290 KQPLLGD-CVEFIDLLHDIYSWVELQNILGSAHTS-EPSISAAMIQRYEDHKNDLKLLKDVIRKY-LPKKYFEVFRDEKS 366 KDA45870 276 LLAEAGDQYLDIFVAAKKVYDAAILASILDVKDTQTKTVFSQAMIERYEEHQKDLIELKRVFKKY-LPEKCHDFFSE-PK 353 WP_039099354 286 LESSLDDNAHQIIESLQELYSGVLLAGIVPENQSLS-----QAMITKYDDHQKHLKMLKAVREAL-APEDRQRLKQAYDQ 359 AKP02966 279 LDSILDDDQFTVLDTANRIYSTITLNEIL-----NGESYFSMAKVNQYENHAIDLCKLRDMWHTT----KNEKAV-GLSR 348 WP_010991369 284 LLALIGDEYAELFVAAKNAYSAVVLSSIITVAETETNAKLSASMIERFDTHEEDLGELKAFIKLH-LPKHYEEIFSNTEK 362 WP_033838504 284 LLALIGDEYAELFVAAKNAYSAVVLSSIITVAETETNAKLSASMIERFDTHEEDLGELKAFIKLH-LPKHYEEIFSNTEK 362 EHN60060 287 LLALIGDEYAELFVAAKNAYSAVVLSSIITVAETETNAKLSASMIERFDTHEEDLGELKAFIKLH-LPKHYEEIFSNTEK 365 EFR89594 53 LLALIGDEYAELFVAAKNAYSAVVLSSIITVAETETNAKLSASMIERFDTHEEDLGELKAFIKLH-LPKHYEEIFSNTEK 131 WP_038409211 284 LLAKIGDEYAEIFVAAKSTYNAVVLSNIITVTDTETKAKLSASMIERFDKHAKDLKRLKAFFKMQ-LPEKFNEVFNDIEK 362 EFR95520 -------------------------------------------------------------------------------- WP_003723650 284 LLAIIGDEYAELFVAAKNTYNAVVLSSIITVTDTETNAKLSASMIERFDAHEKDLVELKAFIKLN-LPKQYEEIFSNAAI 362 WP_003727705 284 LLAIIGDEYAELFVAAKNTYNAVVLSSIITVTATETNAKLSASMIERFDAHEKELGELKAFIKLH-LPKQYQEIFNNAEI 362 WP_003730785 284 LLAIIGDEYAELFVAAKNTYNAVVLSSIITVTATETNAKLSASMIERFDAHEKELGELKAFIKLH-LPKQYQEIFNNAEI 362 WP_003733029 284 LLAIIGDEFAEVFVAAKNAYNAVVLSNIITVTDSTTRAKLSASLIERFENHKEDLKKMKRFVRTY-LPEKYDEIFDDTEK 362 WP_003739838 284 LLAIIGDEYAELFVAAKNTYNAVVLSSIITVTDTETNAKLSASMIERFDAHEKDLSELKAFIKLH-LPKQYEEIFSNVAI 362 WP_014601172 284 LLAIIGDEYAELFVAAKNTYNAVVLSSIITVTATETNAKLSASMIERFDAHEKDLGELKAFIKLH-LPKQYQEIFNNAAI 362 WP_023548323 284 LLAIIGDEYAELFVAAKNTYNAVVLSSIITVTDTETNAKLSASMIERFDAHEKDLVELKAFIKLN-LPKQYEEIFSNAAI 362 WP_031665337 284 LLAIIGDEYAELFVAAKNTYNAVVLSSIITVNDTETNAKLSASMIERFDAHEKDLVELKAFIKLN-LPKQYEEIFSNAAI 362 WP_031669209 284 LLAIIGDEFAEVFVAAKNAYNAVVLSNIITVTDSTTRAKLSASLIERFENHKEDLKKMKRFVRTY-LPEKYDEIFDDTEK 362 WP_033920898 284 LLAIIGDEYAELFVAAKNTYNAVVLSSIITVTDTETNAKLSASMIERFDAHEKDLVELKAFIKLN-LPKQYEEIFSNAAI  362 AKI42028 287 LLAIIGDEYAELFVAAKNTYNAVVLSSIITVTATETNAKLSASMIERFDAHEKDLGELKAFIKLH-LPKQYQEIFNNAAI 365 AKI50529 287 LLAIIGDEYAELFVAAKNTYNAVVLSSIITVTDTETNAKLSASMIERFDAHEKDLVELKAFIKLN-LPKQYEEIFSNAAI  365 EFR83390 -------------------------------------------------------------------------------- WP_046323366 284 LLARVGDEYAEIFVAAKNAYNAVVLSSIITVSNTETKAKLSASMIERFDKHDKDLKRMKAFFKVR-LPENFNEVFNDVEK 362 AKE81011 294 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 372 CUO82355 288 VENDLGE-YVEFIDSLHNIYSWVELQTIMGATHTD-NASISEAMVSRYNKHHEDLQLLKKCIKDN-VPKKYFDMFRNDSE 364 WP_033162887 289 LQSELGE-YIEFIEMLHNIYSWVELQAILGATHTD-NPSISAAMVERYEEHKKDLRVLKKVIREE-LPDKYNEVFRKDNR 365 AGZ01981 311 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 389 AKA60242 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 AKS40380 278 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 356 4UN5_B 282 LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ-LPEKYKEIFFDQSK 360 WP_010922251 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNG

IPHQIHLGEL 419 WP_039695303 358 --NGYAG YIEN G VKQDEFYKYLKNILSK-IkiDGSDYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 422 WP_045635197 357 --DGYAG YIDG K TTQETFYKYIKNLLSK-F--EGTDYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 5AXW_A 169 ------G SINR - ---------------K------TSDYVk----------------------------EA 183 WP_009880683 41 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPHQIHLGEL 103 WP_010922251 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL 419 WP_011054416 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPYQIHLGEL 419 WP_011284745 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPHQIHLGEL 419 WP_011285506 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL 419 WP_011527619 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPHQIHLGEL 419 WP_012560673 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPHQIHLGEL 419 WP_014407541 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL 419 WP_020905136 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPHQIHLGEL 419 WP_023080005 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPYQIHLGEL 419 WP_023610282 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPYQIHLGEL 419 WP_030125963 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL 419 WP_030126706 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPYQIHLGEL 419 WP_031488318 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPHQIHLGEL 419 WP_032460140 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPHQIHLGEL 419 WP_032461047 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPHQIHLGEL 419 WP_032462016 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL 419 WP_032462936 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPHQIHLGEL 419 WP_032464890 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNRKDLLRKQRTFDNGSIPHQIHLGEL 419 WP_033888930 182 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL 244 WP_038431314 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPHQIHLGEL 419 WP_038432938 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPYQIHLGEL 419 WP_038434062 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPHQIHLGEL 419 BAQ51233 268 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL 330 KGE60162 ------- ---- - ---------------------------------------------------------- KGE60856 ------- ---- - ---------------------------------------------------------- WP_002989955 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLRKQRTFDNGSIPHQIHLGEL 419 WP_003030002 357 --KGYAG YIEN G VKQDEFYKYLKGILLQ-I--NGSGDFL--DKIDREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_003065552 360 --NGYAG YIEN G VKQDEFYKYLKNTLSK-Ia--GSDYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 422 WP_001040076 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EGSEYFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_001040078 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_001040080 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_001040081 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_001040083 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_001040085 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_001040087 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_001040088 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_001040089 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_001040090 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_001040091 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_001040092 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSEYFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_001040094 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EGSEYLL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_001040095 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EGSEYLL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_001040096 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EGSEYLL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_001040097 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EGSEYLL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_001040098 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EGSEYLL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_001040099 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EGSEYLL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_001040100 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EGSEYLL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_001040104 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_001040105 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_001040106 358 --DGYAG YIEG K TNQGAFYKYLSKLLTK-Q--EGSEYFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_001040107 358 --DGYAG YIEG K TNQGAFYKYLSKLLTK-Q--EGSEYFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_001040108 358 --DGYAG YIEG K TNQGAFYKYLSKLLTK-Q--EGSEYFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_001040109 358 --DGYAG YIEG K TNQGAFYKYLSKLLTK-Q--EGSEYFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_001040110 358 --DGYAG YIEG K TNQGAFYKYLSKLLTK-Q--EGSEYFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_015058523 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSEYFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_017643650 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EGSEYLL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_017647151 358 --DGYAG YIEG K TNQGAFYKYLSKLLTK-Q--EGSEYFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_017648376 358 --DGYAG YIEG K TNQGAFYKYLSKLLTK-Q--EGSEYFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_017649527 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_017771611 358 --DGYAG YIEG K TNQGAFYKYLSKLLTK-Q--EGSEYFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 WP_017771984 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 CFQ25032 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 CFV16040 358 --DGYAG YIEG K TNQEAFYKYLSKLLTK-Q--EDSENFL--EKIKNEDFLRKQRTFDNGSIPHQVHLTEL 420 KLJ37842 358 --DGYAG YIEG K TNQEAFYKYLSELLTK-Q--EDSENFL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL 420 KLJ72361 358 --DGYAG YIEG K TNQEAFYKYLSELLTK-Q--EDSENFL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL 420 ELL20707 358 --DGYAG YIEG K TNQEAFYKYLSELLTK-Q--EDSENFL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL 420 KLL42645 358 --DGYAG YIEG K TNQGAFYKYLSELLTK-Q--EGSEYFL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL 420 WP_047207273 358 --DGYAG YIEG K TNQEAFYKYLSELLTK-Q--EDSENFL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL 420 WP_047209694 358 --DGYAG YIEG K TNQEAFYKYLSELLTK-Q--EGSEYLL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL 420 WP_050198062 358 --DGYAG YIEG K TNQEAFYKYLSELLTK-Q--EDSENFL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL 420 WP_050201642 358 --DGYAG YIEG K TNQEAFYKYLSELLTK-Q--EDSENFL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL 420 WP_050204027 358 --DGYAG YIES K TNQGAFYKYLSELLTK-Q--EGSEYFL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL 420 WP_050881965 358 --DGYAG YIEG K TNQEAFYKYLSELLTK-Q--EDSENFL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL 420 WP_050886065 358 --DGYAG YIEG K TNQEAFYKYLSELLTK-Q--EDSENFL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL 420 AHN30376 358 --DGYAG YIEG K TNQEAFYKYLSELLTK-Q--EDSEYFL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL 420 EA078426 358 --DGYAG YIEG K TNQEAFYKYLSELLTK-Q--EDSENFL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL 420 CCW42055 358 --DGYAG YIEG K TNQEAFYKYLSELLTK-Q--EGSEYLL--EKIKNEDFLREQRTEDNGSIPHQVHLTEL 420 WP_003041502 357 --KGYAG YIES G VKQDEFYKYLEGILLQ-I--NGSGDFL--DKIDREDFLREQRTEDNGSIPHQIHLQEM 419 WP_037593752 358 --KGYAG YIES G VEQDEFYKYLEGILLK-I--NGSGDFL--DKIDCEDFLREQRTEDNGSIPHQIHLQEM 420 WP_049516684 358 --NGYAG YIEN G VKQDEFYKYLENTLSK-I--DGSDYFL--DKIDREDFLREQRTEDNGSIPHQIHLQEM 420 GAD46167 357 --KGYAG YIES G VEQDEFYKYLEGILLK-I--NGSGDFL--DKIDCEDFLREQRTEDNGSIPHQIHLQEM 419 WP_018363470 358 --NGYAG YIEN G VKQDEFYKYLEGILTK-I--NGSDYFL--DKIEREDFLREQRTEDNGSIPHQIHLQEM 420 WP_003043819 357 --NGYAG YVGI G ATQEEFYKFIKPILEK-M--DGAEELLa--KLNRDDLLREQRTEDNGSIPHQIHLKEL 429 WP_006269658 357 --KGYAS YIES G VKQDEFYKYLEGILLK-I--NGSGDFL--DKIDREDFLREQRTEDNGSIPHQIHLQEM 419 WP_048800889 357 --NGYAG YIEN G VKQDEFYKYLENTLSK-I--DGSGYFL--DKIEREDFLREQRTEDNGSIPHQIHLQEM 419 WP_012767106 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLREQRTEDNGSIPHQIHLGEL 419 WP_014612333 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLREQRTEDNGSIPHQIHLGEL 419 WP_015017095 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLREQRTEDNGSIPHQIHLGEL 419 WP_015057649 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLREQRTEDNGSIPHQIHLGEL 419 WP_048327215 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLREQRTEDNGSIPHQIHLGEL 419 WP_049519324 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLa--KLNREDLLREQRTEDNGSIPHQIHLGEL 419 WP_012515931 357 --NGYAG YIEG Q VSQEEFYKYLKPILAR-L--DGSEPLL1--KIDREDFLREQRTEDNGSIPHQIHLEEL 419 WP_021320964 357 --NGYAG YIEG Q VSQEEFYKYLKPILAR-L--DGSEPLL1--KIDREDFLREQRTEDNGSIPHQIHLEEL 419 WP_037581760 357 --NGYAG YIEG Q VSQEEFYKYLKPILAR-L--DGSEPLL1--KIDREDFLREQRTEDNGSIPHQIHLEEL 419 WP_004232481 357 --NGYAG YIEN G VKQDIFYKHLKSIISE-K--NGGQYFL--DKIEREDFLREQRTEDNGSIPYQIHLQEM 419 WP_009854540 358 --NGYAG YIEN G VKQDEFYKYLENTLSK-I--DGSDYFL--DKIEREDFLREQRTEDNGSIPHQIHLQEM 420 WP_012962174 358 --NGYAG YIEN G VKQDEFYKYLETTLSK-I--DGSDYFL--DKIEREDFLREQRTEDNGSIPHQIHLQEM 420 WP_039695303 358 --NGYAG YIEN G VKQDEFYKYLKNILSK-IkiDGSDYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 422 WP_014334983 357 --NGYAG YIDN G VKQDEFYKYLKTILTK-I--DDSDYFL--DKIERDDFLRKQRTFDNGSIPHQIHLQEM 419 WP_003099269 357 --NGYAG YIDG K TSQEEFYKYIKPILLK-L--DGTEKLIs--KLEREDFLRKQRTFDNGSIPHQIHLNEL 419 AHY15608 357 --NGYAG YIDG K TSQEEFYKYIKPILLK-L--DGTEKLIs--KLEREDFLRKQRTFDNGSIPHQIHLNEL 419 AHY17476 357 --NGYAG YIDG K TSQEEFYKYIKPILLK-L--DGTEKLIs--KLEREDFLRKQRTFDNGSIPHQIHLNEL 419 ESR09100 ------- ---- - --------------------------------------------------------- AGM98575 357 --NGYAG YIDG K TSQEEFYKYIKPILLK-L--DGTEKLIs--KLEREDFLRKQRTFDNGSIPHQIHLNEL 419 ALF27331 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_018372492 355 --PSYAA YVSG A VTEDDFYKFSKGLLID-V--EGAEYFL--EKIEREDFLRKQRTFDNGAIPNQVHVKEL 432 WP_045618028 358 --DGYAG YIDG K TTQEAFYKYIKNLLSK-L--EGADYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 420 WP_045635197 357 --DGYAG YIDG K TTQETFYKYIKNLLSK-F--EGTDYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002263549 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002263887 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002264920 357 --NGYAG YIEN G VKQDEFYKYLKNTLSK-I--AGSDYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002269043 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002269448 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002271977 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002272766 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002273241 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002275430 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002276448 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002277050 357 --NGYAG YIEN G VKQDEFYKYLKNTLSK-I--AGSDYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002277364 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002279025 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002279859 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002280230 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002281696 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002282247 357 --NGYAG YIEN G VKQDEFYKYLKNTLSK-I--TGSDYFL--DQIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002282906 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002283846 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002287255 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002288990 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002289641 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002290427 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002295753 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002296423 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002304487 357 --NGYAG YVGA D ATEEEFYKYVKGILNK-V--EGADVWL--DKIDREDFLRKQRTFDNGSIPHQIHLQEM 429 WP_002305844 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002307203 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002310390 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002352408 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_012997688 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_014677909 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_019312892 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_019313659 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_019314093 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_019315370 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGNGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_019803776 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_019805234 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_024783594 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_024784288 357 --NGYAG YIEN G VKQDEFYKYLKNTLSK-I--TGSDYFL--DQIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_024784666 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_024784894 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_024786433 357 --NGYAG YIEN G VKQDEFYKYLKNTLSK-I--AGSDYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_049473442 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_049474547 357 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 EMC03581 350 --DGYAG YIDG K TNQEAFYKYLKGLLNK-I--EGSGYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 412 WP_000428612 358 --DGYAG YIDG K TTQESFYKYIKNLLSK-F--EGADYFL--EKIEREDFLRKQRTFDNGSIPHQIHLQEM 420 WP_000428613 358 --DGYAG YIDG K TTQEAFYKYIKNLLSK-F--EGTDYFL--EKIEREDFLRKQRTFDNGSIPHQIHLQEM 420 WP_049523028 357 --DGYAG YIDG K TTQEGFYKYIKNLISK-I--EGAEYFL--EKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_003107102 326 --NGYAG YING K TSQEDFYKYIKPILSK-L--KGAESLIs--KLEREDFLRKQRTFDNGSIPHQIHLNEL 388 WP_054279288 359 --DGYAG YISG K TSQEAFYKYIKPILET-L--DGAEDFLt--KINREDFLRKQRTFDNGSIPHQIHLGEL 421 WP_049531101 358 --EGYAG YIDS K TTQEAFYKYIKNLLSK-I--DGADYLL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 420 WP_049538452 358 --DGYAG YVDG K TTQEAFYKYIKNLLSK-F--EGADYFL--EKIEREDFLRKQRTFDNGSIPHQIHLQEM 420 WP_049549711 358 --DGYAG YIDG K TTQEAFYKYIKNLLSK-F--EGTDYFL--EKIEREDFLRKQRTFDNGSIPHQIHLQEM 420 WP_007896501 359 --NGYAG YIEG K VSQEDFYRYIKPILSR-L--KGGDEFLa--KIDRDDFLRKQRTFDNGSIPHQIHLKEL 421 EFR44625 311 --NGYAG YIEG K VSQEDFYRYIKPILSR-L--KGGDEFLa--KIDRDDFLRKQRTFDNGSIPHQIHLKEL 373 WP_002897477 357 --DGYAG YIDG K TTQEAFYKYIKNLLSK-F--EGADYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_002906454 357 --DGYAG FIDG K TTQEAFYKYIKNLLSK-L--EGADYFL--NKIEREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_009729476 358 --DGYAG YIDG K TTQETFYKYIKNLLSK-F--EGADYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 420 CQR24647 358 --NGYAG YIDG K TNQEDFYKYLKNLLQK-V--DGGDYFI--EKIEREDFLRKQRTFDNGSIPHQVHLDEM 420 WP_000066813 358 --DGYAG YIDG K TTQEAFYKYIKNLLSK-F--EGADYFL--DKIEREDFLKKQRTFDNGSIPHQIHLQEM 420 WP_009754323 358 --DGYAG YIDG K TTQEAFYKYIKNLLSK-F--EGADYFL--DKIEREDFLRKQRTFDNGSIPHQIHLQEM 420 WP_044674937 357 --DGYAG YIEG K TTQENFYRFIKKAIEK-I--EGSDYFI--DKIDREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_044676715 357 --DGYAG YIEG K TTQENFYRFIKKAIEK-I--EGSNYFI--DKIDREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_044680361 357 --DGYAG YIEG K TTQENFYRFIKKAIEK-I--EGSNYFI--DKIDREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_044681799 357 --DGYAG YIEG K TTQENFYRFIKKAIEK-I--EGSDYFI--DKIDREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_049533112 357 --KGYAG YIEN G VKQDEFYKYLKGILLQ-I--NGSGDFL--DKIDREDFLRKQRTFDNGSIPHQIHLQEM 419 WP_029090905 316 fyTDYIG YEES K SKEERLFKHIELLLAKeNv1TTVEHAL1eKNITFASLLPLQRSSRNAVIPYQVHEKEL 403 WP_006506696 361 ksKGYYN YINR K APVDEFYKYVKKCIEK-VdtPEAKQILn--DIELENFLLKQNSRTNGSVPYQMQLDEM 429 AIT42264 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL 419 WP_034440723 363 --NGYAG YIDG K TSQEDFYKFVKAQLKG---eENGEYFL--EAIENENFLRKQRSFYNGVIPYQIHLQEL 425 AKQ21048 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL 419 WP_004636532 356 --NGYAG YIDG K TNQEDFYKYIEKVMKT-IksDKKDYFL--DKIDREVFLRKQRSFYNSVIPHQIHLQEM 420 WP_002364836 363 --DGYAG YIAH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL 427 WP_016631044 314 --DGYAG YIAH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL 378 EMS75795 100 --NGYAG YIDG K TTQEDFYKFLKKELNG-I--AGSERFM--EKVDQENFLLKQRTTANGVIPHQVHLTEL 162 WP_002373311 363 --DGYAG YIAH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL 427 WP_002378009 363 --DGYAG YITH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL 427 WP_002407324 363 --DGYAG YITH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL 427 WP_002413717 363 --DGYAG YIAH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL 427 WP_010775580 365 --DGYAG YIAH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL 429 WP_010818269 363 --DGYAG YIAH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL 427 WP_010824395 363 --DGYAG YITH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL 427 WP_016622645 363 --DGYAG YIAH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL 427 WP_033624816 363 --DGYAG YIAH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL 427 WP_033625576 363 --DGYAG YIAH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL 427 WP_033789179 363 --DGYAG YIAH A VSQLKFYQYVKKIIQD-I--AGAEYFL--EKIAQENFLRKQRTFDNGVIPHQIHLAEL 427 WP_002310644 361 --NGYAG YIEG H ATQEDFYKFVKKELTG-I--RGSEVFL--TKIEQENFLRKQRTFDNGVIPHQIHLTEL 423 WP_002312694 362 --NGYAG YIEG H ATQEAFYKFVKKELTG-I--RGSEVFL--TKIEQENFLRKQRTFDNGVIPHQIHLSEL 424 WP_002314015 362 --NGYAG YIEG H ATQEDFYKFVKKELTG-I--RGSEVFL--TKIEQENFLRKQRTFDNGVIPHQIHLTEL 424 WP_002320716 362 --NGYAG YIEG H ATQEDFYKFVKKELTG-I--RGSEVFL--TKIEQENFLRKQRTFDNGVIPHQIHLTEL 424 WP_002330729 361 --NGYAG YIEG H ATQEDFYKFVKKELTG-I--RGSEVFL--TKIEQENFLRKQRTFDNGVIPHQIHLTEL 423 WP_002335161 362 --NGYAG YIEG H ATQEDFYKFVKKELTG-I--RGSEVFL--TKIEQENFLRKQRTFDNGVIPHQIHLTEL 424 WP_002345439 362 --NGYAG YIEG H ATQEDFYKFVKKELTG-I--RGSEVFL--TKIEQENFLRKQRTFDNGVIPHQIHLTEL 424 WP_034867970 355 --NGYAG YIKG K TTQEEFYKFVKKELSG-V--VGSEPFL--EKIDQETFLLKQRTYTNGVIPHQVHLIEL 417 WP_047937432 362 --NGYAG YIEG H ATQEDFYKFVKKELTG-I--RGSEVFL--TKIEQENFLRKQRTFDNGVIPHQIHLTEL 424 WP_010720994 355 --NGYAG YIKG K TTQEEFYKFVKKELSG-V--VGSEPFL--EKIDQETFLLKQRTYTNGVIPHQVHLIEL 417 WP_010737004 355 --NGYAG YIKG K TTQEEFYKFVKKELSG-V--VGSEPFL--EKIDQETFLLKQRTYTNGVIPHQVHLIEL 417 WP_034700478 355 --NGYAG YIKG K TTQEEFYKFVKKELSG-V--VGSEPFL--EKIDQETFLLKQRTYTNGVIPHQVHLIEL 417 WP_007209003 359 --NGYAG YIDG K TKEEEFYKYLKTTLVQ---kSGYQYFI--EKIEQENFLRKQRIYDNGVIPHQVHAEEL 421 WP_023519017 355 --NGYAG YVKG K ATQEDFYKFLRTELAG-L--EESQSIM--EKIDLEIYLLKQRTFANGVIPHQIHLVEM 417 WP_010770040 358 --SGYAG YVEN S VTQAEFYKYIKKAIEK-V--PGAEYFL--EKIEQETFLDKQRTFNNGVIPHQIHLEEL 422 WP_048604708 354 --DGYAG YIDN S TSQEKFYKYITNLIEK-I--DGAEYFL--KKIENEDFLRKQRTFDNGIIPHQIHLEEL 418 WP_010750235 355 --DGYAG YIDG K TTQADFYKFLKKELTG-V--PGSEPML--AKIDQENFLLKQRTPTNGVIPHQVHLTEF 417 AII16583 396 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTEDNGSIPHQIHLGEL 458 WP_029073316 367 kkNNYCN YINH K TPVDEFYKYIKKLIEK-IddPDVKTILn--KIELESFMLKQNSRTNGAVPYQMQLDEL 435 WP_031589969 367 kkNNYCN YINH K TPVDEFYKYIKKLIEK-IddPDVKTILn--KIELESFMLKQNSRTNGAVPYQMQLDEL 435 KDA45870 354 -iSGYAG YIDG K VSEEDFYKYTKKTLKG-I--PETEEILq--KIDANNYLRKQRTFDNGAIPHQVHLKEL 417 WP_039099354 360 ------- YVDG K -SKEDFYGDITKALKNnPdhPIVSEIKk--LIELDQFMPKQRTKDNGAIPHQLHQQEL 425 AKP02966 349 --QAYDD YINK K ---KELYTSLKKFLKVaLp-TNLAKEAe-EKISKGTYLVKPRNSENGVVPYQLNKIEM 415 WP_010991369 363 --HGYAG YIDG - TKQADFYKYMKMTLEN-I--EGADYFI--AKIEKENFLRKQRTFDNGAIPHQLHLEEL 425 WP_033838504 363 --HGYAG YIDG - TKQADFYKYMKMTLEN-I--EGADYFI--AKIEKENFLRKQRTFDNGAIPHQLHLEEL 425 EHN60060 366 --HGYAG YIDG - TKQADFYKYMKMTLEN-I--EGADYFI--AKIEKENFLRKQRTFDNGAIPHQLHLEEL 428 EFR89594 132 --HGYAG YIDG - TKQADFYKYMKTTLEN-I--EGADYFI--AKIEKENFLRKQRTFDNGAIPHQLHLEEL 194 WP_038409211 363 --DGYAG YIDG - TTQEKFYKYMKKMLAN-I--DGADYFI--DQIEEENFLRKQRTFDNGTIPHQLHLEEL 425 EFR95520 1 ------- ---- - ---------MKKMLAN-I--DGADYFI--DQIEEENFLRKQRTFDNGTIPHQLHLEEL 44 WP_003723650 363 --DGYAG YIDG - TKQVDFYKYLKTILEN-I--EGSDYFI--AKIEEENFLRKQRTFDNGAIPHQLHLEEL 425 WP_003727705 363 --DGYAG YIDG - TKQVDFYKYLKTTLEN-V--EGADYFI--TKIEEENFLRKQRTFDNGVIPHQLHLEEL 425 WP_003730785 363 --DGYAG YIDG - TKQVDFYKYLKTTLEN-V--EGADYFI--TKIEEENFLRKQRTFDNGVIPHQLHLEEL 425 WP_003733029 363 --HGYAG YISG - TKQADFYKYMKATLEK-I--EGADYFI--AKIEEENFLRKQRTFDNGVIPHQLHLEEL 425 WP_003739838 363 --DGYAG YIDG - TKQVDFYKYLKTLLEN-I--EGADYFI--AKIEEENFLRKQRTFDNGAIPHQLHLEEL 425 WP_014601172 363 --DGYAG YIDG - TKQVDFYKYLKTILEN-I--EGADYFI--AKIEEENFLRKQRTFDNGAIPHQLHLEEL 425 WP_023548323 363 --DGYAG YIDG - TKQVDFYKYLKTTLEN-V--EGADYFI--TKIEEENFLRKQRTFDNGVIPHQLHLEEL 425 WP_031665337 363 --DGYAG YIDG - TKQVDFYKYLKTILEN-I--EGSDYFI--AKIEEENFLRKQRTFDNGAIPHQLHLEEL 425 WP_031669209 363 --HGYAG YISG - TKQADFYKYMKATLEK-I--EGADYFI--AKIEEENFLRKQRTFDNGVIPHQLHLEEL 425 WP_033920898 363 --DGYAG YIDG - TKQVDFYKYLKTILEN-I--EGADYFI--AKIEEENFLRKQRTFDNGAIPHQLHLEEL 425 AKI42028 366 --DGYAG YIDG - TKQVDFYKYLKTILEN-I--EGADYFI--AKIEEENFLRKQRTFDNGAIPHQLHLEEL 428 AKI50529 366 --DGYAG YIDG - TKQVDFYKYLKTILEN-I--EGADYFI--AKIEEENFLRKQRTFDNGAIPHQLHLEEL 428 EFR83390 ------- ---- - ---------------------------------------------------------- WP_046323366 363 --DGYAG YIEG - TKQEAFYKYMKKMLEH-V--EGADYFI--NQIEEENFLRKQRTFDNGAIPHQLHLEEL 425 AKE81011 373 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL 435 CUO82355 365 kvKGYYN YINR K APVDEFYKFVKKCIEK-VdtPEAKQILh--DIELENFLLKQNSRTNGSVPYQMQLDEM 433 WP_033162887 366 klHNYLG YIKY D TPVEEFYKYIKGLLAK-VdtDEAREILe--RIDLEKFMLKQNSRTNGSIPYQMQKDEM 434 AGZ01981 390 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL 452 AKA60242 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL 419 AKS40380 357 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL 419 4UN5_B 361 --NGYAG YIDG G ASQEEFYKFIKPILEK-M--DGTEELLv--KLNREDLLRKQRTFDNGSIPHQIHLGEL 423 WP_010922251 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFE

VVDKGA 486 WP_039695303 423 HAILRRQGDYYPFLKE--KQD RIEKILTFRIPYYVGPL VRKD--SRFAWAEY---RSDEKITPWNFDKVIDKEK 489 WP_045635197 420 NAILRRQGEYYPFLKD--NKE KIEKILTFRIPYYVGPL ARGN--RDFAWLTR---NSDEAIRPWNFEEIVDKAS 486 5AXW_A 184 KQLLKVQKAYHQLDQSfi--D TYIDLLETRRTYYEGPG ---Eg-SPFGWKDI---------------------- 229 WP_009880683 104 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 170 WP_010922251 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_011054416 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_011284745 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_011285506 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_011527619 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_012560673 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_014407541 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_020905136 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_023080005 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_023610282 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_030125963 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_030126706 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_031488318 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_032460140 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_032461047 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_032462016 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_032462936 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_032464890 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_033888930 245 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 311 WP_038431314 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_038432938 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_038434062 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 BAQ51233 331 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 397 KGE60162 --------------------- ----------------- ------------------------------------ KGE60856 --------------------- ----------------- ------------------------------------  WP_002989955 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_003030002 420 HAILRRQEEHYPFLKE--NQD KIEKILTFRIPYYVGPL ARKG--SRFAWAEY---KADEKITPWNFDDILDKEK 486 WP_003065552 423 HAILRRQGDYYPFLKE--NQD RIEKILTFRIPYYVGPL ARKD--SRFSWAEY---HSDEKITPWNFDKVIDKEK 489 WP_001040076 421 RAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_001040078 421 KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_001040080 421 KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_001040081 421 KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_001040083 421 KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_001040085 421 KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_001040087 421 KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_001040088 421 KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_001040089 421 KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_001040090 421 KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_001040091 421 KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_001040092 421 KAIIRRQSEYYPFLKE--NQD KIEKILTFRIPYYVGPL ARGN--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_001040094 421 RAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_001040095 421 RAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_001040096 421 RAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_001040097 421 RAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_001040098 421 RAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_001040099 421 RAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_001040100 421 RAIIRRQSEYYPLLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_001040104 421 KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_001040105 421 KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_001040106 421 KAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEELVDKEA 487 WP_001040107 421 KAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEELVDKEA 487 WP_001040108 421 KAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEELVDKEA 487 WP_001040109 421 KAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEELVDKEA 487 WP_001040110 421 KAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEELVDKEA 487 WP_015058523 421 KAIIRRQSEYYPFLKE--NQD KIEKILTFRIPYYVGPL ARGN--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_017643650 421 RAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_017647151 421 KAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEELVDKEA 487 WP_017648376 421 KAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEELVDKEA 487 WP_017649527 421 KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_017771611 421 KAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEELVDKEA 487 WP_017771984 421 KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 CFQ25032 421 KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 CFV16040 421 KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 KLJ37842 421 KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 KLJ72361 421 KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 KLL20707 421 KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 KLL42645 421 KAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEELVDKEA 487 WP_047207273 421 KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_047209694 421 RAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_050198062 421 KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_050201642 421 KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_050204027 421 KAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEELVDKEA 487 WP_050881965 421 KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 WP_050886065 421 KDIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 AHN30376 421 KAIIRRQSEYYPFLKE--NQD KIEKILTFRIPYYVGPL ARGN--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 EA078426 421 KAIIRRQSEYYPFLKE--NQD RIEKILTFRIPYYIGPL AREK--SDFAWMTR---KTDDSIRPWNFEDLVDKEK 487 CCW42055 421 RAIIRRQSEYYPFLKE--NLD RIEKILTFRIPYYVGPL AREK--SDFAWMTR---KTDDSIRPWNFEELVDKEA 487 WP_003041502 420 HAILRRQGEHYPFLKE--NQD KIEKILTFRIPYYVGPL ARKG--SRFAWAEY---KADEKITPWNFDDILDKEK 486 WP_037593752 421 HAILRRQGEHYPFLKE--NQD KIEKILTFRIPYYVGPL ARKG--SRFAWAEY---KADEKITPWNFDDILDKEK 487 WP_049516684 421 HAILRRQGEHYPFLKE--NQD KIEKILTFRIPYYVGPL ARKG--SRFAWAEY---KADEKITPWNFDDILDKEK 487 GAD46167 420 HAILRRQGEHYPFLKE--NQD KIEKILTFRIPYYVGPL ARKG--SRFAWAEY---KADEKITPWNFDDILDKEK 486 WP_018363470 421 HAILRRQGDYYPFLKE--NQE EIEKILTFRIPYYVGPL ARKD--SRFAWAEY---RSDEKITPWNFDKVIDKEK 487 WP_003043819 430 HAILRRQEEFYPFLKE--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWLTR---KSEEAITPWNFEEVVDKGA 496 WP_006269658 420 HAILRRQGEHYPFLKE--NQD KIEKILTFRIPYYVGPL ARKG--SRFAWAEY---KADEKITPWNFDDILDKEK 486 WP_048800889 420 HAILRRQGEHYPFLKE--NQD KIEKILTFRIPYYVGPL VRKG--SRFAWAEY---KADEKITPWNFDDILDKEK 486 WP_012767106 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_014612333 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_015017095 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_015057649 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_048327215 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_049519324 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_012515931 420 HAILRRQEVEYPFLKD--NRK KIESLLTFRIPYYVGPL ARG-h-SRFAWVKR---KFDGAIRPWNFEEIVDEEA 486 WP_021320964 420 HAILRRQEVEYPFLKD--NRK KIESLLTFRIPYYVGPL ARG-h-SRFAWVKR---KFDGAIRPWNFEEIVDEEA 486 WP_037581760 420 HAILRRQEVEYPFLKD--NRK KIESLLTFRIPYYVGPL ARG-h-SRFAWVKR---KFDGAIRPWNFEEIVDEEA 486 WP_004232481 420 RTILRRQGEYYPFLKE--NQA KIEKILTFRIPYYVGPL ARKN--SRFAWAKY---HSDEPITPWNFDEVVDKEK 486 WP_009854540 421 HAILRRQGDYYPFLKE--KQD RIEKILTFRIPYYVGPL VRKD--SRFAWAEY---RSDEKITPWNFDKVIDKEK 487 WP_012962174 421 HAILRRQGEHYAFLKE--NQA KIEKILTFRIPYYVGPL ARKN--SRFAWAEY---HSDEKITPWNFDEIIDKEK  487 WP_039695303 423 HAILRRQGDYYPFLKE--KQD RIEKILTFRIPYYVGPL VRKD--SRFAWAEY---RSDEKITPWNFDKVIDKEK 489 WP_014334983 420 HSILRRQGDYYPFLKE--NQA KIEKILTFRIPYYVGPL ARKD--SRFAWANY---HSDEPITPWNFDEVVDKEK 486 WP_003099269 420 KAIIRRQEKFYPFLKE--NQK KIEKLFTFKIPYYVGPL ANG-q-SSFAWLKR---QSNESITPWNFEEVVDQEA 486 AHY15608 420 KAIIRRQEKFYPFLKE--NQK KIEKLFTFKIPYYVGPL ANG-q-SSFAWLKR---QSNESITPWNFEEVVDQEA 486 AHY17476 420 KAIIRRQEKFYPFLKE--NQK KIEKLFTFKIPYYVGPL ANG-q-SSFAWLKR---QSNESITPWNFEEVVDQEA 486 ESR09100 --------------------- ----------------- ------------------------------------ AGM98575 420 KAIIRRQEKFYPFLKE--NQK KIEKLFTFKIPYYVGPL ANG-q-SSFAWLKR---QSNESITPWNFEEVVDQEA 486 ALF27331 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYIGPL ARGK--SDFSWLSR---KSADKITPWNFDEIVDKES 486 WP_018372492 433 QAIILNQSKYYPFLAE--NKE KIEKILTFRIPYYVGPL ARGN--SSFAWLQR---KSDEAIRPWNFEQVVDMET 499 WP_045618028 421 NAIIRRQGEHYPFLQE--NKE KIEKILTFRIPYYVGPL ARGN--RDFAWLTR---NSDQAIRPWNFEEIVDKAR 487 WP_045635197 420 NAILRRQGEYYPFLKD--NKE KIEKILTFRIPYYVGPL ARGN--RDFAWLTR---NSDEAIRPWNFEEIVDKAS 486 WP_002263549 420 RAIIRRQAEFYPFLAD--NQD RIEKLLTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002263887 420 RAIIRRQAEFYPFLAD--NQD RIEKLLTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002264920 420 HAILRRQGDYYPFLKE--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002269043 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002269448 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002271977 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002272766 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002273241 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002275430 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002276448 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002277050 420 HAILRRQGDYYPFLKE--NQD RIEKILTFRIPYYVGPL ARKN--SRFAWAEY---HSDEAVMPWNFDQVIDKES 486 WP_002277364 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002279025 420 RAIIRRQSEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002279859 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002280230 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002281696 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002282247 420 HAILRRQGDYYPFLKE--NQD RIEKILTFRIPYYVGPL ARKN--SRFAWAEY---HSDEAVTPWNFDQVIDKES 486 WP_002282906 420 RAIIRRQAEFYPFLAD--NQD RIEKLLTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002283846 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002287255 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002288990 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002289641 420 RAIIRRQAEFYPFLAD--NQD RIEKLLTFRIPYYVGPL ASGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002290427 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002295753 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002296423 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002304487 430 HAILRRQGEHYPFLKE--NQD KIEKILTFRIPYYVGPL VRKG--SRFAWAEY---KADEKITPWNFDDILDKEK 496 WP_002305844 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002307203 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002310390 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_002352408 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_012997688 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_014677909 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_019312892 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_019313659 420 RAIIRRQAEFYPFLAD--NQD RIEKLLTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_019314093 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_019315370 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_019803776 420 RAIIRRQAEFYPFLAD--NQD RIEKLLTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_019805234 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_024783594 420 RAIIRRQAEFYPFLAD--NQD RIEKLLTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_024784288 420 HAILRRQGDYYPFLKE--NQD RIEKILTFRIPYYVGPL ARKN--SRFAWAEY---HSDEAVTPWNFDQVIDKES 486 WP_024784666 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_024784894 420 RAIIRRQAEFYPFLAD--NQD RIEKLLTFRIPYYVGPL ASGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_024786433 420 HAILRRQGDYYPFLKE--NQD RIEKILTFRIPYYVGPL ARKN--SRFAWAEY---HSDEAVTPWNFDQVIDKES 486 WP_049473442 420 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 WP_049474547 420 RAIIRRQAEFYPFLAD--NQD RIEKLLTFRIPYYVGPL ASGK--SDFAWLSR---KSADKITPWNFDEIVDKES 486 EMC03581 413 RAIIRRQAEFYPFLAD--NQD RIEKILTFRIPYYVGPL ARGK--SDFAWLSR---KSADKITPWNFDEIVDKES 479 WP_000428612 421 NAILRRQGEHYPFLKE--NKE KIEKILTFRIPYYVGPL ARGN--RDFAWLTR---NSDQAIRPWNFEEIVDKAS 487 WP_000428613 421 NAILRRQGEHYPFLKD--NKE KIEKILTFRIPYYVGPL ARGN--RDFAWLTR---NSDEAIRPWNFEEIVDKAS 487 WP_049523028 420 NAILRHQGEYYPFLKE--NKD KIEQILTFRIPYYVGPL ARGN--SDFAWLSR---NSDEAIRPWNFEEMVDKSS 486 WP_003107102 389 KSIIRRQEKYYPFLKD--KQV RIEKIFTFRIPYFVGPL ANG-n-SSFAWVKR---RSNESITPWNFEEVVEQEA 455 WP_054279288 422 QAILERQQAYYPFLKD--NQE KIEKILTFRIPYYIGPL ARG-n-SRFAWLTR---TSDQKITPWNFDEMVDQEA 488 WP_049531101 421 NAILRRQGEHYPFLKE--NRE KIEKILTFRIPYYVGPL ARGN--RDFAWLTR---NSDQAIRPWNFEEIVDKAS 487 WP_049538452 421 NAILRRQGEHYPFLKE--NKE KIEKILTFRIPYYVGPL ARGN--RDFAWLTR---NSDQAIRPWNFEEIVDKAS 487 WP_049549711 421 NAILRRQGEHYPFLKE--NKE KIEKILTFRIPYYVGPL ARGN--RDFAWLTR---NSDQAIRPWNFEEIVDKAS 487 WP_007896501 422 HAILRRQEKYYPFLAE--QKE KIEQLLCFRIPYYVGPL AKGGn-SSFAWLKR---RSDEPITPWNFKDVVDEEA 489 EFR44625 374 HAILRRQEKYYPFLAE--QKE KIEQLLCFRIPYYVGPL AKGGn-SSFAWLKR---RSDEPITPWNFKDVVDEEA 441 WP_002897477 420 NAILRRQGEHYPFLKE--NRE KIEKILTFRIPYYVGPL ARDN--RDFSWLTR---NSDEPIRPWNFEEVVDKAR 486 WP_002906454 420 NAILRRQGEHYLFLKE--NRE KIEKILAFRIPYYVGPL ARGN--RDFAWLTR---NSDQAIRPWNFEEVVDKAS 486 WP_009729476 421 NAILRRQGEHYPFLKE--NKE KIEKILTFRIPYYVGPL ARGN--RDFAWLTR---NSDQAIRPWNFEEIVDKAS 487 CQR24647 421 KAILRRQGEFYPFLKE--NAE KIQQILTFKIPYYVGPL ARGN--SRFAWASY---NSNEKMTPWNFDNVIDKTS 487 WP_000066813 421 NAIIRRQGEHYPFLQE--NKE KIEKILTFRIPYYVGPL ARGN--GDFAWLTR---NSDQAIRPWNFEEIVDQAS 487 WP_009754323 421 NAILRRQGEHYPLLKE--NKE KIEKILTFRIPYYVGPL ARGN--RDFAWLTR---NSDQAIRPWNFEEIVDKAS 487 WP_044674937 420 HAIIRRQAEFYPFLVE--NQD KIEKILTFRIPYYVGPL ARGK--SEFAWLNR---KSDEKIRPWNFDEMVDKET 486 WP_044676715 420 HAIIRRQAEFYPFLVE--NQD KIEKILTFRIPYYVGPL ARGK--SEFAWLNR---KSDEKIRPWNFDEMVDKET 486 WP_044680361 420 HAIIRRQAEFYPFLVE--NQD KIEKILTFRIPYYVGPL ARGK--SEFAWLNR---KSDEKIRPWNFDEMVDKET 486 WP_044681799 420 HAIIRRQAEFYPFLVE--NQD KIEKILTFRIPYYVGPL ARGK--SEFAWLNR---KSDEKIRPWNFDEMVDKET 486 WP_049533112 420 HAILRRQEEHYPFLKE--NQD KIEKILTFRIPYYVGPL ARKG--SRFAWAEY---KADEKITPWNFDDILDKEK 486 WP_029090905 404 VAILENQATYYPELLE--QKD NIHKLLTFRIPYYVGPL ADQKd-SEFAWMVR---KQAGKITPFNFEEMVDIDA 471 WP_006506696 430 IKIIDNQAEYYPILKE--KRE QLLSILTFRIPYYFGPL ETSEh----AWIKRlegKENQRILPWNYQDIVDVDA 498 AIT42264 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_034440723 426 TAVLDQQEKHYSFLKE--NRD KIISLLTFRIPYYVGPL AKGE--SRFAWLER--sNSEEKIKPWNEDKIVDIDK 493 AKQ21048 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 WP_004636532 421 QAILDRQSQYYPFLAE--NRD KIESLVTFRIPYYVGPL TVSDq-SEFAWMER---QSDEPIRPWNFDEIVNKER 488 WP_002364836 428 QAIIHRQAAYYPFLKE--NQE KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR---QSEEPIRPWNLQETVDLDQ 495 WP_016631044 379 QAIIHRQAAYYPFLKE--NQE KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR---QSEEPIRPWNLQETVDLDQ 446 EMS75795 163 KAIIERQKPYYPSLEE--ARD KMIRLLTFRIPYYVGPL AQGEetSSFAWLER---KTPEKVTPWNATEVIDYSA 231 WP_002373311 428 QAIIHRQAAYYPFLKE--NQE KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR---QSEEPIRPWNLQETVDLDQ 495 WP_002378009 428 QAIIHRQAAYYPFLKE--NQE KIEQLVTFRIPYYVGPL SKGDa-NTFAWLKR---QSEEPIRPWNLQETVDLDQ 495 WP_002407324 428 QAIIHRQAAYYPFLKE--NQE KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR---QSEEPIRPWNLQETVDLDQ 495 WP_002413717 428 QAIIHRQAAYYPFLKE--NQE KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR---QSEEPIRPWNLQETVDLDQ 495 WP_010775580 430 QAIIHRQAAYYPFLKE--NQK KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR---QSEEPIRPWNLQETVDLDQ 497 WP_010818269 428 QAIIHRQAAYYPFLKE--NQE KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR---QSEEPIRPWNLQETVDLDQ 495 WP_010824395 428 QAIIHRQAAYYPFLKE--NQE KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR---QSEEPIRPWNLQETVDLDQ 495 WP_016622645 428 QAIIHRQAAYYPFLKE--NQE KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR---QSEEPIRPWNLQETVDLDQ 495 WP_033624816 428 QAIIHRQAAYYPFLKE--NQK KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR---QSEEPIRPWNLQETVDLDQ 495 WP_033625576 428 QAIIHRQAAYYPFLKE--NQE KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR---QNEKPIRPWNLQETVDLDQ 495 WP_033789179 428 QAIIHRQAAYYPFLKE--NQK KIEQLVTFRIPYYVGPL SKGDa-STFAWLKR---QSEEPIRPWNLQETVDLDQ 495 WP_002310644 424 RAIIANQKKHYPFLKE--EQE KLESLLTFKIPYYVGPL AKKQenSPFAWLIR---KSEEKIKPWNLPEIVDMEG 492 WP_002312694 425 RAIIANQKKHYPFLKE--EQE KLESLLTFKIPYYVGPL AKKQenSPFAWLIR---KSEEKIKPWNLPEIVDMEG 493 WP_002314015 425 RAIIANQKKHYPFLKE--EQE KLESLLTFKIPYYVGPL AKKQenSPFAWLIR---KSEEKIKPWNLPEIVDMEG 493 WP_002320716 425 RAIIANQKKHYPFLKE--EQE KLESLLTFKIPYYVGPL AKKQenSPFAWLIR---KSEEKIKPWNLPEIVDMEG 493 WP_002330729 424 RAIIANQKKHYPFLKE--EQE KLESLLTFKIPYYVGPL AKKQenSPFAWLIR---KSEEKIKPWNLPEIVDMEG 492 WP_002335161 425 RAIIANQKKHYPFLKE--EQE KLESLLTFKIPYYVGPL AKKQenSPFAWLIR---KSEEKIKPWNLPEIVDMEG 493 WP_002345439 425 RAIIANQKKHYPFLKE--EQE KLESLLTFKIPYYVGPL AKKQenSPFAWLIR---KSEEKIKPWNLPEIVDMEG 493 WP_034867970 418 KAIIDQQKQHYPFLEE--AGP KIIALFKFRIPYYVGPL AKEQeaSSFAWIER---KTAEKINPWNFSEVVDIEK 486 WP_047937432 425 RAIIANQKKHYPFLKE--EQE KLESLLTFKIPYYVGPL AKKQenSPFAWLIR---KSEEKIKPWNLPEIVDMEG 493 WP_010720994 418 KAIIDQQKQHYPFLEE--AGP KIIALFKFRIPYYVGPL AKEQeaSSFAWIER---KTAEKINPWNFSEVVDIEK 486 WP_010737004 418 KAIIDQQKQHYPFLEE--AGP KIIALFKFRIPYYVGPL AKEQeaSSFAWIER---KTAEKINPWNFSEVVDIEK 486 WP_034700478 418 KAIIDQQKQHYPFLEE--AGP KIIALFKFRIPYYVGPL AKEQeaSSFAWIER---KTAEKINPWNFSEVVDIEK 486 WP_007209003 422 RAILRKQEKYYSFLKE--NHE KIEQIFKVRIPYYVGPL AKHNeqSRFAWNIR---KSDEPIRPWNMNDVVDENA 490 WP_023519017 418 REIMDRQKRFYPFLKG--AQG KIEKLLTFRIPYYVGPL AQEGq-SPFAWIKR---KSPSQITPWNFAEVVDKEN 485 WP_010770040 423 EAIIQKQATYYPFLAD--NKE EMKQLVTFRIPYYVGPL ADGN--SPFAWLER---ISSEPIRPGNLAEVVDIKK 489 WP_048604708 419 KAILHHQAMYYPFLQE--KFS NFVDLLTFRIPYYVGPL ANGN--SRFSWLSR---KSDEPIRPWNLAEVVDLSK 485 WP_010750235 418 KAIIDQQKQYYPFLEK--SKE KMIQLLTFRIPYYVGPL AQDKetSSFAWLER---KTTEKIKPWNAKDVIDYGA 486 AII16583 459 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 525 WP_029073316 436 NKILENQSVYYSDLKD--NED KIRSILTFRIPYYFGPL ITKDr--QFDWIIKkegKENERILPWNANEIVDVDK 506 WP_031589969 436 NKILENQSVYYSDLKD--NED KIRSILTFRIPYYFGPL ITKDr--QFDWIIKkegKENERILPWNANEIVDVDK 506 KDA45870 418 VAIVENQGKYYPFLRE--NKD KFEKILNFRIPYYVGPL ARGN--SKFAWLTR--a-GEGKITPYNFDEMIDKET 484 WP_039099354 426 DRIIENQQQYYPWLAE-1NPN KLDELVAFRVPYYVGPL QQQSsdAKFAWMIR---KAEGQITPWNFDDKVDRQA 509 AKP02966 416 EKIIDNQSQYYPFLKE--NKE KLLSILSFRIPYYVGPL -QSSekNPFAWMER---KSNGHARPWNFDEIVDREK 483 WP_010991369 426 EAILHQQAKYYPFLKE--NYD KIKSLVTFRIPYFVGPL ANGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK 492 WP_033838504 426 EAILHQQAKYYPFLKE--NYD KIKSLVTFRIPYFVGPL ANGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK 492 EHN60060 429 EAILHQQAKYYPFLKE--NYD KIKSLVTFRIPYFVGPL ANGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK 495 EFR89594 195 EAILHQQAKYYPFLKE--NYD KIKSLVTFRIPYFVGPL ANGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK 261 WP_038409211 426 EAILHQQAKYYPFLRK--DYE KIRSLVTFRIPYFIGPL ANGQ--SDFAWLTR---KADGEIRPWNIEEKVDFGK 492 EFR95520 45 EAILHQQAKYYPFLRK--DYE KIRSLVTFRIPYFIGPL ANGQ--SDFAWLTR---KADGEIRPWNIEEKVDFGK 111 WP_003723650 426 EAIIHQQAKYYPFLKE--DYD KIKSLVTFRIPYFVGPL ANGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK 492 WP_003727705 426 EAILHQQAKYYPFLRE--GYD KIKSLVTFRIPYFVGPL ANGQ--SEFAWLTR---KDDGEIRPWNIEEKVDFGK 492 WP_003730785 426 EAILHQQAKYYPFLRE--GYD KIKSLVTFRIPYFVGPL ANGQ--SEFAWLTR---KDDGEIRPWNIEEKVDFGK 492 WP_003733029 426 EAILHQQAKYYPFLRE--DYE KIKSLVTFRIPYFVGPL AKGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK 492 WP_003739838 426 EAILHQQAKYYPFLKE--AYD KIKSLVTFRIPYFVGPL ANGQ--SDFAWLTR---KADGEIRPWNIEEKVDFGK 492 WP_014601172 426 EAIIHQQAKYYPFLRE--DYE KIKSLVTFRIPYFVGPL AKGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK 492 WP_023548323 426 EAILHQQAKYYPFLRE--DYE KIKSLVTFRIPYFVGPL AKGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK 492 WP_031665337 426 EAIIHQQAKYYTFLKE--DYD KIKSLVTFRIPYFVGPL ANGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK 492 WP_031669209 426 EAILHQQAKYYPFLRE--DYE KIKSLVTFRIPYFVGPL AKGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK 492 WP_033920898 426 EAIIHQQAKYYPFLRE--DYE KIKSLVTFRIPYFVGPL AKGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK 492 AKI42028 429 EAIIHQQAKYYPFLRE--DYE KIKSLVTFRIPYFVGPL AKGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK 495 AKI50529 429 EAIIHQQAKYYPFLRE--DYE KIKSLVTFRIPYFVGPL AKGQ--SEFAWLTR---KADGEIRPWNIEEKVDFGK 495 EFR83390 --------------------- ----------------- ------------------------------------ WP_046323366 426 EAILHQQAKYYPFLKV--DYE KIKSLVTFRIPYFVGPL ANGQ--SEFSWLTR---KADGEIRPWNIEEKVDFGK 492 AKE81011 436 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 502 CUO82355 434 IKIIDNQAKYYPVLKE--KRE QLLSILTFRIPYYFGPL ETSEh----AWIKRlegKENQRILPWNYQDTVDVDA 502 WP_033162887 435 IQIIDNQSVYYPQLKE--NRD KLISILEFRIPYYFGPL AHSE----FAWIKKfedKQKERILPWNYDQIVDIDA 503 AGZ01981 453 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 519 AKA60242 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 AKS40380 420 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 486 4UN5_B 424 HAILRRQEDFYPFLKD--NRE KIEKILTFRIPYYVGPL ARG-n-SRFAWMTR---KSEETITPWNFEEVVDKGA 490 WP_010922251 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSG

QKKAIVDLLFK--TNR-KVTV 561 WP_039695303 490 SAEKFITRMTLNDLYLPEEKVLPKHSHVYETYAVYNELTKIKYVN--EQGKES-FFDSNMKQEIFDHVFK--ENR-KVTK 563 WP_045635197 487 SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLRDYqFLDSGQKKQIVNQLFK--ENR-KVTE 561 5AXW_A 230 --KEWYEMLMGHCTYFFEELRSVKYAYNADLYNALNDLNNLVITR--DENEKLeYYE---KFQIIENVFK--QKK-KPTL 299 WP_009880683 171 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV 245 WP_010922251 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV 561 WP_011054416 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV 561 WP_011284745 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV 561 WP_011285506 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV 561 WP_011527619 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV 561 WP_012560673 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV 561 WP_014407541 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV 561 WP_020905136 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV 561 WP_023080005 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV 561 WP_023610282 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV 561 WP_030125963 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV 561 WP_030126706 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV 561 WP_031488318 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPeFLSGEQKKAIVDLLFK--TNR-KVTV 561 WP_032460140 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV 561 WP_032461047 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV 561 WP_032462016 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV 561 WP_032462936 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV 561 WP_032464890 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV 561 WP_033888930 312 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV 386 WP_038431314 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV 561 WP_038432938 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV 561 WP_038434062 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV 561 BAQ51233 398 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV 472 KGE60162 -------------------------------------------------------------------------------- KGE60856 -------------------------------------------------------------------------------- WP_002989955 487 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV 561 WP_003030002 487 SAEKFITRMTLNDLYLPEEKVLPKHSLLYETFTVYNELTKVKYVN--EQGEAK-FFDANMKQEIFDHVFK--ENR-KVTK 560 WP_003065552 490 SAEKFITRMTLNDLYLPEEKVLPKHSHVYETYAVYNELTKIKYVN--EQGKDS-FFDSNMKQEIFDHVFK--ENR-KVTK 563 WP_001040076 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA--EGFKDFqFLNRKQKETIFNSLFK--EKR-KVTE 562 WP_001040078 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561 WP_001040080 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561 WP_001040081 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561 WP_001040083 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561 WP_001040085 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561 WP_001040087 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561 WP_001040088 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561 WP_001040089 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561 WP_001040090 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561 WP_001040091 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561 WP_001040092 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNVKQEIFDGVFK--EHR-KVSK 561 WP_001040094 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA--EGFKDFqFLNRKQKETIENSLEK--EKR-KVTE 562 WP_001040095 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA--EGFKDFqFLNRKQKETIENSLEK--EKR-KVTE 562 WP_001040096 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA--EGFKDFqFLNRKQKETIENSLEK--EKR-KVTE 562 WP_001040097 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA--EGFKDFqFLNRKQKETIENSLEK--EKR-KVTE 562 WP_001040098 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA--EGFKDFqFLNRKQKETIENSLEK--EKR-KVTE 562 WP_001040099 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA--EGFKDFqFLNRKQKETIENSLEK--EKR-KVTE 562 WP_001040100 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA--EGFKDFqFLNRKQKETIENSLEK--EKR-KVTE 562 WP_001040104 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561 WP_001040105 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561 WP_001040106 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561 WP_001040107 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561 WP_001040108 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561 WP_001040109 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561 WP_001040110 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561 WP_015058523 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNVKQEIFDGVFK--EHR-KVSK 561 WP_017643650 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA--EGFKDFqFLNRKQKETIENSLEK--EKR-KVTE 562 WP_017647151 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561 WP_017648376 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561 WP_017649527 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561 WP_017771611 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561 WP_017771984 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561 CFQ25032 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561 CFV16040 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIFDGVFK--EHR-KVSK 561 KLJ37842 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIEDGVEK--EHR-KVSK 561 KLJ72361 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIEDGVEK--EHR-KVSK 561 KLL20707 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIEDGVEK--EHR-KVSK 561 KLL42645 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIEDGVEK--EHR-KVSK 561 WP_047207273 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIEDGVEK--EHR-KVSK 561 WP_047209694 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRFLA--EGFKDFqFLNRKQKETIFNELFK--EKR-KVTE 562 WP_050198062 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIEDGVEK--EHR-KVSK 561 WP_050201642 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIEDGVEK--EHR-KVSK 561 WP_050204027 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIEDGVEK--EHR-KVSK 561 WP_050881965 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIEDGVEK--EHR-KVSK 561 WP_050886065 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIEDGVEK--EHR-KVSK 561 AHN30376 488 SAEAFIHRMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDENVKQEIEDGVEK--EHR-KVSK 561 EA078426 488 SAEAFIHRMTNNDFYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIEDGVEK--EHR-KVSK 561 CCW42055 488 SAEAFIHCMTNNDLYLPEEKVLPKHSLIYEKFTVYNELTKVRYKN--EQGETY-FFDSNIKQEIEDGVEK--EYR-KVSK 561 WP_003041502 487 SAEKFITRMTLNDLYLPEEKVLPKHELLYETFTVYNELTKVKYVN--EQGEAK-FFDANMKQEIFDHVFK--ENR-KVTK 560 WP_037593752 488 SAEKFITRMTLNDLYLPEEKVLPKHSPLYETFTVYNELTKVKYVN--EQGEAK-FFDTNMKQEIFDHVFK--ENR-KVTK 561 WP_049516684 488 SAEKFITRMTLNDLYLPEEKVLPKHSPLYETFTVYNELTKVKYVN--EQGEAK-FFDTNMKQEIFDHVFK--ENR-KVTK 561 GAD46167 487 SAEKFITRMTLNDLYLPEEKVLPKHSPLYETFTVYNELTKVKYVN--EQGEAK-FFDTNMKQEIFDHVFK--ENR-KVTK 560 WP_018363470 488 SAEKFITRMTLNDLYLPEEKVLPKHSHVYETFAVYNELTKVKYVN--EQGKDS-FFDSNMKQEIFDHVFK--ENR-KVTK 561 WP_003043819 497 SAQSFIERMTNEDEQLPNKKVLPKHELLYEYFTVYNELTKVKYVT--ERMRKPeFLSGEQKKAIVDLLFK--TNR-KVTV 571 WP_006269658 487 SAEKFITRMTLNDLYLPEEKVLPKHSPLYEAFTVYNELTKVKYVN--EQGEAK-FFDTNMKQEIFDHVFK--ENR-KVTK 560 WP_048800889 487 SAEKFITRMTLNDLYLPEEKVLPKHSLLYEIFTVYNELTKVKYVN--EQGEAK-FFDANMKQEIFDHVEK--ENP-KVTK 560 WP_012767106 487 SAQSFIERMTNEDKNLPNEKVLPKHELLYEYFTVYNELTKVKYVT--EGMRKPeFLEGKQKEAIVDLLFK--TNR-KVTV 561 WP_014612333 487 SAQSFIERMTNEDKNLPNEKVLPKHELLYEYFTVYNELTKVKYVT--EGMRKPeFLEGKQKEAIVDLLFK--TNR-KVTV 561 WP_015017095 487 SAQSFIERMTNEDKNLPNEKVLPKHELLYEYFTVYNELTKVKYVT--EGMRKPeFLEGKQKEAIVDLLFK--TNR-KVTV 561 WP_015057649 487 SAQSFIERMTNEDKNLPNEKVLPKHELLYEYFTVYNELTKVKYVT--EGMRKPeFLEGKQKEAIVDLLFK--TNR-KVTV 561 WP_048327215 487 SAQSFIERMTNEDKNLPNEKVLPKHELLYEYFTVYNELTKVKYVT--EGMRKPeFLEGKQKEAIVDLLFK--TNR-KVTV 561 WP_049519324 487 SAQSFIERMTNEDKNLPNEKVLPKHELLYEYFTVYNELTKVKYVT--EGMRKPaELSGEQKKAIVDLLFK--TNR-KVTV 561 WP_012515931 487 SAQIFIEKMTKNDLYLPNEKVLPKHELLYETFTVYNELTKVKYAT--EGMTRPqFLEADQKQAIVDLLFK--TNR-KVTV 561 WP_021320964 487 SAQIFIEKMTKNDLYLPNEKVLPKHELLYETFTVYNELTKVKYAT--EGMTRPqFLEADQKQAIVDLLFK--TNR-KVTV 561 WP_037581760 487 SAQIFIEKMTKNDLYLPNEKVLPKHELLYETFTVYNELTKVKYAT--EGMTRPqFLEADQKQAIVDLLFK--TNR-KVTV 561 WP_004232481 487 SAEKFITRMTLNDLYLPEEKVLPKHEYVYETFAVYNELTKIKYVN--EQGKSF-FFDANMKQEIFDHVFK--ENR-KVTK 560 WP_009854540 488 SAEKFITRMTLNDLYLPEEKVLPKHSHVYETYAVYNELTKIKYVN--EQGKES-FFDSNMKQEIFDHVFK--ENR-KVTK 561 WP_012962174 488 SAEKFITRMTLNDLYLPEEKVLPKHELVYETYTVYNELTKVKYVN--EQGKEN-FFDANMKQEIFEHVFK--ENR-KVTK 561 WP_039695303 490 SAEKFITRMTLNDLYLPEEKVLPKHSHVYETYAVYNELTKIKYVN--EQGKES-FFDSNMKQEIFDHVFK--ENR-KVTK 563 WP_014334983 487 SAEKFITRMTLNDLYLPEEKVLPKHSHVYETFTVYNELTKIKYVN--EQGESF-FFDANMKQEIFDHVFK--ENR-KVTK 560 WP_003099269 487 SARAFIERMTNFDTYLPEEKVLPKHSPLYEMFMVYNELTKVKYQT--EGMKRPvFLSSEDKEEIVNLLFK--KER-KVTV 561 AHY15608 487 SARAFIERMTNFDTYLPEEKVLPKHSPLYEMFMVYNELTKVKYQT--EGMKRPvFLSSEDKEEIVNLLFK--KER-KVTV 561 AHY17476 487 SARAFIERMTNFDTYLPEEKVLPKHSPLYEMFMVYNELTKVKYQT--EGMKRPvFLSSEDKEEIVNLLFK--KER-KVTV 561 ESR09100 -------------------------------------------------------------------------------- AGM98575 487 SARAFIERMTNFDTYLPEEKVLPKHSPLYEMFMVYNELTKVKYQT--EGMKRPvFLSSEDKEEIVNLLFK--KER-KVTV 561 ALF27331 487 SAEAFINRMTNYDLYLPNQKVLPRHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_018372492 500 SASRFIERMTLHDLYLPDEKVLPRHSLIYEKYTVFNELTKVRFTP--EGGKEV-YFSKTDKENIFDSLFK--RYR-KVTK 573 WP_045618028 488 SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLRDYqFLDSGQKQQIVTQLFK--EKR-KVTE 562 WP_045635197 487 SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLRDYqFLDSGQKKQIVNQLFK--ENR-KVTE 561 WP_002263549 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002263887 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELIKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002264920 487 SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002269043 487 SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002269448 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002271977 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002272766 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002273241 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002275430 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002276448 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002277050 487 SAQAFIEHMTNNDLYLPNEKVLPKHSPLYEKYTVYNELTKIKYVT--EIGEAK-FFDANLKQEIFDGLFK--HER-KVTK 560 WP_002277364 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002279025 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGETA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002279859 487 SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002280230 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002281696 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002282247 487 SAQAFIEHMTNNDLYLPNEKVLPKHSPLYEKYTVYNELTKIKYVT--EIGEAK-FFDANLKQEIFDGLFK--HER-KVTK 560 WP_002282906 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002283846 487 SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002287255 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002288990 487 SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002289641 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002290427 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002295753 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002296423 487 SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002304487 497 SAEKFITRMTLNDLYLPEEKVLPKHSLLYETFTVYNELTKVKYVN--EQGEAK-FFDANMKQEIFDHVFK--ENR-KVTK 570 WP_002305844 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002307203 487 SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002310390 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_002352408 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_012997688 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_014677909 487 SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_019312892 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_019313659 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_019314093 487 SVEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_019315370 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_019803776 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_019805234 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_024783594 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_024784288 487 SAQAFIEHMTNNDLYLPNEKVLPKHSPLYEKYTVYNELTKIKYVT--EIGEAK-FFDANLKQEIFDGLFK--HER-KVTK 560 WP_024784666 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_024784894 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_024786433 487 SAQAFIEHMTNNDLYLPNEKVLPKHSPLYEKYTVYNELTKIKYVT--EIGEAK-FFDANLKQEIFDGLFK--HER-KVTK 560 WP_049473442 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 WP_049474547 487 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 560 EMC03581 480 SAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYKT--EQGKTA-FFDANMKQEIFDGVFK--VYR-KVTK 553 WP_000428612 488 SAESFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLRDYqFLDSRQKKDIFYTLFKaeDKR-KVTE 564 WP_000428613 488 SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLRDYqFLDSGQKKQIVTQLFK--EKR-KVTE 562 WP_049523028 487 SAEDFIHRMTNYDLYLPEEKVLPKHSLLYETFTVYNELTKVKYIA--EGMKDYqFLDSGQKKQIVNQLFK--EKR-KVTE 561 WP_003107102 456 SAKVFIERMTNFDTYLPEEKVLPKHSLLYEMFTVYNELTKVKYQA--EGMRKPeFLSSEEKIEIVSNLFK--TER-KVTV 530 WP_054279288 489 SAQAFIERMTNFDEYLPQEKVLPKHSLTYEYFTVYNELTKVKYVT--EGMTKPeFLSAGQKEQIVELLFK--KYR-KVTV 563 WP_049531101 488 SAEAFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLRDYqFLDSGQKKKIINQLFK--EKR-KVTE 562 WP_049538452 488 SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLRDYqFLDSGQKKQIVNQLFK--EKR-KVTE 562 WP_049549711 488 SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLRDYqFLDSGQKKQIVNQLFK--EKR-KVTE 562 WP_007896501 490 SAQAFIEGMTNYDTYLPEEKVLPKHSPLYEMFTVYNELTKVKYIA--ENMTKPlYLSAEQKEATIDHLFK--QTR-KVTV 564 EFR44625 442 SAQAFIEGMTNYDTYLPEEKVLPKHSPLYEMFTVYNELTKVKYIA--ENMTKPlYLSAEQKEATIDHLFK--QTR-KVTV 516 WP_002897477 487 SAEDFIHRMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLRDYqFLDSGQKKQIVNQLFK--EKR-KVTE 561 WP_002906454 487 SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLRDYqFLDSGQKKQIVNQLFK--DKR-KVTE 561 WP_009729476 488 SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLRDYqFLDSGQKKQIVTQLFK--EKR-KVTE 562 CQR24647 488 SAQAFIERMTNNDLYLPDQKVLPKHSLLYQKFAVYNELTKIKYVT--ETGEAR-LEDVFLKKEIFDGLEK--KER-KVTK 561 WP_000066813 488 SAEDFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLTRYqFLDKKQKKDIFDTFFKaeNKR-KVTE 564 WP_009754323 488 SAESFINKMTNYDLYLPEEKVLPKHSLLYETFAVYNELTKVKFIA--EGLRDYqFFDSGQKKQIVNQLFK--EKR-KVTE 562 WP_044674937 487 SAENFITRMTNYDQYLPDQKVLPKHSLLYEKFAVYNELTKVKFIA--EGMRDYqFLDSGQKKDIVKTLFK--TKR-KVTA 561 WP_044676715 487 SAENFITRMTNYDQYLPDQKVLPKHSLLYEKFAVYNELTKVRYVT--EQGKSF-FFDANMKQEIFDGVEK--VYR-KVTK 560 WP_044680361 487 SAENFITRMTNYDQYLPDQKVLPKHSLLYEKFAVYNELTKVRYVT--EQGKSF-FFDANMKQEIFDGVEK--VYR-KVTK 560 WP_044681799 487 SAENFITRMTNYDQYLPDQKVLPKHSLLYEKFAVYNELTKVKFIA--EGMRDYqFLDSGQKKDIVKTLFK--TKR-KVTA 561 WP_049533112 487 SAEKFITRMTLNDLYLPEEKVLPKHSLLYETFTVYNELTKVKYVN--EQGEAK-FFDANMKQEIFDHVEK--ENR-KVTK 560 WP_029090905 472 SSEAFIKRMTNKCTYLIHEDVIPKHSFSYAKFEVLNELNKIRLDG------KP--IDIPLKKRIFEGLFL---EKtKVTQ 540 WP_006506696 499 TAEGFIKRMRSYCTYFPDEEVLPKNSLIVSKYEVYNELNKIRVDD--------kLLEVDVKNDIYNELFM--KNK-TVTE 567 AIT42264 487 SAQSFIERMTNEDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaELSGEQKKAIVDLLFK--TNR-KVTV 561 WP_034440723 494 SAELFIENLTSRDTYLPDEPVLPKRSLIYQKFTIFNELTKISYID--ERGILQ-NFSSREKIAIENDLFK---NKsKVTK 567 AKQ21048 487 SAQSFIERMTNEDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaELSGEQKKAIVDLLFK--TNR-KVTV 561 WP_004636532 489 SAEKFIERMTNMDTYLLEEKVLPKRSLLYQTFEVYNELTKVRYTN--EQGKTE-KLNRQQKAEIIETLFK-qKNR--VRE 562 WP_002364836 496 SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK 569 WP_016631044 447 SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK 520 EMS75795 232 SAMKFIQRMINYDTYLPTEKVLPKHSILYQKYTIFNELTKVAYKD--ERGIKH-QESSKEKREIFKELFQ--KQR-KVTV 305 WP_002373311 496 SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK 569 WP_002378009 496 SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK 569 WP_002407324 496 SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK 569 WP_002413717 496 SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK 569 WP_010775580 498 SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK 571 WP_010818269 496 SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK 569 WP_010824395 496 SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK 569 WP_016622645 496 SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK 569 WP_033624816 496 SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK 569 WP_033625576 496 SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK 569 WP_033789179 496 SATAFIERMTNEDTYLPSEKVLPKHSLLYEKFMVFNELTKISYTD--DRGIKA-NFSGKEKEKIFDYLFK--TRR-KVKK 569 WP_002310644 493 SAVRFIERMINTDMYMPHNKVLPKNSLLYQKFSIYNELTKVRYQD--ERGQMN-YFSSIEKKEIFHELFE--KNR-KVTK 566 WP_002312694 494 SAVRFIERMINTDMYMPHNKVLPKNSLLYQKFSIYNELTKVRYQD--ERGQMN-YFSSIEKKEIFHELFE--KNR-KVTK 567 WP_002314015 494 SAVRFIERMNNTDMYIPHNKVLPKNSLLYQKFSIYNELTKVRYQD--ERGQMN-YFSSIEKKEIFHELFE--KNR-KVTK 567 WP_002320716 494 SAVRFIERMINTDMYIPHNKVLPKNSLLYQKFSIYNELTKVRYQD--ERGQMN-YFSSIEKKEIFHELFE--KNR-KVTK 567 WP_002330729 493 SAVRFIERMINTDMYIPHNKVLPKNSLLYQKFSIYNELTKVRYQD--ERGQMN-YESSIEKKEIFHELFE--KNR-KVTK 566 WP_002335161 494 SAVRFIERMINTDMYMPHNKVLPKNSLLYQKFSIYNELTKVRYQD--ERGQMN-YESSIEKKEIFHELFE--KNR-KVTK 567 WP_002345439 494 SAVRFIERMINTDMYIPHNKVLPKNSLLYQKFSIYNELTKVRYQD--ERGQMN-YESSIEKKEIFHELFE--KNR-KVTK 567 WP_034867970 487 SAMRFIQRMTKQDTYLPTEKVLPKNSLLYQKYMIFNELTKVSYKD--ERGVKQ-YFSGDEKQQIFKQLFQ--KERgKITV 561 WP_047937432 494 SAVRFIERMINTDMYMPHNKVLPKNSLLYQKFSIYNELTKVRYQD--ERGQMN-YESSIEKKEIFHELFE--KNR-KVTK 567 WP_010720994 487 SAMRFIQRMTKQDTYLPTEKVLPKNSLFYQKYMIFNELTKVSYKD--ERGVKQ-YFSGDEKQQIFKQLFQ--KERgKITV 561 WP_010737004 487 SAMRFIQRMTKQDTYLPTEKVLPKNSLLYQKYMIFNELTKVSYKD--ERGVKQ-YFSGDEKQQIFKQLFQ--KERgKITV 561 WP_034700478 487 SAMRFIQRMTKQDTYLPTEKVLPKNSLLYQKYMIFNELTKVSYKD--ERGVKQ-YFSGDEKQQIFKQLFQ--KERgKITV 561 WP_007209003 491 SAVAFIERMTIKDIYL-NENVLPRHSLIYEKFTVFNELTKVLYAD--DRGVFQ-RFSAEEKEDIFEKLFK--SER-KVTK 563 WP_023519017 486 SAIEFIERMTNQDTYLPKEKVLPKQSLIYQRFMIFNELTKVSYTD--ERGKSH-YFSSEQKRKIFNELFK--QHP-RVTE 559 WP_010770040 490 SATKFIERMTNEDTYLPTEKVLPKHSMIYEKYMVYNELTKVSYVD--ERGMNQ-RFSGEEKKQIVEELFK--QSR-KVTK 563 WP_048604708 486 SAELFIERMTNFDLYLPSEKVLPKHSMLYEKYTVYNELTKVTYKD--EQGKVQ-NFSSEEKERIFIDLFK--QHR-KVTK 559 WP_010750235 487 SATKFIQRMINYDTYLPTEKVLPKYSMLYQKYTIFNELTKVAYKD--DRGIKH-QFSSEEKLRIFQELFK--KQR-RVTK 560 AII16583 526 SAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaFLSGEQKKAIVDLLFK--TNR-KVTV 600 WP_029073316 507 TADEFIKRMRNFCTYFPDEPVLAKNSLTVSKYEVLNEINKLRIND--------hLIKRDIKDKMLHTLFM--DHK-SISA 575 WP_031589969 507 TADEFIKRMRNFCTYFPDEPVMAKNSLTVSKYEVLNEINKLRIND--------hLIKRDMKDKMLHTLFM--DHK-SISA 575 KDA45870 485 SAEDFIKRMTINDLYLPTEPVLPKHSLLYERYTIFNELAGVRYVT--ENGEAK-YEDAQTKRSIFE-LFK1--DR-KVSE 557 WP_039099354 510 SANEFIKRMTTTDTYLLAEDVLPKQSLIYQRFEVLNELNGLKIDD--QPITTE------LKQAIFTDLFM---QKtSVTV 578 AKP02966 484 SSNKFIRRMTVTDSYLVGEPVLPKNSLIYQRYEVLNELNNIRITEn1KTNPTGsRLTVETKQHIYNELFK--NYK-KITV 560 WP_010991369 493 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYLVYNELTKVRYIN--DQGKTS-YFSGQEKEQIENDLFK--QKR-KVKK 566 WP_033838504 493 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYLVYNELTKVRYIN--DQGKTS-YFSGQEKEQIENDLFK--QKR-KVKK 566 EHN60060 496 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYLVYNELTKVRYIN--DQGKTS-YFSGQEKEQIENDLFK--QKR-KVKK 569 EFR89594 262 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYLVYNELTKVRYIN--DQGKTS-YFSGQEKEQIENDLFK--QKR-KVKK 335 WP_038409211 493 SAIDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKIRYID--DQGKTH-HFSGQEKQQIFNGLFK--QQR-KVKK 566 EFR95520 112 SAIDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKIRYID--DQGKTH-HFSGQEKQQIFNGLFK--QQR-KVKK 185 WP_003723650 493 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKIRYID--DQGKTN-YFSGREKQQVFNDLFK--QKR-KVKK 566 WP_003727705 493 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKIRYID--DQGKTN-YFSGREKQQIENDLFK--QKR-KVKK 566 WP_003730785 493 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKIRYID--DQGKTN-YFSGREKQQIENDLFK--QKR-KVKK 566 WP_003733029 493 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKVRYID--DQGKTN-YFSGQEKQQIENDLFK--QKR-KVKK 566 WP_003739838 493 SAVDFIEKMTNKDTYLPKENVLPKHSLYYQKYMVYNELTKVRYID--DQGKTN-YFSGQEKQQIENDYFK--QKR-KVSK 566 WP_014601172 493 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKVRYID--DQGKTN-YFSGQEKQQIENDLFK--QKR-KVKK 566 WP_023548323 493 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKIRYID--DQGKTN-YFSGQEKQQIENDLFK--QKR-KVKK 566 WP_031665337 493 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKVRYID--DQGKTN-YFSGQEKQQIENDLFK--QKR-KVKK 566 WP_031669209 493 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKVRYID--DQGKTN-YFSGQEKQQIENDLFK--QKR-KVKK 566 WP_033920898 493 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKIRYID--DQGKTN-YESGQEKQQIENDLEK--QKR-KVKK 566 AKI42028 496 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKVRYID--DQGKTN-YESGQEKQQIENDLEK--QKR-KVKK 569 AKI50529 496 SAVDFIEKMTNKDTYLPKENVLPKHSLCYQKYMVYNELTKIRYID--DQGKTN-YESGQEKQQIENDLEK--QKR-KVKK 569 EFR83390 1 ---------------------------------------------------------------IFNDLEK--QKR-KVKK 14 WP_046323366 493 SAIDFIEKMTNKDTYLPKENVLPKHSMCYQKYMVYNELTKIRYTD--DQGKTH-YESGQEKQQIENDLEK--QKR-KVKK 566 AKE81011 503 SAQSFIERMTNEDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaELSGEQKKAIVDLLFK--TNR-KVTV 577 CUO82355 503 TAEGFIKRMRSYCTYFPDEEVLPKNSLIVSKYEVYNELNKIRVDD--------kLLEVDVKNDIYNELFM--KNK-TVTE 571 WP_033162887 504 TAEGFIERMKNTGTYFPDEPVMAKNSLTVSKFEVLNELNKIRING--------kLIAVETKKELLSDLFM--KNK-TITD 572 AGZ01981 520 SAQSFIERMTNEDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaELSGEQKKAIVDLLFK--TNR-KVTV 594 AKA60242 487 SAQSFIERMTNEDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaELSGEQKKAIVDLLFK--TNR-KVTV 561 AKS40380 487 SAQSFIERMTNEDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaELSGEQKKAIVDLLFK--TNR-KVTV 561 4UN5_B 491 SAQSFIERMTNEDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVT--EGMRKPaELSGEQKKAIVDLLFK--TNR-KVTV 565 WP_010922251 562 KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633 WP_039695303 564 EKLLNYLNKE--FPEYRIKDLIGLDKEnkSFNASLGTYHDLKKIL-DK AFLDDKVNEEVIEDIIKTLTLFEDKDMIH 637 WP_045635197 562 KDIIHYLHN---VDGYDGIELKGIEKQ---FNASLSTYHDLLKIIKDK EFMDDAKNEAILENIVHTLTIFEDREMIK 632 5AXW_A 300 KQIAKEILVNe--EDIKGYRVTSTGKPe---FTNLKVYHDIKDITARK ------ENAELLDQIAKILTIYQSSEDIQ 368 WP_009880683 246 KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 317 WP_010922251 562 KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633 WP_011054416 562 KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633 WP_011284745 562 KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633 WP_011285506 562 KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633 WP_011527619 562 KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633 WP_012560673 562 KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633 WP_014407541 562 KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGAYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDRGMIE 633 WP_020905136 562 KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633 WP_023080005 562 KQLKEDYFKK--IECFDSVEISGVEDR---FNTSLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE 633 WP_023610282 562 KQLKEDYFKK--IECFDSVEISGVEDR---FNTSLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE 633 WP_030125963 562 KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633 WP_030126706 562 KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633 WP_031488318 562 KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633 WP_032460140 562 KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633 WP_032461047 562 KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633 WP_032462016 562 KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633 WP_032462936 562 KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE 633 WP_032464890 562 KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633 WP_033888930 387 KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 458 WP_038431314 562 KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633 WP_038432938 562 KQLKEDYFKK--IECFDSVEISGVEDR---FNTSLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE 633 WP_038434062 562 KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633 BAQ51233 473 KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 544 KGE60162 ------------------------------------------------ ----------------------------- KGE60856 ------------------------------------------------ ----------------------------- WP_002989955 562 KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633 WP_003030002 561 DKLLNYLNKE--FEEFRIVNLTGLDKEnkAFNSSLGTYHDLRKIL-DK SFLDDKANEKTIEDIIQTLTLFEDREMIR 634 WP_003065552 564 EKLLNYLNKE--FPEYRIKDLIGLDKEnkSFNASLGTYHDLKKIL-DK AFLDDKVNEEVIEDIIKTLTLFEDKDMIH 637 WP_001040076 563 KDIISFLNK---VDGYEGIAIKGIEKQ---FNASLSTYHDLKKIL-GK DFLDNTDNELILEDIVQTLTLFEDREMIK 632 WP_001040078 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_001040080 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_001040081 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_001040083 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIIQTLTLFEDREMIK 635 WP_001040085 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_001040087 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_001040088 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_001040089 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_001040090 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_001040091 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_001040092 562 KQLLDFLAKE--FEEFRIVDVTGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTITLFEDREMIK 635 WP_001040094 563 KDIISFLNK---VDGYEGIAIKGIEKQ---FNASLSTYHDLKKIL-GK DFLDNTDNELILEDIVQTLTLFEDREMIR 632 WP_001040095 563 KDIISFLNK---VDGYEGIAIKGIEKQ---FNASLSTYHDLKKIL-GK DFLDNTDNELILEDIVQTLTLFEDREMIR 632 WP_001040096 563 KDIISFLNK---VDGYEGIAIKGIEKQ---FNASLSTYHDLKKIL-GK DFLDNTDNELILEDIVQTLTLFEDREMIR 632 WP_001040097 563 KDIISFLNK---VDGYEGIAIKGIEKQ---FNASLSTYHDLKKIL-GK DFLDNTDNELILEDIVQTLTLFEDREMIR 632 WP_001040098 563 KDIISFLNK---VDGYEGIAIKGIEKQ---FNASLSTYHDLKKIL-GK DFLDNTDNELILEDIVQTLTLFEDREMIR 632 WP_001040099 563 KDIISFLNK---VDGYEGIAIKGIEKQ---FNASLSTYHDLKKIL-GK DFLDNTDNELILEDIVQTLTLFEDREMIR 632 WP_001040100 563 KDIISFLNK---VDGYEGIAIKGIEKQ---FNASLSTYHDLKKIL-GK DFLDNTDNELILEDIVQTLTLFEDREMIR 632 WP_001040104 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_001040105 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_001040106 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_001040107 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_001040108 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_001040109 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_001040110 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_015058523 562 KQLLDFLAKE--FEEFRIVDVTGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTITLFEDREMIK 635 WP_017643650 563 KDIISFLNK---VDGYEGIAIKGIEKQ---FNASLSTYHDLKKIL-GK DFLDNTDNELILEDIVQTLTLFEDREMIR 632 WP_017647151 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_017648376 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_017649527 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_017771611 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_017771984 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 CFQ25032 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 CFV16040 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 KLJ37842 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 KLJ72361 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 KLL20707 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 KLL42645 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_047207273 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_047209694 563 KDIISELNK---VDGYEGIAIKGIEKQ---FNASLSTYHDLKKIL-GK DFLDNTDNELILEDIVQTLTLFEDREMIR 632 WP_050198062 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_050201642 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_050204027 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_050881965 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_050886065 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 AHN30376 562 KQLLDFLAKE--FEEFRIVDVTGLDKEnkAFNASLGTYHDLKKIL-DK DFLDNPDNESILEDIVQTITLFEDREMIK 635 EA078426 562 KKLLDFLAKE--YEEFRIVDVIGLDKEnkAFNASLGTYHDLEKIL-DK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 CCW42055 562 KQLLDFLAKE--FEEFRIVDVTGLDKEnkAFNASLGTYHDLEKIL-GK DFLDNPDNESILEDIVQTLTLFEDREMIK 635 WP_003041502 561 DKLLNYLNKE--FEEFRIVNLTGLDKEnkVENSSLGTYHDLRKIL-NK SFLDNKENAQIIEDIIQTLTLFEDREMIR 634 WP_037593752 562 DKLLNYLNKE--FEEFRIVNLTGLDKEnkAENSSLGTYHDLRKIL-DK SFLDDKANEKTIEDIIQTLTLFEDREMIR 635 WP_049516684 562 DKLLNYLNKE--FEEFRIVNLTGLDKEnkAFNASLGTYHDLRKIL-DK SFLDDKVNEKIIEDIIQTLTLFEDREMIR 635 GAD46167 561 DKLLNYLNKE--FEEFRIVNLTGLDKEnkAENSSLGTYHDLRKIL-DK SFLDDKANEKTIEDIIQTLTLFEDREMIR 634 WP_018363470 562 EKLLNYLDKE--FPEYRIQDLVGLDKEnkSFNASLGTYHDLKKIL-DK SFLDDKVNEEVIEDIIKTLTLFEDREMIQ 635 WP_003043819 572 KQLKEDYFKK--IECEDSVEIIGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 643 WP_006269658 561 DKLLNYLNKE--FEEFRIVNLTGLDKEnkAENSSLGTYHDLRKIL-DK SFLDDKANEKTIEDIIQTLTLFEDREMIR 634 WP_048800889 561 DKLLNYLDKE--FDEFRIVDLTGLDKEnkAFNASLGTYHDLRKIL-DK SFLDDKANEKTIEDIIQTLTLFEDREMIR 634 WP_012767106 562 KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE 633 WP_014612333 562 KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE 633 WP_015017095 562 KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE 633 WP_015057649 562 KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE 633 WP_048327215 562 KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE 633 WP_049519324 562 KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDKEMIE 633 WP_012515931 562 KQLKENYFKK--IECWDSVEITGVEDS---FNASLGTYHDLLKIIQDK DFLDNPDNQKIIEDIILTLTLFEDKKMIS 633 WP_021320964 562 KQLKENYFKK--IECWDSVEITGVEDS---FNASLGTYHDLLKIIQDK DFLDNPDNQKIIEDIILTLTLFEDKKMIS 633 WP_037581760 562 KQLKENYFKK--IECWDSVEITGVEDS---FNASLGTYHDLLKIIQDK DFLDNPDNQKIIEDIILTLTLFEDKKMIS 633 WP_004232481 561 AKLLSYLNNE--FEEFRINDLIGLDKDskSFNASLGTYHDLKKIL-DK SFLDDKTNEQIIEDIVLTLTLFEDRDMIH 634 WP_009854540 562 EKLLNYLNKE--FPEYRIKDLIGLDKEnkSFNASLGTYHDLKKIL-DK AFLDDKVNEEVIEDIIKTLTLFEDKDMIH 635 WP_012962174 562 DKFLNYLNKE--FPEYRIQDLIGLDKEnkSFNASLGTYHDLKKIL-DK SFLDDKTNETIIEDIIQTLTLFEDRDMIR 635 WP_039695303 564 EKLLNYLNKE--FPEYRIKDLIGLDKEnkSFNASLGTYHDLKKIL-DK AFLDDKVNEEVIEDIIKTLTLFEDKDMIH 637 WP_014334983 561 AKLLSYLNNE--FEEFRINDLIGLDKDskSFNASLGTYHDLKKIL-DK SFLDDKTNGQIIEDIVLTLTLFEDRDMIH 634 WP_003099269 562 KQLKEEYESK--MKCFHTVTILGVEDR---FNASLGTYHDLLKIFKDK AFLDDEANQDILEEIVWTLTLFEDQAMIE 633 AHY15608 562 KQLKEEYESK--MKCFHTVTILGVEDR---FNASLGTYHDLLKIFKDK AFLDDEANQDILEEIVWTLTLFEDQAMIE 633 AHY17476 562 KQLKEEYESK--MKCFHTVTILGVEDR---FNASLGTYHDLLKIFKDK AFLDDEANQDILEEIVWTLTLFEDQAMIE 633 ESR09100 ------------------------------------------------ ----------------------------- AGM98575 562 KQLKEEYESK--MKCFHTVTILGVEDR---FNASLGTYHDLLKIFKDK AFLDDEANQDILEEIVWTLTLFEDQAMIE 633 ALF27331 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_018372492 574 RKLKDFIEKElgYGYIDIDNIKGVEEQ---FNASYTTYQDLLKIIGDK EFLDNEENKDLLEEIIYILTVFEDRKMIE 647 WP_045618028 563 KDIIQYLHN---VDSYDGIELKGIEKQ---FNASLSTYHDLLKIIKDK EFMDDSKNEAILENIVHTLTIFEDREMIK 633 WP_045635197 562 KDIIHYLHN---VDGYDGIELKGIEKQ---FNASLSTYHDLLKIIKDK EFMDDAKNEAILENIVHTLTIFEDREMIK 632 WP_002263549 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002263887 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002264920 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002269043 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002269448 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002271977 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002272766 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002273241 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002275430 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002276448 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002277050 561 KKLRTFLDKN--FDEFRIVDIQGLDKEteTENASYATYQDLLKVIKDK VFMDNPENAEILENIVLTLTLFEDREMIK 635 WP_002277364 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002279025 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002279859 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002280230 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002281696 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002282247 561 KKLRTFLDKN--FDEFRIVDIQGLDKEteTENASYATYQDLLKVIKDK VFMDNPENAEILENIVLTLTLFEDREMIK 635 WP_002282906 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002283846 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002287255 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002288990 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002289641 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002290427 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002295753 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002296423 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002304487 571 DKLLNYLNKE--FEEFRIVNLTGLDKEnkVENSSLGTYHDLRKIL-NK SFLDNKENEQIIEDIIQTLTLFEDREMIR 644 WP_002305844 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002307203 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002310390 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_002352408 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_012997688 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_014677909 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_019312892 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_019313659 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_019314093 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_019315370 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_019803776 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_019805234 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_024783594 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_024784288 561 KKLRTFLDKN--FDEFRIVDIQGLDKEteTFNASYATYQDLLKVIKDK VFMDNPENAEILENIVLTLTLFEDREMIK 635 WP_024784666 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_024784894 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_024786433 561 KKLRTFLDKN--FDEFRIVDIQGLDKEteTFNASYATYQDLLKVIKDK VFMDNPENAEILENIVLTLTLFEDREMIK 635 WP_049473442 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 WP_049474547 561 DKLMDFLEKE--FDEFRIVDLTGLDKEnkVFNASYGTYHDLCKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 634 EMC03581 554 DKLMDFLEKE--FDEFRIVDLTGLDKEnkAFNASYGTYHDLRKIL-DK DFLDNSKNEKILEDIVLTLTLFEDREMIR 627 WP_000428612 565 KDIIQYLHT---VDGYDGIELKGIEKQ---FNASLSTYHDLLKIIKDK EFMDDPNNEEILENIVHTLTIFEDREMIK 635 WP_000428613 563 KDIIQFLHN---VDGYDGIELKGIEKQ---FNASLSTYHDLLKIIKDK EFMDDSKNEEILENIVHTLTIFEDREMIK 633 WP_049523028 562 KDIIHYLHN---VDGYDGIELKGIEKH---FNSSLSTYHDLLKIIKDK EFMDDPKNEEIFENIVHTLTIFEDRVMIK 632 WP_003107102 531 KQLKENYFNK--IRCLDSITISGVEDK---FNASLGTYHDLLNIIKNQ KILDDEQNQDSLEDIVLTLTLFEDEKMIA 602 WP_054279288 564 KQLKEDFFSK--IECFDTVDISGVEDK---FNASLGTYHDLLKIIKDK AFLDNSENENIIEDIILTLTLFEDKEMIA 635 WP_049531101 563 KDLIHYLHN---VDGYDGIELKGIEKQ---FNASLSTYHDLLKIIKDK RFMDEPKNQEILENIVHTLTIFEDREMIK 633 WP_049538452 563 KDIIQYLHN---VDGYDGIELKGIEKQ---FNASLSTYHDLLKIIKDK EFMDDSKNEEILENIVHTLTIFEDREMIK 633 WP_049549711 563 KDIIHYLHT---VDGYDGIELKGIEKQ---FNASLSTYHDLLKIIKDK EFMDDSKNEAILENIVHTLTIFEDREMIK 633 WP_007896501 565 KDLKEKYFSQ--IEGLENVDVTGVEGA---FNASLGTYNDLLKIIKDK AFLDDEANAEILEEIVLILTLFQDEKLIE 636 EFR44625 517 KDLKEKYFSQ--IEGLENVDVTGVEGA---FNASLGTYNDLLKIIKDK AFLDDEANAEILEEIVLILTLFQDEKLIE 588 WP_002897477 562 KDIIHYLHN---VDGYDGIELKGIEKQ---FNANLSTYHDLLKITKDK EFMDDPKNEEILENIVHTLTIFEDREMIK 632 WP_002906454 562 KDIIHYLHN---VDGYDGIELKGIEKQ---FNASLSTYHDLLKIIKDK EFMDNPKNGEILENIIHTLTIFEDREMIK 632 WP_009729476 563 KDIIQFLHN---VDGYDGIELKGIEKQ---FNASLSTYHDLLKIIKDK AFMDDAKNEAILENIVHTLTIFEDREMIK 633 CQR24647 562 KKILNFLDKN--FDEFRITDIQGLDNEtgNENASYGTYHDLLKIIGDK EFMDSSDNVDVLEDIVLSLTLFEDREMIK 636 WP_000066813 565 KDIIHYLHN---VDGYDGIELKGIEKQ---FNASLSTYHDLLKIIKDK AFMDDSKNEEILENIIHTLTIFEDREMIK 635 WP_009754323 563 KDIIHYLHN---VDGYDGIELKGIEKQ---FNASLSTYHDLLKIIKDK EFMDNHKNQEILENIVHTLTIFEDREMIK 633 WP_044674937 562 KDIKAYL-EN--SNGYAGVELKGLEEQ---FNASLPTYHDLLKILRDK AFIDAEENQEILEDIVLTLTLFEDREMIR 632 WP_044676715 561 EKLMDFLGKE--FDEFRIVDLLGLDKDnkSFNASLGTYHDLKKIV-SK DLLDNPENEDILENVVLTLTLFEDREMIR 634 WP_044680361 561 EKLMDFLGKE--FDEFRIVDLLGLDKDnkSFNASLGTYHDLKKIV-SK DLLDNPENEDILENVVLTLTLFEDREMIR 634 WP_044681799 562 KDIKAYL-EN--SNGYAGVELKGLEEQ---FNASLPTYHDLLKILRDK AFIDAEENQEILEDIVLTLTLFEDREMIR 632 WP_049533112 561 DKLLNYLGKE--FDEFRIVDLTGLDKEnkVENSSLGTYHDLRKIL-DK SFLDNKENEQIIEDIIQTLTLFEDREMIR 634 WP_029090905 541 TSLKKWLAEH---EHMTVSVVQGTQKEt-EFATSLQAEHREVKIF-DR ETVSNPANEEMFEKIIYWSTVFEDKKIMR 612 WP_006506696 568 KKLKNWLVNNqcCS--KDAEIKGFQKEn-QESTSLTPWIDETNIFGKI ----DQSNFDLIENIIYDLTVFEDKKIMK 637 AIT42264 562 KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633 WP_034440723 568 NQLVKYIENK---EQIIAPEIKGIEDS---FNSNYSTYIDLSKIPDMK --LLEKDEDEILEEIIKILTIFEDRKMRK 637 AKQ21048 562 KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633 WP_004636532 563 KDIANYLEQ---YGYVDGTDIKGVEDK---FNASLSTYNDLAKIDGAK AYLDDPEYADVWEDIIKILTIFEDKAMRK 633 WP_002364836 570 KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 641 WP_016631044 521 KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 592 EMS75795 306 KKLQQFLSAN--YN-IEDAEILGVDKA---FNSSYATYHDFLDLAKPN ELLEQPEMNAMFEDIVKILTIFEDREMIR 381 WP_002373311 570 KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 641 WP_002378009 570 KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 641 WP_002407324 570 KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 641 WP_002413717 570 KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 641 WP_010775580 572 KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 643 WP_010818269 570 KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 641 WP_010824395 570 KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 641 WP_016622645 570 KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 641 WP_033624816 570 KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 641 WP_033625576 570 KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 641 WP_033789179 570 KDIIQFYRNE--YN-TEIVTLSGLEED--QFNASFSTYQDLLKCGLTR AELDHPDNAEKLEDIIKILTIFEDRQRIR 641 WP_002310644 567 KDLQEFLYLK--YD-IKHAELSGIEKA---FNASYTTYHDFLTMSENK QWLEDPELASMFEEIIKTLTVFEDREMIK 641 WP_002312694 568 KDLQEFLYLK--YD-IKHAELSGIEKA---FNASYTTYHDFLTMSENK QWLEDPELASMFEEIIKTLTVFEDREMIK 642 WP_002314015 568 KDLQEFLYLK--YD-IKHAELSGIEKA---FNASYTTYHDFLTMSENK QWLEDPELASMFEEIIKTLTVFEDREMIK 642 WP_002320716 568 KDLQEFLYLK--YD-IKHAELSGIEKA---FNASYTTYHDFLTMSENK QWLEDPELASMFEEIIKTLTVFEDREMIK 642 WP_002330729 567 KDLQEFLYLK--YD-IKHAELSGIEKA---FNASYTTYHDFLTMSENK QWLEDPELASMFEEIIKTLTVFEDREMIK 641 WP_002335161 568 KDLQEFLYLK--YD-IKHAELSGIEKA---FNASYTTYHDFLTMSENK QWLEDPELASMFEEIIKTLTVFEDREMIK 642 WP_002345439 568 KDLQEFLYLK--YD-IKHAELSGIEKA---FNASYTTYHDFLTMSENK QWLEDPELASMFEEIIKTLTVFEDREMIK 642 WP_034867970 562 KKLQNFLYTH--YH-IENAQIFGIEKA---FNASYSTYHDFMKLAKTN EWLEQPEMEPIFEDIVKILTIFEDRQMIK 637 WP_047937432 568 KDLQEFLYLK--YD-IKHAELSGIEKA---FNASYTTYHDFLTMSENK QWLEDPELASMFEEIIKTLTVFEDREMIK 642 WP_010720994 562 KKLQNFLYTH--YH-IENAQIFGIEKA---FNASYSTYHDFMKLAKTN EWLEQPEMEPIFEDIVKILTIFEDRQMIK 637 WP_010737004 562 KKLQNFLYTH--YH-IENAQIFGIEKA---FNASYSTYHDFMKLAKTN EWLEQPEMEPIFEDIVKILTIFEDRQMIK 637 WP_034700478 562 KKLQNFLYTH--YH-IENAQIFGIEKA---FNASYSTYHDFMKLAKTN EWLEQPEMEPIFEDIVKILTIFEDRQMIK 637 WP_007209003 564 KKLENYLRIE1---SISSPSVKGIEEQ---FNANFGTYLDLKKFDELH PYLDDEKYQDTLEEVIKVLTVFEDRSMIQ 634 WP_023519017 560 KQLRKFLELN--EQ-IDSTEIKGIETS---FNASYSTYHDLLKLS--- TLLDDPDMTTMFEEIIKILTIFEDREMIR 631 WP_010770040 564 KLLEKFLSNE--FG-LVDVAIKGIE-T--SFNAGYGTYHDFLKIGITR EQLDKEENSETLEEIVKILTVFEDRKMIR 634 WP_048604708 560 KDLSNFLRNE--YN-LDDVIIDGIE-N--KFNASFNTYHDFLKLKIDP KVLDDPANEPMFEEIVKILTIFEDRKMLR 630 WP_010750235 561 KKLQHFLSAN--YN-IEDAEILGVDKV---FNSSYATYHDFLELAKPY ELLEQPEMEEMFEDIVKIITIFEDREMVR 636 AII16583 601 KQLKEDYFKK--IECFDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 672 WP_029073316 576 NAMKKWLVKNqyFSNTDDIKIEGFQKEn-ACSTSLTPWIDFTKIFGEI ----NNSNYELIEKIIYDVTVFEDKKILR 647 WP_031589969 576 NAMKKWLVKNqyFSNTDDIKIEGFQKEn-ACSTSLTPWIDFTKIFGKI ----NESNYDFIEKIIYDVTVFEDKKILR 647 KDA45870 558 KMVIKHLKVV--MPAIRIQALKGLDNGk--FNASYGTYKDLVDMGVAP ELLNDEVNSEKWEDIIKTLTIFEGRKLIK 630 WP_039099354 579 KNIQDYLVSEk--RYASRPAITGLSDEnk-FNSRLSTYHDLKTIVGDA --VDDVDKQADLEKCIEWSTIFEDGKIYS 650 AKP02966 561 KKLTKWLIAQg---YYKNPILIGLSQKd-EFNSTLTTYLDMKKIFGSS -FMENNKNYNQIEELIEWLTIFEDKQILN 632 WP_010991369 567 KDLELFLRNM--SH-VESPTIEGLE-D--SFNSSYSTYHDLLKVGIKQ EILDNPVNTEMLENIVKILTVFEDKRMIK 637 WP_033838504 567 KDLELFLRNM--SH-VESPTIEGLE-D--SFNSSYSTYHDLLKVGIKQ EILDNPVNTEMLENIVKILTVFEDKRMIK 637 EHN60060 570 KDLELFLRNM--SH-VESPTIEGLE-D--SFNSSYSTYHDLLKVGIKQ EILDNPVNTEMLENIVKILTVFEDKRMIK 640 EFR89594 336 KDLELFLRNM--SH-VESPTIEGLE-D--SFNSSYSTYHDLLKVGIKQ EILDNPVNTEMLENIVKILTVFEDKRMIK 406 WP_038409211 567 KDLERFLYTI--NH-IESPTIEGVE-D--AFNSSFATYHDLQKGGVTQ EILDNPLNADMLEEIVKILTVFEDKRMIK 637 EFR95520 186 KDLERFLYTI--NH-IESPTIEGVE-D--AFNSSFATYHDLQKGGVTQ EILDNPLNADMLEEIVKILTVFEDKRMIK 256 WP_003723650 567 KDLELFLRNI--NH-IESPTIEGLE-D--SFNASYATYHDLLKVGMKQ EILDNPLNTEMLEDIVKILTVFEDKPMIK 637 WP_003727705 567 KDLELFLRNI--NH-IESPTIEGLE-D--SFNASYATYHDLLKVGLKQ EILDNPLNTEILEDIVKILTVFEDKRMIK 637 WP_003730785 567 KDLELFLRNI--NH-IESPTIEGLE-D--SFNASYATYHDLLKVGLKQ EILDNPLNTEILEDIVKILTVFEDKRMIK 637 WP_003733029 567 KDLELFLRNI--NQ-IESPTIEGLE-D--SFNASYATYHDLLKVGMKQ EILDNPLNTEMLEDIVKILTVFEDKRMIK 637 WP_003739838 567 KDLEQFLRNM--SH-IESPTIEGLE-D--SFNSSYATYHDLLKVGIKQ EVLENPLNTEMLEDIVKILTVFEDKRMIK 637 WP_014601172 567 KDLELFLRNI--NH-IESPTIEGLE-D--SFNASYATYHDLLKVGMKQ EILDNPLNTEMLEDIVKILTVFEDKPMIK 637 WP_023548323 567 KDLELFLRNI--NH-VESPTIEGLE-D--SFNASYATYHDLMKVGIKQ EILDNPLNTEMLEDIVKILTVFEDKRMIK 637 WP_031665337 567 KDLELFLRNI--NQ-IESPTIEGLE-D--SFNASYATYHDLLKVGMKQ EILDNPLNTEMLEDIVKILTVFEDKRMIK 637 WP_031669209 567 KDLELFLRNI--NQ-IESPTIEGLE-D--SFNASYATYHDLLKVGMKQ EILDNPLNTEMLEDIVKILTVFEDKRMIK 637 WP_033920898 567 KDLELFLRNI--NH-VESPTIEGLE-D--SFNASYATYHDLMKVGIKQ EILDNPLNTEMLEDIVKILTVFEDKRMIK 637 AKI42028 570 KDLELFLRNI--NH-IESPTIEGLE-D--SFNASYATYHDLLKVGMKQ EILDNPLNTEMLEDIVKILTVFEDKPMIK 640 AKI50529 570 KDLELFLRNI--NH-VESPTIEGLE-D--SFNASYATYHDLMKVGIKQ EILDNPLNTEMLEDIVKILTVFEDKRMIK 640 EFR83390 15 KDLELFLRNI--NQ-IESPTIEGLE-D--SFNASYATYHDLLKVGMKQ EILDNPLNTEMLEDIVKILTVFEDKRMIK 85 WP_046323366 567 KDLELFLYNM--NH-VESPTVEGVE-D--AFNSSETTYHDLQKVGVPQ EILDDPLNTEMLEEIIKILTVFEDKRMIN 637 AKE81011 578 KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 649 CUO82355 572 KKLKNWLVNNqcCR--KDAEIKGFQKEn-QESTSLTPWIDETNIFGKI ----DQSNFDLIEKIIYDLTVFEDKKIMK 641 WP_033162887 573 KKLKDWLVTHqyYDINEELKIEGYQKD1-QESTSLAPWIDETKIFGEI ----NASNYQLIEKIIYDISIFEDKKILK 644 AGZ01981 595 KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 666 AKA60242 562 KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633 AKS40380 562 KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 633 4UN5_B 566 KQLKEDYFKK--IECEDSVEISGVEDR---FNASLGTYHDLLKIIKDK DFLDNEENEDILEDIVLTLTLFEDREMIE 637 WP_010922251 634 ERLKTYAHLFDDKVMKQLKR-RRYTGW

RLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNF

QLIHDDSL 702 WP_039695303 638 ERLQKYSDIFTANQLKKLER-RHYTGWGRLSYKLINGIRNK ENNKTILDYLI DDG---SANRNFMQLINDDTL 706 WP_045635197 633 QRLAQYDSLFDEKVIKALTR-RHYTGWGKLSAKLINGICDK QTGNTILDYLI DDG---KINRNFMQLINDDGL 701 5AXW_A 369 EELTNLNSELTQEEIEQISN1KGYTGTHNLSLKAINLILDE ---------LW -------TNDNQIAIFNRLKL 426 WP_009880683 318 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 386 WP_010922251 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 702 WP_011054416 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 702 WP_011284745 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 702 WP_011285506 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 702 WP_011527619 634 ERLKTYAHLFDDKVMKQLKR-RRYTVWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 702 WP_012560673 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 702 WP_014407541 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 702 WP_020905136 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 702 WP_023080005 634 ERLKKYANLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLINDDSL 702 WP_023610282 634 ERLKKYANLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLINDDSL 702 WP_030125963 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 702 WP_030126706 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 702 WP_031488318 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 702 WP_032460140 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 702 WP_032461047 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 702 WP_032462016 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 702 WP_032462936 634 ERLKKYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 702 WP_032464890 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 702 WP_033888930 459 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 527 WP_038431314 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 702 WP_038432938 634 ERLKKYANLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLINDDSL 702 WP_038434062 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 702 BAQ51233 545 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 613 KGE60162 ----------------------------------------- ----------- --------------------- KGE60856 ----------------------------------------- ----------- --------------------- WP_002989955 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 702 WP_003030002 635 QRLQKYSDIFTKAQLKKLER-RHYTGWGRLSYKLINGIRNK ENKKTILDYLI DDG---YANRNFMQLINDDAL 703 WP_003065552 638 ERLQKYSDIFTADQLKKLER-RHYTGWGRLSYKLINGIRNK ENNKTILDYLI DDG---SANRNFMQLINDDTL 706 WP_001040076 633 KRLDIYKDFFTESQLKKLYR-RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG---SANRNFMQLIKDAGL 701 WP_001040078 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL 704 WP_001040080 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL 704 WP_001040081 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL 704 WP_001040083 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL 704 WP_001040085 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL 704 WP_001040087 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL 704 WP_001040088 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL 704 WP_001040089 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL 704 WP_001040090 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL 704 WP_001040091 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL 704 WP_001040092 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDR ESQKTILDYLI SDG---RANRNFMQLINDDGL 704 WP_001040094 633 KRLDIYKDFFTESQLKKLYR-RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG---SANRNFMQLIKDAGL 701 WP_001040095 633 KRLDIYKDFFTESQLKKLYR-RHYTGWERLSAKLINGIRNK ENQKTILDYLI DDG---SANRNFMQLIKDAGL 701 WP_001040096 633 KRLDIYKDFFTESQLKKLYR-RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG---SANRNFMQLIKDAGL 701 WP_001040097 633 KRLDIYKDFFTESQLKKLYR-RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG---SANRNFMQLIKDAGL 701 WP_001040098 633 KRLDIYKDFFTESQLKKLYR-RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG---SANRNFMQLIKDAGL 701 WP_001040099 633 KRLDIYKDFFTESQLKKLYR-RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG---SANRNFMQLIKDAGL 701 WP_001040100 633 KRLDIYKDFFTESQLKKLYR-RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG---SANRNFMQLIKDAGL 701 WP_001040104 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL 704 WP_001040105 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL 704 WP_001040106 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI SDG---RANRNFMQLIHDDGL 704 WP_001040107 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI SDG---RANRNFMQLIHDDGL 704 WP_001040108 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI SDG---RANRNFMQLIHDDGL 704 WP_001040109 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI SDG---RANRNFMQLIHDDGL 704 WP_001040110 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI SDG---RANRNFMQLIHDDGL 704 WP_015058523 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDR ESQKTILDYLI SDG---RANRNFMQLINDDGL 704 WP_017643650 633 KRLDIYKDFFTESQLKKLYR-RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG---SANRNFMQLIKDAGL 701 WP_017647151 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---KSNRNFMQLIHDDGL 704 WP_017648376 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---KSNRNFMQLIHDDGL 704 WP_017649527 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL 704 WP_017771611 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI SDG---RANRNFMQLIHDDGL 704 WP_017771984 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL 704 CFQ25032 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL 704 CFV16040 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL 704 KLJ37842 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL 704 KLJ72361 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL 704 KLL20707 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL 718 KLL42645 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI SDG---RANRNFMQLIHDDGL 704 WP_047207273 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL 704 WP_047209694 633 KRLDIYKDFFTESQLKKLYR-RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG---SANRNFMQLIKDAGL 701 WP_050198062 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL 704 WP_050201642 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL 704 WP_050204027 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI SDG---RANRNFMQLIHDDGL 704 WP_050881965 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL 704 WP_050886065 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL 704 AHN30376 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDR ESQKIILDYLI SDG---RANRNFMQLINDDGL 704 EA078426 636 KRLENYKDLFTESQLKKLYR-RHYTGWGRLSAKLINGIRDK ESQKTILDYLI DDG---RSNRNFMQLINDDGL 704 CCW42055 636 KRLDIYKDFFTESQLKKLYR-RHYTGWGRLSAKLINGIRNK ENQKTILDYLI DDG---SANRNFMQLIKDAGL 704 WP_003041502 635 QRLQKYSDIFTKAQLKKLER-RHYTGWGRLSYKLINGIRNK ENKKTILDYLI DDG---YANRNFMQLINDDAL 703 WP_037593752 636 QRLQKYSDIFTKAQLKKLER-RHYTGWGRLSYKLINGIRNK ENKKTILDYLI DDG---YANRNFMQLINDDAL 704 WP_049516684 636 QRLQKYSDIFTTQQLKKLER-RHYTGWGRLSYKLINGIRNK ENKKTILDYLI DDG---YANRNFMQLINDDAL 704 GAD46167 635 QRLQKYSDIFTKAQLKKLER-RHYTGWGRLSYKLINGIRNK ENKKTILDYLI DDG---YANRNFMQLINDDAL 703 WP_018363470 636 QRLQKYSDIFTKQQLKKLER-RHYTGWGRLSYKLINGIRNK ENNKTILDYLI DDG---SANRNFMQLINDDAL 704 WP_003043819 644 ERLKTYAHLFDDKVMKQLKR-RHYTGWGRLSRKMINGIRDK QSGKTILDFLK -DGf---SNRNFMQLIHDDSL 712 WP_006269658 635 QRLQKYSDIFTKAQLKKLER-RHYTGWGRLSYKLINGIRNK ENKKTILDYLI DDG---YANRNFMQLINDDAL 703 WP_048800889 635 QRLQKYSDIFTKAQLKKLER-RHYTGWGRLSYKLINGIRNK ENNKTILEYLV DDG---YANRNFMQLINDDTL 703 WP_012767106 634 ERLKKYANLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLINDDSL 702 WP_014612333 634 ERLKKYANLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLINDDSL 702 WP_015017095 634 ERLKTYAHLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFIQLIHDDSL 702 WP_015057649 634 ERLKKYANLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLINDDSL 702 WP_048327215 634 ERLKTYAHLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFIQLIHDDSL 702 WP_049519324 634 ERLKTYAHLFDDKVMKQLKR-RHYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFIQLIHDDSL 702 WP_012515931 634 KRLDQYAHLFDKVVLNKLER-HHYTGWGRLSGKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDSEL 702 WP_021320964 634 KRLDQYAHLFDKVVLNKLER-HHYTGWGRLSGKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDSEL 702 WP_037581760 634 KRLDQYAHLFDKVVLNKLER-HHYTGWGRLSGKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDSEL 702 WP_004232481 635 ERLQKYSDIFTSQQLKKLER-RHYTGWGRLSYKLINGIRNK ENNKTILDFLI DDG---DANRNFMQLINDDSL 703 WP_009854540 636 ERLQKYSDIFTANQLKKLER-RHYTGWGRLSYKLINGIRNK ENNKTILDYLI DDG---SANRNFMQLINDDTL 704 WP_012962174 636 QRLQKYSDIFTPQQLKKLER-RHYTGWGRLSYKLINGIRNK ENGKSILDYLI DDG---YANRNFMQLISDDTL 704 WP_039695303 638 ERLQKYSDIFTANQLKKLER-RHYTGWGRLSYKLINGIRNK ENNKTILDYLI DDG---SANRNFMQLINDDTL 706 WP_014334983 635 ERLQKYSDFFTSQQLKKLER-RHYTGWGRLSYKLINGIRNK ENNKTILDFLI DDG---HANRNFMQLINDESL 703 WP_003099269 634 RRLVKYADVFEKSVLKKLKK-RHYTGWGRLSQKLINGIKDK QTGKTILGFLK -DGv---ANRNFMQLINDSSL 702 AHY15608 634 RRLVKYADVFEKSVLKKLKK-RHYTGWGRLSQKLINGIKDK QTGKTILGFLK -DGv---ANRNFMQLINDSSL 702 AHY17476 634 RRLVKYADVFEKSVLKKLKK-RHYTGWGRLSQKLINGIKDK QTGKTILGFLK -DGv---ANRNFMQLINDSSL 702 ESR09100 ----------------------------------------- ----------- --------------------- AGM98575 634 RRLVKYADVFEKSVLKKLKK-RHYTGWGRLSQKLINGIKDK QTGKTILGFLK -DGv---ANRNFMQLINDSSL 702 ALF27331 635 KRLENYSDLLTKEQVKNLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_018372492 648 KRLSELNIPFENKIIKKLAR-KKYTGWGNLSRKLIDGIRNR ETNRTILGHLI DDGf---SNRNLMQLINDDGL 716 WP_045618028 634 QRLAHYASIFDEKVIKALTR-RHYTGWGKLSAKLINGIYDK QSKKTILDYLI DDG---EINRNFMQLINDDGL 702 WP_045635197 633 QRLAQYDSLFDEKVIKALTR-RHYTGWGKLSAKLINGICDK QTGNTILDYLI DDG---KINRNFMQLINDDGL 701 WP_002263549 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_002263887 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_002264920 635 KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_002269043 635 KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_002269448 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_002271977 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_002272766 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_002273241 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_002275430 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTLLDYLI DDG---NSNRNFMQLINDDAL 703 WP_002276448 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_002277050 636 QRLAKYADVFDKKVIDQLAR-RHYTGWGRLSAKLLNGIRDK QSCKTIMDYLI DDA---QSNRNLMQLITDDNL 704 WP_002277364 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_002279025 635 KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_002279859 635 KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_002280230 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_002281696 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_002282247 636 QRLAKYADVFDKKVIDQLAR-RHYTGWGRLSAKLLNGIRDK QSCKTIMDYLI DDA---QSNRNLMQLITDDNL 704 WP_002282906 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_002283846 635 KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_002287255 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_002288990 635 KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_002289641 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_002290427 635 KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_002295753 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_002296423 635 KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_002304487 645 QRLQKYSDIFTKAQLKKLER-RHYTGWGRLSYKLINGIRDK QSNKTILGYLI DDG---YSNRNFMQLINDDAL 713 WP_002305844 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_002307203 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTLLDYLI DDG---NSNRNFMQLINDDAL 703 WP_002310390 635 KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_002352408 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTLLDYLI DDG---NSNRNFMQLINDDAL 703 WP_012997688 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_014677909 635 KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_019312892 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_019313659 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_019314093 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTLLDYLI DDG---NSNRNFMQLINDDAL 703 WP_019315370 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTLLDYLI DDG---NSNRNFMQLINDDAL 703 WP_019803776 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_019805234 635 KRLKNYSDLLTKEQLKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_024783594 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_024784288 636 QRLAKYADVFDKKVIDQLAR-RHYTGWGRLSAKLLNGIRDK QSCKTIMDYLI DDA---QSNRNLMQLITDDNL 704 WP_024784666 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_024784894 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_024786433 636 QRLAKYADVFDKKVIDQLAR-RHYTGWGRLSAKLLNGIRDK QSCKTIMDYLI DDA---QSNRNLMQLITDDNL 704 WP_049473442 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 WP_049474547 635 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 703 EMC03581 628 KRLENYSDLLTKEQVKKLER-RHYTGWGRLSAELIHGIRNK ESRKTILDYLI DDG---NSNRNFMQLINDDAL 696 WP_000428612 636 QRLAQYDSLFDEKVIKALTR-RHYTGWGKLSSKLINGIRDK QTGKTILDYLM DDG---YNNRNFMQLINDDEL 704 WP_000428613 634 QRLAQYDSLFDEKVIKALIR-RHYTGWGKLSAKLIDGICDK QTGNTILDYLI DDG---KNNRNFMQLINDDGL 702 WP_049523028 633 QRLNQYDSIFDEKVIKALTR-RHYTGWGKLSAKLINGIRDK KTSKTILDYLI DDG---YSNRNFMQLINDDGL 701 WP_003107102 603 KRLSKYESIFDPSILKKLKK-RHYTGWGRLSQKLINGIRDK QTGKTILDFLI -DGq---ANRNFMQLINDPSL 671 WP_054279288 636 NRLAVYEDLFDQNVLKQLKR-RHYTGWGRLSKQLINGMRDK HTGKTILDFLK -DGf---INRNFMQLINDDNL 704 WP_049531101 634 QRLAQYASIFDEKVIKTLTR-RHYTGWGKLSAKLINCIRDR KTGKTILDYLI DDG---YNNRNFMQLINDDGL 702 WP_049538452 634 QRLAQYDSIFDEKVIKALTR-RHYTGWGKLSAKLINGIRDK QTGKTILDYLI DDG---YSNRNFMQLINDDGL 702 WP_049549711 634 QRLAQYDSLFDKKVIKALTR-RHYTGWGKLSAKLINGICDK QTGNTILDYLI DDG---EINRNFMQLINDDGL 702 WP_007896501 637 KRLAKYANLFEKSVLKKLRK-RHYRGWGRLSRQLIDGMKDK ASGKTILDFLK -DDf---ANRNFIQLINDSSL  705 EFR44625 589 KRLAKYANLFEKSVLKKLRK-RHYRGWGRLSRQLIDGMKDK ASGKTILDFLK -DDf---ANRNFIQLINDSSL  657 WP_002897477 633 QRLAQYDTLFDEKVIKALTR-RHYTGWGKLSAKLINGIRDK QSGKTILDYLI DDD---KINRNFMQLINDDGL 701 WP_002906454 633 QRLAQYDTLFDEKVIKALTR-RHYTGWGKLSAKLINGIRDK QTGKTILEYLI DDG---DCNRNFMQLINDDGL 701 WP_009729476 634 QRLAQYDSLFDEKVIKALTR-RHYTGWGKLSAKLINGISDK QTGNTILDYLI DDG---EINRNFMQLINDDGL 702 CQR24647 637 QRLLKYEDIFSKKVIANLTR-RHYTGWGRLSAKLINGIKDK HSRKTILDYLI DDG---HSNRNFMQLINDDNL 705 WP_000066813 636 QRLAQYDSLFDEKVIKALTR-RHYTGWGKLSAKLINGIRDK KSGKTILDYLI DDG---EINRNFMQLIHDDGL 704 WP_009754323 634 QRLAQYDSIFDEKVIKALTR-RHYTGWGKLSAKLINGICDK KTGKTILDYLI DDG---YNNRNFMQLINDDGL 702 WP_044674937 633 KRLEKYKDILTEEQRKKLER-RHYTGWGRLSAKLINGILDK VTRKTILGYLI DDG---TSNRNFMQLINDDTL 701 WP_044676715 635 KRLEKYKDVLTEEQRKKLER-RHYTGWGRLSAKLINGIRDK VTRKTILDYLI DDG---TSNRNFMQLINDDTL 703 WP_044680361 635 KRLEKYKDVLTEEQRKKLER-RHYTGWGRLSAKLINGIRDK VTRKTILDYLI DDG---TSNRNFMQLINDDTL 703 WP_044681799 633 KRLEKYKDILTEEQRKKLER-RHYTGWGRLSAKLINGILDK VTRKTILGYLI DDG---TSNRNFMQLINDDTL 701 WP_049533112 635 QRLQKYSDIFTKAQLKKLER-CHYTGWGRLSYKLINGIRNK ENKKTILDYLI DDG---YANRNFMQLINDDAL 703 WP_029090905 613 RKLSEYPQLTEQQQVQLAQV--RFRGWGRLSQRLINRIKTP EDHKLSINEIL ------QTNENFMQIIRNKDY 682 WP_006506696 638 RRLKKKYALPDDKVKQILKL--KYKDWSRLSKKLLDGIVAD SV--TVLDVLE -------SRLNLMEIINDKDL 705 AIT42264 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 702 WP_034440723 638 RQLMKFKDKLSEKAINQLSK-KHYTGWGQLSEKLINGIRDE QSNKTILDYLI DNGcpkNMNRNFMQLINDDTL 710 AKQ21048 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 702 WP_004636532 634 KQLQTYSDTLSPEILKKLER-KHYTGWGRFSKKLINGLRDE GSNKTILDYLK DEGssgPTNRNFMQLIRDNTL 706 WP_002364836 642 TQLSTFKGQFSAEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILGYLI DDGvskHYNRNFMQLINDSQL 714 WP_016631044 593 TQLSTFKGQFSAEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILDYLV DDGvskHYNRNFMQLINDSQL 665 EMS75795 382 TQLKKYQSVLGDGFEKKLVK-KHYTGWGRLSERLINGIRDK KTNKTILDYLI DDDfpyNRNRNFMQLINDDSL 454 WP_002373311 642 TQLSTFKGQFSAEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILDYLV DDGvskHYNRNFMQLINDSQL 714 WP_002378009 642 TQLSTFKGQFSAEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILDYLI DDGvskHYNRNFMQLINDSQL 714 WP_002407324 642 TQLSTFKGQFSAEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILDYLV DDGvskHYNRNFMQLINDSQL 714 WP_002413717 642 TQLSTFKGQFSAEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILDYLV DDGvskHYNRNFMQLINDSQL 714 WP_010775580 644 TQLSTFKGQFSEEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILDYLI DDGvskHYNRNFMQLINDSQL 716 WP_010818269 642 TQLSTFKGQFSAEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILGYLI DDGvskHYNRNFMQLINDSQL 714 WP_010824395 642 TQLSTFKGQFSAEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILDYLI DDGvskHYNRNFMQLINDSQL 714 WP_016622645 642 TQLSTFKGQFSAEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILDYLV DDGvskHYNRNFMQLINDSQL 714 WP_033624816 642 TQLSTFKGQFSAEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILDYLI DDGvskHYNRNFMQLINDSQL 714 WP_033625576 642 TQLSTFKGQFSAEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILDYLI DDGvskHYNRNFMQLINDSQL 714 WP_033789179 642 TQLSTFKGQFSEEVLKKLER-KHYTGWGRLSKKLINGIYDK ESGKTILDYLI DDGvskHYNRNFMQLINDSQL 714 WP_002310644 642 TRLSHHEATLGKHIIKKLTK-KHYTGWGRLSKELIQGIRDK QSNKTILDYLI DDDfphHRNRNFMQLINDDSL 714 WP_002312694 643 TRLSHHEATLGKHIIKKLTK-KHYTGWGRLSKELIQGIRDK QSNKTILDYLI DDDfphHRNRNFMQLINDDSL 715 WP_002314015 643 TRLSHHEATLGKHIIKKLTK-KHYTGWGRLSKELIQGIRDK QSNKTILDYLI DDDfphHRNRNFMQLINDDSL 715 WP_002320716 643 TRLSHHEATLGKHIIKKLTK-KHYTGWGRLSKELIQGIRDK QSNKTILDYLI DDDfphHRNRNFMQLINDDSL 715 WP_002330729 642 TRLSHHEATLGKHIIKKLTK-KHYTGWGRLSKELIQGIRDK QSNKTILDYLI DDDfphHRNRNFMQLINDDSL 714 WP_002335161 643 TRLSHHEATLGKHIIKKLTK-KHYTGWGRLSKELIQGIRDK QSNKTILDYLI DDDfphHRNRNFMQLINDDSL 715 WP_002345439 643 TRLSHHEATLGKHIIKKLTK-KHYTGWGRLSKELIQGIRDK QSNKTILDYLI DDDfphHRNRNCMQLINDDSL 715 WP_034867970 638 HQLSKYQEVFGEKLLKEFAR-KHYTGWGRFSAKLIHGIRDR KTNKTILDYLI DDDvpaNRNRNLMQLINDEHL 710 WP_047937432 643 TRLSHHEATLGKHIIKKLTK-KHYTGWGRLSKELIQGIRDK QSNKTILDYLI DDDfphHRNRNFMQLINDDSL 715 WP_010720994 638 HQLSKYQEVFGEKLLKEFAR-KHYTGWGRFSAKLIHGIRDR KTNKTILDYLI DDDvpaNRNRNLMQLINDEHL 710 WP_010737004 638 HQLSKYQEVFGEKLLKEFAR-KHYTGWGRFSAKLIHGIRDR KTNKTILDYLI DDDvpaNRNRNLMQLINDEHL 710 WP_034700478 638 HQLSKYQEVFGEKLLKEFAR-KHYTGWGRFSAKLIHGIRDR KTNKTILDYLI DDDvpaNRNRNLMQLINDEHL 710 WP_007209003 635 NQLEQLPLNLSTKTIKALSR-RKYTGWGRLSARLIDGIHDK NSGKTILDYLI DESdsyIVNRNFMQLINDDHL 707 WP_023519017 632 EQLKPYETVLGLPAIKKLAK-KHYTGWGRLSEKMIQGMREK QSRKTILDYLI DDDfpcNRNRNFMQLINDDHL 704 WP_010770040 635 EQLKKYTYLFDEEVLKKLER-RHYTGWGRLSAKLLIGIKEK RTHKTILDYLI DDGgkqPINRNLMQLINDSDL 707 WP_048604708 631 EQLSKFSDRLSEKTIKDLER-RHYTGWGRLSAKLINGIHDK QSNKTILDYLI DDApkkNINRNFMQLINDNRL 703 WP_010750235 637 TQLKKYQRILGEEIFKKLVK-KKYTGWGRLSKRLINGIRDQ KTNKTILDYLI DDDfpyNRNRNFMQLINDDHL 709 AII16583 673 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 741 WP_029073316 648 RRLKKEYDLDEEKIKKILKL--KYSGWSRLSKKLLSGIKTK RTPETVLEVME -------TNMNLMQVINDEKL 717 WP_031589969 648 RRLKKEYDLDEEKIKKILKL--KYSGWSRLSKKLLSGIKTK RTPETVLEVME -------TNMNLMQVINDEKL 717 KDA45870 631 RRLENYRDFLGEDILRKLSR-KKYTGWGRLSAKLLDGIYDK KTHKTILDCLM EDYs-----QNFMQLINDDTY 698 WP_039099354 651 AKLNEIDWLTDQQRVQLAAK--RYRGWGRLSAKLLTQIVN- ANGQRIMDLLW -------TTDNFMRIVHSE-- 712 AKP02966 633 EKLHSSNYSYTSDQIKKISN-MRYKGWGRLSKKILTCITTE TNTPKSLQLSN -DLm-wTTNNNFISIISNDKY 706 WP_010991369 638 EQLQQFSDVLDGVVLKKLER-RHYTGWGRLSAKLLMGIRDK QSHLTILDYLM DDG----LNRNLMQLINDSNL 706 WP_033838504 638 EQLQQFSDVLDGVVLKKLER-RHYTGWGRLSAKLLMGIRDK QSHLTILDYLM DDG----LNRNLMQLINDSNL 706 EHN60060 641 EQLQQFSDVLDGVVLKKLER-RHYTGWGRLSAKLLMGIRDK QSHLTILDYLM DDG----LNRNLMQLINDSNL 709 EFR89594 407 EQLQQFSDVLDGVVLKKLER-RHYTGWGRLSAKLLMGIRDK QSHLTILDYLM DDG----LNRNLMQLINDSNL 475 WP_038409211 638 EQLQSFSDVLDGTILKKLER-RHYTGWGRLSAKLLTGIRDK HSHLTILDYLM DDG----LNRNLMQLINDSNL 706 EFR95520 257 EQLQSFSDVLDGTILKKLER-RHYTGWGRLSAKLLTGIRDK HSHLTILDYLM DDG----LNRNLMQLINDSNL 325 WP_003723650 638 EQLQQFSDVLDGGVLKKLER-RHYTGWGRLSAKLLVGIREK QSHLTILDYLM DDG----LNRNLMQLINDSNL 706 WP_003727705 638 EQLEQFSDVLDGVVLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILDYLM DDG----LNRNLMQLINDSNL 706 WP_003730785 638 EQLEQFSDVLDGVVLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILDYLM DDG----LNRNLMQLINDSNL 706 WP_003733029 638 EQLQQFSDVLDGTVLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILDYLM DDG----LNRNLMQLINDSNL 706 WP_003739838 638 EQLQQFSDVLDGAVLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILDYLM DDG----LNRNLMQLINDSNL 706 WP_014601172 638 EQLQQFSDVLDGGVLKKLER-RHYTGWGRLSAKLLVGIREK QSHLTILDYLM DDG----LNRNLMQLINDSNL 706 WP_023548323 638 EQLQQFSDVLDGTVLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILDYLM DDG----LNRNLMQLINDSNL 706 WP_031665337 638 EQLQQFSDVLDGVVLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILEYLM DDG----LNRNLMQLINDSNL 706 WP_031669209 638 EQLQQFSDVLDGTVLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILDYLM DDG----LNRNLMQLINDSNL 706 WP_033920898 638 EQLQQFSDVLDGTVLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILDYLM DDG----LNRNLMQLINDSNL 706 AKI42028 641 EQLQQFSDVLDGGVLKKLER-RHYTGWGRLSAKLLVGIREK QSHLTILDYLM DDG----LNRNLMQLINDSNL 709 AKI50529 641 EQLQQFSDVLDGTVLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILDYLM DDG----LNRNLMQLINDSNL 709 EFR83390 86 EQLQQFSDVLDGVVLKKLER-RHYTGWGRLSAKLLVGIRDK QSHLTILEYLM DDG----LNRNLMQLINDSNL 154 WP_046323366 638 ERLQEFSNVLDEAVLKKLER-RHYTGWGRLSAKLLIGIRDK ESHLTILDYLM DDK----HNRNLMQLINDSNL 706 AKE81011 650 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 718 CUO82355 642 RRLKKKYALPDDKIKQILKL--KYKDWSRLSKKLLDGIVAD SV--TVLDVLE -------SRLNLMEIINDKEL 709 WP_033162887 645 RRLKKVYQLDDLLVDKILKL--NYTGWSRLSEKLLTGMTAD KA--TVLFVLE -------SNKNLMEIINDEKL 712 AGZ01981 667 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 735 AKA60242 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 702 AKS40380 634 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 702 4UN5_B 638 ERLKTYAHLFDDKVMKQLKR-RRYTGWGRLSRKLINGIRDK QSGKTILDFLK -DGf---ANRNFMQLIHDDSL 706 WP_010922251 703 TFKEDIQKAQVSG-QG

RENQ TTQKG QKNS 777 WP_039695303 707 PFKQIIQKSQVVG-DVDD-IEAVVHDLPGSPAIKKGILQSVKIVDELVKVMG-GNPDNIVIEMARENQ TTNRGRSQS 780 WP_045635197 702 SFKEIIQKAQVIG-KTDD-VKQVVQELSGSPAIKKGILQSIKIVDELVKVMG-HAPESIVIEMARENQ TTARGKKNS 775 5AXW_A 427 VPKKVDLSQQKEI---PT---TLVDDFILSPVVKRSFIQSIKVINAIIKKYG--LPNDIIIELAREKN --------S 487 WP_009880683 387 TFKEDLQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 461 WP_010922251 703 TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777 WP_011054416 703 TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777 WP_011284745 703 TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777 WP_011285506 703 TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777 WP_011527619 703 TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777 WP_012560673 703 TFKEDLQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777 WP_014407541 703 TFKEDIQKAQVSG-QGHS-LHEQIANLAGSPAIKKGILQTVKIVDELVKVMG-HKPENIVIEMARENQ TTQKGQKNS 776 WP_020905136 703 TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777 WP_023080005 703 TFKEAIQKAQVSG-QGHS-LHEQIANLAGSPAIKKGILQTVKIVDELVKVMG-HKPENIVIEMARENQ TTQKGQKNS 776 WP_023610282 703 TFKEAIQKAQVSG-QGHS-LHEQIANLAGSPAIKKGILQTVKIVDELVKVMG-HKPENIVIEMARENQ TTQKGQKNS 776 WP_030125963 703 TFKEDLQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777 WP_030126706 703 TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777 WP_031488318 703 TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777 WP_032460140 703 TFKEDLQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777 WP_032461047 703 TFKEDLQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777 WP_032462016 703 TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777 WP_032462936 703 TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777 WP_032464890 703 TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777 WP_033888930 528 TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 602 WP_038431314 703 TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777 WP_038432938 703 TFKEAIQKAQVSG-QGHS-LHEQIANLAGSPAIKKGILQTVKIVDELVKVMG-HKPENIVIEMARENQ TTQKGQKNS 776 WP_038434062 703 TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKIVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777 BAQ51233 614 TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 688 KGE60162 -------------------------------------------------------------------- --------- KGE60856 -------------------------------------------------------------------- --------- WP_002989955 703 TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777 WP_003030002 704 SFKEEIARAQIIG-DVDD-IANVVHDLPGSPAIKKGILQSVKIVDELVKVMG-HNPANIIIEMARENQ MTDKGRRNS 777 WP_003065552 707 PFKQIIQKSQVVG-DVDD-IEAVVHDLPGSPAIKKGILQSVKIVDELVKVMG-DNPDNIVIEMARENQ TTNRGRSQS 780 WP_001040076 702 SFKPIIDKARTGS-HSDN-LKEVIGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTAKGLSRS 775 WP_001040078 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 WP_001040080 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 WP_001040081 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 WP_001040083 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 WP_001040085 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 WP_001040087 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 WP_001040088 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 WP_001040089 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 WP_001040090 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVVG-YEPEQIVVEMARENQ TTNQGRRNS 778 WP_001040091 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 WP_001040092 705 SFKSIISKAQSGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 WP_001040094 702 SFKPIIDKARTGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTAKGLSRS 775 WP_001040095 702 SFKPIIDKARTGS-HLDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTAKGLSRS 775 WP_001040096 702 SFKPIIDKARTGS-HLDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTAKGLSRS 775 WP_001040097 702 SFKPIIDKARTGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTAKGLSRL 775 WP_001040098 702 SFKPIIDKARTGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTAKGLSRS 775 WP_001040099 702 SFKPIIDKARTGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTAKGLSRS 775 WP_001040100 702 SFKPIIDKARTGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTAKGLSRS 775 WP_001040104 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 WP_001040105 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 WP_001040106 705 SFKPIIDKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQVVVEMARENQ TTNQGRRNT 778 WP_001040107 705 SFKPIIDKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQVVVEMARENQ TTNQGRRNT 778 WP_001040108 705 SFKPIIDKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQVVVEMARENQ TTNQGRRNT 778 WP_001040109 705 SFKPIIDKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQVVVEMARENQ TTNQGRRNT 778 WP_001040110 705 SFKPIIDKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQVVVEMARENQ TTNQGRRNT 778 WP_015058523 705 SFKSIISKAQSGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 WP_017643650 702 SFKPIIDKARTGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTAKGLSRL 775 WP_017647151 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 WP_017648376 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 WP_017649527 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 WP_017771611 705 SFKPIIDKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQVVVEMARENQ TTNQGRRNT 778 WP_017771984 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 CFQ25032 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 CFV16040 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 KLJ37842 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 KLJ72361 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 KLL20707 719 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 792 KLL42645 705 SFKPIIDKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQVVVEMARENQ TTNKGRRNT 778 WP_047207273 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 WP_047209694 702 SFKPIIDKARTGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTAKGLSRS 775 WP_050198062 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 WP_050201642 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 WP_050204027 705 SFKPIIDKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQVVVEMARENQ TTNQGRRNT 778 WP_050881965 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 WP_050886065 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 AHN30376 705 SFKSIISKAQSGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 EA078426 705 SFKSIISKAQAGS-HSDN-LKEVVGELAGSPAIKKGILQSLKIVDELVKVMG-YEPEQIVVEMARENQ TTNQGRRNS 778 CCW42055 705 SFKSIISKAQSGS-HSDN-LKEVVSELAGSPAIKKGILQSLKIVDELVKVMG-YKPEQIVVEMARENQ TTNQGRRNS 778 WP_003041502 704 SFKEEIAKAQIIG-DVDD-IANVVHDLPGSPAIKKGILQSVKIVDELVKVMG-HNPANIIIEMARENQ TTDRGRRNS 777 WP_037593752 705 SFKEEIARAQIIG-DVDD-IANVVHDLPGSPAIKKGILQSVKIVDELVKVMG-HNPANIIIEMARENQ TTDKGRRNS 778 WP_049516684 705 SFKEEIARAQIIG-DVDD-IANVVHDLPGSPAIKKGILQSVKIVDELVKVMG-HNPANIIIEMARENQ TTDKGRRNS 778 GAD46167 704 SFKEEIARAQIIG-DVDD-IANVVHDLPGSPAIKKGILQSVKIVDELVKVMG-HNPANIIIEMARENQ TTDKGRRNS 777 WP_018363470 705 SFKQIIQEAQVVG-DVDD-IETVVHDLPGSPAIKKGILQSVKIVDELIKVMG-DNPDNIVIEMARENQ TTNRGRSQS 778 WP_003043819 713 TFKEEIEKAQVSG-QGDS-LHEQIADLAGSPAIKKGILQTVKIVDELVKVMG-HKPENIVIEMARENQ TTTKGLQQS 786 WP_006269658 704 SFKEEIARAQIID-DVDD-IANVVHDLPGSPAIKKGILQSVKIVDELVKVMG-HNPANIIIEMARENQ TTDKGRRNS 777 WP_048800889 704 PFKQIIKDAQAID-DVDD-IELIVHDLPGSPAIKKGILQSIKIVDELVKVMG-YNPDNIVIEMARENQ TTTKGRRNS 777 WP_012767106 703 TFKEAIQKAQVSG-QGHS-LHEQIANLAGSPAIKKGILQSVKVVDELVKVMG-HKPENIVIEMARENQ TTQKGQKNS 776 WP_014612333 703 TFKEAIQKAQVSG-QGHS-LHEQIANLAGSPAIKKGILQSVKVVDELVKVMG-HKPENIVIEMARENQ TTQKGQKNS 776 WP_015017095 703 TFKEAIQKAQVSG-QGHS-LHEQIANLAGSPAIKKGILQSVKVVDELVKVMG-HKPENIVIEMARENQ TTQKGQKNS 776 WP_015057649 703 TFKEAIQKAQVSG-QGHS-LHEQIANLAGSPAIKKGILQSVKVVDELVKVMG-HKPENIVIEMARENQ TTQKGQKNS 776 WP_048327215 703 TFKEAIQKAQVSG-QGHS-LHEQIANLAGSPAIKKGILQSVKVVDELVKVMG-HKPENIVIEMARENQ TTQKGQKNS 776 WP_049519324 703 TFKEAIQKAQVSG-QGHS-LHEQIANLAGSPAIKKGILQSVKVVDELVKVMG-HKPENIVIEMARENQ TTQKGQKNS 776 WP_012515931 703 SFIDEIAKAQVIG-KTEY-SKDLVGNLAGSPAIKKGISQTIKIVDELVKIMG-YLPQQIVIEMARENQ TTAQGIKNA 776 WP_021320964 703 SFIDEIAKAQVIG-KTEY-SKDLVGNLASSPAIKKGISQTIKIVDELVKIMG-YLPQQIVIEMARENQ TTAQGIKNA 776 WP_037581760 703 SFIDEIAKAQVIG-KTEY-SKDLVGNLAGSPAIKKGISQTIKIVDELVKIMG-YLPQQIVIEMARENQ TTAQGIKNA 776 WP_004232481 704 SFKTTIQEAQVVG-DVDD-IEAVVHDLPGSPAIKKGILQSVKIVDELVKVMG-HNPQNIVIEMARENQ ITGYGRNRS 777 WP_009854540 705 PFKQIIQKSQVVG-DVDD-IEAVVHDLPGSPAIKKGILQSVKIVDELVKVMG-DNPDNIVIEMARENQ TTNRGRSQS 778 WP_012962174 705 PFKQIIKDAQIIG-DIDD-VTSVVRELPGSPAIKKGILQSVKIVDELVKVMG-HNPDNIVIEMARENQ TTNRGRNQS 778 WP_039695303 707 PFKQIIQKSQVVG-DVDD-IEAVVHDLPGSPAIKKGILQSVKIVDELVKVMG-GNPDNIVIEMARENQ TTNRGRSQS 780 WP_014334983 704 SFKTIIQEAQVVG-DVDD-IEAVVHDLPGSPAIKKGILQSVKIVDELVKVMG-DNPDNIVIEMARENQ TTGYGRNKS 777 WP_003099269 703 DFAKIIKNEQEKTiKNES-LEETIANLAGSPAIKKGILQSIKIVDEIVKIMG-QNPDNIVIEMARENQ STMQGIKNS 777 AHY15608 703 DFAKIIKNEQEKTiKNES-LEETIANLAGSPAIKKGILQSIKIVDEIVKIMG-QNPDNIVIEMARENQ STMQGIKNS 777 AHY17476 703 DFAKIIKNEQEKTiKNES-LEETIANLAGSPAIKKGILQSIKIVDEIVKIMG-QNPDNIVIEMARENQ STMQGIKNS 777 ESR09100 -------------------------------------------------------------------- --------- AGM98575 703 DFAKIIKNEQEKTiKNES-LEETIANLAGSPAIKKGILQSIKIVDEIVKIMG-QNPDNIVIEMARENQ STMQGIKNS 777 ALF27331 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_018372492 717 DFKEIIRKAQTIE-NIDT-NQALVSSLPGSPAIKKGILQSLNIVDEIIAIMG-YAPTNIVIEMARENQ TTQKGRDNS 790 WP_045618028 703 SFKEIIQKAQVVG-KTND-VKQVVQELPGSPAIKKGILQSIKLVDELVKVMG-HAPESIVIEMARENQ TTARGKKNS 776 WP_045635197 702 SFKEIIQKAQVIG-KTDD-VKQVVQELSGSPAIKKGILQSIKIVDELVKVMG-HAPESIVIEMARENQ TTARGKKNS 775 WP_002263549 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_002263887 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_002264920 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_002269043 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_002269448 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRQNS 777 WP_002271977 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_002272766 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_002273241 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTKQGRRNS 777 WP_002275430 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_002276448 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTKQGRRNS 777 WP_002277050 705 TFKDDIVKAQYVD-NSDD-LHQVVQSLAGSPAIKKGILQSLKIVDELVKVMG-KEPEQIVVEMARENQ TTAKGRRNS 778 WP_002277364 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_002279025 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_002279859 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_002280230 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTKQGRRNS 777 WP_002281696 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_002282247 705 TFKDDIVKAQYVD-NSDD-LHQVVQSLAGSPAIKKGILQSLKIVDELVKVMG-KEPEQIVVEMARENQ TTAKGRRNS 778 WP_002282906 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_002283846 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_002287255 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_002288990 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_002289641 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_002290427 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSLAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_002295753 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTKQGRRNS 777 WP_002296423 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_002304487 714 SFKEEIAKAQVIG-EMDG-LNQVVSDIAGSPAIKKGILQSLKIVDELVKVMG-HNPANIVIEMARENQ TTAKGRRSS 787 WP_002305844 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTKQGRRNS 777 WP_002307203 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_002310390 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSLAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_002352408 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGQRNS 777 WP_012997688 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_014677909 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_019312892 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_019313659 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_019314093 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_019315370 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_019803776 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_019805234 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSLAIKKGILQNLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_024783594 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_024784288 705 TFKDDIVKAQYVD-NSDD-LHQVVQSLAGSPAIKKGILQSLKIVDELVKVMG-KEPEQIVVEMARENQ TTAKGRRNS 778 WP_024784666 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_024784894 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_024786433 705 TFKDDIVKAQYVD-NSDD-LHQVVQSLAGSPAIKKGILQSLKIVDELVKVMG-KEPEQIVVEMARENQ TTAKGRRNS 778 WP_049473442 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 WP_049474547 704 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 777 EMC03581 697 SFKEEIAKAQVIG-ETDN-LNQVVSDIAGSPAIKKGILQSLKIVDELVKIMG-HQPENIVVEMARENQ FTNQGRRNS 770 WP_000428612 705 SFKEIIKKAQVVG-KTDD-VKQVVQELPGSPAIKKGILQSIKLVDELVKVMG-HEPESIVIEMARENQ TTARGKKNS 778 WP_000428613 703 SFKEITQKAQVVG-KTDD-VKQVVQELPGSPAIKKGILQSIKIVDELVKVMG-HTPESIVIEMARENQ TTARGKKNS 776 WP_049523028 702 SFKETIQKAQVVG-ETND-VKQVVQELPGSPAIKKGILQSIKIVDELVKVMG-HAPESVVIEMARENQ TTNKGKSKS 775 WP_003107102 672 DFASIIKEAQEKTiKSEK-LEETIANLAGSPAIKKGILQSVKIVDEVVKVMG-YEPSNIVIEMARENQ STQRGINNS 746 WP_054279288 705 SFKEEIKKAQEGG-LKDS-INDQIRDLAGSPAIKKGILQTINIVDEIVKIMG-KAPQHIVVEMARDVQ KTDIGVKQS 778 WP_049531101 703 SFKEIIQESQVVG-KPDD-VKQIVQELPGSSAIKKGILQSIKLVDELVKVMG-HDPESIVIEMARENQ TTARGKKNS 776 WP_049538452 703 SFKEIIQKAQVFG-KTND-VKQVVQELPGSPAIKKGILQSIKIVEELVKVMG-HEPESIVIEMARENQ TTTRGKKNS 776 WP_049549711 703 SFKKIIQKSQVVG-ETDD-VKQVVRELPGSPAIKKGILQSIKIVDELVKVMD-HAPESIVIEMARENQ TTARGKKNS 776 WP_007896501 706 DFEKLIDDAQKKAiKRES-LTEAVANLAGSPAIKKGILQSLKVVDEIVKVMG-HNPDNIVIEMSRENQ TTAQGLKNA 780 EFR44625 658 DFEKLIDDAQKKAiKRES-LTEAVANLAGSPAIKKGILQSLKVVDEIVKVMG-HNPDNIVIEMSRENQ TTAQGLKNA 732 WP_002897477 702 SFKEIIQKAQVVG-KTDD-VKQVVQELPGSPAIKKGILQSIKIVDELVKVMG-YALESIVIEMARENQ TTARGKKNS 775 WP_002906454 702 SFKEIIQKAQVVG-KTDD-VKQVVQEIPGSPAIKKGILQSIKIVDELVKVMG-HNPESIVIEMARENQ TTAKGKKNS 775 WP_009729476 703 SFKEIIQKAQVVG-KTND-VKQVVQELPGSPAIKKGILQSIKIVDELVKVMG-HAPESIVIEMARENQ TTARGKKNS 776 CQR24647 706 SFKDEIANSQVIG-DGDD-LHQVVQELAGSPAIKKGILQSLKIVDELVKVMG-YNPEQIVVEMARENQ TTARGRNNS 779 WP_000066813 705 SFKEIIQKAQVFG-KTND-VKQVVQELPGSPAIKKGILQSIKIVDELVKVMG-HAPESIVIEMARENQ TTARGKKNS 778 WP_009754323 703 SFKEIIQKAQVVG-KTDD-LTQVVRELSGSPAIKKGILQSIKIVDELVKIMG-YAPESIVIEMARENQ TTAKGKKNS 776 WP_044674937 702 SFVDEIRLAQGSG-EAED-YRAEVQNLAGSPAIKKGILQSLKIVDELIEVMG-YDPEHIVVEMARENQ FTNQGRRNS 775 WP_044676715 704 SFVDEIRLAQGSG-EAED-YRAEVQNLAGSPAIKKGILQSLKIVDELIEVMG-YDPEHIVVEMARENQ FTNQGRRNS 777 WP_044680361 704 SFVDEIRLAQGSG-EAED-YRAEVQNLAGSPAIKKGILQSLKIVDELIEVMG-YDPEHIVVEMARENQ FTNQGRRNS 777 WP_044681799 702 SFVDEIRLAQGSG-EAED-YRAEVQNLAGSPAIKKGILQSLKIVDELIEVMG-YDPEHIVVEMARENQ FTNQGRRNS 775 WP_049533112 704 SEKEETAKAQVIG-ETDD-LNQVVSDIAGSPAIKKGILQSLKIVDELVKVMG-YNPANIVIEMARENQ TTDKGRRNS 777 WP_029090905 683 LFKKIIEEQFENEtALLN--KQRIDELAASPANKKGIWQATKIVKELEKVLQ-QPAENIFIEFARSDE ES----KRS 752 WP_006506696 706 GYAQMIEEATSCPeDGKE-TYEEVERLAGSPALKRGIWQSLQIVEEITKVMK-CRPKYIYIEFERSEE -----KERT 776 AIT42264 703 TEKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777 WP_034440723 711 SFKEKIRKAQDIN-QVND-IKEIVKDLPGSPAIKKGIYQSIRIVDEIIRKMK-DRPKNIVIEMARENQ TTQEGKNKS 784 AKQ21048 703 TEKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777 WP_004636532 707 SFKKKIEDAQTIE-DTTH-IYDTVAELPGSPAIKKGIRQALKIVEEIIDIIG-YEPENIVVEMARESQ TTKKGKDLS 780 WP_002364836 715 SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS 788 WP_016631044 666 SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS 739 EMS75795 455 SFKEELANELALA-GNQS-LLEVVEALLGSPAIKKGIWQTLKIVEELIEIIG-YNPKNIVVEMARENQ RT----NRS 524 WP_002373311 715 SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS 788 WP_002378009 715 SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS 788 WP_002407324 715 SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS 788 WP_002413717 715 SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS 788 WP_010775580 717 SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS 790 WP_010818269 715 SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS 788 WP_010824395 715 SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS 788 WP_016622645 715 SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS 788 WP_033624816 715 SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS 788 WP_033625576 715 SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS 788 WP_033789179 715 SFKNAIQKAQSSE-HEET-LSETVNELAGSPAIKKGIYQSLKIVDELVAIMG-YAPKRIVVEMARENQ TTSTGKRRS 788 WP_002310644 715 SFKKEIKKAQMIT-DTEN-LEEIVKELTGSPAIKKGILQSLKIVDEIVGIMG-YEPANIVVEMARENQ TTGRGLKSS 788 WP_002312694 716 SFKKEIKKAQMIT-DTEN-LEEIVKELTGSPAIKKGILQSLKIVDEIVGIMG-YEPANIVVEMARENQ TTGRGLKSS 789 WP_002314015 716 SFKKEIKKAQMIT-DTEN-LEEIVKELTGSPAIKKGILQSLKIVDEIVGIMG-YEPANIVVEMARENQ TTGRGLKSS 789 WP_002320716 716 SFKKEIKKAQMIT-DTEN-LEEIVKELTGSPAIKKGILQSLKIVDEIVGIMG-YEPANIVVEMARENQ TTGRGLKSS 789 WP_002330729 715 SFKKEIKKAQMIT-DTEN-LEEIVKELTGSPAIKKGILQSLKIVDEIVGIMG-YEPANIVVEMARENQ TTGRGLKSS 788 WP_002335161 716 SFKKEIKKAQMIT-DTEN-LEEIVKELTGSPAIKKGILQSLKIVDEIVGIMG-YEPANIVVEMARENQ TTGRGLKSS 789 WP_002345439 716 SFKKEIKKAQMIT-DTEN-LEEIVKELTGSPAIKKGILQSLKIVDEIVGIMG-YEPANIVVEMARENQ TTGRGLKSS 789 WP_034867970 711 SFKEEIAKATVFS-KHKS-LVDVIQDLPGSPAIKKGIWQSLKIVEELIAIIG-YKPKNIVIEMARENQ KT----HRT 780 WP_047937432 716 SFKKEIKKAQMIT-DTEN-LEEIVKELTGSPAIKKGILQSLKIVDEIVGIMG-YEPANIVVEMARENQ TTGRGLKSS 789 WP_010720994 711 SFKEEIAKATVFS-KHKS-LVDVIQDLPGSPAIKKGIWQSLKIVEELIAIIG-YKPKNIVIEMARENQ KT----HRT 780 WP_010737004 711 SFKEEIAKATVFS-KHKS-LVDVIQDLPGSPAIKKGIWQSLKIVEELIAIIG-YKPKNIVIEMARENQ KT----HRT 780 WP_034700478 711 SFKEEIAKATVFS-KHKS-LVDVIQDLPGSPAIKKGIWQSLKIVEELIAIIG-YKPKNIVIEMARENQ KT----HRT 780 WP_007209003 708 SFKKIIEDSQPYK-EQQS-AEEIVSELSGSPAIKKGILQSLKIVDELVAIMG-YKPKNIVVEMARENQ TTGRGKQNS 781 WP_023519017 705 SFKETIANELIMS-DSNV-LLDQVKAIPGSPAVKKGIWQSIKIVEEIIGIIG-KAPKNIVIEMARENQ RTSR----S 774 WP_010770040 708 SFKSEIAEAQSDM-NTED-LHEVVQNLAGSPAIKKGILQSLKIVDELVDIMG-SLPKNIVVEMARENQ TTSRGRTNS 781 WP_048604708 704 TFKEEIEKEQLKA-NSEEsLIEIVQNLAGSPAIKKGIFQSLKIVDELVEIMG-YAPTNIVVEMARENQ TTANGRRNS 778 WP_010750235 710 SFKEEIAKELTLS-DKQS-LLEVVEAIPGSPAIKKGIWQTLKIVEELIAIIG-YKPKNIVIEMARENQ TTTGGKNRS 783 AII16583 742 TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 816 WP_029073316 718 GFKKTIDDANSTSvSGKF-SYAEVQELAGSPAIKRGIWQALLIVDEIKKIMK-HEPAHVYIEFARNED -----KERK 788 WP_031589969 718 GFKKTIDDANSTSvSGKF-SYAEVQELAGSPAIKRGIWQALLIVDEIKKIMK-HEPAHVYIEFARNED -----KERK 788 KDA45870 699 SFKETIKNAQVIE-KEET-LAKTVQELPGSPAIKKGILQSLEIVDEIIKVMG-YKPKSIVVEMARETQ --THGTRKR 771 WP_039099354 713 DFDKLITEANQMM-LAENdVQDVINDLYTSPQNKKALRQILLVVNDIQKAMKgQAPERILIEFAREDE VNPRLSVQR 788 AKP02966 707 DFKNYIENHNLNKnEDQN-ISNLVNDIHVSPALKRGITQSIKIVQEIVKFMG-HAPKYIFIEVTRETK TTSRGKRIQ 785 WP_010991369 707 SFKSIIEKEQVTT-ADKD-IQSIVADLAGSPAIKKGILQSLKIVDELVSVMG-YPPQTIVVEMARENQ TTGKGKNNS 780 WP_033838504 707 SFKSIIEKEQVTT-ADKD-IQSIVADLAGSPAIKKGILQSLKIVDELVSVMG-YPPQTIVVEMARENQ TTGKGKNNS 780 EHN60060 710 SFKSIIEKEQVTT-ADKD-IQSIVADLAGSPAIKKGILQSLKIVDELVSVMG-YPPQTIVVEMARENQ TTGKGKNNS 783 EFR89594 476 SFKSIIEKEQVTT-ADKD-IQSIVADLAGSPAIKKGILQSLKIVDELVSVMG-YPPQTIVVEMARENQ TTGKGKNNS 549 WP_038409211 707 SFKSIIEKEQVST-ADKG-IQSIVAELAGSPAIKKGILQSLKIVDELVGIMG-YPPQTIVVEMARENQ TTGKGKNNS 780 EFR95520 326 SFKSIIEKEQVST-ADKG-IQSIVAELAGSPAIKKGILQSLKIVDELVGIMG-YPPQTIVVEMARENQ TTGKGKNNS 399 WP_003723650 707 SFKSIIEKEQVST-TDKD-LQSIVAELAGSPAIKKGILQSLKIVDELVSIMG-YPPQTIVVEMARENQ TTGKGKNNS 780 WP_003727705 707 SFKSIIEKEQVST-TDKD-LQSIVADLAGSPAIKKGILQSLKIVDELVSIMG-YPPQTIVVEMARENQ TTGKGKNNS 780 WP_003730785 707 SFKSIIEKEQVST-TDKD-LQSIVADLAGSPAIKKGILQSLKIVDELVSIMG-YPPQTIVVEMARENQ TTGKGKNNS 780 WP_003733029 707 SFKSIIEKEQVST-TDKD-LQSIVAELAGSPAIKKGILQSLKIVDELVSVMG-YPPQTIVVEMARENQ TTNKGKNNS 780 WP_003739838 707 SFKSIIEKEQVST-TDKD-LQSIVADLAGSPAIKKGILQSLKIVDELVSIMG-YPPQTIVVEMARENQ TTVKGKNNS 780 WP_014601172 707 SFKSIIEKEQVST-TDKD-LQSIVADLAGSPAIKKGILQSLKIVDELVSIMG-YPPQTIVVEMARENQ TTGKGKNNS 780 WP_023548323 707 SFKSIIEKEQVST-ADKD-LQSIVADLAGSPAIKKGILQSLKVVEELVSVMG-YPPQTIVVEMARENQ TTNKGKNNS 780 WP_031665337 707 SFKSIIEKEQVST-TDKD-LQSIVAELAGSPAIKKGILQSLKIVDELVSIMG-YPPQTIVVEMARENQ TTGKGKNNS 780 WP_031669209 707 SFKSIIEKEQVST-ADKD-LQSIVADLAGSPAIKKGILQSLKIVDELVSVMG-YPPQTIVVEMARENQ TTNKGKNNS 780 WP_033920898 707 SFKSIIEKEQVST-ADKD-LQSIVADLAGSPAIKKGILQSLKVVEELVSVMG-YPPQTIVVEMARENQ TTNKGKNNS 780 AKI42028 710 SFKSIIEKEQVST-TDKD-LQSIVADLAGSPAIKKGILQSLKIVDELVSIMG-YPPQTIVVEMARENQ TTGKGKNNS 783 AKI50529 710 SFKSIIEKEQVST-ADKD-LQSIVADLAGSPAIKKGILQSLKVVEELVSVMG-YPPQTIVVEMARENQ TTNKGKNNS 783 EFR83390 155 SFKSIIEKEQVST-TDKD-LQSIVADLAGSPAIKKGILQSLKIVDELVSIMG-YPPQTIVVEMARENQ TTVKGKNNS 228 WP_046323366 707 SFKSIIEKEQVST-ADKD-IQSIVADLAGSPAIKKGILQSLKIVDELVGIMG-YPPQTIVVEMARENQ TTGKGKNNS 780 AKE81011 719 TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 793 CUO82355 710 GYAQMIEEASSCPkDGKF-TYEEVAKLAGSPALKRGIWQSLQIVEEITKVMK-CRPKYIYIEFERSEE -----KERT 780 WP_033162887 713 GYKQIIEESNMQDiEGPF-KYDEVKKLAGSPAIKRGIWQALLVVREITKFMK-HEPSHIYIEFAREEQ -----KVRK 783 AGZ01981 736 TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 810 AKA60242 703 TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777 AKS40380 703 TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 777 4UN5_B 707 TFKEDIQKAQVSG-QGDS-LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGrHKPENIVIEMARENQ TTQKGQKNS 781 WP_010922251 778

841 WP_039695303 781 QQRLKKLQNSLK PSYI E----DK--VE---NSHLQNDQLFLYYIQNGKDMYTGDEL--D--IDHLSDYDIDHI 851 WP_045635197 776 QQRYKRIEDSLK ILAS NILKENP--TD---NNQLQNDRLFLYYLQNGKDMYTGEAL--D--INQLSSYDIDHI 843 5AXW_A 488 KDAQKMINEMQK QTNE EIIRTTGk--E---NAKYLIEKIKLHDMQEGKCLYSLEAIplEd1LNNPFNYEVDHI 561 WP_009880683 462 RERMKRIEEGIK ELGS DILKEYP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 525 WP_010922251 778 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 841 WP_011054416 778 RERMKRIEEGIK ELGS DILKEYP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 841 WP_011284745 778 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 841 WP_011285506 778 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 841 WP_011527619 778 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 841 WP_012560673 778 RERMKRIEEGIK ELGS DILKEYP--VE---TTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 841 WP_014407541 777 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 840 WP_020905136 778 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 841 WP_023080005 777 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 840 WP_023610282 777 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 840 WP_030125963 778 RERMKRIEEGIK ELGS DILKEYP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 841 WP_030126706 778 RERMKRIEEGIK ELGS DILKEYP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 841 WP_031488318 778 RERMKRIEEGIK ELGS DILKEYP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 841 WP_032460140 778 RERMKRIEEGIK ELGS DILKEYP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 841 WP_032461047 778 RERMKRIEEGIK ELGS DILKEYP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 841 WP_032462016 778 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 841 WP_032462936 778 RERMKRIEEGIK ELGS DILKEYP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 841 WP_032464890 778 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 841 WP_033888930 603 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 666 WP_038431314 778 RERMKRIEEGIK ELGS DILKEYP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 841 WP_038432938 777 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 840 WP_038434062 778 RERMKRIEEGIK ELGS DILKEYP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 841 BAQ51233 689 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 752 KGE60162 1 ------------ ---- -------------------------------------QEL--D--INRLSGYDVDHI 16 KGE60856 ------------ ---- --------------------------------------------------------- WP_002989955 778 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 841 WP_003030002 778 QQRLKLLQDSLK PVNI K-----N--VE---NQQLQNDRLFLYYIQNGKDMYTGETL--D--INNLSQYDIDHI 840 WP_003065552 781 QQRLKKLQNSLK PSYI E----DK--VE---NSHLQNDQLFLYYIQNGKDMYTGDEL--D--IDHLSDYDIDHI 851 WP_001040076 776 RQRLTTLRESLA NLKS EKKPKYV--KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL--D--IDNLSQYDIDHI 846 WP_001040078 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 WP_001040080 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 WP_001040081 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 WP_001040083 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 WP_001040085 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDDLSQYDIDHI 846 WP_001040087 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 WP_001040088 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 WP_001040089 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 WP_001040090 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 WP_001040091 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 WP_001040092 779 RQRYKLLEDGVK NLAS DILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 WP_001040094 776 RQRLTTLRESLA NLKS EKKPKYV--KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL--D--IDNLSQYDIDHI 846 WP_001040095 776 RQRLTTLRESLA NLKS EKKPKYV--KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL--D--IDNLSQYDIDHI 846 WP_001040096 776 RQRLTTLRESLA NLKS EKKPKYV--KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL--D--IDNLSQYDIDHI 846 WP_001040097 776 RQRLTTLRESLA NLKS EKKPKYV--KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL--D--IDNLSQYDIDHI 846 WP_001040098 776 RQRLTTLRESLA NLKS EKKPKYV--KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL--D--IDNLSQYDIDHI 846 WP_001040099 776 RQRLTTLRESLA NLKS EKKPKYV--KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL--D--IDNLSQYDIDHI 846 WP_001040100 776 RQRLTTLRESLA NLKS EKKPKYV--KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL--D--IDNLSQYDIDHI 846 WP_001040104 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 WP_001040105 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 WP_001040106 779 RQRYKLLEEGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 WP_001040107 779 RQRYKLLEEGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 WP_001040108 779 RQRYKLLEEGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGETL--D--IDNLSQYDIDHI 846 WP_001040109 779 RQRYKLLEEGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 WP_001040110 779 RQRYKLLEEGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 WP_015058523 779 RQRYKLLEDGVK NLAS DILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 WP_017643650 776 RQRLTTLRESLA NLKS EKKPKYV--KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL--D--IDNLSQYDIDLI 846 WP_017647151 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGKAL--D--IDNLSQYDIDHI 846 WP_017648376 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGKAL--D--IDNLSQYDIDHI 846 WP_017649527 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 WP_017771611 779 RQRYKLLEEGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 WP_017771984 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 CFQ25032 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 CFV16040 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 KLJ37842 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 KLJ72361 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 KLL20707 793 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 860 KLL42645 779 RQRYKLLEEGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 WP_047207273 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 WP_047209694 776 RQRLTTLRESLA NLKS EKKPKYV--KDqveNHHLSDDRLFLYYLQNGKDMYTDDEL--D--IDNLSQYDIDHI 846 WP_050198062 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 WP_050201642 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 WP_050204027 779 RQRYKLLEEGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 WP_050881965 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 WP_050886065 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 AHN30376 779 RQRYKLLEDGVK NLAS DILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDSLSQYDIDHI 846 EA078426 779 RQRYKLLDDGVK NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTGEAL--D--IDNLSQYDIDHI 846 CCW42055 779 RQRYKLLDDGVR NLAS NILKEYP--TD---NQALQNERLFLYYLQNGRDMYTEKAL--D--IDNLSQYDIDHI 846 WP_003041502 778 QQRLKLLQDSLK PVNI K-----N--VE---NQQLQNDRLFLYYIQNGKDMYTGETL--D--INNLSQYDIDHI 840 WP_037593752 779 QQRLKLLQDSLK PVNI K-----N--VE---NQQLQNDRLFLYYIQNGKDMYTGETL--D--INNLSQYDIDHI 841 WP_049516684 779 QQRLKLLQDSLK PVNI K-----N--VE---NQQLQNDRLFLYYIQNGKDMYTGETL--D--INNLSQYDIDHI 841 GAD46167 778 QQRLKLLQDSLK PVNI K-----N--VE---NQQLQNDRLFLYYIQNGKDMYTGETL--D--INNLSQYDIDHI 840 WP_018363470 779 QQRLKKLQNSLK PSYI E----DK--VE---NSHLQNDQLFLYYIQNGKDMYTGDEL--D--IDHLSDYDIDHI 849 WP_003043819 787 RERKKRIEEGIK ELES QILKENP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 850 WP_006269658 778 QQRLKLLQDSLK PVNI K-----N--VE---NQQLQNDRLFLYYIQNGKDMYTGETL--D--INNLSQYDIDHI 840 WP_048800889 778 QQRLKLLQDSLT PVSI K-----N--VE---NQQLQNDRLFLYYIQNGKDMYTGEEL--D--IHHLSDYDIDHI 840 WP_012767106 777 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 840 WP_014612333 777 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 840 WP_015017095 777 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 840 WP_015057649 777 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 840 WP_048327215 777 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 840 WP_049519324 777 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 840 WP_012515931 777 RQRMRKLEETAK KLGS NILKEHP--VD---NSQLQNDKRYLYYLQNGKDMYTGDDL--D--IDYLSSYDIDHI 840 WP_021320964 777 RQRMRKLEETAK KLGS NILKEHP--VD---NSQLQNDKRYLYYLQNGKDMYTGDDL--D--IDYLSSYDIDHI 840 WP_037581760 777 RQRMRKLEETAK KLGS NILKEHP--VD---NSQLQNDKRYLYYLQNGKDMYTGDDL--D--IDYLSSYDIDHI 840 WP_004232481 778 NQRLKRLQDSLK PSYV D----SK--VE---NSHLQNDRLFLYYIQNGKDMYTGEEL--D--IDHLSDYDIDHI 848 WP_009854540 779 QQRLKKLQSSLK PSYI E----DK--VE---NSHLQNDQLFLYYIQNGKDMYTGDEL--D--IDHLSDYDIDHI 849 WP_012962174 779 QQRLKKLQDSLK PSYI E----GK--VE---NNHLQDDRLFLYYIQNGKDMYTGDEL--D--IDHLSDYDIDHI 849 WP_039695303 781 QQRLKKLQNSLK PSYI E----DK--VE---NSHLQNDQLFLYYIQNGKDMYTGDEL--D--IDHLSDYDIDHI 851 WP_014334983 778 NQRLKRLQDSLK PSYV D----SK--VE---NSHLQNDRLFLYYIQNGKDMYTGEEL--D--IDRLSDYDIDHI 848 WP_003099269 778 RQRLRKLEEVHK NTGS KILKEYN--VS---NTQLQSDRLYLYLLQDGKDMYTGKEL--D--YDNLSQYDIDHI 841 AHY15608 778 RQRLRKLEEVHK NTGS KILKEYN--VS---NTQLQSDRLYLYLLQDGKDMYTGKEL--D--YDNLSQYDIDHI 841 AHY17476 778 RQRLRKLEEVHK NTGS KILKEYN--VS---NTQLQSDRLYLYLLQDGKDMYTGKEL--D--YDNLSQYDIDHI 841 ESR09100 ------------ ---- --------------------------------------------------------- AGM98575 778 RQRLRKLEEVHK NTGS KILKEYN--VS---NTQLQSDRLYLYLLQDGKDMYTGKEL--D--YDNLSQYDIDHI 841 ALF27331 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_018372492 791 AQRLKKIEDGIK -LGS DLLKQNP--IQd--NKDLQKEKLFLYYMQNGIDLYTGQPLncD--PDSLAFYDVDHI 857 WP_045618028 777 QQRYKRIEDALK NLAH NILKEHP--TD---NIQLQNDRLFLYYLQNGKDMYTGKSL--D--INQLSSCDIDHI 844 WP_045635197 776 QQRYKRIEDSLK ILAS NILKENP--TD---NNQLQNDRLFLYYLQNGKDMYTGEAL--D--INQLSSYDIDHI 843 WP_002263549 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002263887 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002264920 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002269043 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002269448 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002271977 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002272766 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002273241 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002275430 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002276448 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002277050 779 QQRYKRLKEAIK DLNH KILKEHP--TD---NQALQNNRLFLYYLQNGRDMYTGESL--D--INRLSDYDIDHV 846 WP_002277364 778 QQRLKGLTDSIK EFGS QILKEHP--VE---HSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002279025 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002279859 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002280230 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002281696 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002282247 779 QQRYKRLKEAIK DLNH KILKEHP--TD---NQALQNNRLFLYYLQNGRDMYTGESL--D--INRLSDYDIDHV 846 WP_002282906 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002283846 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002287255 778 QQRLKGLTDSIK EFGS QILKEHP--VE---HSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002288990 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002289641 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002290427 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002295753 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002296423 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002304487 788 QKRYKRLEEAIK DLNH KILKEHP--TD---NQALQNDRLFLYYLQNGRDMYTEDPL--D--INRLSDYDIDHI 855 WP_002305844 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002307203 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002310390 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_002352408 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_012997688 778 QQRLKGLTDSIK EFGS QILKEHP--VK---HSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_014677909 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_019312892 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_019313659 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_019314093 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_019315370 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_019803776 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_019805234 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_024783594 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_024784288 779 QQRYKRLKEAIK DLNH KILKEHP--TD---NQALQNNRLFLYYLQNGRDMYTGESL--D--INRLSDYDIDHV 846 WP_024784666 778 QQRLKGLTDSIK EFGS QILKEHP--VE---HSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_024784894 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_024786433 779 QQRYKRLKEAIK DLNH KILKEHP--TD---NQALQNNRLFLYYLQNGRDMYTGESL--D--INRLSDYDIDHV 846 WP_049473442 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 WP_049474547 778 QQRLKGLTDSIK EFGS QILKEHP--VE---NSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 841 EMC03581 771 QQRLKGLTDSIK EFGS QILKEHP--VE---HSQLQNDRLFLYYLQNGRDMYTGEEL--D--IDYLSQYDIDHI 834 WP_000428612 779 QQRYKRIEDSLK ILAS KILKEHP--TD---NIQLQNDRLFLYYLQNGRDMYTGKPL--D--INQLSSYDIDHI 846 WP_000428613 777 QQRYKRIEDALK NLAS NILKEHP--TN---NIQLQNDRLFLYYLQNGRDMYTGKPL--D--INQLSSYDIDHI 844 WP_049523028 776 QQRLKTLSDAIS ELG- NILKEHP--TD---NIQLQNDRLFLYYLQNGKDMYTGEAL--D--INQLSNYDIDHI 839 WP_003107102 747 RERLRKLEEVHK NIGS KILKEHE--IS---NAQLQSDRVYLYLLQDGKDMYTGKDL--D--FDRLSQYDIDHI 810 WP_054279288 779 RERMKRVQEVLK KLGS QLLKEHP--VE---NFQLQNERLYLYYLQNGKDMYTGEEL--S--ISNLSHYDIDHI 842 WP_049531101 777 QQRYKRIEDSLK ILAS NILKEHP--TD---NIQLQNDRLFLYYLQNGKDMYTGNPL--D--INHLSSYDIDHI 844 WP_049538452 777 QQRYKRIENSLK ILAS KILKEHP--TD---NNQLQNDRLFLYYLQNGKDMYTGEAL--D--INQLSSCDIDHI 844 WP_049549711 777 QQRYKRIEDSLK ILAS NILKENP--TD---NNQLQNDRLFLYYLQNGKDMYTGEAL--D--INQLSSYDIDHI 844 WP_007896501 781 RQRLKKIKEVHK KTGS RILEDNSerIT---NLTLQDNRLYLYLLQDGKDMYTGQDL--D--INNLSQYDIDHI 846 EFR44625 733 RQRLKKIKEVHK KTGS RILEDNSerIT---NLTLQDNRLYLYLLQDGKDMYTGQDL--D--INNLSQYDIDHI 798 WP_002897477 776 QQRYKRIEDALK NLAP NILKENP--TD---NIQLKNDRLFLYYLQNGKDMYTGKPL--D--INQLSSYDIDHI 843 WP_002906454 776 QQRYKRIEDALK NLAP NILKENP--TD---NIQLQNDRLFLYYLQNGKDMYTGKAI--D--INQLSNYDIDHI 843 WP_009729476 777 QQRYKRIEDSLK ILAS KILKEHP--TD---NIQLQNDRLFLYYLQNGKDMYTGEAL--D--INQLSSCDIDHI 844 CQR24647 780 QQRLGSLTKAIQ DFGS DILKRYP--VE---NNQLQNDQLYLYYLQNGKDMYTGDTL--D--IHNLSQYDIDHI 843 WP_000066813 779 QQRYKRIEDSLK NLAS NILKENP--TD---NIQLQNDRLFLYYLQNGRDMYTGKPL--E--INQLSNYDIDHI 846 WP_009754323 777 QQRYKRIEDALK NLAP TISKENP--TD---NIQLQNDRLFLYYLQNGKDMYTGEAL--D--INQLSSYDIDHI 844 WP_044674937 776 QQRYKKIENAIK NLNS KILKEYP--TN---NQALQNDRLFLYYLQNGKDMYTDEEL--D--IDQLSQYDIDHI 843 WP_044676715 778 QQRYKKIENAIK NLNS KILKEYP--TN---NQALQNDRLFLYYLQNGKDMYTDEEL--D--IDQLSQYDIDHI 845 WP_044680361 778 QQRYKKIENAIK NLNS KILKEYP--TN---NQALQNDRLFLYYLQNGKDMYTDEEL--D--IDQLSQYDIDHI 845 WP_044681799 776 QQRYKKIENAIK NLNS KILKEYP--TN---NQALQNDRLFLYYLQNGKDMYTDEEL--D--IDQLSQYDIDHI 843 WP_049533112 778 QQRLKLLQDSLK PVNI K-----N--VE---NQQLQNDRLFLYYIQNGKDMYTGETL--D--INNLSQYDIDHI 840 WP_029090905 753 TPRDKFIEKAYA ETDT EHLKELK---Qr--SKQLSSQRLFLYFIQNGKCMYSGEHL--D--IERLDSYEVDHI 823 WP_006506696 777 ESKIKKLENVYK DEQT SVLEELKg-FDn--TKKISSDSLFLYFTQLGKCMYSGKKL--D--IDSLDKYQIDHI 849 AIT42264 778 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 841 WP_034440723 785 KARLKKIQEGLE NLDS HVEKQAL---D---EEMLKSPKYYLYCLQNGKDIYTGKDL--D--IGQLQTYDIDHI 848 AKQ21048 778 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 841 WP_004636532 781 KERLEKLTEAIK EFDG --VKVKD--LK---NENLRNDRLYLYYLQNGRDMYTNEPL--D--INNLSKYDIDHI 845 WP_002364836 789 IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI 852 WP_016631044 740 IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI 803 EMS75795 525 KPRLKALEEALK SFDS PLLKEQP--VD---NQALQKDRLYLYYLQNGKDMYTGEAL--D--IDRLSEYDIDHI 588 WP_002373311 789 IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI 852 WP_002378009 789 IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI 852 WP_002407324 789 IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI 852 WP_002413717 789 IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI 852 WP_010775580 791 IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI 854 WP_010818269 789 IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI 852 WP_010824395 789 IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI 852 WP_016622645 789 IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI 852 WP_033624816 789 IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI 852 WP_033625576 789 IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI 852 WP_033789179 789 IQRLKIVEKAMA EIGS NLLKEQP--TT---NEQLRDTRLFLYYMQNGKDMYTGDEL--S--LHRLSHYDIDHI 852 WP_002310644 789 RPRLKALEESLK DFGS QLLKEYP--TD---NSSLQKDRLYLYYLQNGRDMYTGAPL--D--IHRLSDYDIDHI 852 WP_002312694 790 RPRLKALEESLK DFGS QLLKEYP--TD---NSSLQKDRLYLYYLQNGRDMYTGAPL--D--IHRLSDYDIDHI 853 WP_002314015 790 RPRLKALEESLK DFGS QLLKEYP--TD---NSSLQKDRLYLYYLQNGRDMYTGAPL--D--IHRLSDYDIDHI 853 WP_002320716 790 RPRLKALEESLK DFGS QLLKEYP--TD---NSSLQKDRLYLYYLQNGRDMYTGAPL--D--IHRLSDYDIDHI 853 WP_002330729 789 RPRLKALEESLK DFGS QLLKEYP--TD---NSSLQKDRLYLYYLQNGRDMYTGAPL--D--IHRLSDYDIDHI 852 WP_002335161 790 RPRLKALEESLK DFGS QLLKEYP--TD---NSSLQKDRLYLYYLQNGRDMYTGAPL--D--IHRLSDYDIDHI 853 WP_002345439 790 RPRLKALEESLK DFGS QLLKEYP--TD---NSSLQKDRLYLYYLQNGRDMYTGAPL--D--IHRLSDYDIDHI 853 WP_034867970 781 SPRLKALENGLK QIGS TLLKEQP--TD---NKALQKERLYLYYLQNGRDMYTGEPL--E--IENLHQYEVDHI 844 WP_047937432 790 RPRLKALEESLK DFGS QLLKEYP--TD---NSSLQKDRLYLYYLQNGRDMYTGAPL--D--IHRLSDYDIDHI 853 WP_010720994 781 KPRLKALENGLK QIGS TLLKEQP--TD---NKALQKERLYLYYLQNGRDMYTGEPL--E--IENLHQYEVDHI 844 WP_010737004 781 SPRLKALENGLK QIGS TLLKEQP--TD---NKALQKERLYLYYLQNGRDMYTGEPL--E--IENLHQYEVDHI 844 WP_034700478 781 KPRLKALENGLK QIGS TLLKEQP--TD---NKALQKERLYLYYLQNGRDMYTGEPL--E--IENLHQYEVDHI 844 WP_007209003 782 KPRLKGIENGLK EFSD SVLKGSS--ID---NKQLQNDRLYLYYLQNGKDMYTGHEL--D--IDHLSTYDIDHI 845 WP_023519017 775 RPRLKALEEALK NIDS PLLKDYP--TD---NQALQKDRLYLYYLQNGKDMYTGEPL--E--IHRLSEYDIDHI 838 WP_010770040 782 NPRMKALEEAMR NLRS NLLKEYP--TD---NQALQNDRLYLYYLQNGKDMYTGLDL--S--LHNLSSYDIDHI 845 WP_048604708 779 RPRLKNLEKAID DLDS EILKKHP--VD---NKALQKDRLYLYYLQNGKDMYTNEEL--D--IHKLSTYDIDHI 842 WP_010750235 784 KPRLKSLEEALK NFDS QLLKERP--VD---NQSLQKDRLYLYYLQNGKDMYTGESL--D--IDRLSEYDIDHI 847 AII16583 817 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 880 WP_029073316 789 DSFVNQMLKLYK DFED EANKHLKg-EDa--KSKIRSERLKLYYTQMGKCMYTGKSL--D--IDRLDTYQVDHI 860 WP_031589969 789 DSFVNQMLKLYK DFED EANKHLKg-EDa--KSKIRSERLKLYYTQMGKCMYTGKSL--D--IDRLDTYQVDHI 860 KDA45870 772 EDRVQQIVKNLK ELPK ------P---S---NAELSDERKYLYCLQNGRDMYTGAPL--D--YDHLQFYDVDHI 833 WP_039099354 789 KRQVEQVYQNIS EL-- EIRNELK---D1-sNSALSNTRLFLYFMQGGRDMYTGDSL--N--IDRLSTYDIDHI 856 AKP02966 786 RLQSKLLNKANG -LVP EELKKHKn--D------LSSERIMLYFLQNGKSLYSEESL--N--INKLSDYQVDHI 858 WP_010991369 781 RPRYKSLEKAIK EFGS QILKEHP--TD---NQELRNNRLYLYYLQNGKDMYTGQDL--D--IHNLSNYDIDHI 844 WP_033838504 781 RPRYKSLEKAIK EFGS QILKEHP--TD---NQELRNNRLYLYYLQNGKDMYTGQDL--D--IHNLSNYDIDHI 844 EHN60060 784 RPRYKSLEKAIK EFGS QILKEHP--TD---NQELRNNRLYLYYLQNGKDMYTGQDL--D--IHNLSNYDIDHI 847 EFR89594 550 RPRYKSLEKAIK EFGS QILKEHP--TD---NQELKNNRLYLYYLQNGKDMYTGQDL--D--IHNLSNYDIDHI 613 WP_038409211 781 KPRFISLEKAIK EFGS QILKEHP--TD---NQCLKNDRLYLYYLQNGKDMYTGKEL--D--IHNLSNYDIDHI 844 EFR95520 400 KPRFISLEKAIK EFGS QILKEHP--TD---NQCLKNDRLYLYYLQNGKDMYTGKEL--D--IHNLSNYDIDHI 463 WP_003723650 781 KPRYKSLEKAIK EFGS QILKEHP--TD---NQELKNNRLYLYYLQNGKDMYTGQEL--D--IHNLSNYDIDHI 844 WP_003727705 781 KPRYKSLEKAIK DFGS QILKEHP--TD---NQELKNNRLYLYYLQNGKDIYTGQEL--D--IHNLSNYDIDHI 844 WP_003730785 781 KPRYKSLEKAIK DFGS QILKEHP--TD---NQELKNNRLYLYYLQNGKDIYTGQEL--D--IHNLSNYDIDHI 844 WP_003733029 781 KPRYKSLEKAIK EFGS QILKEHP--TD---NQELKNNRLYLYYLQNGKDMYTGQEL--D--IHNLSNYDIDHI 844 WP_003739838 781 RPRYKSLEKAIK EFGS QILKEHP--TD---NQELRNNRLYLYYLQNGKDMYTGQEL--D--IHNLSNYDIDHI 844 WP_014601172 781 KPRYKSLEKAIK EFGS KILKEHP--TD---NQELKNNRLYLYYLQNGKDMYTGQEL--D--IHNLSNYDIDHI 844 WP_023548323 781 KPRYKSLEKAIK EFGS QILKEHP--TD---NQELKNNRLYLYYLQNGKDMYTGQEL--D--IHNLSNYDIDHI 844 WP_031665337 781 KPRYKSLEKAIK EFGS QILKEHP--TD---NQELKNNRLYLYYLQNGKDMYTGQEL--D--IHNLSNYDIDHI 844 WP_031669209 781 KPRYKSLEKAIK EFGS QILKEHP--TD---NQELKNNRLYLYYLQNGKDMYTGQEL--D--IHNLSNYDIDHI 844 WP_033920898 781 KPRYKSLEKAIK EFGS QILKEHP--TD---NQELKNNRLYLYYLQNGKDMYTGQEL--D--IHNLSNYDIDHI 844 AKI42028 784 KPRYKSLEKAIK EFGS KILKEHP--TD---NQELKNNRLYLYYLQNGKDMYTGQEL--D--IHNLSNYDIDHI 847 AKI50529 784 KPRYKSLEKAIK EFGS QILKEHP--TD---NQELKNNRLYLYYLQNGKDMYTGQEL--D--IHNLSNYDIDHI 847 EFR83390 229 RPRYKSLEKAIK EFGS QILKEHP--TD---NQELKNNRLYLYYLQNGKDIYTGQEL--D--IHNLSNYDIDHI 292 WP_046323366 781 KPRFTSLEKAIK ELGS QILKEHP--TD---NQGLKNDRLYLYYLQNGKDMYTGQEL--D--IHNLSNYDIDHV 844 AKE81011 794 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 857 CUO82355 781 ESKIKKLENVYK DEQT SVLEELKg-FDn--TKKISSDSLFLYFTQLGKCMYSGKKL--D--IDSLDKYQIDHI 853 WP_033162887 784 ESKIAKLQKIYE NLQT QVYESLKk-EDa--KKRMETDALYLYYLQMGKSMYSGKPL--D--IDKLSTYQIDHI 855 AGZ01981 811 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 874 AKA60242 778 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDAI 841 AKS40380 778 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDHI 841 4UN5_B 782 RERMKRIEEGIK ELGS QILKEHP--VE---NTQLQNEKLYLYYLQNGRDMYVDQEL--D--INRLSDYDVDAI 845 WP_010922251 842 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP   S--EEVVKKMKN-YWRQLLNAKLITQRKEDNLTK A--ERG

910 WP_039695303 852 IPQAFIKDDSIDNRVLTSSAKNRG-KSDD--VP S--LDIVRARKA-EWVRLYKSGLISKRKFDNLTKA--ERGGLTE 920 WP_045635197 844 IPQAFIKDDSLDNRVLTSSKDNRG-KSDN--VP S--IEVVQKRKA-FWQQLLDSKLISERKFNNLTKA--ERGGLDE 912 5AXW_A 562 IPRSVSFDNSFNNKVLVKQEEASK-KGNR--TP Fqy-LSSSDSKI-SYETFKKHILNLAKGKGRISKTk-KEYLLEE 632 WP_009880683 526 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWKQLLNAKLITQRKFDNLTKA--ERGGLSE 594 WP_010922251 842 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 910 WP_011054416 842 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 910 WP_011284745 842 VPQSFIKDDSIDNKVLTRSDKNRG-KSNN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 910 WP_011285506 842 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 910 WP_011527619 842 VPQSFIKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 910 WP_012560673 842 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWKQLLNAKLITQRKFDNLTKA--ERGGLSE 910 WP_014407541 841 VPQSFIKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 909 WP_020905136 842 VPQSFIKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 910 WP_023080005 841 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 909 WP_023610282 841 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 909 WP_030125963 842 VPQSFIKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 910 WP_030126706 842 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 910 WP_031488318 842 VPQSFIKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWKQLLNAKLITQRKFDNLTKA--ERGGLSE 910 WP_032460140 842 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWKQLLNAKLITQRKFDNLTKA--ERGGLSE 910 WP_032461047 842 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWKQLLNAKLITQRKFDNLTKA--ERGGLSE 910 WP_032462016 842 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 910 WP_032462936 842 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWKQLLNAKLITQRKFDNLTKA--ERGGLSE 910 WP_032464890 842 VPQSFIKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 910 WP_033888930 667 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 735 WP_038431314 842 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 910 WP_038432938 841 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 909 WP_038434062 842 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWKQLLNAKLITQRKFDNLTKA--ERGGLSE 910 BAQ51233 753 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 821 KGE60162 17 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 85 KGE60856 --------------------------------- -------------------------------------------- WP_002989955 842 VPQSFIKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 910 WP_003030002 841 IPQAFIKDNSLDNRVLTRSDKNRG-KSDD--VP S--IEVVHEMKS-FWSKLLSVKLITQRKFDNLTKA--ERGGLTE 909 WP_003065552 852 IPQAFIKDDSIDNRVLTSSAKNRG-KSDD--VP S--LDIVRARKA-EWVRLYKSGLISKRKFDNLTKA--ERGGLTE 920 WP_001040076 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_001040078 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_001040080 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_001040081 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_001040083 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_001040085 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_001040087 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_001040088 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_001040089 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_001040090 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_001040091 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_001040092 847 VPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--IDIVKARKA-FWKKLLDAKLISQRKYDNLTKA--ERGGLTP 915 WP_001040094 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--VEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_001040095 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_001040096 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_001040097 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--VEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_001040098 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--VEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_001040099 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--VEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_001040100 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--VEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_001040104 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_001040105 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_001040106 847 VPQAFIKDDSIDNRVLVSSAKNRG-KSDN--VP S--IDIVKARKA-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_001040107 847 VPQAFIKDDSIDNRVLVSSAKNRG-KSDN--VP S--IDIVKARKA-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_001040108 847 VPQAFIKDDSIDNRVLVSSAKNRG-KSDN--VP S--IDIVKARKA-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_001040109 847 VPQAFIKDDSIDNRVLVSSAKNRG-KSDN--VP S--IDIVKARKA-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_001040110 847 VPQAFIKDDSIDNRVLVSSAKNRG-KSDN--VP S--IDIVKARKA-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_015058523 847 VPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--IDIVKARKA-FWKKLLDAKLISQRKYDNLTKA--ERGGLTP 915 WP_017643650 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--VEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_017647151 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_017648376 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_017649527 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_017771611 847 VPQAFIKDDSIDNRVLVSSAKNRG-KSDN--VP S--IDIVKARKA-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_017771984 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 CFQ25032 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 CFV16040 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 KLJ37842 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 KLJ72361 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 KLL20707 861 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 929 KLL42645 847 VPQAFIKDDSIDNRVLVSSAKNRG-KSDN--VP S--IDIVKARKA-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_047207273 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_047209694 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--VEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_050198062 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_050201642 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_050204027 847 VPQAFIKDDSIDNRVLVSSAKNRG-KSDN--VP S--IDIVKARKA-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_050881965 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_050886065 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 AHN30376 847 VPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--IDIVKARKA-FWKKLLDAKLISQRKYDNLTKA--ERGGLTP 915 EA078426 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 CCW42055 847 IPQAFIKDDSIDNRVLVSSAKNRG-KSDD--VP S--LEIVKDCKV-FWKKLLDAKLMSQRKYDNLTKA--ERGGLTS 915 WP_003041502 841 IPQAYIKDDSFDNRVLTSSSENRG-KSDN--VP S--IEVVCARKA-DWMRLRKAGLISQRKFDNLTKA--ERGGLTE 909 WP_037593752 842 IPQAFIKDNSLDNRVLTRSDKNRG-KSDD--VP S--IEVVHEMKS-FWSKLLSVKLITQRKFDNLTKA--ERGGLTE 910 WP_049516684 842 IPQAFIKDNSLDNRVLTRSDKNRG-KSDD--VP S--IEVVHEMKS-FWSKLLSVKLITQRKFDNLTKA--ERGGLTE 910 GAD46167 841 IPQAFIKDNSLDNRVLTRSDKNRG-KSDD--VP S--IEVVHEMKS-FWSKLLSVKLITQRKFDNLTKA--ERGGLTE 909 WP_018363470 850 IPQAFIKDDSIDNRVLTSSAKNRG-KSDD--VP S--LGIVRARKA-EWVRLYKSGLISKRKFDNLTKA--ERGGLTE 918 WP_003043819 851 VPQSFIKDDSIDNKVLTRSVENRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 919 WP_006269658 841 IPQAFIKDNSLDNRVLTRSDKNRG-KSDD--VP S--IEVVHEMKS-FWSKLLSVKLITQRKFDNLTKA--ERGGLTE 909 WP_048800889 841 IPQAFIKDDSIDNRVLTSSAKNRG-KSDN--VP N--LEVVCDRKA-DWIRLREAGLISQRKFDNLTKA--ERGGLTE 909 WP_012767106 841 VPQSFIKDDSIDNKILTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 909 WP_014612333 841 VPQSFIKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 909 WP_015017095 841 VPQSFIKDDSIDNKVLTRSDKNRG-KSDD--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 909 WP_015057649 841 VPQSFIKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 909 WP_048327215 841 VPQSFIKDDSIDNKVLTRSDKNRG-KSDD--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 909 WP_049519324 841 VPQSFIKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 909 WP_012515931 841 IPQSFIKNNSIDNKVLTSQGANRG-KLDN--VP S--EAIVRKMKG-YWQSLLRAGAISKQKFDNLTKA--ERGGLTQ 909 WP_021320964 841 IPQSFIKNNSIDNKVLTSQGANRG-KLDN--VP S--EAIVRKMKG-YWQSLLRAGAISKQKFDNLTKA--ERGGLTQ 909 WP_037581760 841 IPQSFIKNNSIDNKVLTSQGANRG-KLDN--VP S--EAIVRKMKG-YWQSLLRAGAISKQKFDNLTKA--ERGGLTQ 909 WP_004232481 849 IPQAFIKDNSIDNRVLTSSAKNRG-KSDD--VP S--IEIVRNRKS-YWYKLYKSGLISKRKFDNLTKA--ERGGLTE 917 WP_009854540 850 IPQAFIKDDSIDNRVLTSSAKNRG-KSDD--VP S--LDIVRARKA-EWVRLYKSGLISKRKFDNLTKA--ERGGLTE 918 WP_012962174 850 IPQAFIKDDSIDNRVLTSSAKNRG-KSDD--VP S--LDIVHDRKA-DWIRLYKSGLISKRKFDNLTKA--ERGGLTE 918 WP_039695303 852 IPQAFIKDDSIDNRVLTSSAKNRG-KSDD--VP S--LDIVRARKA-EWVRLYKSGLISKRKFDNLTKA--ERGGLTE 920 WP_014334983 849 IPQAFIKDNSIDNKVLTSSAKNRG-KSDD--VP S--IEIVRNRRS-YWYKLYKSGLISKRKFDNLTKA--ERGGLTE 917 WP_003099269 842 IPQSFIKDNSIDNTVLTTQASNRG-KSDN--VP N--IETVNKMKS-FWYKQLKSGAISQRKFDHLTKA--ERGALSD 910 AHY15608 842 IPQSFIKDNSIDNTVLTTQASNRG-KSDN--VP N--IETVNKMKS-FWYKQLKSGAISQRKFDHLTKA--ERGALSD 910 AHY17476 842 IPQSFIKDNSIDNTVLTTQASNRG-KSDN--VP N--IETVNKMKS-FWYKQLKSGAISQRKFDHLTKA--ERGALSD 910 ESR09100 --------------------------------- -------------------------------------------- AGM98575 842 IPQSFIKDNSIDNTVLTTQASNRG-KSDN--VP N--IETVNKMKS-FWYKQLKSGAISQRKFDHLTKA--ERGALSD 910 ALF27331 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_018372492 858 VPRSYIKNDSFDNKVLTTSKGNRK-KLDD--VP A--KEVVEKMEN-TWRRLHAAGLISDIKLSYLMKGe-----LTE 923 WP_045618028 845 IPQAFIKDDSLDNRVLTSSKDNRG-KSDN--VP S--LEIVQKRKA-FWQQLLDSKLISERKFNNLTKA--ERGGLDE 913 WP_045635197 844 IPQAFIKDDSLDNRVLTSSKDNRG-KSDN--VP S--IEVVQKRKA-FWQQLLDSKLISERKFNNLTKA--ERGGLDE 912 WP_002263549 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_002263887 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_002264920 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKG--ERGGLTD 910 WP_002269043 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_002269448 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--EDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_002271977 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_002272766 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKP-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_002273241 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_002275430 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKP-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_002276448 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_002277050 847 IPQAFIKDNSIDNRVLTSSKANRG-KSDD--VP S--EDVVNRMRP-FWNKLLSSGLISQRKYNNLTKK--E---LTP 912 WP_002277364 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KNVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_002279025 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKP-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_002279859 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKG--ERGGLTD 910 WP_002280230 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_002281696 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KNVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_002282247 847 IPQAFIKDNSIDNRVLTSSKANRG-KSDD--VP S--EDVVNRMRP-FWNKLLSSGLISQRKYNNLTKK--E---LTL 912 WP_002282906 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_002283846 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KNVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_002287255 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KNVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_002288990 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_002289641 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_002290427 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKG--ERGGLTD 910 WP_002295753 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_002296423 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KNVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_002304487 856 IPQAFIKDNSIDNRVLTRSDKNRG-KSDD--VP S--EEVVHKMKP-FWSKLLSAKLITQRKFDNLTKA--ERGGLTD 924 WP_002305844 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_002307203 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_002310390 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKG--ERGGLTD 910 WP_002352408 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_012997688 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KNVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_014677909 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_019312892 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KNVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_019313659 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_019314093 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_019315370 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKP-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_019803776 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_019805234 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKG--ERGGLTD 910 WP_024783594 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_024784288 847 IPQAFIKDNSIDNRVLTSSKANRG-KSDD--VP S--EDVVNRMRP-FWNKLLSSGLISQRKYNNLTKK--E---LTL 912 WP_024784666 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KNVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_024784894 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_024786433 847 IPQAFIKDNSIDNRVLTSSKANRG-KSDD--VP S--EDVVNRMRP-FWNKLLSSGLISQRKYNNLTKK--E---LTL 912 WP_049473442 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKP-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 WP_049474547 842 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KDVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 910 EMC03581 835 IPQAFIKDNSIDNRVLTSSKENRG-KSDD--VP S--KNVVRKMKS-YWSKLLSAKLITQRKFDNLTKA--ERGGLTD 903 WP_000428612 847 VPQAFIKDDSLDNRVLTSLKDNRG-KSDN--VP S--LEVVEKMKT-FWQQLLDSKLISYRKFNNLTKA--ERGGLDE 915 WP_000428613 845 VPQAFIKDDSLDNRVLTSLKDNRG-KSDN--VP S--IEVVQKRKA-FWQQLLDSKLISERKFNNLTKA--ERGGLDE 913 WP_049523028 840 IPQAFIKDDSLDNRVLTSSKDNRG-KSDN--VP S--LEIVEKMKG-FWQQLLDSKLISERKFNNLTKA--ERGGLDE 908 WP_003107102 811 IPQSFIKDNSIDNIVLTSQESNRG-KSDN--VP Y--IAIVNKMKS-YWQHQLKSGAISQRKEDNLTKA--ERGGLSE 879 WP_054279288 843 IPRSFIKDDSIDNKVLTRSEHNRG-KTDN--VP S--IEVVKRMKP-YWQKLLDTKVISQRKFDNLTKA--ERGGLQE 911 WP_049531101 845 IPQAFIKDDSLDNRVLTSSKDNRG-KSDN--VP S--LEVVQKRKA-FWQQLLESKLISERKFNNLTKA--ERGGLNE 913 WP_049538452 845 IPQAFIKDDSLDNRVLTSSKENRG-KSDN--VP C--LEVVDKMKV-FWQQLLDFKLISYRKFNNLTKA--ERGGLDE 913 WP_049549711 845 IPQAFIKDDSLDNRVLTSSKDNRG-KSDN--VP S--LEVVQKRKA-FWQQLLDSKLISERKFNNLTKAerERDGLNE 915 WP_007896501 847 IPQSFIKDNSIDNLVLTTQKANRG-KSDN--VP S--IEVVRDMKDrVWRRQLANGAISRQKFDHLTKA--ERGGLAD 916 EFR44625 799 IPQSFIKDNSIDNLVLTTQKANRG-KSDN--VP S--IEVVRDMKDrVWRRQLANGAISRQKFDHLTKA--ERGGLAD 868 WP_002897477 844 IPQAFIKDDSIDNRVLTSSKDNRG-KSDN--VP S--LEVVQKRKA-FWQQLLDSKLISERKFNNLTKA--ERGGLDE 912 WP_002906454 844 IPQAFIKDDSLDNRVLTSSKDNRG-KSDN--VP S--IEVVQKRKA-FWQQLLDSKLISERKFNNLTKA--KRGGLDE 912 WP_009729476 845 IPQAFIKDDSLDNRVLTSSKDNRG-KSDN--VP S--LEVVDKMKV-FWQQLLDSKLISYRKFNNLTKA--ERGGLNE 913 CQR24647 844 IPQSFIKDNSLDNRVLTNSKSNRG-KSDN--VP S--NEVVKRMKG-FWLKQLDAKLISQRKFDNLTKA--ERGGLSA 912 WP_000066813 847 IPQAFIKDDSLDNRVLTSSKDNRG-KSDN--VP S--LEVVEKMKA-FWQQLLDSKLISERKFNNLTKAerERGGLNE 917 WP_009754323 845 IPQAFIKDDSLDNRVLTSSKDNRG-KSDN--VP S--LEVVKKRKA-FWQQLLDSKLISERKFNNLTKA--ERGGLDE 913 WP_044674937 844 IPQAFIKDDSLDNKVLTKSAKNRG-KSDD--VP S--LEIVHKKKN-FWKQLLDSQLISQRKFDNLTKA--ERGGLTN 912 WP_044676715 846 IPQAFIKDDSLDNKVLTKSAKNRG-KSDD--VP S--LEIVHKKKN-FWKQLLDSQLISQRKFDNLTKA--ERGGLTN 914 WP_044680361 846 IPQAFIKDDSLDNKVLTKSAKNRG-KSDD--VP S--LEIVHKKKN-FWKQLLDSQLISQRKFDNLTKA--ERGGLTN 914 WP_044681799 844 IPQAFIKDDSLDNKVLTKSAKNRG-KSDD--VP S--LEIVHKKKN-FWKQLLDSQLISQRKFDNLTKA--ERGGLTN 912 WP_049533112 841 IPQAFIKDDSFDNRVLTSSSENRG-KSDN--VP S--IEVVRARKA-DWMRLRKAGLISQRKFDNLTKA--ERGGLTE 909 WP_029090905 824 LPQSYIKDNSIENLALVKKVENQR-KKDS11LN S---SIINQNYS-RWEQLKNAGLIGEKKFRNLTRTk-----ITD 890 WP_006506696 850 VPQSLVKDDSEDNRVLVVPSENQR-KLDD1vVP ---FDIRDKMYR-FWKLLFDHELISPKKFYSLIKTe-----YTE 916 AIT42264 842 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 910 WP_034440723 849 IPRSFITDNSEDNLVLTSSTVNRG-KLDN--VP Sp--DIVRQQKG-FWKQLLRAGLMSQRKFNNLTKGk-----LTD 914 AKQ21048 842 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 910 WP_004636532 846 IPQSFTTDNSIDNKVLVSRTKNQGnKSDD--VP S--INIVHKMKP-FWRQLHKAGLISDRKFKNLTKA--EHGGLTE 915 WP_002364836 853 IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KEVVKDMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL 921 WP_016631044 804 IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KEVVKDMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL 872 EMS75795 589 IPRSFIVDNSIDNKVLVSSKENRL-KMDD--VP D--QKVVIRMRR-YWEKLLRANLISERKFAYLTKLe-----LTP 654 WP_002373311 853 IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KKVVKKMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL 921 WP_002378009 853 IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KEVVKDMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL 921 WP_002407324 853 IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KEVVKDMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL 921 WP_002413717 853 IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KEVVKDMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL 921 WP_010775580 855 IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KEVVKKMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL 923 WP_010818269 853 IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KEVVKDMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL 921 WP_010824395 853 IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KEVVKDMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL 921 WP_016622645 853 IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KEVVKDMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL 921 WP_033624816 853 IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KEVVKKMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL 921 WP_033625576 853 IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KEVVKKMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL 921 WP_033789179 853 IPQSFMKDDSLDNLVLVGSTENRG-KSDD--VP S--KEVVKKMKA-YWEKLYAAGLISQRKFQRLTKG--EQGGLTL 921 WP_002310644 853 IPRSFTTDNSIDNKVLVSSKENRL-KKDD--VP S--EKVVKKMRS-FWYDLYSSKLISKRKLDNLTKIk-----LTE 918 WP_002312694 854 IPRSFTTDNSIDNKVLVSSKENRL-KKDD--VP S--EKVVKKMRS-FWYDLYSSKLISKRKLDNLTKIk-----LTE 919 WP_002314015 854 IPRSFTTDNSIDNKVLVSSKENRL-KKDD--VP S--EKVVKKMRS-FWYDLYSSKLISKRKLDNLTKIk-----LTE 919 WP_002320716 854 IPRSFTTDNSIDNKVLVSSKENRL-KKDD--VP S--EKVVKKMRS-FWYDLYSSKLISKRKLDNLTKIk-----LTE 919 WP_002330729 853 IPRSFTTDNSIDNKVLVSSKENRL-KKDD--VP S--EKVVKKMRS-FWYDLYSSKLISKRKLDNLTKIk-----LTE 918 WP_002335161 854 IPRSFTTDNSIDNKVLVSSKENRL-KKDD--VP S--EKVVKKMRS-FWYDLYSSKLISKRKLDNLTKIk-----LTE 919 WP_002345439 854 IPRSFTTDNSIDNKVLVSSKENRL-KKDD--VP S--EKVVKKMRS-FWYDLYSSKLISKRKLDNLTKIk-----LTE 919 WP_034867970 845 IPRSFIVDNSIDDKVLVASKQNQK-KRDD--VP K--KQIVNEQRI-FWNQLKEAKLISTKKYAYLTKIe-----LTP 910 WP_047937432 854 IPRSFTTDNSIDNKVLVSSKENRL-KKDD--VP S--EKVVKKMRS-FWYDLYSSKLISKRKLDNLTKIk-----LTE 919 WP_010720994 845 IPRSFIVDNSIDNKVLVASKQNQK-KRDD--VP K--KQIVNEQRI-FWNQLKEAKLISPKKYAYLTKIe-----LTP 910 WP_010737004 845 IPRSFIVDNSIDNKVLVASKQNQK-KRDD--VP K--KQIVNEQRI-FWNQLKEAKLISPKKYAYLTKIe-----LTP 910 WP_034700478 845 IPRSFIVDNSIDNKVLVASKQNQK-KRDD--VP N--KQIVNEQRI-FWNQLKEAKLISPKKYAYLTKIe-----LTP 910 WP_007209003 846 IPQSFLTDNSIDNRVLTTSKSNRG-KSDN--VP S--EEVVRKMDR-FWRKLLNAKLISERKYTNLTKKe-----LTE 911 WP_023519017 839 IPRSFIVDNSLDNKVLVSSKVNRG-KLDN--AP D--PLVVKRMRS-HWEKLHQAKLISDKKLANLTKQn-----LTE 904 WP_010770040 846 VPQSFTTDNSLDNRVLVSSKENRG-KKDD--VP S--KEVVQKNIT-LWETLKNSNLISQKKYDNLTKG--LRGGLTE 914 WP_048604708 843 IPQSFIVDNSLDNRVLVSSSKNRG-KLDD--VP S--KEVVKKMRA-FWESLYRSGLISKKKFDNLVKA--ESGGLSE 911 WP_010750235 848 IPRSFIVDHSLDNKVLVSSKENRL-KKDD--VP D--SKVVKRMKA-YWEKLLRANLISERKFSYLTKLe-----LTD 913 AII16583 881 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 949 WP_029073316 861 VPQSLLKDDSIDNKVLVLSSENQR-KLDDlvIP ---EMIRNKMFG-FWNKLYENKIISPKKFYSLIKSe-----YSD 927 WP_031589969 861 VPQSLLKDDSIDNKVLVLSSENQR-KLDDlvIP ---SSIRNKMYG-FWEKLFNNKIISPKKFYSLIKTe-----FNE 927 KDA45870 834 IPQSFLKDDSIENKVLTIKKENVR-KTNG--LP S--EAVIQKMGS-FWKKLLDAGAMTNKKYDNLRRN1--HGGLNE 902 WP_039099354 857 LPQSFIKDNSLDNRVLVSQRMNRS-KADQ--VP S--VELGQKMQI-QWEQMLRAGLITKKKYDNLTLNp--------  923 AKP02966 859 LPRTYIPDDSLENKALVLAKENQR-KADD11LN S---NVIDKNLE-RWTYMLNNNMMGLKKFKNLTRRv-----ITD 925 WP_010991369 845 VPQSFITDNSIDNLVLTSSAGNRE-KGDD--VP P--LEIVRKRKV-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE 913 WP_033838504 845 VPQSFITDNSIDNLVLTSSAGNRE-KGDD--VP P--LEIVRKRKV-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE 913 EHN60060 848 VPQSFITDNSIDNLVLTSSAGNRE-KGDD--VP P--LEIVRKRKV-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE 916 EFR89594 614 VPQSFITDNSIDNLVLTSSAGNRE-KGND--VP P--LEIVQKRKV-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE 682 WP_038409211 845 IPQSFITDNSIDNRVLVSSTANRE-KGDN--VP L--LEVVRKRKA-FWEKLYQAKLMSKRKFDYLTKA--ERGGLTE 913 EFR95520 464 IPQSFITDNSIDNRVLVSSTANRE-KGDN--VP L--LEVVRKRKA-FWEKLYQAKLMSKRKFDYLTKA--ERGGLTE 532 WP_003723650 845 VPQSFITDNSIDNLVLTSSAGNRE-KGGD--VP P--LEIVRKRKV-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE 913 WP_003727705 845 VPQSFITDNSIDNLVLTSSAGNRE-KGGD--VP P--LEIVRKRKV-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE 913 WP_003730785 845 VPQSFITDNSIDNLVLTSSAGNRE-KGGD--VP P--LEIVRKRKV-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE 913 WP_003733029 845 VPQSFITDNSVDNLVLTSSAGNRE-KGDN--VP P--LEIVQKRKI-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE 913 WP_003739838 845 VPQSFITDNSIDNLVLTSSAGNRE-KGDD--VP P--LEIVRKRKV-FWEKLFQGNLMSKRKFDYLTKA--ERGGLTE 913 WP_014601172 845 VPQSFITDNSIDNLVLTSSAGNRE-KGGD--VP P--LEIVRKRKV-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTD 913 WP_023548323 845 VPQSFITDNSIDNLVLTSSAGNRE-KGDN--VP P--LEIVQKRKI-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE 913 WP_031665337 845 VPQSFITDNSIDNLVLTSSAGNRE-KGGD--VP P--LEIVRKRKV-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE 913 WP_031669209 845 VPQSFITDNSVDNLVLTSSAGNRE-KGDN--VP P--LEIVQKRKI-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE 913 WP_033920898 845 VPQSFITDNSIDNLVLTSSAGNRE-KGDN--VP P--LEIVQKRKI-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE 913 AKI42028 848 VPQSFITDNSIDNLVLTSSAGNRE-KGGD--VP P--LEIVRKRKV-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTD 916 AKI50529 848 VPQSFITDNSIDNLVLTSSAGNRE-KGDN--VP P--LEIVQKRKI-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE 916 EFR83390 293 VPQSFITDNSIDNLVLTSSAGNRE-KGDD--VP P--LEIVRKRKV-FWEKLYQGNLMSKRKFDYLTKA--ERGGLTE 361 WP_046323366 845 VPQSFITDNSIDNRVLASSAANRE-KGDN--VP S--LEVVRKRKV-YWEKLYQAKLMSKRKFDYLTKA--ERGGLTE 913 AKE81011 858 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 926 CUO82355 854 VPQSLVKDDSFDNRVLVLPSENQR-KLDD1vVP ---FDIRDKMYR-FWKLLFDHELISPKKFYSLIKTe-----YTE 920 WP_033162887 856 LPQSLIKDDSFDNRVLVLPEENQW-KLDSetVP ---FEIRNKMIG-FWQMLHENGLMSNKKFFSLIRTd-----FSD 922 AGZ01981 875 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 943 AKA60242 842 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 910 AKS40380 842 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 910 4UN5_B 846 VPQSFLKDDSIDNKVLTRSDKNRG-KSDN--VP S--EEVVKKMKN-YWRQLLNAKLITQRKFDNLTKA--ERGGLSE 914 WP_010922251 911

981 WP_039695303 921 AD KAGFIKRQLVETRQITKHVAQILDARFNTEHDENDKVIR--DVKVITLKSNLVSQFRKDF EFYKVREINDY 991 WP_045635197 913 RD KVGFIKRQLVETRQITKHVAQILDARYNTEVNEKDKKNR--TVKIITLKSNLVSNERKEF RLYKVREINDY 983 5AXW_A 633 RD QKDFINRNLVDTRYATRGLMNLLRSYFR---------VNn1DVKVKSINGGFTSFLRRKW KFKKERNKGYK 702 WP_009880683 595 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVRVITLKSKLVSDERKDF QFYKVREINNY 665 WP_010922251 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY 981 WP_011054416 911 LD KVGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVRVITLKSKLVSDERKDF QFYKVREINNY 981 WP_011284745 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY 981 WP_011285506 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY 981 WP_011527619 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY 981 WP_012560673 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVRVITLKSKLVSDERKDF QFYKVREINNY 981 WP_014407541 910 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY 980 WP_020905136 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY 981 WP_023080005 910 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY 980 WP_023610282 910 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY 980 WP_030125963 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY 981 WP_030126706 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY 981 WP_031488318 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY 981 WP_032460140 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVRVITLKSKLVSDERKDF QFYKVREINNY 981 WP_032461047 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVRVITLKSKLVSDERKDF QFYKVREINNY 981 WP_032462016 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY 981 WP_032462936 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVRVITLKSKLVSDERKDF QFYKVREINNY 981 WP_032464890 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY 981 WP_033888930 736 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY 806 WP_038431314 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY 981 WP_038432938 910 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY 980 WP_038434062 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY 981 BAQ51233 822 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY 892 KGE60162 86 LD KVGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVRVITLKSKLVSDERKDF QFYKVREINNY 156 KGE60856 -- ------------------------------------------------------------ ----------- WP_002989955 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY 981 WP_003030002 910 ED KAGFIKRQLVETRQITKHVAQILDERFNTEFDGNKRRIR--NVKIITLKSNLVSNFRKEF ELYKVREINDY 980 WP_003065552 921 AD KAGFIKRQLVETRQITKHVAQILDARFNTESDENDKVIR--DVKVITLKSNLVSQFRKDF EFYKVREINDY 991 WP_001040076 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF VFYKIREVNNY 986 WP_001040078 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNDY 986 WP_001040080 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_001040081 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_001040083 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_001040085 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_001040087 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_001040088 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_001040089 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_001040090 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_001040091 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_001040092 916 DD KAGFIQRQLVETRQITKHVARILDERFNNKVDDNNKPIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_001040094 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_001040095 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_001040096 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_001040097 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_001040098 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_001040099 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_001040100 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_001040104 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_001040105 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_001040106 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNDY 986 WP_001040107 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNDY 986 WP_001040108 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNDY 986 WP_001040109 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNDY 986 WP_001040110 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNDY 986 WP_015058523 916 DD KAGFIQRQLVETRQITKHVARILDERFNNKVDDNNKPIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_017643650 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_017647151 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_017648376 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_017649527 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_017771611 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNDY 986 WP_017771984 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 CFQ25032 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 CFV16040 916 DD KARFIQRQLVEIRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 KLJ37842 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTVKSNLVSNFRKEF GFYKIREVNNY 986 KLJ72361 916 DD KARFIQRQLVETRQITKHVARILDELFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 KLL20707 930 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 1000 KLL42645 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNDY 986 WP_047207273 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_047209694 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_050198062 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_050201642 916 DD KARFIQRQLVETRQITKHVASILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_050204027 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNDY 986 WP_050881965 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 WP_050886065 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 AHN30376 916 DD KAGFIQRQLVETRQITKHVARILDERFNNKVDDNNKPIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 EA078426 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNNY 986 CCW42055 916 DD KARFIQRQLVETRQITKHVARILDERFNNELDSKGRRIR--KVKIVTLKSNLVSNFRKEF GFYKIREVNDY 986 WP_003041502 910 ND KAGFIKRQLVETRQITKHVAQVLDARFNAKHDENKKVIR--DVKIITLKSNLVSQFRKDF KFYKVREINDY 980 WP_037593752 911 ED KAGFIKRQLVETRQITKHVAQILDERFNTEFDGAQRRIR--NVKIITLKSNLVSNFRKEF ELYKVREINDY 981 WP_049516684 911 ED KAGFIKRQLVETRQITKHVAQILDERFNTEFDGAQRRIR--NVKIITLKSNLVSNFRKEF ELYKVREINDY 981 GAD46167 910 ED KAGFIKRQLVETRQITKHVAQILDERFNTEFDGAQRRIR--NVKIITLKSNLVSNFRKEF ELYKVREINDY 980 WP_018363470 919 AD KAGFIKRQLVETRQITKHVAQILDARFNTERDENDKVIR--DVKVITLKSNLVSQFRKEF KFYKVRE INDY 989 WP_003043819 920 AD KAGFIKRQLVETRQITKHVARILDSRMNTKRDKNDKPIR--EVKVITLKSKLVSDFRKDF QLYKVRDINNY 990 WP_006269658 910 ED KAGFIKRQLVETRQITKHVAQILDERFNTEFDGNKRRIR--NVKIITLKSNLVSNFRKEF ELYKVREINDY 980 WP_048800889 910 ND KAGFIHRQLVETRQITKHVAQILDARFNPKRDDNKKVIR--DVKIITLKSNLVSQFRRDF KLYKVREINDY 980 WP_012767106 910 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDFRKDF QFYKVREINNY 980 WP_014612333 910 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDFRKDF QFYKVREINNY 980 WP_015017095 910 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDFRKDF QFYKVREINNY 980 WP_015057649 910 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDFRKDF QFYKVREINNY 980 WP_048327215 910 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDFRKDF QFYKVREINNY 980 WP_049519324 910 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDFRKDF QFYKVREINNY 980 WP_012515931 910 VD KAGFIQRQLVETRQITKHVAQILDSRFNTEFDDHNKRIR--KVHIITLKSKLVSDFRKEF GLYKIRDINHY 980 WP_021320964 910 VD KAGFIQRQLVETRQITKHVAQILDSRFNTEFDDHNKRIR--KVHIITLKSKLVSDFRKEF GLYKIRDINHY 980 WP_037581760 910 VD KAGFIQLQLVETRQITKHVAQILDSRFNTEFDDHNKRIR--KVHIITLKSKLVSDFRKEF GLYKIRDINHY 980 WP_004232481 918 TD KAGFIKRQLVETRQITKHVAQILDARFNTKCDENDKVIR--DVKVITLKSSLVSQFRKEF KFYKVREINDY 988 WP_009854540 919 AD KAGFIKRQLVETRQITKHVAQILDARFNTEHDENDKVIR--DVKVITLKSNLVSQFRKDF EFYKVREINDY 989 WP_012962174 919 ND KAGFIKRQLVETRQITKHVAQILDSRFNTERDENDKVIR--NVKVITLKSNLVSQFRKDF KFYKVREINDY 989 WP_039695303 921 AD KAGFIKRQLVETRQITKHVAQILDARFNTEHDENDKVIR--DVKVITLKSNLVSQFRKDF EFYKVREINDY 991 WP_014334983 918 AD KAGFIKRQLVETRQITKHVAQILDARFNTKRDENDKVIR--DVKVITLKSNLVSQFRKEF KFYKVREINDY 988 WP_003099269 911 FD KAGFIKRQLVETRQITKHVAQILDSRFNSNLTEDSKSNR--NVKIITLKSKMVSDFRKDF GFYKLREVNDY 981 AHY15608 911 FD KAGFIKRQLVETRQITKHVAQILDSRFNSNLTEDSKSNR--NVKIITLKSKMVSDFRKDF GFYKLREVNDY 981 AHY17476 911 FD KAGFIKRQLVETRQITKHVAQILDSRFNSNLTEDSKSNR--NVKIITLKSKMVSDFRKDF GFYKLREVNDY 981 ESR09100 -- ------------------------------------------------------------ ----------- AGM98575 911 FD KAGFIKRQLVETRQITKHVAQILDSRFNSNLTEDSKSNR--NVKIITLKSKMVSDFRKDF GFYKLREVNDY 981 ALF27331 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_018372492 924 ED KAGFIRRQLVETRQITKHVARLLDEKLNRKKNENGEKLR--TTKIITLKSVFASRFRANF DLYKLRELNHY 994 WP_045618028 914 RD KVGFIKRQLVETRQITKHVAQILDARFNTEVTEKDKKDR--SVKIITLKSNLVSNFRKEF RLYKVREINDY 984 WP_045635197 913 RD KVGFIKRQLVETRQITKHVAQILDARYNTEVNEKDKKNR--TVKIITLKSNLVSNFRKEF RLYKVREINDY 983 WP_002263549 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002263887 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002264920 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002269043 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002269448 911 DD KAGFIKRQLVETRQITKHVARILDERFYTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002271977 911 DD KAGFIKRQLVETRQITKHVARILDERFYTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002272766 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002273241 911 DD KAGFIKRQLVETRQITKHVARILDERFYTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002275430 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002276448 911 DD KAGFIKRQLVETRQITKHVARILDERFYTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002277050 913 DD KAGFIKRQLVETRQITKHVARMLDERFNKEFDDNNKRIR--RVKIVTLKSNLVSSFRKEF ELYKVREINDY 983 WP_002277364 911 DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002279025 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002279859 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002280230 911 DD KAGFIKRQLVETRQITKHVARILDERFYTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002281696 911 DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002282247 913 DD KAGFIKRQLVETRQITKHVARMLDERFNKEFDDNNKRIR--RVKIVTLKSNLVSSFRKEF ELYKVREINDY 983 WP_002282906 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002283846 911 DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002287255 911 DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002288990 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002289641 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002290427 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002295753 911 DD KAGFIKRQLVETRQITKHVARILDERFYTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002296423 911 DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002304487 925 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 995 WP_002305844 911 DD KAGFIKRQLVETRQITKHVARILDERFYTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002307203 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002310390 911 DD KAGFIKHQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_002352408 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_012997688 911 DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_014677909 911 DD KAGFIKRQLVETRQITKHVARILDERFYTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_019312892 911 DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_019313659 911 DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_019314093 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_019315370 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_019803776 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_019805234 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_024783594 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_024784288 913 DD KAGFIKRQLVETRQITKHVARMLDERFNKEFDDNNKRIR--RVKIVTLKSNLVSSFRKEF ELYKVREINDY 983 WP_024784666 911 DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_024784894 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_024786433 913 DD KAGFIKRQLVETRQITKHVARMLDERFNKEFDDNNKRIR--RVKIVTLKSNLVSSFRKEF ELYKVREINDY 983 WP_049473442 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 WP_049474547 911 DD KAGFIKRQLVETRQITKHVARILDERFNTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 981 EMC03581 904 DD KAGFIKRQLVETRQITKHVARILDERFHTETDENNKKIR--QVKIVTLKSNLVSNFRKEF ELYKVREINDY 974 WP_000428612 916 RD KVGFIKRQLVETRQITKHVAQILDARYNTEVNEKDKKNR--TVKIITLKSNLVSNFRKEF RLYKIREINDY 986 WP_000428613 914 RD KVGFIKRQLVETRQITKHVAQILDARFNKEVNEKDKKNR--TVKIITLKSNLVSNFRKEF RLYKVREINDY 984 WP_049523028 909 RD KVGFIKRQLVETRQITKHVAQILDDRFNAEVNEKNQKLR--SVKIITLKSNLVSNFRKEF GLYKVREINDY 979 WP_003107102 880 YD KAGFIKRQLVETRQITKHVAQILNNRFNNNVDDSSKNKR--PVKIITLKSKMVSDFRKEF GFYKIREVNDY 950 WP_054279288 912 SD KANFIQRQLVETRQITKHVAQILDSRFNTERDEKDRPIR--RVKVITLKSKFVSDFRQDF GFYKLREINDY 982 WP_049531101 914 RD KVGFIKRQLVETRQITKHVAQILDSRFNTKVNEKNQKIR--TVKIITLKSNLVSNFRKEF RLYKVREINDY 984 WP_049538452 914 RD KVGFIRRQLVETRQITKHVAQILDSRFNTEVTEKDKKNR--NVKIITLKSNLVSNFRKEF GLYKVREINDY 984 WP_049549711 916 LD KVGFIKRQLVETRQITKHVAQILDARFNKEVTEKDKKNR--NVKIITLKSNLVSNFRKEF RLYKVREINDY 986 WP_007896501 917 SD KARFLRRQLVETRQITKHVAQLLDSRFNSKSNQNKKLAR--NVKIITLKSKIVSDFRKDF GLYKLREVNNY 987 EFR44625 869 SD KARFLRRQLVETRQITKHVAQLLDSRFNSKSNQNKKLAR--NVKIITLKSKIVSDFRKDF GLYKLREVNNY 939 WP_002897477 913 RD KVGFIRRQLVETQQITKNVAQILDARFNTEVKEKNQKIR--TVKIITLKSNLVSNFRKEF GLYKVREINNY 983 WP_002906454 913 RD KVGFIKRQLVETRQITKHVAQLLDTRENTEVNEENQKIR--TVKIITLKSNLVSNFRKEF GLYKVREINDY 983 WP_009729476 914 LD KVGFIKRQLVETRQITKHVAQILDARFNKEVTEKDKKNR--TVKIITLKSNLVSNFRKEF ELYKVREINDY 984 CQR24647 913 ED KAGFIKRQLVETRQITKHVARILDERFNRDFDKNDKRIR--NVKIVTLKSNLVSNFRKEF GFYKVREINNF 983 WP_000066813 918 LD KVGFIKRQLVETRQITKHVAQFLDARFNKEVTEKDKKNR--NVKIITLKSNLVSNFRKEF GLYKVREINDY 988 WP_009754323 914 RD KVGFIKRQLVETRQITKHVARILDARENTEVSEKNQKIR--SVKIITLKSNLVSNFRKEF KLYKVREINDY 984 WP_044674937 913 ED KARFIQRQLVETRQITKHVARILDTRENTKLDEAGNRIRdpKVNIITLKSNLVSQFRKDY QLYKVREINNY 985 WP_044676715 915 ED KARFIQRQLVETRQITKHVARILDTRENTKLDEAGNRIRdpKVNIITLKSNLVSQFRKDY QLYKVREINNY 987 WP_044680361 915 ED KARFIQRQLVETRQITKHVARILDTRENTKLDEAGNRIRdpKVNIITLKSNLVSQFRKDY QLYKVREINNY 987 WP_044681799 913 ED KARFIQRQLVETRQITKHVARILDTRENTKLDEAGNRIRdpKVNIITLKSNLVSQFRKDY QLYKVREINNY 985 WP_049533112 910 ND KAGFIKRQLVETRQITKHVAQVLDARFNAKHDENKKVIR--DVKIITLKSNLVSQFRKDF KFYKVREINDY 980 WP_029090905 891 RD KEGFIARQLVETRQITKHVTQLLQQEY-----------K-dTTKVFAIKATLVSGLRRKF EFIKNRNVNDY 951 WP_006506696 917 RD EERFINRQLVETRQITKNVTQIIEDHYST-------------TKVAAIRANLSHEFRVKN HIYKNRDINDY 976 AIT42264 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY 981 WP_034440723 915 RD RQQFINRQLVETRQITKHVANLLSHHLNEK-----KEVG--EINIVLLKSALTSQFRKKE DFYKVREVNDY 980 AKQ21048 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY 981 WP_004636532 916 AD RAHFLNRQLVETRQITKHVANLLDSQYNTAEEQ-----R---INIVLLKSSMTSRFRKEF KLYKVREINDY 980 WP_002364836 922 ED KAHFIQRQLVETRQITKNVAGILDQRYNANSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY 987 WP_016631044 873 ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY 938 EMS75795 655 ED KARFIQRQLVETRQITKHVAAILDQYFN-QPEE-SK-NK--GIRIITLKSSLVSQFRKTF GINKVREINNH 722 WP_002373311 922 ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY 987 WP_002378009 922 ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY 987 WP_002407324 922 ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY 987 WP_002413717 922 ED KAHFIQRQLVETRQITKNVAGILNQRYNANSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY 987 WP_010775580 924 ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY 989 WP_010818269 922 ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY 987 WP_010824395 922 ED KAHFIQRQLVETRQITKNVAGILDQLYNAKSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY 987 WP_016622645 922 ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY 987 WP_033624816 922 ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY 987 WP_033625576 922 ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY 987 WP_033789179 922 ED KAHFIQRQLVETRQITKNVAGILDQRYNAKSKE-----K--KVQIITLKASLTSQFRSIF GLYKVREVNDY 987 WP_002310644 919 ED KAGFIKRQLVETRQITKHVAGILHHREN-KAEDTNEPIR--KVRIITLKSALVSQFRNRF GIYKVREINEY 988 WP_002312694 920 ED KAGFIKRQLVETRQITKHVAGILHHREN-KAEDTNDPIR--KVRIITLKSALVSQFRNRF GIYKVREINEY 989 WP_002314015 920 ED KAGFIKRQLVETRQITKHVAGILHHREN-KAEDTNEPIR--KVRIITLKSALVSQFRNRF GIYKVREINEY 989 WP_002320716 920 ED KAGFIKRQLVETRQITKHVAGILHHREN-KAEDTNEPIR--KVRIITLKSALVSQFRNRF GIYKVREINEY 989 WP_002330729 919 ED KAGFIKRQLVETRQITKHVAGILHHRFN-KAEDTNEPIR--KVRIITLKSALVSQFRNRF GIYKVREINEY 988 WP_002335161 920 ED KAGFIKRQLVETRQITKHVAGILHHRFN-KAEDTNEPIR--KVRIITLKSALVSQFRNRF GIYKVREINEY 989 WP_002345439 920 ED KAGFIKRQLVETRQITKHVAGILHHRFN-KAEDTNEPIR--KVRIITLKSALVSQFRNRF GIYKVREINEY 989 WP_034867970 911 ED KARFIQRQLVETRQITKHVANILHQSFN-QEEEGTD-CD--GVQIITLKATLTSQFRQTF GLYKVREINPH 979 WP_047937432 920 ED KAGFIKRQLVETRQITKHVAGILHHRFN-KAEDTNEPIR--KVRIITLKSALVSQFRNRF GIYKVREINEY 989 WP_010720994 911 ED KARFIQRQLVETRQITKHVANILHQSFN-QEEEGTD-CD--GVQIITLKATLTSQFRQTF GLYKVREINPH 979 WP_010737004 911 ED KARFIQRQLVETRQITKHVANILHQSFN-QEEEGTD-CD--GVQIITLKATLTSQFRQTF GLYKVREINPH 979 WP_034700478 911 ED KARFIQRQLVETRQITKHVANILHQSFN-QEEEGTD-CD--GVQIITLKATLTSQFRQTF GLYKVREINPH 979 WP_007209003 912 SD KAGFLKRQLVETRQITKHVATILDSKFNE--DSNNRDVQ-----IITLKSALVSEFRKTF NLYKVREINDL 977 WP_023519017 905 AD KARFIQRQLVETRQITKHVANLLHQHFN-LPEEVSA-TE--KTSIITLKSTLTSQFRQMF DIYKVREINHH 973 WP_010770040 915 DD RAHFIKRQLVETRQITKHVARILDQRFNSQKDEEGKTIR--AVRVVTLKSSLTSQFRKQF AIHKVREINDY 985 WP_048604708 912 DD KAGFIHRQLVETRQITKNVARILHQRFNSEKDEEGNLIR--KVRIITLKSALTSQFRKNY GIYKIREINDY 982 WP_010750235 914 DD KARFIQRQLVETRQITKHVAAILHQYFN-QTQELEK-EK--DIRIITLKSSLVSQFRQVF GIHKVREINHH 982 AII16583 950 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDERKDF QFYKVREINNY 1020 WP_029073316 928 KD KERFINRQIVETRQITKHVAQIISNHYET-------------TKVVTVRADLSHAFRERY HIYKNRDINDF 987 WP_031589969 928 KD QERFINRQIVETRQITKHVAQIIDNHYEN-------------TKVVTVRADLSHQFRERY HIYKNRDINDF 987 KDA45870 903 KL KERFIERQLVETRQITKYVAQLLDQRLN--YDGNGVELD-eKIAIVTLKAQLASQFRSEF KLRKVRALNNL 972 WP_039099354 924 -D MKGFINRQLVETRQVIKLATNLLMEQYGED-----------NIELITVKSGLTHQMRTEF DFPKNRNLNNH 990 AKP02966 926 KD KLGFIHRQLVQTSQMVKGVANILNSMYK---NQGTTCIQ--------ARANLSTAFRKAL ELVKNRNINDF 999 WP_010991369 914 AD KARFIHRQLVETRQITKNVANILHQRFNYEKDDHGNTMK--QVRIVTLKSALVSQFRKQF QLYKVRDVNDY 984 WP_033838504 914 AD KARFIHRQLVETRQITKNVANILHQRFNYEKDDHGNTMK--QVRIVTLKSALVSQFRKQF QLYKVRDVNDY 984 EHN60060 917 AD KARFIHRQLVETRQITKNVANILHQRFNYEKDDHGNTMK--QVRIVTLKSALVSQFRKQF QLYKVRDVNDY 987 EFR89594 683 AD KARFIHRQLVETRQITKNVANILHQRFNYGKDDHGNTMK--QVRIVTLKSALVSQFRKQF QLYKVRGVNDY 753 WP_038409211 914 AD KANFIQRQLVETRQITKNVANILYQRFNCKQDENGNEVE--QVRIVTLKSTLVSQFRKQF QLYKVREVNDY 984 EFR95520 533 AD KANFIQRQLVETRQITKNVANILYQRFNCKQDENGNEVE--QVRIVTLKSTLVSQFRKQF QLYKVREVNDY 603 WP_003723650 914 AD KARFIHRQLVETRQITKNVANILYQRFNKETDNHGNTME--QVRIVTLKSALVSQFRKQF QLYKVREVNGY 984 WP_003727705 914 AD KARFIHRQLVETRQITKNVANILHQRFNKETDNHGNTME--QVRIVTLKSALVSQFRKQF QLYKVREVNDY 984 WP_003730785 914 AD KARFIHRQLVETRQITKNVANILHQRFNKETDNHGNTME--QVRIVTLKSALVSQFRKQF QLYKVREVNDY 984 WP_003733029 914 AD KARFIHRQLVETRQITKNVANILHQRFNYKTDGNKDTME--TVRIVTLKSALVSQFRKQF QFYKVREVNDY 984 WP_003739838 914 AD KATFIHRQLVETRQITKNVANILHQRFNNETDNHGNNME--QVRIVMLKSALVSQFRKQF QLYKVREVNDY 984 WP_014601172 914 AD KARFIHRQLVETRQITKNVANILHQRFNNETDNHGNTME--QVRIVTLKSALVSQFRKQF QLYKVREVNDY 984 WP_023548323 914 AD KARFIHRQLVETRQITKNVANILHQRFNYKTDDNEDTME--PVRIVTLKSALVSQFRKQF QLYKVREVNDY 984 WP_031665337 914 AD KARFIHRQLVETRQITKNVANILHQRFNKETDNHGNTME--QVRIVTLKSALVSQFRKQF QLYKVREVNDY 984 WP_031669209 914 AD KARFIHRQLVETRQITKNVANILHQRFNYKTDGNKDTME--TVRIVTLKSALVSQFRKQF QFYKVREVNDY 984 WP_033920898 914 AD KARFIHRQLVETRQITKNVANILHQRFNYKTDDNEDTME--PVRIVTLKSALVSQFRKQF QLYKVREVNDY 984 AKI42028 917 AD KARFIHRQLVETRQITKNVANILHQRFNNETDNHGNTME--QVRIVTLKSALVSQFRKQF QLYKVREVNDY 987 AKI50529 917 AD KARFIHRQLVETRQITKNVANILHQRFNYKTDDNEDTME--PVRIVTLKSALVSQFRKQF QLYKVREVNDY 987 EFR83390 362 AD KARFIHRQLVETRQITKNVANILHQRFNNETDNHGNTME--QVRIVTLKSALVSQFRKQF QLYKVREVNDY 432 WP_046323366 914 AD KARFIHRQLVETRQITKNVANILHQRFNCKKDESGNVIE--QVRIVTLKAALVSQFRKQF QLYKVREVNDY 984 AKE81011 927 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDFRKDF QFYKVREINNY 997 CUO82355 921 RD EERFINRQLVETRQITKNVTQIIEDHYST-------------TKVAAIRANLSHEFRVKN HIYKNRDINDY 980 WP_033162887 923 KD KERFINRQLVETRQIIKNVAVIINDHYTN-------------TNIVTVRAELSHQFRERY KIYKNRDINDF 982 AGZ01981 944 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDFRKDF QFYKVREINNY 1014 AKA60242 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDFRKDF QFYKVREINNY 981 AKS40380 911 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDFRKDF QFYKVREINNY 981 4UN5_B 915 LD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR--EVKVITLKSKLVSDFRKDF QFYKVREINNY 985 WP_010922251 982

1051 WP_039695303 992 HHAHDAYLNAVVGTALLKKYPKL-ASEFVYGEYKKYDI S---SD------ KATAK--YfFYSNLM-NFFKTKVK 1058 WP_045635197 984 HHAHDAYLNAVVAKAILKKYPKL-EPEFVYGEYQKYDL SkdpKEV---EK ATEKY--F-FYSNLL-NFFKEEVH 1055 5AXW_A 703 HHAEDALI--------------IaNADFIFKEWKKLDK Nq-mFE----EK ETEQEykEiFITPHQiKHIKDFKD 771 WP_009880683 666 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDI S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 735 WP_010922251 982 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1051 WP_011054416 982 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1051 WP_011284745 982 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1051 WP_011285506 982 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1051 WP_011527619 982 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1051 WP_012560673 982 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDI S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1051 WP_014407541 981 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1050 WP_020905136 982 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1051 WP_023080005 981 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1050 WP_023610282 981 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1050 WP_030125963 982 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1051 WP_030126706 982 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1051 WP_031488318 982 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1051 WP_032460140 982 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDI S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1051 WP_032461047 982 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDI S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1051 WP_032462016 982 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1051 WP_032462936 982 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1051 WP_032464890 982 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1051 WP_033888930 807 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 876 WP_038431314 982 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1051 WP_038432938 981 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1050 WP_038434062 982 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1051 BAQ51233 893 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 962 KGE60162 157 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 226 KGE60856 -------------------------------------- ------------ ------------------------ WP_002989955 982 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1051 WP_003030002 981 HHAHDAYLNAVVGNALLLKYPQL-EPEFVYGEYPKYN- S---YR---sRK SATEK--F1FYSNIL-RFFKKE-- 1041 WP_003065552 992 HHAHDAYLNAVVGTALLKKYPKL-ASEFVYGEYKKYDI S---SD------ KATAK--YfFYSNLM-NFFKRVIR 1058 WP_001040076 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_001040078 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGLYRRKK- L---SKI---VR ATRKM--F-FYSNLM-NMFKRVVR 1057 WP_001040080 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_001040081 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_001040083 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_001040085 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_001040087 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_001040088 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_001040089 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_001040090 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_001040091 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_001040092 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_001040094 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_001040095 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_001040096 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_001040097 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_001040098 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_001040099 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_001040100 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_001040104 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_001040105 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_001040106 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_001040107 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_001040108 987 HHAHDAYLNAVVAKAILTKYPQL-EREFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_001040109 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_001040110 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_015058523 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_017643650 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_017647151 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_017648376 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_017649527 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_017771611 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_017771984 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 CFQ25032 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 CFV16040 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 KLJ37842 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 KLJ72361 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 KLL20707 1001 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1063 KLL42645 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_047207273 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_047209694 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_050198062 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_050201642 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_050204027 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_050881965 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_050886065 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 AHN30376 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 EA078426 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 CCW42055 987 HHAHDAYLNAVVAKAILTKYPQL-EPEFVYGDYPKYN- S---YKT---RK ATEKL--F-FYSNIM-NFFKTKVT 1049 WP_003041502 981 HHAHDAYLNAVIGTALLKKYPKL-ASEFVYGEFKKYDV S---DK---eIG KATAK--YfFYSNLM-NFFKKEVK 1050 WP_037593752 982 HHAHDAYLNAVVGNALLLKYPQL-EPEFVYGEYPKYN- S---YR---sRK SATEK--F1FYSNIL-RFFKKE-- 1042 WP_049516684 982 HHAHDAYLNAVVGNALLLKYPQL-EPEFVYGEYPKYN- S---YR---sRK SATEK--F1FYSNIL-RFFKKE-- 1042 GAD46167 981 HHAHDAYLNAVVGNALLLKYPQL-EPEFVYGEYPKYN- S---YR---sRK SATEK--F1FYSNIL-RFFKKE-- 1041 WP_018363470 990 HHAHDAYLNAVVGTALLKKYPKL-APEFVYGEYKKYDV S---SDDhseMG KATAK--YfFYSNLM-NFFKRVIR 1062 WP_003043819 991 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKR--F-FYSNIM-NFFKTEVK 1060 WP_006269658 981 HHAHDAYLNAVVGNALLLKYPQL-EPEFVYGEYPKYN- S---YR---sRK SATEK--F1FYSNIL-RFFKKE-- 1041 WP_048800889 981 HHAHDAYLNAVVGTALLKKYPKL-TSEFVYGEYKKYDV S---DND--eIG KATAK--YfFYSNLM-NFFKTEVK 1051 WP_012767106 981 HHAHDAYLNAVVGTALIKKYTKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKR--F-FYSNIM-NFFKTEIT 1050 WP_014612333 981 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKR--F-FYSNIM-NFFKTEIT 1050 WP_015017095 981 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKR--F-FYSNIM-NFFKTEIT 1050 WP_015057649 981 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKR--F-FYSNIM-NFFKTEIT 1050 WP_048327215 981 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKR--F-FYSNIM-NFFKTEIT 1050 WP_049519324 981 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKR--F-FYSNIM-NFFKTEIT 1050 WP_012515931 981 HHAHDAYLNAVVAKAILGKYPQL-APEFVYGDYPKYN- S---FKEr--QK ATQKM--L-FYSNIL-KFFKDQES 1043 WP_021320964 981 HHAHDAYLNAVVAKAILGKYPQL-APEFVYGDYPKYN- S---FKEr--QK ATQKT--L-FYSNIL-KFFKDQES 1043 WP_037581760 981 HHAHDAYLNAVVAKAILGKYPQL-APEFVYGDYPKYN- S---FKEr--QK ATQKT--L-FYSNIL-KFFKDQES 1043 WP_004232481 989 HHAHDAYLNAVVGTALLKKYPKL-APEFVYGEYKKYDV S---SDNhseLG KATAK--YfFYSNLM-NFFKTEVK 1061 WP_009854540 990 HHAHDAYLNAVVGTALLKKYPKL-ASEFVYGEYKKYDI S---SD------ KATAK--YfFYSNLM-NFFKTKVK 1056 WP_012962174 990 HHAHDAYLNAVVGTALLKKYPKL-APEFVYGEYKKYDI S---GD------ KATAK--YfFYSNLM-NFFKRVIR 1056 WP_039695303 992 HHAHDAYLNAVVGTALLKKYPKL-ASEFVYGEYKKYDI S---SD------ KATAK--YfFYSNLM-NFFKTKVK 1058 WP_014334983 989 HHAHDAYLNAVVGTALLKKYPKL-TPEFVYGEYKKYDV S---SDDyseMG KATAK--YfFYSNLM-NFFKTEVK 1061 WP_003099269 982 HHAQDAYLNAVVGTALLKKYPKL-EAEFVYGDYKHYDL P---DSS1--GK ATTRM--F-FYSNLM-NFFKKEIK 1051 AHY15608 982 HHAQDAYLNAVVGTALLKKYPKL-EAEFVYGDYKHYDL P---DSS1--GK ATTRM--F-FYSNLM-NFFKKEIK 1051 AHY17476 982 HHAQDAYLNAVVGTALLKKYPKL-EAEFVYGDYKHYDL P---DSS1--GK ATTRM--F-FYSNLM-NFFKKEIK 1051 ESR09100 -------------------------------------- ------------ ------------------------ AGM98575 982 HHAQDAYLNAVVGTALLKKYPKL-EAEFVYGDYKHYDL P---DSS1--GK ATTRM--F-FYSNLM-NFFKKEIK 1051 ALF27331 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_018372492 995 HHAHDAYLNAVVAQALLKVYPKF-ERELVYGSYVKESI ----FS----RK ATERM---rMYNNIL-KFISKD-- 1055 WP_045618028 985 HHAHDPYLNAVVAKAILKKYPKL-EPEFVYGDYQKYDL TkdpKEV---EK ATEKY--F-FYSNLL-NFFKEEVH 1056 WP_045635197 984 HHAHDAYLNAVVAKAILKKYPKL-EPEFVYGEYQKYDL SkdpKEV---EK ATEKY--F-FYSNLL-NFFKEEVH 1055 WP_002263549 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002263887 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002264920 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002269043 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002269448 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002271977 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002272766 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HE---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002273241 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002275430 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HE---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002276448 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002277050 984 HHAHDAYLNAVVVKALLVKYPKL-EPEFVYGEYPKYN- S---YR---eRK ATQKM--F-FYSNIM-NMFKSKVK 1046 WP_002277364 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002279025 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HE---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002279859 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002280230 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002281696 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002282247 984 HHAHDAYLNAVVVKALLVKYPKL-EPEFVYGEYPKYN- S---YR---eRK ATQKM--F-FYSNIM-NMFKSKVK 1046 WP_002282906 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002283846 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002287255 982 HHTHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002288990 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002289641 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002290427 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002295753 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002296423 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002304487 996 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKG-- 1055 WP_002305844 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002307203 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002310390 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_002352408 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_012997688 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_014677909 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_019312892 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_019313659 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_019314093 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_019315370 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HE---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_019803776 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_019805234 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_024783594 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_024784288 984 HHAHDAYLNAVVVKALLVKYPKL-EPEFVYGEYLKYN- S---YR---eRK ATQKM--F-FYSNIM-NMFKSKVK 1046 WP_024784666 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_024784894 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_024786433 984 HHAHDAYLNAVVVKALLVKYPKL-EPEFVYGEYPKYN- S---YR---eRK ATQKM--F-FYSNIM-NMFKSKVK 1046 WP_049473442 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HE---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 WP_049474547 982 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1041 EMC03581 975 HHAHDAYLNAVIGKALLGVYPQL-EPEFVYGDYPHFH- G---HK---eNK ATAKK--F-FYSNIM-NFFKKD-- 1034 WP_000428612 987 HHAHDAYLNAVVAKAILKKYPKL-EPEFVYGDYQKYDL SkdpKEI---EK ATEKY--F-FYSNLL-NFFKEEVH 1058 WP_000428613 985 HHAHDAYLNAVVAKAILKKYPKL-EPEFVYGDYQKYDL SrnpKEV---EK ATEKY--F-FYSNLL-NFFKEEVH 1056 WP_049523028 980 HHAHDAYLNAVVAKAILKKYPKL-EPEFVYGDYQKYDL TkdpKEI---EK ATEKY--F-FYSNLL-NFFKDKVY 1051 WP_003107102 951 HHAHDAYLNAVVGTALLKKYPKL-EAEFVYGDYKHYDL S---DTS1--GK ATAKM--F-FYSNIM-NFFKKEVR 1020 WP_054279288 983 HHAHDAYLNAVVGTALLKMYPKL-ASEFVYGDYQKYDL S---GKAs--GH ATAKY--F-FYSNLM-NFFKSEVK 1052 WP_049531101 985 HHAHDAYLNAVVAKAILKKYPKL-EPEFVYGDYQKYDL SrdpKEI---EK ATEKY--F-FYSNLL-NFFKEEVH 1056 WP_049538452 985 HHAHDAYLNAVVAKAILKKYPKL-EPEFVYGDYQKYDL SkdpKDI---EK ATEKY--F-FYSNLL-NFFKEEVH 1056 WP_049549711 987 HHAHDAYLNAVVAKAILKKYPKL-EPEFVYGDYQKNDL SkdpKDI---EK ATEKY--F-FYSNLL-NFFKEEVH 1058 WP_007896501 988 HHAHDAYLNAVVGTALLKKYPKL-EAEFVYGDYKHFDL S---DPS1--GK ATAKV--F-FYSNIM-NFFKEELS 1057 EFR44625 940 HHAHDAYLNAVVGTALLKKYPKL-EAEFVYGDYKHFDL S---DPS1--GK ATAKV--F-FYSNIM-NFFKEELS 1009 WP_002897477 984 HHAHDAYLNAVVAKAILKKYPKL-EPEFVYGDYQKYDL FkpsKEI---EK ATEKY--F-FYSNLL-NFFKEEVL 1055 WP_002906454 984 HHAHDAYLNAVVAKAILKKYPKL-EPEFVYGDYQKYDL SkasNTI---DK ATEKY--F-FYSNLL-NFFKEKVR 1055 WP_009729476 985 HHAHDAYLNAVVAKAILKKYPKL-EPEFVYGDYQKYDL SkdpKEI---EK ATEKY--F-FYSNLL-NFFKEEVH 1056 CQR24647 984 HHAHDAYLNAVVAKALLIRYPKL-EPEFVYGEYPKYN- S---YRE---RK ATEKM--F-FYSNIM-NMFKTTIK 1046 WP_000066813 989 HHAHDAYLNAVLAKAILKKYPKL-EPEFVYGDYQKYDL SrepKEV---EK ATQKY--F-FYSNLL-NFFKEEVH 1060 WP_009754323 985 HHAHDAYLNAVVAKAILKKYPKL-EPEFVYGDYQKYDL SkdpKEV---EK ATEKY--F-FYSNLL-NFFKEEVH 1056 WP_044674937 986 HHAHDAYLNAVVATALLKKYPQL-APEFVYGDYPKYN- S---YKS---RK ATEKV--L-FYSNIM-NFFRRVLV 1048 WP_044676715 988 HHAHDAYLNAVVATALLKKYPQL-APEFVYGDYPKYN- S---YKS---RK ATEKV--L-FYSNIM-NFFRRVLV 1050 WP_044680361 988 HHAHDAYLNAVVATALLKKYPQL-APEFVYGDYPKYN- S---YKS---RK ATEKV--L-FYSNIM-NFFRRVLV 1050 WP_044681799 986 HHAHDAYLNAVVATALLKKYPQL-APEFVYGDYPKYN- S---YKS---RK ATEKV--L-FYSNIM-NFFRRVLV 1048 WP_049533112 981 HHAHDAYLNAVIGTALLKKYPKL-ASEFVYGEFKKYDV S---DK---eIG KATAK--YfFYSNLM-NFFKKEVK 1050 WP_029090905 952 HHAQDAFLVAFLGTNITSNYPKI-EMEYLFKGYQHYLN ------Ev--GK AAKPKftF-IVENLS---------  1007 WP_006506696 977 HHAHDAYIVALIGGFMRDRYPNMhDSKAVYSEYMKMFR ----NKNd--QK -----g---FVINSM-NYPY-EV- 1038 AIT42264 982 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1051 WP_034440723 981 HHAHDAYLNGVIALKLLELYPYM-AKDLIYGKYSYHRK G---------DK ATQAK--Y-KMSNII-ERFSQDL- 1041 AKQ21048 982 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1051 WP_004636532 981 HHGHDAYLNAVVATTIMKVYPNL-KPQFVYGQYKKTSM ----FKE---EK ATARK--H-FYSNIT-KFFKKEKV 1042 WP_002364836 988 HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQT ----FKE---NK ATAKA--I-IYTNLL-RFFTED-- 1047 WP_016631044 939 HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQT ----FKE---NK ATAKA--I-IYTNLL-RFFTED-- 998 EMS75795 723 HHAHDAYLNGVVAIALLKKYPKL-EPEFVYGNYTKFNL ----AT---eNK ATAKK--E-FYSNIL-RFFEKE-- 782 WP_002373311 988 HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQA ----FKE---NK ATAKT--I-IYTNLM-RFFTED-- 1047 WP_002378009 988 HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQT ----FKE---NK ATAKA--I-IYTNLL-RFFTED-- 1047 WP_002407324 988 HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQT ----FKE---NK ATAKA--I-IYTNLL-RFFTED-- 1047 WP_002413717 988 HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQT ----FKE---NK ATAKA--I-IYTNLL-RFFTED-- 1047 WP_010775580 990 HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQA ----FKE---NK ATAKA--I-IYTNLL-RFFTED-- 1049 WP_010818269 988 HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQT ----FKE---NK ATAKA--I-IYTNLL-RFFTED-- 1047 WP_010824395 988 HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQT ----FKE---NK ATAKT--I-IYTNLM-RFFTED-- 1047 WP_016622645 988 HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQT ----FKE---NK ATAKA--I-IYTNLL-RFFTED-- 1047 WP_033624816 988 HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQA ----FKE---NK AMAKA--I-IYTNLL-RFFTED-- 1047 WP_033625576 988 HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQA ----FKE---NK ATAKA--I-IYTNLM-RFFTEV-- 1047 WP_033789179 988 HHGQDAYLNCVVATTLLKVYPNL-APEFVYGEYPKFQA ----FKE---NK ATAKA--I-IYTNLL-RFFTED-- 1047 WP_002310644 989 HHAHDAYLNGVVALALLKKYPQL-APEFVYGEYLKFNA ----HK---aNK ATVKK--E-FYSNIM-KFFESD-- 1048 WP_002312694 990 HHAHDAYLNGVVALALLKKYPQL-APEFVYGEYLKFNA ----HK---aNK ATVKK--E-FYSNIM-KFFESD-- 1049 WP_002314015 990 HHAHDAYLNGVVALALLKKYPQL-APEFVYGEYLKFNA ----HK---aNK ATVKK--E-FYSNIM-KFFESD-- 1049 WP_002320716 990 HHAHDAYLNGVVALALLKKYPQL-APEFVYGEYLKFNA ----HK---aNK ATVKK--E-FYSNIM-KFFESD-- 1049 WP_002330729 989 HHAHDAYLNGVVALALLKKYPQL-APEFVYGEYLKFNA ----HK---aNK ATVKK--E-FYSNIM-KFFESD-- 1048 WP_002335161 990 HHAHDAYLNGVVALALLKKYPQL-APEFVYGEYLKFNA ----HK---aNK ATVKK--E-FYSNIM-KFFESD-- 1049 WP_002345439 990 HHAHDAYLNGVVALALLKKYPQL-APEFVYGEYLKFNA ----HK---aNK ATVKK--E-FYSNIM-KFFESD-- 1049 WP_034867970 980 HHAHDAYLNGFIANVLLKRYPKL-APEFVYGKYVKYSL ----AR---eNK ATAKK--E-FYSNIL-KFLESD-- 1039 WP_047937432 990 HHAHDAYLNGVIALALLKKYPQL-APEFVYGEYLKFNA ----HK---aNK ATVKK--E-FYSNIM-KFFESD-- 1049 WP_010720994 980 HHAHDAYLNGFIANVLLKRYPKL-APEFVYGKYVKYSL ----AR---eNK ATAKK--E-FYSNIL-KFLESD-- 1039 WP_010737004 980 HHAHDAYLNGFIANVLLKRYPKL-APEFVYGKYVKYSL ----AR---eNK ATAKK--E-FYSNIL-KFLESD-- 1039 WP_034700478 980 HHAHDAYLNGFIANVLLKRYPKL-APEFVYGKYVKYSL ----AR---eNK ATAKK--E-FYSNIL-KFLESD-- 1039 WP_007209003 978 HHAHDAYLNAVVALSLLRVYPQL-KPEFVYGEYGKNS- ----IHDq--NK ATIKK---qFYSNIT-RYFASK-- 1037 WP_023519017 974 HHAHDAYLNGVVAMTLLKKYPKL-APEFVYGSYIKGDI ----NQ---iNK ATAKK--E-FYSNIM-KFFESE-- 1033 WP_010770040 986 HHGHDAYLNGVVANSLLRVYPQL-QPEFVYGDYPKFNA ----YKA---NK ATAKK--Q-LYTNIM-KFFAED-- 1045 WP_048604708 983 HHAHDAYLNGVVATALLKIYPQL-EPEFVYGEFHRFNA ----FKE---NK ATAKK--Q-FYSNLM-EFSKSD-- 1042 WP_010750235 983 HHAHDAYLNAVVALALLKKYPRL-APEFVYGSFAKFHL ----VK---eNK ATAKK--E-FYSNIL-KFFEKE-- 1042 AII16583 1021 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1090 WP_029073316 988 HHAHDAYIATILGTYIGHRFESL-DAKYIYGEYQKIFR ----NKNk--DK ---KDg---FILNSM-RNLYADK- 1052 WP_031589969 988 HHAHDAYIATILGTYIGHRFESL-DAKYIYGEYKRIFR ----QKNk--GK ---NDg---FILNSM-RNIYADK- 1052 KDA45870 973 HHAHDAYLNAVVANLIMAKYPEL-EPEFVYGKYRKTK- ----FKG1--GK ATAKN---tLYANVL-YFLKENEV 1034 WP_039099354 991 HHAFDAYLTAFVGLYLLKRYPKL-KPYFVYGEYQKAS- ----QQ----DK ---RN--F----NFL-NGLKKD-- 1043 AKP02966 1000 HHAQDAYLASFLGTYRLRRFPTD-EMLLMNGEYNKFYG -----KElysKK -SRKN-gF-IISPLV--------- 1062 WP_010991369 985 HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGDYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK-- 1044 WP_033838504 985 HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGDYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK-- 1044 EHN60060 988 HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGDYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK-- 1047 EFR89594 754 HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGDYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK-- 813 WP_038409211 985 HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGDYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-RFFAKE-- 1044 EFR95520 604 HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGDYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-RFFAKE-- 663 WP_003723650 985 HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK-- 1044 WP_003727705 985 HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK-- 1044 WP_003730785 985 HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK-- 1044 WP_003733029 985 HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFGW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK-- 1044 WP_003739838 985 HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK-- 1044 WP_014601172 985 HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFGQK-- 1044 WP_023548323 985 HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK-- 1044 WP_031665337 985 HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK-- 1044 WP_031669209 985 HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK-- 1044 WP_033920898 985 HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK-- 1044 AKI42028 988 HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFGQK-- 1047 AKI50529 988 HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK-- 1047 EFR83390 433 HHAHDAYLNGVVANTLLKVYPQL-EPEFVYGEYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAQK-- 492 WP_046323366 985 HHAHDAYLNCVVANTLLKVYPQL-EPEFVYGDYHQFDW ----FKA---NK ATAKK--Q-FYTNIM-LFFAKK-- 1044 AKE81011 998 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1067 CUO82355 981 HHAHDAYIVALIGGFMRDRYPNMhDSKAVYSEYMKMFR ----NKNd--QK -----g---FVINSM-NYPY-EV- 1042 WP_033162887 983 HHAHDAYIACIVGQFMHQNFEHL-DAKIIYGQYK---- -----KNy--KK ---NYg---FILNSM-NHLQSDI- 1042 AGZ01981 1015 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1084 AKA60242 982 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1051 AK540380 982 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1051 4UN5_B 986 HHAHDAYLNAVVGTALIKKYPKL-ESEFVYGDYKVYDV S---EQEi--GK ATAKY--F-FYSNIM-NFFKTEIT 1055 WP_010922251 1052

 GGFSK ESIL-PKR- 1114 WP_039695303 1059 YAD-GTVFERPIIE T-NAD-GE-IAWNKQIDFEKVRKVLS-YPQVNIVKKVETQT GGFSK ESIL-PKG- 1120 WP_045635197 1056 YAD-GTIVKRENIE Y-SKDLGE-IAWNKEKDFAIIKKVLS-LPQVNIVKKREVQT GGFSK ESIL-PKG- 1118 5AXW_A 772 YKYsHRVDKKPNRE VNNLN-GL---YDKDND--KLKKLINkSPEKLLMYHHDPQT --YQK KLIMeQYGd 852 WP_009880683 736 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 798 WP_010922251 1052 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1114 WP_011054416 1052 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1114 WP_011284745 1052 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1114 WP_011285506 1052 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1114 WP_011527619 1052 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1114 WP_012560673 1052 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1114 WP_014407541 1051 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1113 WP_020905136 1052 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1114 WP_023080005 1051 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1113 WP_023610282 1051 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1113 WP_030125963 1052 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1114 WP_030126706 1052 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1114 WP_031488318 1052 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1114 WP_032460140 1052 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1114 WP_032461047 1052 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1114 WP_032462016 1052 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1114 WP_032462936 1052 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1114 WP_032464890 1052 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1114 WP_033888930 877 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 939 WP_038431314 1052 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1114 WP_038432938 1051 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1113 WP_038434062 1052 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1114 BAQ51233 963 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1025 KGE60162 227 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 289 KGE60856 1 ------------IE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 52 WP_002989955 1052 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1114 WP_003030002 1042 -----------DIQ T-NED-GE-IAWNKEKHIKILRKVLS-YPQVNIVKKTEEQT GGFSK ESIL-PKG- 1093 WP_003065552 1059 YSN-GKVIVRPVVE Y-SKD-TEdIAWDKKSNERTICKVLS-YPQVNIVKKVETQT GGFSK ESIL-PKG- 1121 WP_001040076 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_001040078 1058 LAD-GSIVVRPVIE TGRYM-GK-TAWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG- 1120 WP_001040080 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_001040081 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_001040083 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_001040085 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_001040087 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_001040088 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_001040089 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_001040090 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_001040091 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_001040092 1050 LAD-ETVVVKDDIE VNNET-GE-IAWDKKKHFATVRKVLS-YPQVNIVKKTEVQT GGFSK ESIL-AHS- 1112 WP_001040094 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_001040095 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEVQT GGFSK ESIL-AHG- 1112 WP_001040096 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEVQT GGFSK ESIL-AHG- 1112 WP_001040097 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_001040098 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_001040099 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_001040100 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_001040104 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_001040105 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_001040106 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_001040107 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_001040108 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_001040109 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_001040110 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_015058523 1050 LAD-ETVVVKDDIE VNNET-GE-IAWDKKKHFATVRKVLS-YPQVNIVKKTEVQT GGFSK ESIL-AHS- 1112 WP_017643650 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_017647151 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_017648376 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_017649527 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_017771611 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_017771984 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG- 1112 CFQ25032 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG- 1112 CFV16040 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG- 1112 KLJ37842 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG- 1112 KLJ72361 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-  1112 KLL20707 1064 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-  1126 KLL42645 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG-  1112 WP_047207273 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-  1112 WP_047209694 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG-  1112 WP_050198062 1050 LAD-GTVVIKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-  1112 WP_050201642 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-  1112 WP_050204027 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQVNIVKKTEIQT GGFSK ESIL-AHG-  1112 WP_050881965 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-  1112 WP_050886065 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG-  1112 AHN30376 1050 LAD-ETVVVKDDIE VNNET-GE-IAWDKKKHFATVRKVLS-YPQVNIVKKTEVQT GGFSK ESIL-AHS- 1112 EA078426 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG- 1112 CCW42055 1050 LAD-GTVVVKDDIE VNNDT-GE-IVWDKKKHFATVRKVLS-YPQNNIVKKTEIQT GGFSK ESIL-AHG- 1112 WP_003041502 1051 FAD-GTVVERPDIE T-SED-GE-IAWNKQTDFKIVRKVLS-YPQVNIVKKTEVQT HGLDR PSPK-PKP- 1122 WP_037593752 1043 -----------DIQ T-NED-GE-IAWNKEKHIKILRKVLS-YPQVNIVKKTEEQT GGFSK ESIL-PKG- 1094 WP_049516684 1043 -----------DIQ T-NED-GE-IAWNKEKHIKILRKVLS-YPQVNIVKKTEEQT GGFSK ESIL-PKG- 1094 GAD46167 1042 -----------DIQ T-NED-GE-IAWNKEKHIKILRKVLS-YPQVNIVKKTEEQT GGFSK ESIL-PKG- 1093 WP_018363470 1063 YSN-GKVIVRPVVE Y-SKDtGE-IAWNKRTDFEKVRKVLS-YPQVNIVKKVETQT GGFSK ESIL-PKG- 1125 WP_003043819 1061 LAN-GEIRKRPLIE TNGET-GE-VVWNKEKDFATVRKVLA-MPQVNIVKKTEVQT GGFSK ESIL-SKR- 1123 WP_006269658 1042 -----------DIQ T-NED-GE-IAWNKEKHIKILRKVLS-YPQVNIVKKTEEQT GGFSK ESIL-PKG- 1093 WP_048800889 1052 FAD-GTVVERPDIE T-SED-GE-IAWNKQTDFKIVRKVLS-YPQVNIVKKVEKQT GRFSK ESIL-PKG- 1113 WP_012767106 1051 LAN-GEIRKRPLIE TNEET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GALTN ESIY-ARG- 1113 WP_014612333 1051 LAN-GEIRKRPLIE TNEET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GALTN ESIY-ARG- 1113 WP_015017095 1051 LAN-GEIRKRPLIE TNEET-GE-IVWNKGRDFATVRKVLS-MPQVNIVKKTEVQT GALTN ESIY-ARG- 1113 WP_015057649 1051 LAN-GEIRKRPLIE TNEET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GALTN ESIY-ARG- 1113 WP_048327215 1051 LAN-GEIRKRPLIE TNEET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GALTN ESIY-ARG- 1113 WP_049519324 1051 LAN-GEIRKRPLIE TNEET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GALTN ESIY-ARG- 1113 WP_012515931 1044 L------------H VNSD--GE-EIWNANKHLPIIKNVLS-IPQVNIVKKTEVQT GGFYK ESIL-SKG- 1094 WP_021320964 1044 L------------H VNSD--GE-EIWNANKHLPIIKNVLS-IPQVNIVKKTEVQT GGFYK ESIL-SKG- 1094 WP_037581760 1044 L------------H VNSD--GE-EIWNANKHLPIIKNVLS-IPQVNIVKKTEVQT GGFYK ESIL-SKG- 1094 WP_004232481 1062 YAD-GRVFERPDIE T-NAD-GE-VVWNKQRDFNIVRKVLS-YPQVNIVKKVEVQT GGFSK ESIL-PKG- 1123 WP_009854540 1057 YAD-GTVFERPIIE T-NAD-GE-IAWNKQIDFEKVRKVLS-YPQVNIVKKVETQT GGFSK ESIL-PKG- 1118 WP_012962174 1057 YSN-GKVVVRPVIE C-SKDtGE-IAWNKQTDFEKVRRVLS-YPQVNIVKKVETQT GGFSK ESIL-PKG- 1119 WP_039695303 1059 YAD-GTVFERPIIE T-NAD-GE-IAWNKQIDFEKVRKVLS-YPQVNIVKKVETQT GGFSK ESIL-PKG- 1120 WP_014334983 1062 YAD-GRVFERPDIE T-NAD-GE-VVWNKQKDFDIVRKVLS-YPQVNIVKKVEAQT GGFSK ESIL-SKG- 1123 WP_003099269 1052 LAD-DTIFTRPQIE VNTET-GE-IVWDKVKDMQTIRKVMS-YPQVNIVMKTEVQT GGFSK ESIW-PKG- 1114 AHY15608 1052 LAD-DTIFTRPQIE VNTET-GE-IVWDKVKDMQTIRKVMS-YPQVNIVMKTEVQT GGFSK ESIW-PKG- 1114 AHY17476 1052 LAD-DTIFTRPQIE VNTET-GE-IVWDKVKDMQTIRKVMS-YPQVNIVMKTEVQT GGFSK ESIW-PKG- 1114 ESR09100 -------------- ----------------------------------------- ----- --------- AGM98575 1052 LAD-DTIFTRPQIE VNTET-GE-IVWDKVKDMQTIRKVMS-YPQVNIVMKTEVQT GGFSK ESIW-PKG- 1114 ALF27331 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG- 1093 WP_018372492 1056 --K----------K --DQEtGE-IVWDKKEIENIVKKVIY-SSPVNIVKKREEQS GALFK QSNM-AVGy 1108 WP_045618028 1057 YAD-GTIVKRENIE Y-SKDtGE-IAWNKEKDFATIKKVLS-LPQVNIVKKTEEQT GGLFD NNIV-SKKk 1124 WP_045635197 1056 YAD-GTIVKRENIE Y-SKDtGE-IAWNKEKDFAIIKKVLS-LPQVNIVKKREVQT GGFSK ESIL-PKG- 1118 WP_002263549 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG- 1093 WP_002263887 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG- 1093 WP_002264920 1042 -----------DVR T-DKN-GE-IIWKKDEYISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG- 1093 WP_002269043 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG- 1093 WP_002269448 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG- 1093 WP_002271977 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG- 1093 WP_002272766 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG- 1093 WP_002273241 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG- 1093 WP_002275430 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG- 1093 WP_002276448 1042 -----------DVR T-DRN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG- 1093 WP_002277050 1047 LAD-DQIVERPMIE VNDET-GE-IAWDKTKHITTVKKVLS-YPQVNIVKKVEEQT GGLFD -----PKS- 1111 WP_002277364 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG- 1093 WP_002279025 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG- 1093 WP_002279859 1042 -----------DVR T-DKN-GE-IIWKKDEYISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG- 1093 WP_002280230 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG- 1093 WP_002281696 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG- 1093 WP_002282247 1047 LAD-DQIVERPMIE VNDET-GE-IAWDKTKHITTVKKVLS-YPQVNIVKKVEEQT GGLFD -----PKS- 1111 WP_002282906 1042 -----------DVR I-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG- 1093 WP_002283846 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG- 1093 WP_002287255 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG- 1093 WP_002288990 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG- 1093 WP_002289641 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG- 1093 WP_002290427 1042 -----------DVR T-DKN-GE-IIWKKDEYISNIKKVLS-YPQVNIVKKVEEQT GGFFK ESIL-PKG- 1093 WP_002295753 1042 -----------DVR T-DKN-GE-IIWKKDEYISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-  1093 WP_002296423 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-  1093 WP_002304487 1056 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-  1107 WP_002305844 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-  1093 WP_002307203 1042 -----------DVR T-DKN-GE-IIWKKDEYISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-  1093 WP_002310390 1042 -----------DVR T-DKN-GE-IIWKKDEYISNIKKVLS-YPQVNIVKKVEEQT GGFFK ESIL-PKG-  1093 WP_002352408 1042 -----------DVR T-DKN-GE-IIWKKDEYISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-  1093 WP_012997688 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-  1093 WP_014677909 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-  1093 WP_019312892 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-  1093 WP_019313659 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-  1093 WP_019314093 1042 -----------DVR T-DKN-GE-IIWKKDEYISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-  1093 WP_019315370 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-  1093 WP_019803776 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-  1093 WP_019805234 1042 -----------DVR T-DKN-GE-IIWKKDEYISNIKKVLS-YPQVNIVKKVEEQT GGFFK ESIL-PKG-  1093 WP_024783594 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-  1093 WP_024784288 1047 LAD-DQIVERPMIE VNDET-GE-IAWDKTKHITTVKKVLS-YPQVNIVKKVEEQT GGLFD -----PKS- 1111 WP_024784666 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-  1093 WP_024784894 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG-  1093 WP_024786433 1047 LAD-DQIVERPMIE VNDET-GE-IAWDKTKHITTVKKVLS-YPQVNIVKKVEEQT GGLFD -----PKS- 1111 WP_049473442 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG- 1093 WP_049474547 1042 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG- 1093 EMC03581 1035 -----------DVR T-DKN-GE-IIWKKDEHISNIKKVLS-YPQVNIVKKVEEQT GGFSK ESIL-PKG- 1086 WP_000428612 1059 YAD-GTIVKRENIE Y-SKDtGE-IAWNKEKDFATIKKVLS-LPQVNIVKKREVQT GGFSK ESIL-PKG-  1121 WP_000428613 1057 YAD-GTIVKRENIE Y-SKDtGE-IAWNKEKDFATIKKVLS-YPQVNIVKKREVQT GGFSK ESIL-PKG-  1119 WP_049523028 1052 YAD-GTIIQRGNVE Y-SKDtGE-IAWNKKRDFAIVRKVLS-YPQVNIVKKTEEQT GGFSK ESIL-PKG-  1114 WP_003107102 1021 LAD-GTVITRPQIE TNTET-GE-IVWDKVKDIKTIRKVLS-IPQINVVKKTEVQT GGFSK ESIL-SKR- 1083 WP_054279288 1053 LAN-GNIIKRSPIE VNEET-GE-IVWDKTKDFGTVRKVLS-APQVNIVKKTEIQT GGFSN ETIL-SKG- 1115 WP_049531101 1057 YAD-GTIVKRENIE Y-SKDtGE-IAWNKEIDFATIRKILS-LSQVNIVKKTEEQT GGLFD NNIV-SKKk 1124 WP_049538452 1057 YAD-GTIVKRENIE Y-SKDtGE-IAWNKEKDFATIKKILS-LPQVNIVKKTEEQT GGLFD NNIV-SKKk 1124 WP_049549711 1059 YAD-GTIVKRENIE Y-SKDtGE-IAWNKEKDFATIKKVLS-YPQVNIVKKTEEQT GGLFD NNIV-SKEk 1126 WP_007896501 1058 LAD-GTLMKRPVIE TNTET-GE-VVWDKVKDFKTIRKVLS-YPQVNIVKKTEIQS GAFSK ESVL-SKG- 1120 EFR44625 1010 LAD-GTLMKRPVIE TNTET-GE-VVWDKVKDFKTIRKVLS-YPQVNIVKKTEIQS GAFSK ESVL-SKG- 1072 WP_002897477 1056 YAD-GTIRKRENIE Y-SKDtGE-IAWDKEKDFATIKKVLS-YPQVNIVKKREVQT GGFSK ESIL-PKG- 1118 WP_002906454 1056 YAD-GTIKKRENIE Y-SNDtGE-IAWNKEKDFATIKKVLS-LPQVNIVKKTEEQT GGLFD NNIV-SKKk  1123 WP_009729476 1057 YAD-GTIVKRENIE Y-SKDtGE-IAWNKEKDFATIKKVLS-LPQVNIVKKREVQT GGFSK ESIL-PKG- 1119 CQR24647 1047 LAD-GRVVEKPVIE ANEET-GE-IAWDKTKHFANVKKVLS-YPQVSIVKKVEEQT GGFSK ESIL-PKG- 1109 WP_000066813 1061 YAD-GTIVKRENIE Y-SKDtGE-IAWNKEKDFATVKKVLS-LPQVNIVKKTEVQT GGFSK ESIL-PKG- 1123 WP_009754323 1057 YAD-GTIVKRENIE Y-SKDtGE-IAWNKEKDFVTIKKVLS-YPQVNIVKKREVQT GGFSK ESIL-PKG- 1119 WP_044674937 1049 YSKtGEVRIRPVIE VNKET-GE-IVWDKKSDFRTVRKVLS-YPQVNVVKKVEMQT GGFSK ESIL-QHG- 1112 WP_044676715 1051 YSKtGEVRIRPVIE VNKET-GE-IVWDKKSDFRTVRKVLS-YPQVNVVKKVEMQT GGFSK ESIL-QHG- 1114 WP_044680361 1051 YSKtGEVRIRPVIE VNKET-GE-IVWDKKSDFRTVRKVLS-YPQVNVVKKVEMQT GGFSK ESIL-QHG- 1114 WP_044681799 1049 YSKtGEVRIRPVIE VNKET-GE-IVWDKKSDFKTVRKVLS-YPQVNVVKKVEMQT GGFSK ESIL-QHG- 1112 WP_049533112 1051 FAD-GTVVERPDIE T-SED-GE-IAWNKQTDFKIVRKVLS-YPQVNIVKKTEVQT HGLDR PSPK-PKP- 1122 WP_029090905 1008 -KQ----------Q --NSTtGE-VKWNPEVDIAKLKRILN-FKQCNIVRKVEEQS GALFK ETIY-PVEe 1061 WP_006506696 1039 --D----------- ------GK-LIWNP-DLINEIKKCFY-YKDCYCTTKLDQKS GQLFN -TVL-SNDa  1084 AIT42264 1052 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1114 WP_034440723 1042 ------------LA --NPD-GE-IAWEKDKDLNTIRKVLS-SKQINIIKKAEEGK GRLFK ETIN-SRPs 1092 AKQ21048 1052 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1114 WP_004636532 1043 -------------- VNEET-GE-ILWDTERHLSTIKRVLS-WKQMNIVKKVEKQK GQLWK ETIY-PKG- 1092 WP_002364836 1048 --E----------P RFTKD-GE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG- 1098 WP_016631044 999 --E----------P RFTKD-GE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG- 1049 EMS75795 783 --E----------Y SYDEN-GE-IFWDKARHIPQIKKVIS-SHQVNIVKKVEVQT GGFYK ETVN-PKG- 834 WP_002373311 1048 --E----------P RFTKD-SE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG- 1098 WP_002378009 1048 --E----------P RFTKD-GE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG- 1098 WP_002407324 1048 --E----------P RFTKD-GE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG- 1098 WP_002413717 1048 --E----------P RFTKD-GE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG- 1098 WP_010775580 1050 --E----------P RFTKD-GE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG- 1100 WP_010818269 1048 --E----------P RFTKD-GE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG- 1098 WP_010824395 1048 --E----------P RFTKD-GE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG- 1098 WP_016622645 1048 --E----------P RFTKD-GE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG- 1098 WP_033624816 1048 --E----------P RFTKD-GE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG- 1098 WP_033625576 1048 --E----------P RFTKD-GE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG- 1098 WP_033789179 1048 --E----------P RFTKD-GE-ILWSN-SYLKTIKKELN-YHQMNIVKKVEVQK GGFSK ESIK-PKG- 1098 WP_002310644 1049 --T----------P VCDEN-GE-IFWDKSKSIAQVKKVIN-HHHMNIVKKTEIQK GGFSK ETVE-PKK- 1100 WP_002312694 1050 --T----------P VCDEN-GE-IFWDKSKSIAQVKKVIN-HHHMNIVKKTEIQK GGFSK ETVE-PKK- 1101 WP_002314015 1050 --T----------P VCDEN-GE-IFWDKSKSIAQVKKVIN-HHHMNIVKKTEIQK GGFSK ETVE-PKK- 1101 WP_002320716 1050 --T----------P VCDEN-GE-IFWDKSKSIAQVKKVIN-HHHMNIVKKTEIQK GGFSK ETVE-PKK- 1101 WP_002330729 1049 --T----------P VCDEN-GE-IFWDKSKSIAQVKKVIN-HHHMNIVKKTEIQK GGFSE ETVE-PKK- 1100 WP_002335161 1050 --T----------P VCDEN-GE-IFWDKSKSIAQVKKVIN-HHHMNIVKKTEIQK GGFSK ETVE-PKK- 1101 WP_002345439 1050 --T----------P VCDEN-GE-IFWDKSKSIAQVKKVIN-HHHMNIVKKTEIQK GGFSK ETVE-PKK- 1101 WP_034867970 1040 --E----------P FCDEN-GE-IYWEKSHHLPRIKKVLS-SHQVNVVKKVEQQK GGFYK ETVN-SKE- 1091 WP_047937432 1050 --T----------P VCDEN-GE-IFWDKSKSIAQVKKVIN-HHHMNIVKKTEIQK GGFSK ETVE-PKK- 1101 WP_010720994 1040 --E----------P FCDEN-GE-IYWEKSHHLPRIKKVLS-SHQVNVVKKVEQQK GGFYK ETVN-SKE- 1091 WP_010737004 1040 --E----------P FCDEN-GE-IYWEKSHHLPRIKKVLS-SHQVNVVKKVEQQK GGFYK ETVN-SKE- 1091 WP_034700478 1040 --E----------P FCDEN-GE-IYWEKSHHLPRIKKVLS-SHQVNVVKKVEQQK GGFYK ETVN-SKE- 1091 WP_007209003 1038 --D----------- IINDD-GE-ILWNKQETIAQVIKTLG-MHQVNVVKKVEIQK GGFSK ESIQ-PKG-  1089 WP_023519017 1034 --E----------I ICDEQ-GE-VIWNKKRDLSTIKKTIG-AHQVNIVKKVEKQK GGFYK ETIN-SKA- 1085 WP_010770040 1046 --A----------V IIDEN-GE-ILWDK-KNIATVKKVMS-YPQMNIVKKPEIQT GSFSK ETIK-PKG- 1096 WP_048604708 1043 --K----------V IIDEN-GE-ILWNQ-KKIVTVKKVMN-YRQMNIVKKVEIQK GGFSK ESIL-PKG- 1093 WP_010750235 1043 --E----------Q FCDEN-GE-IFWDKRKHIQQIKKVIS-SHQVNIVKKVEVQT GSFYK ETVN-TKE- 1094 AIII6583 1091 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1153 WP_029073316 1053 --D----------- ----T-GE-VVWDP-EWISRIKKCFY-YKDCFVTKKLEENN GSFFN -TVR-PNDe 1099 WP_031589969 1053 --D----------- ----T-GE-IVWDP-NYIDRIKKCFY-YKDCFVTKKLEENN GTFFN -TVL-PNDt 1099 KDA45870 1035 YPF----------- -----------WDKARDLPTIKRYLY-RAQVNKVRKAERQT GGFSD EMLV-PKS- 1078 WP_039099354 1044 -------------E LVDEN-TEaVIWNKESGLAYLNKIYQ-FKKILVTREVHENS GALFN QTLYaAKDd 1097 AKP02966 1063 --N-------GTTQ --DRNtGE-IIWNVG-FRDKILKIFN-YHQCNVTRKTEIKT GQFYD QTIYsPKNp  1118 WP_010991369 1045 --D----------R IIDEN-GE-ILWDK-KYLDTVKKVMS-YRQMNIVKKTEIQK GEFSK ATIK-PKG- 1095 WP_033838504 1045 --D----------R IIDEN-GE-ILWDK-KYLDTVKKVMS-YRQMNIVKKTEIQK GEFSK ATIK-PKG- 1095 EHN60060 1048 --D----------R IIDEN-GE-ILWDK-KYLDTVKKVMS-YRQMNIVKKTEIQK GEFSK ATIK-PKG- 1098 EFR89594 814 --D----------R IIDEN-GE-ILWDK-KYLDTVKKVMS-YRQMNIVKKTEIQK GEFSK ATIK-PKG- 864 WP_038409211 1045 --N----------Q IIDKN-GE-ILWDN-RYLDTIKKVLS-YRQMNIVKKTEIQK GEFSN ATVN-PKG- 1095 EFR95520 664 --N----------Q IIDKN-GE-ILWDN-RYLDTIKKVLS-YRQMNIVKKTEIQK GEFSN ATVN-PKG- 714 WP_003723650 1045 --E----------R IIDEN-GE-ILWDK-KYLETIKKVLD-YRQMNIVKKTEIQK GEFSK ATIK-PKG- 1095 WP_003727705 1045 --E----------R IIDEN-GE-ILWDK-KYLETIKKVLD-YRQINIVKKTEIQK GEFSK ATIK-PKG- 1095 WP_003730785 1045 --E----------R IIDEN-GE-ILWDK-KYLETIKKVLD-YRQINIVKKTEIQK GEFSK ATIK-PKG- 1095 WP_003733029 1045 --D----------R IIDEN-GE-ILWDK-RYLETVKKVLG-YRQMNIVKKTEIQK GEFSN VTPN-PKG- 1095 WP_003739838 1045 --E----------R IIDEN-GE-ILWDK-KYLETIKKVLD-YRQMNIVKKTEIQK GEFSK ATIK-PKG- 1095 WP_014601172 1045 --E----------R IIDEN-GE-ILWDK-KYLETIKKVLD-YRQMNIVKKTEIQK GEFSK ATIK-PKG- 1095 WP_023548323 1045 --E----------R IIDEN-GE-ILWDK-KYLETIKKVLN-YRQMNIVKKTEIQK GEFSN QNPK-PRG- 1095 WP_031665337 1045 --E----------R IIDEN-GE-ILWDK-KYLETIKKVLD-YRQMNIVKKTEIQK GEFSK ATIK-PKG- 1095 WP_031669209 1045 --D----------R IIDEN-GE-ILWDK-RYLETVKKVLG-YRQMNIVKKTEIQK GEFSN VTPN-PKG- 1095 WP_033920898 1045 --E----------R IIDEN-GE-ILWDK-KYLETIKKVLN-YRQMNIVKKTEIQK GEFSN QNPK-PRG- 1095 AKI42028 1048 --E----------R IIDEN-GE-ILWDK-KYLETIKKVLD-YRQMNIVKKTEIQK GEFSK ATIK-PKG- 1098 AKI50529 1048 --E----------R IIDEN-GE-ILWDK-KYLETIKKVLN-YRQMNIVKKTEIQK GEFSN QNPK-PRG- 1098 EFR83390 493 --E----------R IIDEN-GE-ILWDK-KYLETIKKVLD-YRQMNIVKKTEIQK GEFSK ATIK-PKG- 543 WP_046323366 1045 --D----------R IIDEN-GE-ILWDK-KYLDTIKKVLN-YRQMNIVKKTEIQK GEFSN ATAN-PKG- 1095 AKE81011 1068 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 130 CUO82355 1043 --D----------- ------GK-LIWNP-DLINEIKKCFY-YKDCYCTTKLDQKS GQMFN -TVL-PNDa 1088 WP_033162887 1043 --D----------- ----T-GE-VMWDP-AKIGKIKSCFY-YKDVYVTKKLEQNS GTLFN -TVL-PNDa 1089 AGZ01981 1085 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1147 AKA60242 1052 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1114 AKS40380 1052 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1114 4UN5_B 1056 LAN-GEIRKRPLIE TNGET-GE-IVWDKGRDFATVRKVLS-MPQVNIVKKTEVQT GGFSK ESIL-PKR- 1118 WP_010922251 1115 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1176 WP_039695303 1121 --DSD KLIPRKTkKV-YW-DTKKYGGFDSPTVAYSV-FVVAD--VE--KGKAKKLKTVKELVGISIME RSFFEE 1185 WP_045635197 1119 --NSD KLIPRKT-KDILL-DTTKYGGFDSPVIAYSI-LLIAD--IE--KGKAKKLKTVKTLVGITIME KAAFEE 1183 5AXW_A 853 --EKN -LYKYYEeTGNYL---TKYSKKDNGPVIKKI------------KYYGNKLNAHLDITDDYPNS -VKLSL 912 WP_009880683 799 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELVGITIME RSSFEK 860 WP_010922251 1115 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1176 WP_011054416 1115 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1176 WP_011284745 1115 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1176 WP_011285506 1115 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1176 WP_011527619 1115 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1176 WP_012560673 1115 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELVGITIME RSSFEK 1176 WP_014407541 1114 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1175 WP_020905136 1115 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGLTIME RSSFEK 1176 WP_023080005 1114 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1175 WP_023610282 1114 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1175 WP_030125963 1115 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1176 WP_030126706 1115 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1176 WP_031488318 1115 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1176 WP_032460140 1115 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELVGITIME RSSFEK 1176 WP_032461047 1115 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELVGITIME RSSFEK 1176 WP_032462016 1115 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1176 WP_032462936 1115 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1176 WP_032464890 1115 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1176 WP_033888930 940 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1001 WP_038431314 1115 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1176 WP_038432938 1114 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1175 WP_038434062 1115 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1176 BAQ51233 1026 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1087 KGE60162 290 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 351 KGE60856 53 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 114 WP_002989955 1115 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1176 WP_003030002 1094 --ESD KLIPRKT-KNSYW-NPKKYGGFDSPVVAYSI-LVFAD--VE--KGKSKKLRKVQDMVGITIME KKRFEK 1158 WP_003065552 1122 --DSD KLIPRKTkKA-YW-DTKKYGGFDSPTVAYSV-FVVAD--VE--KGKAKKLKTVKELVGISIME RSFFEE 1186 WP_001040076 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_001040078 1121 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSKFEK 1185 WP_001040080 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_001040081 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_001040083 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_001040085 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_001040087 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_001040088 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_001040089 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_001040090 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_001040091 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_001040092 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVLAD--IK--KGKAQKLKTVKELIGITIME RERFEK 1177 WP_001040094 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_001040095 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_001040096 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_001040097 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_001040098 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_001040099 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPKVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_001040100 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_001040104 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_001040105 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_001040106 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RFRFEK 1177 WP_001040107 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RFRFEK 1177 WP_001040108 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RFRFEK 1177 WP_001040109 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RFRFEK 1177 WP_001040110 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RFRFEK 1177 WP_015058523 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVLAD--IK--KGKAQKLKTVKELIGITIME RERFEK 1177 WP_017643650 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_017647151 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_017648376 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_017649527 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_017771611 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RFRFEK 1177 WP_017771984 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVAAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 CFQ25032 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 CFV16040 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 KLJ37842 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 KLJ72361 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 KLL20707 1127 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1191 KLL42645 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RFRFEK 1177 WP_047207273 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_047209694 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_050198062 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_050201642 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_050204027 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RFRFEK 1177 WP_050881965 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_050886065 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 AHN30376 1113 --NSD KLIPRKT-KDIYL-DPKKYGGEDSPIVAYSV-LVLAD--IK--KGKAQKLKTVKELIGITIME RERFEK 1177 EA078426 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 CCW42055 1113 --NSD KLIPRKT-KDIYL-DPKKYGGFDSPIVAYSV-LVVAD--IK--KGKAQKLKTVTELLGITIME RSRFEK 1177 WP_003041502 1123 --DSS ENLVGVK-RNL---DPKKYGGYAGISNSYAV-LVKAI--IE--KGVKKKETMVLEFQGISILD RITFEK 1185 WP_037593752 1095 --ESD KLIPRKT-KNSYW-NPKKYGGFDSPVVAYSI-LVFAD--VE--KGKSKKLRKVQDMVGITIME KKRFEK 1159 WP_049516684 1095 --ESD KLIPRKT-KNSYW-NPKKYGGFDSPVVAYSI-LVFAD--VE--KGKSKKLRKVQDMVGITIME KKRFEK 1159 GAD46167 1094 --ESD KLIPRKT-KNSYW-NPKKYGGFDSPVVAYSI-LVFAD--VE--KGKSKKLRKVQDMVGITIME KKRFEK 1158 WP_018363470 1126 --DSD KLIPRKTkKV-LW-EPKKYGGEDSPTVAYSV-LVVAD--VE--KGKTKKLKTVKELVGISIME RSFFEK 1190 WP_003043819 1124 --ESA KLIP----RKKGW-DTRKYGGFGSPTVAYSI-LVVAK--VE--KGKAKKLKSVKVLVGITIME KGSYEK 1185 WP_006269658 1094 --ESD KLIPRKT-KNSYW-DPKKYGGFDSPVVAYSI-LVFAD--VE--KGKSKKLRKVQDMVGITIME KKRFEK 1158 WP_048800889 1114 --DSD KLIARKTkEN-YW-DTKKYGGEDSPTVAYSV-LVVAD--IK--KGKAKKLKTVKELVGISIME RPFFEK 1178 WP_012767106 1114 --SFD KLIS----RKHRF-ESSKYGGEGSPTVTYSV-LVVAKskVQ--DGKVKKIKTGKELIGMTLLD KLVFEK 1177 WP_014612333 1114 --SFD KLIS----RKHRF-ESSKYGGEGSPTVTYSV-LVVAKskVQ--DGKVKKIKTGKELIGITLLD KLVFEK 1177 WP_015017095 1114 --SFD KLIS----RKHRF-ESSKYGGEGSPTVTYSV-LVVAKskVQ--DGKVKKIKTGKELIGITLLD KLVFEK 1177 WP_015057649 1114 --SFD KLIS----RKHRF-ESSKYGGEGSPTVTYSV-LVVAKskVQ--DGKVKKIKTGKELIGITLLD KLVFEK 1177 WP_048327215 1114 --SFD KLIS----RKHRF-ESSKYGGEGSPTVTYSV-LVVAKckVQ--DGKVKKIKTGKELIGITLLD KLVFEK 1177 WP_049519324 1114 --SFD KLIS----RKHRF-ESSKYGGEGSPTVTYSV-LVVAKskVQ--DGKVKKIKTGKELIGITLLD KLVFEK 1177 WP_012515931 1095 --NSD KLIP----RKNNW-DTRKYGGFDSPTVAYSV-LVIAK--ME--KGKAKVLKPVKEMVGITIME RTAFEE 1156 WP_021320964 1095 --NSD KLIP----RKNNW-DTRKYGGFDSPTVAYSV-LVIAK--ME--KGKAKVLKPVKEMVGITIME RIAFEE 1156 WP_037581760 1095 --NSD KLIP----RKNNW-DTRKYGGFDSPTVAYSV-LVIAK--ME--KGKAKVLKPVKEMVGITIME RIAFEE 1156 WP_004232481 1124 --DSD KLIPRKTkKL-QW-ETQKYGGEDSPTVAYSV-LVVAD--VE--KGKTRKLKTVKELVGISIME RSSFEE 1188 WP_009854540 1119 --DSD KLIPRKTkKV-YW-DTKKYGGEDSPTVAYSV-FVVAD--VE--KGKAKKLKTVKELVGISIME RSFFEE 1183 WP_012962174 1120 --NSD KLIPRKTkKF-RW-DTPKYGGEDSPNIAYSV-FVIAD--VE--KGKAKKLKTVKELVGISIME RSSFEE 1184 WP_039695303 1121 --DSD KLIPRKTkKV-YW-DTKKYGGFDSPTVAYSV-FVVAD--VE--KGKAKKLKTVKELVGISIME RSFFEE 1185 WP_014334983 1124 --DSD KLIPRKTkKV-YW-NTKKYGGFDSPTVAYSV-LVVAD--IE--KGKAKKLKTVKELVGISIME RSFFEE 1188 WP_003099269 1115 --DSD KLIA----RKKSW-DPKKYGGFDSPIIAYSV-LVVAK--IA--KGKTQKLKTIKELVGIKIME QDEFEK 1176 AHY15608 1115 --DSD KLIA----RKKSW-DPKKYGGFDSPIIAYSV-LVVAK--IA--KGKTQKLKTIKELVGIKIME QDEFEK 1176 AHY17476 1115 --DSD KLIA----RKKSW-DPKKYGGFDSPIIAYSV-LVVAK--IA--KGKTQKLKTIKELVGIKIME QDEFEK 1176 ESR09100 1 ----- -------------------------------------------------------------ME QDEFEK 8 AGM98575 1115 --DSD KLIA----RKKSW-DPKKYGGFDSPIIAYSV-LVVAK--IA--KGKTQKLKTIKELVGIKIME QDEFEK 1176 ALF27331 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAN--IE--KGKSKKLKLVKDLVGITIME RTIFEK 1158 WP_018372492 1109 ---NN KLIP----RKKDW-SVDKYGGFIEPAESYSLaIFYTD--IN-----GKKPKKKSTIIAISRME KKDYEK 1167 WP_045618028 1125 vvDAS KLTPIKS-G---L-SPEKYGGYARPTIAYSV-LVIAD--IE--KGKAKKLKRIKEMVGITVQD KKKFEA 1188 WP_045635197 1119 --NSD KLIPRKT-KDILL-DTTKYGGFDSPVIAYSI-LLIAD--IE--KGKAKKLKTVKTLVGITIME KAAFEE 1183 WP_002263549 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002263887 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002264920 1094 --DSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002269043 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002269448 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002271977 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002272766 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002273241 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002275430 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002276448 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002277050 1112 --PLE KLVPLKK----AL-NPEKYGGYQKPTTAYPI-LLIVD---------------TKQLIPISVMD KKRFEQ 1166 WP_002277364 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002279025 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002279859 1094 --DSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002280230 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002281696 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002282247 1112 --PLE KLVPLKK----AL-NPEKYGGYQKPTTAYPI-LLIVD---------------TKQLIPISVMD KKRFEQ 1166 WP_002282906 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002283846 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002287255 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002288990 1094 --NSY KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002289641 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002290427 1094 --DSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002295753 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002296423 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002304487 1108 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1172 WP_002305844 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002307203 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002310390 1094 --DSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_002352408 1094 --DSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_012997688 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_014677909 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_019312892 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_019313659 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_019314093 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_019315370 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_019803776 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_019805234 1094 --DSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_024783594 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KSKSKKLKTVKALVGVTIME KMTFER 1158 WP_024784288 1112 --PLE KLVPLKK----AL-NPEKYGGYQKPTTAYPI-LLIVD---------------TKQLIPISVMD KKRFEQ 1166 WP_024784666 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_024784894 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_024786433 1112 --PLE KLVPLKK----AL-NPEKYGGYQKPTTAYPI-LLIVD---------------TKQLIPISVMD KKRFEQ 1166 WP_049473442 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 WP_049474547 1094 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1158 EMC03581 1087 --NSD KLIPRKT-KKFYW-DTKKYGGFDSPIVAYSI-LVIAD--IE--KGKSKKLKTVKALVGVTIME KMTFER 1151 WP_000428612 1122 --NSD KLIPRKT-KDILW-DTTKYGGFDSPVIAYSI-LLIAD--IE--KGKAKRLKTVKTLVGITIME KATFEK 1186 WP_000428613 1120 --NSD KLIPRKT-KDILW-ETTKYGGFDSPVIAYSI-LLIAD--IE--KGKAKKLKTVKTLVGITIME KAAFEE 1184 WP_049523028 1115 --NSD KLIPRKT-KNVQL-DTTKYGGFDSPVIAYSI-LLVAD--VE--KGKSKKLKTVKSLIGITIME KVKFEA 1179 WP_003107102 1084 --DSD KLIP----RKNNW-DPKKYGGFGSPIIAYSV-LVVAK--VT--KGKSQKTKSVKELVGITIME QNEFEK 1145 WP_054279288 1116 --KSS KLIP----RKNKWrDTTKYGGFNTPTVAYSV-LVVAK--VE--KGKAKKLKPVKELVGITIME RTKFEA 1178 WP_049531101 1125 vvDAS KLIPIKS-G---L-SPEKYGGYARPTIAYSV-LVIAD--IE--KGKAKKLKRIKEMVGITIQD KKKFEA 1188 WP_049538452 1125 vvDAS KLIPIKS-G---L-SPEKYGGYARPTIAYSV-LVIAD--IE--KGKTKKLKRIKEMIGITVQD KKIFES 1188 WP_049549711 1127 vvDAS KLIPIKS-G---L-SPEKYGGYARPTIAYSV-LVIAD--IE--KGKTKKLKRIKEMVGITIQD KKKFEA 1190 WP_007896501 1121 --NSD KLIE----RKKGW-DPKKYGGFDSPNTAYSI-FVVAK--VA--KRKAQKLKTVKEIVGITIME QAEYEK 1182 EFR44625 1073 --NSD KLIE----RKKGW-DPKKYGGFDSPNTAYSI-FVVAK--VA--KRKAQKLKTVKEIVGITIME QAEYEK 1134 WP_002897477 1119 --NSD KLIPRKT-KDILW-DTTKYGGFDSPVIAYSI-LLIAD--IE--KGKAKKLKTVKTLVGITIME KAAFEE 1183 WP_002906454 1124 vvDAS KLIPIKS-S---L-SPEKYGGYARPTIAYSV-LVIAD--IEkgKGKAKKLKRIKEIVGITIQD KKKFES 1189 WP_009729476 1120 --NSD KLIPRKT-KDILW-DTTKYGGFDSPVIAYSI-LLIAD--IE--KGKAKKLKTVKTLVGITIME KDAFEK 1184 CQR24647 1110 --GSD KLIARKT-KNNYL-STQKYGGFDSPTVAYSI-MFVAD--IE--KGKSKRLKTVKEMIGITIME RSRFES 1174 WP_000066813 1124 --NSD KLIPRKT-KEILW-DTTKYGGFDSPVIAYSI-LLIAD--IE--KGKAKKLKTVKTLVGITIME KATFEK 1188 WP_009754323 1120 --NSD KLIPRKT-KDILW-DTTKYGGFDSPVIAYSI-LLIAD--IE--KGKAKKLKTVKTLVGITIME KAAFEK 1184 WP_044674937 1113 --DSD KLIPRKT-EKFYL-DTKKYGGFDSPTIAYSV-LLIAD--IE--KGKAKKLKRVKELIGITIME RMAFEK 1177 WP_044676715 1115 --DSD KLIPRKT-EKFYL-DTKKYGGFDSPTIAYSV-LLIAD--IE--KGKAKKLKRVKELIGITIME RMAFEK 1179 WP_044680361 1115 --DSD KLIPRKT-EKFYL-DTKKYGGFDSPTIAYSV-LLIAD--IE--KGKAKKLKRVKELIGITIME RMAFEK 1179 WP_044681799 1113 --DSD KLIPRKT-EKFYL-DTKKYGGFDSPTIAYSV-LLIAD--IE--KGKAKKLKRVKELIGITIME RMAFEK 1177 WP_049533112 1123 --DSS ENLVGVK-RNL---DPKKYGGYAGISNSYAV-LVKAI--IE--KGVKKKETMVLEFQGISILD RITFEK 1185 WP_029090905 1062 --SSS KTIP----LKKHL-DTAIYGGYTAVNYASYA---LIQ--FK----KGRKLK--REIIGIPLAV QTRIDN 1117 WP_006506696 1085 haDKG AVVP---vNKNRS-DVHKYGGFSG--LQYTI----VA--IEggKKKGKKTELVKKISGVPLHL KAASIN 1149 AIT42264 1115 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1176 WP_034440723 1093 k-KTE KRIP----IKNNL-DPNIYGGYIEEKMAYYI----AInyLE--NGKTKK-----AIVGISIKD KKDFEG 1149 AKQ21048 1115 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1176 WP_004636532 1093 --DSS KLIP----VKEGM-DPQKYGGLSQVSEAFAV-VIT----HE--KGKKKQLK--SDLISIPIVD QKAYEQ 1150 WP_002364836 1099 --PSN KLIP----VKNGL-DPQKYGGFDSPIVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTRFEQ 1156 WP_016631044 1050 --PSN KLIP----VKNGL-DPQKYGGFDSPVVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTRFEQ 1107 EMS75795 835 --KPD KLIQ----RKAGW-DVSKYGGFGSPVVAYAV-AFI----YE--KGKAR--KKAKAIEGITIMK QSLFEQ 892 WP_002373311 1099 --PSN KLIP----VKNGL-DPQKYGGFDSPVVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTRFEQ 1156 WP_002378009 1099 --PSN KLIP----VKNGL-DPQKYGGFDSPIVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTRFEQ 1156 WP_002407324 1099 --PSN KLIP----VKNGL-DPQKYGGFDSPIVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTRFEQ 1156 WP_002413717 1099 --PSN KLIP----VKNGL-DPQKYGGFDSPVVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTRFEQ 1156 WP_010775580 1101 --PSN KLIP----VKNGL-DPQKYGGFDSPVVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTRFEQ 1158 WP_010818269 1099 --PSN KLIP----VKNGL-DPQKYGGFDSPIVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTRFEQ 1156 WP_010824395 1099 --PSN KLIP----VKNGL-DPQKYGGFDSPVVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTRFEQ 1156 WP_016622645 1099 --PSN KLIP----VKNGL-DPQKYGGFDSPIVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTRFEQ 1156 WP_033624816 1099 --PSN KLIP----VKNGL-DPQKYGGFDSPVVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTRFEQ 1156 WP_033625576 1099 --PSN KLIP----VKNGL-DPQKYGGFDSPVVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTKFEQ 1156 WP_033789179 1099 --PSN KLIP----VKNGL-DPQKYGGFDSPVVAYTV-LF--T--HE--KGK-KPL-IKQEILGITIME KTRFEQ 1156 WP_002310644 1101 --DSS KLLP----RKNNW-DPAKYGGLGSPNVAYTV-AFT----YE--KGKAR--KRTNALEGITIME REAFEQ 1158 WP_002312694 1102 --DSS KLLP----RKNNW-DPAKYGGLGSPNVAYTV-AFT----YE--KGKAR--KRTNALEGITIME REAFEQ 1159 WP_002314015 1102 --DSS KLLP----RKNNW-DPAKYGGLGSPNVAYTV-AFT----YE--KGKAR--KRTNALEGITIME REAFEQ 1159 WP_002320716 1102 --DSS KLLP----RKNNW-DPAKYGGLGSPNVAYTV-AFT----YE--KGKAR--KRTNALEGITIME REAFEQ 1159 WP_002330729 1101 --DSS KLLP----RKNNW-DPAKYGGLGSPNVAYTV-AFT----YE--KGKAR--KRTNALEGITIME REAFEQ 1158 WP_002335161 1102 --DSS KLLP----RKNNW-DPAKYGGLGSPNVAYTV-AFT----YE--KGKAR--KRTNALEGITIME REAFEQ 1159 WP_002345439 1102 --DSS KLLP----RKNNW-DPTKYGGLGSPNVAYTV-AFT----YE--KGKAR--KRTNALEGITIME REAFEQ 1159 WP_034867970 1092 --KPD KLIE----RKNNW-DVTKYGGFGSPVIAYAI-AFV----YA--KGKTQ--KKTRAIEGITIME QAAFEK 1149 WP_047937432 1102 --DSS KLLP----RKNNW-DPAKYGGLGSPNVAYTV-AFT----YE--KGKAR--KRTNALEGITIME REAFEQ 1159 WP_010720994 1092 --KPD KLIE----RKNNW-DVTKYGGFGSPVIAYAI-AFV----YA--KGKTQ--KKTKAIEGITIME QAAFEK 1149 WP_010737004 1092 --KPD KLIE----RKNNW-DVTKYGGFGSPVIAYAI-AFV----YA--KGKTQ--KKTRAIEGITIME QAAFEK 1149 WP_034700478 1092 --KPD KLIE----RKNNW-DVTKYGGFGSPVIAYAI-AFV----YA--KGKTQ--KKTRAIEGITIME QAAFEK 1149 WP_007209003 1090 --ESQ KLIR----RKQQW-NTKKYGGFDSPVVAYAI---LLS--FD--KGK-RKARSFK-IVGITIQD RESFEG 1147 WP_023519017 1086 --NPE KLIP----RKASL-DPLKYGGYGSPLVAYTV-IFI----FE--KGKQK--KVTKGIEGITVME QLRFEQ 1143 WP_010770040 1097 --DSD KLIS----RKTNW-SPKLYGGFDSPQVAYSV-II--T--YE--KGK-KKVRA-KAIVGITIME QSLFKK 1154 WP_048604708 1094 --DSD KLIS----RKKEW-DTTKYGGFDSPNVAYSV-VI--R--YE--KGK-TRKLV-KTIVGITIME RAAFEK 1151 WP_010750235 1095 --KPD KLIK----RKNNW-DVTKYGGFGSPVVAYAV-VFT----YE--KGKNH--KKAKAIEGITIME QALFEK 1152 AII16583 1154 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1215 WP_029073316 1100 hsEKG AKVP---vNKLRS-NVHKYGGFEG--LKYSI----VA--IKgkKKKGKKIIDVNKLVGIPLMY KNVDDE 1164 WP_031589969 1100 nsDKD ATVP---vNKYRS-NVNKYGGFSG--VNSFI----VA--IKgkKKKGKKVIEVNKLTGIPLMY KNADEE 1164 KDA45870 1079 --DSG KLLP----RKEGL-DPVKYGGYAKAVESYAV-LITAD-eVK--KGKTKKVKT---LVNIPIID SKKYEA 1138 WP_039099354 1098 k-ASG QLIPAKQdRPTAL-----YGGYSGKTVAYMC---IVR--IKnkKGDLYKVCGVETSWLAQLKQ KKAFLK 1170 AKP02966 1119 k---- KLIA----QKKDM-DPNIYGGFSGDNKSSIT---IVK--ID-----NNKIKPVA--IPIRLIN ----DK 1172 WP_010991369 1096 --NSS KLIP----RKTNW-DPMKYGGLDSPNMAYAV-VI--E--YA--KGK-NKLVFEKKIIRVTIME RKAFEK 1154 WP_033838504 1096 --NSS KLIS----RKTNW-DPMKYGGLDSPNMAYAV-VI--E--YA--KGK-NKLVFEKKIIRVTIME RKAFEK 1154 EHN60060 1099 --NSS KLIS----RKTNW-DPMKYGGLDSPNMAYAV-VI--E--YA--KGK-NKLVFEKKIIRVTIME RKAFEK 1157 EFR89594 865 --NSS KLIP----RKTNW-DPMKYGGLDSPNMAYAV-VI--E--YA--KGK-NKLVFEKKIIRVTIME RKAFEK 923 WP_038409211 1096 --NSS KLIS----RKADW-NPIKYGGFDGSNMAYSI-VI--E--YE--KRK-KKTVIKKELIQINIME RVAFEK 1154 EFR95520 715 --NSS KLIS----RKADW-NPIKYGGFDGSNMAYSI-VI--E--YE--KRK-KKTVIKKELIQINIME RVAFEK 773 WP_003723650 1096 --NSS KLIP----RKENW-DPMKYGGLDSPNMAYAV-II--E--HA--KGK-KKIVIEKKLIQINIME RKMFEK 1154 WP_003727705 1096 --NSS KLIP----RKENW-DPMKYGGLDSPNMAYAV-II--E--HA--KGK-KKIVIEKKLIQINIME RKMFEK 1154 WP_003730785 1096 --NSS KLIP----RKENW-DPVKYGGLDSPNMAYAV-II--E--HA--KGK-KKIVIEKKLIQINIME RKMFEK 1154 WP_003733029 1096 --KSN KLIP----RKKDW-DPIKYGGFDGSKMAYAI-II--E--YE--KQK-RKVRIEKKLIQINIME REAFEK 1154 WP_003739838 1096 --NSS KLIP----RKENW-DPMKYGGLDSPNMAYAV-II--E--HA--KGK-KKVVFEKKIIRITIME RKAFEK 1154 WP_014601172 1096 --NSS KLIP----RKENW-DPMKYGGLDSPNMAYAV-II--E--HA--KGK-KKLIFEKKIIRITIME RKMFEK 1154 WP_023548323 1096 --DSS KLIP----KKTNL-NPIKYGGFEGSNMAYAI-II--E--HE--KRK-KKVTIEKKLIQINIME RKAFEK 1154 WP_031665337 1096 --NSS KLIP----RKENW-DPMKYGGLDSPNMAYAV-II--E--HA--KGK-KRIVIEKKLIQINIME RKMFEK 1154 WP_031669209 1096 --KSN KLIP----RKKDW-DPIKYGGFDGSKMAYAI-II--E--YE--KQK-RKVRIEKKLIQINIME REAFEK 1154 WP_033920898 1096 --DSS KLIP----KKTNL-NPIKYGGFEGSNMAYAI-II--E--HE--KRK-KKVTIEKKLIQINIME RKAFEK 1154 AKI42028 1099 --NSS KLIP----RKENW-DPMKYGGLDSPNMAYAV-II--E--HA--KGK-KKLIFEKKIIRITIME RKMFEK 1157 AKI50529 1099 --DSS KLIP----KKTNL-NPIKYGGFEGSNMAYAI-II--E--HE--KRK-KKVTIEKKLIQINIME RKAFEK 1157 EFR83390 544 --NSS KLIP----RKENW-DPMKYGGLDSPNMAYAV-II--E--HA--KGK-KKIVIEKKLIQINIME RKMFEK 602 WP_046323366 1096 --NSS KLIP----RKADW-DPIKYGGFDGSNMAYAI-VI--E--HE--KRK-KKTVIKKELIQINIME RTAFEK 1154 AKE81011 1131 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1192 CUO82355 1089 hsAKG AVIP---vNKNRK-DVNKYGGFSG--LQYVI----AA--IEgtKKKGKKLVKVRKLSGIPLYL KQADIK  1153 WP_033162887 1090 hsEKG ATVP---1NKYRA-DVHKYGGFGN--VQSII----VA--IEgkKKKGKKLIDVRKLTSIPLHL KNAPVE 1154 AGZ01981 1148 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1209 AKA60242 1115 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1176 AKS40380 1115 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1176 4UN5_B 1119 --NSD KLIA----RKKDW-DPKKYGGFDSPTVAYSV-LVVAK--VE--KGKSKKLKSVKELLGITIME RSSFEK 1180 WP_010922251 1177 NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -G

LQKGNELALPSKYVNFLYLA 1239 WP_039695303 1186 NPV---EFLE---NKGYHN--I-REDKLIK--LPKYSLFE---FEGGRRRLLAS ASELQKGNEMVLPGYLVELLYHA 1248 WP_045635197 1184 NPI---TFLE---NKGYHN--V-RKENILC--LPKYSLFE---LENGRRRLLAS AKELQKGNEIVLPVYLTTLLYHS 1246 5AXW_A 913 KPYrfdVYLD---NGVYKFvtV-KNLDVIK----KENYYE---VNSKAYEEAKK -KKISNQAEFIASFYNNDLIKIN 978 WP_009880683 861 DPV---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 923 WP_010922251 1177 NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239 WP_011054416 1177 DPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239 WP_011284745 1177 NPI---DFLE---AKGYKE--V-RKDLIVK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239 WP_011285506 1177 NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239 WP_011527619 1177 NPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239 WP_012560673 1177 DPV---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239 WP_014407541 1176 NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1238 WP_020905136 1177 NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239 WP_023080005 1176 NPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1238 WP_023610282 1176 NPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1238 WP_030125963 1177 NPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239 WP_030126706 1177 NPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239 WP_031488318 1177 NPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239 WP_032460140 1177 DPV---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239 WP_032461047 1177 DPV---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239 WP_032462016 1177 NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239 WP_032462936 1177 NPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239 WP_032464890 1177 NPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239 WP_033888930 1002 NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1064 WP_038431314 1177 NPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239 WP_038432938 1176 NPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1238 WP_038434062 1177 NPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239 BAQ51233 1088 NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1150 KGE60162 352 DPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 414 KGE60856 115 DPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 177 WP_002989955 1177 NPI---DFLE---AKGYKE--V-RKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239 WP_003030002 1159 HPV---DFLE---QRGYRN--V-RLEKIIK--LPKYSLFE---LENKRRRLLAS ARELQKGNELVIPQRFTTLLYHS 1221 WP_003065552 1187 NPV---EFLE---NKGYHN--I-REDKLIK--LPKYSLFE---FEGGKRRLLAS ASELQKGNEMVIPGHLVKLLYHA 1249 WP_001040076 1178 NPS---AFLE---SKGYLN--I-RTDKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 WP_001040078 1186 NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1248 WP_001040080 1178 NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 WP_001040081 1178 NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGETIDRLQKGNELALPTQFMKFLYLA 1240 WP_001040083 1178 NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 WP_001040085 1178 NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 WP_001040087 1178 NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 WP_001040088 1178 NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 WP_001040089 1178 NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 WP_001040090 1178 NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 WP_001040091 1178 NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 WP_001040092 1178 NPS---AFLE---SKGYLN--I-RTDKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240 WP_001040094 1178 NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 WP_001040095 1178 NPS---AFLE---SKGYLN--I-RTDKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240 WP_001040096 1178 NPS---AFLE---SKGYLN--I-RTDKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240 WP_001040097 1178 NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS ADELQKGNELALPTQFMKFLYLA 1240 WP_001040098 1178 NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 WP_001040099 1178 NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 WP_001040100 1178 NPS---AFLE---SKGYLD--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 WP_001040104 1178 NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 WP_001040105 1178 NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 WP_001040106 1178 NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240 WP_001040107 1178 NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240 WP_001040108 1178 NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240 WP_001040109 1178 NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240 WP_001040110 1178 NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240 WP_015058523 1178 NPS---AFLE---SKGYLN--I-RTDKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240 WP_017643650 1178 NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS ADELQKGNELALPTQFMKFLYLA 1240 WP_017647151 1178 NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 WP_017648376 1178 NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 WP_017649527 1178 NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 WP_017771611 1178 NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240 WP_017771984 1178 NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 CFQ25032 1178 NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 CFV16040 1178 NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 KLJ37842 1178 NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 KLJ72361 1178 NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 KLL20707 1192 NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1254 KLL42645 1178 NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240 WP_047207273 1178 NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 WP_047209694 1178 NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 WP_050198062 1178 NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 WP_050201642 1178 NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 WP_050204027 1178 NPS---AFLE---SKGYLN--I-RDDKLMI--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240 WP_050881965 1178 NLS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 WP_050886065 1178 NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 AHN30376 1178 NPS---AFLE---SKGYLN--I-RTDKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQYMKFLYLA 1240 EA078426 1178 NPS---AFLE---SKGYLN--I-RADKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 CCW42055 1178 NPS---AFLE---SKGYLN--I-RTDKLII--LPKYSLFE---LENGRRRLLAS AGELQKGNELALPTQFMKFLYLA 1240 WP_003041502 1186 DKR---AFLL---GKGYKD--I-K--KIIE--LPKYSLFE---LKDGSRRMLAS RGEIHKGNELFVPQKFTTLLYHA 1253 WP_037593752 1160 NPV---DFLE---QRGYRN--V-RLEKIIK--LPKYSLFE---LENKRRRLLAS ARELQKGNELVIPQRFTTLLYHS 1222 WP_049516684 1160 HPV---DFLE---QRGYRN--V-RLEKIIK--LPKYSLFE---LENKRRRLLAS ARELQKGNELVIPQRFTTLLYHS 1222 GAD46167 1159 NPV---DFLE---QRGYRN--V-RLEKIIK--LPKYSLFE---LENKRRRLLAS ARELQKGNELVIPQRFTTLLYHS 1221 WP_018363470 1191 NPV---EFLK---NKGYQN--V-QEDKLMK--LPKYSLFE---FEGGRRRLLAS ATELQKGNEIMLSAHLVALLYHA 1253 WP_003043819 1186 DPI---GFLE---AKGYKD--I-KKELIFK--LPKYSLFE---LENGRRRMLAS --ELQKANELVLPQHLVRLLYYT 1248 WP_006269658 1159 NPV---DFLE---QRGYRN--V-RLEKIIK--LPKYSLFE---LENKRRRLLAS AKELQKGNELVIPQRFTTLLYHS 1221 WP_048800889 1179 NPI---MFLE---SKGYRN--I-QKDKLIK--LPKYSLFE---FEGGRRRLLAS AVELQKGNEMVLPQYLNNLLYHA 1241 WP_012767106 1178 NPL---KFIE---DKGYGN--V-QIDKCIK--LPKYSLFE---FENGTRRMLAS RGDLQKANEMFLPAKLVTLLY-- 1245 WP_014612333 1178 NPL---KFIE---DKGYGN--V-QIDKCIK--LPKYSLFE---FENGTRRMLAS RGDLQKANEMFLPAKLVTLLY-- 1245 WP_015017095 1178 NPL---KFIE---DKGYGN--V-QIDKCIK--LPKYSLFE---FENGTRRMLAS RGDLQKANEMFLPAKLVTLLY-- 1245 WP_015057649 1178 NPL---KFIE---DKGYGN--V-QIDKCIK--LPKYSLFE---FENGTRRMLAS RGDLQKANEMFLPAKLVTLLY-- 1245 WP_048327215 1178 NPL---KFIE---DKGYGN--V-QIDKCIK--LPKYSLFE---FENGTRRMLAS RGDLQKANEMFLPAKLVTLLY-- 1245 WP_049519324 1178 NPL---KFIE---DKGYGN--V-QIDKCIK--LPKYSLFE---FENGTRRMLAS RGDLQKANEMFLPAKLVTLLY-- 1245 WP_012515931 1157 NPV---VFLE---ARGYRE--I-QEHLIIK--LPKYSLFE---LENGRRRLLAS -SELQKGNELFLPVDYMTFLYLA 1219 WP_021320964 1157 NPV---VFLE---AKGYRE--I-QEHLIIK--LPKYSLFE---LENGRRRLLAS -SELQKGNELFLPVDYMTFLYLA 1219 WP_037581760 1157 NPV---VFLE---AKGYRE--I-QEHLIIK--LPKYSLFE---LENGRRRLLAS -SELQKGNELFLPVDYMTFLYLA 1219 WP_004232481 1189 NPV---SFLE---KKGYHN--V-QEDKLIK--LPKYSLFE---FEGGRRRLLAS ATELQKGNEVVLPQYMVNLLYHS 1251 WP_009854540 1184 NPV---EFLE---NKGYHN--I-REDKLIK--LPKYSLFE---FEGGRRRLLAS ASELQKGNEMVLPGYLVELLYHA 1246 WP_012962174 1185 NPV---VFLE---KKGYQN--V-QEDNLIK--LPKYSLFE---FEGGRRRLLAS ASELQKGNEVVLSRHLVELLYHA 1247 WP_039695303 1186 NPV---EFLE---NKGYHN--I-REDKLIK--LPKYSLFE---FEGGRRRLLAS ASELQKGNEMVLPGYLVELLYHA 1248 WP_014334983 1189 NPV---SFLE---KKGYHN--V-QEDKLIK--LPKYSLFE---FEGGRRRLLAS ATELQKGNEVMLPAHLVELLYHA 1251 WP_003099269 1177 DPI---AFLE---KKGYQD--I-QTSSIIK--LPKYSLFE---LENGRKRLLAS --ELQKGNELALPNKYVKFLYLA 1239 AHY15608 1177 DPI---AFLE---KKGYQD--I-QTSSIIK--LPKYSLFE---LENGRKRLLAS --ELQKGNELALPNKYVKFLYLA 1239 AHY17476 1177 DPI---AFLE---KKGYQD--I-QTSSIIK--LPKYSLFE---LENGRKRLLAS --ELQKGNELALPNKYVKFLYLA 1239 ESR09100 9 DPI---AFLE---KKGYQD--I-QTSSIIK--LPKYSLFE---LENGRKRLLAS -KELQKGNELALPNKYVKFLYLA 71 AGM98575 1177 DPI---AFLE---KKGYQD--I-QTSSIIK--LPKYSLFE---LENGRKRLLAS --ELQKGNELALPNKYVKFLYLA 1239 ALF27331 1159 NPV---AFLE---RKGYRN--V-QEENIVK--LPKYSLFE---LENGRRRLLAS ARELQKGNEIVLPNHLGTMLYHA 1221 WP_018372492 1168 EPEr---FLA---QKGFER--V-EKT--IK--LPKYSLFE---MEKGRRRLLAS SGELQKGNQVLLPEHLIRLLSYA 1228 WP_045618028 1189 NPI---AYLE---ECGYKN--I-NPNLIIK--LPKYSLFE---FNNGQRRLLAS SIELQKGNELIVPYHFTALLYHA 1251 WP_045635197 1184 NPI---TFLE---NKGYHN--V-RKENILC--LPKYSLFE---LENGRRRLLAS AKELQKGNEIVLPVYLTTLLYHS 1246 WP_002263549 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002263887 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002264920 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002269043 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002269448 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002271977 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002272766 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002273241 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002275430 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002276448 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002277050 1167 NPV---KFLK---DKGYQQ--I-EKNNFVK--LPKYTLVD---IGNGIKRLWAS SKEVHKGNQLVVSKKSQDLLYHA 1229 WP_002277364 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002279025 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002279859 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002280230 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002281696 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002282247 1167 NPV---KFLK---DKGYQQ--I-EKNNFVK--LPKYTLVD---IGNGIKRLWAS SKEVHKGNQLVVSKKSQDLLYHA 1229 WP_002282906 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002283846 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002287255 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002288990 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002289641 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002290427 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002295753 1159 DPI---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002296423 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002304487 1173 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLETLLYHA 1235 WP_002305844 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002307203 1159 DPI---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002310390 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_002352408 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPDHLGTLLYHA 1221 WP_012997688 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_014677909 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_019312892 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_019313659 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_019314093 1159 DPI---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_019315370 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_019803776 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_019805234 1159 DPI---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_024783594 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_024784288 1167 NPV---KFLK---DKGYQQ--I-EKNNFVK--LPKYTLVD---IGNGIKRLWAS SKEVHKGNQLVVSKKSQDLLYHA 1229 WP_024784666 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_024784894 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_024786433 1167 NPV---KFLK---DKGYQQ--I-EKNNFVK--LPKYTLVD---IGNGIKRLWAS SKEVHKGNQLVVSKKSQDLLYHA 1229 WP_049473442 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 WP_049474547 1159 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1221 EMC03581 1152 DPV---AFLE---RKGYRN--V-QEENIIK--LPKYSLFK---LENGRKRLLAS ARELQKGNEIVLPNHLGTLLYHA 1214 WP_000428612 1187 SPI---AFLE---NKGYHN--V-RKENILC--LPKYSLFE---LKNGRRRMLAS AKELQKGNEIVLPVHLTTLLYHA 1249 WP_000428613 1185 NPI---TFLE---NKGYHN--V-RKENILC--LPKYSLFE---LENGRRRLLAS AKELQKGNEIVLPVYLTTLLYHS 1247 WP_049523028 1180 NPV---AFLE---GKGYQN--V-VEENIIR--LPKYSLFE---LENGRRRMLAS AKELQKGNEMVLPSYLIALLYHA 1242 WP_003107102 1146 DRI---TFLE---KKGYQD--I-QESLIIK--LPKFSLFE---LENGRKRLLAS --ELQKGNELSLPNKYIQFLYLA 1208 WP_054279288 1179 NPI---AFLE---SKGYHD--I-QEHLMIT--LPKYSLFE---LENGRRRLLAS --ELQKGNEMVLPQHLVTFLYRV 1241 WP_049531101 1189 NPT---AYLE---EYGYKN--I-NPNLIIK--LPKYSLFK---FNDGQRRLLAS SIELQKGNELILPYHFTTLLYHA 1251 WP_049538452 1189 NPI---AYLE---ECGYKN--I-NPNLIIK--LPKYSLFE---FNGGQRRLLAS SIELQKGNELILPYHFTALLYHT 1251 WP_049549711 1191 NPI---AYLE---ECGYKN--I-NPNLIIK--LPKYSLFE---FNGGQRRLLAS SIELQKGNELILPYHFTALLYHA 1253 WP_007896501 1183 DNI---AFLE---KKGYQD--I-QEKLLIK--LPKYSLFE---LENGRRRLLAS --EFQKGNELALSGKYMKFLYLA 1245 EFR44625 1135 DNI---AFLE---KKGYQD--I-QEKLLIK--LPKYSLFE---LENGRRRLLAS --EFQKGNELALSGKYMKFLYLA 1197 WP_002897477 1184 NPI---TFLE---NKGYHN--V-RKENILC--LPKYSLFE---LENGRRRLLAS AKELQKGNEIVLPVCLTTLLYHS 1246 WP_002906454 1190 NPV---TYLE---ECGYKN--I-NSNLIIK--LPKYSLFE---FNDGQRRLLAS SIELQKGNELILPYHLTALLYHA 1252 WP_009729476 1185 NPI---AFLE---NKGYHN--V-CKENILC--LPKYSLFE---LENGRRRLLAS AKELQKCNEIVLPVYLTTLLYHS 1247 CQR24647 1175 NSV---TFLE---EKGYRN--I-RENTIIK--FPKYSLFE---LENGRRRLLAS AIELQKGNEMFLPQQFVNLLYHA 1237 WP_000066813 1189 NPI---TFLE---NKGYHN--V-RKENILC--LPKYSLFE---LESGRRRMLAS AKELQKGNEIVLPVYLTTLLYHS 1251 WP_009754323 1185 NPI---TFLE---NKGYHN--V-RKENILC--LPKYSLFE---LENGRRRLLAS AKELQKGNEIVLPVYLTTLLYHS 1247 WP_044674937 1178 NPI---EFLE---HKGYKN--I-LEKNIIK--LPKYSLFE---LENGRRRLLAS AKELQKGNEMILPPHLVTLLYHS 1240 WP_044676715 1180 NPI---EFLE---HKGYKN--I-LEKNIIK--LPKYSLFE---LENGRRRLLAS AKELQKGNEMILPPHLVTLLYHS 1242 WP_044680361 1180 NPI---EFLE---HKGYKN--I-LEKNIIK--LPKYSLFE---LENGRRRLLAS AKELQKGNEMILPPHLVTLLYHS 1242 WP_044681799 1178 NPI---EFLE---HKGYKN--I-LEKNIIK--LPKYSLFE---LENGRRRLLAS AKELQKGNEMILPPHLVTLLYHS 1240 WP_049533112 1186 DKR---AFLL---GKGYKD--I-K--KIIE--LPKYSLFE---LKDGSRRMLAS RGEIHKGNELFVPQKFTTLLYHA 1253 WP_029090905 1118 SETslqAYIA---EQIKSE--VeILN----grILKYQLIS----NNGNRLYIAG -SERHNARQLIVSDEAAKVIWLI 1181 WP_006506696 1150 EKI---NYIE--eKEGLSD--VrIIK---Dn-IPVNQMIEm----DGGEYLLTS --EYVNARQLVLNEKQCALIADI 1211 AIT42264 1177 NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239 WP_034440723 1150 QTT---EYLG---KIGFNK--AsIIN---S--FKNYTLFE---LENGSRRMIVG KGELQKGNQMYLPQNLLEFVYHL 1217 AKQ21048 1177 NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239 WP_004636532 1151 HPT---AYLE---EAGYNN--P-TV--LHE--LFKYQLFE---LEDGSRRMIAS AKEFQKGNQMVLPLELVELLYHA 1211 WP_002364836 1157 NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYE---FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA 1217 WP_016631044 1108 NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYE---FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA 1168 EM575795 893 DPI---GFLS---NKGYSN--V-TKF--IK--LSKYTLYE---LENGRRRMVAS -KEAQKANSFILPEKLVTLLYHA 953 WP_002373311 1157 NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYE---FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA 1217 WP_002378009 1157 NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYQ---FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA 1217 WP_002407324 1157 NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYE---FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA 1217 WP_002413717 1157 NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYE---FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA 1217 WP_010775580 1159 NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYE---FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA 1219 WP_010818269 1157 NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYE---FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA 1217 WP_010824395 1157 NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYE---FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA 1217 WP_016622645 1157 NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYE---FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA 1217 WP_033624816 1157 NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYE---FPEGRRRLLAS AKEAQKGNQMVLPERLLTLLYHA 1217 WP_033625576 1157 NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYE---FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA 1217 WP_033789179 1157 NPI---LFLE---EKGFLR--P-RV--LMK--LPKYTLYE---FPEGRRRLLAS AKEAQKGNQMVLPEHLLTLLYHA 1217 WP_002310644 1159 SPV---LFLK---NKGYEQ--A-EIE--MK--LPKYALFE---LENGRKRMVAS -KEAQKANSFLLPEHLVTLLYHA 1219 WP_002312694 1160 SPV---LFLK---NKGYEQ--A-EIE--MK--LPKYALFE---LENGRKRMVAS -KEAQKANSFLLPEHLVTLLYHA 1220 WP_002314015 1160 SPV---LFLK---NKGYEQ--A-EIE--MK--LPKYALFE---LENGRKRMVAS -KEAQKANSFLLPEHLVTLLYHA 1220 WP_002320716 1160 SPV---LFLK---NKGYEQ--A-EIE--MK--LPKYALFE---LENGRKRMVAS -KEAQKANSFLLPEHLVTLLYHA 1220 WP_002330729 1159 SPV---LFLK---NKGYEQ--A-EIE--MK--LPKYALFE---LENGRKRMVAS -KEAQKANSFLLPEHLVTLLYHA 1219 WP_002335161 1160 SPV---LFLK---NKGYEQ--A-EIE--MK--LPKYALFE---LENGRKRMVAS -KEAQKANSFLLPEHLVTLLYHA 1220 WP_002345439 1160 SPV---LFLK---NKGYEQ--A-EIE--MK--LPKYALFE---LENGRKRMVAS -KEAQKANSFLLPEHLVTLLYHA 1220 WP_034867970 1150 DPT---TFLK---EKGFPQ--V-TEF--IK--LPKYTLFE---FDNGRRRFLAS -KESQKGNPFILSDQLVTLLYHA 1210 WP_047937432 1160 SPV---LFLK---NKGYEQ--A-EIE--MK--LPKYALFE---LENGRKRMVAS -KEAQKANSFLLPEHLVTLLYHA 1220 WP_010720994 1150 DPT---TFLK---DKGFPQ--V-TEF--IK--LPKYTLFE---FDNGRRRFLAS -KESQKGNPFILSDQLVTLLYHA 1210 WP_010737004 1150 DPT---TFLK---EKGFPQ--V-TEF--IK--LPKYTLFE---FDNGRRRFLAS -KESQKGNPFILSDQLVTLLYHA 1210 WP_034700478 1150 DPT---TFLK---DKGFPH--V-TEF--IK--LPKYTLFE---FDNGRRRFLAS -KESQKGNPFILSDQLVTLLYHA 1210 WP_007209003 1148 NPI1---YLS---KKDYHN---pKVEAI----LPKYSLFE---FENGRRRMVAS -SETQKGNQLIIPGHLMELLYHS 1208 WP_023519017 1144 DPR---EFLK---TKGYEG--V-KQW--LI--LPKYILFE---AQGGYRRMIAS -QETQKANSLILPENLVTLLYHA 1204 WP_010770040 1155 DPV---SLLE---EKGYAN--P-EV--LIH--LPKYTLYE---LENGRRRLLAS ANEAQKGNQLVLPASLVTLLYHA 1215 WP_048604708 1152 NER---EFLK---NKGYQN--P-QI--CMK--LPKYSLYE---FDDGRRRLLAS AKEAQKGNQMVLPAHLVTFLYHA 1212 WP_010750235 1153 DPI---SFLI---EKGYSN--V-NQF--IK--LPKYTLFE---LANGQRRMLAS -QELQKANSFILPEKLVTLLYHA 1213 AII16583 1216 NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1278 WP_029073316 1165 TKI---NYIK--eSEGLEE--VkIIK---E--ILKNQLIET----NGGLFYVTS --EIVNARQLILDFNCTRIIDGI 1225 WP_031589969 1165 IKI---NYLK--qAEDLEE--VqIGK---E--ILKNQLIEk----DGGLYYIVA --EIINAKQLILNESQTKLVCEI 1225 KDA45870 1139 DPT---AYLA---SRGYTNvtNsFIL-------PKYSLLEd---PEGRRRYLAS -KEFQKANELILPQHLVELLYWV 1199 WP_039099354 1171 QKI-spQFTKv---KKQKGtiV-KVVEDFEv-IAPHILINqrfFDNGQELTLGS ----HNEQELILDKTAVKLLNGA 1241 AKP02966 1173 KTL--qNWLE---ENVKHKksIqIIK---Nn-VPIGQIIY------SKKVGLLS -REIANRQQLILPPEHSALLRIL 1237 WP_010991369 1155 DEK---AFLE---EQGYRQ--P-KV--LAK--LPKYTLYE---CEEGRRRMLAS ANEAQKGNQQVLPNHLVTLLHHA 1215 WP_033838504 1155 DEK---AFLE---EQGYRQ--P-KV--LAK--LPKYTLYE---CEEGRRRMLAS ANEAQKGNQQVLPNHLVTLLHHV 1215 EHN60060 1158 DEK---AFLE---EQGYRQ--P-KV--LAK--LPKYTLYE---CEEGRRRMLAS ANEAQKGNQQVLPNHLVTLLHHV 1218 EFR89594 924 DEK---AFLE---EQGYRQ--P-KV--LAK--LPKYTLYE---CEEGRRRMLAS ANEAQKGNQQVLPNHLVTLLHHA 984 WP_038409211 1155 DQK---AFLE---EKGYYS--P-KV--LTK--IPKYTLYE---CENGRRRMLGS ANEAQKGNQMVLPNHLMTLLYHA 1215 EFR95520 774 DQK---AFLE---EKGYYS--P-KV--LTK--IPKYTLYE---CENGRRRMLGS ANEAQKGNQMVLPNHLMTLLYHA 834 WP_003723650 1155 DEE---AFLE---EKGYRH--P-KV--LTK--LPKYTLYE---CEKGRRRMLAS ANEAQKGNQLVLSNHLVSLLYHA 1215 WP_003727705 1155 DEE---AFLE---EKGYHQ--P-KV--LTK--LPKYTLYE---CEKGRRRMLSS ANEAQKGNQLVLSNHLVSLLYHA 1215 WP_003730785 1155 DEE---AFLE---EKGYHQ--P-KV--LTK--LPKYTLYE---CEKGRRRMLSS ANEAQKGNQLVLSNHLVSLLYHA 1215 WP_003733029 1155 DEK---TFLE---EKGYHQ--P-KV--LIK--VPKYTLYE---CKNGRRRMLGS ANEAHKGNQMLLPNHLMALLYHA 1215 WP_003739838 1155 DEK---SFLE---KQGYRQ--P-KV--LTK--LPKYTLYE---CENGRRRMLAS ANEAQKGNQQVLKGQLITLLHHA 1215 WP_014601172 1155 DEE---AFLE---EKGYRH--P-KV--LTK--LPKYTLYE---CEKGRRRMLAS ANEAQKGNQLVLSNHLVSLLYHA 1215 WP_023548323 1155 DEK---VFLE---GKGYHQ--P-KV--LTK--LPKYALYE---CENGRRRMLGS ANEVHKGNQMLLPNHLMTLLYHA 1215 WP_031665337 1155 DEE---AFLE---EKGYRH--P-KV--LTK--LPKYTLYE---CEKGRRRMLAS ANEAQKGNQLVLSNHLVSLLYHA 1215 WP_031669209 1155 DEK---TFLE---EKGYHQ--P-KV--LIK--VPKYTLYE---CENGRRRMLGS ANEAHKGNQMLLPNHLMALLYHA 1215 WP_033920898 1155 DEK---VFLE---GKGYHQ--P-KV--LTK--LPKYALYE---CENGRRRMLGS ANEVHKGNQMLLPNHLMTLLYHA 1215 AKI42028 1158 DEE---AFLE---EKGYRH--P-KV--LTK--LPKYTLYE---CEKGRRRMLAS ANEAQKGNQLVLSNHLVSLLYHA 1218 AKI50529 1158 DEK---VFLE---GKGYHQ--P-KV--LTK--LPKYALYE---CENGRRRMLGS ANEVHKGNQMLLPNHLMTLLYHA 1218 EFR83390 603 DEE---AFLE---EKGYRH--P-KV--LTK--LPKYTLYE---CEKGRRRMLAS ANEAQKGNQLVLSNHLVSLLYHA 663 WP_046323366 1155 DQK---EFLE---GKGYRN--P-KV--ITK--IPKYTLYE---CENGRRRMLGS ANEAQKGNQMVLPNHLMTLLYHA 1215 AKE81011 1193 NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1255 CUO82355 1154 EQI---EYVE--kEEKLSD--VkIIK---Nn-IPLNQLIEi----DGRQYLLTS --ECVNAMQLVLNEEQCKLIADI 1215 WP_033162887 1155 EQL---SYIAspeHEDLID--VrIVK---E--ILKNQLIEi----DGGLYYVTS --EYVTARQLSLNEQSCKLISEI 1217 AGZ01981 1210 NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1272 AKA60242 1177 NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239 AK540380 1177 NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1239 4UN5_B 1181 NPI---DFLE---AKGYKE--V-KKDLIIK--LPKYSLFE---LENGRKRMLAS -GELQKGNELALPSKYVNFLYLA 1243 WP_010922251 1240 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1305 WP_039695303 1249 HRAD----NFNS-TEYLN--YVSEHKKEFEKVLSCVEDFANLYVDVE--KNLSKIR-A VAD-SM---DNFSIEE-- 1308 WP_045635197 1247 KNVH----KLDE-PGHLE--YIQKHRNEFKDLLNLVSEFSQKYVLAD--ANLEKIK-S LYA-DN---EQADIEI-- 1306 5AXW_A 979 GELYRVIgVNND1LNRIE---VNMIDITYREYLENMNDKRPPRIIKTiaSKTQSIK-K LYEvKSk--KHPQIIKkg 1056 WP_009880683 924 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 989 WP_010922251 1240 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1305 WP_011054416 1240 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1305 WP_011284745 1240 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1305 WP_011285506 1240 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1305 WP_011527619 1240 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1305 WP_012560673 1240 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1305 WP_014407541 1239 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1304 WP_020905136 1240 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1305 WP_023080005 1239 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1304 WP_023610282 1239 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1304 WP_030125963 1240 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1305 WP_030126706 1240 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1305 WP_031488318 1240 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1305 WP_032460140 1240 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1305 WP_032461047 1240 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1305 WP_032462016 1240 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1305 WP_032462936 1240 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1305 WP_032464890 1240 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1305 WP_033888930 1065 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1130 WP_038431314 1240 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1305 WP_038432938 1239 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1304 WP_038434062 1240 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1305 BAQ51233 1151 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1216 KGE60162 415 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 480 KGE60856 178 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 243 WP_002989955 1240 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1305 WP_003030002 1222 YQIE----KNYE-PEHRE--YVEKHKDEFKELLEYISVFSRKYVLAD--NNLTKIE-M LFS-KN---KDAEVSS-- 1281 WP_003065552 1250 QRIN----SENS-TKYLD--YVSAHKKEFEKVLSCVEDFANLYVDVE--KNLSKIR-A VAD-SM---DNFSIEE-- 1309 WP_001040076 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDIFQIINDFSKRVILAD--ANLEKIN-R LYQ-DNk--ENIPVDE-- 1306 WP_001040078 1249 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1314 WP_001040080 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_001040081 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_001040083 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_001040085 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_001040087 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_001040088 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_001040089 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_001040090 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_001040091 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_001040092 1241 SRYNESKgKPEEiEKKQE--FVNQHISYFDDILQLINDFSKRVILAD--ANLEKIN-K LYS-DNk--DNTPVDE-- 1306 WP_001040094 1241 SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENIPVDE-- 1306 WP_001040095 1241 SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENIPVDE-- 1306 WP_001040096 1241 SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENIPVDE-- 1306 WP_001040097 1241 SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENIPVDE-- 1306 WP_001040098 1241 SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENIPVDE-- 1306 WP_001040099 1241 SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENIPVDE-- 1306 WP_001040100 1241 SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENIPVDE-- 1306 WP_001040104 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_001040105 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_001040106 1241 SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_001040107 1241 SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_001040108 1241 SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_001040109 1241 SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_001040110 1241 SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_015058523 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYS-DNk--DNTPVDE-- 1306 WP_017643650 1241 SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENIPVDE-- 1306 WP_017647151 1241 SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_017648376 1241 SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_017649527 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_017771611 1241 SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_017771984 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 CFQ25032 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 CFV16040 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 KLJ37842 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 KLJ72361 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 KLL20707 1255 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1320 KLL42645 1241 SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_047207273 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_047209694 1241 SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENIPVDE-- 1306 WP_050198062 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_050201642 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_050204027 1241 SRYNELKgKPEEiEQKQE--FVVQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_050881965 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_050886065 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 AHN30376 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYS-DNk--DNTPVDE-- 1306 EA078426 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQLINDFSKRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 CCW42055 1241 SRYNESKgKPEEiEKKQE--FVNQHVSYFDDILQIINDFSNRVILAD--ANLEKIN-K LYQ-DNk--ENISVDE-- 1306 WP_003041502 1254 KRIN----NPIN-KDHIE--YVKKHRDDFKELLNYVLEFNEKYVGAT--KNGERLK-E AVA-DF---DSKSNEE-- 1313 WP_037593752 1223 YQIE----KNYE-PEHRE--YVEKHKDEFKELLEYISVFSRKYVLAD--NNLTKIE-M LFS-KN---KDAEVSS-- 1282 WP_049516684 1223 YRIE----KDYE-PEHRE--YVEKHKDEFKELLEYISVFSRKYVLAD--NNLTKIE-M LFS-KN---KDAEVSS-- 1282 GAD46167 1222 YQIE----KNYE-PEHRE--YVEKHKDEFKELLEYISVFSRKYVLAD--NNLTKIE-M LFS-KN---KDAEVSS-- 1281 WP_018363470 1254 HRIG----NFNS-AEHLK--YVSEHKKEFEEVLSCVENFANVYVDVE--KNLSKIR-A AAD-SM---DNFSIEE-- 1313 WP_003043819 1249 QNISATTgSNNLg-------YIEQHREEFKEIFEKIIDFSEKYILKN--KVNSNLK-S SFD-EQfavSDSIL--1- 1310 WP_006269658 1222 YRIE----KDYE-PEHRE--YVEKHKDEFKELLEYISVFSRKYVLAD--NNLTKIE-M LFS-KN---KDAEVSS-- 1281 WP_048800889 1242 HRID----NSDN-SEHLK--YITEHKEEFGKLLSYIENFAKSYVDVD--KNLEKIQ-L AVE-KI---DSFSVKE-- 1301 WP_012767106 1246 -HAHKIEsSKE--LEHEA--YILDHYNDLYQLLSYIERFASLYVDVE--KNISKVK-E LFS-NI---ESYSISEi- 1308 WP_014612333 1246 -HAHKIEsSKE--LEHEA--YILDHYNDLYQLLSYIERFASLYVDVE--KNISKVK-E LFS-NI---ESYSISEi- 1308 WP_015017095 1246 -HAHKIEsSKE--LEHEA--YILDHYNDLYQLLSYIERFASLYVDVE--KNISKVK-E LFS-NI---ESYSISEi- 1308 WP_015057649 1246 -HAHKIEsSKE--LEHEA--YILDHYNDLYQLLSYIERFASLYVDVE--KNISKVK-E LFS-NI---ESYSISEi- 1308 WP_048327215 1246 -HAHKIEsSKE--LEHEA--YILDHYNDLYQLLSYIERFASLYVDVE--KNISKVK-E LFS-NI---ESYSISEi- 1308 WP_049519324 1246 -HAHKIEsSKE--LEHEA--YILDHYNDLYQLLSYIERFASLYVDVE--KNISKVK-E LFS-NI---ESYSISEi- 1308 WP_012515931 1220 AHYHELTgSSEDvLRKKY--FVDRHLHYFDDIIQMINDFAERHILAS--SNLEKIN-H TYH-NN---SDLPVNEr- 1285 WP_021320964 1220 AHYHELTgSSEDvLRKKY--FVERHLHYFDDIIQMINDFAERHILAS--SNLEKIN-H TYH-NN---SDLPINEr- 1285 WP_037581760 1220 AHYHELTgSSEDvLRKKY--FVERHLHYFDDIIQMINDFAERHILAS--SNLEKIN-H TYH-NN---SDLPVNEr- 1285 WP_004232481 1252 QHVN----NSHK-PEHLN--YVKQHKDEFKDIFNLIISIARINILKP--KVVDNL--- -IN-EF---TEYGQED-- 1308 WP_009854540 1247 HRAD----NFNS-TEYLN--YVSEHKKEFEKVLSCVEDFANLYVDVE--KNLSKIR-A VAD-SM---DNFSIEE-- 1306 WP_012962174 1248 HRVN----SFNN-SEHLK--YVSEHKKEFGEVLSCVENFAKSYVDVE--KNLGKIR-A VAD-KI---DTFSIED-- 1307 WP_039695303 1249 HRAD----NENS-TEYLN--YVSEHKKEFEKVLSCVEDFANLYVDVE--KNLSKIR-A VAD-SM---DNFSIEE-- 1308 WP_014334983 1252 HRID----SFNS-TEHLK--YVSEHKKEFEKVLSCVENFSNLYVDVE--KNLSKVR-A AAE-SM---TNFSLEE-- 1311 WP_003099269 1240 SHYTKFTgKEEDrEKKRS--YVESHLYYFDEIMQIIVEYSNRYILAD--SNLIKIQ-N LYK-EKd---NFSIEEq- 1305 AHY15608 1240 SHYTKFTgKEEDrEKKRS--YVESHLYYFXEVKSSF---------------------- ------------------  1273 AHY17476 1240 SHYTKFTgKEEDrEKKRS--YVESHLYXFX---------------------------- ------------------  1267 ESR09100 72 SHYTKFTgKEEDrEKKRS--YVESHLYYFDEIMQIIVEYSNRYILAD--SNLIKIQ-N LYK--Ek--DNFSIEEq- 137 AGM98575 1240 SHYTKFTgKEEDrEKKRS--YVESHLYYFDVRLSQVFRVTNVEF-------------- ------- ---------- 1281 ALF27331 1222 KNIH----KVDE-PKHLD--YVKKHKDEFKELLDVVSNFSKKNILAE--SNLEKIE-E LYA-QN---NNKDITE-- 1281 WP_018372492 1229 KKVDVLVkSKDD---DYD---LEEHRAEFAELLDCIKKFNDMYILAS--SNMSKIE-E IYQ-KNi---DAPIEE-- 1289 WP_045618028 1252 QRIN----KISE-PIHKQ--YVETHQSEFKELLTAIISLSKKYI-QK--PNVESL--- LQQ-AF---DQSDKDIyq 1310 WP_045635197 1247 KNVH----KLDE-PGHLE--YIQKHRNEFKDLLNLVSEFSQKYVLAD--ANLEKIK-S LYA-DN---EQADIEI-- 1306 WP_002263549 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002263887 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002264920 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002269043 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002269448 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002271977 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002272766 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002273241 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002275430 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002276448 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002277050 1230 HHL-------DN-DYSNE--YVKNHYQQFDILFNEITSFSKKCKLGK--EHIQKIE-E AYSkER---DSASIEE-- 1287 WP_002277364 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002279025 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002279859 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002280230 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002281696 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002282247 1230 HHL-------DN-DYSNE--YVKNHYQQFDILFNEITSFSKKCKLGK--EHIQKIE-E AYSkER---DFASIEE-- 1287 WP_002282906 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002283846 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002287255 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002288990 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002289641 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002290427 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002295753 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002296423 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002304487 1236 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1295 WP_002305844 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002307203 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002310390 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_002352408 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_012997688 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_014677909 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_019312892 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_019313659 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_019314093 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_019315370 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_019803776 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_019805234 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_024783594 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_024784288 1230 HHL-------DN-DYSNE--YVKNHYQQFDILFNEITSFSKKCKLGK--EHIQKIE-E AYSkER---DFASIEE-- 1287 WP_024784666 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_024784894 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_024786433 1230 HHL-------DN-DYSNE--YVKNHYQQFDILFNEITSFSKKCKLGK--EHIQKIE-E AYSkER---DSASIEE-- 1287 WP_049473442 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 WP_049474547 1222 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1281 EMC03581 1215 KNIH----KVDE-PKHLD--YVDKHKDEFKELLDVVSNFSKKYTLAE--GNLEKIK-E LYA-QN---NGEDLKE-- 1274 WP_000428612 1250 KNIH----RLDE-PEHLE--YIQKHRNEFKGLLNLVSEFSQKYVLAD--ANLEKIK-N LYA-DN---EQADIEI-- 1309 WP_000428613 1248 KNVH----KLDE-PEHLE--YIQKHRNEFKDLLNLVSEFSQKYVLAD--ANLEKIQ-N LYA-DN---EQADIEI-- 1307 WP_049523028 1243 KRIQ----KKDE-PEHLE--YIKQHHSEFNDLLNFVSEFSQKYVLAE--SNLEKIK-N LYI-DN---EQTNMEE-- 1302 WP_003107102 1209 SRYTSFSgKEEDrEKHRH--FVESHLHYFDEIKDIIADFSRRYILAD--ANLEKIL-T LYN-EKn---QFSIEEq- 1274 WP_054279288 1242 SKRDK--gTQSEnME-----YISNHKEKFIEIFHYIIRYAEKNVIKP--KVIERLN-D TENqKF---NDSDLTE1- 1303 WP_049531101 1252 QRIN----KISE-PIHKQ--YVETHQSEFEELLTTIISLSKKYI-QK--PIVESL--- LQQ-AF---EQADKDIyq 1310 WP_049538452 1252 QRIN----KISE-PIHKQ--YVEAHQNEFKELLTTIISLSKKYI-QK--PNVESL--- LQQ-AF---EQADKDIyq 1310 WP_049549711 1254 QRIN----KFSE-PIHKQ--YVEAHQNEFKELLTIIISLSKKYI-QK--PNVESL--- LHQ-AF---EQADNDIyq 1312 WP_007896501 1246 SRYDKLSsKIESeQQKKL--FVEQHLHYFDEILDIVVKHATCYIKAE--NNLKKII-S LYK-KK---EAYSINEq- 1311 EFR44625 1198 SRYDKLSsKIESeQQKKL--FVEQHLHYFDEILDIVVKHATCYIKAE--NNLKKII-S LYK-KK---EAYSINEq- 1263 WP_002897477 1247 KNLH----KLDE-PEHLE--YIQKHRNEFKDLLNLVSEFSQKYILAE--ANLEKIK-D LYA-DN---EQADIEI-- 1306 WP_002906454 1253 QRIN----KISE-PIHKQ--YVEAHQNEFKELLTTIISLSKKYI-QK--PNVELL--- LQQ-AF---DQADKDIyq 1311 WP_009729476 1248 KNVH----KLDE-PGHLE--YIQKHRNEFKDLLNLVSEFSQKYVLAD--ANLEKIK-N LYA-DN---EQADIEI-- 1307 CQR24647 1238 QHAN----KEDS----VI--YLEKHRHELSELFHHIIGVSEKTILKP--KVEMTLN-E AFE-KHf--EFDEVSE-- 1295 WP_000066813 1252 KNVH----KLDE-PEHLE--YIQKHRYEFKDLLNLVSEFSQKYVLAD--ANLEKIK-N LYA-DN---EQADIEI-- 1311 WP_009754323 1248 KNVH----KLDE-PEHLE--YIQKHRYEFKDLLNLVSEFSQKYVLAE--ANLEKIK-S LYV-DN---EQADIEI-- 1307 WP_044674937 1241 SNIH----KITE-PIHLN--YVNKNKHEFKELLRHISDFSTRYILAQ--DRLSKIE-E LYD-KN---DGDDISD-- 1300 WP_044676715 1243 SNIH----KITE-PIHLN--YVNKNKHEFKELLRHISDFSTRYILAQ--DRLSKIE-E LYD-KN---DGDDISD-- 1302 WP_044680361 1243 SNIH----KITE-PIHLN--YVNKNKHEFKELLRHISDFSTRYILAQ--DRLSKIE-E LYD-KN---DGDDISD-- 1302 WP_044681799 1241 SNIH----KITE-PIHLN--YVNKNKHEFKELLRHISDFSTRYILAQ--DRLSKIE-E LYD-KN---DGDDISD-- 1300 WP_049533112 1254 KRIN----NPIN-KDHIE--YVKKHRDDFKELLNYVLEFNEKYVGAT--KNGERLK-E AVA-DF---DSKSNEE-- 1313 WP_029090905 1182 STKQA-----DE-AMFLKyyRLEHLEAVFEEL---IRKQAADYQIFE--KLIKKIEvN FYS----c----TYNEk- 1240 WP_006506696 1212 YNAIYKQ-DYDN1DDILMi-----------QLYIELTNKMKVLYPAY-rGIAEKFE-S YVV----i----SKEEk- 1268 AIT42264 1240 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1305 WP_034440723 1218 KHYNE-----DE--TSHK--FIVEHKAYFDELLNYIVEFANKYLELE--NSIEKIK-D LYH-----gKGPDVEEke 1276 AKQ21048 1240 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1305 WP_004636532 1212 NRYDKVK-----fPDSIE--YVHDNLAKFDDLLEYVIDFSNKYINAD--KNVQKIQ-K IYK-EH---GTEDVEL-- 1271 WP_002364836 1218 KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-AN---QTADVKE-- 1277 WP_016631044 1169 KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-AN---QTADVKE-- 1228 EM575795 954 QHYDEIAhKESF-----D--YVNDHLSEFREILDQVIDFSNRYTIAA--KNTEKIA-E LFE-QN---QESTVQS-- 1013 WP_002373311 1218 KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-AN---QTADVKE-- 1277 WP_002378009 1218 KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-AN---QTADVKE-- 1277 WP_002407324 1218 KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-AN---QTADVKE-- 1277 WP_002413717 1218 KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-AN---QTADVKE-- 1277 WP_010775580 1220 KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-AN---QTADVKE-- 1279 WP_010818269 1218 KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-AN---QTADVKE-- 1277 WP_010824395 1218 KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-AN---QTADVKE-- 1277 WP_016622645 1218 KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-AN---QTADVKE-- 1277 WP_033624816 1218 KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-AN---QTADVKE-- 1277 WP_033625576 1218 KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-TN---QTADVKE-- 1277 WP_033789179 1218 KQCLL----PNQ-SESLA--YVEQHQPEFQEILERVVDFAEVHTLAK--SKVQQIV-K LFE-AN---QTADVKE-- 1277 WP_002310644 1220 KQYDEIShKESF-----D--YVNEHHKEFSEVFARVLEFAGKYTLAE--KNIEKLE-K IYK-EN---QTDDLAK-- 1279 WP_002312694 1221 KQYDEIShKESF-----D--YVNEHHKEFSEVFARVLEFAGKYTLAE--KNIEKLE-K IYK-EN---QTDDLAK-- 1280 WP_002314015 1221 KQYDEIShKESF-----D--YVNEHHKEFSEVFARVLEFAGKYTLAE--KNIEKLE-K IYK-EN---QTDDLAK-- 1280 WP_002320716 1221 KQYDEIShKESF-----D--YVNEHHKEFSEVFARVLEFAGKYTLAE--KNIEKLE-K IYK-EN---QTDDLAK-- 1280 WP_002330729 1220 KQYDEIShKESF-----D--YVNEHHKEFSEVFARVLEFAGKYTLAE--KNIEKLE-K IYK-EN---QTDDLAK-- 1279 WP_002335161 1221 KQYDEIShKESF-----D--YVNEHHKEFSEVFARVLEFAGKYTLAE--KNIEKLE-K IYK-EN---QTDDLAK-- 1280 WP_002345439 1221 KQYDEIShKESF-----D--YVNEHHKEFSEVFARVLEFAGKYTLAE--KNIEKLE-K IYK-EN---QTDDLAK-- 1280 WP_034867970 1211 QHYDKITyQESF-----D--YVNTHLSDFSAILTEVLAFAEKYTLAD--KNIERIQ-E LYE-EN---KYGETSM-- 1270 WP_047937432 1221 KQYDEIShKESF-----D--YVNEHHKEFSEVFARVLEFAGKYTLAE--KNIEKLE-K IYK-EN---QTDDLAK-- 1280 WP_010720994 1211 QHYDKITyQESF-----D--YVNTHLSDFSAILTEVLAFAEKYTLAD--KNIERIQ-E LYE-EN---KYGEISM-- 1270 WP_010737004 1211 QHYDKITyQESF-----D--YVNTHLSDFSAILTEVLAFAEKYTLAD--KNIERIQ-E LYE-EN---KYGETSM-- 1270 WP_034700478 1211 QHYDKITyQESF-----D--YVNTHLSDFSAILTEVLAFAEKYTLAD--KNIERIQ-E LYE-EN---KYGEISM-- 1270 WP_007209003 1209 KKIIN--gKNSD---SVS--YIQNNKEKFREIFEYIVDFSSKYISAD--ANLNKIE-K IFE-NNfh----KASEqe 1269 WP_023519017 1205 RHYDEINhKVSF-----D--YVNAHKEGENDIFDFISDEGVRYILAP--QHLEKIK-V AYE-KN---KEVDLKE-- 1264 WP_010770040 1216 KQVDE-----DS-GKSEE--YVREHRAEFAEILNYVQAFSETKILAN--KNLQTIL-K LYE-EN---KEADIKE-- 1274 WP_048604708 1213 KHCNE-----KP-D-SLK--YVTEHQSGFSEIMAHVKDFAEKYTLVD--KNLEKIL-S LYA-KN---MDSEVKE-- 1270 WP_010750235 1214 NHYDEIAyKDSY-----D--YVNEHFSNFQDILDKVIIFAEKYTSAP--QKLNQII-A TYE-KN---QEADRKI-- 1273 AII16583 1279 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1344 WP_029073316 1226 YKAMKYK-NYSE1SQEEIm-----------NVYDIFVEKLKLYYPTY-kNIATNFE-N FEN----i----SDEEk- 1282 WP_031589969 1226 YKAMKYK-NYDN1DSEKIi-----------DLYRLLINKMELYYPEYrkQLVKKFE-D LKV----i----SIEEk- 1283 KDA45870 1200 NAKDG--------EQKLE-----DHKAEFKELFDKIMEFADKYVVAP--KNSEKIR-R LYE-ENq-----DATPme 1253 WP_039099354 1242 LPLTQ-----SEeLAEQV----------YDEILDQVMHYFPLYDTNQfrAKLSAGKaA DGN-KMv-----QVGQqv 1306 AKP02966 1238 QIPDE------DpDQILAf----YDKNILVEILQELITKMKKFYPFY--KNEQEFLaS FNQ--------ATTSEk- 1296 WP_010991369 1216 ANCEV-----SD-GKSLD--YIESNREMFAELLAHVSEFAKRYTLAE--ANLNKIN-Q LFE-QN---KEGDIKA-- 1274 WP_033838504 1216 ANCEV-----SD-GKSLD--YIESNREMFAELLAHVSEFAKRYTLAE--ANLNKIN-Q LFE-QN---KEGDIKA-- 1274 EHN60060 1219 ANCEV-----SD-GKSLD--YIESNREMFAELLAHVSEFAKRYTLAE--ANLNKIN-Q LFE-QN---KEGDIKA-- 1277 EFR89594 985 ANCEV-----SD-GKSLD--YIESNREMFAELLAHVSEFAKRYTLAE--ANLNKIN-Q LFE-QN---KEGDIKA-- 1043 WP_038409211 1216 KNCEA-----ND-GESLA--YIEMHREMFAELLAYISEFAKRYTLAN--DRLEKIN-M FFE-QN---KKGDIKV-- 1274 EFR95520 835 KNCEA-----ND-GESLA--YIEMHREMFAELLAYISEFAKRYTLAN--DRLEKIN-M FFE-QN---KKGDIKV-- 893 WP_003723650 1216 KNCEA-----SD-GKSLK--YIEAHRETFSELLAQVSEFATRYTLAD--ANLSKIN-N LFE-QN---KEGDIKA-- 1274 WP_003727705 1216 KNCEA-----SD-GKSLK--YIEAHRETFSELLAQVSEFATKYTLAD--ANLSKIN-N LFE-QN---KEGDIKA-- 1274 WP_003730785 1216 KNCEA-----SD-GKSLK--YIEAHRETFSELLAQVSEFATKYTLAD--ANLSKIN-N LFE-QN---KEGDIKA-- 1274 WP_003733029 1216 EKYEA-----ID-GESLA--YIEVHRALFDELLAYISEFARKYTLSN--DRLDEIN-M LYE-RN---KDGDVKS-- 1274 WP_003739838 1216 KNCEA-----SD-GKSLD--YIESNREMFGELLAHVSEFAKRYTLAD--ANLSKIN-Q LFE-QN---KDNDIKV-- 1274 WP_014601172 1216 KNCEA-----SD-GKSLK--YIEAHRETFSELLAQVSEFATRYTLAD--ANLSKIN-N LFE-QN---KEGDIQA-- 1274 WP_023548323 1216 EKREA-----ID-GESLA--YIEAHKAVFGELLAHISEFARKYTLAN--DKLDEIN-M LYE-RN---KDGDVKS-- 1274 WP_031665337 1216 KNCEA-----SD-GKSLK--YIEAHRETFSELLAQVSEFATRYTLAD--ANLSKIN-N LFE-QN---KEGDIKA-- 1274 WP_031669209 1216 EKYEA-----ID-GESLA--YIEVHRALFDELLAYISEFARKYTLSN--DRLDEIN-M LYE-RN---KDGDVKS-- 1274 WP_033920898 1216 EKREA-----ID-GESLA--YIEAHKAVFGELLAHISEFARKYTLAN--DKLDEIN-M LYE-RN---KDGDVKS-- 1274 AKI42028 1219 KNCEA-----SD-GKSLK--YIEAHRETFSELLAQVSEFATRYTLAD--ANLSKIN-N LFE-QN---KEGDIQA-- 1277 AKI50529 1219 EKREA-----ID-GESLA--YIEAHKAVFGELLAHISEFARKYTLAN--DKLDEIN-M LYE-RN---KDGDVKS-- 1277 EFR83390 664 KNCEA-----SD-GKSLK--YTEAHRETFSELLAQVSEFATRYTLAD--ANLSKIN-N LFE-QN---KEGDIKX-- 722 WP_046323366 1216 KNCEA-----SD-GKSLA--YIESHREMFAELLDSISEFASRYTLAD--ANLEKIN-T IFE-QN---KSGDVKV-- 1274 AKE81011 1256 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1321 CUO82355 1216 YNAIYKQ-DFDG1DNMLMi-----------QLYLQLIDKLKTLYPIY-mGIVEKFE-K FVS----i----SKEEk- 1272 WP_033162887 1218 YAAMLKK-RYEY1DEEEIf-----------DLYLQLLQKMDTLYPAY-kGIAKRFF-D FKN----i----DVVEk- 1274 AGZ01981 1273 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1338 AKA60242 1240 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1305 AK540380 1240 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1305 4UN5_B 1244 SHYEKLKgSPEDnEQKQL--FVEQHKHYLDEIIEQISEFSKRVILAD--ANLDKVL-S AYN-KH---RDKPIREq- 1309 WP_010922251 1306 -AE---NII HLFTLTNLGAP-AAFKYFD--

TI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL-- 1365 WP_039695303 1309 ISN---SFI NLLTLTALGAP-ADFNFLG--EKI--PRK--R-YTSTKECL NATLIHQSITGLYETRIDLSKL-- 1369 WP_045635197 1307 LAN---SFI NLLTFTALGAP-AAFKFFG--KDI--DRK--R-YTTVSEIL NATLIHQSITGLYETWIDLSKL-- 1367 5AXW_A --------- ----------------------------------------- ------------------------ WP_009880683 990 -AE---NII HLFTLTNLGAP-AAFKCFD--TTI--GRN--R-YKSIKEVL DATLIHQSITGLYETRIDLSQL-- 1049 WP_010922251 1306 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL-- 1365 WP_011054416 1306 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL-- 1365 WP_011284745 1306 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATFIHQSITGLYETRIDLSQL-- 1365 WP_011285506 1306 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL-- 1365 WP_011527619 1306 -AE---NII HLFTLTNLGAP-TAFKYFD--TTI--DRK--R-YTSTKEVL DATFIHQSITGLYETRIDLSQL-- 1365 WP_012560673 1306 -AE---NII HLFTLTNLGAP-AAFKCFD--TTI--GRN--R-YKSIKEVL DATLIHQSITGLYETRIDLSQL-- 1365 WP_014407541 1305 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL-- 1364 WP_020905136 1306 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL-- 1365 WP_023080005 1305 -AK---NII HLFTLTNLGAP-AAFKYFD--TTI--ERN--R-YKSIKEVL DATLIHQSITGLYETRIDLSQL-- 1364 WP_023610282 1305 -AK---NII HLFTLTNLGAP-AAFKYFD--TTI--ERN--R-YKSIKEVL DATLIHQSITGLYEIRIDLSQL-- 1364 WP_030125963 1306 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--GRN--R-YKSIKEVL DATLIHQSITGLYETRIDLSQL-- 1365 WP_030126706 1306 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL-- 1365 WP_031488318 1306 -AE---NII HLFTLTNFGAP-AAFIYFD--TTI--GRN--R-YKSIKEVL DATLIHQSITGLYETRIDLSQL-- 1365 WP_032460140 1306 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--GRN--R-YKSIKEVL DATLIHQSITGLYETRIDLSQL-- 1365 WP_032461047 1306 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--GRN--R-YKSIKEVL DATLIHQSITGLYETRIDLSQL-- 1365 WP_032462016 1306 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL-- 1365 WP_032462936 1306 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL-- 1365 WP_032464890 1306 -AE---NII HLFTLTNLGAP-TAFKYFD--TTI--DRK--R-YTSTKEVL DATFIHQSITGLYETRIDLSQL-- 1365 WP_033888930 1131 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL-- 1190 WP_038431314 1306 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL-- 1365 WP_038432938 1305 -AK---NII HLFTLTNLGAP-AAFKYFD--TTI--ERN--R-YKSIKEVL DATLIHQSITGLYETRIDLSQL-- 1364 WP_038434062 1306 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--GRN--R-YKSIKEVL DATLIHQSITGLYETRIDLSQL-- 1365 BAQ51233 1217 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL-- 1276 KGE60162 481 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL-- 540 KGE60856 244 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL-- 303 WP_002989955 1306 -AE---NII HLFTLTNLGAP-TAFKYFD--TTI--DRK--R-YTSTKEVL DATFIHQSITGLYETRIDLSQL-- 1365 WP_003030002 1282 LAK---SFI SLLTFTAFGAP-AAFNFFG--ENI--DRK--R-YTSVTECL NATLIHQSITGLYETRIDLSKL-- 1342 WP_003065552 1310 ISN---SFI NLLTLTALGAP-ADFNFLG--EKI--PRK--R-YTSTKECL NATLIHQSITGLYETRIDLSKI-- 1370 WP_001040076 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_001040078 1315 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLSKL-- 1375 WP_001040080 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_001040081 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_001040083 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_001040085 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_001040087 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_001040088 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_001040089 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_001040090 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_001040091 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_001040092 1307 LAK---NII NLFTFTSLGAP-AAFKFFD--KSV--DRK--R-YTSTKEVL DSTLIHQSITGLYETRIDLGKL-- 1367 WP_001040094 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_001040095 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_001040096 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_001040097 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_001040098 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_001040099 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHKSITGLYETRIDLGKL-- 1367 WP_001040100 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_001040104 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_001040105 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_001040106 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_001040107 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_001040108 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_001040109 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQFITGLYETRIDLGKL-- 1367 WP_001040110 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_015058523 1307 LAK---NII NLFTFTSLGAP-AAFKFFD--KSV--DRK--R-YTSTKEVL DSTLIHQSITGLYETRIDLGKL-- 1367 WP_017643650 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_017647151 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_017648376 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_017649527 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_017771611 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_017771984 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 CFQ25032 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 CFV16040 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 KLJ37842 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 KLJ72361 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 KLL20707 1321 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1381 KLL42645 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_047207273 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_047209694 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHKSITGLYETRIDLGKL-- 1367 WP_050198062 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_050201642 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_050204027 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_050881965 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KII--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_050886065 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 AHN30376 1307 LAK---NII NLFTFTSLGAP-AAFKFFD--KSV--DRK--R-YTSTKEVL DSTLIHQSITGLYETRIDLGKL-- 1367 EA078426 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 CCW42055 1307 LAN---NII NLFTFTSLGAP-AAFKFFD--KIV--DRK--R-YTSTKEVL NSTLIHQSITGLYETRIDLGKL-- 1367 WP_003041502 1314 ICT---SFL GLFELTSLGSA-SDFEFLG--VKI--PRY--RdYTPSSLLK DSTLIHQSITGLYETRIDLSKL-- 1383 WP_037593752 1283 LAK---SFI SLLTFTAFGAP-AAFNFFG--ENI--DRK--R-YTSVTECL NATLIHQSITGLYETRIDLSKL-- 1343 WP_049516684 1283 LAK---SFI SLLTFTAFGAP-AAFNFFG--ENI--DRK--R-YTSVTECL NATLIHQSITGLYETRIDLSKL-- 1343 GAD46167 1282 LAK---SFI SLLTFTAFGAP-AAFNFFG--ENI--DRK--R-YTSVTECL NATLIHQSITGLYETRIDLSKL-- 1342 WP_018363470 1314 ISD---SFI NLLTLTALGAP-ADFNFLG--EKI--PRK--R-YNSTKECL NATLIHQSITGLYETRIDLSKL-- 1374 WP_003043819 1311 -SN---SFV SLLKYTSFGAS-GGFTFLD--LDVkqGRL--R-YQTVTEVL DATLIYQSITGLYETRTDLSQL-- 1372 WP_006269658 1282 LAK---SFI SLLTFTAFGAP-AAFNFFG--ENI--DRK--R-YTSVTECL NATLIHQSITGLYETRIDLSKL-- 1342 WP_048800889 1302 ISN---SFI HLLTLTALGAP-ADFNFLG--EKI--PRK--R-YTSTKECL NATLIHQSITGLYETQTDLSKL-- 1362 WP_012767106 1309 -CS---SVI NLLTLTASGAP-ADFKFLG--TTI--PRK--R-YGSPQSIL SSTLIHQSITGLYETRIDLSQL-- 1368 WP_014612333 1309 -CS---SVI NLLTLTASGAP-ADFKFLG--TTI--PRK--R-YGSPQSIL SSTLIHQSITGLYETRIDLSQL-- 1368 WP_015017095 1309 -CS---SVI NLLTLTASGAP-ADFKFLG--TTI--PRK--R-YGSPQSIL SSTLIHQSITGLYETRIDLSQL-- 1368 WP_015057649 1309 -CS---SVI NLLTLTASGAP-ADFKFLG--TTI--PRK--R-YGSPQSIL SSTLIHQSITGLYETRIDLSQL-- 1368 WP_048327215 1309 -CS---SVI NLLTLTASGAP-ADFKFLG--TTI--PRK--R-YGSPQSIL SSTLIHQSITGLYETRIDLSQL-- 1368 WP_049519324 1309 -CS---SVI NLLTLTASGAP-ADFKFLG--TTI--PRK--R-YGSPQSIL SSTLIHQSITGLYETRIDLSQL-- 1368 WP_012515931 1286 -AE---NII NVFTFVALGAP-AAFKFFD--ATI--DRK--R-YTSTKEVL NATLIHQSVTGLYETRIDLSQL-- 1345 WP_021320964 1286 -AE---NII NVFTFVALGAP-AAFKFFD--ATI--DRK--R-YTSTKEVL NATLIHQSVTGLYETRIDLSQL-- 1345 WP_037581760 1286 -AE---NII NVFTFVALGAP-AAFKFFD--ATI--DRK--R-YTSTKEVL NATLIHQSVTGLYETRIDLSQL-- 1345 WP_004232481 1309 ISS1seSFI NLLKFISFGAP-GAFKFLK--LDV--KQSn1R-YKSTTEAL SATLIHQSVTGLYETRIDLSKL-- 1374 WP_009854540 1307 ISN---SFI NLLTLTALGAP-ADFNFLG--EKI--PRK--R-YTSTKECL TATLIHQSITGLYETRIDLSKL-- 1367 WP_012962174 1308 ISI---SFV NLLTLTALGAP-ADFNFLG--EKI--PRK--R-YTSTKECL NATLIHQSITGLYETRIDLSKL-- 1368 WP_039695303 1309 ISN---SFI NLLTLTALGAP-ADFNFLG--EKI--PRK--R-YTSTKECL NATLIHQSITGLYETRIDLSKL-- 1369 WP_014334983 1312 ISA---SFI NLLTLTALGAP-ADFNFLG--EKI--PRK--R-YTSTKECL SATLIHQSVTGLYETRIDLSKL-- 1372 WP_003099269 1306 -AI---NML NLFTFTDLGAP-SAFKFFN--GDI--DRK--R-YSSTNEII NSTLIYQSPTGLYETRIDLSKL-- 1365 AHY15608 --------- ----------------------------------------- ------------------------ AHY17476 --------- ----------------------------------------- ------------------------ ESR09100 138 -AI---NML NLFTFTDLGAP-SAFKFFNg--DI--DRK--R-YSSTNEII NSTLIYQSPTGLYETRIDLSKL-- 197 AGM98575 --------- ----------------------------------------- ------------------------ ALF27331 1282 LAS---SFI NLLTFTAIGAP-AAFKFFD--NNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSRL-- 1342 WP_018372492 1290 VAR---SFV -LLNFTMMGAA-TDFKFFG--QII--PRK--R-YPSTTECL KSTLIHQSVTGLYETRIDLSKL-- 1350 WP_045618028 1311 LSE---SFI SLLKLISFGAP-GTFKFLG--VEI--SQSnvR-YQSVSSCF NATLIHQSITGLYETRIDLSKL-- 1373 WP_045635197 1307 LAN---SFI NLLTFTALGAP-AAFKFFG--KDI--DRK--R-YTTVSEIL NATLIHQSITGLYETWIDLSKL-- 1367 WP_002263549 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLNKL-- 1342 WP_002263887 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLNKL-- 1342 WP_002264920 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_002269043 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLNKL-- 1342 WP_002269448 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_002271977 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_002272766 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_002273241 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_002275430 1282 LSS---SFI NLLTFTAIGAP-AAFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_002276448 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_002277050 1288 LAD---GFI KLLGFTQLGAT-SPFSFLG--IKL--NQK--Q-YTGKKDYL EATLIHQSITGLYETRIDLNKL-- 1352 WP_002277364 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_002279025 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_002279859 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_002280230 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_002281696 1282 LSS---SFI NLLTFTAIGAP-AAFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_002282247 1288 LAD---GFI KLLGFTQLGAT-SPFSFLG--IKL--NQK--Q-YTGKKDYL EATLIHQSITGLYETRIDLSKL-- 1352 WP_002282906 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_002283846 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_002287255 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_002288990 1282 LAS---SFI NLLTFTAIGAP-AAFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_002289641 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_002290427 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_002295753 1282 LAS---SFI NLLTFTAIGAP-AAFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_002296423 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_002304487 1296 LAS---SFI NLLTFTAIGAP-AAFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLNKL-- 1356 WP_002305844 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_002307203 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_002310390 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_002352408 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_012997688 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_014677909 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_019312892 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_019313659 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLNKL-- 1342 WP_019314093 1282 LAS---SFI NLLTFTAIGAP-AAFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_019315370 1282 LSS---SFI NLLTFTAIGAP-AAFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_019803776 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLNKL-- 1342 WP_019805234 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_024783594 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLNKL-- 1342 WP_024784288 1288 LAD---GFI KLLGFTQLGAT-SPFSFLG--IKL--NQK--Q-YTGKKDYL EATLIHQSITGLYETRIDLSKL-- 1352 WP_024784666 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_024784894 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_024786433 1288 LAD---GFI KLLGFTQLGAT-SPFSFLG--IKL--NQK--Q-YTGKKDYL EATLIHQSITGLYETRIDLSKL-- 1352 WP_049473442 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1342 WP_049474547 1282 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL KATLIHQSITGLYETRIDLSKL-- 1342 EMC03581 1275 LAS---SFI NLLTFTAIGAP-ATFKFFD--KNI--DRK--R-YTSTTEIL NATLIHQSITGLYETRIDLSKL-- 1335 WP_000428612 1310 LAN---SFI NLLTFTALGAP-AAFKFFG--KDV--DRK--R-YTTVSEIL NATLIHQSITGLYETRIDLSKL-- 1370 WP_000428613 1308 LAN---SFI NLLTFTALGAP-AAFKFFG--KDI--DRK--R-YTTVSEIL NATLIHQSITGLYETRIDLSKL-- 1368 WP_049523028 1303 IAN---SFI NLLTFTAFGAP-AVFKFFG--KDI--ERK--R-YSTVTEIL KATLIHQSLTGLYETRIDLSKL-- 1363 WP_003107102 1275 -AT---NML NLFTFTGLGAP-ATLKFFN--VDI--DRK--R-YTSSTEIL NSTLIRQSITGLYETRIDLSKI-- 1334 WP_054279288 1304 -SI---SFL NLFKFTSFGAP-EKFTFLN--SEIkqDDV--R-YRSTKECL NSTLIHQSVTGLYETRIDLSQF-- 1365 WP_049531101 1311 LSE---SFI SLLKLTSFGAP-GAFRFLG--VEI--SQSnvR-YQSVSSCF NATLIHQSITGLYETRIDLSKL-- 1373 WP_049538452 1311 LSE---SFI SLLKLTSFGAP-GAFKFLG--VEI--SQSsvR-YKPNSQFL DATLIHQSITGLYETRIDLSKL-- 1373 WP_049549711 1313 LSE---SFI SLLKLTSFGAP-GAFKFLG--AEI--SQSsvR-YKPNSQFL DTTLIHQSITGLYETRIDLSKL-- 1375 WP_007896501 1312 -AL---NML NLFIFTSLGAP-STFVFFD--ETI--DRK--R-YTTSSDVL NGILIQQSITGLYETRIDLSRF-- 1371 EFR44625 1264 -AL---NML NLFIFTSLGAP-STFVFFD--ETI--DRK--R-YTTSSDVL NGILIQQSITGLYETRIDLSRF-- 1323 WP_002897477 1307 LAN---SFI NLLTFTALGAP-AAFKFFG--KDV--DRK--R-YTTVSEIL NATLIHQSITGLYETRIDLSKL-- 1367 WP_002906454 1312 LSE---SFI SLLKLTSFGAP-GAFKFLG--VEI--SQSsvR-YKPNSQFL DTTLIHQSITGLYETRIDLSKL-- 1374 WP_009729476 1308 LAN---SFI NLLTFTALGAP-AAFKFFG--KDV--DRK--R-YTTVSEIL NATLIHQSITGLYETRIDLSKL-- 1368 CQR24647 1296 LAQ---SFI SLLKFTAFGAP-GGFKFLD--ADI--KQSn1R-YQTVTEVL SSTLIHQSVTGLYETRIDLSKL-- 1358 WP_000066813 1312 LAN---SFI NLLTFTALGAP-AAFKFLG--KDV--DRK--R-YTTVSEIL NATLIHQSITGLYETRIDLSKL-- 1372 WP_009754323 1308 LAN---SFI NLLTFTALGAP-AAFKFFG--KDV--DRK--R-YTTVSEIL NATLIHQSITGLYETRIDLSKL-- 1368 WP_044674937 1301 LTS---SFV NLLTFTAIGAP-AAFKFLG--SVI--DRK--R-YTSIAEIL EATLIHQSVTGLYETRIDLSKL-- 1361 WP_044676715 1303 LTS---SFV NLLTFTAIGAP-AAFKFLG--SVI--DRK--R-YTSIAEIL EATLIHQSVTGLYETRIDLSKL-- 1363 WP_044680361 1303 LTS---SFV NLLTFTAIGAP-AAFKFLG--SVI--DRK--R-YTSIAEIL EATLIHQSVTGLYETRIDLSKL-- 1363 WP_044681799 1301 LTS---SFV NLLTFTAIGAP-AAFKFLG--SVI--DRK--R-YTSIAEIL EATLIHQSVTGLYETRIDLSKL-- 1361 WP_049533112 1314 ICT---SFL GLFELTSLGSA-SDFEFLG--VKI--PRY--RdYTPSSLLK DSTLIHQSITGLYETRIDLSKL-- 1383 WP_029090905 1241 -VK----VI ELLKITQANATnGDLKLLK----M-sNREg-R-LGSVSVAL DFKIINQSVTGLYQSIEDYNN--- 1300 WP_006506696 1269 -AN----II QMLIVMHRGPQnGNIVYDDf--KI-sDRIg-R-LKTKNHNL NIVFISQSPTGIYTKKYKL----- 1329 AIT42264 1306 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL-- 1365 WP_034440723 1277 LVE---SFI NLLAITKCGPA-ADITFLG--EKI--SRK--R-YRSTNCLW GSEVIFQSPTGLYETRLRLE---- 1335 AKQ21048 1306 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL-- 1365 WP_004636532 1272 TVE---SFV NLMTFTAMGAP-ATFKFYG--ESI--TRS--R-YTSITEFR GSTLIFQSITGLYETRYKL----- 1329 WP_002364836 1278 IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSTTGLYETRRKV----- 1335 WP_016631044 1229 IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSPTGLYETRRKV----- 1286 EM575795 1014 LSQ---SFI NLMQLNAMGAP-ADFKFFD--VII--PRK--R-YPSLTEIW ESTITYQSITGLRETRTRMATLwd 1076 WP_002373311 1278 IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSTTGLYETRRKV----- 1335 WP_002378009 1278 IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSTTGLYETRRKV----- 1335 WP_002407324 1278 IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSTTGLYETRRKV----- 1335 WP_002413717 1278 IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSTTGLYETRRKV----- 1335 WP_010775580 1280 IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSTTGLYETRRKV----- 1337 WP_010818269 1278 IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSTTGLYETRRKV----- 1335 WP_010824395 1278 IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSTTGLYETRRKV----- 1335 WP_016622645 1278 IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSTTGLYETRRKV----- 1335 WP_033624816 1278 IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSTTGLYETRRKV----- 1335 WP_033625576 1278 IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSTTGLYETRRKV----- 1335 WP_033789179 1278 IAA---SFI QLMQFNAMGAP-STFKFFQ--KDI--ERA--R-YTSIKEIF DATIIYQSTTGLYETRRKV----- 1335 WP_002310644 1280 LAS---SFV NLMQFNAMGAP-ADFKFFD--VTI--PRK--R-YTSLTEIW QSTIIHQSITGLYETRIRMGK--- 1339 WP_002312694 1281 LAS---SFV NLMQFNAMGAP-ADFKFFD--VTI--PRK--R-YTSLTEIW QSTIIHQSITGLYETRIRMGK--- 1340 WP_002314015 1281 LAS---SFV NLMQFNAMGAP-ADFKFFD--VTI--PRK--R-YTSLTEIW QSTIIHQSITGLYETRIRMGK--- 1340 WP_002320716 1281 LAS---SFV NLMQFNAMGAP-ADFKFFD--VTI--PRK--R-YTSLTEIW QSTIIHQSITGLYETRIRMGK--- 1340 WP_002330729 1280 LAS---SFV NLMQFNAMGAP-ADFKFFD--VTI--PRK--R-YTSLTEIW QSTIIHQSITGLYETRIRMGK--- 1339 WP_002335161 1281 LAS---SFV NLMQFNAMGAP-ADFKFFD--VTI--PRK--R-YTSLTEIW QSTIIHQSITGLYETRIRMGK--- 1340 WP_002345439 1281 LAS---SFV NLMQFNAMGAP-ADFKFFD--VTI--PRK--R-YTSLTEIW QSTIIHQSITGLYETRIRMGK--- 1340 WP_034867970 1271 IAQ---SFL QLLQFNAIGAP-ADFKFFG--VTI--PRK--R-YTSLTEIW DATIIYQSVTGLYETRIRMGDLwa 1333 WP_047937432 1281 LAS---SFV NLMQFNAMGAP-ADFKFFD--VTI--PRK--R-YTSLTEIW QSTIIHQSITGLYETRIRMGK--- 1340 WP_010720994 1271 IAQ---SFL QLLQFNAIGAP-ADFKFFG--VTI--PRK--R-YTSLTEIW DATIIYQSVTGLYETRIRMGDLwa 1333 WP_010737004 1271 IAQ---SFL QLLQFNAIGAP-ADFKFFG--VTI--PRK--R-YTSLTEIW DATIIYQSVTGLYETRIRMGDLwa 1333 WP_034700478 1271 IAQ---SFL QLLQFNAIGAP-ADFKFFG--VTI--PRK--R-YTSLTEIW DATIIYQSVTGLYETRIRMGDLwa 1333 WP_007209003 1270 IAK---SFI NLLTFTAMGAP-ADFEFFG--EKI--PRK--R-YVSISEII DAVFIHQSITGLYETRVRLTEV-- 1330 WP_023519017 1265 MID---AIL SLLKFTLFGAS-VEFKFFD--IKI---LK--R-YKSLTDIW EATIIYQSVTGLYERRVEVRKLwd 1326 WP_010770040 1275 IAE---SFV NLMKFSAYGAP-MDFKFFG--KTI--PRS--R-YTSVGELL SATIINQSITGLYETRRKL----- 1332 WP_048604708 1271 IAQ---SFV DLMQLNAFGAP-ADFKFFG--ETI--PRK--R-YTSVNELL EATIINQSITGLYETRRRL----- 1328 WP_010750235 1274 MAH---SFV NLMQFNALGAP-ADFKFFD--TTI--TRK--R-YTSLTEIW QSTIIYQSVTGLYETRRRMADLwd 1336 AII16583 1345 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL-- 1404 WP_029073316 1283 -CE----VI QMLVVMHAGPQnGNITFDDf--KL-sNRLg-R-LNCKTISL TTVFIADSPTGMYSKKYKL----- 1343 WP_031589969 1284 -CN----II QILATLHCNSSiGKIMYSDf--KI-sTTIg-R-LNGRTISL DISFIAESPTGMYSKKYKL----- 1344 KDA45870 1254 LGK---NFV ELLRYTADGAA-SDFKFFG--ENI--PRK--R-YNSAGSLL NGTLIYQSKTGLYETRIDLGKL-- 1314 WP_039099354 1307 ILDr----V -LIGLHANAAV-SDLGVLKisTPL--GKM--Q---QPSGIS DTQIIYQSPTGLFERRVALRDL-- 1368 AKP02966 1297 INS1-eELI TLLHANSTSAH-LIFNNIE-kKAF--GRK-------THGLT DTDFIYQSVTGLYETRIHIE---- 1356 WP_010991369 1275 IAQ---SFV DLMAFNAMGAP-ASFKFFE--TTI--ERK--R-YNNLKELL NSTIIYQSITGLYESRKRL----- 1332 WP_033838504 1275 IAQ---SFV DLMAFNAMGAP-ASFKFFE--TTI--ERK--R-YNNLKELL NSTIIYQSITGLYESRKRL----- 1332 EHN60060 1278 IAQ---SFV DLMAFNAMGAP-ASFKFFE--TTI--ERK--R-YNNLKELL NSTIIYQSITGLYESRKRL----- 1335 EFR89594 1044 IAQ---SFV DLMAFNAMGAP-ASFKFFE--TTI--ERK--R-YNNLKELL NSTIIYQSITGLYESRKRL----- 1101 WP_038409211 1275 IAK---SFD KLKVFNAFGAP-RDFEFFE--TTI--KRK--R-YYNIKELL NATIIYQSITGLYEARKRL----- 1332 EFR95520 894 IAK---SFD KLKVFNAFGAP-RDFEFFE--TTI--KRK--R-YYNIKELL NATIIYQSITGLYEARKRL----- 951 WP_003723650 1275 IAQ---SFV DLMAFNAMGAP-ASFKFFE--ATI--DRK--R-YTNLKELL SSTIIYQSITGLYESRKRL----- 1332 WP_003727705 1275 IAQ---SFV DLMAFNAMGAP-ASFKFFE--ATI--DRK--R-YTNLKELL SSTIIYQSITGLYESRKRL----- 1332 WP_003730785 1275 IAQ---SFV DLMAFNAMGAP-ASFKFFE--ATI--DRK--R-YTNLKELL SSTIIYQSITGLYESRKRL----- 1332 WP_003733029 1275 IAE---SFV SLKKFNAFGVH-QDFSFFG--TKI--ERK--R-DRKLNELL NSTIIYQSITGLYESRKRL----- 1332 WP_003739838 1275 IAQ---SFV NLMAFNAMGAP-ASFKFFE--ATI--ERK--R-YTNLKELL SATIIYQSITGLYEARKRL----- 1332 WP_014601172 1275 IAQ---SFV DLMAFNAMGAP-ASFKFFE--ATI--DRK--R-YTNLKELL SSTIIYQSITGLYESRKRL----- 1332 WP_023548323 1275 IAE---SFV SLKKFNAFGVH-KDFNFFG--TTI--KRK--R-DRKLKELL NSTIIYQSITGLYESRKRL----- 1332 WP_031665337 1275 IAQ---SFV DLMAFNAMGAP-ASFKFFE--ATI--DRK--R-YTNLKELL SSTIIYQSITGLYESRKRL----- 1332 WP_031669209 1275 IAE---SFV SLKKFNAFGVH-QDFSFFG--TKI--ERK--R-DRKLNELL NSTIIYQSITGLYESRKRL----- 1332 WP_033920898 1275 IAE---SFV SLKKFNAFGVH-KDFNFFG--TTI--KRK--R-DRKLKELL NSTIIYQSITGLYESRKRL----- 1332 AKI42028 1278 IAQ---SFV DLMAFNAMGAP-ASFKFFE--ATI--DRK--R-YTNLKELL SSTIIYQSITGLYESRKRL----- 1335 AKI50529 1278 IAE---SFV SLKKFNAFGVH-KDFNFFG--TTI--KRK--R-DRKLKELL NSTIIYQSITGLYESRKRL----- 1335 EFR83390 723 IAQ---SFV DLMVFNAMGAP-ASFKFFE--ATI--DRK--R-YTNLKELL SSTIIYQSITGLYESRKRL----- 780 WP_046323366 1275 IAQ---SFV NLLEFNAMGAP-ASFKYFE--TNI--ERK--R-YNNLKELL NATIIYQSITGLYEARKRL----- 1332 AKE81011 1322 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL-- 1381 CUO82355 1273 -AN----VI QMLIIMHKGPQnGNIIYDDf--NV-gKRIg-R-LNGRTFYL NIEFISQSPTGIYTKKYKL----- 1333 WP_033162887 1275 -CD----VI QILIIMHAGPMnGNIMYDDf--KF-tNRIg-R-FTHKNIDL KTTFISTSVTGLFSKKYKL----- 1335 AGZ01981 1339 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL-- 1398 AKA60242 1306 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL-- 1365 AKS40380 1306 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL-- 1365 4UN5_B 1310 -AE---NII HLFTLTNLGAP-AAFKYFD--TTI--DRK--R-YTSTKEVL DATLIHQSITGLYETRIDLSQL-- 1369 WP_010922251 1366 GGD 1368 WP_039695303 1370 GEE 1372 WP_045635197 1368 GED 1370 5AXW_A ---  WP_009880683 1050 GGD 1052 WP_010922251 1366 GGD 1368 WP_011054416 1366 GGD 1368 WP_011284745 1366 GGD 1368 WP_011285506 1366 GGD 1368 WP_011527619 1366 GGD 1368 WP_012560673 1366 GGD 1368 WP_014407541 1365 GGD 1367 WP_020905136 1366 GGD 1368 WP_023080005 1365 GGD 1367 WP_023610282 1365 GGD 1367 WP_030125963 1366 GGD 1368 WP_030126706 1366 GGD 1368 WP_031488318 1366 GGD 1368 WP_032460140 1366 GGD 1368 WP_032461047 1366 GGD 1368 WP_032462016 1366 GGD 1368 WP_032462936 1366 GGD 1368 WP_032464890 1366 GGD 1368 WP_033888930 1191 GGD 1193 WP_038431314 1366 GGD 1368 WP_038432938 1365 GGD 1367 WP_038434062 1366 GGD 1368 BAQ51233 1277 GGD 1279 KGE60162 541 GGD 543 KGE60856 304 GGD 306 WP_002989955 1366 GGD 1368 WP_003030002 1343 GED 1345 WP_003065552 1371 GEE 1373 WP_001040076 1368 GED 1370 WP_001040078 1376 GED 1378 WP_001040080 1368 GED 1370 WP_001040081 1368 GED 1370 WP_001040083 1368 GED 1370 WP_001040085 1368 GED 1370 WP_001040087 1368 GED 1370 WP_001040088 1368 GGD 1370 WP_001040089 1368 GED 1370 WP_001040090 1368 GED 1370 WP_001040091 1368 GED 1370 WP_001040092 1368 GED 1370 WP_001040094 1368 GED 1370 WP_001040095 1368 GEG 1370 WP_001040096 1368 GEG 1370 WP_001040097 1368 GED 1370 WP_001040098 1368 GED 1370 WP_001040099 1368 GED 1370 WP_001040100 1368 GED 1370 WP_001040104 1368 GED 1370 WP_001040105 1368 GED 1370 WP_001040106 1368 GED 1370 WP_001040107 1368 GED 1370 WP_001040108 1368 GED 1370 WP_001040109 1368 GED 1370 WP_001040110 1368 GED 1370 WP_015058523 1368 GED 1370 WP_017643650 1368 GED 1370 WP_017647151 1368 GED 1370 WP_017648376 1368 GED 1370 WP_017649527 1368 GED 1370 WP_017771611 1368 GED 1370 WP_017771984 1368 GED 1370 CFQ25032 1368 GED 1370 CFV16040 1368 GED 1370 KLJ37842 1368 GED 1370 KLJ72361 1368 GGD 1370 KLL20707 1382 GED 1384 KLL42645 1368 GED 1370 WP_047207273 1368 GED 1370 WP_047209694 1368 GED 1370 WP_050198062 1368 GED 1370 WP_050201642 1368 GED 1370 WP_050204027 1368 GED 1370 WP_050881965 1368 GED 1370 WP_050886065 1368 GED 1370 AHN30376 1368 GED 1370 EA078426 1368 GED 1370 CCW42055 1368 GED 1370 WP_003041502 1384 GED 1386 WP_037593752 1344 GED 1346 WP_049516684 1344 GED 1346 GAD46167 1343 GED 1345 WP_018363470 1375 GEE 1377 WP_003043819 1373 GGD 1375 WP_006269658 1343 GED 1345 WP_048800889 1363 GED 1365 WP_012767106 1369 GGD 1371 WP_014612333 1369 GGD 1371 WP_015017095 1369 GGD 1371 WP_015057649 1369 GGD 1371 WP_048327215 1369 GGD 1371 WP_049519324 1369 GGD 1371 WP_012515931 1346 GEN 1348 WP_021320964 1346 GEN 1348 WP_037581760 1346 GEN 1348 WP_004232481 1375 GEE 1377 WP_009854540 1368 GEE 1370 WP_012962174 1369 GEE 1371 WP_039695303 1370 GEE 1372 WP_014334983 1373 GEE 1375 WP_003099269 1366 GGK 1368 AHY15608 --- AHY17476 --- ESR09100 198 GGK 200 AGM98575 --- ALF27331 1343 GGD 1345 WP_018372492 1351 GEN 1353 WP_045618028 1374 GED 1376 WP_045635197 1368 GED 1370 WP_002263549 1343 GGD 1345 WP_002263887 1343 GGD 1345 WP_002264920 1343 GGD 1345 WP_002269043 1343 GGD 1345 WP_002269448 1343 GGD 1345 WP_002271977 1343 GGD 1345 WP_002272766 1343 GGD 1345 WP_002273241 1343 GGD 1345 WP_002275430 1343 GGD 1345 WP_002276448 1343 GGD 1345 WP_002277050 1353 GGD 1355 WP_002277364 1343 GGD 1345 WP_002279025 1343 GGD 1345 WP_002279859 1343 GGD 1345 WP_002280230 1343 GGD 1345 WP_002281696 1343 GGD 1345 WP_002282247 1353 GGD 1355 WP_002282906 1343 GGD 1345 WP_002283846 1343 GGD 1345 WP_002287255 1343 GGD 1345 WP_002288990 1343 GGD 1345 WP_002289641 1343 GGD 1345 WP_002290427 1343 GGD 1345 WP_002295753 1343 GGD 1345 WP_002296423 1343 GGD 1345 WP_002304487 1357 GGD 1359 WP_002305844 1343 GGD 1345 WP_002307203 1343 GGD 1345 WP_002310390 1343 GGD 1345 WP_002352408 1343 GGD 1345 WP_012997688 1343 GGD 1345 WP_014677909 1343 GGD 1345 WP_019312892 1343 GGD 1345 WP_019313659 1343 GGD 1345 WP_019314093 1343 GGD 1345 WP_019315370 1343 GGD 1345 WP_019803776 1343 GGD 1345 WP_019805234 1343 GGD 1345 WP_024783594 1343 GGD 1345 WP_024784288 1353 GGD 1355 WP_024784666 1343 GGD 1345 WP_024784894 1343 GGD 1345 WP_024786433 1353 GGD 1355 WP_049473442 1343 GGD 1345 WP_049474547 1343 GGD 1345 EMC03581 1336 GGD 1338 WP_000428612 1371 GED 1373 WP_000428613 1369 GED 1371 WP_049523028 1364 GEE 1366 WP_003107102 1335 GGD 1337 WP_054279288 1366 GGD 1368 WP_049531101 1374 GED 1376 WP_049538452 1374 GED 1376 WP_049549711 1376 GED 1378 WP_007896501 1372 GGD 1374 EFR44625 1324 GGD 1326 WP_002897477 1368 GEE 1370 WP_002906454 1375 GED 1377 WP_009729476 1369 GED 1371 CQR24647 1359 GGE 1361 WP_000066813 1373 GED 1375 WP_009754323 1369 GED 1371 WP_044674937 1362 GGD 1364 WP_044676715 1364 GGD 1366 WP_044680361 1364 GGD 1366 WP_044681799 1362 GGD 1364 WP_049533112 1384 GED 1386 WP_029090905 --- WP_006506696 --- A1T42264 1366 GGD 1389 WP_034440723 AKQ21048 1366 GGD 1384 WP_004636532 1330 -ED 1332 WP_002364836 1336 -VD 1337 WP_016631044 1287 -VD 1288 EMS75795 1077 GEQ 1079 WP_002373311 1336 -VD 1337 WP_002378009 1336 -VD 1337 WP_002407324 1336 -VD 1337 WP_002413717 1336 -VD 1337 WP_010775580 1338 -VD 1339 WP_010818269 1336 -VD 1337 WP_010824395 1336 -VD 1337 WP_016622645 1336 -VD 1337 WP_033624816 1336 -VD 1337 WP_033625576 1336 -VD 1337 WP_033789179 1336 -VD 1337 WP_002310644 --- WP_002312694 --- WP_002314015 --- WP_002320716 --- WP_002330729 --- WP_002335161 --- WP_002345439 --- WP_034867970 1334 GEQ 1336 WP_047937432 --- WP_010720994 1334 GEQ 1336 WP_010737004 1334 GEQ 1336 WP_034700478 1334 GEQ 1336 WP_007209003 --- WP_023519017 1327 GER 1330 WP_010770040 1333 -VD 1334 WP_048604708 1329 -GD 1330 WP_010750235 1337 GVQ 1339 AII16583 1405 GGD 1424 WP_029073316 --- WP_031589969 --- KDA45870 --- WP_039099354 --- AKP02966 --- WP_010991369 1333 -DD 1334 WP_033838504 1333 -DD 1334 EHN60060 1336 -DD 1337 EFR89594 1102 -DD 1103 WP_038409211 1333 -ED 1334 EFR95520 952 -ED 953 WP_003723650 1333 -DD 1334 WP_003727705 1333 -DD 1334 WP_003730785 1333 -DD 1334 WP_003733029 1333 -DN 1334 WP_003739838 1333 -DG 1334 WP_014601172 1333 -DD 1334 WP_023548323 1333 -DS 1334 WP_031665337 1333 -DD 1334 WP_031669209 1333 -DN 1334 WP_033920898 1333 -DS 1334 AKI42028 1336 -DD 1337 AKI50529 1336 -DS 1337 EFR83390 781 -DD 782 WP_046323366 1333 -DD 1334 AKE81011 1382 GGD 1400 CUO82355 --- WP_033162887 --- AGZ01981 1399 GGD 1417 AKA60242 1366 GGD 1368 AKS40380 1366 GGD 1376 4UN5_B 1370 GGD 1372

TABLE 2 T to C changes with NGG PAM. Table 2 shows a list of T to C mutations that may be corrected using any of the base editors provided herein. GRNAs and gRNAall indicate the protospacer and PAM sequence, where the PAM sequence is the last 3 nucleotides of each of the sequences in GRNAs and gRNAall. SEQ SEQ SEQ Gene Gene ID ID ID Name ID Symbol NO: Flanks NO: GRNAs NO: gRNAall NM_000071.2 875 CBS 2540 [′CTGAAGCCGC 2703- [′ATCAYTGGGGTG 2907- [′ATCAYTGGGGTG (CBS):c.833T>C GCCCTCTGCAG 2704 GATCCCGAAGG′, 2908 GATCCCGAAGG′, (p.Ile278Thr) ATCAYTGGGGT ′TCAYTGGGGTGGA ′TCAYTGGGGTGG GGATCCCGAA TCCCGAAGGG′] ATCCCGAAGGG′] GGGTCCATC′] NM_001385.2 1807 DPYS 2541 [′TGTTGAAGAT 2705- [′CGTAATAYGGGA 2909- [′CGTAATAYGGGA (DPYS):c.1078T>C CGGATGTCCGT 2707 AAAAGGCGTGG′, 2911 AAAAGGCGTGG′, (p.Trp360Arg) AATAYGGGAA ′AATAYGGGAAAA ′AATAYGGGAAAA AAAGGCGTGG AGGCGTGGTGG′, AGGCGTGGTGG′, TGGGTTTCAC′] ′ATAYGGGAAAAA ′ATAYGGGAAAAA GGCGTGGTGGG′] GGCGTGGTGGG′] NM_000027.3 175 AGA 2542 [′TCCAGAATTC 2708 [′GTTATAYGTGCC 2912 [′GTTATAYGTGCC (AGA):c.916T>C TTTGGGGCTGT AATGTGACTGG′] AATGTGACTGG′] (p.Cys306Arg) TATAYGTGCCA ATGTGACTGGA AGTTACGG′] NM_000035.3 229 ALDOB 2543 [′GAAAGATGGT 2709 [′GGAAGYGGCGTG 2913 [′GGAAGYGGCGT (ALDOB):c.442T>C GTTGACTTTGG CTGTGCTGAGG′] GCTGTGCTGAGG′] (p.Trp148Arg) GAAGYGGCGT GCTGTGCTGAG GATTGCCGA′] NM_173560.3 222546 RFX6 2544 [′GCAGACACAG 2710- [′CAGTGGYGAGAC 2914- [′CAGTGGYGAGAC (RFX6):c.380+2T>C CTCACGCTGCA 2711 TCGCCCGCAGG′, 2915 TCGCCCGCAGG′, GTGGYGAGAC ′AGTGGYGAGACTC ′AGTGGYGAGACT TCGCCCGCAGG GCCCGCAGGG′] CGCCCGCAGGG′] GTACACTGA′] NM_153704.5 91147 TMEM67 2545 [′AGAACGTTTT 2712 [′TGGAHGTGCCTTT 2916 [′TGGAHGTGCCTT (TMEM67):c.1843T>C GTCACTTATGT GCTCTGAAGG′] TGCTCTGAAGG′] (p.Cys615Arg) TGGAHGTGCCT TTGCTCTGAAG GTAAGTTT′] NM_000124.3 2074 ERCC6 2546 [′AAGCAGTTTT 2713 [′TGCYAAAAGACC 2917 [′TGCYAAAAGACC (ERCC6):c.2960T>C TGACAAATAG CAAAACAAAGG′] CAAAACAAAGG′] (p.Leu987Pro) AGTGCYAAAA GACCCAAAAC AAAGGCGGTTT′] NM_020435.3 57165 GJC2 2547 [′TGCCTGCTGC 2714 [′TGAGAYGGCCCA 2918- [′TGAGAYGGCCCA (GJC2):c.857T>C TCAACCTCTGT CCTGGGCTTGG′] 2919 CCTGGGCTTGG′, (p.Met286Thr) GAGAYGGCCC ′GAGAYGGCCCAC ACCTGGGCTTG CTGGGCTTGGG′] GGCAGCGCG′] NM_000920.3 5091 PC 2548 [′CGGTTTATTG 2715 [′CCAGAAGBGGTC 2920 [′CCAGAAGBGGTC (PC):c.434T>C GGCCAAGCCC CGCAAGATGGG′] CGCAAGATGGG′] (p.Val145Ala) AGAAGBGGTC CGCAAGATGG GAGACAAGGTG′] NM_000026.2 158 ADSL 2549 [′TCCAAGGTAG 2716 [′AAGAYGGTGACA 2921 [′AAGAYGGTGAC (ADSL):c.674T>C AGCAGCTTGAC GAAAAGGCAGG′] AGAAAAGGCAGG′] (p.Met225Thr) AAGAYGGTGA CAGAAAAGGC AGGATTTAAG′] NM_000391.3 1200 TPP1 2550 [′TCTCTCAGGT 2717 [′GCCGGGYGTTGG 2922 [′GCCGGGYGTTGG (TPP1):c.1093T>C GACAGTGGGG TCTGTCTCTGG′] TCTGTCTCTGG′] (p.Cys365Arg) CCGGGYGTTG GTCTGTCTCTG GAAGACACCA′] NM_004183.3 7439 BEST1 2551 [′TACGACTGGA 2718 [′CACTGGYGTATA 2923 [′CACTGGYGTATA (BEST1):c.704T>C TTAGTATCCCA CACAGGTGAGG′] CACAGGTGAGG′] (p.Val235Ala) CTGGYGTATAC ACAGGTGAGG ACTAGGCTG′] NM_000019.3 38 ACAT1 2552 [′CTCAATGTTA 2719 [′CAAGAAYAGTAG 2924 [′CAAGAAYAGTA (ACAT1):c.935T>C CACCACTGGCA GTAAGGCCAGG′] GGTAAGGCCAGG′] (p.Ile312Thr) AGAAYAGTAG GTAAGGCCAG GCGAGGTGGC′] NM_000543.4 6609 SMPD1 2553 [′CGGGCCCTGA 2720 [′CACYTGTGAGGA 2925- [′AGCACYTGTGAG (SMPD1):c.911T>C CCACCGTCACA AGTTCCTGGGG′] 2927 GAAGTTCCTGG′, (p.Leu304Pro) GCACYTGTGA ′GCACYTGTGAGG GGAAGTTCCTG AAGTTCCTGGG′, GGGCCAGTG′] ′CACYTGTGAGGA AGTTCCTGGGG′] NM_000527.4 3949 LDLR 2554 [′ACAAATCTGA 2721 [′CGGYATGGGCGG 2928- [′ACTGCGGYATGG (LDLR):c.694+2T>C CGAGGAAAAC GGCCAGGGTGG′] 2930 GCGGGGCCAGG′, TGCGGYATGG ′CTGCGGYATGGG GCGGGGCCAG CGGGGCCAGGG′, GGTGGGGGCGG′] ′CGGYATGGGCGG GGCCAGGGTGG′] NM_012464.4 7092 TLL1 2555 [′AAGAACTGTG 2722 [′GGGATTGYTGTTC 2931 [′GGGATTGYTGTT (TLL1):c.713T>C ATAAATTTGGG ATGAATTGGG′] CATGAATTGGG′] (p.Val238Ala) ATTGYTGTTCA TGAATTGGGTC ATGTGATA′] NM_000112.3 1836 SLC26A2 2556 [′CCTGCAGCGG 2723 [′GAGAGGYGAGAA 2932 [′GAGAGGYGAGA (SLC26A2):c.-26+2T>C CCCGGACCCG GAGGGAAGCGG′] AGAGGGAAGCGG′] AGAGGYGAGA AGAGGGAAGC GGACCAGGGA A′] NM_001005741.2 2629 GBA 2557 [′CATCTACCAC 2724 [′GCCAGAYACTTT 2933- [′GCCAGAYACTTT (GBA):c.751T>C CAGACCTGGG GTGAAGTAAGG′] 2934 GTGAAGTAAGG′, (p.Tyr251His) CCAGAYACTTT ′CCAGAYACTTTGT GTGAAGTAAG GAAGTAAGGG′] GGATCAGCAA′] NM_020365.4 8891 EIF2B3 2558 [′CCACCAGTCC 2725 [′CCAGAYTGTCAG 2935 [′CCAGAYTGTCAG (EIF2B3):c.1037T>C ATTCGTCAGCC CAAACACCTGG′] CAAACACCTGG′] (p.Ile346Thr) CAGAYTGTCA GCAAACACCT GGTAAGTGCT′] NM_022041.3 8139 GAN 2559 [′TGCTATGCAG 2726 [′AAGAAAAYCTAC 2936-2937 [′AAGAAAAYCTAC (GAN):c.1268T>C CTATGAAAAA GCCATGGGTGG′] GCCATGGGTGG′, (p.Ile423Thr) GAAAAYCTAC ′AAAAYCTACGCC GCCATGGGTG ATGGGTGGAGG′] GAGGCTCCTAC′] NM_054027.4 56172 ANKH 2560 [′GCTGTCAAGG 2727- [′GTCGAGAYGCTG 2938-2939 [′GTCGAGAYGCTG (ANKH):c.143T>C AGGATGCAGT 2728 GCCAGCTACGG′, GCCAGCTACGG′, (p.Met48Thr) CGAGAYGCTG ′TCGAGAYGCTGGC ′TCGAGAYGCTGG GCCAGCTACG CAGCTACGGG′] CCAGCTACGGG′] GGCTGGCGTAC′] NM_006329.3 10516 FBLN5 2561 [′TTGCTTGCAT 2729 [′GACAYTGATGAA 2940 [′GACAYTGATGAA (FBLN5):c.506T>C TTCTGTTTCCA TGTCGCTATGG′] TGTCGCTATGG′] (p.Ile169Thr) GACAYTGATG AATGTCGCTAT GGTTACTGC′] NM_004086.2 −1 — 2562 [′GCACCTCTGG 2730 [′AGATAYGGCTTC 2941 [′AGATAYGGCTTC (COCH):c.1535T>C ATGACCTGAA TAAACCGAAGG′] TAAACCGAAGG′] (p.Met512Thr) AGATAYGGCTT CTAAACCGAA GGAGTCTCAT′] NM_002942.4 6092 ROBO2 2563 [′AATAGCAACA 2731 [′GAGAYTGGAAAT 2942 [′GAGAYTGGAAAT (ROBO2):c.2834T>C GTGGCCCAAAT TTTGGCCGTGG′] TTTGGCCGTGG′] (p.Ile945Thr) GAGAYTGGAA ATTTTGGCCGT GGAGGTAAG′] NM_001300.5 1316 KLF6 2564 [′CAAATTTGAC 2732 [′TCTGYGGACCAA 2943 [′TCTGYGGACCAA (KLF6):c.190T>C AGCCAGGAAG AATCATTCTGG′] AATCATTCTGG′] (p.Trp64Arg) ATCTGYGGACC AAAATCATTCT GGCTCGGGA′] NM_030653.3 1663 DDX11 2565 [′CTGGCATATT 2733 [′TCCAGGYGCGGG 2944-2945 [′TCCAGGYGCGGG (DDX11):c.2271+2T>C CCAGGTGCATC CGTCATGCTGG′] CGTCATGCTGG′, CAGGYGCGGG ′CCAGGYGCGGGC CGTCATGCTGG GTCATGCTGGG′] GCTTGGGTC′] NM_001451.2 2294 FOXF1 2566 [′CCAAGACATC 2734 [′TGATGYGAGGCT 2946 [′TGATGYGAGGCT (FOXF1):c.1138T>C AAGCCTTGCGT GCCGCCGCAGG′] GCCGCCGCAGG′] (p.Ter380Arg) GATGYGAGGC TGCCGCCGCAG GCCCTCCTG′] NM_000435.2 4854 NOTCH3 2567 [′CCTCGACCGC 2735 [′ACCYGTATCTGTA 294-72948 [′TTCACCYGTATC (NOTCH3):c.1363T>C ATAGGCCAGTT TGGCAGGTGG′] TGTATGGCAGG′, (p.Cys455Arg) CACCYGTATCT ′ACCYGTATCTGTA GTATGGCAGGT TGGCAGGTGG′] GGGTGGTG′] NM_002427.3 4322 MMP13 2568 [′CTTGACGATA 2736- [′GTCAYGAAAAAG 2949-2950 [′GTCAYGAAAAA (MMP13):c.272T>C ACACCTTAGAT 2737 CCAAGATGCGG′, GCCAAGATGCGG′, (p.Met91Thr) GTCAYGAAAA ′TCAYGAAAAAGCC ′TCAYGAAAAAGC AGCCAAGATG AAGATGCGGG′] CAAGATGCGGG′] CGGGGTTCCT′] NM_000211.4 3689 ITGB2 2569 [′GATGACCTCA 2738 [′AGCYAGGTGGCG 2951 [′AGCYAGGTGGCG (ITGB2):c.446T>C GGAATGTCAA ACCTGCTCCGG′] ACCTGCTCCGG′] (p.Leu149Pro) GAAGCYAGGT GGCGACCTGCT CCGGGCCCTC′] NM_005502.3 19 ABCA1 2570 [′CAAAATCAAG 2739- [′CCTGTGYGTCCCC 2952-2955 [′CCTGTGYGTCCC (ABCA1):c.4429T>C AAGATGCTGCC 2740 CAGGGGCAGG′, CCAGGGGCAGG′, (p.Cys1477Arg) TGTGYGTCCCC ′CTGTGYGTCCCCC ′CTGTGYGTCCCCC CAGGGGCAGG AGGGGCAGGG′] AGGGGCAGGG′, GGGGCTGCC′] ′TGTGYGTCCCCCA GGGGCAGGGG′, ′GTGYGTCCCCCA GGGGCAGGGGG′] m.12297T>C 4568 MT-TL2 2571 [′AAAGGATAAC 2741 [′GTCYTAGGCCCC 2956 [′GTCYTAGGCCCC AGCTATCCATT AAAAATTTTGG′] AAAAATTTTGG′] GGTCYTAGGCC CCAAAAATTTT GGTGCAAC′] m.4290T>C 4565 MT-TI 2572 [′AAATATGTCT 2742 [′ACTYTGATAGAG 2957 [′ACTYTGATAGAG GATAAAAGAG TAAATAATAGG′] TAAATAATAGG′] TTACTYTGATA GAGTAAATAA TAGGAGCTTA′] m.4291T>C 4565 MT-TI 2573 [′AATATGTCTG 2743 [′ACTTYGATAGAG 2958 [′ACTTYGATAGAG ATAAAAGAGT TAAATAATAGG′] TAAATAATAGG′] TACTTYGATAG AGTAAATAAT AGGAGCTTAA′] m.3394T>C 4535 MT-ND1 2574 [′GCTTACCGAA 2744 [′GGCYATATACAA 2959 [′GGCYATATACAA CGAAAAATTCT CTACGCAAAGG′] CTACGCAAAGG′] AGGCYATATA CAACTACGCA AAGGCCCCAA′] NM_002764.3 5631 PRPS1 2575 [′ATCTCAGCCA 2745 [′GCAAATAYGCTA 2960 [′GCAAATAYGCTA (PRPS1):c.344T>C AGCTTGTTGCA TCTGTAGCAGG′] TCTGTAGCAGG′] (p.Met115Thr) AATAYGCTATC TGTAGCAGGTG CAGATCAT′] NM_000132.3 2157 F8 2576 [′AGAGCAGAA 2746 [′TCAYGGTGAGTT 2961 [′TCAYGGTGAGTT (F8):c.5372T>C GTTGAAGATA AAGGACAGTGG′] AAGGACAGTGG′] (p.Met1791Thr) ATATCAYGGTG AGTTAAGGAC AGTGGAATTAC′] NM_000132.3 2157 F8 2577 [′CCTTTCAATA 2747 [′AACAGAYAATGT 2962 [′AACAGAYAATGT (F8):c.1754T>C TATGTAATTAA CAGACAAGAGG′] CAGACAAGAGG′] (p.Ile585Thr) CAGAYAATGT CAGACAAGAG GAATGTCATC′] NM_000133.3 2158 F9 2578 [′TGTGCAATGA 2748 [′GAAYATATACCA 2963 [′GAAYATATACCA (F9):c.1328T>C AAGGCAAATA AGGTATCCCGG′] AGGTATCCCGG′] (p.Ile443Thr) TGGAAYATAT ACCAAGGTATC CCGGTATGTC′] NM_000169.2 −1 — 2579 [′TTATTTCATTC 2749 [′CAGTTAGYGATT 2964 [′CAGTTAGYGATT (GLA):c.806T>C TTTTTCTCAGT GGCAACTTTGG′] GGCAACTTTGG′] (p.Val269Ala) TAGYGATTGGC AACTTTGGCCT CAGCTGG′] NM_000116.4 6901 TAZ 2580 [′CTCCCACTTC 2750 [′AAGYGTGTGCCT 2965 [′AAGYGTGTGCCT (TAZ):c.352T>C TTCAGCTTGGG GTGTGCCGAGG′] GTGTGCCGAGG′] (p.Cys118Arg) CAAGYGTGTG CCTGTGTGCCG AGGTGAGCT′] NM_000061.2 695 BTK 2581 [′GGTGAACTCC 2751 [′AGCTAYGGCCGC 2966 [′AGCTAYGGCCGC (BTK):c.2T>C AGAAAGAAGA AGTGATTCTGG′] AGTGATTCTGG′] (p.Met1Thr) AGCTAYGGCC GCAGTGATTCT GGAGAGCATC′] NM_000061.2 695 BTK 2582 [′AAGGACCTGA 2752 [′AGCYGGGGACTG 2967-2968 [′GAGCYGGGGACT (BTK):c.1223T>C CCTTCTTGAAG GACAATTTGGG′] GGACAATTTGG′, (p.Leu408Pro) GAGCYGGGGA ′AGCYGGGGACTG CTGGACAATTT GACAATTTGGG′] GGGGTAGTG′] NM_000061.2 695 BTK 2583 [′CAAGTTCAGC 2753 [′ACATTYGGGCTTT 2969 [′ACATTYGGGCTT (BTK):c.1741T>C AGCAAATCTG TGGTAAGTGG′] TTGGTAAGTGG′] (p.Trp581Arg) ACATTYGGGCT TTTGGTAAGTG GATAAGATT′] NM_014009.3 50943 FOXP3 2584 [′GATTCATCCC 2754 [′GACAGAGYTCCT 2970 [′GACAGAGYTCCT (FOXP3):c.970T>C CACCCTCTGAC CCACAACATGG′] CCACAACATGG′] (p.Phe324Leu) AGAGYTCCTCC ACAACATGGA CTACTTCAA′] NM_003688.3 8573 CASK 2585 [′TGAGCTCGTG 2755- [′CACAGYGGGTCC 2971-2972 [′CACAGYGGGTCC (CASK):c.2740T>C TGCACAGCCCC 2756 CTGTCTCCTGG′, CTGTCTCCTGG′, (p.Trp914Arg) ACAGYGGGTC ′ACAGYGGGTCCCT ′ACAGYGGGTCCC CCTGTCTCCTG GTCTCCTGGG′] TGTCTCCTGGG′] GGTCTATTA′] NM_004992.3 4204 MECP2 2586 [′GACACATCCC 2757 [′GATTBTGACTTCA 2973-2974 [′GATTBTGACTTC (MECP2):c.464T>C TGGACCCTAAT CGGTAACTGG′] ACGGTAACTGG′, (p.Phe155Ser) GATTBTGACTT ′ATTBTGACTTCAC CACGGTAACTG GGTAACTGGG′] GGAGAGGG′] NM_000431.3 4598 MVK 2587 [′ATCGTGGCCC 2758 [′CTCAAYAGATGC 2975 [′CTCAAYAGATGC (MVK):c.803T>C CCCTCCTGACC CATCTCCCTGG′] CATCTCCCTGG′] (p.Ile268Thr) TCAAYAGATG CCATCTCCCTG GAGTGTGAG′] NM_021961.5 7003 TEAD1 2588 [′TGAACACGGA 2759 [′TCATATTYACAG 2976 [′TCATATTYACAG (TEAD1):c.1261T>C GCACAACATC GCTTGTAAAGG′] GCTTGTAAAGG′] (p.Tyr?His) ATATTYACAGG CTTGTAAAGGA CTGAACATG′] NM_005633.3 6654 SOS1 2589 [′CGAGATTCAG 2760 [′GGTYGGGAGGGA 2977 [′GGTYGGGAGGG (SOS1):c.1294T>C AAGAATATTG AAAGACATTGG′] AAAAGACATTGG′] (p.Trp432Arg) ATGGTYGGGA GGGAAAAGAC ATTGGACAGTG′] NM_006920.4 −1 — 2590 [′TGTGGAAGAA 2761 [′AACAAYGGTGGA 2978 [′AACAAYGGTGG (SCN1A):c.3577T>C GGCAGAGGAA ACCTGAGAAGG′] AACCTGAGAAGG′] (p.Trp1193Arg) AACAAYGGTG GAACCTGAGA AGGACGTGTTT′] NM_000141.4 2263 FGFR2 2591 [′TGTAACTTTT 2762- [′TGGGGAAYATAC 2979-2980 [′TGGGGAAYATAC (FGFR2):c.1018T>C GAGGACGCTG 2763 GTGCTTGGCGG′, GTGCTTGGCGG′, (p.Tyr340His) GGGAAYATAC ′GGGGAAYATACGT ′GGGGAAYATACG GTGCTTGGCGG GCTTGGCGGG′] TGCTTGGCGGG′] GTAATTCTAT′] NM_000174.4 2815 GP9 2592 [′GGCCACCAAG 2764 [′CCCAYGTACCTG 2981 [′CCCAYGTACCTG (GP9):c.70T>C GACTGCCCCAG CCGCGCCCTGG′] CCGCGCCCTGG′] (p.Cys24Arg) CCCAYGTACCT GCCGCGCCCTG GAAACCAT′] NM_000175.3 2821 GPI 2593 [′CTGGGAAAGC 2765 [′AAAABAGAGCCT 2982 [′AAAABAGAGCCT (GPI):c.1574T>C AGCTGGCTAA GAGCTTGATGG′] GAGCTTGATGG′] (p.Ile525Thr) GAAAABAGAG CCTGAGCTTGA TGGCAGTGCT′] NM_000315.2 5741 PTH 2594 [′AGTTATGATT 2766 [′AATTYGTTTTCTT 2983 [′AATTYGTTTTCTT (PTH):c.52T>C GTCATGTTGGC ACAAAATCGG′] ACAAAATCGG′] (p.Cys18Arg) AATTYGTTTTC TTACAAAATCG GATGGGAA′] NM_000222.2 3815 KIT 2595 [′CCCATGTATG 2767 [′AAGGNTGTTGAG 2984 [′AAGGNTGTTGAG (KIT):c.1676T>C AAGTACAGTG GAGATAAATGG′] GAGATAAATGG′] (p.Val559Ala) GAAGGNTGTT GAGGAGATAA ATGGAAACAAT′] NM_016835.4 4137 MAPT 2596 [′AGTCCAAGTG 2768- [′GGATAAYATCAA 2985-2986 [′GGATAAYATCAA (MAPT):c.1839T>C TGGCTCAAAG 2769 ACACGTCCCGG′, ACACGTCCCGG′, (p.Asn613=) GATAAYATCA ′GATAAYATCAAAC ′GATAAYATCAAA AACACGTCCCG ACGTCCCGGG′] CACGTCCCGGG′] GGAGGCGGCA′] NM_170707.3 4000 LMNA 2597 [′GAGATCCACG 2770 [′TCTYGGAGGGCG 2987 [′TCTYGGAGGGCG (LMNA):c.1139T>C CCTACCGCAAG AGGAGGAGAGG′] AGGAGGAGAGG′] (p.Leu380Ser) CTCTYGGAGG GCGAGGAGGA GAGGTGGGCT′] NM_000424.3 3852 KRT5 2598 [′GCCACCATGT 2771- [′TCAAGTGYGTCCT 2988-2991 [′TCAAGTGYGTCC (KRT5):c.20T>C CTCGCCAGTCA 2773 TCCGGAGCGG′, TTCCGGAGCGG′, (p.Val7Ala) AGTGYGTCCTT ′CAAGTGYGTCCTT ′CAAGTGYGTCCTT CCGGAGCGGG CCGGAGCGGG′, CCGGAGCGGG′, GGCAGTCGT′] ′AAGTGYGTCCTTC ′AAGTGYGTCCTTC CGGAGCGGGG′] CGGAGCGGGG′, ′AGTGYGTCCTTCC GGAGCGGGGG′] NM_000184.2 3048 HBG2 2599 [′GTTGTCTACC 2774 [′CAGAGGTYCTTT 2992 [′CAGAGGTYCTTT (HBG2):c.125T>C CATGGACCCA GACAGCTTTGG′] GACAGCTTTGG′] (p.Phe42Ser) GAGGTYCTTTG ACAGCTTTGGC AACCTGTCC′] NM_000515.4 2688 GH1 2600 [′AGGAAACAC 2775 [′TGAGYGGATGCC 2993 [′TGAGYGGATGCC (GH1):c.291+6T>C AACAGAAATC TTCTCCCCAGG′] TTCTCCCCAGG′] CGTGAGYGGA TGCCTTCTCCC CAGGCGGGGAT′] NM_002087.3 2896 GRN 2601 [′TCCTTGGTAC 2776 [′CCAYGTGGACCC 2994 [′CCAYGTGGACCC GRN):c.2T>C TTTGCAGGCAG TGGTGAGCTGG′] TGGTGAGCTGG′] (p.Met1Thr) ACCAYGTGGA CCCTGGTGAGC TGGGTGGCC′] NM_001083112.2 2820 GPD2 2602 [′AGGTATAAGA 2777 [′AAGTYTGATGCA 2995 [′AAGTYTGATGCA (GPD2):c.1904T>C AGAGATTTCAT GACCAGAAAGG′] GACCAGAAAGG′] (p.Phe635Ser) AAGTYTGATGC AGACCAGAAA GGCTTTATT′] NM_00101807 2908 NR3C1 2603 [′CTCAACATGT 2778 [′AAGYGATTGCAG 2996 [′AAGYGATTGCAG 7.1(NR3C1):c.1712T>C TAGGAGGGCG CAGTGAAATGG′] CAGTGAAATGG′] (p.Val571Ala) GCAAGYGATT GCAGCAGTGA AATGGGCAAAG′] NM_006306.3 8243 SMC1A 2621 [′GTGTTTGAAG 2798 [′AGAYTGGTGTGC 3017 [′AGAYTGGTGTGC (SMC1A):c.2351T>C AGTTTTGTCGG GCAACATCCGG′] GCAACATCCGG′] (p.11e784Thr) GAGAYTGGTG TGCGCAACATC CGGGAGTTT′] NM_002242.4 −1 — 2622 [′TGGTGTAATG 2799 [′GTTDGTGGAAAG 3018 [′GTTDGTGGAAAG (KCN.113):c.722T>C GAGTGATAGT ATGAAGAATGG′] ATGAAGAATGG′] (p.Leu241Pro) ACGTTDGTGGA AAGATGAAGA ATGGACATTC′] NM_000199.3 6448 SGSH 2623 [′CCCCAGCGTT 2800 [′TCCGGGGRTGAC 3019 [′TCCGGGGRTGAC (SGSH):c.892T>C TTGGGTGCTCC ACCAGTAAGGG′] ACCAGTAAGGG′] (p.Ser298Pro) GGGGRTGACA CCAGTAAGGG TTCAGCAGTG′] NM_020191.2 56945 MRPS22 2624 [′CCAATAATTT 2801 [′ATCYTAGGGTAA 3020 [′ATCYTAGGGTAA (MRPS22):c.644T>C TCAAGGAAGA GGTGACTTAGG′] GGTGACTTAGG′] (p.Leu215Pro) AAATCYTAGG GTAAGGTGACT TAGGTTTTAT′] NM_017882.2 54982 CLN6 2625 [′CCCATTCTTC 2802 [′AGCYGGTATTCC 3021 [′AGCYGGTATTCC (CLN6):c.200T>C CATTTGCTCCG CTCTCGAGTGG′] CTCTCGAGTGG′] (p.Leu67Pro) CAGCYGGTATT CCCTCTCGAGT GGTTTCCA′] NM_014874.3 9927 MFN2 2626 [′GTAGTCCTCA 2803 [′AATGWGAGTCAT 3022 [′AATGWGAGTCA (MFN2):c.1392+2T>C AGGTTTATAAG GGAGCAACAGG′] TGGAGCAACAGG′] AATGWGAGTC ATGGAGCAAC AGGTCCTCTT′] NM_024599.5 79651 RHBDF2 2627 [′GCTTACCGCC 2804 [′AGAYTGTGGATC 3023 [′AGAYTGTGGATC (RHBDF2):c.557T>C CCCCTCCCTTC CGCTGGCCCGG′] CGCTGGCCCGG′] (p.11e186Thr) CAGAYTGTGG ATCCGCTGGCC CGGGGCCGG′] NM_020894.2 57654 UVSSA 2628 [′GAAAATGAA 2805 [′AAAATTYGCAAG 3024-3025 [′AAAATTYGCAAG (UVSSA):c.94T>C GGAACTGAAG TATGTCTTAGG′] TATGTCTTAGG′, (p.Cys32Arg) AAAATTYGCA ′AAATTYGCAAGT AGTATGTCTTA ATGTCTTAGGG′] GGGTTCAGTAA′] NM_001161581.1 25886 POC1A 2629 [′GCCAGTGATG 2806 [′AGCYGTGGGACA 3026 [′AGCYGTGGGACA (POC1A):c.398T>C ACAAGACTGTT AGAGCAGCCGG′] AGAGCAGCCGG′] (p.Leu133Pro) AAGCYGTGGG ACAAGAGCAG CCGGGAATGT′] NM_005340.6 3094 HINT1 2630 [′ACACTTAATG 2807- [′CAAGAAAYGTGC 3027-3028 [′CAAGAAAYGTGC (HINT1):c.250T>C ATTGTTGGCAA 2808 TGCTGATCTGG′, TGCTGATCTGG′, (p.Cys84Arg) GAAAYGTGCT ′AAGAAAYGTGCTG ′AAGAAAYGTGCT GCTGATCTGGG CTGATCTGGG′] GCTGATCTGGG′] CCTGAATAA′] NM_000495 1287 COL4A5 2631 [′TTTCCTGGTTT 2809 [′TCCAGYAAGTTA 3029-3030 [′CTCCAGYAAGTT (COL4A5):c.438+2T>C ACAGGGTCCTC TAAAATTTGGG′] ATAAAATTTGG′, CAGYAAGTTAT ′TCCAGYAAGTTA AAAATTTGGG TAAAATTTGGG′] ATTATGAT′] NM_000344.3 6606 SMN1 2632 [′AACCTGTGTT 2810 [′CACTGGAYATGG 3031 [′CACTGGAYATGG (SMN1):c.388T>C GTGGTTTACAC AAATAGAGAGG′] AAATAGAGAGG′] (p.Tyr130His) TGGAYATGGA AATAGAGAGG AGCAAAATCT′] NM_005334.2 3054 HCFC1 2633 [′TTAGTTGTTA 2811 [′CAAGAYGGCGGC 3032 [′CAAGAYGGCGG (HCFC1):c.-970T>C CTTCTTCACAC TCCCAGGGAGG′] CTCCCAGGGAGG′] AAGAYGGCGG CTCCCAGGGA GGAGGCATGA′] NM_000431.3 4598 MVK 2634 [′GTGGCATCAC 2812 [′CCAGGYATCCCG 3033-3034 [′CCAGGYATCCCG (MVK):c.1039+2T>C ACTCCTCAAGC GGGGTAGGTGG′] GGGGTAGGTGG′, CAGGYATCCC ′CAGGYATCCCGG GGGGGTAGGT GGGTAGGTGGG′] GGGCCAGGCT′] NM_018344.5 55315 SLC29A3 2635 [′TATGAGGAAC 2813 [′ACTGATAYCAGG 3035-3036 [′ACTGATAYCAGG (SLC29A3):c.607T>C TCCCAGGCACT TGAGAGCCAGG′] TGAGAGCCAGG′, (p.Ser203Pro) GATAYCAGGT ′CTGATAYCAGGT GAGAGCCAGG GAGAGCCAGGG′] GTCCGGGCAG′] NM_000108.4 1738 DLD 2636 [′GTAGTTGATG 2815 [′ACAGTTAYAGGT 3037-3038 [′ACAGTTAYAGGT (DLD):c.140T>C CTGATGTAACA TCTGGTCCTGG′, TCTGGTCCTGG′, (p.Ile47Thr) GTTAYAGGTTC ′GTTAYAGGTTCTG ′GTTAYAGGTTCTG TGGTCCTGGAG GTCCTGGAGG′] GTCCTGGAGG′] GATATGTT′] NM_004333.4 673 BRAF 2637 [′GGACAAAGA 2816- [′ATCATYTGGAAC 3039-3040 [′ATCATYTGGAAC (BRAF):c.1403T>C ATTGGATCTGG 2817 AGTCTACAAGG′, AGTCTACAAGG′, (p.Phe468Ser) ATCATYTGGAA ′TCATYTGGAACAG ′TCATYTGGAACA CAGTCTACAAG TCTACAAGGG′] GTCTACAAGGG′] GGAAAGTGG′] NM_000540.2 6261 RYR1 2638 [′CAGGAGGAGT 2818 [′CGCAYGATCCAC 3041 [′CGCAYGATCCAC (RYR1):c.1205T>C CCCAGGCCGCC AGCACCAATGG′] AGCACCAATGG′] (p.Met402Thr) CGCAYGATCC ACAGCACCAA TGGCCTATAC′] NM_000256.3 4607 MYBPC3 2639 [′GTAGCACGGA 2819 [′AAAGGYGGGCCT 3042 [′AAAGGYGGGCCT (MYBPC3):c.1351+2T>C GCTCTTTGTGA GGGACCTGAGG′] GGGACCTGAGG′] AAGGYGGGCC TGGGACCTGA GGATGTGGGA′] NM_000256.3 4607 MYBPC3 2640 [′CCTCCTATCA 2820 [′CACGYGAGTGGC 3043-3044 CCATCCTCAGG′, GCCTTCCGCCG CATCCTCAGGG′] ′CACGYGAGTGGC (MYBPC3):c.821+2T>C CACGYGAGTG CATCCTCAGGG′] GCCATCCTCAG GGCCTGGGG′] NM_000257.3 4625 MYH7 2641 [′AAGAGTGCAG 2821 [′GGAGAYGGCCTC 3045 [′GGAGAYGGCCTC (MYH7):c.2546T>C AAAGAGAGAA CATGAAGGAGG′] CATGAAGGAGG′] (p.Met849Thr) GGAGAYGGCC TCCATGAAGG AGGAGTTCACA′] NM_206933.2 7399 USH2A 2642 [′CGACACAACA 2822 [′ATATAGAYGCCT 3046 [′ATATAGAYGCCT (USH2A):c.1606T>C AGCCAGCCAT CTGCTCCCAGG′] CTGCTCCCAGG′] (p.Cys536Arg) ATAGAYGCCTC TGCTCCCAGGA GAGCTTCAC′] NM_000059.3 675 BRCA2 2643 [′TAGATAAATT 2823 [′CTTAGGYAAGTA 3047 [′CTTAGGYAAGTA (BRCA2):c.316+2T>C CAAATTAGACT ATGCAATATGG′] ATGCAATATGG′] TAGGYAAGTA ATGCAATATGG TAGACTGGG′] NM_007294.3 672 BRCA1 2644 [′CTCTTCTTCC 2824 [′GGCYAGAAATCT 3048-3049 [′GGGCYAGAAATC (BRCA1):c.5291T>C AGATCTTCAGG GTTGCTATGGG′] TGTTGCTATGG′, (p.Leu1764Pro) GGGCYAGAAA ′GGCYAGAAATCT TCTGTTGCTAT GTTGCTATGGG′] GGGCCCTTC′] NM_00113008 3735 KARS 2645 [′AGCTTCTGGG 2825 [′TTCYATGATCTTC 3050-3051 [′CTTCYATGATCT 9.1(KARS):c.517T>C GGAAAGCTCA GAGGAGAGGG′] TCGAGGAGAGG′, (p.Tyr173His) TCTTCYATGAT ′TTCYATGATCTTC CTTCGAGGAG GAGGAGAGGG′] AGGGGGTGAA′] NM_00128300 −1 — 2646 [′CGGGCCCCTC 2826 [′CTGTGTGYGCCA 3052 [′CTGTGTGYGCCA 9.1(RTEL1):c.3730T>C TCAGCAGGCTG GGGCTGTGGGG′] GGGCTGTGGGG′] (p.Cys1244Arg) TGTGYGCCAG GGCTGTGGGG CAGAGGACGT′] NM_005554.3 3853 KRT6A 2647 [′GAGATCGCCA 2827 [′TGCBGGAGGGTG 3053 [′TGCBGGAGGGTG (KRT6A):c.1406T>C CCTACCGCAAG AGGAGTGCAGG′] AGGAGTGCAGG′] (p.Leu469Pro) CTGCBGGAGG GTGAGGAGTG CAGGTGGGTA′] NM_000218.2 3784 KCNQ1 2648 [′CTGGTCCGCC 2828 [′AGCAAGBACGTG 3054-3056 [′CAGCAAGBACGT (KCNQ1):c.550T>C GGCTGCCGCA GGCCTCTGGGG′] GGGCCTCTGGG′, (p.Tyr184His) GCAAGBACGT ′AGCAAGBACGTG GGGCCTCTGGG GGCCTCTGGGG′, GGCGGCTGCG′] ′GCAAGBACGTGG NM_198056.2 6331 SCN5A 2649 [′GAGATGGACG 2829 [′CCAGAHGGAGGA 3057 [′CCAGAHGGAGG (SCN5A):c.5624T>C CCCTGAAGATC GAAGTTCATGG′] AGAAGTTCATGG′] (p.Met1875Thr) CAGAHGGAGG AGAAGTTCATG GCAGCCAAC′] NM_006920.4 6323 SCN1A 2650 [′TGTTGTGTTC 2830- [′ACTTYTATAGTAT 3058-3059 [′ACTTYTATAGTA (SCN1A):c.269T>C CTGTCTTACAG 2831 TGAATAAAGG′, TTGAATAAAGG′, (p.Phe90Ser) ACTTYTATAGT ′CTTYTATAGTATT ′CTTYTATAGTATT ATTGAATAAA GAATAAAGGG′] GAATAAAGGG′] GGGAAGGCC′] NM_006920.4 6323 SCN1A 2651 [′TGTGTTCCTG 2832- [′ACTTTTAYAGTAT 3060-3061 [′ACTTTTAYAGTA (SCN1A):c.272T>C TCTTACAGACT 2833 TGAATAAAGG′, TTGAATAAAGG′, (p.Ile91Thr) TTTAYAGTATT ′CTTTTAYAGTATT ′CTTTTAYAGTATT GAATAAAGGG GAATAAAGGG′] GAATAAAGGG′] AAGGCCATC′] NM_006514.3 6336 SCN10A 2652 [′GGAGTCAGGG 2834- [′GAGGARGAGGGC 3062-3064 [′GAGGARGAGGG (SCN10A):c.1661T>C TTGCTGGGTTG 2836 TTCTAGGGAGG′, CTTCTAGGGAGG′, (p.Leu554Pro) AGGARGAGGG ′AGGARGAGGGCTT ′AGGARGAGGGCT CTTCTAGGGAG CTAGGGAGGG′, TCTAGGGAGGG′, GGGGCCTTG′] ′GGARGAGGGCTTC ′GGARGAGGGCTT TAGGGAGGGG′] CTAGGGAGGGG′] NM_000251.2 4436 MSH2 2653 [′AACAGATGTT 2837- [′CTGGYAAAAAAC 3065-3066 (MSH2):c.2005+2T>C CCACATCATTA 2838 CTGGTTTTTGG′, [′CTGGYAAAAAAC CTGGYAAAAA ′TGGYAAAAAACCT CTGGTTTTTGG′, ACCTGGTTTTT GGTTTTTGGG′] ′TGGYAAAAAACC GGGCTTTGT′] TGGTTTTTGGG′] NM_000251.2 4436 MSH2 2654 [′CCTCATCCAG 2839 [′AAGGAAYGTGTT 3067 [′AAGGAAYGTGTT (MSH2):c.595T>C ATTGGACCAA TTACCCGGAGG′] TTACCCGGAGG′] (p.Cys199Arg) AGGAAYGTGT TTTACCCGGAG GAGAGACTGC′] NM_001005741.2 2629 GBA 2655 [′TTCACCGCTC 2840 [′GCCRAGTGGGTG 3068-3070 [′GAGCCRAGTGGG (GBA):c.667T>C CATTGGTCTTG ATGTCCAGGGG′] TGATGTCCAGG′, (p.Trp223Arg) AGCCRAGTGG ′AGCCRAGTGGGT GTGATGTCCAG GATGTCCAGGG′, GGGCTGGCA′] ′GCCRAGTGGGTG ATGTCCAGGGG′] NM_003494.3 8291 DYSF 2656 [′GAGGTCAGCT 2841 [′ATGGYAAGGAGC 3071 [′ATGGYAAGGAG (DYSF):c.1284+2T>C TTGCGGGGAA AAGGGAGCAGG′] CAAGGGAGCAGG′] AATGGYAAGG AGCAAGGGAG CAGGAGGGTTC′] 2842 [′CACTGYGAGTAA 3072 [′CACTGYGAGTAA NM_012463.3 2354 ATP6V50A2 2657 [′ACCCGCATCC GCTGGAAGTGG′] GCTGGAAGTGG′] (ATP6V0A2):c.825+2T>C AGGATCTCTAC ACTGYGAGTA AGCTGGAAGT GGATTGCCTC′] NM_016725.2 2348 FOLR1 2658 [′ACAAGGGCTG 2843 [′AGGYGAGGGCTG 3073-3074 [′CTTCAGGYGAGG (FOLR1):c.493+2T>C GAACTGGACTT GGGTGGGCAGG′] GCTGGGGTGGG′, CAGGYGAGGG ′AGGYGAGGGCTG CTGGGGTGGG GGGTGGGCAGG′] CAGGAATGGA′] NM_003764.3 8676 STX11 2659 [′GACATTCAGG 2844 [′TGCYGGTGGCCG 3075 [′TGCYGGTGGCCG (STX11):c.173T>C ATGAAAACCA ACGTGAAGCGG′] ACGTGAAGCGG′] (p.Leu58Pro) GCTGCYGGTG GCCGACGTGA AGCGGCTGGGA′] NM_014714.3 9742 IFT140 2660 [′GGACCCCAAG 2845 [′GCAGYGTGAGCT 3076-3077 [′CAAGCAGYGTGA (1FT140):c.4078T>C GAGTCCATCAA GCTCCTGGAGG′] GCTGCTCCTGG′, (p.Cys1360Arg) GCAGYGTGAG ′GCAGYGTGAGCT CTGCTCCTGGA GCTCCTGGAGG′] GGAACCAGA′] NM_000531.5 5009 OTC 2661 [′GAAAACAGA 2846 [′ATCATGGYAAGC 3078 [′ATCATGGYAAGC (OTC):c.1005+2T>C AAGTGGACAA AAGAAACAAGG′] AAGAAACAAGG′] TCATGGYAAG CAAGAAACAA GGAATGGAGGAT′] NM_000531.5 5009 OTC 2662 [′CTAAAAAACT 2847 [′AAGAAABTAAAT 3079 [′AAGAAABTAAAT (OTC):c.158T>C TTACCGGAGA ATATGCTATGG′] ATATGCTATGG′] (p.Ile53Thr) AGAAABTAAA TATATGCTATG GCTATCAGCA′] NM_000531.5 5009 OTC 2663 [′GAGAAAAGA 2848 [′ACAAGATYGTCT 3080 [′ACAAGATYGTCT (OTC):c.284T>C AGTACTCGAAC ACAGAAACAGG′] ACAGAAACAGG′] (p.Leu95Ser) AAGATYGTCTA CAGAAACAGG TAAGTCCACT′] NM_000531.5 5009 OTC 2664 [′CGTCCTTTAC 2849 [′AGAAGAYGCTGT 3081 [′AGAAGAYGCTGT (OTC):c.2T>C ACAATTAAAA TTAATCTGAGG′] TTAATCTGAGG′] (p.Met1Thr) GAAGAYGCTG TTTAATCTGAG GATCCTGTTA′] NM_000531.5 5009 OTC 2665 [′CCATCCTATC 2850 [′GGCTGATYACCT 3082-3083 [′GGCTGATYACCT (OTC):c.526T>C CAGATCCTGGC CACGCTCCAGG′] CACGCTCCAGG′, (p.Tyr176His) TGATYACCTCA ′GATYACCTCACG CGCTCCAGGTT CTCCAGGTTGG′] GGTTTATT′] NM_000531.5 5009 OTC 2666 [′GAAGCAGCGC 2851 [′ATGTATYAATTAC 3084 [′ATGTATYAATTA (OTC):c.779T>C ATGGAGGCAA AGACACTTGG′] CAGACACTTGG′] (p.Leu260Ser) TGTATYAATTA CAGACACTTGG ATAAGCATG′] NM_000322.4 5961 PRPH2 2667 [′CCACCAGACG 2852- [′ACCTGYGGGTGC 3085-3086 [′ACCTGYGGGTGC (PRPH2):c.736T>C GAGGAGCTCA 2853 GTGGCTGCAGG′, GTGGCTGCAGG′, (p.Trp246Arg) ACCTGYGGGT ′CCTGYGGGTGCGT ′CCTGYGGGTGCG GCGTGGCTGCA GGCTGCAGGG′] TGGCTGCAGGG′] GGGCTGCCCT′] NM_000211.4 3689 ITGB2 2668 [′CCCCTCACCC 2854 [′CATGYGAGTGCA 3087 [′CATGYGAGTGCA (ITGB2):c.1877+2T>C TGTGGCAAGTA GGCGGAGCAGG′] GGCGGAGCAGG′] CATGYGAGTG CAGGCGGAGC AGGCAGGGCG′] NM_015474.3 25939 SAMHD1 2669 [′TTTGTGTTGA 2855 [′GGTGTRAAGAGT 3088 [′GGTGTRAAGAGT (SAMHD1):c.1106T>C TAAGCTCTACG TGCGAGTGTGG′] TGCGAGTGTGG′] (p.Leu369Ser) GTGTRAAGAGT TGCGAGTGTGG AACATGTC′] NM_001101.3 60 ACTB 2670 [′AACCCCAAGG 2856 [′GAGAAGAYGACC 3089 [′GAGAAGAYGAC (ACTB):c.356T>C CCAACCGCGA CAGGTGAGTGG′] CCAGGTGAGTGG′] (p.Met119Thr) GAAGAYGACC CAGGTGAGTG GCCCGCTACCT′] NM_015713.4 50484 RRM2B 2671 [′CTCGATGAGA 2857 [′CCATAGRAACAG 3090 [′CCATAGRAACAG (RRM2B):c.368T>C ATTTGAAAGCC CGAGCCTCTGG′] CGAGCCTCTGG′] (p.Phe123Ser) ATAGRAACAG CGAGCCTCTGG AACCTGCAC′] NM_015599.2 5238 PGM3 2672 [′TTGGTTGATC 2858 [′AATGTYGGCACC 3091 [′AATGTYGGCACC (PGM3):c.248T>C CTTTGGGTGAA ATCCTGGGAGG′] ATCCTGGGAGG′] (p.Leu83Ser) ATGTYGGCACC ATCCTGGGAG GAACATGCC′] NM_002136.2 3178 HNRNPA1 2673 [′GAATTACAAC 2859- [′TTCAAATBTTGGA 3092-3094 [′TTCAAATBTTGG (HNRNPA1):c.817T>C AATCAGTCTTC 2861 CCCATGAAGG′, ACCCATGAAGG′, (p.Phe273Leu) AAATBTTGGAC ′TCAAATBTTGGAC ′TCAAATBTTGGAC CCATGAAGGG CCATGAAGGG′, CCATGAAGGG′, AGGAAATTT′] ′AATBTTGGACCCA ′AATBTTGGACCC TGAAGGGAGG′] ATGAAGGGAGG′] NM_002136.2 3178 HNRNPA1 2674 [′TTTTGGACCC 2862 [′AATYTTGGAGGC 3095 [′AATYTTGGAGGC (HNRNPA1):c.841T>C ATGAAGGGAG AGAAGCTCTGG′] AGAAGCTCTGG′] (p.Phe281Leu) GAAATYTTGG AGGCAGAAGC TCTGGCCCCTA′] NM_022552.4 1788 DNMT3A 2675 [′CGCAAAATAC 2863 [′GCGRAGAGGTGG (DNMT3A):c.2705T>C TCCTTCAGCGG CGGATGACTGG′] 3096 [′GCGRAGAGGTGG (p.Phe902Ser) AGCGRAGAGG CGGATGACTGG′] TGGCGGATGA CTGGCACGCT′] NM_000076.2 1028 CDKN1C 2676 [′GCGCAAGAG 2864- [′CCAAGYGAGTAC 3097-3099 [′CCAAGYGAGTAC (CDKN1C):c.*5+2T>C GCTGCGGTGA 2866 AGCGCACCTGG′, AGCGCACCTGG′, GCCAAGYGAG ′CAAGYGAGTACA ′CAAGYGAGTACA TACAGCGCACC GCGCACCTGGG′, GCGCACCTGGG′, TGGGGGGGCGC′] ′AAGYGAGTACAG ′AAGYGAGTACAG CGCACCTGGGG′] CGCACCTGGGG′] NC_012920.1:m.9478T>C 4514 MTCO3 2677 [′ATAATCCTAT 2867 [′TCAGAAGYTTTTT 3100 [′TCAGAAGYTTTT TTATTACCTCA TCTTCGCAGG′] TTCTTCGCAGG′] GAAGYTTTTTT CTTCGCAGGAT TTTTCTGA′] NM_002049.3 2623 GATA1 2678 [′CGCAGGTTAA 2868- [′TCCAYGGAGTTC 3101-3103 [′CTCCAYGGAGTT (GATA1):c.2T>C TCCCCAGAGGC 2869 CCTGGCCTGGG′, CCCTGGCCTGG′, (p.Met1Thr) TCCAYGGAGTT ′CCAYGGAGTTCCC ′TCCAYGGAGTTC CCCTGGCCTGG TGGCCTGGGG′] CCTGGCCTGGG′, GGTCCCTG′] ′CCAYGGAGTTCC CTGGCCTGGGG′] NM_005740.2 10126 DNAL4 2679 [′GAGAAATTCT 2870 [′CGAGGYATTGCC 3104 [′CGAGGYATTGCC (DNAL4):c.153+2T>C CCAACAACAA AGCAGTGCAGG′] AGCAGTGCAGG′] CGAGGYATTG CCAGCAGTGC AGGCGGCCCCT′] NM_001287223.1 11280 SCN11A 2680 [′GGGCTCTACT 2871 [′TTCAYTGTGGTCA 3105-3106 [′CTTCAYTGTGGT (SCN11A):c.1142T>C CAGTCTTCTTC TTTTCCTGGG′] CATTTTCCTGG′, (p.Ile381Thr) TTCAYTGTGGT ′TTCAYTGTGGTCA CATTTTCCTGG TTTTCCTGGG′] GCTCCTTC′] NM_001302946.1 51095 TRNT1 2681 [′TAATGAATAG 2872 [′ACTTYATTTGACT 3107 [′ACTTYATTTGAC (TRNT1):c.497T>C GTTTTGATGGC ACTTTAATGG′] TACTTTAATGG′] (p.Leu166Ser) ACTTYATTTGA CTACTTTAATG GTTATGAA′] NM_178151.2 1641 DCX 2682 [′AGGTCTCTGA 2873 [′CAAAATAYGGAA 3108 [′CAAAATAYGGA (DCX):c.2T>C GGTTCCACCAA CTTGATTTTGG′] ACTTGATTTTGG′] (p.Met1Thr) AATAYGGAAC TTGATTTTGGA CACTTTGAC′] NM_000169.2 −1 — 2683 [′TGGACATCTT 2874 [′GAGAGAAYTGTT 3109 [′GAGAGAAYTGTT (GLA):c.758T>C TTAACCAGGA GATGTTGCTGG′] GATGTTGCTGG′] (p.Ile253Thr) GAGAAYTGTT GATGTTGCTGG ACCAGGGGGT′] NM_170707.3 4000 LMNA 2684 [′ATTGACAATG 2875 [′TGAGTYTGAGAG 3110 [′TGAGTYTGAGAG (LMNA):c.710T>C GGAAGCAGCG CCGGCTGGCGG′] CCGGCTGGCGG′] (p.Phe237Ser) TGAGTYTGAG AGCCGGCTGG CGGATGCGCTG′] NM_000256.3 4607 MYBPC3 2685 [′CAGAAAGCCG 2876- [′ACCATGGBGAGC 3111-3113 [′ACCATGGBGAGC (MYBPC3):c.3330+2T>C ACAAGAAGAC 2878 CCAGGGTCTGG′, CCAGGGTCTGG′, CATGGBGAGC ′CCATGGBGAGCCC ′CCATGGBGAGCC CCAGGGTCTGG AGGGTCTGGG′, CAGGGTCTGGG′, GGTCCCCACG′] ′CATGGBGAGCCCA ′CATGGBGAGCCC GGGTCTGGGG′] AGGGTCTGGGG′] NM_005957.4 4524 MTHFR 2686 [′AGCGGGGGCT 2879- [′GAAGGYGTGGTA 3114-3116 [′GAAGGYGTGGTA (MTHFR):c.1530+2T>C ATGTCTTCCAG 2881 GGGAGGCACGG′, GGGAGGCACGG′, AAGGYGTGGT ′AAGGYGTGGTAG ′AAGGYGTGGTAG AGGGAGGCAC GGAGGCACGGG′, GGAGGCACGGG′, GGGGTGCCCC′] ′AGGYGTGGTAGG ′AGGYGTGGTAGG GAGGCACGGGG′] GAGGCACGGGG′] NM_000264.3 5727 PTCH1 2687 [′AACCCCTGGA 2882- [′ATCATTGYGAGT 3117-3119 [′ATCATTGYGAGT (PTCH1):c.3168+2T>C CGGCCGGGAT 2884 GTATTATAAGG′, GTATTATAAGG′, CATTGYGAGTG ′TCATTGYGAGTGT ′TCATTGYGAGTGT TATTATAAGGG ATTATAAGGG′, ATTATAAGGG′, GCTTTGTGG′] ′CATTGYGAGTGTA ′CATTGYGAGTGT TTATAAGGGG′] ATTATAAGGGG′] NM_000030.2 189 AGXT 2688 [′CTTCCTGGTT 2885 [′CATTYGGGGGCA 3120 [′CATTYGGGGGCA (AGXT):c.322T>C GGGGCCAATG GCGAGCCGTGG′] GCGAGCCGTGG′] (p.Trp108Arg) GCATTYGGGG GCAGCGAGCC GTGGACATCGG′] NM_000023.2 6442 SGCA 2689 [′ACTCGGCAGA 2886 [′CTGGAGAYTGGG 3121 [′CTGGAGAYTGGG (SGCA):c.371T>C GGCTGGTGCTG GACCCAGAAGG′] GACCCAGAAGG′] (p.Ile124Thr) GAGAYTGGGG ACCCAGAAGG TACCTCTAGC′] NM_001103.3 88 ACTN2 2690 [′GAGAAGCACC 2887 [′CCTAAAAYGTTG 3122 [′CCTAAAAYGTTG (ACTN2):c.683T>C TGGATATTCCT GATGCTGAAGG′] GATGCTGAAGG′] (p.Met228Thr) AAAAYGTTGG ATGCTGAAGGT GAGATGAAA′] NM_001165963.1 −1 — 2691 [′ATTCCATCCA 2888 [′TTCYGGTTTGTCT 3123 [′TTCYGGTTTGTC (SCN1A):c.4055T>C TCATGAATGTG TATATTCTGG′] TTATATTCTGG′] (p.Leu1352Pro) CTTCYGGTTTG TCTTATATTCT GGCTAATT′] NM_001165963.1 6323 SCN1A 2692 [′CTAATAAATT 2889 [′TGTGGHGGCCAT 3124 [′TGTGGHGGCCAT (SCN1A):c.1265T>C TGATCCTGGCT GGCCTACGAGG′] GGCCTACGAGG′] (p.Val422Ala) GTGGHGGCCA TGGCCTACGAG GAACAGAAT′] NM_000426.3 3908 LAMA2 2693 [′GCAGAATCAG 2890- [′TTGAYAGGGAGC 3125-3126 [′TTGAYAGGGAGC (LAMA2):c.8282T>C AACCAGCTCTT 2891 AAGCAGTTCGG′, AAGCAGTTCGG′, (p.Ile2761Thr) TTGAYAGGGA ′TGAYAGGGAGCA ′TGAYAGGGAGCA GCAAGCAGTTC AGCAGTTCGGG′] AGCAGTTCGGG′] GGGCTTTCA′] NM_000257.3 −1 — 2694 [′TCCCGGAAGC 2892 [′AGCYGATTGAGA 3127 [′AGCYGATTGAGA (MYH7):c.5117T>C TGGCGGAGCA CTAGTGAGCGG′] CTAGTGAGCGG′] (p.Leu1706Pro) GGAGCYGATT GAGACTAGTG AGCGGGTGCAG′] NM_001399.4 1896 EDA 2695 [′TCTGACTCCC 2893- [′ACCAGGKGAGTC 3128-3130 [′CACCAGGKGAGT (EDA):c.396+2T>C AGGACGGGCA 2894 ACCTAGTAGGG′, CACCTAGTAGG′, CCAGGKGAGT ′CCAGGKGAGTCAC ′ACCAGGKGAGTC CACCTAGTAGG CTAGTAGGGG′] ACCTAGTAGGG′, GGCGGCGGCG′] ′CCAGGKGAGTCA CCTAGTAGGGG′] NM_001848.2 1291 COL6A1 2696 [′TCCAGGGGAC 2895- [′ACAAGGYGAGCG 3131-3132 [′ACAAGGYGAGC (COL6A1):c.957+2T>C CCAAGGGCTA 2896 TGGGCTGCTGG′, GTGGGCTGCTGG′, CAAGGYGAGC ′CAAGGYGAGCGT ′CAAGGYGAGCGT GTGGGCTGCTG GGGCTGCTGGG′] GGGCTGCTGGG′] GGAGGGGGGA′] NM_000238.3 3757 KCNH2 2697 [′CTGCGTCATG 2897- [′CTGTGAGYGTGC 3133-3134 [′CTGTGAGYGTGC (KCNH2):c.1945+6T>C CTCATTGGCTG 2898 CCAGGGGCGGG′, CCAGGGGCGGG′, TGAGYGTGCCC ′TGAGYGTGCCCAG ′TGAGYGTGCCCA AGGGGCGGGC GGGCGGGCGG′] GGGGCGGGCGG′] GGCGGGGAG′] NM_021007.2 6326 SCN2A 2698 [′CTAATAAATT 2899 [′TGTGGYGGCCAT 3135 [′TGTGGYGGCCAT (SCN2A):c.1271T>C TGATCTTGGCT GGCCTATGAGG′] GGCCTATGAGG′] (p.Val424Ala) GTGGYGGCCA TGGCCTATGAG GAACAGAAT′] NM_021007.2 6326 SCN2A 2699 [′TATGCAGCTG 2900- [′CGAAATGYAAGT 3136-3137 [′CGAAATGYAAGT (SCN2A):c.4308+2T>C TTGATTCACGA 2901 CTAGTTAGAGG′, CTAGTTAGAGG′, AATGYAAGTCT ′GAAATGYAAGTCT ′GAAATGYAAGTC AGTTAGAGGG AGTTAGAGGG′] TAGTTAGAGGG′] AAATTGTTT′] NM_000083.2 1180 CLCN1 2700 [′CCCCGCGAAG 2902- [′CTTTGTYTGACAA 3138-3139 [′CTTTGTYTGACA (CLCN1):c.1283T>C CCATCAGTACT 2903 CAATACATGG′, ACAATACATGG′, (p.Phe428Ser) TTGTYTGACAA ′TTTGTYTGACAAC ′TTTGTYTGACAAC CAATACATGG AATACATGGG′] AATACATGGG′] GTGAAACAC′] NM_004550.4 4720 NDUFS2 2701 [′CATTATGCTC 2904 [′GGAGTGAYGCTT 3140 [′GGAGTGAYGCTT (NDUFS2):c.875T>C TCCACAGTGGA CGGGGCTCAGG′] CGGGGCTCAGG′] (p.Met292Thr) GTGAYGCTTCG GGGCTCAGGC ATCCAGTGG′] NM_000546.5 7157 TP53 2702 [′CACACGCAAA 2905- [′CTCGGRTAAGAT 3141-3143 [′ACTCGGRTAAGA (TP53):c.584T>C TTTCCTTCCAC 2906 GCTGAGGAGGG′, TGCTGAGGAGG′, (p.Ile195Thr) TCGGRTAAGAT ′TCGGRTAAGATGC ′CTCGGRTAAGAT GCTGAGGAGG TGAGGAGGGG′] GCTGAGGAGGG′, GGCCAGACC′] ′TCGGRTAAGATG CTGAGGAGGGG′]

TABLE 3 A to G with NGG PAM. Table 2 shows a list of A to G mutations that may be corrected using any of the base editors provided herein. GRNAs and gRNAall indicate the protospacer and PAM sequence, where the PAM sequence is the last 3 nucleotides of each of the sequences in GRNAs and gRNAall. SEQ SEQ SEQ Gene Gene ID ID ID Name ID Symbol NO: Flanks NO: GRNAs NO: gRNAall NM_017547.3 55572 FOXRED1 5084 [′GTGGGCCCCCACC 5261 [′CCACCCGCTAGT 5464- [′CCCACCCGCTAG (FOXRED1):c.1289A>G CGCTAGTTGTCAVC TGTCAVCATGT′] 5466 TTGTCAVCATG′, (p.Asn430Ser) ATGTACTTTGCTACT ′CCACCCGCTAGTT GGCTTCAGT′] GTCAVCATGT′, ′CCCGCTAGTTGTC AVCATGTACT′] NM_000071.2 875 CBS 5085 [′GGTGACTCCCCCAT 5262 [′CCCCATCCCGCA 5467- [′CCCCCATCCCGC (CBS):c.1150A>G CCCGCAGGACCRAG GGACCRAGTTC′] 5470 AGGACCRAGTT′, (p.Lys384Glu) TTCCTGAGCGACAG ′CCCCATCCCGCA GTGGATGCT′] GGACCRAGTTC′, ′CCCATCCCGCAG GACCRAGTTCC′, ′CCATCCCGCAGG ACCRAGTTCCT′] NM_000552.3 7450 VWF 5086 [′GAGTGTACCAAAA 5263 [′CCAAAACGTGCC 5471 [′CCAAAACGTGCC (VWF):c.2384A>G CGTGCCAGAACTRT AGAACTRTGAC′] AGAACTRTGAC′] (p.Tyr795Cys) GACCTGGAGTGCAT GAGCATGGGC′] NM_000552.3 7450 VWF 5087 [′ACCTGCGGCCTGT 5264 [′CCTGTGTGGGAA 5472 [′CCTGTGTGGGAA (VWF):c.1583A>G GTGGGAATTACART TTACARTGGCA′] TTACARTGGCA′] (p.Asn528Ser) GGCAACCAGGGCGA CGACTTCCTT′] NM_000308.2 5476 CTSA 5088 [′CTTTAGAAATACC 5265 [′CCAGATCCTATT 5473 [′CCAGATCCTATT (CTSA):c.1238A>G AGATCCTATTATRTA ATRTAATGGAG′] ATRTAATGGAG′] (p.Tyr413Cys) ATGGAGATGTAGAC ATGGCCTGC′] NM_000277.1 5053 PAH 5089 [′TTCTATTTTCCCCC 5266 [′CCCCCAATTACA 5474- [′CCCCCAATTACA (PAH):c.916A>G AATTACAGGAARTT GGAARTTGGCC′] 5476 GGAARTTGGCC′, (p.Ile306Val) GGCCTTGCCTCTCTG ′CCCCAATTACAG GGTGCACC′] GAARTTGGCCT′, ′CCCAATTACAGG AARTTGGCCTT′] NM_000512.4 2588 GALNS 5090 [′TTGGTCCCCGCGCA 5267 [′CCGCGCAGCCCC 5477 [′CCGCGCAGCCCC (GALNS):c.1460A>G GCCCCAGCTCARCG AGCTCARCGTG′] AGCTCARCGTG′] (p.Asn487Ser) TGTGCAACTGGGCG GTCATGGTA′] NM_013319.2 29914 UBIAD1 5091 [′GTGCACGGGGCCG 5268 [′CCGGTAATTTGG 5478 [′CCGGTAATTTGG (UBIAD1):c.305A>G GTAATTTGGTCARC TCARCACTTAC′] TCARCACTTAC′] (p.Asn102Ser) ACTTACTATGACTTT TCCAAGGGC′] NM_013319.2 29914 UBIAD1 5092 [′AGCACCGAGGCCA 5269 [′CCATTCTCCATT 5479 [′CCATTCTCCATT (UBIAD1):c.695A>G TTCTCCATTCCARCA CCARCAACACC′] CCARCAACACC′] (p.Asn232Ser) ACACCAGGGACATG GAGTCCGAC′] NM_000275.2 4948 OCA2 5093 [′TGCCACTGCCATCG 5270 [′CCATCGGGGACC 5480 [′CCATCGGGGACC (OCA2):c.1465A>G GGGACCCTCCARAT CTCCARATGTC′] CTCCARATGTC′] (p.Asn489Asp) GTCATTATTGTTTCC AACCAAGA′] NM_001127255.1 −1 — 5094 [′CTCACAAACCTGG 5271 [′CCTGGACTTGAG 5481 [′CCTGGACTTGAG (NLRP7):c.2738A>G ACTTGAGTATCARC TATCARCCAGA′] TATCARCCAGA′] (p.Asn913Ser) CAGATAGCTCGTGG ATTGTGGATT′] NM_152783.4 728294 D2HGDH 5095 [′TGCCCTTGTCCCTC 5272 [′CCTCCAGGAGAT 5482- [′CCCTCCAGGAGA (D2HGDH):c.1315A>G CAGGAGATGGTRAC GGTRACCTGCA′] 5483 TGGTRACCTGC′, (p.Asn439Asp) CTGCACCTCAATGT ′CCTCCAGGAGAT GACGGCGGA′] GGTRACCTGCA′] NM_022132.4 64087 MCCC2 5096 [′TGTGGCCTGTGCCC 5273 [′CCCAAGTGCCTA 5484 [′CCCAAGTGCCTA (MCCC2):c.1309A>G AAGTGCCTAAGDTA AGDTAACCCTC′] AGDTAACCCTC′] (p.Ile437Val) ACCCTCATCATTGG GGGCTCCTA′] NM_000022.2 100 ADA 5097 [′TTCCCAACCCCTTT 5274 [′CCCCTTTCTTCCC 5485- [′CCCCTTTCTTCCC (ADA):c.219-2A>G CTTCCCTTCCCRGGG TTCCCRGGGG′] 5487 TTCCCRGGGG′, GCTGCCGGGAGGCT ′CCCTTTCTTCCCT ATCAAAAG′] TCCCRGGGGC′, ′CCTTTCTTCCCTT CCCRGGGGCT′] NM_017780.3 55636 CHD7 5098 [′TTTAGTAATTGCCC 5275 [′CCCCATTGTCCA 5488 [′CCCCATTGTCCA (CHD7):c.3082A>G CATTGTCCACARTC CARTCCCCAAC′] CARTCCCCAAC′] (p.Ile1028Val) CCCAACTGGGAAAG GGAATTCCG′] NM_000483.4 −1 — 5099 [′TCAATGTTCCAGGT 5276 [′CCAGGTCTCTGG 5489 [′CCAGGTCTCTGG (APOC2):c.1A>G CTCTGGACACTRTG ACACTRTGGGC′] ACACTRTGGGC′] (p.MetlVal) GGCACACGACTCCT CCCAGCTCT′] NM_000391.3 1200 TPP1 5100 [′TGTCCCTCATGCCG 5277 [′CCGGCCTGGATT 5490 [′CCGGCCTGGATT (TPP1):c.887-10A>G GCCTGGATTTTYTTT TTYTTTTTTTT′] TTYTTTTTTTT′] TTTTTTTTTTTTGAG GGATGGG′] NM_017890.4 157680 VPS13B 5101 [′CTTCTGCCCTGGGC 5278 [′CCTGGGCCCTGC 5491 [′CCTGGGCCCTGC (VPS13B):c.8978A>G CCTGCTTATCARTG TTATCARTGAA′] TTATCARTGAA′] (p.Asn2993Ser) AATCCAAATGGGAC CTCTGGCTA′] NM_000226.3 3857 KRT9 5102 [′GAGAAGAGCACCA 5279 [′CCATGCAGGAAC 5492 [′CCATGCAGGAAC (KRT9):c.482A>G TGCAGGAACTCADT TCADTTCTCGG′] TCADTTCTCGG′] (p.Asn161Ser) TCTCGGCTGGCCTCT TACTTGGAT′] NM_000529.2 4158 MC2R 5103 [′CCAAGTAACCCCT 5280- [′CCCTACTGCGCC 5493- [′CCCCTACTGCGC (MC2R):c.761A>G ACTGCGCCTGCTRC 5281 TGCTRCATGTC′, 5495 CTGCTRCATGT′, (p.Tyr254Cys) ATGTCTCTCTTCCAG ′CCTACTGCGCCTG ′CCCTACTGCGCCT GTGAACGGC′] CTRCATGTCT′] GCTRCATGTC′, ′CCTACTGCGCCTG CTRCATGTCT′] NM_005957.4 4524 MTHFR 5104 [′CCAGGCCTCCACTT 5282 [′CCACTTCTACAC 5496 [′CCACTTCTACAC (MTHFR):c.971A>G CTACACCCTCARCC CCTCARCCGCG′] CCTCARCCGCG′] (p.Asn324Ser) GCGAGATGGCTACC ACAGAGGTG′] NM_000403.3 2582 GALE 5105 [′GGCTACTTGCCTGT 5283 [′CCTGTGGTCATC 5497 [′CCTGTGGTCATC (GALE):c.101A>G GGTCATCGATARCT GATARCTTCCA′] GATARCTTCCA′] (p.Asn34Ser) TCCATAATGCCTTCC GTGGTGAG′] NM_000356.3 6949 TCOF1 5106 [′CAGCCCGTAACCC 5284- [′CCCTTCTGGACA 5498- [′CCCTTCTGGACA (TCOF1):c.149A>G TTCTGGACATCTRTA 5285 TCTRTACACAC′, 5499 TCTRTACACAC′, (p.Tyr50Cys) CACACTGGCAACAG ′CCTTCTGGACATC ′CCTTCTGGACATC TAAGTGGTG′] TRTACACACT′] TRTACACACT′] NM_012464.4 7092 TLL1 5107 [′ACTTCTTACCAAAC 5286 [′CCAAACTTAACG 5500 [′CCAAACTTAACG (TLL1):c.1885A>G TTAACGGCACCRTA GCACCRTAACC′] GCACCRTAACC′] (p.Ile629Val) ACCACCCCTGGCTG GCCCAAGGA′] NM_000112.3 1836 SLC26A2 5108 [′GGAAATGTATGCC 5287 [′CCATTGGCTTTT 5501 [′CCATTGGCTTTT (SLC26A2):c.1273A>G ATTGGCTTTTGTRAT GTRATATCATC′] GTRATATCATC′] (p.Asn425Asp) ATCATCCCTTCCTTC TTCCACTG′] NM_000157.3 2629 GBA 5109 [′ACATCACCCACTTG 5288 [′CCACTTGGCTCA 5502 [′CCACTTGGCTCA (GBA):c.680A>G GCTCAAGACCARTG AGACCARTGGA′] AGACCARTGGA′] (p.Asn227Ser) GAGCGGTGAATGGG AAGGGGTCA′] NM_175073.2 54840 APTX 5110 [′GATAAATACCCAA 5289- [′CCCAAAGGCCCG 5503- [′CCCAAAGGCCCG (APTX):c.602A>G AGGCCCGTTACCRT 5290 TTACCRTTGGC′, 5504 TTACCRTTGGC′, (p.His201Arg) TGGCTGGTCTTACC ′CCAAAGGCCCGT ′CCAAAGGCCCGT GTGGACCTCC′] TACCRTTGGCT′] TACCRTTGGCT′] NM_020638.2 8074 FGF23 5111 [′TGGCGCACCCCAT 5291 [′CCCCATCAGACC 5505- [′CCCCATCAGACC (FGF23):c.211A>G CAGACCATCTACRG ATCTACRGTGA′] 5507 ATCTACRGTGA′, (p.Ser71Gly) TGAGTAGGGCTTCA ′CCCATCAGACCA GGCTGGGAAG′] TCTACRGTGAG′, ′CCATCAGACCAT CTACRGTGAGT′] NM_021102.3 10653 SPINT2 5112 [′AGGAACTCCTGCA 5292 [′CCTGCAATAACT 5508 [′CCTGCAATAACT (SPINT2):c.488A>G ATAACTTCATCTRTG TCATCTRTGGA′] TCATCTRTGGA′] (p.Tyr163Cys) GAGGCTGCCGGGGC AATAAGAAC′] NM_004795.3 9365 KL 5113 [′GTGCAGCCCGTGG 5293 [′CCGTGGTCACCC 5509 [′CCGTGGTCACCC (KL):c.578A>G TCACCCTGTACCRCT TGTACCRCTGG′] TGTACCRCTGG′] (p.His193Arg) GGGACCTGCCCCAG CGCCTGCAG′] NM_012193.3 −1 — 5114 [′GTTTTCCTACCCTG 5294- [′CCCTGAGCGCCC 5510- [′CCCTGAGCGCCC (FZD4):c.766A>G AGCGCCCCATCRTA 5295 CATCRTATTTC′, 5511 CATCRTATTTC′, (p.Ile256Val) TTTCTCAGTATGTGC ′CCTGAGCGCCCC ′CCTGAGCGCCCC TATAATAT′] ATCRTATTTCT′] ATCRTATTTCT′] NM_001099274.1 26277 TINF2 5115 [′ATGGGCCTCCACT 5296 [′CCACTAGGGGAG 5512 [′CCACTAGGGGAG (TINF2):c.838A>G AGGGGAGGCCATDA GCCATDAGGAG′] GCCATDAGGAG′] (p.Lys280Glu) GGAGCGCCCCACAG TCATGCTGTT′] NM_005682.6 9289 ADGRG1 5116 [′TCCTTCCCTGACCC 5297 [′CCCCAGGGGCCT 5513 [′CCCCAGGGGCCT (ADGRG1):c.263A>G CAGGGGCCTCTRCC CTRCCACTTCT′] CTRCCACTTCT′] (p.Tyr88Cys) ACTTCTGCCTCTACT GGAACCGA′] NM_000369.2 7253 TSHR 5117 [′CCGCAGTACAACC 5298 [′CCCAGGGGACAA 5514 [′CCCAGGGGACAA (TSHR):c.1856A>G CAGGGGACAAAGRT AGRTACCAAAA′] AGRTACCAAAA′] (p.Asp619Gly) ACCAAAATTGCCAA GAGGATGGCT′] NM_024009.2 2707 GJB3 5118 [′ATGCCGCGCCTGG 5299 [′CCTGGTGCAGTG 5515 [′CCTGGTGCAGTG (GJB3):c.497A>G TGCAGTGTGCCADC TGCCADCGTGG′] TGCCADCGTGG′] (p.Asn166Ser) GTGGCCCCCTGCCC CAACATCGTG′] NM_003722.4 8626 TP63 5119 [′TATCCGCGCCATGC 5300 [′CCATGCCTGTCT 5516 [′CCATGCCTGTCT (TP63):c.697A>G CTGTCTACAAARAA ACAAARAAGCT′] ACAAARAAGCT′] (p.Lys233Glu) GCTGAGCACGTCAC GGAGGTGGT′] NM_003494.3 8291 DYSF 5120 [′CAGCTCTTAACCAC 5301 [′CCACTCCAGCCA 5517 [′CCACTCCAGCCA (DYSF):c.3443-33A>G TCCAGCCACTCRCT CTCRCTCTGGC′] CTCRCTCTGGC′] CTGGCACCTCTGTTT TTTCCCTT′] NM_003494.3 8291 DYSF 5121 [′AACTTGTCCCCTCC 5302 [′CCCCTCCCTGTG 5518- [′CCCCTCCCTGTG (DYSF):c.1285-2A>G CTGTGTCTTCTRGCT TCTTCTRGCTG′] 5520 TCTTCTRGCTG′, GTGCAGCAAGATCT ′CCCTCCCTGTGTC TGGAGAAG′] TTCTRGCTGT′, ′CCTCCCTGTGTCT TCTRGCTGTG′] NM_002408.3 4247 MGAT2 5122 [′CTTATACTTTTCCT 5303 [′CCTAGAAGAGGA 5521 [′CCTAGAAGAGGA (MGAT2):c.785A>G AGAAGAGGATCRCT TCRCTACTTAG′] TCRCTACTTAG′] (p.His262Arg) ACTTAGCCCCAGAC TTTTACCAT′] NM_000492.3 1080 CFTR 5123 [′GTGATTATCACCA 5304 [′CCAGCACCAGTT 5522 [′CCAGCACCAGTT (CFTR):c.2738A>G GCACCAGTTCGTRT CGTRTTATGTG′] CGTRTTATGTG′] (p.Tyr913Cys) TATGTGTTTTACATT TACGTGGGA′] NM_001814.4 1075 CTSC 5124 [′TCTCAGACCCCAAT 5305 [′CCCCAATCCTAA 5523- [′CCCCAATCCTAA (CTSC):c.857A>G CCTAAGCCCTCRGG GCCCTCRGGAG′] 5525 GCCCTCRGGAG′, (p.Gln286Arg) AGGTTGTGTCTTGTA ′CCCAATCCTAAG GCCAGTAT′] CCCTCRGGAGG′, ′CCAATCCTAAGC CCTCRGGAGGT′] NM_005144.4 55806 HR 5125 [′TCCGACCCCTCCAA 5306 [′CCTCCAACCTGC 5526- [′CCTCCAACCTGC (HR):c.-218A>G CCTGCGGCCCTRGA GGCCCTRGAGC′] 5527 GGCCCTRGAGC′, GCGCCCCCGCCGCC ′CCAACCTGCGGC CCGGGGGAA′] CCTRGAGCGCC′] NM_018488.2 9496 TBX4 5126 [′TCCTTGTCCCGAGA 5307 [′CCCGAGAATCTT 5528- [′CCCGAGAATCTT (TBX4):c.1592A>G ATCTTCCTTACRGTA CCTTACRGTAC′] 5529 CCTTACRGTAC′, (p.G1n531Arg) CCATTCAGGAATGG ′CCGAGAATCTTCC GGACTGTG′] TTACRGTACC′] NM_001089.2 21 ABCA3 5127 [′ACAGATCACCGTC 5308 [′CCGTCCTGCTGG 5530 [′CCGTCCTGCTGG (ABCA3):c.1702A>G CTGCTGGGCCACRA GCCACRACGGT′] GCCACRACGGT′] (p.Asn568Asp) CGGTGCCGGGAAGA CCACCACCCT′] NM_000525.3 37671 KCNJ1 5128 [′CTGGTGGCCCCGCT 5309- [′CCCCGCTGATCA 5531- [′CCCCGCTGATCA (KCNDJ11):c.776A>G GATCATCTACCRTG 5310 TCTACCRTGTC′, 5533 TCTACCRTGTC′, (p.His259Arg) TCATTGATGCCAAC ′CCCGCTGATCATC ′CCCGCTGATCATC AGCCCACTC′] TACCRTGTCA′] TACCRTGTCA′, ′CCGCTGATCATCT ACCRTGTCAT′] NM_005587.2 4205 MEF2A 5129 [′TCTCCCCCTCCACC 5311 [′CCACCAGGTGGT 5534 [′CCACCAGGTGGT (MEF2A):c.788A>G AGGTGGTGGTARTC GGTARTCTTGG′] GGTARTCTTGG′] (p.Asn263Ser) TTGGAATGAACAGT AGGAAACCA′] NM_000098.2 1376 CPT2 5130 [′TTTTTAGGACCCTG 5312 [′CCTGGTTTGATA 5535- [′CCCTGGTTTGAT (CPT2):c.359A>G GTTTGATATGTRCCT TGTRCCTATCT′] 5536 ATGTRCCTATC′, (p.Tyr120Cys) ATCTGCTCGAGACT ′CCTGGTTTGATAT CCGTTGTT′] GTRCCTATCT′] NM_178138.4 8022 LHX3 5131 [′GTGCGCCGCGCCC 5313- [′CCCAGGACTTCG 5537- [′CCCAGGACTTCG (LHX3):c.332A>G AGGACTTCGTGTRC 5314 TGTRCCACCTG′, 5538 TGTRCCACCTG′, (p.Tyr111Cys) CACCTGCACTGCTTT ′CCAGGACTTCGT ′CCAGGACTTCGT GCCTGCGTC′] GTRCCACCTGC′] GTRCCACCTGC′] NM_005502.3 19 ABCA1 5132 [′CAGATCACCTCCTT 5315 [′CCTCCTTCCTGG 5539- [′CCTCCTTCCTGG (ABCA1):c.2804A>G CCTGGGCCACARTG GCCACARTGGA′] 5540 GCCACARTGGA′, (p.Asn935Ser) GAGCGGGGAAGAC ′CCTTCCTGGGCCA GACCACCATG′] CARTGGAGCG′] m.3260A>G 4567 MT-TL1 5133 [′GATGGCAGAGCCC 5316- [′CCCGGTAATCGC 5541- [′CCCGGTAATCGC GGTAATCGCATARA 5317 ATARAACTTAA′, 5542 ATARAACTTAA′, ACTTAAAACTTTAC ′CCGGTAATCGCA ′CCGGTAATCGCA AGTCAGAGGT′] TARAACTTAAA′] TARAACTTAAA′] m.4269A>G 4565 MT-TI 5134 [′GCATTCCCCCTCAA 5318- [′CCCTCAAACCTA 5543- [′CCCTCAAACCTA ACCTAAGAAATRTG 5319 AGAAATRTGTC′, 5544 AGAAATRTGTC′, TCTGATAAAAGAGT ′CCTCAAACCTAA ′CCTCAAACCTAA TACTTTGAT′] GAAATRTGTCT′] GAAATRTGTCT′] m.14495A>G 4541 MT- 5135 [′TCCAAAGACAACC 5320 [′CCATCATTCCCC 5545 [′CCATCATTCCCC ND6 ATCATTCCCCCTRA CTRAATAAATT′] CTRAATAAATT′] ATAAATTAAAAAAA CTATTAAACC′] NM_002764.3 5631 PRPS1 5136 [′CCAATCTCAGCCA 5321 [′CCAAGCTTGTTG 5546 [′CCAAGCTTGTTG (PRPS1):c.341A>G AGCTTGTTGCAART CAARTATGCTA′] CAARTATGCTA′] (p.Asn114Ser) ATGCTATCTGTAGC AGGTGCAGAT′] NM_000054.4 554 AVPR2 5137 [′GCGGAGCCCTGGG 5322 [′CCTGGGGCCGTC 5547 [′CCTGGGGCCGTC (AVPR2):c.614A>G GCCGTCGCACCTRT GCACCTRTGTC′] GCACCTRTGTC′] (p.Tyr205Cys) GTCACCTGGATTGC CCTGATGGTG′] NM_000033.3 215 ABCD1 5138 [′ATCGCCCTCCCTGC 5323- [′CCCTGCTACCTT 5548- [′CCCTGCTACCTT (ABCD1):c.443A>G TACCTTCGTCARCA 5324 CGTCARCAGTG′, 5549 CGTCARCAGTG′, (p.Asn148Ser) GTGCCATCCGTTAC ′CCTGCTACCTTCG ′CCTGCTACCTTCG CTGGAGGGC′] TCARCAGTGC′] TCARCAGTGC′] NM_000061.2 695 BTK 5139 [′AGCACCATCCCTG 5325- [′CCCTGAGCTCAT 5550- [′CCCTGAGCTCAT (BTK):c.1082A>G AGCTCATTAACTRC 5326 TAACTRCCATC′, 5551 TAACTRCCATC′, (p.Tyr361Cys) CATCAGCACAACTC ′CCTGAGCTCATTA ′CCTGAGCTCATTA TGCAGGTGAG′] ACTRCCATCA′] ACTRCCATCA′] NM_003413.3 7547 ZIC3 5140 [′CTACACGCACCCG 5327 [′CCGAGCTCCCTG 5552- [′CCCGAGCTCCCT (ZIC3):c.1213A>G AGCTCCCTGCGCRA CGCRAACACAT′] 5553 GCGCRAACACA′, (p.Lys405Glu) ACACATGAAGGTAA ′CCGAGCTCCCTGC TTACCTCTTT′] GCRAACACAT′] NM_005448.2 9210 BMP15 5141 [′TTGGACATTGCCTT 5328 [′CCTTCTTGTTACT 5554 [′CCTTCTTGTTACT (BMP15):c.704A>G CTTGTTACTCTRTTT CTRTTTCAAT′] CTRTTTCAAT′] (p.Tyr235Cys) CAATGATACTCATA AAAGCATT′] NM_001363.4 1736 DKC1 5142 [′ATTAATGACCACA 5329 [′CCACAGCGGTCA 5555 [′CCACAGCGGTCA (DKC1):c.1069A>G GCGGTCATCTCTRC TCTCTRCCTGC′] TCTCTRCCTGC′] (p.Thr357Ala) CTGCGACCATGGTA TAGTAGCCAA′] NM_000481.3 275 AMT 5143 [′CGCAGGACACCGC 5330 [′CCGCTCTATGAC 5556 [′CCGCTCTATGAC (AMT):c.125A>G TCTATGACTTCCRCC TTCCRCCTGGC′] TTCCRCCTGGC′] (p.His42Arg) TGGCCCACGGCGGG AAAATGGTG′] NM_003361.3 7369 UMOD 5144 [′TGCCACGCCCTGG 5331 [′CCTGGCCACATG 5557- [′CCCTGGCCACAT (UMOD):c.383A>G CCACATGTGTCART TGTCARTGTGG′] 5558 GTGTCARTGTG′, (p.Asn128Ser) GTGGTGGGCAGCTA ′CCTGGCCACATGT CTTGTGCGTA′] GTCARTGTGG′] NM_001382.3 1798 DPAGT1 5145 [′TCTCTCCCCGCAGG 5332 [′CCGCAGGAATCC 5559 [′CCGCAGGAATCC (DPAGT1):c.509A>G AATCCTGTACTRTGT TGTACTRTGTC′] TGTACTRTGTC′] (p.Tyr170Cys) CTACATGGGGCTGC TGGCAGTG′] NM_001128177.1 7068 THRB 5146 [′CTGCCATGCCAGC 5333 [′CCAGCCGCTTCC 5560 [′CCAGCCGCTTCC (THRB):c.1324A>G CGCTTCCTGCACRT TGCACRTGAAG′] TGCACRTGAAG′] (p.Met442Val) GAAGGTGGAATGCC CCACAGAACT′] NM_000141.4 2263 FGFR2 5147 [′TGCCCAGCCCCAC 5334 [′CCCACATCCAGT 5561- [′CCCCACATCCAG (FGFR2):c.874A>G ATCCAGTGGATCRA GGATCRAGCAC′] 5563 TGGATCRAGCA′, (p.Lys292Glu) GCACGTGGAAAAGA ′CCCACATCCAGT ACGGCAGTAA′] GGATCRAGCAC′, ′CCACATCCAGTG GATCRAGCACG′] NM_000371.3 7276 TTR 5148 [′ACCATTGCCGCCCT 5335- [′CCGCCCTGCTGA 5564- [′CCGCCCTGCTGA (TTR):c.401A>G GCTGAGCCCCTRCT 5337 GCCCCTRCTCC′, 5566 GCCCCTRCTCC′, (p.Tyr134Cys) CCTATTCCACCACG ′CCCTGCTGAGCCC ′CCCTGCTGAGCCC GCTGTCGTC′] CTRCTCCTAT′, CTRCTCCTAT′, ′CCTGCTGAGCCCC ′CCTGCTGAGCCCC TRCTCCTATT′] TRCTCCTATT′] NM_000371.3 7276 TTR 5149 [′CGACTCCGGCCCC 5338 [′CCCCCGCCGCTA 5567- [′CCCCCGCCGCTA (TTR):c.379A>G CGCCGCTACACCRT CACCRTTGCCG′] 5569 CACCRTTGCCG′, (p.Ile127Val) TGCCGCCCTGCTGA ′CCCCGCCGCTAC GCCCCTACTC′] ACCRTTGCCGC′, ′CCCGCCGCTACA CCRTTGCCGCC′] NM_000174.4 2815 GP9 5150 [′ACCCGCCACCTTCT 5339 [′CCTTCTGCTGGC 5570 [′CCTTCTGCTGGC (GP9):c.182A>G GCTGGCCAACARCA CAACARCAGCC′] CAACARCAGCC′] (p.Asn61Ser) GCCTTCAGTCCGTG CCCCCGGGA′] NM_000222.2 3815 KIT 5151 [′ACGGGAAGCCCTC 5340- [′CCCTCATGTCTG 5571- [′CCCTCATGTCTG (KIT):c.1924A>G ATGTCTGAACTCRA 5341 AACTCRAAGTC′, 5572 AACTCRAAGTC′, (p.Lys642Glu) AGTCCTGAGTTACC ′CCTCATGTCTGAA ′CCTCATGTCTGAA TTGGTAATCA′] CTCRAAGTCC′] CTCRAAGTCC′] NM_000530.6 4359 MPZ 5152 [′TCCCCTCATTCCTC 5342 [′CCTCATAGATCT 5573 [′CCTCATAGATCT (MPZ):c.242A>G ATAGATCTTCCRCT TCCRCTATGCC′] TCCRCTATGCC′] (p.His8lArg) ATGCCAAGGGACAA CCCTACATT′] NM_000233.3 −1 — 5153 [′AAAATGGCAATCC 5343 [′CCTCATCTTCAC 5574 [′CCTCATCTTCAC (LHCGR):c.1733A>G TCATCTTCACCGRTT CGRTTTCACCT′] CGRTTTCACCT′] (p.Asp578Gly) TCACCTGCATGGCA CCTATCTCT′] NM_000421.3 −1 — 5154 [′CCGCCGCGTCCGC 5344 [′CCGCCGCCTCCG 5575 [′CCGCCGCCTCCG (KRT10):c.1374-2A>G CGCCTCCGGAACYA GAACYAAACGG′] GAACYAAACGG′] AACGGGGTGAGGTC ACATTCGGTT′] NM_000422.2 3872 KRT17 5155 [′TGAGAAGGCCACC 5345 [′CCACCATGCAGA 5576- [′CCACCATGCAGA (KRT17):c.274A>G ATGCAGAACCTCVA ACCTCVATGAC′] 5577 ACCTCVATGAC′, (p.Asn92Asp) TGACCGCCTGGCCT ′CCATGCAGAACC CCTACCTGGA′] TCVATGACCGC′] NM_000422.2 3872 KRT17 5156 [′GAGAAGGCCACCA 5346 [′CCACCATGCAGA 5578- [′CCACCATGCAGA (KRT17):c.275A>G TGCAGAACCTCART ACCTCARTGAC′] 5579 ACCTCARTGAC′, (p.Asn92Ser) GACCGCCTGGCCTC ′CCATGCAGAACC CTACCTGGAC′] TCARTGACCGC′] NM_000823.3 2692 GHRHR 5157 [′TTGTCTTTCCTGCA 5347 [′CCTGCAGGCGTC 5580 [′CCTGCAGGCGTC (GHRHR):c.985A>G GGCGTCTCTCCRAG TCTCCRAGTCG′] TCTCCRAGTCG′] (p.Lys329Glu) TCGACACTTTTCCTG ATCCCACT′] NM_000407.4 −1 — 5158 [′GCCGGCCGCCCCG 5348- [′CCCCGAGCGTGC 5581- [′CCCCGAGCGTGC (GP1BB):c.338A>G AGCGTGCGCCCTDC 5349 GCCCTDCCGCG′, 5583 GCCCTDCCGCG′, (p.Tyr113Cys) CGCGACCTGCGTTG ′CCCGAGCGTGCG ′CCCGAGCGTGCG CGTGGCGCCC′] CCCTDCCGCGA′] CCCTDCCGCGA′, ′CCGAGCGTGCGC CCTDCCGCGAC′] NM_001146040.1 2741 GLRA1 5159 [′CCTCCACCCCCACT 5350- [′CCCCACTCTAGG 5584- [′CCCCACTCTAGG (GLRA1):c.920A>G CTAGGTGTCCTVTGT 5351 TGTCCTVTGTG′, 5586 TGTCCTVTGTG′, (p.Tyr307Cys) GAAAGCCATTGACA ′CCCACTCTAGGTG ′CCCACTCTAGGTG TTTGGATG′] TCCTVTGTGA′] TCCTVTGTGA′, ′CCACTCTAGGTGT CCTVTGTGAA′] NM_182925.4 2324 FLT4 5160 [′CGCCTCCCCGCACC 5352 [′CCGCACCCCAGT 5587 [′CCGCACCCCAGT (FLT4):c.3104A>G CCAGTGCATCCRCA GCATCCRCAGA′] GCATCCRCAGA′] (p.His1035Arg) GAGACCTGGCTGCT CGGAACATT′] NM_212482.1 2335 FN1 5161 [′ACCGGGCTGTCCC 5353- [′CCCCTGGGGTCA 5588- [′CCCCTGGGGTCA (FN1):c.2918A>G CTGGGGTCACCTRT 5354 CCTRTTACTTC′, 5589 CCTRTTACTTC′, (p.Tyr973Cys) TACTTCAAAGTCTTT ′CCCTGGGGTCAC ′CCCTGGGGTCAC GCAGTGAGC′] CTRTTACTTCA′] CTRTTACTTCA′] NM_000121.3 2057 EPOR 5162 [′GGCTTATCCGATG 5355 [′CCGATGGCCCCT 5590 [′CCGATGGCCCCT (EPOR):c.1460A>G GCCCCTACTCCARC ACTCCARCCCT′] ACTCCARCCCT′] (p.Asn487Ser) CCTTATGAGAACAG CCTTATCCCA′] NM_001735.2 727 C5 5163 [′CGTCTACCCCCTCA 5356- [′CCCCTCACCCAA 5591- [′CCCCTCACCCAA (C5):c.1115A>G CCCAATCTACCYTG 5357 TCTACCYTGAT′, 5593 TCTACCYTGAT′, (p.Lys372Arg) ATGGGATATGGAAT ′CCCTCACCCAATC ′CCCTCACCCAATC CCCAGGCTT′] TACCYTGATG′] TACCYTGATG′, ′CCTCACCCAATCT ACCYTGATGG′] NM_001844.4 1280 COL2A1 5164 [′ACGGAAGGCTCCC 5358- [′CCCAGAACATCA 5594- [′CCCAGAACATCA (COL2A1):c.4172A>G AGAACATCACCTRC 5359 CCTRCCACTGC′, 5595 CCTRCCACTGC′, (p.Tyr1391Cys) CACTGCAAGAACAG ′CCAGAACATCAC ′CCAGAACATCAC CATTGCCTAT′] CTRCCACTGCA′] CTRCCACTGCA′] NM_001904.3 1499 CTNNB1 5165 [′CTCTGGAATCCATT 5360 [′CCATTCTGGTGC 5596 [′CCATTCTGGTGC (CTNNB1):c.121A>G CTGGTGCCACTNCC CACTNCCACAG′] CACTNCCACAG′] (p.Thr41Ala) ACAGCTCCTTCTCTG AGTGGTAA′] NM_000040.1 345 APOC3 5166 [′GGATTTGGACCCT 5361- [′CCCTGAGGTCAG 5597- [′CCCTGAGGTCAG (APOC3):c.280A>G GAGGTCAGACCARC 5362 5598 ACCARCTTCAG′, (p.Thr94Ala) TTCAGCCGTGGCTG ′CCTGAGGTCAGA ′CCTGAGGTCAGA CCTGAGACCT′] CCARCTTCAGC′] CCARCTTCAGC′] NM_000488.3 462 SERPINC1 5167 [′TGCAGAGCAATCC 5363 [′CCAGAGCGGCCA 5599 [′CCAGAGCGGCCA (SERPINC1):c.655A>G AGAGCGGCCATCRA TCRACAAATGG′] TCRACAAATGG′] CAAATGGGTGTCCA (p.Asn219Asp) ATAAGACCGA′] NM_001085.4 12 SERPINA3 5168 [′TACAGACACCCAG 5364 [′CCCAGAACATCT 5600- [′CCCAGAACATCT (SERPINA3):c.1240A>G AACATCTTCTTCRTG TCTTCRTGAGC′] 5601 TCTTCRTGAGC′, (p.Met414Val) AGCAAAGTCACCAA ′CCAGAACATCTTC TCCCAAGCA′] TTCRTGAGCA′] NM_001145.4 −1 — 5169 [′CTTCCTGACCCAGC 5365 [′CCAGCACTATGA 5602- [′CCCAGCACTATG (ANG):c.121A>G ACTATGATGCCRAA TGCCRAACCAC′] 5603 ATGCCRAACCA′, (p.Lys41Glu) CCACAGGGCCGGGA ′CCAGCACTATGA TGACAGATA′] TGCCRAACCAC′] NM_001100.3 58 ACTA1 5170 [′GAGGCCCCCCTCA 5366 [′CCTCAATCCCAA 5604- [′CCCTCAATCCCA (ACTA1):c.350A>G ATCCCAAGGCCARC GGCCARCCGCG′] 5605 AGGCCARCCGC′, (p.Asn117Ser) CGCGAGAAGATGAC ′CCTCAATCCCAA CCAGATCATG′] GGCCARCCGCG′] NM_014053.3 28982 FLVCR1 5171 [′GATCTTCAGCCTGT 5367 [′CCTGTACTCGCT 5606 [′CCTGTACTCGCT (FLVCR1):c.361A>G ACTCGCTGGTCRAC GGTCRACGCCT′] GGTCRACGCCT′] (p.Asn121Asp) GCCTTTCAGTGGAT CCAGTACAG′] NM_000334.4 6329 SCN4A 5172 [′GAAGCAGGCCTTC 5368 [′CCTTCGACATCA 5607 [′CCTTCGACATCA (SCN4A):c.4078A>G GACATCACCATCRT CCATCRTGATC′] CCATCRTGATC′] (p.Met1360Val) GATCCTCATCTGCCT CAACATGGT′] NM_004519.3 3786 KCNQ3 5173 [′GAACCAAAGCCTG 5369 [′CCTGTTGGCTTA 5608 [′CCTGTTGGCTTA (KCNQ3):c.1403A>G TTGGCTTAAACART AACARTAAAGA′] AACARTAAAGA′] (p.Asn468Ser) AAAGAGCGTTTCCG CACGGCCTTC′] NM_007375.3 23435 TARDBP 5174 [′AATGCCGAACCTA 5370 [′CCTAAGCACAAT 5609 [′CCTAAGCACAAT (TARDBP):c.800A>G AGCACAATAGCART AGCARTAGACA′] AGCARTAGACA′] (p.Asn267Ser) AGACAGTTAGAAAG AAGTGGAAGA′] NM_032520.4 84572 GNPTG 5175 [′TGCTGCCCCTGCAT 5371 [′CCTGCATCCTCC 5610 [′CCTGCATCCTCC (GNPTG):c.6102A>G CCTCCACCTTCRGG ACCTTCRGGGC′] ACCTTCRGGGC′] GCCATGAGAAGTTG CTGAGGACA′] NM_000495.4 1287 COL4A5 5176 [′AGAACTTCCATTG 5372 [′CCATTGATGGCT 5611 [′CCATTGATGGCT (COL4A5):c.466-2A>G ATGGCTTCTTTTRGG TCTTTTRGGGT′] TCTTTTRGGGT′] GTGAACCAGGTAGT ATAATTATG′] NM_000495.4 12875 COMA 5177 [′TTGCTATCCTTTCT 5373 [′CCTTTCTTTATCT 5612 [′CCTTTCTTTATCT (COL4A5):c.1340-2A>G TTATCTTACTCRGGT TACTCRGGTG′] TACTCRGGTG′] GATGAGATATGTGA ACCAGGCC′] NM_000060.3 686 BTD 5178 [′CTCATGAACCAGA 5374 [′CCAGAACCTTGA 5613 [′CCAGAACCTTGA (BTD):c.278A>G ACCTTGACATCTRT CATCTRTGAAC′] CATCTRTGAAC′] (p.Tyr93Cys) GAACAGCAAGTGAT GACTGCAGCC′] NM_000060.3 686 BTD 5179 [′CTTGTTGACCGCTA 5375 [′CCGCTACCGTAA 5614 [′CCGCTACCGTAA (BTD):c.641A>G CCGTAAACACARCC ACACARCCTCT′] ACACARCCTCT′] (p.Asn214Ser) TCTACTTTGAGGCA GCATTCGAT′] NM_000094.3 1294 COL7A1 5180 [′CAGCTGGCCCGAC 5376 [′CCCGACCTGGTG 5615- [′CCCGACCTGGTG (COL7A1):c.425A>G CTGGTGTCCCCARG TCCCCARGGTG′] 5616 TCCCCARGGTG′, (p.Lys142Arg) GTGATCCCTACCCC ′CCGACCTGGTGTC TACCATGCCT′] CCCARGGTGA′] NM_005247.2 2248 FGF3 5181 [′GGGGCGCCCCGGC 5377- [′CCCGGCGCCGCA 5617- [′CCCGGCGCCGCA (FGF3):c.146A>G GCCGCAAGCTCTRC 5378 AGCTCTRCTGC′, 5618 AGCTCTRCTGC′, (p.Tyr49Cys) TGCGCCACGAAGTA ′CCGGCGCCGCAA ′CCGGCGCCGCAA CCACCTCCAG′] GCTCTRCTGCG′] GCTCTRCTGCG′] NM_000313.3 5627 PROS1 5182 [′TGTGAATGCCCCG 5379- [′CCCGAAGGCTAC 5619- [′CCCCGAAGGCTA (PROS1):c.701A>G AAGGCTACAGATRT 5380 AGATRTAATCT′, 5621 CAGATRTAATC′, (p.Tyr234Cys) AATCTCAAATCAAA ′CCGAAGGCTACA ′CCCGAAGGCTAC GTCTTGTGAA′] GATRTAATCTC′] AGATRTAATCT′, ′CCGAAGGCTACA GATRTAATCTC′] NM_004612.3 7046 TGFBR1 5183 [′TTCTGCCACCTCTG 5381 [′CCTCTGTACAAA 5622 [′CCTCTGTACAAA (TGFBR1):c.134A>G TACAAAAGACARTT AGACARTTTTA′] AGACARTTTTA′] (p.Asn45Ser) TTACTTGTGTGACA GATGGGCTC′] m.608A>G 4558 MT-TF 5184 [′GTAGCTTACCTCCT 5382 [′CCTCCTCAAAGC 5623- [′CCTCCTCAAAGC CAAAGCAATACRCT AATACRCTGAA′] 5624 AATACRCTGAA′, GAAAATGTTTAGAC ′CCTCAAAGCAAT GGGCTCACA′] ACRCTGAAAAT′] NM_001376.4 1778 DYNC1H1 5185 [′CTAAGAATAACCA 5383 [′CCAATCAGGTAA 5625 [′CCAATCAGGTAA (DYNC1H1):c.2909A>G ATCAGGTAATCTRC TCTRCTTGAAT′] TCTRCTTGAAT′] (p.Tyr970Cys) TTGAATCCACCAAT TGAAGAGTGC′] NM_000459.4 7010 TEK 5186 [′ATGCTCTCTTCCTT 5384 [′CCTTCCCTCCAG 5626 [′CCTTCCCTCCAG (TEK):c.2690A>G CCCTCCAGGCTVCT GCTVCTTGTAC′] GCTVCTTGTAC′] (p.Tyr897Cys) TGTACCTGGCCATT GAGTACGCG′] NM_014191.3 6334 SCN8A 5187 [′CATGTACATTGCCA 5385 [′CCATCATCCTGG 5627 [′CCATCATCCTGG (SCN8A):c.5302A>G TCATCCTGGAGRAC AGRACTTCAGT′] AGRACTTCAGT′] (p.Asn1768Asp) TTCAGTGTAGCCAC AGAGGAAAG′] NM_002552.4 5000 ORC4 5188 [′CATCATAAAAACC 5386 [′CCAAACACTTCT 5628 [′CCAAACACTTCT (ORC4):c.521A>G AAACACTTCTCTRT CTRTAATCTTT′] CTRTAATCTTT′] (p.Tyr174Cys) AATCTTTTTGACATT TCTCAGTCT′] NM_004813.2 9409 PEX16 5189 [′TACTTGCCCACCTG 5387- [′CCACCTGGCAGA 5629- [′CCACCTGGCAGA (PEX16):c.992A>G GCAGAAAATCTRCT 5388 AAATCTRCTTC′, 5630 AAATCTRCTTC′, (p.Tyr331Cys) TCTACAGTTGGGGC ′CCTGGCAGAAAA ′CCTGGCAGAAAA TGACAGACC′] TCTRCTTCTAC′] TCTRCTTCTAC′] NM_016952.4 50937 CDON 5190 [′GTTTTTGTTTTCCC 5389 [′CCCTCAAAGGTT 5631 [′CCCTCAAAGGTT (CDON):c.2368A>G TCAAAGGTTCARCA CARCATACAAA′] CARCATACAAA′] (p.Thr790Ala) TACAAATTTAGGGT CATTGCCAT′] NM_016464.4 51524 TMEM138 5191 [′TACTTTGCCCTCAG 5390- [′CCCTCAGCATCT 5632- [′CCCTCAGCATCT (TMEM138):c.287A>G CATCTCCCTTCRTGT 5391 CCCTTCRTGTC′, 5633 CCCTTCRTGTC′, (p.His96Arg) CTGGGTCATGGTAA ′CCTCAGCATCTCC ′CCTCAGCATCTCC GAGTGGCA′] CTTCRTGTCT′] CTTCRTGTCT′] NM_005022.3 5216 PFN1 5192 [′GTTGATCAAACCA 5392 [′CCACCGTGGACA 5634 [′CCACCGTGGACA (PFN1):c.350A>G CCGTGGACACCTYC CCTYCTTTGCC′] CCTYCTTTGCC′] (p.Glu117Gly) TTTGCCCATCAGCA GGACTAGCGC′] NM_022787.3 64802 NMNAT1 5193 [′GGTCATCCTGGCCC 5393 [′CCCCTTTGCAGA 5635 [′CCCCTTTGCAGA (NMNAT1):c.817A>G CTTTGCAGAGARAC GARACACTGCA′] GARACACTGCA′] (p.Asn273Asp) ACTGCAGAAGCTAA GACATAGGA′] NM_005340.6 3094 HINT1 5194 [′GACATTTCCCCTCA 5394- [′CCCCTCAAGCAC 5636- [′CCCCTCAAGCAC (HINT1):c.152A>G AGCACCAACACRTT 5396 CAACACRTTTT′, 5638 CAACACRTTTT′, (p.His5lArg) TTCTGGTGATACCC ′CCCTCAAGCACC ′CCCTCAAGCACC AAGAAACAT′] AACACRTTTTC′, AACACRTTTTC′, ′CCTCAAGCACCA ′CCTCAAGCACCA ACACRTTTTCT′] ACACRTTTTCT′] NM_005211.3 1436 CSF1R 5195 [′GACTAACCCTGCA 5397 [′CCTGCAGTGCTT 5639 [′CCTGCAGTGCTT (CSF1R):c.2320-2A>G GTGCTTTCCCTCRGT TCCCTCRGTGC′] TCCCTCRGTGC′] GCATCCACCGGGAC GTGGCAGCG′] NM_001039958.1 145873 MESP2 5196 [′GCGGCAGAGCGCC 5398 [′CCAGCGAGCGGG 5640 [′CCAGCGAGCGGG (MESP2):c.271A>G AGCGAGCGGGAGRA AGRAACTGCGC′] AGRAACTGCGC′] (p.Lys91Glu) ACTGCGCATGCGCA CGCTGGCCCG′] NM_001099274.1 26277 TINF2 5197 [′TAGGGGAGGCCAT 5399 [′CCATAAGGAGCG 5641 [′CCATAAGGAGCG (TINF2):c.850A>G AAGGAGCGCCCCRC CCCCRCAGTCA′] CCCCRCAGTCA′] (p.Thr284Ala) AGTCATGCTGTTTCC CTTTAGGAA′] NM_003863.3 8818 DPM2 5198 [′GCCGTTAGCCTGAT 5400 [′CCTGATCATCTT 5642 [′CCTGATCATCTT (DPM2):c.68A>G CATCTTCACCTRCTA CACCTRCTACA′] CACCTRCTACA′] (p.Tyr23Cys) CACCGCCTGGGTGA TTCTCTTG′] NM_000530.6 4359 MPZ 5199 [′AAGGATGGCTCCA 5401 [′CCATTGTCATAC 5643 [′CCATTGTCATAC (MPZ):c.347A>G TTGTCATACACARC ACARCCTAGAC′] ACARCCTAGAC′] (p.Asn116Ser) CTAGACTACAGTGA CAATGGCACG′] NM_000138.4 2200 FBN1 5200 [′ACCCGGATTTGCC 5402 [′CCACAAAAGAA 5644 [′CCACAAAAGAA (FBN1):c.3058A>G ACAAAAGAAATTRC ATTRCAAATGGA′] ATTRCAAATGGA′] (p.Thr1020Ala) AAATGGAAAGCCTT TCTTCAAAGG′] NM_000169.2 −1 — 5201 [′GGCCTGTAATCCTG 5403 [′CCTGCCTGCTTC 5645 [′CCTGCCTGCTTC (GLA):c.1153A>G CCTGCTTCATCRCAC ATCRCACAGCT′] ATCRCACAGCT′] (p.Thr385Ala) AGCTCCTCCCTGTG AAAAGGAA′] NM_000257.3 4625 MYH7 5202 [′AGCGGCCATCCCT 5404 [′CCCTGAGGGACA 5646- [′CCCTGAGGGACA (MYH7):c.2206A>G GAGGGACAGTTCRT GTTCRTTGATA′] 5647 GTTCRTTGATA′, (p.Ile736Val) TGATAGCAGGAAGG ′CCTGAGGGACAG GGGCAGAGAA′] TTCRTTGATAG′] NM_018972.2 54332 GDAP1 5203 [′AGCATGTATTACCC 5405 [′CCCACGGGTACA 5648 [′CCCACGGGTACA (GDAP1):c.368A>G ACGGGTACAACRTT ACRTTACCGAG′] ACRTTACCGAG′] (p.His123Arg) ACCGAGAGCTGCTT GACTCCTTG′] NM_001946.3 1848 DUSP6 5204 [′ACTACCATCCGAG 5406 [′CCGAGTCTGTTG 5649 [′CCGAGTCTGTTG (DUSP6):c.566A>G TCTGTTGCACTAYTG CACTAYTGGGG′] CACTAYTGGGG′] (p.Asn189Ser) GGGTCTCGGTCAAG GTCAGACTC′] NM_003867.3 8822 FGF17 5205 [′TACCAAGGCCAGC 5407 [′CCAGCTGCCCTT 5650 [′CCAGCTGCCCTT (FGF17):c.560A>G TGCCCTTCCCCARCC CCCCARCCACG′] CCCCARCCACG′] (p.Asn187Ser) ACGCCGAGAAGCAG AAGCAGTTC′] NM_015560.2 4976 OPA1 5206 [′TTTTTATTTTTCCT 5408 [′CCTGAGTAGACC 5651 [′CCTGAGTAGACC (OPA1):c.1146A>G GAGTAGACCATRTC ATRTCCTTAAA′] ATRTCCTTAAA′] (p.Ile382Met) CTTAAATGTAAAAG GCCCTGGAC′] NM_002972.3 6305 SBF1 5207 [′AAGGCCATGCCCT 5409 [′CCCTCCAGCACC 5652- [′CCCTCCAGCACC (SBF1):c.1249A>G CCAGCACCTTCAYC TTCAYCAGGAA′] 5653 TTCAYCAGGAA′, (p.Met417Val) AGGAAATCGTCCTC ′CCTCCAGCACCTT TACCAGCCCA′] CAYCAGGAAA′] NM_006876.2 11041 B4GAT1 5208 [′GTTCCATCCCCAAA 5410 [′CCAAAAGGAGG 5654- [′CCCCAAAAGGAG (B4GAT1):c.1168A>G AGGAGGCTGAARAT CTGAARATCAGC′] 5656 GCTGAARATCA′, (p.Asn390Asp) CAGCACAATAAGAT ′CCCAAAAGGAGG CCTATATCG′] CTGAARATCAG′, ′CCAAAAGGAGGC TGAARATCAGC′] NM_000218.2 3784 KCNQ1 5209 [′CGCACCCACGTCC 5411 [′CCAGGGCCGCGT 5657 [′CCAGGGCCGCGT (KCNQ1):c.332A>G AGGGCCGCGTCTRC CTRCAACTTCC′] CTRCAACTTCC′] (p.Tyr111Cys) AACTTCCTCGAGCG TCCCACCGGC′] NM_000492.3 1080 CFTR 5210 [′CAGGGACCCCAGC 5412 [′CCAGCGCCCGAG 5658- [′CCCAGCGCCCGA (CFTR):c.1A>G GCCCGAGAGACCRT AGACCRTGCAG′] 5659 GAGACCRTGCA′, (p.MetlVal) GCAGAGGTCGCCTC ′CCAGCGCCCGAG TGGAAAAGGC′] AGACCRTGCAG′] NM_007294.3 672 BRCA1 5211 [′GAACCTGTCTCCAC 5413 [′CCACAAAGTGTG 5660 [′CCACAAAGTGTG (BRCA1):c.122A>G AAAGTGTGACCRCA ACCRCATATTT′] ACCRCATATTT′] (p.His41Arg) TATTTTGCAAGTAA GTTTGAATG′] NM_007294.3 672 BRCA1 5212 [′GTTTTCTCCTTCCA 5414 [′CCTTCCATTTATC 5661- [′CCTTCCATTTATC (BRCA1):c.44852A>G TTTATCTTTCTRGGT TTTCTRGGTC′] 5662 TTTCTRGGTC′, CATCCCCTTCTAAAT ′CCATTTATCTTTC GCCCATC′] TRGGTCATCC′] NM_014795.3 9839 ZEB2 5213 [′AAACACAAGCACC 5415 [′CCACCTTATCGA 5663 [′CCACCTTATCGA (ZEB2):c.3134A>G ACCTTATCGAGCRC GCRCTCAAGGC′] GCRCTCAAGGC′] (p.His1045Arg) TCAAGGCTTCACTC GGGCGAGAAG′] NM_001287.5 1186 CLCN7 5214 [′TGTCCCGGCCTGCA 5416 [′CCTGCAGAGCTT 5664 [′CCTGCAGAGCTT (CLCN7):c.296A>G GAGCTTGGACTRTG GGACTRTGACA′] GGACTRTGACA′] (p.Tyr99Cys) ACAACAGTGAGAAC CAGCTGTTC′] NM_080605.3 126792 B3GALT6 5215 [′CGCCACGCCCGCC 5417 [′CCCGCCGCAGCA 5665- [′CCCGCCGCAGCA (B3GALT6):c.1A>G GCAGCAGCTTCAYG GCTTCAYGGCG′] 5667 GCTTCAYGGCG′, (p.MetlVal) GCGCCCGCGCCGGG ′CCGCCGCAGCAG CCGGCGGCCC′] CTTCAYGGCGC′, ′CCGCAGCAGCTT CAYGGCGCCCG′] NM_000207.2 −1 — 5216 [′TCCTGCACCGAGA 5418 [′CCGAGAGAGATG 5668 [′CCGAGAGAGATG (1NS):c.*59A>G GAGATGGAATAARG GAATAARGCCC′] GAATAARGCCC′] CCCTTGAACCAGCC CTGCTGTGCC′] NM_000784.3 1593 CYP27A1 5217 [′TGGGCCCTGTACC 5419 [′CCACCTCTCAAA 5669 [′CCACCTCTCAAA (CYP27A1):c.1061A>G ACCTCTCAAAGGRC GGRCCCTGAGA′] GGRCCCTGAGA′] (p.Asp354Gly) CCTGAGATCCAGGA GGCCTTGCAC′] NM_000540.2 6261 RYR1 5218 [′CTACCTGTACACCG 5420 [′CCGTGGTGGCCT 5670 [′CCGTGGTGGCCT (RYRO:c.14572A>G TGGTGGCCTTCRAC TCRACTTCTTC′] TCRACTTCTTC′] (p.Asn4858Asp) TTCTTCCGCAAGTTC TACAACAA′] NM_000238.3 3757 KCNH2 5219 [′CACCCCGGCCGCA 5421 [′CCGCATCGCCGT 5671 [′CCGCATCGCCGT (KCNH2):c.1478A>G TCGCCGTCCACTNC CCACTNCTTCA′] CCACTNCTTCA′] (p.Tyr493Cys) TTCAAGGGCTGGTT CCTCATCGAC′] NM_000335.4 6331 SCN5A 5220 [′CCGAGTCCTCCGG 5422 [′CCGGGCCCTGAA 5672 [′CCGGGCCCTGAA (SCN5A):c.688A>G GCCCTGAAAACTRT AACTRTATCAG′] AACTRTATCAG′] (p.Ile230Val) ATCAGTCATTTCAG GTGAAAATCA′] NM_000169.2 −1 — 5221 [′TATTTTACCCATTG 5423 [′CCCATTGTTTTCT 5673- [′CCCATTGTTTTCT (GLA):c.548-2A>G TTTTCTCATACRGGT CATACRGGTT′] 5674 CATACRGGTT′, TATAAGCACATGTC ′CCATTGTTTTCTC CTTGGCCC′] ATACRGGTTA′] NM_000146.3 2512 FTL 5222 [′GTTAGCTCCTTCTT 5424 [′CCTTCTTGCCAA 5675 [′CCTTCTTGCCAA (FTL):c.1A>G GCCAACCAACCRTG CCAACCRTGAG′] CCAACCRTGAG′] (p.MetlVal) AGCTCCCAGATTCG TCAGAATTA′] NM_000531.5 5009 OTC 5223 [′GTCATGGTGTCCCT 5425- [′CCCTGCTGACAG 5676- [′CCCTGCTGACAG (OTC):c.1034A>G GCTGACAGATTRCT 5426 ATTRCTCACCT′, 5677 ATTRCTCACCT′, (p.Tyr345Cys) CACCTCAGCTCCAG ′CCTGCTGACAGA ′CCTGCTGACAGA AAGCCTAAA′] TTRCTCACCTC′] TTRCTCACCTC′] NM_000531.5 5009 OTC 5224 [′TGTTTTCTTACCAC 5427 [′CCACACAAGATA 5678 [′CCACACAAGATA (OTC):c.350A>G ACAAGATATTCDTT TTCDTTTGGGT′] TTCDTTTGGGT′] (p.His117Arg) TGGGTGTGAATGAA AGTCTCACG′] NM_000531.5 5009 OTC 5225 [′TACCATCCTATCCA 5428 [′CCAGATCCTGGC 5679 [′CCAGATCCTGGC (OTC):c.524A>G GATCCTGGCTGDTT TGDTTACCTCA′] TGDTTACCTCA′] (p.Asp175Gly) ACCTCACGCTCCAG GTTGGTTTA′] NM_000531.5 5009 OTC 5226 [′CATCCTATCCAGAT 5429 [′CCAGATCCTGGC 5680 [′CCAGATCCTGGC (OTC):c.527A>G CCTGGCTGATTRCCT TGATTRCCTCA′] TGATTRCCTCA′] (p.Tyr176Cys) CACGCTCCAGGTTG GTTTATTT′] NM_000531.5 5009 OTC 5227 [′TCTCCTTCATCCCG 5430 [′CCGTGCCTTTTA 5681- [′CCCGTGCCTTTT (OTC):c.542A>G TGCCTTTTAGGRAC GGRACACTATA′] 5682 AGGRACACTAT′, (p.Glu181Gly) ACTATAGCTCTCTG ′CCGTGCCTTTTAG AAAGGTCTT′] GRACACTATA′] NM_024301.4 79147 FKRP 5228 [′CCAGCTAGCCCCA 5431 [′CCCCAGACTTCG 5683- [′CCCCAGACTTCG (FKRP):c.1A>G GACTTCGGCCCCRT GCCCCRTGCGG′] 5685 GCCCCRTGCGG′, (p.MetlVal) GCGGCTCACCCGCT ′CCCAGACTTCGG GCCAGGCTGC′] CCCCRTGCGGC′, ′CCAGACTTCGGC CCCRTGCGGCT′] NM_000321.2 5925 RB1 5229 [′AGCCTTCCAGACC 5432 [′CCCAGAAGCCAT 5686 [′CCCAGAAGCCAT (RBO:c.1927A>G CAGAAGCCATTGRA TGRAATCTACC′] TGRAATCTACC′] (p.Lys643Glu) ATCTACCTCTCTTTC ACTGTTTTA′] NM_015713.4 50484 RRM2B 5230 [′AAAAGATCCTGAG 5433 [′CCTGAGAAGAAA 5687 [′CCTGAGAAGAAA (RRM2B):c.581A> AAGAAAACTCCTYC ACTCCTYCTAC′] ACTCCTYCTAC′] G(p.Glu194Gly) TACAGCAGCAAAGG CCACCACTCT′] NM_000219.5 3753 KCNE1 5231 [′CACTCGAACGACC 5434 [′CCCATTCAACGT 5688 [′CCCATTCAACGT (KCNE1):c.242A>G CATTCAACGTCTDC CTDCATCGAGT′] CTDCATCGAGT′] (p.Tyr81Cys) ATCGAGTCCGATGC CTGGCAAGAG′] NM_003108.3 6664 SOX11 5232 [′AAGCACATGGCCG 5435 [′CCGACTACCCCG 5689 [′CCGACTACCCCG (SOX11):c.347A>G ACTACCCCGACTRC ACTRCAAGTAC′] ACTRCAAGTAC′] (p.Tyr116Cys) AAGTACCGGCCCCG GAAAAAGCCC′] NM_002764.3 5631 PRPS1 5233 [′AATCTCAGCCAAG 5436 [′CCAAGCTTGTTG 5690 [′CCAAGCTTGTTG (PRPSO:c.343A>G CTTGTTGCAAATRTG CAAATRTGCTA′] CAAATRTGCTA′] (p.Met115Val) CTATCTGTAGCAGG TGCAGATCA′] NM_000546.5 7157 TP53 5234 [′TCTCCTCCCTGCTT 5437 [′CCTGCTTCTGTCT 5691 [′CCTGCTTCTGTCT (TP53):c.1101-2A>G CTGTCTCCTACRGCC CCTACRGCCA′] CCTACRGCCA′] ACCTGAAGTCCAAA AAGGGTCA′] NM_000166.5 2705 GJB1 5235 [′CGAGAAAACCGTC 5438 [′CCGTCTTCACCG 5692 [′CCGTCTTCACCG (GJB1):c.580A>G TTCACCGTCTTCRTG TCTTCRTGCTA′] TCTTCRTGCTA′] (p.Met194Val) CTAGCTGCCTCTGG CATCTGCAT′] NM_003159.2 6792 CDKL5 5236 [′TTAATCAGCCACA 5439 [′CCACAATGATGT 5693 [′CCACAATGATGT (CDKL5):c.449A>G ATGATGTCCTAARA CCTAARACTGT′] CCTAARACTGT′] (p.Lys150Arg) CTGTGTGACTTTGGT AAGTTAAAA′] NM_000053.3 540 ATP7B 5237 [′ATCCAGACCACCTT 5440 [′CCACCTTCATAG 5694- [′CCACCTTCATAG (ATP7B):c.122A>G CATAGCCAACAYTG CCAACAYTGTC′] 5695 CCAACAYTGTC′, (p.Asn41Ser) TCAAAAGCAAAACT ′CCTTCATAGCCAA CTTCTTCAT′] CAYTGTCAAA′] NM_006306.3 8243 SMC1A 5238 [′GTGGCTACCAACA 5441 [′CCAACATTGATG 5696 [′CCAACATTGATG (SMC1A):c.3254A>G TTGATGAGATCTRT AGATCTRTAAG′] AGATCTRTAAG′] (p.Tyr1085Cys) AAGGCCCTGTCCCG CAATAGCAGT′] NM_005154.4 9101 USP8 5239 [′GAACCTTCCAAAC 5442 [′CCAAACTGAAGC 5697 [′CCAAACTGAAGC (USP8):c.2150A>G TGAAGCGCTCCTDC GCTCCTDCTCC′] GCTCCTDCTCC′] (p.Tyr717Cys) TCCTCCCCAGATAT AACCCAGGCT′] NM_000117.2 2010 EMD 5240 [′TCTGCTACCGCTGC 5443 [′CCGCTGCCCCCC 5698 [′CCGCTGCCCCCC (EMD):c.266-2A>G CCCCCTTCCCARGG TTCCCARGGCT′] TTCCCARGGCT′] CTACAATGACGACT ACTATGAAG′] NM_207352.3 285440 CYP4V2 5241 [′CTACGTGCCCTTCT 5444 [′CCCTTCTCTGCT 5699- [′CCCTTCTCTGCT (CYP4V2):c.1393A>G CTGCTGGCCCCRGG GGCCCCRGGAA′] 5700 GGCCCCRGGAA′, (p.Arg465Gly) AACTGTATAGGTTT ′CCTTCTCTGCTGG GTATCCATC′] CCCCRGGAAC′] NM_000546.5 7157 TP53 5242 [′CTGTACCACCATCC 5445 [′CCATCCACTACA 5701 [′CCATCCACTACA (TP53):c.709A>G ACTACAACTACRTG ACTACRTGTGT′] ACTACRTGTGT′] (p.Met237Val) TGTAACAGTTCCTG CATGGGCGG′] NM_016069.9 −1 — 5243 [′CTCACCCGTCCCCT 5446 [′CCTCTCCTCTGC 5702- [′CCCCTCTCCTCT (PAM16):c.226A>G CTCCTCTGCAGRAC AGRACTATGAA′] 5704 GCAGRACTATG′, (p.Asn76Asp) TATGAACACTTATTT ′CCCTCTCCTCTGC AAGGTGAA′] AGRACTATGA′, ′CCTCTCCTCTGCA GRACTATGAA′] NM_006785.3 10892 MALT1 5244 [′AACACCCCCTTTCT 5447 [′CCTTTCTTTTTTT 5705 [′CCTTTCTTTTTTT (MALT1):c.1019-2A>G TTTTTTTTCAARGCG TTCAARGCGA′] TTCAARGCGA′] AAGGACAAGGTTGC CCTTTTGA′] NM_004771.3 9313 MMP20 5245 [′GGAGAAGGCCTGG 5448 [′CCTGGGAGGAGA 5706 [′CCTGGGAGGAGA (MMP20):c.611A>G GAGGAGATACACRT TACACRTTTCG′] TACACRTTTCG′] (p.His204Arg) TTCGACAATGCTGA GAAGTGGACT′] NM_003159.2 6792 CDKL5 5246 [′CACAATGATGTCCT 5449 [′CCTAAAACTGTG 5707 [′CCTAAAACTGTG (CDKL5):c.458A>G AAAACTGTGTGRCT TGRCTTTGGTA′] TGRCTTTGGTA′] (p.Asp153Gly) TTGGTAAGTTAAAA AGAAATTAA′] NM_001204830.1 −1 — 5247 [′CCGGACTACTGCCT 5450 [′CCTATCACCATT 5708 [′CCTATCACCATT (LIPT1):c.535A>G ATCACCATTGCRCTT GCRCTTTATTA′] GCRCTTTATTA′] (p.Thr179Ala) TATTATGTAGTACTG ATGGGAC′] NM_000921.4 5139 PDE3A 5248 [′AGTTTCTTCCACTT 5451 [′CCACTTGGACCA 5709 [′CCACTTGGACCA (PDE3A):c.1333A>G GGACCACCACCRCC CCACCRCCTCG′] CCACCRCCTCG′] (p.Thr445Ala) TCGGCCACAGGTCT ACCCACCTT′] NM_000182.4 3030 HADHA 5249 [′TTGCTCAATTCCAG 5452 [′CCAGTCTTTACC 5710 [′CCAGTCTTTACC (HADHA):c.9192A>G TCTTTACCACCYAA ACCYAAAAAAC′] ACCYAAAAAAC′] AAAACATATAAAGC ACTTGCTCA′] NM_000169.2 −1 — 5250 [′GTGTACTCCTGTGA 5453 [′CCTGTGAGTGGC 5711 [′CCTGTGAGTGGC (GLA):c.620A>G GTGGCCTCTTTRTAT CTCTTTRTATG′] CTCTTTRTATG′] (p.Tyr207Cys) GTGGCCCTTTCAAA AGGTGAGA′] NM_000238.3 3757 KCNH2 5251 [′TGGTCCAGCCTGG 5454 [′CCTGGAGATCAC 5712 [′CCTGGAGATCAC (KCNH2):c.2582A>G AGATCACCTTCANC CTTCANCCTGC′] CTTCANCCTGC′] (p.Asn861Ser) CTGCGAGATGTGAG TTGGCTGCCC′] NM_000218.2 3784 KCNQ1 5252 [′GCTCCCCCTCTCCT 5455 [′CCTGCACTCCAC 5713 [′CCTGCACTCCAC (KCNQ1):c.605A>G GCACTCCACAGRCC AGRCCTCATCG′] AGRCCTCATCG′] (p.Asp202Gly) TCATCGTGGTCGTG GCCTCCATG′] NM_012203.1 9380 GRHPR 5253 [′CACCATGTCCTTGT 5456 [′CCTTGTTGGCAG 5714 [′CCTTGTTGGCAG (GRHPR):c.934A>G TGGCAGCTAACRAC CTAACRACTTG′] CTAACRACTTG′] (p.Asn312Asp) TTGCTGGCTGGCCT GAGAGGGGA′] NM_021007.2 6326 SCN2A 5254 [′ACTTTGTCTTCCTT 5457 [′CCTTGACGATAT 5715 [′CCTTGACGATAT (SCN2A):c.3872A>G GACGATATTCTRCTT TCTRCTTTATT′] TCTRCTTTATT′] TATTCAATATGCTCA TTATGTG′] NM_002693.2 8542 POLG 5255 [′GTGGGCATCAGCC 5458 [′CCGTGAGCATGC 5716 [′CCGTGAGCATGC (POLG):c.2840A>G GTGAGCATGCCARA CARAATCTTCA′] CARAATCTTCA′] (p.Lys947Arg) ATCTTCAACTACGG CCGCATCTAT′] NM_020533.2 57192 MCOLN1 5256 [′TCTGAGTGCCTGTT 5459 [′CCTGTTCTCGCT 5717 [′CCTGTTCTCGCT (MCOLN1):c.1406A>G CTCGCTCATCARTG CATCARTGGGG′] CATCARTGGGG′] (p.Asn469Ser) GGGACGACATGTTT GTGACGTTC′] NM_000069.2 779 CACNA1S 5257 [′TCGCTTTCCCATCC 5460 [′CCCATCCTTTTCC 5718- [′CCCATCCTTTTCC (CACNA1S):c.3526-2A>G TTTTCCTTCCCRGGG TTCCCRGGGC′] 5719 TTCCCRGGGC′, CTACTTTGGAGACC ′CCATCCTTTTCCT CCTGGAAT′] TCCCRGGGCT′] NM_017662.4 140803 TRPM6 5258 [′CAAGCTGTCTACCT 5461 [′CCTCTTCGTGCA 5720 [′CCTCTTCGTGCA (TRPM6):c.3173A>G CTTCGTGCAATRTAT ATRTATCATCA′] ATRTATCATCA′] (p.Tyr1058Cys) CATCATGGTGAACC TGTTGATT′] NM_006642.3 10806 SDCCAG8 5259 [′AATAAACCCTCTG 5462 [′CCTCTGCTTTTGC 5721 [′CCTCTGCTTTTGC (SDCCAG8):c.2212A>G CTTTTGCTCTATRGT TCTATRGTTA′] TCTATRGTTA′] TAATCAGCTCAAAG ATTTGTTGC′] NM_003560.2 8398 PLA2G6 5260 [′CAGCATGCCCTGCT 5463 [′CCCTGCTCTGTG 5722- [′CCCTGCTCTGTG (PLA2G6):c.1349-2A>G CTGTGCCTCACRGA CCTCACRGAAC′] 5723 CCTCACRGAAC′, ACTACAGGATCTCA ′CCTGCTCTGTGCC TGCACATCT′] TCACRGAACT′]

Example 6 Next Generation C to T Editors

Other families of cytidine deaminases as alternatives to base editor 3 (BE3) constructs were examined. The different C to T editors were developed to have a narrow or different editing window, alternate sequence specificity to expand targetable substrates, and to have higher activity.

Using the methods described in Example 4, the pmCDA1 (cytidine deaminase 1 from Petromyzon marinus) activity at the HeK-3 site is evaluated (FIG. 42). The pmCDA1-nCas9-UGI-NLS (nCas9 indicates the Cas9 nickase described herein) construct is active on some sites (e.g., the C bases on the complementary strand at position 9, 5, 4, and 3) that are not accessible with rAPOBEC1 (BE3).

The pmCDA1 activity at the HeK-2 site is given in FIG. 43. The pmCDA1-XTEN-nCas9-UGI-NLS construct is active on sites adjacent to “G,” while rAPOBEC1 analog (BE3 construct) has low activity on “C”s that are adjacent to “G”s, e.g., the C base at position 11 on the complementary strand.

The percent of total sequencing reads with target C converted to T (FIG. 44), C converted to A (FIG. 45), and C converted to G (FIG. 46) are shown for CDA and APOBEC1 (the BE3 construct).

The huAPOBEC3G activity at the HeK-2 site is shown in FIG. 47. Two constructs were used: huAPOBEC3G-XTEN-nCas9-UGI-NLS and huAPOBEC3G*(D316R_D317R)-XTEN-nCas9-UGI-NLS. The huAPOBEC3G-XTEN-nCas9-UGI-NLS construct has different sequence specificity than rAPOBEC1 (BE3), as shown in FIG. 47, the editing window appears narrow, as indicated by APOBEC3G's descreased activity at position 4 compared to APOBEC1. Mutations made in huAPOBEC3G (D316R and D317R) increased ssDNA binding and resulted in an observable effect on expanding the sites which were edited (compare APOBEC3G with APOBEC3G_RR in FIG. 47). Mutations were chosen based on APOBEC3G crystal structure, see: Holden et al., Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implication. Nature. (2008); 121-4, the entire contents of which are incorporated herein by reference.

Example 7 pmCDA1/huAPOBEC3G/rAPOBEC1 Work in E. coli

LacZ selection optimization for the A to I conversion was performed using a bacterial strain with lacZ encoded on the F plasmid. A critical glutamic acid residue was mutated (e.g., GAG to GGG, Glu to Gly mutation) so that G to A by a cytidine deaminase would restore lacZ activity (FIG. 48). Strain CC102 was selected for the selection assay. APOBEC1 and CDA constructs were used in a selection assay to optimize G to A conversion.

To evaluate the the effect of copy number of the plasmids encoding the deaminase constructs on lacZ reversion frequency, the CDA and APOBEC1 deaminases were cloned into 4 plasmids with different replication origins (hence different copy numbers), SC101, CloDF3, RSF1030, and PUC (copy number: PUC>RSF1030>CloDF3>SC101) and placed under an inducible promoter. The plasmids were individually transformed into E. coli cells harboring F plasmid containing the mutated LacZ gene. The expression of the deaminases were induced and LacZ activity was detected for each construct (FIG. 49). As shown in FIG. 49, CDA exhibited significantly higher activity than APOBEC1 in all instances, regardless of the plasmid copy number the deaminases were cloned in. Further, In terms of the copy number, the deaminase activity was positively correlated with the copy number of the plasmid they are cloned in, i.e., PUC>CloDF3>SC101.

LacZ reversions were confirmed by sequencing of the genomic DNA at the lacZ locus. To obtain the genomic DNA containing the corrected LacZ gene, cells were grown media containing X-gal, where cells having LacZ activity form blue colonies. Blue colonies were selected and grown in minimal media containing lactose. The cells were spun down, washed, and re-plated on minimal media plates (lactose). The blue colony at the highest dilution was then selected, and its genomic DNA was sequenced at the lacZ locus (FIG. 50).

A chloramphenicol reversion assay was designed to test the activity of different cytidine deaminases (e.g., CDA, and APOBEC1). A plasmid harboring a mutant CAT1 gene which confers chloramphenicol resistance to bacteria is constructed with RSF1030 as the replication origin. The mutant CAT1 gene encodings a CAT1 protein that has a H195R (CAC to CGC) mutation, rendering the protein inactive (FIG. 51). Deamination of the C base-paired to the G base in the CGC codon would convert the codon back to a CAC codon, restoring the activity of the protein. As shown in FIG. 52, CDA outperforms rAPOBEC in E. coli in restoring the activity of the chloramphenicol resistance gene. The minimum inhibitory concentration (MIC) of chlor in S1030 with the selection plasmid (pNMG_ch_5) was approximately 1 μg/mL. Both rAPOBEC-XTEN-dCas9-UGI and CDA-XTEN-dCas9-UGI induced DNA correction on the selection plasmid (FIG. 53).

Next, the huAPOBEC3G-XTEN-dCas9-UGI protein was tested in the same assay. Interestingly, huAPOBEC3G-XTEN-dCas9-UGI exhibited different sequence specificity than the rAPOBEC1-XTEN-dCas9-UGI fusion protein. Only position 8 was edited with APOBEC3G-XTEN-dCas9-UGI fusion, as compared to the rAPOBEC11-XTEN-dCas9-UGIfusion (in which positions 3, 6, and 8 were edited) (FIG. 54).

Example 8 C to T Base Editors with Less Off Target Editing

Current base editing technologies allow for the sequence-specific conversion of a C:G base pair into a T:A base pair in genomic DNA. This is done via the direct catalytic conversion of cytosine to uracil by a cytidine deaminase enzyme and thus, unlike traditional genome editing technologies, does not introduce double-stranded DNA breaks (DSBs) into the DNA as a first step. See, Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., and Liu, D. R. (2016), “Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage.” Nature 533, 420-424; the entire contents of which are incorporated by reference herein. Instead, catalytically dead SpCas9 (dCas9) or a SpCas9 nickase (dCas9(A840H)) is tethered to a cytidine deaminase enzyme such as rAPOBEC1, pmCDA1, or hAPOBEC3G. The genomic locus of interest is encoded by an sgRNA, and DNA binding and local denaturation is facilitated by the dCas9 portion of the fusion. However, just as wt dCas9 and wt Cas9 exhibit off-target DNA binding and cleavage, current base editors also exhibit C to T editing at Cas9 off-target loci, which limits their therapeutic usefulness.

It has been reported that the introduction of just three to four mutations into SpCas9 that neutralize nonspecific electrostatic interactions between the protein and the sugar-phosphate backbone of its target DNA, increases the DNA binding specificity of SpCas9. See, Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., and Joung, J. K. (2016) “High-fidelity CRISPR—Cas9 nucleases with no detectable genome-wide off-target effects.” Nature 529, 490-495; and Slaymaker, I. M., Gao, L., Zetsche, B., Scott, D. A., Yan, W. X., and Zhang, F. (2015) “Rationally engineered Cas9 nucleases with improved specificity. Science 351, 84-88; the entire contents of each are hereby incorporated by reference herein. Four reported neutralizing mutations were therefore incorporated into the initially reported base editor BE3 (SEQ ID NO: 285), and found that off-target C to T editing of this enzyme is also drastically reduced (FIG. 55), with no decrease in on-target editing (FIG. 56).

As shown in FIG. 55, HEK293T cells were transfected with plasmids expressing BE3 or HF-BE3 and a sgRNA matching the EMX1 sequence using Lipofectamine 2000. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target locus, plus the top ten known Cas9 off-target loci for the EMX1 sgRNA, as previously determined by Joung and coworkers using the GUIDE-seq method. See Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) “GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases.” Nat Biotech 33, 187-197; the entire contents of which are incorporated by reference herein. EMX1 off-target 5 locus did not amplify and is not shown. Sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are displayed (FIG. 55). Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with T at each position of an original C within the protospacer, are shown for BE3 and HF-BE3.

In FIG. 56, HEK293T cells were transfected with plasmids expressing BE3 or HF-BE3 and sgRNAs matching the genomic loci indicated using Lipofectamine 2000. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target loci. The percentage of total DNA sequencing reads with all four bases at the target Cs within each protospacer are shown for treatment with BE3 or HF-BE3 (FIG. 56). Frequencies of indel formation are shown as well.

Primary Protein Sequence of HF-BE3 (SEQ ID NO: 285):

MSSHTGPVAVDPTLRRRIHPHHFHVFFDPRELRKBTCLLYHINWGGRH SIWRHTSQNTNKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGEC SRAITEFLSRYPHVTLFIYIARLYHHADPRNRQGLRDLISSGVTIQIM TEQESGYCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPC LNILRRKQPQLTFFTIALQSCHYQRLPPHILWATGLKSGSETPGTSES ATPESDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIK KNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAK VDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRK KLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQL VQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNG LFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGD QYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDL TLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPIL EKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQED FYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPW NFEEVVDKGASAQSFIERMTAFDKNLPNEKVLPKHSLLYEYFTVYNEL TKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKI ECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIV LTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGALSRKLIN GIRDKQSGKTILDFLKSDGFANRNFMALIHDDSLTFKEDIQKAQVSGQ GDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENTVIEMA RENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLY LYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRS DKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGL SELDKAGFIKRQLVETRAITKHVAQILDSRMNTKYDENDKLIREVKVI TLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKL ESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITL ANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVMVKKTEVQ TGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKV EKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIK LPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKL KGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSA YNKHRDKPIREQAENIIHLFTLTNLGAPAAFNYFDTTIDRKRYTSTKE VLDATLIHQSITGLYETRIDLSQLGGDSGGSTNLSDIIEKETGKQLVI QESILMLPEEVEEVIGNKPESDILVHTAYDESTDENVMLLTSDAPEYK PWALVIQDSNGENKIKMLSGGSPKKKRKV

Example 9 Development of Base Editors that Use Cas9 Variants and Modulation of the Base Editor Processivity to Increase the Target Range and Precision of the Base Editing Technology

Unlike traditional genome editing platforms, base editing technology allows precise single nucleotide changes in the DNA without inducing double-stranded breaks(DSBs). See, Komor, A. C. et al. Nature 533, 420-424 (2016). The current generation of base editor uses the NGG PAM exclusively. This limits its ability to edit desired bases within the genome, as the base editor needs to be placed at a precise location where the target base is placed within a 4-base region (the ‘deamination window’), approximately 15 bases upstream of the PAM . See, Komor, A. C. et al. Nature 533, 420-424 (2016). Moreover, due to the high processivity of cytidine deaminase, the base editor may convert all cytidines within its deamination window into thymidines, which could induce amino acid changes other than the one desired by the researcher. See, Komor, A. C. et al. Nature 533, 420-424 (2016).

Expanding the Scope of Base Editing Through the Development of Base Editors with Cas9 Variants

Cas9 homologs and other RNA-guided DNA binders that have different PAM specificities were incorporated into the base editor architecture. See, Kleinstiver, B. P. et al. Nature 523, 481-485 (2015); Kleinstiver, B. P. et al. Nature Biotechnology 33, 1293-1298 (2015); and Zetsche, B. et al. Cell 163, 759-771 (2015); the entire contents of each are incorporated by reference herein. Furthermore, innovations that have broadened the PAM specificities of various Cas9 proteins were also incorporated to expand the target reach of the base editor even more. See, Kleinstiver, B. P. et al. Nature 523, 481-485 (2015); and Kleinstiver, B. P. et al. Nature Biotechnology 33, 1293-1298 (2015). The current palette of base editors is summarized in Table 4.

Table 4. New base editors made from Cas9 Variants

Base Editor Reference for Species PAM Name Cas9 variant S. pyogenes . . . NGG BE3 Wild-type . . . NGA VQR BE3 or Kleinstiver, B. P. EQR BE3 et al. . . . NGCG VRER BE3 Kleinstiver, B. P. et al. S. aureus . . . NNGRRT SaBE3 Wild-type . . . NNNRRT SaKKH BE3 Kleinstiver, B. P. et al. L. bacterium TTTN . . . dCpf1 BE2 Zetsche, B. et at. Modulating Base Editor's Processivity Through Site-directed Mutagenesis of rAPOBEC1

It was reasoned that the processivity of the base editor could be modulated by making point mutations in the deaminase enzyme. The incorporatation of mutations that slightly reduce the catalytic activity of deaminase in which the base editor could still catalyze on average one round of cytidine deamination but was unlikely to access and catalyze another deamination within the relevant timescale were pursued. In effect, the resulting base editor would have a narrower deamination window.

rAPOBEC1 mutations probed in this work are listed in Table 5. Some of the mutations resulted in slight apparent impairment of rAPOBEC1 catalysis, which manifested as preferential editing of one cytidine over another when multiple cytidines are found within the deamination window. Combining some of these mutations had an additive effect, allowing the base editor to discriminate substrate cytidines with higher stringency. Some of the double mutants and the triple mutant allowed selective editing of one cytidine among multiple cytidines that are right next to one another (FIG. 57).

TABLE 5 rAPOBEC1 Point Mutations Investigated rAPOBEC1 mutation Corresponding mutation studied in this work in APOBEC3G Reference H121R/H122R D315R/D316R Holden, L. G. et al. R126A R320A Chen, K-M. et al. R126E R320E Chen, K-M. et al. R118A R313A Chen, K-M. et al. W90A W285A Chen, K-M. et al. W90Y W285Y R132E R326E Base Editor PAM Expansion and Processivity Modulation

The next generation of base editors were designed to expand editable cytidines in the genome by using other RNA-guided DNA binders (FIG. 58). Using a NGG PAM only allows for a single target within the “window” whereas the use of multiple different PAMs allows for Cas9 to be positioned anywhere to effect selective deamination. A variety of new base editors have been created from Cas9 variants (FIG. 59 and Table 4). Different PAM sites (NGA, FIG. 60; NGCG, FIG. 61; NNGRRT, FIG. 62; and NNHRRT, FIG. 63) were explored. Selective deamination was successfully achieved through kinetic modulation of cytidine deaminase point mutagenesis (FIG. 65 and Table 5).

The effect of various mutations on the deamination window was then investigated in cell culture using spacers with multiple cytidines (FIGS. 66 and 67).

Further, the effect of various mutations on different genomic sites with limited numbers of cytidines was examined (FIGS. 68 to 71). It was found that approximately one cytidine will be edited within the deamination windown in the spacer, while the rest of the cytidines will be left intact. Overall, the preference for editing is as follows: C₆>C₅>>C₇≈C₄.

Base Editing Using Cpf1

Cpf1, a Cas9 homolog, can be obtained as AsCpf1, LbCpf1, or from any other species. Schematics of fusion constructs, including BE2 and BE3 equivalents, are shown in FIG. 73. The BE2 equivalent uses catalytically inactive Cpf2 enzyme (dCpf1) instead of Cas9, while the BE3 equivalent includes the Cpf1mutant, which nicks the target strand. The bottom schematic depicts different fusion architectures to combine the two innovations illustrated above it (FIG. 73). The base editing results of HEK293T cell TTTN PAM sites using Cpf1BE2 were examined with different spacers (FIGS. 64A to 64C). In some embodiments, Cpf1may be used in place of a Cas9 domain in any of the base editors provided herein. In some embodiments, the Cpf1is a protein that is at lesst 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 99.5% identical to SEQ ID NO 5807.

MSIYQEFVNKYSLSKTLRFELIPQGKTLENIKARGLILDDEKRAKDYK KAKQIIDKYHQFFIEEILSSVCISEDLLQNYSDVYFKLKKSDDDNLQK DFKSAKDTIKKQISEYIKDSEKFKNLFNQNLIDAKKGQESDLILWLKQ SKDNGIELFKANSDITDIDEALEIIKSFKGWITYFKGFHENRKNVYSS NDIPTSIIYRIVDDNLPKFLENKAKYESLKDKAPEAINYEQIKKDLAE ELTFDIDYKTSEVNQRVFSLDEVFEIANFNNYLNQSGITKFNTIIGGK FVNGENTKRKGINEYINLYSQQTNDKTLKKYKMSVLFKQILSDTESKS FVIDKLEDDSDVVTTMQSFYEQIAAFKTVEEKSIKETLSLLFDDLKAQ KLDLSKIYFKNDKSLTDLSQQVFDDYSVIGTAVLEYITQQIAPKNLDN PSKKEQELIAKKTEKAKYLSLETIKLALEEFNKHRDIDKQCRFEEILA NFAAIPMIFDEIAQNKDNLAQISIKYQNQGKKDLLQASAEDDVKAIKD LLDQTNNLLHKLKIFHISQSEDKANILDKDEHFYLVFEECYFELAMVP LYNKIRNYITQKPYSDEKFKLNFENSTLANGWDKNKEPDNTAILFIKD DKYYLGVMNKKNNKIFDDKAIKENKGEGYKKIVYKLLPGANKMLPKVF FSAKSIKFYNPSEDTLRIRNHSTHTKNGSPQKGYEKFEFNIEDCRKFI DFYKQSISKHPEWKDFGFRFSDTQRYNSIDEFYREVENQGYKLTFENI SESYIDSVVNQGKLYLFQIYNKDFSAYSKGRPNLHTLYWKALFDERXL QDVVYKLNGEAELFYRKQSIPKKITHPAKEAIANKNKDNPKKESVFEY DLIKDKRITEDKFFFHCPITINFKSSGANKFNDEINLLLKEKANDVHI LSIDRGERHLAYYTLVDGKGNIIKQDTFNIIGNDRMKTNYHDKLAAIE KDRDSARKDWKKINNIKEMKEGYLSQVVHEIAKLVIEYNAIVVFEDLN FGFKRGRFKVEKQVYQKLEKMLIEKLNYLVFKDNEFDKTGGVLRAYQL TAPFETFKKMGKQTGIIYYVPAGFTSKICPVTGFVNQLYPKYESVSKS QEFFSKFDKICYNLDKGYFEFSFDYKNFGDKAAKGKWTIASFGSRLIN FRNSDKNHNWDTREVYPTKELEKLLKDYSIEYGHGECIKAAICGESDK KFFAKLTSVLNTILQMRNSKTGTELDYLISPVADVNGNFFDSRQAPKN MPQDADANGAYHIGLKGLMLLGRIKNNQEGKKLNLVIKNEEYFEFVQN RNN

Example 10 Increased Fidelity of Base Editing

Examining the difference between plasmid delivery of BE3 and HF-BE3, it was found that the two edit on-target loci with comparable efficiency (FIGS. 74 and 75). However, HF-BE3 edited off-target loci much less than BE3, meaning that HF-BE3 has a much higher DNA specificity than BE3 (FIG. 76). Deaminase protein lipofection to HEK cells demonstrated that protein delivery of BE3 results in comparable on-target activity, but much better specificity, than plasmid DNA delivery of BE3. Using improved transfection procedures and better plasmids (n=2), the experiment used the following conditions: protein delivery was 125 nM Cas9:sgRNA complex, plasmid delivery was 750 ng BE3/HF-BE3 plasmid+250 ng sgRNA plasmid, and lipofection was with 1.5 μL of Lipofectamine 2000 per well. EMX-1 off target site 2 and FANCF off-target site 1 showed the most off-target editing with BE3, compared to all of the off-targets assayed (FIGS. 77 and 78), while HEK-3 showed no significant editing at off-targets for any of the delivery methods (FIG. 79). HEK-4 shows some C-to-G editing on at the on-target site, while its off-target sites 1, 3, and 4 showed the most off-target editing of all the assayed sites (FIG. 80).

Delivery of BE3 Protein via Micro-injection to Zebrafish

TYR guide RNAs were tested in an in vitro assay for sgRNA activity (FIGS. 81 and 82). The % HTS reads shows how many C residues were converted to T residues during a 2 h incubation with purified BE3 protein and PCR of the resulting product. Experiments used an 80-mer synthetic DNA substate with the target deamination site in 60 bp of its genomic context. This is not the same as % edited DNA strands because only one strand was nicked, so the product is not amplified by PCR. The proportion of HTS reads edited is equal to x/(2−x), where x is the actual proportion of THS reads edited. For 60% editing, the actual proportion of bases edited is 75%. “Off target” is represents BE3 incubated with the same DNA substrate, while bound to an off-target sgRNA. It was found sgRNAs sgRH_13, sgHR_17, and possibly sgHR_16 appeared to be promising targets for in vivo injection experiments.

The delivery of BE3 protein in was tested in vivo in zebrafish. Zebrafish embryos (n=16-24) were injected with either scramled sgRNA, sgHR_13, sgHR_16, or sgHR_17 and purified BE3. Three embryos from each condition were analyzed independently (single embryo) and for each condition, all of the injected embryos were pooled and sequenced as a pool. The results are shown in FIGS. 83 to 85.

Example 11 Uses of Base Editors to Treat Disease

Base editors or complexes provided herein (e.g., BE3) may be used to modify nucleic acids. For example, base editors may be used to change a cytosine to a thymine in a nucleic acid (e.g., DNA). Such changes may be made to, inter alia, alter the amino acid sequence of a protein, to destroy or create a start codon, to create a stop codon, to distupt splicing donors, to disrupt splicing acceptors or edit regulatory sequences. Examples of possible nucleotide changes are shown in FIG. 86.

Base editors or complexes provided herein (e.g., BE3) may be used to edit an isoform of Apolipoprotein E in a subject. For example, an Apolipoprotein E isoform may be edited to yield an isoform associated with a lower risk of developing Alzheimer's disease. Apolipoprotein E has four isoforms that differ at amino acids 112 and 158. APOE4 is the largest and most common genetic risk factor for late-onset Alzheimer's disease. Arginine residue 158 of APOE4, encoded by the nucleic acid sequence CGC, may be changed to a cysteine by using a base editor (e.g., BE3) to change the CGC nucleic acid sequence to TGC, which encodes cysteine at residue 158. This change yields an APOE3r isoform, which is associated with lower Alzheimer's disease risk. See FIG. 87.

It was tested whether base editor BE3 could be used to edit APOE4 to APOE3r in mouse astrocytes (FIG. 88). APOE 4 mouse astrocytes were nucleofected with Cas9+ template or BE3, targeting the nucleic acid encoding Arginine 158 of APOE4. The Cas9+ template yielded only 0.3% editing with 26% indels, while BE3 yielded 75% editing with 5% indels. Two additional base-edited cytosines are silent and do not yield changes to the amino acid sequence (FIG. 88).

Base editors or complexes provided herein may be used to treat prion protein diseases such as Creutzfeldt-Jakob disease and fatal familial insomnia, for example, by introducing mutations into a PRNP gene. Reverting PRNP mutations may not yield therapeutic results, and intels in PRNP may be pathogenic. Accordingly, it was tested whether PRNP could be mutated using base editors (e.g., BE3) to introduce a premature stop codon in the PRNP gene. BE3, associated with its guide RNA,was introduced into HEK cells or glioblastoma cells and was capable of editing the PRNP gene to change the encoded arginine at residue 37 to a stop codon. BE3 yielded 41% editing (FIG. 89).

Additional genes that may be edited include the following: APOE editing of Arg 112 and Arg 158 to treat increased Alzheimer's risk; APP editing of Ala 673 to decrease Alzheimer's risk; PRNP editing of Arg 37 to treat fatal familial insomnia and other prion protein diseases; DMD editing of the exons 23 and 51 splice sites to treat Duchenne muscular dystrophy; FTO editing of intron 1 to treat obesity risk; PDS editing of exon 8 to treat Pendred syndrome (genetic deafness); TMCI editing of exon 8 to treat congenital hearing loss; CYBB editing of various patient-relevant mutations to treat chronic granulomatous disease. Additional diseases that may be treated using the base editors provided herein are shown in Table 6, below.

UGI also plays a key role. Knocking out UDG (which UGI inhibits) was shown to dramatically improve the cleanliness and efficiency of C to T base editing (FIG. 90). Furthermore, base editors with nickase and without UGI were shown to produce a mixture of outcomes, with very high indel rates (FIG. 91).

Example 12 Expanding the Targeting Scope of Base Editing

Base editing is a new approach to genome editing that uses a fusion protein containing a catalytically defective Streptococcus pyogenes Cas9, a cytidine deaminase, and an inhibitor of base excision repair to induce programmable, single-nucleotide C→T (or G→A) changes in DNA without generating double-strand DNA breaks, without requiring a donor DNA template, and without inducing an excess of stochastic insertions and deletions¹. The development of five new C→T (or G→A) base editors that use natural and engineered Cas9 variants with different protospacer-adjacent motif (PAM) specificities to expand the number of sites that can be targeted by base editing by 2.5-fold are described herein. Additionally, new base editors containing mutated cytidine deaminase domains that narrow the width of the apparent editing window from approximately 5 nucleotides to 1 or 2 nucleotides were engineered, enabling the discrimination of neighboring C nucleotides that would previously be edited with comparable efficiency. Together, these developments substantially increase the targeting scope of base editing.

CRISPR-Cas9 nucleases have been widely used to mediate targeted genome editing². In most genome editing applications, Cas9 forms a complex with a single guide RNA (sgRNA) and induces a double-stranded DNA break (DSB) at the target site specified by the sgRNA sequence. Cells primarily respond to this DSB through the non-homologuous end-joining (NHEJ) repair pathway, which results in stochastic insertions or deletions (indels) that can cause frameshift mutations that disrupt the gene. In the presence of a donor DNA template with a high degree of homology to the sequences flanking the DSB, gene correction can be achieved through an alternative pathway known as homology directed repair (HDR).^(3,4) Unfortunately, under most non-perturbative conditions HDR is inefficient, dependent on cell state and cell type, and dominated by a larger frequency of indels.^(3,4) As most of the known genetic variations associated with human disease are point mutations, methods⁵, that can more efficiently and cleanly make precise point mutations are needed.

Base editing, which enables targeted replacement of a C:G base pair with a T:A base pair in a programmable manner without inducing DSBs¹, has been recently described. Base editing uses a fusion protein between a catalytically inactivated (dCas9) or nickase form of Streptococcus pyogenes Cas9 (SpCas9), a cytidine deaminase such as APOBEC1, and an inhibitor of base excision repair such as uracil glycosylase inhibitor (UGI) to convert cytidines into uridines within a five-nucleotide window specified by the sgRNA.¹ The third-generation base editor, BE3, converts C:G base pairs to T:A base pairs, including disease-relevant point mutations, in a variety of cell lines with higher efficiency and lower indel frequency than what can be achieved using other genome editing methods¹. Subsequent studies have validated the deaminase-dCas9 fusion approach in a variety of settings^(6,7).

Efficient editing by BE3 requires the presence of an NGG PAM that places the target C within a five-nucleotide window near the PAM-distal end of the protospacer (positions 4-8, counting the PAM as positions 21-23)¹. This PAM requirement substantially limits the number of sites in the human genome that can be efficiently targeted by BE3, as many sites of interest lack an NGG 13- to 17-nucleotides downstream of the target C. Moreover, the high activity and processivity of BE3 results in conversion of all Cs within the editing window to Ts, which can potentially introduce undesired changes to the target locus. Herein, new C:G to T:A base editors that address both of these limitations are described.

It was thought that any Cas9 homolog that binds DNA and forms an “R-loop” complex⁸ containing a single-stranded DNA bubble could in principle be converted into a base editor. These new base editors would expand the number of targetable loci by allowing non-NGG PAM sites to be edited. The Cas9 homolog from Staphylococcus aureus (SaCas9) is considerably smaller than SpCas9 (1053 vs. 1368 residues), can mediate efficient genome editing in mammalian cells, and requires an NNGRRT PAM⁹. SpCas9 was replaced with SaCas9 in BE3 to generate SaBE3 and transfected HEK293T cells with plasmids encoding SaBE3 and sgRNAs targeting six human genomic loci (FIGS. 92A and 92B). After 3 d, the genomic loci were subjected to high-throughput DNA sequencing (HTS) to quantify base editing efficiency. SaBE3 enabled C to T base editing of target Cs at a variety of genomic sites in human cells, with very high conversion efficiencies (approximately 50-75% of total DNA sequences converted from C to T, without enrichment for transfected cells) arising from targeting Cs at positions 6-11. The efficiency of SaBE3 on NNGRRT-containing target sites in general exceeded that of BE3 on NGG-containing target sites¹. Perhaps due to its higher average efficiency, SaBE3 can also result in detectable base editing at target Cs at positions outside of the canonical BE3 activity window (FIG. 92C). In comparison, BE3 showed significantly reduced editing under the same conditions (0-11%), in accordance with the known SpCas9 PAM preference (FIG. 106A)¹⁰. These data show that SaBE3 can facilitate very efficient base editing at sites not accessible to BE3.

The targeting range of base editors was further expanded by applying recently engineered Cas9 variants that expand or alter PAM specificities. Joung and coworkers recently reported three SpCas9 mutants that accept NGA (VQR-Cas9), NGAG (EQR-Cas9), or NGCG(VRER-Cas9) PAM sequences¹¹. In addition, Joung and coworkers engineered a SaCas9 variant containing three mutations (SaKKH-Cas9) that relax its PAM requirement to NNNRRT¹². The SpCas9 portion of BE3 was replaced with these four Cas9 variants to produce VQR-BE3, EQR-BE3, VRER-BE3, and SaKKH-BE3, which target NNNRRT, NGA, NGAG, and NGCG PAMs respectively. HEK293T cells were transfected with plasmids encoding these constructs and sgRNAs targeting six genomic loci for each new base editor, and measured C to T base conversions using HTS.

SaKKH-BE3 edited sites with NNNRRT PAMs with efficiencies up to 62% of treated, non-enriched cells (FIG. 92D). As expected, SaBE3 was unable to efficiently edit targets containing PAMs that were NNNHRRT (where H=A, C, or T) (FIG. 92D). VQR-BE3, EQR-BE3, and VRER-BE3 exhibited more modest, but still substantial base editing efficiencies of up to 50% of treated, non-enriched cells at genomic loci with the expected PAM requirements with an editing window similar to that of BE3 (FIGS. 92E and 92F). Base editing efficiencies of VQR-BE3, EQR-BE3, and VRER-BE3 in general closely paralleled the reported PAM requirements of the corresponding Cas9 nucleases; for example, EQR-BE3 was unable to efficiently edit targets containing NGAH PAM sequences (FIG. 92F). In contrast, BE3 was unable to edit sites with NGA or NGCG PAMs efficiently (0-3%), likely due to its PAM restrictions (FIG. 106B).

Collectively, the properties of SaBE3, SaKKH-BE3, VQR-BE3, EQR-BE3, and VRER-BE3 establish that base editors exhibit a modularity that facilitates their ability to exploit Cas9 homologs and engineered variants.

Next, base editors with altered activity window widths were developed. All Cs within the activity window of BE3 can be efficiently converted to Ts¹. The ability to modulate the width of this window would be useful in cases in which it is important to edit only a subset of Cs present in the BE3 activity window.

The length of the linker between APOBEC1 and dCas9 was previously observed to modulate the number of bases that are accessible by APOBEC1 in vitro¹. In HEK293T cells, however, varying the linker length did not significantly modulate the width of the editing window, suggesting that in the complex cellular milieu, the relative orientation and flexibility of dCas9 and the cytidine deaminase are not strongly determined by linker length (FIG. 96). Next, it was thought that truncating the 5′ end of the sgRNA might narrow the base editing window by reducing the length of single-stranded DNA accessible to the deaminase upon formation of the RNA-DNA heteroduplex. HEK293T cells were co-transfected with plasmids encoding BE3 and sgRNAs of different spacer lengths targeting a locus with multiple Cs in the editing window. No consistent changes in the width of base editing when using truncated sgRNAs with 17- to 19-base spacers were observed (FIGS. 95A to 95C). Truncating the sgRNA spacer to fewer than 17 bases resulted in large losses in activity (FIG. 95A).

As an alternative approach, it was thought that mutations to the deaminase domain might narrow the width of the editing window through multiple possible mechanisms. First, some mutations may alter substrate binding, the conformation of bound DNA, or substrate accessibility to the active site in ways that reduce tolerance for non-optimal presentation of a C to the deaminase active site. Second, because the high activity of APOBEC1 likely contributes to the deamination of multiple Cs per DNA binding event,^(1,13,14) mutations that reduce the catalytic efficiency of the deaminase domain of a base editor might prevent it from catalyzing successive rounds of deamination before dissociating from the DNA. Once any C:G to T:A editing event has taken place, the sgRNA no longer perfectly matches the target DNA sequence and re-binding of the base editor to the target locus should be less favorable. Both strategies were tested in an effort to discover new base editors that distinguish among multiple cytidines within the original editing window.

Given the absence of an available APOBEC1 structure, several mutations previously reported to modulate the catalytic activity of APOBEC3G, a cytidine deaminase from the same family that shares 42% sequence similarity of its active site-containing domain to that of APOBEC1, were identified¹⁵. Corresponding APOBEC1 mutations were incorporated into BE3 and evaluated their effect on base editing efficiency and editing window width in HEK293T cells at two C-rich genomic sites containing Cs at positions 3, 4, 5, 6, 8, 9, 10, 12, 13, and 14 (site A); or containing Cs at positions 5, 6, 7, 8, 9, 10, 11, and 13 (site B).

The APOBEC1 mutations R118A and W90A each led to dramatic loss of base editing efficiency (FIG. 97C). R132E led to a general decrease in editing efficiency but did not change the substantially narrow the shape of the editing window (FIG. 97C). In contrast, several mutations that narrowed the width of the editing window while maintaining substantial editing efficiency were found (FIGS. 93A and 97C). The “editing window width” was defined to represent the artificially calculated window width within which editing efficiency exceeds the half-maximal value for that target. The editing window width of BE3 for the two C-rich genomic sites tested was 5.0 (site A) and 6.1 (site B) nucleotides.

R126 in APOBEC1 is predicted to interact with the phosphate backbone of ssDNA¹³. Previous studies have shown that introducing the corresponding mutation into APOBEC3G decreased catalysis by at least 5-fold¹⁴. Interestingly, when introduced into APOBEC1 in BE3, R126A and R126E increased or maintained activity relative to BE3 at the most strongly edited positions (C5, C6, and C7), while decreasing editing activity at other positions (FIGS. 93A and 97C). Each of these two mutations therefore narrowed the width of the editing window at site A and site B to 4.4 and 3.4 nucleotides (R126A), or to 4.2 and 3.1 nucleotides (R126E), respectively (FIGS. 93A and 97C).

W90 in APOBEC1 (corresponding to W285 in APOBEC3G) is predicted to form a hydrophobic pocket in the APOBEC3G active site and assist in substrate binding¹³. Mutating this residue to Ala abrogated APOBEC3G's catalytic activity³. In BE3, W90A almost completely abrogated base editing efficiency (FIG. 97C). In contrast, it was found that W90Y only modestly decreased base editing activity while narrowing the editing window width at site A and site B to 3.8 and 4.9 nucleotides, respectively (FIG. 93A). These results demonstrate that mutations to the cytidine deaminase domain can narrow the activity window width of the corresponding base editors.

W90Y, R126E, and R132E, the three mutations that narrowed the editing window without drastically reducing base editing activity, were combined into doubly and triply mutated base editors. The double mutant W90Y+R126E resulted in a base editor (YE1-BE3) with BE3-like maximal editing efficiencies, but substantially narrowed editing window width (width at site A and site B=2.9 and 3.0 nucleotides, respectively (FIG. 93A). The W90Y+R132E base editor (YE2-BE3) exhibited modestly lower editing efficiencies (averaging 1.4-fold lower maximal editing yields across the five sites tested compared with BE3), and also substantially narrowed editing window width (width at site A and site B=2.7 and 2.8 nucleotides, respectively) (FIG. 97C). The R126E+R132E double mutant (EE-BE3) showed similar maximal editing efficiencies and editing window width as YE2-BE3 (FIG. 97C). The triple mutant W90Y+R126E+R132E (YEE-BE3) exhibited 2.0-fold lower average maximal editing yields but very little editing beyond the C6 position and an editing window width of 2.1 and 1.4 nucleotides for site A and site B, respectively (FIG. 97C). These data taken together indicate that mutations in the cytidine deaminase domain can strongly affect editing window widths, in some cases with minimal or only modest effects on editing efficiency.

The base editing outcomes of BE3, YE1-BE3, YE2-BE3, EE-BE3, and YEE-BE3 were further compared in HEK293T cells targeting four well-studied human genomic sites that contain multiple Cs within the BE3 activity window¹. These target loci contained target Cs at positions 4 and 5 (HEK site 3), positions 4 and 6 (HEK site 2), positions 5 and 6 (EMX1), or positions 6, 7, 8, and 11 (FANCF). BE3 exhibited little (<1.2-fold) preference for editing any Cs within the position 4-8 activity window. In contrast, YE1-BE3, exhibited a 1.3-fold preference for editing C5 over C4 (HEK site 3), 2.6-fold preference for C6 over C4 (HEK site 2), 2.0-fold preference for C5 over C6 (EMX1), and 1.5-fold preference for C6 over C7 (FANCF) (FIG. 93B). YE2-BE3 and EE-BE3 exhibited somewhat greater positional specificity (narrower activity window) than YE1-BE3, averaging 2.4-fold preference for editing C5 over C4 (HEK site 3), 9.5-fold preference for C6 over C4 (HEK site 2), 2.9-fold preference for C5 over C6 (EMX1), and 2.6-fold preference for C7 over C6 (FANCF) (FIG. 93B). YEE-BE3 showed the greatest positional selectivity, with a 2.9-fold preference for editing C5 over C4 (HEK site 3), 29.7-fold preference for C6 over C4 (HEK site 2), 7.9-fold preference for C5 over C6 (EMX1), and 7.9-fold preference for C7 over C6 (FANCF) (FIG. 93B). The findings establish that mutant base editors can discriminate between adjacent Cs, even when both nucleotides are within the BE3 editing window.

The product distributions of these four mutants and BE3 were further analyzed by HTS to evaluate their apparent processivity. BE3 generated predominantly T4-T5 (HEK site 3), T4-T6 (HEK site 2), and T5-T6 (EMX1) products in treated HEK293T cells, resulting in, on average, 7.4-fold more products containing two Ts, than products containing a single T. In contrast, YE1-BE3, YE2-BE3, EE-BE3, and YEE-BE3 showed substantially higher preferences for singly edited C4-T5, C4-T6, and T5-C6 products (FIG. 93C). YE1-BE3 yielded products with an average single-T to double-T product ratio of 1.4. YE2-BE3 and EE-BE3 yielded products with an average single-T to double-T product ratio of 4.3 and 5.1, respectively (FIG. 93C). Consistent with the above results, the YEE-BE3 triple mutant favored single-T products by an average of 14.3-fold across the three genomic loci. (FIG. 93C). For the target site in which only one C is within the target window (HEK site 4, at position C5), all four mutants exhibited comparable editing efficiencies as BE3 (FIG. 98). These findings indicate that these BE3 mutants have decreased apparent processivity and can favor the conversion of only a single C at target sites containing multiple Cs within the BE3 editing window. These data also suggest a positional preference of C5>C6>C7≈C4 for these mutant base editors, although this preference could differ depending on the target sequence.

The window-modulating mutations in APOBEC1 were applied to VQR-BE3, allowing selective base editing of substrates at sites targeted by NGA PAM (FIG. 107A). However, when these mutations were applied to SaKKH-BE3, a linear decrease in base editing efficiency was observed without the improvement in substrate selectivity, suggesting a different kinetic equilibrium and substrate accessibility of this base editor than those of BE3 and its variants (FIG. 107B).

The five base editors with altered PAM specificities described in this study together increase the number of disease-associated mutations in the ClinVar database that can in principle be corrected by base editing by 2.5-fold (FIGS. 94A and 94B). Similarly, the development of base editors with narrowed editing windows approximately doubles the fraction of ClinVar entries with a properly positioned NGG PAM that can be corrected by base editing without comparable modification of a non-target C (from 31% for BE3 to 59% for YEE-BE3) (FIGS. 94A and 94B).

In summary, the targeting scope of base editing was substantially expanded by developing base editors that use Cas9 variants with different PAM specificities, and by developing a collection of deaminase mutants with varying editing window widths. In theory, base editing should be possible using other programmable DNA-binding proteins (such as Cpf1¹⁶) that create a bubble of single-stranded DNA that can serve as a substrate for a single-strand-specific nucleotide deaminase enzyme.

Materials and Methods

Cloning. PCR was performed using Q5 Hot Start High-Fidelity DNA Polymerase (New England Biolabs). Plasmids for BE and sgRNA were constructed using USER cloning (New England Biolabs), obtained from previously reported plasmids¹. DNA vector amplification was carried out using NEB 10beta competent cells (New England Biolabs).

Cell culture. HEK293T (ATCC CRL-3216) were cultured in Dulbecco's Modified Eagle's Medium plus GlutaMax (ThermoFisher) supplemented with 10% (v/v) fetal bovine serum (FBS), at 37° C. with 5% CO₂. Immortalized rat astrocytes containing the ApoE4 isoform of the APOE gene (Taconic Biosciences) were maintained in Dulbecco's Modified Eagle's Medium plus GlutaMax (ThermoFisher Scientific) supplemented with 10% (v/v) fetal bovine serum (FBS) and 200 μg/mL Geneticin (ThermoFisher Scientific).

Transfections. HEK293T cells were seeded on 48-well collagen-coated BioCoat plates (Corning) and transfected at approximately 85% confluency. 750 ng of BE and 250 ng of sgRNA expression plasmids were transfected using 1.5 μl of Lipofectamine 2000 (ThermoFisher Scientific) per well according to the manufacturer's protocol.

High-throughput DNA sequencing of genomic DNA samples. Transfected cells were harvested after 3 d and the genomic DNA was isolated using the Agencourt DNAdvance Genomic DNA Isolation Kit (Beckman Coulter) according to the manufacturer's instructions. Genomic regions of interest were amplified by PCR with flanking HTS primer pairs listed in the Supplementary Sequences. PCR amplification was carried out with Phusion hot-start II DNA polymerase (ThermoFisher) according to the manufacturer's instructions. PCR products were purified using RapidTips (Diffinity Genomics). Secondary PCR was performed to attach sequencing adaptors. The products were gel-purified and quantified using the KAPA Library Quantification Kit-Illumina (KAPA Biosystems). Samples were sequenced on an Illumina MiSeq as previously described¹.

Data analysis. Nucleotide frequencies were assessed using a previously described MATLAB script¹. Briefly, the reads were aligned to the reference sequence via the Smith-Waterman algorithm. Base calls with Q-scores below 30 were replaced with a placeholder nucleotide (N). This quality threshold results in nucleotide frequencies with an expected theoretical error rate of 1 in 1000.

Analyses of base editing processivity were performed using a custom python script. This program trims sequencing reads to the 20 nucleotide protospacer sequence as determined by a perfect match for the 7 nucleotide sequences that should flank the target site. These targets were then consolidated and sorted by abundance to assess the frequency of base editing products.

Bioinformatic analysis of the ClinVar database of human disease-associated mutations was performed in a manner similar to that previously described but with small adjustments¹. These adjustments enable the identification of targets with PAMs of customizable length and sequence. In addition, this improved script includes a priority ranking of target C positions (C5>C6>C7>C8≈C4), thus enabling the identification of target sites in which the on-target C is either the only cytosine within the window or is placed at a position with higher predicted editing efficiency than any off-target C within the editing window.

References for Example 12

-   1 Komor, A. C. et al. Programmable editing of a target base in     genomic DNA without double-stranded DNA cleavage. Nature 533,     420-424 (2016). -   2 Sander, J. D. & Joung, J. K. CRISPR-Cas systems for editing,     regulating and targeting genomes. Nature biotechnology 32, 347-355     (2014). -   3 Cong, L. et al. Multiplex genome engineering using CRISPR/Cas     systems. Science 339, 819-823 (2013). -   4 Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system.     Nat. Protocols 8, 2281-2308 (2013). -   5 Landrum, M. J. et al. ClinVar: public archive of interpretations     of clinically relevant variants. Nucleic Acids Res. 44, D862-D868     (2015). -   6 Nishida, K. et al. Targeted nucleotide editing using hybrid     prokaryotic and vertebrate adaptive immune systems. Science 353,     aaf8729-1-8 (2016). -   7 Ma, Y. et al. Targeted AID-mediated mutagenesis (TAM) enables     efficient genomic diversification in mammalian cells. Nat. Methods     doi:10.1038/nmeth.4027 (2016). -   8 Jiang, F. et al. Structures of a CRISPR-Cas9 R-loop complex primed     for DNA cleavage. Science 351, 867-71 (2016). -   9 Ran, F. A. et al. In vivo genome editing using Staphylococcus     aureus Cas9. Nature 520, 186-191 (2015). -   10 Zhang, Y. et al. Comparison of non-canonical PAMs for     CRISPR/Cas9-mediated DNA cleavage in human cells. Sci. Rep. 4,     (2014). -   11 Kleinstiver, B. P. et. al. Engineered CRISPR-Cas9 nucleases with     altered PAM specificities. Nature 523, 481-485 (2015). -   12 Kleinstiver, B. P. et. al. Broadening the targeting range of     Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition. Nat.     Biotechnol. 33, 1293-1298 (2015). -   13 Holden, L. G. et al. Crystal structure of the anti-viral APOBEC3G     catalytic domain and functional implications. Nature 452, 121-124     (2008). -   14 Chen, K.-M. et al. Structure of the DNA deaminase domain of the     HIV-1 restriction factor APOBEC3G. Nature 452, 116-119 (2008). -   15 Harris, R. S., Petersen-Mahrt, S. K. & Neuberger, M. S. RNA     Editing Enzyme APOBEC1 and Some of Its Homologs Can Act as DNA     Mutators. Molecular Cell 10, 1247-1253 (2002). -   16 Zetsche, B. et al. Cpf1 Is a Single RNA-Guided Endonuclease of a     Class 2 CRISPR-Cas System. Cell 163, 759-771 (2015).

Example 13

Using improved transfection procedures and better plasmids, biological replicates (n=3) were used to install the four HF mutations into the Cas9 portion of BE3. The muations do not significantly effect on-targeting editing with plasmid delivery (FIG. 99). At the tested concentration, BE3 protein delivery works; however, the on-target editing is lower than for plasmid delivery (FIG. 100). Protein delivery of BE3 with the HF mutations installed reduces on-targeting ediing efficiency but still yields some edited cells (FIG. 101).

Both lipofection and installing HF mutations were shown to decrease off-target deamination events. For the four sites shown in FIG. 102, the off-target sitest (OT) with the highest GUIDE-Seq reads and deamination events were assayed (Komor et al., Nature, 2016). The specificity ratio was calculated by dividing the off-target editing by the on-target editing at the closest corresponding C. In cases where off-target editing was not detectable, the ratio was set to 100. Thus, a higher specificity ratio indicates a more specific construct. BE3 plasmid delivery showed much higher off-target/on-target editing than protein delivery of BE3, plasmid delivery of HF-BE3, or protein delivery of HF-BE3 (FIGS. 102 and 105).

Purified proteins HF-BE3 and BE3 were analyzed in vitro for their capabilities to convert C to T residues at different positions in the spacer with the most permissive motif. Both BE3 and HF-BE3 proteins were found to have the same “window” for base editing (FIGS. 103 and 104).

A list of the disease targets is given in Table 9. The base to be edited in Table 9 is indicated in bold and underlined.

TABLE 9 Base Editor Disease Targets SEQ GENE DISEASE SPACER ID NO: PAM EDITOR DEFECT CELL RB1 RETINO- AAT C TAGTAAA 4120 AAA SAKKH- SPLICING J82 BLASTOMA TAAATTGATGT AGT BE3 IMPAIRMENT PTEN CANCER GACCAA C GGCT 4121 TGA VQR- W111R MC116 AAGTGAAGA BE3 PIK3CA CANCER TC C TTTCTTCA 4122 ACT SAKKH- K111R CRL- CGGTTGCCT GGT BE3 5853 PIK3CA CANCER CTC C TGCTCAG 4123 AGA VQR- Q546R CRL- TGATTTCAG BE3 2505 TP53 CANCER TGT C ACACATG 4124 TGG YEE- N239D SNU475 TAGTTGTAG BE3 HRAS CANCER CCTCC C GGCCG 4125 AGO YEE- Q61R MC/CAR GCGGTATCC BE3

TABLE 6 Exemplary diseases that may be treated using base editors. The protospacer and PAM sequences are shown in the sgRNA (PAM) column. The PAM sequence is shown in parentheses and with the base to be edited indicated by underlining. The sgRNA (PAM) sequences, from top to bottom, correspond to SEQ ID NOs: 4126-4138. gene Base Disease target symbol changed sgRNA (PAM) Base editor Prion disease PRNP R37* GGCAGCCGATACCCGGGGCA(GGG) BE3 GGGCAGCCGATACCCGGGGC(AGG) Pendred syndrome Slc26a4 c.919-2A > G TTATTGTCCGAAATAAAAGA(AGA) BE3 ATTGTCCGAAATAAAAGAAG(AGG) (VQR TTGTCCGAAATAAAAGAAGA(GGA) SaCas9) GTCCGAAATAAAAGAAGAGGAAAA(AAT) GTCCGAAATAAAAGAAGAGGAAAAA(ATT) Congenital deafness Tmc1 c.545A > G CAGGAAGCACGAGGCCACTG(AGG) BE3 AACAGGAAGCACGAGGCCAC(TGA) YE-BE3 AGGAAGCACGAGGCCACTGA(GGA) YEE-BE3 Acquired deafness SNHL S33F TTGGATTCTGGAATCCATTC(TGG) BE3 Alzheimer′s Disease APP A673T TCTGCATCCATCTTCACTTC(AGA) BE3 VQR Niemann-Pick Disease NPC1 I1061T CTTACAGCCAGTAATGTCAC(CGA) BE3 VQR Type C

Additional exemplary genes in the human genome that may be targeted by the base editors or complexes of this disclosure are provided herein in Tables 7 and 8. Table 7 includes gene mutations that may be correcteded by changing a cytosine (C) to a thymine (T), for example, using a BE3 nucleobase editor. Table 8 includes gene mutations that may be corrected by changing a guanine (G) to an adenine (A), for example, using a BE3 nucleobase editor.

TABLE 7 Human gene mutations that may be corrected by changing a cytosine (C) to a thymine (T). The gene name, gene symbol, and dbSNP database reference number (RS#) are indicated. Also indicated are exemplary protospacers with their PAM sequences (gRNAs and gRNAall) and the base to be edited, e.g., a C, indicated by a “Y”. The “gRNAs” sequences, from top to bottom, correspond to SEQ ID NOs: 1914-2090. The “gRNA all” sequences, from top to bottom, correspond to SEQ ID NOs: 2091-2539, 3144-3333. Name RS# (dbSNP) GeneSymbol gRNAs gRNAall Phenotypes NM_000138.4(FBN1): 137854465 FBN1 [ ] [ ] [ ] c.3220T > C (p.Cys1074Arg) NM_001927.3(DES): 57955682 DES [ ] [ ] [‘Myofibrillar c.1154T > C myopathy 1’, ‘not (p.Leu385Pro) provided’] NM_025152.2(NUBPL): 118161496 NUBPL [ ] [‘TGGTTCYAATGG [‘Mitochondrial c.815-27T > C ATGTCTGCTGG’, complex I ‘GGTTCYAATGGA deficiency’, ‘not TGTCTGCTGGG’] provided’] NM_003000.2(SDHB): 786202732 SDHB [ ] [ ] [‘Hereditary cancer- c.574T > C predisposing (p.Cys192Arg) syndrome’] NM_004586.2(RPS6KA3): 122454131 RPS6KA3 [ ] [ ] [‘Coffin-Lowry c.803T > C syndrome’] (p.Phe268Ser) NM_005609.2(PYGM): 764313717 PYGM [ ] [‘TGGCTGYCAGG [ ] c.425_528del GACCCAGCAAGG’, ‘CTGYCAGGGACC CAGCAAGGAGG’] NM_000124.3(ERCC6): 373227647 ERCC6 [ ] [ ] [‘Cockayne c.2830-2A > G syndrome, type B’] NM_000059.3(BRCA2): 81002805 BRCA2 [‘CTTAG [‘CTTAGGYAAGTA [‘Familial cancer of c.316 + 2T > C GYAAG ATGCAATATGG’] breast’, ‘Breast- TAATG ovarian cancer, CAATA familial 2’, TGG’] ‘Hereditary cancer- predisposing syndrome’] NM_003242.5(TGFBR2): 28934568 TGFBR2 [ ] [‘AGTTCCYGACGG [‘Loeys-Dietz c.923T > C CTGAGGAGCGG’] syndrome 2’] (p.Leu308Pro) NM_000410.3(HFE): 28934596 HFE [ ] [ ] [‘Hemochromatosis c.314T > C (p.Ile105Thr) type 1’] NM_000308.2(CTSA): 28934603 CTSA [ ] [ ] [‘Combined c.247T > C deficiency of (p.Trp83Arg) sialidase AND beta galactosidase’] NM_033290.3(MID1): 28934611 MID1 [ ] [ ] [‘Opitz-Frias c.1877T > C syndrome’] (p.Leu626Pro) NM_000329.2(RPE65): 62653011 RPE65 [ ] [ ] [‘Leber congenital c.1102T > C amaurosis 2’, (p.Tyr368His) ‘Retinitis pigmentosa 20’, ‘not provided’] NM_007313.2(ABL1): 121913461 ABL1 [ ] [‘CCAGYACGGGG [ ] c.814T > C AGGTGTACGAGG’, (p.Tyr272His) ‘CAGYACGGGGAG GTGTACGAGGG’] NM_000546.5(TP53): 28934873 TP53 [ ] [ ] [‘Li-Fraumeni c.398T > C syndrome 1’] (p.Met133Thr) NM_000490.4(AVP): 28934878 AVP [ ] [ ] [‘Neurohypophyseal c.200T > C (p.Val67Ala) diabetes insipidus’] NM_021961.5(TEAD1): 11567847 TEAD1 [‘TCATA [‘TCATATTYACAG [ ] c.1261T > C TTYAC GCTTGTAAAGG’] (p.Tyr?His) AGGCT TGTAA AGG’] NM_002609.3(PDGFRB): 397509381 PDGFRB [ ] [ ] [‘Basal ganglia c.1973T > C calcification, (p.Leu658Pro) idiopathic, 4’] NM_005236.2(ERCC4): 397509402 ERCC4 [ ] [ ] [‘Fanconi anemia, c.689T > C complementation (p.Leu230Pro) group Q’] NM_005236.2(ERCC4): 397509403 ERCC4 [ ] [ ] [‘XERODERMA c.706T > C PIGMENTOSUM, (p.Cys236Arg) TYPE F/COCKAYNE SYNDROME’] NM_173551.4(ANKS6): 377750405 ANKS6 [ ] [‘AGGGCYGTCGG [‘Nephronophthisis c.1322A > G ACCTTCGAGTGG’, 16’] (p.Gln441Arg) ‘GGGCYGTCGGAC CTTCGAGTGGG’, ‘GGCYGTCGGACC TTCGAGTGGGG1 NM_000142.4(FGFR3): 80053154 FGFR3 [ ] [ ] [‘Hypochondroplasia’] c.1612A > G (p.Ile538Val) NM_000441.1(SLC26A4): 80338848 SLC26A4 [ ] [ ] [‘Pendred syndrome’, c.707T > C ‘Enlarged vestibular (p.Leu236Pro) aqueduct syndrome’] NM_000518.4(HBB): 35849199 HBB [ ] [ ] [ ] c.337T > C (p.Cys113Arg) NM_000104.3(CYP1B1): 72549389 CYP1B1 [ ] [ ] [‘Irido-corneo- c.2T > C (p.Met1Thr) trabecular dysgenesis’] NM_000169.2(GLA): 28935196 — [ ] [ ] [‘Fabry disease’] c.484T > C (p.Trp162Arg) NM_001927.3(DES): 57639980 DES [ ] [‘ATTCCCYGATGA [‘Myofibrillar c.1034T > C GGCAGATGCGG’, myopathy 1’, ‘not (p.Leu345Pro) ‘TTCCCYGATGAG provided’] GCAGATGCGGG] NM_006517.4(SLC16A2): 122455132 SLC16A2 [ ] [ ] [‘Allan-Herndon- c.1190T > C Dudley syndrome’] (p.Leu397Pro) NM_020320.3(RARS2): 147391618 RARS2 [ ] [‘ATACCYGGCAA [‘Pontocerebellar c.35A > G GCAATAGCGCGG’] hypoplasia type 6’] (p.Gln12Arg) NM_000239.2(LYZ): 121913547 LYZ [ ] [ ] [‘Familial visceral c.221T > C (p.Ile74Thr) amyloidosis, Ostertag type’] NM_002977.3(SCN9A): 182650126 — [ ] [‘GTAAYTGCAAG [‘Small fiber c.2215A > G ATCTACAAAAGG’] neuropathy’, ‘not (p.Ile739Val) provided’] NM_004700.3(KCNQ4): 80358278 KCNQ4 [ ] [‘ACATYGACAAC [‘DFNA 2 c.842T > C CATCGGCTATGG’] Nonsyndromic (p.Leu281Ser) Hearing Loss’] NM_000169.2(GLA):c. 28935488 — [‘CAGTT [‘CAGTTAGYGATT [‘Fabry disease’] 806T > C AGYGA GGCAACTTTGG’] (p.Val269Ala) TTGGC AACTT TGG’] NM_000228.2(LAMB3): 370148688 LAMB3 [ ] [ ] [‘Junctional c.565-2A > G epidermolysis bullosa gravis of Herlitz’] NM_052867.2(NALCN): 786203987 NALCN [ ] [ ] [‘CONGENITAL c.1526T > C CONTRACTURES (p.Leu509Ser) OF THE LIMBS AND FACE, HYPOTONIA, AND DEVELOPMENTAL DELAY’] NM_001031.4(RP528): 786203997 RP528 [‘CCAY [‘TGTCCAYGATGG [‘Diamond-Blackfan c.1A > G (p.Met1Val) GATGG CGGCGCGGCGG’, anemia with CGGCG ‘CCAYGATGGCGG microtia and cleft CGGCG CGCGGCGGCGG’] palate’] GCGG’] NM_005957.4(MTHFR): 786204012 MTHFR [ ] [‘GACCYGCTGCCG [‘Homocysteinemia c.388T > C TCAGCGCCTGG’] due to MTHFR (p.Cys130Arg) deficiency’] NM_005957.4(MTHFR): 786204027 MTHFR [‘GAAG [‘GAAGGYGTGGT [‘Homocysteinemia c.1530 + 2T > C GYGTG AGGGAGGCACGG’, due to MTHFR GTAGG ‘AAGGYGTGGTAG deficiency’] GAGGC GGAGGCACGGG’, ACGG’, ‘AGGYGTGGTAGG ‘AAGGY GAGGCACGGG’] GTGGT AGGGA GGCAC GGG’, ‘AGGYG TGGTA GGGAG GCACG GGG’] NM_005957.4(MTHFR): 786204034 MTHFR [ ] [ ] [‘Homocysteinemia c.1793T > C due to MTHFR (p.Leu598Pro) deficiency’] NM_005957.4(MTHFR): 786204037 MTHFR [ ] [‘TCCCACYGGACA [‘Homocysteinemia c.1883T > C ACTGCCTCTGG’] due to MTHFR (p.Leu628Pro) deficiency’] NM_000264.3(PTCH1): 786204056 PTCH1 [‘ATCAT [‘ATCATTGYGAGT [‘Gorlin syndrome’] c.3168 + 2T > C TGYGA GTATTATAAGG’, GTGTA ‘TCATTGYGAGTG TTATA TATTATAAGGG’, AGG’, ‘CATTGYGAGTGT ‘TCATT ATTATAAGGGG’] GYGAG TGTAT TATAA GGG’, ‘CATTG YGAGT GTATT ATAAG GGG’] NM_000182.4(HADHA): 200017313 HADHA [ ] [ ] [‘Mitochondrial c.919-2A > G trifunctional protein deficiency’, ‘Long- chain 3- hydroxyacyl-CoA dehydrogenase deficiency’, ‘not provided’] NM_000030.2(AGXT): 180177271 AGXT [ ] [ ] [‘Primary c.806T > C hyperoxaluria, type (p.Leu269Pro) I’] NM_006121.3(KRT1): 57837128 KRT1 [ ] [ ] [‘Ichthyosis, cyclic, c.1436T > C with epidermolytic (p.Ile479Thr) hyperkeratosis’, ‘not provided’] NM_000521.3(HEXB): 820878 HEXB [ ] [ ] [‘Sandhoff disease, c.185C > T infantile type’] (p.Ser62Leu) NM_000140.3(FECH): 202147607 FECH [ ] [‘GTAGAYACCTTA [‘Erythropoietic c.1137 + 3A > G GAGAACAATGG’] protoporphyria’] NM_015046.5(SETX): 29001584 SETX [ ] [ ] [‘Amyotrophic c.1166T > C lateral sclerosis type (p.Leu389Ser) 4’] NM_020365.4(EIF2B3): 119474039 EIF2B3 [‘CCAG [‘CCAGAYTGTCAG [‘Leukoencephalopat c.1037T > C AYTGT CAAACACCTGG’] hy with vanishing (p.Ile346Thr) CAGCA white matter’] AACAC CTGG’] NM_139058.2(ARX): 28936077 ARX [ ] [ ] [‘Mental retardation, c.98T > C (p.Leu33Pro) with or without seizures, ARX- related, X-linked’] NM_005183.3(CACNA1F): 122456136 CACNA1F [ ] [‘TGCCAYTGCTGT [ ] c.2267T > C GGACAACCTGG’] (p.Ile756Thr) NM_007374.2(SIX6): 786204851 SIX6 [ ] [GTCGCYGCCCGT [‘Cataract, c.110T > C (p.Leu37Pro) GGCCCCTGCGG’] microphthalmia and nystagmus’] NM_000339.2(SLC12A3): 28936387 SLC12A3 [ ] [ ] [‘Familial c.1261T > C hypokalemia- (p.Cys421Arg) hypomagnesemia’] NM_003865.2(HESX1): 28936416 HESX1 [ ] [ ] [‘Pituitary hormone c.77T > C (p.Ile26Thr) deficiency, combined 5’] NM_022114.3(PRDM16): 202115331 PRDM16 [ ] [ ] [‘Dilated c.2660T > C cardiomyopathy (p.Leu887Pro) 1LL’] NM_001159287.1(TPI1): 121964847 TPI1 [ ] [ ] [‘Triosephosphate c.832T > C isomerase (p.Phe278Leu) deficiency’] NM_001692.3(ATP6V1B1): 121964880 ATP6V1B1 [ ] [ ] [ ] c.242T > C (p.Leu81Pro) NM_000490.4(AVP): 121964893 AVP [ ] [ ] [‘Neurohypophyseal c.61T > C (p.Tyr21His) diabetes insipidus’] NM_000027.3(AGA): 121964906 AGA [‘GTTAT [‘GTTATAYGTGCC [‘Aspartylglycosaminuria’] c.916T > C AYGTG AATGTGACTGG’] (p.Cys306Arg) CCAAT GTGAC TGG’] NM_000138.4(FBN1): 794728167 FBN1 [ ] [‘ATTGGYACGTGA [‘Thoracic aortic c.1468 + 2T > C TCCATCCTAGG’] aneurysms and aortic dissections’] NM_000027.3(AGA): 121964909 AGA [ ] [‘GACGGCYCTGTA [‘Aspartylglycosaminuria’] c.214T > C (p.Ser72Pro) GGCTTTGGAGG’] NM_004453.3(ETFDH): 377686388 ETFDH [ ] [ ] [‘Glutaric aciduria, c.1001T > C type 2’] (p.Leu334Pro) NM_001385.2(DPYS): 121964924 DPYS [‘CGTA [‘CGTAATAYGGG [‘Dihydropyrimidinase c.1078T > C ATAYG AAAAAGGCGTGG’, deficiency’] (p.Trp360Arg) GGAAA ‘AATAYGGGAAAA AAGGC AGGCGTGGTGG’, GTGG’, ‘ATAYGGGAAAAA ‘AATAY GGCGTGGTGGG’] GGGAA AAAGG CGTGG TGG’, ‘ATAYG GGAAA AAGGC GTGGT GGG’] NM_004453.3(ETFDH): 121964953 ETFDH [ ] [ ] [‘Glutaric acidemia c.2T > C (p.Met1Thr) IIC’] NM_000071.2(CBS): 121964968 CBS [ ] [ ] [‘Homocystinuria, c.1616T > C pyridoxine- (p.Leu539Ser) responsive’] NM_000170.2(GLDC): 121964978 GLDC [ ] [‘CGGCCAYGCAG [‘Non-ketotic c.2T > C (p.Met1Thr) TCCTGTGCCAGG’, hyperglycinemia’] ‘GGCCAYGCAGTC CTGTGCCAGGG’] NM_000108.4(DLD): 121964991 DLD [ ] [ ] [‘Maple syrup urine c.1178T > C disease, type 3’] (p.Ile393Thr) NM_014425.3(INVS): 121964995 INVS [ ] [ ] [‘Infantile c.1478T > C nephronophthisis’] (p.Leu493Ser) NM_000398.6(CYB5R3): 121965006 CYB5R3 [ ] [ ] [‘Methemoglobinemia c.382T > C type 2’] (p.Ser128Pro) NM_000398.6(CYB5R3): 121965008 CYB5R3 [ ] [‘CTGCYGGTCTAC [‘METHEMOGLOBINEMIA, c.446T > C CAGGGCAAAGG’] TYPE I’] (p.Leu149Pro) NM_000398.6(CYB5R3): 121965011 CYB5R3 [ ] [ ] [‘Methemoglobinemia c.610T > C type 2’] (p.Cys204Arg) NM_000398.6(CYB5R3): 121965013 CYB5R3 [ ] [ ] [‘METHEMOGLOBINEMIA, c.218T > C TYPE I’] (p.Leu73Pro) NM_001103.3(ACTN2): 786205144 ACTN2 [‘CCTA [‘CCTAAAAYGTTG [‘Dilated c.683T > C AAAYG GATGCTGAAGG’] cardiomyopathy (p.Met228Thr) TTGGA 1AA’] TGCTG AAGG’] NM_000548.3(TSC2): 45517281 TSC2 [ ] [ ] [‘Tuberous sclerosis c.3106T > C syndrome’, (p.Ser1036Pro) ‘Tuberous sclerosis 2’] NM_000203.4(IDUA): 121965027 IDUA [ ] [ ] [‘Mucopolysaccharidosis, c.1469T > C MPS-I-H/S’, (p.Leu490Pro) ‘Hurler syndrome’, ‘not provided’] NM_001122764.1(PPOX): 28936677 PPOX [ ] [ ] [‘Variegate c.35T > C porphyria’] (p.Ile12Thr) NM_000525.3(KCNJ11): 28936678 KCNJ11 [ ] [ ] [‘Islet cell c.440T > C hyperplasia’] (p.Leu147Pro) NM_001025107.2(ADAR): 28936680 ADAR [ ] [ ] [‘Symmetrical c.1883T > C dyschromatosis of (p.Leu628Pro) extremities’] NM_001025107.2(ADAR): 28936681 ADAR [ ] [ ] [‘Symmetrical c.2609T > C dyschromatosis of (p.Phe870Ser) extremities’] NM_000557.4(GDF5): 28936683 — [ ] [ ] [‘Brachydactyly type c.1322T > C A2’, ‘Fibular (p.Leu441Pro) hypoplasia and complex brachydactyly’] NM_000274.3(OAT): 121965037 OAT [ ] [ ] [Ornithine c.163T > C (p.Tyr55His) aminotransferase deficiency’] NM_000274.3(OAT): 121965043 OAT [ ] [ ] [Ornithine c.1205T > C aminotransferase (p.Leu402Pro) deficiency’] NM_000223.3(KRT12): 28936695 KRT12 [ ] [ ] [‘Meesman corneal c.386T > C dystrophy’, ‘not (p.Met129Thr) provided’] NM_000128.3(F11): 121965064 F11 [ ] [‘TGATYTCTTGGG [‘Hereditary factor c.901T > C AGAAGAACTGG’] XI deficiency (p.Phe301Leu) disease’] NM_000128.3(F11): 121965069 F11 [ ] [ ] [‘Hereditary factor c.166T > C (p.Cys56Arg) XI deficiency disease’] NM_000235.3(LIPA): 121965086 LIPA [ ] [ ] [‘Lysosomal acid c.599T > C lipase deficiency’] (p.Leu200Pro) NM_001199.3(BMP1): 786205217 BMP1 [ ] [ ] [‘Osteogenesis c.*241T > C imperfecta type 13’] NM_004974.3(KCNA2): 786205231 KCNA2 [ ] [ ] [‘EPILEPTIC c.788T > C ENCEPHALOPATHY, (p.Ile263Thr) EARLY INFANTILE, 32’] NM_000548.3(TSC2): 45517398 TSC2 [ ] [‘GCCCYGCACGC [‘Tuberous sclerosis c.5150T > C AAATGTGAGTGG’, syndrome’, ‘not (p.Leu1717Pro) ‘CCCYGCACGCAA provided’] ATGTGAGTGG’] NM_000212.2(ITGB3): 5918 ITGB3 [ ] [ ] [‘Myocardial c.176T > C infarction’, (p.Leu59Pro) ‘Posttransfusion purpura’, ‘Thrombocytopenia, neonatal alloimmune’, ‘Fracture, hip, susceptibility to’] m.9191T > C 386829069 MT-ATP6 [ ] [ ] [‘Leigh disease’] NM_000419.3(ITGA2B): 76811038 ITGA2B [ ] [ ] [‘Glanzmann c.1787T > C thrombasthenia’] (p.Ile596Thr) NM_002294.2(LAMP2): 730880485 LAMP2 [ ] [ ] [‘Cardiomyopathy’, c.864 + 2T > C ‘Danon disease’] NM_000138.4(FBN1): 794728264 FBN1 [ ] [ ] [‘Thoracic aortic c.7111T > C aneurysms and (p.Trp2371Arg) aortic dissections’] NM_000531.5(OTC): 72554315 OTC [ ] [ ] [‘not provided’] c.143T > C (p.Phe48Ser) NM_178454.4(DRAM2): 786205662 DRAM2 [ ] [ ] [‘Retinal dystrophy’] c.79T > C (p.Tyr27His) NM_000138.4(FBN1): 794728272 FBN1 [ ] [ ] [‘Thoracic aortic c.7531T > C aneurysms and (p.Cys2511Arg) aortic dissections’] NM_016218.2(POLK): 786205684 POLK [ ] [ ] [‘Malignant tumor of c.609T > C (p.Asn203=) prostate’] NM_016218.2(POLK): 786205688 POLK [ ] [ ] [‘Malignant tumor of c.*66T > C prostate’] NM_000354.5(SERPINA7): 28937312 SERPINA7 [ ] [ ] [ ] c.740T > C (p.Leu247Pro) NM_000531.5(OTC): 72554346 OTC [‘ACAA [‘ACAAGATYGTCT [‘not provided’] c.284T > C (p.Leu95Ser) GATYG ACAGAAACAGG’] TCTAC AGAAA CAGG’] NM_015662.2(IFT172): 786205857 IFT172 [ ] [‘TTGTGCYAGGAA [‘RETINITIS c.770T > C GTTATGACAGG’] PIGMENTOSA 71’] (p.Leu257Pro) NM_000531.5(OTC): 72554359 OTC [ ] [ ] [‘not provided’] c.386 + 2T > C NM_001135669.1(XPR1): 786205901 XPR1 [ ] [ ] [‘BASAL c.434T > C GANGLIA (p.Leu145Pro) CALCIFICATION, IDIOPATHIC, 6’] NM_001135669.1(XPR1): 786205903 XPR1 [ ] [ ] [‘BASAL c.419T > C GANGLIA (p.Leu140Pro) CALCIFICATION, IDIOPATHIC, 6’] NM_001135669.1(XPR1): 786205904 XPR1 [ ] [‘GCGTTYACGTGT [‘BASAL c.653T > C CCCCCCTTTGG’, GANGLIA (p.Leu218Ser) ‘CGTTYACGTGTC CALCIFICATION, CCCCCTTTGGG’] IDIOPATHIC, 6’] NM_181457.3(PAX3): 104893654 PAX3 [ ] [ ] [‘Klein-Waardenberg c.268T > C syndrome’] (p.Tyr90His) NM_001987.4(ETV6): 786205155 ETV6 [ ] [ ] [‘Thrombocytopenia’, c.1046T > C ‘LEUKEMIA, (p.Leu349Pro) ACUTE LYMPHOBLASTIC; ALL’] NM_000055.2(BCHE): 104893684 BCHE [ ] [ ] [‘Deficiency of c.1004T > C butyrylcholine (p.Leu335Pro) esterase’] NM_000388.3(CASR): 104893696 CASR [ ] [ ] [‘Hypocalcemia, c.382T > C autosomal dominant (p.Phe128Leu) 1’] NM_000388.3(CASR): 104893698 CASR [ ] [ ] [‘Hypocalcemia, c.1835T > C autosomal dominant (p.Phe612Ser) 1’] NM_000388.3(CASR): 104893704 CASR [ ] [‘ACGCTYTCAAGG [‘Hypercalciuric c.2641T > C TGGCTGCCCGG’, hypercalcemia’] (p.Phe881Leu) ‘CGCTYTCAAGGT GGCTGCCCGGG’] NM_000388.3(CASR): 104893708 CASR [ ] [ ] [‘Hypocalcemia, c.374T > C autosomal dominant (p.Leu125Pro) 1’, ‘Hypocalcemia, autosomal dominant 1, with bartter syndrome’] NM_000388.3(CASR): 104893711 CASR [ ] [ ] [‘Hypocalcemia, c.2362T > C autosomal dominant (p.Phe788Leu) 1’] NM_000388.3(CASR): 104893717 CASR [ ] [ ] [‘Hypocalciuric c.38T > C (p.Leu13Pro) hypercalcemia, familial, type 1’] NM_006580.3(CLDN16): 104893725 CLDN16 [ ] [ ] [‘Primary c.500T > C hypomagnesemia’] (p.Leu167Pro) NM_006580.3(CLDN16): 104893731 CLDN16 [ ] [ ] [‘Primary c.434T > C hypomagnesemia’] (p.Leu145Pro) NM_000041.3(APOE): 429358 APOE [ ] [ ] [‘Familial type 3 c.388T > C hyperlipoproteinemia’] (p.Cys130Arg) NM_198159.2(MITF): 104893744 MITF [ ] [ ] [‘Waardenburg c.1051T > C syndrome type 2A’] (p.Ser351Pro) NM_198159.2(MITF): 104893747 MITF [ ] [‘ACTTYCCCTTAT [‘Waardenburg c.1195T > C TCCATCCACGG’, syndrome type 2A’] (p.Ser399Pro) ‘CTTYCCCTTATTC CATCCACGGG’] NM_001122757.2(POU1F1): 104893758 POU1F1 [ ] [ ] [‘Pituitary hormone c.655T > C deficiency, (p.Trp219Arg) combined 1’] NM_000539.3(RHO): 104893770 RHO [ ] [‘CATGYTTCTGCT [‘Retinitis c.133T > C (p.Phe45Leu) GATCGTGCTGG’, pigmentosa 4’] ‘ATGYTTCTGCTG ATCGTGCTGGG’] NM_003106.3(SOX2): 104893802 — [ ] [ ] [‘Microphthalmia c.290T > C syndromic 3’] (p.Leu97Pro) NM_024009.2(GJB3): 28937583 GJB3 [ ] [ ] [‘Erythrokeratodermia c.101T > C variabilis’] (p.Leu34Pro) NM_003907.2(EIF2B5): 28937596 EIF2B5 [ ] [AGGCCYGGAGC [‘Leukoencephalopathy c.1882T > C CCTGTTTTTAGG’] with vanishing (p.Trp628Arg) white matter’] NM_000551.3(VHL): 104893827 VHL [ ] [ ] [‘Pheochromocytoma’] c.188T > C (p.Leu63Pro) NM_000320.2(QDPR): 104893865 QDPR [ ] [ ] [‘Dihydropteridine c.106T > C reductase (p.Trp36Arg) deficiency’] NM_001151.3(SLC25A4): 104893876 SLC25A4 [ ] [‘GCAGCYCTTCTT [‘Autosomal c.293T > C AGGGGGTGTGG’] dominant (p.Leu98Pro) progressive external ophthalmoplegia with mitochondrial DNA deletions 2’] NM_006005.3(WFS1): 104893883 WFS1 [ ] [‘ACCATCCYGGA [‘WFS1-Related c.2486T > C GGGCCGCCTGGG’] Disorders’] (p.Leu829Pro) NM_001018077.1(NR3C1): 104893911 NR3C1 [‘AAGY [‘AAGYGATTGCA [‘Pseudohermaphroditism, c.1712T > C GATTG GCAGTGAAATGG’] female, with (p.Val571Ala) CAGCA hypokalemia, due to GTGAA glucocorticoid ATGG’] resistance’] NM_001018077.1(NR3C1): 104893912 NR3C1 [ ] [ ] [‘Glucocorticoid c.2318T > C resistance, (p.Leu773Pro) generalized’] NM_003122.4(SPINK1): 104893938 SPINK1 [ ] [ ] [‘Hereditary c.2T > C (p.Met1Thr) pancreatitis’] NM_000165.4(GJA1): 104893962 GJA1 [ ] [‘CTACYCAACTGC [‘Oculodentodigital c.52T > C (p.Ser18Pro) TGGAGGGAAGG’] dysplasia’] NM_000416.2(IFNGR1): 104893973 IFNGR1 [‘TGTA [‘TGTAATAYTTCT [‘Disseminated c.260T > C ATAYT GATCATGTTGG’] atypical (p.Ile87Thr) TCTGA mycobacterial TCATG infection’, TTGG’] ‘Mycobacterium tuberculosis, susceptibility to’] NM_000434.3(NEU1): 104893978 NEU1 [ ] [‘GCCTCCYGGCGC [‘Sialidosis, type II’] c.718T > C TACGGAAGTGG’, (p.Trp240Arg) ‘CCTCCYGGCGCT ACGGAAGTGGG’, ‘CTCCYGGCGCTA CGGAAGTGGGG’] NM_153704.5(TMEM67): 202149403 TMEM67 [ ] [ ] [‘Joubert syndrome c.755T > C 6’] (p.Met252Thr) NM_000162.3(GCK): 104894010 GCK [ ] [ ] [‘Maturity-onset c.391T > C diabetes of the (p.Ser131Pro) young, type 2’] NM_004577.3(PSPH): 104894036 PSPH [ ] [ ] [‘Deficiency of c.155T > C phosphoserine (p.Met52Thr) phosphatase’] NM_000193.3(SHH): 104894052 SHH [ ] [ ] [‘Single upper c.995T > C central incisor’] (p.Val332Ala) NM_000282.3(PCCA): 202247815 PCCA [ ] [ ] [‘Propionic c.491T > C acidemia’] (p.Ile164Thr) NM_002546.3(TNFRSF11B): 104894092 TNFRSF11B [ ] [‘TAGAGYTCTGCT [‘Hyperphosphatasemia c.349T > C TGAAACATAGG’] with bone (p.Phe117Leu) disease’] NM_000532.4(PCCB): 202247822 PCCB [ ] [ ] [‘Propionic c.1556T > C acidemia’] (p.Leu519Pro) NM_006412.3(AGPAT2): 104894100 AGPAT2 [ ] [ ] [‘Congenital c.683T > C generalized (p.Leu228Pro) lipodystrophy type 1’] NM_000238.3(KCNH2): 794728388 KCNH2 [ ] [ ] [‘Cardiac c.2366T > C arrhythmia’] (p.Ile789Thr) NM_001243133.1(NLRP3): 28937896 NLRP3 [ ] [ ] [‘Familial cold c.1058T > C urticaria’] (p.Leu353Pro) NM_021020.3(LZTS1): 28937897 LZTS1 [ ] [ ] [ ] c.85T > C (p.Ser29Pro) NM_000102.3(CYP17A1): 104894135 CYP17A1 [ ] [CATCGCGYCCAA [‘Complete c.316T > C CAACCGTAAGG’, combined 17-alpha- (p.Ser106Pro) ‘ATCGCGYCCAAC hydroxylase/17,20- AACCGTAAGGG’] lyase deficiency’] NM_000102.3(CYP17A1): 104894143 CYP17A1 [ ] [ ] [‘Complete c.1216T > C combined 17-alpha- (p.Trp406Arg) hydroxylase/17,20- lyase deficiency’] NM_000102.3(CYP17A1): 104894151 CYP17A1 [ ] [AGCTCTYCCTCA [‘Combined partial c.1358T > C TCATGGCCTGG’] 17-alpha- (p.Phe453Ser) hydroxylase/17,20- lyase deficiency’] NM_005097.3(LGI1): 104894166 LGI1 [ ] [ ] [‘Epilepsy, lateral c.136T > C (p.Cys46Arg) temporal lobe, autosomal dominant’] NM_005097.3(LGI1): 104894167 LGI1 [ ] [ ] [‘Epilepsy, lateral c.695T > C temporal lobe, (p.Leu232Pro) autosomal dominant’] NM_000281.3(PCBD1): 104894177 PCBD1 [ ] [ ] [‘Hyperphenylalaninemia, c.244T > C BH4-deficient, D’] (p.Cys82Arg) NM_003476.4(CSRP3): 104894205 CSRP3 [ ] [ ] [‘Familial c.131T > C hypertrophic (p.Leu44Pro) cardiomyopathy 12’, ‘not specified’] NM_000315.2(PTH):c. 104894272 PTH [ ] [ ] [‘Hypoparathyroidism 67T > C (p.Ser23Pro) familial isolated’] NM_005055.4(RAPSN): 104894293 RAPSN [ ] [ ] [‘Myasthenic c.848T > C syndrome, (p.Leu283Pro) congenital, associated with acetylcholine receptor deficiency’, ‘MYASTHENIC SYNDROME, CONGENITAL, 11, ASSOCIATED WITH ACETYLCHOLINE RECEPTOR DEFICIENCY’] NM_000518.4(HBB):c. 36015961 HBB [ ] [IGTGTGCYGGCC [‘Beta thalassemia 344T > C CATCACTTTGG’] intermedia’] (p.Leu115Pro) NM_005055.4(RAPSN): 104894300 RAPSN [ ] [ ] [‘MYASTHENIC c.41T > C SYNDROME, (p.Leu14Pro) CONGENITAL, 11, ASSOCIATED WITH ACETYLCHOLINE RECEPTOR DEFICIENCY’] NM_000531.5(OTC):c. 72552295 OTC [‘AGAA [‘AGAAGAYGCTG [‘not provided’] 2T > C (p.Met1Thr) GAYGC TTTAATCTGAGG’] TGTTT AATCT GAGG’] NM_020661.2(AICDA): 104894320 AICDA [ ] [ ] [‘Immunodeficiency c.238T > C with hyper IgM type (p.Trp80Arg) 2’] NM_020661.2(AICDA): 104894321 AICDA [ ] [ ] [‘Immunodeficiency c.317T > C with hyper IgM type (p.Leu106Pro) 2’] NM_020661.2(AICDA): 104894327 AICDA [ ] [ ] [‘Immunodeficiency c.452T > C with hyper IgM type (p.Phe151Ser) 2’] NM_000486.5(AQP2): 104894329 — [ ] [ ] [ ] c.646T > C (p.Ser216Pro) NM_020638.2(FGF23): 104894343 FGF23 [ ] [ ] [‘Tumoral calcinosis, c.287T > C familial, (p.Met96Thr) hyperphosphatemic’] NM_021044.2(DHH):c. 104894346 DHH [ ] [ ] [‘46,XY gonadal 2T > C (p.Met1Thr) dysgenesis, partial, with minifascicular neuropathy’] NM_000217.2(KCNA1): 104894352 KCNA1 [ ] [ ] [‘Episodic ataxia c.1223T > C type 1’] (p.Val408Ala) NM_000432.3(MYL2): 104894370 MYL2 [ ] [ ] [‘Familial c.52T > C hypertrophic (p.Phe18Leu) cardiomyopathy 10’] NM_080911.2(UNG):c. 104894380 UNG [ ] [ ] [‘Immunodeficiency 752T > C with hyper IgM type (p.Phe251Ser) 5’] NM_000192.3(TBX5): 104894384 TBX5 [ ] [ ] [‘Holt-Oram c.161T > C (p.Ile54Thr) syndrome’] NM_175929.2(FGF14): 104894393 FGF14 [ ] [ ] [‘Spinocerebellar c.449T > C ataxia 27’] (p.Phe150Ser) NM_007262.4(PARK7): 28938172 PARK7 [ ] [ ] [‘Parkinson disease c.497T > C 7’] (p.Leu166Pro) NM_004004.5(GJB2): 104894397 GJB2 [ ] [ ] [‘Deafness, c.229T > C autosomal recessive (p.Trp77Arg) 1A’, ‘not provided’] NM_001130089.1(KARS): 397514745 KARS [‘TTCYA [‘CTTCYATGATCT [‘Deafness, c.517T > C TGATC TCGAGGAGAGG’, autosomal recessive (p.Tyr173His) TTCGA ‘TTCYATGATCTTC 89’] GGAGA GAGGAGAGGG’] GGG’] NM_000161.2(GCH1): 104894434 GCH1 [ ] [ ] [‘Dystonia, dopa- c.662T > C responsive, with or (p.Met221Thr) without hyperphenylalaninemia, autosomal recessive’] NM_032409.2(PINK1): 28940285 — [ ] [ ] [‘Parkinson disease c.1040T > C 6, autosomal (p.Leu347Pro) recessive early- onset’] NM_006177.3(NRL): 104894463 NRL [ ] [ ] [‘Retinal c.479T > C degeneration, (p.Leu160Pro) autosomal recessive, clumped pigment type’] NM_152443.2(RDH12): 104894472 RDH12 [ ] [ICCYCGGTGGCT [‘Leber congenital c.523T > C CACCACATTGG’] amaurosis 13’] (p.Ser175Pro) NM_002435.2(MPI): 104894495 MPI [ ] [ ] [‘Congenital disorder c.413T > C of glycosylation type (p.Met138Thr) 1B’] NM_001159702.2(FHL1): 122458144 FHL1 [ ] [ ] [‘Myopathy, c.457T > C reducing body, X- (p.Cys153Arg) linked, childhood- onset’] NM_183235.2(RAB27A): 104894498 RAB27A [ ] [ ] [‘Griscelli syndrome c.389T > C type 2’] (p.Leu130Pro) NM_001018005.1(TPM1): 104894504 TPM1 [ ] [ ] [‘Familial c.284T > C hypertrophic (p.Val95Ala) cardiomyopathy 3’, ‘Cardiomyopathy’] NM_000485.2(APRT): 104894508 APRT [ ] [ ] [‘Adenine c.329T > C phosphoribosyltransferase (p.Leu110Pro) deficiency’] NM_000303.2(PMM2): 104894534 PMM2 [ ] [ ] [‘Carbohydrate- c.131T > C deficient (p.Val44Ala) glycoprotein syndrome type I’] NM_024006.5(VKORC1): 104894540 VKORC1 [ ] [ ] [‘Warfarin response’] c.134T > C (p.Val45Ala) NM_001614.3(ACTG1): 104894547 ACTG1 [ ] [ ] [‘Deafness, c.1109T > C autosomal dominant (p.Val370Ala) 20’] NM_001128085.1(ASPA): 104894548 — [ ] [ ] [‘Spongy c.454T > C degeneration of (p.Cys152Arg) central nervous system’] NM_004870.3(MPDU1): 104894587 MPDU1 [ ] [‘TCCYGGTCATG [‘Congenital disorder c.356T > C CACTACAGAGG’] of glycosylation type (p.Leu119Pro) 1F’] NM_004870.3(MPDU1): 104894588 MPDU1 [ ] [‘AATAYGGCGGC [‘Congenital disorder c.2T > C (p.Met1Thr) CGAGGCGGACGG’] of glycosylation type 1F’] NM_004870.3(MPDU1): 104894589 MPDU1 [ ] [ ] [‘Congenital disorder c.221T > C of glycosylation type (p.Leu74Ser) 1F’] NM_153006.2(NAGS): 104894605 — [ ] [ ] [‘Hyperammonemia, c.1289T > C type III’] (p.Leu430Pro) NM_000304.3(PMP22): 104894617 PMP22 [ ] [ ] [Charcot-Marie- c.47T > C Tooth disease, type (p.Leu16Pro) IA’] NM_000304.3(PMP22): 104894626 PMP22 [ ] [TAGCAAYGGAT [Charcot-Marie- c.82T > C CGTGGGCAATGG’] Tooth disease, type (p.Trp28Arg) IE’] NM_018129.3(PNPO): 104894631 PNPO [ ] [ACCTYAACTCTG [“Pyridoxal 5’- c.784T > C GGACCTGCTGG’] phosphate- (p.Ter262Gln) dependent epilepsy”] NM_173477.4(USH1G): 104894651 USH1G [ ] [ ] [‘Usher syndrome, c.143T > C type 1G’] (p.Leu48Pro) NM_000371.3(TTR):c. 104894665 TTR [ ] [ ] [‘Amyloidogenic 191T > C (p.Phe64Ser) transthyretin amyloidosis’, ‘AMYLOIDOSIS, LEPTOMENINGEAL, TRANSTHYRETIN- RELATED’] NM_024301.4(FKRP): 104894691 FKRP [ ] [ ] [‘Limb-girdle c.899T > C muscular dystrophy- (p.Val300Ala) dystroglycanopathy, type C5’] NM_032551.4(KISS1R): 104894703 KISS1R [ ] [‘GCCCTGCYGTAC [ ] c.305T > C CCGCTGCCCGG’, (p.Leu102Pro) ‘TGCYGTACCCGC TGCCCGGCTGG’] NM_000660.5(TGFB1): 104894719 TGFB1 [ ] [ ] [‘Diaphyseal c.673T > C dysplasia’] (p.Cys225Arg) NM_000229.1(LCAT): 794726664 LCAT [ ] [ ] [‘Fish-eye disease’] c.524-22T > C NM_003332.3(TYROBP): 104894732 TYROBP [ ] [ ] [‘Polycystic c.2T > C lipomembranous (p.Met1Thr) osteodysplasia with sclerosing leukoencephalopathy’] NM_000074.2(CD40LG): 104894769 CD40LG [ ] [ ] [‘Immunodeficiency c.464T > C with hyper IgM type (p.Leu155Pro) 1’] NM_000495.4(COL4A5): 281874738 COL4A5 [‘TCCA [‘CTCCAGYAAGTT [‘Alport syndrome, c.438 + 2T > C GYAAG ATAAAATTTGG’, X-linked recessive’] TTATA ‘TCCAGYAAGTTA AAATT TAAAATTTGGG’] TGGG’] NM_000495.4(COL4A5): 281874745 COL4A5 [ ] [ ] [‘Alport syndrome, c.4690T > C X-linked recessive’] (p.Cys1564Arg) NM_178152.2(DCX):c. 104894781 DCX [ ] [ ] [‘Lissencephaly, X- 373T > C linked’, ‘Subcortical (p.Tyr125His) laminar heterotopia, X-linked’] NM_006579.2(EBP):c. 104894795 EBP [ ] [ ] [‘MEND 53T > C (p.Leu18Pro) SYNDROME’] NM_001097642.2(GJB1): 104894813 GJB1 [ ] [ ] [‘X-linked hereditary c.397T > C motor and sensory (p.Trp133Arg) neuropathy’] NM_001165963.1(SCN1A): 794726761 SCN1A [ ] [ ] [‘Severe myoclonic c.2690T > C epilepsy in infancy’] (p.Leu897Ser) NM_000166.5(GJB1): 104894826 GJB1 [ ] [‘ATGYCATCAGCG [‘Dejerine-Sottas c.407T > C TGGTGTTCCGG’] disease’, ‘X-linked (p.Val136Ala) hereditary motor and sensory neuropathy’] NM_001165963.1(SCN1A): 794726771 SCN1A [ ] [ ] [‘Severe myoclonic c.769T > C epilepsy in infancy’, (p.Cys257Arg) ‘not provided’] NM_001165963.1(SCN1A): 794726782 SCN1A [ ] [ ] [‘Severe myoclonic c.1033T > C epilepsy in infancy’] (p.Cys345Arg) NM_001122606.1(LAMP2): 104894859 LAMP2 [ ] [CAGCTACYGGG [‘Danon disease’] c.961T > C ATGCCCCCCTGG’, (p.Trp321Arg) ‘AGCTACYGGGAT GCCCCCCTGGG’] m.10237T > C 193302927 MT-ND3 [ ] [ ] [‘Leber optic atrophy’] NM_033290.3(MID1): 104894866 MID1 [ ] [ ] [‘Opitz-Frias c.884T > C syndrome’] (p.Leu295Pro) m.10663T > C 193302933 MT-ND4L [ ] [ ] [‘Leber optic atrophy’] NM_001165963.1(SCN1A):c 794726821 — [‘TTCYG [‘TTCYGGTTTGTC [‘Severe myoclonic .4055T > C GTTTG TTATATTCTGG’] epilepsy in infancy’] (p.Leu1352Pro) TCTTAT ATTCT GG’] NM_000475.4(NR0B1): 104894907 NR0B1 [ ] [ ] [‘Congenital adrenal c.890T > C hypoplasia, X- (p.Leu297Pro) linked’] NM_022567.2(NYX): 104894911 NYX [ ] [ ] [‘Congenital c.302T > C (p.Ile101Thr) stationary night blindness, type 1A’] NM_000513.2(OPN1MW): 104894914 OPN1MW [ ] [ ] [‘Colorblindness, c.607T > C partial, deutan (p.Cys203Arg) series’, ‘Cone monochromatism’] NM_006517.4(SLC16A2): 104894931 SLC16A2 [ ] [‘TGAGCYGGTGG [‘Allan-Herndon- c.1313T > C GCCCAATGCAGG’] Dudley syndrome’] (p.Leu438Pro) NM_000330.3(RS1):c. 104894935 RS1 [ ] [‘TTACTTCYCTTT [‘Juvenile 38T > C (p.Leu13Pro) GGCTATGAAGG’] retinoschisis’, ‘not provided’] NM_000116.4(TAZ):c. 104894937 TAZ [‘AAGY [‘AAGYGTGTGCCT [‘3-Methylglutaconic 352T > C GTGTG GTGTGCCGAGG’] aciduria type 2’] (p.Cys118Arg) CCTGT GTGCC GAGG’] NM_006517.4(SLC16A2): 104894938 SLC16A2 [ ] [ ] [‘Allan-Herndon- c.1481T > C Dudley syndrome’] (p.Leu494Pro) NM_001109878.1(TBX22): 104894946 TBX22 [ ] [ ] [‘Cleft palate with c.641T > C ankyloglossia’] (p.Leu214Pro) NM_001011658.3(TRAPPC2): 104894948 — [ ] [ ] [‘Spondyloepiphyseal c.248T > C dysplasia tarda’] (p.Phe83Ser) NM_003140.2(SRY):c. 104894956 SRY [ ] [ ] [‘46,XY sex reversal, 326T > C type 1’] (p.Phe109Ser) NM_003140.2(SRY):c. 104894968 SRY [ ] [ ] [‘46,XY sex reversal, 203T > C (p.Ile68Thr) type 1’] NM_201269.2(ZNF644): 146936371 ZNF644 [ ] [ ] [‘Myopia 21, c.1759A > G autosomal (p.Ile587Val) dominant’] NM_001004434.2(SLC30A2): 587776926 SLC30A2 [ ] [ ] [‘Reduced zinc in c.161A > G breast milk’] (p.His54Arg) NM_000492.3(CFTR): 373002889 CFTR [ ] [ ] [‘Cystic fibrosis’] c.3469-20T > C NM_001848.2(COL6A1): 794727060 COL6A1 [‘ACAA [‘ACAAGGYGAGC [‘Ullrich congenital c.957 + 2T > C GGYGA GTGGGCTGCTGG’, muscular dystrophy’, GCGTG ‘CAAGGYGAGCGT ‘Bethlem myopathy’] GGCTG GGGCTGCTGGG’] CTGG’, ‘CAAGG YGAGC GTGGG CTGCT GGG’] m.4336T > C 41456348 MT-TQ [ ] [ ] [ ] NM_001065.3(TNFRSF1A): 104895217 TNFRSF1A [ ] [‘TGCYGTACCAAG [‘TNF receptor- c.175T > C TGCCACAAAGG’] associated periodic (p.Cys59Arg) fever syndrome (TRAPS)’] NM_003072.3(SMARCA4): 281875229 SMARCA4 [ ] [ ] [‘Mental retardation, c.3032T > C autosomal dominant (p.Met1011Thr) 16’, ‘not provided’] NM_019885.3(CYP26B1): 281875232 CYP26B1 [ ] [ ] [‘Radiohumeral c.436T > C fusions with other (p.Ser146Pro) skeletal and craniofacial anomalies’, ‘not provided’] NM_000182.4(HADHA): 781222705 HADHA [ ] [ ] [‘Mitochondrial c.180 + 3A > G trifunctional protein deficiency’, ‘Long- chain 3- hydroxyacyl-CoA dehydrogenase deficiency’, ‘not provided’] NM_000208.2(INSR): 587776819 INSR [ ] [ ] [‘Pineal hyperplasia c.1124-2A > G AND diabetes mellitus syndrome’] NM_006329.3(FBLN5): 28939072 FBLN5 [‘GACA [‘GACAYTGATGA [‘Age-related c.506T > C YTGAT ATGTCGCTATGG’] macular (p.Ile169Thr) GAATG degeneration 3’] TCGCT ATGG’] NM_000431.3(MVK): 104895304 MVK [‘CTCA [‘CTCAAYAGATGC [‘Hyperimmunoglobulin c.803T > C AYAGA CATCTCCCTGG’] D with periodic (p.Ile268Thr) TGCCA fever’, ‘Mevalonic TCTCC aciduria’] CTGG’] NM_024960.4(PANK2): 28939088 PANK2 [ ] [ ] [‘Hypoprebetalipo- c.437T > C proteinemia, (p.Met146Thr) acanthocytosis, retinitis pigmentosa, and pallidal degeneration’] NM_005359.5(SMAD4): 281875321 SMAD4 [ ] [ ] [‘Myhre syndrome’, c.1499T > C ‘not provided’] (p.Ile500Thr) NM_003793.3(CTSF): 143889283 CTSF [ ] [‘CTCCAYACTGAG [‘Ceroid c.692A > G CTGTGCCACGG’] lipofuscinosis, (p.Tyr231Cys) neuronal, 13’] NM_001159702.2(FHL1): 122459147 FHL1 [ ] [‘GGGGYGCTTCA [‘Myopathy, c.310T > C AGGCCATTGTGG’] reducing body, X- (p.Cys104Arg) linked, childhood- onset’] NM_001159702.2(FHL1): 122459149 FHL1 [ ] [ ] [‘Emery-dreifuss c.625T > C muscular dystrophy (p.Cys209Arg) 6’] NM_006214.3(PHYH): 201578674 PHYH [ ] [ ] [‘Refsum disease, c.135-2A > G adult, 1’] NM_006329.3(FBLN5): 28939370 FBLN5 [ ] [ ] [‘Autosomal c.679T > C recessive cutis laxa (p.Ser227Pro) type IA’] NM_004329.2(BMPR1A): 199476089 BMPR1A [ ] [ ] [‘Juvenile polyposis c.1409T > C syndrome’] (p.Met470Thr) NM_005154.4(USP8): 672601307 USP8 [ ] [ ] [‘Pituitary dependent c.2152T > C hypercortisolism’] (p.Ser718Pro) NM_020184.3(CNNM4): 74552543 CNNM4 [ ] [‘AAGCTCCYGGA [‘Cone-rod c.971T > C CTTTTTTCTGGG’] dystrophy (p.Leu324Pro) amelogenesis imperfecta’] NM_000734.3(CD247): 672601318 CD247 [ ] [ ] [‘Immunodeficiency c.2T > C (p.Met1Thr) due to defect in cd3- zeta’] NM_016042.3(EXOSC3): 672601332 EXOSC3 [ ] [ ] [‘Pontocerebellar c.712T > C hypoplasia, type 1b’] (p.Trp238Arg) NC_012920.1:m.1448 199476104 MT-ND6 [ ] [ ] [‘Leber optic 4T > C atrophy’, ‘Leigh disease’] m.10158T > C 199476117 MT-ND3 [ ] [‘AAAYCCACCCCT [‘Leigh disease’, TACGAGTGCGG’] ‘Leigh syndrome due to mitochondrial complex I deficiency’, ‘Mitochondrial complex I deficiency’] NM_020451.2(SEPN1): 794727808 SEPN1 [ ] [‘TCCGGYGAGTG [‘Congenital c.872 + 2T > C GGCCACACTGG’] myopathy with fiber type disproportion’, ‘Eichsfeld type congenital muscular dystrophy’] NM_005022.3(PFN1): 140547520 PFN1 [ ] [‘CACCTYCTTTGC [‘Amyotrophic c.350A > G CCATCAGCAGG’] lateral sclerosis 18’] (p.Glu117Gly) NM_032551.4(KISS1R): 28939719 KISS1R [ ] [ ] [ ] c.443T > C (p.Leu148Ser) NM_000084.4(CLCN5): 273585645 CLCN5 [ ] [ ] [‘Dent disease 1’] c.674T > C (p.Leu225Pro) NM_000030.2(AGXT): 536352238 AGXT [ ] [ ] [‘Primary c.605T > A hyperoxaluria, type (p.Ile202Asn) I’] NM_000060.3(BTD): 397514333 BTD [ ] [ ] [‘Biotinidase c.212T > C (p.Leu71Pro) deficiency’] NM_000060.3(BTD): 397514347 BTD [ ] [ ] [‘Biotinidase c.248T > C (p.Leu83Ser) deficiency’] NM_000060.3(BTD): 397514359 BTD [ ] [‘TCACCGCYTCAA [‘Biotinidase c.445T > C TGACACAGAGG’] deficiency’] (p.Phe149Leu) NM_000060.3(BTD): 397514382 BTD [ ] [ ] [‘Biotinidase c.743T > C (p.Ile248Thr) deficiency’] NM_000060.3(BTD): 397514384 BTD [ ] [ ] [‘Biotinidase c.764T > C (p.Ile255Thr) deficiency’] NM_000060.3(BTD): 397514389 BTD [ ] [ ] [‘Biotinidase c.833T > C deficiency’] (p.Leu278Pro) NM_000061.2(BTK): 128620186 BTK [‘AGCT [‘AGCTAYGGCCG [‘X-linked c.2T > C (p.Met1Thr) AYGGC CAGTGATTCTGG’] agammaglobulinemia’] CGCAG TGATT CTGG’] m.15572T > C 207459996 MT-CYB [ ] [ ] [‘Familial colorectal cancer’] NM_000060.3(BTD): 397514399 BTD [ ] [ ] [‘Biotinidase c.1096T > C deficiency’] (p.Ser366Pro) m.15197T > C 207460001 MT-CYB [ ] [‘CTAYCCGCCATC [‘Exercise CCATACATTGG’] intolerance’] m.14849T > C 207460004 MT-CYB [ ] [ ] [ ] NM_000060.3(BTD): 397514406 BTD [ ] [‘TTCACCCYGGTC [‘Biotinidase c.1214T > C CCTGTCTGGGG’] deficiency’] (p.Leu405Pro) NM_000060.3(BTD): 397514408 BTD [ ] [ ] [‘Biotinidase c.1252T > C deficiency’] (p.Cys418Arg) NM_000060.3(BTD): 397514412 BTD [ ] [ ] [‘Biotinidase c.1267T > C deficiency’] (p.Cys423Arg) NM_001128177.1(THRB): 121918703 THRB [ ] [ ] [‘Thyroid hormone c.1336T > C resistance, (p.Cys446Arg) generalized, autosomal dominant’] NM_000060.3(BTD): 397514422 BTD [ ] [ ] [‘Biotinidase c.1459T > C deficiency’] (p.Trp487Arg) NM_198056.2(SCN5A): 397514447 SCN5A [ ] [ ] [‘Progressive c.3963 + 2T > C familial heart block type 1A’] NM_020461.3(TUBGCP6): 368449236 TUBGCP6 [ ] [ ] [‘Microcephaly with c.2546A > G chorioretinopathy, (p.Glu849Gly) autosomal recessive’] NM_006225.3 (PLCD1): 397514471 PLCD1 [ ] [ ] [‘Leukonychia c.562T > C totalis’] (p.Cys188Arg) NM_001161581.1(POC1A): 397514488 POC1A [‘AGCY [‘AGCYGTGGGAC [‘Short stature, c.398T > C GTGGG AAGAGCAGCCGG’] onychodysplasia, (p.Leu133Pro) ACAAG facial dysmorphism, AGCAG and hypotrichosis’] CCGG’] NM_005340.6(HINT1): 397514489 HINT1 [‘CAAG [‘CAAGAAAYGTG [‘Gamstorp-Wohlfart c.250T > C AAAYG CTGCTGATCTGG’, syndrome’] (p.Cys84Arg) TGCTG ‘AAGAAAYGTGCT CTGAT GCTGATCTGGG’] CTGG’, ‘AAGAA AYGTG CTGCT GATCT GGG’] NM_000051.3(ATM): 786203606 ATM [ ] [ ] [‘Ataxia- c.2T > C (p.Met1Thr) telangiectasia syndrome’, ‘Hereditary cancer- predisposing syndrome’] NM_004281.3(BAG3): 397514507 BAG3 [ ] [ ] [‘Dilated c.1385T > C cardiomyopathy (p.Leu462Pro) 1HH’] NM_183075.2(CYP2U1): 397514515 CYP2U1 [ ] [ ] [‘Spastic paraplegia c.784T > C 56, autosomal (p.Cys262Arg) recessive’] NM_006177.3(NRL): 397514516 NRL [ ] MAGGCCAYGGA [‘Retinitis c.287T > C (p.Met96Thr) GCTGCTGCAGGG’] pigmentosa 27’] NM_000344.3(SMN1): 397514518 SMN1 [‘CACT [‘CACTGGAYATG [‘Kugelberg- c.388T > C GGAYA GAAATAGAGAGG’] Welander disease’] (p.Tyr130His) TGGAA ATAGA GAGG’] NM_152692.4(C1GALT1C1): 397514537 C1GALT1C1 [ ] [ ] [‘Polyagglutinable c.577T > C erythrocyte (p.Ser193Pro) syndrome’] NM_024531.4(SLC52A2): 397514538 SLC52A2 [ ] [ ] [Brown-Vialetto- c.368T > C Van Laere syndrome (p.Leu123Pro) 2’] NM_000138.4(FBN1): 794728238 FBN1 [ ] [ ] [‘Thoracic aortic c.5746T > C aneurysms and (p.Cys1916Arg) aortic dissections’] NM_000138.4(FBN1): 794728246 FBN1 [ ] [ ] [‘Thoracic aortic c.6274T > C aneurysms and (p.Trp2092Arg) aortic dissections’] NM_017802.3(DNAAF5): 397514561 DNAAF5 [ ] [ ] [‘Ciliary dyskinesia, c.2384T > C primary, 18’] (p.Leu795Pro) NM_206933.2(USH2A): 151148854 USH2A [ ] [ ] [‘Usher syndrome, c.12295-2A > G type 2A’] NM_000531.5 (OTC): 72554312 OTC [ ] [‘CTCACTCYAAAA [‘Ornithine c.134T > C (p.Leu45Pro) AACTTTACCGG’] carbamoyltransferase deficiency’, ‘not provided’] NM_178012.4(TUBB2B): 397514569 TUBB2B [ ] [‘GGTCCYGGATGT [‘Polymicrogyria, c.350T > C GGTGAGGAAGG’] asymmetric’] (p.Leu117Pro) NM_000431.3(MVK): 397514570 MVK [ ] [ ] [‘Porokeratosis, c.764T > C disseminated (p.Leu255Pro) superficial actinic 1’] NM_000431.3(MVK): 397514571 MVK [ ] [‘CGGCYTCAACCC [‘Porokeratosis, c.122T > C CACAGCAATGG’, disseminated (p.Leu41Pro) ‘GGCYTCAACCCC superficial actinic 1’] ACAGCAATGGG’] NM_000531.5 (OTC): 72554320 OTC [ ] [ ] [‘not provided’] c.167T > C (p.Met56Thr) NM_000531.5 (OTC): 72554324 OTC [ ] [ ] [‘not provided’] c.188T > C (p.Leu63Pro) NM_000531.5 (OTC): 72554328 OTC [ ] [ ] [‘not provided’] c.227T > C (p.Leu76Ser) NM_004055.4(CAPN5): 397514602 CAPN5 [ ] [ ] [‘Vitreoretinopathy, c.731T > C neovascular (p.Leu244Pro) inflammatory’] NM_133497.3(KCNV2): 397514604 KCNV2 [ ] [ ] [‘Retinal cone c.491T > C dystrophy 3B’] (p.Phe164Ser) NM_006567.3(FARS2): 397514611 FARS2 [ ] [ ] [‘Combined c.986T > C oxidative (p.Ile329Thr) phosphorylation deficiency 14’] NM_018344.5(SLC29A3): 397514626 SLC29A3 [‘ACTG [‘ACTGATAYCAG [‘Histiocytosis- c.607T > C ATAYC GTGAGAGCCAGG’, lymphadenopathy (p.Ser203Pro) AGGTG ‘CTGATAYCAGGT plus syndrome’] AGAGC GAGAGCCAGGG’] CAGG’] NM_000108.4(DLD): 397514651 DLD [‘ACAG [‘ACAGTTAYAGGT [‘Maple syrup urine c.140T > C (p.Ile47Thr) TTAYA TCTGGTCCTGG’, disease, type 3’] GGTTC ‘GTTAYAGGTTCT TGGTC GGTCCTGGAGG’] CTGG’, ‘GTTAY AGGTT CTGGT CCTGG AGG’] NM_020632.2(ATP6V0A4): 3807153 ATP6V0A4 [ ] [ ] [‘Renal tubular c.1739T > C acidosis, distal, (p.Met580Thr) autosomal recessive’] NM_000238.3(KCNH2): 794728380 KCNH2 [‘CTGTG [‘CTGTGAGYGTGC [‘Cardiac c.1945 + 6T > C AGYGT CCAGGGGCGGG’, arrhythmia’] GCCCA ‘TGAGYGTGCCCA GGGGC GGGGCGGGCGG’] GGG’, ‘TGAGY GTGCC CAGGG GCGGG CGG’] NM_001033053.2(NLRP1): 397514692 NLRP1 [ ] [ ] [‘Corneal c.230T > C intraepithelial (p.Met77Thr) dyskeratosis and ectodermal dysplasia’] NM_000238.3(KCNH2): 794728390 KCNH2 [ ] [‘GCCATCCYGGGT [‘Cardiac c.2396T > C ATGGGGTGGGG’, arrhythmia’] (p.Leu799Pro) ‘CCATCCYGGGTA TGGGGTGGGGG’, ‘CATCCYGGGTAT GGGGTGGGGGG’] NM_014845.5(FIG4): 397514707 FIG4 [ ] [ ] [‘Yunis Varon c.524T > C syndrome’] (p.Leu175Pro) NM_001199107.1(TBC1D24): 397514713 TBC1D24 [ ] [‘GGTCTYTGACGT [‘Early infantile c.686T > C CTTCCTGGTGG’] epileptic (p.Phe229Ser) encephalopathy 16’] NM_080605.3(B3GALT6): 397514719 B3GALT6 [ ] [‘CGCYGGCCACC [‘Spondyloepimetap c.193A > G AGCACTGCCAGG’] hyseal dysplasia (p.Ser65Gly) with joint laxity’] NM_004183.3(BEST1): 28940274 BEST1 [ ] [ ] [‘Vitelliform c.253T > C dystrophy’, ‘not (p.Tyr85His) provided’] NM_005689.2(ABCB6): 397514756 ABCB6 [ ] [ ] [‘Dyschromatosis c.1067T > C universalis (p.Leu356Pro) hereditaria 3’] NM_000551.3(VHL): 28940297 VHL [ ] [ ] [ ] c.488T > C (p.Leu163Pro) NM_000218.2(KCNQ1): 794728522 KCNQ1 [ ] [ ] [‘Cardiac c.1025T > C arrhythmia’] (p.Leu342Pro) NM_000218.2(KCNQ1): 794728528 KCNQ1 [ ] [ ] [‘Cardiac c.1251 + 2T > C arrhythmia’] NM_000498.3(CYP11B2): 72554627 — [ ] [ ] [‘Corticosterone c.1382T > C methyloxidase type (p.Leu461Pro) 1 deficiency’] NM_130799.2(MEN1): 794728649 MEN1 [ ] [ ] [‘not provided’] c.547T > C (p.Trp183Arg) NM_213653.3(HFE2): 28940586 HFE2 [ ] [ ] [‘Hemochromatosis c.238T > C type 2A’] (p.Cys80Arg) NM_198056.2(SCN5A): 794728934 SCN5A [ ] [ ] [‘not provided’] c.4299 + 6T > C NM_000548.3(TSC2): 397515247 TSC2 [ ] [ ] [‘Tuberous sclerosis c.1946 + 2T > C syndrome’] NM_000256.3(MYBPC3): 730880608 MYBPC3 [ ] MAGYGCCGCCT [‘Cardiomyopathy’] c.3796T > C GGAGGTGCGAGG’] (p.Cys1266Arg) NM_016381.5(TREX1): 79993407 TREX1 [ ] [ ] [‘Aicardi Goutieres c.530T > C syndrome 1’] (p.Val177Ala) NM_001382.3(DPAGT1): 397515329 DPAGT1 [ ] [‘AATCCYGTACTA [‘Congenital disorder c.503T > C TGTCTACATGG’, of glycosylation type (p.Leu168Pro) ‘ATCCYGTACTAT 1J’] GTCTACATGGG’, ‘TCCYGTACTATG TCTACATGGGG’] NM_000372.4(TYR): 28940877 TYR [ ] [ ] [‘Tyrosinase- c.265T > C (p.Cys89Arg) negative oculocutaneous albinism’, ‘not provided’] NM_000375.2(UROS): 397515348 UROS [ ] [ ] [‘Congenital c.-26-177T > C erythropoietic porphyria’] NM_015102.4(NPHP4): 28940891 NPHP4 [ ] [ ] [‘Nephronophthisis c.2972T > C 4’] (p.Phe991Ser) NM_020822.2(KCNT1): 397515406 KCNT1 [ ] [ ] [‘Epilepsy, nocturnal c.2386T > C frontal lobe, 5’] (p.Tyr796His) NM_000061.2(BTK): 128621200 BTK [ ] [ ] [‘X-linked c.1516T > C agammaglobulinemia’] (p.Cys506Arg) NM_006383.3(CIB2): 397515411 CIB2 [ ] [ ] [‘Deafness, c.272T > C (p.Phe91Ser) autosomal recessive 48’] NM_000061.2(BTK): 128621205 BTK [‘ACATT [‘ACATTYGGGCTT [‘X-linked c.1741T > C YGGGC TTGGTAAGTGG’] agammaglobulinemia’] (p.Trp581Arg) TTTTG GTAAG TGG’] NM_018127.6(ELAC2): 397515465 ELAC2 [ ] [‘ATAYTTTCTGGT [‘Combined c.460T > C CCATTGAAAGG’] oxidative (p.Phe154Leu) phosphorylation deficiency 17’] NM_199355.2(ADAMTS18): 397515468 ADAMTS18 [ ] [ ] [‘Microcornea, c.605T > C myopic chorioretinal (p.Leu202Pro) atrophy, and telecanthus’] NM_023110.2(FGFR1): 397515481 FGFR1 [ ] [ ] [‘Hartsfield c.494T > C syndrome’] (p.Leu165Ser) NM_001059.2(TACR3): 397515483 TACR3 [ ] [ ] [‘Hypogonadotropic c.766T > C hypogonadism 11 (p.Tyr256His) with or without anosmia’] m.14325T > C 397515505 MT-ND6 [ ] [ ] [‘Leber optic atrophy’] NM_004333.4(BRAF): 794729219 BRAF [ ] [ ] [‘Cardiofaciocutaneous c.1783T > C syndrome’] (p.Phe595Leu) NM_000370.3(TTPA): 397515525 TTPA [ ] [ ] [‘Ataxia with c.548T > C vitamin E (p.Leu183Pro) deficiency’] NM_000375.2(UROS): 397515527 UROS [ ] [ ] [‘Congenital c.139T > C erythropoietic (p.Ser47Pro) porphyria’] NM_001006657.1(WDR35): 397515533 WDR35 [ ] [ ] [‘Cranioectodermal c.1592T > C dysplasia 2’] (p.Leu531Pro) NM_004595.4(SMS): 397515552 SMS [ ] [ ] [‘Snyder Robinson c.449T > C (p.Ile150Thr) syndrome’] NM_005211.3(CSF1R): 397515557 CSF1R [ ] [‘CATCTYTGACTG [‘Hereditary diffuse c.2483T > C TGTCTACACGG’] leukoencephalopathy (p.Phe828Ser) with spheroids’] NM_000026.2(ADSL): 777821034 ADSL [ ] [ ] [‘not provided’] c.1339T > C (p.Ser447Pro) NM_194248.2(OTOF): 397515599 OTOF [ ] [‘AGGTGCYGTTCT [‘Deafness, c.3413T > C GGGGCCTACGG’, autosomal recessive (p.Leu1138Pro) ‘GGTGCYGTTCTG 9’] GGGCCTACGGG’] NM_002608.2(PDGFB): 397515632 PDGFB [ ] [ ] [‘Idiopathic basal c.356T > C ganglia calcification (p.Leu119Pro) 5’] NM_000404.2(GLB1): 72555390 GLB1 [ ] [ ] [‘Gangliosidosis c.152T > C (p.Ile51Thr) GM1 type 3’] NM_000116.4(TAZ): 397515741 TAZ [ ] [ ] [‘3-Methylglutaconic c.310T > C aciduria type 2’] (p.Phe104Leu) NM_000138.4(FBN1): 397515766 FBN1 [ ] [‘GGACAAYGTAG [‘Marfan syndrome’] c.2341T > C AAATACTCCTGG’] (p.Cys781Arg) NM_000138.4(FBN1): 397515802 FBN1 [ ] [ ] [‘Marfan syndrome’] c.4222T > C (p.Cys1408Arg) NM_000112.3(SLC26A2): 386833492 SLC26A2 [‘GAGA [‘GAGAGGYGAGA [‘Diastrophic c.-26 + 2T > C GGYGA AGAGGGAAGCGG’] dysplasia’] GAAGA GGGAA GCGG’] NM_000256.3(MYBPC3): 397515897 MYBPC3 [‘AAAG [‘AAAGGYGGGCC [‘Familial c.1351 + 2T > C GYGGG TGGGACCTGAGG’] hypertrophic CCTGG cardiomyopathy 4’, GACCT ‘Cardiomyopathy’] GAGG’] NM_000045.3(ARG1): 28941474 ARG1 [ ] [ ] [‘Arginase c.32T > C (p.Ile11Thr) deficiency’] NM_004820.3(CYP7B1): 587777222 CYP7B1 [ ] [ ] [‘Spastic paraplegia’, c.889A > G ‘Spastic paraplegia (p.Thr297Ala) 5A] NM_017909.3(RMND1): 144972972 RMND1 [ ] [ ] [‘Combined c.713A > G oxidative (p.Asn238Ser) phosphorylation deficiency 11’] NM_000314.6(PTEN): 794729664 PTEN [ ] [ ] [‘Macrocephaly/autism c.545T > C syndrome’] (p.Leu182Ser) NM_000256.3(MYBPC3): 397516076 MYBPC3 [‘CACG [‘GCACGYGAGTG [‘Familial c.821 + 2T > C YGAGT GCCATCCTCAGG’, hypertrophic GGCCA ‘CACGYGAGTGGC cardiomyopathy 4’, TCCTC CATCCTCAGGG’] ‘not specified’] AGGG’] NM_000257.3(MYH7): 397516103 MYH7 [ ] [ ] [Cardiomyopathy’, c.1370T > C ‘not specified’] (p.Ile457Thr) NM_000257.3(MYH7): 397516130 MYH7 [ ] [ ] [‘Familial c.2093T > C hypertrophic (p.Val698Ala) cardiomyopathy 1’, ‘not specified’] NM_000257.3(MYH7): 397516156 MYH7 [‘GGAG [‘GGAGAYGGCCT [‘Primary familial c.2546T > C AYGGC CCATGAAGGAGG’] hypertrophic (p.Met849Thr) CTCCA cardiomyopathy’, TGAAG ‘Cardiomyopathy’] GAGG’] NM_000271.4(NPC1): 120074134 NPC1 [ ] [ ] [‘Niemann-Pick c.1133T > C disease type C1’] (p.Val378Ala) NM_000520.4(HEXA): 28941771 HEXA [ ] [ ] [ ] c.538T > C (p.Tyr180His) NM_024426.4(WT1): 28941777 WT1 [ ] [ ] [‘Diffuse mesangial c.1351T > C sclerosis’] (p.Phe451Leu) NM_024426.4(WT1): 28941779 WT1 [ ] [ ] [‘Frasier syndrome’] c.1378T > C (p.Phe460Leu) NM_000257.3(MYH7): 397516258 MYH7 [ ] [ ] [‘Dilated c.602T > C cardiomyopathy 1S’, (p.Ile201Thr) ‘Cardiomyopathy’] NM_000257.3(MYH7): 397516269 MYH7 [ ] [ ] [‘Primary familial c.788T > C hypertrophic (p.Ile263Thr) cardiomyopathy’, ‘Familial hypertrophic cardiomyopathy 1’, ‘Cardiomyopathy’] NM_001429.3(EP300): 565779970 EP300 [ ] [‘CTTAYTACAGTT [‘Rubinstein-Taybi c.3573T > A ACCAGAACAGG’] syndrome 2’] (p.Tyr1191Ter) NM_080605.3(B3GALT6): 786200938 B3GALT6 [ ] [AGCTTCAYGGCG [‘Spondyloepimetaphyseal c.1A > G CCCGCGCCGGG’, dysplasia with (p.Met1Val) ‘TCAYGGCGCCCG joint laxity’] CGCCGGGCCGG’] NM_032551.4(KISS1R): 587777844 KISS1R [ ] [ ] [ ] c.937T > C (p.Tyr313His) NM_000257.3(MYH7): 369437262 MYH7 [ ] [ ] [‘Familial c.5326A > G hypertrophic (p.Ser1776Gly) cardiomyopathy 1’, ‘Cardiomyopathy’, ‘not specified’] NM_000441.1(SLC26A4): 397516420 SLC26A4 [ ] [ ] [‘Pendred syndrome’, c.164 + 2T > C ‘Enlarged vestibular aqueduct syndrome’] NM_000441.1(SLC26A4): 397516432 SLC26A4 [ ] [ ] [‘Pendred syndrome’, c.765 + 2T > C ‘Enlarged vestibular aqueduct syndrome’] NM_000551.3(VHL): 397516445 VHL [ ] [ ] [‘Von Hippel-Lindau c.497T > C syndrome’, (p.Val166Ala) ‘Hereditary cancer- predisposing syndrome’] NM_000256.3(MYBPC3): 730880624 MYBPC3 [ ] [ ] [‘Cardiomyopathy’] c.709T > C (p.Tyr237His) NM_000531.5(OTC): 72556252 OTC [ ] [ ] [‘not provided’] c.392T > C (p.Leu131Ser) NM_000531.5(OTC): 72556253 OTC [ ] [ ] [‘not provided’] c.394T > C (p.Ser132Pro) NM_000531.5(OTC): 72556259 OTC [ ] [ ] [‘not provided’] c.416T > C (p.Leu139Ser) NM_000531.5(OTC): 72556269 OTC [ ] [ ] [‘not provided’] c.476T > C (p.Ile159Thr) NM_000531.5(OTC): 72556273 OTC [ ] [ ] [‘not provided’] c.490T > C (p.Ser164Pro) NM_000531.5(OTC): 72556282 OTC [‘GGCT [‘GGCTGATYACCT [‘not provided’] c.526T > C GATYA CACGCTCCAGG’, (p.Tyr176His) CCTCA ‘GATYACCTCACG CGCTC CTCCAGGTTGG’] CAGG’] NM_000531.5(OTC): 72556286 OTC [ ] [ ] [‘not provided’] c.536T > C (p.Leu179Pro) NM_000229.1(LCAT): 28942087 LCAT [ ] [‘ATCTCTCYTGGG [‘Norum disease’] c.698T > C GCTCCCTGGGG’, (p.Leu233Pro) ‘TCTCYTGGGGCT CCCTGGGGTGG’] NM_174936.3(PCSK9): 28942112 PCSK9 [ ] [ ] [‘Hypercholesterolemia, c.646T > C autosomal (p.Phe216Leu) dominant, 3’] NM_004572.3(PKP2): 794729098 PKP2 [ ] [ ] [‘not provided’] c.2386T > C (p.Cys796Arg) NM_000061.2(BTK): 128621198 BTK [‘AGCY [‘GAGCYGGGGAC [‘X-linked c.1223T > C GGGGA TGGACAATTTGG’, agammaglobulinemia’] (p.Leu408Pro) CTGGA ‘AGCYGGGGACTG CAATT GACAATTTGGG’] TGGG’] NM_000061.2(BTK): 128621203 BTK [ ] [ICGGCCYGTCCA [‘X-linked c.1625T > C GGTGAGTGTGG’] agammaglobulinemia (p.Leu542Pro) with growth hormone deficiency’] NM_006383.3(CIB2): 397515412 CIB2 [ ] [‘CTTCAYCTGCAA [‘Deafness, c.368T > C (p.Ile123Thr) GGAGGACCTGG’] autosomal recessive 48’] NM_001943.3(DSG2): 397516709 DSG2 [ ] [ ] [‘Arrhythmogenic c.523 + 2T > C right ventricular cardiomyopathy, type 10’, ‘Cardiomyopathy’] NM_032575.2(GLIS2): 587777353 GLIS2 [ ] [ ] [‘Nephronophthisis c.523T > C 7’] (p.Cys175Arg) NM_000492.3(CFTR): 139304906 CFTR [ ] [ ] [‘Cystic fibrosis’] c.3230T > C (p.Leu1077Pro) NM_000492.3(CFTR): 139468767 CFTR [ ] [ ] [‘Cystic fibrosis’, ‘not c.1853T > C provided’] (p.Ile618Thr) NM_002755.3(MAP2K1): 397516793 MAP2K1 [ ] [ ] [‘Cardiofaciocutaneous c.388T > C syndrome 3’] (p.Tyr130His) NM_000525.3(KCNJ11): 193929352 KCNJ11 [ ] [ ] [‘Permanent neonatal c.755T > C diabetes mellitus’] (p.Val252Ala) NM_000352.4(ABCC8): 193929364 ABCC8 [ ] [‘AAGCYGCTAATT [‘Permanent neonatal c.404T > C GGTAGGTGAGG’] diabetes mellitus’] (p.Leu135Pro) NM_000071.2(CBS): 5742905 CBS [‘ATCA [‘ATCAYTGGGGTG [‘Homocystinuria c.833T > C (p.Ile278Thr) YTGGG GATCCCGAAGG’, due to CBS GTGGA ‘TCAYTGGGGTGG deficiency’, TCCCG ATCCCGAAGGG’] ‘Homocystinuria, AAGG’, pyridoxine- ‘TCAYT responsive’, ‘not GGGGT provided’] GGATC CCGAA GGG’] NM_001038.5(SCNN1A): 5742912 SCNN1A [ ] [ ] [‘Bronchiectasis with c.1477T > C or without elevated (p.Trp493Arg) sweat chloride 2’, ‘not specified’] NM_000030.2(AGXT): 138584408 AGXT [ ] [ ] [‘Primary c.2T > C (p.Met1Thr) hyperoxaluria, type I’] NM_005633.3(SOS1): 397517153 SOS1 [ ] [ ] [‘Noonan syndrome c.1649T > C 4’, ‘Rasopathy’] (p.Leu550Pro) NM_014714.3(IFT140): 431905520 IFT140 [‘GCAG [CAAGCAGYGTG [‘Renal dysplasia, c.4078T > C YGTGA AGCTGCTCCTGG’, retinal pigmentary (p.Cys1360Arg) GCTGC ‘GCAGYGTGAGCT dystrophy, cerebellar TCCTG GCTCCTGGAGG’] ataxia and skeletal GAGG’] dysplasia’] NM_022168.3(IFIH1): 587777447 IFIH1 [ ] [ ] [‘Aicardi-goutieres c.1009A > G syndrome 7’] (p.Arg337Gly) NG_012123.1:g.2493 1024611 CCL2 [ ] [ ] [‘Coronary artery A > G disease, modifier of’, ‘Coronary artery disease, development of, in hiv’, ‘Mycobacterium tuberculosis, susceptibility to’] m.3394T > C 41460449 MT-ND1 [‘GGCY [‘GGCYATATACA [‘Leber optic ATATA ACTACGCAAAGG’] atrophy’] CAACT ACGCA AAGG’] NM_001127328.2(ACADM): 77931234 ACADM [ ] [ ] [‘Medium-chain c.997A > G acyl-coenzyme A (p.Lys333Glu) dehydrogenase deficiency’, ‘not provided’] NM_005859.4(PURA): 587782995 PURA [ ] [ ] [‘Neonatal c.299T > C hypotonia’, (p.Leu100Pro) ‘Intellectual disability’, ‘Seizures’, ‘Delayed speech and language development’, ‘Global developmental delay’, ‘Mental retardation, autosomal dominant 31’] NM_000368.4(T5C1): 118203396 TSC1 [ ] [ ] [‘Tuberous sclerosis c.539T > C syndrome’, (p.Leu180Pro) ‘Tuberous sclerosis 1’] NM_000256.3(MYBPC3): 730880695 MYBPC3 [ ] [ ] [‘Cardiomyopathy’] c.1696T > C (p.Cys566Arg) m.7275T > C 267606884 MT-CO1 [ ] [ ] [‘Familial colorectal cancer’] NM_000257.3(MYH7): 730880872 MYH7 [ ] [‘TCGAGAYCTTCG [‘Cardiomyopathy’] c.1400T > C ATGTGAGTTGG’, (p.Ile467Thr) ‘CGAGAYCTTCGA TGTGAGTTGGG’] NM_002977.3(SCN9A): 80356469 SCN9A [ ] [ ] [‘Primary c.647T > C erythromelalgia’] (p.Phe216Ser) NM_002977.3(SCN9A): 80356474 — [ ] [‘AAGATCAYTGGT [‘Primary c.2543T > C AACTCAGTAGG’, erythromelalgia’] (p.Ile848Thr) ‘AGATCAYTGGTA ACTCAGTAGGG’, ‘GATCAYTGGTAA CTCAGTAGGGG’] NM_001164277.1(SLC37A4): 80356489 SLC37A4 [ ] [‘GGGCYGGCCCC [‘Glucose-6- c.352T > C CATGTGGGAAGG’] phosphate transport (p.Trp118Arg) defect’, ‘not provided’] NM_001457.3(FLNB): 80356501 FLNB [ ] [ ] [ ] c.4804T > C (p.Ser1602Pro) NM_152296.4(ATP1A3): 80356536 ATP1A3 [ ] [‘GCCCYTCCTGCT [‘Dystonia 12’] c.2338T > C GTTCATCATGG’] (p.Phe780Leu) NM_206933.2(USH2A): 397518022 — [ ] [ ] [‘Usher syndrome, c.5857 + 2T > C type 2A’] NM_194248.2(OTOF): 80356586 OTOF [ ] [ ] [‘Deafness, c.1544T > C autosomal recessive (p.Ile515Thr) 9’, ‘Auditory neuropathy, autosomal recessive, 1’] NM_000335.4(SCN5A): 45589741 SCN5A [ ] [ ] [‘Acquired long QT c.3745T > C syndrome’] (p.Phe1249Leu) NM_194248.2(OTOF): 80356596 OTOF [ ] [GATGCYGGTGTT [‘Deafness, c.3032T > C CGACAACCTGG’] autosomal recessive (p.Leu1011Pro) 9’, ‘Auditory neuropathy, autosomal recessive, 1’] NM_000525.3(KCNJ11): 80356610 KCNJ11 [ ] [ ] [‘Permanent neonatal c.124T > C diabetes mellitus’, (p.Cys42Arg) ‘Transient neonatal diabetes mellitus 3’, ‘MATURITY- ONSET DIABETES OF THE YOUNG, TYPE 13’] NM_000257.3(MYH7): 730880900 MYH7 [ ] [ ] [‘Cardiomyopathy’] c.2723T > C (p.Leu908Pro) NM_152296.4(ATP1A3): 606231433 ATP1A3 [ ] [ ] [‘Alternating c.1112T > C hemiplegia of (p.Leu371Pro) childhood 2’] NM_000083.2(CLCN1): 80356689 CLCN1 [ ] [AGGAGYGCTATT [‘Myotonia c.857T > C TAGCATCGAGG’] congenita’] (p.Val286Ala) NM_000083.2(CLCN1): 80356701 CLCN1 [ ] [ ] [‘Myotonia c.920T > C congenita’] (p.Phe307Ser) NM_007375.3(TARDBP): 80356744 TARDBP [ ] [ ] [‘Amyotrophic c.*83T > C lateral sclerosis type 10’] NM_152296.4(ATP1A3): 606231449 ATP1A3 [ ] [ ] [‘Dystonia 12’] c.1250T > C (p.Leu417Pro) NM_001876.3(CPT1A): 80356793 CPT1A [ ] [ ] [Carnitine c.1451T > C palmitoyltransferase (p.Leu484Pro) I deficiency’] NM_000088.3(COL1A1): 72656353 COL1A1 [ ] [ ] [‘Osteogenesis c.4391T > C imperfecta type III’] (p.Leu1464Pro) NM_000089.3(COL1A2): 72656357 COL1A2 [ ] [ ] [‘Ehlers-Danlos c.279 + 2T > C syndrome, type 7B’] NM_015046.5(SETX): 116205032 SETX [ ] [ ] [‘Spinocerebellar c.1807A > G ataxia autosomal (p.Asn603Asp) recessive 1’] m.4409T > C 118203884 MT-TM [ ] [‘AGGYCAGCTAA [‘Mitochondrial ATAAGCTATCGG’] myopathy’] m.5874T > C 118203891 MT-TY [ ] [ ] [ ] NM_000130.4(F5): 118203911 F5 [ ] [ ] [‘Thrombophilia due c.1160T > C (p.Ile387Thr) to activated protein C resistance’] NM_173596.2(SLC39A5): 587777625 SLC39A5 [ ] [‘AGAACAYGCTG [‘Myopia 24, c.911T > C GGGCTTTTGCGG’] autosomal (p.Met304Thr) dominant’] NM_024120.4(NDUFAF5): 118203929 NDUFAF5 [ ] [ ] [‘Mitochondrial c.686T > C complex I (p.Leu229Pro) deficiency’] NM_003159.2(CDKL5): 587783087 CDKL5 [ ] [‘ATTCYTGGGGAG [‘not provided’] c.602T > C CTTAGCGATGG’] (p.Leu201Pro) NM_000046.3(ARSB): 118203939 ARSB [ ] [ ] [‘MUCOPOLYSAC c.349T > C CHARIDOSIS, (p.Cys117Arg) TYPE VI, SEVERE’] NM_000046.3(ARSB): 118203940 ARSB [ ] [ ] [‘MUCOPOLYSAC c.707T > C CHARIDOSIS, (p.Leu236Pro) TYPE VI, MILD’] NM_013319.2(UBIAD1): 118203951 UBIAD1 [ ] [‘TCTGGCYCCTTT [‘Schnyder c.511T > C CTCTACACAGG’, crystalline corneal (p.5er171Pro) ‘GGCYCCTTTCTCT dystrophy’] ACACAGGAGG’] NM_138387.3(G6PC3): 118203969 G6PC3 [ ] [ ] [‘Severe congenital c.554T > C neutropenia 4, (p.Leu185Pro) autosomal recessive’] NM_006364.2(5EC23A): 118204000 SEC23A [ ] [ ] [‘Craniolenticulosutural c.1144T > C dysplasia’] (p.Phe382Leu) NM_000429.2(MAT1A): 118204004 MAT1A [ ] [ ] [‘Methionine c.914T > C adenosyltransferase (p.Leu305Pro) deficiency, autosomal recessive’] NM_000018.3(ACADVL): 118204017 ACADVL [ ] [‘TCGCATCYTCCG [‘Very long chain c.1372T > C GATCTTTGAGG’, acyl-CoA (p.Phe458Leu) ‘CGCATCYTCCGG dehydrogenase ATCTTTGAGGG’, deficiency’] ‘GCATCYTCCGGA TCTTTGAGGGG’] NM_000833.4(GRIN2A): 397518466 GRIN2A [ ] [‘CTAYGGGCAGA [‘Focal epilepsy with c.2T > C GTGGGCTATTGG’] speech disorder with (p.Met1Thr) or without mental retardation’] NM_015702.2(MMADHC): 118204044 MMADHC [ ] [ ] [‘Homocystinuria, c.776T > C cblD type, variant 1’] (p.Leu259Pro) NM_018077.2(RBM28): 118204055 RBM28 [ ] [ ] [‘Alopecia, c.1052T > C neurologic defects, (p.Leu351Pro) and endocrinopathy syndrome’] NM_000237.2(LPL): 118204061 LPL [ ] [ ] [‘Hyperlipoproteinemia, c.662T > C (p.Ile221Thr) type I’] NM_000237.2(LPL): 118204069 LPL [ ] [‘GGACYGGCTGTC [‘Hyperlipoproteinemia, c.337T > C ACGGGCTCAGG’] type I’] (p.Trp113Arg) NM_000237.2(LPL): 118204080 LPL [ ] [‘GTGAYTGCAGA [‘Hyperlipoproteinemia, c.755T > C (p.Ile252Thr) GAGAGGACTTGG’] type I’] NM_000155.3(GALT): 111033726 GALT [ ] [ ] [‘Deficiency of c.580T > C UDPglucose- (p.Phe194Leu) hexose-1-phosphate uridylyltransferase’] NM_000190.3(HMBS): 118204111 HMBS [ ] [‘GCTTCGCYGCAT [‘Acute intermittent c.739T > C CGCTGAAAGGG’] porphyria’] (p.Cys247Arg) NM_000190.3(HMBS): 118204119 HMBS [ ] [ ] [‘Acute intermittent c.242T > C porphyria’] (p.Leu81Pro) NM_001363.4(DKC1): 199422253 DKC1 [ ] [ ] [‘Dyskeratosis c.1193T > C congenita X-linked’] (p.Leu398Pro) NM_004278.3(PIGL): 145303331 PIGL [ ] [ ] [‘Zunich c.500T > C neuroectodermal (p.Leu167Pro) syndrome’] NM_000531.5(OTC): 72558407 OTC [ ] [ ] [‘not provided’] c.602T > C (p.Leu201Pro) NM_000531.5(OTC): 72558441 OTC [‘ATGT [‘ATGTATYAATTA [‘not provided’] c.779T > C ATYAA CAGACACTTGG’] (p.Leu260Ser) TTACA GACAC TTGG’] NM_000531.5(OTC): 72558449 OTC [ ] [ ] [‘not provided’] c.803T > C (p.Met268Thr) NM_000256.3(MYBPC3): 372371774 MYBPC3 [ ] [ ] [‘Primary dilated c.1814A > G cardiomyopathy’, (p.Asp605Gly) ‘Cardiomyopathy’, ‘not specified’] NM_000531.5(OTC): 72558471 OTC [ ] [ ] [‘not provided’] c.947T > C (p.Phe316Ser) NM_000531.5(OTC): 72558484 OTC [‘ATCAT [‘ATCATGGYAAG [‘not provided’] c.1005 + 2T > C GGYAA CAAGAAACAAGG’] GCAAG AAACA AGG’] NM_000531.5(OTC): 72558489 OTC [ ] [ ] [‘not provided’] c.1018T > C (p.Ser340Pro) NM_000531.5(OTC): 72558490 OTC [ ] [ ] [‘not provided’] c.1022T > C (p.Leu341Pro) NM_007294.3(BRCA1): 80357281 BRCA1 [‘GGCY [‘GGGCYAGAAAT [‘Familial cancer of c.5291T > C AGAAA CTGTTGCTATGG’, breast’, ‘Breast- (p.Leu1764Pro) TCTGTT ‘GGCYAGAAATCT ovarian cancer, GCTAT GTTGCTATGGG’] familial 1’] GGG’] NM_000035.3(ALDOB): 118204430 ALDOB [‘GGAA [‘GGAAGYGGCGT [‘Hereditary c.442T > C GYGGC GCTGTGCTGAGG’] fructosuria’] (p.Trp148Arg) GTGCT GTGCT GAGG’] NM_000512.4(GALNS): 118204436 GALNS [ ] [ ] [‘Mucopolysaccharidosis, c.413T > C MPS-IV-A’] (p.Val138Ala) NM_024782.2(NHEJ1): 118204452 NHEJ1 [ ] [ ] [‘Severe combined c.367T > C immunodeficiency (p.Cys123Arg) with microcephaly, growth retardation, and sensitivity to ionizing radiation’] NM_007294.3(BRCA1): 80357438 BRCA1 [ ] [‘AAATCTYAGAGT [‘Familial cancer of c.65T > C GTCCCATCTGG’] breast’, ‘Breast- (p.Leu22Ser) ovarian cancer, familial 1’, ‘Hereditary cancer- predisposing syndrome’] m.12297T > C 121434464 MT-TL2 [‘GTCYT [‘GTCYTAGGCCCC [‘Cardiomyopathy, AGGCC AAAAATTTTGG’] mitochondrial’] CCAAA AATTT TGG’] NM_001040431.2(COA3): 139877390 COA3 [ ] [‘CCAYCTGGGGA [ ] c.215A > G GGTAGGTTCAGG’] (p.Tyr72Cys) m.10010T > C 121434476 MT-TG [ ] [ ] [‘Exercise intolerance’] NM_000860.5(HPGD): 121434481 HPGD [ ] [ ] [‘Digital clubbing, c.577T > C isolated congenital’] (p.Ser193Pro) NM_024915.3(GRHL2): 587777737 GRHL2 [ ] [ ] [‘Ectodermal c.1192T > C dysplasia/short (p.Tyr398His) stature syndrome’] NM_032374.4(APOPT1): 587777786 APOPT1 [ ] [ ] [‘Cytochrome-c c.353T > C oxidase deficiency’] (p.Phe1185er) NM_001605.2(AARS): 143370729 AARS [ ] [ ] [‘EPILEPTIC c.2251A > G ENCEPHALOPATHY, (p.Arg751Gly) EARLY INFANTILE, 29’] NM_000257.3(MYH7): 730880744 MYH7 [ ] [ ] [‘Cardiomyopathy’] c.2479T > C (p.Trp827Arg) NM_017415.2(KLHL3): 199469630 KLHL3 [‘Pseudohypoaldosteronism, c.1160T > C type 2’] (p.Leu387Pro) NM_017415.2(KLHL3): 199469642 KLHL3 [‘Pseudohypoaldosteronism, c.1280T > C type 2’] (p.Met427Thr) NM_005859.4(PURA): 793888527 PURA [ ] [‘GACCAYTGCGCT [‘not provided’, c.563T > C GCCCGCGCAGG’, ‘Mental retardation, (p.Ile188Thr) ‘ACCAYTGCGCTG autosomal dominant CCCGCGCAGGG’, 31’] ‘CCAYTGCGCTGC CCGCGCAGGGG’] NM_007294.3(BRCA1): 80358026 BRCA1 [ ] [ ] [‘Familial cancer of c.212 + 2T > C breast’, ‘Breast- ovarian cancer, familial 1’] NM_002878.3(RAD51D): 561425038 — [ ] [‘CGCCCAYGTTCC [‘Hereditary cancer- c.1A > G CCGCAGGCCGG’] predisposing (p.Met1Val) syndrome’] NM_018960.4(GNMT): 121907888 GNMT [ ] [ ] [‘Glycine N- c.149T > C methyltransferase (p.Leu50Pro) deficiency’] NM_007294.3(BRCA1): 80358089 BRCA1 [ ] [ ] [‘Breast-ovarian c.5074 + 2T > C cancer, familial 1’] NC_012920.1:m.1198 200911567 MT-ND4 [ ] [ ] [‘Leigh disease’] 4T > C NM_000280.4(PAX6): 121907925 PAX6 [ ] [ ] [‘Congenital ocular c.773T > C coloboma’, (p.Phe258Ser) ‘Coloboma of optic disc’] NM_020117.9(LARS): 201861847 LARS [ ] [ ] [‘Infantile liver c.1118A > G failure syndrome 1’] (p.Tyr373Cys) NM_024105.3(ALG12): 121907934 ALG12 [ ] [‘TCCYGCTGGCCC [‘Congenital disorder c.473T > C TCGCGGCCTGG’] of glycosylation type (p.Leu158Pro) 1G’] NM_000152.3(GAA): 121907936 GAA [ ] [ ] [‘Glycogen storage c.953T > C disease type II, (p.Met318Thr) infantile’] NM_000520.4(HEXA): 121907968 HEXA [ ] [ ] [‘Tay-Sachs disease’] c.1453T > C (p.Trp485Arg) NM_000520.4(HEXA): 121907974 HEXA [ ] [ ] [‘Tay-Sachs disease’] c.632T > C (p.Phe211Ser) NM_000053.3(ATP7B): 121908000 ATP7B [ ] [ ] [‘Wilson disease’] c.2123T > C (p.Leu708Pro) NM_000375.2(UROS): 121908012 UROS [ ] [ ] [‘Congenital c.217T > C erythropoietic (p.Cys73Arg) porphyria’] NM_153212.2(GJB4): 80358207 GJB4 [ ] [‘CCTCATCYTCAA [‘Erythrokeratodermia c.409T > C GGCCGCCGTGG’] variabilis’] (p.Phe137Leu) NM_000403.3(GALE): 121908045 GALE [ ] [ ] [‘UDPglucose-4- c.548T > C epimerase (p.Leu183Pro) deficiency’] NM_002353.2(TACSTD2): 80358228 TACSTD2 [ ] [ICGGCYGCACCC [‘Lattice corneal c.557T > C CAAGTTCGTGG’] dystrophy Type III’] (p.Leu186Pro) NM_001563.3(IMPG1): 713993047 IMPG1 [ ] [ ] [‘Macular dystrophy, c.461T > C vitelliform, 4’] (p.Leu154Pro) NM_138691.2(TMC1): 121908076 TMC1 [ ] [‘AGGACCTYGCTG [‘Deafness, c.1543T > C GGAAACAATGG’, autosomal recessive (p.Cys515Arg) ‘ACCTYGCTGGGA 7’] AACAATGGTGG’, ‘CCTYGCTGGGAA ACAATGGTGGG’] NM_000271.4(NPC1): 80358259 NPC1 [ ] [ ] [‘Niemann-Pick c.3182T > C disease type C1’] (p.Ile1061Thr) NM_006432.3(NPC2): 80358264 NPC2 [ ] [ ] [‘Niemann-Pick c.295T > C disease type C2’] (p.Cys99Arg) NM_017838.3(NHP2): 121908089 NHP2 [ ] [‘GGAGGCTYACG [‘Dyskeratosis c.415T > C ATGAGTGCCTGG’, congenita autosomal (p.Tyr139His) ‘GGCTYACGATGA recessive 1’, GTGCCTGGAGG’] ‘Dyskeratosis congenita, autosomal recessive 2’] NM_005857.4(ZMPSTE24): 121908093 ZMPSTE24 [ ] [ ] [‘Mandibuloacral c.1018T > C dysplasia with type (p.Trp340Arg) B lipodystrophy’, ‘not provided’] NM_001195794.1(CLRN1): 121908142 CLRN1 [ ] [ ] [‘Usher syndrome, c.488T > C type 3’] (p.Leu163Pro) NM_057176.2(BSND): 121908144 BSND [ ] [ ] [‘Sensorineural c.35T > C (p.Ile12Thr) deafness with mild renal dysfunction’] NM_001243133.1(NLRP3): 121908152 NLRP3 [ ] [ ] [‘Familial cold c.1718T > C urticaria’, ‘Chronic (p.Phe573Ser) infantile neurological, cutaneous and articular syndrome’] NM_001243133.1(NLRP3): 121908154 NLRP3 [ ] [‘GGTGCCTYTGAC [‘Familial cold c.926T > C GAGCACATAGG’] urticaria’, ‘Chronic (p.Phe309Ser) infantile neurological, cutaneous and articular syndrome’] NM_153741.1(DPM3): 121908155 DPM3 [ ] [ ] [‘Congenital disorder c.254T > C of glycosylation type (p.Leu85Ser) 1O’] NM_001033855.2(DCLRE1C): 121908158 DCLRE1C [ ] [‘GGCGCTAYGAG [‘Histiocytic c.2T > C TTCTTTCGAGGG’, medullary (p.Met1Thr) ‘GCGCTAYGAGTT reticulosis’] CTTTCGAGGGG’] NM_017696.2(MCM9): 587777871 MCM9 [ ] [ ] [‘Premature ovarian c.1732 + 2T > C failure 1’, ‘Ovarian dysgenesis 4’] NM_031433.3(MFRP): 121908190 — [ ] [ ] [‘Nanophthalmos 2’] c.545T > C (p.Ile182Thr) NM_001127221.1(CACNA1A): 121908213 CACNA1A [ ] [ ] [‘Familial c.2141T > C hemiplegic migraine (p.Val714Ala) type 1’] NM_001127221.1(CACNA1A): 121908233 CACNA1A [ ] [ ] [‘Episodic ataxia c.4469T > C type 2’] (p.Phe1490Ser) NM_133459.3(CCBE1): 121908254 CCBE1 [ ] [ ] [‘Hennekam c.520T > C lymphangiectasia- (p.Cys174Arg) lymphedema syndrome’] NM_018129.3(PNPO): 796052870 PNPO [ ] [‘CCCCCAYGACGT [‘not provided’] c.2T > C (p.Met1Thr) GCTGGCTGCGG’, ‘CCCCAYGACGTG CTGGCTGCGGG’, ‘CCCAYGACGTGC TGGCTGCGGGG’] NM_014845.5(FIG4): 121908287 FIG4 [ ] [ ] [‘Charcot-Marie- c.122T > C (p.Ile41Thr) Tooth disease, type 4J’, ‘not provided’] NM_001005741.2(GBA): 121908300 GBA [‘GCCA [‘GCCAGAYACTTT [‘Gaucher disease, c.751T > C GAYAC GTGAAGTAAGG’, type 1’] (p.Tyr251His) TTTGT ‘CCAGAYACTTTG GAAGT TGAAGTAAGGG’] AAGG’] NM_020427.2(SLURP1): 121908318 SLURP1 [ ] [‘GCAGCCYGGAG [Acroerythro- c.43T > C CATGGGCTGTGG’] keratoderma’] (p.Trp15Arg) NM_020427.2(SLURP1): 121908319 SLURP1 [ ] [ ] [‘Acroerythro- c.229T > C keratoderma’] (p.Cys77Arg) NM_000787.3(DBH): 74853476 DBH [ ] [ ] [‘Dopamine beta c.339 + 2T > C hydroxylase deficiency’] NM_017882.2(CLN6): 154774633 CLN6 [‘AGCY [‘AGCYGGTATTCC [‘Adult neuronal c.200T > C GGTAT CTCTCGAGTGG’] ceroid (p.Leu67Pro) TCCCT lipofuscinosis’, ‘not CTCGA provided’] GTGG’] NM_022124.5(CDH23): 121908352 CDH23 [ ] [‘CTCACCTYCAAC [‘Deafness, c.5663T > C ATCACTGCGGG’] autosomal recessive (p.Phe1888Ser) 12’] NM_054027.4(ANKH): 121908407 ANKH [‘GTCG [‘GTCGAGAYGCT [‘Chondrocalcinosis c.143T > C AGAYG GGCCAGCTACGG’, 2’] (p.Met48Thr) CTGGC ‘TCGAGAYGCTGG CAGCT CCAGCTACGGG’] ACGG’, ‘TCGAG AYGCT GGCCA GCTAC GGG’] NM_004924.4(ACTN4): 121908417 ACTN4 [ ] [ ] [‘Focal segmental c.784T > C glomerulosclerosis (p.Ser262Pro) 1’] NM_014384.2(ACAD8): 121908418 ACAD8 [ ] [ ] [‘Deficiency of c.455T > C isobutyryl-CoA (p.Met152Thr) dehydrogenase’] NM_153717.2(EVC): 121908426 EVC [ ] [ ] [‘Chondroectodermal c.919T > C dysplasia’, ‘Curry- (p.Ser307Pro) Hall syndrome’] NM_001040108.1(MLH3): 121908439 MLH3 [ ] [ ] [‘Hereditary c.3826T > C nonpolyposis (p.Trp1276Arg) colorectal cancer type 7’] NM_013339.3(ALG6): 121908444 ALG6 [ ] [ ] [‘Congenital disorder c.1432T > C of glycosylation type (p.Ser478Pro) 1C’] NM_003835.3(RGS9): 121908449 RGS9 [ ] [ ] [‘Prolonged c.895T > C electroretinal (p.Trp299Arg) response suppression’] NM_022336.3(EDAR): 121908451 EDAR [ ] [ ] [‘Autosomal c.259T > C recessive (p.Cys87Arg) hypohidrotic ectodermal dysplasia syndrome’] NM_014270.4(SLC7A9): 121908485 SLC7A9 [ ] [ ] [‘Cystinuria’] c.131T > C (p.Ile44Thr) NM_000030.2(AGXT): 121908520 AGXT [ ] [CCTGTACYCGGG [‘Primary c.613T > C CTCCCAGAAGG’] hyperoxaluria, type (p.Ser205Pro) I’] NM_000030.2(AGXT): 121908525 AGXT [ ] [ ] [‘Primary c.731T > C hyperoxaluria, type (p.Ile244Thr) I’] NM_000026.2(ADSL): 119450940 ADSL [ ] [ ] [‘Adenylosuccinate c.1312T > C lyase deficiency’] (p.Ser438Pro) NM_000026.2(ADSL): 119450945 ADSL [‘AAGA [‘AAGAYGGTGAC [‘Adenylosuccinate c.674T > C YGGTG AGAAAAGGCAGG’] lyase deficiency’] (p.Met225Thr) ACAGA AAAGG CAGG’] NM_014985.3(CEP152): 200879436 CEP152 [ ] [ ] [‘Seckel syndrome c.2000A > G 5’, ‘not specified’] (p.Lys667Arg) NM_002755.3(MAP2K1): 121908594 MAP2K1 [ ] [ ] [‘Cardiofaciocutaneous c.158T > C syndrome 3’, (p.Phe53Ser) ‘Rasopathy’] NM_004820.3(CYP7B1): 121908612 CYP7B1 [ ] [ ] [‘Spastic paraplegia c.647T > C 5A’] (p.Phe216Ser) NM_004273.4(CHST3): 121908616 CHST3 [ ] [ ] [‘Spondyloepiphyseal c.776T > C dysplasia with (p.Leu259Pro) congenital joint dislocations’] NM_004273.4(CHST3): 121908618 CHST3 [ ] [‘CGTGCYGGCCTC [‘Spondyloepiphyseal c.920T > C GCGCATGGTGG’] dysplasia with (p.Leu307Pro) congenital joint dislocations’] NM_004273.4(CHST3): 121908620 CHST3 [ ] [ ] [‘Spondyloepiphyseal c.857T > C dysplasia with (p.Leu286Pro) congenital joint dislocations’] NM_000050.4(ASS1): 121908646 ASS1 [ ] [ ] [ ] c.535T > C (p.Trp179Arg) NM_030761.4(WNT4): 121908653 WNT4 [ ] [ ] [‘Mullerian aplasia c.35T > C (p.Leu12Pro) and hyperandrogenism’] NM_006432.3(NPC2): 11694 NPC2 [ ] [‘TATTCAGYCTAA [‘Niemann-Pick c.199T > C (p.Ser67Pro) AAGCAGCAAGG’] disease type C2’] NM_003839.3(TNFRSF11A): 121908656 TNFRSF11A [ ] [ ] [‘Osteopetrosis c.523T > C autosomal recessive (p.Cys175Arg) 7’] NM_000022.2(ADA): 121908739 ADA [ ] [‘CCTGCYGGCCAA [‘Severe combined c.320T > C CTCCAAAGTGG’] immunodeficiency (p.Leu107Pro) due to ADA deficiency’] NM_000140.3(FECH): 2272783 FECH [ ] [ ] [‘Erythropoietic c.315-48T > C protoporphyria’] NM_000059.3(BRCA2): 80358979 BRCA2 [ ] [ ] [‘Familial cancer of c.7529T > C breast’, ‘Breast- (p .Leu2510Pro) ovarian cancer, familial 2’, ‘Fanconi anemia, complementation group D1’] NM_003722.4(TP63): 121908837 TP63 [ ] [ ] [‘Ectrodactyly, c.1033T > C ectodermal (p.Cys345Arg) dysplasia, and cleft lip/palate syndrome 3’] NM_003722.4(TP63): 121908845 TP63 [ ] [ ] [‘Hay-Wells c.1646T > C syndrome of (p.Ile549Thr) ectodermal dysplasia’, ‘Rapp- Hodgkin ectodermal dysplasia syndrome’] NM_000059.3(BRCA2): 80359022 BRCA2 [ ] [‘TGCYTCTTCAAC [‘Familial cancer of c.7958T > C TAAAATACAGG’] breast’, ‘Breast- (p.Leu2653Pro) ovarian cancer, familial 2’] NM_000369.2(TSHR): 121908861 TSHR [ ] [ ] [‘Hyperthyroidism, c.1891T > C nonautoimmune’, (p.Phe631Leu) ‘Thyroid adenoma, hyperfunctioning’] NM_000369.2(TSHR): 121908864 TSHR [ ] [ ] [‘Hyperthyroidism, c.1358T > C nonautoimmune’] (p.Met453Thr) NM_000369.2(TSHR): 121908874 TSHR [ ] [ ] [‘Hyperthyroidism, c.1526T > C nonautoimmune’] (p.Val509Ala) NM_000369.2(TSHR): 121908884 TSHR [ ] [ ] [‘Hypothyroidism, c.1798T > C congenital, (p.Cys600Arg) nongoitrous, 1’] NM_000369.2(TSHR): 121908885 TSHR [ ] [ ] [‘Hypothyroidism, c.1400T > C congenital, (p.Leu467Pro) nongoitrous, 1’] NM_001457.3(FLNB): 121908896 FLNB [ ] [ ] [‘Boomerang c.703T > C dysplasia’] (p.Ser235Pro) NM_003880.3(WISP3): 121908902 WISP3 [ ] [‘AAAATCYGTGCC [‘Progressive c.232T > C AAGCAACCAGG’, pseudorheumatoid (p.Cys78Arg) ‘AAATCYGTGCCA dysplasia’] AGCAACCAGGG’, ‘AATCYGTGCCAA GCAACCAGGGG’] NM_003880.3(WISP3): 121908903 WISP3 [ ] [ ] [‘Progressive c.1000T > C pseudorheumatoid (p.Ser334Pro) dysplasia’] NM_002977.3(SCN9A): 121908914 — [ ] [ ] [‘Paroxysmal c.4382T > C extreme pain (p.Ile1461Thr) disorder’] NM_004086.2(COCH): 121908929 — [ ] [ ] [‘Deafness, c.349T > C autosomal dominant (p.Trp117Arg) 9’] NM_004086.2(COCH): 121908934 — [‘AGAT [‘AGATAYGGCTTC [‘Deafness, c.1535T > C AYGGC TAAACCGAAGG’] autosomal dominant (p.Met512Thr) TTCTA 9’] AACCG AAGG’] NM_006892.3(DNMT3B): 121908947 DNMT3B [ ] [‘CAAGTTCYCCGA [‘Centromeric c.808T > C GGTGAGTCCGG’, instability of (p.Ser270Pro) ‘AAGTTCYCCGAG chromosomes 1,9 GTGAGTCCGGG’, and 16 and ‘AGTTCYCCGAGG immunodeficiency’] TGAGTCCGGGG’] NM_000226.3(KRT9): 61157095 KRT9 [ ] [ ] [‘Epidermolytic c.503T > C palmoplantar (p.Leu168Ser) keratoderma’, ‘not provided’] NM_000051.3(ATM): 730881326 — [ ] [ ] [‘Hereditary cancer- c.8584 + 2T > C predisposing syndrome’] NM_000492.3(CFTR): 121909028 CFTR [ ] [‘AGCCTYTGGAGT [‘Cystic fibrosis’] c.3857T > C GATACCACAGG’] (p.Phe1286Ser) NM_000492.3(CFTR): 121909041 CFTR [ ] [ ] [‘Cystic fibrosis’] c.3763T > C (p.Ser1255Pro) NM_001040667.2(HSF4): 121909048 HSF4 [ ] [ ] [‘Cataract, zonular’] c.341T > C (p.Leu114Pro) NM_005025.4(SERPINI1): 121909051 SERPINI1 [ ] [ ] [‘Familial c.145T > C encephalopathy with (p.Ser49Pro) neuroserpin inclusion bodies’] NM_002700.2(POU4F3): 121909057 POU4F3 [ ] [ ] [‘Deafness, c.668T > C autosomal dominant (p.Leu223Pro) 15’] NM_003322.4(TULP1): 121909074 TULP1 [ ] [ ] [‘Retinitis c.1471T > C pigmentosa 14’] (p.Phe491Leu) NM_003322.4(TULP1): 121909076 TULP1 [ ] [ ] [‘Retinitis c.1145T > C pigmentosa’, (p.Phe382Ser) ‘Retinitis pigmentosa 14’] NM_003000.2(SDHB): 33927012 SDHB [ ] [ ] [‘Pheochromocytom c.487T > C a’, ‘Hereditary (p.Ser163Pro) Paraganglioma- Pheochromocytoma Syndromes’, ‘Hereditary cancer- predisposing syndrome’, ‘Cowden syndrome 2’, ‘not specified’, ‘not provided’] NM_005603.4(ATP8B1): 121909099 ATP8B1 [ ] [ ] [‘Progressive c.863T > C intrahepatic (p.Leu288Ser) cholestasis’] NM_005603.4(ATP8B1): 121909100 ATP8B1 [ ] [ ] [‘Progressive c.1982T > C intrahepatic (p.Ile661Thr) cholestasis’, ‘Benign recurrent intrahepatic cholestasis 1’] NM_000483.4(APOC2): 120074115 — [ ] [ ] [‘Apolipoprotein C2 c.142T > C deficiency’] (p.Trp48Arg) NM_000543.4(SMPD1): 120074124 SMPD1 [‘CACY [AGCACYTGTGA [‘Sphingomyelin/cho c.911T > C TGTGA GGAAGTTCCTGG’, lesterol lipidosis’, (p.Leu304Pro) GGAAG ‘GCACYTGTGAGG ‘Niemann-Pick TTCCT AAGTTCCTGGG’, disease, type A’, GGGG1 ‘CACYTGTGAGGA ‘Niemann-Pick AGTTCCTGGGG’] disease, type B’, ‘not provided’] NM_000085.4(CLCNKB): 121909135 CLCNKB [ ] [‘CTTTGTCYATGG [‘Bartter syndrome c.1294T > C TGAGTCTGGGG’] type 3’] (p.Tyr432His) NM_001300.5(KLF6): 121909139 KLF6 [ ] [ ] [ ] c.346T > C (p.Ser116Pro) m.12338T > C 201863060 MT-NDS [ ] [ ] [‘Leber optic atrophy’] NM_001300.5(KLF6): 121909142 KLF6 [‘TCTGY [‘TCTGYGGACCAA [ ] c.190T > C GGACC AATCATTCTGG’] (p.Trp64Arg) AAAAT CATTC TGG’] NM_001300.5(KLF6): 121909143 KLF6 [ ] [‘GGAGCYGCCCTC [ ] c.506T > C GCCAGGGAAGG’] (p.Leu169Pro) NM_000271.4(NPC1): 120074136 NPC1 [ ] [ ] [‘Niemann-Pick c.337T > C disease type Cl’] (p.Cys113Arg) NM_000019.3(ACAT1): 120074146 ACAT1 [‘CAAG [‘CAAGAAYAGTA [‘Deficiency of c.935T > C AAYAG GGTAAGGCCAGG’] acetyl-CoA (p.Ile312Thr) TAGGT acetyltransferase’] AAGGC CAGG’] NM_017890.4(VPS13B): 120074155 VPS13B [ ] [ ] [‘Cohen syndrome’] c.8459T > C (p.Ile2820Thr) NM_017653.3(DYM): 120074165 DYM [ ] [ ] [‘Smith McCort c.1624T > C dysplasia’] (p.Cys542Arg) NM_001089.2(ABCA3): 121909182 ABCA3 [ ] [‘GCACYTGTGATC [‘Surfactant c.302T > C AACATGCGAGG’] metabolism (p.Leu101Pro) dysfunction, pulmonary, 3’] NM_001089.2(ABCA3): 121909183 ABCA3 [ ] [ ] [‘Surfactant c.4658T > C metabolism (p.Leu1553Pro) dysfunction, pulmonary, 3’] NM_001089.2(ABCA3): 121909185 ABCA3 [ ] [ ] [‘Surfactant c.977T > C metabolism (p.Leu326Pro) dysfunction, pulmonary, 3’] NM_000474.3(TWIST1): 121909189 TWIST1 [ ] [ ] [‘Saethre-Chotzen c.392T > C syndrome’] (p.Leu131Pro) NM_000503.5(EYA1): 121909200 EYA1 [ ] [‘CACTCYCGCTCA [‘Melnick-Fraser c.1459T > C TTCACTCCCGG’] syndrome’] (p.Ser487Pro) NM_000358.2(TGFBI): 121909214 TGFBI [ ] [ ] [‘Lattice corneal c.1619T > C dystrophy type 3A’] (p.Phe540Ser) NM_000426.3(LAMA2): 115650537 LAMA2 [‘TTGA [‘TTGAYAGGGAG [‘Merosin deficient c.8282T > C YAGGG CAAGCAGTTCGG’, congenital muscular (p.Ile2761Thr) AGCAA ‘TGAYAGGGAGCA dystrophy’] GCAGT AGCAGTTCGGG’] TCGG’, ‘TGAYA GGGAG CAAGC AGTTC GGG’] NM_000314.6(PTEN): 121909226 PTEN [ ] [ ] [‘Cowden syndrome c.209T > C 1’, ‘Hereditary (p.Leu70Pro) cancer-predisposing syndrome’] NM_000314.6(PTEN): 121909230 PTEN [ ] [ ] [‘Lhermitte-Duclos c.335T > C disease’] (p.Leull2Pro) NM_000314.6(PTEN): 121909240 PTEN [ ] [ ] [‘Macrocephaly/autis c.722T > C m syndrome’] (p.Phe241Ser) NM_004970.2(IGFALS): 121909247 IGFALS [ ] [‘GGACYGTGGCT [‘Acid-labile subunit c.1618T > C GCCCTCTCAAGG’] deficiency’] (p.Cys540Arg) NM_005570.3(LMAN1): 121909253 LMAN1 [ ] [AGAYGGCGGGA [‘Combined c.2T > C (p.Met1Thr) TCCAGGCAAAGG’] deficiency of factor V and factor VIII, 1’] NM_005055.4(RAPSN): 121909256 RAPSN [ ] [ ] [‘Pena-Shokeir c.416T > C syndrome type I’] (p.Phe139Ser) NM_000391.3(TPP1): 755445790 TPP1 [‘TTTYT [‘TTTYTTTTTTTTT [‘Ceroid c.887-10A > G TTTTTT TTTTTTGAGG’] lipofuscinosis, TTTTTT neuronal, 2’, ‘not TTGAG provided’] G’] NM_006302.2(MOGS): 121909292 MOGS [ ] [ ] [‘Congenital disorder c.1954T > C of glycosylation type (p.Phe652Leu) 2B’] NM_005379.3(MYO1A): 121909306 MYO1A [ ] [ ] [‘Deafness, c.2728T > C autosomal dominant (p.Ser910Pro) 48’] NM_178151.2(DCX): 587783521 DCX [ ] [ ] [‘Heterotopia’] c.128T > C (p.Leu43Ser) NM_001127221.1(CACNA1A): 121909326 CACNA1A [ ] [ ] [‘Spinocerebellar c.5126T > C ataxia 6’, ‘Familial (p.Ile1709Thr) hemiplegic migraine type 1’, ‘Episodic ataxia type 2’] NM_001451.2(FOXF1): 121909337 FOXF1 [‘TGAT [‘TGATGYGAGGCT [‘Alveolar capillary c.1138T > C GYGAG GCCGCCGCAGG’] dysplasia with (p.Ter380Arg) GCTGC misalignment of CGCCG pulmonary veins’] CAGG’] NM_000163.4(GHR): 121909357 GHR [ ] [ ] [‘Laron-type isolated c.341T > C somatotropin (p.Phel 14Ser) defect’] NM_000163.4(GHR): 121909367 GHR [ ] [ ] [‘Laron-type isolated c.512T > C (p.Ile171Thr) somatotropin defect’] NM_000339.2(SLC12A3): 121909385 SLC12A3 [ ] [CAACCYGGCCCT [‘Familial c.1868T > C CAGCTACTCGG’] hypokalemia- (p.Leu623Pro) hypomagnesemia’] NM_001174089.1(SLC4A11): 121909394 SLC4A11 [ ] [ ] [‘Corneal dystrophy c.2480T > C and perceptive (p.Leu827Pro) deafness’] NM_001174089.1(SLC4A11): 121909395 SLC4A11 [ ] [ ] [‘Corneal dystrophy c.589T > C and perceptive (p.Ser197Pro) deafness’] NM_000519.3(HBD): 34975911 HBD [ ] [ ] [‘delta Thalassemia’] c.-127T > C NM_002427.3(MMP13): 121909497 MMP13 [ ] [‘TTCTYCGGCTTA [‘Spondyloepimetap c.224T > C GAGGTGACTGG’] hyseal dysplasia, (p.Phe75Ser) Missouri type’] NM_002427.3(MMP13): 121909498 MMP13 [ ] [ ] [ ] c.221T > C (p.Phe74Ser) NM_002427.3(MMP13): 121909499 MMP13 [‘GTCA [‘GTCAYGAAAAA [ ] c.272T > C YGAAA GCCAAGATGCGG’, (p.Met91Thr) AAGCC ‘TCAYGAAAAAGC AAGAT CAAGATGCGGGG] GCGG’, ‘TCAYG AAAAA GCCAA GATGC GGG’] NM_000751.2(CHRND): 121909506 CHRND [ ] [ ] [‘Lethal multiple c.283T > C pterygium (p.Phe95Leu) syndrome’] NM_000751.2(CHRND): 121909508 CHRND [ ] [‘AACCYCATCTCC [‘MYASTHENIC c.188T > C CTGGTGAGAGG’] SYNDROME, (p.Leu63Pro) CONGENITAL, 3B, FAST-CHANNEL’] NM_001100.3(ACTA1): 121909519 ACTA1 [ ] [‘CGAGCYTCGCGT [‘Nemaline c.287T > C GGCTCCCGAGG’] myopathy 3’] (p.Leu96Pro) NM_001100.3(ACTA1): 121909530 ACTA1 [ ] [ ] [‘Congenital c.668T > C myopathy with fiber (p.Leu223Pro) type disproportion’] NM_000488.3(SERPINC1): 121909565 SERPINC1 [ ] [ ] [‘Antithrombin III c.1141T > C deficiency’] (p.Ser381Pro) NM_000488.3(SERPINC1): 121909569 SERPINC1 [ ] [ ] [‘Antithrombin III c.442T > C deficiency’] (p.Ser148Pro) NM_000488.3(SERPINC1): 121909572 SERPINC1 [ ] [‘TGGGTGYCCAAT [‘Antithrombin III c.667T > C AAGACCGAAGG’] deficiency’] (p.Ser223Pro) NM_000488.3(SERPINC1): 121909573 SERPINC1 [ ] [ ] [‘Antithrombin III c.379T > C deficiency’] (p.Cys127Arg) NM_023110.2(FGFR1): 121909633 FGFR1 [ ] [ ] [‘Interfrontal c.899T > C craniofaciosynostosi (p.Ile300Thr) s’] NM_023110.2(FGFR1): 121909634 FGFR1 [ ] [ ] [‘Osteoglophonic c.1141T > C dysplasia’] (p.Cys381Arg) NM_182925.4(FLT4): 121909651 FLT4 [ ] [ ] [‘Hereditary c.3131T > C lymphedema type I’] (p.Leu1044Pro) NM_182925.4(FLT4): 121909655 FLT4 [ ] [ ] [‘Hereditary c.3257T > C lymphedema type I’] (p.Ile1086Thr) NM_000145.3(FSHR): 121909659 FSHR [ ] [ ] [‘Ovarian dysgenesis c.479T > C l’] (p.Ile160Thr) NM_000145.3(FSHR): 121909664 FSHR [ ] [ ] [‘Ovarian c.1634T > C hyperstimulation (p.Ile545Thr) syndrome’] NM_000821.6(GGCX): 121909677 GGCX [ ] [‘TATGTYCTCCTA [‘Pseudoxanthoma c.896T > C CGTCATGCTGG’] elasticum-like (p.Phe299Ser) disorder with multiple coagulation factor deficiency’] NM_001018077.1(NR3C1): 121909727 NR3C1 [ ] [‘CTATTGCYTCCA [‘Glucocorticoid c.2209T > C AACATTTTTGG’] resistance, (p.Phe737Leu) generalized’] NM_005271.3(GLUD1): 121909732 GLUD1 [ ] [ ] [‘Hyperinsulinism- c.1501T > C hyperammonemia (p.Ser501Pro) syndrome’] NM_004614.4(TK2): 142291440 TK2 [ ] [ ] [‘Mitochondrial c.278A > G (p.Asn93Ser) DNA depletion syndrome 2’] NM_032977.3(CASP10): 121909776 CASP10 [ ] [ ] [‘Neoplasm of c.440T > C stomach’] (p.Met147Thr) NM_000250.1(MPO): 78950939 MPO [‘TGCG [‘GTGCGGYATTTG [‘Myeloperoxidase c.518A > G GYATT TCCTGCTCCGG’, deficiency’] (p.Tyr173Cys) TGTCC ‘TGCGGYATTTGT TGCTC CCTGCTCCGGG’] CGGG’] NM_001139.2(ALOX12B): 199766569 ALOX12B [ ] [ ] [‘Autosomal c.1562A > G recessive congenital (p.Tyr521Cys) ichthyosis 2’] NM_022041.3(GAN): 119485091 GAN [‘AAGA [‘AAGAAAAYCTA [‘Giant axonal c.1268T > C AAAYC CGCCATGGGTGG’, neuropathy’] (p.Ile423Thr) TACGC ‘AAAAYCTACGCC CATGG ATGGGTGGAGG’] GTGG’] NM_014009.3(FOXP3): 122467173 FOXP3 [‘GACA [‘GACAGAGYTCCT [‘Insulin-dependent c.970T > C GAGYT CCACAACATGG’] diabetes mellitus (p.Phe324Leu) CCTCC secretory diarrhea ACAAC syndrome’] ATGG’] NM_014009.3(FOXP3): 122467175 FOXP3 [ ] [ ] [‘Insulin-dependent c.1099T > C diabetes mellitus (p.Phe367Leu) secretory diarrhea syndrome’] NM_004239.3(TRIP11): 139539448 TRIP11 [ ] [ ] [‘Achondrogenesis, c.2102A > G type IA’] (p.Asn701Ser) NM_001104.3(ACTN3): 1815739 ACTN3 [ ] [ ] [‘Sprinting c.1729C > T performance’, ‘Actn3 (p.Arg577Ter) deficiency’] NM_002693.2(POLG): 368587966 POLG [ ] [ ] [‘not provided’] c.2636A > G (p.Gln879Arg) NM_000552.3(VWF): 61748497 VWF [ ] [ ] [‘von Willebrand c.3178T > C disease type 2N’, (p.Cys1060Arg) ‘not provided’] NM_000552.3(VWF): 61748511 VWF [ ] [ ] [‘von Willebrand c.3445T > C disease type 1’, ‘not (p.Cys1149Arg) provided’] NM_000184.2(HBG2): 34878913 HBG2 [‘CAGA [‘CAGAGGTYCTTT [‘Cyanosis, transient c.125T > C GGTYC GACAGCTTTGG’] neonatal’] (p.Phe42Ser) TTTGA CAGCT TTGG’] NM_000371.3(TTR): 138065384 TTR [ ] [ ] [‘Cardiomyopathy’, c.190T > C (p.Phe64Leu) ‘not specified’] NM_000402.4(G6PD): 76723693 G6PD [ ] [ ] [‘Glucose 6 c.1058T > C phosphate (p.Leu353Pro) dehydrogenase deficiency’, ‘Anemia, nonspherocytic hemolytic, due to G6PD deficiency’, ‘not provided’] NM_177405.2(CECR1): 775440641 CECR1 [ ] [ ] [‘Idiopathic livedo c.355A > G reticularis with (p.Thr119Ala) systemic involvement’] NM_000218.2(KCNQ1): 199472685 KCNQ1 [‘Congenital long c.401T > C QT syndrome’, (p.Leu134Pro) ‘Cardiac arrhythmia’] NM_000218.2(KCNQ1): 199472705 KCNQ1 [‘Atrial fibrillation, c.625T > C familial, 3’, ‘Atrial (p.Ser209Pro) fibrillation’] NM_000218.2(KCNQ1): 199472716 KCNQ1 [‘Congenital long c.752T > C QT syndrome’, (p.Leu251Pro) ‘Cardiac arrhythmia’, ‘Long QT syndrome, LQT1 subtype’] NM_000218.2(KCNQ1): 199472729 KCNQ1 [‘Congenital long c.824T > C QT syndrome’, (p.Phe275Ser) ‘Long QT syndrome, LQT1 subtype’] NM_000218.2(KCNQ1): 199472731 KCNQ1 [‘Congenital long c.832T > C QT syndrome’] (p.Tyr278His) NM_000218.2(KCNQ1): 199472733 KCNQ1 [‘Congenital long c.845T > C QT syndrome’] (p.Leu282Pro) NM_000257.3(MYH7): 730880849 MYH7 [ ] [ ] [‘Cardiomyopathy’] c.730T > C (p.Phe244Leu) NM_000218.2(KCNQ1): 199472740 KCNQ1 [‘Congenital long c.908T > C QT syndrome’] (p.Leu303Pro) NM_000218.2(KCNQ1): 199472741 KCNQ1 [‘Congenital long c.913T > C QT syndrome’, (p.Trp305Arg) ‘Long QT syndrome, LQT1 subtype’] NM_000218.2(KCNQ1): 199472764 KCNQ1 [‘Congenital long c.1045T > C QT syndrome’, (p.Ser349Pro) ‘Long QT syndrome, LQT1 subtype’] NM_000218.2(KCNQ1): 199472766 KCNQ1 [‘Congenital long c.1117T > C QT syndrome’] (p.Ser373Pro) NM_000218.2(KCNQ1): 199472772 KCNQ1 [‘Congenital long c.1165T > C QT syndrome’] (p.Ser389Pro) NM_000218.2(KCNQ1): 199472774 KCNQ1 [‘Congenital long c.1174T > C QT syndrome’] (p.Trp392Arg) NM_000218.2(KCNQ1): 199472786 KCNQ1 [‘Congenital long c.1541T > C QT syndrome’, (p.Ile514Thr) ‘Long QT syndrome, LQT1 subtype’] NM_000218.2(KCNQ1): 199472803 KCNQ1 [‘Congenital long c.1696T > C QT syndrome’] (p.Ser566Pro) NM_000218.2(KCNQ1): 199472818 — [‘Congenital long c.1805T > C QT syndrome’] (p.Leu602Pro) NM_000218.2(KCNQ1): 199472823 KCNQ1 [‘Congenital long c.608T > C QT syndrome’, (p.Leu203Pro) ‘Cardiac arrhythmia’] NM_000238.3(KCNH2): 199472826 KCNH2 [‘Congenital long c.65T > C QT syndrome’] (p.Phe22Ser) NM_000238.3(KCNH2): 199472831 KCNH2 [‘Congenital long c.86T > C QT syndrome’] (p.Phe29Ser) NM_000238.3(KCNH2): 199472832 KCNH2 [‘Congenital long c.89T > C QT syndrome’] (p.Ile30Thr) NM_000238.3(KCNH2): 199472843 KCNH2 [‘Congenital long c.160T > C QT syndrome’] (p.Tyr54His) NM_001165963.1(SCN1A): 796052961 SCN1A [ ] [ ] [‘not provided’] c.662T > C (p.Leu221Pro) NM_000238.3(KCNH2): 199472853 KCNH2 [‘Congenital long c.287T > C QT syndrome’] (p.Ile96Thr) NM_000238.3(KCNH2): 199472859 KCNH2 [‘Congenital long c.322T > C QT syndrome’] (p.Cys108Arg) NM_000238.3(KCNH2): 199472881 KCNH2 [‘Congenital long c.872T > C QT syndrome’] (p.Met291Thr) NM_000238.3(KCNH2): 199472893 KCNH2 [‘Congenital long c.1238T > C QT syndrome’] (p.Leu413Pro) NM_000238.3(KCNH2): 199472898 KCNH2 [‘Congenital long c.1279T > C QT syndrome’] (p.Tyr427His) NM_000238.3(KCNH2): 199472904 KCNH2 [‘Congenital long c.1387T > C QT syndrome’] (p.Phe463Leu) NM_000238.3(KCNH2): 199472918 KCNH2 [ ] [ ] [‘Congenital long c.1655T > C QT syndrome’, (p.Leu552Ser) ‘Cardiac arrhythmia’] NM_000061.2(BTK): 128622212 BTK [ ] [ ] [‘X-linked c.1955T > C agammaglobulinemi (p.Leu652Pro) a’] NM_000238.3(KCNH2): 199472924 KCNH2 [‘Congenital long c.1691T > C QT syndrome’] (p.Leu564Pro) NM_000238.3(KCNH2): 199472927 KCNH2 [‘Congenital long c.1702T > C QT syndrome’] (p.Trp568Arg) NM_000138.4(FBN1): 794728333 FBN1 [ ] [ ] [‘Thoracic aortic c.5726T > C aneurysms and (p.Ile1909Thr) aortic dissections’] NM_015884.3(MBTPS2): 122468179 MBTPS2 [ ] [ ] [‘IFAP syndrome c.1424T > C with or without (p.Phe475Ser) BRESHECK syndrome’] NM_000238.3(KCNH2): 199472980 KCNH2 [‘Congenital long c.1985T > C QT syndrome’] (p.Ile662Thr) NM_000238.3(KCNH2): 199472981 KCNH2 [‘Congenital long c.2033T > C QT syndrome’] (p.Leu678Pro) NM_000238.3(KCNH2): 199472983 KCNH2 [‘Congenital long c.2078T > C QT syndrome’, (p.Leu693Pro) ‘Cardiac arrhythmia’] NM_000238.3(KCNH2): 199472994 KCNH2 [‘Congenital long c.2309T > C QT syndrome’] (p.Val770Ala) NM_000238.3(KCNH2): 199473026 KCNH2 [‘Congenital long c.3146T > C QT syndrome’] (p.Leu1049Pro) NM_000335.4(SCN5A): 199473052 SCN5A [‘Brugada c.278T > C syndrome’] (p.Phe93Ser) NM_000335.4(SCN5A): 199473066 SCN5A [‘Brugada c.544T > C syndrome’] (p.Cys182Arg) NM_000335.4(SCN5A): 199473073 SCN5A [‘Cardiac conduction c.689T > C defect, nonspecific’] (p.Ile230Thr) NM_000335.4(SCN5A): 199473103 SCN5A [‘Brugada c.1187T > C syndrome’] (p.Val396Ala) NM_000335.4(SCN5A): 199473105 SCN5A [‘Congenital long c.1190T > C QT syndrome’] (p.Ile397Thr) NM_000335.4(SCN5A): 199473141 SCN5A [‘Congenital long c.2018T > C QT syndrome’] (p.Leu673Pro) NM_000335.4(SCN5A): 199473164 SCN5A [‘Brugada c.2516T > C syndrome’] (p.Leu839Pro) NM_000335.4(SCN5A): 199473178 SCN5A [‘Brugada c.2783T > C syndrome’] (p.Leu928Pro) NM_000335.4(SCN5A): 199473179 SCN5A [‘Brugada c.2804T > C syndrome’] (p.Leu935Pro) NM_198056.2(SCN5A): 199473183 SCN5A [ ] [ ] [‘Congenital long c.3010T > C QT syndrome’, ‘not (p.Cys1004Arg) specified’, ‘not provided’] NM_000335.4(SCN5A): 199473205 SCN5A [ ] [ ] [‘Brugada c.3679T > C syndrome’] (p.Tyr1227His) NM_000335.4(SCN5A): 199473210 SCN5A [‘Brugada c.3713T > C syndrome’] (p.Leu1238Pro) NM_000492.3(CFTR): 139573311 CFTR [ ] [‘TTCACYTCTAAT [‘Cystic fibrosis’] c.1400T > C GGTGATTATGG’, (p.Leu467Pro) ‘TCACYTCTAATG GTGATTATGGG’] NM_000335.4(SCN5A): 199473219 SCN5A [‘Brugada c.3929T > C syndrome’] (p.Leu1310Pro) NM_000335.4(SCN5A): 199473228 SCN5A [‘Brugada c.4027T > C syndrome’] (p.Phe1343Leu) NM_000335.4(SCN5A): 199473229 SCN5A [‘Brugada c.4028T > C syndrome’] (p.Phe1343Ser) NM_000335.4(SCN5A): 199473231 SCN5A [‘Brugada c.4034T > C syndrome’] (p.Leu1345Pro) NM_000335.4(SCN5A): 199473251 SCN5A [‘Brugada c.4340T > C syndrome’] (p.Ile1447Thr) NM_198056.2(SCN5A): 199473263 SCN5A [‘Congenital long c.4493T > C QT syndrome’, ‘not (p.Met1498Thr) provided’] NM_000335.4(SCN5A): 199473275 SCN5A [‘Brugada c.4742T > C syndrome’] (p.Leu1581Pro) NM_000335.4(SCN5A): 199473277 SCN5A [‘Congenital long c.4778T > C QT syndrome’] (p.Phe1593Ser) NM_000335.4(SCN5A): 199473302 SCN5A [‘Brugada c.5179T > C syndrome’] (p.Cys1727Arg) NM_000219.5(KCNE1): 199473355 KCNE1 [‘Congenital long c.158T > C QT syndrome’] (p.Phe53Ser) NM_000219.5(KCNE1): 199473361 KCNE1 [‘Congenital long c.259T > C QT syndrome’] (p.Trp87Arg) NM_000891.2(KCNJ2): 199473374 KCNJ2 [‘Ventricular c.301T > C tachycardia’] (p.Cys101Arg) NM_000218.2(KCNQ1): 199473399 KCNQ1 [ ] [ ] [‘Congenital long c.560T > C QT syndrome’, (p.Leu187Pro) ‘Cardiac arrhythmia’, ‘Long QT syndrome, LQT1 subtype’] NM_000218.2(KCNQ1): 199473401 KCNQ1 [‘Congenital long c.572T > C QT syndrome’, (p.Leu191Pro) ‘Long QT syndrome, LQT1 subtype’] NM_000218.2(KCNQ1): 199473402 KCNQ1 [‘Congenital long c.1052T > C QT syndrome’, (p.Phe351Ser) ‘Long QT syndrome, LQT1 subtype’] NM_000218.2(KCNQ1): 199473403 KCNQ1 [‘Congenital long c.1058T > C QT syndrome’, (p.Leu353Pro) ‘Cardiac arrhythmia’, ‘Long QT syndrome, LQT1 subtype’] NM_000238.3(KCNH2): 199473417 KCNH2 [‘Congenital long c.202T > C QT syndrome’, (p.Phe68Leu) ‘Cardiac arrhythmia’] NM_000218.2(KCNQ1): 199473448 KCNQ1 [‘Congenital long c.341T > C QT syndrome’, (p.Leull4Pro) ‘Long QT syndrome, LQT1 subtype’] NM_000218.2(KCNQ1): 199473458 KCNQ1 [‘Congenital long c.716T > C QT syndrome’, (p.Leu239Pro) ‘Long QT syndrome, LQT1 subtype’] NM_000218.2(KCNQ1): 199473459 KCNQ1 [‘Congenital long c.742T > C QT syndrome’, (p.Trp248Arg) ‘Cardiac arrhythmia’] NM_000218.2(KCNQ1): 199473460 KCNQ1 [‘Long QT c.797T > C syndrome’, (p.Leu266Pro) ‘Congenital long QT syndrome’, ‘Cardiac arrhythmia’] NM_000218.2(KCNQ1): 199473461 KCNQ1 [‘Congenital long c.829T > C QT syndrome’] (p.Ser277Pro) NM_000218.2(KCNQ1): 199473466 KCNQ1 [‘Congenital long c.910T > C QT syndrome’, (p.Trp304Arg) ‘Long QT syndrome, LQT1 subtype’] NM_000218.2(KCNQ1): 199473478 KCNQ1 [‘Congenital long c.1550T > C QT syndrome’] (p.Ile517Thr) NM_000218.2(KCNQ1): 199473481 KCNQ1 [‘Congenital long c.1661T > C QT syndrome’, (p.Val554Ala) ‘Long QT syndrome, LQT1 subtype’] NM_000218.2(KCNQ1): 199473485 KCNQ1 [‘Congenital long c.2T > C (p.Met1Thr) QT syndrome’, ‘KCNQ1-related Jervell and Lange- Nielsen syndrome’] NM_000238.3(KCNH2): 199473495 KCNH2 [‘Congenital long c.260T > C QT syndrome’] (p.Leu87Pro) NM_000238.3(KCNH2): 199473519 KCNH2 [‘Congenital long c.1700T > C QT syndrome’] (p.Ile567Thr) NM_000238.3(KCNH2): 199473520 KCNH2 [‘Congenital long c.1705T > C QT syndrome’] (p.Tyr569His) NM_000238.3(KCNH2): 199473523 KCNH2 [‘Congenital long c.1816T > C QT syndrome’] (p.Ser606Pro) NM_000238.3(KCNH2): 199473526 KCNH2 [‘Congenital long c.1889T > C QT syndrome’] (p.Val630Ala) NM_000238.3(KCNH2): 199473530 KCNH2 [‘Congenital long c.1945T > C QT syndrome’] (p.Ser649Pro) NM_000238.3(KCNH2): 199473537 KCNH2 [‘Congenital long c.2452T > C QT syndrome’] (p.Ser818Pro) NM_000238.3(KCNH2): 199473539 KCNH2 [‘Congenital long c.2573T > C QT syndrome’] (p.Ile858Thr) NM_000335.4(SCN5A): 199473557 SCN5A [‘Brugada c.407T > C syndrome’] (p.Leu136Pro) NM_020166.4(MCCC1): 119103215 MCCC1 [ ] [ ] [‘3 Methylcrotonyl- c.1310T > C CoA carboxylase 1 (p.Leu437Pro) deficiency’] NM_198056.2(SCN5A): 199473564 SCN5A [‘Brugada c.944T > C syndrome’, ‘not (p.Leu315Pro) provided’] NM_002972.3(SBF1): 587776986 SBF1 [ ] [ ] [‘Charcot-Marie- c.1249A > G Tooth disease, type (p.Met417Val) 4B3’] NM_000335.4(SCN5A): 199473586 SCN5A [‘Brugada c.2551T > C syndrome’] (p.Phe851Leu) NM_000335.4(SCN5A): 199473588 SCN5A [‘Brugada c.2743T > C syndrome’] (p.Cys915Arg) NM_000335.4(SCN5A): 199473607 SCN5A [‘Brugada c.4046T > C syndrome’] (p.Ile1349Thr) NM_000335.4(SCN5A): 199473615 SCN5A [‘Sudden infant c.4453T > C death syndrome’] (p.Phe1485Leu) NM_000335.4(SCN5A): 199473627 SCN5A [‘Sudden infant c.5111T > C death syndrome’] (p.Phe1704Ser) NM_000891.2(KCNJ2): 199473656 KCNJ2 [‘Congenital long c.650T > C QT syndrome’] (p.Leu217Pro) NM_000218.2(KCNQ1): 199473661 KCNQ1 [‘AGCA [‘CAGCAAGBACG [‘Congenital long c.550T > C AGBAC TGGGCCTCTGGG’, QT syndrome’, (p.Tyr184His) GTGGG ‘AGCAAGBACGTG ‘Cardiac arrhythmia’] CCTCT GGCCTCTGGGG’, GGGG’] ‘GCAAGBACGTGG GCCTCTGGGGG’] NM_000238.3(KCNH2): 199473665 KCNH2 [‘Congenital long c.206T > C QT syndrome’] (p.Leu69Pro) NM_001130823.1(DNMT1): 199473692 DNMT1 [‘Hereditary sensory c.1531T > C neuropathy type IE’] (p.Tyr511His) NM_031226.2(CYP19Al): 786205107 — [‘CTGTG [‘CTGTGYAAGTAA [‘Aromatase c.743 + 2T > C YAAGT TACAACTTTGG’] deficiency’] AATAC AACTT TGG’] NM_016373.3(WW0X): 119487098 WWOX [ ] [ ] [ ] c.872T > C (p.Leu291Pro) NM_001287223.1(SCN11A): 606231280 SCN11A [‘TTCAY [‘CTTCAYTGTGGT [‘Episodic pain c.1142T > C TGTGG CATTTTCCTGG’, syndrome, familial, (p.Ile381Thr) TCATTT ‘TTCAYTGTGGTC 3’] TCCTG ATTTTCCTGGG’] GG’] NM_003640.3(IKBKAP): 111033171 IKBKAP [ ] [ ] [‘Familial c.2204 + 6T > C dysautonomia’, ‘not provided’] NM_000238.3(KCNH2): 794728368 KCNH2 [ ] [ ] [‘Cardiac c.1282T > C arrhythmia’] (p.Ser428Pro) NM_000441.1(SLC26A4): 111033254 SLC26A4 [ ] [ ] [‘Pendred syndrome’, c.1588T > C ‘Enlarged vestibular (p.Tyr530His) aqueduct syndrome’] NM_206933.2(USH2A): 111033264 USH2A [ ] [ ] [‘Usher syndrome, c.10561T > C type 2A’] (p.Trp3521Arg) NM_206933.2(USH2A): 111033273 USH2A [‘ATAT [‘ATATAGAYGCCT [‘Usher syndrome, c.1606T > C AGAYG CTGCTCCCAGG’] type 2A’] (p.Cys536Arg) CCTCT GCTCC CAGG’] NM_001363.4(DKC1): 121912300 DKC1 [ ] [ ] [‘Dyskeratosis c.1049T > C congenita X-linked’] (p.Met350Thr) NM_000274.3(OAT): 121965054 OAT [ ] [ ] [Ornithine c.1180T > C aminotransferase (p.Cys394Arg) deficiency’] NM_001302946.1(TRNT1): 606231289 TRNT1 [‘ACTTY [‘ACTTYATTTGAC [‘Sideroblastic c.497T > C ATTTG TACTTTAATGG’] anemia with B-cell (p.Leu166Ser) ACTAC immunodeficiency, TTTAA periodic fevers, and TGG’] developmental delay’] NM_000454.4(SOD1): 121912441 SOD1 [ ] [‘CATCAYTGGCCG [‘Amyotrophic c.341T > C CACACTGGTGG’] lateral sclerosis type (p.Ile114Thr) l’] NM_000454.4(SOD1): 121912446 SOD1 [ ] [‘CGTTYGGCTTGT [‘Amyotrophic c.434T > C GGTGTAATTGG’, lateral sclerosis type (p.Leu145Ser) ‘GTTYGGCTTGTG l’] GTGTAATTGGG’] NM_000454.4(SOD1): 121912449 SOD1 [ ] [ ] [‘Amyotrophic c.455T > C lateral sclerosis type (p.Ile152Thr) l’] NM_000213.3(ITGB4): 121912461 ITGB4 [ ] [ ] [‘Epidermolysis c.467T > C bullosa with pyloric (p.Leu156Pro) atresia’] NM_000213.3(ITGB4): 121912463 ITGB4 [ ] [‘GGCCAGYGTGT [‘Epidermolysis c.1684T > C GTGTGAGCCTGG’] bullosa with pyloric (p.Cys562Arg) atresia’] NM_000213.3(ITGB4): 121912465 ITGB4 [ ] [ ] [‘Epidermolysis c.112T > C bullosa with pyloric (p.Cys38Arg) atresia’] NM_002198.2(IRF1): 121912470 IRF1 [ ] [ ] [‘Non-small cell lung c.31T > C (p.TrpllArg) cancer’] NM_000424.3(KRT5): 121912474 KRT5 [‘TCAA [‘TCAAGTGYGTCC [‘Epidermolysis c.20T > C (p.Val7Ala) GTGYG TTCCGGAGCGG’, bullosa simplex, TCCTTC ‘CAAGTGYGTCCT Koebner type’] CGGAG TCCGGAGCGGG’, CGG’, ‘AAGTGYGTCCTT ‘CAAGT CCGGAGCGGGG’, GYGTC ‘AGTGYGTCCTTC CTTCC CGGAGCGGGGG’] GGAGC GGG’, ‘AAGTG YGTCC TTCCG GAGCG GGG’] NM_002292.3(LAMB2): 121912492 LAMB2 [ ] [CCTCAACYGCGA [‘Nephrotic c.961T > C GCAGTGTCAGG’] syndrome, type 5, (p.Cys321Arg) with or without ocular abnormalities’] NM_170707.3(LMNA): 121912495 LMNA [‘TCTYG [‘TCTYGGAGGGC [‘Congenital c.1139T > C GAGGG GAGGAGGAGAGG’] muscular dystrophy, (p.Leu380Ser) CGAGG LMNA-related’, ‘not AGGAG provided’] AGG’] NM_001399.4(EDA): 397516659 EDA [ ] [‘GGCCAYGGGCT [‘Hypohidrotic X- c.2T > C (p.Met1Thr) ACCCGGAGGTGG’] linked ectodermal dysplasia’] NM_000493.3(C0L10Al): 111033549 — [ ] [ ] [‘Metaphyseal c.1951T > C chondrodysplasia, (p.Trp651Arg) Schmid type’] NM_000233.3(LHCGR): 121912526 — [ ] [ ] [‘Gonadotropin- c.1193T > C independent familial (p.Met398Thr) sexual precocity’] NM_000233.3(LHCGR): 121912527 — [ ] [ ] [‘Leydig cell c.391T > C hypoplasia, partial’] (p.Cys131Arg) NM_000493.3(COL10Al): 111033555 — [ ] [ ] [‘Metaphyseal c.1798T > C chondrodysplasia, (p.Ser600Pro) Schmid type’] NM_000233.3(LHCGR): 121912533 — [ ] [ ] [‘Gonadotropin- c.1103T > C independent familial (p.Leu368Pro) sexual precocity’] NM_000233.3(LHCGR): 121912537 — [ ] [ ] [‘Leydig cell c.1627T > C agenesis’] (p.Cys543Arg) NM_000233.3(LHCGR): 121912538 — [ ] [ ] [‘Leydig cell c.1505T > C agenesis’] (p.Leu502Pro) NM_000901.4(NR3C2): 121912563 NR3C2 [ ] [ ] [‘Pseudohypoaldoste c.2771T > C ronism type 1 (p.Leu924Pro) autosomal dominant’] NM_021044.2(DHH): 111033589 DHH [ ] [‘GTTGCYGGCGCG [‘46,XY gonadal c.485T > C CCTCGCAGTGG’] dysgenesis, (p.Leu162Pro) complete, dhh- related’] NM_000901.4(NR3C2): 121912567 NR3C2 [ ] [ ] [‘Pseudohypoaldoste c.2936T > C ronism type 1 (p.Leu979Pro) autosomal dominant’] NM_000517.4(HBA2): 111033603 HBA2 [ ] [ ] [‘alpha Thalassemia’] c.2T > C (p.Met1Thr) NM_000762.5(CYP2A6): 111033610 — [ ] [ ] [‘Tegafur response’] c.670T > C (p.Ser224Pro) NM_000660.5(TGFB1): 111033611 TGFB1 [ ] [ ] [‘Diaphyseal c.241T > C dysplasia’] (p.Tyr81His) NM_001173464.1(KIF21A): 121912588 KIF21A [ ] [ ] [‘Fibrosis of c.1067T > C extraocular muscles, (p.Met356Thr) congenital, 1’] NM_000206.2(IL2RG): 111033622 IL2RG [ ] [‘TGGCYGTCAGTT [‘X-linked severe c.343T > C GCAAAAAAAGG’] combined (p.Cys115Arg) immunodeficiency’] NM_001041.3(SI): 121912613 SI [ ] [‘ATGCYGGAGTTC [‘Sucrase-isomaltase c.1859T > C (p.Leu620Pro) AGTTTGTTTGG’] deficiency’] NM_016180.4(SLC45A2): 121912619 SLC45A2 [ ] [‘GAGTTTCYCATC [‘Oculocutaneous c.1082T > C TACGAAAGAGG’] albinism type 4’, ‘not (p.Leu361Pro) provided’] NM_000552.3(VWF): 61750581 VWF [ ] [‘CTGCCYCTGATG [‘von Willebrand c.4837T > C AGATCAAGAGG’] disease, type 2a’, ‘not (p.Ser1613Pro) provided’] NM_000552.3(VWF): 61750584 VWF [ ] [ ] [‘von Willebrand c.4883T > C disease, type 2a’, ‘not (p.Ile1628Thr) provided’] NM_000180.3(GUCY2D): 61749755 GUCY2D [ ] [ ] [‘Leber congenital c.1694T > C amaurosis 1’, ‘not (p.Phe565Ser) provided’] NM_003235.4(TG): 121912647 TG [ ] [ ] [‘Iodotyrosyl c.3733T > C coupling defect’] (p.Cys1245Arg) NM_000546.5(TP53): 121912653 TP53 [ ] [‘CATCCYCACCAT [‘Li-Fraumeni c.755T > C CATCACACTGG’] syndrome 1’] (p.Leu252Pro) NM_000155.3(GALT): 111033679 GALT [ ] [ ] [‘Deficiency of c.350T > C UDPglucose- (p.Phel 17Ser) hexose- 1-phosphate uridylyltransferase’] NM_000155.3(GALT): 111033680 GALT [ ] [ ] [‘Deficiency of c.374T > C UDPglucose- (p.Val125Ala) hexose- 1-phosphate uridylyltransferase’] NM_000155.3(GALT): 111033683 GALT [ ] [‘AGGTCAYGTGCT [‘Deficiency of c.386T > C TCCACCCCTGG’] UDPglucose- (p.Met129Thr) hexose- 1-phosphate uridylyltransferase’] NM_000546.5(TP53): 121912662 TP53 [ ] [ ] [‘Li-Fraumeni c.1031T > C syndrome 1’] (p.Leu344Pro) NM_000155.3(GALT): 111033687 GALT [ ] [ ] [‘Deficiency of c.416T > C UDPglucose- (p.Leu139Pro) hexose- 1-phosphate uridylyltransferase’] NM_000155.3(GALT): 111033701 GALT [ ] [ ] [‘Deficiency of c.452T > C UDPglucose- (p.Val151Ala) hexose- 1-phosphate uridylyltransferase’] NM_000155.3(GALT): 111033708 GALT [‘CCCTY [‘CCCTYGGGTGCA [‘Deficiency of c.499T > C GGGTG GGTTTGTGAGG’] UDPglucose- (p.Trp167Arg) CAGGT hexose-1-phosphate TTGTG uridylyltransferase’] AGG’] NM_000155.3(GALT): 111033710 GALT [ ] [ ] [‘Deficiency of c.507 + 2T > C UDPglucose- hexose- 1-phosphate uridylyltransferase’] NM_000155.3(GALT): 111033715 GALT [ ] [ ] [‘Deficiency of c.512T > C UDPglucose- (p.Phe171Ser) hexose-1-phosphate uridylyltransferase’] NM_000341.3(SLC3A1): 121912693 — [ ] [ ] [‘Cystinuria’] c.2033T > C (p.Leu678Pro) NM_000540.2(RYR1): 147012990 RYR1 [ ] [ ] [‘Minicore myopathy c.9242T > C with external (p.Met3081Thr) ophthalmoplegia’] NM_000155.3(GALT): 111033728 GALT [ ] [ ] [‘Deficiency of c.584T > C UDPglucose- (p.Leu195Pro) hexose- 1-phosphate uridylyltransferase’] NM_000155.3(GALT): 111033741 GALT [ ] [ ] [‘Deficiency of c.650T > C UDPglucose- (p.Leu217Pro) hexose- 1-phosphate uridylyltransferase’] NM_000155.3(GALT): 111033748 GALT [ ] [ ] [‘Deficiency of c.687 + 2T > C UDPglucose- hexose- 1-phosphate uridylyltransferase’] NM_000039.1(APOA1): 121912726 — [ ] [ ] [‘Familial visceral c.220T > C amyloidosis, (p.Trp74Arg) Ostertag type’] NM_000155.3(GALT): 111033752 GALT [ ] [‘CAGGAGCYACT [‘Deficiency of c.677T > C CAGGAAGGTGGG’] UDPglucose- (p.Leu226Pro) hexose-1-phosphate uridylyltransferase’] NM_000039.1(APOA1): 121912729 APOA1 [ ] [‘GCGCTYGGCCGC [‘Familial visceral c.593T > C GCGCCTTGAGG’] amyloidosis, (p.Leu198Ser) Ostertag type’] NM_000155.3(GALT): 111033757 GALT [ ] [ ] [‘Deficiency of c.745T > C UDPglucose- (p.Trp249Arg) hexose-1-phosphate uridylyltransferase’] NM_001681.3(ATP2A2): 121912734 ATP2A2 [ ] [ ] [‘Keratosis c.1678T > C follicularis’] (p.Cys560Arg) NM_000041.3(APOE): 769452 APOE [ ] [‘AACYGGCACTG [ ] c.137T > C GGTCGCTTTTGG’] (p.Leu46Pro) NM_000342.3(SLC4A1): 121912753 SLC4A1 [ ] [ ] [‘Renal tubular c.2317T > C acidosis, distal, with (p.Ser773Pro) normal red cell morphology’] NM_003002.3(SDHD): 80338846 SDHD [ ] [ ] [‘Hereditary c.284T > C Paraganglioma- (p.Leu95Pro) Pheochromocytoma Syndromes’] NM_016124.4(RHD): 121912762 RHD [ ] [‘ACACYGTTCAGG [ ] c.329T > C TATTGGGATGG’] (p.Leu110Pro) NM_003002.3(SDHD): 80338847 SDHD [ ] [ ] [‘Hereditary c.416T > C Paraganglioma- (p.Leu139Pro) Pheochromocytoma Syndromes’, ‘Paragangliomas 1’] NM_001822.5(CHN1): 121912794 CHN1 [ ] [ ] [‘Duane syndrome c.427T > C type 2’] (p.Tyr143His) NM_000155.3(GALT): 111033824 GALT [ ] [CGCCYGACCAC [‘Deficiency of c.1138T > C GCCGACCACAGG’, UDPglucose- (p.Ter380Arg) ‘GCCYGACCACGC hexose-1-phosphate CGACCACAGGG’] uridylyltransferase’] m.3271T > C 199474658 MT-TL1 [ ] [ ] [‘Juvenile myopathy, encephalopathy, lactic acidosis AND stroke’] NM_000155.3(GALT): 111033832 GALT [ ] [‘TCCYGCGCTCTG [‘Deficiency of c.980T > C CCACTGTCCGG’] UDPglucose- (p.Leu327Pro) hexose-1-phosphate uridylyltransferase’] m.3290T > C 199474665 MT-TL1 [ ] [ ] [‘Sudden infant death syndrome’] NM_020549.4(CHAT): 121912820 CHAT [ ] [ ] [‘Familial infantile c.629T > C myasthenia’] (p.Leu210Pro) NM_020549.4(CHAT): 121912823 CHAT [ ] [ ] [‘Familial infantile c.1007T > C myasthenia’] (p.Ile336Thr) NM_000155.3(GALT): 111033849 GALT [ ] [ ] [‘Deficiency of c.328 + 2T > C UDPglucose- hexose-1 -phosphate uridylyltransferase’] NM_000267.3(NF1): 199474737 NF1 [ ] [ ] [‘Neurofibromatosis, c.1595T > C type 1’, ‘not (p.Leu532Pro) provided’] NM_000455.4(STK11): 730881974 STK11 [ ] [‘GGGAACCYGCT [‘Hereditary cancer- c.545T > C GCTCACCACCGG’, predisposing (p.Leu182Pro) ‘AACCYGCTGCTC syndrome’] ACCACCGGTGG’] NM_001042492.2(NF1): 199474762 NF1 [ ] [ ] [‘Hereditary cancer- c.2288T > C predisposing (p.Leu763Pro) syndrome’, ‘not provided’] NM_001042492.2(NF1): 199474792 NF1 [ ] [ ] [‘Neurofibromatosis, c.5858T > C type 1’, ‘not (p.Leu1953Pro) provided’] m.7512T > C 199474817 MT-TS1 [ ] [ ] [‘MERRF/MELAS overlap syndrome’] m.7510T > C 199474820 MT-TS1 [ ] [ ] [‘Deafness, nonsyndromic sensorineural, mitochondrial’] m.7511T > C 199474821 MT-TS1 [ ] [ ] [‘Deafness, nonsyndromic sensorineural, mitochondrial’] m.2991T > C 199474823 MT-RNR2 [ ] [ ] [‘Chloramphenicol resistance’] NM_201253.2(CRB1): 62635656 CRB1 [ ] [ ] [‘Retinitis c.3122T > C pigmentosa 12’, ‘not (p.Met1041Thr) provided’] m.7587T > C 199474825 MT-OO2 [ ] [ ] [‘Cytochrome-c oxidase deficiency’] NM_000400.3(ERCC2): 121913025 ERCC2 [ ] [ ] [‘Xeroderma c.1454T > C pigmentosum, group (p.Leu485Pro) D’] NM_000157.3(GBA): 1064644 GBA [ ] [‘GGGYCACTCAA [‘Gaucher disease’] c.703T > C GGGACAGCCCGG’] (p.Ser235Pro) NM_001113755.2(TYMP): 121913042 TYMP [ ] [ ] [ ] c.854T > C (p.Leu285Pro) NM_000122.1(ERCC3): 121913045 ERCC3 [ ] [ ] [‘Xeroderma c.296T > C pigmentosum, (p.Phe99Ser) complementation group b’] NM_000186.3(CFH): 121913052 CFH [ ] [ ] [‘Factor H c.1606T > C deficiency’] (p.Cys536Arg) NM_138413.3(HOGA1): 796052090 HOGA1 [ ] [‘GGACCYGCCTGT [‘Primary c.533T > C GGATGCAGTGG’] hyperoxaluria, type (p.Leu178Pro) III’] NM_004370.5(COL12A1): 796052093 COL12A1 [ ] [ ] [‘BETHLEM c.7001T > C MYOPATHY 2’] (p.Ile2334Thr) NM_000043.4(FAS): 121913084 FAS [ ] [ ] [ ] c.532T > C (p.Cys178Arg) NM_000208.2(INSR): 121913141 INSR [ ] [CTACCYGGACG [‘Leprechaunism c.779T > C GCAGGTGTGTGG’] syndrome’] (p.Leu260Pro) NM_000208.2(INSR): 121913152 INSR [ ] [ ] [‘Leprechaunism c.164T > C syndrome’] (p.Val55Ala) NM_000026.2(ADSL): 374259530 ADSL [ ] [ ] [‘Adenylosuccinate c.340T > C lyase deficiency’, (p.Tyr114His) ‘not provided’] NM_153490.2(KRT13): 60440396 KRT13 [ ] [ ] [‘White sponge c.356T > C nevus 2’, ‘not (p.Leull9Pro) provided’] NM_022455.4(NSD1): 587784162 NSD1 [ ] [ ] [‘Sotos syndrome 1’] c.5885T > C (p.Ile1962Thr) NM_006218.2(PIK3CA): 121913272 PIK3CA [ ] [‘GGAACACYGTC [‘Congenital c.1258T > C CATTGGCATGGG’, lipomatous (p.Cys420Arg) ‘GAACACYGTCCA overgrowth, vascular TTGGCATGGGG’] malformations, and epidermal nevi’, ‘Neoplasm of ovary’, ‘PIK3CA Related Overgrowth Spectrum’] NM_000552.3(VWF): 61751310 VWF [ ] [‘GCTCCYGCTGCT [‘von Willebrand c.8317T > C CTCCGACACGG’] disease, type 2a’, ‘not (p.Cys2773Arg) provided’] NM_000335.4(SCN5A): 45563942 SCN5A [ ] [ ] [‘Primary dilated c.5504T > C cardiomyopathy’, (p.Ile1835Thr) ‘Dilated cardiomyopathy 1E’, ‘not provided’] NM_183415.2(UBE3B): 398123020 UBE3B [ ] [ ] [‘Kaufman c.1741 + 2T > C oculocerebrofacial syndrome’] NM_000021.3(PSEN1): 63750218 PSEN1 [ ] [ ] [‘Alzheimer disease, c.1175T > C type 3’, ‘not (p.Leu392Pro) provided’] NM_000350.2(ABCA4): 61751392 ABCA4 [ ] [ ] [‘Stargardt disease c.1622T > C 1’, ‘Cone-rod (p.Leu541Pro) dystrophy 3’, ‘not provided’] NM_007313.2(ABL1): 121913457 ABL1 [ ] [ ] [ ] c.1109T > C (p.Met370Thr) NM_024408.3(NOTCH2): 312262793 NOTCH2 [ ] [ ] [‘Alagille syndrome c.1117T > C 2’] (p.Cys373Arg) NM_024408.3(NOTCH2): 312262799 NOTCH2 [ ] [‘TTCACAYGTCTG [‘Alagille syndrome c.1438T > C TGCATGCCAGG’] 2’] (p.Cys480Arg) NM_003611.2(0FD1): 312262809 OFD1 [ ] [ ] [‘Oral-facial-digital c.111 + 2T > C syndrome’, ‘not provided’] NM_003611.2(0FD1): 312262819 OFD1 [ ] [ ] [‘Oral-facial-digital c.274T > C (p.Ser92Pro) syndrome’] NM_020631.4(PLEKHG5): 63750315 PLEKHG5 [ ] [ ] [‘Distal spinal c.1940T > C muscular atrophy, (p.Phe647Ser) autosomal recessive 4’] NM_001288953.1(TTC7A): 149602485 TTC7A [ ] [ ] [‘Multiple c.1912T > C gastrointestinal (p.Ser638Pro) atresias’] NM_000391.3(TPP1): 119455953 TPP1 [‘GCCG [‘GCCGGGYGTTG [‘Ceroid c.1093T > C GGYGT GTCTGTCTCTGG’] lipofuscinosis, (p.Cys365Arg) TGGTC neuronal, 2’, ‘not TGTCT provided’] CTGG’] NM_000426.3(LAMA2): 121913570 LAMA2 [ ] [‘ATCATTCYTTTG [‘Merosin deficient c.7691T > C GGAAGTGGAGG’, congenital muscular (p.Leu2564Pro) ‘TCATTCYTTTGGG dystrophy’] AAGTGGAGGG’] NM_000426.3(LAMA2): 121913573 LAMA2 [ ] [ ] [‘Congenital c.2584T > C muscular dystrophy (p.Cys862Arg) due to partial LAMA2 deficiency’] NM_000530.6(MPZ): 121913587 MPZ [ ] [ ] [‘Charcot-Marie- c.404T > C (p.Ile135Thr) Tooth disease type 1B’] NM_201253.2(CRB1): 62636291 CRB1 [ ] [ ] [‘Retinitis c.3541T > C pigmentosa 12’, ‘not (p.Cys1181Arg) provided’] NM_000257.3(MYH7): 121913640 MYH7 [ ] [‘AACTCCAYGTAT [‘Familial c.1046T > C AAGCTGACAGG’] hypertrophic (p.Met349Thr) cardiomyopathy 1’, ‘Cardiomyopathy’] NM_000257.3(MYH7): 121913642 MYH7 [ ] [‘CATCATGYCCAT [‘Dilated c.1594T > C CCTGGAAGAGG’] cardiomyopathy 1S’] (p.Ser532Pro) NM_000257.3(MYH7): 121913654 MYH7 [ ] [ ] [‘Familial c.5378T > C hypertrophic (p.Leu1793Pro) cardiomyopathy 1’, ‘Myosin storage myopathy’, ‘Left ventricular noncompaction 5’, ‘Cardiomyopathy’] NM_001127500.1(MET): 121913668 MET [ ] [ ] [‘Renal cell c.3446T > C carcinoma, (p.Met1149Thr) papillary, 1’] NM_002443.3(MSMB): 10993994 MSMB [ ] [ ] [‘Prostate cancer, c.-89T= hereditary, 13’] NM_001079802.1(FKTN): 119463996 FKTN [ ] [‘GTAGTCTYTCAT [‘Limb-girdle c.527T > C GAGAGGAGTGG’] muscular dystrophy- (p.Phe176Ser) dystroglycanopathy, type C4’] NM_000169.2(GLA): 140329381 — [ ] [ ] [‘Fabry disease’] c.865A > T (p.Ile289Phe) NM_000420.2(KEL): 8176038 KEL [ ] [ ] [ ] c.1790T > C (p.Leu597Pro) NM_003999.2(OSMR): 63750567 OSMR [ ] [ ] [‘Primary localized c.2072T > C cutaneous (p.Ile691Thr) amyloidosis 1’] NC_012920.1:m.9478 587776437 MT-003 [‘TCAG [‘TCAGAAGYTTTT [‘Leigh disease’] T > C AAGYT TTCTTCGCAGG’] TTTTTC TTCGC AGG’] NM_002775.4(HTRA1): 587776447 HTRA1 [ ] [ ] [‘Cerebral autosomal c.1091T > C recessive (p.Leu364Pro) arteriopathy with subcortical infarcts and leukoencephalopath 3’] NM_002049.3(GATA1): 587776451 GATA1 [‘TCCA [‘CTCCAYGGAGTT [‘GATA-1-related c.2T > C (p.Met1Thr) YGGAG CCCTGGCCTGG’, thrombocytopenia TTCCCT ‘TCCAYGGAGTTC with GGCCT CCTGGCCTGGG’, dyserythropoiesis’] GGG’, ‘CCAYGGAGTTCC ‘CCAYG CTGGCCTGGGG’] GAGTT CCCTG GCCTG GGG’] NM_000021.3(PSEN1): 63750599 PSEN1 [ ] [ ] [‘Alzheimer disease, c.254T > C familial, 3, with (p.Leu85Pro) spastic paraparesis and apraxia’, ‘not provided’] NM_002049.3(GATA1): 587776456 GATA1 [ ] [‘GCTCAYGAGGG [‘GATA-1-related c.1240T > C CACAGAGCATGG’] thrombocytopenia (p.Ter414Arg) with dyserythropoiesis’] NM_006158.4(NEFL): 62636505 NEFL [ ] [ ] [‘Charcot-Marie- c.281T > C Tooth disease type (p.Leu94Pro) 2E’, ‘not provided’] NM_000184.2(HBG2): 63750654 HBG2 [ ] [‘ATGCAAAYATCT [‘Fetal hemoglobin c.-228T > C GTCTGAAACGG’] quantitative trait locus 1’] NM_000353.2(TAT): 587776512 TAT [ ] [ ] [‘Tyrosinemia type c.236-5A > G 2’] NM_173560.3(RFX6): 587776514 RFX6 [‘CAGT [‘CAGTGGYGAGA [‘Mitchell-Riley c.380 + 2T > C GGYGA CTCGCCCGCAGG’, syndrome’] GACTC ‘AGTGGYGAGACT GCCCG CGCCCGCAGGG’] CAGG’, ‘AGTGG YGAGA CTCGC CCGCA GGG’] NM_001999.3(FBN2): 587776519 FBN2 [ ] [‘AGCAYTGCAAC [‘Congenital c.3725-15A > G CACATTGTCAGG’] contractural arachnodactyly’] NM_000404.2(GLB1): 587776526 GLB1 [ ] [ ] [‘GM1- c.1480-2A > G GANGLIOSIDOSIS, TYPE I, WITH CARDIAC INVOLVEMENT’] NM_000402.4(G6PD): 78365220 G6PD [ ] [‘TGCCCYCCACCT [‘Anemia, c.473T > C GGGGTCACAGG’] nonspherocytic (p.Leu158Pro) hemolytic, due to G6PD deficiency’, ‘not provided’] NM_000179.2(MSH6): 63750741 MSH6 [ ] [‘CTGGGGCYGGT [‘Hereditary c.1346T > C ATTCATGAAAGG’] Nonpolyposis (p.Leu449Pro) Colorectal Neoplasms’] NM_145046.4(CALR3): 142951029 CALR3 [‘CGGT [‘CGGTYTGAAGC [‘Arrhythmogenic c.245A > G YTGAA GTGCAGAGATGG’] right ventricular (p.Lys82Arg) GCGTG cardiomyopathy’, CAGAG ‘Familial ATGG’] hypertrophic cardiomyopathy 19’, ‘Hypertrophic cardiomyopathy’] NM_000260.3(MY07A): 368657015 MY07A [ ] [ ] [‘Usher syndrome, c.5573T > C type 1’] (p.Leu1858Pro) NM_024753.4(TTC21B): 766132877 TTC21B [ ] [ ] [‘Nephronophthisis c.2758-2A > G 12’] NM_001195129.1(PRSS56): 730882161 PRSS56 [ ] [ ] [‘Microphthalmia, c.1183T > C isolated 6’] (p.Cys395Arg) NM_001184.3(ATR): 587776690 ATR [ ] [ ] [‘Seckel syndrome c.2022A > G 1’] (p.Gly674=) NM_000354.5(SERPINA7): 587776720 SERPINA7 [ ] [ ] [ ] c.623-2A > G NM_000133.3(F9):c.2 587776735 F9 [ ] [ ] [‘Hereditary factor 77 + 2T > C IX deficiency disease’] NM_004006.2(DMD): 587776747 DMD [ ] [ ] [‘Becker muscular c.9225-285A > G dystrophy’] NM_016835.4(MAPT): 63750912 MAPT [‘GGAT [‘GGATAAYATCA [‘Frontotemporal c.1839T > C AAYAT AACACGTCCCGG’, dementia’, ‘not (p.Asn613=) CAAAC ‘GATAAYATCAAA provided’] ACGTC CACGTCCCGGG’] CCGG’, ‘GATAA YATCA AACAC GTCCC GGG’] NM_000321.2(RB1): 587776780 RB1 [ ] [ ] [‘Retinoblastoma’] c.1960 + 2T > C NM_006517.4(SLC16A2): 367543059 SLC16A2 [ ] [ ] [‘Allan-Herndon- c.1253T > C Dudley syndrome’] (p.Leu418Pro) NM_000421.3(KRT10): 587776815 — [ ] [ ] [‘Erythroderma, c.1374-2A > G ichthyosiform, congenital reticular’] NM_000251.2(MSH2): 63750961 MSH2 [ ] [ ] [‘Hereditary c.2089T > C Nonpolyposis (p.Cys697Arg) Colorectal Neoplasms’] NM_002618.3(PEX13): 61752115 PEX13 [ ] [ ] [‘Peroxisome c.977T > C biogenesis disorder (p.Ile326Thr) 11B’] NM_001079867.1(PEX2): 61752128 PEX2 [ ] [ ] [‘Peroxisome c.739T > C biogenesis disorder (p.Cys247Arg) 5A’] NM_017929.5(PEX26): 61752132 PEX26 [ ] [ ] [‘Peroxisome c.134T > C biogenesis disorder (p.Leu45Pro) 7B’] NG_012088.1:g.2209 587776843 IL10 [‘ACCY [‘ACCYTATGATCC [ ] A > G TATGA GCCCGCCTTGG’] TCCGC CCGCC TTGG’] NM_001735.2(C5): 587776846 C5 [ ] [ ] [‘Leiner disease’] c.1115A > G (p.Lys372Arg) NM_002087.3(GRN): 63751006 GRN [‘CCAY [‘CCAYGTGGACCC [‘Frontotemporal c.2T > C (p.Met1Thr) GTGGA TGGTGAGCTGG’] dementia, ubiquitin- CCCTG positive’, ‘not GTGAG provided’] CTGG’] NM_004656.3(BAP1): 587776878 BAP1 [ ] [ ] [‘Tumor c.2057-2A > G predisposition syndrome’] NM_004656.3(BAP1): 587776879 BAP1 [‘GCCY [‘GCCYGGGGAAA [‘Tumor c.438-2A > G GGGGA AACAGAGTCAGG’] predisposition AAAAC syndrome’] AGAGT CAGG’] NM_004329.2(BMPR1A): 199476087 BMPR1A [ ] [ ] [‘Juvenile polyposis c.370T > C syndrome’, (p.Cys124Arg) ‘Hereditary cancer- predisposing syndrome’] NM_000510.2(FSHB): 5030777 FSHB [ ] [ ] [‘Follicle-stimulating c.298T > C hormone deficiency, (p.Cys100Arg) isolated’] NM_001009944.2(PKD1): 199476100 PKD1 [ ] [ ] [‘Polycystic kidney c.2534T > C disease, adult type’] (p.Leu845Ser) NM_004963.3(GUCY2C): 587776905 GUCY2C [ ] [ ] [‘Meconium ileus’] c.1160A > G (p.Asp387Gly) m.14487T > C 199476109 MT-ND6 [ ] [ ] [‘Leigh disease’, ‘Leigh syndrome due to mitochondrial complex I deficiency’] NM_017565.3(FAM20A): 587776912 — [ ] [ ] [‘Enamel-renal c.813-2A > G syndrome’] NM_017565.3(FAM20A): 587776914 FAM20A [ ] [‘GTAATCYGCAA [‘Enamel-renal c.590-2A > G AGGAGGAGAAGG’, syndrome’] ‘TAATCYGCAAAG GAGGAGAAGGG’] NM_014165.3(NDUFAF4): 63751061 NDUFAF4 [ ] [ ] [‘Mitochondrial c.194T > C complex I (p.Leu65Pro) deficiency’] m.4160T > C 199476119 MT-ND1 [ ] [ ] [‘Leber optic atrophy’] NM_000551.3(VHL): 5030809 VHL [ ] [‘CCCYACCCAACG [‘Von Hippel-Lindau c.292T > C (p.Tyr98His) CTGCCGCCTGG’] syndrome’, ‘Hereditary cancer- predisposing syndrome’] m.3949T > C 199476124 MT-ND1 [ ] [ ] [‘Juvenile myopathy, encephalopathy, lactic acidosis AND stroke’] m.6742T > C 199476126 MT-CO1 [ ] [ ] [ ] m.6721T > C 199476127 MT-CO1 [ ] [ ] [ ] m.5692T > C 199476131 MT-TN [ ] [ ] [ ] m.5728T > C 199476132 MT-TN [ ] [‘CAATCYACTTCT [‘Cytochrome-c CCCGCCGCCGG’, oxidase deficiency’, ‘AATCYACTTCTC ‘Mitochondrial CCGCCGCCGGG’] complex ] deficiency’] m.9101T > C 199476134 MT-ATP6 [ ] [ ] [‘Leber optic atrophy’] m.8851T > C 199476136 MT-ATP6 [ ] [ ] [‘Leigh disease’, ‘Striatonigral degeneration, infantile, mitochondrial’] m.9185T > C 199476138 MT-ATP6 [ ] [ ] [‘Leigh disease’] NM_000277.1(PAH): 5030841 PAH [ ] [ ] [‘Phenylketonuria’, c.143T > C (p.Leu48Ser) ‘not provided’] NM_000277.1(PAH): 5030845 PAH [ ] [ ] [‘Phenylketonuria’, c.691T > C ‘not provided’] (p.Ser231Pro) NM_000251.2(MSH2): 63751110 MSH2 [‘AAGG [‘AAGGAAYGTGT [‘Hereditary c.595T > C AAYGT TTTACCCGGAGG’] Nonpolyposis (p.Cys199Arg) GTTTT Colorectal ACCCG Neoplasms’] GAGG’] NM_000039.1(AP0A1): 28931575 — [ ] [ ] [ ] c.341T > C (p.Leull4Pro) NM_001288953.1(TTC7A): 587776972 TTC7A [ ] [ ] [‘Multiple c.2366T > C gastrointestinal (p.Leu789Pro) atresias’] NM_014336.4(AIPL1): 62637012 AIPL1 [ ] [CTGCCAGYGCCT [‘Leber congenital c.715T > C GCTGAAGAAGG’, amaurosis 4’, ‘not (p.Cys239Arg) ‘CCAGYGCCTGCT provided’] GAAGAAGGAGG’] NM_000155.3(GALT): 367543254 GALT [ ] [ ] [‘Deficiency of c.336T > C (p.Ser112=) UDPglucose- hexose-1-phosphate uridylyltransferase’] NM_207352.3(CYP4V2): 199476191 CYP4V2 [ ] [ ] [‘Bietti crystalline c.655T > C corneoretinal (p.Tyr219His) dystrophy’] NM_207352.3(CYP4V2): 199476199 CYP4V2 [ ] [AAACTGGYCCTT [‘Bietti crystalline c.1021T > C ATACCTGTTGG’, corneoretinal (p.Ser341Pro) ‘AACTGGYCCTTA dystrophy’] TACCTGTTGGG’] NM_001142519.1(FAM111A): 587777012 FAM111A [ ] [ ] [‘Kenny-Caffey c.1531T > C syndrome type 2’] (p.Tyr511His) NM_000435.2(NOTCH3): 367543285 NOTCH3 [ ] [ ] [‘Infantile c.4556T > C myofibromatosis 1’, (p.Leu1519Pro) ‘Infantile myofibromatosis 2’] NM_000021.3(PSEN1): 63751163 PSEN1 [ ] [ ] [‘Alzheimer disease, c.749T > C type 3’, ‘not (p.Leu250Ser) provided’] NM_001283009.1(RTEL1): 587777037 — [‘CTGTG [‘CTGTGTGYGCCA [‘Dyskeratosis c.3730T > C TGYGC GGGCTGTGGGG’] congenita, (p.Cys1244Arg) CAGGG autosomal recessive, CTGTG 5’] GGG’] NM_001135021.1(ELMOD3): 587777040 ELMOD3 [ ] [ ] [‘Deafness, c.794T > C autosomal recessive (p.Leu265Ser) 88’] NM_001001557.2(GDF6): 63751220 GDF6 [ ] [ ] [‘Klippel-Feil c.866T > C syndrome 1, (p.Leu289Pro) autosomal dominant’] NM_014754.2(PTDSS1): 587777090 PTDSS1 [ ] [ ] [Lenz-Majewski c.794T > C hyperostosis (p.Leu265Pro) syndrome’] NM_052844.3(WDR34): 587777098 WDR34 [ ] [ ] [‘Short-rib thoracic c.1307A > G dysplasia 11 with or (p.Lys436Arg) without polydactyly’] NM_001290048.1(ATL3): 587777108 ATL3 [ ] [ ] [‘Hereditary sensory c.521A > G neuropathy type IF’] (p.Tyr174Cys) NM_001018005.1(TPM1): 199476312 TPM1 [ ] [ ] [‘Primary familial c.515T > C hypertrophic (p.Ile172Thr) cardiomyopathy’, ‘Cardiomyopathy’, ‘not provided’] NM_018849.2(ABCB4): 58238559 ABCB4 [ ] [ ] [‘Cholecystitis’] c.523A > G (p.Thr175Ala) NM_001018005.1(TPM1): 199476321 TPM1 [ ] [ ] [‘Cardiomyopathy’, c.842T > C ‘not specified’, ‘not (p.Met281Thr) provided’] NM_005763.3(AASS): 587777122 AASS [ ] [ ] [‘Hyperlysinemia’] c.874A > G (p.Ile292Val) NM_194442.2(LBR): 587777171 LBR [ ] [ ] [‘Greenberg c.1639A > G dysplasia’] (p.Asn547Asp) NM_006702.4(PNPLA6): 587777183 PNPLA6 [ ] [‘CCTYTAACCGCA [‘Boucher Neuhauser c.3053T > C GCATCCATCGG’] syndrome’] (p.Phe1018Ser) NM_000487.5(ARSA) 199476389 ARSA [ ] [‘GGTCTCTYGCGG [‘Metachromatic :c.899T > C TGTGGAAAGGG’] leukodystrophy’, ‘not (p.Leu300Ser) provided’] NM_016599.4(MYOZ2): 199476398 MYOZ2 [ ] [‘TTAYCCCATCTC [‘Familial c.142T > C AGTAACCGTGG’] hypertrophic (p.Ser48Pro) cardiomyopathy 16’, ‘not provided’] NM_014740.3(EIF4A3): 587777204 EIF4A3 [ ] [ ] [‘Richieri Costa c.809A > G Pereira syndrome’] (p.Asp270G1y) NM_001040436.2(YARS2): 587777215 YARS2 [ ] [ ] [‘Myopathy, lactic c.1303A > G acidosis, and (p.Ser435Gly) sideroblastic anemia 2’] NM_001278503.1(STT3A): 587777216 STT3A [ ] [ ] [‘Congenital disorder c.1877T > C of glycosylation type (p.Val626Ala) 1w’] NM_001037633.1(SIL1): 119456967 SIL1 [ ] [‘TTGCYGAAGGA [Marinesco- c.1370T > C GCTGAGATGAGG’] Sj\xc3\xb6gren (p.Leu457Pro) syndrome’] NM_006888.4(CALM1): 730882253 CALM1 [ ] [‘GGCAYTCCGAGT [‘Long QT syndrome c.268T > C CTTTGACAAGG’] 14’] (p.Phe90Leu) NM_001003811.1(TEX11): 143246552 TEX11 [‘TCCA [‘TCCAYGGTCAAG [‘Spermatogenic c.511A > G YGGTC TCAGCCTCAGG’, failure, X-linked, 2’] (p.Met171Val) AAGTC ‘CCAYGGTCAAGT AGCCT CAGCCTCAGGG’] CAGG’] NM_033419.4(PGAP3): 587777252 PGAP3 [ ] [ ] [‘Hyperphosphatasia c.914A > G with mental (p.Asp305Gly) retardation syndrome 4’] NM_000021.3(PSEN1): 63751399 PSEN1 [ ] [ ] [‘Alzheimer disease, c.338T > C type 3’, (p.Leull3Pro) ‘Frontotemporal dementia’, ‘not provided’] NM_000097.5(CPOX): 587777271 CPOX [ ] [ ] [‘Harderoporphyria’] c.980A > G (p.His327Arg) NM_005654.5(NR2F1): 587777276 NR2F1 [ ] [ ] [‘Bosch-boonstra- c.755T > C schaaf optic atrophy (p.Leu252Pro) syndrome’] NM_012338.3(TSPAN12): 587777283 TSPAN12 [ ] [‘TAATCCAYAATT [‘Exudative c.413A > G TGTCATCCTGG’] vitreoretinopathy 5’] (p.Tyr138Cys) NM_003181.3(T): 587777303 T [ ] [ ] [‘Sacral agenesis c.512A > G (p.His171Arg) with vertebral anomalies’] NM_015884.3(MBTPS2): 587777306 MBTPS2 [ ] [‘GCTYTGCTTTGG [‘Palmoplantar c.1391T > C ATGGACAATGG’] keratoderma, (p.Phe464Ser) mutilating, with periorificial keratotic plaques, X- linked’] NM_020435.3(GJC2): 74315311 GJC2 [‘TGAG [‘TGAGAYGGCCC [‘Leukodystrophy, c.857T > C AYGGC ACCTGGGCTTGG’, hypomyelinating, 2’] (p.Met286Thr) CCACC ‘GAGAYGGCCCAC TGGGC CTGGGCTTGGG’] TTGG’] NM_005356.4(LCK): 587777335 LCK [ ] [ ] [‘Immunodeficiency c.1022T > C 22’] (p.Leu341Pro) NM_005861.3(STUB1): 587777345 — [ ] [ ] [‘Spinocerebellar c.719T > C ataxia, autosomal (p.Met240Thr) recessive 16’] NM_000250.1(MPO): 56378716 MPO [ ] [‘TCACTCAYGTTC [‘Myeloperoxidase c.752T > C ATGCAATGGGG’] deficiency’] (p.Met251Thr) NM_017890.4(VPS13B): 587777382 VPS13B [ ] [ ] [‘Cohen syndrome’] c.11119 + 2T > C NM_005026.3(PIK3CD): 587777390 PIK3CD [ ] [‘GCAGGACYGCC [‘Activated PI3K- c.1246T > C CCATTGCCTGGG’] delta syndrome’] (p.Cys416Arg) NM_002633.2(PGM1): 587777401 PGM1 [ ] [ ] [‘Congenital disorder c.1547T > C of glycosylation type (p.Leu516Pro) it’] NM_000261.1(MYOC): 74315328 MYOC [ ] [ ] [‘Primary open angle c.1309T > C glaucoma juvenile (p.Tyr437His) onset 1’] NM_001159287.1(TPI1): 587777440 TPI1 [ ] [ ] [‘Triosephosphate c.833T > C isomerase (p.Phe278Ser) deficiency’] NM_000414.3(HSD17B4): 587777443 HSD17B4 [ ] [ ] [‘Gonadal c.1547T > C dysgenesis with (p.Ile516Thr) auditory dysfunction, autosomal recessive inheritance’] NM_005359.5(SMAD4): 377767339 SMAD4 [ ] [ ] [‘Juvenile polyposis c.970T > C syndrome’] (p.Cys324Arg) NM_000211.4(ITGB2): 483352818 ITGB2 [‘CATG [‘CATGYGAGTGC [‘Leukocyte c.1877 + 2T > C YGAGT AGGCGGAGCAGG’] adhesion deficiency GCAGG type 1’] CGGAG CAGG’] NM_005359.5(SMAD4): 377767348 SMAD4 [ ] [ ] [‘Juvenile polyposis c.1087T > C syndrome’] (p.Cys363Arg) NM_001128159.2(VPS53): 587777465 VPS53 [ ] [ ] [‘Pontocerebellar c.2084A > G hypoplasia, type 2e’] (p.Gln695Arg) NM_000249.3(MLH1): 63751616 MLH1 [ ] [ ] [‘Hereditary c.1745T > C Nonpolyposis (p.Leu582Pro) Colorectal Neoplasms’] NM_003108.3(SOX11): 587777480 SOX11 [ ] [‘TATGGYCCAAG [‘Mental retardation, c.178T > C ATCGAACGCAGG’] autosomal dominant (p.Ser60Pro) 27’] NM_020630.4(RET): 377767404 RET [ ] [ ] [ ] c.1888T > C (p.Cys630Arg) NM_017565.3(FAM20A): 587777530 — [ ] [ ] [‘Enamel-renal c.720-2A > G syndrome’] NM_015599.2(PGM3): 587777562 PGM3 [‘TAAA [‘TAAATGAYTGA [‘Immunodeficiency c.737A > G TGAYT GTTTGCCCTTGG’] 23’] (p.Asn246Ser) GAGTT TGCCC TTGG’] NM_015599.2(PGM3): 587777565 PGM3 [ ] [ ] [‘Immunodeficiency c.1352A > G 23’] (p.Gln451Arg) NM_000206.2(IL2RG): 137852511 IL2RG [ ] [ ] [‘X-linked severe c.452T > C combined (p.Leu151Pro) immunodeficiency’] NM_198282.3(TMEM173): 587777609 TMEM173 [ ] [ ] [‘Sting-associated c.461A > G vasculopathy, (p.Asn154Ser) infantile-onset’] NM_000329.2(RPE65): 61752909 RPE65 [ ] [ ] [‘Retinitis c.1022T > C pigmentosa 20’, ‘not (p.Leu341Ser) provided’] NM_001127899.3(CLCN5): 151340623 CLCN5 [ ] [ ] [‘Dent disease 1’] c.1768T > C (p.Ser590Pro) NM_005027.3(PIK3R2): 587777624 PIK3R2 [ ] [ ] [‘Megalencephaly c.1202T > C polymicrogyria- (p.Leu401Pro) polydactyly hydrocephalus syndrome’] NM_007315.3(STAT1): 587777629 STAT1 [ ] [ ] [‘Immunodeficiency c.854A > G 31C’] (p.Gln285Arg) NM_139276.2(STAT3): 587777648 STAT3 [ ] [ ] [‘Autoimmune c.1175A > G disease, (p.Lys392Arg) multisystem, infantile-onset’] NM_001037811.2(HSD17B10): 587777651 HSD17B10 [ ] [ ] [2-methy1-3- c.257A > G hydroxybutyric (p.Asp86Gly) aciduria’] NM_001288767.1(ARMC5): 587777661 ARMC5 [ ] [ ] [‘Acth-independent c.1928T > C macronodular (p.Leu643Pro) adrenal hyperplasia 2’] NM_001288767.1(ARMC5): 587777663 ARMC5 [ ] [‘GCCCGACYGCG [‘Acth-independent c.1379T > C GGATGCTGGTGG’] macronodular (p.Leu460Pro) adrenal hyperplasia 2’] NM_007315.3(STAT1): 587777704 STAT1 [ ] [ ] [‘Immunodeficiency c.2018A > G 31a’] (p.Lys673Arg) NM_007315.3(STAT1): 587777705 STAT1 [ ] [ ] [‘Immunodeficiency c.1909A > G 31a’] (p.Lys637Glu) NM_014845.5(FIG4): 587777713 FIG4 [ ] [ ] [‘Charcot-Marie- c.50T > C (p.Leu17Pro) Tooth disease, type 4J’] 4J’] NM_000350.2(ABCA4): 61753033 ABCA4 [ ] [‘AAGGCYACATG [‘Stargardt disease’, c.5819T > C AACTAACCAAGG’] ‘Stargardt disease 1’, (p.Leu1940Pro) ‘Cone-rod dystrophy 3’, ‘not provided’] NM_002972.3(SBF1): 200488568 SBF1 [ ] [CAGGCGYCCTCT [Charcot-Marie- c.4768A > G TGCTCAGCCGG’] Tooth disease, type (p.Thr1590Ala) 4B3’] NM_000377.2(WAS): 132630272 WAS [ ] [ ] [ ] c.244T > C (p.Ser82Pro) NM_000377.2(WAS): 132630274 WAS [ ] [‘CGGAGTCYGTTC [‘Severe congenital c.809T > C TCCAGGGCAGG’] neutropenia X- (p.Leu270Pro) linked’] NM_001128834.2(PLP1): 132630279 PLP1 [ ] [ ] [‘Pelizaeus- c.487T > C Merzbacher disease’, (p.Trp163Arg) ‘not provided’] NM_001128834.2(PLP1): 132630283 PLP1 [ ] [ ] [‘Pelizaeus- c.671T > C Merzbacher disease’] (p.Leu224Pro) NM_001128834.2(PLP1): 132630288 PLP1 [ ] [ ] [‘Spastic paraplegia c.560T > C 2’] (p.Ile187Thr) NM_001128834.2(PLP1): 132630291 PLP1 [ ] [ ] [‘Spastic paraplegia c.710T > C 2’] (p.Phe237Ser) NM_001015877.1(PHF6): 132630300 PHF6 [ ] [ ] [‘Borjeson- c.2T > C Forssman-Lehmann (p.Met1Thr) syndrome’] NM_001399.4(EDA): 132630308 EDA [ ] [‘CTGCYACCTAGA [‘Hypohidrotic X- c.181T > C (p.Tyr61His) GTTGCGCTCGG’] linked ectodermal dysplasia’] NM_001205019.1(GK): 132630330 GK [ ] [ ] [‘Deficiency of c.1525T > C glycerol kinase’] (p.Trp509Arg) NM_000076.2(CDKN1C): 587777866 CDKN1C [‘CCAA [‘CCAAGYGAGTA [‘Beckwith- c.*5 + 2T > C GYGAG CAGCGCACCTGG’, Wiedemann TACAG ‘CAAGYGAGTACA syndrome’] CGCAC GCGCACCTGGG’, CTGG’, ‘AAGYGAGTACAG ‘CAAGY CGCACCTGGGG’] GAGTA CAGCG CACCT GGG’, ‘AAGYG AGTAC AGCGC ACCTG GGG’] NM_000271.4(NPC1): 483352888 NPC1 [ ] [ ] [‘Niemann-Pick c.2054T > C disease type C1’] (p.Ile685Thr) NM_170707.3(LMNA): 60934003 LMNA [ ] [ACGGCTCYCATC [‘Benign c.1589T > C AACTCCACTGG’, scapuloperoneal (p.Leu530Pro) ‘CGGCTCYCATCA muscular dystrophy ACTCCACTGGG’, with ‘GGCTCYCATCAA cardiomyopathy’, CTCCACTGGGG’] ‘not provided’] NM_001165963.1(SCN1A): 372098964 — [ ] [ ] [‘Severe myoclonic c.5536A > T epilepsy in infancy’] (p.Lys1846Ter) NM_130838.1(UBE3A): 587784526 UBE3A [ ] [ ] [‘Angelman c.2485T > C syndrome’] (p.Tyr829His) NM_014588.5(VSX1): 74315436 VSX1 [ ] [ ] [‘Keratoconus 1’] c.50T > C (p.Leu17Pro) NM_000404.2(GLB1): 398123354 GLB1 [ ] [ ] [‘Mucopolysaccharid c.457 + 2T > C osis, MPS-IV-B’, ‘Infantile GM1 gangliosidosis’, ‘Juvenile GM > l< gangliosidosis’, ‘Gangliosidosis GM1 type 3’, ‘not provided’] NM_003159.2(CDKL5): 267608430 CDKL5 [ ] [ ] [‘Atypical Rett c.145 + 2T > C syndrome’, ‘not provided’] NM_002764.3(PRPS1): 180177153 PRPS1 [ ] [ ] [‘Deafness, high- c.869T > C frequency (p.Ile290Thr) sensorineural, X- linked’] NM_000030.2(AGXT): 180177160 AGXT [ ] [‘GGTGCYGCGGA [‘Primary c.1076T > C TCGGCCTGCTGG’, hyperoxaluria, type (p.Leu359Pro) ‘GTGCYGCGGATC I’] GGCCTGCTGGG’] NM_000030.2(AGXT): 180177165 AGXT [ ] [ ] [‘Primary c.1151T > C hyperoxaluria, type (p.Leu384Pro) I’] NM_000030.2(AGXT): 180177222 AGXT [ ] [GTGCYGCTGTTC [‘Primary c.449T > C TTAACCCACGG’, hyperoxaluria, type (p.Leu150Pro) ‘TGCYGCTGTTCTT I’] AACCCACGGG’] NM_000268.3(NF2): 74315492 NF2 [ ] [ ] [‘Neurofibromatosis, c.1079T > C type 2’] (p.Leu360Pro) NM_000030.2(AGXT): 180177254 AGXT [ ] [‘GCTCATCYCCTT [‘Primary c.661T > C CAGTGACAAGG’] hyperoxaluria, type (p.Ser221Pro) I’] NM_000030.2(AGXT): 180177264 AGXT [ ] [‘GGGGCYGTGAC [‘Primary c.757T > C GACCAGCCCAGG’] hyperoxaluria, type (p.Cys253Arg) I’] NM_000030.2(AGXT): 180177268 AGXT [ ] [ ] [‘Primary c.77T > C (p.Leu26Pro) hyperoxaluria, type I’] NM_000030.2(AGXT): 180177287 AGXT [ ] [ ] [‘Primary c.851T > C hyperoxaluria, type (p.Leu284Pro) I’] NM_000030.2(AGXT): 180177293 AGXT [ ] [GTATCYGCATGG [‘Primary c.893T > C GCGCCTGCAGG’] hyperoxaluria, type (p.Leu298Pro) I’] NM_012203.1(GRHPR): 180177305 GRHPR [ ] [ ] [‘Primary c.203T > C hyperoxaluria, type (p.Leu68Pro) II’] NM_000017.3(ACADS): 796051904 ACADS [ ] [ ] [‘not provided’] c.1057T > C (p.Ser353Pro) NM_000406.2(GNRHR): 606231406 GNRHR [ ] [ ] [‘Hypogonadotropic c.392T > C hypogonadism’] (p.Met131Thr) NM_000255.3(MUT): 796052007 MUT [ ] [ ] [‘not provided’] c.842T > C (p.Leu281Ser) NM_000030.2(AGXT): 796052063 AGXT [ ] [ ] [‘Primary c.947T > C hyperoxaluria, type (p.Leu316Pro) I’] NM_138413.3(HOGA1): 796052087 HOGA1 [ ] [ ] [‘Primary c.875T > C hyperoxaluria, type (p.Met292Thr) III’] NM_013382.5(POMT2): 200198778 POMT2 [‘GGAA [‘GGAAGYAGTGG [‘Congenital c.1997A > G GYAGT TGGAAGTAGAGG’] muscular dystrophy’, (p.Tyr666Cys) GGTGG ‘Congenital AAGTA muscular dystrophy- GAGG’] dystroglycanopathy with brain and eye anomalies, type A2’, ‘Muscular dystrophy’, ‘Congenital muscular dystrophy- dystroglycanopathy with mental retardation, type B2’, ‘not provided’] NM_015909.3(NBAS): 796052121 NBAS [ ] [ ] [‘Infantile liver c.3164T > C failure syndrome 2’] (p.Leu1055Pro) NM_000263.3(NAGLU): 796052122 NAGLU [ ] [ ] [‘Charcot-Marie- c.1208T > C Tooth disease, (p.Ile403Thr) axonal type 2V’] NM_203290.2(POLR1C): 796052125 POLR1C [ ] [ ] [‘LEUKODYSTROPHY, c.436T > C HYPOMYELINATING, (p.Cys146Arg) 11’] NM_018359.3(UFSP2): 796052130 — [ ] [ ] [‘Hip dysplasia, c.868T > C beukes type’] (p.Tyr290His) NM_000053.3(ATP7B): 201738967 ATP7B [ ] [ ] [‘Wilson disease’] c.122A > G (p.Asn41Ser) NM_001356.4(DDX3X): 796052224 DDX3X [ ] [ ] [‘not provided’] c.704T > C (p.Leu235Pro) NM_001356.4(DDX3X): 796052226 DDX3X [ ] [ ] [‘not provided’] c.1541T > C (p.Ile514Thr) NM_001356.4(DDX3X): 796052232 DDX3X [ ] [ ] [‘not provided’] c.1175T > C (p.Leu392Pro) NM_000321.2(RB1): 587778839 RB1 [ ] [ ] [‘Retinoblastoma’] c.2663 + 2T > C NM_000321.2(RB1): 587778848 RB1 [ ] [ ] [‘Retinoblastoma’] c.1472T > C (p.Leu491Pro) NM_006894.5(FMO3): 28363581 FMO3 [ ] [ ] [‘Trimethylaminuria’ c.1079T > C ] (p.Leu360Pro) NM_172107.2(KCNQ2): 796052620 KCNQ2 [ ] [ ] [‘not provided’] c.583T > C (p.Ser195Pro) NM_001282227.1(CECR1): 376785840 CECR1 [ ] [‘GAAATCAYAGG [‘Polyarteritis c.1232A > G ACAAGCCTTTGG’] nodosa’] (p.Tyr411Cys) NM_170707.3(LMNA): 61295588 LMNA [ ] [ ] [‘Dilated c.644T > C cardiomyopathy 1A’, (p.Leu215Pro) ‘not provided’] NM_005249.4(FOXG1): 796052482 FOXG1 [ ] [ ] [‘not provided’] c.673T > C (p.Trp225Arg) NM_000806.5(GABRA1): 796052491 GABRA1 [ ] [ ] [‘not provided’] c.788T > C (p.Met263Thr) NM_000251.2(MSH2): 587779084 MSH2 [ ] [ ] [‘Hereditary c.1319T > C Nonpolyposis (p.Leu440Pro) Colorectal Neoplasms’] NM_003401.3(XRCC4): 587779351 XRCC4 [ ] [ ] [‘Ateleiotic c.127T > C dwarfism’] (p.Trp43Arg) NM_198056.2(SCN5A): 372395294 SCN5A [‘CTCA [‘CTCAYAGGCCAT [‘not provided’] c.1247A > G YAGGC TGCGACCACGG’] (p.Tyr416Cys) CATTG CGACC ACGG’] NM_000257.3(MYH7): 587779392 — [ ] [ ] [‘Myopathy, distal, c.4835T > C l’] (p.Leu1612Pro) NM_000257.3(MYH7): 587779393 — [ ] [‘GAGCCYCCAGA [‘Myopathy, distal, c.4937T > C GCTTGTTGAAGG’] l’] (p.Leu1646Pro) NM_000404.2(GLB1): 587779404 GLB1 [ ] [ ] [‘Infantile GM1 c.922T > C gangliosidosis’] (p.Phe308Leu) NM_012434.4(SLC17A5): 587779410 SLC17A5 [ ] [‘ATTGTACYCAGA [‘Sialic acid storage c.500T > C GCACTAGAAGG’] disease, severe (p.Leu167Pro) infantile type’] NM_000257.3(MYH7): 587779414 — [ ] [ ] [‘Myopathy, distal, c.4442T > C l’] (p.Leu1481Pro) NM_000090.3(COL3A1): 587779429 COL3A1 [ ] [ ] [‘Ehlers-Danlos c.2022 + 2T > C syndrome, type 4’] (p.Gly660_Lys674del) NM_004453.3(ETFDH): 765742496 ETFDH [ ] [ ] [‘not provided’] c.1852T > C (p.Ter618Gln) NM_000090.3(COL3A1): 587779513 COL3A1 [ ] [‘AGGYAACCCTTA [‘Ehlers-Danlos c.2337 + 2T > C ATACTACCTGG’] syndrome, type 4’] (p.Gly762_Lys779del) NM_000310.3(PPT1): 796052927 PPT1 [ ] [ ] [‘not provided’] c.2T > C (p.Met1Thr) NM_020376.3(PNPLA2): 777539013 PNPLA2 [ ] [‘GAACGGYGCGC [‘Neutral lipid c.757 + 2T > C GGACCCGGGCGG’, storage disease with ‘AACGGYGCGCGG myopathy’] ACCCGGGCGGG’] NM_000090.3(COL3A1): 587779532 COL3A1 [ ] [ ] [‘Ehlers-Danlos c.3039 + 6T > C syndrome, type 4’] (p.Asp1013_Gly1014i nsVSSSFYSTSQ) NM_012452.2(TNFRSF13B): 34557412 TNFRSF13B [ ] [‘ACTTCYGTGAGA [‘Immunoglobulin A c.310T > C ACAAGCTCAGG’] deficiency 2’, (p.Cys104Arg) ‘Common variable immunodeficiency 2’] NM_000570.4(FCGR3B): 147574249 FCGR3B [ ] [ ] [ ] c.244A= (p.Asn82=) NM_001165963.1(SCN1A): 796052970 SCN1A [ ] [‘CAAGCTYTGATA [‘not provided’] c.1094T > C CCTTCAGTTGG’, (p.Phe365Ser) ‘AAGCTYTGATAC CTTCAGTTGGG’] NC_012920.1:m.7505 724159989 MT-TS1 [ ] [‘CCTCCAYGACTT [‘Deafness, T > C TTTCAAAAAGG’] nonsyndromic sensorineural, mitochondrial’] NM_000663.4(ABAT): 724159991 ABAT [ ] [ ] [‘Gamma- c.1433T > C aminobutyric acid (p.Leu478Pro) transaminase deficiency’] NM_153818.1(PEX10): 724160000 PEX10 [ ] [ ] [‘Peroxisome c.890T > C biogenesis disorder (p.Leu297Pro) 6B’] NM_153818.1(PEX10): 724160002 PEX10 [ ] [ ] [‘Peroxisome c.2T > C (p.Met1Thr) biogenesis disorder 6B’] NM_000090.3(COL3A1): 587779618 COL3A1 [ ] [ ] [‘Ehlers-Danlos c.4399T > C syndrome, type 4’] (p.Ter1467Gln) NM_002485.4(NBN): 61754966 NBN [ ] [ ] [‘Microcephaly, c.511A > G (p.Ile171Val) normal intelligence and immunodeficiency’, ‘Aplastic anemia’, ‘Hereditary cancer- predisposing syndrome’, ‘Leukemia, acute lymphoblastic, susceptibility to’, ‘not specified’, ‘not provided’] NM_000090.3(COL3A1): 587779684 COL3A1 [ ] [ ] [‘Ehlers-Danlos c.2553 + 2T > C syndrome, type 4’] (p.Gly816_Ala851del) NM_021007.2(SCN2A): 796053139 SCN2A [‘CGAA [‘CGAAATGYAAG [‘not provided’] c.4308 + 2T > C ATGYA TCTAGTTAGAGG’, AGTCT ‘GAAATGYAAGTC AGTTA TAGTTAGAGGG’] GAGG’, ‘GAAAT GYAAG TCTAG TTAGA GGG’] NM_021007.2(SCN2A): 796053152 SCN2A [ ] [ ] [‘not provided’] c.4718T > C (p.Leu1573Pro) NM_001101.3(ACTB): 587779773 ACTB [‘GAGA [‘GAGAAGAYGAC [‘Baraitser-Winter c.356T > C AGAYG CCAGGTGAGTGG’ syndrome 1’] (p.Met119Thr) ACCCA ] GGTGA GTGG’] NM_021007.2(SCN2A): 796053191 SCN2A [ ] [ ] [‘not provided’] c.2306T > C (p.Ile769Thr) NM_014191.3(SCN8A): 796053222 SCN8A [ ] [‘CGTCYGATCAAA [‘not provided’] c.4889T > C GGCGCCAAAGG’, (p.Leu1630Pro) ‘GTCYGATCAAAG GCGCCAAAGGG’] NM_012415.3(RAD54B): 114216685 RAD54B [ ] [ ] [‘Malignant c.1778A > G lymphoma, non- (p.Asn593Ser) Hodgkin’] NM_007215.3(POLG2): 201936720 POLG2 [ ] [ ] [‘Autosomal c.1105A > G dominant (p.Arg369Gly) progressive external ophthalmoplegia with mitochondrial DNA deletions 4’, ‘not specified’] NM_004006.2(DMD): 754896795 DMD [‘GCTTT [‘GCTTTTYTTCAA [‘Duchenne c.6982A > T TYTTC GCTGCCCAAGG’] muscular dystrophy’, (p.Lys2328Ter) AAGCT ‘Becker muscular GCCCA dystrophy’, ‘Dilated AGG’] cardiomyopathy 3B’] NM_001061.4(TBXAS1): 140005285 TBXAS1 [ ] [ ] [‘not provided’] c.248T > C (p.Leu83Pro) NM_000540.2(RYR1): 118192127 RYR1 [ ] [‘TACTACCYGGAC [‘Central core c.10817T > C CAGGTGGGTGG’, disease’, ‘not (p.Leu3606Pro) ‘ACTACCYGGACC provided’] AGGTGGGTGGG’, ‘CTACCYGGACCA GGTGGGTGGGG’] NM_000138.4(FBN1): 727503054 FBN1 [ ] [ ] [‘Thoracic aortic c.7754T > C aneurysms and (p.Ile2585Thr) aortic dissections’, ‘Marfan syndrome’] NM_001128227.2(GNE): 28937594 GNE [ ] [ ] [‘Inclusion body c.2228T > C myopathy 2’, (p.Met743Thr) ‘Nonaka myopathy’] NM_000540.2(RYR1): 118192170 RYR1 [ ] [AGGCAYTGGGG [‘Malignant c.14693T > C ACGAGATCGAGG’] hyperthermia (p.Ile4898Thr) susceptibility type 1’, ‘Central core disease’, ‘not provided’] NM_005247.2(FGF3): 121917703 FGF3 [ ] [‘GTACGTGYCTGT [‘Deafness with c.466T > C GAACGGCAAGG’, labyrinthine aplasia (p.Ser156Pro) ‘TACGTGYCTGTG microtia and AACGGCAAGGG’] microdontia (LAMM)’] NM_005247.2(FGF3): 121917706 FGF3 [ ] [ ] [‘Deafness with c.17T > C (p.Leu6Pro) labyrinthine aplasia microtia and microdontia (LAMM)’] NM_005211.3(CSF1R): 690016549 CSF1R [ ] [‘CCGCCYGCCTGT [‘Hereditary diffuse c.2450T > C GAAGTGGATGG’] leukoencephalopathy (p.Leu817Pro) with spheroids’] NM_005211.3(CSF1R): 690016550 CSF1R [ ] [ ] [‘Hereditary diffuse c.2480T > C leukoencephalopathy (p.Ile827Thr) with spheroids’] NM_005211.3(CSF1R): 690016552 CSF1R [ ] [‘GAATCCCYACCC [‘Hereditary diffuse c.2566T > C TGGCATCCTGG’] leukoencephalopathy (p.Tyr856His) with spheroids’] NM_001098668.2(SFTPA2): 121917738 SFTPA2 [ ] [‘GGAGACTYCCG [‘Idiopathic fibrosing c.593T > C CTACTCAGATGG’, alveolitis, chronic (p.Phe198Ser) ‘GAGACTYCCGCT form’] ACTCAGATGGM NM_005211.3(CSF1R): 690016559 CSF1R [ ] [‘AGCCYGTACCCA [‘Hereditary diffuse c.1957T > C TGGAGGTAAGG’, leukoencephalopathy (p.Cys653Arg) ‘GCCYGTACCCAT with spheroids’] GGAGGTAAGGG’] NM_005211.3(CSF1R): 690016560 CSF1R [ ] [‘GCAGAYCTGCTC [‘Hereditary diffuse c.2717T > C CTTCCTTCAGG’] leukoencephalopath (p.Ile906Thr) y with spheroids’] NM_000540.2(RYR1): 118192179 RYR1 [ ] [ ] [‘Central core c.14378T > C disease’, ‘not (p.Leu4793Pro) provided’] NM_199292.2(TH): 121917763 TH [ ] [ ] [‘Segawa syndrome, c.707T > C (p.Leu236Pro) autosomal recessive’] NM_000256.3(MYBPC3): 727503176 MYBPC3 [ ] [ ] [‘Familial c.2994 + 2T > C hypertrophic cardiomyopathy 4’] NM_003361.3(UMOD): 121917769 UMOD [ ] [‘GGCCACAYGTGT [‘Familial juvenile c.376T > C CAATGTGGTGG’, gout’] (p.Cys126Arg) ‘GCCACAYGTGTC AATGTGGTGGG’] NM_003361.3(UMOD): 121917773 UMOD [ ] [‘ATGGCACYGCC [‘Glomerulocystic c.943T > C AGTGCAAACAGG’ kidney disease with (p.Cys315Arg) ] hyperuricemia and isosthenuria’] NM_024649.4(BBS1): 121917778 — [ ] [ ] [‘Bardet-Biedl c.1553T > C syndrome 1’] (p.Leu518Pro) NM_172107.2(KCNQ2): 118192186 KCNQ2 [ ] [ ] [‘Benign familial c.2T > C (p.Met1Thr) neonatal seizures 1’] NM_014324.5(AMACR): 121917814 — [ ] [ ] [‘Alpha-methylacyl- c.154T > C CoA racemase (p.Ser52Pro) deficiency’, ‘Bile acid synthesis defect, congenital, 4’] NM_014324.5(AMACR): 121917816 — [ ] [ ] [‘Bile acid synthesis c.320T > C defect, congenital, (p.Leu107Pro) 4’] NM_007255.2(B4GALT7): 121917818 B4GALT7 [ ] [‘TGCYCTCCAAGC [‘Ehlers-Danlos c.617T > C AGCACTACCGG’] syndrome progeroid (p.Leu206Pro) type’] NM_021615.4(CHST6): 121917824 CHST6 [ ] [‘GGACCYGGCGC [‘Macular corneal c.827T > C GGGAGCCGCTGG’] dystrophy Type I’] (p.Leu276Pro) NM_006261.4(PROP1): 121917841 PROP1 [ ] [ ] [‘Pituitary hormone c.263T > C deficiency, (p.Phe88Ser) combined 2’] NM_000452.2(SLC10A2): 121917848 SLC10A2 [ ] [‘TTTCYTCTGGCT [‘Bile acid c.728T > C AGAATTGCTGG’] malabsorption, (p.Leu243Pro) primary’] NM_000322.4(PRPH2): 61755802 PRPH2 [ ] [ ] [‘Patterned c.637T > C dystrophy of retinal (p.Cys213Arg) pigment epithelium’, ‘not provided’, ‘Leber congenital amaurosis 18’] NM_000517.4(HBA2): 41341344 HBA2 [ ] [ ] [‘Hemoglobin H c.89T > C (p.Leu30Pro) disease, nondeletional’] NM_002181.3(IHH): 121917857 IHH [ ] [ ] [‘Acrocapitofemoral c.569T > C (p.Val190Ala) dysplasia’] NM_000322.4(PRPH2): 61755817 PRPH2 [‘ACCT [‘ACCTGYGGGTGC [‘Retinitis c.736T > C GYGGG GTGGCTGCAGG’, pigmentosa’, ‘not (p.Trp246Arg) TGCGT ‘CCTGYGGGTGCG provided’] GGCTG TGGCTGCAGGG’] CAGG’, ‘CCTGY GGGTG CGTGG CTGCA GGG’] NM_005413.3(SIX3): 121917880 SIX3 [ ] [ ] [‘Holoprosencephaly c.749T > C 2’] (p.Val250Ala) NM_000124.3(ERCC6): 121917905 ERCC6 [‘TGCY [‘TGCYAAAAGAC [Cerebro-oculo- c.2960T > C AAAAG CCAAAACAAAGG’ facio-skeletal (p.Leu987Pro) ACCCA ] syndrome’] AAACA AAGG’] NM_006920.4(SCN1A): 121917919 — [ ] [ ] [‘Severe myoclonic c.4729T > C epilepsy in infancy’, (p.Cys1577Arg) ‘not provided’] NM_006920.4(SCN1A): 121917926 — [ ] [ ] [‘Severe myoclonic c.5113T > C epilepsy in infancy’, (p.Cys1705Arg) ‘not provided’] NM_006920.4(SCN1A): 121917930 — [‘AACA [‘AACAAYGGTGG [‘Generalized c.3577T > C AYGGT AACCTGAGAAGG’] epilepsy with febrile (p.Trp1193Arg) GGAAC seizures plus, type CTGAG 1’, ‘Generalized AAGG’] epilepsy with febrile seizures plus, type 2’] NM_006920.4(SCN1A): 121917938 SCN1A [ ] [ ] [‘Severe myoclonic c.838T > C epilepsy in infancy’] (p.Trp280Arg) NM_000478.4(ALPL): 121918006 ALPL [ ] [IGGACYATGGTG [‘Infantile c.1306T > C AGACCTCCAGG’] hypophosphatasia’] (p.Tyr436His) NM_000478.4(ALPL): 121918010 ALPL [ ] [CAAAGGCYTCTT [‘Infantile c.979T > C CTTGCTGGTGG’, hypophosphatasia’] (p.Phe327Leu) ‘GGCYTCTTCTTGC TGGTGGAAGG’] NM_000301.3(PLG): 121918029 PLG [ ] [ ] [‘Dysplasminogenem c.1771T > C ia’] (p.5er591Pro) NM_000174.4(GP9): 121918038 GP9 [ ] [ ] [‘Bernard-Soulier c.20T > C (p.Leu7Pro) syndrome type C’] NM_000371.3(TTR): 121918079 TTR [ ] [ ] [‘Amyloidogenic c.224T > C (p.Leu75Pro) transthyretin amyloidosis’] NM_000371.3(TTR): 121918083 TTR [ ] [ ] [‘Amyloidogenic c.88T > C (p.Cys30Arg) transthyretin amyloidosis’, ‘Cardiomyopathy’] NM_000371.3(TTR): 121918084 TTR [ ] [ ] [‘Amyloidogenic c.272T > C (p.Val91Ala) transthyretin amyloidosis’] NM_000371.3(TTR): 121918088 TTR [ ] [‘TCCCYACTCCTA [ ] c.400T > C (p.Tyr134His) TTCCACCACGG’] NM_012275.2(IL36R 148755083 IL36RN [ ] [ ] [‘Pustular psoriasis, N):c.115 + 6T > C generalized’] NM_000371.3(TTR): 121918094 TTR [ ] [ ] [‘Amyloidogenic c.95T > C (p.Leu32Pro) transthyretin amyloidosis’] NM_000371.3(TTR): 121918100 TTR [ ] [ ] [‘AMYLOIDOSIS, c.265T > C (p.Tyr89His) LEPTOMENINGEA L, TRANSTHYRETIN -RELATED’] NM_001042465.1(PSAP): 121918110 PSAP [ ] [‘GAAGCYGCCGA [‘Gaucher disease, c.1055T > C AGTCCCTGTCGG’] atypical, due to (p.Leu352Pro) saposin C deficiency’] NM_013251.3(TAC3): 121918123 TAC3 [ ] [ ] [‘not provided’] c.269T > C (p.Met90Thr) NM_199069.1(NDUFAF3): 121918136 NDUFAF3 [ ] [ ] [‘Mitochondrial c.2T > C complex I (p.Met1Thr) deficiency’] NM_003730.4(RNASET2): 121918137 RNASET2 [ ] [CCAGYGCCTTCC [‘Leukoencephalopat c.550T > C ACCAAGCCAGG’] hy, cystic, without (p.Cys184Arg) megalencephaly’] NM_203395.2(IYD): 121918139 IYD [ ] [ ] [‘Iodotyrosine c.347T > C (p.Ile116Thr) deiodination defect’] NM_001127628.1(FBP1): 121918191 FBP1 [ ] [‘GGAGTYCATTTT [‘Fructose- c.581T > C GGTGGACAAGG’] biphosphatase (p.Phe194Ser) deficiency’] NM_015506.2(MMACHC): 121918240 MMACHC [ ] [ ] [‘Methylmalonic c.347T > C acidemia with (p.Leull6Pro) homocystinuria’] NM_000255.3(MUT): 121918249 MUT [ ] [ ] [‘METHYLMALON c.313T > C IC ACIDURIA, (p.Trp105Arg) mut(0) TYPE’] NM_022370.3(ROBO3): 121918275 ROB03 [ ] [ ] [‘Gaze palsy, c.14T > C familial horizontal, (p.Leu5Pro) with progressive scoliosis’] NM_018400.3(SCN3B): 121918282 SCN3B [ ] [ ] [‘Brugada c.29T > C syndrome’, ‘Brugada (p.Leul0Pro) syndrome 7’, ‘Cardiac arrhythmia’, ‘Atrial fibrillation, familial, 16’] NM_004183.3(BEST1): 121918288 BEST1 [ ] [ ] [‘Bestrophinopathy, c.122T > C autosomal recessive’, (p.Leu41Pro) ‘not provided’] NM_020166.4(MCCC1): 772395858 MCCC1 [ ] [ ] [‘3 Methylcrotonyl- c.640-2A > G CoA carboxylase 1 deficiency’] NM_004817.3(TJP2): 121918299 TJP2 [ ] [ ] [‘Hypercholanemia, c.143T > C (p.Val48Ala) familial’] NM_006946.2(SPTBN2): 121918306 SPTBN2 [ ] [‘ACCAAGCYGCT [‘Spinocerebellar c.758T > C GGATCCCGAAGG’, ataxia 5’] (p.Leu253Pro) ‘AAGCYGCTGGAT CCCGAAGGTGG’, ‘AGCYGCTGGATC CCGAAGGTGGG’] NM_000214.2(JAG1): 121918352 JAG1 [ ] [ ] [‘Alagille syndrome c.110T > C l’] (p.Leu37Ser) NM_007194.3(CHEK2): 17879961 CHEK2 [ ] [ ] [‘Familial cancer of c.470T > C breast’, ‘Hereditary (p.Ile157Thr) cancer-predisposing syndrome’, ‘Li- Fraumeni syndrome 2’, ‘not specified’] NM_015384.4(NIPBL): 727503772 NIPBL [ ] [ ] [‘Cornelia de Lange c.7637T > C syndrome 1’] (p.Leu2546Pro) NM_001083112.2(GPD2): 121918407 GPD2 [‘AAGT [‘AAGTYTGATGCA [‘Diabetes mellitus c.1904T > C YTGAT GACCAGAAAGG’] type 2’] (p.Phe635Ser) GCAGA CCAGA AAGG’] NM_021957.3(GYS2): 121918424 GYS2 [ ] [ ] [‘Hypoglycemia with c.1447T > C deficiency of (p.Ser483Pro) glycogen synthetase in the liver’] NM_018849.2(ABCB4): 121918443 ABCB4 [ ] [ ] [‘Progressive c.1207T > C familial intrahepatic (p.Tyr403His) cholestasis 3’] NM_000212.2(ITGB3): 121918447 — [ ] [ ] [‘Glanzmann c.2332T > C thrombasthenia’] (p.Ser778Pro) NM_000506.3(F2): 121918481 F2 [ ] [ ] [‘Hereditary factor II c.1139T > C deficiency disease’] (p.Met380Thr) NM_000141.4(FGFR2): 121918489 FGFR2 [‘TGGG [‘TGGGGAAYATA [‘Crouzon c.1018T > C GAAYA CGTGCTTGGCGG’, syndrome’] (p.Tyr340His) TACGT ‘GGGGAAYATACG GCTTG TGCTTGGCGGG’] GCGG’, ‘GGGGA AYATA CGTGC TTGGC GGG’] NM_000141.4(FGFR2): 121918505 FGFR2 [ ] [‘AATGCCYCCACA [‘Pfeiffer syndrome’, c.799T > C GTGGTCGGAGG’] ‘Neoplasm of (p.Ser267Pro) stomach’] NM_002739.3(PRKCG): 121918512 PRKCG [ ] [ ] [‘Spinocerebellar c.355T > C ataxia 14’] (p.Ser119Pro) NM_002739.3(PRKCG): 121918516 PRKCG [ ] [ ] [‘Spinocerebellar c.1927T > C ataxia 14’] (p.Phe643Leu) NM_015107.2(PHF8): 121918524 PHF8 [ ] [ ] [Siderius X-linked c.836T > C mental retardation (p.Phe279Ser) syndrome’] NM_000311.3(PRNP): 74315405 PRNP [ ] [ ] [‘Gerstmann- c.593T > C Straussler-Scheinker (p.Phe198Ser) syndrome’, ‘Genetic prion diseases’] NM_015665.5(AAAS): 121918550 AAAS [ ] [ ] [Glucocorticoid c.787T > C deficiency with (p.Ser263Pro) achalasia’] NM_003018.3(SFTPC): 121918560 SFTPC [ ] [ ] [‘Surfactant c.581T > C metabolism (p.Leu194Pro) dysfunction, pulmonary, 2’] NM_000322.4(PRPH2): 121918563 PRPH2 [ ] [ ] [‘Patterned c.554T > C dystrophy of retinal (p.Leu185Pro) pigment epithelium’, ‘Retinitis pigmentosa 7, digenic’, ‘not provided’, ‘Leber congenital amaurosis 181 NM_000322.4(PRPH2): 121918565 PRPH2 [ ] [ ] [‘Macular dystrophy, c.2T > C (p.Met1Thr) vitelliform, adult- onset’, ‘not provided’] NM_001035.2(RYR2): 121918602 RYR2 [ ] [ ] [‘Arrhythmogenic c.1298T > C right ventricular (p.Leu433Pro) cardiomyopathy, type 2’, ‘Catecholaminergic polymorphic ventricular tachycardia’, ‘Long QT syndrome’] NM_001199138.1(NLRC4): 587781260 NLRC4 [ ] [ ] [‘Syndrome of c.1022T > C entercolitis and (p.Val341Ala) autoinflmmation caused by mutation of NLRC4 (SCAN4)’, ‘Autoinflammation with infantile enterocolitis’] NM_000702.3(ATP1A2): 121918617 ATP1A2 [ ] [ ] [‘Familial c.857T > C hemiplegic migraine (p.Ile286Thr) type 2’] NM_006920.4(SCN1A): 121918627 — [ ] [ ] [‘Generalized c.4250T > C epilepsy with febrile (p.Val1417Ala) seizures plus, type 1’, ‘Generalized epilepsy with febrile seizures plus, type 2’] NM_006920.4(SCN1A): 121918631 SCN1A [ ] [ ] [‘Generalized c.434T > C epilepsy with febrile (p.Met145Thr) seizures plus, type 2’] NM_006920.4(SCN1A): 121918632 — [ ] [ ] [‘Familial c.4462T > C hemiplegic migraine (p.Phe1488Leu) type 3’] NM_003126.2(SPTA1): 121918636 SPTA1 [ ] [ ] [‘Elliptocytosis 2’] c.781T > C (p.Ser261Pro) NM_003126.2(SPTA1): 121918643 SPTA1 [ ] [‘GTGGAGCYGGT [‘Hereditary c.620T > C AGCTAAAGAAGG’, pyropoikilocytosis’, (p.Leu207Pro) ‘TGGAGCYGGTAG ‘Elliptocytosis 2’] CTAAAGAAGGG’] NM_001024858.2(SPTB): 121918646 SPTB [ ] [CTCCAGCYGGA [‘Spherocytosis type c.604T > C AGGATGGCTTGG’] 2’] (p.Trp202Arg) NM_001024858.2(SPTB): 121918648 SPTB [ ] [‘ATGCCYCTGTGG [ ] c.6055T > C CTGAGGCGTGG’] (p.Ser2019Pro) NM_001128177.1(THRB): 121918699 THRB [ ] [ ] [ ] c.929T > C (p.Met310Thr) NM_001128177.1(THRB): 121918704 THRB [ ] [ ] [‘Thyroid hormone c.1373T > C resistance, (p.Val458Ala) generalized, autosomal recessive’] NM_000421.3(KRT10): 60118264 — [ ] [ ] [‘Bullous c.482T > C ichthyosiform (p.Leu161Ser) erythroderma’, ‘not provided’] NM_006920.4(SCN1A): 121918733 SCN1A [‘ACTTY [‘ACTTYTATAGTA [‘Severe myoclonic c.269T > C TATAG TTGAATAAAGG’, epilepsy in infancy’] (p.Phe90Ser) TATTG ‘CTTYTATAGTATT AATAA GAATAAAGGG’] AGG’, ‘CTTYT ATAGT ATTGA ATAAA GGG’] NM_006920.4(SCN1A): 121918734 SCN1A [‘ACTTT [‘ACTTTTAYAGTA [‘Severe myoclonic c.272T > C TAYAG TTGAATAAAGG’, epilepsy in infancy’] (p.Ile91Thr) TATTG ‘CTTTTAYAGTATT AATAA GAATAAAGGAG’] AGG’, ‘CTTTT AYAGT ATTGA ATAAA GGG’] NM_006920.4(SCN1A): 121918740 — [ ] [ ] [‘Severe myoclonic c.3827T > C epilepsy in infancy’] (p.Leu1276Pro) NM_000543.4(SMPD1): 727504166 SMPD1 [ ] [IGAGGCCYGTG [‘Niemann-Pick c.475T > C GCCTGCTCCTGG’, disease, type A’, (p.Cys159Arg) ‘GAGGCCYGTGGC ‘Niemann-Pick CTGCTCCTGGG’] disease, type B’] NM_006920.4(SCN1A): 121918773 SCN1A [ ] [ ] [‘Severe myoclonic c.568T > C epilepsy in infancy’] (p.Trp190Arg) NM_006920.4(SCN1A): 121918783 — [ ] [ ] [‘Severe myoclonic c.5522T > C epilepsy in infancy’, (p.Met1841Thr) ‘Generalized epilepsy with febrile seizures plus, type 1’] NM_002538.3(0CLN): 267606926 OCLN [ ] [ ] [‘Band-like c.656T > C calcification with (p.Phe219Ser) simplified gyration and polymicrogyria’] NM_000434.3(NEU1): 193922915 NEU1 [ ] [CAGCYATGGCC [Sialidosis, type II’] c.1088T > C AGGCCCCAGTGG’] (p.Leu363Pro) NM_198578.3(LRRK2): 35870237 LRRK2 [ ] [ ] [‘Parkinson disease c.6059T > C 8, autosomal (p.Ile2020Thr) dominant’] NM_000501.3(ELN): 727504419 ELN [ ] [‘CAGGYAACATCT [Supravalvar aortic c.889 + 2T > C GTCCCAGCAGG’, stenosis’] ‘AGGYAACATCTG TCCCAGCAGGG’] NM_001085.4(SERPINA3): 1800463 SERPINA3 [ ] [ ] [ ] c.233T > C (p.Leu78Pro) NM_000238.3(KCNH2): 199473425 KCNH2 [‘Congenital long c.1736T > C QT syndrome’] (p.Met579Thr) NM_001211.5(BUB1B): 28989185 — [ ] [ ] [‘Mosaic variegated c.3035T > C aneuploidy (p.Leu1012Pro) syndrome’, ‘Premature chromatid separation trait’] NM_000256.3(MYBPC3): 376395543 MYBPC3 [ ] [‘GAGACYGAAGG [‘Primary familial c.26-2A > G GCCAGGTGGAGG’] hypertrophic cardiomyopathy’, ‘Familial hypertrophic cardiomyopathy 4’, ‘Cardiomyopathy’] NM_000051.3(ATM): 587781927 ATM [ ] [ ] [‘Ataxia- c.4776 + 2T > C telangiectasia syndrome’, ‘Hereditary cancer- predisposing syndrome’] NM_006412.3(AGPAT2): 116807569 AGPAT2 [ ] [ ] [‘Congenital c.589-2A > G generalized lipodystrophy type 1’] NM_000545.6(HNF1A): 1169305 HNFlA [ ] [GATGCYGGCAG [‘Maturity-onset c.1720G > A GGTCCTGGCTGG’, diabetes of the (p.Gly574Ser) ‘ATGCYGGCAGGG young, type 3’] TCCTGGCTGGG’, ‘TGCYGGCAGGGT CCTGGCTGGGG’] NM_024514.4(CYP2R1): 61495246 CYP2R1 [ ] [ ] [‘Vitamin d c.296T > C hydroxylation- (p.Leu99Pro) deficient rickets, type 1b’] NM_012213.2(MLYCD): 28937908 MLYCD [ ] [ ] [‘Deficiency of c.119T > C malonyl-CoA (p.Met40Thr) decarboxylase’] NM_001101.3(ACTB): 587779771 ACTB [ ] [ ] [‘Baraitser-Winter c.224T > C syndrome 1’] (p.Ile75Thr) NM_021007.2(SCN2A): 796053181 SCN2A [‘TGTG [‘TGTGGYGGCCAT [‘not provided’] c.1271T > C GYGGC GGCCTATGAGG’] (p.Val424Ala) CATGG CCTAT GAGGl NM_002880.3(RAF1): 727505017 RAF1 [ ] [ ] [‘Rasopathy’, ‘not c.769T > C specified’] (p.Ser257Pro) NM_000527.4(LDLR): 730880130 LDLR [ ] [CTACYGGACCG [‘Familial c.1468T > C ACTCTGTCCTGG’, hypercholesterolemial (p.Trp490Arg) ‘TACYGGACCGAC TCTGTCCTGGG] NM_170707.3(LMNA): 730880132 LMNA [‘TGAG [‘TGAGTYTGAGA [‘Primary dilated c.710T > C TYTGA GCCGGCTGGCGG’] cardiomyopathy’] (p.Phe237Ser) GAGCC GGCTG GCGG’] NM_000080.3(CHRNE): 193919341 — [ ] [ ] [‘MYASTHENIC c.223T > C SYNDROME, (p.Trp75Arg) CONGENITAL, 4B, FAST-CHANNEL’] NM_005211.3(CSF1R): 281860270 CSF1R [ ] [ ] [‘Hereditary diffuse c.2297T > C leukoencephalopath (p.Met766Thr) y with spheroids’] NM_005211.3(CSF1R): 281860274 CSF1R [‘CAAG [‘CAAGAYTGGGG [‘Hereditary diffuse c.2381T > C AYTGG ACTTCGGGCTGG’] leukoencephalopathy (p.Ile794Thr) GGACT with spheroids’] TCGGG CTGG’] NM_005211.3(CSF1R): 281860277 CSF1R [ ] [ ] [‘Hereditary diffuse c.2546T > C leukoencephalopath (p.Phe849Ser) y with spheroids’] NM_005211.3(CSF1R): 281860279 CSF1R [ ] [ ] [‘Hereditary diffuse c.2624T > C leukoencephalopath (p.Met875Thr) y with spheroids’] NM_018713.2(SLC30A10): 281860284 SLC30A10 [ ] [ ] [‘Hypermanganesem c.266T > C ia with dystonia, (p.Leu89Pro) polycythemia and cirrhosis’] NM_018713.2(SLC30A10): 281860286 SLC30A10 [ ] [‘GGCGCTTYCGGG [‘Hypermanganesem c.500T > C GGGCCTCAGGG’] ia with dystonia, (p.Phe167Ser) polycythemia and cirrhosis’] NM_018713.2(SLC30A10): 281860291 SLC30A10 [ ] [ ] [‘Hypermanganesem c.1046T > C ia with dystonia, (p.Leu349Pro) polycythemia and cirrhosis’] NM_016218.2(POLK): 772307321 POLK [ ] [ ] [‘Malignant tumor of c.2287T > A prostate’] (p.Tyr763Asn) NM_000570.4(FCGR3B): 448740 FCGR3B [ ] [ ] [ ] c.194A > G (p.Asn65Ser) NM_030653.3(DDX11): 730880279 DDX11 [‘TCCA [‘TCCAGGYGCGG [‘Warsaw breakage c.2271 + 2T > C GGYGC GCGTCATGCTGG’, syndrome’] GGGCG ‘CCAGGYGCGGGC TCATG GTCATGCTGGG’] CTGG’] NM_145693.2(LPIN1): 730880306 LPIN1 [ ] [AAGGYACCGCG [‘Myoglobinuria, c.1441 + 2T > C GGCCTCGCGCGG’, acute recurrent, ‘AGGYACCGCGGG autosomal CCTCGCGCGGG’] recessive’] NM_002546.3(TNFRSH1B): 200071478 TNFRSF11B [ ] [ ] [‘Hyperphosphatase c.226A > C mia with bone (p.Thr76Pro) disease’] NM_000166.5(GJB1): 116840817 GJB1 [ ] [ ] [‘X-linked hereditary c.145T > C (p.Ser49Pro) motor and sensory neuropathy’] NM_005159.4(ACTC1): 730880398 — [ ] [ ] [‘Cardiomyopathy’] c.755T > C (p.Ile252Thr) NM_020166.4(MCCC1): 147741073 MCCC1 [ ] [ ] [‘3 Methylcrotonyl- c.205A > T CoA carboxylase 1 (p.Lys69Ter) deficiency’] NM_000454.4(SOD1): 74315452 SOD1 [ ] [‘TTGCAYCATTGG [‘Amyotrophic c.338T > C CCGCACACTGG’] lateral sclerosis type (p.Ile113Thr) 1’] NM_000169.2(GLA): 730880455 — [ ] [‘CGCGCYTGCGCT [‘not provided’] c.41T > C (p.Leu14Pro) TCGCTTCCTGG’] NM_152743.3(BRAT1): 727505363 BRAT1 [ ] [ ] [‘Rigidity and c.176T > C multifocal seizure (p.Leu59Pro) syndrome, lethal neonatal’] NM_005633.3(SOS1): 727505381 SOS1 [ ] [ ] [‘Noonan syndrome’, c.2104T > C ‘Rasopathy’] (p.Tyr702His) m.1095T > C 267606618 MT-RNR1 [ ] [ ] [‘Aminoglycoside- induced deafness’, ‘Auditory neuropathy’, ‘Deafness, nonsyndromic sensorineural, mitochondrial’, ‘not specified’] m.1291T > C 267606620 MT-RNR1 [ ] [ ] [‘Deafness, nonsyndromic sensorineural, mitochondrial’] NM_020247.4(ADCK3): 606231138 ADCK3 [ ] [ ] [‘Coenzyme Q10 c.1398 + 2T > C deficiency, primary, 4’] NM_000256.3(MYBPC3): 730880616 MYBPC3 [ ] [ ] [‘Cardiomyopathy’] c.467T > C (p.Leu156Pro) NM_022458.3(LMBR1): 606231149 LMBR1 [ ] [ ] [‘Triphalangeal c.423 + 4842T > C thumb’, ‘Preaxial polydactyly 2’] NM_022458.3(LMBR1): 606231152 LMBR1 [ ] [ ] [‘Triphalangeal c.423 + 4808T > C thumb’, ‘Preaxial polydactyly 2’] NM_021102.3(SPINT2): 606231155 SPINT2 [ ] [ ] [‘Diarrhea 3, c.337 + 2T > C secretory sodium, congenital, syndromic’] NM_001004127.2(ALG11): 267606652 ALG11 [ ] [ ] [‘Congenital disorder c.257T > C of glycosylation type (p.Leu86Ser) 1P’] NM_054027.4(ANKH): 267606656 ANKH [ ] [‘AGCTCYGTTTCG [‘Craniometaphyseal c.1015T > C TGATGTTTTGG’] dysplasia, autosomal (p.Cys339Arg) dominant’] NM_054027.4(ANKH): 267606658 — [ ] [ ] [‘Craniometaphyseal c.1172T > C dysplasia, autosomal (p.Leu391Pro) dominant’] NM_175073.2(APTX): 267606665 APTX [ ] [ ] [‘Adult onset ataxia c.668T > C with oculomotor (p.Leu223Pro) apraxia’] NM_004183.3(BEST1): 267606679 BEST1 [‘CACT [‘CACTGGYGTATA [‘Vitreoretinochoroid c.704T > C GGYGT CACAGGTGAGG’] opathy dominant’] (p.Val235Ala) ATACA CAGGT GAGG’] NM_004183.3(BEST1): 267606680 BEST1 [ ] [ ] [‘Retinitis c.614T > C pigmentosa 50’] (p.Ile205Thr) NM_033409.3(SLC52A3): 267606685 SLC52A3 [ ] [ ] [Brown-Vialetto- c.670T > C Van laere (p.Phe224Leu) syndrome’] NM_033409.3(SLC52A3): 267606687 SLC52A3 [ ] [‘AGTTACGYCAA [Brown-Vialetto- c.1238T > C GGTGATGCTGGG’] Van laere (p.Val413Ala) syndrome’] NM_004056.4(CA8): 267606695 CA8 [ ] [ ] [‘Cerebellar ataxia, c.298T > C (p.Ser100Pro) mental retardation, and dysequilibrium syndrome 3’] NM_000256.3(MYBPC3): 730880702 MYBPC3 [ ] [ ] [‘Cardiomyopathy’] c.3713T > C (p.Leu1238Pro) NM_001928.2(CFD): 267606721 CFD [ ] [‘GGTGYGCGGGG [‘Complement factor c.640T > C GCGTGCTCGAGG’, d deficiency’] (p.Cys214Arg) ‘GTGYGCGGGGGC GTGCTCGAGGM NM_005740.2(DNAL4): 606231254 DNAL4 [‘CGAG [‘CGAGGYATTGCC [‘Mirror movements c.153 + 2T > C GYATT AGCAGTGCAGG’] 3’] GCCAG CAGTG CAGG’] NM_020975.4(RET): 74799832 RET [ ] [ ] [‘Multiple endocrine c.2753T > C neoplasia, type 2a’, (p.Met918Thr) ‘Multiple endocrine neoplasia, type 2b’, ‘Multiple endocrine neoplasia, type 2’, ‘Pheochromocytoma’, ‘not provided’] NM_001849.3(COL6A2): 267606747 COL6A2 [ ] [‘CGCCYGCGACA [‘Ullrich congenital c.2329T > C AGCCACAGCAGG’] muscular dystrophy’] (p.Cys777Arg) NM_001006657.1(WDR35): 431905505 WDR35 [ ] [ ] [‘Short rib c.781T > C polydactyly (p.Trp261Arg) syndrome 5’] NM_003764.3(STX11): 431905512 STX11 [‘TGCY [‘TGCYGGTGGCCG [‘Hemophagocytic c.173T > C GGTGG ACGTGAAGCGG’] lymphohistiocytosis, (p.Leu58Pro) CCGAC familial, 4’] GTGAA GCGG’] NM_001044.4(SLC6A3): 431905515 SLC6A3 [ ] [‘CTGCACCYCCAC [‘Infantile c.671T > C CAGAGCCATGG’] Parkinsonism- (p.Leu224Pro) dystonia’] NM_000277.1(PAH): 62642930 PAH [ ] [ ] [‘Phenylketonuria’, c.764T > C ‘not provided’] (p.Leu255Ser) NM_000277.1(PAH): 62642936 PAH [ ] [ ] [‘Phenylketonuria’, c.932T > C ‘not provided’] (p.Leu311Pro) NM_000118.3(ENG): 267606783 ENG [ ] [ ] [‘Osler hemorrhagic c.2T > C (p.Met1Thr) telangiectasia syndrome’] NM_000129.3(F13A1): 267606788 F13A1 [‘TGTG [‘TGTGAYGGACA [‘Factor xiii, a c.728T > C AYGGA GAGCACAAATGG’] subunit, deficiency (p.Met243Thr) CAGAG of’] CACAA ATGG’] NM_000257.3(MYH7): 606231328 MYH7 [ ] [ ] [‘Familial c.1952A > G cardiomyopathy’] (p.His651Arg) NM_014053.3(FLVCR1): 267606821 FLVCR1 [ ] [ ] [‘Posterior column c.574T > C ataxia with retinitis (p.Cys192Arg) pigmentosa’] NM_005249.4(FOXG1): 267606828 FOXG1 [ ] [ ] [‘Rett syndrome, c.643T > C congenital variant’] (p.Phe215Leu) NM_015474.3(SAMHD1): 515726140 SAMHD1 [ ] [ ] [‘Aicardi Goutieres c.1153A > G syndrome 5’] (p.Met385Val) NM_015474.3(SAMHD1): 515726141 SAMHD1 [ ] [ ] [‘Aicardi Goutieres c.1411-2A > G syndrome 5’] NM_000180.3(GUCY2D): 267606857 GUCY2D [ ] [‘AGAGAYCGCCA [‘Cone-rod c.2846T > C ACATGTCACTGG’] dystrophy 6’] (p.Ile949Thr) NM_022489.3(INF2): 267606877 INF2 [ ] [ ] [‘Focal segmental c.556T > C glomerulosclerosis (p.Ser186Pro) 5’] NM_000257.3(MYH7): 730880863 MYH7 [ ] [ ] [‘Cardiomyopathy’] c.1048T > C (p.Tyr350His) NM_022489.3(INF2): 267606880 INF2 [ ] [‘GCTGCYCCAGAT [‘Focal segmental c.125T > C (p.Leu42Pro) GCCCTCTGTGG’] glomerulosclerosis 5’] m.4681T > C 267606889 MT-ND2 [ ] [ ] [‘Leigh disease’, ‘Leigh syndrome due to mitochondrial complex I deficiency’] m.10191T > C 267606890 MT-ND3 [ ] [ ] [‘Leigh disease’, ‘Mitochondrial complex I deficiency’] m.10563T > C 267606892 MT-ND4L [ ] [ ] [‘Familial colorectal cancer’] m.12706T > C 267606893 MT-NDS [ ] [ ] [‘Leigh disease’, ‘Leigh syndrome due to mitochondrial complex I deficiency’] NM_015713.4(RRM2B): 515726190 RRM2B [ ] [ ] [‘RRM2B-related c.556A > G mitochondrial (p.Arg186G1y) disease’] NM_015713.4(RRM2B): 515726191 RRM2B [ ] [‘AACTCCTYCTAC [‘RRM2B-related c.581A > G AGCAGCAAAGG’] mitochondrial (p.Glu194G1y) disease’] NM_000315.2(PTH): 104894271 PTH [‘AATT [‘AATTYGTTTTCT [‘Hypoparathyroidism c.52T > C (p.Cys18Arg) YGTTT TACAAAATCGG’] familial isolated’] TCTTA CAAAA TCGG’] NM_001136271.2(NKX2-6): 267606914 NKX2-6 [ ] [ ] [‘Persistent truncus c.451T > C arteriosus’] (p.Phe151Leu) NM_004646.3(NPHS1): 267606917 NPHS1 [ ] [‘GCTGCCGYGCGT [‘Finnish congenital c.793T > C GGCCCGAGGGG’, nephrotic (p.Cys265Arg) ‘CTGCCGYGCGTG syndrome’] GCCCGAGGGGG’] NM_000406.2(GNRHR): 515726219 GNRHR [ ] [ ] [‘Hypogonadotropic c.94A > G hypogonadism’] (p.Thr32Ala) NM_152296.4(ATP1A3): 606231436 ATP1A3 [ ] [ ] [‘Alternating c.2270T > C hemiplegia of (p.Leu757Pro) childhood 2’] NM_000513.2(OPN1MW): 267606927 OPN1MW [ ] [ ] [‘Cone dystrophy 5, c.529T > C X-linked’] (p.Trp177Arg) NM_152296.4(ATP1A3): 606231448 ATP1A3 [ ] [ ] [‘Dystonia 12’] c.1144T > C (p.Trp382Arg) NM_024411.4(PDYN): 267606940 PDYN [ ] [ ] [‘Spinocerebellar c.632T > C ataxia 23’] (p.Leu211Ser) NM_000444.5(PHEX): 267606945 PHEX [ ] [ ] [‘Familial X-linked c.755T > C hypophosphatemic (p.Phe252Ser) vitamin D refractory rickets’] NM_001543.4(NDST1): 606231458 NDST1 [ ] [ ] [‘Mental retardation, c.1918T > C autosomal recessive (p.Phe640Leu) 46’] NM_013382.5(POMT2): 267606964 POMT2 [ ] [ ] [‘Congenital c.2242T > C muscular dystrophy- (p.Trp748Arg) dystroglycanopathy with mental retardation, type B2’] NM_006121.3(KRT1): 57695159 KRT1 [ ] [ ] [‘Bullous c.482T > C ichthyosiform (p.Leu161Pro) erythroderma’, ‘not provided’] NM_016203.3(PRKAG2): 267606976 PRKAG2 [ ] [ ] [‘Familial c.1459T > C hypertrophic (p.Tyr487His) cardiomyopathy 6’, ‘not provided’] NM_016203.3(PRKAG2): 267606979 PRKAG2 [ ] [ ] [‘Familial c.1642T > C hypertrophic (p.Ser548Pro) cardiomyopathy 6’, ‘not provided’] NM_198965.1(PTHLH): 267606985 PTHLH [ ] [ ] [‘Brachydactyly type c.179T > C E2’] (p.Leu60Pro) NM_198965.1(PTHLH): 267606986 PTHLH [ ] [ ] [‘Brachydactyly type c.131T > C E2’] (p.Leu44Pro) NM_004990.3(MARS): 140467171 MARS [ ] [ ] [‘Interstitial lung and c.1108T > C liver disease’] (p.Phe370Leu) NM_173560.3(RFX6): 267607012 RFX6 [ ] [ ] [‘Mitchell-Riley c.649T > C syndrome’] (p.Ser217Pro) NM_002942.4(ROBO2): 267607014 ROB02 [‘GAGA [‘GAGAYTGGAAA [‘Vesicoureteral c.2834T > C YTGGA TTTTGGCCGTGG’] reflux 2’] (p.Ile945Thr) AATTT TGGCC GTGG’] NM_178857.5(RP1L1): 267607018 RP1L1 [ ] [ ] [‘Occult macular c.2878T > C dystrophy’] (p.Trp960Arg) NM_002880.3(RAF1): 730881003 RAF1 [ ] [ ] [‘Rasopathy’] c.1423T > C (p.Phe475Leu) NM_015272.3(RPGRIP1L): 267607020 RPGRIP1L [ ] [ ] [‘Joubert syndrome c.1975T > C 7’, ‘COACH (p.Ser659Pro) syndrome’] NM_015559.2(SETBP1): 267607038 SETBP1 [ ] [ ] [‘Schinzel-Giedion c.2612T > C syndrome’] (p.Ile871Thr) NM_000433.3(NCF2): 137878529 NCF2 [ ] [ ] [‘Chronic c.481A > G granulomatous (p.Lys161Glu) disease, autosomal recessive cytochrome b- positive, type 2’] NM_001041.3(SI): 267607049 SI [ ] [ ] [‘Sucrase-isomaltase c.1022T > C (p.Leu341Pro) deficiency’] NM_005633.3(SOS 1): 267607080 SOS 1 [‘GGTY [‘GGTYGGGAGGG [‘Noonan syndrome c.1294T > C GGGAG AAAAGACATTGG’] 4’, ‘Rasopathy’] (p.Trp432Arg) GGAAA AGACA TTGG’] NM_018136.4(ASPM): 587783225 ASPM [ ] [ ] [‘Primary autosomal c.2419 + 2T > C recessive microcephaly 5’] NM_001199107.1(TBC1D24): 267607104 TBC1D24 [ ] [‘CAAGTTCYTCCA [‘Myoclonic c.751T > C CAAGGTGAGGG’, epilepsy, familial (p.Phe251Leu) ‘TTCYTCCACAAG infantile’] GTGAGGGCCGG’] NM_153704.5(TMEM67): 267607115 TMEM67 [ ] [ ] [‘Joubert syndrome c.1769T > C 6’, ‘COACH (p.Phe590Ser) syndrome’] NM_153704.5(TMEM67): 267607119 TMEM67 [ ] [ ] [‘Joubert syndrome c.2498T > C 6’, ‘COACH (p.Ile833Thr) syndrome’] NM_133378.4(TTN): 267607156 — [ ] [ ] [‘Distal myopathy c.100163T > C Markesbery-Griggs (p.Leu33388Pro) type’] m.12811T > C 199974018 MT-ND5 [ ] [ ] [‘Leber optic atrophy’] NM_144631.5(ZNF513): 267607182 ZNF513 [ ] [‘TGGGCGCYGCAT [‘Retinitis c.1015T > C GCGAGGAGAGG’, pigmentosa 58’] (p.Cys339Arg) ‘CGCYGCATGCGA GGAGAGGCTGG’] NM_004737.4(LARGE): 267607209 LARGE [ ] [ ] [‘Congenital c.1483T > C muscular dystrophy- (p.Trp495Arg) dystroglycanopathy with brain and eye anomalies, type A6’] NM_000229.1(LCAT): 267607211 LCAT [ ] [‘TATGACYGGCG [‘Norum disease’] c.508T > C GCTGGAGCCCGG’] (p.Trp170Arg) NM_016269.4(LEF1): 267607215 — [ ] [‘GAACGAGYCTG [‘Sebaceous tumors, c.181T > C (p.Ser61Pro) AAATCATCCCGG’] somatic’] NM_139248.2(LIPH): 267607219 LIPH [ ] [ ] [‘Woolly hair, c.322T > C autosomal recessive (p.Trp108Arg) 2, with or without hypotrichosis’] NM_004268.4(MED17): 267607232 MED17 [ ] [ ] [‘Microcephaly, c.1112T > C postnatal (p.Leu371Pro) progressive, with seizures and brain atrophy’] NM_000530.6(MPZ): 267607241 MPZ [ ] [ ] [ ] c.341T > C (p.Ile114Thr) NM_000489.4(ATRX): 122445094 ATRX [ ] [ ] [‘ATR-X syndrome’] :c.4840T > C (p.Cys1614Arg) NM_000489.4(ATRX): 122445097 ATRX [ ] [ ] [‘ATR-X syndrome’] c.6250T > C (p.Tyr2084His) NM_000489.4(ATRX): 122445109 ATRX [ ] [ ] [ ] c.1226T > C (p.Leu409Ser) NM_000489.4(ATRX): 122445110 ATRX [ ] [ ] [‘Multiple congenital c.6149T > C anomalies’] (p.Ile2050Thr) NM_178151.2(DCX): 587783536 DCX [ ] [ ] [‘Heterotopia’] c.272T > C (p.Leu91Pro) NM_178151.2(DCX): 587783539 DCX [‘CAAA [‘CAAAATAYGGA [‘Heterotopia’] c.2T > C (p.Met1Thr) ATAYG ACTTGATTTTGG’] GAACT TGATT TTGG’] NM_178151.2(DCX): 587783551 DCX [ ] [ ] [‘Heterotopia’] c.412T > C (p.Tyr138His) NM_000212.2(ITGB3): 398122374 — [ ] [ ] [‘Platelet-type c.2231T > C bleeding disorder (p.Leu744Pro) 16’] NM_178151.2(DCX): 587783574 DCX [ ] [ ] [‘Heterotopia’] c.641T > C (p.Ile214Thr) NM_178151.2(DCX): 587783580 DCX [ ] [‘AAAAAACYCTA [‘Heterotopia’] c.683T > C CACTCTGGATGG’] (p.Leu228Pro) NM_001005360.2(DNM2): 587783597 DNM2 [ ] [ ] [‘Myopathy, c.1862T > C centronuclear’] (p.Leu621Pro) NM_006579.2(EBP): 587783609 EBP [ ] [ ] [‘Chondrodysplasia c.310T > C (p.Tyr104His) punctata 2 X-linked dominant’] NM_004004.5(GJB2): 587783644 GJB2 [ ] [‘GATCCYCGTTGT [‘Hearing c.107T > C GGCTGCAAAGG’] impairment’] (p.Leu36Pro) NM_005682.6(ADGRG1): 587783653 ADGRG1 [ ] [VCCTGCYCACCT [‘Polymicrogyria, c.1460T > C GCCTTTCCTGG’] bilateral (p.Leu487Pro) frontoparietal’] NM_000525.3(KCNJ11): 587783675 KCNJ11 [ ] [ ] [‘Diabetes mellitus’] c.988T > C (p.Tyr330His) NM_170707.3(LMNA): 267607593 LMNA [ ] [ ] [‘Dilated c.799T > C cardiomyopathy 1A’, (p.Tyr267His) ‘not provided’] NM_000252.2(MTM1): 587783780 MTM1 [ ] [ ] [‘Severe X-linked c.1353 + 2T > C myotubular myopathy’] NM_000252.2(MTM1): 587783783 MTM1 [ ] [ ] [‘Severe X-linked c.1367T > C myotubular (p.Phe456Ser) myopathy’] NM_000252.2(MTM1): 587783794 MTM1 [ ] [ ] [‘Severe X-linked c.1433T > C myotubular (p.Phe478Ser) myopathy’] NM_000252.2(MTM1): 587783801 MTM1 [ ] [ ] [‘Severe X-linked c.1495T > C myotubular (p.Trp499Arg) myopathy’] NM_000252.2(MTM1): 587783816 MTM1 [ ] [ ] [‘Severe X-linked c.260T > C myotubular (p.Leu87Pro) myopathy’] NM_000252.2(MTM1): 587783851 MTM1 [ ] [ ] [‘Severe X-linked c.683T > C myotubular (p.Leu228Pro) myopathy’] NM_000252.2(MTM1): 587783863 MTM1 [ ] [‘GGAAYCTTTAAA [‘Severe X-linked c.958T > C AAAAGTGAAGG’] myotubular (p.Ser320Pro) myopathy’] NM_000526.4(KRT14): 59629244 KRT14 [ ] [ ] [‘Epidermolysis c.1151T > C bullosa simplex, (p.Leu384Pro) Koebner type’, ‘not provided’] NM_000249.3(MLH1): 267607751 MLH1 [ ] [ATCACGGYAAG [‘Hereditary c.453 + 2T > C AATGGTACATGG’, Nonpolyposis ‘TCACGGYAAGAA Colorectal TGGTACATGGG’] Neoplasms’] NM_002764.3(PRPS1): 80338676 PRPS1 [ ] [ ] [‘Arts syndrome’, c.455T > C ‘not provided’] (p.Leu152Pro) NM_022132.4(MCCC2): 119103222 MCCC2 [ ] [ ] [‘3-methylcrotonyl c.499T > C CoA carboxylase 2 (p.Cys167Arg) deficiency’] NM_000411.6(HLCS): 119103227 HLCS [ ] [‘CTATCYTTCTCA [‘Holocarboxylase c.710T > C GGGAGGGAAGG’] synthetase (p.Leu237Pro) deficiency’] NM_005787.5(ALG3): 119103237 ALG3 [ ] MATTGACYGGA [‘Congenital disorder c.211T > C AGGCCTACATGG’] of glycosylation type (p.Trp71Arg) 1D’] NM_005609.2(PYGM): 119103254 PYGM [ ] [ ] [‘Glycogen storage c.1187T > C disease, type V’] (p.Leu396Pro) m.3250T > C 199474664 MT-TL1 [ ] [ ] [ ] NM_002764.3(PRPS1): 80338732 PRPS1 [‘GCAA [‘GCAAATAYGCT [Charcot-Marie- :c.344T > C ATAYG ATCTGTAGCAGG’] Tooth disease, X- (p.Met115Thr) CTATC linked recessive, TGTAG type 5’] CAGG’] NM_003172.3(SURF1): 398122806 SURF1 [ ] [‘CCACYGGCATTA [‘Congenital c.679T > C TCGAGACCTGG’] myasthenic (p.Trp227Arg) syndrome, acetazolamide-responsive’] NM_004525.2(LRP2): 80338747 LRP2 [ ] [‘GTACCTGYACTG [‘Donnai Barrow c.7564T > C GGCTGACTGGG’] syndrome’] (p.Tyr2522His) NM_006329.3(FBLN5): 80338766 FBLN5 [ ] [ ] [‘Autosomal c.649T > C recessive cutis laxa (p.Cys217Arg) type IA’] NM_001271723.1(FBXO38): 398122838 FBXO38 [ ] [‘TTCCTYGTATCC [‘Distal hereditary c.616T > C CAATGCTAAGG’] motor neuronopathy (p.Cys206Arg) 2D’] NM_133433.3(NIPBL): 587784032 NIPBL [ ] [ ] [‘Cornelia de Lange c.7062 + 2T > C syndrome 1’] NM_000334.4(SCN4A): 80338790 SCN4A [ ] [ ] [‘Hyperkalemic c.4468T > C Periodic Paralysis (p.Phe1490Leu) Type 1’] NM_058216.2(RAD51C): 730881931 RAD51C [ ] [ ] [‘Hereditary cancer- c.404 + 2T > C predisposing syndrome’] NM_001111.4(ADAR): 398122897 ADAR [ ] [ ] [‘Aicardi-goutieres c.2615T > C syndrome 6’] (p.Ile872Thr) NM_005334.2(HCFC1): 398122908 HCFC1 [‘CAAG [‘CAAGAYGGCGG [‘Mental retardation c.-970T > C AYGGC CTCCCAGGGAGG’ 3, X-linked’] GGCTC ] CCAGG GAGG’] NM_000431.3(MVK): 398122910 MVK [‘CCAG [‘CCAGGYATCCCG [‘Porokeratosis, c.1039 + 2T > C GYATC GGGGTAGGTGG’, disseminated CCGGG ‘CAGGYATCCCGG superficial actinic 1’] GGTAG GGGTAGGTGGG’] GTGG’] NM_000431.3(MVK): 398122911 MVK [ ] [ ] [‘Porokeratosis, c.1094T > C disseminated (p.Phe365Ser) superficial actinic 1’] NM_005050.3(ABCD4): 201777056 ABCD4 [‘GATG [‘GATGAGGYAGA [‘METHYLMALONIC c.956A > G AGGYA TGCACACAAAGG’] ACIDURIA (p.Tyr319Cys) GATGC AND ACACA HOMOCYSTINURI AAGG’] A, cb1J TYPE’, ‘not provided’] NM_000251.2(MSH2): 267607987 MSH2 [‘CTGG [‘CTGGYAAAAAA [‘Hereditary c.2005 + 2T > C YAAAA CCTGGTTTTTGG’, Nonpolyposis AACCT ‘TGGYAAAAAACC Colorectal GGTTT TGGTTTTTGGG’] Neoplasms’] TTGG’, ‘TGGYA AAAAA CCTGG TTTTTG GG’] NM_000518.4(HBB): 35693898 HBB [ ] [ ] [‘Hemoglobinopathy’] c.257T > C (p.Phe86Ser) NM_001194998.1(CEP152): 398122977 CEP152 [ ] [ ] [‘Primary autosomal c.3149T > C recessive (p.Leu1050Pro) microcephaly 9’] NM_022455.4(NSD1): 587784171 NSD1 [ ] [ ] [‘Sotos syndrome 1’] c.5989T > C (p.Tyr1997His) NM_014495.3(ANGPTL3): 398122989 — [ ] [‘ACAAAACYTCA [‘Hypobetalipoprotei c.883T > C ATGAAACGTGGG’] nemia, familial, 2’] (p.Phe295Leu) NM_024577.3(SH3TC2): 80338927 SH3TC2 [ ] [ ] [‘Charcot-Marie- c.1982T > C Tooth disease, type (p.Leu661Pro) 4C’] NM_000551.3(VHL): 730882033 VHL [ ] [ ] [‘Hereditary cancer- c.227T > C (p.Phe76Ser) predisposing syndrome’] NM_004004.5(GJB2): 80338945 GJB2 [ ] [‘GCTCCYAGTGGC [‘Deafness, c.269T > C CATGCACGTGG’] autosomal recessive (p.Leu90Pro) 1A’, ‘Hearing impairment’, ‘not provided’] NM_000334.4(SCN4A): 80338956 SCN4A [ ] [‘AAGATCAYTGG [‘Hyperkalemic c.2078T > C CAATTCAGTGGG’, Periodic Paralysis (p.Ile693Thr) ‘AGATCAYTGGCA Type 1’, ATTCAGTGGGG’, ‘Paramyotonia ‘GATCAYTGGCAA congenita of von TTCAGTGGGGG’] Eulenburg’] NM_004523.3(KIF11): 730882063 KIF11 [‘GGAG [‘GGAGGYAATAA [‘Microcephaly with c.2547 + 2T > C GYAAT CTTTGTAAGTGG’] or without AACTT chorioretinopathy, TGTAA lymphedema, or GTGG’] mental retardation’] NM_003060.3(SLC22A5): 68018207 SLC22A5 [ ] [ ] [‘Renal carnitine c.1051T > C transport defect’] (p.Trp351Arg) NM_001070.4(TUBG1): 398123045 TUBG1 [ ] [ ] [‘Cortical dysplasia, c.1160T > C complex, with other (p.Leu387Pro) brain malformations 4’] NM_000441.1(SLC26A4): 60284988 — [ ] [ ] [‘Pendred syndrome’, c.-103T > C ‘Enlarged vestibular aqueduct syndrome’] NM_000016.5(ACADM): 398123074 ACADM [ ] [ ] [‘Medium-chain c.233T > C acyl-coenzyme A (p.Ile78Thr) dehydrogenase deficiency’, ‘not provided’] NM_000179.2(MSH6): 267608131 MSH6 [ ] [VGGYAACTAACT [‘Hereditary c.4001 + 2T > C AACTATAATGG’] Nonpolyposis Colorectal Neoplasms’] NM_000019.3(ACAT1): 398123096 ACAT1 [ ] [ ] [‘Deficiency of c.730 + 2T > C acetyl-CoA acetyltransferase’, ‘not provided’] NM_000430.3(PAFAH1B1): 587784288 PAFAH1B1 [ ] [ ] [‘Lissencephaly 1’] c.841T > C (p.Cys281Arg) NM_000899.4(KITLG): 730882156 KITLG [ ] [ ] [‘Familial c.98T > C progressive (p.Val33Ala) hyperpigmentation with or without hypopigmentation’] NM_015599.2(PGM3): 267608260 PGM3 [‘AATG [‘AATGTYGGCACC [‘Immunodeficiency c.248T > C TYGGC ATCCTGGGAGG’] 23’] (p.Leu83Ser) ACCAT CCTGG GAGG’] NM_000169.2(GLA): 398123223 — [ ] [ ] [‘Fabry disease’] c.899T > C (p.Leu300Pro) NM_001256047.1(C19orf12): 146170087 Cl9orf12 [ ] [ ] [‘Neurodegeneration c.391A > G with brain iron (p.Lys131Glu) accumulation 4’] NM_172337.2(0TX2): 370761964 OTX2 [ ] [ ] [‘Pituitary hormone c.674A > G deficiency, (p.Asn225Ser) combined 6’] NM_000202.6(IDS): 398123250 IDS [ ] [ ] [‘Mucopolysaccharid c.587T > C (p.Leu196Ser) osis, MPS-II’, ‘not provided’] NM_000252.2(MTM1): 398123274 MTM1 [ ] [ ] [‘Severe X-linked c.688T > C myotubular (p.Trp230Arg) myopathy’, ‘not provided’] NM_022445.3(TPK1): 371271054 TPK1 [ ] [ ] [‘THIAMINE c.656A > G METABOLISM (p.Asn219Ser) DYSFUNCTION SYNDROME 5 (EPISODIC ENCEPHALOPATHY TYPE)’] NM_014139.2(SCN11A): 483352920 SCN11A [ ] [ ] [‘NEUROPATHY, c.2432T > C HEREDITARY (p.Leu811Pro) SENSORY AND AUTONOMIC, TYPE VII’] NM_000733.3(CD3E): 483352928 CD3E [ ] [ ] [‘Immunodeficiency c.520 + 2T > C 18’] NM_017653.3(DYM): 775414124 DYM [ ] [ ] [‘Dyggve-Melchior- c.621-2A > G Clausen syndrome’] NM_001253816.1(SL052A2): 148234606 5LC52A2 [ ] [ ] [Brown-Vialetto- c.1016T > C Van Laere syndrome (p.Leu339Pro) 2’] NM_004963.3(GUCY2C): 587784573 — [ ] [‘TCCCYGTGCTGC [‘Meconium ileus’] c.2782T > C TGGAGTTGTGG’, (p.Cys928Arg) ‘CCCYGTGCTGCT GGAGTTGTGGG’] NM_003159.2(CDKL5): 267608511 CDKL5 [ ] [‘CCAACYTTTTAC [‘Early infantile c.659T > C TATTCAGAAGG’] epileptic (p.Leu220Pro) encephalopathy 2’] NM_000528.3(MAN2B1): 398123457 MAN2B1 [ ] [ ] [‘not provided’] c.2436 + 2T > C NM_002136.2(HNRNPA1): 483353031 HNRNPA1 [‘AATY [‘AATYTTGGAGGC [‘Chronic c.841T > C TTGGA AGAAGCTCTGG’] progressive multiple (p.Phe281Leu) GGCAG sclerosis’] AAGCT CTGG’] NM_006920.4(SCN1A): 398123595 — [ ] [ ] [‘Severe myoclonic c.4251 + 2T > C epilepsy in infancy’, ‘Generalized epilepsy with febrile seizures plus, type 2’] NM_002225.3(IVD): 398123683 IVD [ ] [ ] [‘Isovaleryl-CoA c.465 + 2T > C dehydrogenase deficiency’, ‘not provided’] NM_000118.3(ENG): 373842615 ENG [ ] [‘CCGCCYGCGGG [‘Haemorrhagic c.1273-2A > G GATAAAGCCAGG’, telangiectasia 1’] ‘CGCCYGCGGGGA TAAAGCCAGGG’] NM_005859.4(PURA): 793888535 PURA [ ] [ ] [‘not provided’] c.218T > C (p.Phe73Ser) NM_003494.3(DYSF): 398123765 DYSF [‘ATGG [‘ATGGYAAGGAG [‘Limb-girdle c.1284 + 2T > C YAAGG CAAGGGAGCAGG’] muscular dystrophy, AGCAA ] type 2B’, ‘not GGGAG provided’] CAGG’] NM_004006.2(DMD): 398123885 DMD [ ] [ ] [‘Dilated c.2380 + 2T > C cardiomyopathy 3B’] NM 006364.2(SEC23A): 138568622 SEC23A [ ] [ ] [‘Craniolenticulosutu c.2104A > G ral dysplasia’] (p.Met702Val) NM_000335.4(SCN5A): 185492581 SCN5A [ ] [‘GAATCTYCACAG [‘Brugada c.376A > G CCGCTCTCCGG’] syndrome’] (p.Lys126Glu) NM_015865.6(SLC14Al): 78242949 SLC14A1 [ ] [ ] [ ] c.871T > C (p.Ser291Pro) NM_003995.3(NPR2): 796065355 NPR2 [ ] [ ] [‘SHORT c.226T > C (p.Ser76Pro) STATURE WITH NONSPECIFIC SKELETAL ABNORMALITIES’] NM_012463.3(ATP6V0A2): 398124257 ATP6V0A2 [‘CACT [‘CACTGYGAGTA [‘Cutis laxa with c.825 + 2T > C GYGAG AGCTGGAAGTGG’] osteodystrophy’, ‘not TAAGC provided’] TGGAA GTGG’] NM_014795.3(ZEB2): 398124282 ZEB2 [ ] [ ] [‘Mowat-Wilson c.73 + 2T > C syndrome’] NM_000424.3(KRT5): 57599352 KRT5 [ ] [ ] [‘Epidermolysis c.1388T > C bullosa simplex, (p.Leu463Pro) Koebner type’, ‘not provided’] NM_133499.2(SYN1): 200533370 SYN1 [ ] [‘GATGYCTGACG [‘Epilepsy, X-linked, c.1699A > G GGTAGCCTGTGG’, with variable (p.Thr567Ala) ‘ATGYCTGACGGG learning disabilities TAGCCTGTGGG’] and behavior disorders’, ‘not specified’] NM_148960.2(CLDN19): 118203981 CLDN19 [ ] [‘GCTCCYGGGCTT [‘Hypomagnesemia c.269T > C CGTGGCCATGG’] 5, renal, with ocular (p.Leu90Pro) involvement’] NM_018006.4(TRMU): 118203990 TRMU [ ] [ ] [‘Liver failure acute c.229T > C infantile’] (p.Tyr77His) NM_000056.3(BCKDHB): 398124593 BCKDHB [ ] [ ] [‘Maple syrup urine c.752T > C disease’, ‘not (p.Val251Ala) provided’] NM_182680.1(AMELX): 104894737 — [ ] [ ] [‘Amelogenesis c.2T > C imperfecta, type 1E’] (p.Met1Thr) NM_018105.2(THAP1): 118204013 THAP1 [ ] [ ] [‘Dystonia 6, c.241T > C torsion’] (p.Phe81Leu) NM_001235.3(SERPINH1): 137853892 SERPINH1 [ ] [GTCGCYAGGGCT [‘Osteogenesis c.233T > C CGTGTCGCTGG’, imperfecta type 10’] (p.Leu78Pro) ‘TCGCYAGGGCTC GTGTCGCTGGG’] NM_004482.3(GALNT3): 761396172 GALNT3 [ ] [ ] [‘Tumoral calcinosis, c.516_688del familial, hyperphosphatemic’] NM_000263.3(NAGLU): 118204024 NAGLU [ ] [‘GGCCGACYTCTC [‘Mucopolysaccharid c.142T > C CGTGTCGGTGG’] osis, MPS-III-B’] (p.Phe48Leu) NM_000559.2(HBG1): 35710727 HBG1 [ ] [ ] [‘Fetal hemoglobin c.-251T > C quantitative trait locus 1’] NM_000527.4(LDLR): 200238879 LDLR [‘CGGY [‘ACTGCGGYATG [‘Familial c.694 + 2T > C ATGGG GGCGGGGCCAGG’, hypercholesterolemia’] CGGGG ‘CTGCGGYATGGG CCAGG CGGGGCCAGGG’, GTGG’] ‘CGGYATGGGCGG GGCCAGGGTGG’] NM_001012515.2(FECH): 118204039 FECH [ ] [ ] [‘Erythropoietic c.1268T > C protoporphyria’] (p.Phe423Ser) NM_005211.3(CSF1R): 690016563 CSF1R [ ] [‘CAACCYGCAGTT [‘Hereditary diffuse c.1745T > C TGGTGAGATGG’] leukoencephalopathy (p.Leu582Pro) with spheroids’] NM_000526.4(KRT14): 58380626 KRT14 [ ] [‘CGCCACCYACCG [‘Epidermolysis c.1243T > C CCGCCTGCTGG’, bullosa (p.Tyr415His) ‘CACCYACCGCCG herpetiformis, CCTGCTGGAGG’, Dowling-Meara’, ‘ACCYACCGCCGC ‘not provided’] CTGCTGGAGGG’] NM_006493.2(CLN5): 201615354 CLN5 [ ] [ ] [‘not provided’] c.2T > C (p.Met1Thr) NM_002863.4(PYGL): 113993988 PYGL [‘AAGA [‘AAGAAYATGCC [‘Glycogen storage c.2461T > C AYATG CAAAACATCTGG’] disease, type VI’] (p.Tyr821His) CCCAA AACAT CTGG’] NM_016038.2(SBDS): 113993993 SBDS [ ] [ ] [‘Shwachman c.258 + 2T > C syndrome’, ‘Aplastic anemia, susceptibility to’] NM_000110.3(DPYD): 1801265 DPYD [ ] [ ] [‘Dihydropyrimidine c.85T > C dehydrogenase (p.Cys29Arg) deficiency’] NM_001034116.1(EIF2B4): 113994038 EIF2B4 [ ] [ ] [‘Ovarioleukodystrophy’] c.1393T > C (p.Cys465Arg) NM_001165963.1(SCN1A): 794726793 SCN1A [ ] [ ] [‘Severe myoclonic c.323T > C epilepsy in infancy’] (p.Leu108Pro) NM_001034116.1(EIF2B4): 113994040 EIF2B4 [ ] [ ] [‘Ovarioleukodystrophy’] c.1465T > C (p.Tyr489His) NM_004304.4(ALK): 113994092 ALK [ ] [ ] [‘Neuroblastoma 3’] c.3749T > C (p.Ile1250Thr) NM_207346.2(TSEN54): 113994151 TSEN54 [ ] [‘TTGAAGYCTCCC [‘Pontocerebellar c.277T > C GCGGTGAGCGG’, hypoplasia type 4’] (p.Ser93Pro) ‘AAGYCTCCCGCG GTGAGCGGCGG’] NM_000018.3(ACADVL): 113994167 ACADVL [‘TTTGY [‘TTTGYGGTGGAG [‘Very long chain c.848T > C GGTGG AGGGGCTTCGG’, acyl-CoA (p.Val283Ala) AGAGG ‘TTGYGGTGGAGA dehydrogenase GGCTT GGGGCTTCGGG’] deficiency’, ‘not CGG’, provided’] ‘TTGYG GTGGA GAGGG GCTTC GGG’] NM_000430.3(PAFAH1B1): 113994202 PAFAH1B1 [ ] [ ] [‘Lissencephaly 1’] c.569-10T > C NM_004937.2(CTNS): 113994206 CTNS [ ] [‘TGGTCYGAGCTT [‘Cystinosis’] c.473T > C CGACTTCGTGG’] (p.Leu158Pro) NM_000546.5(TP53): 148924904 TP53 [‘GCTTG [‘GCTTGYAGATGG [‘Hereditary cancer- c.488A > G YAGAT CCATGGCGCGG’] predisposing (p.Tyr163Cys) GGCCA syndrome’] TGGCG CGG’] NM_004211.3(SLC6A5): 281864925 SLC6A5 [ ] [ ] [‘Hyperekplexia 3’] c.1444T > C (p.Trp482Arg) NM_024312.4(GNPTAB): 281864973 GNPTAB [ ] [ ] [‘Pseudo-Hurler c.1208T > C polydystrophy’] (p.Ile403Thr) NM_024312.4(GNPTAB): 281865006 GNPTAB [ ] [ ] [‘I cell disease’] c.3002T > C (p.Leu1001Pro) NM_000540.2(RYR1): 118192123 RYR1 [ ] [ ] [‘Central core c.7358T > C disease’, ‘not (p.Ile2453Thr) provided’] NM_000748.2(CHRNB2): 281865070 CHRNB2 [ ] [ ] [‘Epilepsy, nocturnal c.923T > C frontal lobe, type 3’] (p.Val308Ala) NM_000526.4(KRT14): 28928893 KRT14 [ ] [ ] [‘Epidermolysis c.356T > C bullosa (p.Met119Thr) herpetiformis, Dowling-Meara’, ‘not provided’] NM_000093.4(COL5A1): 183495554 — [ ] [ ] [‘Ehlers-Danlos c.5137-11T > A syndrome, classic type’] NM_000277.1(PAH): 62516109 PAH [ ] [CCACTTCYTGAA [‘Phenylketonuria’, c.638T > C AAGTACTGTGG’] ‘not provided’] (p.Leu213Pro) NM_000531.5 (OTC): 72558427 OTC [ ] [ ] [‘not provided’] c.663 + 2T > C NM_000531.5 (OTC): 72558431 OTC [ ] [ ] [Ornithine c.717 + 2T > C carbamoyltransferas e deficiency’, ‘not provided’] NM_000531.5 (OTC): 72558445 OTC [ ] [ ] [‘not provided’] c.793T > C (p.Trp265Arg) NM_000493.3(COL10Al): 111033545 — [ ] [ ] [‘Metaphyseal c.1841T > C chondrodysplasia, (p.Leu614Pro) Schmid type’] NM_000493.3(COL10Al): 111033546 — [ ] [ ] [‘Metaphyseal c.1771T > C chondrodysplasia, (p.Cys591Arg) Schmid type’] NM_000493.3(COL10Al): 111033552 — [ ] [ ] [‘Metaphyseal c.2011T > C chondrodysplasia, (p.Ser671Pro) Schmid type’] NM_004614.4(TK2): 138439950 TK2 [ ] [ ] [‘Mitochondrial c.173A > G (p.Asn58Ser) DNA depletion syndrome 2’] NM_004614.4(TK2): 281865497 TK2 [ ] [ ] [‘Mitochondrial c.644T > C DNA depletion (p.Leu215Pro) syndrome 2’] NM_004614.4(TK2): 281865499 TK2 [ ] [ ] [‘Mitochondrial c.156 + 2T > C DNA depletion syndrome 2’] NM_153026.2(PRICKLE1): 281865564 PRICKLE1 [ ] [ ] [‘Progressive c.1414T > C myoclonus epilepsy (p.Tyr472His) with ataxia’] NM_017882.2(CLN6): 143781303 CLN6 [ ] [ ] [‘not provided’] c.767A > G (p.Asp256Gly) NM_130838.1(UBE3A): 111033597 UBE3A [ ] [ ] [‘Angelman c.389T > C syndrome’] (p.Ile130Thr) NM_001198799.2(ASCC1): 146370051 ASCC1 [ ] [ ] [ ] c.953A > G (p.Asn318Ser) NM_000174.4(GP9): 28933378 GP9 [‘CCCA [VCCAYGTACCTG [‘Bernard Soulier c.70T > C (p.Cys24Arg) YGTAC CCGCGCCCTGG’] syndrome’, ‘Bernard- CTGCC Soulier syndrome GCGCC type C’] CTGG’] NM_001173464.1(KIF21A): 121912587 KIF21A [ ] [ ] [‘Fibrosis of c.3029T > C extraocular muscles, (p.Ile1010Thr) congenital, 1’] NM_001302946.1(TRNT1): 370011798 TRNT1 [ ] [‘GCAAYTGCAGA [‘Sideroblastic c.668T > C AAATGCAAAAGG’] anemia with B-cell (p.Ile223Thr) immunodeficiency, periodic fevers, and developmental delay’] NM_000371.3(TTR): 121918091 TTR [ ] [ ] [‘Amyloidogenic c.250T > C (p.Phe84Leu) transthyretin amyloidosis’] m.5814T > C 200077222 MT-TC [ ] [ ] [‘Juvenile myopathy, encephalopathy, lactic acidosis AND stroke’] NM_000277.1(PAH): 62517167 PAH [ ] [‘AAGATCTYGAG [‘Mild non-PKU c.293T > C (p.Leu98Ser) GCATGACATTGG’] hyperphenylalanemia’, ‘not provided’] NM_017882.2(CLN6): 796052355 CLN6 [ ] [ ] [‘not provided’] c.486 + 2T > C NM_001813.2(CENPE): 141488085 CENPE [ ] [ ] [‘Primary autosomal c.4063A > G recessive (p.Lys1355Glu) microcephaly 13’] NM_001918.3(DBT): 12021720 DBT [ ] [‘GACYCACAGAG [‘Intermediate maple c.1150G > A CCCAATTTCTGG’] syrup urine disease (p.Gly384Ser) type 2’] NM_000495.4(COL4A5): 104886288 COL4A5 [‘AGTA [‘AGTAYGTGAAG [‘Alport syndrome, c.4699T > C YGTGA CTCCAGCTGTGG’] X-linked recessive’] (p.Cys1567Arg) AGCTC CAGCT GTGG’] NM_000495.4(COL4A5): 104886289 COL4A5 [ ] [‘TCCCCATYGTCC [‘Alport syndrome, c.4756T > C TCAGGGATGGG’] X-linked recessive’] (p.Cys1586Arg) NM_000495.4(COL4A5): 104886310 COL4A5 [ ] [ ] [‘Alport syndrome, c.5032T > C X-linked recessive’] (p.Cys1678Arg) NM_000155.3(GALT): 111033700 GALT [‘AGCY [‘AGCYGGGTGCC [‘Deficiency of c.482T > C GGGTG CAGTACCCTTGG’] UDPglucose- (p.Leu161Pro) CCCAG hexose- 1-phosphate TACCC uridylyltransferase’] TTGG’] NM_001199252.2(SGOL1): 199815268 — [ ] [ ] [‘Chronic atrial and c.67A > G intestinal (p.Lys23Glu) dysrhythmia’] NC_012920.1:m.5559 370471013 MT-TW [ ] [‘CAACYTACTGAG [‘Leigh disease’] A > G GGCTTTGAAGG’] NM_000487.5(ARSA): 121434215 ARSA [ ] [‘GCCTTCCYGCCC [‘Metachromatic c.410T > C CCCCATCAGGG’] leukodystrophy, (p.Leu137Pro) adult type’] NM_000051.3(ATM): 121434218 — [ ] [ ] [ ] c.7967T > C (p.Leu2656Pro) NM_000096.3(CP): 386134125 CP [ ] [ ] [‘Deficiency of c.650T > C (p.Phe217Ser) ferroxidasel NM_000096.3(CP): 386134128 CP [ ] [‘ACACTACYACAT [‘Deficiency of c.1123T > C (p.Tyr375His) TGCCGCTGAGG’] ferroxidasel NM_000268.3(NF2): 121434261 NF2 [ ] [ ] [‘Neurofibromatosis, c.185T > C (p.Phe62Ser) type 2’] NM_000495.4(COL4A5): 104886423 COL4A5 [ ] [ ] [‘Alport syndrome, c.4803 + 121T > C X-linked recessive’] NM_024529.4(CDC73): 121434264 CDC73 [ ] [ ] [‘Hyperparathyroidism c.191T > C 1’] (p.Leu64Pro) NM_001061.4(TBXAS1): 199422114 TBXAS1 [ ] [ ] [ ] c.1463T > C (p.Leu488Pro) NM_001127328.2(ACADM): 121434275 ACADM [ ] [‘GTGCAGAYACTT [‘Medium-chain c.1136T > C GGAGGCAATGG’] acyl-coenzyme A (p.Ile379Thr) dehydrogenase deficiency’] NM_001127328.2(ACADM): 121434276 ACADM [ ] [CAGCGAYGTTCA [‘Medium-chain c.742T > C GATACTAGAGG’] acyl-coenzyme A (p.Cys248Arg) dehydrogenase deficiency’] NM_000016.5(ACADM): 121434280 ACADM [ ] [ ] [‘Medium-chain c.199T > C acyl-coenzyme A (p.Tyr67His) dehydrogenase deficiency’, ‘not provided’] NM_002225.3(IVD): 121434284 IVD [ ] [ATGGGCYAAGC [‘ISOVALERIC c.134T > C (p.Leu45Pro) GAGGAGCAGAGG’] ACIDEMIA, TYPE I’] NM_005957.4(MTHFR): 121434297 MTHFR [ ] [ ] [‘Homocystinuria c.968T > C due to MTHFR (p.Leu323Pro) deficiency’] NM_000136.2(FANCC): 104886458 — [ ] [ ] [‘Fanconi anemia, c.1661T > C complementation (p.Leu554Pro) group C’, ‘not provided’] NM_005908.3(MANBA): 121434334 MANBA [ ] [‘ATTACGYCCAGT [Beta-D- c.1513T > C CCTACAAATGG’, mannosidosis’] (p.Ser505Pro) ‘TTACGYCCAGTC CTACAAATGGG’, ‘TACGYCCAGTCC TACAAATGGGG’] NM_000244.3(MEN1): 386134256 MEN1 [ ] [ ] [‘Multiple endocrine c.518T > C neoplasia, type 1’] (p.Leu173Pro) NM_199242.2(UNC13D): 121434353 UNC13D [ ] [ ] [‘Hemophagocytic c.1208T > C lymphohistiocytosis, (p.Leu403Pro) familial, 3’] NM_152783.4(D2HGDH): 121434360 D2HGDH [ ] [ ] [‘D-2- c.1331T > C hydroxyglutaric (p.Val444Ala) aciduria 1’] NM_207118.2(GTF2H5): 121434365 GTF2H5 [ ] [ ] [‘Photosensitive c.62T > C trichothiodystrophy’] (p.Leu21Pro) NM_000159.3(GCDH): 121434366 GCDH [ ] [‘CGCCCGGYACG [‘Glutaric aciduria, c.883T > C GCATCGCGTGGG’, type 1’] (p.Tyr295His) ‘GCCCGGYACGGC ATCGCGTGGGG’] NM_018668.4(VPS33B): 121434385 VPS33B [ ] [ ] [‘Arthrogryposis c.89T > C renal dysfunction (p.Leu30Pro) cholestasis syndrome’] NM_000424.3(KRT5): 60715293 KRT5 [ ] [GTTTGCCYCCTT [‘Epidermolysis c.541T > C CATCGACAAGG’] bullosa (p.Ser181Pro) herpetiformis, Dowling-Meara’, ‘not provided’] NM_001003722.1(GLE1): 121434409 GLE1 [ ] [‘AAGGACAYTCCT [‘Lethal c.2051T > C GTCCCCAAGGG’] arthrogryposis with (p.Ile684Thr) anterior horn cell disease’] NM_003659.3(AGPS): 121434413 AGPS [ ] [ ] [‘Rhizomelic c.1406T > C chondrodysplasia (p.Leu469Pro) punctata type 3’] NM_004550.4(NDUFS2): 121434429 NDUFS2 [ ] [ ] [‘Mitochondrial c.1237T > C complex I (p.Ser413Pro) deficiency’, ‘not provided’] NM_001287.5(CLCN7): 121434434 CLCN7 [ ] [‘GGGCCYGCGGC [‘Osteopetrosis c.2297T > C ACCTGGTGGTGG’] autosomal recessive (p.Leu766Pro) 4’] m.14709T > C 121434453 MT-TE [ ] [ ] [‘Diabetes-deafness syndrome maternally transmitted’] NM_000466.2(PEX1): 121434455 PEX1 [ ] [‘GATGACCYTGAC [‘Zellweger c.1991T > C CTCATTGCTGG’] syndrome’] (p.Leu664Pro) NM_198253.2(TERT): 199422307 TERT [ ] [ ] [‘Aplastic anemia’] c.3043T > C (p.Cys1015Arg) m.4290T > C 121434469 MT-TI [‘ACTYT [‘ACTYTGATAGAG [ ] GATAG TAAATAATAGG’] AGTAA ATAAT AGG’] m.4291T > C 121434471 MT-TI [‘ACTTY [‘ACTTYGATAGAG [‘Hypertension, GATAG TAAATAATAGG’] hypercholesterolemia, AGTAA and ATAAT hypomagnesemia, AGG’] mitochondrial’] m.9997T > C 121434475 MT-TG [ ] [ ] [‘Primary familial hypertrophic cardiomyopathy’] NM_001099274.1(TINF2): 199422316 TINF2 [ ] [ ] [‘Dyskeratosis c.860T > C congenita autosomal (p.Leu287Pro) dominant’] NM_001099274.1(TINF2): 199422317 TINF2 [ ] [‘CTGYTTCCCTTT [‘Aplastic anemia’] c.862T > C AGGAATCTCGM (p.Phe288Leu) NM_000430.3(PAFAH1B1): 121434484 PAFAH1B1 [ ] [ ] [‘Subcortical band c.505T > C heterotopia’] (p.Ser169Pro) NM_000430.3(PAFAH1B1): 121434486 PAFAH1B1 [ ] [ ] [‘Lissencephaly 1’] c.92T > C (p.Phe31Ser) NM_005535.2(IL12RB1): 121434495 IL12RB1 [ ] [ ] [‘Immunodeficiency c.592T > C 301 (p.Cys198Arg) NM_030662.3(MAP2K2): 121434499 MAP2K2 [ ] [ ] [‘Cardiofaciocutaneo c.400T > C us syndrome 4’, (p.Tyr134His) ‘Rasopathy’, ‘Noonan syndrome and Noonan-related syndrome’] NM_001065.3(TNFRSFl A): 104895221 TNFRSF1A [ ] [‘CTCTTCTYGCAC [‘TNF receptor- c.349T > C AGTGGACCGGG’] associated periodic (p.Cys117Arg) fever syndrome (TRAPS)’] NM_000123.3(ERCC5): 121434575 — [ ] [ ] [‘Xeroderma c.2573T > C pigmentosum, group (p.Leu858Pro) G’] NM_001493.2(GDI1): 121434607 GDI1 [ ] [ ] [‘X-Linked Mental c.275T > C Retardation 41’] (p.Leu92Pro) NM_020061.5(0PN1LW): 121434621 OPN1LW [ ] [ ] [‘Cone c.607T > C monochromatism’] (p.Cys203Arg) NM_024420.2(PLA2G4A): 121434634 PLA2G4A [ ] [ ] [ ] c.331T > C (p.Ser111Pro) NM_005557.3(KRT16): 60944949 KRT16 [ ] [ ] [‘Pachyonychia c.395T > C congenita, type 1’, (p.Leu132Pro) ‘not provided’] NM_000485.2(APRT): 28999113 APRT [ ] [ ] [‘Adenine c.407T > C phosphoribosyltransf (p.Met136Thr) erase deficiency’, ‘APRT deficiency, Japanese type’] NM_005270.4(GLI2): 144372453 GLI2 [ ] [ ] [‘Holoprosencephaly c.4663T > C 9’, ‘not specified’] (p.Ser1555Pro) NM_024753.4(TTC21B): 387907060 TTC21B [ ] [ ] [‘Asphyxiating c.2384T > C thoracic dystrophy (p.Leu795Pro) 4’] NM_000155.3(GALT): 111033846 GALT [ ] [ ] [‘Deficiency of c.680T > C UDPglucose- (p.Leu227Pro) hexose-1-phosphate uridylyltransferase’] NM_000138.4(FBN1): 137854459 FBN1 [ ] [‘GGGACAYGTTA [‘Marfan syndrome’] c.4987T > C CAACACCGTTGG’] (p.Cys1663Arg)10): NM_032446.2(MEGF 387907073 MEGF10 [ ] [ ] [‘Myopathy, c.976T > C areflexia, respiratory (p.Cys326Arg) distress, and dysphagia, early- onset, mild variant’] NM_024027.4(COLEC11): 387907075 COLEC11 [ ] [CAGCTGYCCTGC [‘Carnevale c.505T > C CAGGGCCGCGG’, syndrome’] (p.Ser169Pro) ‘AGCTGYCCTGCC AGGGCCGCGGG’, ‘GCTGYCCTGCCA GGGCCGCGGGG’, ‘CTGYCCTGCCAG GGCCGCGGGGG’] NM_001946.3(DUSP6): 143946794 DUSP6 [‘CACT [‘CACTAYTGGGGT [‘Hypogonadotropic c.566A > G AYTGG CTCGGTCAAGG’] hypogonadism 19 (p.Asn189Ser) GGTCT with or without CGGTC anosmia’] AAGG’] NM_000138.4(FBN1): 137854474 FBN1 [‘CTTGY [‘CTTGYGTTATGA [‘Marfan syndrome’] c.3793T > C GTTAT TGGATTCATGG’] (p.Cys1265Arg) GATGG ATTCA TGG’] NM_022068.3(PIEZO2): 587777453 PIEZ02 [ ] [ ] [‘Oculomelic c.2134A > G amyoplasia’] (p.Met712Val) NM_000570.4(FCGR3B): 2290834 FCGR3B [ ] [ ] [ ] c.316A= (p.Ile106=) NM_000352.4(ABCC8): 1048095 ABCC8 [ ] [‘TGCYGTCCAAAG [‘Permanent neonatal c.674T > C GCACCTACTGG’] diabetes mellitus’] (p.Leu225Pro) NM_153490.2(KRT13): 59897026 KRT13 [ ] [ ] [‘White sponge c.332T > C nevus 2’, ‘not (p.Leull1Pro) provided’] NM_000132.3(F8): 28933669 F8 [ ] [ ] [‘Hereditary factor c.1174T > C (p.Ser392Pro) VIII deficiency disease’] NM_000492.3(CFTR): 397508144 CFTR [ ] [ ] [‘Cystic fibrosis’] c.1021T > C (p.Ser341Pro) NM_000133.3(F9): 137852255 F9 [ ] [ ] [‘Hereditary factor c.1058T > C (p.Val353Ala) IX deficiency disease’] NM_001202.3(BMP4): 376960358 BMP4 [‘TTCGT [‘TTCGTGGYGGAA [‘Microphthalmia c.362A > G GGYGG GCTCCTCACGG’] syndromic 6’] (p.His121Arg) AAGCT CCTCA CGG’] NM_000133.3(F9): 137852268 F9 [‘GAAY [‘GAAYATATACC [‘Hereditary factor c.1328T > C (p.Ile443Thr) ATATA AAGGTATCCCGG’] IX deficiency CCAAG disease’] GTATC CCGG’] NM_000133.3(F9): 137852269 F9 [ ] [ ] [‘Hereditary factor c.1357T > C IX deficiency (p.Trp453Arg) disease’] NM_000435.2(NOTCH3): 28933698 NOTCH3 [‘ACCY [‘TTCACCYGTATC [‘Cerebral autosomal c.1363T > C GTATC TGTATGGCAGG’, dominant (p.Cys455Arg) TGTAT ‘ACCYGTATCTGT arteriopathy with GGCAG ATGGCAGGTGG’] subcortical infarcts GTGG’] and leukoencephalopath 3’] NM_019074.3(DLL4): 796065347 DLL4 [ ] [‘GAAYGTCCCCCC [‘Adams-Oliver c.1168T > C AACTTCACCGG’] syndrome’, (p.Cys390Arg) ‘ADAMS-OLIVER SYNDROME 6’] NM_000032.4(ALAS2): 137852310 ALAS2 [ ] [ ] [‘Hereditary c.595T > C sideroblastic (p.Tyr199His) anemia’] NM_019074.3(DLL4): 796065351 DLL4 [ ] [ ] [‘Adams-Oliver c.583T > C syndrome’] (p.Phe195Leu) NM_000402.4(G6PD): 137852347 G6PD [ ] [‘AGGGYACCTGG [‘Anemia, c.1054T > C ACGACCCCACGG’] nonspherocytic (p.Tyr352His) hemolytic, due to G6PD deficiency’] NM_007325.4(GRIA3): 137852352 GRIA3 [ ] [ ] [‘Mental retardation, c.2117T > C X-linked, (p.Met706Thr) syndromic, wu type’] NM_000132.3(F8): 137852365 F8 [ ] [ ] [‘Hereditary factor c.6554T > C VIII deficiency (p.Leu2185Ser) disease’] NM_000132.3(F8): 137852375 F8 [‘TCAY [‘TCAYGGTGAGTT [‘Hereditary factor c.5372T > C GGTGA AAGGACAGTGG’] VIII deficiency (p.Met1791Thr) GTTAA disease’] GGACA GTGG’] NM_000132.3(F8): 137852376 F8 [‘AACA [‘AACAGAYAATG [‘Hereditary factor c.1754T > C (p.Ile585Thr) GAYAA TCAGACAAGAGG’] VIII deficiency TGTCA disease’] GACAA GAGG’] NM_001127695.1(CTSA): 137854546 CTSA [ ] [ ] [‘Galactosialidosis, c.707T > C early infantile’] (p.Leu236Pro) NM_000132.3(F8): 137852405 F8 [ ] [ ] [‘Hereditary factor c.935T > C (p.Phe312Ser) VIII deficiency disease’] NM_000132.3(F8): 137852407 F8 [ ] [ ] [‘Hereditary factor c.980T > C (p.Leu327Pro) VIII deficiency disease’] NM_000308.2(CTSA): 137854548 CTSA [ ] [ ] [‘Galactosialidosis, c.1271T > C late infantile’] (p.Met424Thr) NM_000132.3(F8): 137852413 F8 [ ] [ ] [‘Hereditary factor c.1481T > C (p.Ile494Thr) VIII deficiency disease’] NM_001250.5(CD40): 28931586 CD40 [ ] [ ] [‘Immunodeficiency c.247T > C with hyper IgM type (p.Cys83Arg) 3’] NM_000165.4(GJA1): 121912969 GJA1 [ ] [ ] [‘Oculodentodigital c.32T > C (p.Leu11Pro) dysplasia’] NM_000132.3(F8): 137852430 F8 [ ] [ ] [‘Hereditary factor c.1958T > C (p.Val653Ala) VIII deficiency disease’] NM_001972.2(ELANE): 28931611 ELANE [ ] [ ] [‘Severe congenital c.211T > C neutropenia (p.Cys7lArg) autosomal dominant’] NM_000098.2(CPT2): 74315297 CPT2 [ ] [ ] [‘CARNITINE c.1342T > C PALMITOYLTRA (p.Phe448Leu) NSFERASE II DEFICIENCY, LATE-ONSET’, ‘not provided’] NM_213653.3(HFE2): 74315326 HFE2 [ ] [ ] [‘Hemochromatosis c.842T > C type 2A’] (p.Ile281Thr) NM_213653.3(HFE2): 74315327 HFE2 [ ] [‘GGACCYCGCCTT [‘Hemochromatosis c.302T > C CCATTCGGCGG’] type 2A’] (p.Leu101Pro) NM_000194.2(HPRT1): 137852480 HPRT1 [ ] [ ] [‘Lesch-Nyhan c.122T > C syndrome’] (p.Leu41Pro) NM_000261.1(MY0C): 74315338 MYOC [ ] [ ] [‘Primary open angle c.1297T > C glaucoma juvenile (p.Cys433Arg) onset 1’] NM_000194.2(HPRT1): 137852495 HPRT1 [ ] [ ] [‘Lesch-nyhan c.170T > C syndrome, (p.Met57Thr) neurologic variant’] NM_000267.3(NF1): 137854564 NF1 [ ] [ ] [‘Neurofibromatosis, c.3728T > C type 1’] (p.Leu1243Pro) NM_000291.3(PGK1): 137852531 PGK1 [ ] [ ] [‘Phosphoglycerate c.263T > C kinase 1 deficiency’] (p.Leu88Pro) NM_000291.3(PGK1): 137852533 PGK1 [ ] [ ] [‘Phosphoglycerate c.946T > C kinase 1 deficiency’] (p.Cys316Arg) NM_000291.3(PGK1): 137852534 PGK1 [ ] [ ] [‘Phosphoglycerate c.758T > C kinase 1 deficiency’] (p.Ile253Thr) NM_170784.2(MKKS): 74315398 MKKS [ ] [ ] [‘Bardet-Biedl c.830T > C syndrome 6’, ‘not (p.Leu277Pro) provided’] NM_000451.3(SHOX): 137852559 SHOX [ ] [ ] [Leri Weill c.877T > C dyschondrosteosis’] (p.Ter293Arg) NM_001029871.3(RSPO4): 74315421 RSPO4 [ ] [ ] [‘Anonychia’] c.319T > C (p.Cys107Arg) NM_000044.3(AR): 137852579 AR [ ] [‘GTCCYGGAAGC [ ] c.2033T > C CATTGAGCCAGG’] (p.Leu678Pro) NM_000044.3(AR): 137852592 AR [ ] [ ] [‘Reifenstein c.2423T > C syndrome’] (p.Met808Thr) NM_000044.3(AR): 137852597 AR [ ] [ ] [‘Androgen c.2596T > C (p.Ser866Pro) resistance syndrome’] NM_172201.1(KCNE2): 74315447 KCNE2 [ ] [ ] [‘Long QT syndrome c.161T > C 6’, ‘Congenital long (p.Met54Thr) QT syndrome’, ‘Cardiac arrhythmia’] NM_172201.1(KCNE2): 74315448 KCNE2 [ ] [ ] [‘Long QT syndrome c.170T > C 6’, ‘Cardiac (p.Ile57Thr) arrhythmia’, ‘not provided’] NM_000211.4(ITGB2): 137852611 ITGB2 [‘AGCY [‘AGCYAGGTGGC [‘Leukocyte c.446T > C AGGTG GACCTGCTCCGG’] adhesion (p.Leu149Pro) GCGAC deficiency’] CTGCT CCGG’] NM_000211.4(ITGB2): 137852617 ITGB2 [ ] [ ] [‘Leukocyte c.412T > C adhesion (p.Ser138Pro) deficiency’] NM_000023.2(SGCA): 137852622 SGCA [ ] [ ] [‘Limb-girdle c.524T > C muscular dystrophy, (p.Val175Ala) type 2D’] NM_001166107.1(HMGCS2): 137852636 HMGCS2 [ ] [‘CCCTCYTCAATG [‘mitochondrial 3- c.520T > C CTGCCAACTGG’] hydroxy-3- (p.Phe174Leu) methylglutaryl-CoA synthase deficiency’] NM_001886.2(CRYBA4): 74315486 CRYBA4 [ ] [ ] [‘Cataract 23’] c.281T > C (p.Phe94Ser) NM_001886.2(CRYBA4): 74315487 CRYBA4 [ ] [ ] [‘Cataract 23’] c.206T > C (p.Leu69Pro) NM_002047.2(GARS): 137852644 GARS [ ] [ ] [‘Distal hereditary c.548T > C motor neuronopathy (p.Leu183Pro) type 5’] NM_000268.3(NF2): 74315493 NF2 [ ] [ ] [‘Neurofibromatosis, c.1604T > C type 2’] (p.Leu535Pro) NM_000095.2(COMP): 137852653 COMP [ ] [ ] [‘Pseudo- c.982T > C achondroplastic (p.Cys328Arg) spondyloepiphyseal dysplasia syndrome’] NM_000095.2(COMP): 137852656 COMP [ ] [ ] [‘Pseudo- c.1042T > C achondroplastic (p.Cys348Arg) spondyloepiphyseal dysplasia syndrome’] NM_017929.5(PEX26): 74315506 PEX26 [ ] [ ] [‘Peroxisome c.2T > C (p.Met1Thr) biogenesis disorder 7B’] NM_033163.3(FGF8): 137852661 FGF8 [ ] [‘TTCCCTGYTCCG [‘Kallmann c.118T > C GGCTGGCCGGG’] syndrome 6’] (p.Phe40Leu) NM_007315.3(STAT1): 137852677 STAT1 [ ] [ ] [‘Immunodeficiency c.2117T > C 31a’] (p.Leu706Ser) NM_007315.3(STAT1): 137852678 STAT1 [ ] [ ] [‘Mycobacterial and c.1799T > C viral infections, (p.Leu600Pro) susceptibility to, autosomal recessive’] NM_000336.2(SCNN1B): 137852707 SCNN1B [ ] [ ] [‘Pseudoprimary c.1858T > C hyperaldosteronism’] (p.Tyr620His) NM_005215.3(DCC): 121912967 DCC [ ] [‘AGCCCAYGCCA [ ] c.503T > C ACAATCCACTGG’] (p.Met168Thr) NM_001034850.2(FAM134B): 137852738 FAM134B [ ] [ ] [‘Hereditary sensory c.873 + 2T > C and autonomic neuropathy type IIA’] NM_000182.4(HADHA): 137852772 HADHA [ ] [ ] [‘Mitochondrial c.1025T > C trifunctional protein (p.Leu342Pro) deficiency’] NM_001165974.1(UR0C1): 137852796 UROC1 [ ] [ ] [‘Urocanate c.209T > C hydratase (p.Leu70Pro) deficiency’] NM_000405.4(GM2A): 137852797 GM2A [ ] [ ] [‘Tay-Sachs disease, c.412T > C variant AB’] (p.Cys138Arg) NM_001039523.2(CHRNA1): 137852806 CHRNA1 [ ] [‘TGTGYTCCTTCT [‘Myasthenic c.901T > C GGTCATCGTGG’] syndrome, (p.Phe301Leu) congenital, fast-channel’] NM_003688.3(CASK): 137852817 CASK [ ] [ ] [‘FG syndrome 4’] c.802T > C (p.Tyr268His) NM_003688.3(CASK): 137852819 CASK [‘CACA [‘CACAGYGGGTC [‘FG syndrome 4’] c.2740T > C GYGGG CCTGTCTCCTGG’, (p.Trp914Arg) TCCCT ‘ACAGYGGGTCCC GTCTC TGTCTCCTGGG’] CTGG’, ‘ACAGY GGGTC CCTGT CTCCT GGG’] NM_182760.3(SUMF1): 137852848 SUMF1 [ ] [ ] [‘Multiple sulfatase c.1006T > C deficiency’] (p.Cys336Arg) NM_182760.3(SUMF1): 137852850 SUMF1 [ ] [‘GGCGACYCCTTT [‘Multiple sulfatase c.463T > C GTCTTTGAAGG’] deficiency’, ‘not (p.Ser155Pro) provided’] NM_000158.3(GBE1): 137852886 GBE1 [ ] [‘AATGTACYACCA [‘Glycogen storage c.671T > C AGAATCAAAGG’] disease, type IV’, (p.Leu224Pro) ‘GLYCOGEN STORAGE DISEASE IV, NONPROGRESSIVE HEPATIC’] m.8356T > C 118192099 MT-TK [ ] [ ] [‘Myoclonus with epilepsy with ragged red fibers’, ‘MERRF/MELAS overlap syndrome’] NM_024312.4(GNPTAB): 137852900 GNPTAB [ ] [ ] [‘Pseudo-Hurler c.1120T > C polydystrophy’, ‘I (p.Phe374Leu) cell disease’] NM_031924.4(RSPH3): 142800871 RSPH3 [ ] [ ] [‘Kartagener c.631-2A > G syndrome’] NM_058172.5(ANTXR2): 137852905 ANTXR2 [ ] [ ] [‘Hyaline c.566T > C fibromatosis (p.Ile189Thr) syndrome’] NM_000419.3(ITGA2B): 137852911 ITGA2B [ ] [CTGGTGCYTGGG [‘Glanzmann c.641T > C GCTCCTGGCGG’] thrombasthenia’] (p.Leu214Pro) NM_001171507.2(MCFD2): 137852914 MCFD2 [ ] [ ] [‘Factor v and factor c.407T > C viii, combined (p.Ile136Thr) deficiency of, 2’] NM_000540.2(RYR1): 118192117 RYR1 [‘CGCA [‘CGCAYGATCCAC [‘Congenital c.1205T > C YGATC AGCACCAATGG’] myopathy with fiber (p.Met402Thr) CACAG type disproportion’, CACCA ‘Central core ATGG’] disease’, ‘not provided’] NM_000540.2(RYR1): 118192131 RYR1 [ ] [ ] [‘Central core c.13703T > C disease’, ‘not (p.Leu4568Pro) provided’] NM_000540.2(RYR1): 118192138 RYR1 [ ] [ ] [‘Central core c.13949T > C disease’, ‘not (p.Leu4650Pro) provided’] NM_138694.3(PKHD1): 137852948 PKHD1 [ ] [‘GAGCCCAYTGA [‘Polycystic kidney c.10658T > C AATACGCTCAGG’] disease, infantile (p.Ile3553Thr) type’] NM_012464.4(TLL1): 137852952 TLL1 [‘GGGA [‘GGGATTGYTGTT [‘Atrial septal defect c.713T > C TTGYT CATGAATTGGG’] 6’] (p.Val238Ala) GTTCA TGAAT TGGG’] NM_000540.2(RYR1): 118192156 RYR1 [ ] [ ] [‘Central core c.14762T > C disease’, ‘not (p.Phe4921Ser) provided’] NM_024960.4(PANK2): 137852964 PANK2 [ ] [‘ATTGACYCAGTC [ ] c.178T > C GGATTCAATGG’] (p.Ser60Pro) NM_001001486.1(ATP2C1): 137853015 ATP2C1 [ ] [ ] [‘Familial benign c.1751T > C pemphigus’] (p.Leu584Pro) NM_014363.5(SACS): 137853017 SACS [ ] [ ] [‘Spastic ataxia c.5836T > C Charlevoix- (p.Trp1946Arg) Saguenay type’] NM_014363.5(SACS): 137853018 SACS [ ] [ ] [‘Spastic ataxia c.9742T > C Charlevoix- (p.Trp3248Arg) Saguenay type’] NM_014363.5(SACS): 137853019 SACS [ ] [ ] [‘Spastic ataxia c.3161T > C Charlevoix- (p.Phe1054Ser) Saguenay type’] NM_006899.3(IDH3B): 137853020 IDH3B [ ] [‘TGCGGCYGAGG [‘Retinitis c.395T > C TAGGTGGTCTGG’, pigmentosa 46’] (p.Leu132Pro) ‘GCGGCYGAGGTA GGTGGTCTGGG’] NM_001139.2(ALOX12B): 137853023 ALOX12B [ ] [ ] [‘Autosomal c.1277T > C recessive congenital (p.Leu426Pro) ichthyosis 2’] NM_001080463.1(DYNC2H1): 137853028 DYNC2H1 [ ] [ ] [‘Short-rib thoracic c.3719T > C dysplasia 3 with or (p.Ile1240Thr) without polydactyly’] NM_006009.3(TUBA1A): 137853048 TUBA1A [ ] [ ] [‘Lissencephaly 3’] c.1190T > C (p.Leu397Pro) NM_004519.3(KCNQ3): 118192249 KCNQ3 [ ] [ ] [‘Benign familial c.925T > C neonatal seizures 2’] (p.Trp309Arg) NM_000531.5 (OTC): 1800324 OTC [ ] [ ] [Ornithine c.332T > C carbamoyltransferas (p.Leull1Pro) e deficiency’] NM_001172567.1(MYD88): 137853065 MYD88 [ ] [ ] [‘Myd88 deficiency’] c.317T > C (p.Leu106Pro) NM_002241.4(KCNJ10): 137853068 KCNJ10 [ ] [ ] [SeSAME c.418T > C syndrome’] (p.Cys140Arg) NM_000455.4(STK11): 137853077 STK11 [ ] [ ] [‘Peutz-Jeghers c.200T > C syndrome’] (p.Leu67Pro) NM_000518.4(HBB): 35256489 HBB [ ] [ ] [‘Beta thalassemia c.332T > C major’] (p.Leull1Pro) NM_005094.3(5LC27A4): 137853133 5LC27A4 [ ] [ ] [‘Ichthyosis c.739T > C prematurity (p.Ser247Pro) syndrome’] NM_001145308.4(LRTOMT): 137853186 LRTOMT [ ] [ ] [‘Deafness, c.313T > C autosomal recessive (p.Trp105Arg) 631 NM_178012.4(TUBB2B): 137853194 TUBB2B [ ] [ ] [‘Polymicrogyria, c.514T > C asymmetric’] (p.Ser172Pro) NM_178012.4(TUBB2B): 137853195 TUBB2B [ ] [ ] [‘Polymicrogyria, c.683T > C asymmetric’] (p.Leu228Pro) NM_178012.4(TUBB2B): 137853196 TUBB2B [ ] [ ] [‘Polymicrogyria, c.793T > C asymmetric’] (p.Phe265Leu) NM_001082971.1(DDC): 137853209 DDC [ ] [ ] [‘Deficiency of c.925T > C aromatic-L-amino- (p.Phe309Leu) acid decarboxylase’] NM_006121.3(KRT1): 137853225 KRT1 [ ] [ ] [‘Bullous c.1424T > C ichthyosiform (p.Leu475Pro) erythroderma’] NM_033500.2(HK1): 137853249 HK1 [ ] [‘GACTTCTYGGCC [‘Hemolytic anemia c.1550T > C CTGGATCTTGG’, due to hexokinase (p.Leu517Ser) ‘TTCTYGGCCCTG deficiency’] GATCTTGGAGG’] NM_000249.3(MLH1): 63749859 MLH1 [ ] [ ] [‘Hereditary c.229T > C Nonpolyposis (p.Cys77Arg) Colorectal Neoplasms’] NM_000444.5(PHEX): 137853270 PHEX [ ] [‘AGCYCCAGAAG [‘Familial X-linked c.1664T > C CCTTTCTTTTGG’] hypophosphatemic (p.Leu555Pro) vitamin D refractory rickets’] NM_000321.2(RB1): 137853296 RB1 [ ] [ ] [‘Retinoblastoma’] c.2134T > C (p.Cys712Arg) NM_007313.2(ABL1): 137853304 ABL1 [ ] [ ] [ ] c.988T > C (p.Phe330Leu) NM_003639.4(IKBKG): 137853325 IKBKG [ ] [‘TGGAGYGCATTG [‘Hypohidrotic c.1249T > C AGTAGGGCCGG’] ectodermal dysplasia (p.Cys417Arg) with immune deficiency’, ‘Hyper- IgM immunodeficiency, X-linked, with hypohidrotic ectodermal dysplasia’] NM_017534.5(MYH2): 786201023 — [ ] [ ] [‘Inclusion body c.5609T > C myopathy 3’] (p.Leu1870Pro) NM_000314.6(PTEN): 786201044 PTEN [ ] [ ] [‘Hereditary cancer- c.406T > C predisposing (p.Cys136Arg) syndrome’] NM_001257988.1(TYMP): 149977726 TYMP [‘CACG [‘CACGAGTYTCTT [ ] c.665A > G AGTYT ACTGAGAATGG’, (p.Lys222Arg) CTTAC ‘GAGTYTCTTACT TGAGA GAGAATGGAGG’] ATGG’] NM_016725.2(FOLR1): 144637717 FOLR1 [‘AGGY [‘CTTCAGGYGAG [‘not provided’] c.493 + 2T > C GAGGG GGCTGGGGTGGG’, CTGGG ‘AGGYGAGGGCTG GTGGG GGGTGGGCAGG’] CAGG’] NM_002225.3(IVD): 748026507 IVD [ ] [ ] [‘not provided’] c.295 + 2T > C NM_000175.3(GPI): 137853587 GPI [ ] [ ] [ ] c.1016T > C (p.Leu339Pro) NM_002055.4(GFAP): 28932769 GFAP [ ] [‘GGACCYGCTCA [‘Alexander disease’, c.1055T > C ATGTCAAGCTGG’] ‘not provided’] (p.Leu352Pro) NM_020921.3(NIN): 187464517 NIN [ ] [ ] [‘Seckel syndrome c.3665A > G 7’] (p.Gln1222Arg) NM_005603.4(ATP8B1) 387906381 ATP8B1 [ ] [ ] [‘Progressive :c.2097 + 2T > C intrahepatic cholestasis’] NM_005144.4(HR): 387906382 HR [ ] [ ] [‘Marie Unna c.-320T > C hereditary hypotrichosis 1’] NM_001303.3(COX10): 387906383 COX10 [ ] [ ] [‘Congenital c.2T > C (p.Met1Thr) myasthenic syndrome, acetazolamide-responsive’] NM_004415.2(DSP): 749730642 DSP [ ] [ ] [‘not provided’] c.4961T > C (p.Leu1654Pro) NM_000392.4(ABCC2): 387906396 ABCC2 [ ] [ ] [‘Dubin-Johnson c.1967 + 2T > C syndrome’] NM_002769.4(PRSS1): 397507439 — [ ] [TACCAGGYGTCC [‘Hereditary c.116T > C CTGAATTCTGG’] pancreatitis’] (p.Val39Ala) NM_130439.3(MXI1): 387906417 MXI1 [ ] [ ] [‘Malignant tumor of c.552 + 2T > C prostate’] m.8528T > C 387906422 — [ ] [ ] [‘Cardiomyopathy, infantile hypertrophic’] NM_000132.3(F8): 387906430 F8 [ ] [ ] [‘Hereditary factor c.985T > C (p.Cys329Arg) VIII deficiency disease’] NM_000132.3(F8): 387906443 F8 [ ] [ ] [‘Hereditary factor c.1417T > C (p.Tyr473His) VIII deficiency disease’] NM_000132.3(F8): 387906446 F8 [ ] [‘AAAGAAYCTGT [‘Hereditary factor c.1729T > C (p.Ser577Pro) AGATCAAAGAGG’] VIII deficiency disease’] NM_004333.4(BRAF): 397507473 BRAF [‘ATCAT [‘ATCATYTGGAAC [‘Cardiofaciocutaneo c.1403T > C YTGGA AGTCTACAAGG’, us syndrome’, (p.Phe468Ser) ACAGT ‘TCATYTGGAACA ‘Rasopathy’] CTACA GTCTACAAGGG’] AGG’, ‘TCATY TGGAA CAGTC TACAA GGG’] NM_004333.4(BRAF): 397507475 BRAF [ ] [ ] [‘Cardiofaciocutaneo c.1454T > C us syndrome’, (p.Leu485Ser) ‘Rasopathy’] NM_005188.3(CBL): 397507492 CBL [ ] [ ] [‘Rasopathy’] c.1201T > C (p.Cys401Arg) NM_000133.3(F9): 387906474 F9 [ ] [ ] [‘Hereditary factor c.52T > C (p.Cys18Arg) IX deficiency disease’] NM_005249.4(FOXG1): 786205008 FOXG1 [ ] [ ] [‘Rett syndrome, c.700T > C congenital variant’, (p.Ser234Pro) ‘not provided’] NM_000133.3(F9): 387906481 F9 [ ] [ ] [‘Hereditary factor c.82T > C (p.Cys28Arg) IX deficiency disease’] NM_000133.3(F9): 387906482 F9 [ ] [‘ACGAACAYCTTC [‘Hereditary factor c.1031T > C (p.Ile344Thr) CTCAAATTTGG’] IX deficiency disease’] m.11253T > C 200145866 MT-ND4 [ ] [ ] [‘Leber optic atrophy’] NM_000131.4(F7): 387906507 F7 [ ] [ ] [‘Factor VII c.38T > C (p.Leu13Pro) deficiency’] NM_000131.4(F7): 387906508 F7 [ ] [‘GACGTYCTCTGA [‘Factor VII c.983T > C (p.Phe328Ser) GAGGACGCTGG’] deficiency’] NM_000422.2(KRT17): 28933089 KRT17 [ ] [ ] [‘Pachyonychia c.296T > C congenita type 2’, (p.Leu99Pro) ‘not provided’] NM_001040113.1(MYH11): 387906532 MYH11 [ ] [‘GAAGCYGGAGG [‘Aortic aneurysm, c.3791T > C CGCAGGTGCAGG’] familial thoracic 4’] (p.Leu1264Pro) NM_013246.2(CLCF1): 137853934 — [ ] [ ] [‘Cold-induced c.46T > C sweating syndrome (p.Cys16Arg) 2’] NM_013246.2(CLCF1): 137853935 — [ ] [ ] [‘Cold-induced c.676T > C sweating syndrome (p.Ter226Arg) 2’] NM_001077620.2(PRCD): 527236092 — [ ] [ ] [‘Retinitis c.2T > C pigmentosa’] (p.Met1Thr) NM_000488.3(SERPINC1): 387906575 SERPINC1 [ ] [ ] [‘Antithrombin III c.68T > C deficiency’] (p.Leu23Pro) NM_206933.2(USH2A): 527236118 USH2A [ ] [ ] [‘Retinitis c.9751T > C pigmentosa’] (p.Cys3251Arg) NM_001458.4(FLNC): 387906586 FLNC [ ] [ ] [‘Myopathy, distal, c.752T > C 4’] (p.Met251Thr) NM_000781.2(CYP11A1): 387906601 CYP11A1 [ ] [ ] [‘Adrenal c.665T > C insufficiency, (p.Leu222Pro) congenital, with 46,XY sex reversal, partial or complete’] NM_000548.3(TSC2): 137853995 TSC2 [ ] [ ] [‘Tuberous sclerosis c.2410T > C syndrome’, (p.Cys804Arg) ‘Tuberous sclerosis 2’, ‘not provided’] NM_001145661.1(GATA2): 387906633 GATA2 [ ] [ ] [‘Lymphedema, c.1117T > C primary, with (p.Cys373Arg) myelodysplasia’] NM_002693.2(POLG): 548076633 POLG [‘CAAG [‘CAAGAGGYTGG [‘not provided’] c.3470A > G AGGYT TGATCTGCAAGG’] (p.Asn1157Ser) GGTGA TCTGC AAGG’] NM_002465.3(MYBPC1): 387906657 MYBPC1 [ ] [ ] [‘Distal c.706T > C arthrogryposis type (p.Trp236Arg) 1B’] NM_002465.3(MYBPC1): 387906658 MYBPC1 [ ] [‘CAAACCYATATC [‘Distal c.2566T > C CGCAGAGTTGG’] arthrogryposis type (p.Tyr856His) 1B’] NM_003392.4(WNT5A): 387906663 WNT5A [ ] [ ] [‘Robinow c.544T > C syndrome’] (p.Cys182Arg) NM_005188.3(CBL): 387906665 CBL [ ] [ ] [‘Rasopathy’] c.1186T > C (p.Cys396Arg) NM_006902.4(PRRX1): 387906667 PRRX1 [ ] [ ] [‘Dysgnathia c.338T > C complex’] (p.Phel 13Ser) NM_001111035.1(ACP5): 387906672 — [ ] [ ] [‘Spondyloenchondr c.602T > C odysplasia with (p.Leu201Pro) immune dysregulation’] NM_002734.4(PRKAR1A): 387906693 PRKAR1A [ ] [ ] [‘Acrodysostosis 1 c.1117T > C with or without (p.Tyr373His) hormone resistance’] NM_002734.4(PRKAR1A): 387906695 PRKAR1A [ ] [ ] [‘Acrodysostosis 1 c.980T > C with or without (p.Ile327Thr) hormone resistance’] NM_003491.3(NAA10): 387906701 NAA10 [ ] [‘TGGCCTTYCCTG [‘N-terminal c.109T > C GCCCCAGGTGG’, acetyltransferase (p.Ser37Pro) ‘GGCCTTYCCTGG deficiency’] CCCCAGGTGGG’] NM_006306.3(SMC1A): 387906702 SMC1A [‘AGAY [‘AGAYTGGTGTGC [‘Congenital c.2351T > C TGGTG GCAACATCCGG’] muscular (p.Ile784Thr) TGCGC hypertrophy-cerebral AACAT syndrome’] CCGG’] NM_000377.2(WAS): 387906716 WAS [ ] [ ] [‘Severe congenital c.814T > C neutropenia X- (p.Ser272Pro) linked’] NM_000377.2(WAS): 387906717 WAS [ ] [‘GACTTCAYTGAG [‘Severe congenital c.881T > C GACCAGGGTGG’, neutropenia X- (p.Ile294Thr) ‘ACTTCAYTGAGG linked’] ACCAGGGTGGG’] m.12201T > C 387906733 MT-TH [ ] [ ] [‘Deafness, nonsyndromic sensorineural, mitochondrial’] NM_139125.3(MASP1): 387906753 MASP1 [ ] [ ] [‘Michels syndrome’] c.1888T > C (p.Cys630Arg) NM_007315.3(STAT1): 387906763 STAT1 [ ] [ ] [‘Immunodeficiency c.520T > C 31C’] (p.Cys174Arg) NM_053025.3(MYLK): 387906781 — [ ] [ ] [‘Aortic aneurysm, c.5275T > C familial thoracic 7’] (p.Ser1759Pro) NM_000287.3(PEX6): 387906809 PEX6 [ ] [‘CTTCYGGGCCGG [‘Peroxisome c.1601T > C GACCGTGATGG’, biogenesis disorder (p.Leu534Pro) ‘TTCYGGGCCGGG 4B’] ACCGTGATGGG’] NM_000174.4(GP9): 28933377 GP9 [ ] [ ] [‘Bernard-Soulier c.167T > C (p.Leu56Pro) syndrome type C’] NM_004153.3(ORC1): 387906827 ORC1 [ ] [ ] [‘Meier-Gorlin c.266T > C syndrome 1’] (p.Phe89Ser) NM_021252.4(RAB18): 387906833 RAB18 [ ] [ ] [‘Warburg micro c.619T > C syndrome 3’] (p.Ter207Gln) NM_000702.3(ATP1A2): 28933398 ATP1A2 [ ] [ ] [‘Familial c.2291T > C hemiplegic migraine (p.Leu764Pro) type 2’] NM_000702.3(ATP1A2): 28933399 ATP1A2 [ ] [ ] [‘Familial c.2659T > C hemiplegic migraine (p.Trp887Arg) type 2’] NM_000702.3(ATP1A2): 28933400 ATP1A2 [ ] [ ] [‘Familial c.2192T > C hemiplegic migraine (p.Met731Thr) type 2’] NM_020433.4(JPH2): 387906897 JPH2 [ ] [ ] [‘Familial c.421T > C hypertrophic (p.Tyr141His) cardiomyopathy 17’] NM_173170.1(IL36RN): 387906914 IL36RN [ ] [ ] [‘Pustular psoriasis, c.80T > C generalized’] (p.Leu27Pro) NM_004990.3(MARS): 201555303 MARS [ ] [ ] [‘Interstitial lung and c.1568T > C liver disease’] (p.Ile523Thr) NM_020191.2(MRPS22): 387906924 MRPS22 [‘ATCYT [‘ATCYTAGGGTAA [‘Combined c.644T > C AGGGT GGTGACTTAGG’] oxidative (p.Leu215Pro) AAGGT phosphorylation GACTT deficiency 5’] AGG’] NM_022445.3(TPK1): 387906936 TPK1 [ ] [ ] [‘THIAMINE c.119T > C METABOLISM (p.Leu40Pro) DYSFUNCTION SYNDROME 5 (EPISODIC ENCEPHALOPATHY TYPE)’] NM_020634.1(GDF3): 387906945 GDF3 [ ] [ ] [‘Congenital ocular c.914T > C coloboma’, (p.Leu305Pro) ‘Microphthalmia, isolated 7’] NM_024513.3(FYCO1): 387906965 FYCO1 [ ] [CAGCCYGATCCC [‘Cataract, autosomal c.4127T > C CATCACTGTGG’] recessive congenital (p.Leu1376Pro) 2’] NM_006147.3(IRF6): 387906967 IRF6 [ ] [‘GCCYCTACCCTG [‘Van der Woude c.65T > C (p.Leu22Pro) GGCTCATCTGG’] syndrome’, ‘Popliteal pterygium syndrome’] NM_025132.3(WDR19): 387906980 WDR19 [ ] [ ] [‘Cranioectodermal c.2129T > C dysplasia 4’, (p.Leu710Ser) ‘SENIOR-LOKEN SYNDROME 8’] NM_025132.3(WDR19): 387906982 WDR19 [ ] [‘TCTCACYGCTAG [‘Asphyxiating c.20T > C AAAAGACTTGG’] thoracic dystrophy (p.Leu7Pro) 5’] NM_014874.3(MFN2): 387906990 MFN2 [ ] [ ] [ ] c.647T > C (p.Phe216Ser) NM_016097.4(IER3IP1): 387907012 IER3IP1 [ ] [ ] [‘Microcephaly, c.233T > C epilepsy, and (p.Leu78Pro) diabetes syndrome’] NM_022489.3(INF2): 387907034 INF2 [ ] [ ] [‘Charcot-Marie- c.310T > C Tooth disease, (p.Cys104Arg) dominant intermediate E’] NM_022489.3(INF2): 387907037 INF2 [ ] [ ] [‘Charcot-Marie- c.383T > C Tooth disease, (p.Leu128Pro) dominant intermediate E’] NM_003235.4(TG): 137854433 TG [ ] [ ] [‘Iodotyrosyl c.3229T > C coupling defect’] (p.Cys1077Arg) NM_058246.3(DNAJB6): 387907046 DNAJB6 [ ] [ ] [‘Limb-girdle c.277T > C muscular dystrophy, (p.Phe93Leu) type 1E’] NM_032446.2(MEGF10): 387907072 MEGF10 [ ] [‘GGGCAGYGTAC [‘Myopathy, c.2320T > C TTGCCGCACTGG’] areflexia, respiratory (p.Cys774Arg) distress, and dysphagia, early- onset’, ‘Myopathy, areflexia, respiratory distress, and dysphagia, early- onset, mild variant’] NM_005502.3(ABCA1): 137854494 ABCA1 [‘CCTGT [‘CCTGTGYGTCCC [‘Tangier disease’] c.4429T > C GYGTC CCAGGGGCAGG’, (p.Cys1477Arg) CCCCA ‘CTGTGYGTCCCC GGGGC CAGGGGCAGGG’, AGG’, ‘TGTGYGTCCCCC ‘CTGTG AGGGGCAGGGG’, YGTCC ‘GTGYGTCCCCCA CCCAG GGGGCAGGGGG’] GGGCA GGG’] NM_005502.3(ABCA1): 137854499 ABCA1 [ ] [‘GAGTYCTTTGCC [‘Familial c.6026T > C CTTTTGAGAGG’] hypoalphalipoprotei (p.Phe2009Ser) nemia’] NM_015175.2(NBEAL2): 387907113 NBEAL2 [ ] [ ] [‘Gray platelet c.1163T > C syndrome’] (p.Leu388Pro) NM_000196.3(HSD11B2): 387907117 HSD11B2 [ ] [‘CCGCCGCYATTA [‘Apparent c.1012T > C CCCCGGCCAGG’, mineralocorticoid (p.Tyr338His) ‘CGCCGCYATTAC excess’] CCCGGCCAGGG’] NM_024599.5(RHBDF2): 387907129 RHBDF2 [‘AGAY [‘AGAYTGTGGATC [‘Howel-Evans c.557T > C TGTGG CGCTGGCCCGG’] syndrome’] (p.Ile186Thr) ATCCG CTGGC CCGG’] NM_001077488.3(GNAS): 137854531 GNAS [ ] [ ] [‘Pseudohypoparathy c.299T > C roidism type 1A’] (p.LeulOOPro) NM_001256714.1(DNAAF3): 387907151 DNAAF3 [ ] [ ] [‘Kartagener c.386T > C syndrome’, ‘Ciliary (p.Leu129Pro) dyskinesia, primary, 2’] NM_020894.2(UVSSA): 387907164 UVSSA [‘AAAA [‘AAAATTYGCAA [‘UV-sensitive c.94T > C TTYGC GTATGTCTTAGG’, syndrome 3’] (p.Cys32Arg) AAGTA ‘AAATTYGCAAGT TGTCTT ATGTCTTAGGG’] AGG’] NM_000267.3(NF1): 137854558 NF1 [ ] [ ] [‘Neurofibromatosis, c.1523T > C type 1’] (p.Leu508Pro) NM_000267.3(NF1): 137854561 NF1 [ ] [ ] [‘Neurofibromatosis, c.6200T > C familial spinal’] (p.Leu2067Pro) NM_004453.3(ETFDH): 387907170 ETFDH [ ] [‘CCAAAACYCAC [ ] c.1130T > C CTTTCCTGGTGG’] (p.Leu377Pro) NM_000267.3(NF1): 137854563 NF1 [ ] [ ] [‘Neurofibromatosis, c.1070T > C type 1’, (p.Leu357Pro) ‘Neurofibromatosis, familial spinal’] NM_024306.4(FA2H): 387907172 FA2H [ ] [ ] [‘Spastic paraplegia c.707T > C 35’] (p.Phe236Ser) NM_001004127.2(ALG11): 387907182 — [ ] [ ] [‘Congenital disorder c.1142T > C of glycosylation type (p.Leu381Ser) 1P’] NM_021167.4(GATAD1): 387907188 GATAD1 [ ] [ ] [‘Cardiomyopathy, c.304T > C dilated, 2b’] (p.Ser102Pro) NM_033360.3(KRAS): 387907205 KRAS [ ] [‘GGACCAGYACA [‘Cardiofaciocutaneous c.211T > C TGAGGACTGGGG’, syndrome 2’] (p.Tyr71His) ‘CCAGYACATGAG GACTGGGGAGG’, ‘CAGYACATGAGG ACTGGGGAGGG’] NM_006265.2(RAD21): 387907213 — [ ] [ ] [‘Cornelia de Lange c.1753T > C syndrome 4’] (p.Cys585Arg) NM_000222.2(KIT): 387907217 KIT [ ] [ ] [ ] c.1859T > C (p.Val620Ala) NM_000335.4(SCN5A): 137854615 SCN5A [ ] [ ] [‘Brugada c.5380T > C syndrome’, ‘Brugada (p.Tyr1794His) syndrome 1’] NM_000076.2(CDKN1C): 387907224 CDKN1C [ ] [ ] [‘Intrauterine growth c.827T > C retardation, (p.Phe276Ser) metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies’] NM_005691.3(ABCC9): 387907229 ABCC9 [ ] [ ] [‘Hypertrichotic c.3058T > C osteochondrodysplas (p.Ser1020Pro) ia’] NM_012343.3(NNT): 387907233 NNT [ ] [ ] [‘Glucocorticoid c.2930T > C deficiency 4’] (p.Leu977Pro) NM_024110.4(CARD14): 387907240 CARD14 [ ] [‘CAGCAGCYGCA [‘Pityriasis rubra c.467T > C GGAGCACCTGGG’] pilaris’] (p.Leu156Pro) NM_002501.3(NFIX): 387907254 NFIX [ ] [ ] [‘Sotos syndrome 2’] c.179T > C (p.Leu60Pro) NM_001165963.1(SCN1A): 764444350 SCN1A [ ] [ ] [‘Severe myoclonic c.121A > T epilepsy in infancy’] (p.Lys41Ter) NM_005022.3(PFN1): 387907265 PFN1 [ ] [ ] [‘Amyotrophic c.341T > C lateral sclerosis 18’] (p.Met114Thr) NM_001172567.1(MYD88): 387907272 MYD88 [ ] [ ] [‘Macroglobulinemia, c.818T > C waldenstrom, (p.Leu273Pro) somatic’] NM_152296.4(ATP1A3): 387907282 ATP1A3 [ ] [‘TGCCATCYCACT [‘Alternating c.2431T > C GGCGTACGAGG’] hemiplegia of (p.Ser811Pro) childhood 2’] NM_022787.3(NMNAT1): 387907290 NMNAT1 [ ] [ ] [‘Leber congenital c.838T > C amaurosis 9’] (p.Ter280Gln) NM_005120.2(MED12): 387907361 MED12 [ ] [‘AGGACYCTGAG [‘Ohdo syndrome, c.3493T > C CCAGGGGCCCGG’] X-linked’] (p.Ser1165Pro) NM_006194.3(PAX9): 28933970 PAX9 [ ] [‘GGCCGCYGCCC [‘Tooth agenesis, c.62T > C (p.Leu21Pro) AACGCCATCCGG’] selective, 3’] NM_000492.3(CFTR): 397508435 CFTR [ ] [ ] [‘Cystic fibrosis’] c.2780T > C (p.Leu927Pro) NM_177976.2(ARL6): 137854907 ARL6 [ ] [ ] [‘Bardet-Biedl c.272T > C (p.Ile91Thr) syndrome’]

TABLE 8 Human gene mutations that may be corrected by changing a guanine (G) to an adenine (A). The gene name, gene symbol, and dbSNP database reference number (RS#) are indicated. Also indicated are exemplary protospacers with their PAM sequences (gRNAs and gRNAall) and the base to be edited e.g., a C, indicated by a “Y”. The “gRNAs” sequences, from top to bottom, correspond to SEQ ID NOs: 3334-3501. The “gRNA all” sequences, from top to bottom, correspond to SEQ ID NOs: 3502-4119. RS# Name (dbSNP) GeneSymbol gRNAs gRNAall Phenotypes NM_000138.4 137854472 FBN1 [ ] [′TGCACYTGCCGT [ ] (FBN1):c.3128A>G GGGTGCAGAGG′] (p.Lys1043Arg) NM_000237.2 268 LPL [ ] [ ] [′Hyperlipidemia, (LPL):c.953A>G familial combined′] (p.Asn318Ser) NM_000257.3 727504261 MYH7 [ ] [′AGCGCYCCTCAG [′Cardiomyopathy′, (MYH7):c.2708A>G CATCTGCCAGG′] ′not specified′] (p.Glu903Gly) NM_000059.3 81002853 BRCA2 [ ] [′ACCACYGGGGG [′Familial cancer of (BRCA2):c.476-2A>G TAAAAAAAGGGG′, breast′, ′Breast- ′TACCACYGGGGG ovarian cancer, TAAAAAAAGGG′, familial 2′, ′ATACCACYGGGG ′Hereditary cancer- GTAAAAAAAGG′] predisposing syndrome′] NM_000059.3 81002862 BRCA2 [ ] [ ] [′Familial cancer of (BRCA2):c.9118-2A>G breast′, ′Breast- ovarian cancer, familial 2′] NM_000059.3 81002895 BRCA2 [ ] [ ] [′Familial cancer of (BRCA2):c.9649-2A>G breast′, ′Breast- ovarian cancer, familial 2′] NM_000387.5 28934589 SLC25A20 [ ] [ ] [′Carnitine (SLC25A20):c.713A>G acylcarnitine (p.Gln238Arg) translocase deficiency′, ′not provided′] NM_000060.3 28934601 BTD [ ] [ ] [′Biotinidase (BTD):c.755A>G deficiency′] (p.Asp252Gly) NM_172107.2 28939683 KCNQ2 [ ] [ ] [′Benign familial (KCNQ2):c.851A>G neonatal seizures 1′] (p.Tyr284Cys) NM_006158.4 58982919 NEFL [ ] [ ] [′Charcot-Marie- (NEFL):c.293A>G Tooth disease, type (p.Asn98Ser) IF′, ′not provided′] NM_000019.3 199524907 ACAT1 [ ] [ ] [′Deficiency of (ACAT1):c.473A>G acetyl-CoA (p.Asn158Ser) acetyltransferase′] NM_007294.3 397509212 BRCA1 [ ] [ ] [′Familial cancer of (BRCA1):c.4987-2A>G breast′] NM_007294.3 80358163 BRCA1 [ ] [ ] [′Familial cancer of (BRCA1):c.213-12A>G breast′, ′Hereditary breast and ovarian cancer syndrome′, ′Breast-ovarian cancer, familial 1′, ′Hereditary cancer- predisposing syndrome′] NM_001382.3 28934876 DPAGT1 [′ACAYAGT [′ACAYAGTACAG [′Congenital disorder (DPAGT1):c.509A>G ACAGGATT GATTCCTGCGGG′, of glycosylation type (p.Tyr170Cys) CCTGCGGG′, ′GACAYAGTACAG 1J′] ′GACAYAG GATTCCTGCGG′] TACAGGAT TCCTGCGG′] NM_032237.4 397509386 POMK [ ] [ ] [′Congenital (POMK):c.773A>G muscular dystrophy- (p.Gln258Arg) dystroglycanopathy with brain and eye anomalies, type A12′] NM_201647.2 397509387 STAMBP [ ] [ ] [′Microcephaly- (STAMBP):c.125A>G capillary (p.Glu42Gly) malformation syndrome′] NM_006876.2 397509397 B4GAT1 [′CTGATYT [′TGATYTTCAGCC [′Congenital (B4GAT1):c.1168A>G TCAGCCTC TCCTTTTGGGG′, muscular dystrophy- (p.Asn390Asp) CTTTTGGG′, ′CTGATYTTCAGC dystroglycanopathy ′GCTGATYT CTCCTTTTGGG′, with brain and eye TCAGCCTC ′GCTGATYTTCAG anomalies, type CTTTTGG′] CCTCCTTTTGG′] A13′] NM_004315.4 397509415 ASAH1 [ ] [ ] [′Farber (ASAH1):c.965+4A>G lipogranulomatosis′] NM_000257.3 730880875 MYH7 [ ] [ ] [′Cardiomyopathy′] (MYH7):c.1477A>G (p.Met493Val) NM_021020.3 119473032 LZTS1 [ ] [′CCCTYCTCGGAG [ ] (LZTS1):c.355A>G CCCTGTAGAGG′] (p.Lys119Glu) NM_022455.4 587784163 NSD1 [ ] [ ] [′Sotos syndrome 1′] (NSD1):c.5893-2A>G NM_006894.5 72549322 FMO3 [ ] [ ] [′Trimethylaminuria′] (FMO3):c.182A>G (p.Asn61Ser) NM_000403.3 121908046 GALE [′TGGAAGY [′TGGAAGYTATCG [′UDPglucose-4- (GALE):c.101A>G TATCGATG ATGACCACAGG′] epimerase (p.Asn34Ser) ACCACAGG′] deficiency′] NM_000314.6 757498880 PTEN [ ] [ ] [′Hereditary cancer- (PTEN):c.527A>G predisposing (p.Tyr176Cys) syndrome′] NM_000053.3 193922103 ATP7B [ ] [ ] [′Wilson disease′, (ATP7B):c.2305A>G ′not specified′, ′not (p.Met769Val) provided′] NM_000173.6 121908064 GP1BA [ ] [ ] [′Pseudo von (GP1BA):c.763A>G Willebrand disease′] (p.Met255Val) NM_000422.2 59151893 KRT17 [′GTCAYTG [′GTCAYTGAGGTT [′Pachyonychia (KRT17):c.275A>G AGGTTCTG CTGCATGGTGG′, congenita type 2′, (p.Asn92Ser) CATGGTGG′] ′GCGGTCAYTGAG ′not provided′] GTTCTGCATGG′] NM_000288.3 62653611 PEX7 [ ] [ ] [′Rhizomelic (PEX7):c.854A>G chondrodysplasia (p.His285Arg) punctata type 1′] NM_003742.2 11568372 ABCB11 [ ] [ ] [′Progressive (ABCB11):c.890A>G familial intrahepatic (p.Glu297Gly) cholestasis 2′, ′Benign recurrent intrahepatic cholestasis 2′] NM_012243.2 141952252 SLC35A3 [ ] [ ] [′Arthrogryposis, (SLC35A3):c.886A>G mental retardation, (p.Ser296Gly) and seizures′] NM_000061.2 28935478 BTK [′GATGGYA [′GATGGYAGTTA [ ] (BTK):c.1082A>G GTTAATGA ATGAGCTCAGGG′, (p.Tyr361Cys) GCTCAGGG′, ′TGATGGYAGTTA ′TGATGGY ATGAGCTCAGG′] AGTTAATG AGCTCAGG′] NM_000169.2 28935495 — [ ] [ ] [′Fabry disease′] (GLA):c.815A>G (p.Asn272Ser) NM_016069.9 786203989 — [′TCATAGT [′CATAGTYCTGCA [′Chondrodysplasia, (PAM16):c.226A>G YCTGCAGA GAGGAGAGGGG′, megarbane-dagher- (p.Asn76Asp) GGAGAGG ′TCATAGTYCTGC melki type′] G′] AGAGGAGAGGG′] NM_058163.1 786203996 TSR2 [ ] [ ] [′Diamond-Blackfan (TSR2):c.191A>G anemia with (p.Glu64Gly) microtia and cleft palate′, ′DIAMOND- BLACKFAN ANEMIA 14 WITH MANDIBULOFACIAL DYSOSTOSIS′] NM_001098398.1 794727994 — [ ] [ ] [ ] (COPA):c.728A>G (p.Asp243Gly) NM_005957.4 786204024 MTHFR [ ] [ ] [′Homocysteinemia (MTHFR):c.1114A>G due to MTHFR (p.Lys372Glu) deficiency′] NM_012193.3 80358293 — [ ] [ ] [′Exudative (FZD4):c.1024A>G vitreoretinopathy 1′] (p.Met342Val) NM_000186.3 460184 CFH [′CAGYTGA [′CAGYTGAATTTG [′Atypical (CFH):c.3590T>C ATTTGTGT TGTGTAAACGG′] hemolytic-uremic (p.Val1197Ala) GTAAACGG′] syndrome 1′] NM_014846.3 80338865 KIAA0196 [ ] [ ] [′Spastic paraplegia (KIAA0196):c.1411A>G 8′] (p.Asn471Asp) NM_014946.3 786204132 SPAST [′AGCATTG [′ATTGYCTTCCCA [′Spastic paraplegia (SPAST):c.1165A>G YCTTCCCA TTCCCAGGTGG′, 4, autosomal (p.Thr389Ala) TTCCCAGG′] AGCATTGYCTTC dominant′] CCATTCCCAGG′] NM_000925.3 28935769 PDHB [ ] [ ] [′Pyruvate (PDHB):c.395A>G dehydrogenase E1- (p.Tyr132Cys) beta deficiency′] NM_000090.3 794728050 COL3A1 [ ] [ ] [′Thoracic aortic (COL3A1):c.2338-2A>G aneurysms and aortic dissections′] NM_000540.2 193922746 RYR1 [ ] [ ] [′King Denborough (RYR1):c.97A>G syndrome′, ′not (p.Lys33Glu) provided′] NM_000540.2 193922801 RYR1 [ ] [′TTCYCCTCCACG [′not provided′] (RYR1):c.7043A>G CTCTCGCCTGG′] (p.Glu2348Gly) NM_000218.2 36210419 KCNQ1 [ ] [′GCCCCTYGGAGC [′Torsades de (KCNQ1):c.652A>G CCACGCAGAGG′] pointes′, ′Cardiac (p.Lys218Glu) arrhythmia′] NM_000540.2 193922886 RYR1 [ ] [ ] [′Minicore myopathy (RYR1):c.14647-1449A>G with external ophthalmoplegia′, ′not provided′] NM_004429.4 28936071 EFNB1 [ ] [ ] [′Craniofrontonasal (EFNB1):c.472A>G dysplasia′] (p.Met158Val) NM_007254.3 199919568 PNKP [′CCGGYGA [′CCGGYGAGGCC [′not provided′] (PNKP):c.1029+2T>C GGCCCTGG CTGGGGCGGGGG′, GGCGGGGG′, ′TCCGGYGAGGCC ′TCCGGYG CTGGGGCGGGG′, AGGCCCTG ′ATCCGGYGAGGC GGGCGGG CCTGGGGCGGG′, G′] ′GATCCGGYGAGG CCCTGGGGCGG′] NM_005448.2 104894765 BMP15 [′ATTGAAA [′ATTGAAAYAGA [′Ovarian dysgenesis (BMP15):c.704A>G YAGAGTAA GTAACAAGAAGG′] 2′] (p.Tyr235Cys) CAAGAAGG′] NM_004415.2 794728111 DSP [ ] [ ] [′not provided′] (DSP):c.1141-2A>G NM_016035.4 786204770 COQ4 [′GCTGTYG [′GCTGTYGGCCGC [′COENZYME Q10 (COQ4):c.155T>C GCCGCCGG CGGCTCCGCGG′] DEFICIENCY, (p.Leu52Ser) CTCCGCGG′] PRIMARY, 7′] NM_015717.4 200837270 CD207 [ ] [ ] [′Birbeck granule (CD207):c.790T>C deficiency′] (p.Trp264Arg) NM_004771.3 786204826 MMP20 [′CGAAAYG [′CGAAAYGTGTAT [′Amelogenesis (MMP20):c.611A>G TGTATCTC CTCCTCCCAGG′] imperfecta, (p.His204Arg) CTCCCAGG′] hypomaturation type, IIA2′] NM_003392.4 786204836 WNT5A [ ] [ ] [′Robinow (WNT5A):c.257A>G syndrome′] (p.Tyr86Cys) NM_000918.3 786204843 P4HB [ ] [ ] [′Cole Carpenter (P4HB):c.1178A>G syndrome′] (p.Tyr393Cys) NM_000314.6 786204855 PTEN [ ] [ ] [′Hereditary cancer- (PTEN):c.139A>G predisposing (p.Arg47Gly) syndrome′] NM_000314.6 786204858 PTEN [ ] [ ] [′Hereditary cancer- (PTEN):c.320A>G predisposing (p.Asp107Gly) syndrome′] NM_000447.2 28936379 PSEN2 [ ] [ ] [′Alzheimer disease, (PSEN2):c.715A>G type 4′, ′not (p.Met239Val) provided′] NM_005263.3 28936381 GFIl [ ] [ ] [′Severe congenital (GFI1):c.1145A>G neutropenia 2, (p.Asn382Ser) autosomal dominant′] NM_005263.3 28936382 GFIl [ ] [ ] [′Neutropenia, (GFI1):c.1208A>G nonimmune chronic (p.Lys403Arg) idiopathic, of adults′] NM_000314.6 786204865 PTEN [ ] [ ] [′Hereditary cancer- (PTEN):c.512A>G predisposing (p.Gln171Arg) syndrome′] NM_000314.6 786204926 PTEN [ ] [ ] [′Hereditary cancer- (PTEN):c.254-2A>G predisposing syndrome′] NM_001103.3 786204951 ACTN2 [ ] [ ] [′Familial (ACTN2):c.1883A>G hypertrophic (p.Glu628Gly) cardiomyopathy 23′] NM_003159.2 786204973 CDKL5 [ ] [ ] [′Early infantile (CDKL5):c.-162-2A>G epileptic encephalopathy 2′] NM_001159287.1 121964849 TPI1 [ ] [ ] [′Triosephosphate (TPI1):c.622A>G isomerase (p.Ile208Val) deficiency′] NM_003159.2 786204979 CDKL5 [ ] [ ] [′Early infantile (CDKL5):c.2277-2A>G epileptic encephalopathy 2′] NM_003159.2 786204985 CDKL5 [ ] [ ] [′Early infantile (CDKL5):c.458A>G epileptic (p.Asp153Gly) encephalopathy 2′] NM_003159.2 786204991 CDKL5 [ ] [ ] [′Early infantile (CDKL5):c.91A>G epileptic (p.Arg31Gly) encephalopathy 2′] NM_001007792.1 121964869 NTRK1 [ ] [ ] [′Hereditary (NTRK1):c.986A>G insensitivity to pain (p.Tyr329Cys) with anhidrosis′] NM_001007792.1 121964870 NTRK1 [ ] [ ] [′Hereditary (NTRK1):c.1651A>G insensitivity to pain (p.Met551Val) with anhidrosis′] NM_004360.3 121964872 CDH1 [ ] [ ] [′Hereditary diffuse (CDH1):c.2512A>G gastric cancer′, (p.Ser838Gly) ′Hereditary cancer- predisposing syndrome′, ′Neoplasm of ovary′] NM_003122.4 17107315 SPINK1 [ ] [ ] [′Hereditary (SPINK1):c.101A>G pancreatitis′, (p.Asn34Ser) ′Tropical calcific pancreatitis′, ′Pancreatitis, chronic, susceptibility to′] NM_021098.2 786205050 CACNA1H [ ] [ ] [′Primary (CACNA1H):c.4645A>G hyperaldosteronism′] (p.Met1549Val) NM_001385.2 121964923 DPYS [ ] [ ] [′Dihydropyrimidinase (DPYS):c.1001A>G deficiency′] (p.Gln334Arg) NM_003494.3 786205083 DYSF [′GCCAGAG [′GCCAGAGYGAG [′Limb-girdle (DYSF):c.3443-33A>G YGAGTGGC TGGCTGGAGTGG′] muscular dystrophy, TGGAGTGG′] type 2B′] NM_003816.2 786205086 ADAM9 [ ] [ ] [ ] (ADAM9):c.411-8A>G NM_000532.4 121964961 PCCB [ ] [ ] [′Propionic (PCCB):c.1304A>G acidemia′] (p.Tyr435Cys) NM_000071.2 121964967 CBS [′AACTYGG [′AACTYGGTCCTG [′Homocystinuria, (CBS):c.1150A>G TCCTGCGG CGGGATGGGGG′, pyridoxine- (p.Lys384Glu) GATGGGGG′] ′GAACTYGGTCCT responsive′] GCGGGATGGGG′, ′GGAACTYGGTCC TGCGGGATGGG′, ′AGGAACTYGGTC CTGCGGGATGG′] NM_000093.4 786205101 COL5A1 [ ] [ ] [′Ehlers-Danlos (COL5A1):c.655-2A>G syndrome, classic type′] NM_000481.3 121964983 AMT [′GCCAGGY [′GCCAGGYGGAA [′Non-ketotic (AMT):c.125A>G GGAAGTCA GTCATAGAGCGG′] hyperglycinemia′] (p.His42Arg) TAGAGCGG′] NM_000108.4 121964987 DLD [ ] [ ] [′Maple syrup urine (DLD):c.214A>G disease, type 3′] (p.Lys72Glu) NM_000108.4 121964989 DLD [ ] [′TTCTCYAAAAGC [′Maple syrup urine (DLD):c.1483A>G TTCTGATAAGG′] disease, type 3′] (p.Arg495Gly) NM_000108.4 121964993 DLD [ ] [ ] [′Maple syrup urine (DLD):c.1081A>G disease, type 3′] (p.Met361Val) NM_001918.3 121965002 DBT [ ] [ ] [ ] (DBT):c.1355A>G (p.His452Arg) NM_030813.5 786205138 CLPB [ ] [ ] [3- (CLPB):c.1850A>G METHYLGLUTACONIC (p.Tyr617Cys) ACIDURIA WITH CATARACTS, NEUROLOGIC INVOLVEMENT, AND NEUTROPENIA′] NM_006610.3 72550870 MASP2 [ ] [ ] [′MASP2 (MASP2):c.359A>G deficiency′] (p.Asp120Gly) NM_000398.6 121965018 CYB5R3 [ ] [ ] [′METHEMO- (CYB5R3):c.719A>G GLOBINEMIA, (p.Asp240Gly) TYPE I′] NM_000095.2 28936668 COMP [ ] [ ] [ ] (COMP):c.1358A>G (p.Asn453Ser) NM_000095.2 28936669 COMP [ ] [′ATTGYCGTCGTC [ ] (COMP):c.1418A>G GTCGTCGCAGG′] (p.Asp473Gly) NM_003816.2 786205151 ADAM9 [ ] [ ] [ ] (ADAM9):c.1396-2A>G NM_001204830.1 786205156 — [ ] [ ] [′LIPOYL- (LIPT1):c.535A>G TRANSFERASE 1 (p.Thr179Ala) DEFICIENCY′] NM_000274.3 121965046 OAT [ ] [ ] [′Ornithine (OAT):c.734A>G aminotransferase (p.Tyr245Cys) deficiency′] NM_018488.2 28936696 TBX4 [ ] [′GTACYGTAAGG [′Ischiopatellar (TBX4):c.1592A>G AAGATTCTCGGG′, dysplasia′] (p.Gln531Arg) ′GGTACYGTAAGG AAGATTCTCGG′] NM_001110556.1 786205183 FLNA [ ] [ ] [′X-linked (FLNA):c.1829-2A>G periventricular heterotopia′] NM_003865.2 28936704 HESX1 [ ] [ ] [′Growth hormone (HESX1):c.541A>G deficiency with (p.Thr181Ala) pituitary anomalies′] NM_000137.2 121965077 FAH [ ] [′TCCYGGTCTGAC [′Tyrosinemia type (FAH):c.1141A>G CATTCCCCAGG′] I′] (p.Arg381Gly) NM_000137.2 121965078 FAH [ ] [ ] [′Tyrosinemia type (FAH):c.836A>G I′] (p.Gln279Arg) NM_006129.4 786205219 BMP1 [ ] [ ] [′Osteogenesis (BMP1):c.808A>G imperfecta type 13′] (p.Met270Val) NM_001987.4 786205226 ETV6 [ ] [ ] [′Thrombocytopenia (ETV6):c.1252A>G 5′] (p.Arg418Gly) NM_014423.3 786205233 AFF4 [ ] [ ] [′CHOPS (AFF4):c.760A>G SYNDROME′] (p.Thr254Ala) NM_000140.3 786205247 FECH [ ] [ ] [′Erythropoietic (FECH):c.68_194del protoporphyria′] NM_000138.4 794728203 FBN1 [ ] [′ACTCAYCAATAT [′Thoracic aortic (FBN1):c.3344A>G CTGCAAAATGG′] aneurysms and (p.Asp1115Gly) aortic dissections′] NM_198270.3 786205257 NHS [ ] [ ] [′Nance-Horan (NHS):c.853-2A>G syndrome′] NM_005502.3 2853578 ABCA1 [ ] [ ] [′Tangier disease′] (ABCA1):c.1790A>G (p.Gln597Arg) NM_003002.3 786205436 SDHD [ ] [′GAATAGYCCATC [′Fatal infantile (SDHD):c.275A>G GCAGAGCAAGG′] mitochondrial (p.Asp92Gly) cardiomyopathy′] NM_005259.2 1805086 — [ ] [ ] [ ] (MSTN):c.458A>G (p.Lys153Arg) NM_198056.2 1805124 SCN5A [ ] [ ] [′Progressive (SCN5A):c.1673A>G familial heart block (p.His558Arg) type 1A′, ′not specified′, ′not provided′] NM_000784.3 72551317 CYP27A1 [ ] [′AGTCCACYTGGG [′Cholestanol storage (CYP27Al):c.776A>G GAGGAAGGTGG′] disease′] (p.Lys259Arg) NM_000784.3 72551320 CYP27A1 [ ] [ ] [′Cholestanol storage (CYP27Al):c.1061A>G disease′] (p.Asp354Gly) NM_000463.2 72551348 — [ ] [ ] [′Crigler-Najjar (UGT1A1):c.992A>G syndrome, type II′] (p.Gln331Arg) NM_000463.2 72551351 — [ ] [ ] [′Crigler Najjar (UGT1A1):c.1070A>G syndrome, type 1′] (p.Gln357Arg) NM_016218.2 786205687 POLK [ ] [′ATTCACAYTCTT [′Malignant tumor of (POLK):c.1385A>G CAACTTAATGG′] prostate′] (p.Asn462Ser) NM_016218.2 786205689 POLK [ ] [ ] [′Malignant tumor of (POLK):c.181A>G prostate′] (p.Asn61Asp) NM_016218.2 786205692 POLK [ ] [ ] [′Malignant tumor of (POLK):c.1477A>G prostate′] (p.Lys493Glu) NM_000138.4 794728280 FBN1 [ ] [′TGTTCAYACTGG [′Thoracic aortic (FBN1):c.7916A>G AAGCCGGCGGG′, aneurysms and (p.Tyr2639Cys) ′CTGTTCAYACTG aortic dissections′] GAAGCCGGCGG′] NM_000132.3 28937272 F8 [ ] [ ] [′Hereditary factor (F8):c.1331A>G VIII deficiency (p.Lys444Arg) disease′] NM_000531.5 72554340 OTC [ ] [ ] [′not provided′] (OTC):c.268A>G (p.Ser90Gly) NM_005502.3 28937313 ABCA1 [′TCCAYTG [′TCCAYTGTGGCC [′Tangier disease′] (ABCA1):c.2804A>G TGGCCCAG CAGGAAGGAGG′, (p.Asn935Ser) GAAGGAG ′CGCTCCAYTGTG G′] GCCCAGGAAGG′] NM_004380.2 28937315 CREBBP [ ] [ ] [′Rubinstein-Taybi (CREBBP):c.3524A>G syndrome′] (p.Tyr1175Cys) NM_000335.4 28937317 SCN5A [ ] [′GCAYTGACCACC [′Long QT syndrome (SCN5A):c.3971A>G ACCTCAAGTGG′] 3′, ′Congenital long (p.Asn1324Ser) QT syndrome′] NM_000891.2 786205818 KCNJ2 [ ] [ ] [′Cardiac (KCNJ2):c.901A>G arrhythmia′] (p.Met301Val) NM_144499.2 786205854 GNAT1 [ ] [′CGGAGYCCTTCC [′NIGHT (GNAT1):c.386A>G ACAGCCGCTGG′] BLINDNESS, (p.Asp129Gly) CONGENITAL STATIONARY, TYPE 1G′] NM_000523.3 104893635 HOXD13 [ ] [ ] [′Syndactyly type 5′] (HOXD13):c.974A>G (p.Gln325Arg) NM_013953.3 104893660 — [ ] [ ] [′Thyroid agenesis′] (PAX8):c.160A>G (p.Ser54Gly) NM_014585.5 104893663 SLC40A1 [ ] [ ] [′Hemochromatosis (SLC40A1):c.470A>G type 4′] (p.Asp157Gly) NM_003124.4 104893665 SPR [ ] [ ] [′Sepiapterin (SPR):c.448A>G reductase (p.Arg150Gly) deficiency′] NM_000258.2 104893748 MYL3 [ ] [ ] [′Familial (MYL3):c.445A>G hypertrophic (p.Met149Val) cardiomyopathy 8′, ′Cardiomyopathy′, ′Hypertrophic cardiomyopathy′] NM_000539.3 104893776 RHO [ ] [′GGATGYACCTG [′Retinitis (RHO):c.533A>G AGGACAGGCAGG′] pigmentosa 4′] (p.Tyr178Cys) NM_000539.3 104893777 RHO [ ] [ ] [′Retinitis (RHO):c.569A>G pigmentosa 4′] (p.Asp190Gly) NM_000539.3 104893786 RHO [ ] [ ] [′Retinitis (RHO):c.44A>G pigmentosa′, (p.Asn15Ser) ′Retinitis pigmentosa 4′] NM_001814.4 28937571 CTSC [ ] [ ] [′Periodontitis, (CTSC):c.1235A>G aggressive, 1′] (p.Tyr412Cys) NM_001701.3 28937579 BAAT [ ] [ ] [′Hypercholanemia, (BAAT):c.226A>G familial′] (p.Met76Val) NM_001257342.1 28937590 BCS1L [ ] [′GACACYGAGGT [′GRACILE (BCS1L):c.232A>G GCTGAGTACGGG′, syndrome′] (p.Ser78Gly) ′CGACACYGAGGT GCTGAGTACGG′] NM_004407.3 104893834 DMP1 [ ] [ ] [′Autosomal (DMP1):c.1A>G recessive (p.Met1Val) hypophosphatemic vitamin D refractory rickets′] NM_000406.2 104893836 GNRHR [ ] [ ] [′Hypogonadotropic (GNRHR):c.317A>G hypogonadism′] (p.Gln106Arg) NM_172250.2 104893849 MMAA [ ] [ ] [′Methylmalonic (MMAA):c.620A>G aciduria cblA type′] (p.Tyr207Cys) NM_000320.2 104893866 QDPR [ ] [′TGCCGYACCCGA [′Dihydropteridine (QDPR):c.449A>G TCATACCTGGG′, reductase (p.Tyr150Cys) ′ATGCCGYACCCG deficiency′] ATCATACCTGG′] NM_015629.3 587776590 PRPF31 [ ] [′GACAYACCCCTG [′Retinitis (PRPF31):c.527+3A>G GGTGGTGGAGG′, pigmentosa 11′] ′GCGGACAYACCC CTGGGTGGTGG′] NM_000112.3 104893920 SLC26A2 [ ] [ ] [′Diastrophic (SLC26A2):c.1273A>G dysplasia′, (p.Asn425Asp) ′Achondrogenesis, type IB′] NM_000344.3 104893922 SMN1 [ ] [ ] [′Werdnig-Hoffmann (SMN1):c.815A>G disease′] (p.Tyr272Cys) NM_000344.3 104893932 SMN1 [ ] [ ] [′Kugelberg- (SMN1):c.784A>G Welander disease′] (p.Ser262Gly) NM_000409.3 104893967 GUCA1A [ ] [ ] [′Cone dystrophy 3′] (GUCA1A):c.296A>G (p.Tyr99Cys) NM_182548.3 104893975 LHFPL5 [ ] [ ] [′Deafness, (LHFPL5):c.380A>G autosomal recessive (p.Tyr127Cys) 67′] NM_001024630.3 104893993 RUNX2 [ ] [ ] [′Cleidocranial (RUNX2):c.598A>G dysostosis′, (p.Thr200Ala) ′Cleidocranial dysplasia, forme fruste, dental anomalies only′] NM_000162.3 104894015 GCK [ ] [′GTAGYAGCAGG [′Hyperinsulinemic (GCK):c.641A>G AGATCATCGTGG′] hypoglycemia (p.Tyr214Cys) familial 3′] NM_001002010.2 104894028 NT5C3A [ ] [ ] [′Uridine 5-prime (NT5C3A):c.686A>G monophosphate (p.Asn229Ser) hydrolase deficiency, hemolytic anemia due to′] NM_203288.1 104894039 RP9 [ ] [ ] [′Retinitis (RP9):c.509A>G pigmentosa 9′] (p.Asp170Gly) NM_000474.3 104894059 TWIST1 [ ] [ ] [′Saethre-Chotzen (TWIST1):c.466A>G syndrome′] (p.Ile156Val) NM_000532.4 202247823 PCCB [ ] [′ATATYTGCATGT [′Propionic (PCCB):c.1606A>G TTTCTCCAAGG′] acidemia′, ′not (p.Asn536Asp) provided′] NM_021615.4 28937877 CHST6 [ ] [ ] [′Macular corneal (CHST6):c.521A>G dystrophy Type I′] (p.Lys174Arg) NM_178138.4 104894117 LHX3 [′CAGGTGG [′CAGGTGGYACA [′Pituitary hormone (LHX3):c.332A>G YACACGAA CGAAGTCCTGGG′] deficiency, (p.Tyr111Cys) GTCCTGGG′] combined 3′] NM_004897.4 104894171 MINPP1 [ ] [ ] [′Thyroid cancer, (MINPP1):c.809A>G follicular′] (p.Gln270Arg) NM_000073.2 104894199 CD3G [ ] [′CCAYGTCAGTCT [′Immunodeficiency (CD3G):c.1A>G CTGTCCTCCGG′] 17′] (p.Met1Val) NM_001885.2 104894201 CRYAB [ ] [ ] [′Alpha-B (CRYAB):c.358A>G crystallinopathy′] (p.Arg120Gly) NM_001814.4 104894208 CTSC [ ] [′CTCCYGAGGGCT [′Papillon- (CTSC):c.857A>G TAGGATTGGGG′, Lef\xc3\xa8vre (p.Gln286Arg) ′CCTCCYGAGGGC syndrome′, ′Haim- TTAGGATTGGG′, Munk syndrome′] ′ACCTCCYGAGGG CTTAGGATTGG′] NM_001814.4 104894211 CTSC [ ] [′TCCTACAYAGTG [′Papillon- (CTSC):c.1040A>G GTACTCAGAGG′] Lef\xc3\xa8vre (p.Tyr347Cys) syndrome′, ′Periodontitis, aggressive, 1′] NM_012193.3 104894223 — [′GAAATAY [′GAAATAYGATG [′Retinopathy of (FZD4):c.766A>G GATGGGGC GGGCGCTCAGGG′, prematurity′] (p.Ile256Val) GCTCAGGG′, ′AGAAATAYGATG ′AGAAATA GGGCGCTCAGG′] YGATGGGG CGCTCAGG′] NM_005343.2 104894227 — [ ] [ ] [′Costello (HRAS):c.350A>G syndrome′] (p.Lys117Arg) NM_145014.2 104894232 — [ ] [ ] [′Hydrolethalus (HYLS1):c.632A>G syndrome′] (p.Asp211Gly) NM_000525.3 104894248 KCNJ11 [′GACAYGG [′GACAYGGTAGA [′Islet cell (KCNJ11):c.776A>G TAGATGAT TGATCAGCGGGG′, hyperplasia′] (p.His259Arg) CAGCGGGG′] ′TGACAYGGTAGA TGATCAGCGGG′, ′ATGACAYGGTAG ATGATCAGCGG′] NM_000317.2 104894275 PTS [′TAAYTGT [′TAAYTGTGCCCA [′6-pyruvoyl- (PTS):c.155A>G GCCCATGG TGGCCATTTGG′] tetrahydropterin (p.Asn52Ser) CCATTTGG′] synthase deficiency′] NM_000317.2 104894278 PTS [ ] [ ] [′Hyperphenyl- (PTS):c.139A>G alaninemia, bh4-deficient, (p.Asn47Asp) a, due to partial pts deficiency′] NM_000317.2 104894279 PTS [ ] [ ] [′Hyperphenyl- (PTS):c.347A>G alaninemia, bh4-deficient, (p.Asp116Gly) a, due to partial pts deficiency′] NM_022051.2 119476045 EGLN1 [ ] [ ] [′Erythrocytosis, (EGLN1):c.1121A>G familial, 3′] (p.His374Arg) NM_015915.4 119476048 ATL1 [ ] [ ] [′Spastic paraplegia (ATL1):c.773A>G 3′] (p.His258Arg) NM_000448.2 104894290 RAG1 [ ] [′CTGYACTGGCAG [′Histiocytic (RAG1):c.2735A>G AGGGATTCTGG′] medullary (p.Tyr912Cys) reticulosis′] NM_000448.2 104894292 RAG1 [ ] [ ] [′Histiocytic (RAG1):c.1286A>G medullary (p.Asp429Gly) reticulosis′] NM_003002.3 104894304 SDHD [ ] [ ] [′Hereditary (SDHD):c.341A>G Paraganglioma- (p.Tyr114Cys) Pheochromocytoma Syndromes′, ′Paragangliomas 1′] NM_015141.3 72552293 GPD1L [ ] [ ] [′Brugada syndrome (GPD1L):c.370A>G 2′, ′Primary familial (p.Ile124Val) hypertrophic cardiomyopathy′, ′Long QT syndrome′, ′Sudden infant death syndrome′, ′Cardiomyopathy′] NM_020661.2A 104894322 AICDA [ ] [ ] [′Immunodeficiency (AICDA):c.415A>G with hyper IgM type (p.Met139Val) 2′] NM_014365.2 104894351 HSPB8 [ ] [ ] [′Charcot-Marie- (HSPB8):c.421A>G Tooth disease′, (p.Lys141Glu) ′Distal hereditary motor neuronopathy type 2A′] NM_000217.2 104894354 KCNA1 [ ] [′GCGYTTCCACGA [′Episodic ataxia (KCNA1):c.676A>G TGAAGAAGGGG′, type 1′] (p.Thr226Ala) ′AGCGYTTCCACG ATGAAGAAGGG′, ′CAGCGYTTCCAC GATGAAGAAGG′] NM_014239.3 104894425 EIF2B2 [ ] [′AGTTGTCYCAAT [′Leukoencephalopathy (EIF2B2):c.638A>G ACCTGCTTTGG′] with vanishing (p.Glu213Gly) white matter′, ′Ovarioleuko- dystrophy′] NM_002408.3 104894447 MGAT2 [ ] [ ] [′Carbohydrate- (MGAT2):c.785A>G deficient (p.His262Arg) glycoprotein syndrome type II′] NM_002408.3 104894448 MGAT2 [ ] [ ] [′Carbohydrate- (MGAT2):c.952A>G deficient (p.Asn318Asp) glycoprotein syndrome type II′] NM_000270.3 104894450 PNP [ ] [′ATAYCTCCAACC [′Purine-nucleoside (PNP):c.383A>G TCAAACTTGGG′, phosphorylase (p.Asp128Gly) ′GATAYCTCCAAC deficiency′] CTCAAACTTGG′] NM_000270.3 104894452 PNP [ ] [ ] [′Purine-nucleoside (PNP):c.575A>G phosphorylase (p.Tyr192Cys) deficiency′] NM_005982.3 104894478 SIX1 [ ] [ ] [′Melnick-Fraser (SIX1):c.386A>G syndrome′, (p.Tyr129Cys) ′Branchiootic syndrome 3′] NM_000101.3 104894510 CYBA [ ] [ ] [′Granulomatous (CYBA):c.281A>G disease, chronic, (p.His94Arg) autosomal recessive, cytochrome b- negative′] NM_024887.3 147394623 DHDDS [ ] [′GGCACTYCTTGG [′Retinitis (DHDDS):c.124A>G CATAGCGACGG′] pigmentosa 59′] (p.Lys42Glu) NM_024006.5 104894541 VKORC1 [ ] [ ] [′Warfarin response′] (VKORC1):c.172A>G (p.Arg58Gly) NM_001128085.1 104894550 — [ ] [ ] [′Spongy (ASPA):c.692A>G degeneration of (p.Tyr231Cys) central nervous system′] NM_001128085.1 104894551 — [ ] [ ] [′Spongy (ASPA):c.71A>G degeneration of (p.Glu24Gly) central nervous system′] NM_000019.3 148639841 ACAT1 [ ] [ ] [′Deficiency of (ACAT1):c.472A>G acetyl-CoA (p.Asn158Asp) acetyltransferase′, ′not provided′] NM_014254.2 150736997 TMEM5 [ ] [ ] [′Congenital (TMEM5):c.1016A>G muscular dystrophy- (p.Tyr339Cys) dystroglycanopathy with brain and eye anomalies, type A10′] NM_005557.3 60723330 KRT16 [ ] [′GCGGTCAYTGA [′Pachyonychia (KRT16):c.374A>G GGTTCTGCATGG′] congenita, type 1′, (p.Asn125Ser) ′Palmoplantar keratoderma, nonepidermolytic, focal′, ′not provided′] NM_005450.4 104894602 NOG [ ] [ ] [′Tarsal carpal (NOG):c.665A>G coalition syndrome′, (p.Tyr222Cys) ′Cushing symphalangism′] NM_030665.3 104894634 RAI1 [ ] [′CTGCTGCYGTCG [′Smith-Magenis (RAI1):c.4685A>G TCGTCGCTTGG′] syndrome′] (p.Gln1562Arg) NM_000346.3 104894647 SOX9 [ ] [ ] [′Acampomelic (SOX9):c.517A>G campomelic (p.Lys173Glu) dysplasia′] NM_024301.4 104894679 FKRP [ ] [ ] [′Congenital (FKRP):c.926A>G muscular dystrophy- (p.Tyr309Cys) dystroglycanopathy without mental retardation, type B5′] NM_000495.4 281874691 COL4A5 [ ] [ ] [′Alport syndrome, (COL4A5):c.2394A>G X-linked recessive′] (p.Lys798=) NM_001604.5 794726661 PAX6 [ ] [ ] [′Congenital (PAX6):c.1075-2A>G aniridia′] NM_000363.4 104894728 TNNI3 [ ] [ ] [′Familial restrictive (TNNI3):c.569A>G cardiomyopathy 1′, (p.Asp190Gly) ′Familial hypertrophic cardiomyopathy 7′] NM_000363.4 104894730 TNNI3 [ ] [′CCTYCTTCACCT [′Familial restrictive (TNNI3):c.532A>G GCTTGAGGTGG′, cardiomyopathy 1′] (p.Lys178Glu) ′CCTCCTYCTTCAC CTGCTTGAGG′] NM_000054.4 104894752 AVPR2 [ ] [ ] [′Nephrogenic (AVPR2):c.839A>G diabetes insipidus, (p.Tyr280Cys) X-linked′] NM_000074.2 104894772 CD40LG [ ] [ ] [′Immunodeficiency (CD40LG):c.386A>G with hyper IgM type (p.Glu129Gly) 1′] NM_000495.4 281874752 COL4A5 [ ] [ ] [′Alport syndrome, (COL4A5):c.4977-2A>G X-linked recessive′] NM_001165963.1 794726722 — [ ] [ ] [′Severe myoclonic (SCN1A):c.5264A>G epilepsy in infancy′] (p.Asp1755Gly) NM_000495.4 281874756 COL4A5 [ ] [ ] [′Alport syndrome, (COL4A5):c.547-2A>G X-linked recessive′] NM_000495.4 281874758 COL4A5 [ ] [ ] [′Alport syndrome, (COL4A5):c.610-2A>G X-linked recessive′] NM_032520.4 193302855 GNPTG [′CCCYGAA [′CCCYGAAGGTG [′Mucolipidosis III (GNPTG):c.610-2A>G GGTGGAGG GAGGATGCAGGG′, Gamma′] ATGCAGGG′] ′GCCCYGAAGGTG GAGGATGCAGG′] NM_002049.3 104894816 GATA1 [ ] [′GTCCTGYCCCTC [′GATA-1-related (GATA1):c.653A>G CGCCACAGTGG′] thrombocytopenia (p.Asp218Gly) with dyserythropoiesis′] NM_000157.3 364897 GBA [′CCAYTGG [′CCAYTGGTCTTG [′Gaucher disease′, (GBA):c.680A>G TCTTGAGC AGCCAAGTGGG′, ′Subacute (p.Asn227Ser) CAAGTGGG′, ′TCCAYTGGTCTT neuronopathic ′TCCAYTGG GAGCCAAGTGG′] Gaucher disease′, TCTTGAGC ′Gaucher disease, CAAGTGG′] type 1′] NM_001097642.2 104894819 GJB1 [ ] [ ] [′X-linked hereditary (GJB1):c.194A>G motor and sensory (p.Tyr65Cys) neuropathy′] NM_000166.5 104894822 GJB1 [ ] [ ] [′X-linked hereditary (GJB1):c.614A>G motor and sensory (p.Asn205Ser) neuropathy′] NM_001165963.1 773407463 SCN1A [ ] [ ] [′Severe myoclonic (SCN1A):c.747T>G epilepsy in infancy′] (p.Asp249Glu) NM_000169.2 104894830 — [ ] [ ] [′Fabry disease′, (GLA):c.886A>G ′Fabry disease, (p.Met296Val) cardiac variant′] NM_000169.2 104894835 — [ ] [ ] [′Fabry disease′] (GLA):c.101A>G (p.Asn34Ser) NM_001165963.1 794726773 SCN1A [ ] [′GTGCCAYACCTG [′Severe myoclonic (SCN1A):c.1662+3A>G GTGTGGGGAGG′] epilepsy in infancy′] NM_000169.2 104894852 — [ ] [ ] [′Fabry disease′] (GLA):c.1228A>G (p.Thr410Ala) NM_000202.6 104894861 IDS [ ] [′AAAGACTYTTCC [′Mucopolysaccharidosis, (IDS):c.404A>G CACCGACATGG′] MPS-II′] (p.Lys135Arg) NM_001165963.1 794726803 SCN1A [ ] [ ] [′Severe myoclonic (SCN1A):c.383+1A>G epilepsy in infancy′] NM_000266.3 104894870 NDP [ ] [ ] [′Atrophia bulborum (NDP):c.131A>G hereditaria′] (p.Tyr44Cys) NM_000266.3 104894874 NDP [ ] [′TGGYGCCTCATG [ ] (NDP):c.125A>G CAGCGTCGAGG′] (p.His42Arg) NM_001128227.2 121908634 GNE [ ] [ ] [′Inclusion body (GNE):c.604A>G myopathy 2′] (p.Met202Val) NM_001165963.1 794726816 — [ ] [ ] [′Severe myoclonic (SCN1A):c.3880-2A>G epilepsy in infancy′] NM_001165963.1 794726844 SCN1A [′ACATAYA [′ACATAYATCCCT [′Severe myoclonic (SCN1A):c.1046A>G TCCCTCTG CTGGACATTGG′] epilepsy in infancy′] (p.Tyr349Cys) GACATTGG′] NM_001015877.1 104894917 PHF6 [ ] [ ] [′Borjeson- (PHF6):c.700A>G Forssman-Lehmann (p.Lys234Glu) syndrome′] NM_001015877.1 104894918 PHF6 [ ] [ ] [′Borjeson— (PHF6):c.686A>G Forssman-Lehmann (p.His229Arg syndrome′] NM_001015877.1 104894919 PHF6 [′CTCYTGA [′CTCYTGATGTTG [Borjeson- (PHF6):c.769A>G TGTTGTTG TTGTGAGCTGG′] Forssman-Lehmann (p.Arg257Gly) TGAGCTGG′] syndrome′] NM_000307.4 104894922 POU3F4 [ ] [ ] [′Deafness, X-linked (POU3F4):c.1000A>G 2′] (p.Lys334Glu) NM_000330.3 104894929 — [ ] [ ] [′Juvenile (RS1):c.667T>C retinoschisis′] (p.Cys223Arg) NM_003413.3 104894962 ZIC3 [′TGTGTTY [′TGTGTTYGCGCA [′Heterotaxy, (ZIC3):c.1213A>G GCGCAGGG GGGAGCTCGGG′, visceral, X-linked′] (p.Lys405Glu) AGCTCGGG′, ′ATGTGTTYGCGC ′ATGTGTTY AGGGAGCTCGG′] GCGCAGGG AGCTCGG′] NM_002420.5 191205969 TRPM1 [ ] [′AAGCYCTTAATA [′Congenital (TRPM1):c.296T>C TCTGTGCATGG′] stationary night (p.Leu99Pro) blindness, type 1C′] NM_004006.2 794727030 DMD [ ] [ ] [′Duchenne (DMD):c.1150-2A>G muscular dystrophy′, ′Becker muscular dystrophy′] NM_203290.2 371802902 POLR1C [ ] [ ] [′LEUKODYSTROPHY, (POLR1C):c.221A>G HYPOMYELINATING, (p.Asn74Ser) 11′] NM_019109.4 794727073 ALG1 [ ] [′TAAACYGCAGA [′Congenital disorder (ALG1):c.1188-2A>G GAGAACCAAGGG′, of glycosylation type ′GTAAACYGCAGA 1K′] GAGAACCAAGG′] NM_004463.2 794727099 FGD1 [ ] [ ] [′Aarskog (FGD1):c.2016-2A>G syndrome′] NM_024110.4 281875213 CARD14 [ ] [ ] [′Psoriasis (CARD14):c.425A>G susceptibility 2′, ′not (p.Glu142Gly) provided′] NM_001004334.3 281875236 GPR179 [ ] [′CCCACAYATCCA [′Congenital (GPR179):c.659A>G TCTGCCTGCGG′] stationary night (p.Tyr220Cys) blindness, type 1E′, ′not provided′] NM_018965.3 28939079 TREM2 [′CCGGTGA [′TGAYCCAGGGG [′Polycystic (TREM2):c.401A>G YCCAGGGG GTCTATGGGAGG′, lipomembranous (p.Asp134Gly) GTCTATGG′] ′CGGTGAYCCAGG osteodysplasia with GGGTCTATGGG′, sclerosing ′CCGGTGAYCCAG leukoencephalopathy′] GGGGTCTATGG′] NM_015915.4 28939094 ATL1 [ ] [′CACCCAYCTTCT [′Spastic paraplegia (ATL1):c.1222A>G TCACCCCTCGG′] 3′] (p.Met408Val) NM_002437.4 147952488 MPV17 [′TGGYAAG [′TGGYAAGTTCTC [′Navajo (MPV17):c.186+2T>C TTCTCCCC CCCTCAACAGG′] neurohepatopathy′, TCAACAGG′] ′not provided′] NM_005359.5 281875320 SMAD4 [′TGAGYAT [′TGAGYATGCATA [′Myhre syndrome′, (SMAD4):c.1500A>G GCATAAGC AGCGACGAAGG′] ′not provided′] (p.Ile500Met) GACGAAG G′] NM_005359.5 281875322 SMAD4 [′TGAGTAY [′TGAGTAYGCATA [′Hereditary cancer- (SMAD4):c.1498A>G GCATAAGC AGCGACGAAGG′] predisposing (p.Ile500Val) GACGAAG syndrome′, ′Myhre G′] syndrome′, ′not provided′] NM_005359.5 281875324 SMAD4 [ ] [′ATCCATTYCAAA [′Juvenile polyposis (SMAD4):c.989A>G GTAAGCAATGG′] syndrome′, (p.Glu330Gly) ′Hereditary cancer- predisposing syndrome′, ′not provided′] NM_000342.3 5036 SLC4A1 [ ] [ ] [ ] (SLC4A1):c.166A>G (p.Lys56Glu) NM_000518.4 33985472 HBB [ ] [ ] [ ] (HBB):c.*113A>G NM_001127255.1 104895503 — [′TCTGGYT [′TCTGGYTGATAC [′Hydatidiform (NLRP7):c.2738A>G GATACTCA TCAAGTCCAGG′] mole′] (p.Asn913Ser) AGTCCAGG′] NM_000037.3 77173848 ANK1 [ ] [′GGGCCYGGCCC [′Spherocytosis, type (ANK1):c.-108T>C GCACGTCACAGG′] 1, autosomal recessive′] NM_201631.3 115677373 TGM5 [′TGCGGAG [′TGCGGAGYGGA [′Peeling skin (TGM5):c.763T>C YGGACGG CGGGCAGCGTGG′ syndrome, acral (p.Trp255Arg) GCAGCGTG ] type′] G′] NM_020435.3 587776888 GJC2 [ ] [ ] [′Leukodystrophy, (GJC2):c.-167A>G hypomyelinating, 2′] NM_130466.3 672601304 UBE3B [ ] [ ] [′Kaufman (UBE3B):c.1A>G oculocerebrofacial (p.Met1Val) syndrome′] NM_022124.5 794727649 — [ ] [ ] [′Usher syndrome, (CDH23):c.146-2A>G type 1D′] NM_014191.3 672601319 SCN8A [ ] [ ] [′Early infantile (SCN8A):c.667A>G epileptic (p.Arg223Gly) encephalopathy 13′] NM_001164405.1 672601337 BHLHA9 [ ] [ ] [′Syndactyly type 9′] (BHLHA9):c.211A>G (p.Asn71Asp) NM_021830.4 672601360 C10orf2 [ ] [ ] [′Perrault syndrome 5′] (C10orf2):c.1754A>G (p.Asn585Ser) NM_002887.3 672601372 RARS [ ] [ ] [′Leukodystrophy, (RARS):c.5A>G hypomyelinating, 9′] (p.Asp2Gly) NM_002887.3 672601375 RARS [ ] [ ] [′Leukodystrophy, (RARS):c.1A>G hypomyelinating, 9′] (p.Met1Val) NM_001943.3 397514038 DSG2 [ ] [ ] [′Arrhythmogenic (DSG2):c.1880-2A>G right ventricular cardiomyopathy, type 10′, ′Cardiomyopathy′] NM_024422.4 397514042 DSC2 [ ] [ ] [′Arrhythmogenic (DSC2):c.631-2A>G right ventricular cardiomyopathy, type 11′, ′Cardiomyopathy′] NM_001159772.1 150181226 CANT1 [ ] [′CGTCYGTACGTG [′Desbuquois (CANT1):c.671T>C GGCGGCCTGGG′, syndrome′] (p.Leu224Pro) ′GCGTCYGTACGT GGGCGGCCTGG′] NM_031418.2 587776923 ANO3 [ ] [ ] [′Dystonia 24′] (ANO3):c.2053A>G (p.Ser685Gly) NM_014191.3 202151337 SCN8A [ ] [ ] [′Early infantile (SCN8A):c.5302A>G epileptic (p.Asn1768Asp) encephalopathy 13′] NM_000367.3 1142345 TPMT [ ] [ ] [′Thiopurine (TPMT):c.719A>G methyltransferase (p.Tyr240Cys) deficiency′] NM_003907.2 28939717 EIF2B5 [′AAATGYT [′AAATGYTTCCTG [′Leukoencephalopathy (EIF2B5):c.271A>G TCCTGTAC TACACCTGTGG′] with vanishing (p.Thr91Ala) ACCTGTGG′] white matter′] NM_004006.2 794727890 DMD [ ] [ ] [′Duchenne (DMD):c.10554-2A>G muscular dystrophy′, ′Becker muscular dystrophy′, ′Dilated cardiomyopathy 3B′] NM_000084.4 273585644 CLCN5 [ ] [ ] [′Dent disease 1′] (CLCN5):c.815A>G (p.Tyr272Cys) NM_000084.4 273585649 CLCN5 [ ] [ ] [′Dent disease 1′] (CLCN5):c.1637A>G (p.Lys546Arg) NM_000041.3 397514253 APOE [ ] [′CGCCCYGCGGCC [′Familial type 3 (APOE):c.237-2A>G GAGAGGGCGGG′, hyperlipoproteinemia′] ′GCGCCCYGCGGC CGAGAGGGCGG′] NM_000155.3 2070074 GALT [ ] [ ] [′Deficiency of (GALT):c.940A>G UDPglucose- (p.Asn314Asp) hexose-1-phosphate uridylyltransferase′, ′not provided′] NM_005045.3 794727998 RELN [ ] [ ] [′EPILEPSY, (RELN):c.2288A>G FAMILIAL (p.Asp763Gly) TEMPORAL LOBE, 7′] NM_001914.3 794728010 CYB5A [ ] [ ] [′Methemoglobinemia (CYB5A):c.130-2A>G type 4′] NM_001613.2 794728019 ACTA2 [ ] [ ] [′Thoracic aortic (ACTA2):c.1A>G aneurysms and (p.Met1Val) aortic dissections′] NM_000109.3 370644567 DMD [ ] [ ] [′Becker muscular (DMD):c.1700T>C dystrophy′, (p.Leu567Pro) ′Exertional myalgia, muscle stiffness and myoglobinuria′, ′not provided′] NM_000060.3 397514341 BTD [ ] [ ] [′Biotinidase (BTD):c.194A>G deficiency′] (p.His65Arg) NM_000060.3 397514348 BTD [ ] [′GTTCAYAGATGT [′Biotinidase (BTD):c.278A>G CAAGGTTCTGG′] deficiency′] (p.Tyr93Cys) NM_000060.3 397514353 BTD [ ] [ ] [′Biotinidase (BTD):c.356A>G deficiency′] (p.Asn119Ser) NM_000060.3 397514354 BTD [ ] [ ] [′Biotinidase (BTD):c.364A>G deficiency′] (p.Arg122Gly) NM_000060.3 397514366 BTD [ ] [ ] [′Biotinidase (BTD):c.515A>G deficiency′] (p.Asn172Ser) NM_000060.3 397514370 BTD [ ] [ ] [′Biotinidase (BTD):c.583A>G deficiency′] (p.Asn195Asp) NM_000060.3 397514371 BTD [ ] [ ] [′Biotinidase (BTD):c.584A>G deficiency′, ′not (p.Asn195Ser) provided′] NM_000060.3 397514377 BTD [′AGAGGYT [′AGAGGYTGTGTT [′Biotinidase (BTD):c.641A>G GTGTTTAC TACGGTAGCGG′] deficiency′] (p.Asn214Ser) GGTAGCGG′] NM_000061.2 128620184 BTK [′TCTYGAT [′TCTYGATGGCCA [′X-linked (BTK):c.1288A>G GGCCACGT CGTCGTACTGG′] agammaglobulinemia′] (p.Lys430Glu) CGTACTGG′] NM_001002294.2 2266780 FMO3 [ ] [ ] [′Trimethylaminuria′] (FMO3):c.923A>G (p.Glu308Gly) m.15579A>G 207460002 MT-CYB [ ] [ ] [′Multisystem disorder′] NM_000060.3 397514415 BTD [ ] [′GGCAYACAGCT [′Biotinidase (BTD):c.1313A>G CTTTGGATAAGG′] deficiency′] (p.Tyr438Cys) NM_000060.3 397514431 BTD [ ] [ ] [′Biotinidase (BTD):c.1619A>G deficiency′] (p.Tyr540Cys) NM_000023.2 397514451 SGCA [ ] [ ] [′Limb-girdle (SGCA):c.410A>G muscular dystrophy, (p.Glu137Gly) type 2D′] NM_004813.2 397514472 PEX16 [′AAGYAGA [′AAGYAGATTTTC [′Peroxisome (PEX16):c.992A>G TTTTCTGC TGCCAGGTGGG′, biogenesis disorder (p.Tyr331Cys) CAGGTGGG′, ′GAAGYAGATTTT 8B′] ′GAAGYAG CTGCCAGGTGG′, ATTTTCTG ′GTAGAAGYAGAT CCAGGTGG′, TTTCTGCCAGG′] ′GTAGAAG YAGATTTT CTGCCAGG′] NM_000933.3 397514480 PLCB4 [ ] [ ] [′Auriculocondylar (PLCB4):c.1868A>G syndrome 1′, (p.Tyr623Cys) ′Auriculocondylar syndrome 2′] NM_005340.6 397514491 HINT1 [′AAAAYGT [′AAAAYGTGTTG [′Gamstorp-Wohlfart (HINT1):c.152A>G GTTGGTGC GTGCTTGAGGGG′, syndrome′] (p.His5lArg) TTGAGGGG′, ′GAAAAYGTGTTG ′GAAAAYG GTGCTTGAGGG′, TGTTGGTG ′AGAAAAYGTGTT CTTGAGGG′, GGTGCTTGAGG′] ′AGAAAAY GTGTTGGT GCTTGAGG′] NM_007171.3 397514501 POMT1 [ ] [′GAGCATYCTCTG [′Limb-girdle (POMT1):c.430A>G TTTCAAAGAGG′] muscular dystrophy- (p.Asn144Asp) dystroglycanopathy, type C1′] NM_003863.3 397514503 DPM2 [′TGTAGYA [′TGTAGYAGGTG [′Congenital disorder (DPM2):c.68A>G GGTGAAGA AAGATGATCAGG′] of glycosylation type (p.Tyr23Cys) TGATCAGG′] 1u′] NM_174917.4 370382601 ACSF3 [ ] [′GGCAGCAYTGC [′not provided′] (ACSF3):c.1A>G ACTGACAGGCGG′] (p.Met1Val) NM_183075.2 397514514 CYP2U1 [ ] [ ] [′Spastic paraplegia (CYP2U1):c.1139A>G 56, autosomal (p.Glu380Gly) recessive′] NM_000344.3 397514517 SMN1 [ ] [ ] [′Kugelberg- (SMN1):c.389A>G Welander disease′] (p.Tyr130Cys) NM_000138.4 794728216 FBN1 [ ] [ ] [′Thoracic aortic (FBN1):c.4337-2A>G aneurysms and aortic dissections′] NM_012082.3 397514521 — [ ] [ ] [′Double outlet right (ZFPM2):c.2209A>G ventricle′] (p.Lys737Glu) NM_001168272.1 397514536 ITPR1 [ ] [ ] [′Spinocerebellar (ITPR1):c.1759A>G ataxia 29′] (p.Asn587Asp) NM_178012.4 397514568 TUBB2B [ ] [ ] [′Polymicrogyria, (TUBB2B):c.767A>G asymmetric′] (p.Asn256Ser) NM_000531.5 72554317 OTC [ ] [ ] [′not provided′] (OTC):c.155A>G (p.Glu52Gly) NM_001866.2 397514584 COX7B [ ] [ ] [′Aplasia cutis (COX7B):c.41-2A>G congenita, reticulolinear, with microcephaly, facial dysmorphism, and other congenital anomalies′] NM_001099922.2 397514587 ALG13 [ ] [ ] [′Congenital disorder (ALG13):c.339A>G of glycosylation type (p.Ala113=) 1s′] NM_000531.5 72554332 OTC [ ] [′AAGGACTYCCCT [′Ornithine (OTC):c.238A>G TGCAATAAAGG′] carbamoyltransferase (p.Lys80Glu) deficiency′, ′not provided′] NM_001083614.1 397514591 EARS2 [ ] [ ] [′Combined (EAR52):c.502A>G oxidative (p.Arg168Gly) phosphorylation deficiency 12′] NM_001083614.1 397514595 EARS2 [ ] [ ] [′Combined (EARS2):c.193A>G oxidative (p.Lys65Glu) phosphorylation deficiency 12′] NM_198578.3 34805604 LRRK2 [ ] [ ] [′Parkinson disease (LRRK2):c.3364A>G 8, autosomal (p.Ile1122Val) dominant′] NM_033109.4 397514598 PNPT1 [ ] [ ] [′Combined (PNPT1):c.1160A>G oxidative (p.Gln387Arg) phosphorylation deficiency 13′] NM_033109.4 397514599 PNPT1 [ ] [′GACTYCAGATGT [′Deafness, (PNPT1):c.1424A>G AACTCTTATGG′] autosomal recessive (p.Glu475Gly) 70′] NM_000531.5 72554344 OTC [ ] [ ] [′not provided′] (OTC):c.277A>G (p.Thr93Ala) NM_000390.2 397514603 CHM [ ] [ ] [′Choroideremia′] (CHM):c.1520A>G (p.His507Arg) NM_181690.2 397514605 AKT3 [ ] [ ] [′Megalencephaly- (AKT3):c.686A>G polymicrogyria- (p.Asn229Ser) polydactyly- hydrocephalus syndrome 2′] NM_006567.3 397514610 FARS2 [ ] [ ] [′Mitochondrial (FARS2):c.431A>G encephalomyopathy′, (p.Tyr144Cys) ′Combined oxidative phosphorylation deficiency 14′, ′Global developmental delay′] NM_000531.5 72554358 OTC [ ] [ ] [′not provided′] (OTC):c.377A>G (p.Asp126Gly) NM_005609.2 397514631 PYGM [ ] [ ] [′Glycogen storage (PYGM):c.152A>G disease, type V′] (p.Asp51Gly) NM_000130.4 6025 F5 [ ] [ ] [′Recurrent (F5):c.1601G>A abortion′, (p.Arg534Gln) ′Thrombophilia due to factor V Leiden′] NM_000108.4 397514650 DLD [ ] [′GACTCYAGCTAT [′Maple syrup urine (DLD):c.1444A>G ATCTTCACAGG′] disease, type 3′] (p.Arg482Gly) NM_138554.4 4986790 TLR4 [ ] [ ] [′Endotoxin (TLR4):c.896A>G hyporesponsiveness′] (p.Asp299Gly) NM_003156.3 397514675 STIM1 [ ] [′TTCCACAYCCAC [′Myopathy with (STIM1):c.251A>G ATCACCATTGG′] tubular aggregates′] (p.Asp84Gly) NM_003156.3 397514677 STIM1 [ ] [ ] [′Myopathy with (STIM1):c.326A>G tubular aggregates′] (p.His109Arg) NM_000238.3 794728377 KCNH2 [ ] [ ] [′Cardiac (KCNH2):c.1900A>G arrhythmia′] (p.Thr634Ala) NM_000238.3 794728378 KCNH2 [ ] [′ATCYTCTCTGAG [′Cardiac (KCNH2):c.1913A>G TTGGTGTTGGG′, arrhythmia′] (p.Lys638Arg) ′GATCYTCTCTGA GTTGGTGTTGG′] NM_001457.3 121908895 FLNB [ ] [ ] [′Atelosteogenesis (FLNB):c.604A>G type 1′] (p.Met202Val) NM_001893.4 397514693 CSNK1D [ ] [ ] [′Advanced sleep (CSNK1D):c.137A>G phase syndrome, (p.His46Arg) familial, 2′] NM_002163.2 397514710 IRF8 [ ] [ ] [′Monocyte and (IRF8):c.322A>G dendritic cell (p.Lys108Glu) deficiency, autosomal recessive′] NM_002163.2 397514711 IRF8 [ ] [′AACCTCGYCTTC [′Autosomal (IRF8):c.238A>G CAAGTGGCTGG′] dominant (p.Thr80Ala) CD11C+/CD1C+ dendritic cell deficiency′] NM_001127217.2 397514715 SMAD9 [ ] [ ] [′Primary pulmonary (SMAD9):c.127A>G hypertension 2′] (p.Lys43Glu) NM_001035.2 794728784 RYR2 [ ] [ ] [′not provided′] (RYR2):c.12290A>G (p.Asn4097Ser) NM_000388.3 397514729 CASR [ ] [′CCCCCTYCTTTT [′Hypocalcemia, (CASR):c.85A>G GGGCTCGCTGG′] autosomal dominant (p.Lys29Glu) 1, with bartter syndrome′] NM_003793.3 397514731 CTSF [ ] [ ] [′Ceroid (CTSF):c.962A>G lipofuscinosis, (p.Gln321Arg) neuronal, 13′] NM_173076.2 28940269 ABCA12 [ ] [ ] [′Autosomal (ABCA12):c.4139A>G recessive congenital (p.Asn1380Ser) ichthyosis 4A′] NM_017890.4 28940272 VPS13B [′TCAYTGA [′TCAYTGATAAGC [′Cohen syndrome′, (VPS13B):c.8978A>G TAAGCAGG AGGGCCCAGGG′, ′not specified′] (p.Asn2993Ser) GCCCAGGG′, ′TTCAYTGATAAG ′TTCAYTGA CAGGGCCCAGG′] TAAGCAGG GCCCAGG′] NM_022114.3 397514743 PRDM16 [ ] [′GCCGCCGYTTTG [′Left ventricular (PRDM16):c.2447A>G GCTGGCACGGG′] noncompaction 8′] (p.Asn816Ser) NM_005689.2 397514757 ABCB6 [ ] [′TGGGCYGTTCCA [′Dyschromatosis (ABCB6):c.508A>G AGACACCAGGG′, universalis (p.Ser170Gly) ′GTGGGCYGTTCC hereditaria 3′] AAGACACCAGG′] NM_015335.4 28940309 MED13L [ ] [ ] [′Transposition of (MED13L):c.752A>G great arteries′] (p.Glu251Gly) NM_152443.2 28940313 RDH12 [ ] [′CACTGCGYAGGT [′Leber congenital (RDH12):c.677A>G GGTGACCCCGG′] amaurosis 13′] (p.Tyr226Cys) NM_000517.4 41457746 HBA2 [ ] [ ] [ ] (HBA2):c.96-2A>G NM_000218.2 794728538 KCNQ1 [ ] [′GTCTYCTACTCG [′Cardiac (KCNQ1):c.1787A>G GTTCAGGCGGG′, arrhythmia′] (p.Glu596Gly) ′TGTCTYCTACTCG GTTCAGGCGG′] NM_000218.2 794728569 KCNQ1 [ ] [′AGGYCTGTGGA [′Cardiac (KCNQ1):c.605A>G GTGCAGGAGAGG′] arrhythmia′] (p.Asp202Gly) NM_000218.2 794728573 KCNQ1 [ ] [′GCCYGCAGTGG [′Cardiac (KCNQ1):c.1515-2A>G AGAGAGGAGAGG′] arrhythmia′] NM_000498.3 72554626 — [ ] [ ] [′Corticosterone (CYP11B2):c.1492A>G methyloxidase type (p.Thr498Ala) 2 deficiency′] NM_000169.2 28935197 — [ ] [ ] [′Fabry disease′, ′not (GLA):c.644A>G provided′] (p.Asn215Ser) NM_000218.2 12720458 KCNQ1 [ ] [ ] [′Congenital long (KCNQ1):c.1085A>G QT syndrome′, (p.Lys362Arg) ′Cardiac arrhythmia′, ′Long QT syndrome, LQT1 subtype′] NM_001035.2 794728787 RYR2 [ ] [ ] [′not provided′] (RYR2):c.12533A>G (p.Asn4178Ser) NM_003494.3 370874727 DYSF [ ] [′CCGCCCYGGAG [′Limb-girdle (DYSF):c.3349-2A>G ACACGAAGCTGG′] muscular dystrophy, type 2B′] NM_001035.2 794728814 RYR2 [ ] [ ] [′not provided′] (RYR2):c.568A>G (p.Arg190Gly) NM_198056.2 794728859 SCN5A [ ] [′ACCYGTCGAGAT [′not provided′] (SCN5A):c.2788-2A>G AATGGGTCAGG′] NM_198056.2 794728886 SCN5A [ ] [ ] [′not provided′] (SCN5A):c.4453A>G (p.Ile1485Val) NM_198056.2 794728887 SCN5A [ ] [′CCTCTGYCATGA [′not provided′] (SCN5A):c.4462A>G AGATGTCCTGG′] (p.Thr1488Ala) NM_001927.3 794728995 DES [ ] [ ] [′not provided′] (DES):c.1324A>G (p.Thr442Ala) NM_001613.2 397515325 ACTA2 [ ] [ ] [′Aortic aneurysm, (ACTA2):c.145A>G familial thoracic 6′] (p.Met49Val) NM_000782.4 6068812 CYP24A1 [ ] [ ] [′Idiopathic (CYP24A1):c.1226T>C hypercalcemia of (p.Leu409Ser) infancy′] NM_000372.4 28940878 TYR [ ] [′CTCCTGYCCCCG [′Tyrosinase- (TYR):c.125A>G CTCCACGGTGG′] negative (p.Asp42Gly) oculocutaneous albinism′, ′not provided′] NM_000372.4 28940881 TYR [ ] [ ] [′Tyrosinase- (TYR):c.1A>G negative (p.Met1Val) oculocutaneous albinism′, ′Oculocutaneous albinism type 1B′, ′not provided′] NM_000403.3 28940884 GALE [ ] [ ] [′UDPglucose-4- (GALE):c.770A>G epimerase (p.Lys257Arg) deficiency′] NM_000529.2 28940892 MC2R [′ACATGYA [′ACATGYAGCAG [′ACTH resistance′] (MC2R):c.761A>G GCAGGCGC GCGCAGTAGGGG′ (p.Tyr254Cys) AGTAGGGG′, ′GACATGYAGCAG ′GACATGY GCGCAGTAGGG′, AGCAGGCG ′AGACATGYAGCA CAGTAGGG′] GGCGCAGTAGG′] NM_000061.2 128621195 BTK [ ] [ ] [′X-linked (BTK):c.919A>G agammaglobulinemia′] (p.Arg307Gly) NM_000061.2 128621206 BTK [ ] [ ] [′X-linked (BTK):c.1766A>G agammaglobulinemia′] (p.Glu589Gly) NM_018486.2 397515416 HDAC8 [ ] [ ] [′Cornelia de Lange (HDAC8):c.539A>G syndrome 5′] (p.His180Arg) NM_018486.2 397515418 HDAC8 [′CTCAYGA [′CTCAYGATCTGG [′Cornelia de Lange (HDAC8):c.1001A>G TCTGGGAT GATCTCAGAGG′] syndrome 5′] (p.His334Arg) CTCAGAGG′] NM_172107.2 397515420 KCNQ2 [ ] [′GCAYGACACTG [′Early infantile (KCNQ2):c.1636A>G CAGGGGGGTGGG′, epileptic (p.Met546Val) ′CGCAYGACACTG encephalopathy 7′] CAGGGGGGTGG′, ′AACCGCAYGACA CTGCAGGGGGG′] NM_001410.2 397515428 MEGF8 [ ] [′GACYCCCGTGA [′Carpenter (MEGF8):c.7099A>G AATGATTCCCGG′] syndrome 2′] (p.Ser2367Gly) NM_004247.3 397515431 EFTUD2 [ ] [ ] [′Growth and mental (EFTUD2):c.623A>G retardation, (p.His208Arg) mandibulofacial dysostosis, microcephaly, and cleft palate′] NM_004572.3 794729133 PKP2 [ ] [ ] [′not provided′] (PKP2):c.1171-2A>G NM_018972.2 397515442 GDAP1 [ ] [ ] [′Charcot-Marie- (GDAP1):c.368A>G Tooth disease type (p.His123Arg 2K′] NM_014795.3 397515449 ZEB2 [ ] [ ] [′Mowat-Wilson (ZEB2):c.3134A>G syndrome′] (p.His1045Arg) NM_002336.2 397515473 LRP6 [ ] [ ] [′Coronary artery (LRP6):c.1298A>G disease, autosomal (p.Asn433Ser) dominant 2′] NM_001015879.1 397515484 AURKC [ ] [ ] [′Infertility (AURKC):c.379-2A>G associated with multi-tailed spermatozoa and excessive DNA′] NM_000495.4 397515497 COL4A5 [ ] [ ] [′Alport syndrome, (COL4A5):c.3107-4A>G X-linked recessive′] NM_201631.3 143601447 TGM5 [ ] [′TCAACCYCACCC [′Peeling skin (TGM5):c.122T>C TGTACTTCAGG′] syndrome, acral (p.Leu41Pro) type′] NM_013254.3 756751089 TBK1 [ ] [ ] [′FRONTOTEMPORAL (TBK1):c.1201A>G DEMENTIA (p.Lys401Glu) AND/OR AMYOTROPHIC LATERAL SCLEROSIS 4′] NM_000207.2 397515519 — [ ] [′GGGCYTTATTCC [′Permanent neonatal (INS):c.*59A>G ATCTCTCTCGG′] diabetes mellitus′] NM_000370.3 397515523 TTPA [ ] [′CAGGYCCAGAT [′Ataxia with (TTPA):c.191A>G CGAAATCCCGGG′, vitamin E (p.Asp64Gly) ′CCAGGYCCAGAT deficiency′] CGAAATCCCGG′] NM_001006657.1 397515535 WDR35 [ ] [ ] [′Cranioectodermal (WDR35):c.2912A>G dysplasia 2′] (p.Tyr971Cys) NM_000424.3 61348633 KRT5 [ ] [ ] [′Epidermolysis (KRT5):c.1424A>G bullosa (p.Glu475Gly) herpetiformis, Dowling-Meara′, ′not provided′] NM_004595.4 397515551 SMS [ ] [ ] [′Snyder Robinson (SMS):c.443A>G syndrome′] (p.Gln148Arg) NM_001256850.1 794729266 — [ ] [ ] [′not provided′] (TTN):c.45629-2A>G NM_000404.2 72555361 GLB1 [ ] [ ] [′Infantile GM1 (GLB1):c.947A>G gangliosidosis′] (p.Tyr316Cys) NM_000404.2 72555368 GLB1 [ ] [ ] [′Mucopolysaccharidosis, (GLB1):c.1498A>G MPS-IV-B′] (p.Thr500Ala) NM_000404.2 72555371 GLB1 [ ] [ ] [′GM1- (GLB1):c.1772A>G GANGLIOSIDOSIS, (p.Tyr591Cys) TYPE I, WITH CARDIAC INVOLVEMENT′] NM_000487.5 2071421 ARSA [ ] [ ] [′Metachromatic (ARSA):c.1055A>G leukodystrophy′, ′not (p.Asn352Ser) provided′] NM_001037811.2 122461163 HSD17B10 [ ] [ ] [2-methy1-3- (HSD17B10):c.713A>G hydroxybutyric (p.Asn238Ser) aciduria′] NM_000138.4 397515756 FBN1 [ ] [ ] [′Marfan syndrome′] (FBN1):c.1148-2A>G NM_001875.4 28940283 CPS1 [ ] [ ] [′Congenital (CPS1):c.1010A>G hyperammonemia, (p.His337Arg) type I′] NM_000169.2 397515869 — [′AGCTGTG [′AGCTGTGYGATG [′not specified′, ′not (GLA):c.1153A>G YGATGAAG AAGCAGGCAGG′] provided′] (p.Thr385Ala) CAGGCAGG′] NM_000256.3 397515891 MYBPC3 [ ] [′TACTTGCYGTAG [′Familial (MYBPC3):c.1224-2A>G AACAGAAGGGG′] hypertrophic cardiomyopathy 4′, ′Cardiomyopathy′] NM_000048.3 28941472 ASL [ ] [ ] [′Argininosuccinate (ASL):c.857A>G lyase deficiency′, (p.Gln286Arg) ′not provided′] NM_000256.3 397515937 MYBPC3 [ ] [ ] [′Primary familial (MYBPC3):c.1928-2A>G hypertrophic cardiomyopathy′, ′Familial hypertrophic cardiomyopathy 4′, ′Cardiomyopathy′] NM_002693.2 774610098 POLG [ ] [ ] [′not provided′] (POLG):c.1283T>C (p.Leu428Pro) NM_004628.4 794729657 XPC [ ] [ ] [′Xeroderma (XPC):c.413-24A>G pigmentosum, group C′] NM_030973.3 794729668 MED25 [ ] [ ] [′BASEL- (MED25):c.116A>G VANAGAITE- (p.Tyr39Cys) SMIRIN-YOSEF SYNDROME′] NM_001955.4 587777231 EDN1 [ ] [ ] [′Auriculocondylar (EDN1):c.271A>G syndrome 3′] (p.Lys91Glu) NM_003002.3 11214077 SDHD [ ] [ ] [′Pheochromocytoma′, (SDHD):c.149A>G ′Merkel cell (p.His50Arg) carcinoma′, ′Hereditary cancer- predisposing syndrome′, ′Carcinoid tumor of intestine′, ′Cowden syndrome 3′, ′not specified′, ′not provided′] NM_001003722.1 386833693 GLE1 [ ] [ ] [′Lethal (GLE1):c.433-10A>G arthrogryposis with anterior horn cell disease′] NM_000371.3 11541796 TTR [ ] [ ] [′Amyloidogenic (TTR):c.185A>G transthyretin (p.Glu62Gly) amyloidosis′] NM_000256.3 397516082 MYBPC3 [ ] [′GTCCCYGTGTCC [′Familial (MYBPC3):c.927-2A>G CGCAGTCTAGG′] hypertrophic cardiomyopathy 4′, ′Cardiomyopathy′] NM_001148.4 72544141 ANK2 [ ] [ ] [′Long QT (ANK2):c.4373A>G syndrome′, (p.Glu1458Gly) ′Congenital long QT syndrome′, ′Long QT syndrome 4′, ′Cardiac arrhythmia, ankyrin B-related′, ′Cardiac arrhythmia′] NM_000257.3 397516138 MYH7 [ ] [′TATCAAYGAACT [′Familial (MYH7):c.2206A>G GTCCCTCAGGG′, hypertrophic (p.Ile736Val) ′CTATCAAYGAAC cardiomyopathy 1′, TGTCCCTCAGG′] ′Cardiomyopathy′, ′not specified′] NM_000356.3 28941769 TCOF1 [′GTGTGTA [′GTGTGTAYAGAT [′Treacher collins (TCOF1):c.149A>G YAGATGTC GTCCAGAAGGG′] syndrome 1′] (p.Tyr50Cys) CAGAAGGG′] NM_002150.2 1154510 HPD [ ] [′ATGACGYGGCCT [4-Alpha— (HPD):c.97G>A GAATCACAGGG′, hydroxyphenylpyruvate (p.Ala33Thr) ′AATGACGYGGCC hydroxylase TGAATCACAGG′] deficiency′] NM_000375.2 28941775 UROS [ ] [ ] [′Congenital (UROS):c.184A>G erythropoietic (p.Thr62Ala) porphyria′] NM_001008216.1 28940883 GALE [ ] [ ] [′UDPglucose-4- (GALE):c.308A>G epimerase (p.Asp103Gly) deficiency′] NM_000260.3 397516330 MYO7A [ ] [′ATATCCYGGGG [′Usher syndrome, (MYO7A):c.6439-2A>G GAGCAGAAAGGG′, type 1′] ′GATATCCYGGGG GAGCAGAAAGG′] NM_033071.3 606231134 SYNE1 [ ] [ ] [′Spinocerebellar (SYNE1):c.15705-12A>G ataxia, autosomal recessive 8′] NM_000187.3 120074172 HGD [ ] [ ] [′Alkaptonuria′] (HGD):c.1112A>G (p.His371Arg) NM_000053.3 60431989 ATP7B [′TGCTGAY [′TGCTGAYTGGAA [′Wilson disease′] (ATP7B1:c.3443T>C TGGAAACC ACCGTGAGTGG′] (p.Ile1148Thr) GTGAGTGG′] NM_000441.1 397516411 — [ ] [ ] [′Pendred syndrome′, (SLC26A4):c.-3-2A>G ′Enlarged vestibular aqueduct syndrome′] NM_003041.3 61742739 — [ ] [ ] [′Familial renal (SLC5A2):c.1961A>G glucosuria′] (p.Asn654Ser) NM_000551.3 397516441 VHL [ ] [ ] [′Von Hippel-Lindau (VHL):c.467A>G syndrome′] (p.Tyr156Cys) NM_000531.5 72556270 OTC [ ] [ ] [′not provided′] (OTC):c.481A>G (p.Asn161Asp) NM_000531.5 72556271 OTC [ ] [′CAGCCCAYTGAT [′not provided′] (OTC):c.482A>G AATTGGGATGG′] (p.Asn161Ser) NM_000531.5 72556289 OTC [′TCCYAAA [′TCCYAAAAGGC [′not provided′] (OTC):c.541-2A>G AGGCACGG ACGGGATGAAGG′] GATGAAGG′] NM_000531.5 72556290 OTC [′ATAGTGT [′ATAGTGTYCCTA [′not provided′] (OTC):c.542A>G YCCTAAAA AAAGGCACGGG′] (p.Glu181Gly) GGCACGGG′] NM_000527.4 28942085 LDLR [ ] [ ] [′Familial (LDLR):c.2483A>G hypercholesterolemia′, (p.Tyr828Cys) ′not provided′] NM_000271.4 28942105 NPC1 [ ] [ ] [′Niemann-Pick (NPC1):c.3467A>G disease type C1′] (p.Asn1156Ser) NM_000271.4 28942106 NPC1 [ ] [ ] [′NIEMANN-PICK (NPC1):c.3263A>G DISEASE, TYPE (p.Tyr1088Cys) C1, JUVENILE FORM′] NM_020247.4 119468008 ADCK3 [ ] [ ] [′Coenzyme Q10 (ADCK3):c.1541A>G deficiency, primary, (p.Tyr514Cys) 4′] NM_001063.3 41295774 TF [ ] [ ] [ ] (TF):c.956A>G (p.His319Arg) NM_172201.1 74424227 KCNE2 [ ] [ ] [′Congenital long (KCNE2):c.281A>G QT syndrome′] (p.Glu94Gly) NM_002294.2 397516743 LAMP2 [ ] [ ] [′Danon disease′] (LAMP2):c.65-2A>G NM_002880.3 397516822 RAF1 [ ] [ ] [′Noonan syndrome (RAF1):c.524A>G 5′] (p.His175Arg) NM_033360.3 193929331 KRAS [ ] [ ] [′Noonan syndrome (KRAS):c.13A>G 3′, ′Rasopathy′] (p.Lys5Glu) NM_000525.3 193929337 KCNJ11 [ ] [ ] [′Permanent neonatal (KCNJ11):c.155A>G diabetes mellitus′] (p.Gln52Arg) NM_000525.3 193929348 KCNJ11 [′AGAYGAG [′AGAYGAGGGTC [′Permanent neonatal (KCNJ11):c.544A>G GGTCTCAG TCAGCCCTGCGG′] diabetes mellitus′] (p.Ile182Val) CCCTGCGG′] NM_000525.3 193929356 KCNJ11 [ ] [ ] [′Permanent neonatal (KCNJ11):c.989A>G diabetes mellitus′, (p.Tyr330Cys) ′Neonatal insulin- dependent diabetes mellitus′] NM_001288953.1 139010200 TTC7A [ ] [ ] [′Multiple (TTC7A):c.1715A>G gastrointestinal (p.Lys572Arg) atresias′] NM_024809.4 374349989 TCTN2 [ ] [ ] [′Meckel syndrome (TCTN2):c.1506-2A>G type 8′] NM_012275.2 187015338 IL36RN [ ] [ ] [′Pustular psoriasis, (IL36RN):c.104A>G generalized′] (p.Lys35Arg) NM_178517.3 200024253 PIGW [ ] [ ] [′Hyperphosphatasia (PIGW):c.499A>G with mental (p.Met167Val) retardation syndrome 5′] NM_015662.2 149614625 — [ ] [ ] [′Short-rib thoracic (IFT172):c.5179T>C dysplasia 10 with or (p.Cys1727Arg) without polydactyly′] NM_000226.3 58597584 KRT9 [ ] [ ] [′Epidermolytic (KRT9):c.469A>G palmoplantar (p.Met157Val) keratoderma′, ′not provided′] NM_023073.3 606231260 C5orf42 [ ] [′ATCYATCAAATA [′Orofaciodigital (C5orf42):c.3290-2A>G CAAAAATTTGG′] syndrome 6′] NM_005633.3 397517172 SOS1 [ ] [ ] [′Noonan syndrome (SOS1):c.508A>G 4′, ′Rasopathy′, ′not (p.Lys170Glu) provided′] NM_006306.3 587784418 SMC1A [′CTTAYAG [′CTTAYAGATCTC [′Congenital (SMC1A):c.3254A>G ATCTCATC ATCAATGTTGG′] muscular (p.Tyr1085Cys) AATGTTGG′] hypertrophy-cerebral syndrome′] NM_006218.2 397517201 PIK3CA [ ] [ ] [′Neoplasm of (PIK3CA):c.1637A>G ovary′] (p.Gln546Arg) NM_006218.2 397517202 PIK3CA [ ] [ ] [′Non-small cell lung (PIK3CA):c.3073A>G cancer′] (p.Thr1025Ala) NM_002354.2 606231281 EPCAM [ ] [ ] [′Diarrhea 5, with (EPCAM):c.492-2A>G tufting enteropathy, congenital′] NM_033056.3 397517452 PCDH15 [ ] [ ] [′Usher syndrome, (PCDH15):c.1998-2A>G type 1F′] NM_000301.3 73015965 PLG [ ] [ ] [′Plasminogen (PLG):c.112A>G deficiency, type I′] (p.Lys38Glu) NM_000155.3 111033692 GALT [ ] [ ] [′Deficiency of (GALT):c.424A>G UDPglucose- (p.Met142Val) hexose-1-phosphate uridylyltransferase′] NM_000096.3 386134132 CP [ ] [ ] [′Deficiency of (CP):c.2953A>G ferroxidase′] (p.Met985Val) NM_000197.1 119481074 HSD17B3 [ ] [ ] [′Testosterone 17- (HSD17B3):c.703A>G beta-dehydrogenase (p.Met235Val) deficiency′] NM_000197.1 119481079 HSD17B3 [ ] [ ] [′Testosterone 17- (HSD17B3):c.389A>G beta-dehydrogenase (p.Asn130Ser) deficiency′] NM_015474.3 515726139 SAMHD1 [ ] [ ] [′Aicardi Goutieres (SAMHD1):c.1106T>C syndrome 5′] (p.Leu369Ser) NM_004817.3 587777521 TJP2 [ ] [′CAGCTCYGAGA [′Progressive (TJP2):c.1992-2A>G AGAAACCACGGG′, familial intrahepatic ′TCAGCTCYGAGA cholestasis 4′] AGAAACCACGG′] NM_000257.3 730880846 MYH7 [ ] [′CTTCYTGCTGCG [′Cardiomyopathy′] (MYH7):c.617A>G GTCCCCAATGG′] (p.Lys206Arg) NM_020919.3 386134184 ALS2 [ ] [ ] [′Juvenile primary (ALS2):c.2980-2A>G lateral sclerosis′] m.10044A>G 41362547 MT-TG [ ] [ ] [′Sudden death′] NM_002977.3 80356468 SCN9A [ ] [ ] [′Primary (SCN9A):c.406A>G erythromelalgia′] (p.Ile136Val) NM_001128425.1 34612342 MUTYH [ ] [ ] [′MYH-associated (MUTYH):c.536A>G polyposis′, (p.Tyr179Cys) ′Hereditary cancer- predisposing syndrome′, ′Endometrial carcinoma′, ′Carcinoma of colon′, ′not specified′, ′not provided′] NM_206933.2 397517978 USH2A [ ] [′TTCCCYGTAAGA [′Usher syndrome, (USH2A):c.12067-2A>G AAATTAACAGG′] type 2A′, ′Retinitis pigmentosa 39′] NM_000216.2 606231409 ANOS1 [ ] [′GCACCAYGGCT [′Kallmann (ANOS1):c.1A>G GCGGGTCGAGGG′, syndrome 1′] (p.Met1Val) ′GGCACCAYGGCT GCGGGTCGAGG′] NM_206933.2 397518003 USH2A [ ] [ ] [′Usher syndrome, (USH2A):c.1841-2A>G type 2A′] NM_000368.4 118203576 TSC1 [ ] [ ] [′Tuberous sclerosis (TSC1):c.1760A>G syndrome′, (p.Lys587Arg) ′Tuberous sclerosis 1′, ′Hereditary cancer-predisposing syndrome′, ′not specified′] NM_021830.4 80356540 C10orf2 [ ] [ ] [′Mitochondrial (C10orf2):c.1523A>G DNA depletion (p.Tyr508Cys) syndrome 7 (hepatocerebral type)′, ′not provided′] NM_003334.3 80356546 UBA1 [ ] [′TGGCYTGTCACC [′Arthrogryposis (UBA1):c.1639A>G CGGATATGTGG′] multiplex congenita, (p.Ser547Gly) distal, X-linked′] NM_206933.2 397518039 USH2A [′ATCYAAA [′ATCYAAAGCAA [′Retinitis (USH2A):c.8559-2A>G GCAAAAG AAGACAAGCAGG′] pigmentosa′, ′Usher ACAAGCAGG′] syndrome, type 2A′] NM_000038.5 587783035 APC [′TCCYAGT [′TCCYAGTAAGA [′Familial (APC):c.1744-2A>G AAGAAAC AACAGAATATGG′] adenomatous AGAATATGG′] polyposis 1′] NM_194248.2 80356584 OTOF [ ] [′GACCYGCAGGC [′Deafness, (OTOF):c.766-2A>G AGGAGAAGGGGG′, autosomal recessive ′TGACCYGCAGGC 9′] AGGAGAAGGGG′, ′CTGACCYGCAGG CAGGAGAAGGG′, ′GCTGACCYGCAG GCAGGAGAAGG′] NM_000525.3 80356621 KCNJ11 [ ] [ ] [′Permanent neonatal (KCNJ11):c.509A>G diabetes mellitus′] (p.Lys170Arg) NM_000352.4 80356634 ABCC8 [ ] [ ] [′Permanent neonatal (ABCC8):c.215A>G diabetes mellitus′] (p.Asn72Ser) NM_000352.4 80356653 ABCC8 [ ] [ ] [′Permanent neonatal (ABCC8):c.4270A>G diabetes mellitus′] (p.Ile1424Val) NM_000207.2 80356672 — [ ] [ ] [′Permanent neonatal (INS):c.323A>G diabetes mellitus′] (p.Tyr108Cys) NM_000083.2 80356699 CLCN1 [ ] [ ] [′Myotonia (CLCN1):c.382A>G congenita′, (p.Met128Val) ′Congenital myotonia, autosomal dominant form′] NM_001008211.1 267606929 OPTN [ ] [ ] [′Amyotrophic (OPTN):c.1433A>G lateral sclerosis type (p.Glu478Gly) 12′] NM_007375.3 80356717 TARDBP [ ] [ ] [′Amyotrophic (TARDBP):c.506A>G lateral sclerosis type (p.Asp169Gly) 10′] NM_007375.3 80356730 TARDBP [ ] [ ] [′Amyotrophic (TARDBP):c.1009A>G lateral sclerosis type (p.Met337Val) 10′] NM_007375.3 80356731 TARDBP [ ] [ ] [′Amyotrophic (TARDBP):c.1028A>G lateral sclerosis type (p.Gln343Arg) 10′] NM_001701.3 80356747 BAAT [′CAAYGAA [′CAAYGAAGAGG [′Atypical (BAAT):c.967A>G GAGGAATT AATTGCCCCTGG′] hemolytic-uremic (p.Ile323Val) GCCCCTGG′] syndrome 1′] NM_012463.3 80356753 ATP6V0A2 [ ] [ ] [′Cutis laxa with (ATP6V0A2):c.732-2A>G osteodystrophy′] NM_001876.3 80356778 CPT1A [ ] [ ] [′Carnitine (CPT1A):c.1361A>G palmitoyltransferase (p.Asp454Gly) I deficiency′] NM_001876.3 80356787 CPT1A [ ] [ ] [′Carnitine (CPT1A):c.1079A>G palmitoyltransferase (p.Glu360Gly) I deficiency′] NM_001876.3 80356791 CPT1A [ ] [ ] [′Carnitine (CPT1A):c.1493A>G palmitoyltransferase (p.Tyr498Cys) I deficiency′] NM_003159.2 587783072 CDKL5 [ ] [ ] [′Atypical Rett (CDKL5):c.211A>G syndrome′, ′not (p.Asn71Asp) provided′] NM_000257.3 730880930 MYH7 [ ] [′GGAACAYGCAC [′Cardiomyopathy′] (MYH7):c.1615A>G TCCTCTTCCAGG′] (p.Met539Val) m.5843A>G 118203894 MT-TY [ ] [ ] [ ] NM_000130.4 118203905 F5 [ ] [ ] [ ] (F5):c.1000A>G (p.Arg334Gly) NM_000130.4 118203907 F5 [′GTAGYAG [′GTAGYAGGCCC [′Factor V (F5):c.5189A>G GCCCAAGC AAGCCCGACAGG′] deficiency′] (p.Tyr1730Cys) CCGACAGG′] NM_000052.6 151340632 ATP7A [ ] [ ] [′Menkes kinky-hair (ATP7A):c.3911A>G syndrome′, ′Cutis (p.Asn1304Ser) laxa, X-linked′] NM_007294.3 80356890 BRCA1 [ ] [ ] [′Familial cancer of (BRCA1):c.5053A>G breast′, ′Breast- (p.Thr1685Ala) ovarian cancer, familial 1′, ′Hereditary cancer- predisposing syndrome′] NM_000046.3 118203943 ARSB [ ] [ ] [′Mucopolysaccharidosis (ARSB):c.629A>G type VI′, ′not (p.Tyr210Cys) provided′] NM_013319.2 118203945 UBIAD1 [′GTAAGTG [′GTAAGTGYTGAC [′Schnyder (UBIAD1):c.305A>G YTGACCAA CAAATTACCGG′] crystalline corneal (p.Asn102Ser) ATTACCGG′] dystrophy′] NM_013319.2 118203947 UBIAD1 [ ] [′TCCYGTCATCAC [′Schnyder (UBIAD1):c.355A>G TCTTTTTGTGG′] crystalline corneal (p.Arg119Gly) dystrophy′] NM_013319.2 118203949 UBIAD1 [′GGTGTTG [′GGTGTTGYTGGA [′Schnyder (UBIAD1):c.695A>G YTGGAATG ATGGAGAATGG′] crystalline corneal (p.Asn232Ser) GAGAATGG′] dystrophy′] NM_013319.2 118203950 UBIAD1 [ ] [ ] [′Schnyder (UBIAD1):c.335A>G crystalline corneal (p.Asp112Gly) dystrophy′] NM_024334.2 144811578 TMEM43 [ ] [ ] [′Emery-Dreifuss (TMEM43):c.271A>G muscular dystrophy (p.Ile91Val) 7, autosomal dominant′, ′not provided′] NM_012073.4 118203986 CCT5 [ ] [ ] [′Neuropathy, (CCT5):c.440A>G hereditary sensory, (p.His147Arg) with spastic paraplegia, autosomal recessive′] NM_000033.3 128624216 ABCD1 [′CACTGYT [′CACTGYTGACGA [′Adrenoleukodystrophy′] (ABCD1):c.443A>G GACGAAG AGGTAGCAGGG′, (p.Asn148Ser) GTAGCAGG ′GCACTGYTGACG G′] AAGGTAGCAGG′] NM_000146.3 139732572 FTL [′CTCAYGG [′CTCAYGGTTGGT [′L-ferritin (FTL):c.1A>G TTGGTTGG TGGCAAGAAGG′] deficiency′] (p.Met1Val) CAAGAAGG′] NM_000785.3 118204012 CYP27B1 [ ] [ ] [′Vitamin D- (CYP27B1):c.566A>G dependent rickets, (p.Glu189Gly) type 1′] NM_000252.2 397518445 MTM1 [ ] [ ] [′Severe X-linked (MTM1):c.1261-10A>G myotubular myopathy′] NM_139281.2 118204022 WDR36 [ ] [ ] [′Glaucoma 1, open (WDR36):c.1064A>G angle, G′] (p.Asn355Ser) NM_000392.4 72558202 ABCC2 [ ] [ ] [′Dubin-Johnson (ABCC2):c.4145A>G syndrome′] (p.Gln1382Arg) NM_000165.4 397518464 GJA1 [ ] [ ] [′Oculodentodigital (GJA1):c.617A>G dysplasia′] (p.Lys206Arg) NM_000833.4 397518469 GRIN2A [ ] [ ] [′Focal epilepsy with (GRIN2A):c.1123-2A>G speech disorder with or without mental retardation′] NM_015702.2 118204046 MMADHC [ ] [ ] [′Homocystinuria, (MMADHC):c.746A>G cblD type, variant 1′] (p.Tyr249Cys) NM_000526.4 60171927 KRT14 [ ] [′GCGGTCAYTGA [′Epidermolysis (KRT14):c.368A>G GGTTCTGCATGG′] bullosa (p.Asn123Ser) herpetiformis, Dowling-Meara′, ′not provided′] NM_000237.2 118204064 LPL [′AGCTGGA [′GCTGGAYCGAG [′Hyperlipoproteinemia, (LPL):c.548A>G YCGAGGCC GCCTTAAAAGGG′, type I′] (p.Asp183Gly) TTAAAAGG′] ′AGCTGGAYCGAG GCCTTAAAAGG′] NM_016247.3 201893545 IMPG2 [′ACTYTTT [′ACTYTTTGGGAT [′Macular dystrophy, (IMPG2):c.370T>C GGGATCGA CGACTTCCTGG′] vitelliform, 5′] (p.Phe124Leu) CTTCCTGG′] NM_004035.6 118204090 ACOX1 [ ] [ ] [′Pseudoneonatal (ACOX1):c.832A>G adrenoleukodystrophy′] (p.Met278Val) NM_004035.6 118204092 ACOX1 [ ] [ ] [′Pseudoneonatal (ACOX1):c.926A>G adrenoleukodystrophy′] (p.Gln309Arg) NM_000190.3 118204118 HMBS [ ] [ ] [′Porphyria, acute (HMBS):c.1A>G intermittent, (p.Met1Val) nonerythroid variant′] NM_001363.4 199422248 DKC1 [ ] [′AATCYTGGCCCC [′Dyskeratosis (DKC1):c.941A>G ATAGCAGATGG′] congenita X-linked′] (p.Lys314Arg) NM_000078.2 2303790 CETP [ ] [ ] [′Hyperalphalipo- (CETP):c.1376A>G proteinemia′] (p.Asp459Gly) NM_000531.5 72558405 OTC [ ] [ ] [′not provided′] (OTC):c.595A>G (p.Asn199Asp) NM_000531.5 72558406 OTC [ ] [ ] [′not provided′] (OTC):c.596A>G (p.Asn199Ser) NM_000531.5 72558411 OTC [ ] [ ] [′not provided′] (OTC):c.613A>G (p.Met205Val) NM_000531.5 72558432 OTC [ ] [ ] [′not provided′] (OTC):c.717+3A>G NM_000531.5 72558433 OTC [ ] [ ] [′not provided′] (OTC):c.718-2A>G NM_000531.5 72558443 OTC [ ] [ ] [′not provided′] (OTC):c.788A>G (p.Asp263Gly) NM_000531.5 72558444 OTC [ ] [ ] [′not provided′] (OTC):c.790A>G (p.Thr264Ala) NM_000531.5 72558467 OTC [ ] [′TCCACTYCTTCT [′not provided′] (OTC):c.929A>G GGCTTTCTGGG′, (p.Glu310Gly) ′ATCCACTYCTTCT GGCTTTCTGG′] NM_000531.5 72558478 OTC [ ] [′ACTTTCYGTTTT [′not provided′] (OTC):c.988A>G CTGCCTCTGGG′, (p.Arg330Gly) ′CACTTTCYGTTTT CTGCCTCTGG′] NM_000488.3 121909571 SERPINC1 [ ] [ ] [′Antithrombin III (SERPINC1):c.655A>G deficiency′] (p.Asn219Asp) NM_007294.3 80357276 BRCA1 [′AAATATG [′AAATATGYGGTC [′Familial cancer of (BRCA1):c.122A>G YGGTCACA ACACTTTGTGG′] breast′, ′Breast- (p.His41Arg) CTTTGTGG′] ovarian cancer, familial 1′] NM_007294.3 80357287 BRCA1 [ ] [ ] [′Familial cancer of (BRCA1):c.1A>G breast′, ′Breast- (p.Met1Val) ovarian cancer, familial 1′, ′Hereditary cancer- predisposing syndrome′] NM_198056.2 373172185 SCN5A [ ] [ ] [′not provided′] (SCN5A):c.1134T>A (p.Tyr378Ter) m.7526A>G 121434454 MT-TD [ ] [ ] [ ] NM_007294.3 80357382 BRCA1 [ ] [ ] [′Familial cancer of (BRCA1):c.211A>G breast′, ′Hereditary (p.Arg71Gly) breast and ovarian cancer syndrome′, ′Breast-ovarian cancer, familial 1′, ′Hereditary cancer- predisposing syndrome′] NM_000512.4 118204440 GALNS [′ACGYTGA [′ACGYTGAGCTG [′Mucopolysaccharidosis, (GALNS):c.1460A>G GCTGGGGC GGGCTGCGCGGG′, MPS-IV-A′] (p.Asn487Ser) TGCGCGGG′, ′CACGYTGAGCTG ′CACGYTG GGGCTGCGCGG′] AGCTGGGG CTGCGCGG′] NM_000505.3 118204455 F12 [ ] [′GGTGGYACTGG [ ] (F12):c.158A>G AAGGGGAAGTGG′] (p.Tyr53Cys) NM_007294.3 80357477 BRCA1 [ ] [′TTGYCCTCTGTC [′Familial cancer of (BRCA1):c.5453A>G CAGGCATCTGG′] breast′, ′Breast- (p.Asp1818Gly) ovarian cancer, familial 1′] NM_032492.3 587777730 JAGN1 [ ] [ ] [′Severe congenital (JAGN1):c.485A>G neutropenia′, ′Severe (p.Gln162Arg) congenital neutropenia 6, autosomal recessive′] NM_000257.3 730880732 MYH7 [ ] [ ] [′Cardiomyopathy′] (MYH7):c.2087A>G (p.Asn696Ser) NM_000430.3 121434482 PAFAH1B1 [ ] [ ] [′Lissencephaly 1′] (PAFAH1B1):c.446A>G (p.His149Arg) NM_000363.4 730881077 TNNI3 [ ] [ ] [′Cardiomyopathy′] (TNNI3):c.547A>G (p.Lys183Glu) NM_018105.2 267607111 THAP1 [ ] [ ] [′Dystonia 6, (THAP1):c.266A>G torsion′] (p.Lys89Arg) NM_016599.4 140126678 MYOZ2 [ ] [ ] [′Familial (MYOZ2):c.738A>G hypertrophic (p.Ile246Met) cardiomyopathy 16′, ′not specified′, ′not provided′] NM_000161.2 41298442 GCH1 [ ] [ ] [′Dystonia 5, Dopa- (GCH1):c.671A>G responsive type′, (p.Lys224Arg) ′Dystonia, dopa- responsive, with or without hyperphenylalaninemia, autosomal recessive′] NM_017415.2 199469627 KLHL3 [′Pseudohypo- (KLHL3):c.926A>G aldosteronism, type 2′] (p.Gln309Arg) NM_017415.2 199469645 KLHL3 [′Pseudohypo- (KLHL3):c.1670A>G aldosteronism, type 2′, (p.Tyr557Cys) ′Pseudohypo aldosteronism type 2D′] NM_003590.4 199469650 CUL3 [′Pseudohypo- (CUL3):c.1207-26A>G aldosteronism, type 2′] NM_003590.4 199469656 CUL3 [′Pseudohypo- (CUL3):c.1238A>G aldosteronism, type 2′, (p.Asp413Gly) ′Pseudohypo- aldosteronism type 2E′] NM_003590.4 199469658 CUL3 [′Pseudohypo- (CUL3):c.1376A>G aldosteronism, type 2′] (p.Lys459Arg) NM_003590.4 199469661 CUL3 [′Pseudohypo- (CUL3):c.1377+3A>G aldosteronism, type 2′] NM_007294.3 80358015 BRCA1 [ ] [ ] [′Hereditary breast (BRCA1):c.4096+3A>G and ovarian cancer syndrome′, ′Breast- ovarian cancer, familial 1′, ′Hereditary cancer- predisposing syndrome′] NM_007294.3 80358065 BRCA1 [ ] [ ] [′Breast-ovarian (BRCA1):c.135-2A>G cancer, familial 1′] NM_024426.4 121907902 WT1 [ ] [ ] [′Drash syndrome′] (WT1):c.1391A>G (p.Asp464Gly) NM_007294.3 80358083 BRCA1 [ ] [ ] [′Familial cancer of (BRCA1):c.212+3A>G breast′, ′Breast- ovarian cancer, familial 1′] NM_024426.4 121907908 WT1 [ ] [′CGCYCTCGTACC [′Mesothelioma′] (WT1):c.1021A>G CTGTGCTGTGG′] (p.Ser341Gly) NM_007294.3 80358096 BRCA1 [ ] [ ] [′Breast-ovarian (BRCA1):c.4676-2A>G cancer, familial 1′, ′Hereditary cancer- predisposing syndrome′] NM_000280.4 121907926 PAX6 [ ] [′GTGGYGCCCGA [′Optic nerve (PAX6):c.1171A>G GGTGCCCATTGG′] aplasia, bilateral′] (p.Thr391Ala) NM_000520.4 121907976 HEXA [ ] [ ] [′Tay-Sachs disease′] (HEXA):c.611A>G (p.His204Arg) NM_000159.3 141437721 GCDH [ ] [ ] [′Glutaric aciduria, (GCDH):c.1213A>G type 1′] (p.Met405Val) NM_024740.2 121908023 ALG9 [ ] [′TTAYACAAAAC [′Congenital disorder (ALG9):c.860A>G AATGTTGAGTGG′] of glycosylation type (p.Tyr287Cys) 1L′] NM_003051.3 80358222 SLC16A1 [ ] [ ] [′Erythrocyte lactate (SLC16A1):c.610A>G transporter defect′] (p.Lys204Glu) NM_000229.1 121908057 LCAT [ ] [ ] [′Fish-eye disease′] (LCAT):c.463A>G (p.Asn155Asp) NM_000639.2 80358238 FASLG [ ] [ ] [′Autoimmune (FASLG):c.466A>G lymphoproliferative (p.Arg156Gly) syndrome′] NM_001369.2 147499872 DNAH5 [ ] [ ] [′Ciliary dyskinesia, (DNAH5):c.1121T>C primary, 3′] (p.Ile374Thr) NM_138691.2 121908074 TMC1 [ ] [ ] [′Deafness, (TMC1):c.1960A>G autosomal recessive (p.Met654Val) 7′] NM_024301.4 121908110 FKRP [ ] [ ] [′Congenital (FKRP):c.1387A>G muscular dystrophy- (p.Asn463Asp) dystroglycanopathy (with or without mental retardation) type B5′, ′Limb- girdle muscular dystrophy- dystroglycanopathy, type C5′, ′Muscular dystrophy′, ′Congenital muscular dystrophy- dystroglycanopathy with brain and eye anomalies type A5′, ′Congenital muscular dystrophy- dystroglycanopathy without mental retardation, type B5′, ′not provided′] NM_175073.2 121908133 APTX [′GCCAAYG [′GCCAAYGGTAA [′Adult onset ataxia (APTX):c.602A>G GTAACGGG CGGGCCTTTGGG′, with oculomotor (p.His201Arg) CCTTTGGG′] ′AGCCAAYGGTAA apraxia′] CGGGCCTTTGG′] NM_001243133.1 121908148 NLRP3 [ ] [′ACAATYCCAGCT [′Familial cold (NLRP3):c.1880A>G GGCTGGGCTGG′] urticaria′] (p.Glu627Gly) NM_006492.2 121908166 ALX3 [ ] [′CGGYTCTGGAAC [′Frontonasal (ALX3):c.608A>G CAGACCTGGGG′, dysplasia 1′] (p.Asn203Ser) ′GCGGYTCTGGAA CCAGACCTGGG′, ′TGCGGYTCTGGA ACCAGACCTGG′] NM_020451.2 121908184 SEPN1 [ ] [′CCCAYGGCTGCG [′Eichsfeld type (SEPN1):c.1A>G GCTGGCGGCGG′, congenital muscular (p.Met1Val) ′CGGCCCAYGGCT dystrophy′] GCGGCTGGCGG′] NM_001127221.1 121908219 CACNA1A [ ] [ ] [′Familial (CACNA1A):c.4151A>G hemiplegic migraine (p.Tyr1384Cys) type 1′] NM_005249.4 199502880 FOXG1 [ ] [ ] [′not provided′] (FOXG1):c.686T>A (p.Ile229Asn) NM_130468.3 121908258 CHST14 [ ] [′AAGTCAYAGTG [′Ehlers-Danlos (CHST14):c.878A>G CACGGCACAAGG′] syndrome, (p.Tyr293Cys) musculocontractural type′] NM_013391.3 121908331 DMGDH [ ] [ ] [′Dimethylglycine (DMGDH):c.326A>G dehydrogenase (p.His109Arg) deficiency′] NM_015166.3 121908344 MLC1 [ ] [ ] [′Megalencephalic (MLC1):c.422A>G leukoencephalopathy (p.Asn141Ser) with subcortical cysts 1′] NM_000441.1 121908361 SLC26A4 [ ] [ ] [′Enlarged vestibular (SLC26A4):c.1105A>G aqueduct syndrome′] (p.Lys369Glu) NM_000441.1 121908362 SLC26A4 [ ] [ ] [′Pendred syndrome′, (SLC26A4):c.2168A>G ′Enlarged vestibular (p.His723Arg) aqueduct syndrome′] NM_015560.2 121908376 OPA1 [ ] [ ] [′Optic Atrophy (OPA1):c.1745A>G Type 1′] (p.Tyr582Cys) NM_001128425.1 121908383 MUTYH [ ] [′AAGCYGCTCTGA [′Neoplasm of (MUTYH):c.1241A>G GGGCTCCCAGG′] stomach′] (p.Gln414Arg) NM_015247.2 121908389 CYLD [ ] [ ] [′Familial multiple (CYLD):c.2240A>G trichoepitheliomata′, (p.Glu747Gly) ′Spiegler-Brooke syndrome′] NM_021102.3 121908403 SPINT2 [′TCCAYAG [′TCCAYAGATGA [′Diarrhea 3, (SPINT2):c.488A>G ATGAAGTT AGTTATTGCAGG′] secretory sodium, (p.Tyr163Cys) ATTGCAGG′] congenital, syndromic′] NM_004924.4 121908415 ACTN4 [ ] [ ] [′Focal segmental (ACTN4):c.763A>G glomerulosclerosis (p.Lys255Glu) 1′] NM_004795.3 121908423 KL [′CAGYGGT [′CAGYGGTACAG [ ] (KL):c.578A>G ACAGGGTG GGTGACCACGGG′, (p.His193Arg) ACCACGGG′, ′CCAGYGGTACAG ′CCAGYGG GGTGACCACGG′] TACAGGGT GACCACGG′] NM_005682.6 121908466 ADGRG1 [′TGGYAGA [′TGGYAGAGGCC [′Polymicrogyria, (ADGRG1):c.263A>G GGCCCCTG CCTGGGGTCAGG′] bilateral (p.Tyr88Cys) GGGTCAGG′] frontoparietal′] NM_139025.4 121908473 ADAMTS13 [ ] [ ] [′Upshaw-Schulman (ADAMTS13):c.1582A>G syndrome′] (p.Arg528Gly) NM_014270.4 121908487 SLC7A9 [ ] [ ] [′Cystinuria′] (SLC7A9):c.695A>G (p.Tyr232Cys) NM_004211.3 121908494 SLC6A5 [ ] [ ] [′Hyperekplexia 3′] (SLC6A5):c.1472A>G (p.Tyr491Cys) NM_004211.3 121908497 SLC6A5 [ ] [ ] [′Hyperekplexia 3′] (SLC6A5):c.1526A>G (p.Asn509Ser) NM_182643.2 121908500 DLC1 [ ] [ ] [′Carcinoma of (DLC1):c.2875A>G colon′] (p.Thr959Ala) NM_014946.3 121908512 SPAST [ ] [ ] [′Spastic paraplegia (SPAST):c.1322A>G 4, autosomal (p.Asp441Gly) dominant′] NM_014946.3 121908514 SPAST [ ] [ ] [′Spastic paraplegia (SPAST):c.1157A>G 4, autosomal (p.Asn386Ser) dominant′] NM_000026.2 119450944 ADSL [ ] [ ] [′Adenylosuccinate (ADSL):c.736A>G lyase deficiency′] (p.Lys246Glu) NM_000334.4 121908549 SCN4A [′TGAYGGA [′TGAYGGAGGGG [ ] (SCN4A):c.3478A>G GGGGATGG ATGGCGCCTAGG′] (p.Ile1160Val) CGCCTAGG′] NM_000334.4 121908561 SCN4A [ ] [ ] [′Paramyotonia (SCN4A):c.421A>G congenita of von (p.Ile141Val) Eulenburg′] NM_004328.4 121908580 BCS1L [ ] [′GTGYGATCATGT [′Mitochondrial (BCS1L):c.148A>G AATGGCGCCGG′] complex III (p.Thr50Ala) deficiency′] NM_152384.2 121908582 BBS5 [ ] [ ] [′Bardet-Biedl (BBS5):c.547A>G syndrome 5′] (p.Thr183Ala) NM_016417.2 121908584 GLRX5 [ ] [′CCTGACCYTGTC [′Anemia, (GLRX5):c.294A>G GGAGCTCCGGG′] sideroblastic, (p.Gln98=) pyridoxine-refractory, autosomal recessive′] NM_006206.4 121908589 PDGFRA [ ] [ ] [ ] (PDGFRA):c.1664A>G (p.Tyr555Cys) NM_002755.3 121908595 MAP2K1 [′CCAYAGA [′CCAYAGAAGCC [′Cardiofaciocutaneous (MAP2K1):c.389A>G AGCCCACG CACGATGTACGG′] syndrome 3′, (p.Tyr130Cys) ATGTACGG′] ′Rasopathy′] NM_012082.3 121908601 ZFPM2 [ ] [ ] [′Double outlet right (ZFPM2):c.89A>G ventricle′, ′Tetralogy (p.Glu30Gly) of Fallot′, ′Diaphragmatic hernia 3′] NM_012082.3 121908604 — [ ] [ ] [′Diaphragmatic (ZFPM2):c.2527A>G hernia 3′] (p.Thr843Ala) NM_022817.2 121908635 PER2 [ ] [′GCCACACYCTCT [′Advanced sleep (PER2):c.1984A>G GCCTTGCCCGG′] phase syndrome, (p.Ser662Gly) familial′] NM_030761.4 121908650 WNT4 [ ] [ ] [′Mullerian aplasia (WNT4):c.647A>G and (p.Glu216Gly) hyperandrogenism′] NM_003839.3 121908655 TNFRSF11A [ ] [′GGGTCYGCATTT [′Osteopetrosis (TNFRSF11A):c.508A>G GTCCGTGGAGG′] autosomal recessive (p.Arg170Gly) 7′] NM_000539.3 29001653 RHO [ ] [′CGCTCTYGGCAA [′Retinitis (RHO):c.886A>G AGAACGCTGGG′, pigmentosa 4′] (p.Lys296Glu) ′GCGCTCTYGGCA AAGAACGCTGG′] NM_004006.2 128626244 DMD [ ] [ ] [′Duchenne (DMD):c.2317A>G muscular dystrophy′] (p.Lys773Glu) NM_003722.4 121908838 TP63 [′AGCTTYT [′AGCTTYTTTGTA [′Split-hand/foot (TP63):c.697A>G TTGTAGAC GACAGGCATGG′] malformation 4′] (p.Lys233Glu) AGGCATGG′] NM_003722.4 121908844 TP63 [ ] [ ] [′Ectrodactyly, (TP63):c.1052A>G ectodermal (p.Asp351Gly) dysplasia, and cleft lip/palate syndrome 3′] NM_003722.4 121908847 TP63 [ ] [ ] [′ADULT (TP63):c.1054A>G syndrome′, (p.Arg352Gly) ′Orofacial cleft 8′] NM_000369.2 121908859 TSHR [ ] [ ] [′Thyroid adenoma, (TSHR):c.1856A>G hyperfunctioning′] (p.Asp619Gly) NM_000369.2(TSHR): 121908879 TSHR [ ] [ ] [′Hyperthyroidism, c.548A>G familial gestational′] (p.Lys183Arg) NM_003060.3 121908888 SLC22A5 [ ] [ ] [′Renal carnitine (SLC22A5):c.632A>G transport defect′, ′not (p.Tyr211Cys) provided′] NM_006502.2 56307355 POLH [ ] [′AGACTTTYCTGC [′Xeroderma (POLH):c.1603A>G TTAAAGAAGGG′] pigmentosum, (p.Lys535Glu) variant type′] NM_002977.3 121908919 — [ ] [′CCTTTTCYTGTG [′Generalized (SCN9A):c.1964A>G TATTTGATTGG′] epilepsy with febrile (p.Lys655Arg) seizures plus, type 7′, ′not specified′] NM_002977.3 121908920 SCN9A [ ] [ ] [′Febrile seizures, (SCN9A):c.184A>G familial, 3b′] (p.Ile62Val) NM_006892.3 121908939 DNMT3B [ ] [′GACACGYCTGTG [′Centromeric (DNMT3B):c.2450A>G TAGTGCACAGG′] instability of (p.Asp817Gly) chromosomes 1,9 and 16 and immunodeficiency′] NM_001130978.1 121908954 DYSF [ ] [ ] [′Miyoshi muscular (DYSF):c.3892A>G dystrophy 1′, ′Limb- (p.Ile1298Val) girdle muscular dystrophy, type 2B′, ′not specified′] NM_001130978.1 121908961 DYSF [ ] [ ] [′Limb-girdle (DYSF):c.5264A>G muscular dystrophy, (p.Glu1755Gly) type 2B′] NM_016203.3 121908988 PRKAG2 [ ] [ ] [′Familial (PRKAG2):c.1148A>G hypertrophic (p.His383Arg) cardiomyopathy 6′] NM_000492.3 121909008 CFTR [′CACATAA [′CACATAAYACG [′Cystic fibrosis′] (CFTR):c.2738A>G YACGAACT AACTGGTGCTGG′] (p.Tyr913Cys) GGTGCTGG′] NM_000492.3 121909031 CFTR [ ] [ ] [′Cystic fibrosis′] (CFTR):c.326A>G (p.Tyr109Cys) NM_000492.3 121909046 CFTR [ ] [ ] [′Cystic fibrosis′] (CFTR):c.650A>G (p.Glu217Gly) NM_001040667.2 121909050 HSF4 [ ] [ ] [′Cataract, zonular′] (HSF4):c.256A>G (p.Ile86Val) NM_005025.4 121909052 SERPINI1 [ ] [ ] [′Familial (SERPINI1):c.1013A>G encephalopathy with (p.His338Arg) neuroserpin inclusion bodies′] NM_005422.2 121909058 TECTA [ ] [ ] [′Deafness, (TECTA):c.5609A>G autosomal dominant (p.Tyr1870Cys) 12′] NM_170695.3 121909068 TGIF1 [ ] [ ] [′Holoprosencephaly (TGIF1):c.838A>G 4′] (p.Thr280Ala) NM_001005360.2 121909088 DNM2 [ ] [′ACTYCTTCTCTT [′Charcot-Marie- (DNM2):c.1684A>G TCTCCTGAGGG′, Tooth disease, (p.Lys562Glu) ′TACTYCTTCTCTT dominant TCTCCTGAGG′] intermediate b, with neutropenia′] NM_000483.4 120074112 — [ ] [′GCCCAYAGTGTC [′Apolipoprotein C2 (APOC2):c.1A>G CAGAGACCTGG′] deficiency′] (p.Met1Val) NM_000543.4 120074123 SMPD1 [ ] [ ] [′Niemann-Pick (SMPD1):c.1154A>G disease, type B′] (p.Asn385Ser) NM_000019.3 120074145 ACAT1 [ ] [ ] [′Deficiency of (ACAT1):c.278A>G acetyl-CoA (p.Asn93Ser) acetyltransferase′] NM_138477.2 120074166 CDAN1 [ ] [ ] [′Congenital (CDAN1):c.1796A>G dyserythropoietic (p.Asn599Ser) anemia, type I′] NM_000187.3 120074173 HGD [ ] [ ] [′Alkaptonuria′] (HGD):c.1102A>G (p.Met368Val) NM_001089.2 121909184 ABCA3 [′ACCGTYG [′ACCGTYGTGGCC [′Surfactant (ABCA3):c.1702A>G TGGCCCAG CAGCAGGACGG′] metabolism (p.Asn568Asp) CAGGACGG′] dysfunction, pulmonary, 3′] NM_000503.5 121909197 EYA1 [ ] [ ] [ ] (EYA1):c.1639A>G (p.Arg547Gly) NM_000218.2 120074192 KCNQ1 [′CGCYGAA [′CGCYGAAGATG [′Atrial fibrillation, (KCNQ1):c.418A>G GATGAGGC AGGCAGACCAGG′] familial, 3′, ′Atrial (p.Ser140Gly) AGACCAGG′] fibrillation′] NM_000314.6 121909222 PTEN [ ] [ ] [′Cowden syndrome (PTEN):c.368A>G 1′] (p.His123Arg) NM_000314.6 121909238 PTEN [ ] [ ] [′Hereditary cancer- (PTEN):c.278A>G predisposing (p.His93Arg) syndrome′, ′Macrocephaly/autism syndrome′] NM_000314.6 121909239 PTEN [ ] [′ATAYCACCACAC [′Macrocephaly/autism (PTEN):c.755A>G ACAGGTAACGG′] syndrome′] (p.Asp252Gly) NM_198217.2 121909251 ING1 [ ] [′TGGYTGCACAG [′Squamous cell (ING1):c.515A>G ACAGTACGTGGG′, carcinoma of the (p.Asn172Ser) ′CTGGYTGCACAG head and neck′] ACAGTACGTGG′] NM_012338.3 200519776 TSPAN12 [ ] [ ] [′Exudative (TSPAN12):c.734T>C vitreoretinopathy 5′] (p.Leu245Pro) NM_001001557.2 121909353 GDF6 [ ] [ ] [′Klippel-Feil (GDF6):c.1271A>G syndrome 1, (p.Lys424Arg) autosomal dominant′] NM_000163.4 121909360 GHR [ ] [ ] [′Laron-type isolated (GHR):c.594A>G somatotropin (p.Glu198=) defect′] NM_000256.3 121909375 MYBPC3 [ ] [ ] [′Familial (MYBPC3):c.175A>G hypertrophic (p.Thr59Ala) cardiomyopathy 4′] NM_001174089.1 121909396 SLC4A11 [ ] [′GATCAYCTTCAT [′Corneal dystrophy (SLC4A11):c.2518A>G GTAGGGCAGGG′, and perceptive (p.Met840Val) ′AGATCAYCTTCA deafness′] TGTAGGGCAGG′] NM_001100.3 121909520 ACTA1 [′GCGGYTG [′CGGYTGGCCTTG [′Nemaline (ACTA1):c.350A>G GCCTTGGG GGATTGAGGGG′, myopathy 3′] (p.Asn117Ser) ATTGAGGG′, ′GCGGYTGGCCTT ′CGCGGYT GGGATTGAGGG′, GGCCTTGG ′CGCGGYTGGCCT GATTGAGG′] TGGGATTGAGG′] NM_000034.3 121909533 ALDOA [ ] [′CCAYCCAACCCT [′HNSHA due to (ALDOA):c.386A>G AAGAGAAGAGG′] aldolase A (p.Asp129Gly) deficiency′] NM_000495.4 104886388 COL4A5 [ ] [ ] [′Alport syndrome, (COL4A5):c.3455-9A>G X-linked recessive′] NM_001145.4 121909541 — [ ] [ ] [′Amyotrophic (ANG):c.208A>G lateral sclerosis type (p.Ile70Val) 9′] NM_000051.3 3092857 ATM [ ] [ ] [′Hereditary cancer- (ATM):c.3118A>G predisposing (p.Met1040Val) syndrome′, ′not specified′] NM_023110.2 121909631 FGFR1 [ ] [ ] [′Osteoglophonic (FGFR1):c.1121A>G dysplasia′] (p.Tyr374Cys) NM_182925.4 121909653 FLT4 [′CTGYGGA [′CTGYGGATGCAC [ ] (FLT4):c.3104A>G TGCACTGG TGGGGTGCGGG′, (p.His1035Arg) GGTGCGGG′, ′TCTGYGGATGCA ′TCTGYGG CTGGGGTGCGG′] ATGCACTG GGGTGCGG′] NM_000145.3 121909663 FSHR [ ] [ ] [′Ovarian (FSHR):c.1345A>G hyperstimulation (p.Thr449Ala) syndrome′] NM_001017420.2 80359862 ESCO2 [ ] [ ] [′Roberts-SC (ESCO2):c.1132-7A>G phocomelia syndrome′] NM_001017420.2 80359869 ESCO2 [ ] [ ] [′Roberts-SC (ESCO2):c.1674-2A>G phocomelia syndrome′] NM_024577.3 80359890 SH3TC2 [ ] [ ] [′Charcot-Marie- (SH3TC2):c.505T>C Tooth disease, type (p.Tyr169His) 4C′, ′Charcot-Marie- Tooth disease, type IV′, ′Mononeuropathy of the median nerve, mild′] NM_032119.3 121909763 ADGRV1 [ ] [ ] [′Usher syndrome, (ADGRV1):c.18131A>G type 2C′] (p.Tyr6044Cys) NM_001360.2 121909766 DHCR7 [ ] [ ] [′Smith-Lemli-Opitz (DHCR7):c.839A>G syndrome′] (p.Tyr280Cys) NM_000517.4 121909803 HBA2 [ ] [ ] [′Hemoglobin H (HBA2):c.1A>G disease, (p.Met1Val) nondeletional′] NM_004006.2 128627255 DMD [ ] [′TGACCGYGATCT [′Dilated (DMD):c.835A>G GCAGAGAAGGG′, cardiomyopathy 3B′] (p.Thr279Ala) ′CTGACCGYGATC TGCAGAGAAGG′] NM_015896.3 200913791 ZMYND10 [ ] [ ] [′Kartagener (ZMYND10):c.797T>C syndrome′, ′Ciliary (p.Leu266Pro) dyskinesia, primary, 22′] NM_001085.4 116929575 SERPINA3 [ ] [′GCTCAYGAAGA [ ] (SERPINA3):c.1240A>G AGATGTTCTGGG′, (p.Met414Val) ′TGCTCAYGAAGA AGATGTTCTGG′] NM_058216.2 587780835 RAD51C [ ] [ ] [′Fanconi anemia, (RAD51C):c.1027-2A>G complementation group O′] NM_006231.3 398122515 POLE [ ] [ ] [′Facial (POLE):c.4444+3A>G dysmorphism, immunodeficiency, livedo, and short stature′] NM_002769.4 144422014 — [ ] [ ] [′Hereditary (PRSS1):c.161A>G pancreatitis′] (p.Asn54Ser) NM_001204316.1 398122522 PRLR [ ] [ ] [′Hyperprolactinemia′] (PRLR):c.635A>G (p.His212Arg) NM_004992.3 61748392 MECP2 [ ] [′CAACYCCACTTT [′Mental retardation, (MECP2):c.410A>G AGAGCGAAAGG′] X-linked, syndromic (p.Glu137Gly) 13′] NM_020366.3 376517859 RPGRIP1 [ ] [ ] [′Cone-rod (RPGRIP1):c.3749-2A>G dystrophy 13′] NM_000552.3 61748478 VWF [′GTCAYAG [′GTCAYAGTTCTG [′von Willebrand (VWF):c.2384A>G TTCTGGCA GCACGTTTTGG′] disease type 2N′, (p.Tyr795Cys) CGTTTTGG′] ′not provided′] NM_001040613.2 183973249 TMEM70 [ ] [ ] [′Nuclearly-encoded (TMEM70):c.*7-2A>G mitochondrial complex V (ATP synthase) deficiency 2′] NM_001005741.2 78198234 GBA [ ] [ ] [′Gaucher disease, (GBA):c.1049A>G perinatal lethal′] (p.His350Arg) NM_000218.2 199472678 KCNQ1 [ ] [ ] [′Congenital long (KCNQ1):c.332A>G QT syndrome′, (p.Tyr111Cys) ′Cardiac arrhythmia′, ′Long QT syndrome, LQT1 subtype′] NM_000218.2 199472679 KCNQ1 [′Congenital long (KCNQ1):c.344A>G QT syndrome′, (p.Glu115Gly) ′Long QT syndrome, LQT1 subtype′] NM_000218.2 199472689 KCNQ1 [′Atrial fibrillation′] (KCNQ1):c.440A>G (p.Gln147Arg) NM_000218.2 199472700 KCNQ1 [ ] [ ] [′Congenital long (KCNQ1):c.592A>G QT syndrome′] (p.Ile198Val) NM_001943.3 752432726 DSG2 [ ] [ ] [′Cardiomyopathy′] (DSG2):c.880A>G (p.Lys294Glu) NM_000218.2 199472728 KCNQ1 [ ] [ ] [′Sudden infant (KCNQ1):c.820A>G death syndrome′, (p.Ile274Val) ′Congenital long QT syndrome′, ′Cardiac arrhythmia′] NM_000218.2 199472732 KCNQ1 [′Congenital long (KCNQ1):c.842A>G QT syndrome′] (p.Tyr281Cys) NM_000218.2 199472750 KCNQ1 [′Congenital long (KCNQ1):c.950A>G QT syndrome′] (p.Asp317Gly) NM_000218.2 199472754 KCNQ1 [′Congenital long (KCNQ1):c.964A>G QT syndrome′, (p.Thr322Ala) ′Cardiac arrhythmia′, ′Long QT syndrome, LQT1 subtype′] NM_000218.2 199472770 KCNQ1 [′Congenital long (KCNQ1):c.1138A>G QT syndrome′] (p.Arg380Gly) NM_000218.2 199472777 KCNQ1 [′Congenital long (KCNQ1):c.1193A>G QT syndrome′, (p.Lys398Arg) ′Cardiac arrhythmia′] NM_000218.2 199472798 KCNQ1 [′Congenital long (KCNQ1):c.1640A>G QT syndrome′] (p.Gln547Arg) NM_000218.2 199472801 KCNQ1 [′Congenital long (KCNQ1):c.1669A>G QT syndrome′] (p.Lys557Glu) NM_000218.2 199472808 KCNQ1 [′Congenital long (KCNQ1):c.1705A>G QT syndrome′] (p.Lys569Glu) NM_001005741.2 61748906 GBA [ ] [′CCACTYGGCTC [′Gaucher disease, (GBA):c.667T>C AAGACCAATGG′] type 1′, ′not (p.Trp223Arg) provided′] NM_000218.2 199472812 KCNQ1 [′Congenital long (KCNQ1):c.1756A>G QT syndrome′, (p.Asn586Asp) ′Long QT syndrome, LQT1 subtype′] NM_000218.2 199472817 KCNQ1 [′Sudden infant (KCNQ1):c.1793A>G death syndrome′] (p.Lys598Arg) NM_000238.3 199472829 KCNH2 [′Congenital long (KCNH2):c.82A>G QT syndrome′] (p.Lys28Glu) NM_000238.3 199472836 KCNH2 [′Congenital long (KCNH2):c.128A>G QT syndrome′, (p.Tyr43Cys) ′Cardiac arrhythmia′] NM_000238.3 199472856 KCNH2 [ ] [ ] [′Congenital long (KCNH2):c.301A>G QT syndrome′, (p.Lys101Glu) ′Cardiac arrhythmia′] NM_000238.3 199472869 KCNH2 [′Congenital long (KCNH2):c.652A>G QT syndrome′] (p.Met218Val) NM_000238.3 199472907 KCNH2 [′Congenital long (KCNH2):c.1424A>G QT syndrome′] (p.Tyr475Cys) NM_000238.3 199472930 KCNH2 [′Congenital long (KCNH2):c.1777A>G QT syndrome′] (p.Ile593Val) NM_000238.3 199472932 KCNH2 [′Congenital long (KCNH2):c.1783A>G QT syndrome′] (p.Lys595Glu) NM_000238.3 199472934 KCNH2 [′Long QT (KCNH2):c.1790A>G syndrome′, (p.Tyr597Cys) ′Congenital long QT syndrome′] NM_000238.3 199472940 KCNH2 [′Congenital long (KCNH2):c.1826A>G QT syndrome′] (p.Asp609Gly) NM_000238.3 199472946 KCNH2 [′Long QT (KCNH2):c.1847A>G syndrome′, (p.Tyr616Cys) ′Congenital long QT syndrome′, ′Cardiac arrhythmia′] NM_000238.3 199472956 KCNH2 [′Congenital long (KCNH2):c.1885A>G QT syndrome′, (p.Asn629Asp) ′Cardiac arrhythmia′] NM_000238.3 199472960 KCNH2 [′Congenital long (KCNH2):c.1897A>G QT syndrome′] (p.Asn633Asp) NM_000238.3 199472963 KCNH2 [′Congenital long (KCNH2):c.1903A>G QT syndrome′] (p.Asn635Asp) NM_000238.3 199472967 KCNH2 [′Congenital long (KCNH2):c.1910A>G QT syndrome′] (p.Glu637Gly) NM_000238.3 199473004 KCNH2 [′Congenital long (KCNH2):c.2510A>G QT syndrome′, (p.Asp837Gly) ′Cardiac arrhythmia′] NM_000238.3 199473008 KCNH2 [′Congenital long (KCNH2):c.2591A>G QT syndrome′] (p.Asp864Gly) NM_000238.3 199473024 KCNH2 [ ] [′CTGCYCTCCACG [′Sudden infant (KCNH2):c.3118A>G TCGCCCCGGGG′, death syndrome′] (p.Ser1040Gly) ′CCTGCYCTCCAC GTCGCCCCGGG′, ′GCCTGCYCTCCA CGTCGCCCCGG′] NM_000238.3 199473029 KCNH2 [′Congenital long (KCNH2):c.3233A>G QT syndrome′] (p.Tyr1078Cys) NM_000335.4 199473057 SCN5A [′Congenital long (SCN5A):c.343A>G QT syndrome′] (p.Ser115Gly) m.827A>G 28358569 MT-RNR1 [ ] [ ] [′Aminoglycoside- induced deafness′, ′Deafness, nonsyndromic sensorineural, mitochondrial′] NM_000335.4 199473074 SCN5A [′ATAYAGT [′ATAYAGTTTTCA [′Brugada (SCN5A):c.688A>G TTTCAGGG GGGCCCGGAGG′, syndrome′] (p.Ile230Val) CCCGGAGG′, ′CTGATAYAGTTT ′CTGATAY TCAGGGCCCGG′] AGTTTTCA GGGCCCGG′] NM_000335.4 199473075 SCN5A [′Congenital long (SCN5A):c.715A>G QT syndrome′] (p.Ile239Val) NM_000252.2 587783838 MTM1 [ ] [ ] [′Severe X-linked (MTM1):c.575A>G myotubular (p.Tyr192Cys) myopathy′] NM_004572.3 763639737 PKP2 [ ] [ ] [′not provided′] (PKP2):c.275T>A (p.Leu92Ter) NM_000335.4 199473117 SCN5A [′Brugada (SCN5A):c.1502A>G syndrome′] (p.Asp501Gly) NM_000335.4 199473152 SCN5A [′Congenital long (SCN5A):c.2249A>G QT syndrome′] (p.Gln750Arg) NM_198056.2 199473165 SCN5A [′Congenital long (SCN5A):c.2527A>G QT syndrome′, ′not (p.Thr843Ala) provided′] NM_001165963.1 796052973 SCN1A [ ] [ ] [′not provided′] (SCN1A):c.1277A>G (p.Tyr426Cys) NM_000335.4 199473214 SCN5A [′Brugada (SCN5A):c.3755A>G syndrome′] (p.Glu1252Gly) NM_198056.2 199473226 SCN5A [ ] [ ] [′Congenital long (SCN5A):c.4000A>G QT syndrome′, ′not (p.Ile1334Val) provided′] NM_000335.4 199473242 SCN5A [′Brugada (SCN5A):c.4252A>G syndrome′] (p.Lys1418Glu) NM_000335.4 199473245 SCN5A [′Brugada (SCN5A):c.4291A>G syndrome′] (p.Arg1431Gly) NM_000335.4 199473255 SCN5A [′Congenital long (SCN5A):c.4412A>G QT syndrome′] (p.Asn1471Ser) NM_198056.2 199473260 SCN5A [ ] [ ] [′Atrial fibrillation′, (SCN5A):c.4478A>G ′Congenital long QT (p.Lys1493Arg) syndrome′, ′not provided′] NM_000335.4 199473264 SCN5A [′Congenital long (SCN5A):c.4489A>G QT syndrome′] (p.Met1497Val) NM_000335.4 199473270 SCN5A [′Brugada (SCN5A):c.4577A>G syndrome′] (p.Lys1526Arg) NM_000335.4 199473299 SCN5A [′Brugada (SCN5A):c.5161A>G syndrome′] (p.Asn1721Asp) NM_198056.2 199473311 SCN5A [′Congenital long (SCN5A):c.5302A>G QT syndrome′, ′not (p.Ile1768Val) provided′] NM_000335.4 199473313 SCN5A [′Brugada (SCN5A):c.5318A>G syndrome′] (p.Asn1773Ser) NM_000335.4 199473317 SCN5A [′Congenital long (SCN5A):c.5366A>G QT syndrome′] (p.Asp1789Gly) NM_000335.4 199473318 SCN5A [′Congenital long (SCN5A):c.5402A>G QT syndrome′] (p.Asp1801Gly) NM_000335.4 199473321 SCN5A [′Congenital long (SCN5A):c.5513A>G QT syndrome′] (p.Asp1838Gly) NM_198056.2 199473326 SCN5A [′Congenital long (SCN5A):c.5726A>G QT syndrome′, ′not (p.Gln1909Arg) provided′] NM_172201.1 199473366 KCNE2 [′Atrial fibrillation′] (KCNE2):c.269A>G (p.Glu90Gly) NM_000891.2 199473370 KCNJ2 [′Congenital long (KCNJ2):c.223A>G QT syndrome′] (p.Thr75Ala) NM_000891.2 199473371 KCNJ2 [′Andersen Tawil (KCNJ2):c.233A>G syndrome′, (p.Asp78Gly) ′Congenital long QT syndrome′] NM_000891.2 199473382 KCNJ2 [′Congenital long (KCNJ2):c.574A>G QT syndrome′] (p.Thr192Ala) NM_000218.2 199473396 KCNQ1 [′Congenital long (KCNQ1):c.548A>G QT syndrome′] (p.Lys183Arg) NM_000218.2 199473404 KCNQ1 [′Congenital long (KCNQ1):c.1061A>G QT syndrome′] (p.Lys354Arg) NM_000218.2 199473405 KCNQ1 [′Congenital long (KCNQ1):c.1070A>G QT syndrome′, (p.Gln357Arg) ′Cardiac arrhythmia′, ′Long QT syndrome, LQT1 subtype′] NM_000218.2 199473406 KCNQ1 [ ] [ ] [′Congenital long (KCNQ1):c.1078A>G QT syndrome′] (p.Arg360Gly) NM_000238.3 199473419 KCNH2 [′Congenital long (KCNH2):c.209A>G QT syndrome′, (p.His70Arg) ′Cardiac arrhythmia′] NM_000238.3 199473424 KCNH2 [′Congenital long (KCNH2):c.1724A>G QT syndrome′] (p.Glu575Gly) NM_000238.3 199473427 KCNH2 [′Congenital long (KCNH2):c.1747A>G QT syndrome′] (p.Ile583Val) NM_000238.3 199473431 KCNH2 [′Congenital long (KCNH2):c.1762A>G QT syndrome′] (p.Asn588Asp) NM_000218.2 199473451 KCNQ1 [′Congenital long (KCNQ1):c.430A>G QT syndrome′] (p.Thr144Ala) NM_000218.2 199473469 KCNQ1 [′Congenital long (KCNQ1):c.931A>G QT syndrome′] (p.Thr311Ala) NM_000238.3 199473496 KCNH2 [′Congenital long (KCNH2):c.286A>G QT syndrome′] (p.Ile96Val) NM_000238.3 199473506 KCNH2 [′Congenital long (KCNH2):c.1205A>G QT syndrome′] (p.His402Arg) NM_000238.3 199473507 KCNH2 [′Congenital long (KCNH2):c.1259A>G QT syndrome′] (p.Tyr420Cys) NM_000238.3 199473513 KCNH2 [′Congenital long (KCNH2):c.1502A>G QT syndrome′, (p.Asp501Gly) ′Cardiac arrhythmia′] NM_000238.3 199473528 KCNH2 [′Congenital long (KCNH2):c.1912A>G QT syndrome′] (p.Lys638Glu) NM_000238.3 199473532 KCNH2 [ ] [ ] [′Long QT (KCNH2):c.2131A>G syndrome′, (p.Ile711Val) ′Congenital long QT syndrome′, ′Cardiac arrhythmia′] NM_000238.3 199473534 KCNH2 [′Acquired long QT (KCNH2):c.2266A>G syndrome′] (p.Met756Val) NM_000238.3 199473546 KCNH2 [′Congenital long (KCNH2):c.3343A>G QT syndrome′, (p.Met1115Val) ′Cardiac arrhythmia′] NM_000335.4 199473551 SCN5A [′Congenital long (SCN5A):c.89A>G QT syndrome′] (p.Glu30Gly) NM_000335.4 199473568 SCN5A [′Brugada (SCN5A):c.1217A>G syndrome′] (p.Asn406Ser) NM_000249.3 267607794 MLH1 [ ] [ ] [′Hereditary (MLH1):c.791-2A>G Nonpolyposis Colorectal Neoplasms′, ′Hereditary cancer- predisposing syndrome′] NM_000335.4 199473589 SCN5A [′Brugada (SCN5A):c.2780A>G syndrome′] (p.Asn927Ser) NM_000335.4 199473593 SCN5A [′Brugada (SCN5A):c.3164A>G syndrome′] (p.Asp1055Gly) NM_000335.4 199473610 SCN5A [′Brugada (SCN5A):c.4223A>G syndrome′] (p.Tyr1408Cys) NM_198056.2 199473613 SCN5A [′Brugada (SCN5A):c.4346A>G syndrome′, ′not (p.Tyr1449Cys) provided′] NM_198056.2 199473625 SCN5A [′CGAYGTT [′CGAYGTTGAAG [′Brugada (SCN5A):c.4978A>G GAAGAGG AGGGCAGGCAGG′, syndrome′, ′not (p.Ile1660Val) GCAGGCAG ′AGCCCGAYGTTG provided′] G′] AAGAGGGCAGG′] NM_000335.4 199473628 SCN5A [′Brugada (SCN5A):c.5138A>G syndrome′] (p.Asp1713Gly) NM_000335.4 199473632 SCN5A [′Congenital long (SCN5A):c.5297A>G QT syndrome′] (p.Tyr1766Cys) NM_000335.4 199473633 SCN5A [′Congenital long (SCN5A):c.5317A>G QT syndrome′] (p.Asn1773Asp) NM_000531.5 72556283 OTC [′TGAGGYA [′TGAGGYAATCA [′not provided′] (OTC):c.527A>G ATCAGCCA GCCAGGATCTGG′] (p.Tyr176Cys) GGATCTGG′] NM_001130823.1 199473690 DNMT1 [′Hereditary sensory (DNMT1):c.1532A>G neuropathy type IE′] (p.Tyr511Cys) NM_000303.2 80338704 PMM2 [ ] [ ] [′Carbohydrate- (PMM2):c.563A>G deficient (p.Asp188Gly) glycoprotein syndrome type I′, ′not provided′] NM_000051.3 28942103 — [ ] [ ] [′Ataxia- (ATM):c.8030A>G telangiectasia (p.Tyr2677Cys) variant′] NM_175053.3 147962513 KRT74 [ ] [ ] [″Ectodermal (KRT74):c.821T>C dysplasia, ′pure′ (p.Phe274Ser) hair-nail type″, ′Ectodermal dysplasia 7, hair/nail type′] NM_000059.3 398122779 BRCA2 [ ] [ ] [′Familial cancer of (BRCA2):c.426-2A>G breast′, ′Breast- ovarian cancer, familial 2′] NM_133433.3 587783974 NIPBL [ ] [ ] [′Cornelia de Lange (NIPBL):c.5428-2A>G syndrome 1′] NM_000238.3 794728365 KCNH2 [ ] [′GGACCYGCACC [′Cardiac (KCNH2):c.1129-2A>G CGGGGAAGGCGG′] arrhythmia′] NM_000260.3 111033175 MYO7A [ ] [ ] [′Usher syndrome, (MYO7A):c.6029A>G type 1′] (p.Asp2010Gly) NM_000531.5 72556293 OTC [ ] [′AGAGCTAYAGT [′not provided′] (OTC):c.548A>G GTTCCTAAAAGG′] (p.Tyr183Cys) NM_000441.1 111033244 SLC26A4 [ ] [′TGAATYCCTAAG [′Pendred syndrome′, (SLC26A4):c.1151A>G GAAGAGACTGG′] ′Enlarged vestibular (p.Glu384Gly) aqueduct syndrome′] NM_004004.5 111033294 GJB2 [ ] [ ] [′Deafness, (GJB2):c.617A>G autosomal recessive (p.Asn206Ser) 1A′, ′Hearing impairment′] NM_000441.1 111033313 SLC26A4 [ ] [ ] [′Pendred syndrome′, (SLC26A4):c.919-2A>G ′Enlarged vestibular aqueduct syndrome′] NM_001363.4 121912296 DKC1 [ ] [ ] [′Dyskeratosis (DKC1):c.115A>G congenita X-linked′] (p.Lys39Glu) NM_001363.4 121912297 DKC1 [ ] [ ] [′Dyskeratosis (DKC1):c.196A>G congenita X-linked′] (p.Thr66Ala) NM_001363.4 121912305 DKC1 [ ] [ ] [′Dyskeratosis (DKC1):c.361A>G congenita X-linked′, (p.Ser121Gly) ′Hoyeraal Hreidarsson syndrome′] NM_178151.2 587783552 DCX [ ] [ ] [′Heterotopia′] (DCX):c.413A>G (p.Tyr138Cys) NM_024675.3 730881879 PALB2 [ ] [ ] [′Hereditary cancer- (PALB2):c.212-2A>G predisposing syndrome′] NM_000260.3 111033415 MYO7A [ ] [′AGCYGCAGGGG [′Usher syndrome, (MYO7A):c.1344-2A>G CACAGGGATGGG′, type 1′] ′AAGCYGCAGGGG CACAGGGATGG′] NM_000454.4 121912435 SOD1 [ ] [ ] [′Amyotrophic (SOD1):c.131A>G lateral sclerosis type (p.His44Arg) 1′] NM_000454.4 121912439 SOD1 [ ] [′AGAATCTYCAAT [′Amyotrophic (SOD1):c.302A>G AGACACATCGG′] lateral sclerosis type (p.Glu101Gly) 1′] NM_000454.4 121912443 SOD1 [ ] [ ] [′Amyotrophic (SOD1):c.140A>G lateral sclerosis type (p.His47Arg) 1′] NM_133433.3 587784042 NIPBL [ ] [ ] [′Cornelia de Lange (NIPBL):c.737A>G syndrome 1′] (p.Asp246Gly) NM_000454.4(SOD1): 121912458 SOD1 [ ] [ ] [′Amyotrophic c.242A>G lateral sclerosis type (p.His81Arg) 1′] NM_001754.4 121912498 RUNX1 [ ] [ ] [′Familial platelet (RUNX1):c.328A>G disorder with (p.Lys110Glu) associated myeloid malignancy′] NM_000238.3 121912505 KCNH2 [ ] [ ] [′Long QT syndrome (KCNH2):c.1408A>G 2′, ′Congenital long (p.Asn470Asp) QT syndrome′] NM_000233.3 121912518 — [ ] [ ] [′Gonadotropin- (LHCGR):c.1733A>G independent familial (p.Asp578Gly) sexual precocity′] NM_000493.3 111033554 — [ ] [ ] [′Metaphyseal (COL10A1):c.1790A>G chondrodysplasia, (p.Tyr597Cys) Schmid type′] NM_000233.3 121912540 — [ ] [ ] [′Gonadotropin- (LHCGR):c.1691A>G independent familial (p.Asp564Gly) sexual precocity′] NM_002769.4 111033567 — [ ] [′ATCYTGTCATCA [′Hereditary (PRSS1):c.68A>G TCATCAAAGGG′, pancreatitis′] (p.Lys23Arg) ′GATCYTGTCATC ATCATCAAAGG′] NM_004999.3 121912560 MYO6 [ ] [ ] [′Sensorineural (MYO6):c.737A>G deafness with (p.His246Arg) hypertrophic cardiomyopathy′] NM_000901.4 121912565 NR3C2 [ ] [′TCATCYGTTTGC [′Pseudohypoaldosteronism (NR3C2):c.2327A>G CTGCTAAGCGG′] type 1 (p.Gln776Arg) autosomal dominant′] NM_000901.4 121912574 NR3C2 [ ] [′CCGACYCCACCT [′Pseudohypo- (NR3C2):c.2915A>G TGGGCAGCTGG′] aldosteronism type 1 (p.Glu972Gly) autosomal dominant′] NM_001173464.1 121912589 KIF21A [ ] [′ATTCAYATCTGC [′Fibrosis of (KIF21A):c.2839A>G CTCCATGTTGG′] extraocular muscles, (p.Met947Val) congenital, 1′] NM_000155.3 111033635 GALT [ ] [ ] [′Deficiency of (GALT):c.67A>G UDPglucose- (p.Thr23Ala) hexose-1-phosphate uridylyltransferase′] NM_001041.3 121912612 SI [ ] [ ] [′Sucrase-isomaltase (SI):c.350A>G deficiency′] (p.Gln117Arg) NM_000155.3 111033639 GALT [ ] [ ] [′Deficiency of (GALT):c.1A>G UDPglucose- (p.Met1Val) hexose-1-phosphate uridylyltransferase′] NM_021625.4 121912634 TRPV4 [ ] [ ] [′Spondylometaphyseal (TRPV4):c.998A>G dysplasia, (p.Asp333Gly) Kozlowski type′] NM_000155.3 111033661 GALT [ ] [′ATTCACCYACCG [′Deficiency of (GALT):c.253-2A>G ACAAGGATAGG′] UDPglucose- hexose-1-phosphate uridylyltransferase′, ′not provided′] NM_000155.3 111033669 GALT [ ] [′GAAGTCGYTGTC [′Deficiency of (GALT):c.290A>G AAACAGGAAGG′] UDPglucose- (p.Asn97Ser) hexose-1-phosphate uridylyltransferase′] NM_000155.3 111033682 GALT [ ] [′TGACCTYACTGG [′Deficiency of (GALT):c.379A>G GTGGTGACGGG′, UDPglucose- (p.Lys127Glu) ′ATGACCTYACTG hexose-1-phosphate GGTGGTGACGG′] uridylyltransferase′] NM_000343.3 121912669 SLC5A1 [ ] [ ] [′Congenital (SLC5A1):c.83A>G glucose-galactose (p.Asp28Gly) malabsorption′] NM_005159.4 121912674 — [ ] [ ] [′Dilated (ACTC1):c.1088A>G cardiomyopathy 1R′] (p.Glu363Gly) NM_005159.4 121912677 — [ ] [ ] [′Atrial septal defect (ACTC1):c.373A>G 5′] (p.Met125Val) NM_000155.3 111033731 GALT [ ] [ ] [′Deficiency of (GALT):c.565-2A>G UDPglucose- hexose-1-phosphate uridylyltransferase′] NM_001681.3 121912732 ATP2A2 [ ] [ ] [′Darier disease, (ATP2A2):c.2300A>G acral hemorrhagic (p.Asn767Ser) type′] NM_000155.3 111033767 GALT [ ] [ ] [′Deficiency of (GALT):c.821-2A>G UDPglucose- hexose-1-phosphate uridylyltransferase′] NM_000342.3 121912750 SLC4A1 [ ] [ ] [′Spherocytosis type (SLC4A1):c.2509A>G 4′] (p.Thr837Ala) NM_000155.3 111033786 GALT [ ] [′CAGCYGCCAAT [′Deficiency of (GALT):c.950A>G GGTTCCAGTTGG′] UDPglucose- (p.Gln317Arg) hexose-1-phosphate uridylyltransferase′] NM_001202.3 121912765 BMP4 [ ] [′CCTCCYCCCCAG [′Microphthalmia (BMP4):c.278A>G ACTGAAGCCGG′] syndromic 6′] (p.Glu93Gly) NM_000155.3 111033809 GALT [ ] [ ] [′Deficiency of (GALT):c.1001A>G UDPglucose- (p.Lys334Arg) hexose-1-phosphate uridylyltransferase′] NM_000155.3 111033817 GALT [ ] [ ] [′Deficiency of (GALT):c.1048A>G UDPglucose- (p.Thr350Ala) hexose-1-phosphate uridylyltransferase′] NM_000155.3 111033819 GALT [ ] [ ] [′Deficiency of (GALT):c.1132A>G UDPglucose- (p.Ile378Val) hexose-1-phosphate uridylyltransferase′] m.3243A>G 199474657 MT-TL1 [ ] [ ] [′Leigh disease′, ′Cyclical vomiting syndrome′, ′Juvenile myopathy, encephalopathy, lactic acidosis AND stroke′, ′Myoclonus with epilepsy with ragged red fibers′, ′Cytochrome-c oxidase deficiency′, ′Diabetes-deafness syndrome maternally transmitted′, ′3- Methylglutaconic aciduria′, ′Age- related macular degeneration 2′, ′MERRF/MELAS overlap syndrome′] m.3252A>G 199474661 MT-TL1 [ ] [ ] [′Mitochondrial encephalomyopathy′] m.3251A>G 199474662 MT-TL1 [ ] [ ] [ ] NM_000258.2 199474708 MYL3 [ ] [ ] [′Cardiomyopathy′, (MYL3):c.517A>G ′not specified′, ′not (p.Met173Val) provided′] NM_000094.3 121912856 COL7A1 [ ] [′CACCYTGGGGA [′Epidermolysis (COL7A1):c.425A>G CACCAGGTCGGG′, bullosa dystrophica (p.Lys142Arg) ′TCACCYTGGGGA inversa, autosomal CACCAGGTCGG′] recessive′] NM_152263.3 199474715 TPM3 [ ] [′CCAACTYACGA [′Congenital (TPM3):c.505A>G GCCACCTACAGG′] myopathy with fiber (p.Lys169Glu) type disproportion′, ′not provided′] NM_152263.3 199474718 TPM3 [ ] [′ATCYCTCAGCAA [′Congenital (TPM3):c.733A>G ACTCAGCACGG′] myopathy with fiber (p.Arg245Gly) type disproportion′, ′not provided′] NM_001844.4 121912889 COL2A1 [′GCAGTGG [′GCAGTGGYAGG [Spondyloperipheral (COL2A1):c.4172A>G YAGGTGAT TGATGTTCTGGG′] dysplasia′, (p.Tyr1391Cys) GTTCTGGG′] ′Platyspondylic lethal skeletal dysplasia Torrance type′] NM_001844.4 121912895 COL2A1 [ ] [′CCTCYCTCACCA [′Spondyloepimeta- (COL2A1):c.2974A>G CGTTGCCCAGG′] physeal dysplasia (p.Arg992Gly) Strudwick type′] NM_001848.2 121912936 COL6A1 [ ] [ ] [Ullrich congenital (COL6A1):c.362A>G muscular dystrophy′, (p.Lys121Arg) ′Bethlem myopathy′, ′not provided′] NM_004004.5 121912968 GJB2 [ ] [ ] [′Keratoderma (GJB2):c.218A>G palmoplantar (p.His73Arg) deafness′] NM_000941.2 121912975 POR [ ] [ ] [′Antley-Bixler (POR):c.1733A>G syndrome with (p.Tyr578Cys) genital anomalies and disordered steroidogenesis′] NM_001943.3 121913011 DSG2 [ ] [ ] [′Arrhythmogenic (DSG2):c.797A>G right ventricular (p.Asn266Ser) cardiomyopathy, type 10′] NM_000129.3 121913074 F13A1 [ ] [′ATAGGCAYAGA [′Factor xiii, a (F13A1):c.851A>G TATTGTCCCAGG′] subunit, deficiency (p.Tyr284Cys) of′] NM_000043.4 121913079 FAS [ ] [ ] [′Autoimmune (FAS):c.695A>G lymphoproliferative (p.Tyr232Cys) syndrome, type 1a′] NM_000043.4 121913082 FAS [ ] [ ] [ ] (FAS):c.763A>G (p.Asn255Asp) NM_000043.4 121913083 FAS [ ] [ ] [ ] (FAS):c.353A>G (p.Asn118Ser) NM_206933.2 80338904 USH2A [ ] [ ] [′Retinitis (USH2A):c.14020A>G pigmentosa′, (p.Arg4674Gly) ′Retinitis pigmentosa 39′] NM_000142.4 121913115 FGFR3 [ ] [ ] [′Hypochondroplasia′] (FGFR3):c.833A>G (p.Tyr278Cys) NM_000183.2 121913131 HADHB [ ] [ ] [′Mitochondrial (HADHB):c.788A>G trifunctional protein (p.Asp263Gly) deficiency′] NM_001079817.1 121913136 INSR [ ] [ ] [′Leprechaunism (INSR):c.1459A>G syndrome′] (p.Lys487Glu) NM_000208.2 121913145 INSR [ ] [′GCTGYGGCAAC [′Leprechaunism (INSR):c.707A>G AGAGGCCTTCGG′] syndrome′] (p.His236Arg) NM_000208.2 121913147 INSR [ ] [ ] [′Insulin-resistant (INSR):c.1466A>G diabetes mellitus (p.Asn489Ser) AND acanthosis nigricans′] NM_000208.2 121913160 INSR [ ] [ ] [′Leprechaunism (INSR):c.1372A>G syndrome′] (p.Asn458Asp) NM_000016.5 201375579 ACADM [ ] [ ] [′not provided′] (ACADM):c.797A>G (p.Asp266Gly) NM_024577.3 80338920 SH3TC2 [ ] [ ] [′Charcot-Marie- (SH3TC2):c.530-2A>G Tooth disease, type 4C′] NM_001127500.1 121913246 MET [ ] [ ] [′Renal cell (MET):c.3743A>G carcinoma, (p.Tyr1248Cys) papillary, 1′] NM_000517.4 63750067 HBA2 [′ACTTYAT [′CTTYATTCAAAG [′Hemoglobin H (HBA2):c.*92A>G TCAAAGAC ACCAGGAAGGG′, disease, CAGGAAG ′ACTTYATTCAAA nondeletional′] G′] GACCAGGAAGG′] NM_199440.1 72466451 HSPD1 [ ] [ ] [′Leukodystrophy, (HSPD1):c.86A>G hypomyelinating, 4′] (p.Asp29Gly) NM_000249.3 63750211 MLH1 [ ] [ ] [′Hereditary (MLH1):c.544A>G Nonpolyposis (p.Arg182Gly) Colorectal Neoplasms′] NM_025137.3 312262726 SPG11 [ ] [ ] [′Spastic paraplegia (SPG11):c.1457-2A>G 11, autosomal recessive′] NM_025137.3 312262745 SPG11 [ ] [′ACTTAYCCTGGG [′Spastic paraplegia (SPG11):c.2608A>G GAGAAGGATGG′] 11, autosomal (p.Ile870Val) recessive′] NM_025137.3 312262748 SPG11 [ ] [ ] [′Spastic paraplegia (SPG11):c.2833A>G 11, autosomal (p.Arg945Gly) recessive′] NM_003867.3 398123026 FGF17 [′CGTGGYT [′CGTGGYTGGGG [′Hypogonadotropic (FGF17):c.560A>G GGGGAAG AAGGGCAGCTGG′] hypogonadism 20 (p.Asn187Ser) GGCAGCTG with or without G′] anosmia′] NM_025137.3 312262780 SPG11 [ ] [ ] [′Spastic paraplegia (SPG11):c.6477+4A>G 11, autosomal recessive′] NM_000141.4 121913478 FGFR2 [ ] [ ] [′Cutis Gyrata (FGFR2):c.1124A>G syndrome of Beare (p.Tyr375Cys) and Stevenson′, ′Endometrial carcinoma′] NM_000142.4 121913485 FGFR3 [ ] [ ] [′Thanatophoric (FGFR3):c.1118A>G dysplasia type 1′] (p.Tyr373Cys) NM_003611.2 312262820 OFD1 [ ] [ ] [′Oral-facial-digital (OFD1):c.290A>G syndrome′] (p.Glu97Gly) NM_000222.2 121913512 KIT [′GACTTYG [′GACTTYGAGTTC [ ] (KIT):c.1924A>G AGTTCAGA AGACATGAGGG′, (p.Lys642Glu) CATGAGGG′] ′GGACTTYGAGTT CAGACATGAGG′] NM_003611.2 312262829 OFD1 [ ] [ ] [′Oral-facial-digital (OFD1):c.382-2A>G syndrome′] NM_000391.3 119455958 TPP1 [ ] [ ] [′Ceroid (TPP1):c.857A>G lipofuscinosis, (p.Asn286Ser) neuronal, 2′] NM_005912.2 121913560 MC4R [ ] [ ] [′Obesity′] (MC4R):c.508A>G (p.Ile170Val) NM_005912.2 121913561 MC4R [ ] [ ] [′Obesity′] (MC4R):c.821A>G (p.Asn274Ser) NM_005912.2 121913565 MC4R [ ] [ ] [′Obesity′] (MC4R):c.289A>G (p.Asn97Asp) NM_005912.2 121913566 MC4R [ ] [ ] [′Obesity′] (MC4R):c.185A>G (p.Asn62Ser) NM_000530.6 121913583 MPZ [ ] [ ] [′Charcot-Marie- (MPZ):c.286A>G Tooth disease type (p.Lys96Glu) 1B′] NM_000095.2 312262901 COMP [ ] [ ] [′Pseudoachondro- (COMP):c.1760A>G plastic (p.His587Arg) spondyloepiphyseal dysplasia syndrome′] NM_000530.6 121913594 MPZ [′GGCATAG [′GGCATAGYGGA [′Charcot-Marie- (MPZ):c.242A>G YGGAAGAT AGATCTATGAGG′] Tooth disease type (p.His81Arg) CTATGAGG′] 1B′] NM_000484.3 63750399 APP [ ] [ ] [′Alzheimer disease, (APP):c.2146A>G type 1′, ′not (p.Ile716Val) provided′] NM_000329.2 62636300 RPE65 [ ] [ ] [′Leber congenital (RPE65):c.1292A>G amaurosis 2′, ′not (p.Tyr431Cys) provided′] NM_002470.3 121913622 MYH3 [ ] [ ] [′Distal (MYH3):c.1385A>G arthrogryposis type (p.Asp462Gly) 2B′] NM_000257.3 121913634 MYH7 [ ] [ ] [′Familial (MYH7):c.2333A>G hypertrophic (p.Asp778Gly) cardiomyopathy 1′, ′not specified′] NM_001127500.1 121913677 MET [ ] [ ] [′Childhood (MET):c.3785A>G hepatocellular (p.Lys1262Arg) carcinoma′] NM_000222.2 121913682 KIT [ ] [′AGAAYCATTCTT [′Mast cell disease, (KIT):c.2459A>G GATGTCTCTGG′] systemic′] (p.Asp820Gly) NM_000222.2 121913684 KIT [ ] [ ] [ ] (KIT):c.2386A>G (p.Arg796Gly) NM_006005.3 398123066 WFS1 [ ] [ ] [′Cataract, nuclear (WFS1):c.1385A>G total′] (p.Glu462Gly) NM_000495.4 587776400 COL4A5 [ ] [ ] [′Alport syndrome, (COL4A5):c.3925-2A>G X-linked recessive′] NC_012920.1: 587776440 MT-NDS [ ] [ ] [′Leigh disease′] m.13514A>G NM_000021.3 63750590 PSEN1 [ ] [ ] [′Alzheimer disease, (PSEN1):c.488A>G type 3′, ′not (p.His163Arg) provided′] NM_000484.3 63750643 APP [ ] [ ] [′Alzheimer disease, (APP):c.2140A>G type 1′, ′not (p.Thr714Ala) provided′] NM_173560.3 587776515 RFX6 [ ] [ ] [′Mitchell-Riley (RFX6):c.224-12A>G syndrome′] NM_014043.3 63750818 CHMP2B [ ] [ ] [′Frontotemporal (CHMP2B):c.85A>G Dementia, (p.Ile29Val) Chromosome 3- Linked′, ′Amyotrophic lateral sclerosis 17′, ′not provided′] NM_000057.3 367543015 BLM [ ] [ ] [′Bloom syndrome′] (BLM):c.1088-2A>G NM_001011658.3 587776753 — [ ] [ ] [′Spondyloepiphyseal (TRAPPC2):c.238+4T>C dysplasia tarda′] NM_000151.3 587776757 G6PC [ ] [′GTTCYTACCACT [′Glycogen storage (G6PC):c.230+4A>G TAAAGACGAGG′] disease type 1A′] NM_000463.2 587776766 — [′ACCYGAG [′ACCYGAGATGC [′Crigler Najjar (UGT1A1):c.1085-2A>G ATGCAAAA AAAATAGGGAGG′, syndrome, type 1′] TAGGGAGG′] ′GTGACCYGAGAT GCAAAATAGGG′, ′GGTGACCYGAGA TGCAAAATAGG′] NM_000330.3 61752063 — [ ] [′TTCTTCGYGGAC [′Juvenile (RS1):c.286T>C TGCAAACAAGG′] retinoschisis′, ′not (p.Trp96Arg) provided′] NM_001024847.2 587776770 TGFBR2 [ ] [ ] [′Loeys-Dietz (TGFBR2):c.1472-2A>G syndrome 2′] NM_000257.3 367543053 MYH7 [ ] [ ] [′Congenital (MYH7):c.5807A>G myopathy with fiber (p.Ter1936Trp) type disproportion′] NM_000321.2 587776791 RB1 [ ] [ ] [′Retinoblastoma′] (RB1):c.2490-1398A>G NM_024549.5 367543065 TCTN1 [ ] [′AGCAACYGCAG [′Joubert syndrome (TCTN1):c.221-2A>G AAAAAAGAGGGG′, 13′] ′CAGCAACYGCAG AAAAAAGAGGG′] NM_000228.2 587776813 LAMB3 [ ] [ ] [′Adult junctional (LAMB3):c.565-3T>C epidermolysis bullosa′] NM_015884.3 587776867 MBTPS2 [ ] [ ] [′Keratosis pilaris (MBTPS2):c.1523A>G decalvans′] (p.Asn508Ser) NM_000174.4 5030764 GP9 [′GGCTGYT [′GGCTGYTGTTGG [′Bernard-Soulier (GP9):c.182A>G GTTGGCCA CCAGCAGAAGG′] syndrome type C′] (p.Asn61Ser) GCAGAAG G′] NM_000894.2 5030773 LHB [ ] [′CCACCYGAGGC [′Isolated lutropin (LHB):c.221A>G AGGGGCGGCAGG′] deficiency′] (p.Gln74Arg) NM_000264.3 199476092 — [ ] [′CGTTACYGAAAC [′Gorlin syndrome′, (PTCH1):c.2479A>G TCCTGTGTAGG′] ′Holoprosencephaly (p.Ser827Gly) 7′, ′not specified′, ′not provided′] NM_000021.3 63751037 PSEN1 [ ] [ ] [′Alzheimer disease, (PSEN1):c.415A>G type 3′, ′not (p.Met139Val) provided′] NM_000484.3 63751039 APP [ ] [ ] [′Alzheimer disease′, (APP):c.2078A>G ′Alzheimer disease, (p.Glu693Gly) type 1′, ′Cerebral amyloid angiopathy, APP-related′, ′not provided′] NM_000117.2 398123158 EMD [ ] [′CGTTCCCYGAGG [′not provided′] (EMD):c.450-2A>G CAAAAGAGGGG′] RMRP:n.71A>G 199476103 RMRP [ ] [′ACTTYCCCCTAG [′Metaphyseal GCGGAAAGGGG′, chondrodysplasia, ′GACTTYCCCCTA McKusick type′, GGCGGAAAGGG′, ′Metaphyseal ′GGACTTYCCCCT dysplasia without AGGCGGAAAGG′] hypotrichosis′] m.14495A>G 199476106 MT-ND6 [ ] [ ] [′Leber optic atrophy′] m.11084A>G 199476113 MT-ND4 [ ] [ ] [′Juvenile myopathy, encephalopathy, lactic acidosis AND stroke′] NM_000551.3 5030804 VHL [′TGCGAYT [′GCGAYTGCAGA [′Von Hippel-Lindau (VHL):c.233A>G GCAGAAG AGATGACCTGGG′, syndrome′] (p.Asn78Ser) ATGACCTG ′TGCGAYTGCAGA G′] AGATGACCTGG′] m.3397A>G 199476120 MT-ND1 [ ] [ ] [′Alzheimer disease′, ′Parkinson disease, late-onset′] m.4136A>G 199476121 MT-ND1 [ ] [ ] [′Leber optic atrophy′] NM_003094.3 587776924 SNRPE [ ] [ ] [′Hypotrichosis 11′] (SNRPE):c.1A>G (p.Met1Val) NM_001310338.1 587776944 MGME1 [ ] [ ] [′Mitochondrial (MGME1):c.743A>G DNA depletion (p.Tyr248Cys) syndrome 11′] NM_000249.3 63751094 MLH1 [ ] [ ] [′Hereditary (MLH1):c.122A>G Nonpolyposis (p.Asp41Gly) Colorectal Neoplasms′] NM_138425.3 587776954 C12orf57 [ ] [ ] [′Temtamy (C12orf57):c.1A>G syndrome′, (p.Met1Val) ′Seizures′, ′Corpus callosum abnormalities′, ′Colobomatous microphthalmia′, ′Global developmental delay′] NM_000277.1 5030856 PAH [ ] [′CTCYCTGCCACG [′Phenylketonuria′, (PAH):c.1169A>G TAATACAGGGG′, ′Hyperphenylalaninemia, (p.Glu390Gly) ′ACTCYCTGCCAC non-pku′, ′not GTAATACAGGG′, provided′] ′AACTCYCTGCCA CGTAATACAGG′] NM_000277.1 5030860 PAH [ ] [′GGGTCGYAGCG [′Phenylketonuria′, (PAH):c.1241A>G AACTGAGAAGGG′, ′Hyperphenylalaninemia, (p.Tyr414Cys) ′TGGGTCGYAGCG non-pku′, ′not AACTGAGAAGG′] provided′] NM_000155.3 367543252 GALT [ ] [ ] [′Deficiency of (GALT):c.308A>G UDPglucose- (p.Gln103Arg) hexose-1-phosphate uridylyltransferase′] NM_207352.3 199476183 CYP4V2 [ ] [ ] [′Bietti crystalline (CYP4V2):c.1091-2A>G corneoretinal dystrophy′] NM_000518.4 63751128 HBB [ ] [ ] [ ] (HBB):c.*111A>G NM_000155.3 367543262 GALT [ ] [ ] [′Deficiency of (GALT):c.857A>G UDPglucose- (p.Tyr286Cys) hexose-1-phosphate uridylyltransferase′] NM_000155.3 367543263 GALT [ ] [ ] [′Deficiency of (GALT):c.854A>G UDPglucose- (p.Lys285Arg) hexose-1-phosphate uridylyltransferase′] NM_207352.3 199476193 CYP4V2 [ ] [ ] [′Bietti crystalline (CYP4V2):c.761A>G corneoretinal (p.His254Arg) dystrophy′] NM_000155.3 367543267 GALT [ ] [ ] [′Deficiency of (GALT):c.968A>G UDPglucose- (p.Tyr323Cys) hexose-1-phosphate uridylyltransferase′] NM_001142519.1 587777014 FAM111A [ ] [ ] [′Gracile bone (FAM111A):c.1012A>G dysplasia′] (p.Thr338Ala) NM_000132.3 137852419 F8 [′AACYAGA [′AACYAGAGTAA [′Hereditary factor (F8):c.1660A>G GTAATAGC TAGCGGGTCAGG′] VIII deficiency (p.Ser554Gly) GGGTCAGG′] disease′] NM_020988.2 587777055 GNAO1 [ ] [′GGATGYCCTGCT [′Early infantile (GNAO1):c.521A>G CGGTGGGCTGG′] epileptic (p.Asp174Gly) encephalopathy 17′] NM_000155.3 398123187 GALT [ ] [ ] [′Deficiency of (GALT):c.905-2A>G UDPglucose- hexose-1-phosphate uridylyltransferase′] NM_015662.2 587777080 IFT172 [ ] [ ] [ ] (IFT172):c.4607T>C (p.Leu1536Pro) NM_014754.2 587777088 PTDSS1 [ ] [ ] [Lenz-Majewski (PTDSS1):c.1058A>G hyperostosis (p.Gln353Arg) syndrome′] NM_003859.1 587777114 — [ ] [ ] [′Congenital disorder (DPM1):c.742T>C of glycosylation type (p.Ser248Pro) 1E′] NM_001018005.1 199476319 TPM1 [ ] [ ] [′Left ventricular (TPM1):c.742A>G noncompaction 9′, (p.Lys248Glu) ′not provided′] NM_004826.3 587777129 ECEL1 [ ] [ ] [′Arthrogryposis, (ECEL1):c.2278T>C distal, type 5d′] (p.Cys760Arg) NM_014908.3 587777137 DOLK [ ] [ ] [′Congenital disorder (DOLK):c.2T>C of glycosylation type (p.Met1Thr) 1M′] NM_000350.2 61752435 ABCA4 [ ] [ ] [′Stargardt disease (ABCA4):c.4540-2A>G 1′, ′not provided′] NM_001128085.1 63751297 — [ ] [ ] [′Spongy (ASPA):c.433-2A>G degeneration of central nervous system′] NM_176787.4 587777186 PIGN [ ] [ ] [′Multiple congenital (PIGN):c.808T>C anomalies- (p.Ser270Pro) hypotonia-seizures syndrome 1′] NM_001165899.1 587777188 PDE4D [′CTATAYT [′CTATAYTGTTCA [′Acrodysostosis 2, (PDE4D):c.1850T>C GTTCATCC TCCCCTCTGGG′, with or without (p.Ile617Thr) CCTCTGGG′, ′ACTATAYTGTTC hormone resistance′] ′ACTATAYT ATCCCCTCTGG′] GTTCATCC CCTCTGG′] NM_005017.3 587777195 PCYT1A [′GCATGYT [′GCATGYTTGCTC [′Spondylometaphyseal (PCYT1A):c.571T>C TGCTCCAA CAACACAGAGG′] dysplasia with (p.Phe191Leu) CACAGAGG′] cone-rod dystrophy′] NM_024301.4 587777223 FKRP [ ] [′CCGCAYGGGGC [′Congenital (FKRP):c.1A>G CGAAGTCTGGGG′, muscular dystrophy— (p.Met1Val) ′GCCGCAYGGGGC dystroglycanopathy CGAAGTCTGGG′, with brain and eye ′AGCCGCAYGGGG anomalies type A5′] CCGAAGTCTGG′] NM_198947.3 587777237 FAM111B [ ] [ ] [′Poikiloderma, (FAM111B):c.1879A>G hereditary fibrosing, (p.Arg627Gly) with tendon contractures, myopathy, and pulmonary fibrosis′] NM_003638.2 587777279 ITGA8 [ ] [ ] [′Renal adysplasia′] (ITGA8):c.2982+2T>C NM_199189.2 587777301 MATR3 [′CGGYTGA [′CGGYTGAACTCT [′Myopathy, distal, (MATR3):c.1864A>G ACTCTCAG CAGTCTTCTGG′] 2′] (p.Thr622Ala) TCTTCTGG′] NM_001739.1 587777316 CA5A [ ] [ ] [′Carbonic (CA5A):c.697T>C anhydrase VA (p.Ser233Pro) deficiency, hyperammonemia due to′] NM_005051.2 587777333 QARS [ ] [ ] [′Microcephaly, (QARS):c.169T>C progressive, with (p.Tyr57His) seizures and cerebral and cerebellar atrophy′] NM_002234.3 587777336 KCNA5 [ ] [ ] [′Atrial fibrillation, (KCNA5):c.143A>G familial, 7′] (p.Glu48Gly) NM_021803.3 587777338 IL21 [ ] [ ] [′Common variable (IL21):c.146T>C immunodeficiency (p.Leu49Pro) 11′] NM_000132.3 137852470 F8 [ ] [ ] [′Hereditary factor (F8):c.6794A>G VIII deficiency (p.Gln2265Arg) disease′] NM_178014.3 587777355 TUBB [ ] [ ] [′Cortical dysplasia, (TUBB):c.895A>G complex, with other (p.Met299Val) brain malformations 6′] NM_005957.4 768434408 MTHFR [ ] [ ] [′Homocysteinemia (MTHFR):c.1969T>C due to MTHFR (p.Ter657Arg) deficiency′] NM_005359.5 377767327 SMAD4 [ ] [ ] [′Juvenile polyposis (SMAD4):c.425-6A>G syndrome′] NM_022068.3 587777454 PIEZO2 [ ] [ ] [′Oculomelic (PIEZO2):c.8215T>C amyoplasia′] (p.Ser2739Pro) NM_003108.3 587777479 SOX11 [ ] [′GTACTTGYAGTC [′Mental retardation, (SOX11):c.347A>G GGGGTAGTCGG′] autosomal dominant (p.Tyr116Cys) 27′] NM_021072.3 587777493 HCN1 [ ] [ ] [′Epileptic (HCN1):c.814T>C encephalopathy, (p.Ser272Pro) early infantile, 24′] NM_020435.3 587777496 GJC2 [ ] [′TTGYTCCCCCCT [′Leukodystrophy, (GJC2):c.-170A>G CGGCCTCAGGG′, hypomyelinating, 2′] ′ATTGYTCCCCCCT CGGCCTCAGG′] NM_022552.4 587777507 DNMT3A [ ] [′CTCCYGGTGCTG [′Tatton-Brown- (DNMT3A):c.1943T>C AAGGACTTGGG′, rahman syndrome′] (p.Leu648Pro) ′GCTCCYGGTGCT GAAGGACTTGG′] NM_022552.4 587777510 DNMT3A [ ] [ ] [′Tatton-Brown- (DNMT3A):c.2705T>C rahman syndrome′] (p.Phe902Ser) NM_000223.3 58410481 KRT12 [ ] [ ] [′Meesman corneal (KRT12):c.403A>G dystrophy′, ′not (p.Arg135Gly) provided′] NM_000232.4 398123262 SGCB [ ] [ ] [′Limb-girdle (SGCB):c.1A>G muscular dystrophy, (p.Met1Val) type 2E′, ′not provided′] NM_020630.4 377767416 RET [ ] [ ] [′MEN2 phenotype: (RET):c.2342A>G Unclassified′] (p.Gln781Arg) NM_018400.3 587777557 SCN3B [ ] [′AATCAYGATGTA [′Atrial fibrillation, (SCN3B):c.482T>C CATCCTTCTGG′] familial, 16′] (p.Met161Thr) NM_001030001.2 587777569 RPS29 [ ] [′GATAYCGGTTTC [′Diamond-Blackfan (RPS29):c.149T>C ATTAAGGTAGG′] anemia 13′] (p.Ile50Thr) NM_177550.4 587777578 SLC13A5 [ ] [ ] [′Epileptic (SLC13A5):c.1463T>C encephalopathy, (p.Leu488Pro) early infantile, 25′] NM_002880.3 587777586 RAF1 [ ] [ ] [′Cardiomyopathy, (RAF1):c.1808T>C dilated, 1NN′] (p.Leu603Pro) NM_025150.4 587777594 TARS2 [ ] [ ] [′Combined (TARS2):c.695+3A>G oxidative phosphorylation deficiency 21′] NM_001759.3 587777618 CCND2 [ ] [ ] Negalencephaly- (CCND2):c.838A>G polymicrogyria- (p.Thr280Ala) polydactyly- hydrocephalus syndrome 3′] NM_153334.6 587777657 SCARF2 [ ] [′CCACGYGCTGCG [′Marden Walker (SCARF2):c.190T>C CTGGCTGGAGG′] like syndrome′] (p.Cys64Arg) NM_005726.5 587777689 TSFM [ ] [′ACTTCYCACCGG [′Combined (TSFM):c.57+4A>G GTAGCTCCCGG′] oxidative phosphorylation deficiency 3′] NM_000255.3 796052005 MUT [ ] [′GCAYACTGGCG [′not provided′] (MUT):c.329A>G GATGGTCCAGGG′, (p.Tyr110Cys) ′AGCAYACTGGCG GATGGTCCAGG′] NM_021870.2 587777720 FGG [ ] [ ] [′Hypodysfibrinogenemia′] (FGG):c.1210T>C (p.Ser404Pro) NM_017617.3 587777736 NOTCH1 [′GGCAAGY [′GGCAAGYGCAT [′Adams-Oliver (NOTCH1):c.1285T>C GCATCAAC CAACACGCTGGG′, syndrome 1′, (p.Cys429Arg) ACGCTGGG′] ′GGGCAAGYGCAT ′Adams-Oliver CAACACGCTGG′] syndrome 5′] NM_014946.3 587777752 SPAST [′TTCYGTA [′TTCYGTAAAACA [′Spastic paraplegia (SPAST):c.1688-2A>G AAACATAA TAAAAGTCAGG′] 4, autosomal AAGTCAGG′] dominant′] NM_014946.3 587777755 SPAST [ ] [ ] [′Spastic paraplegia (SPAST):c.1245+4A>G 4, autosomal dominant′] NM_014946.3 587777757 SPAST [ ] [ ] [′Spastic paraplegia (SPAST):c.1216A>G 4, autosomal (p.Ile406Val) dominant′] NM_144596.3 587777809 TTC8 [ ] [′GTTCCYGGAAA [′Retinitis (TTC8):c.115-2A>G GCATTAAGAAGG′] pigmentosa 51′] NM_170784.2 74315396 MKKS [ ] [ ] [′Bardet-Biedl (MKKS):c.110A>G syndrome 6′, (p.Tyr37Cys) ′McKusick Kaufman syndrome′] NM_000252.2 132630302 MTM1 [ ] [ ] [′Severe X-linked (MTM1):c.566A>G myotubular (p.Asn189Ser) myopathy′] NM_000252.2 132630303 MTM1 [ ] [ ] [′Severe X-linked (MTM1):c.1190A>G myotubular (p.Tyr397Cys) myopathy′] NM_152384.2(BBS5): 587777828 BBS5 [ ] [ ] [′Bardet-Biedl c.522+3A>G syndrome 5′] NM_001205019.1 132630331 GK [ ] [ ] [′Deficiency of (GK):c.880A>G glycerol kinase′] (p.Asn294Asp) NM_000166.5 587777878 GJB1 [ ] [′TAGCAYGAAGA [′X-linked hereditary (GJB1):c.580A>G CGGTGAAGACGG′] motor and sensory (p.Met194Val) neuropathy′] NM_000311.3 74315411 PRNP [ ] [ ] [′Genetic prion (PRNP):c.547A>G diseases′, (p.Thr183Ala) ′Spongiform encephalopathy with neuropsychiatric features′] NM_144773.2 74315417 PROKR2 [ ] [ ] [′Kallmann (PROKR2):c.629A>G syndrome 3′] (p.Gln210Arg) NM_000531.5 796052013 OTC [ ] [ ] [′not provided′] (OTC):c.919A>G (p.Lys307Glu) NM_001029871.3 74315420 RSPO4 [ ] [′CGTACYGGCGG [′Anonychia′] (RSPO4):c.194A>G ATGCCTTCCCGG′] (p.Gln65Arg) NM_004333.4 180177035 BRAF [ ] [ ] [′Noonan syndrome (BRAF):c.770A>G 7′, (p.Gln257Arg) ′Cardiofaciocutaneous syndrome′, ′Rasopathy′, ′not provided′] NM_004333.4 180177037 BRAF [ ] [ ] [′Cardiofaciocutaneous (BRAF):c.1495A>G syndrome′, (p.Lys499Glu) ′Rasopathy′] NM_198056.2 752476527 SCN5A [ ] [ ] [′not provided′] (SCN5A):c.5297T>A (p.Met1766Lys) NM_000030.2 180177186 AGXT [ ] [ ] [′Primary (AGXT):c.248A>G hyperoxaluria, type (p.His83Arg) I′] NM_000030.2 180177219 AGXT [ ] [′AGGCCCYGAGG [′Primary (AGXT):c.424-2A>G AAGCAGGGACGG′] hyperoxaluria, type (p.Gly_142Gln145del) I′] NM_198578.3 35801418 LRRK2 [ ] [ ] [′Parkinson disease (LRRK2):c.5096A>G 8, autosomal (p.Tyr1699Cys) dominant′] NM_002693.2 367610201 POLG [ ] [′CTCAYGGCACTT [′not provided′] (POLG):c.1808T>C ACCTGGGATGG′] (p.Met603Thr) NM_000030.2 180177245 AGXT [ ] [ ] [′Primary (AGXT):c.596-2A>G hyperoxaluria, type I′] NM_020223.3 796051853 FAM20C [ ] [ ] [′Raine syndrome′] (FAM20C):c.1364-2A>G NM_012203.1 180177319 GRHPR [ ] [′TCACAGCYGCG [′Primary (GRHPR):c.84-2A>G GGGAAAGGGAGG′] hyperoxaluria, type II′] NM_006017.2 796051882 PROM1 [ ] [ ] [′Cone-rod (PROM1):c.2077-521A>G dystrophy 2′] NM_012203.1 180177324 GRHPR [′CAAGTYG [′CAAGTYGTTAGC [′Primary (GRHPR):c.934A>G TTAGCTGC TGCCAACAAGG′] hyperoxaluria, type (p.Asn312Asp) CAACAAGG′] II′] NM_000016.5 796051900 ACADM [ ] [ ] [′not provided′] (ACADM):c.329A>G (p.Glu110Gly) NM_004453.3 796051958 ETFDH [ ] [ ] [′not provided′] (ETFDH):c.929A>G (p.Tyr310Cys) NM_000255.3 796052004 MUT [ ] [ ] [′not provided′] (MUT):c.1885A>G (p.Arg629Gly) NM_012434.4 119491109 SLC17A5 [ ] [ ] [′Sialic acid storage (SLC17A5):c.548A>G disease, severe (p.His183Arg) infantile type′] NM_000328.2 62638632 RPGR [ ] [ ] [′Retinitis (RPGR):c.155-2A>G pigmentosa 15′, ′not provided′] NM_005557.3 58608173 KRT16 [ ] [ ] [′Pachyonychia (KRT16):c.373A>G congenita, type 1′, (p.Asn125Asp) ′not provided′] NM_000532.4 796052020 PCCB [ ] [ ] [′not provided′] (PCCB):c.655-2A>G NM_000030.2 796052068 AGXT [ ] [′GGTACCYGGAA [′Primary (AGXT):c.777-2A>G GACACGAGGGGG′, hyperoxaluria, type ′TGGTACCYGGAA I′] GACACGAGGGG′] NM_000121.3 62638745 EPOR [′AGGGYTG [′AGGGYTGGAGT [′Acute myeloid (EPOR):c.1460A>G GAGTAGGG AGGGGCCATCGG′] leukemia, M6 type′, (p.Asn487Ser) GCCATCGG′] ′Familial erythrocytosis, 1′] NM_000552.3 61754010 VWF [ ] [′TGCCAYTGTAAT [′von Willebrand (VWF):c.1583A>G TCCCACACAGG′] disease, type 2a′, ′not (p.Asn528Ser) provided′] NM_001918.3 796052135 DBT [ ] [ ] [′Intermediate maple (DBT): syrup urine disease c.1017_1018insNC_000001.11: type 2′] g.100207187_100207312 NM_001243473.1 143149764 B9D1 [ ] [ ] [′Meckel syndrome, (B9D1):c.400+2T>C type 9′, ′not provided′] NM_001165963.1 764037830 — [ ] [ ] [′Severe myoclonic (SCN1A):c.4766T>G epilepsy in infancy′] (p.Val1589Gly) NM_000321.2 587778866 RB1 [ ] [′ATTYCAATGGCT [′Retinoblastoma′] (RB1):c.1927A>G TCTGGGTCTGG′] (p.Lys643Glu) NM_006331.7 74435397 EMG1 [ ] [′ATAYCTGGCCGC [′Bowen-Conradi (EMG1):c.257A>G GCTTCCCCAGG′] syndrome′] (p.Asp86Gly) NM_000249.3 587778888 MLH1 [ ] [ ] [′Hereditary (MLH1):c.113A>G Nonpolyposis (p.Asn38Ser) Colorectal Neoplasms′] NM_017777.3 730882120 MKS1 [ ] [ ] [′Bardet-Biedl (MKS1):c.1382A>G syndrome 13′] (p.Tyr461Cys) NM_000261.1 74315335 MYOC [ ] [ ] [′Primary open angle (MYOC):c.1010A>G glaucoma juvenile (p.Gln337Arg) onset 1′] NM_152515.4 548949031 CKAP2L [ ] [ ] [′Filippi syndrome′] (CKAP2L):c.2T>C (p.Met1Thr) NM_000156.5 796052527 GAMT [ ] [′CGCTCAYGCTGC [′not provided′] (GAMT):c.1A>G AGGCTGGACGG′] (p.Met1Val) NM_000833.4 796052544 GRIN2A [ ] [ ] [′not provided′] (GRIN2A):c.1930A>G (p.Ser644Gly) NM_000144.4 140987490 FXN [ ] [ ] [′Friedreich ataxia′] (FXN):c.385-2A>G NM_172107.2 796052615 KCNQ2 [ ] [ ] [′not provided′] (KCNQ2):c.297-2A>G NM_172107.2 796052624 KCNQ2 [ ] [ ] [′not provided′] (KCNQ2):c.611A>G (p.Gln204Arg) NM_172107.2 796052637 KCNQ2 [ ] [′GTACYTGTCCCC [′not provided′] (KCNQ2):c.848A>G GTAGCCAATGG′] (p.Lys283Arg) NM_052859.3 772820136 RFT1 [ ] [ ] [′Congenital disorder (RFT1):c.887T>A of glycosylation type (p.Ile296Lys) 1N′] NM_000553.4 775802030 WRN [ ] [ ] [′Werner syndrome′] (WRN):c.561A>G (p.Lys187=) NM_194277.2 786205896 FRMD7 [ ] [ ] [′Infantile (FRMD7):c.556A>G nystagmus, (p.Met186Val) X-linked′] NM_000535.5 587779347 PMS2 [ ] [ ] [′Hereditary (PMS2):c.989-2A>G Nonpolyposis Colorectal Neoplasms′, ′Hereditary cancer- predisposing syndrome′] NM_000203.4 587779401 IDUA [ ] [ ] [′Hurler syndrome′] (IDUA):c.1874A>G (p.Tyr625Cys) NM_001105243.1 796052839 PCDH19 [ ] [ ] [′not provided′] (PCDH19):c.1019A>G (p.Asn340Ser) NM_002693.2 796052891 POLG [ ] [ ] [′not provided′] (POLG):c.2840A>G (p.Lys947Arg) NM_032228.5 724159963 FAR1 [ ] [′GATAYCATACA [′Peroxisomal fatty (FAR1):c.1094A>G GGAATGCTGGGG′, acyl-coa reductase 1 (p.Asp365Gly) ′AGATAYCATACA disorder′] GGAATGCTGGG′, ′TAGATAYCATAC AGGAATGCTGG′] NM_000090.3 587779558 COL3A1 [ ] [ ] [′Ehlers-Danlos (COL3A1):c.2284-2A>G syndrome, type 4′] (p.Gly762_Lys779del) NM_014305.3 724160004 TGDS [ ] [ ] [′Catel Manzke (TGDS):c.269A>G syndrome′] (p.Glu90Gly) NM_014305.3 724160005 TGDS [ ] [ ] [′Catel Manzke (TGDS):c.892A>G syndrome′] (p.Asn298Asp) NM_000090.3 587779602 COL3A1 [ ] [ ] [′Ehlers-Danlos (COL3A1):c.997-2A>G syndrome, type 4′] (p.Gly333_Lys350del+) NM_002185.3 1494558 IL7R [ ] [ ] [′Severe combined (IL7R):c.197T>C immunodeficiency, (p.Ile66Thr) autosomal recessive, T cell-negative, B cell-positive, NK cell-positive′, ′not specified′] NM_000277.1 62508578 PAH [ ] [ ] [′Phenylketonuria′, (PAH):c.974A>G ′not provided′] (p.Tyr325Cys) NM_000090.3 587779670 COL3A1 [ ] [ ] [′Ehlers-Danlos (COL3A1):c.997-10A>G syndrome, type 4′] (p.Pro332_Gly333insFFQ) NM_000090.3 587779682 COL3A1 [ ] [ ] [′Ehlers-Danlos (COL3A1):c.3202-2A>G syndrome, type 4′] (p.Gly1068_Pro1085de1) NM_000090.3 587779722 COL3A1 [ ] [′CACCCYAAAGA [′Ehlers-Danlos (COL3A1):c.1762-2A>G AGAAGTGGTCGG′] syndrome, type 4′] (p.Gly588_Gln605del) NM_021007.2 796053135 SCN2A [ ] [ ] [′not provided′] (SCN2A):c.4036A>G (p.Ile1346Val) m.13637A>G 200855215 MT-ND5 [ ] [ ] [′Leber optic atrophy′] NM_021007.2 796053169 SCN2A [′AATAAAG [′AATAAAGYAGA [′not provided′] (SCN2A):c.387-2A>G YAGAATAT ATATCGTCAAGG′] CGTCAAGG′] NM_021007.2 796053173 SCN2A [ ] [ ] [′not provided′] (SCN2A):c.851A>G (p.Asp284Gly) NM_006516.2 796053251 SLC2A1 [ ] [ ] [′not provided′] (SLC2A1):c.848A>G (p.Gln283Arg) NM_006516.2 796053272 SLC2A1 [ ] [ ] [′not provided′] (SLC2A1):c.19-2A>G NM_000136.2 587779898 FANCC [ ] [ ] [′Hereditary cancer- (FANCC):c.-78-2A>G predisposing syndrome′] m.8296A>G 118192102 MT-TK [ ] [′TTTACAGYGGGC [′Diabetes-deafness TCTAGAGGGGG′] syndrome maternally transmitted′] NM_005360.4 727502767 MAF [ ] [ ] [′Cataracts, (MAF):c.172A>G congenital, with (p.Thr58Ala) sensorineural deafness, down syndrome-like facial appearance, short stature, and mental retardation′] NM_001145901.1 727502784 SARS2 [ ] [ ] [′Hyperuricemia, (SARS2):c.1175A>G pulmonary (p.Asp392Gly) hypertension, renal failure, and alkalosis′] NM_001077494.3 727502787 NFKB2 [ ] [′CTGYCTTCCTTC [′Common variable (NFKB2):c.2594A>G ACCTCTGCTGG′] immunodeficiency (p.Asp865Gly) 10′] NM_002238.3 727502819 KCNH1 [ ] [ ] [′Zimmermann- (KCNH1):c.1399A>G Laband syndrome′, (p.Ile467Val) ′Temple-Baraitser syndrome′] NM_172362.2 727502821 KCNH1 [ ] [ ] [′Temple-Baraitser (KCNH1):c.1508A>G syndrome′] (p.Gln503Arg) NM_000546.5 587780073 TP53 [ ] [ ] [′Li-Fraumeni (TP53):c.701A>G syndrome′, (p.Tyr234Cys) ′Hereditary cancer- predisposing syndrome′] NM_003060.3 188698686 SLC22A5 [ ] [ ] [′not provided′] (SLC22A5):c.694A>C (p.Thr232Pro) NM_000540.2 118192146 RYR1 [ ] [ ] [′Central core (RYR1):c.14591A>G disease′, ′not (p.Tyr4864Cys) provided′] NM_058216.2 587780259 RAD51C [ ] [ ] [′Hereditary cancer- (RAD51C):c.706-2A>G predisposing syndrome′] NM_000501.3 727503027 ELN [ ] [ ] [′Supravalvar aortic (ELN):c.800-2A>G stenosis′, ′not provided′] NM_000117.2 727503036 EMD [ ] [′AGCCYTGGGAA [Emery-Dreifuss (EMD):c.266-2A>G GGGGGGCAGCGG′] muscular dystrophy 1, X-linked′] NM_003242.5 104893817 TGFBR2 [ ] [ ] [′Loeys-Dietz (TGFBR2):c.1273A>G syndrome 2′] (p.Met425Val) NM_153638.2 137852965 PANK2 [ ] [ ] [ ] (PANK2):c.700A>G (p.Thr234Ala) NM_005861.3 690016544 STUB1 [ ] [′GGCCCGGYTGGT [′Spinocerebellar (STUB1):c.194A>G GTAATACACGG′] ataxia, autosomal (p.Asn65Ser) recessive 16′] NM_005360.4 121917736 MAF [ ] [ ] [′Cataract, (MAF):c.890A>G pulverulent, (p.Lys297Arg) juvenile-onset′] NM_005211.3 690016554 CSF1R [ ] [′GTATCYGGGAG [′Hereditary diffuse (CSF1R):c.2655-2A>G ATAGGACAGAGG′] leukoencephalopathy with spheroids′] NM_003361.3 121917770 UMOD [′CACAYTG [′CACAYTGACAC [′Familial juvenile (UMOD):c.383A>G ACACATGT ATGTGGCCAGGG′, gout′] (p.Asn128Ser) GGCCAGGG′] ′CCACAYTGACAC ATGTGGCCAGG′] NM_000256.3 727503190 MYBPC3 [ ] [ ] [′Familial (MYBPC3):c.2234A>G hypertrophic (p.Asp745Gly) cardiomyopathy 4′, ′Familial hypertrophic cardiomyopathy 1′, ′not specified′] NM_172107.2 118192185 KCNQ2 [ ] [′GCACCAYGGTG [′Benign familial (KCNQ2):c.1A>G CCTGGCGGGAGG′] neonatal seizures 1′] (p.Met1Val) NM_000256.3 727503207 MYBPC3 [ ] [ ] [′Cardiomyopathy′, (MYBPC3):c.1213A>G ′not specified′] (p.Met405Val) NM_000021.3 121917809 PSEN1 [ ] [ ] [′Primary dilated (PSEN1):c.998A>G cardiomyopathy′, (p.Asp333Gly) ′Cardiomyopathy, dilated, 1u′, ′Heart failure′] NM_021954.3 121917823 GJA3 [ ] [ ] [′Zonular (GJA3):c.188A>G pulverulent cataract (p.Asn63Ser) 3′] NM_000322.4 61755781 PRPH2 [ ] [ ] [′Macular dystrophy, (PRPH2):c.422A>G vitelliform, adult- (p.Tyr141Cys) onset′, ′Patterned dystrophy of retinal pigment epithelium′, ′not provided′] NM_007035.3 121917858 KERA [ ] [ ] [′Cornea plana 2′] (KERA):c.740A>G (p.Asn247Ser) NM_002181.3 121917859 IHH [ ] [ ] [′Brachydactyly type (IHH):c.284A>G A1′] (p.Glu95Gly) NM_000257.3 727503269 MYH7 [ ] [ ] [′Primary familial (MYH7):c.1157A>G hypertrophic (p.Tyr386Cys) cardiomyopathy′] NM_000097.5 121917868 CPOX [ ] [ ] [′Harderoporphyria′] (CPOX):c.1210A>G (p.Lys404Glu) NM_012064.3 121917869 MIP [ ] [′AGATCYCCACTG [′Cataract 15, (MIP):c.401A>G TGGTTGCCTGG′] multiple types′] (p.Glu134Gly) NM_025243.3 121917884 SLC19A3 [ ] [ ] [′Basal ganglia (SLC19A3):c.1264A>G disease, biotin- (p.Thr422Ala) responsive′] NM_000373.3 121917890 UMPS [ ] [ ] [′Orotic aciduria′] (UMPS):c.286A>G (p.Arg96Gly) NM_000536.3 121917897 RAG2 [ ] [ ] [′Histiocytic (RAG2):c.115A>G medullary (p.Arg39Gly) reticulosis′] NM_130838.1 587780579 UBE3A [ ] [ ] [′Angelman (UBE3A):c.1694-2A>G syndrome′] NM_016335.4 2904551 PRODH [ ] [ ] [′Proline (PRODH):c.1322T>C dehydrogenase (p.Leu441Pro) deficiency′, ′Schizophrenia 4′] NM_006920.4 121917962 — [ ] [ ] [′Severe myoclonic (SCN1A):c.4352A>G epilepsy in infancy′, (p.Tyr1451Cys) ′not provided′] NM_006920.4 121917990 SCN1A [ ] [ ] [′Severe myoclonic (SCN1A):c.1876A>G epilepsy in infancy′, (p.Ser626Gly) ′Generalized epilepsy′] NM_000478.4 121918014 ALPL [ ] [′AGGCCCAYTGCC [′Infantile (ALPL):c.1250A>G ATACAGGATGG′] hypophosphatasia′] (p.Asn417Ser) NM_000174.4 121918036 GP9 [ ] [′GCAGYCCACCC [′Bernard-Soulier (GP9):c.110A>G ACAGCCCCATGG′] syndrome type C′] (p.Asp37Gly) NM_002693.2 121918050 POLG [ ] [ ] [′Mitochondrial (POLG):c.2591A>G DNA depletion (p.Asn864Ser) syndrome 4B, MNGIE type′] NM_000374.4 121918061 UROD [ ] [ ] [′Hepatoerythropoietic (UROD):c.932A>G porphyria′] (p.Tyr311Cys) NM_000217.2 121918067 KCNA1 [ ] [ ] [ ] (KCNA1):c.763A>G (p.Asn255Asp) NM_000371.3 121918070 TTR [ ] [ ] [′Amyloidogenic (TTR):c.238A>G transthyretin (p.Thr80Ala) amyloidosis′, ′Cardiomyopathy′] NM_000371.3 121918075 TTR [′GGAGYAG [′GGAGYAGGGGC [′Amyloidogenic (TTR):c.401A>G GGGCTCAG TCAGCAGGGCGG′, transthyretin (p.Tyr134Cys) CAGGGCGG′, ′ATAGGAGYAGGG amyloidosis′] ′ATAGGAG GCTCAGCAGGG′] YAGGGGCT CAGCAGGG′] NM_000371.3 121918081 TTR [ ] [ ] [′Amyloidogenic (TTR):c.205A>G transthyretin (p.Thr69Ala) amyloidosis′] NM_000371.3 121918089 TTR [ ] [′CGGCAAYGGTG [′Amyloidogenic (TTR):c.379A>G TAGCGGCGGGGG′, transthyretin (p.Ile127Val) ′GCGGCAAYGGTG amyloidosis′] TAGCGGCGGGG′] NM_000371.3 121918098 TTR [ ] [ ] [′Amyloidogenic (TTR):c.113A>G transthyretin (p.Asp38Gly) amyloidosis′, ′AMYLOIDOSIS, LEPTOMENINGEAL, TRANSTHYRETIN- RELATED′] NM_000823.3 121918121 GHRHR [ ] [′CGACTYGGAGA [′Isolated growth (GHRHR):c.985A>G GACGCCTGCAGG′] hormone deficiency (p.Lys329Glu) type 1B′] NM_000275.2 121918170 OCA2 [′GACATYT [′GACATYTGGAG [′Tyrosinase-positive (OCA2):c.1465A>G GGAGGGTC GGTCCCCGATGG′] oculocutaneous (p.Asn489Asp) CCCGATGG′] albinism′] NM_000181.3 121918178 GUSB [ ] [ ] [′Mucopolysaccharidosis (GUSB):c.1484A>G type VII′] (p.Tyr495Cys) NM_018122.4 121918209 DARS2 [ ] [ ] [′Leukoencephalopathy (DARS2):c.133A>G with Brainstem (p.Ser45Gly) and Spinal Cord Involvement and Lactate Elevation′] NM_015697.7 121918230 COQ2 [ ] [ ] [′Coenzyme Q10 (COQ2):c.890A>G deficiency, primary (p.Tyr297Cys) 1′] NM_015697.7 121918232 COQ2 [ ] [ ] [′Coenzyme Q10 (COQ2):c.683A>G deficiency, primary (p.Asn228Ser) 1′] NM_015384.4 121918265 NIPBL [ ] [ ] [′Cornelia de Lange (NIPBL):c.7289A>G syndrome 1′] (p.Tyr2430Cys) NM_004183.3 121918291 BEST1 [ ] [ ] [′Vitreoretinochoroidopathy (BEST1):c.707A>G dominant′] (p.Tyr236Cys) NM_014362.3 121918329 HIBCH [ ] [ ] [Beta- (HIBCH):c.365A>G hydroxyisobutyryl- (p.Tyr122Cys) CoA deacylase deficiency′] NM_015335.4 121918333 MED13L [ ] [′ATATCAYCTAGA [′Transposition of (MED13L):c.6068A>G GGGAAGGGGGG′, great arteries′] (p.Asp2023Gly) ′CATATCAYCTAG AGGGAAGGGGG′] NM_015040.3 121918336 PIKFYVE [ ] [ ] [′Fleck corneal (PIKFYVE):c.3308A>G dystrophy′] (p.Lys1103Arg) NM_006306.3 727503774 SMC1A [ ] [ ] [′Congenital (SMC1A):c.2974-2A>G muscular hypertrophy-cerebral syndrome′] NM_002633.2 121918371 PGM1 [ ] [ ] [′Congenital disorder (PGM1):c.343A>G of glycosylation type (p.Thr115Ala) 1t′] NM_000040.1 121918381 APOC3 [′CTGAAGY [′CTGAAGYTGGTC [ ] (APOC3):c.280A>G TGGTCTGA TGACCTCAGGG′, (p.Thr94Ala) CCTCAGGG′, ′GCTGAAGYTGGT ′GCTGAAG CTGACCTCAGG′] YTGGTCTG ACCTCAGG′] NM_000040.1 121918382 APOC3 [ ] [ ] [′Hyperalphalipo- (APOC3):c.232A>G proteinemia 2′] (p.Lys78Glu) NM_001146040.1 121918412 GLRA1 [ ] [ ] [′Hyperekplexia (GLRA1):c.910A>G hereditary′] (p.Lys304Glu) NM_000171.3 121918414 GLRA1 [ ] [ ] [′Hyperekplexia (GLRA1):c.523A>G hereditary′] (p.Met175Val) NM_021957.3 121918423 GYS2 [ ] [ ] [′Hypoglycemia with (GYS2):c.116A>G deficiency of (p.Asn39Ser) glycogen synthetase in the liver′] NM_002834.3 121918459 PTPN11 [ ] [ ] [′Noonan syndrome′, (PTPN11):c.188A>G ′Noonan syndrome (p.Tyr63Cys) 1′, ′Rasopathy′, ′not provided′] NM_013382.5 727503873 POMT2 [ ] [ ] [′not provided′] (POMT2):c.1726-2A>G NM_002834.3 121918466 PTPN11 [ ] [ ] [′Noonan syndrome′, (PTPN11):c.236A>G ′Noonan syndrome (p.Gln79Arg) 1′, ′Rasopathy′, ′not provided′] NM_000313.3 121918473 PROS1 [ ] [ ] [′Protein S (PROS1):c.773A>G deficiency′] (p.Asn258Ser) NM_000313.3 121918474 PROS1 [ ] [ ] [′Protein S (PROS1):c.586A>G deficiency′] (p.Lys196Glu) NM_000141.4 121918493 FGFR2 [ ] [ ] [′Crouzon (FGFR2):c.983A>G syndrome′] (p.Tyr328Cys) NM_000141.4 121918500 FGFR2 [′TGCTYGA [′TGCTYGATCCAC [′Crouzon (FGFR2):c.874A>G TCCACTGG TGGATGTGGGG′, syndrome′] (p.Lys292Glu) ATGTGGGG′] ′GTGCTYGATCCA CTGGATGTGGG′, ′CGTGCTYGATCC ACTGGATGTGG′] NM_000141.4 121918507 FGFR2 [ ] [ ] [′Crouzon (FGFR2):c.1576A>G syndrome′, (p.Lys526Glu) ′Scaphocephaly, maxillary retrusion, and mental retardation′] NM_002739.3 121918515 PRKCG [ ] [ ] [′Spinocerebellar (PRKCG):c.380A>G ataxia 14′] (p.Gln127Arg) NM_002739.3 121918517 PRKCG [ ] [ ] [′Spinocerebellar (PRKCG):c.1081A>G ataxia 14′] (p.Ser361Gly) NM_000098.2 121918528 CPT2 [′GATAGGY [′GATAGGYACAT [′Carnitine (CPT2):c.359A>G ACATATCA ATCAAACCAGGG′, palmitoyltransferase (p.Tyr120Cys) AACCAGGG′, ′AGATAGGYACAT II deficiency, ′AGATAGG ATCAAACCAGG′] infantile′] YACATATC AAACCAGG′] NM_005587.2 121918530 MEF2A [′CCAAGAY [′AGAYTACCACC [ ] (MEF2A):c.788A>G TACCACCA ACCTGGTGGAGG′, (p.Asn263Ser) CCTGGTGG′] ′CCAAGAYTACCA CCACCTGGTGG′] NM_006204.3 121918539 PDE6C [ ] [ ] [′Achromatopsia 5′] (PDE6C):c.1363A>G (p.Met455Val) NM_017654.3 121918554 SAMD9 [ ] [ ] [′Tumoral calcinosis, (SAMD9):c.4483A>G familial, (p.Lys1495Glu) normophosphatemic′] NM_000191.2 727503963 HMGCL [ ] [ ] [′not provided′] (HMGCL):c.698A>G (p.His233Arg) NM_020166.4 727504006 MCCC1 [ ] [ ] [′3 Methylcrotonyl- (MCCC1):c.137-2A>G CoA carboxylase 1 deficiency′, ′not provided′] NM_001035.2 121918605 RYR2 [ ] [′CGCCAGCYGCAT [′Catecholaminergic (RYR2):c.12602A>G TTCAAAGATGG′] polymorphic (p.Gln4201Arg) ventricular tachycardia′] NM_002764.3 587781262 PRPS1 [ ] [′TAGCAYATTTGC [′Charcot-Marie-Tooth disease, (PRPS1):c.343A>G AACAAGCTTGG′] X-linked recessive, (p.Met115Val) type 5′, ′Deafness, high-frequency sensorineural, X-linked′] NM_001161766.1 121918608 AHCY [ ] [′GCGGGYACTTG [′Hypermethioninemia (AHCY):c.344A>G GTGTGGATGAGG′] with s- (p.Tyr115Cys) adenosylhomocysteine hydrolase deficiency′] NM_000702.3 121918613 ATP1A2 [ ] [′CTGYCAGGGTCA [′Familial (ATP1A2):c.1033A>G GGCACACCTGG′] hemiplegic migraine (p.Thr345Ala) type 2′] NM_003126.2 121918644 SPTA1 [ ] [ ] [′Hereditary (SPTA1):c.143A>G pyropoikilocytosis′] (p.Lys48Arg) NM_001024858.2 121918651 SPTB [ ] [ ] [′Elliptocytosis 3′] (SPTB):c.1A>G (p.Met1Val) NM_000899.4 121918653 KITLG [ ] [ ] [′Familial (KITLG):c.107A>G progressive (p.Asn36Ser) hyperpigmentation with or without hypopigmentation′] NM_198253.2 121918663 TERT [ ] [ ] [′Aplastic anemia′, (TERT):c.2315A>G ′PULMONARY (p.Tyr772Cys) FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE- RELATED, 1′] NM_001063.3 121918678 TF [ ] [ ] [ ] (TF):c.1936A>G (p.Lys646Glu) NM_000535.5 587781339 PMS2 [ ] [′GCAGACCYGCA [′Hereditary cancer- (PMS2):c.904-2A>G CAAAATACAAGG′] predisposing syndrome′] NM_001128177.1 121918691 THRB [ ] [′CTTCAYGTGCAG [′Thyroid hormone (THRB):c.1324A>G GAAGCGGCTGG′] resistance, (p.Met442Val) generalized, autosomal dominant′] NM_001128177.1 121918692 THRB [ ] [′CCACCTYCATGT [′Thyroid hormone (THRB):c.1327A>G GCAGGAAGCGG′] resistance, (p.Lys443Glu) generalized, autosomal dominant′] NM_001128177.1 121918709 THRB [ ] [ ] [′Thyroid hormone (THRB):c.1009A>G resistance, selective (p.Thr337Ala) pituitary′] NM_004612.3 121918711 TGFBR1 [′ATAGATG [′ATAGATGYCAG [′Loeys-Dietz (TGFBR1):c.1199A>G YCAGCACG CACGTTTGAAGG′] syndrome 1′] (p.Asp400Gly) TTTGAAGG′] NM_000359.2 121918724 TGM1 [ ] [ ] [′Autosomal (TGM1):c.1469A>G recessive congenital (p.Asp490Gly) ichthyosis 1′] NM_000257.3 727504238 MYH7 [ ] [ ] [′Familial (MYH7):c.1727A>G hypertrophic (p.His576Arg) cardiomyopathy 1′, ′Cardiomyopathy′, ′not specified′] NM_000257.3 727504239 MYH7 [ ] [ ] [′Primary familial (MYH7):c.1954A>G hypertrophic (p.Arg652Gly) cardiomyopathy′, ′Familial hypertrophic cardiomyopathy 1′] NM_000257.3 727504270 MYH7 [ ] [ ] [′Cardiomyopathy′, (MYH7):c.1496A>G ′not specified′] (p.Glu499Gly) NM_000257.3 727504310 MYH7 [ ] [ ] [′Familial (MYH7):c.2539A>G hypertrophic (p.Lys847Glu) cardiomyopathy 1′, ′Cardiomyopathy′, ′not specified′] NM_000256.3 727504333 MYBPC3 [ ] [′CCGTTCYGTGGG [′Familial (MYBPC3):c.2906-2A>G TATAGAGTGGG′, hypertrophic ′GCCGTTCYGTGG cardiomyopathy 4′] GTATAGAGTGG′] NM_001128425.1 587781628 MUTYH [′ACCYGAG [′ACCYGAGAGGG [′Hereditary cancer- (MUTYH):c.1187-2A>G AGGGAGG AGGGCAGCCAGG′] predisposing GCAGCCAG syndrome′, G′] ′Carcinoma of colon′] NM_005188.3 727504426 CBL [ ] [ ] [′Juvenile (CBL):c.1228-2A>G myelomonocytic leukemia′, ′Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia′, ′Rasopathy′] NM_000501.3 727504434 ELN [′GCCYGAA [′GCCYGAAAACA [′Supravalvar aortic (ELN):c.890-2A>G AACACAGC CAGCCACAGAGG′] stenosis′] CACAGAGG′] NM_001165963.1 775214722 SCN1A [ ] [ ] [′not provided′] (SCN1A):c.2877T>A (p.Cys959Ter) NM_000833.4 796052551 GRIN2A [′CCAYGTT [′CCAYGTTGTCAA [′not provided′] (GRIN2A):c.2449A>G GTCAATGT TGTCCAGCTGG′] (p.Met817Val) CCAGCTGG′] NM_000314.6 587781784 PTEN [ ] [ ] [′Hereditary cancer- (PTEN):c.493-2A>G predisposing syndrome′] NM_000498.3 61757294 — [ ] [ ] [′Corticosterone (CYP11B2):c.1157T>C methyloxidase type (p.Val386Ala) 2 deficiency′, ′Corticosterone methyloxidase type 1 deficiency′] NM_006204.3 786200910 PDE6C [ ] [′CTTTCYGTTGAA [′Achromatopsia 5′] (PDE6C):c.1483-2A>G ATAAGGATGGG′, ′TCTTTCYGTTGAA ATAAGGATGG′] NM_003588.3 786200913 CUL4B [ ] [ ] [′Syndromic X- (CUL4B):c.901-2A>G linked mental retardation, Cabezas type′] NM_000397.3 137854591 CYBB [ ] [ ] [′Granulomatous (CYBB):c.302A>G disease, chronic, X- (p.His101Arg) linked, variant′, ′not provided′] NM_000311.3 1799990 PRNP [ ] [ ] [′Jakob-Creutzfeldt (PRNP):c.385A>G disease′, ′Genetic (p.Met129Val) prion diseases′, ′Fatal familial insomnia′, ′not specified′] NM_000051.3 587782276 ATM [ ] [ ] [′Ataxia- (ATM):c.3994-2A>G telangiectasia syndrome′, ′Hereditary cancer- predisposing syndrome′] NM_005211.3 281860267 CSF1R [ ] [ ] [′Hereditary diffuse (CSF1R):c.1754-2A>G leukoencephalopathy with spheroids′] NM_004646.3 730880174 NPHS1 [ ] [ ] [′Finnish congenital (NPHS1):c.1756A>G nephrotic (p.Arg586Gly) syndrome′] NM_005211.3 281860272 CSF1R [′CACYGAG [′CACYGAGGGAA [′Hereditary diffuse (CSF1R):c.2320-2A>G GGAAAGC AGCACTGCAGGG′, leukoencephalopathy ACTGCAGG ′GCACYGAGGGAA with spheroids′] G′] AGCACTGCAGG′] NM_000256.3 370890951 MYBPC3 [ ] [ ] [′Cardiomyopathy′, (MYBPC3):c.3392T>C ′Cardiac arrest′, ′not (p.Ile1131Thr) specified′] NM_000551.3 281860296 VHL [ ] [′GGTCTTYCTGCA [′Von Hippel-Lindau (VHL):c.586A>T CATTTGGGTGG′] syndrome′] (p.Lys196Ter) NM_005247.2 281860300 FGF3 [′CAGYAGA [′CAGYAGAGCTT [′Deafness with (FGF3):c.146A>G GCTTGCGG GCGGCGCCGGGG′, labyrinthine aplasia (p.Tyr49Cys) CGCCGGGG′, ′GCAGYAGAGCTT microtia and ′GCAGYAG GCGGCGCCGGG′, microdontia AGCTTGCG ′CGCAGYAGAGCT (LAMM)′] GCGCCGGG′, TGCGGCGCCGG′] ′CGCAGYA GAGCTTGC GGCGCCGG′] NM_005247.2 281860306 FGF3 [ ] [ ] [′Deafness with (FGF3):c.317A>G labyrinthine aplasia (p.Tyr106Cys) microtia and microdontia (LAMM)′] NM_000314.6 587782360 PTEN [ ] [ ] [′Hereditary cancer- (PTEN):c.403A>G predisposing (p.Ile135Val) syndrome′] NM_004990.3 766466297 MARS [ ] [ ] [′Pulmonary alveolar (MARS):c.1031A>G proteinosis′, (p.Tyr344Cys) ′Interstitial lung and liver disease′] NM_006343.2 730880273 MERTK [ ] [ ] [′Retinitis (MERTK):c.1605-2A>G pigmentosa 38′] NM_003611.2 730880283 OFD1 [ ] [ ] [′Retinitis (OFD1):c.935+706A>G Pigmentosa 23′] NM_004793.3 730880293 LONP1 [ ] [ ] [′CODAS (LONP1):c.2353A>G syndrome′] (p.Arg785Gly) NM_001698.2 730880311 AUH [ ] [ ] [′3-Methylglutaconic (AUH):c.263-2A>G aciduria′] NM_001698.2 730880312 AUH [ ] [ ] [′3-Methylglutaconic (AUH):c.943-2A>G aciduria′] NM_000169.2 730880444 — [ ] [′GTGAACCYGAA [′not provided′] (GLA):c.370-2A>G ATGAGAGGGAGG′] NM_001110792.1 727505391 MECP2 [ ] [ ] [′Rett disorder′] (MECP2):c.520A>G (p.Arg174Gly) NM_030662.3 730880517 MAP2K2 [ ] [ ] [′Cardiofaciocutaneous (MAP2K2):c.181A>G syndrome′, (p.Lys61Glu) ′Rasopathy′] NM_000256.3 730880531 MYBPC3 [ ] [′GTACCYGGGTG [′Familial (MYBPC3):c.1227-2A>G GGGGCCGCAGGG′, hypertrophic ′TGTACCYGGGTG cardiomyopathy 4′, GGGGCCGCAGG′] ′Cardiomyopathy′] NM_000642.2 369973784 AGL [ ] [ ] [′Glycogen storage (AGL):c.4260-12A>G disease type III′, ′Glycogen storage disease IIIa′, ′Glycogen storage disease IIIb′] NM_000267.3 267606602 NF1 [ ] [ ] [′Neurofibromatosis, (NF1):c.1642-8A>G type 1′, ′Juvenile myelomonocytic leukemia′] NM_000267.3 267606604 NF1 [ ] [ ] [′Neurofibromatosis, (NF1):c.5944-5A>G type 1′, ′Neurofibromatosis, familial spinal′] m.1555A>G 267606617 MT- [ ] [ ] [′Aminoglycoside- RNR1 induced deafness′, ′Cardiomyopathy, restrictive′, ′Deafness, nonsyndromic sensorineural, mitochondrial′] NM_022458.3 606231150 LMBR1 [ ] [ ] [′Triphalangeal (LMBR1):c.423+5252A>G thumb′, ′Preaxial polydactyly 2′] NM_000642.2 267606639 AGL [ ] [ ] [′Glycogen storage (AGL):c.3439A>G disease IIIc′] (p.Arg1147Gly) NM_013411.4 267606643 AK2 [ ] [′TCAYCTTTCATG [′Reticular (AK2):c.494A>G GGCTCTTTTGG′] dysgenesis′] (p.Asp165Gly) NM_001142800.1 183589498 EYS [ ] [ ] [′Retinitis (EYS):c.9209T>C pigmentosa′] (p.Ile3070Thr) NM_004183.3 267606677 BEST1 [ ] [ ] [′Vitelliform (BEST1):c.680A>G dystrophy′, ′Retinitis (p.Tyr227Cys) pigmentosa, concentric′, ′not provided′] NM_005188.3 267606705 CBL [ ] [′TATTTYACATAG [′Noonan syndrome- (CBL):c.1144A>G TTGGAATGTGG′] like disorder with or (p.Lys382Glu) without juvenile myelomonocytic leukemia′] NM_001017361.2 606231235 KHDC3L [ ] [ ] [′Hydatidiform mole, (KHDC3L):c.1A>G recurrent, 2′] (p.Met1Val) NM_144577.3 606231239 CCDC114 [ ] [ ] [′Ciliary dyskinesia, (CCDC114):c.487-2A>G primary, 20′] NM_000277.1 62642934 PAH [ ] [′GGCCAAYTTCCT [′Phenylketonuria′, (PAH):c.916A>G GTAATTGGGGG′, ′Hyperphenylalanine (p.Ile306Val) ′AGGCCAAYTTCC mia, non-pku′, ′not TGTAATTGGGG′] provided′] NM_000257.3 730880760 MYH7 [ ] [ ] [′Cardiomyopathy′] (MYH7):c.2792A>G (p.Glu931Gly) NM_207034.2 267606778 EDN3 [ ] [ ] [′Waardenburg (EDN3):c.335A>G syndrome type 4B′] (p.His112Arg) NM_000117.2 267606782 EMD [ ] [′TCCAYGGCGGGT [′Emery-Dreifuss (EMD):c.1A>G GCGGGCTCAGG′] muscular dystrophy, (p.Met1Val) X-linked′] NM_003937.2 606231307 KYNU [ ] [ ] [′Hydroxykynureninuria′] (KYNU):c.592A>G (p.Thr198Ala) NM_004387.3 587782928 NKX2-5 [ ] [ ] [′Atrial septal defect (NKX2-5):c.461A>G 7 with or without (p.Glu154Gly) atrioventricular conduction defects′] NM_000142.4 267606808 FGFR3 [ ] [ ] [′Thanatophoric (FGFR3):c.1454A>G dysplasia type 1′] (p.Gln485Arg) NM_014053.3 267606820 FLVCR1 [ ] [′AGGCGTYGACC [′Posterior column (FLVCR1):c.361A>G AGCGAGTACAGG′] ataxia with retinitis (p.Asn121Asp) pigmentosa′] NM_000257.3 730880805 — [ ] [′GCCCYCCTCGTG [′Cardiomyopathy′] (MYH7):c.4664A>G CTCCAGGGAGG′, (p.Glu1555Gly) ′CTTGCCCYCCTC GTGCTCCAGGG′] NM_138387.3 267606834 G6PC3 [ ] [′TGATCAYGCAGT [′Dursun syndrome′] (G6PC3):c.346A>G GTCCAGAAGGG′, (p.Met116Val) ′GTGATCAYGCAG TGTCCAGAAGG′] NM_020347.3 515726135 LZTFL1 [ ] [ ] [′Bardet-Biedl (LZTFL1):c.260T>C syndrome′, ′Bardet- (p.Leu87Pro) Biedl syndrome 17′] NM_000175.3 267606851 GPI [ ] [′GTACYGGTCATA [′Hemolytic anemia, (GPI):c.1028A>G GGGCAGCATGG′] nonspherocytic, due (p.Gln343Arg) to glucose phosphate isomerase deficiency′] NM_005859.4 587782994 PURA [ ] [ ] [′Neonatal (PURA):c.289A>G hypotonia′, (p.Lys97Glu) ′Intellectual disability′, ′Seizures′, ′Delayed speech and language development′, ′Global developmental delay′, ′Mental retardation, autosomal dominant 31′] NM_005144.4 267606869 HR [′CTCYAGG [′CTCYAGGGCCGC [′Marie Unna (HR):c.-218A>G GCCGCAGG AGGTTGGAGGG′, hereditary TTGGAGGG′] ′GCTCYAGGGCCG hypotrichosis 1′] CAGGTTGGAGG′, ′GGCGCTCYAGGG CCGCAGGTTGG′] NM_000257.3 730880855 MYH7 [ ] [ ] [′Cardiomyopathy′] (MYH7):c.789A>G (p.Ile263Met) NM_000060.3 587783004 BTD [ ] [ ] [′Biotinidase (BTD):c.683A>G deficiency′] (p.Asp228Gly) NM_000257.3 730880864 MYH7 [ ] [ ] [′Cardiomyopathy′] (MYH7):c.1051A>G (p.Lys351Glu) NM_015713.4 515726182 RRM2B [ ] [′TTCCTTCYGGAC [′RRM2B-related (RRM2B):c.190T>C AGCAGAAGAGG′] mitochondrial (p.Trp64Arg) disease′] NM_005957.4 267606887 MTHFR [′CGCGGYT [′CGCGGYTGAGG [′Homocystinuria (MTHFR):c.971A>G GAGGGTGT GTGTAGAAGTGG′] due to MTHFR (p.Asn324Ser) AGAAGTGG′] deficiency′] NM_015713.4 515726187 RRM2B [ ] [ ] [′RRM2B-related (RRM2B):c.368T>C mitochondrial (p.Phe123Ser) disease′] m.12770A>G 267606894 MT-ND5 [ ] [ ] [′Juvenile myopathy, encephalopathy, lactic acidosis AND stroke′] NM_000257.3 730880880 MYH7 [ ] [ ] [′Cardiomyopathy′] (MYH7):c.1805A>G (p.Asn602Ser) NM_018109.3 267606900 MTPAP [′AATGGAT [′AATGGATYCTGA [′Ataxia, spastic, 4, (MTPAP):c.1432A>G YCTGAATG ATGTACAGAGG′] autosomal (p.Asn478Asp) TACAGAGG′] recessive′] NM_000257.3 267606908 MYH7 [ ] [ ] [′Primary familial (MYH7):c.2717A>G hypertrophic (p.Asp906Gly) cardiomyopathy′, ′Familial hypertrophic cardiomyopathy 1′, ′Cardiomyopathy′] NM_003122.4 515726207 SPINK1 [ ] [ ] [′Hereditary (SPINK1):c.160T>C pancreatitis′] (p.Tyr54His) NM_003159.2 587783080 CDKL5 [ ] [ ] [′not provided′] (CDKL5):c.404-2A>G NM_003159.2 587783083 CDKL5 [′ACAGTYT [′ACAGTYTTAGGA [′not provided′] (CDKL5):c.449A>G TAGGACAT CATCATTGTGG′] (p.Lys150Arg) CATTGTGG′] NM_016203.3 267606977 PRKAG2 [ ] [ ] [′Familial (PRKAG2):c.1589A>G hypertrophic (p.His530Arg) cardiomyopathy 6′, ′not provided′] NM_198965.1 267606987 PTHLH [ ] [ ] [′Brachydactyly type (PTHLH):c.534A>G E2′] (p.Ter178Trp) NM_000531.5 74518351 OTC [ ] [ ] [′not provided′] (OTC):c.122A>G (p.Asp41Gly) NM_001134363.2 267607005 RBM20 [ ] [ ] [′Dilated (RBM20):c.1909A>G cardiomyopathy (p.Ser637Gly) 1DD′] NM_000553.4 267607008 WRN [ ] [ ] [′Werner syndrome′] (WRN):c.403A>G (p.Lys135Glu) NM_002880.3 730881002 RAF1 [ ] [′GCTGCYGCCCTC [′Rasopathy′] (RAF1):c.1279A>G GCACCACTGGG′, (p.Ser427Gly) ′GGCTGCYGCCCT CGCACCACTGG′] NM_002977.3 267607030 SCN9A [ ] [′AAGCTCYGAGG [′Primary (SCN9A):c.29A>G TCCTGGGGGAGG′] erythromelalgia′] (p.Gln10Arg) NM_016955.3 267607036 SEPSECS [ ] [ ] [′Pontocerebellar (SEPSECS):c.1001A>G hypoplasia type 2D′] (p.Tyr334Cys) NM_007373.3 267607048 SHOC2 [ ] [′TACYCATGGTGA [′Noonan-like (SHOC2):c.4A>G CTCAAGCCTGG′] syndrome with loose (p.Ser2Gly) anagen hair′, ′Rasopathy′] NM_005633.3 730881044 SOS1 [ ] [ ] [′Rasopathy′] (SOS1):c.1430A>G (p.Gln477Arg) NM_007375.3 267607102 TARDBP [ ] [ ] [′FRONTOTEMPORAL (TARDBP):c.787A>G DEMENTIA (p.Lys263Glu) WITH TDP43 INCLUSIONS, TARDBP- RELATED′] NM_003286.2 267607131 — [ ] [ ] [ ] (TOP1):c.1598A>G (p.Asp533Gly) NM_021625.4 267607150 TRPV4 [ ] [ ] [′Spondyloepiphyseal (TRPV4):c.1805A>G dysplasia (p.Tyr602Cys) Maroteaux type′] NM_000551.3 267607170 VHL [ ] [ ] [′Von Hippel-Lindau (VHL):c.491A>G syndrome′] (p.Gln164Arg) NM_001006657.1 267607174 WDR35 [ ] [ ] [′Cranioectodermal (WDR35):c.1877A>G dysplasia 2′] (p.Glu626Gly) NM_024884.2 267607206 L2HGDH [ ] [ ] [′L-2- (L2HGDH):c.293A>G hydroxyglutaric (p.His98Arg) aciduria′] NM_002437.4 267607256 MPV17 [ ] [ ] [′Navajo (MPV17):c.262A>G neurohepatopathy′] (p.Lys88Glu) NM_006888.4 267607277 CALM1 [ ] [ ] [′Catecholaminergic (CALM1):c.293A>G polymorphic (p.Asn98Ser) ventricular tachycardia′, ′Ventricular tachycardia, catecholaminergic polymorphic, 4′] NM_000487.5 6151429 ARSA [ ] [ ] [′Metachromatic (ARSA):c.*96A>G leukodystrophy′, ′Arylsulfatase A pseudodeficiency′, ′not provided′] NM_003122.4 148954387 SPINK1 [ ] [ ] [′Hereditary (SPINK1):c.194+2T>C pancreatitis′] NM_000552.3 267607326 VWF [ ] [ ] [′von Willebrand (VWF):c.3437A>G disease type 2′, ′not (p.Tyr1146Cys) provided′] NM_000489.4 122445093 ATRX [ ] [ ] [′ATR-X syndrome′] (ATRX):c.4826A>G (p.His1609Arg) NM_000489.4 122445098 ATRX [ ] [ ] [′ATR-X syndrome′] (ATRX):c.6488A>G (p.Tyr2163Cys) NM_000489.4 122445112 ATRX [ ] [ ] [ ] (ATRX):c.6811A>G (p.Arg2271Gly) NM_004380.2 587783486 CREBBP [ ] [′GCAGCCCYAGG [′Rubinstein-Taybi (CREBBP):c.3983-2A>G AAGTCCAGAAGG′] syndrome′] NM_004380.2 587783497 CREBBP [ ] [ ] [′Rubinstein-Taybi (CREBBP):c.4508A>G syndrome′] (p.Tyr1503Cys) NM_000051.3 730881357 ATM [ ] [′AGCCYACGGGA [′Hereditary cancer- (ATM):c.3154-2A>G AAAGAACTGTGG′] predisposing syndrome′] NM_178151.2 587783518 DCX [ ] [ ] [′Heterotopia′] (DCX):c.1027-2A>G NM_178151.2 587783557 DCX [ ] [ ] [′Heterotopia′] (DCX):c.520A>G (p.Lys174Glu) NM_178151.2 587783560 DCX [ ] [ ] [′Heterotopia′] (DCX):c.538A>G (p.Lys180Glu) NM_178151.2 587783570 DCX [ ] [ ] [′Heterotopia′] (DCX):c.607A>G (p.Thr203Ala) NM_001257235.1 398122394 ALG13 [ ] [ ] [′Congenital disorder (ALG13):c.8A>G of glycosylation type (p.Asn3Ser) 1s′] NM_001256864.1 398122404 DNAJC6 [ ] [′AGGTATCYGAA [′Parkinson disease (DNAJC6):c.801-2A>G ACAGAAGGTTGG′] 19, juvenile-onset′] NM_001927.3 267607482 DES [ ] [′GAATCGTYCTGC [′Myofibrillar (DES):c.1024A>G AGGAGAGGGGG′] myopathy 1′, ′not (p.Asn342Asp) provided′] NM_001927.3 267607483 DES [ ] [ ] [′Myofibrillar (DES):c.735+3A>G myopathy 1′, ′not provided′] NM_001927.3 267607498 DES [ ] [ ] [′not provided′] (DES):c.1333A>G (p.Thr445Ala) NM_005249.4 587783641 FOXG1 [ ] [ ] [′Rett syndrome, (FOXG1):c.757A>G congenital variant′] (p.Asn253Asp) NM_000252.2 587783789 MTM1 [ ] [ ] [′Severe X-linked (MTM1):c.1406A>G myotubular (p.His469Arg) myopathy′] NM_000391.3 796053439 TPP1 [ ] [′CAGGTACYGCA [′not provided′] (TPP1):c.833A>G CATCTAGACTGG′] (p.Gln278Arg) NM_000252.2 587783818 MTM1 [ ] [ ] [′Severe X-linked (MTM1):c.301A>G myotubular (p.Ser101Gly) myopathy′] NM_000252.2 587783821 MTM1 [ ] [ ] [′Severe X-linked (MTM1):c.343-2A>G myotubular myopathy′] NM_000252.2 587783831 MTM1 [ ] [ ] [′Severe X-linked (MTM1):c.529-2A>G myotubular myopathy′] NM_000252.2 587783835 MTM1 [ ] [′GTTATTCYCCAA [′Severe X-linked (MTM1):c.550A>G TGGTGATTGGG′] myotubular (p.Arg184Gly) myopathy′] NM_000158.3 192044702 GBE1 [ ] [ ] [′Glycogen storage (GBE1):c.691+2T>C disease, type IV′] NM_000252.2 587783842 MTM1 [ ] [′TCATCAYCTGAG [′Severe X-linked (MTM1):c.629A>G GCACGATACGG′] myotubular (p.Asp210Gly) myopathy′] NM_000249.3 267607760 MLH1 [ ] [ ] [′Hereditary (MLH1):c.545+3A>G Nonpolyposis Colorectal Neoplasms′] NM_000249.3 267607767 MLH1 [ ] [ ] [′Hereditary (MLH1):c.589-2A>G Nonpolyposis Colorectal Neoplasms′, ′Hereditary cancer- predisposing syndrome′] NM_000249.3 267607777 MLH1 [ ] [′TGCTACAYTACC [′Hereditary (MLH1):c.884+4A>G TGAGGTACAGG′] Nonpolyposis Colorectal Neoplasms′] NM_000081.3 80338669 LYST [ ] [ ] [′Ch\xc3\xa9diak- (LYST):c.10127A>G Higashi syndrome′] (p.Asn3376Ser) NM_000528.3 80338678 MAN2B1 [ ] [ ] [′Deficiency of (MAN2B1):c.1831-2A>G alpha-mannosidase′] NM_022132.4 119103225 MCCC2 [ ] [ ] [′3-methylcrotonyl (MCCC2):c.569A>G CoA carboxylase 2 (p.His190Arg) deficiency′] m.3260A>G 199474663 MT-TL1 [′TTAAGTT [′TTAAGTTYTATG [′Cardiomyopathy YTATGCGA CGATTACCGGG′] with or without TTACCGGG′] skeletal myopathy′] NM_014874.3 119103264 MFN2 [ ] [ ] [′Hereditary motor (MFN2):c.827A>G and sensory (p.Gln276Arg) neuropathy with optic atrophy′] NM_004525.2 80338743 LRP2 [ ] [ ] [′Donnai Barrow (LRP2):c.770-2A>G syndrome′] NM_005120.2 80338759 MED12 [ ] [ ] [′X-linked mental (MED12):c.3020A>G retardation with (p.Asn1007Ser) marfanoid habitus syndrome′] NM_000834.3 398122824 GRIN2B [ ] [ ] [′Mental retardation, (GRIN2B):c.2172-2A>G autosomal dominant 6′] NM_000249.3 267607883 MLH1 [ ] [ ] [′Hereditary (MLH1):c.1990-2A>G Nonpolyposis Colorectal Neoplasms′, ′not provided′] NM_000518.4 33972047 HBB [ ] [′CACGYTCACCTT [′alpha Thalassemia′] (HBB):c.59A>G GCCCCACAGGG′, (p.Asn20Ser) ′CCACGYTCACCT TGCCCCACAGG′] NM_003688.3 398122844 CASK [ ] [ ] [′FG syndrome 4′, (CASK):c.2168A>G ′Mental retardation (p.Tyr723Cys) and microcephaly with pontine and cerebellar hypoplasia′] NM_024675.3 730881897 PALB2 [ ] [ ] [′Hereditary cancer- (PALB2):c.109-2A>G predisposing syndrome′] NM_000251.2 267607962 MSH2 [ ] [ ] [′Hereditary (MSH2):c.1511-2A>G Nonpolyposis Colorectal Neoplasms′] NM_003124.4 398122922 SPR [ ] [ ] [Sepiapterin (SPR):c.596-2A>G reductase deficiency′] NM_022455.4 587784120 NSD1 [ ] [ ] [′Sotos syndrome 1′] (NSD1):c.4498-3A>G NM_000455.4 730881978 STK11 [ ] [ ] [′Hereditary cancer- (STK11):c.889A>G predisposing (p.Arg297Gly) syndrome′] NM_001927.3 398122940 DES [ ] [ ] [′Muscular (DES):c.1289-2A>G dystrophy, limb- girdle, type 2r′] NM_000546.5 730882004 TP53 [ ] [′ACACAYGTAGTT [′Li-Fraumeni (TP53):c.709A>G GTAGTGGATGG′] syndrome′, (p.Met237Val) ′Hereditary cancer- predisposing syndrome′] NM_024876.3 398122979 ADCK4 [ ] [ ] [′Nephrotic (ADCK4):c.857A>G syndrome, type 9′] (p.Asp286Gly) NM_022455.4 587784178 NSD1 [ ] [ ] [′Sotos syndrome 1′] (NSD1):c.6059A>G (p.Asn2020Ser) NM_022455.4 587784191 NSD1 [ ] [ ] [′Sotos syndrome 1′] (NSD1):c.6356A>G (p.Asp2119Gly) NM_007332.2 398123010 — [ ] [ ] [′Familial episodic (TRPA1):c.2564A>G pain syndrome 1′] (p.Asn855Ser) NM_001231.4 730882052 CASQ1 [ ] [′GGCTTGYCTGGG [′Myopathy, (CASQ1):c.731A>G ATGGTCACAGG′] vacuolar, with casq1 (p.Asp244Gly) aggregates′] NM_004004.5 80338949 GJB2 [ ] [ ] [′Deafness, (GJB2):c.487A>G autosomal recessive (p.Met163Val) 1A′, ′not specified′] NM_130466.3 398123022 UBE3B [ ] [ ] [′Kaufman (UBE3B):c.545-2A>G oculocerebrofacial syndrome′] NM_000334.4 80338959 SCN4A [ ] [′GATCAYGATGGT [′Hyperkalemic (SCN4A):c.4078A>G GATGTCGAAGG′] Periodic Paralysis (p.Met1360Val) Type 1′] NM_000334.4 80338960 SCN4A [ ] [′CCATCAYGGTGA [′Hyperkalemic (SCN4A):c.4108A>G CCATGTTGAGG′] Periodic Paralysis (p.Met1370Val) Type 1′] NM_000334.4 80338962 SCN4A [ ] [′TGTACAYGTTGA [′Hyperkalemic (SCN4A):c.4774A>G CCACGATGAGG′] Periodic Paralysis (p.Met1592Val) Type 1′, ′Familial hyperkalemic periodic paralysis′] NM_015250.3 398123030 BICD2 [ ] [ ] [′Spinal muscular (BICD2):c.2321A>G atrophy, lower (p.Glu774Gly) extremity predominant 2, autosomal dominant′] NM_006012.2 398123035 CLPP [ ] [ ] [′Autosomal (CLPP):c.270+4A>G recessive hearing impairment with normal menstrual cycles′] NM_000179.2 267608098 MSH6 [ ] [ ] [′Hereditary (MSH6):c.3439-2A>G Nonpolyposis Colorectal Neoplasms′, ′Hereditary cancer- predisposing syndrome′, ′not provided′] NM_002246.2 398123043 KCNK3 [ ] [ ] [′Primary pulmonary (KCNK3):c.575A>G hypertension 4′] (p.Tyr192Cys) NM_001070.4 398123046 TUBG1 [ ] [ ] [′Cortical dysplasia, (TUBG1):c.275A>G complex, with other (p.Tyr92Cys) brain malformations 4′] NM_000383.3 179363882 AIRE [ ] [ ] [′Polyglandular (AIRE):c.254A>G autoimmune (p.Tyr85Cys) syndrome, type 1′, ′not provided′] NM_001651.3 398123057 AQP5 [ ] [ ] [′Diffuse (AQP5):c.367A>G palmoplantar (p.Asn123Asp) keratoderma, Bothnian type′] NM_012160.4 398123062 FBXL4 [ ] [′TATGYCCAGCTG [′Mitochondrial (FBXL4):c.1694A>G CTGTAACCTGG′] DNA depletion (p.Asp565Gly) syndrome 13 (encephalomyopathic type)′] NM_024531.4 398123068 SLC52A2 [ ] [ ] [Brown-Vialetto- (SLC52A2):c.914A>G Van Laere syndrome (p.Tyr305Cys) 2′] NM_001039550.1 730882140 DNAJB2 [ ] [′GATCTCGYAGTA [′Charcot-Marie- (DNAJB2):c.14A>G GGATGCCATGG′] Tooth disease′, (p.Tyr5Cys) ′Charcot-Marie- Tooth disease, axonal, type 2T′] NM_052859.3 796053522 RFT1 [ ] [′GCAYCACAAAA [′Congenital disorder (RFT1):c.1222A>G TTGTACCTGGGG′, of glycosylation type (p.Met408Val) ′AGCAYCACAAAA 1N′] TTGTACCTGGG′, ′CAGCAYCACAAA ATTGTACCTGG′] NM_007294.3 730882166 BRCA1 [ ] [ ] [′Breast-ovarian (BRCA1):c.5057A>G cancer, familial 1′] (p.His1686Arg) NM_000050.4 398123130 ASS1 [ ] [ ] [′Citrullinemia type (ASS1):c.496-2A>G I′] NM_012233.2 730882183 RAB3GAP1 [ ] [ ] [′Warburg micro (RAB3GAP1):c.649-2A>G syndrome 1′] NM_000159.3 398123194 GCDH [ ] [ ] [′Glutaric aciduria, (GCDH):c.542A>G type 1′, ′not (p.Glu181Gly) provided′] NM_000288.3 267608255 PEX7 [ ] [ ] [′Phytanic acid (PEX7):c.340-10A>G storage disease′, ′Peroxisome biogenesis disorder 9B′] NM_000038.5 786201291 APC [ ] [ ] [′Hereditary cancer- (APC):c.221-2A>G predisposing syndrome′] NM_000169.2 398123210 — [ ] [ ] [′Fabry disease′] (GLA):c.509A>G (p.Asp170Gly) NM_000169.2 398123211 — [ ] [′AACCYGTATGA [′Fabry disease′] (GLA):c.548-2A>G GAAAACAATGGG′, ′TAACCYGTATGA GAAAACAATGG′] NM_006888.4 730882252 CALM1 [ ] [ ] [′Long QT syndrome (CALM1):c.389A>G 14′] (p.Asp130Gly) NM_000169.2 398123217 — [ ] [ ] [′Fabry disease′] (GLA):c.647A>G (p.Tyr216Cys) NM_006306.3 587784423 SMC1A [ ] [′AGCCYGTGCAA [′Congenital (SMC1A):c.616-2A>G ACAGGGGAATGG′] muscular hypertrophy-cerebral syndrome′] NM_000255.3 398123276 MUT [ ] [ ] [′Methylmalonic (MUT):c.1445-2A>G aciduria due to methylmalonyl-CoA mutase deficiency′, ′not provided′] NM_001083962.1 587784470 TCF4 [ ] [ ] [′Pitt-Hopkins (TCF4):c.991-2A>G syndrome′] NM_000060.3 201023772 BTD [ ] [ ] [′Biotinidase (BTD):c.1205A>G deficiency′] (p.Asn402Ser) NC_000007.14: 483352872 — [ ] [ ] [′Isolated growth g.62535490A>G hormone deficiency type 1B′] NM_000271.4 483352887 NPC1 [ ] [ ] [′Niemann-Pick (NPC1):c.1832A>G disease type C1′] (p.Asp611Gly) NM_152419.2 483352896 HGSNAT [ ] [ ] [′Mucopolysaccharidosis, (HGSNAT):c.372-2A>G MPS-III-C′] NM_001199397.1 483352906 NEK1 [ ] [ ] [′Short rib- (NEK1):c.869-2A>G polydactyly syndrome, Majewski type′] NM_000350.2 398123339 ABCA4 [ ] [ ] [′Stargardt disease (ABCA4):c.67-2A>G 1′] NM_004992.3 267608412 MECP2 [ ] [ ] [′Rett disorder′, ′not (MECP2):c.27-2A>G provided′] NM_003159.2 267608423 CDKL5 [ ] [ ] [′Early infantile (CDKL5):c.100-2A>G epileptic encephalopathy 2′, ′not provided′] NM_003159.2 267608429 CDKL5 [ ] [ ] [′Early infantile (CDKL5):c.125A>G epileptic (p.Lys42Arg) encephalopathy 2′, ′not provided′] NM_000487.5 398123411 ARSA [ ] [′GGCTCYGGGGG [′Metachromatic (ARSA):c.1108-2A>G CAGAGTCAGGGG′, leukodystrophy′] ′GGGCTCYGGGGG CAGAGTCAGGG′, ′AGGGCTCYGGGG GCAGAGTCAGG′] NM_003159.2 267608468 CDKL5 [ ] [ ] [′Atypical Rett (CDKL5):c.380A>G syndrome′, ′not (p.His127Arg) provided′] NM_000489.4 398123420 ATRX [ ] [ ] [′not provided′] (ATRX):c.134-2A>G NM_003159.2 267608480 CDKL5 [ ] [ ] [′Early infantile (CDKL5):c.464-2A>G epileptic encephalopathy 2′, ′not provided′] NM_000489.4 398123425 ATRX [ ] [ ] [′not provided′] (ATRX):c.536A>G (p.Asn179Ser) NM_000512.4 398123429 GALNS [ ] [′CCGCCAYCAGC [′Mucopolysaccharidosis, (GALNS):c.1171A>G GTGTCGCCACGG′] MPS-IV-A′, (p.Met391Val) ′not provided′] NM_003159.2 267608500 CDKL5 [ ] [′ATGYCCACGGA [′Early infantile (CDKL5):c.578A>G CTTTCCATAGGG′, epileptic (p.Asp193Gly) ′CATGYCCACGGA encephalopathy 2′] CTTTCCATAGG′] NM_000521.3 398123446 HEXB [ ] [ ] [′Sandhoff disease′, (HEXB):c.1243-2A>G ′not provided′] NM_003159.2 267608553 CDKL5 [ ] [ ] [′Early infantile (CDKL5):c.978-2A>G epileptic encephalopathy 2′, ′not provided′] NM_001164342.2 483353066 ZBTB20 [ ] [ ] [′Primrose (ZBTB20):c.1787A>G syndrome′] (p.His596Arg) NM_000402.4 398123552 — [ ] [′ACACACAYATTC [′Anemia, (G6PD):c.188T>C ATCATCATGGG′] nonspherocytic (p.Ile63Thr) hemolytic, due to G6PD deficiency′, ′not provided′] NM_001893.4 104894561 CSNK1D [ ] [ ] [′Advanced sleep (CSNK1D):c.130A>G phase syndrome, (p.Thr44Ala) familial, 2′] NM_000155.3 75391579 GALT [ ] [′TTACCYGGCAGT [′Deficiency of (GALT):c.563A>G GGGGGTGGGGG′, UDPglucose- (p.Gln188Arg) ′CTTACCYGGCAG hexose-1-phosphate TGGGGGTGGGG′, uridylyltransferase′, ′CCTTACCYGGCA ′not provided′] GTGGGGGTGGG′] NM_007055.3 267608671 POLR3A [ ] [ ] [′Hypomyelinating (POLR3A):c.2554A>G leukodystrophy 7′] (p.Met852Val) NM_001848.2 398123639 COL6A1 [ ] [′TTCTCCCYGGAA [′Ullrich congenital (COL6A1):c.805-2A>G CACAAAACAGG′] muscular dystrophy′, ′Bethlem myopathy′, ′not provided′] NM_001918.3 398123674 DBT [ ] [ ] [′Maple syrup urine (DBT):c.773-2A>G disease′, ′not provided′] NM_001999.3 149054177 FBN2 [′GAATGTA [′GAATGTAYGAT [′not specified′, (FBN2):c.3740T>C YGATAATG AATGAACGGAGG′] ′Macular (p.Met1247Thr) AACGGAG degeneration, early- G′] onset′] NM_003482.3 398123750 KMT2D [ ] [′GCAGTTCYGTGG [′Kabuki make-up (KMT2D):c.5645-2A>G GGGAATGAAGG′] syndrome′, ′not provided′] NM_003494.3 398123769 DYSF [ ] [ ] [′Limb-girdle (DYSF):c.1398-2A>G muscular dystrophy, type 2B′, ′not provided′] NM_015560.2 143319805 OPA1 [ ] [ ] [′Dominant (OPA1):c.1146A>G hereditary optic (p.Ile382Met) atrophy′, ′Optic Atrophy Type 1′, ′not specified′, ′not provided′] NM_203447.3 112321280 DOCK8 [ ] [ ] [′Hyperimmunoglobulin (DOCK8):c.1418A>G E recurrent (p.Lys473Arg) infection syndrome, autosomal recessive′] NM_001145.4 121909537 — [′TGGTTYG [′TGGTTYGGCATC [′Amyotrophic (ANG):c.121A>G GCATCATA ATAGTGCTGGG′, lateral sclerosis type (p.Lys41Glu) GTGCTGGG, ′GTGGTTYGGCAT 9′] ′GTGGTTYG CATAGTGCTGG′] GCATCATA GTGCTGG′] NM_004006.2 398123938 DMD [ ] [ ] [′Dilated (DMD):c.3432+3A>G cardiomyopathy 3B′] NM_006514.3 138404783 SCN10A [ ] [ ] [′Episodic pain (SCN10A):c.1661T>C syndrome, familial, (p.Leu554Pro) 2′] NM_004006.2 398124033 DMD [ ] [ ] [′Dilated (DMD):c.6763-2A>G cardiomyopathy 3B′] NM_001079802.1 119464998 FKTN [ ] [ ] [ ] (FKTN):c.1112A>G (p.Tyr371Cys) NM_004006.2 398124084 DMD [ ] [ ] [′Dilated (DMD):c.9224+61934A>G cardiomyopathy 3B′] NM_004006.2 398124091 DMD [ ] [ ] [′Duchenne (DMD):c.9225-647A>G muscular dystrophy′, ′Becker muscular dystrophy′, ′Dilated cardiomyopathy 3B′] NM_004006.2 398124100 DMD [ ] [ ] [′Duchenne (DMD):c.9650-2A>G muscular dystrophy′, ′Becker muscular dystrophy′, ′Dilated cardiomyopathy 3B′] NM_198578.3 35808389 LRRK2 [ ] [ ] [′Parkinson disease (LRRK2):c.3342A>G 8, autosomal (p.Leu1114=) dominant′] NM_031229.2 566912235 RBCK1 [ ] [ ] [′Polyglucosan body (RBCK1):c.1160A>G myopathy 1 with or (p.Asn387Ser) without immunodeficiency′] NM_000178.2 28938472 GSS [ ] [ ] [′Glutathione (GSS):c.656A>G synthetase (p.Asp219Gly) deficiency of erythrocytes, hemolytic anemia due to′] NM_025132.3 374400438 WDR19 [ ] [ ] [SENIOR-LOKEN (WDR19):c.407-2A>G SYNDROME 8′] NM_144997.5 398124528 FLCN [ ] [′CCCACYGGGGA [′Hereditary cancer- (FLCN):c.1433-2A>G GAAGGGCAGGGG′, predisposing ′GCCCACYGGGGA syndrome′, ′not GAAGGGCAGGG′, provided′] ′GGCCCACYGGGG AGAAGGGCAGG′] NM_144997.5 398124533 FLCN [ ] [ ] [′not provided′] (FLCN):c.250-2A>G NM_000146.3 398124633 FTL [ ] [ ] [Hyperferritinemia (FTL):c.-160A>G cataract syndrome′] NM_003184.3 398124645 TAF2 [ ] [ ] [′Mental retardation, (TAF2):c.1945T>C autosomal recessive (p.Trp649Arg) 40′] NM_013281.3 398124654 — [ ] [ ] [′Hypogonadotropic (FLRT3):c.1016A>G hypogonadism 21 (p.Lys339Arg) with or without anosmia′] NM_002834.3 397507523 PTPN11 [ ] [ ] [′Noonan syndrome (PTPN11):c.767A>G 1′, ′Rasopathy′, ′not (p.Gln256Arg) provided′] NM_000054.4 104894749 AVPR2 [′ACAYAGG [′ACAYAGGTGCG [′Nephrogenic (AVPR2):c.614A>G TGCGACGG ACGGCCCCAGGG′, diabetes insipidus′, (p.Tyr205Cys) CCCCAGGG, ′GACAYAGGTGCG ′Nephrogenic ′GACAYAG ACGGCCCCAGG′] diabetes insipidus, GTGCGACG X-linked′] GCCCCAGG′] NM_031157.2 397518454 HNRNPA1 [ ] [ ] [′Amyotrophic (HNRNPA1):c.956A>G lateral sclerosis 20′] (p.Asn319Ser) NM_000277.1 62514934 PAH [ ] [ ] [′Phenylketonuria′, (PAH):c.662A>G ′not provided′] (p.Glu221Gly) NM_000219.5 141813529 KCNE1 [ ] [ ] [′Congenital long (KCNE1):c.176T>C QT syndrome′] (p.Leu59Pro) NM_001165963.1 794726713 SCN1A [ ] [ ] [′Severe myoclonic (SCN1A):c.1076A>G epilepsy in infancy′] (p.Asn359Ser) NM_013339.3 35383149 ALG6 [ ] [ ] [′Congenital disorder (ALG6):c.391T>C of glycosylation type (p.Tyr131His) 1C′, ′not specified′] NM_153767.3 59172778 KCNJ1 [ ] [ ] [′Bartter syndrome (KCNJ1):c.1013T>C antenatal type 2′] (p.Met338Thr) NM_176824.2 119466001 BBS7 [ ] [ ] [′Bardet-Biedl (BBS7):c.968A>G syndrome 7′] (p.His323Arg) NM_000199.3 138504221 SGSH [ ] [ ] [′Mucopolysaccharidosis, (SGSH):c.892T>C MPS-III-A′, (p.Ser298Pro) ′not provided′] NM_000891.2 199473652 KCNJ2 [′Congenital long (KCNJ2):c.220A>G QT syndrome′] (p.Thr74Ala) NM_001165963.1 794726768 SCN1A [′ACAYATA [′ACAYATATCCCT [′Severe myoclonic (SCN1A):c.1048A>G TCCCTCTG CTGGACATTGG′] epilepsy in infancy′] (p.Met350Val) GACATTGG′] NM_002863.4 113993976 PYGL [ ] [ ] [′Glycogen storage (PYGL):c.1016A>G disease, type VI′] (p.Asn339Ser) NM_001165963.1 794726794 SCN1A [ ] [ ] [′Severe myoclonic (SCN1A):c.2537A>G epilepsy in infancy′] (p.Glu846Gly) NM_002693.2 113994099 POLG [ ] [ ] [′Autosomal (POLG):c.2864A>G dominant (p.Tyr955Cys) progressive external ophthalmoplegia with mitochondrial DNA deletions 1′] NM_000920.3 113994144 PC [ ] [ ] [′Pyruvate (PC):c.1705A>G carboxylase (p.Thr569Ala) deficiency′] NM_025265.3 113994149 TSEN2 [ ] [′CAGAGCAYAGA [′Pontocerebellar (TSEN2):c.926A>G CCAAGAAAAAGG′] hypoplasia type 2B′] (p.Tyr309Cys) NM_001039958.1 113994156 MESP2 [ ] [ ] [′Spondylocostal (MESP2):c.271A>G dysostosis 2′] (p.Lys91Glu) NM_024649.4 113994180 — [ ] [ ] [′Bardet-Biedl (BBS1):c.1340-2A>G syndrome′] NM_033028.4 113994192 BBS4 [ ] [ ] [′Bardet-Biedl (BBS4):c.157-2A>G syndrome′, ′Bardet- Biedl syndrome 4′] NM_212472.2 281864779 PRKAR1A [ ] [ ] [′Carney complex, (PRKAR1A):c.1A>G type 1′] (p.Met1Val) NM_212472.2 281864796 PRKAR1A [ ] [ ] [′Carney complex, (PRKAR1A):c.178-2A>G type 1′] NM_212472.2 281864799 PRKAR1A [ ] [ ] [′Carney complex, (PRKAR1A):c.891+3A>G type 1′] NM_001165963.1 794726849 SCN1A [ ] [ ] [′Severe myoclonic (SCN1A):c.433A>G epilepsy in infancy′] (p.Met145Val) NM_005710.2 121917899 PQBP1 [ ] [ ] [′Renpenning (PQBP1):c.194A>G syndrome 1′] (p.Tyr65Cys) NM_000921.4 794726865 PDE3A [′CGAGGYG [′CGAGGYGGTGG [′Brachydactyly with (PDE3A):c.1333A>G GTGGTGGT TGGTCCAAGTGG′] hypertension′] (p.Thr445Ala) CCAAGTGG′] NM_024312.4 281864974 GNPTAB [ ] [ ] [′Pseudo-Hurler (GNPTAB):c.1285-2A>G polydystrophy′] NM_024312.4 281865003 GNPTAB [ ] [ ] [′I cell disease′] (GNPTAB):c.2783A>G (p.Lys928Arg) NM_024312.4 281865005 GNPTAB [ ] [ ] [′Pseudo-Hurler (GNPTAB):c.2867A>G polydystrophy′] (p.His956Arg) NM_024312.4 281865007 GNPTAB [ ] [ ] [′I cell disease′] (GNPTAB):c.3053A>G (p.Asp1018Gly) NM_024312.4 281865019 GNPTAB [ ] [ ] [′Pseudo-Hurler (GNPTAB):c.3458A>G polydystrophy′] (p.Asn1153Ser) NM_024312.4 281865023 GNPTAB [ ] [ ] [′I cell disease′] (GNPTAB):c.118-2A>G NM_198578.3 281865052 LRRK2 [ ] [′TCAACAYAATAT [′Parkinson disease (LRRK2):c.5605A>G TTCTAGGCAGG′] 8, autosomal (p.Met1869Val) dominant′] NM_139241.3 281865065 FGD4 [ ] [ ] [′Charcot-Marie- (FGD4):c.1762-2A>G Tooth disease, type 4H′] NM_006121.3 58420087 KRT1 [ ] [ ] [′Bullous (KRT1):c.1445A>G ichthyosiform (p.Tyr482Cys) erythroderma′, ′not provided′] NM_000195.4 281865080 HPS1 [ ] [ ] [′Hermansky-Pudlak (HPS1):c.716T>C syndrome 1′] (p.Leu239Pro) NM_000195.4 281865090 HPS1 [ ] [ ] [′Hermansky-Pudlak (HPS1):c.2003T>C syndrome 1′] (p.Leu668Pro) NM_022081.5(HPS4): 281865098 HPS4 [ ] [ ] [′Hermansky-Pudlak c.461A>G syndrome 4′] (p.His154Arg) NM_000277.1 62516141 PAH [ ] [ ] [′Phenylketonuria′, (PAH):c.1157A>G ′not provided′] (p.Tyr386Cys) NM_025114.3 281865192 CEP290 [′GAGATAY [′GATAYTCACAAT [′Leber congenital (CEP290):c.2991+1655A>G TCACAATT TACAACTGGGG′, amaurosis 10′, ′not ACAACTGG′] ′AGATAYTCACAA provided′] TTACAACTGGG′, ′GAGATAYTCACA ATTACAACTGG′] NM_018319.3 119467003 TDP1 [ ] [ ] [′Spinocerebellar (TDP1):c.1478A>G ataxia autosomal (p.His493Arg) recessive with axonal neuropathy′] NM_000051.3 774925473 ATM [ ] [ ] [′Ataxia- (ATM): telangiectasia c.5762_5763insNG_009830.1: variant′] g.91138_91274 NM_004614.4 281865495 TK2 [ ] [′AAGYCTCAGGA [′Mitochondrial (TK2):c.562A>G TTGGTCCGAAGG′] DNA depletion (p.Thr188Ala) syndrome 2′] NM_003494.3 756328339 DYSF [ ] [′CTAYACTCCCAG [′Limb-girdle (DYSF):c.3041A>G CCTGGGGGAGG′, muscular dystrophy, (p.Tyr1014Cys) ′ATGCTAYACTCC type 2B′] CAGCCTGGGGG′, ′GATGCTAYACTC CCAGCCTGGGG′] NM_000531.5 72558492 OTC [′AGGTGAG [′AGGTGAGYAAT [′not provided′] (OTC):c.1034A>G YAATCTGT CTGTCAGCAGGG′] (p.Tyr345Cys) CAGCAGGG′] NM_000518.4 34165323 HBB [ ] [ ] [′Hemoglobinopathy′] (HBB):c.199A>G (p.Lys67Glu) NM_153427.2 387906810 PITX2 [ ] [′TCTYGAACCAAA [′Axenfeld-Rieger (PITX2):c.262A>G CCTGGGGGCGG′, syndrome type 1′] (p.Lys88Glu) ′GATTCTYGAACC AAACCTGGGGG′, ′CGATTCTYGAAC CAAACCTGGGG′] NM_030964.3 78310959 SPRY4 [ ] [′AGTGCYTGTCCA [′Hypogonadotropic (SPRY4):c.530A>G GCTCGGGTGGG′, hypogonadism 17 (p.Lys177Arg) ′AAGTGCYTGTCC with or without AGCTCGGGTGG′] anosmia′] NM_002834.3 28933386 PTPN11 [ ] [ ] [′Noonan syndrome′, (PTPN11):c.922A>G ′Noonan syndrome (p.Asn308Asp) 1′, ′Rasopathy′, ′not provided′] NM_000518.4 34598529 HBB [ ] [ ] [′alpha Thalassemia′, (HBB):c.-50-29A>G ′Beta thalassemia intermedia′] NM_207352.3 144109267 CYP4V2 [ ] [′TTCCYGGGGCCA [′Bietti crystalline (CYP4V2):c.1393A>G GCAGAGAAGGG′, corneoretinal (p.Arg465Gly) ′GTTCCYGGGGCC dystrophy′] AGCAGAGAAGG′] NM_001360.2 104886033 DHCR7 [ ] [ ] [′Smith-Lemli-Opitz (DHCR7):c.1A>G syndrome′] (p.Met1Val) NM_000495.4 104886050 COL4A5 [ ] [ ] [′Alport syndrome, (COL4A5):c.1A>G X-linked recessive′] (p.Met1Val) NM_000495.4 104886192 COL4A5 [ ] [ ] [′Alport syndrome, (COL4A5):c.2692A>G X-linked recessive′] (p.Met898Val) NM_000495.4 104886193 COL4A5 [ ] [ ] [′Alport syndrome, (COL4A5):c.2746A>G X-linked recessive′] (p.Ser916Gly) NM_004572.3 144601090 PKP2 [ ] [ ] [′Arrhythmogenic (PKP2):c.2062T>C right ventricular (p.Ser688Pro) cardiomyopathy′, ′not specified′, ′not provided′] NM_000495.4 104886298 COL4A5 [ ] [ ] [′Alport syndrome, (COL4A5):c.4790A>G X-linked recessive′] (p.Tyr1597Cys) NM_000495.4 104886319 COL4A5 [ ] [′CACCYGAGTAA [′Alport syndrome, (COL4A5):c.1340-2A>G GATAAAGAAAGG′] X-linked recessive′] NM_000495.4 104886341 COL4A5 [ ] [ ] [′Alport syndrome, (COL4A5):c.2042-18A>G X-linked recessive′] NM_000495.4 104886344 COL4A5 [ ] [ ] [′Alport syndrome, (COL4A5):c.2147-2A>G X-linked recessive′] NM_000495.4 104886358 COL4A5 [ ] [ ] [′Alport syndrome, (COL4A5):c.2510-33A>G X-linked recessive′] NM_000495.4 104886379 COL4A5 [ ] [ ] [′Alport syndrome, (COL4A5):c.3107-2A>G X-linked recessive′] NM_000051.3 121434221 ATM [ ] [ ] [′Mantle cell (ATM):c.7268A>G lymphoma′] (p.Glu2423Gly) NM_000495.4 104886385 COL4A5 [ ] [ ] [′Alport syndrome, (COL4A5):c.3605-2A>G X-linked recessive′] NM_000096.3 386134137 CP [ ] [ ] [′Deficiency of (CP):c.1209-2A>G ferroxidase′] NM_000348.3 121434251 SRD5A2 [ ] [ ] [′3-Oxo-5 alpha- (SRD5A2):c.692A>G steroid delta 4- (p.His231Arg) dehydrogenase deficiency′] NM_002739.3 386134157 PRKCG [ ] [ ] [′Spinocerebellar (PRKCG):c.76A>G ataxia 14′] (p.Arg26Gly) NM_000383.3 121434255 AIRE [ ] [ ] [′AUTOIMMUNE (AIRE):c.247A>G POLYENDOCRIN- (p.Lys83Glu) OPATHY SYNDROME, TYPE I′] NM_000495.4 104886416 COL4A5 [ ] [′ACCCYAAAAGA [′Alport syndrome, (COL4A5):c.466-2A>G AGCCATCAATGG′] X-linked recessive′] NM_001127328.2 121434279 ACADM [ ] [ ] [′Medium-chain (ACADM):c.589A>G acyl-coenzyme A (p.Thr197Ala) dehydrogenase deficiency′] NM_000495.4 104886453 COL4A5 [ ] [ ] [′Alport syndrome, (COL4A5):c.892-2A>G X-linked recessive′] NM_020533.2 104886461 MCOLN1 [′TACYGTG [′TACYGTGGGCA [′Ganglioside (MCOLN1):c.406-2A>G GGCAGAG GAGAAGGGGAGG′, sialidase deficiency′, AAGGGGA ′AGGTACYGTGGG ′not provided′] GG′] CAGAGAAGGGG′, ′CAGGTACYGTGG GCAGAGAAGGG′] NM_018136.4 199422149 ASPM [ ] [ ] [′Primary autosomal (ASPM):c.2761-25A>G recessive microcephaly 5′] NM_017780.3 121434338 CHD7 [ ] [ ] [′CHARGE (CHD7):c.3082A>G association′, ′not (p.Ile1028Val) provided′] NM_017780.3 121434345 CHD7 [ ] [ ] [′Kallmann (CHD7):c.164A>G syndrome 5′] (p.His55Arg) NM_152783.4 121434362 D2HGDH [′GCAGGTY [′GCAGGTYACCAT [D-2- (D2HGDH):c.1315A>G ACCATCTC CTCCTGGAGGG′, hydroxyglutaric (p.Asn439Asp) CTGGAGGG′, ′TGCAGGTYACCA aciduria 1′] ′TGCAGGT TCTCCTGGAGG′] YACCATCT CCTGGAGG′] NM_005006.6 199422224 NDUFS1 [ ] [ ] [′Mitochondrial (NDUFS1):c.755A>G complex I (p.Asp252Gly) deficiency′, ′not provided′] NM_002894.2 121434388 RBBP8 [ ] [ ] [′Carcinoma of (RBBP8):c.1009A>G pancreas′] (p.Lys337Glu) NM_004621.5 121434391 TRPC6 [ ] [ ] [′Focal segmental (TRPC6):c.428A>G glomerulosclerosis (p.Asn143Ser) 2′] NM_003705.4 121434396 SLC25A12 [ ] [ ] [′Hypomyelination, (SLC25A12):c.1769A>G global cerebral′] (p.Gln590Arg) NM_001363.4 199422243 DKC1 [ ] [ ] [′Dyskeratosis (DKC1):c.127A>G congenita X-linked′] (p.Lys43Glu) NM_001084.4 121434414 PLOD3 [ ] [ ] [′Bone fragility with (PLOD3):c.668A>G contractures, arterial (p.Asn223Ser) rupture, and deafness′] NM_006702.4 121434415 PNPLA6 [ ] [ ] [′Spastic paraplegia (PNPLA6):c.3034A>G 39′] (p.Met1012Val) NR_001566.1 199422262 TERC [ ] [ ] [′Dyskeratosis (TERC):n.48A>G congenita autosomal dominant′] NM_004984.2 121434441 KIF5A [ ] [ ] [′Spastic paraplegia (KIF5A):c.767A>G 10′] (p.Asn256Ser) NM_004984.2 121434443 KIF5A [ ] [′GAACAYAGCTTT [′Spastic paraplegia (KIF5A):c.827A>G TCTGGGGGAGG′] 10′] (p.Tyr276Cys) m.10438A>G 121434456 MT-TR [ ] [ ] [′Mitochondrial encephalomyopathy′] NM_198253.2 199422302 TERT [ ] [ ] [′Aplastic anemia′] (TERT):c.2537A>G (p.Tyr846Cys) m.12320A>G 121434463 MT-TL2 [′TGGAGTY [′GAGTYGCACCA [′Mitochondrial GCACCAAA AAATTTTTGGGG′, myopathy′] ATTTTTGG′] ′GGAGTYGCACCA AAATTTTTGGG′, ′TGGAGTYGCACC AAAATTTTTGG′] m.4317A>G 121434465 MT-TI [ ] [ ] [ ] m.4269A>G 121434466 MT-TI [′ACAYATT [′ACAYATTTCTTA [ ] TCTTAGGT GGTTTGAGGGG′, TTGAGGGG′, ′GACAYATTTCTT ′GACAYAT AGGTTTGAGGG′, TTCTTAGG ′AGACAYATTTCT TTTGAGGG′] TAGGTTTGAGG′] m.4295A>G 121434467 MT-TI [ ] [ ] [′Primary familial hypertrophic cardiomyopathy′, ′Deafness, nonsyndromic sensorineural, mitochondrial′] m.4300A>G 121434470 MT-TI [ ] [ ] [′Primary familial hypertrophic cardiomyopathy′] NM_001099274.1 199422314 TINF2 [ ] [′TGACTGYGGGG [′Dyskeratosis (TINF2):c.850A>G CGCTCCTTATGG′] congenita autosomal (p.Thr284Ala) dominant′] NM_004044.6 121434478 ATIC [ ] [′AGTGTACYTGAC [′AICAR (ATIC):c.1277A>G AGCAATGGTGG′] transformylase/IMP (p.Lys426Arg) cyclohydrolase deficiency′] NM_001099274.1 199422319 TINF2 [ ] [ ] [′Dyskeratosis (TINF2):c.871A>G congenita autosomal (p.Arg291Gly) dominant′] NM_015474.3 121434521 SAMHD1 [ ] [ ] [′Aicardi Goutieres (SAMHD1):c.760A>G syndrome 5′] (p.Met254Val) NM_001103.3 121434525 ACTN2 [ ] [ ] [′Dilated (ACTN2):c.26A>G cardiomyopathy (p.Gln9Arg) 1AA′, ′Cardiomyopathy′, ′Dilated cardiomyopathy′, ′not specified′] NM_000155.3 111033765 GALT [ ] [′CGCYCAGCAGG [′Deficiency of (GALT):c.812A>G GGTCAGCTCAGG′] UDPglucose- (p.Glu271Gly) hexose-1-phosphate uridylyltransferase′, ′not provided′] NM_000316.2 121434597 PTH1R [ ] [ ] [′Metaphyseal (PTH1R):c.668A>G chondrodysplasia, (p.His223Arg) Jansen type′] NM_006006.4 121434606 ZBTB16 [ ] [′GATCAYGGCCG [′Skeletal defects, (ZBTB16):c.1849A>G AGTAGTCCCGGG′, genital hypoplasia, (p.Met617Val) ′TGATCAYGGCCG and mental AGTAGTCCCGG′] retardation′] NM_014305.3 544436734 TGDS [ ] [ ] [′Catel Manzke (TGDS):c.700T>C syndrome′] (p.Tyr234His) NM_002835.3 121434623 PTPN12 [ ] [ ] [′Carcinoma of (PTPN12):c.182A>G colon′] (p.Lys61Arg) NM_000035.3 369586696 ALDOB [ ] [ ] [′Hereditary (ALDOB):c.1027T>C fructosuria′] (p.Tyr343His) NM_006180.4 121434633 NTRK2 [ ] [ ] [′Obesity, (NTRK2):c.2165A>G hyperphagia, and (p.Tyr722Cys) developmental delay′] NM_000107.2 121434639 DDB2 [ ] [ ] [′Xeroderma (DDB2):c.730A>G pigmentosum, group (p.Lys244Glu) E′] NM_000017.3 566325901 ACADS [ ] [′AGCCCAYGCCG [′not provided′] (ACADS):c.1108A>G CCCAGGATCTGG′] (p.Met370Val) NM_001151.3 28999114 SLC25A4 [ ] [ ] [′Autosomal (SLC25A4):c.311A>G dominant (p.Asp104Gly) progressive external ophthalmoplegia with mitochondrial DNA deletions 2′] NM_012079.5 148665132 DGAT1 [ ] [′ACCGCGGYGAG [′Diarrhea 7′] (DGAT1):c.751+2T>C GACCTCTGTGGG′] NM_002036.3 2814778 ACKR1 [ ] [ ] [′White blood cell (ACKR1):c.-67T>C count quantitative trait locus 1′] NM_000492.3 75789129 CFTR [ ] [ ] [′Cystic fibrosis′, ′not (CFTR):c.1666A>G specified′] (p.Ile556Val) NM_000155.3 111033830 GALT [ ] [′TGCYGGCCCATA [′Deficiency of (GALT):c.574A>G CCTGTCAAGGG′, UDPglucose- (p.Ser192Gly) ′CTGCYGGCCCAT hexose-1-phosphate ACCTGTCAAGG′] uridylyltransferase′] NM_174916.2 119477054 UBR1 [ ] [ ] [′Johanson-Blizzard (UBR1):c.407A>G syndrome′] (p.His136Arg) m.3274A>G 199474666 MT-TL1 [ ] [ ] [ ] NM_000060.3 146011150 BTD [ ] [ ] [′Biotinidase (BTD):c.128A>G deficiency′] (p.His43Arg) NM_172107.2 118192202 KCNQ2 [ ] [ ] [′Benign familial (KCNQ2):c.635A>G neonatal seizures 1′] (p.Asp212Gly) NM_006493.2 148862100 CLN5 [ ] [ ] [′Ceroid (CLN5):c.1121A>G lipofuscinosis (p.Tyr374Cys) neuronal 5′] NM_000060.3 35976361 BTD [ ] [ ] [′Biotinidase (BTD):c.880A>G deficiency′] (p.Ile294Val) NM_000132.3 28933671 F8 [ ] [ ] [′Hereditary factor (F8):c.1226A>G VIII deficiency (p.Glu409Gly) disease′] NM_000132.3 28933679 F8 [ ] [′GAGYGCACATCT [′Hereditary factor (F8):c.5600A>G TTTTCCTAGGG′, VIII deficiency (p.His1867Arg) ′TGAGYGCACATC disease′] TTTTTCCTAGG′] NM_000266.3 28933685 NDP [ ] [ ] [′Atrophia bulborum (NDP):c.1A>G hereditaria′] (p.Met1Val) NM_000133.3 137852230 F9 [ ] [ ] [′Hereditary factor (F9):c.278A>G IX deficiency (p.Asp93Gly) disease′] NM_000133.3 137852234 F9 [ ] [ ] [′Hereditary factor (F9):c.329A>G IX deficiency (p.Asp110Gly) disease′] NM_000133.3 137852251 F9 [ ] [′GCTGCAYTGTAG [′Hereditary factor (F9):c.917A>G TTGTGGTGAGG′] IX deficiency (p.Asn306Ser) disease′] NM_000133.3 137852262 F9 [ ] [ ] [′Hereditary factor (F9):c.1180A>G IX deficiency (p.Met394Val) disease′] NM_000133.3 137852277 F9 [ ] [ ] [′Hereditary factor (F9):c.1231A>G IX deficiency (p.Ser411Gly) disease′] NM_000292.2 137852289 PHKA2 [ ] [ ] [′Glycogen storage (PHKA2):c.896A>G disease type IXa1′] (p.Asp299Gly) NM_000292.2 137852295 PHKA2 [ ] [ ] [′Glycogen storage (PHKA2):c.565A>G disease IXa2′] (p.Lys189Glu) NM_000032.4 137852306 ALAS2 [ ] [ ] [′Hereditary (ALAS2):c.1702A>G sideroblastic (p.Ser568Gly) anemia′] NM_001287223.1 141686175 SCN11A [ ] [′CGTGCGCYGTCC [′Episodic pain (SCN11A):c.3473T>C CAGTTTGAAGG′] syndrome, familial, (p.Leu1158Pro) 3′] NM_000402.4 137852331 G6PD [ ] [′ATGCGGTYCCAG [′Favism, (G6PD):c.583A>G CCTCTGCTGGG′] susceptibility to′, (p.Asn195Asp) ′Anemia, nonspherocytic hemolytic, due to G6PD deficiency′] NM_000132.3 137852359 F8 [ ] [ ] [′Hereditary factor (F8):c.872A>G VIII deficiency (p.Glu291Gly) disease′] NM_018718.2 368178632 CEP41 [ ] [ ] [′Joubert syndrome (CEP41):c.107T>C 9/15, digenic′] (p.Met36Thr) NM_000132.3 137852362 F8 [ ] [ ] [′Hereditary factor (F8):c.5183A>G VIII deficiency (p.Tyr1728Cys) disease′] NM_000132.3 137852369 F8 [ ] [′TAGCCATYGATT [′Hereditary factor (F8):c.5821A>G GCTGGAGAAGG′] VIII deficiency (p.Asn1941Asp) disease′] NM_000132.3 137852385 F8 [ ] [ ] [′Hereditary factor (F8):c.328A>G VIII deficiency (p.Met110Val) disease′] NM_000132.3 137852389 F8 [ ] [′TCAYATTCAGCT [′Hereditary factor (F8):c.398A>G CCTATAGCAGG′] VIII deficiency (p.Tyr133Cys) disease′] NM_000132.3 137852390 F8 [ ] [ ] [′Hereditary factor (F8):c.404A>G VIII deficiency (p.Asp135Gly) disease′] NM_000132.3 137852406 F8 [ ] [′TGAGCAGYAAG [′Hereditary factor (F8):c.940A>G GAAAGTTATTGG′] VIII deficiency (p.Thr314Ala) disease′] NM_000041.3 28931576 APOE [ ] [′ACAGTGYCTGCA [ ] (APOE):c.178A>G CCCAGCGCAGG′] (p.Thr60Ala) NM_000132.3 137852420 F8 [ ] [ ] [′Hereditary factor (F8):c.1682A>G VIII deficiency (p.Asp561Gly) disease′] NM_000132.3 137852429 F8 [′ATGYTGG [′ATGYTGGAGGCT [′Hereditary factor (F8):c.1892A>G AGGCTTGG TGGAACTCTGG′] VIII deficiency (p.Asn631Ser) AACTCTGG′] disease′] NM_012082.3 28374544 — [ ] [ ] [′Tetralogy of (ZFPM2):c.1969A>G Fallot′] (p.Ser657Gly) NM_000098.2 74315300 CPT2 [ ] [ ] [′CARNITINE (CPT2):c.638A>G PALMITOYL- (p.Asp213Gly) TRANSFERASE II DEFICIENCY, LATE-ONSET′] NM_000396.3 74315301 CTSK [ ] [′GAGYCACATCTT [′Pyknodysostosis′] (CTSK):c.990A>G GGGGAAGCTGG′] (p.Ter330Trp) NM_000132.3 137852454 F8 [ ] [ ] [′Hereditary factor (F8):c.6113A>G VIII deficiency (p.Asn2038Ser) disease′] NM_000132.3 137852457 F8 [ ] [ ] [′Hereditary factor (F8):c.6278A>G VIII deficiency (p.Asp2093Gly) disease′] NM_024009.2 74315320 GJB3 [′CAAYGAT [′CAAYGATGAGC [′Deafness, (GJB3):c.421A>G GAGCTTGA TTGAAGATGAGG′] autosomal (p.Ile141Val) AGATGAGG′] recessive′] NM_000132.3 137852476 F8 [ ] [ ] [′Hereditary factor (F8):c.104A>G VIII deficiency (p.Tyr35Cys) disease′] NM_000194.2 137852479 HPRT1 [ ] [ ] [′Partial (HPRT1):c.602A>G hypoxanthine- (p.Asp201Gly) guanine phosphoribosyl- transferase deficiency′] NM_000261.1 74315336 MYOC [ ] [ ] [′Primary open angle (MYOC):c.1267A>G glaucoma juvenile (p.Lys423Glu) onset 1′] NM_014625.3 74315346 NPHS2 [ ] [ ] [′Nephrotic (NPHS2):c.479A>G syndrome, (p.Asp160Gly) idiopathic, steroid- resistant′] NM_000194.2 137852502 HPRT1 [ ] [ ] [′Partial (HPRT1):c.155A>G hypoxanthine- (p.Asp52Gly) guanine phosphoribosyl- transferase deficiency′] NM_002764.3 137852540 PRPS1 [ ] [′TAGCATAYTTGC [′Phosphoribosyl- (PRPS1):c.341A>G AACAAGCTTGG′] pyrophosphate (p.Asn114Ser) synthetase superactivity′] NM_000055.2 1799807 BCHE [ ] [ ] [′Postanesthetic (BCHE):c.293A>G apnea′] (p.Asp98Gly) NM_170784.2 74315399 MKKS [ ] [ ] [′Bardet-Biedl (MKKS):c.169A>G syndrome 6′] (p.Thr57Ala) NM_000311.3 74315406 PRNP [ ] [ ] [′Gerstmann- (PRNP):c.650A>G Straussler-Scheinker (p.Gln217Arg) syndrome′, ′Genetic prion diseases′] NM_000311.3 74315413 PRNP [ ] [ ] [′Gerstmann- (PRNP):c.560A>G Straussler-Scheinker (p.His187Arg) syndrome′, ′Genetic prion diseases′, ′Spongiform encephalopathy with neuropsychiatric features′] NM_000044.3 137852567 AR [ ] [ ] [′Reifenstein (AR):c.2291A>G syndrome′] (p.Tyr764Cys) NM_000044.3 137852570 AR [ ] [ ] [ ] (AR):c.2362A>G (p.Met788Val) NM_000044.3 137852578 AR [ ] [ ] [′Malignant tumor of (AR):c.2632A>G prostate′] (p.Thr878Ala) NM_020436.3 74315429 SALL4 [ ] [ ] [′Duane-radial ray (SALL4):c.2663A>G syndrome′] (p.His888Arg) NM_000044.3 137852582 AR [ ] [ ] [′Malignant tumor of (AR):c.2708A>G prostate′] (p.Gln903Arg) NM_000211.4 137852613 ITGB2 [ ] [ ] [′Leukocyte (ITGB2):c.1052A>G adhesion (p.Asn351Ser) deficiency′] NM_000215.3 137852624 JAK3 [ ] [′AATCCTGYACAG [′Severe combined (JAK3):c.299A>G CAGGACTTGGG′] immunodeficiency, (p.Tyr100Cys) autosomal recessive, T cell-negative, B cell-positive, NK cell-negative′] NM_001166107.1 137852640 HMGCS2 [ ] [′ACCACCGYAGC [′mitochondrial 3- (HMGCS2):c.500A>G AGGCATTGGTGG′] hydroxy-3- (p.Tyr167Cys) methylglutaryl-CoA synthase deficiency′] NM_002047.2 137852645 GARS [ ] [ ] [′Charcot-Marie- (GARS):c.374A>G Tooth disease type (p.Glu125Gly) 2D′, ′Distal hereditary motor neuronopathy type 5′] NM_033163.3 137852662 FGF8 [ ] [ ] [′Kallmann (FGF8):c.298A>G syndrome 6′] (p.Lys100Glu) NM_002180.2 137852666 IGHMBP2 [ ] [ ] [′Werdnig-Hoffmann (IGHMBP2):c.638A>G disease′] (p.His213Arg) NM_004387.3 137852683 NKX2-5 [ ] [ ] [′Atrial septal defect (NKX2-5):c.896A>G 7 with or without (p.Asp299Gly) atrioventricular conduction defects′] NM_004387.3 137852686 NKX2-5 [ ] [ ] [ ] (NKX2-5):c.547A>G (p.Lys183Glu) NM_000310.3 137852697 PPT1 [ ] [ ] [′Ceroid (PPT1):c.236A>G lipofuscinosis (p.Asp79Gly) neuronal 1′] NM_000336.2 137852712 SCNN1B [ ] [ ] [′Bronchiectasis′] (SCNN1B):c.863A>G (p.Asn288Ser) NM_000579.3 1799987 — [ ] [ ] [′Human (CCR5):c.-301+246A>G immunodeficiency virus type 1, susceptibility to′] NM_001204.6 137852745 BMPR2 [ ] [ ] [′Primary pulmonary (BMPR2):c.1454A>G hypertension′] (p.Asp485Gly) NM_005591.3 137852760 MRE11A [ ] [ ] [′Hereditary cancer- (MRE11A):c.350A>G predisposing (p.Asn117Ser) syndrome′, ′Ataxia- telangiectasia-like disorder′] NM_003476.4 137852764 CSRP3 [ ] [ ] [′Dilated (CSRP3):c.206A>G cardiomyopathy (p.Lys69Arg) 1M′, ′Cardiomyopathy′, ′Familial hypertrophic cardiomyopathy 12′] NM_000519.3 35518301 HBD [ ] [ ] [ ] (HBD):c.-81A>G NM_005633.3 137852814 SOS1 [ ] [′GCATCCYTTCCA [′Noonan syndrome′, (SOS1):c.1654A>G GTGTACTCCGG′] ′Noonan syndrome (p.Arg552Gly) 4′, ′Rasopathy′, ′not provided′] NM_003688.3 137852818 CASK [ ] [ ] [′FG syndrome 4′] (CASK):c.2129A>G (p.Asp710Gly) NM_031443.3 137852842 CCM2 [ ] [ ] [′Cerebral cavernous (CCM2):c.1A>G malformations 2′] (p.Met1Val) NM_182760.3 137852855 SUMF1 [ ] [ ] [′Multiple sulfatase (SUMF1):c.1A>G deficiency′] (p.Met1Val) NM_001171993.1 137852865 HPD [ ] [′CCTCAYATCCAG [4- (HPD):c.362A>G GCAAGAATTGG′] Hydroxyphenyl- (p.Tyr121Cys) pyruvate dioxygenase deficiency′] NM_024996.5 119470018 GFM1 [′TTGYTAA [′TTGYTAATAAAA [′Combined (GFM1):c.521A>G TAAAAGTT GTTAGAAACGG′] oxidative (p.Asn174Ser) AGAAACG phosphorylation G′] deficiency 1′] NM_000158.3 137852889 GBE1 [ ] [ ] [′Glycogen storage (GBE1):c.1634A>G disease, type IV′, (p.His545Arg) ′GLYCOGEN STORAGE DISEASE IV, FATAL PERINATAL NEUROMUSCULAR′] NM_000158.3 137852891 GBE1 [ ] [ ] [′Glycogen storage (GBE1):c.1883A>G disease, type IV′, (p.His628Arg) ′GLYCOGEN STORAGE DISEASE IV, CHILDHOOD NEUROMUSCULAR] m.8344A>G 118192098 MT-TK [ ] [ ] [′Parkinson disease, mitochondrial′, ′Leigh disease′, ′Myoclonus with epilepsy with ragged red fibers′] NM_000540.2 118192126 RYR1 [ ] [ ] [′Central core (RYR1):c.10100A>G disease′, ′not (p.Lys3367Arg) provided′] NM_000540.2 118192144 RYR1 [ ] [ ] [′Central core (RYR1):c.14572A>G disease′, ′not (p.Asn4858Asp) provided′] NM_012464.4 137852953 TLL1 [′GGTTAYG [′GGTTAYGGTGCC [′Atrial septal defect (TLL1):c.1885A>G GTGCCGTT GTTAAGTTTGG′] 6′] (p.Ile629Val) AAGTTTGG′] NM_025243.3 137852957 SLC19A3 [ ] [ ] [′Basal ganglia (SLC19A3):c.130A>G disease, biotin- (p.Lys44Glu) responsive′] NM_138691.2 370898981 TMC1 [ ] [′TGGCCYACCAG [′Deafness, (TMC1):c.1763+3A>G ATCATGCCTTGG′] autosomal recessive 7′] NM_000540.2 118192166 RYR1 [ ] [ ] [′Central core (RYR1):c.13909A>G disease′, ′not (p.Thr4637Ala) provided′] NM_000540.2 118192167 RYR1 [ ] [′CCATAYACCAGC [′Malignant (RYR1):c.14387A>G CCAGGTACAGG′] hyperthermia (p.Tyr4796Cys) susceptibility type 1′, ′Central core disease′, ′not provided′] NM_032667.6 137852972 — [ ] [′CGAGACAYTGG [′Distal hereditary (BSCL2):c.263A>G CAACAGGGAAGG′] motor neuronopathy (p.Asn88Ser) type 5′, ′Silver spastic paraplegia syndrome′, ′Charcot- Marie-Tooth disease, type 2′] NM_014795.3 137852983 ZEB2 [ ] [ ] [′Mowat-Wilson (ZEB2):c.3356A>G syndrome′] (p.Gln1119Arg) NM_000540.2 118192184 RYR1 [ ] [ ] [′Central core (RYR1):c.14740A>G disease′, ′not (p.Arg4914Gly) provided′] NM_172107.2 118192193 KCNQ2 [ ] [′CTTCYCATACTC [′Benign familial (KCNQ2):c.356A>G CTTGATGGTGG′, neonatal seizures 1′] (p.Glu119Gly) ′GCTCTTCYCATA CTCCTTGATGG′] NM_172107.2 118192201 KCNQ2 [ ] [′GGATCAYCCGC [′Benign familial (KCNQ2):c.622A>G AGAATCTGCAGG′] neonatal seizures 1′] (p.Met208Val) NM_172107.2 118192207 KCNQ2 [ ] [ ] [′Benign familial (KCNQ2):c.773A>G neonatal seizures 1′] (p.Asn258Ser) NM_004006.2 1800278 DMD [ ] [ ] [′Duchenne (DMD):c.8734A>G muscular dystrophy′, (p.Asn2912Asp) ′not specified′] NM_004006.2 1800279 DMD [ ] [ ] [′Becker muscular (DMD):c.8762A>G dystrophy′, ′not (p.His2921Arg) specified′] NM_001080463.1 137853026 DYNC2H1 [ ] [ ] [′Short-rib thoracic (DYNC2H1):c.11284A>G dysplasia 3 with or (p.Met3762Val) without polydactyly′] NM_001080463.1 137853027 DYNC2H1 [ ] [′ATAYCTCTAATT [′Short-rib thoracic (DYNC2H1):c.9044A>G ACATCAGGTGG′, dysplasia 3 with or (p.Asp3015Gly) ′AGAATAYCTCTA without ATTACATCAGG′] polydactyly′] NM_001080463.1 137853033 DYNC2H1 [′ACCYGTG [′ACCYGTGAAGG [′Short-rib thoracic (DYNC2H1):c.4610A>G AAGGGAA GAACAGAGATGG′] dysplasia 3 with or (p.Gln1537Arg) CAGAGATG without G′] polydactyly′] NM_001080463.1 137853035 DYNC2H1 [ ] [ ] [′Short-rib thoracic (DYNC2H1):c.5959A>G dysplasia 3 with or (p.Thr1987Ala) without polydactyly′] NM_001430.4 137853037 EPAS1 [ ] [ ] [′Erythrocytosis, (EPAS1):c.1603A>G familial, 4′] (p.Met535Val) NM_172107.2 118192238 KCNQ2 [ ] [ ] [′Benign familial (KCNQ2):c.1764-2A>G neonatal seizures 1′] NM_004519.3 118192248 KCNQ3 [ ] [ ] [′Benign familial (KCNQ3):c.914A>G neonatal seizures 2′] (p.Asp305Gly) NM_004519.3 118192252 KCNQ3 [′TCTTTAY [′TCTTTAYTGTTT [′Benign familial (KCNQ3):c.1403A>G TGTTTAAG AAGCCAACAGG′] neonatal seizures 2′, (p.Asn468Ser) CCAACAGG′] ′not specified′, ′not provided′] NM_004519.3 118192254 KCNQ3 [ ] [ ] [′Benign familial (KCNQ3):c.2462A>G neonatal seizures 2′, (p.Asn821Ser) ′not specified′, ′not provided′] NM_138701.3 137853117 MPLKIP [ ] [ ] [′Trichothiodystrophy, (MPLKIP):c.430A>G nonphotosensitive (p.Met144Val) 1′] NM_005094.3 137853134 SLC27A4 [ ] [ ] [′Ichthyosis (SLC27A4):c.899A>G prematurity (p.Gln300Arg) syndrome′] NM_194456.1 137853139 KRIT1 [ ] [ ] [′Cerebral cavernous (KRIT1):c.410A>G malformations 1′] (p.Asp137Gly) NM_000351.4 137853169 STS [ ] [ ] [′X-linked ichthyosis (STS):c.1331A>G with steryl-sulfatase (p.His444Arg) deficiency′] NM_152416.3 137853184 NDUFAF6 [ ] [ ] [′Leigh syndrome (NDUFAF6):c.296A>G due to mitochondrial (p.Gln99Arg) complex I deficiency′] NM_144573.3 137853197 NEXN [ ] [′ATAYACTCTCCT [′Dilated (NEXN):c.1955A>G CCATCTTCTGG′] cardiomyopathy (p.Tyr652Cys) 1CC′, ′Cardiomyopathy′, ′not specified′] NM_000476.2 137853203 AK1 [ ] [′TTCTCAYAGAAG [′Adenylate kinase (AK1):c.491A>G GCGATGACGGG′, deficiency, (p.Tyr164Cys) ′TTTCTCAYAGAA hemolytic anemia GGCGATGACGG′] due to′] NM_013411.4 137853206 AK2 [ ] [ ] [′Reticular (AK2):c.1A>G dysgenesis′] (p.Met1Val) NM_000308.2 786200859 CTSA [ ] [′TCCCAYACCTGT [′Galactosialidosis, (CTSA):c.746+3A>G TCCCCAGAAGG′] adult′] NM_002890.2 137853215 RASA1 [ ] [ ] [ ] (RASA1):c.1198A>G (p.Lys400Glu) NM_002890.2 137853216 RASA1 [ ] [ ] [ ] (RASA1):c.1201A>G (p.Ile401Val) NM_000515.4 137853221 GH1 [ ] [ ] [′Kowarski (GH1):c.413A>G syndrome′] (p.Asp138Gly) NM_017636.3 172151858 TRPM4 [ ] [ ] [′Progressive (TRPM4):c.2741A>G familial heart block (p.Lys914Arg) type 1B′] NM_000545.6 137853237 HNFlA [ ] [ ] [′Maturity-onset (HNF1A):c.365A>G diabetes of the (p.Tyr122Cys) young, type 3′] NM_003494.3 786200897 DYSF [ ] [′CAGCYAGAAGA [′Limb-girdle (DYSF):c.1285-2A>G CACAGGGAGGGG′, muscular dystrophy, ′ACAGCYAGAAGA type 2B′] CACAGGGAGGG′, ′CACAGCYAGAAG ACACAGGGAGG′] NM_005055.4 786200905 RAPSN [ ] [ ] [′MYASTHENIC (RAPSN):c.-210A>G SYNDROME, CONGENITAL, 11, ASSOCIATED WITH ACETYLCHOLINE RECEPTOR DEFICIENCY′] NM_000276.3 137853262 OCRL [ ] [ ] [′Dent disease 2′] (OCRL):c.1436A>G (p.Tyr479Cys) NM_004463.2 137853267 FGD1 [ ] [ ] [′Aarskog (FGD1):c.1396A>G syndrome′] (p.Met466Val) NM_153252.4 137853272 BRWD3 [ ] [ ] [′Mental retardation, (BRWD3):c.4786A>G X-linked 93′] (p.Lys1596Glu) NM_206933.2 786200928 USH2A [ ] [′CTCTTAYCTTGG [′Usher syndrome, (USH2A):c.7595-2144A>G GAAAGGAGAGG′] type 2A′] NM_000362.4 137853299 — [′TGCAGYA [′TGCAGYAGCCG [′Sorsby fundus (TIMP3):c.572A>G GCCGCCCT CCCTTCTGCCGG′] dystrophy′] (p.Tyr191Cys) TCTGCCGG′] NM_006785.3 786200953 MALT1 [′CGCYTTG [′CGCYTTGAAAA [′Combined (MALT1):c.1019-2A>G AAAAAAA AAAAAGAAAGGG′, immunodeficiency′] AAGAAAG ′TCGCYTTGAAAA GG′] AAAAAGAAAGG′] NM_003639.4 137853321 IKBKG [ ] [ ] [′Incontinentia (IKBKG):c.1259A>G pigmenti syndrome′, (p.Ter420Trp) ′Ectodermal dysplasia, anhidrotic, with immunodeficiency, osteopetrosis, and lymphedema′] NM_003639.4 137853322 IKBKG [ ] [′CCAYATCAGGG [′Incontinentia (IKBKG):c.1219A>G GCCTGATACTGG′] pigmenti syndrome′] (p.Met407Val) NM_001014797.2 137853333 KCNMA1 [ ] [ ] [′Generalized (KCNMA1):c.1301A>G epilepsy and (p.Asp434Gly) paroxysmal dyskinesia′] NM_016218.2 757103131 POLK [ ] [ ] [′Malignant tumor of (POLK):c.1679A>T prostate′] (p.Glu560Val) NM_003000.2 786201161 SDHB [ ] [ ] [′Hereditary cancer- (SDHB):c.541-2A>G predisposing syndrome′] NM_032383.4 397507168 — [ ] [ ] [′Hermansky-Pudlak (HPS3):c.2482-2A>G syndrome 3′] NM_000060.3 397507176 BTD [ ] [ ] [′Biotinidase (BTD):c.968A>G deficiency′, ′not (p.His323Arg) provided′] NM_004315.4 137853595 ASAH1 [ ] [ ] [′Farber (ASAH1):c.155A>G lipogranulomatosis′] (p.Tyr52Cys) NM_004315.4 137853596 ASAH1 [ ] [ ] [′Farber (ASAH1):c.1006A>G lipogranulomatosis′] (p.Asn336Asp) NM_000059.3 397507276 BRCA2 [ ] [ ] [′Breast-ovarian (BRCA2):c.1799A>G cancer, familial 2′] (p.Tyr600Cys) NM_022912.2 387906264 REEP1 [ ] [ ] [′Spastic paraplegia (REEP1):c.183-2A>G 31, autosomal dominant′] NM_000022.2 387906267 ADA [ ] [′CCCCYGGGAAG [′Severe combined (ADA):c.219-2A>G GGAAGAAAGGGG′, immunodeficiency ′GCCCCYGGGAAG due to ADA GGAAGAAAGGG′, deficiency′] ′AGCCCCYGGGAA GGGAAGAAAGG′] NM_018249.5 387906274 CDK5RAP2 [ ] [ ] [′Primary autosomal (CDK5RAP2):c.4005-15A>G recessive microcephaly 3′] NM_032119.3 371981035 ADGRV1 [ ] [ ] [′Usher syndrome, (ADGRV1):c.14973-2A>G type 2C] NM_020366.3 17103671 RPGRIP1 [ ] [ ] [′Leber congenital (RPGRIP1):c.3341A>G amaurosis 6′, ′not (p.Asp1114Gly) specified′] NM_000492.3 387906362 CFTR [ ] [′TCAAATCYCACC [′Cystic fibrosis′] (CFTR):c.3717+4A>G CTCTGGCCAGG′] NM_000492.3 387906374 CFTR [ ] [ ] [′Cystic fibrosis′] (CFTR):c.273+4A>G NM_002769.4 397507442 — [ ] [′CTTGYCATCATC [′Hereditary (PRSS1):c.65A>G ATCAAAGGGGG′, pancreatitis′] (p.Asp22Gly) ′TCTTGYCATCATC ATCAAAGGGG′, ′ATCTTGYCATCA TCATCAAAGGG′, ′GATCTTGYCATC ATCATCAAAGG′] NM_004006.2 794727575 DMD [ ] [ ] [′Duchenne (DMD):c.4675-2A>G muscular dystrophy′, ′Becker muscular dystrophy′] NM_000132.3 387906444 F8 [ ] [ ] [′Hereditary factor (F8):c.1418A>G VIII deficiency (p.Tyr473Cys) disease′] NM_004333.4 397507486 BRAF [ ] [ ] [′Rasopathy′] (BRAF):c.2126A>G (p.Gln709Arg) NM_002834.3 397507501 PTPN11 [ ] [ ] [′Noonan syndrome′, (PTPN11):c.124A>G ′Noonan syndrome (p.Thr42Ala) 1′, ′Rasopathy′, ′not provided′] NM_000834.3 527236034 GRIN2B [ ] [ ] [′Mental retardation, (GRIN2B):c.1238A>G autosomal dominant (p.Glu413Gly) 6′] NM_004830.3 527236035 MED23 [ ] [ ] [′Mental retardation, (MED23):c.3638A>G autosomal recessive (p.His1213Arg) 18′] NM_002834.3 397507529 PTPN11 [ ] [ ] [′Noonan syndrome (PTPN11):c.844A>G 1′, ′Rasopathy′, ′not (p.Ile282Val) provided′] NM_000406.2 28933074 GNRHR [ ] [ ] [ ] (GNRHR):c.851A>G (p.Tyr284Cys) NM_002834.3 397507547 PTPN11 [ ] [ ] [′Noonan syndrome′, (PTPN11):c.1510A>G ′Noonan syndrome (p.Met504Val) 1′, ′Rasopathy′, ′not provided′] NM_004629.1 397507561 FANCG [ ] [ ] [′Fanconi anemia, (FANCG):c.925-2A>G complementation group G′] NM_000492.3 76151804 CFTR [ ] [ ] [′Cystic fibrosis′] (CFTR):c.3140-26A>G NM_024598.3 137853971 USB1 [ ] [′CCACCYGGTTTT [′Poikiloderma with (USB1):c.502A>G CTCTTGATTGG′] neutropenia′] (p.Arg168Gly) NM_000067.2 2228063 CA2 [ ] [′TGTYCTTCAGTG [ ] (CA2):c.754A>G GCTGAGCTGGG′, (p.Asn252Asp) ′CTGTYCTTCAGT GGCTGAGCTGG′] NM_000138.4 387906622 FBN1 [ ] [ ] [′Geleophysic (FBN1):c.5096A>G dysplasia 2′] (p.Tyr1699Cys) NM_001194958.2 527236159 KCNJ18 [ ] [ ] [′Thyrotoxic (KCNJ18):c.1097A>G periodic paralysis′, (p.Lys366Arg) ′Thyrotoxic periodic paralysis 2′] NM_000138.4 387906625 FBN1 [ ] [ ] [′Geleophysic (FBN1):c.5087A>G dysplasia 2′] (p.Tyr1696Cys) NM_000138.4 387906626 FBN1 [ ] [ ] [ ] (FBN1):c.5099A>G (p.Tyr1700Cys) NM_001244710.1 387906638 GFPT1 [ ] [ ] [′Congenital (GFPT1):c.43A>G myasthenic (p.Thr15Ala) syndrome with tubular aggregates 1′] NM_002292.3 387906644 LAMB2 [ ] [ ] [′Nephrotic (LAMB2):c.440A>G syndrome, type 5, (p.His147Arg) with or without ocular abnormalities′] NM_005188.3 387906666 CBL [ ] [ ] [ ] (CBL):c.1112A>G (p.Tyr371Cys) NM_000313.3 387906675 PROS1 [′GATTAYA [′GATTAYATCTGT [′Thrombophilia due (PROS1):c.701A>G TCTGTAGC AGCCTTCGGGG′, to protein S (p.Tyr234Cys) CTTCGGGG′, ′AGATTAYATCTG deficiency, ′AGATTAY TAGCCTTCGGG′, autosomal ATCTGTAG ′GAGATTAYATCT recessive′] CCTTCGGG′, GTAGCCTTCGG′] ′GAGATTA YATCTGTA GCCTTCGG′] NM_032018.6 527236213 SPRTN [ ] [ ] [′Ruijs-aalfs (SPRTN):c.350A>G syndrome′] (p.Tyr117Cys) NM_022464.4 548535414 SIL1 [ ] [ ] [′Marinesco- (SIL1):c.645+2T>C Sj\xc3\xb6gren syndrome′] NM_001040142.1 387906685 SCN2A [ ] [ ] [′Early infantile (SCN2A):c.4419A>G epileptic (p.Ile1473Met) encephalopathy 11′] NM_001040142.1 387906687 SCN2A [ ] [ ] [′Benign familial (SCN2A):c.754A>G neonatal-infantile (p.Met252Val) seizures′] m.10450A>G 387906731 MT-TR [ ] [ ] [′Mitochondrial encephalomyopathy′] m.5816A>G 387906732 MT-TC [ ] [ ] [ ] m.608A>G 387906735 MT-TF [′TTCAGYG [′TTCAGYGTATTG [ ] TATTGCTT CTTTGAGGAGG′] TGAGGAGG′] NM_001376.4 387906738 DYNC1H1 [ ] [ ] [′Charcot-Marie- (DYNC1H1):c.917A>G Tooth disease, (p.His306Arg) axonal, type 2O′, ′Charcot-Marie- Tooth disease′, ′Spinal muscular atrophy, lower extremity predominant 1, autosomal dominant′] NM_001376.4 387906742 DYNC1H1 [ ] [ ] [′Spinal muscular (DYNC1H1):c.2011A>G atrophy, lower (p.Lys671Glu) extremity predominant 1, autosomal dominant′] NM_001376.4 387906743 DYNC1H1 [ ] [′ATTCAAGYAGAT [′Spinal muscular (DYNC1H1):c.2909A>G TACCTGATTGG′] atrophy, lower (p.Tyr970Cys) extremity predominant 1, autosomal dominant′] NM_001354.5 387906750 AKR1C2 [ ] [ ] [′46,XY sex reversal (AKR1C2):c.235A>G 8′] (p.Ile79Val) NM_007315.3 387906762 STAT1 [ ] [ ] [′Immunodeficiency (STAT1):c.604A>G 31C′] (p.Met202Val) NM_007315.3 387906764 STAT1 [ ] [ ] [′Immunodeficiency (STAT1):c.494A>G 31C′] (p.Asp165Gly) NM_007315.3 387906765 STAT1 [ ] [ ] [′Immunodeficiency (STAT1):c.862A>G 31C′] (p.Thr288Ala) NM_002052.4 387906772 GATA4 [ ] [′TCCGCAYTGCAA [′Atrial septal defect (GATA4):c.928A>G GAGGCCTGGGG′, 2′] (p.Met310Val) ′TTCCGCAYTGCA AGAGGCCTGGG′] NM_021615.4 72547544 CHST6 [ ] [ ] [′Macular corneal (CHST6):c.329A>G dystrophy Type I′] (p.Tyr110Cys) NM_000209.3 387906777 PDX1 [ ] [ ] [′Pancreatic (PDX1):c.533A>G agenesis, (p.Glu178Gly) congenital′] NM_000890.3 387906778 KCNJ5 [ ] [ ] [′Andersen Tawil (KCNJ5):c.472A>G syndrome′, ′Familial (p.Thr158Ala) hyperaldosteronism type 3′] NM_001184.3 387906797 ATR [ ] [ ] [′Cutaneous (ATR):c.6431A>G telangiectasia and (p.Gln2144Arg) cancer syndrome, familial′] NM_000382.2 72547575 ALDH3A2 [ ] [ ] [′Sj\xc3\xb6gren- (ALDH3A2):c.1157A>G Larsson syndrome′] (p.Asn386Ser) NM_001005862.2 28933370 ERBB2 [ ] [ ] [′Neoplasm of (ERBB2):c.2480A>G ovary′] (p.Asn827Ser) NM_006194.3 28933373 PAX9 [ ] [ ] [′Tooth agenesis, (PAX9):c.271A>G selective, 3′] (p.Lys91Glu) NM_001083116.1 28933375 PRF1 [ ] [ ] [′Hemophagocytic (PRF1):c.755A>G lymphohistiocytosis, (p.Asn252Ser) familial, 2′, ′Malignant lymphoma, non- Hodgkin′] NM_005257.5 387906817 GATA6 [ ] [ ] [′Pancreatic agenesis (GATA6):c.1354A>G and congenital heart (p.Thr452Ala) disease′] NM_000414.3 387906825 HSD17B4 [ ] [′TGCCACAYACTC [′Gonadal (HSD17B4):c.650A>G TGGCTTCAGGG′] dysgenesis with (p.Tyr217Cys) auditory dysfunction, autosomal recessive inheritance′] NM_004153.3 387906826 ORC1 [ ] [ ] [′Meier-Gorlin (ORC1):c.380A>G syndrome 1′] (p.Glu127Gly) NM_002552.4 387906847 ORC4 [ ] [ ] [′Meier-Gorlin (ORC4):c.521A>G syndrome 2′] (p.Tyr174Cys) NM_004544.3 387906872 NDUFA10 [ ] [ ] [′Leigh syndrome (NDUFA10):c.1A>G due to mitochondrial (p.Met1Val) complex I deficiency′] NM_004544.3 387906873 NDUFA10 [ ] [ ] [′Leigh syndrome (NDUFA10):c.425A>G due to mitochondrial (p.Gln142Arg) complex I deficiency′] NM_006796.2 387906889 AFG3L2 [′GTAYAGA [′GTAYAGAGGTA [′Spastic ataxia 5, (AFG3L2):c.1847A>G GGTATTGT TTGTTCTTTTGG′] autosomal (p.Tyr616Cys) TCTTTTGG′] recessive′] NM_006587.3 387906894 CORIN [ ] [ ] [′Preeclampsia/ (CORIN):c.949A>G eclampsia 5′] (p.Lys317Glu) NM_006587.3 387906895 CORIN [ ] [′GGATAACYTGTA [′Preeclampsia/ (CORIN):c.1414A>G CTGTTGTAGGG′] eclampsia 5′] (p.Ser472Gly) NM_015560.2 387906899 OPA1 [ ] [ ] [′Optic Atrophy (OPA1):c.1294A>G Type 1′] (p.Ile432Val) NM_021625.4 387906903 TRPV4 [ ] [ ] [′Metatrophic (TRPV4):c.590A>G dysplasia′] (p.Lys197Arg) NM_021625.4 387906907 TRPV4 [ ] [ ] [′Metatrophic (TRPV4):c.826A>G dysplasia′] (p.Lys276Glu) NM_024022.2 387906915 TMPRSS3 [ ] [ ] [′Deafness, (TMPRSS3):c.308A>G autosomal recessive (p.Asp103Gly) 8′] NM_019109.4 387906925 ALG1 [ ] [ ] [′Congenital disorder (ALG1):c.1129A>G of glycosylation type (p.Met377Val) 1K′] NM_006886.3 387906929 — [ ] [ ] [′Nuclearly-encoded (ATP5E):c.35A>G mitochondrial (p.Tyr12Cys) complex V (ATP synthase) deficiency 3′] NM_032578.3 140148105 MYPN [ ] [ ] [′Primary dilated (MYPN):c.59A>G cardiomyopathy′, (p.Tyr20Cys) ′Cardiomyopathy′, ′Dilated cardiomyopathy 1KK′, ′Familial hypertrophic cardiomyopathy 22′, ′not provided′] NM_016013.3 387906957 NDUFAF1 [ ] [′ACCYTGACCTCC [′Mitochondrial (NDUFAF1):c.758A>G TGCCAGTAGGG′, complex I (p.Lys253Arg) ′TACCYTGACCTC deficiency′] CTGCCAGTAGG′] NM_032580.3 387906979 HES7 [ ] [ ] [′Spondylocostal (HES7):c.172A>G dysostosis 5′] (p.Ile58Val) NM_024700.3 387906986 SNIP1 [ ] [ ] [′Psychomotor (SNIP1):c.1097A>G retardation, epilepsy, (p.Glu366Gly) and craniofacial dysmorphism′] NM_016952.4 387906997 CDON [ ] [ ] [′Holoprosencephaly (CDON):c.2368A>G 11′] (p.Thr790Ala) NM_031427.3 387907021 DNAL1 [′AGGGAYT [′AGGGAYTGCCT [′Kartagener (DNAL1):c.449A>G GCCTACAA ACAAACACCAGG′] syndrome′, ′Ciliary (p.Asn150Ser) ACACCAGG′] dyskinesia, primary, 16′] NM_020320.3 387907048 RARS2 [ ] [ ] [′Pontocerebellar (RARS2):c.1024A>G hypoplasia type 6′] (p.Met342Val) NM_000138.4 137854461 FBN1 [ ] [ ] [′Marfan syndrome′] (FBN1):c.6431A>G (p.Asn2144Ser) NM_000138.4 137854479 FBN1 [ ] [ ] [′Marfan syndrome′] (FBN1):c.2261A>G (p.Tyr754Cys) NM_212482.1 137854488 FN1 [′GAAGTAA [′GAAGTAAYAGG [′Glomerulopathy (FN1):c.2918A>G YAGGTGAC TGACCCCAGGGG′] with fibronectin (p.Tyr973Cys) CCCAGGGG′] deposits 2′] NM_198994.2 387907098 TGM6 [ ] [ ] [′Spinocerebellar (TGM6):c.980A>G ataxia 35′] (p.Asp327Gly) NM_001363.4 137854492 DKC1 [′GCAGGYA [′GCAGGYAGAGA [′Dyskeratosis (DKC1):c.1069A>G GAGATGAC TGACCGCTGTGG′] congenita X-linked′] (p.Thr357Ala) CGCTGTGG′] NM_052873.2 387907107 IF143 [ ] [ ] [′Cranioectodermal (IFT43):c.1A>G dysplasia 3′] (p.Met1Val) NM_201269.2 387907109 ZNF644 [ ] [ ] [′Myopia 21, (ZNF644):c.2014A>G autosomal (p.Ser672Gly) dominant′] NM_018699.3 387907111 PRDM5 [ ] [ ] [′Brittle cornea (PRDM5):c.320A>G syndrome 2′] (p.Tyr107Cys) NM_000132.3 28933682 F8 [ ] [′TAGCCAYTGATT [′Hereditary factor (F8):c.5822A>G GCTGGAGAAGG′] VIII deficiency (p.Asn1941Ser) disease′] NM_016464.4 387907132 TMEM138 [′GACAYGA [′GACAYGAAGGG [′Joubert syndrome (TMEM138):c.287A>G AGGGAGAT AGATGCTGAGGG′, 16′] (p.His96Arg) GCTGAGGG′] ′AGACAYGAAGGG AGATGCTGAGG′] NM_016464.4 387907135 TMEM138 [ ] [′CAGYACAACAC [′Joubert syndrome (TMEM138):c.389A>G TGCTGCTGTGGG′, 16′] (p.Tyr130Cys) ′GCAGYACAACAC TGCTGCTGTGG′] NM_177965.3 387907137 C8orf37 [ ] [ ] [′Retinitis (C8orf37):c.545A>G pigmentosa 64′] (p.Gln182Arg) NM_001077488.3 137854530 GNAS [ ] [′GCCCAYGGCGG [′Pseudohypopara- (GNAS):c.1A>G CGGCGGCGGCGG′] thyroidism type 1A′] (p.Met1Val) NM_006920.4 727504140 SCN1A [ ] [ ] [′Severe myoclonic (SCN1A):c.2557-2A>G epilepsy in infancy′, ′Generalized epilepsy with febrile seizures plus, type 2′] NM_000308.2 137854541 CTSA [ ] [ ] [′Combined (CTSA):c.200A>G deficiency of (p.Gln67Arg) sialidase AND beta galactosidase′] NM_000308.2 137854543 CTSA [ ] [ ] [′Combined (CTSA):c.1238A>G deficiency of (p.Tyr413Cys) sialidase AND beta galactosidase′] NM_000308.2 137854549 CTSA [ ] [ ] [′Galactosialidosis, (CTSA):c.1411A>G late infantile′] (p.Lys471Glu) NM_000267.3 137854550 NF1 [ ] [ ] [′Neurofibromatosis, (NF1):c.4267A>G type 1′] (p.Lys1423Glu) NM_000267.3 137854557 NF1 [′ACTTAYA [′ACTTAYAGCTTC [′Neurofibromatosis, (NF1):c.1466A>G GCTTCTTG TTGTCTCCAGG′] type 1′] (p.Tyr489Cys) TCTCCAGG′] NM_018105.2 387907176 THAP1 [ ] [′CCTCACTYGTGG [′Dystonia 6, (THAP1):c.70A>G AAAGAAACGGG′] torsion′] (p.Lys24Glu) NM_000492.3 397508201 CFTR [ ] [ ] [′Cystic fibrosis′] (CFTR):c.1393-2A>G NM_001172646.1 387907179 PLCB4 [ ] [ ] [′Auriculocondylar (PLCB4):c.986A>G syndrome 2′] (p.Asn329Ser) NM_005850.4 387907185 SF3B4 [ ] [ ] [′Nager syndrome′] (SF3B4):c.1A>G (p.Met1Val) NM_014714.3 387907193 IFT140 [ ] [ ] [′Renal dysplasia, (IFT140):c.932A>G retinal pigmentary (p.Tyr311Cys) dystrophy, cerebellar ataxia and skeletal dysplasia′] NM_005006.6 387907199 NDUFS1 [ ] [ ] [′Mitochondrial (NDUFS1):c.1783A>G complex I (p.Thr595Ala) deficiency′] NM_000397.3 137854593 CYBB [ ] [′TCACAYCTTTCT [′Chronic (CYBB):c.1499A>G CCTCATCATGG′] granulomatous (p.Asp500Gly) disease, X-linked′, ′not provided′] NM_033360.3 387907206 KRAS [ ] [ ] [′Cardiofaciocutaneous (KRAS):c.439A>G syndrome 2′] (p.Lys147Glu) NM_000335.4 137854614 SCN5A [ ] [ ] [′Long QT syndrome (SCN5A):c.5381A>G 3′, ′Congenital long (p.Tyr1794Cys) QT syndrome′] NM_000076.2 387907226 CDKN1C [ ] [′CGCTYGGCGAA [′Intrauterine growth (CDKN1C):c.832A>G GAAATCTGCGGG′, retardation, (p.Lys278Glu) ′GCGCTYGGCGAA metaphyseal GAAATCTGCGG′] dysplasia, adrenal hypoplasia congenita, and genital anomalies′] NM_022912.2 387907242 REEP1 [ ] [′TCCYGTCAAAGG [′Distal hereditary (REEP1):c.304-2A>G AAAAACAGAGG′] motor neuronopathy type 5B′] NM_198253.2 387907250 TERT [ ] [ ] [′PULMONARY (TERT):c.2705A>G FIBROSIS (p.Lys902Arg) AND/OR BONE MARROW FAILURE, TELOMERE- RELATED, 1′] NM_005349.3 387907270 RBPJ [ ] [ ] [′Adams-Oliver (RBPJ):c.188A>G syndrome 3′] (p.Glu63Gly) NM_005349.3 387907271 RBPJ [ ] [ ] [′Adams-Oliver (RBPJ):c.505A>G syndrome 3′] (p.Lys169Glu) NM_022787.3 387907291 NMNAT1 [ ] [′TGTYTCTCTGCA [′Leber congenital (NMNAT1):c.817A>G AAGGGGCCAGG′] amaurosis 9′] (p.Asn273Asp) NM_000492.3 397508328 CFTR [′TGCAYGG [′GCAYGGTCTCTC [′Cystic fibrosis′] (CFTR):c.1A>G TCTCTCGG GGGCGCTGGGG′, (p.Met1Val) GCGCTGGG′] ′TGCAYGGTCTCT CGGGCGCTGGG′, ′CTGCAYGGTCTC TCGGGCGCTGG′] NM_020921.3 387907308 NIN [ ] [ ] [′Seckel syndrome (NIN):c.5126A>G 7′] (p.Asn1709Ser) NM_021629.3 387907341 GNB4 [ ] [ ] [′Charcot-Marie- (GNB4):c.265A>G Tooth disease, (p.Lys89Glu) dominant intermediate F′] NM_000355.3 372866837 TCN2 [ ] [ ] [ ] (TCN2):c.580+624A>T NM_032415.5 387907351 CARD11 [ ] [ ] [′B-CELL (CARD11):c.401A>G EXPANSION (p.Glu134Gly) WITH NFKB AND T-CELL ANERGY′] NM_005430.3 387907354 WNT1 [ ] [ ] [′Osteogenesis (WNT1):c.624+4A>G imperfecta type 15′] NM_207352.3 149684063 CYP4V2 [ ] [ ] [′Bietti crystalline (CYP4V2):c.367A>G corneoretinal (p.Met123Val) dystrophy′, ′not provided′] NM_031885.3 137854887 BBS2 [ ] [ ] [′Bardet-Biedl (BBS2):c.472-2A>G syndrome 2′] NM_015268.3(DNAJC 387907571 DNAJC13 [ ] [ ] [′Parkinson disease, 13):c.2564A>G late-onset′, ′Essential (p.Asn855Ser) tremor′, ′PARKINSON DISEASE 21′] NM_001287.5 387907576 CLCN7 [ ] [′TGTCAYAGTCCA [′Osteopetrosis (CLCN7):c.296A>G AGCTCTGCAGG′] autosomal dominant (p.Tyr99Cys) type 2′, ′Osteopetrosis autosomal recessive 4′]

REFERENCES

-   1. Humbert O, Davis L, Maizels N. Targeted gene therapies: tools,     applications, optimization. Crit Rev Biochem Mol. 2012;     47(3):264-81. PMID: 22530743. -   2. Perez-Pinera P, Ousterout D G, Gersbach C A. Advances in targeted     genome editing. Curr Opin Chem Biol. 2012; 16(3-4):268-77. PMID:     22819644. -   3. Urnov F D, Rebar E J, Holmes M C, Zhang H S, Gregory P D. Genome     editing with engineered zinc finger nucleases. Nat Rev Genet. 2010;     11(9):636-46. PMID: 20717154. -   4. Joung J K, Sander J D. TALENs: a widely applicable technology for     targeted genome editing. Nat Rev Mol Cell Biol. 2013; 14(1):49-55.     PMID: 23169466. -   5. Charpentier E, Doudna J A. Biotechnology: Rewriting a genome.     Nature. 2013; 495, (7439):50-1. PMID: 23467164. -   6. Pan Y, Xia L, Li A S, Zhang X, Sirois P, Zhang J, Li K.     Biological and biomedical applications of engineered nucleases. Mol     Biotechnol. 2013; 55(1):54-62. PMID: 23089945. -   7. De Souza, N. Primer: genome editing with engineered nucleases.     Nat Methods. 2012; 9(1):27. PMID: 22312638. -   8. Santiago Y, Chan E, Liu PQ, Orlando S, Zhang L, Urnov F D, Holmes     M C, Guschin D, Waite A, Miller J C, Rebar E J, Gregory P D, Klug A,     Collingwood T N. Targeted gene knockout in mammalian cells by using     engineered zinc-finger nucleases. Proc Natl Acad Sci USA. 2008;     105(15):5809-14. PMID: 18359850. -   9. Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N,     Lane C R, Lim E P, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L,     Rolfe A, Warrington J, Lipshutz R, Daley G Q, Lander E S.     Characterization of single-nucleotide polymorphisms in coding     regions of human genes. Nat Genet. 1999; 22(3):231-8. PMID:     10391209. -   10. Jansen R, van Embden J D, Gaastra W, Schouls L M. Identification     of genes that are associated with DNA repeats in prokaryotes. Mol     Microbiol. 2002; 43(6):1565-75. PMID: 11952905. -   11. Mali P, Esvelt K M, Church G M. Cas9 as a versatile tool for     engineering biology. Nat Methods. 2013; 10(10):957-63. PMID:     24076990. -   12. Jore M M, Lundgren M, van Duijin E, Bultema J B, Westra E R,     Waghmare S P, Wiedenheft B, Pul U, Wurm R, Wagner R, Beijer M R,     Barendregt A, Shou K, Snijders A P, Dickman M J, Doudna J A, Boekema     E J, Heck A J, van der Oost J, Brouns S J. Structural basis for     CRISPR RNA-guided DNA recognition by Cascade. Nat Struct Mol Biol.     2011; 18(5):529-36. PMID: 21460843. -   13. Horvath P, Barrangou R. CRISPR/Cas, the immune system of     bacteria and archaea. Science. 2010; 327(5962):167-70. PMID:     20056882. -   14. Wiedenheft B, Sternberg S H, Doudna J A. RNA-guided genetic     silencing systems in bacteria and archaea. Nature. 2012;     482(7385):331-8. PMID: 22337052. -   15. Gasiunas G, Siksnys V. RNA-dependent DNA endonuclease Cas9 of     the CRISPR system: Holy Grail of genome editing? Trends Microbiol.     2013; 21(11):562-7. PMID: 24095303. -   16. Qi L S, Larson M H, Gilbert L A, Doudna J A, Weissman J S, Arkin     A P, Lim W A. Repurposing CRISPR as an RNA-guided platform for     sequence-specific control of gene expression. Cell. 2013;     152(5):1173-83. PMID: 23452860. -   17. Perez-Pinera P, Kocak D D, Vockley C M, Adler A F, Kabadi A M,     Polstein L R, Thakore P I, Glass K A, Ousterout D G, Leong K W,     Guilak F, Crawford G E, Reddy T E, Gersbach C A. RNA-guided gene     activation by CRISPR-Cas9-based transcription factors. Nat Methods.     2013; 10(10):973-6. PMID: 23892895. -   18. Mali P, Aach J, Stranges P B, Esvelt K M, Moosburner M, Kosuri     S, Yang L, Church G M. CAS9 transcriptional activators for target     specificity screening and paired nickases for cooperative genome     engineering. Nat Biotechnol. 2013; 31(9):833-8. PMID: 23907171. -   19. Gilbert L A, Larson M H, Morsut L, Liu Z, Brar G A, Torres S E,     Stern-Ginossar N, Brandman O, Whitehead E H, Doudna J A, Lim W A,     Weissman J S, Qi LS. CRISPR-mediated modular RNA-guided regulation     of transcription in eukaryotes. Cell. 2013; 154(2):442-51. PMID:     23849981. -   20. Larson M H, Gilbert L A, Wang X, Lim W A, Weissman J S, Qi L S.     CRISPR interference (CRISPRi) for sequence-specific control of gene     expression. Nat Protoc. 2013; 8(11):2180-96. PMID: 24136345. -   21. Mali P, Yang L, Esvelt K M, Aach J, Guell M, DiCarlo J E,     Norville J E, Church G M. RNA-guided human genome engineering via     Cas9. Science. 2013; 339(6121):823-6. PMID: 23287722. -   22. Cole-Strauss A, Yoon K, Xiang Y, Byrne B C, Rice M C, Gryn J,     Holloman W K, Kmiec E B. Correction of the mutation responsible for     sickle cell anemia by an RNA-DNA oligonucleotide. Science. 1996;     273(5280):1386-9. PMID: 8703073. -   23. Tagalakis A D, Owen J S, Simons J P. Lack of RNA-DNA     oligonucleotide (chimeraplast) mutagenic activity in mouse embryos.     Mol Reprod Dev. 2005; 71(2):140-4. PMID: 15791601. -   24. Ray A, Langer M. Homologous recombination: ends as the means.     Trends Plant Sci. 2002; 7(10):435-40. PMID 12399177. -   25. Britt A B, May G D. Re-engineering plant gene targeting. Trends     Plant Sci. 2003; 8(2):90-5. PMID: 12597876. -   26. Vagner V, Ehrlich S D. Efficiency of homologous DNA     recombination varies along the Bacillus subtilis chromosome. J     Bacteriol. 1988; 170(9):3978-82. PMID: 3137211. -   27. Saleh-Gohari N, Helleday T. Conservative homologous     recombination preferentially repairs DNA double-strand breaks in the     S phase of the cell cycle in human cells. Nucleic Acids Res. 2004;     32(12):3683-8. PMID: 15252152. -   28. Lombardo A, Genovese P, Beausejour C M, Colleoni S, Lee Y L, Kim     K A, Ando D, Urnov F D, Galli C, Gregory P D, Holmes M C, Naldini L.     Gene editing in human stem cells using zinc finger nucleases and     integrase-defective lentiviral vector delivery. Nat Biotechnol.     2007; 25(11):1298-306. PMID: 17965707. -   29. Conticello S G. The AID/APOBEC family of nucleic acid mutators.     Genome Biol. 2008; 9(6):229. PMID: 18598372. -   30. Reynaud C A, Aoufouchi S, Faili A, Weill J C. What role for AID:     mutator, or assembler of the immunoglobulin mutasome? Nat Immunol.     2003; 4(7):631-8. -   31. Bhagwat A S. DNA-cytosine deaminases: from antibody maturation     to antiviral defense. DNA Repair (Amst). 2004; 3(1):85-9. PMID:     14697763. -   32. Navaratnam N, Sarwar R. An overview of cytidine deaminases. Int     J Hematol. 2006; 83(3):195-200. PMID: 16720547. -   33. Holden L G, Prochnow C, Chang Y P, Bransteitter R, Chelico L,     Sen U, Stevens R C, Goodman M F, Chen X S. Crystal structure of the     anti-viral APOBEC3G catalytic domain and functional implications.     Nature. 2008; 456(7218):121-4. PMID: 18849968. -   34. Chelico L, Pham P, Petruska J, Goodman M F. Biochemical basis of     immunological and retroviral responses to DNA-targeted cytosine     deamination by activation-induced cytidine deaminase and APOBEC3G. J     Biol Chem. 2009; 284(41). 27761-5. PMID: 19684020. -   35. Pham P, Bransteitter R, Goodman M F. Reward versus risk: DNA     cytidine deaminases triggering immunity and disease. Biochemistry.     2005; 44(8):2703-15. PMID 15723516. -   36. Chen X, Zaro J L, Shen W C. Fusion protein linkers: property,     design and functionality. Adv Drug Deliv Rev. 2013; 65(10):1357-69.     PMID: 23026637. -   37. Lee J W, Soung Y H, Kim S Y, Lee H W, Park W S, Nam S W, Kim S     H, Lee J Y, Yoo N J, Lee S H. PIK3CA gene is frequently mutated in     breast carcinomas and hepatocellular carcinomas. Oncogene. 2005;     24(8):1477-80. PMID: 15608678. -   38. Ikediobi O N, Davies H, Bignell G, Edkins S, Stevens C, O′Meara     S, Santarius T, Avis T, Barthorpe S, Brackenbury L, Buck G, Butler     A, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K,     Harrison R, Hills K, Hinton J, Hunter C, Jenkinson A, Jones D,     Kosmidou V, Lugg R, Menzies A, Mironenko T, Parker A, Perry J, Raine     K, Richardson D, Shepherd R, Small A, Smith R, Solomon H, Stephens     P, Teague J, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A,     Reinhold W, Weinstein J N, Stratton M R, Futreal P A, Wooster R.     Mutation analysis of 24 known cancer genes in the NCI-60 cell line     set. Mol Cancer Ther. 2006; 5(11):2606-12. PMID: 17088437. -   39. Cox, D. B., Platt, R. J. & Zhang, F. Therapeutic genome editing:     prospects and challenges. Nature medicine 21,121-131,     doi:10.1038/nm.3793 (2015). -   40. Hilton, I. B. & Gersbach, C. A. Enabling functional genomics     with genome engineering. Genome research 25,1442-1455,     doi:10.1101/gr.190124.115 (2015). -   41. Sander, J. D. & Joung, J. K. CRISPR-Cas systems for editing,     regulating and targeting genomes. Nature biotechnology 32,347-355,     doi:10.1038/nbt.2842 (2014). -   42. Maruyama, T. et al. Increasing the efficiency of precise genome     editing with CRISPR-Cas9 by inhibition of nonhomologous end joining.     Nature biotechnology 33,538-542, doi:10.1038/nbt.3190 (2015). -   43. Chu, V. T. et al. Increasing the efficiency of homology-directed     repair for CRISPR-Cas9-induced precise gene editing in mammalian     cells. Nature biotechnology 33, 543-548, doi:10.1038/nbt.3198     (2015). -   44. Lin, S., Staahl, B. T., Alla, R. K. & Doudna, J. A. Enhanced     homology-directed human genome engineering by controlled timing of     CRISPR/Cas9 delivery. eLife 3, e04766, doi:10.7554/eLife.04766     (2014). -   45. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas     systems. Science 339,819-823, doi:10.1126/science.1231143 (2013). -   46. Rong, Z., Zhu, S., Xu, Y. & Fu, X. Homologous recombination in     human embryonic stem cells using CRISPR/Cas9 nickase and a long DNA     donor template. Protein & cell 5, 258-260,     doi:10.1007/s13238-014-0032-5 (2014). -   47. Jinek, M. et al. A Programmable Dual-RNA-Guided DNA Endonuclease     in Adaptive Bacterial Immunity. Science 337, 816-821,     doi:10.1126/science.1225829 (2012). -   48. Harris, R. S., Petersen-Mahrt, S. K. & Neuberger, M. S. RNA     Editing Enzyme APOBEC1 and Some of Its Homologs Can Act as DNA     Mutators. Molecular Cell 10, 1247-1253 (2002). -   49. Jinek, M. et al. Structures of Cas9 endonucleases reveal     RNA-mediated conformational activation. Science 343, 1247997,     doi:10.1126/science.1247997 (2014). -   50. Schellenberger, V. et al. A recombinant polypeptide extends the     in vivo half-life of peptides and proteins in a tunable manner.     Nature biotechnology 27, 1186-1190, doi:10.1038/nbt.1588 (2009). -   51. Saraconi, G., Severi, F., Sala, C., Mattiuz, G. &     Conticello, S. G. The RNA editing enzyme APOBEC1 induces somatic     mutations and a compatible mutational signature is present in     esophageal adenocarcinomas. Genome biology 15, 417-(2014). -   52. Anders, C., Niewoehner, O., Duerst, A. & Jinek, M. Structural     basis of PAM-dependent target DNA recognition by the Cas9     endonuclease. Nature 513, 569-573, doi:10.1038/nature13579 (2014). -   53. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas     systems. Science 339, 819-823 (2013). -   54. Tsai, S. Q. et al. GUIDE-seq enables genome-wide profiling of     off-target cleavage by CRISPR-Cas nucleases. Nature biotechnology     33, 187-197, doi:10.1038/nbt.3117 (2015). -   55. Kunz, C., Saito, Y. & Schar, P. DNA Repair in mammalian cells:     Mismatched repair: variations on a theme. Cellular and molecular     life sciences: CMLS 66, 1021-1038, doi:10.1007/s00018-009-8739-9     (2009). -   56. D., M. C. et al. Crystal structure of human uracil-DNA     glycosylase in complex with a protein inhibitor: protein mimicry of     DNA. Cell 82, 701-708 (1995). -   57. Caldecott, K. W. Single-strand break repair and genetic disease.     Nature reviews. Genetics 9, 619-631, doi:10.1038/nrg2380 (2008). -   58. Fukui, K. DNA mismatch repair in eukaryotes and bacteria.     Journal of nucleic acids 2010, doi:10.4061/2010/260512 (2010). -   59. Gasiunas, G., Barrangou, R., Horvath, P. & Siksnys, V.     Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage     for adaptive immunity in bacteria. Proceedings of the National     Academy of Sciences 109, E2579-E2586, doi:10.1073/pnas.1208507109     (2012). -   60. Ran, F. A. et al. In vivo genome editing using Staphylococcus     aureus Cas9. Nature 520, 186-191, doi:10.1038/nature14299 (2015). -   61. Kuscu, C., Arslan, S., Singh, R., Thorpe, J. & Adli, M.     Genome-wide analysis reveals characteristics of off-target sites     bound by the Cas9 endonuclease. Nature biotechnology 32, 677-683,     doi:10.1038/nbt.2916 (2014). -   62. Wu, X. et al. Genome-wide binding of the CRISPR endonuclease     Cas9 in mammalian cells. Nature biotechnology 32, 670-676,     doi:10.1038/nbt.2889 (2014). -   63. Beale, R. C. L. et al. Comparison of the Differential     Context-dependence of DNA Deamination by APOBEC Enzymes: Correlation     with Mutation Spectra in Vivo. Journal of Molecular Biology 337,     585-596, doi:10.1016/j.jmb.2004.01.046 (2004). -   64. Kim, J., Basak, J. M. & Holtzman, D. M. The role of     apolipoprotein E in Alzheimer's disease. Neuron 63, 287-303,     doi:10.1016/j.neuron.2009.06.026 (2009). -   65. Liu, C. C., Kanekiyo, T., Xu, H. & Bu, G. Apolipoprotein E and     Alzheimer disease: risk, mechanisms and therapy. Nature reviews.     Neurology 9, 106-118, doi:10.1038/nrneuro1.2012.263 (2013). -   66. Sjöblom, T. et al. The Consensus Coding Sequences of Human     Breast and Colorectal Cancers. Science 314, 268-274,     doi:10.1126/science.1133427 (2006). -   67. Stephens, P. J. et al. The landscape of cancer genes and     mutational processes in breast cancer. Nature 486, 400-404,     doi:10.1038/nature11017 (2012). -   68. Landrum, M. J. et al. ClinVar: public archive of interpretations     of clinically relevant variants. Nucleic Acids Research,     doi:10.1093/nar/gkv1222 (2015). -   69. Slaymaker, I. M. et al. Rationally engineered Cas9 nucleases     with improved specificity. Science, doi:10.1126/science.aad5227     (2015). -   70. Davis, K. M., Pattanayak, V., Thompson, D. B., Zuris, J. A. &     Liu, D. R. Small molecule-triggered Cas9 protein with improved     genome-editing specificity. Nature chemical biology 11, 316-318,     doi:10.1038/nchembio.1793 (2015). -   71. Zuris, J. A. et al. Cationic lipid-mediated delivery of proteins     enables efficient protein-based genome editing in vitro and in vivo.     Nature biotechnology 33, 73-80, doi:10.1038/nbt.3081 (2015). -   72. Kleinstiver, B. P. et al. Engineered CRISPR-Cas9 nucleases with     altered PAM specificities. Nature 523, 481-485,     doi:10.1038/nature14592 (2015). -   73. Pattanayak, V. et al. High-throughput profiling of off-target     DNA cleavage reveals RNA-programmed Cas9 nuclease specificity.     Nature Biotechnology 31, 839-843, doi:10.1038/nbt.2673 (2013). -   74. Shcherbakova, D. M. & Verkhusha, V. V. Near-infrared fluorescent     proteins for multicolor in vivo imaging. Nature Methods 10, 751-754,     doi:10.1038/nmeth.2521 (2013). -   75. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9     system. Nat. Protocols 8, 2281-2308, doi:10.1038/nprot.2013.143     (2013). -   76. Jiang, F. et al. Structures of a CRISPR-Cas9 R-loop complex     primed for DNA cleavage. Science, doi:10.1126/science.aad8282     (2016). -   77. Tsai, S. Q. et al. Dimeric CRISPR RNA-guided FokI nucleases for     highly specific genome editing. Nat Biotech 32, 569-576,     doi:10.1038/nbt.2908 (2014). -   78. Lieber, M. R., Ma, Y., Pannicke, U. & Schwarz, K. Mechanism and     regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell     Biol 4, 712-720 (2003). -   79. Heller, R. C. & Marians, K. J. Replisome assembly and the direct     restart of stalled replication forks. Nat Rev Mol Cell Biol 7,     932-943 (2006). -   80. Pluciennik, A. et al. PCNA function in the activation and strand     direction of MutLα endonuclease in mismatch repair. Proceedings of     the National Academy of Sciences of the United States of America     107, 16066-16071, doi:10.1073/pnas.1010662107 (2010). -   81. Seripa, D. et al. The missing ApoE allele. Annals of human     genetics 71, 496-500, doi:10.1111/j.1469-1809.2006.00344.x (2007). -   82. Kleinstiver, B. P. et al. High-fidelity CRISPR-Cas9 nucleases     with no detectable genome-wide off-target effects. Nature 529,     490-495, doi:10.1038/nature16526 (2016). -   83. Richardson, C. D., Ray, G. J., DeWitt, M. A., Curie, G. L. &     Corn, J. E. Enhancing homology-directed genome editing by     catalytically active and inactive CRISPR-Cas9 using asymmetric donor     DNA. Nat Biotech 34, 339-344, doi:10.1038/nbt.3481 (2016). -   84. Simonelli, V., Narciso, L., Dogliotti, E. & Fortini, P. Base     excision repair intermediates are mutagenic in mammalian cells.     Nucleic acids research 33, 4404-4411, doi:10.1093/nar/gki749 (2005). -   85. Barnes, D. E. & Lindahl, T. Repair and Genetic Consequences of     Endogenous DNA Base Damage in Mammalian Cells. Annual Review of     Genetics 38, 445-476, doi:doi:10.1146/annurev.genet.38.072902.092448     (2004).

EQUIVALENTS AND SCOPE

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the embodiments described herein. The scope of the present disclosure is not intended to be limited to the above description, but rather is as set forth in the appended claims.

Articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include “or” between two or more members of a group are considered satisfied if one, more than one, or all of the group members are present, unless indicated to the contrary or otherwise evident from the context. The disclosure of a group that includes “or” between two or more group members provides embodiments in which exactly one member of the group is present, embodiments in which more than one members of the group are present, and embodiments in which all of the group members are present. For purposes of brevity those embodiments have not been individually spelled out herein, but it will be understood that each of these embodiments is provided herein and may be specifically claimed or disclaimed.

It is to be understood that the invention encompasses all variations, combinations, and permutations in which one or more limitation, element, clause, or descriptive term, from one or more of the claims or from one or more relevant portion of the description, is introduced into another claim. For example, a claim that is dependent on another claim can be modified to include one or more of the limitations found in any other claim that is dependent on the same base claim. Furthermore, where the claims recite a composition, it is to be understood that methods of making or using the composition according to any of the methods of making or using disclosed herein or according to methods known in the art, if any, are included, unless otherwise indicated or unless it would be evident to one of ordinary skill in the art that a contradiction or inconsistency would arise.

Where elements are presented as lists, e.g., in Markush group format, it is to be understood that every possible subgroup of the elements is also disclosed, and that any element or subgroup of elements can be removed from the group. It is also noted that the term “comprising” is intended to be open and permits the inclusion of additional elements or steps. It should be understood that, in general, where an embodiment, product, or method is referred to as comprising particular elements, features, or steps, embodiments, products, or methods that consist, or consist essentially of, such elements, features, or steps, are provided as well. For purposes of brevity those embodiments have not been individually spelled out herein, but it will be understood that each of these embodiments is provided herein and may be specifically claimed or disclaimed.

Where ranges are given, endpoints are included. Furthermore, it is to be understood that unless otherwise indicated or otherwise evident from the context and/or the understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value within the stated ranges in some embodiments, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise. For purposes of brevity, the values in each range have not been individually spelled out herein, but it will be understood that each of these values is provided herein and may be specifically claimed or disclaimed. It is also to be understood that unless otherwise indicated or otherwise evident from the context and/or the understanding of one of ordinary skill in the art, values expressed as ranges can assume any subrange within the given range, wherein the endpoints of the subrange are expressed to the same degree of accuracy as the tenth of the unit of the lower limit of the range.

In addition, it is to be understood that any particular embodiment of the present invention may be explicitly excluded from any one or more of the claims. Where ranges are given, any value within the range may explicitly be excluded from any one or more of the claims. Any embodiment, element, feature, application, or aspect of the compositions and/or methods of the invention, can be excluded from any one or more claims. For purposes of brevity, all of the embodiments in which one or more elements, features, purposes, or aspects is excluded are not set forth explicitly herein. 

What is claimed is:
 1. A fusion protein comprising: (i) a Cas9 domain, wherein the Cas9 domain when in conjunction with a bound guide RNA (gRNA) specifically binds to a target nucleic acid sequence; (ii) a cytidine deaminase domain, wherein the cytidine deaminase domain deaminates a cytosine base in a single-stranded portion of the target nucleic acid sequence when in conjunction with the Cas9 domain and the gRNA; and (iii) an uracil glycosylase inhibitor (UGI) domain, wherein the UGI domain inhibits a uracil-DNA glycosylase.
 2. The fusion protein of claim 1, wherein the Cas9 domain comprises the amino acid sequence provided in SEQ ID NO:
 674. 3. The fusion protein of claim 1, wherein the Cas9 domain is a Cas9 nickase (nCas9) domain that cuts a nucleotide target strand of a nucleotide duplex, wherein the nucleotide target strand is the strand that binds to the gRNA.
 4. The fusion protein of claim 1, wherein the Cas9 domain is a Cas9 nickase (nCas9) domain that comprises a D10A mutation in the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260.
 5. The fusion protein of claim 1, wherein the Cas9 domain is a Cas9 nickase (nCas9) domain that comprises one or more of N497A, R661A, Q695A, or Q926A mutations in the amino acid sequence provided in SEQ ID NO: 10, or one or more corresponding mutations in any of the amino acid sequences provided in SEQ ID NOs: 11-260.
 6. The fusion protein of claim 1, wherein the cytidine deaminase domain is a deaminase from an apolipoprotein B mRNA-editing complex (APOBEC) family deaminase.
 7. The fusion protein of claim 6, wherein the APOBEC family deaminase is selected from the group consisting of APOBEC1 deaminase, APOBEC2 deaminase, APOBEC3A deaminase, APOBEC3B deaminase, APOBEC3C deaminase, APOBEC3D deaminase, APOBEC3F deaminase, APOBEC3G deaminase, and APOBEC3H deaminase.
 8. The fusion protein of claim 1, wherein the cytidine deaminase domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 266-284, 607-610, 5724-5736, and 5738-5741.
 9. The fusion protein of claim 1, wherein the cytidine deaminase domain is a rat APOBEC1 (rAPOBEC1) deaminase comprising one or more mutations selected from the group consisting of W90Y, R126E, and R132E in SEQ ID NO: 284, or one or more corresponding mutations in another APOBEC deaminase.
 10. The fusion protein of claim 1, wherein the cytidine deaminase domain is a human APOBEC1 (hAPOBEC1) deaminase comprising one or more mutations selected from the group consisting of W90Y, Q126E, and R132E in SEQ ID NO: 5724, or one or more corresponding mutations in another APOBEC deaminase.
 11. The fusion protein of claim 1, wherein the cytidine deaminase domain is a human APOBEC3G (hAPOBEC3G) deaminase comprising one or more mutations selected from the group consisting of W285Y, R320E, and R326E in SEQ ID NO: 275, or one or more corresponding mutations in another APOBEC deaminase.
 12. The fusion protein of claim 1, wherein the cytidine deaminase domain is an activation-induced deaminase (AID).
 13. The fusion protein of claim 1, wherein the cytidine deaminase domain is a cytidine deaminase 1 from Petromyzon marinus (pmCDA1).
 14. The fusion protein of claim 1, wherein the UGI domain comprises the amino acid sequence as set forth in SEQ ID NO:
 600. 15. The fusion protein of claim 1, wherein the fusion protein comprises the structure: NH₂-[cytidine deaminase domain]-[Cas9 domain]-[UGI domain]-COOH, and wherein each instance of “-” comprises an optional linker.
 16. The fusion protein of claim 1, wherein the cytidine deaminase domain of (ii) and the Cas9 domain of (i) are linked via a linker comprising the amino acid sequence (GGGS)_(n)(SEQ ID NO: 265)_(n), (GGGGS)_(n)(SEQ ID NO: 5)_(n), (G)_(n), (EAAAK)_(n)(SEQ ID NO: 6)_(n), (GGS)_(n), (SGGS)_(n)(SEQ ID NO: 4288)_(n), SGSETPGTSESATPES (SEQ ID NO: 7)_(n), or (XP)_(n)motif, or a combination thereof, wherein n is independently an integer between 1 and 30, inclusive, and wherein X is any amino acid.
 17. The fusion protein of claim 1, wherein the cytidine deaminase domain of (ii) and the Cas9 domain of (i) are linked via a linker comprising the amino acid sequence: SGSETPGTSESATPES (SEQ ID NO: 7).
 18. The fusion protein of claim 1 further comprising a nuclear localization sequence (NLS).
 19. The fusion protein of claim 18, wherein the NLS comprises the amino acid sequence PKKKRKV (SEQ ID NO: 741) or MDSLLMNRRKFLYQFKNVRWAKGRRETYLC (SEQ ID NO: 742).
 20. The fusion protein of claim 18, wherein the fusion protein comprises the structure: NH₂-[cytidine deaminase domain]-[Cas9 domain]-[UGI domain]-[NLS]-COOH, and wherein each instance of “-” comprises an optional linker.
 21. The fusion protein of claim 18, wherein the UGI domain and the NLS are linked via a linker comprising the amino acid sequence: SGGS (SEQ ID NO: 4288), or wherein the Cas9 domain and the UGI domain are linked via a linker comprising the amino acid sequence: SGGS (SEQ ID NO: 4288).
 22. The fusion protein of claim 1, wherein the fusion protein comprises the amino acid sequence set forth in SEQ ID NO:
 594. 23. A complex comprising the fusion protein of claim 1 and the guide RNA bound to the Cas9 domain of the fusion protein. 